{
  "file_name": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
  "total_pages": 105,
  "pdf_type": "normal",
  "font_analysis": {
    "font_sizes_frequency": {
      "8.992650032043457": 108,
      "27.937164306640625": 4,
      "23.021183013916016": 1,
      "17.985300064086914": 1,
      "17.02608299255371": 2,
      "14.2186279296875": 2,
      "14.028532981872559": 17,
      "13.816503524780273": 6,
      "11.030982971191406": 541,
      "12.94941520690918": 1278,
      "11.99020004272461": 15,
      "32.013832092285156": 2,
      "20.02363395690918": 9,
      "15.946965217590332": 51,
      "15.543179512023926": 2,
      "14.987749099731445": 496,
      "9.951866149902344": 515,
      "14.837115287780762": 1,
      "43.406349182128906": 10,
      "6.715545177459717": 10,
      "18.944515228271484": 2,
      "20.98284912109375": 2
    },
    "heading_sizes": [
      43.406349182128906,
      32.013832092285156,
      27.937164306640625,
      20.98284912109375,
      20.02363395690918,
      18.944515228271484,
      17.02608299255371,
      15.946965217590332,
      15.543179512023926,
      14.987749099731445,
      14.2186279296875,
      14.028532981872559,
      13.816503524780273
    ]
  },
  "table_analysis": {
    "total_tables": 12,
    "tables_info": [
      {
        "bbox": [
          81.79566955566406,
          166.84194946289062,
          533.0318603515625,
          754.2440795898438
        ],
        "num_rows": 8,
        "num_cols": 2
      },
      {
        "bbox": [
          61.64658737182617,
          188.91354370117188,
          463.83660888671875,
          347.140625
        ],
        "num_rows": 3,
        "num_cols": 3
      },
      {
        "bbox": [
          73.76002502441406,
          310.8203125,
          531.072998046875,
          663.4169921875
        ],
        "num_rows": 8,
        "num_cols": 2
      },
      {
        "bbox": [
          56.609317779541016,
          122.985595703125,
          538.1483154296875,
          560.4924926757812
        ],
        "num_rows": 3,
        "num_cols": 2
      },
      {
        "bbox": [
          66.32405090332031,
          584.3613891601562,
          523.7332153320312,
          641.4559936523438
        ],
        "num_rows": 5,
        "num_cols": 4
      },
      {
        "bbox": [
          68.60282135009766,
          265.74957275390625,
          525.6251831054688,
          317.594970703125
        ],
        "num_rows": 3,
        "num_cols": 2
      },
      {
        "bbox": [
          162.0321807861328,
          576.4500122070312,
          499.5043029785156,
          661.5939331054688
        ],
        "num_rows": 6,
        "num_cols": 2
      },
      {
        "bbox": [
          162.0321807861328,
          295.7168273925781,
          499.5043029785156,
          380.8607177734375
        ],
        "num_rows": 6,
        "num_cols": 2
      },
      {
        "bbox": [
          134.80694580078125,
          127.90023040771484,
          500.94354248046875,
          621.1981201171875
        ],
        "num_rows": 12,
        "num_cols": 2
      },
      {
        "bbox": [
          134.80694580078125,
          132.81484985351562,
          510.8973693847656,
          572.4114379882812
        ],
        "num_rows": 12,
        "num_cols": 2
      },
      {
        "bbox": [
          153.2769317626953,
          127.90023040771484,
          510.8973693847656,
          210.1672821044922
        ],
        "num_rows": 6,
        "num_cols": 2
      },
      {
        "bbox": [
          92.94962310791016,
          206.89389038085938,
          506.6054382324219,
          403.35919189453125
        ],
        "num_rows": 14,
        "num_cols": 5
      }
    ]
  },
  "text_blocks": [
    {
      "text": "발간등록번호",
      "font_size": 8.992650032043457,
      "font_name": "Haansoft Batang",
      "bbox": [
        97.86695861816406,
        76.4308853149414,
        151.83770751953125,
        85.42106628417969
      ],
      "page_num": 1,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안내서-0662-01",
      "font_size": 8.992650032043457,
      "font_name": "Haansoft Batang",
      "bbox": [
        88.1522216796875,
        91.05490112304688,
        161.51919555664062,
        100.04508209228516
      ],
      "page_num": 1,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "출혈시간 및 항혈소판제제",
      "font_size": 27.937164306640625,
      "font_name": "H2hdrM",
      "bbox": [
        137.2056427001953,
        243.45310974121094,
        457.5530090332031,
        271.3825988769531
      ],
      "page_num": 1,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "저항성 복합검사기기 안전성·성능 및",
      "font_size": 27.937164306640625,
      "font_name": "H2hdrM",
      "bbox": [
        64.16522216796875,
        288.2841491699219,
        540.0181884765625,
        316.213623046875
      ],
      "page_num": 1,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험계획서 평가 가이드라인",
      "font_size": 27.937164306640625,
      "font_name": "H2hdrM",
      "bbox": [
        97.38722229003906,
        332.9952697753906,
        497.4913024902344,
        360.92474365234375
      ],
      "page_num": 1,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(민원인 안내서)",
      "font_size": 27.937164306640625,
      "font_name": "H2hdrM",
      "bbox": [
        203.04995727539062,
        377.7064208984375,
        391.7663879394531,
        405.6358947753906
      ],
      "page_num": 1,
      "block_type": "heading",
      "level": 3,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2016. 12.",
      "font_size": 23.021183013916016,
      "font_name": "T4",
      "bbox": [
        251.62362670898438,
        518.3135986328125,
        343.20806884765625,
        545.9083862304688
      ],
      "page_num": 1,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기심사부 체외진단기기과",
      "font_size": 17.985300064086914,
      "font_name": "MalgunGothicBold",
      "bbox": [
        166.94952392578125,
        704.4393310546875,
        427.80816650390625,
        728.3546142578125
      ],
      "page_num": 1,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제․개정 이력",
      "font_size": 17.02608299255371,
      "font_name": "H2gtrE",
      "bbox": [
        249.2249298095703,
        82.72248077392578,
        345.65264892578125,
        99.74388122558594
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성·성능 및",
      "font_size": 14.2186279296875,
      "font_name": "T7",
      "bbox": [
        90.67086029052734,
        128.6194305419922,
        504.1467590332031,
        146.5997772216797
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 11,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험계획서 평가 가이드라인(민원인 안내서)",
      "font_size": 14.2186279296875,
      "font_name": "T7",
      "bbox": [
        141.6432342529297,
        152.59323120117188,
        453.1878967285156,
        170.57357788085938
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 11,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제․개정번호",
      "font_size": 14.028532981872559,
      "font_name": "T7",
      "bbox": [
        64.64496612548828,
        209.17140197753906,
        431.04681396484375,
        226.00100708007812
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 12,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "승인일자",
      "font_size": 14.028532981872559,
      "font_name": "T7",
      "bbox": [
        64.64496612548828,
        209.17140197753906,
        431.04681396484375,
        226.00100708007812
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 12,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주요 내용",
      "font_size": 14.028532981872559,
      "font_name": "T7",
      "bbox": [
        64.64496612548828,
        209.17140197753906,
        431.04681396484375,
        226.00100708007812
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 12,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "B1-2016-5-054",
      "font_size": 14.028532981872559,
      "font_name": "T8",
      "bbox": [
        65.00476837158203,
        261.07470703125,
        237.6495361328125,
        277.904296875
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 12,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2016.12.30",
      "font_size": 14.028532981872559,
      "font_name": "T8",
      "bbox": [
        65.00476837158203,
        261.07470703125,
        237.6495361328125,
        277.904296875
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 12,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "출혈시간 및 항혈소판제제 저항성 복합검사",
      "font_size": 14.028532981872559,
      "font_name": "T8",
      "bbox": [
        265.7759704589844,
        242.85459899902344,
        530.35302734375,
        296.1243896484375
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 12,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기기 안전성·성능 및 임상시험계획서 평가",
      "font_size": 14.028532981872559,
      "font_name": "T8",
      "bbox": [
        265.7759704589844,
        242.85459899902344,
        530.35302734375,
        296.1243896484375
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 12,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가이드라인",
      "font_size": 14.028532981872559,
      "font_name": "T8",
      "bbox": [
        265.7759704589844,
        242.85459899902344,
        530.35302734375,
        296.1243896484375
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 12,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안내서-0662-01",
      "font_size": 14.028532981872559,
      "font_name": "T8",
      "bbox": [
        64.76490020751953,
        346.541259765625,
        144.94265747070312,
        363.3708801269531
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 12,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "「출혈시간 및 항혈소판제제 저항성 복합검사기기",
      "font_size": 13.816503524780273,
      "font_name": "T8",
      "bbox": [
        265.7759704589844,
        300.9910888671875,
        530.29248046875,
        372.3610534667969
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전성·성능 및 임상시험계획서 평가 가이드라인",
      "font_size": 13.816503524780273,
      "font_name": "T8",
      "bbox": [
        265.7759704589844,
        300.9910888671875,
        530.29248046875,
        372.3610534667969
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(민원인 안내서)」 명칭 변경 및 제·개정 점검표",
      "font_size": 13.816503524780273,
      "font_name": "T8",
      "bbox": [
        265.7759704589844,
        300.9910888671875,
        530.29248046875,
        372.3610534667969
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등 추가",
      "font_size": 13.816503524780273,
      "font_name": "T8",
      "bbox": [
        265.7759704589844,
        300.9910888671875,
        530.29248046875,
        372.3610534667969
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[근거: 「식품의약품안전처 지침서등의 관리에",
      "font_size": 13.816503524780273,
      "font_name": "T8",
      "bbox": [
        265.7759704589844,
        378.78607177734375,
        530.2919921875,
        413.71588134765625
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관한 규정」 개정, ‘17.5.1.]",
      "font_size": 13.816503524780273,
      "font_name": "T8",
      "bbox": [
        265.7759704589844,
        378.78607177734375,
        530.2919921875,
        413.71588134765625
      ],
      "page_num": 2,
      "block_type": "heading",
      "level": 13,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지침서ᆞ안내서 제ᆞ개정 점검표",
      "font_size": 17.02608299255371,
      "font_name": "H2hdrM",
      "bbox": [
        169.3482208251953,
        80.5648422241211,
        424.2100830078125,
        97.58624267578125
      ],
      "page_num": 3,
      "block_type": "heading",
      "level": 7,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "명칭",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        82.5152816772461,
        118.1751480102539,
        103.02421569824219,
        132.8431854248047
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성·성능 및",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        170.90737915039062,
        109.30484008789062,
        495.8521728515625,
        123.97286987304688
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험계획서 평가 가이드라인(민원인 안내서)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        210.0061798095703,
        126.92559051513672,
        452.9982604980469,
        141.5936279296875
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아래에 해당하는 사항에 체크하여 주시기 바랍니다.",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        166.34983825683594,
        145.02581787109375,
        427.57763671875,
        159.69384765625
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등록대상",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        70.76165008544922,
        307.20855712890625,
        114.77745819091797,
        321.8765869140625
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "여부",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        81.79566955566406,
        324.7094421386719,
        103.86370849609375,
        339.3774719238281
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        166.84194946289062,
        422.21209716796875,
        181.50999450683594
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지침서ㆍ안내서가 있습니까?",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        149.79881286621094,
        183.38388061523438,
        296.1605224609375,
        198.0519256591797
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        456.95233154296875,
        167.44131469726562,
        506.365234375,
        197.45257568359375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        456.95233154296875,
        167.44131469726562,
        506.365234375,
        197.45257568359375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        208.43649291992188,
        530.2322387695312,
        223.1045379638672
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "으로 고려하시기 바랍니다. 그럼에도 불구하고 동 지침서ㆍ안내서의 제정이",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        149.07920837402344,
        224.97842407226562,
        534.1119995117188,
        256.1883850097656
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        149.07920837402344,
        224.97842407226562,
        534.1119995117188,
        256.1883850097656
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(사유 :                                                                 )",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        257.9423828125,
        525.1990966796875,
        272.61041259765625
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 법령(법ㆍ시행령ㆍ시행규칙) 또는",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        278.7995910644531,
        314.51055908203125,
        293.4676208496094
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        149.79881286621094,
        295.3415222167969,
        415.4958190917969,
        326.5514831542969
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나열한 것입니까?",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        149.79881286621094,
        295.3415222167969,
        415.4958190917969,
        326.5514831542969
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        456.95233154296875,
        287.669921875,
        506.365234375,
        317.6811828613281
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        456.95233154296875,
        287.669921875,
        506.365234375,
        317.6811828613281
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        325.66839599609375,
        506.365234375,
        355.6796569824219
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        325.66839599609375,
        506.365234375,
        355.6796569824219
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        325.66839599609375,
        506.365234375,
        355.6796569824219
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        354.7965393066406,
        450.2768859863281,
        369.4645690917969
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "내용입니까?",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        149.07920837402344,
        370.2596435546875,
        209.20457458496094,
        384.92767333984375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        456.95233154296875,
        354.7965393066406,
        506.365234375,
        384.92767333984375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        456.95233154296875,
        354.7965393066406,
        506.365234375,
        384.92767333984375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 외국 규정을 번역하거나 설명하는 내용입니까?",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        384.0445861816406,
        506.365234375,
        414.05584716796875
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        384.0445861816406,
        506.365234375,
        414.05584716796875
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        384.0445861816406,
        506.365234375,
        414.05584716796875
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        413.1727600097656,
        438.6431884765625,
        427.8407897949219
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정리한 자료입니까?",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        149.07920837402344,
        428.6358642578125,
        251.4247589111328,
        443.30389404296875
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        456.95233154296875,
        413.1727600097656,
        506.365234375,
        443.30389404296875
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        456.95233154296875,
        413.1727600097656,
        506.365234375,
        443.30389404296875
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        447.5751647949219,
        527.3955078125,
        478.78509521484375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        447.5751647949219,
        527.3955078125,
        478.78509521484375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지침서ㆍ안내서",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        63.205745697021484,
        513.6229858398438,
        126.21337890625,
        528.291015625
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구분",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        83.2348861694336,
        531.2437744140625,
        102.30498504638672,
        545.9118041992188
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        488.21075439453125,
        446.6377868652344,
        502.8787841796875
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사무의 세부기준이나 절차를 제시하는 것입니까? (공무원용)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        149.1991424560547,
        503.5539855957031,
        431.4099426269531,
        518.2220458984375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예(☞지침서)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        456.95233154296875,
        488.21075439453125,
        533.0318603515625,
        518.2220458984375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        456.95233154296875,
        488.21075439453125,
        533.0318603515625,
        518.2220458984375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        526.688720703125,
        450.51708984375,
        541.3567504882812
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        149.1991424560547,
        542.15185546875,
        446.7575988769531,
        572.1630859375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하는 것입니까? (민원인용)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        149.1991424560547,
        542.15185546875,
        446.7575988769531,
        572.1630859375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 예(☞안내서)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        456.95233154296875,
        534.480224609375,
        534.1112670898438,
        564.491455078125
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        456.95233154296875,
        534.480224609375,
        534.1112670898438,
        564.491455078125
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기타 확인",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        68.00314331054688,
        600.4081420898438,
        117.53630065917969,
        615.076171875
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사항",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        81.79566955566406,
        618.0289306640625,
        103.86370849609375,
        632.6969604492188
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        582.0681762695312,
        433.24578857421875,
        596.7362060546875
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "민원인을 구속하는 내용이 있습니까?",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        149.1991424560547,
        597.4114379882812,
        335.6160888671875,
        612.0794677734375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        456.95233154296875,
        582.0681762695312,
        506.365234375,
        612.0794677734375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "■ 아니오",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        456.95233154296875,
        582.0681762695312,
        506.365234375,
        612.0794677734375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        132.64810180664062,
        622.1044311523438,
        530.2326049804688,
        636.7724609375
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안내서 제ㆍ개정 절차를 진행하시기 바랍니다.",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        149.07920837402344,
        638.6463623046875,
        370.6141357421875,
        653.3143920898438
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상기 사항에 대하여 확인하였음.",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        214.56370544433594,
        660.8221435546875,
        380.3232727050781,
        675.4901733398438
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2017 년    5 월   31  일",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        210.2460479736328,
        695.1046752929688,
        373.23773193359375,
        709.772705078125
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "담당자",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        328.981689453125,
        725.3116455078125,
        403.8124694824219,
        754.2440795898438
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확  인(부서장)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicBold",
      "bbox": [
        328.981689453125,
        725.3116455078125,
        403.8124694824219,
        754.2440795898438
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "서 두 원",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        448.0771484375,
        723.6334838867188,
        491.9733581542969,
        738.301513671875
      ],
      "page_num": 3,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "오 현 주",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        447.71734619140625,
        741.2542114257812,
        492.33319091796875,
        755.9222412109375
      ],
      "page_num": 3,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이 안내서는 출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성·성능",
      "font_size": 14.028532981872559,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        64.52503204345703,
        73.19916534423828,
        529.4090576171875,
        91.85308074951172
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 12,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 임상시험계획서 평가 시 요구되는 신청서 작성 방법 및 제출자료 요건에",
      "font_size": 14.028532981872559,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        64.52503204345703,
        102.56707000732422,
        529.4090576171875,
        121.22098541259766
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 12,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.",
      "font_size": 14.028532981872559,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        64.52503204345703,
        131.93496704101562,
        526.1707763671875,
        150.58888244628906
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 12,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식",
      "font_size": 14.028532981872559,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        64.52503204345703,
        171.3718719482422,
        524.595458984375,
        190.02578735351562
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 12,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는",
      "font_size": 14.028532981872559,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        64.52503204345703,
        200.73977661132812,
        529.5289916992188,
        219.39369201660156
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 12,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사항이 아님을 알려드립니다. 또한, 본 안내서는 2016년 12월 30일 현재의 과학적",
      "font_size": 14.028532981872559,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        64.52503204345703,
        230.10768127441406,
        524.5969848632812,
        248.7615966796875
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 12,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ㆍ기술적 사실 및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규",
      "font_size": 14.028532981872559,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        64.52503204345703,
        259.4755859375,
        529.4103393554688,
        278.1294860839844
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 12,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.",
      "font_size": 14.028532981872559,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        64.52503204345703,
        288.843505859375,
        488.27166748046875,
        307.4974060058594
      ],
      "page_num": 4,
      "block_type": "heading",
      "level": 12,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        64.52503204345703,
        340.84210205078125,
        529.029541015625,
        358.06109619140625
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        88.63196563720703,
        357.74365234375,
        524.4757690429688,
        391.8641662597656
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(식품의약품안전처 지침서등의 관리에 관한 규정 제2조)",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        88.63196563720703,
        357.74365234375,
        524.4757690429688,
        391.8641662597656
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 식품의약품안전평가원",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        65.72438049316406,
        443.6897277832031,
        542.7020874023438,
        460.9087219238281
      ],
      "page_num": 4,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "체외진단기기과에 문의하시기 바랍니다.",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        83.71463012695312,
        464.54693603515625,
        289.1183166503906,
        481.76593017578125
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화번호: 043-719-4652~63",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        85.75352478027344,
        485.2842712402344,
        256.1170349121094,
        502.5032653808594
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "팩스번호: 043-719-4650",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        85.75352478027344,
        506.0215759277344,
        232.13070678710938,
        523.2406005859375
      ],
      "page_num": 4,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 관련 법규 등",
      "font_size": 11.99020004272461,
      "font_name": "T10",
      "bbox": [
        61.64658737182617,
        69.04454803466797,
        152.07757568359375,
        83.42882537841797
      ],
      "page_num": 5,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 「의료기기법」",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        61.64658737182617,
        116.99214935302734,
        166.82958984375,
        131.37643432617188
      ],
      "page_num": 5,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2) 「의료기기법 시행령」",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        61.64658737182617,
        140.9659423828125,
        208.8068389892578,
        155.35023498535156
      ],
      "page_num": 5,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(3) 「의료기기법 시행규칙」",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        61.64658737182617,
        164.93975830078125,
        220.8003387451172,
        179.32403564453125
      ],
      "page_num": 5,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(4) 「의료기기 허가",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        61.64658737182617,
        188.91354370117188,
        172.8263397216797,
        203.29783630371094
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "신고",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        178.82308959960938,
        188.91354370117188,
        202.81008911132812,
        203.29783630371094
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "심사 등에 관한 규정」(식약처 고시)",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        208.8068389892578,
        188.91354370117188,
        409.8658447265625,
        203.29783630371094
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(5) 「의료기기 품목 및 품목별 등급에 관한 규정」(식약처 고시)",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        61.64658737182617,
        212.88735961914062,
        421.859375,
        227.27163696289062
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(6) 「의료기기의 전기",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        61.64658737182617,
        236.86114501953125,
        184.81983947753906,
        251.2454376220703
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기계적 안전에 관한 공통기준규격」(식약처 고시)",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        190.81658935546875,
        236.86114501953125,
        463.83660888671875,
        251.2454376220703
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(7) 「의료기기의 전자파 안전에 관한 공통기준규격」(식약처 고시)",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        61.64658737182617,
        260.8349304199219,
        433.8528747558594,
        275.2192077636719
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(8) 「의료기기의 안정성시험 기준」(식약처 고시)",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        61.64658737182617,
        284.8087463378906,
        337.90484619140625,
        299.1930236816406
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(9) 「의료기기 제조 및 품질관리 기준」(식약처 고시)",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        61.64658737182617,
        308.78253173828125,
        361.891845703125,
        323.16680908203125
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(10)「의료기기 표시",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        61.64658737182617,
        332.75634765625,
        172.8263397216797,
        347.140625
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기재 등에 관한 규정」(식약처 고시)",
      "font_size": 11.99020004272461,
      "font_name": "T11",
      "bbox": [
        178.82308959960938,
        332.75634765625,
        379.8821105957031,
        347.140625
      ],
      "page_num": 5,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "목",
      "font_size": 32.013832092285156,
      "font_name": "T12",
      "bbox": [
        239.98992919921875,
        68.8048095703125,
        352.00921630859375,
        107.21083068847656
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 2,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "차",
      "font_size": 32.013832092285156,
      "font_name": "T12",
      "bbox": [
        239.98992919921875,
        68.8048095703125,
        352.00921630859375,
        107.21083068847656
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 2,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅰ. 안전성·성능 평가",
      "font_size": 20.02363395690918,
      "font_name": "T14",
      "bbox": [
        64.88483428955078,
        150.91506958007812,
        514.309326171875,
        174.93682861328125
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1",
      "font_size": 15.946965217590332,
      "font_name": "T2",
      "bbox": [
        64.88483428955078,
        150.91506958007812,
        514.309326171875,
        174.93682861328125
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 적용 범위",
      "font_size": 15.946965217590332,
      "font_name": "T15",
      "bbox": [
        79.876708984375,
        187.59498596191406,
        507.3531188964844,
        206.71014404296875
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1",
      "font_size": 15.946965217590332,
      "font_name": "T2",
      "bbox": [
        79.876708984375,
        187.59498596191406,
        507.3531188964844,
        206.71014404296875
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 약어 및 용어 정리",
      "font_size": 15.946965217590332,
      "font_name": "T15",
      "bbox": [
        79.876708984375,
        216.36354064941406,
        507.3531188964844,
        235.47869873046875
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2",
      "font_size": 15.946965217590332,
      "font_name": "T2",
      "bbox": [
        79.876708984375,
        216.36354064941406,
        507.3531188964844,
        235.47869873046875
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 출혈시간 및 항혈소판제제 저항성 복합검사기기정의 및 분류",
      "font_size": 15.946965217590332,
      "font_name": "T15",
      "bbox": [
        79.876708984375,
        245.13209533691406,
        507.3531188964844,
        264.24725341796875
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5",
      "font_size": 15.946965217590332,
      "font_name": "T2",
      "bbox": [
        79.876708984375,
        245.13209533691406,
        507.3531188964844,
        264.24725341796875
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4. 출혈시간 및 항혈소판제제 저항성 복합검사기기 관련국내",
      "font_size": 15.543179512023926,
      "font_name": "T15",
      "bbox": [
        79.876708984375,
        273.9006652832031,
        422.0939636230469,
        293.01580810546875
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "외 규격",
      "font_size": 15.543179512023926,
      "font_name": "T15",
      "bbox": [
        424.9296875,
        273.9006652832031,
        507.35247802734375,
        293.01580810546875
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10",
      "font_size": 15.946965217590332,
      "font_name": "T2",
      "bbox": [
        424.9296875,
        273.9006652832031,
        507.35247802734375,
        293.01580810546875
      ],
      "page_num": 6,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5. 안전성 평가 항목",
      "font_size": 15.946965217590332,
      "font_name": "T15",
      "bbox": [
        79.876708984375,
        302.66925048828125,
        507.35247802734375,
        321.7843933105469
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "11",
      "font_size": 15.946965217590332,
      "font_name": "T2",
      "bbox": [
        79.876708984375,
        302.66925048828125,
        507.35247802734375,
        321.7843933105469
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6. 분석적 성능 평가 항목",
      "font_size": 15.946965217590332,
      "font_name": "T15",
      "bbox": [
        79.876708984375,
        331.43780517578125,
        507.35247802734375,
        350.5529479980469
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "14",
      "font_size": 15.946965217590332,
      "font_name": "T2",
      "bbox": [
        79.876708984375,
        331.43780517578125,
        507.35247802734375,
        350.5529479980469
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7. 안정성 평가 항목",
      "font_size": 15.946965217590332,
      "font_name": "T15",
      "bbox": [
        79.876708984375,
        360.20635986328125,
        507.35247802734375,
        379.3215026855469
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "23",
      "font_size": 15.946965217590332,
      "font_name": "T2",
      "bbox": [
        79.876708984375,
        360.20635986328125,
        507.35247802734375,
        379.3215026855469
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "8. 참고 문헌",
      "font_size": 15.946965217590332,
      "font_name": "T15",
      "bbox": [
        79.876708984375,
        388.97491455078125,
        507.35247802734375,
        408.0900573730469
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "26",
      "font_size": 15.946965217590332,
      "font_name": "T2",
      "bbox": [
        79.876708984375,
        388.97491455078125,
        507.35247802734375,
        408.0900573730469
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[별첨] 국내·외 연구동향",
      "font_size": 15.946965217590332,
      "font_name": "T15",
      "bbox": [
        79.876708984375,
        417.74346923828125,
        507.35247802734375,
        436.8745422363281
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "27",
      "font_size": 15.946965217590332,
      "font_name": "T2",
      "bbox": [
        79.876708984375,
        417.74346923828125,
        507.35247802734375,
        436.8745422363281
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅱ. 임상시험계획서 작성 및 평가",
      "font_size": 20.02363395690918,
      "font_name": "T14",
      "bbox": [
        61.64658737182617,
        477.7978210449219,
        519.345947265625,
        501.819580078125
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "28",
      "font_size": 15.946965217590332,
      "font_name": "T2",
      "bbox": [
        61.64658737182617,
        477.7978210449219,
        519.345947265625,
        501.819580078125
      ],
      "page_num": 6,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개",
      "font_size": 20.02363395690918,
      "font_name": "T14",
      "bbox": [
        248.9850616455078,
        143.72293090820312,
        339.8957824707031,
        167.72467041015625
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "요",
      "font_size": 20.02363395690918,
      "font_name": "T14",
      "bbox": [
        248.9850616455078,
        143.72293090820312,
        339.8957824707031,
        167.72467041015625
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "식품의약품안전처는 정부지원과제 중 제품화가 임박한 제품에 대한",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.6011962890625,
        224.394775390625,
        538.268310546875,
        242.36013793945312
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험방법 개발, 안전성·성능 평가, 임상시험계획서의 선제적 제공을 통한",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        254.3620147705078,
        538.268310546875,
        272.3423767089844
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품화 지원체계 구축을 위하여 「융복합 신개발의료기기 제품화 지원을",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        284.32928466796875,
        538.268310546875,
        302.30963134765625
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위한 사업」을 진행하고 있다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        314.2965393066406,
        252.4631805419922,
        332.2768859863281
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 가이드라인은 ‘16년 「융복합 신개발의료기기 제품화 지원을 위한",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.6011962890625,
        344.2637939453125,
        538.268310546875,
        362.244140625
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사업」의 결과물이며, 주요 내용으로 “출혈시간 및 항혈소판제제 저항성",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        374.2310485839844,
        538.268310546875,
        392.2113952636719
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "복합검사기기”의 안전성 및 성능평가방법, 임상시험계획서 작성 및",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        404.1982727050781,
        538.1483154296875,
        422.16363525390625
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평가방법과 관련된 사항을 구체적으로 제시하여 신속제품화를 위한",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        434.16552734375,
        538.268310546875,
        452.1308898925781
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "맞춤형 기술지원을 목적으로 하는 가이드라인이다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        464.1327819824219,
        405.0204772949219,
        482.09814453125
      ],
      "page_num": 7,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 1 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        281.24755859375,
        788.5885009765625,
        313.6467590332031,
        798.5376586914062
      ],
      "page_num": 8,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ⅰ",
      "font_size": 20.02363395690918,
      "font_name": "T10",
      "bbox": [
        68.36294555664062,
        77.07575988769531,
        288.20379638671875,
        101.0975112915039
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전성·성능 평가",
      "font_size": 20.02363395690918,
      "font_name": "H2hdrM",
      "bbox": [
        68.36294555664062,
        77.07575988769531,
        288.20379638671875,
        101.0975112915039
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 적용범위",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        139.98696899414062,
        152.6769561767578,
        155.92955017089844
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 가이드라인은 출혈시간 및 항혈소판제제 저항성 복합검사기기의",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.6011962890625,
        191.5506591796875,
        538.268310546875,
        209.51602172851562
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석적 성능 평가와 안정성에 대한 평가방법을 구축하여 신개발 융복합",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        221.51791381835938,
        538.268310546875,
        239.4832763671875
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기의 평가방법을 제시하고자 한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        251.4851531982422,
        329.4614562988281,
        269.4505310058594
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "출혈시간 및 항혈소판제제 저항성 복합검사기기는 『의료기기 품목 및",
      "font_size": 14.837115287780762,
      "font_name": "T15",
      "bbox": [
        71.24138641357422,
        311.419677734375,
        538.2083129882812,
        329.4000244140625
      ],
      "page_num": 8,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품목별 등급에 관한 규정』의 분류에 따라 “혈액응고검사시약 D01050.01",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        341.3869323730469,
        538.1782836914062,
        359.3672790527344
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(3등급)”과 “자동혈소판응집측정장치 A22290.01(1등급)”로 분류되고 있다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        371.35418701171875,
        535.1499633789062,
        389.3195495605469
      ],
      "page_num": 8,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 2 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        281.24755859375,
        788.5885009765625,
        313.6467590332031,
        798.5376586914062
      ],
      "page_num": 9,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2. 약어 및 용어정리",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        74.19891357421875,
        215.2830352783203,
        93.31405639648438
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 가속노화시험 (Accelerated aging testing) : 제품의 실제 보관기간과",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        128.0200958251953,
        538.268310546875,
        145.98545837402344
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상응되도록 짧은 기간 동안 시험하기 위하여 가혹한 온도조건 등에서",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        81.43586730957031,
        157.98733520507812,
        538.268310546875,
        175.95269775390625
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료기기의 화학적 또는 물리적 퇴보속도를 높이도록 계획한 안정성",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        81.43586730957031,
        187.95458984375,
        538.268310546875,
        205.91995239257812
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        81.43586730957031,
        217.92184448242188,
        110.58007049560547,
        235.88720703125
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 간섭 (Interference) : 분석물질의 농도나 강도가 명백함에도 검출시약",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        247.8890838623047,
        538.268310546875,
        265.8544616699219
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이나 신호 자체에 비특이적으로 반응하는 물질의 존재로 인해 일어",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        80.83618927001953,
        277.8563537597656,
        538.268310546875,
        295.82171630859375
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나는 인위적인 증가나 감소",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        80.83618927001953,
        307.8236083984375,
        261.3383483886719,
        325.7889709472656
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 간섭물질 (Interfering substances) : 임상검체에 존재하는 내부물질",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        337.7908630371094,
        538.1483154296875,
        355.7562255859375
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(예: 혈액 구성요소, acidic polysaccharides) 또는 외부물질(예: 항응고제 등)로",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        77.71788024902344,
        367.75811767578125,
        538.1483154296875,
        385.7234802246094
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위양성 또는 위음성 결과를 야기할 수 있는 물질",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        77.71788024902344,
        397.7253723144531,
        392.5472717285156,
        415.69073486328125
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(4) 검출한계 (Limit of detection, LOD) : 검출될 수 있는 분석 물질의 최소량",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        427.6925964355469,
        538.268310546875,
        445.657958984375
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(5) 공란한계 (Limit of blank, LOB) : blank 검체에서 관찰 가능할 수",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        457.65985107421875,
        538.268310546875,
        475.6252136230469
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는 가장 높은 측정치",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        82.15547180175781,
        487.6271057128906,
        235.31246948242188,
        505.59246826171875
      ],
      "page_num": 9,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(6) 교차반응 (Cross-reactivity) : 항원 이외에 공유 되었거나, 유사한 또는",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        517.5942993164062,
        538.1483154296875,
        535.5596923828125
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동일한 항원 결정기를 가진 항원과 항체가 반응하는 현상",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        80.83618927001953,
        547.5615844726562,
        454.673583984375,
        565.5269775390625
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(7) 대조물질 (Control / Control material) : 정도 관리를 위해 이용되는",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        577.52880859375,
        538.268310546875,
        595.4942016601562
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기기, 액체 또는 동결건조 물질",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        81.67573547363281,
        607.49609375,
        289.2832336425781,
        625.4614868164062
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(8) 변동계수 (Coefficient of Variation, CV) : 표준편차의 크기를 평균치에",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        637.4633178710938,
        538.1483154296875,
        655.4287109375
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한 백분율로 나타낸 것",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        81.67573547363281,
        667.4306030273438,
        244.42752075195312,
        685.39599609375
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(9) 배치(Batch), 로트(Lot) : 특성이 균일하고 단일 또는 일련의 제조공정으로",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        697.3978271484375,
        538.268310546875,
        715.3632202148438
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "생산된 물질의 정의된 양",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        80.71625518798828,
        727.3651123046875,
        237.11148071289062,
        745.3305053710938
      ],
      "page_num": 9,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 3 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        281.24755859375,
        788.5885009765625,
        313.6467590332031,
        798.5376586914062
      ],
      "page_num": 10,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(10) 사용 시 안정성(In-use stability) : 제조사에서 제공한 용기를 개봉한",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        68.5650634765625,
        538.1483154296875,
        86.53043365478516
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이후에 사용자의 작동 조건에서 시약의 유효기간내의 검사수행능",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        87.79241943359375,
        98.53231811523438,
        520.1580810546875,
        116.49768829345703
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(11) 사용기간(유효기간) (Shelf life) : 제조자가 특정한 저장조건 하에서",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        128.49957275390625,
        538.268310546875,
        146.46493530273438
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최종 포장상태의 IVD 제품이 안정성을 유지하는 기간",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        88.51203155517578,
        158.46681213378906,
        449.9961242675781,
        176.4321746826172
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(12) 신뢰구간 (Confidence interval) : 평균, 분율, 비율 등의 변수의 참값이",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        188.43406677246094,
        538.268310546875,
        206.39942932128906
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정해진 확률 범위 내에서 분포할 것으로 예상되는 계산된 구간",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        88.75189971923828,
        218.4013214111328,
        489.8145446777344,
        236.36668395996094
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(13) 실시간 안정성(Real time stability) : IVD 제품을 제조자가 특정한",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        248.3685760498047,
        538.1483154296875,
        266.3339538574219
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용 환경에 노출시켜 그 안정성을 평가하는 실험",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        89.23163604736328,
        278.3358459472656,
        424.09014892578125,
        296.30120849609375
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ 사용 환경은 온도, 이동 조건, 진동, 빛, 습도를 포함한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        92.8296890258789,
        308.3030700683594,
        496.17108154296875,
        326.2834167480469
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(14) 이동거리 (Migration Distance) : 검체가 카트리지에서 이동한 거리를",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        338.27032470703125,
        538.268310546875,
        356.2356872558594
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정하여 혈액 내부의 혈소판 인자의 기능을 확인하는 요소",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        87.6724853515625,
        368.2375793457031,
        475.5422668457031,
        386.20294189453125
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(15) 재현성 (Reproducibility) : 다른 측정조건에서 수행된 동일한 측정물의",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        398.204833984375,
        538.268310546875,
        416.1701965332031
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과값 사이의 일치도의 근접성",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        89.11170196533203,
        428.1720886230469,
        290.2427062988281,
        446.137451171875
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(16) 정밀도 (Precision) : 규정된 조건 하에서 얻어진 독립적인 검사",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        458.13934326171875,
        538.268310546875,
        476.1047058105469
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과들 가운데 일치도의 근접성",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        90.67086029052734,
        488.1065979003906,
        307.9930725097656,
        506.07196044921875
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "☞ 정밀도는 전형적으로 수치로 표현되지 않지만 비정밀도는 반복",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        91.75027465820312,
        518.0737915039062,
        538.268310546875,
        536.0541381835938
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정값 결과들의 ‘표준편차’ 또는 ‘변이계수’라는 용어로 정량적",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        115.25753021240234,
        548.0410766601562,
        538.1483154296875,
        566.0064697265625
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으로 표현",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        115.25753021240234,
        578.00830078125,
        179.42276000976562,
        595.9736938476562
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(17) 정확도 (Accuracy) : 측정치와 참값 사이의 일치도",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        607.9755859375,
        423.85028076171875,
        625.9409790039062
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "☞ 평가대상 검사법에 의한 다수의 연속적인 결과값 들에서 얻은 평균값과",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        85.51365661621094,
        637.9428100585938,
        538.268310546875,
        655.9231567382812
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공인된",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        107.58169555664062,
        667.9100341796875,
        538.268310546875,
        685.8754272460938
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참고값(Accepted",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        107.58169555664062,
        667.9100341796875,
        538.268310546875,
        685.8754272460938
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "reference",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        107.58169555664062,
        667.9100341796875,
        538.268310546875,
        685.8754272460938
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "value)사이의",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        107.58169555664062,
        667.9100341796875,
        538.268310546875,
        685.8754272460938
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일치",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        107.58169555664062,
        667.9100341796875,
        538.268310546875,
        685.8754272460938
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "근접도",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        107.58169555664062,
        667.9100341796875,
        538.268310546875,
        685.8754272460938
      ],
      "page_num": 10,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(Closeness of agreement)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        107.58169555664062,
        697.8773193359375,
        265.8359069824219,
        715.8427124023438
      ],
      "page_num": 10,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 4 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        281.24755859375,
        788.5885009765625,
        313.6467590332031,
        798.5376586914062
      ],
      "page_num": 11,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(18) 직선성 (Linearity) : 실험 검체에 있는 분석물질의 농도[양]에 정비례",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        68.5650634765625,
        538.268310546875,
        86.53043365478516
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는 결과를 제공할 수 있는 능력",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        87.4326171875,
        98.53231811523438,
        308.8326416015625,
        116.49768829345703
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(19) 출혈시간(Bleeding time, BT) 검사 : 출혈시간 측정검사로 Duke법,",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        128.49957275390625,
        538.1483154296875,
        146.46493530273438
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Ivy법, Template법 등을 이용하여 혈소판기능 선별검사로 사용",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        88.99176788330078,
        158.46681213378906,
        509.2440185546875,
        176.4321746826172
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(20) 측정가능범위 (Analytical measurement range, AMR) : 일상적인",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        188.43406677246094,
        538.1483154296875,
        206.39942932128906
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정 과정의 일부가 아닌 희석, 농축 또는 기타 전처리 없이 어떤",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        90.67086029052734,
        218.4013214111328,
        538.268310546875,
        236.36668395996094
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사법이 검체에서 직접 측정할 수 있는 분석물질 값의 범위",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        90.67086029052734,
        248.3685760498047,
        498.3299255371094,
        266.3339538574219
      ],
      "page_num": 11,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(21) 특이도 / 분석특이도 (Specificity / Analytical specificity) : 측정하고자",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        278.3358459472656,
        538.268310546875,
        296.30120849609375
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는 물질만 측정되고 검체 내 다른 물질은 측정 되지 않는 분석법의 능력",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        91.2705307006836,
        308.3030700683594,
        537.6685791015625,
        326.2684326171875
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(22) 판정기준치 (Cut-off value) : 정성검사에서 경계치 이상을 양성으로,",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        338.27032470703125,
        538.2682495117188,
        356.2356872558594
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경계치 미만을 음성으로 보고할 수 있는 경계값을 말한다. 정량검사",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        87.79241943359375,
        368.2375793457031,
        538.1483154296875,
        386.20294189453125
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에서는 측정 결과가 임상적 또는 분석적 결정점(Decision point)의",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        87.79241943359375,
        398.204833984375,
        538.1483154296875,
        416.1701965332031
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위 또는 아래에 있는지(양성 또는 음성) 결정하는데 사용되는 측정",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        87.79241943359375,
        428.1720886230469,
        538.1483154296875,
        446.137451171875
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "물질의 정량값",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        87.79241943359375,
        458.13934326171875,
        181.94140625,
        476.1047058105469
      ],
      "page_num": 11,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(23) 편차 (Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        488.1065979003906,
        513.4417114257812,
        506.07196044921875
      ],
      "page_num": 11,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 5 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        281.24755859375,
        788.5885009765625,
        313.6467590332031,
        798.5376586914062
      ],
      "page_num": 12,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3. 출혈시간 및 항혈소판제제 저항성 복합검사기기의 정의 및 분류",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        51.57204818725586,
        76.45640563964844,
        486.57562255859375,
        92.39897918701172
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 개요",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        128.0200958251953,
        112.97876739501953,
        145.98545837402344
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 혈관벽 손상으로 출혈이 발생하면 혈소판은 손상 부위에 부착,",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        63.805419921875,
        157.98733520507812,
        538.1483154296875,
        175.95269775390625
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다른 혈소판들과 응집, 추가 응집을 촉진시키기 위한 물질 분비 등",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        90.43099212646484,
        187.95458984375,
        538.268310546875,
        205.91995239257812
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3가지 과정을 통해 지혈을 유도한다. 이러한 반응으로 생긴 혈소판",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        90.43099212646484,
        217.92184448242188,
        538.1483154296875,
        235.88720703125
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마개가 형성되는 과정이 1차 혈소판 지혈과정이다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        90.43099212646484,
        247.8890838623047,
        438.8421630859375,
        265.8544616699219
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[그림 1] 1차 혈소판 지혈과정",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        211.20553588867188,
        278.2159423828125,
        383.5512390136719,
        293.738037109375
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈소판 부착",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        105.30292510986328,
        380.8238220214844,
        489.45428466796875,
        396.3459167480469
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "→        응집 유도인자 분비",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        105.30292510986328,
        380.8238220214844,
        489.45428466796875,
        396.3459167480469
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "→     혈소판 응집",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        105.30292510986328,
        380.8238220214844,
        489.45428466796875,
        396.3459167480469
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 혈소판 검사는 주로 선천성 혈소판기능이상이나 수술 전 선별검사로",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        422.05877685546875,
        538.268310546875,
        440.0241394042969
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "많이 사용된다. 특히 혈소판의 수적 이상이 없는 출혈성 질환에서",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        87.912353515625,
        452.0260314941406,
        538.1483154296875,
        469.99139404296875
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "선천성 혹은 후천성 혈소판 기능이상에 의한 출혈성 질환을 감별",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        87.912353515625,
        481.9932556152344,
        538.1483154296875,
        499.9586181640625
      ],
      "page_num": 12,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하는 데 중요한 검사이다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        87.912353515625,
        511.9605407714844,
        262.17791748046875,
        529.9259033203125
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[그림 2] 혈소판 기능검사의 원리",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        201.7306671142578,
        543.9655151367188,
        393.0267028808594,
        559.4876098632812
      ],
      "page_num": 12,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 6 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        281.24755859375,
        788.5885009765625,
        313.6467590332031,
        798.5376586914062
      ],
      "page_num": 13,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[그림 3] 혈소판 약물반응검사의 원리",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        189.1374969482422,
        68.92467498779297,
        405.619873046875,
        84.4467544555664
      ],
      "page_num": 13,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(3) 최근에는 심혈관 및 뇌혈관 질환의 치료 및 예방에 사용되는 항혈소판",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        373.8714294433594,
        538.1483154296875,
        391.8367919921875
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "약제의 선택과정에 있어서 환자에 적합한 올바른 약재 선택을 돕기 위한",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        88.75189971923828,
        403.83868408203125,
        538.1483154296875,
        421.8040466308594
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사 및 약제의 장기간 복용으로 인한 출혈현상의 증가나 약제의 내성에",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        88.75189971923828,
        433.8059387207031,
        538.268310546875,
        451.77130126953125
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한 검사를 위해서도 많이 이용되고 있다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        88.75189971923828,
        463.773193359375,
        349.73046875,
        481.7385559082031
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4) 혈소판 기능검사 및 항혈소판제제 저항성을 측정하기 위한 측정방법은",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        523.7076416015625,
        538.268310546875,
        541.6730346679688
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다양하며 현재 개발된 제품들의 측정방법은 Closure time(CT), 광투과량",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        88.51203155517578,
        553.6749267578125,
        538.1483154296875,
        571.6403198242188
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정, 전기 임피던스 측정, 입사광산란 측정 등이다. CT측정은 혈액이",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        88.51203155517578,
        583.6421508789062,
        538.1483154296875,
        601.6075439453125
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈소판 작용으로 인해 미세구멍이 폐색되기까지의 시간을 측정하는 것이고,",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        88.51203155517578,
        613.609375,
        538.1483154296875,
        631.5747680664062
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "광투과량 측정은 혈소판 응집에 대한 빛의 투과도를 관찰한다. 전기",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        88.51203155517578,
        643.57666015625,
        538.1483154296875,
        661.5420532226562
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임피던스 방식은 혈소판 응집으로 인한 전기장애를 측정하는 방식이고",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        88.51203155517578,
        673.5438842773438,
        538.268310546875,
        691.50927734375
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "입사광산란 측정방식은 콜라겐 코팅에 대한 빛의 산란정도를 측정하는",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        88.51203155517578,
        703.5111694335938,
        538.268310546875,
        721.4765625
      ],
      "page_num": 13,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방식이다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        88.51203155517578,
        733.4783935546875,
        147.40011596679688,
        751.4437866210938
      ],
      "page_num": 13,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 7 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        281.24755859375,
        788.5885009765625,
        313.6467590332031,
        798.5376586914062
      ],
      "page_num": 14,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(5) 본 가이드라인에서 적용하고 있는 출혈시간 및 항혈소판제제 저항성",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        68.5650634765625,
        538.268310546875,
        86.53043365478516
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "복합검사기기는 혈액 이동거리를 기반으로 혈소판의 전단 활성화 기능을",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        89.11170196533203,
        98.53231811523438,
        538.1483154296875,
        116.49768829345703
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정하는 방식으로 혈소판기능 스크리닝과 항혈소판제제에 대한 저항성",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        89.11170196533203,
        128.49957275390625,
        538.268310546875,
        146.46493530273438
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정을 하나의 기기로 동시에 관찰이 가능하다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        89.11170196533203,
        158.46681213378906,
        379.7142028808594,
        176.4321746826172
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[그림 4] 출혈시간 및 항혈소판제제 저항성 복합검사기기",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        132.52816772460938,
        214.8052520751953,
        462.22802734375,
        230.3273162841797
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 제품 허가 현황",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        525.8652954101562,
        188.53781127929688,
        543.8306884765625
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 출혈시간 및 항혈소판제제 저항성 복합검사기기는 주로 수입 의료",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        64.0452880859375,
        555.83251953125,
        538.268310546875,
        573.7979125976562
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기기에 의존하고 있고 국내 개발 제품은 없는 상태이다. (‘16.10.31 기준)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        89.23163604736328,
        585.7998046875,
        536.649169921875,
        603.7651977539062
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2) 출혈시간 및 항혈소판제제 저항성 복합검사기기로 국내에서 수입허가를",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.325679779052734,
        615.7670288085938,
        538.268310546875,
        633.732421875
      ],
      "page_num": 14,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "받은 제품은 아래와 같다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        86.59307098388672,
        645.7343139648438,
        245.26707458496094,
        663.69970703125
      ],
      "page_num": 14,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 8 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        281.24755859375,
        788.5885009765625,
        313.6467590332031,
        798.5376586914062
      ],
      "page_num": 15,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "번호",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.24463653564453,
        122.745849609375,
        474.82269287109375,
        134.6748504638672
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "업체명",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.24463653564453,
        122.745849609375,
        474.82269287109375,
        134.6748504638672
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품목허가번호",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.24463653564453,
        122.745849609375,
        474.82269287109375,
        134.6748504638672
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허가/신고일",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.24463653564453,
        122.745849609375,
        474.82269287109375,
        134.6748504638672
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모델명",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.24463653564453,
        122.745849609375,
        474.82269287109375,
        134.6748504638672
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        138.5685577392578,
        472.5840148925781,
        162.48446655273438
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "티메드(주)",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        138.5685577392578,
        472.5840148925781,
        162.48446655273438
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서울 수신",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        138.5685577392578,
        472.5840148925781,
        162.48446655273438
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "14-1203호",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        138.5685577392578,
        472.5840148925781,
        162.48446655273438
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2014년 4월 14일",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        138.5685577392578,
        472.5840148925781,
        162.48446655273438
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "A-100",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        138.5685577392578,
        472.5840148925781,
        162.48446655273438
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        166.25830078125,
        529.7784423828125,
        190.17420959472656
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지멘스헬스케어(주)",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        166.25830078125,
        529.7784423828125,
        190.17420959472656
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서울 수신",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        166.25830078125,
        529.7784423828125,
        190.17420959472656
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "11-522호",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        166.25830078125,
        529.7784423828125,
        190.17420959472656
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2011년 4월 8일",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        166.25830078125,
        529.7784423828125,
        190.17420959472656
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "INNOVANCE PFA-200 System",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        166.25830078125,
        529.7784423828125,
        190.17420959472656
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        193.8281707763672,
        513.31005859375,
        217.74407958984375
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한국로슈진단(주)",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        193.8281707763672,
        513.31005859375,
        217.74407958984375
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서울 수신",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        193.8281707763672,
        513.31005859375,
        217.74407958984375
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "11-392호",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        193.8281707763672,
        513.31005859375,
        217.74407958984375
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2011년 3월 21일",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        193.8281707763672,
        513.31005859375,
        217.74407958984375
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Multiplate 5.0 - Platelet",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        193.8281707763672,
        513.31005859375,
        217.74407958984375
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Function Analyzer",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        418.5731506347656,
        205.81507873535156,
        501.29290771484375,
        217.74407958984375
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        221.39804077148438,
        502.0718994140625,
        245.31394958496094
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백두대",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        221.39804077148438,
        502.0718994140625,
        245.31394958496094
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경인 수신",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        221.39804077148438,
        502.0718994140625,
        245.31394958496094
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "05-110호",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        221.39804077148438,
        502.0718994140625,
        245.31394958496094
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2005년 9월 2일",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        221.39804077148438,
        502.0718994140625,
        245.31394958496094
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "VerifyNow System",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        221.39804077148438,
        502.0718994140625,
        245.31394958496094
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        249.08779907226562,
        528.9978637695312,
        273.0036926269531
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성원메디칼상사",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        249.08779907226562,
        528.9978637695312,
        273.0036926269531
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서울 수신",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        249.08779907226562,
        528.9978637695312,
        273.0036926269531
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "05-1722호",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        249.08779907226562,
        528.9978637695312,
        273.0036926269531
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2005년 11월 14일",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        249.08779907226562,
        528.9978637695312,
        273.0036926269531
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "HemoRam/AggRAM Analyzer",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        249.08779907226562,
        528.9978637695312,
        273.0036926269531
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[표 1] 국내업체 혈소판 기능검사 장비 허가사항",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        157.7145233154297,
        71.80152893066406,
        437.16217041015625,
        87.3236083984375
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(‘16.10.31 기준)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        448.0771484375,
        97.6932373046875,
        535.4924926757812,
        113.21531677246094
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "번호",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.24463653564453,
        338.15045166015625,
        474.82269287109375,
        350.0794677734375
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "업체명",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.24463653564453,
        338.15045166015625,
        474.82269287109375,
        350.0794677734375
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품목허가번호",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.24463653564453,
        338.15045166015625,
        474.82269287109375,
        350.0794677734375
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "허가/신고일",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.24463653564453,
        338.15045166015625,
        474.82269287109375,
        350.0794677734375
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모델명",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.24463653564453,
        338.15045166015625,
        474.82269287109375,
        350.0794677734375
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        362.7236022949219,
        529.8701782226562,
        374.6526184082031
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "티메드(주)",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        362.7236022949219,
        529.8701782226562,
        374.6526184082031
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수허 16-200 호",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        362.7236022949219,
        529.8701782226562,
        374.6526184082031
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2016년 4월 1일",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        362.7236022949219,
        529.8701782226562,
        374.6526184082031
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "AggreGuide A-100 ADP Assay",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        362.7236022949219,
        529.8701782226562,
        374.6526184082031
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        388.61529541015625,
        503.3281555175781,
        400.5443115234375
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "티메드(주)",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        388.61529541015625,
        503.3281555175781,
        400.5443115234375
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수허 15-467 호",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        388.61529541015625,
        503.3281555175781,
        400.5443115234375
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2015년 2월 12일",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        388.61529541015625,
        503.3281555175781,
        400.5443115234375
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "AA assay cartridge",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        388.61529541015625,
        503.3281555175781,
        400.5443115234375
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        414.6268615722656,
        371.91845703125,
        426.5558776855469
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지멘스헬스케어(주)",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        414.6268615722656,
        371.91845703125,
        426.5558776855469
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수허 12-1743 호",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        414.6268615722656,
        371.91845703125,
        426.5558776855469
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2012년 12월 5일",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        414.6268615722656,
        371.91845703125,
        426.5558776855469
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Dade PFA Collagen/ADP Test",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        390.388427734375,
        406.59564208984375,
        529.3802490234375,
        418.524658203125
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Cartridge",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        439.20196533203125,
        422.5382385253906,
        480.5394592285156,
        434.4672546386719
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        440.5185852050781,
        513.96484375,
        452.4476013183594
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지멘스헬스케어(주)",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        440.5185852050781,
        513.96484375,
        452.4476013183594
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수허 12-1735 호",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        440.5185852050781,
        513.96484375,
        452.4476013183594
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2012년 12월 5일",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        440.5185852050781,
        513.96484375,
        452.4476013183594
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "INNOVANCE PFA P2Y",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        440.5185852050781,
        513.96484375,
        452.4476013183594
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        466.5301513671875,
        371.91845703125,
        478.45916748046875
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "지멘스헬스케어(주)",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        466.5301513671875,
        371.91845703125,
        478.45916748046875
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수허 12-1710 호",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        466.5301513671875,
        371.91845703125,
        478.45916748046875
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2012년 12월 4일",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        466.5301513671875,
        371.91845703125,
        478.45916748046875
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Dade PFA Collagen/EPI Test",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        393.266845703125,
        458.4989318847656,
        526.5017700195312,
        470.4279479980469
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Cartridge",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        439.20196533203125,
        474.5613708496094,
        480.5394592285156,
        486.4903869628906
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        492.4218444824219,
        506.3533630371094,
        504.3508605957031
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성원메디칼상사",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        492.4218444824219,
        506.3533630371094,
        504.3508605957031
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수허 13-1207 호",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        492.4218444824219,
        506.3533630371094,
        504.3508605957031
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2013년 7월 10일",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        492.4218444824219,
        506.3533630371094,
        504.3508605957031
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Epinephrine Reagent",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        492.4218444824219,
        506.3533630371094,
        504.3508605957031
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        515.5565185546875,
        518.9464721679688,
        527.4855346679688
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성원메디칼상사",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        515.5565185546875,
        518.9464721679688,
        527.4855346679688
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수허 13-1206 호",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        515.5565185546875,
        518.9464721679688,
        527.4855346679688
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2013년 7월 10일",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        515.5565185546875,
        518.9464721679688,
        527.4855346679688
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Arachidonic Acid Reagent",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        515.5565185546875,
        518.9464721679688,
        527.4855346679688
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "8",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        538.6912841796875,
        490.16217041015625,
        550.6203002929688
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성원메디칼상사",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        538.6912841796875,
        490.16217041015625,
        550.6203002929688
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수허 13-1205 호",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        538.6912841796875,
        490.16217041015625,
        550.6203002929688
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2013년 7월 10일",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        538.6912841796875,
        490.16217041015625,
        550.6203002929688
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ADP Reagent",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        538.6912841796875,
        490.16217041015625,
        550.6203002929688
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "9",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        561.8260498046875,
        498.9173889160156,
        573.7550048828125
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성원메디칼상사",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        561.8260498046875,
        498.9173889160156,
        573.7550048828125
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수허 13-1208 호",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        561.8260498046875,
        498.9173889160156,
        573.7550048828125
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2013년 7월 10일",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.04041290283203,
        561.8260498046875,
        498.9173889160156,
        573.7550048828125
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Collagen Reagent",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.04041290283203,
        561.8260498046875,
        498.9173889160156,
        573.7550048828125
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "10",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        70.64171600341797,
        587.8375244140625,
        374.43707275390625,
        599.7665405273438
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한국로슈진단(주)",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        70.64171600341797,
        587.8375244140625,
        374.43707275390625,
        599.7665405273438
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수허 12-2234 호",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        70.64171600341797,
        587.8375244140625,
        374.43707275390625,
        599.7665405273438
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2012년 12월 27일",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        70.64171600341797,
        587.8375244140625,
        374.43707275390625,
        599.7665405273438
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Roche Prostagladin E1",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        409.0982666015625,
        579.806396484375,
        510.60369873046875,
        591.7353515625
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Reagent",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        442.4402160644531,
        595.8687744140625,
        477.3291320800781,
        607.7977905273438
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "11",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        70.64171600341797,
        613.84912109375,
        495.91888427734375,
        625.7781372070312
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한국로슈진단(주)",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        70.64171600341797,
        613.84912109375,
        495.91888427734375,
        625.7781372070312
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수허 12-2232 호",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        70.64171600341797,
        613.84912109375,
        495.91888427734375,
        625.7781372070312
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2012년 12월 27일",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        70.64171600341797,
        613.84912109375,
        495.91888427734375,
        625.7781372070312
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Roche TRAPtest",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        70.64171600341797,
        613.84912109375,
        495.91888427734375,
        625.7781372070312
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "12",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        70.64171600341797,
        636.98388671875,
        493.280029296875,
        648.912841796875
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한국로슈진단(주)",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        70.64171600341797,
        636.98388671875,
        493.280029296875,
        648.912841796875
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수허 12-2213 호",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        70.64171600341797,
        636.98388671875,
        493.280029296875,
        648.912841796875
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2012년 12월 27일",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        70.64171600341797,
        636.98388671875,
        493.280029296875,
        648.912841796875
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Roche COLtest",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        70.64171600341797,
        636.98388671875,
        493.280029296875,
        648.912841796875
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "13",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        70.64171600341797,
        660.1185302734375,
        493.87939453125,
        672.0475463867188
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한국로슈진단(주)",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        70.64171600341797,
        660.1185302734375,
        493.87939453125,
        672.0475463867188
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수허 12-2058 호",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        70.64171600341797,
        660.1185302734375,
        493.87939453125,
        672.0475463867188
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2012년 12월 21일",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        70.64171600341797,
        660.1185302734375,
        493.87939453125,
        672.0475463867188
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Roche ASPItest",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        70.64171600341797,
        660.1185302734375,
        493.87939453125,
        672.0475463867188
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "14",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        70.64171600341797,
        683.2532958984375,
        493.51995849609375,
        695.1823120117188
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한국로슈진단(주)",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        70.64171600341797,
        683.2532958984375,
        493.51995849609375,
        695.1823120117188
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수허 12-1932 호",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        70.64171600341797,
        683.2532958984375,
        493.51995849609375,
        695.1823120117188
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2012년 12월 13일",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        70.64171600341797,
        683.2532958984375,
        493.51995849609375,
        695.1823120117188
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Roche ADPtest",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        70.64171600341797,
        683.2532958984375,
        493.51995849609375,
        695.1823120117188
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "15",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        70.64171600341797,
        706.3880615234375,
        511.2700500488281,
        718.3170166015625
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백두대",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        70.64171600341797,
        706.3880615234375,
        511.2700500488281,
        718.3170166015625
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수허 12-1648 호",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        70.64171600341797,
        706.3880615234375,
        511.2700500488281,
        718.3170166015625
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2012년 11월 26일",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        70.64171600341797,
        706.3880615234375,
        511.2700500488281,
        718.3170166015625
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "VerifyNow P2Y12 Test",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        70.64171600341797,
        706.3880615234375,
        511.2700500488281,
        718.3170166015625
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "16",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        70.64171600341797,
        729.522705078125,
        514.2679443359375,
        741.4517211914062
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "백두대",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        70.64171600341797,
        729.522705078125,
        514.2679443359375,
        741.4517211914062
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수허 12-1652 호",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        70.64171600341797,
        729.522705078125,
        514.2679443359375,
        741.4517211914062
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2012년 11월 27일",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        70.64171600341797,
        729.522705078125,
        514.2679443359375,
        741.4517211914062
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "VerifyNow Aspirin Test",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        70.64171600341797,
        729.522705078125,
        514.2679443359375,
        741.4517211914062
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[표 2] 국내업체 혈소판 기능검사 시약 허가사항",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        157.7145233154297,
        285.0484619140625,
        437.16217041015625,
        300.570556640625
      ],
      "page_num": 15,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(‘16.10.31 기준)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        448.0771484375,
        311.06005859375,
        535.4924926757812,
        326.5821533203125
      ],
      "page_num": 15,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 9 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        281.24755859375,
        788.5885009765625,
        313.6467590332031,
        798.5376586914062
      ],
      "page_num": 16,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 국외 허가동향",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        68.5650634765625,
        184.81982421875,
        86.53043365478516
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 혈소판 기능검사는 전혈이 주로 검체로 사용되기 때문에 표준물질",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        98.53231811523438,
        538.268310546875,
        116.49768829345703
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개발이 어려워 제품 개발 및 시험 자체가 어려운 특성이 있다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        88.75189971923828,
        128.49957275390625,
        506.8453063964844,
        146.46493530273438
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2) 혈소판 기능검사를 평가를 위한 기준을 제시하는 국제규격 및 가이드",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.565547943115234,
        158.46681213378906,
        538.1483154296875,
        176.4321746826172
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "라인이 없는 상태이다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        89.47151184082031,
        188.43406677246094,
        232.6739044189453,
        206.39942932128906
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        64.0452880859375,
        218.4013214111328,
        538.1483154296875,
        236.36668395996094
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "침습적",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        64.0452880859375,
        218.4013214111328,
        538.1483154296875,
        236.36668395996094
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방식의",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        64.0452880859375,
        218.4013214111328,
        538.1483154296875,
        236.36668395996094
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "출혈시간(Bleeding",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        64.0452880859375,
        218.4013214111328,
        538.1483154296875,
        236.36668395996094
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "time,",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        64.0452880859375,
        218.4013214111328,
        538.1483154296875,
        236.36668395996094
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "BT)검사",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        64.0452880859375,
        218.4013214111328,
        538.1483154296875,
        236.36668395996094
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이후",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        64.0452880859375,
        218.4013214111328,
        538.1483154296875,
        236.36668395996094
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "독일",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        64.0452880859375,
        218.4013214111328,
        538.1483154296875,
        236.36668395996094
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Siemens사의 PFA-100과 ITC사의 VerifyNow를 통해 혈소판 기능을",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        96.1878662109375,
        248.3685760498047,
        538.268310546875,
        266.3339538574219
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자동 검사법과 항혈소판제제 저항성 검사법이 시장을 확대하며",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        96.1878662109375,
        278.3358459472656,
        538.268310546875,
        296.30120849609375
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용되고 있다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        96.1878662109375,
        308.3030700683594,
        197.29307556152344,
        326.2684326171875
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4) 혈소판 기능검사를 위한 검사법은 지속적으로 개발 및 발전하고",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        338.27032470703125,
        538.268310546875,
        356.2356872558594
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있으며 검사를 위한 작용원리 또한 Closure time(혈소판 작용으로",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        90.5509262084961,
        368.2375793457031,
        538.268310546875,
        386.20294189453125
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈액이 미세구멍을 막는 시간 측정), 광투과량 측정방식, 전기 임피던스",
      "font_size": 14.987749099731445,
      "font_name": "T17",
      "bbox": [
        90.5509262084961,
        398.204833984375,
        538.1483154296875,
        416.1701965332031
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정방식, 입사광산란 파악방식 등으로 업체의 개발 기술에 따라 다양",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        90.5509262084961,
        428.1720886230469,
        538.1483154296875,
        446.137451171875
      ],
      "page_num": 16,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하게 적용되고 있다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        90.5509262084961,
        458.13934326171875,
        225.23793029785156,
        476.1047058105469
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[그림 5] 혈소판 기능검사 및 항혈소판제제 저항성 검사기기",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        123.05330657958984,
        514.4777221679688,
        471.7034606933594,
        529.9998168945312
      ],
      "page_num": 16,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 10 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 17,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4. 출혈시간 및 항혈소판제제 저항성 복합검사기기 관련 국내외 규격",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        51.57204818725586,
        76.45640563964844,
        500.1285705566406,
        92.39897918701172
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "출혈시간 및 항혈소판제제 저항성 복합검사기기에 대한 국제규격이 부재",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        70.52178192138672,
        128.0200958251953,
        538.1483154296875,
        145.98545837402344
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여 체외진단 장비에 대한 안전성과 해당 시약에 대한 성능 및 안정성에",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        157.98733520507812,
        538.1483154296875,
        175.95269775390625
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대해 적용이 가능한 규격을 아래와 같이 제시하였다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        187.95458984375,
        391.22796630859375,
        205.91995239257812
      ],
      "page_num": 17,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "번호",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.96424865722656,
        247.28976440429688,
        424.0902099609375,
        259.2187805175781
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전성 평가 항목",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.96424865722656,
        247.28976440429688,
        424.0902099609375,
        259.2187805175781
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관련 표준 또는 적용 규격",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.96424865722656,
        247.28976440429688,
        424.0902099609375,
        259.2187805175781
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        310.8203125,
        78.71742248535156,
        322.74932861328125
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전기·기계적",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        115.25753021240234,
        302.7890930175781,
        167.5496063232422,
        314.7280578613281
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전에 관한 시험",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        102.54442596435547,
        318.8515319824219,
        180.26226806640625,
        330.7805480957031
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-「의료기기의 전기·기계적 안전에 관한 공통기준규격」",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        194.77444458007812,
        262.8727111816406,
        443.87945556640625,
        274.8116760253906
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- IEC 61010-1 Safety requirements for electrical equipment for",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        194.77444458007812,
        278.8153076171875,
        480.1838073730469,
        290.74432373046875
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "measurement, control, and laboratory use – Part 1: General",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        204.84898376464844,
        294.87774658203125,
        481.4371032714844,
        306.81671142578125
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "requirements",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        204.84898376464844,
        310.8203125,
        262.071044921875,
        322.74932861328125
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- IEC 61010-2-101 Safety requirements for electrical equipment for",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        194.77444458007812,
        326.7629089355469,
        497.93414306640625,
        338.6919250488281
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "measurement, control and laboratory use – Part 2-101: Particular",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        204.84898376464844,
        342.8253479003906,
        505.1306457519531,
        354.7643127441406
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "requirements for in vitro diagnostic (IVD) medical equipment",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        204.84898376464844,
        358.7679138183594,
        486.56488037109375,
        370.6969299316406
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        412.9486999511719,
        78.71742248535156,
        424.8777160644531
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전자파",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        126.77129364013672,
        404.91748046875,
        156.03543090820312,
        416.84649658203125
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전에 관한 시험",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        102.54442596435547,
        420.97991943359375,
        180.26226806640625,
        432.908935546875
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-「의료기기의 전자파안전에 관한 공통기준규격」",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        194.77444458007812,
        373.0323181152344,
        416.05450439453125,
        384.9712829589844
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- IEC 61326-1 Electrical equipment for measurement, control and",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        194.77444458007812,
        388.97491455078125,
        493.35784912109375,
        400.9039306640625
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "laboratory use – EMC requirements – Part 1: General requirements",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        204.84898376464844,
        404.91748046875,
        522.2105102539062,
        416.8564453125
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- IEC 61326-2-6 Electrical equipment for measurement, control and",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        194.77444458007812,
        420.97991943359375,
        501.39447021484375,
        432.908935546875
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "laboratory use – EMC requirements – Part 2-6: Particular",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        204.84898376464844,
        436.9225158691406,
        476.5867004394531,
        448.8614807128906
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "requirements – In vitro diagnostic (IVD) medical equipment",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        204.84898376464844,
        452.8650817871094,
        484.2841491699219,
        464.8040466308594
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[표 3] 출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성 관련 시험 규격",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        84.43424224853516,
        221.03843688964844,
        512.9618530273438,
        236.5605010986328
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "번호",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.96424865722656,
        501.8915100097656,
        489.93450927734375,
        513.8204956054688
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "규격 번호",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.96424865722656,
        501.8915100097656,
        489.93450927734375,
        513.8204956054688
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제목",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.96424865722656,
        501.8915100097656,
        489.93450927734375,
        513.8204956054688
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내용",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.96424865722656,
        501.8915100097656,
        489.93450927734375,
        513.8204956054688
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        516.3956298828125,
        404.2883605957031,
        542.2294311523438
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CLSI EP05",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        516.3956298828125,
        404.2883605957031,
        542.2294311523438
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Evaluation of Precision of Quantitative Measurement",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        516.3956298828125,
        404.2883605957031,
        542.2294311523438
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Methods; Approved Guideline",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        516.3956298828125,
        404.2883605957031,
        542.2294311523438
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정밀도 평가방법에",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        438.96209716796875,
        516.3956298828125,
        521.4777221679688,
        528.3246459960938
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한 기준 가이드라인",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        431.64605712890625,
        530.3004150390625,
        528.673828125,
        542.2294311523438
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        557.151123046875,
        149.5994873046875,
        569.080078125
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CLSI EP06",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        557.151123046875,
        149.5994873046875,
        569.080078125
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Evaluation of the Linearity of Quantitative",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        163.71127319335938,
        543.12646484375,
        387.09881591796875,
        582.9849243164062
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Measurement Procedures; A Statistical Approach;",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        163.71127319335938,
        543.12646484375,
        387.09881591796875,
        582.9849243164062
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Approved Guideline",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        163.71127319335938,
        543.12646484375,
        387.09881591796875,
        582.9849243164062
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "직선성 평가방법에",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        438.96209716796875,
        550.078857421875,
        521.4777221679688,
        562.0078125
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한 기준 가이드라인",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        431.64605712890625,
        564.103515625,
        528.673828125,
        576.0325317382812
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        583.8819580078125,
        404.72607421875,
        609.8355712890625
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CLSI EP07",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        583.8819580078125,
        404.72607421875,
        609.8355712890625
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Interference Testing in Clinical Chemistry; Approved",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        583.8819580078125,
        404.72607421875,
        609.8355712890625
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Guideline",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        583.8819580078125,
        404.72607421875,
        609.8355712890625
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "간섭물질 반응에 대한",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        431.64605712890625,
        583.8819580078125,
        528.6734008789062,
        595.8109130859375
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기준 가이드라인",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        443.7594909667969,
        597.9066162109375,
        516.5608520507812,
        609.8355712890625
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        610.7325439453125,
        416.91192626953125,
        629.6139526367188
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CLSI EP17",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        610.7325439453125,
        416.91192626953125,
        629.6139526367188
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Evaluation",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        610.7325439453125,
        416.91192626953125,
        629.6139526367188
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "of",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        610.7325439453125,
        416.91192626953125,
        629.6139526367188
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Detection",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        610.7325439453125,
        416.91192626953125,
        629.6139526367188
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Capability",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        610.7325439453125,
        416.91192626953125,
        629.6139526367188
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "for",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        610.7325439453125,
        416.91192626953125,
        629.6139526367188
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Clinical",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        610.7325439453125,
        416.91192626953125,
        629.6139526367188
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Laboratory Measurement Procedures",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        163.71127319335938,
        624.6373291015625,
        328.6346435546875,
        636.5663452148438
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검출한계 평가방법에",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        431.64605712890625,
        610.7325439453125,
        528.673828125,
        636.5663452148438
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한 기준 가이드라인",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        431.64605712890625,
        610.7325439453125,
        528.673828125,
        636.5663452148438
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        637.46337890625,
        416.8812561035156,
        656.464599609375
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CLSI EP12",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        637.46337890625,
        416.8812561035156,
        656.464599609375
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "User",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        637.46337890625,
        416.8812561035156,
        656.464599609375
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Protocol",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        637.46337890625,
        416.8812561035156,
        656.464599609375
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "for",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        637.46337890625,
        416.8812561035156,
        656.464599609375
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Evaluation",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        637.46337890625,
        416.8812561035156,
        656.464599609375
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "of",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        637.46337890625,
        416.8812561035156,
        656.464599609375
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Qualitative",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        637.46337890625,
        416.8812561035156,
        656.464599609375
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Test",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        637.46337890625,
        416.8812561035156,
        656.464599609375
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Performance; Approved Guideline",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        163.71127319335938,
        651.488037109375,
        317.4306335449219,
        663.4169921875
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "판정기준치 평가방법에",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        429.2473449707031,
        637.46337890625,
        531.072998046875,
        649.392333984375
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한 가이드라인",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        443.7594909667969,
        651.488037109375,
        516.5608520507812,
        663.4169921875
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[표 4] 출혈시간 및 항혈소판제제 저항성 복합검사기기 성능 관련 시험 규격",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        90.43099212646484,
        476.958740234375,
        507.2049865722656,
        492.4808349609375
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "번호",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.72438049316406,
        699.0760498046875,
        426.12908935546875,
        711.0050048828125
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안전성 평가 항목",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.72438049316406,
        699.0760498046875,
        426.12908935546875,
        711.0050048828125
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관련 표준 또는 적용 규격",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        65.72438049316406,
        699.0760498046875,
        426.12908935546875,
        711.0050048828125
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        73.52015686035156,
        724.368408203125,
        169.46815490722656,
        744.208740234375
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개봉 전/후",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        73.52015686035156,
        724.368408203125,
        169.46815490722656,
        744.208740234375
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "안정성 평가",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        117.89610290527344,
        740.3109130859375,
        171.3870849609375,
        752.2399291992188
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-「의료기기의 안정성시험 기준」",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        201.7306671142578,
        716.337158203125,
        350.33013916015625,
        728.2760620117188
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- ISO 23640 In vitro diagnostic medical devices – Evaluation of",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        201.7306671142578,
        732.27978515625,
        500.0754699707031,
        744.2186889648438
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "stability of in vitro diagnostic reagents",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        211.68527221679688,
        748.3421630859375,
        388.9626159667969,
        760.2711791992188
      ],
      "page_num": 17,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[표 5] 출혈시간 및 항혈소판제제 저항성 복합검사기기 안정성 관련 시험 규격",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        82.9950180053711,
        674.0233764648438,
        511.52264404296875,
        689.5454711914062
      ],
      "page_num": 17,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 11 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 18,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5. 안전성 평가 항목",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        51.57204818725586,
        76.45640563964844,
        208.68690490722656,
        92.39897918701172
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 전기",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        122.985595703125,
        112.97876739501953,
        140.95095825195312
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기계적 안전성 시험",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        121.25428009033203,
        122.985595703125,
        257.620361328125,
        140.95095825195312
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 관련 규격",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        152.95285034179688,
        153.87661743164062,
        170.918212890625
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(가) 「의료기기의 전기",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        70.64171600341797,
        182.9200897216797,
        222.599365234375,
        200.9004364013672
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기계적 안전에 관한 공통기준규격」(식품의약품",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        228.71604919433594,
        182.9200897216797,
        538.1483154296875,
        200.9004364013672
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "안전처고시)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        104.46338653564453,
        212.88734436035156,
        179.7226104736328,
        230.8527069091797
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(나) IEC 61010-1: 2010 Safety requirements for electrical equipment",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        242.85459899902344,
        538.2083129882812,
        260.8199768066406
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "for measurement, control, and laboratory use–Part 1: General",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.7437744140625,
        272.8218688964844,
        538.1932983398438,
        290.8022155761719
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "requirements",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.7437744140625,
        302.78912353515625,
        189.6022491455078,
        320.7544860839844
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(다)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        332.75634765625,
        538.1932983398438,
        350.7217102050781
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "IEC",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        332.75634765625,
        538.1932983398438,
        350.7217102050781
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "61010-2-101:",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        332.75634765625,
        538.1932983398438,
        350.7217102050781
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2015",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        332.75634765625,
        538.1932983398438,
        350.7217102050781
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Safety",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        332.75634765625,
        538.1932983398438,
        350.7217102050781
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "requirements",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        332.75634765625,
        538.1932983398438,
        350.7217102050781
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "for",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        332.75634765625,
        538.1932983398438,
        350.7217102050781
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "electrical",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        332.75634765625,
        538.1932983398438,
        350.7217102050781
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "equipment for measurement, control and laboratory use–Part 2–101:",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        111.05980682373047,
        362.7236022949219,
        538.1483154296875,
        380.7039489746094
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Particular",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        111.05980682373047,
        392.69085693359375,
        538.2083129882812,
        410.6562194824219
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "requirements",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        111.05980682373047,
        392.69085693359375,
        538.2083129882812,
        410.6562194824219
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "for",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        111.05980682373047,
        392.69085693359375,
        538.2083129882812,
        410.6562194824219
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "in",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        111.05980682373047,
        392.69085693359375,
        538.2083129882812,
        410.6562194824219
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "vitro",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        111.05980682373047,
        392.69085693359375,
        538.2083129882812,
        410.6562194824219
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "diagnostic",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        111.05980682373047,
        392.69085693359375,
        538.2083129882812,
        410.6562194824219
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(IVD)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        111.05980682373047,
        392.69085693359375,
        538.2083129882812,
        410.6562194824219
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "medical equipment",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        111.05980682373047,
        422.6581115722656,
        242.8083953857422,
        440.62347412109375
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 적용 범위 : 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        452.6253662109375,
        538.268310546875,
        470.5907287597656
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용되는 체외진단용 분석기기에 적용한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        88.99176788330078,
        482.5926208496094,
        373.357666015625,
        500.5579833984375
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 시험 목적 : 제조자가 채택한 구조의 설계와 방법이 조작자와 주위에",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.68548583984375,
        512.559814453125,
        538.1483154296875,
        530.5252075195312
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대하여 전기",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        88.27215576171875,
        542.527099609375,
        161.192626953125,
        560.4924926757812
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기계적으로 적절하게 보호를 하고 있다는 것을 보증함에 있다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        165.5102996826172,
        542.527099609375,
        536.1094360351562,
        560.4924926757812
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4) 시험 항목",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.68548583984375,
        572.4943237304688,
        151.35797119140625,
        590.459716796875
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(가) 전기충격에 대한 보호 : IEC 61010-1의 6절에 기술된 전기충격",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        602.4616088867188,
        538.1483154296875,
        620.427001953125
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보호시험에 관한 요구사항이 적용된다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        104.46338653564453,
        632.4288330078125,
        362.8033752441406,
        650.3942260742188
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(나) 기계적 위해요인에 대한 보호 : IEC 61010-1의 7절에 기술된 기계적",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        70.52178192138672,
        662.3960571289062,
        538.1483154296875,
        680.3614501953125
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "위해요인 보호시험에 관한 요구사항이 적용된다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.62384033203125,
        692.3633422851562,
        414.13555908203125,
        710.3287353515625
      ],
      "page_num": 18,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(다) 충격과 충돌에 대한 기계적 내성 : IEC 61010-1의 8절에 기술된",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        722.33056640625,
        538.268310546875,
        740.2959594726562
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "충격과 충돌에 대한 기계적 내성에 관한 요구사항이 적용된다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.62384033203125,
        752.2978515625,
        521.7172241210938,
        770.2632446289062
      ],
      "page_num": 18,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 12 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 19,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(라) 화재 확산 방지 : IEC 61010-1의 9절에 기술된 화재 확산 방지에",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        68.5650634765625,
        538.1483154296875,
        86.53043365478516
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관한 요구사항이 적용된다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        102.78429412841797,
        98.53231811523438,
        281.12762451171875,
        116.49768829345703
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(마) 기기 온도 한계치와 내열성 : IEC 61010-1의 10절에 기술된 온도",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        128.49957275390625,
        538.1483154296875,
        146.46493530273438
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한계치와 내열성 시험에 관한 요구사항이 적용된다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        102.90422821044922,
        158.46681213378906,
        448.3170166015625,
        176.4321746826172
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(바) 유체로 인한 위해요인 방지 : IEC 61010-1의 11절에 기술된 유체로",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        70.64171600341797,
        188.43406677246094,
        538.1483154296875,
        206.39942932128906
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인한 위해요인 방지시험에 관한 요구사항이 적용된다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        102.90422821044922,
        218.4013214111328,
        451.3153991699219,
        236.36668395996094
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(사) 유리가스, 폭발, 파열에 대한 보호 : IEC 61010-1의 13절에 기술된",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.00151824951172,
        248.3685760498047,
        538.268310546875,
        266.3339538574219
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가스, 폭발, 파열에 대한 보호시험에 관한 요구사항이 적용된다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.62384033203125,
        278.3358459472656,
        524.5956420898438,
        296.30120849609375
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(아) 구성요소 : IEC 61010-1의 14절에 기술된 구성요소에 관한 요구",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        308.3030700683594,
        538.1483154296875,
        326.2684326171875
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사항이 적용된다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.7437744140625,
        338.27032470703125,
        216.48268127441406,
        356.2356872558594
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(자) 연동 장치에 의한 보호 : IEC 61010-1의 15절에 기술된 연동 장치에",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        70.52178192138672,
        368.2375793457031,
        538.268310546875,
        386.20294189453125
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의한 보호에 관한 요구사항이 적용된다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.50390625,
        398.204833984375,
        358.245849609375,
        416.1701965332031
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(차) 시험 기기와 측정기기 : IEC 61010-1의 16절에 기술된 시험 기기",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        428.1720886230469,
        538.1483154296875,
        446.137451171875
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "측정기기에 관한 요구사항이 적용된다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.62384033203125,
        458.13934326171875,
        361.8439025878906,
        476.1047058105469
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 전자파 안전성 시험",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        504.1690368652344,
        219.12124633789062,
        522.1343994140625
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 관련 규격",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        534.13623046875,
        153.87661743164062,
        552.1016235351562
      ],
      "page_num": 19,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(가) 「의료기기의 전자파 안전에 관한 공통기준규격」(식품의약품안전처고시)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        564.103515625,
        533.0510864257812,
        582.0838623046875
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(나) IEC 61326-1: 2012 Electrical equipment for measurement, control and",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        69.68223571777344,
        594.0707397460938,
        538.163330078125,
        612.0361328125
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "laboratory use -",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        109.50065612792969,
        624.0380249023438,
        534.8950805664062,
        642.0183715820312
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "EMC requirements – Part 1: General requirements",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        109.50065612792969,
        624.0380249023438,
        534.8950805664062,
        642.0183715820312
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(다)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        654.0052490234375,
        538.1483154296875,
        671.9706420898438
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "IEC",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        654.0052490234375,
        538.1483154296875,
        671.9706420898438
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "61326-2-6:",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        654.0052490234375,
        538.1483154296875,
        671.9706420898438
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2012",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        654.0052490234375,
        538.1483154296875,
        671.9706420898438
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Electrical",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        654.0052490234375,
        538.1483154296875,
        671.9706420898438
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "equipment",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        654.0052490234375,
        538.1483154296875,
        671.9706420898438
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "for",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        654.0052490234375,
        538.1483154296875,
        671.9706420898438
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "measurement,",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        654.0052490234375,
        538.1483154296875,
        671.9706420898438
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "control and laboratory use – EMC requirements – Part 2-6:",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        107.82156372070312,
        683.9724731445312,
        538.1483154296875,
        701.9528198242188
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Particular requirements – In vitro diagnostic (IVD) medical",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        107.82156372070312,
        713.9397583007812,
        538.1932983398438,
        731.9201049804688
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "equipment",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        107.82156372070312,
        743.906982421875,
        177.68370056152344,
        761.8723754882812
      ],
      "page_num": 19,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 13 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 20,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2) 적용 범위 : 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        84.62751007080078,
        538.268310546875,
        102.59288024902344
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용되는 체외진단용 분석기기에 적용한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        88.99176788330078,
        114.59475708007812,
        370.2393493652344,
        132.56011962890625
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(3) 시험 목적 :",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        63.805419921875,
        144.56201171875,
        538.268310546875,
        162.52737426757812
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전자 의료기기에 전자파로 인한 전자파장해와 전자파",
      "font_size": 14.987749099731445,
      "font_name": "T17",
      "bbox": [
        63.805419921875,
        144.56201171875,
        538.268310546875,
        162.52737426757812
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내성으로부터 안전성을 보증함에 있다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        88.27215576171875,
        174.52926635742188,
        346.4922180175781,
        192.49462890625
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4) 시험 항목",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        204.49652099609375,
        153.87661743164062,
        222.46188354492188
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(가) 전자파내성 : IEC 61326에 기술된 전자파 내성시험에 관한 요구",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        234.46376037597656,
        538.1483154296875,
        252.4291229248047
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사항이 적용된다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.38397216796875,
        264.4310302734375,
        216.2427978515625,
        282.3963928222656
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 정전기방전(Electrostatic Discharge, ESD) 시험 : IEC 61000-4-2에",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        294.3982849121094,
        538.1483154296875,
        312.3786315917969
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기술된 정전기 방전시험에 관한 요구사항이 적용된다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        100.14572143554688,
        324.36553955078125,
        460.1905822753906,
        342.3309020996094
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 방사성 RF 전자기장 시험 : IEC 61000-4-3에 기술된 방사성 RF",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        78.31755065917969,
        354.3327941894531,
        538.1782836914062,
        372.3131408691406
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전자기장 시험에 관한 요구사항이 적용된다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        101.70487976074219,
        384.3000183105469,
        396.3851623535156,
        402.265380859375
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➂ 전기적 빠른 과도현상(Electrical Fast Transient, EFT)시험",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        414.26727294921875,
        482.1387023925781,
        432.2326354980469
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➃ 서지(Surge) 내성시험",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        444.2345275878906,
        241.90890502929688,
        462.19989013671875
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➄ 전도성 RF 전자기장 내성시험",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        474.2017822265625,
        300.0773620605469,
        492.1671447753906
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➅ 전원주파수 자기장 내성시험",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        504.1690368652344,
        289.6430358886719,
        522.1343994140625
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "➆ 전압강하, 순간정전 및 전압변동 시험",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        534.13623046875,
        351.4095458984375,
        552.1016235351562
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(나) 전자파방사 : IEC 61326에 기술된 전자파 방사시험에 관한 요구",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        580.0460815429688,
        538.1483154296875,
        598.011474609375
      ],
      "page_num": 20,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사항이 적용된다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.38397216796875,
        610.0133056640625,
        216.2427978515625,
        627.9786987304688
      ],
      "page_num": 20,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 14 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 21,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6. 분석적 성능 평가 항목",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        59.60769271850586,
        76.45640563964844,
        248.62525939941406,
        92.39897918701172
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 아래 제시하는 시험항목 등은 식약처장이 인정한 규격(KS, ISO 등)을 참고한 것으로, 관련 규격이",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        56.609317779541016,
        109.20393371582031,
        541.8330688476562,
        120.23188781738281
      ],
      "page_num": 21,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개정되거나 사안에 따라 변경될 수 있으며, 제품의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        73.16034698486328,
        126.70481872558594,
        484.2970886230469,
        137.73275756835938
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6.1 혈소판 기능검사키트에 대한 성능평가",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        142.1646270751953,
        347.6915588378906,
        160.12998962402344
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 분석적 민감도",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        63.805419921875,
        188.1943359375,
        188.53781127929688,
        206.15969848632812
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 검출한계(Limit of detection)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        218.1615753173828,
        278.6689758300781,
        236.12693786621094
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 관련 규격 : CLSI EP17-A2: Evaluation of Detection Capability",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        78.31755065917969,
        248.1288299560547,
        538.1782836914062,
        266.0942077636719
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "for Clinical Laboratory Measurement Procedures",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.983642578125,
        278.0960998535156,
        433.4300842285156,
        296.06146240234375
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 관련 규격을 적용할 수 없는 경우, 제조원에서 설정한 측정범위를",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        85.51365661621094,
        308.0633544921875,
        538.268310546875,
        326.043701171875
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증명하기 위한 평가방법 및 기준을 제시할 수 있다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        108.4212417602539,
        338.0306091308594,
        446.51800537109375,
        355.9959716796875
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        367.9978332519531,
        538.1483154296875,
        385.96319580078125
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "저항성 복합검사기기에 적용한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.62384033203125,
        397.965087890625,
        325.50360107421875,
        415.9304504394531
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 시험 목적 : 출혈시간 및 항혈소판제제 저항성 복합검사기기의",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.43749237060547,
        427.9323425292969,
        538.1483154296875,
        445.897705078125
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈소판 기능이상 측정이 가능한 최소/최대 이동거리를 평가",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        104.58332061767578,
        457.89959716796875,
        506.6054382324219,
        475.8649597167969
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4) 시험 조건",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        487.8668518066406,
        168.38873291015625,
        505.83221435546875
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 시험물질",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        85.51365661621094,
        517.8340454101562,
        156.27529907226562,
        535.7994384765625
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        92.8296890258789,
        547.8013305664062,
        538.268310546875,
        565.7667236328125
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체에 분석대상 물질을 일정량 첨가한 시험물질 사용한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        92.8296890258789,
        577.7685546875,
        468.8258972167969,
        595.7339477539062
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 시험장비",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        85.51365661621094,
        607.73583984375,
        156.27529907226562,
        625.7012329101562
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우",
      "font_size": 14.987749099731445,
      "font_name": "T17",
      "bbox": [
        92.8296890258789,
        637.7030639648438,
        538.268310546875,
        655.66845703125
      ],
      "page_num": 21,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2개 로트로 대체 가능)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        92.8296890258789,
        667.6703491210938,
        243.168212890625,
        685.6357421875
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 출혈시간 및 항혈소판제제 저항성 복합기기: 1대",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        85.51365661621094,
        697.6375732421875,
        421.571533203125,
        715.6029663085938
      ],
      "page_num": 21,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 15 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 22,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(5) 시험 방법 : 3.2% 구연산 처리된 전혈 검체에 분석 대상 물질",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        98.53231811523438,
        538.1483154296875,
        116.49768829345703
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(Agonist or Antagonist)을 일정량 첨가하여 공란한계(LoD)와",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        104.58332061767578,
        128.49957275390625,
        538.268310546875,
        146.46493530273438
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검출한계(LoD)에 해당하는 이동거리의 검체를 각각 4개 이상",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        104.58332061767578,
        158.46681213378906,
        538.268310546875,
        176.4321746826172
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "준비한다. 검출한계로 추정되는 이동거리 기점을 최소 3개 이상",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        104.58332061767578,
        188.43406677246094,
        538.268310546875,
        206.39942932128906
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정하고 낮은값 부터 3일 동안 검체 당 최소 60회 이상 반복",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        104.58332061767578,
        218.4013214111328,
        538.1483154296875,
        236.36668395996094
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "측정한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        104.58332061767578,
        248.3685760498047,
        168.268798828125,
        266.3339538574219
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(6) 결과제시 : 측정된 공란한계값과 검출한계값의 통계적 수치를 이용",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        278.3358459472656,
        538.268310546875,
        296.30120849609375
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여 최소이동거리를 제시한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.86370849609375,
        308.3030700683594,
        304.6348876953125,
        326.2684326171875
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 판정 기준치(Cut-off value)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        338.27032470703125,
        267.87481689453125,
        356.2356872558594
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 관련 규격 : CLSI EP12-A2; User Protocol for Evaluation of",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        78.31755065917969,
        368.2375793457031,
        538.2083129882812,
        386.20294189453125
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Qualitative Test Performance; Approved Guideline",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        105.78266906738281,
        398.204833984375,
        449.366455078125,
        416.1701965332031
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        428.1720886230469,
        538.1483154296875,
        446.137451171875
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "저항성 복합검사기기에 적용한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.62384033203125,
        458.13934326171875,
        325.50360107421875,
        476.1047058105469
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 시험 목적 : 혈소판 기능 이상의 양성, 음성의 판정 기준을 선정",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        488.1065979003906,
        538.1483154296875,
        506.07196044921875
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하기 위한 평가",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        103.02416229248047,
        518.0737915039062,
        205.32870483398438,
        536.0391845703125
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4) 시험 조건",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        548.0410766601562,
        168.38873291015625,
        566.0064697265625
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 시험물질",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        85.51365661621094,
        578.00830078125,
        156.27529907226562,
        595.9736938476562
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 사람의 전혈 검체",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        92.8296890258789,
        607.9755859375,
        538.268310546875,
        625.9409790039062
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 혈소판 기능 이상 검체를 각각 최소 50개 이상 사용한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        92.8296890258789,
        637.9428100585938,
        487.89556884765625,
        655.908203125
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 시험장비",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        85.51365661621094,
        667.9100341796875,
        156.27529907226562,
        685.8754272460938
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우",
      "font_size": 14.987749099731445,
      "font_name": "T17",
      "bbox": [
        92.8296890258789,
        697.8773193359375,
        538.268310546875,
        715.8427124023438
      ],
      "page_num": 22,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2개 로트로 대체 가능)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        92.8296890258789,
        727.8445434570312,
        243.168212890625,
        745.8099365234375
      ],
      "page_num": 22,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 16 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 23,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 출혈시간 및 항혈소판제제 저항성 복합기기: 1대",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        85.51365661621094,
        68.5650634765625,
        421.571533203125,
        86.53043365478516
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(5) 시험 방법",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        98.53231811523438,
        168.38873291015625,
        116.49768829345703
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 사람의 전혈 검체",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        85.51365661621094,
        128.49957275390625,
        538.268310546875,
        146.46493530273438
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 혈소판 기능 이상 검체를 각각 최소 50개 이상 준비한다. 각",
      "font_size": 14.987749099731445,
      "font_name": "T17",
      "bbox": [
        85.51365661621094,
        158.46681213378906,
        538.1483154296875,
        176.4321746826172
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검체에 대한 검사를 실시하여 검체에 대한 이동거리를 구한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        188.43406677246094,
        538.2682495117188,
        206.39942932128906
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체 당 5∼10회 이상 반복 측정한다. 정상 검체의 이동거리와",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        85.51365661621094,
        218.4013214111328,
        538.1483154296875,
        236.3816680908203
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈소판 기능 이상 검체 각각의 이동거리 값을 구한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        248.3685760498047,
        456.592529296875,
        266.3339538574219
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(6) 결과 제시",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        278.3358459472656,
        168.38873291015625,
        296.30120849609375
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정상 검체의 이동거리 구간과 혈소판 기능 이상 검체 이동거리 구간을",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        85.51365661621094,
        308.3030700683594,
        538.1483154296875,
        326.2684326171875
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확인 한 후 정상값과 비정상값의 통계치의 95% 신뢰구간을 구하여 두",
      "font_size": 14.987749099731445,
      "font_name": "T17",
      "bbox": [
        85.51365661621094,
        338.27032470703125,
        538.268310546875,
        356.2356872558594
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정거리 대해 일치되는 기준거리를 구한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        368.2375793457031,
        365.0821228027344,
        386.20294189453125
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 구해진 기준값에 대하여 임상적으로 확증할 수 있다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        398.204833984375,
        460.0706481933594,
        416.1851806640625
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 제품의 특성에 따라 판정기준치 제시는 선택이 가능하다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        428.1720886230469,
        489.2148742675781,
        446.1524353027344
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. 직선성/측정범위",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        458.13934326171875,
        192.97540283203125,
        476.1047058105469
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        488.1065979003906,
        538.08837890625,
        506.07196044921875
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관련",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        488.1065979003906,
        538.08837890625,
        506.07196044921875
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "규격",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        488.1065979003906,
        538.08837890625,
        506.07196044921875
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": ":",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        488.1065979003906,
        538.08837890625,
        506.07196044921875
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "CLSI",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        488.1065979003906,
        538.08837890625,
        506.07196044921875
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "EP06-A:",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        488.1065979003906,
        538.08837890625,
        506.07196044921875
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Evaluation",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        488.1065979003906,
        538.08837890625,
        506.07196044921875
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "of",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        488.1065979003906,
        538.08837890625,
        506.07196044921875
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "the",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        488.1065979003906,
        538.08837890625,
        506.07196044921875
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Linearity",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        488.1065979003906,
        538.08837890625,
        506.07196044921875
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "of",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        488.1065979003906,
        538.08837890625,
        506.07196044921875
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Quantitative Measurement Procedures; A Statistical Approach;",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        101.1052017211914,
        518.0737915039062,
        538.1483154296875,
        536.0391845703125
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Approved Guideline",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        101.1052017211914,
        548.0410766601562,
        238.76060485839844,
        566.0064697265625
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 관련 규격을 적용할 수 없는 경우, 제조원에서 설정한 측정범위를",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        578.00830078125,
        538.1483154296875,
        595.9886474609375
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증명하기 위한 평가방법 및 기준을 제시할 수 있다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        101.46501159667969,
        607.9755859375,
        443.3996887207031,
        625.9409790039062
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        637.9428100585938,
        538.268310546875,
        655.908203125
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "저항성 복합검사기기에 적용한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        97.14734649658203,
        667.9100341796875,
        319.027099609375,
        685.8754272460938
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 해당 성능항목은 적용하지 않는 경우, 그 사유를 제시하여 적용",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        697.8773193359375,
        538.1483154296875,
        715.857666015625
      ],
      "page_num": 23,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에서 제외될 수 있다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        101.46501159667969,
        727.8445434570312,
        243.34811401367188,
        745.8099365234375
      ],
      "page_num": 23,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 17 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 24,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(3) 시험 목적 : 출혈시간 및 항혈소판제제 저항성 복합검사기기의",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.24138641357422,
        98.53231811523438,
        538.268310546875,
        116.49768829345703
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈소판 기능이상 측정이 가능한 최소/최대 이동거리를 평가",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        98.22676086425781,
        128.49957275390625,
        500.2488708496094,
        146.46493530273438
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4) 시험 조건",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        158.46681213378906,
        161.07269287109375,
        176.4321746826172
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 시험물질",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        188.43406677246094,
        149.07919311523438,
        206.39942932128906
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        92.8296890258789,
        218.4013214111328,
        538.1483154296875,
        236.36668395996094
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전혈 검체에 분석대상 물질을 일정량 첨가한 시험물질 사용",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        92.8296890258789,
        248.3685760498047,
        493.1727294921875,
        266.3339538574219
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 시험장비",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        278.3358459472656,
        149.07919311523438,
        296.30120849609375
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우",
      "font_size": 14.987749099731445,
      "font_name": "T17",
      "bbox": [
        92.8296890258789,
        308.3030700683594,
        538.268310546875,
        326.2684326171875
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2개 로트로 대체 가능)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        92.8296890258789,
        338.27032470703125,
        243.168212890625,
        356.2356872558594
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 출혈시간 및 항혈소판제제 저항성 복합기기: 1대",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        368.2375793457031,
        414.37542724609375,
        386.20294189453125
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(5) 시험 방법",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        398.204833984375,
        161.07269287109375,
        416.1701965332031
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3.2%",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        78.31755065917969,
        428.1720886230469,
        538.1483154296875,
        446.137451171875
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "구연산",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        428.1720886230469,
        538.1483154296875,
        446.137451171875
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "처리된",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        428.1720886230469,
        538.1483154296875,
        446.137451171875
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전혈",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        428.1720886230469,
        538.1483154296875,
        446.137451171875
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검체에",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        428.1720886230469,
        538.1483154296875,
        446.137451171875
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분석대상물질(Agonist",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        78.31755065917969,
        428.1720886230469,
        538.1483154296875,
        446.137451171875
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "또는",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        428.1720886230469,
        538.1483154296875,
        446.137451171875
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Antagonist)을 일정량 첨가하여 준비한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        78.31755065917969,
        458.13934326171875,
        354.5278625488281,
        476.1047058105469
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검출한계로 추정되는 최소 검출 한계 이동거리 값을 기점을 최소 3개",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        488.1065979003906,
        538.1483154296875,
        506.07196044921875
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이상 정하고 낮은 값부터 3∼5일 동안 검체 당 5∼10회 이상 반복 측",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        518.0737915039062,
        538.1483154296875,
        536.0541381835938
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        78.31755065917969,
        548.0410766601562,
        124.7323989868164,
        566.0064697265625
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "측정된",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        578.00830078125,
        538.1483154296875,
        595.9736938476562
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "최소",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        578.00830078125,
        538.1483154296875,
        595.9736938476562
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이동거리값을",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        578.00830078125,
        538.1483154296875,
        595.9736938476562
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기준으로",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        578.00830078125,
        538.1483154296875,
        595.9736938476562
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석대상물질(Agonist",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        78.31755065917969,
        578.00830078125,
        538.1483154296875,
        595.9736938476562
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        578.00830078125,
        538.1483154296875,
        595.9736938476562
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Antagonist)을 일정한 비율로 첨가하여 직선성을 보이는 구간을 구",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        607.9755859375,
        538.1483154296875,
        625.9409790039062
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        78.31755065917969,
        637.9428100585938,
        111.17974853515625,
        655.908203125
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(6) 결과제시 : 각 측정값에 대한 직선성을 직선회귀분석을 통해 평가",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        667.9100341796875,
        538.268310546875,
        685.8754272460938
      ],
      "page_num": 24,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여 R2값을 제시한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        95.58819580078125,
        697.8773193359375,
        247.06610107421875,
        715.8427124023438
      ],
      "page_num": 24,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 18 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 25,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 분석적 특이도(간섭물질)",
      "font_size": 14.987749099731445,
      "font_name": "T4",
      "bbox": [
        63.805419921875,
        98.53231811523438,
        259.71923828125,
        116.49768829345703
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 관련 규격 : CLSI EP07 Interference Testing in Clinical Chemistry",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        128.49957275390625,
        538.1782836914062,
        146.46493530273438
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Approved Guideline",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        95.46826171875,
        158.46681213378906,
        231.92431640625,
        176.4321746826172
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        188.43406677246094,
        538.1483154296875,
        206.39942932128906
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "저항성 복합검사기기에 적용한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        96.78754425048828,
        218.4013214111328,
        320.46630859375,
        236.36668395996094
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 시험 목적 : 결과에 영향을 주는 간섭물질을 확인하기 위한 시험",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        248.3685760498047,
        528.1937255859375,
        266.3339538574219
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4) 시험 조건",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        278.3358459472656,
        161.07269287109375,
        296.30120849609375
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 시험물질",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        308.3030700683594,
        149.07919311523438,
        326.2684326171875
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        85.51365661621094,
        338.27032470703125,
        538.1483154296875,
        356.2356872558594
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전혈 검체에 분석대상 물질을 일정량 첨가한 시험물질 사용한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        368.2375793457031,
        521.9570922851562,
        386.20294189453125
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 시험장비",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        398.204833984375,
        149.07919311523438,
        416.1701965332031
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우 2개",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        85.51365661621094,
        428.1720886230469,
        538.1483154296875,
        446.137451171875
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "로트로 대체 가능)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        458.13934326171875,
        200.83116149902344,
        476.1047058105469
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 출혈시간 및 항혈소판제제 저항성 복합기기: 1대",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        488.1065979003906,
        414.37542724609375,
        506.07196044921875
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 간섭반응물질",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        518.0737915039062,
        178.10348510742188,
        536.0391845703125
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "간섭물질은 내부 또는 외부 요인일 수 있고 측정법에 따라 다양하므로,",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        548.0410766601562,
        538.1483154296875,
        566.0064697265625
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사법에 따라 결과에 영향을 미칠 것으로 예측되는 다음과 같은 물질에",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        85.51365661621094,
        578.00830078125,
        538.1483154296875,
        595.9736938476562
      ],
      "page_num": 25,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대한 간섭 평가 시험을 고려한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        607.9755859375,
        291.3221130371094,
        625.9409790039062
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "간섭물질",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        112.019287109375,
        665.872314453125,
        381.99298095703125,
        677.80126953125
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        112.019287109375,
        665.872314453125,
        381.99298095703125,
        677.80126953125
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "외인성 물질",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        105.18299102783203,
        681.5751953125,
        508.40447998046875,
        693.504150390625
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일반의약품, 고혈압, 협심증, 심부전 등 심장질환 치료제 등",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        105.18299102783203,
        681.5751953125,
        508.40447998046875,
        693.504150390625
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "드물지 않게 볼 수 있는 특이",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        65.12470245361328,
        697.1580810546875,
        200.05157470703125,
        709.0870971679688
      ],
      "page_num": 25,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체에 포함된 물질",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        87.6724853515625,
        715.138427734375,
        177.50379943847656,
        727.0674438476562
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "용혈, 혈색소, 지방산과 지질(콜레스테롤, 트리글리세리드), 빌리루빈,",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        215.2833251953125,
        697.1580810546875,
        529.2232666015625,
        709.0870971679688
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이상 단백질 및 펨타이드 등",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        307.2734680175781,
        715.138427734375,
        437.1630859375,
        727.0674438476562
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[표 6] 간섭물질 예",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        247.30596923828125,
        641.1792602539062,
        350.80987548828125,
        656.7013549804688
      ],
      "page_num": 25,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 19 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 26,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(5) 시험 방법",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        98.53231811523438,
        161.07269287109375,
        116.49768829345703
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험할 간섭물질의 목록을 작성한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        78.31755065917969,
        128.49957275390625,
        322.0254821777344,
        146.46493530273438
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "준비된 동일 시료를 반으로 나누어 시험시료와 대조시료로 분리한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        78.31755065917969,
        158.46681213378906,
        535.3898315429688,
        176.4321746826172
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "간섭물질의 농도는 임상검체에서 보일 수 있는 최대 농도의 3배",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        188.43406677246094,
        538.268310546875,
        206.39942932128906
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상이 되도록 준비한 후 시험 시료에 첨가한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        78.31755065917969,
        218.4013214111328,
        411.7368469238281,
        236.36668395996094
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "간섭물질이 포함된 검체와 포함되지 않은 검체를 3회 이상 반복 측정한",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        248.3685760498047,
        538.1483154296875,
        266.3339538574219
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이동거리 값을 구한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        78.31755065917969,
        278.3358459472656,
        219.96078491210938,
        296.30120849609375
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과를",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        308.3030700683594,
        538.1483154296875,
        326.2684326171875
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비교한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        78.31755065917969,
        338.27032470703125,
        140.20401000976562,
        356.2356872558594
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(6) 결과 제시",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        368.2375793457031,
        161.07269287109375,
        386.20294189453125
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "각각의 검체 및 시약 로트 조합을 측정장비로 반복 측정한 샘플의",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        398.204833984375,
        538.1483154296875,
        416.1701965332031
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이동거리값의 평균 및 표준편차를 계산하고 시험시료 측정결과의",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        428.1720886230469,
        538.1483154296875,
        446.137451171875
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평균과 대조시료 측정결과 평균의 편차를 계산한다. 대조시료 대비",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        458.13934326171875,
        538.268310546875,
        476.1047058105469
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험결과의 차이를 구하여 제시한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        78.31755065917969,
        488.1065979003906,
        324.0643615722656,
        506.07196044921875
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 정밀도",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        63.805419921875,
        548.0410766601562,
        135.52655029296875,
        566.0064697265625
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 반복성",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        578.00830078125,
        133.24777221679688,
        595.9736938476562
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 관련 규격 : CLSI EP05-A3: Evaluation of Precision of Quantitative",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        78.31755065917969,
        607.9755859375,
        538.23828125,
        625.9409790039062
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Measurement Methods; Approved Guideline",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        102.54442596435547,
        637.9428100585938,
        391.4378356933594,
        655.908203125
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        667.9100341796875,
        538.1483154296875,
        685.8754272460938
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "저항성 복합검사기기에 적용한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.62384033203125,
        697.8773193359375,
        325.50360107421875,
        715.8427124023438
      ],
      "page_num": 26,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 시험 목적 : 동일한 검체에 대한 시험에서 일정한 결과값이 나오는지",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        727.8445434570312,
        538.1483154296875,
        745.8099365234375
      ],
      "page_num": 26,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 20 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 27,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인하는 시험",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        102.78429412841797,
        68.5650634765625,
        192.73553466796875,
        86.53043365478516
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(4) 시험 조건",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        98.53231811523438,
        168.38873291015625,
        116.49768829345703
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 시험물질",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        85.51365661621094,
        128.49957275390625,
        156.27529907226562,
        146.46493530273438
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        92.8296890258789,
        158.46681213378906,
        538.268310546875,
        176.4321746826172
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상 준비",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        92.8296890258789,
        188.43406677246094,
        538.268310546875,
        206.39942932128906
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여 시험한다. (컷오프 근처의 검체 포함)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        92.8296890258789,
        218.4013214111328,
        360.8244323730469,
        236.36668395996094
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 시험장비",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        85.51365661621094,
        248.3685760498047,
        156.27529907226562,
        266.3339538574219
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우",
      "font_size": 14.987749099731445,
      "font_name": "T17",
      "bbox": [
        92.8296890258789,
        278.3358459472656,
        538.268310546875,
        296.30120849609375
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2개 로트로 대체 가능)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        92.8296890258789,
        308.3030700683594,
        243.168212890625,
        326.2684326171875
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 출혈시간 및 항혈소판제제 저항성 복합기기: 1대",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        85.51365661621094,
        338.27032470703125,
        421.571533203125,
        356.2356872558594
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(5) 시험 방법",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        368.2375793457031,
        168.38873291015625,
        386.20294189453125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        85.51365661621094,
        398.204833984375,
        538.1483154296875,
        416.1701965332031
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상 준비",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        85.51365661621094,
        428.1720886230469,
        538.1483154296875,
        446.137451171875
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한다. 각 검체에 대해 20일간 1일 2회의 반복시험을 실시하여 검체에",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        85.51365661621094,
        458.13934326171875,
        538.1483154296875,
        476.1047058105469
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한 이동거리를 구한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        488.1065979003906,
        249.2249298095703,
        506.07196044921875
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(6) 결과 제시 : 검사 결과에 대한 변동계수값(%)값을 구한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        78.31755065917969,
        518.0737915039062,
        487.89556884765625,
        536.0391845703125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 재현성",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        578.00830078125,
        133.24777221679688,
        595.9736938476562
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 관련 규격 : CLSI EP05-A3: Evaluation of Precision of Quantitative",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        78.31755065917969,
        607.9755859375,
        538.23828125,
        625.9409790039062
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Measurement Methods; Approved Guideline",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        102.54442596435547,
        637.9428100585938,
        391.4378356933594,
        655.908203125
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        667.9100341796875,
        538.1483154296875,
        685.8754272460938
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "저항성 복합검사기기에 적용한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.62384033203125,
        697.8773193359375,
        325.50360107421875,
        715.8427124023438
      ],
      "page_num": 27,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 시험 목적 : 동일 검체를 로트, 사용자, 시험 사이트 간 반복",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        727.8445434570312,
        538.268310546875,
        745.8099365234375
      ],
      "page_num": 27,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 21 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 28,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정하여 재현성을 확인하는 시험",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        103.26403045654297,
        68.5650634765625,
        335.578125,
        86.53043365478516
      ],
      "page_num": 28,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(4) 시험 조건",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        98.53231811523438,
        168.38873291015625,
        116.49768829345703
      ],
      "page_num": 28,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 시험물질",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        85.51365661621094,
        128.49957275390625,
        156.27529907226562,
        146.46493530273438
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        92.8296890258789,
        158.46681213378906,
        538.1483154296875,
        176.4321746826172
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전혈 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        92.8296890258789,
        188.43406677246094,
        538.268310546875,
        206.39942932128906
      ],
      "page_num": 28,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "준비하여 시험한다. (컷오프 근처의 검체 포함)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        92.8296890258789,
        218.4013214111328,
        394.40625,
        236.36668395996094
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 시험장비",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        85.51365661621094,
        248.3685760498047,
        156.27529907226562,
        266.3339538574219
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우",
      "font_size": 14.987749099731445,
      "font_name": "T17",
      "bbox": [
        92.8296890258789,
        278.3358459472656,
        538.268310546875,
        296.30120849609375
      ],
      "page_num": 28,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2개 로트로 대체 가능)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        92.8296890258789,
        308.3030700683594,
        243.168212890625,
        326.2684326171875
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 출혈시간 및 항혈소판제제 저항성 복합기기: 1대",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        85.51365661621094,
        338.27032470703125,
        421.571533203125,
        356.2356872558594
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(5) 시험 방법",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        368.2375793457031,
        168.38873291015625,
        386.20294189453125
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        85.51365661621094,
        398.204833984375,
        538.1483154296875,
        416.1701965332031
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상 준비한다",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        85.51365661621094,
        428.1720886230469,
        536.2293701171875,
        446.137451171875
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "최소 3개의 로트의 시약을 이용하여 2곳 이상의 검사실 2명 이상의",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        85.51365661621094,
        458.13934326171875,
        538.1483154296875,
        476.1047058105469
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검사자로 정상 검체 및 혈소판 기능 이상 검체를 1회 시험 할 때",
      "font_size": 14.987749099731445,
      "font_name": "T17",
      "bbox": [
        85.51365661621094,
        488.1065979003906,
        538.1483154296875,
        506.07196044921875
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "마다 2회 이상 반복 측정을 1일에 2회 이상, 5일 이상 동안 실시한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        518.0737915039062,
        538.2682495117188,
        536.0391845703125
      ],
      "page_num": 28,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각 로트 별 검체에 대한 MD값의 평균, 표준편차, 변동계수를 구한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        548.0410766601562,
        535.6296997070312,
        566.0064697265625
      ],
      "page_num": 28,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(6) 결과 제시 : 로트간 정밀도, 시험기관간 정밀도, 시험자간 정밀도의",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        578.00830078125,
        538.1483154296875,
        595.9736938476562
      ],
      "page_num": 28,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변동계수값을 구한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        102.78429412841797,
        607.9755859375,
        240.22979736328125,
        625.9409790039062
      ],
      "page_num": 28,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라. 정확도",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        63.805419921875,
        667.9100341796875,
        135.52655029296875,
        685.8754272460938
      ],
      "page_num": 28,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표준물질이 부재 또는 기준장비가 명확하지 않은 경우 정확도에 대한",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        697.8773193359375,
        538.268310546875,
        715.8427124023438
      ],
      "page_num": 28,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성능평가항목을 제외한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        727.8445434570312,
        242.1487579345703,
        745.8099365234375
      ],
      "page_num": 28,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 22 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 29,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마. 교차반응",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        63.805419921875,
        98.53231811523438,
        150.75830078125,
        116.49768829345703
      ],
      "page_num": 29,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체에 대한 교차반응이 발생하지 않는 경우 교차반응에 대한 성능평가",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        128.49957275390625,
        538.268310546875,
        146.46493530273438
      ],
      "page_num": 29,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항목을 제외한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        158.46681213378906,
        180.38223266601562,
        176.4321746826172
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "바. 기준물질/보정물질",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        63.805419921875,
        218.4013214111328,
        216.12286376953125,
        236.36668395996094
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "출혈시간 및 항혈소판제제 저항성 복합검사기기에 대한 보정과 정도",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        248.3685760498047,
        538.1483154296875,
        266.3339538574219
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관리를 위한 기준물질 및 보정물질의 개발이 필요하다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        278.3358459472656,
        438.3624267578125,
        296.30120849609375
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "내부 대조물질은 해당 파장에 대한 기기적인 보정에 사용하기 위해",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        308.3030700683594,
        538.268310546875,
        326.2684326171875
      ],
      "page_num": 29,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제공할 수 있다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        338.27032470703125,
        176.54432678222656,
        356.2356872558594
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정도관리물질은 파장의 유사 수치를 나타낼 수 있는 임의의 물질",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        368.2375793457031,
        538.268310546875,
        386.20294189453125
      ],
      "page_num": 29,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(mimic)을 제조하여 제공 또는 각 검사실에서 설정하는 방법 등을",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        398.204833984375,
        538.1483154296875,
        416.1701965332031
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제시할 수 있다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        428.1720886230469,
        177.50379943847656,
        446.137451171875
      ],
      "page_num": 29,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 23 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 30,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7. 안정성 평가 항목",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        51.57204818725586,
        76.45640563964844,
        216.7222442626953,
        92.39897918701172
      ],
      "page_num": 30,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 개봉 전 안정성평가",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        133.05459594726562,
        211.44540405273438,
        151.01995849609375
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 관련 규격",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.445613861083984,
        163.02183532714844,
        149.67886352539062,
        180.98719787597656
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 「의료기기의 안정성시험 기준」(식약처 고시)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        70.40184783935547,
        192.9890899658203,
        383.2522888183594,
        210.9694366455078
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② ISO 23640 In vitro diagnostic medical devices – Evaluation of",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        70.40184783935547,
        222.9563446044922,
        538.08837890625,
        240.9366912841797
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "stability of in vitro diagnostic reagents",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        94.74864959716797,
        252.92359924316406,
        346.4772033691406,
        270.88897705078125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 적용 범위 : 혈소판 기능이상 검사 키트에 적용한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        63.445613861083984,
        282.890869140625,
        417.6136779785156,
        300.8562316894531
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 시험 목적 : 혈소판 기능이상 검사 키트가 특정 조건하에서 사용기간",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.445613861083984,
        312.85809326171875,
        538.1483154296875,
        330.8234558105469
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(유효기간) 동안 의료기기의 특성이나 성능이 제조자가 설정한 한계",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        87.6724853515625,
        342.8253479003906,
        538.268310546875,
        360.79071044921875
      ],
      "page_num": 30,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이내로 유지되는지 평가하기 위함",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        87.6724853515625,
        372.7926025390625,
        302.59600830078125,
        390.7579650878906
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4) 시험 조건",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.445613861083984,
        402.7598571777344,
        149.67886352539062,
        420.7252197265625
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 시험물질",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        70.40184783935547,
        432.72711181640625,
        138.1651153564453,
        450.6924743652344
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        77.2381362915039,
        462.6943664550781,
        538.1483154296875,
        480.65972900390625
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검체를 사용한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        77.2381362915039,
        492.66162109375,
        184.340087890625,
        510.6269836425781
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 시험장비",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        70.40184783935547,
        522.6288452148438,
        138.1651153564453,
        540.59423828125
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우 2개",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        77.2381362915039,
        552.5960693359375,
        538.268310546875,
        570.5614624023438
      ],
      "page_num": 30,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "로트로 대체 가능)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        77.2381362915039,
        582.5633544921875,
        192.55564880371094,
        600.5287475585938
      ],
      "page_num": 30,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 출혈시간 및 항혈소판제제 저항성 복합기기: 1대",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        70.40184783935547,
        612.5305786132812,
        389.78875732421875,
        630.4959716796875
      ],
      "page_num": 30,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가속노화시험의 기간에 따른 장기보존시험(실시간 안정성시험)을 병행한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        77.2381362915039,
        642.497802734375,
        536.948974609375,
        660.4631958007812
      ],
      "page_num": 30,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 24 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 31,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(5) 시험 방법",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.445613861083984,
        68.5650634765625,
        149.67886352539062,
        86.53043365478516
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가속노화시험의 간격, 온도, 시험기간을 설정한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        70.40184783935547,
        98.53231811523438,
        384.271728515625,
        116.49768829345703
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        70.40184783935547,
        128.49957275390625,
        538.268310546875,
        146.46493530273438
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체를 준비한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        70.40184783935547,
        158.46681213378906,
        178.70315551757812,
        176.4321746826172
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "각 로트 별로 검체에 대한 이동거리를 3회에 걸쳐 반복하여 측정한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        70.40184783935547,
        188.43406677246094,
        515.24072265625,
        206.39942932128906
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가속노화시험 개시 시점과 설정된 마지막 시점에 측정을 실시한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        70.40184783935547,
        218.4013214111328,
        494.6119384765625,
        236.36668395996094
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "측정된 각 시점의 샘플의 이동거리값의 평균 및 표준편차를 계산 한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        70.40184783935547,
        248.3685760498047,
        522.1969604492188,
        266.3339538574219
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(6) 결과 제시 : 가속노화 시작시점과 시험 마지막 시점 결과의 차이를 구한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        63.445613861083984,
        278.3358459472656,
        536.46923828125,
        296.30120849609375
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 개봉 후 안정성평가",
      "font_size": 14.987749099731445,
      "font_name": "T14",
      "bbox": [
        56.609317779541016,
        338.27032470703125,
        211.44540405273438,
        356.2356872558594
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 관련 규격",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.445613861083984,
        368.2375793457031,
        149.67886352539062,
        386.20294189453125
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 「의료기기의 안정성시험 기준」(식약처 고시)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        70.40184783935547,
        398.204833984375,
        383.2522888183594,
        416.1851806640625
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② ISO 23640 In vitro diagnostic medical devices – Evaluation of",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        70.40184783935547,
        428.1720886230469,
        538.08837890625,
        446.1524353027344
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "stability of in vitro diagnostic reagents",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        94.74864959716797,
        458.13934326171875,
        346.4772033691406,
        476.1047058105469
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 적용 범위 : 혈소판 기능검사키트에 적용한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        63.445613861083984,
        488.1065979003906,
        376.236083984375,
        506.07196044921875
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 시험 목적 : 혈소판 기능검사키트가 특정 조건하에서 사용 시 안정성을",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.445613861083984,
        518.0737915039062,
        538.1483154296875,
        536.0391845703125
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보기 위해 사용기간(유효기간) 동안 의료기기의 특성이나 성능이",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        87.6724853515625,
        548.0410766601562,
        538.1483154296875,
        566.0064697265625
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제조자가 설정한 한계 이내로 유지되는지 평가하기 위함",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        87.6724853515625,
        578.00830078125,
        469.42559814453125,
        595.9736938476562
      ],
      "page_num": 31,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4) 시험 조건",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.445613861083984,
        607.9755859375,
        149.67886352539062,
        625.9409790039062
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 시험물질",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        70.40184783935547,
        637.9428100585938,
        138.1651153564453,
        655.908203125
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        77.2381362915039,
        667.9100341796875,
        538.1483154296875,
        685.8754272460938
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체를 사용한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        77.2381362915039,
        697.8773193359375,
        184.340087890625,
        715.8427124023438
      ],
      "page_num": 31,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 25 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 32,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 시험장비",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        70.40184783935547,
        68.5650634765625,
        138.1651153564453,
        86.53043365478516
      ],
      "page_num": 32,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우 2개",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        70.40184783935547,
        98.53231811523438,
        538.1483154296875,
        116.49768829345703
      ],
      "page_num": 32,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "로트로 대체 가능)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        70.40184783935547,
        128.49957275390625,
        185.5994110107422,
        146.46493530273438
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 출혈시간 및 항혈소판제제 저항성 복합기기: 1대",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        70.40184783935547,
        158.46681213378906,
        389.78875732421875,
        176.4321746826172
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(5) 시험 방법",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.445613861083984,
        188.43406677246094,
        149.67886352539062,
        206.39942932128906
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        70.40184783935547,
        218.4013214111328,
        538.268310546875,
        236.36668395996094
      ],
      "page_num": 32,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체를 준비한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        70.40184783935547,
        248.3685760498047,
        178.70315551757812,
        266.3339538574219
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개봉 후 검체에 대한 이동거리를 3회에 걸쳐 반복하여 측정한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        70.40184783935547,
        278.3358459472656,
        480.81939697265625,
        296.30120849609375
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "측정된 이동거리의 평균을 구하여 비교대상으로 설정한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        70.40184783935547,
        308.3030700683594,
        439.44183349609375,
        326.2684326171875
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "설정된 3 포인트에서 차례로 이동거리를 3회에 걸쳐 측정한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        70.40184783935547,
        338.27032470703125,
        467.0268859863281,
        356.2356872558594
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개봉시점 및 각 포인트 별 샘플의 이동거리값의 평균 및 표준편차를 계산",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        70.40184783935547,
        368.2375793457031,
        538.268310546875,
        386.20294189453125
      ],
      "page_num": 32,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        70.40184783935547,
        398.204833984375,
        101.34507751464844,
        416.1701965332031
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(6) 결과 제시 : 개봉시점과 각 시점 간 시험결과의 차이를 구한다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        63.445613861083984,
        428.1720886230469,
        486.45635986328125,
        446.137451171875
      ],
      "page_num": 32,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 26 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 33,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "8. 참고 문헌",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        51.57204818725586,
        76.45640563964844,
        160.712890625,
        92.39897918701172
      ],
      "page_num": 33,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 의료기기 품목 및 품목별 등급에 관한 규정",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        133.29434204101562,
        330.7804260253906,
        148.81640625
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 체외진단용 의료기기 1, 2 등급 허가·심사 및 신고서 작성 가이드라인",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        156.06944274902344,
        470.9831848144531,
        171.60446166992188
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. IEC 61010-1 Safety requirements for electrical equipment for measurement,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        178.8445587158203,
        538.2421875,
        194.3666229248047
      ],
      "page_num": 33,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "control, and laboratory use – Part 1: General requirementsK.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        80.47638702392578,
        201.4998016357422,
        447.0906677246094,
        217.03482055664062
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        224.27490234375,
        538.21435546875,
        239.79696655273438
      ],
      "page_num": 33,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "IEC",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        224.27490234375,
        538.21435546875,
        239.79696655273438
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "61010-2-101",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        224.27490234375,
        538.21435546875,
        239.79696655273438
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Safety",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        224.27490234375,
        538.21435546875,
        239.79696655273438
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "requirements",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        224.27490234375,
        538.21435546875,
        239.79696655273438
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "for",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        224.27490234375,
        538.21435546875,
        239.79696655273438
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "electrical",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        224.27490234375,
        538.21435546875,
        239.79696655273438
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "equipment",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        224.27490234375,
        538.21435546875,
        239.79696655273438
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "for",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        224.27490234375,
        538.21435546875,
        239.79696655273438
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "measurement,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.51203155517578,
        247.0500030517578,
        538.2120971679688,
        262.58502197265625
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "control",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.51203155517578,
        247.0500030517578,
        538.2120971679688,
        262.58502197265625
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "and",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.51203155517578,
        247.0500030517578,
        538.2120971679688,
        262.58502197265625
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "laboratory",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.51203155517578,
        247.0500030517578,
        538.2120971679688,
        262.58502197265625
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "use",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.51203155517578,
        247.0500030517578,
        538.2120971679688,
        262.58502197265625
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "–",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        88.51203155517578,
        247.0500030517578,
        538.2120971679688,
        262.58502197265625
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Part",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.51203155517578,
        247.0500030517578,
        538.2120971679688,
        262.58502197265625
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2-101:",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.51203155517578,
        247.0500030517578,
        538.2120971679688,
        262.58502197265625
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Particular",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.51203155517578,
        247.0500030517578,
        538.2120971679688,
        262.58502197265625
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "requirements for in vitro diagnostic (IVD) medical equipment",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.51203155517578,
        269.7052307128906,
        454.1922302246094,
        285.2273254394531
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "마. IEC 61326-1 Electrical equipment for measurement, control and laboratory",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        292.4803466796875,
        538.1257934570312,
        308.00244140625
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "use – EMC requirements – Part 1: General requirements",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        80.95612335205078,
        315.2554626464844,
        428.73077392578125,
        330.7904968261719
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "바. IEC 61326-2-6 Electrical equipment for measurement, control and laboratory",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        337.91070556640625,
        538.2462768554688,
        353.43280029296875
      ],
      "page_num": 33,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "use – EMC requirements – Part 2-6: Particular requirements – In vitro",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        79.75677490234375,
        360.6858215332031,
        538.1453247070312,
        376.2208557128906
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "diagnostic (IVD) medical equipment",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        79.75677490234375,
        383.4609375,
        292.28125,
        398.9830322265625
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사. ISO 23640 In vitro diagnostic medical devices – Evaluation of stability of",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        406.1161804199219,
        538.1305541992188,
        421.6512145996094
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "in vitro diagnostic reagents",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        79.99664306640625,
        428.8912658691406,
        241.38967895507812,
        444.4133605957031
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아. CLSI EP17-A2: Evaluation of Detection Capability for Clinical Laboratory",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        451.6663818359375,
        538.1255493164062,
        467.1884765625
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Measurement Procedures",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.55580139160156,
        474.3216247558594,
        227.35983276367188,
        489.8437194824219
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자. CLSI EP12-A2; User Protocol for Evaluation of Qualitative Test Performance;",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        497.09674072265625,
        538.2426147460938,
        512.6188354492188
      ],
      "page_num": 33,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Approved Guideline",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        79.03716278076172,
        519.871826171875,
        198.4453125,
        535.3939208984375
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "차.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        542.527099609375,
        538.2670288085938,
        558.0491943359375
      ],
      "page_num": 33,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CLSI",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        542.527099609375,
        538.2670288085938,
        558.0491943359375
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "EP06-A:",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        542.527099609375,
        538.2670288085938,
        558.0491943359375
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Evaluation",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        542.527099609375,
        538.2670288085938,
        558.0491943359375
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        542.527099609375,
        538.2670288085938,
        558.0491943359375
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "the",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        542.527099609375,
        538.2670288085938,
        558.0491943359375
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Linearity",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        542.527099609375,
        538.2670288085938,
        558.0491943359375
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "of",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        542.527099609375,
        538.2670288085938,
        558.0491943359375
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Quantitative",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        542.527099609375,
        538.2670288085938,
        558.0491943359375
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Measurement",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        542.527099609375,
        538.2670288085938,
        558.0491943359375
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Procedures; A Statistical Approach; Approved Guideline",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        82.03553771972656,
        565.3021850585938,
        397.41876220703125,
        580.8242797851562
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "카. CLSI EP07: Interference Testing in Clinical Chemistry Approved Guideline",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        588.0773315429688,
        520.5921020507812,
        603.5994262695312
      ],
      "page_num": 33,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "타. CLSI EP05-A3: Evaluation of Precision of Quantitative Measurement Methods;",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        610.7325439453125,
        538.2445068359375,
        626.254638671875
      ],
      "page_num": 33,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Approved Guideline",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        79.876708984375,
        633.5076904296875,
        195.8094482421875,
        649.02978515625
      ],
      "page_num": 33,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "파.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        656.2827758789062,
        538.12060546875,
        671.8048706054688
      ],
      "page_num": 33,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Platelet",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        656.2827758789062,
        538.12060546875,
        671.8048706054688
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Aggregation",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        656.2827758789062,
        538.12060546875,
        671.8048706054688
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Devices",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        656.2827758789062,
        538.12060546875,
        671.8048706054688
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Market",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        656.2827758789062,
        538.12060546875,
        671.8048706054688
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "by",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        656.2827758789062,
        538.12060546875,
        671.8048706054688
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Product",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        656.2827758789062,
        538.12060546875,
        671.8048706054688
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(Systems,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        656.2827758789062,
        538.12060546875,
        671.8048706054688
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Reagents,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        656.2827758789062,
        538.12060546875,
        671.8048706054688
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Consumables,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        678.93798828125,
        538.24169921875,
        694.4600830078125
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Accessories),",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        678.93798828125,
        538.24169921875,
        694.4600830078125
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Application",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        678.93798828125,
        538.24169921875,
        694.4600830078125
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(Research,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        678.93798828125,
        538.24169921875,
        694.4600830078125
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Diagnostic,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        678.93798828125,
        538.24169921875,
        694.4600830078125
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "CVD,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        678.93798828125,
        538.24169921875,
        694.4600830078125
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Orthopedic,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        701.713134765625,
        538.1209716796875,
        717.2352294921875
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Trauma),",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        701.713134765625,
        538.1209716796875,
        717.2352294921875
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "End",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        701.713134765625,
        538.1209716796875,
        717.2352294921875
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "User",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        701.713134765625,
        538.1209716796875,
        717.2352294921875
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(Hospitals,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        701.713134765625,
        538.1209716796875,
        717.2352294921875
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Diagnostic",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        701.713134765625,
        538.1209716796875,
        717.2352294921875
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Laboratories,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        701.713134765625,
        538.1209716796875,
        717.2352294921875
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Academia,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        724.4882202148438,
        538.2417602539062,
        740.0103149414062
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Blood",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        724.4882202148438,
        538.2417602539062,
        740.0103149414062
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Banks)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        724.4882202148438,
        538.2417602539062,
        740.0103149414062
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "-",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        724.4882202148438,
        538.2417602539062,
        740.0103149414062
      ],
      "page_num": 33,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Global",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        724.4882202148438,
        538.2417602539062,
        740.0103149414062
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Forecasts",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        724.4882202148438,
        538.2417602539062,
        740.0103149414062
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "to",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        724.4882202148438,
        538.2417602539062,
        740.0103149414062
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2020.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        724.4882202148438,
        538.2417602539062,
        740.0103149414062
      ],
      "page_num": 33,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "marketsandmarkets.com. August 2015",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.51365661621094,
        747.1434936523438,
        305.6883544921875,
        762.6655883789062
      ],
      "page_num": 33,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 27 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 34,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[별첨] 국내·외 연구동향",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        51.57204818725586,
        76.45640563964844,
        245.74652099609375,
        92.39897918701172
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 출혈시간 및 항혈소판제제 저항성 복합검사기기의 국내 개발 현황",
      "font_size": 14.987749099731445,
      "font_name": "T17",
      "bbox": [
        63.805419921875,
        111.23843383789062,
        532.0316772460938,
        129.20379638671875
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 출혈시간(Bleeding time, BT)검사는 약 100여년 전부터 개발되어",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.6011962890625,
        141.2056884765625,
        538.1483154296875,
        159.18603515625
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용되어 온 Duke법, Ivy법, Template법 등을 이용하여 혈소판",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        93.78916931152344,
        171.1729278564453,
        538.268310546875,
        189.13829040527344
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기능 선별검사로 현재도 사용 중이다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.78916931152344,
        201.1401824951172,
        352.3690185546875,
        219.1055450439453
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 침습적 방식의 출혈시간(Bleeding time, BT)검사는 개인별 차이가",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.00151824951172,
        231.10743713378906,
        538.1483154296875,
        249.08778381347656
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "커서 표준화가 어렵고 임상적 유용성이 적어서 객관적인 데이터로",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        94.50878143310547,
        261.07470703125,
        538.268310546875,
        279.0400695800781
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용하기에는 부적합하다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        94.50878143310547,
        291.0419616699219,
        263.737060546875,
        309.00732421875
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③ 출혈시간 및 항혈소판제제 저항성 복합검사기기는 주로 수입 의료",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.00151824951172,
        321.0091857910156,
        538.268310546875,
        338.9895324707031
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기기에 의존하고 있는 상황이고 국내 개발 제품은 없는 상태이다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.3094253540039,
        350.9764404296875,
        538.1483154296875,
        368.9418029785156
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(‘16.10.31 기준)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        93.3094253540039,
        380.9436950683594,
        193.3951873779297,
        398.9090576171875
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 국내외 개발동향",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        63.805419921875,
        422.8978576660156,
        197.53292846679688,
        440.86322021484375
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(가) 전 세계 혈소판 기능검사 시장 규모는 2015년 기준 약 100억 달러에",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        452.8651123046875,
        538.1483154296875,
        470.8304748535156
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "달한다. 혈소판 기능검사 시장은 매년 10% 이상의 성장률을 보이고",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        103.14409637451172,
        482.83233642578125,
        538.1483154296875,
        500.7976989746094
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있으며 2020년 343억 달러까지 성장할 것으로 예상된다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.14409637451172,
        512.799560546875,
        462.34942626953125,
        530.7649536132812
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(나) 국내의 혈소판 기능검사의 시장도 매년 성장하고 있으며 주로",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        71.12145233154297,
        542.766845703125,
        538.268310546875,
        560.7322387695312
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수입 의료기기에 의존하여 검사를 진행하고 있다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        105.18299102783203,
        572.7340698242188,
        436.0836486816406,
        590.699462890625
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(다) 혈소판 기능검사는 신의료기술로 인정되어 비급여항목으로 각 검사당",
      "font_size": 14.987749099731445,
      "font_name": "T17",
      "bbox": [
        71.12145233154297,
        602.7012939453125,
        538.268310546875,
        620.6666870117188
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "약 4만원에서 8만원 정도의 검사비가 청구되고 있어 국내 기술을",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        103.02416229248047,
        632.6685791015625,
        538.1483154296875,
        650.6339721679688
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이용한 혈소판 기능검사가 요구되고 있다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        103.02416229248047,
        662.6358032226562,
        377.07562255859375,
        680.6011962890625
      ],
      "page_num": 34,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(라) 2016년 9월 현재 급여항목으로 변경된 EPI(Epinephrine, 에피네프린)",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        71.12145233154297,
        692.6030883789062,
        538.2083129882812,
        710.5684814453125
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "테스트 및",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        102.78429412841797,
        722.5703125,
        538.1483154296875,
        740.5357055664062
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ADP(에이디피)의 경우",
      "font_size": 14.987749099731445,
      "font_name": "T17",
      "bbox": [
        102.78429412841797,
        722.5703125,
        538.1483154296875,
        740.5357055664062
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본인부담금으로 9,000원이",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        102.78429412841797,
        722.5703125,
        538.1483154296875,
        740.5357055664062
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "청구되고 있다.",
      "font_size": 14.987749099731445,
      "font_name": "T2",
      "bbox": [
        102.78429412841797,
        752.53759765625,
        203.88949584960938,
        770.5029907226562
      ],
      "page_num": 34,
      "block_type": "heading",
      "level": 10,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 28 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 35,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 임상시험용 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’의 안전성과 유효성을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        201.4998016357422,
        533.3516845703125,
        217.02186584472656
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "증명하고자 하는 임상시험의 목적을 구체적으로 알 수 있도록 기입함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        76.15872192382812,
        227.39149475097656,
        457.7659912109375,
        242.91355895996094
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ⅱ",
      "font_size": 20.02363395690918,
      "font_name": "T10",
      "bbox": [
        68.36294555664062,
        77.07575988769531,
        388.1096496582031,
        101.0975112915039
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험계획서 작성 및 평가",
      "font_size": 20.02363395690918,
      "font_name": "H2hdrM",
      "bbox": [
        68.36294555664062,
        77.07575988769531,
        388.1096496582031,
        101.0975112915039
      ],
      "page_num": 35,
      "block_type": "heading",
      "level": 5,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 임상시험의 제목",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        124.04439544677734,
        208.68690490722656,
        139.98696899414062
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        56.609317779541016,
        156.79193115234375,
        541.8339233398438,
        167.8198699951172
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        73.99989318847656,
        174.4126739501953,
        301.63604736328125,
        185.44061279296875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        377.34759521484375,
        86.93560791015625,
        392.86968994140625
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 혈소판 기능검사",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        403.23931884765625,
        173.42514038085938,
        418.76141357421875
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈소판 기능 부전이 의심되는 환자의 구연산 처리된 전혈에서 혈소판 기능부전",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        429.2508850097656,
        538.1474609375,
        444.7729797363281
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검출을 위해 사용되는 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기-혈소판",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        455.262451171875,
        538.1477661132812,
        470.7845458984375
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기능검사’의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        481.1541748046875,
        538.1292114257812,
        496.67626953125
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상적",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        481.1541748046875,
        538.1292114257812,
        496.67626953125
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성능을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        481.1541748046875,
        538.1292114257812,
        496.67626953125
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "광투과",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        481.1541748046875,
        538.1292114257812,
        496.67626953125
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈소판응집능검사(light",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.84593963623047,
        481.1541748046875,
        538.1292114257812,
        496.67626953125
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "transmission",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.84593963623047,
        481.1541748046875,
        538.1292114257812,
        496.67626953125
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "aggregometry, LTA)를 기준 검사법으로 하여 기허가제품의 민감도 및 특이도와",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        507.16571044921875,
        538.1474609375,
        522.6878051757812
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비교 평가하기 위한 다기관, 비무작위배정, 단일눈가림, 단일설계, 전향적 비교",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        533.1773071289062,
        538.1480712890625,
        548.6994018554688
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "확증임상시험",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        559.0690307617188,
        138.76336669921875,
        574.5911254882812
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 대상질환 : 선천적 · 후천적 혈소판기능장애 환자 :　본 빌레브란트병(von",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        611.0921630859375,
        538.1322631835938,
        626.627197265625
      ],
      "page_num": 35,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Willebrand disease), 글란즈만 혈소판무력증(Glanzmann's thrombasthenia),",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        92.23001098632812,
        636.98388671875,
        538.121337890625,
        652.5059814453125
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "약물유발 혈소판기능부전(drug-induced platelet dysfunction) 등",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        92.23001098632812,
        662.9954223632812,
        462.34942626953125,
        678.5175170898438
      ],
      "page_num": 35,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 해당 의료기기의 사용목적：혈소판 기능부전 검출",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        689.0070190429688,
        380.0736999511719,
        704.5420532226562
      ],
      "page_num": 35,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 구연산 처리된 전혈에서 폐색 전 혈액이동거리를 측정하여 혈소판 기능부전을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        714.8987426757812,
        538.1502075195312,
        730.4208374023438
      ],
      "page_num": 35,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검출하는 체외진단용 의료기기",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        87.19274139404297,
        740.9102783203125,
        262.2992858886719,
        756.432373046875
      ],
      "page_num": 35,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 29 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 36,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(3) 해당 의료기기 : 혈액응고검사시약과 자동혈소판응집측정장치",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        68.92467498779297,
        446.1552734375,
        84.4467544555664
      ],
      "page_num": 36,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(4) 임상시험 평가내용 : 민감도 및 특이도, 일치도",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        94.93624877929688,
        361.1236877441406,
        110.45832824707031
      ],
      "page_num": 36,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(5) 임상시험 디자인 : 다기관, 비무작위배정, 단일눈가림, 단일설계, 전향적 임상시험",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        120.82794952392578,
        536.2291259765625,
        136.3500213623047
      ],
      "page_num": 36,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 혈소판 약물반응검사",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        172.85110473632812,
        198.61090087890625,
        188.3731689453125
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Aspirin 또는 P2Y12 수용제 저해제(clopidogrel) 복용중인 환자의 구연산 처리된",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        198.74281311035156,
        538.1492919921875,
        214.26487731933594
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전혈에서 혈소판 약물반응을 확인하기 위해 사용되는 ‘출혈 시간 및 항혈소판제제",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        224.75437927246094,
        538.1506958007812,
        240.2764434814453
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "저항성 복합검사기기-혈소판 약물반응검사’의 임상적 성능평가를 위하여 aspirin",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.84593963623047,
        250.7659454345703,
        538.2509155273438,
        266.28802490234375
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 P2Y12 수용제 저해제(clopidogrel) 복용 전·후에 대한 민감도와 특이도를",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        276.65765380859375,
        538.1490478515625,
        292.19268798828125
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기허가제품의 민감도 및 특이도와 비교 평가하기 위한 다기관, 비무작위배정, 단일",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        302.6692199707031,
        538.1488037109375,
        318.1913146972656
      ],
      "page_num": 36,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "눈가림, 단일설계, 전향적 비교확증임상시험",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        328.6807861328125,
        312.79376220703125,
        344.202880859375
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 대상질환 : 혈관질환의 병력, 혈관질환의 위험군 등으로 aspirin 또는 P2Y12",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.84593963623047,
        380.5840759277344,
        538.2410278320312,
        396.1061706542969
      ],
      "page_num": 36,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "inhibitor (clopidogrel) 복용 예정인 환자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        85.39372253417969,
        406.59564208984375,
        319.74639892578125,
        422.11773681640625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 해당 의료기기의 사용목적：혈소판 약물반응 검사",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        432.4873352050781,
        373.7171630859375,
        448.0223693847656
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 구연산 처리된 전혈에서 폐색 전 혈액이동거리를 측정하여 혈소판 약물반응을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        458.4989318847656,
        538.147216796875,
        474.0210266113281
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검출하는 체외진단용 의료기기",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        80.23651123046875,
        484.510498046875,
        256.77996826171875,
        500.0325927734375
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 해당 의료기기 : 혈액응고검사시약과 자동혈소판응집측정장치",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        510.4022216796875,
        439.91864013671875,
        525.92431640625
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4) 임상시험 평가내용 : 민감도 및 특이도, 일치도",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        536.4137573242188,
        354.8870544433594,
        551.9358520507812
      ],
      "page_num": 36,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(5) 임상시험 디자인 : 다기관, 비무작위배정, 단일눈가림, 단일설계, 전향적 임상시험",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        562.4253540039062,
        534.3104248046875,
        577.9474487304688
      ],
      "page_num": 36,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 30 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 37,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기관명",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        99.54605102539062,
        319.3310241699219,
        486.4560546875,
        334.8531188964844
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소재지",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        99.54605102539062,
        319.3310241699219,
        486.4560546875,
        334.8531188964844
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        99.54605102539062,
        319.3310241699219,
        486.4560546875,
        334.8531188964844
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "팩스",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        99.54605102539062,
        319.3310241699219,
        486.4560546875,
        334.8531188964844
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○병원",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        86.95287322998047,
        340.7875671386719,
        520.0381469726562,
        356.3226013183594
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○시 ○○구",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        86.95287322998047,
        340.7875671386719,
        520.0381469726562,
        356.3226013183594
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○-○○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        86.95287322998047,
        340.7875671386719,
        520.0381469726562,
        356.3226013183594
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○-○○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        86.95287322998047,
        340.7875671386719,
        520.0381469726562,
        356.3226013183594
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○병원",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        86.95287322998047,
        362.2441101074219,
        520.0381469726562,
        377.7791442871094
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○시 ○○구",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        86.95287322998047,
        362.2441101074219,
        520.0381469726562,
        377.7791442871094
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○-○○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        86.95287322998047,
        362.2441101074219,
        520.0381469726562,
        377.7791442871094
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○-○○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        86.95287322998047,
        362.2441101074219,
        520.0381469726562,
        377.7791442871094
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 의료기기 임상시험기관은 「의료기기 임상시험기관 지정에 관한 규정」(식품",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        157.7476043701172,
        527.7142333984375,
        173.28262329101562
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의약품안전처 고시)에 따라 식품의약품안전처장으로부터 의료기기 임상시험",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.19761657714844,
        183.75918579101562,
        527.7147216796875,
        199.28125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "실시기관으로 지정받은 곳이어야 함",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.19761657714844,
        209.770751953125,
        288.20379638671875,
        225.29281616210938
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 임상시험기관의 명칭 및 소재지",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        74.19891357421875,
        319.26666259765625,
        93.31405639648438
      ],
      "page_num": 37,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        255.0812530517578,
        86.09606170654297,
        270.60333251953125
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 임상시험 실시기관",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        280.9729309082031,
        186.018310546875,
        296.4950256347656
      ],
      "page_num": 37,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 31 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 38,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 시험자는 시험책임자, 시험담당자, 임상시험조정자를 포함함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        137.96922302246094,
        424.4240417480469,
        153.4912872314453
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람으로서,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        163.86093139648438,
        530.806396484375,
        179.38299560546875
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시하기에 충분한",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.1992416381836,
        189.87249755859375,
        530.7120361328125,
        205.39456176757812
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "경험이 있는 자가 선정되어야 함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.1992416381836,
        215.8840789794922,
        267.18927001953125,
        231.40614318847656
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        241.77578735351562,
        530.71240234375,
        257.2978515625
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "담당하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        76.9982681274414,
        267.787353515625,
        530.7120971679688,
        283.3094482421875
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험에 관여하는 사람을 말하며, 각 임상시험기관의 적절한 임상시험의 수행을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        76.9982681274414,
        293.7989196777344,
        530.7133178710938,
        309.3210144042969
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위하여 임상시험기관 및 시험자의 의견을 조정하기 위하여 조정위원회를 설치",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        76.9982681274414,
        319.69061279296875,
        530.71240234375,
        335.21270751953125
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하고 시험조정자를 선정할 수 있음.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        76.9982681274414,
        345.7021789550781,
        281.701416015625,
        361.2242736816406
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 의학통계전문가, 의료기기전문가 등 공동연구자가 있을 경우 이를 포함하여",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        371.7137756347656,
        530.7114868164062,
        387.2358703613281
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "작성할 수 있음",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        77.2381362915039,
        397.60546875,
        165.7498779296875,
        413.1275634765625
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. 임상시험 책임자·담당자 및 공동연구자의 성명 및 직명",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        74.19891357421875,
        503.1273193359375,
        93.31405639648438
      ],
      "page_num": 38,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        430.8091735839844,
        86.09606170654297,
        446.3312683105469
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 시험책임자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        456.82073974609375,
        142.00274658203125,
        472.34283447265625
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성명",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        487.0277404785156,
        400.10284423828125,
        502.5498352050781
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소속 기관명",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        487.0277404785156,
        400.10284423828125,
        502.5498352050781
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전공",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        487.0277404785156,
        400.10284423828125,
        502.5498352050781
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "직위",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        487.0277404785156,
        400.10284423828125,
        502.5498352050781
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        487.0277404785156,
        400.10284423828125,
        502.5498352050781
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        502.8504638671875,
        496.65081787109375,
        518.385498046875
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○병원",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        502.8504638671875,
        496.65081787109375,
        518.385498046875
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        502.8504638671875,
        496.65081787109375,
        518.385498046875
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        502.8504638671875,
        496.65081787109375,
        518.385498046875
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○-○○○-○○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        502.8504638671875,
        496.65081787109375,
        518.385498046875
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 시험담당자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        533.0574340820312,
        142.0030517578125,
        548.5795288085938
      ],
      "page_num": 38,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성명",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        563.264404296875,
        402.9812927246094,
        578.7864990234375
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소속 기관명",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        563.264404296875,
        402.9812927246094,
        578.7864990234375
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전공",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        563.264404296875,
        402.9812927246094,
        578.7864990234375
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "직위",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        563.264404296875,
        402.9812927246094,
        578.7864990234375
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전화",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        563.264404296875,
        402.9812927246094,
        578.7864990234375
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        579.087158203125,
        499.5292663574219,
        594.6221923828125
      ],
      "page_num": 38,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○○병원",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        579.087158203125,
        499.5292663574219,
        594.6221923828125
      ],
      "page_num": 38,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        579.087158203125,
        499.5292663574219,
        594.6221923828125
      ],
      "page_num": 38,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        579.087158203125,
        499.5292663574219,
        594.6221923828125
      ],
      "page_num": 38,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○-○○○-○○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        579.087158203125,
        499.5292663574219,
        594.6221923828125
      ],
      "page_num": 38,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "△△△",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        594.7899780273438,
        499.5292663574219,
        610.3250122070312
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "△△△병원",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        594.7899780273438,
        499.5292663574219,
        610.3250122070312
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "△△△△",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        594.7899780273438,
        499.5292663574219,
        610.3250122070312
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "△△△",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        594.7899780273438,
        499.5292663574219,
        610.3250122070312
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "△△-△△△-△△△△",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        594.7899780273438,
        499.5292663574219,
        610.3250122070312
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□□□",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        610.6126708984375,
        499.5292663574219,
        626.147705078125
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□□□병원",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        610.6126708984375,
        499.5292663574219,
        626.147705078125
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□□□□",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        610.6126708984375,
        499.5292663574219,
        626.147705078125
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□□□",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        610.6126708984375,
        499.5292663574219,
        626.147705078125
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□□-□□□-□□□□",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        610.6126708984375,
        499.5292663574219,
        626.147705078125
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. 공동연구자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        640.8196411132812,
        142.00189208984375,
        656.3417358398438
      ],
      "page_num": 38,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성명",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        671.0266723632812,
        405.73980712890625,
        686.5487670898438
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "소속 기관명",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        671.0266723632812,
        405.73980712890625,
        686.5487670898438
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전공",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        671.0266723632812,
        405.73980712890625,
        686.5487670898438
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "직위",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        671.0266723632812,
        405.73980712890625,
        686.5487670898438
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전화",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        671.0266723632812,
        405.73980712890625,
        686.5487670898438
      ],
      "page_num": 38,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        686.849365234375,
        502.28778076171875,
        702.3843994140625
      ],
      "page_num": 38,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○○병원",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        686.849365234375,
        502.28778076171875,
        702.3843994140625
      ],
      "page_num": 38,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        686.849365234375,
        502.28778076171875,
        702.3843994140625
      ],
      "page_num": 38,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        686.849365234375,
        502.28778076171875,
        702.3843994140625
      ],
      "page_num": 38,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "○○-○○○-○○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        686.849365234375,
        502.28778076171875,
        702.3843994140625
      ],
      "page_num": 38,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 32 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 39,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "성명",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        338.27032470703125,
        414.25518798828125,
        353.79241943359375
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소속 기관명",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        338.27032470703125,
        414.25518798828125,
        353.79241943359375
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전공",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        338.27032470703125,
        414.25518798828125,
        353.79241943359375
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "직위",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        338.27032470703125,
        414.25518798828125,
        353.79241943359375
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        338.27032470703125,
        414.25518798828125,
        353.79241943359375
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        356.8500061035156,
        510.80316162109375,
        372.3850402832031
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○병원",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        356.8500061035156,
        510.80316162109375,
        372.3850402832031
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        356.8500061035156,
        510.80316162109375,
        372.3850402832031
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        356.8500061035156,
        510.80316162109375,
        372.3850402832031
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○-○○○-○○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        356.8500061035156,
        510.80316162109375,
        372.3850402832031
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험기관에서 임상시험용 해당 의료기기를 보관·관리하는 임상의, 의료기사",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        137.96922302246094,
        530.71142578125,
        153.50424194335938
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "또는 간호사 등으로서 임상시험기관의 장이 지정한 자를 말함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        76.15872192382812,
        163.86093139648438,
        438.2165832519531,
        179.38299560546875
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험용 해당 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용할 경우",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        64.52503204345703,
        189.87249755859375,
        530.71240234375,
        205.39456176757812
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "함께 관리함. 임상시험용 의료기기를 관리하는 관리자의 성명, 소속 기관명 및",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.83943939208984,
        215.8840789794922,
        530.71240234375,
        231.40614318847656
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "직명 등 인적사항을 기재함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        74.83943939208984,
        241.77578735351562,
        235.406494140625,
        257.2978515625
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4. 임상시험용 의료기기관리자의 성명 및 직명",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        74.19891357421875,
        407.1793212890625,
        93.31405639648438
      ],
      "page_num": 39,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        274.9794921875,
        86.09606170654297,
        290.5015869140625
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 의료기기 관리자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        300.9910583496094,
        173.4254150390625,
        316.5131530761719
      ],
      "page_num": 39,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 33 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 40,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 해당 의료기기의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        141.0858154296875,
        527.7124633789062,
        156.60787963867188
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조업자 또는 수입업자가 해당됨. 의뢰자는 임상시험모니터 요원을 지정하여야 함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        166.97752380371094,
        527.8080444335938,
        182.4995880126953
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험모니터 요원의 선정, 자격기준, 수행임무 등에 대한 사항을 의료기기",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        192.9890899658203,
        527.713134765625,
        208.5111541748047
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험 관리기준(의료기기법 시행규칙 [별표 3])에서 정하고 있음.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        219.00067138671875,
        455.8470153808594,
        234.52273559570312
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5. 임상시험 의뢰자의 성명 및 주소",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        74.19891357421875,
        327.30230712890625,
        93.31405639648438
      ],
      "page_num": 40,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        254.9613800048828,
        86.09606170654297,
        270.48345947265625
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 의뢰자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        280.9729309082031,
        116.81611633300781,
        296.4950256347656
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "회사명",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        312.61834716796875,
        400.10284423828125,
        328.14044189453125
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대표이사",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        312.61834716796875,
        400.10284423828125,
        328.14044189453125
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소재지",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        312.61834716796875,
        400.10284423828125,
        328.14044189453125
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        312.61834716796875,
        400.10284423828125,
        328.14044189453125
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(주) ○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        331.1980285644531,
        496.65081787109375,
        346.7330627441406
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        331.1980285644531,
        496.65081787109375,
        346.7330627441406
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○ ○○시 ○○구",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        331.1980285644531,
        496.65081787109375,
        346.7330627441406
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○-○○○-○○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        331.1980285644531,
        496.65081787109375,
        346.7330627441406
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 모니터요원",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        362.84344482421875,
        142.00274658203125,
        378.36553955078125
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "회사명",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        394.4888610839844,
        394.4659118652344,
        410.0109558105469
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성명",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        394.4888610839844,
        394.4659118652344,
        410.0109558105469
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소재지",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        394.4888610839844,
        394.4659118652344,
        410.0109558105469
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        394.4888610839844,
        394.4659118652344,
        410.0109558105469
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(주) ○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        413.0685729980469,
        491.0138854980469,
        428.6036071777344
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        413.0685729980469,
        491.0138854980469,
        428.6036071777344
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○ ○○시 ○○구",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        413.0685729980469,
        491.0138854980469,
        428.6036071777344
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○-○○○-○○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        413.0685729980469,
        491.0138854980469,
        428.6036071777344
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 임상시험 수탁업체",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        444.7139892578125,
        186.01889038085938,
        460.236083984375
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "회사명",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        476.3594055175781,
        394.4659118652344,
        491.8815002441406
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성명",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        476.3594055175781,
        394.4659118652344,
        491.8815002441406
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소재지",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        476.3594055175781,
        394.4659118652344,
        491.8815002441406
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        476.3594055175781,
        394.4659118652344,
        491.8815002441406
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(주) ○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        494.9390869140625,
        491.0138854980469,
        510.47412109375
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        494.9390869140625,
        491.0138854980469,
        510.47412109375
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○ ○○시 ○○구",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        494.9390869140625,
        491.0138854980469,
        510.47412109375
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○-○○○-○○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        64.52503204345703,
        494.9390869140625,
        491.0138854980469,
        510.47412109375
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 임상시험 수탁기관(CRO: Contact Reserach Organization)이 있는 경우 해당",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        552.5960693359375,
        538.1483764648438,
        568.131103515625
      ],
      "page_num": 40,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "내용을 기재함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        77.35807037353516,
        578.48779296875,
        162.3660888671875,
        594.0098876953125
      ],
      "page_num": 40,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 34 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 41,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        151.03494262695312,
        530.5908813476562,
        166.5570068359375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기술 하는 것을 말함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        177.04652404785156,
        198.22665405273438,
        192.56858825683594
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의 일반적인 사항,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        202.93821716308594,
        530.5665283203125,
        218.4602813720703
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 또는 디자인",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        76.27865600585938,
        228.94979858398438,
        530.5921630859375,
        244.47186279296875
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "특성, 원자재 및 화학적 구성요소, 성능, 새로운 제조방법 등에 대한 특이성을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        76.27865600585938,
        254.9613800048828,
        530.4716186523438,
        270.48345947265625
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "함께 기재함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        76.27865600585938,
        280.8530578613281,
        148.8134307861328,
        296.3751525878906
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6. 임상시험의 목적 및 배경",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        74.19891357421875,
        271.29296875,
        93.31405639648438
      ],
      "page_num": 41,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        56.609317779541016,
        109.20393371582031,
        541.8339233398438,
        120.23188781738281
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        73.99989318847656,
        126.82469177246094,
        301.63604736328125,
        137.85263061523438
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        314.0567626953125,
        86.09606170654297,
        329.578857421875
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6.1. 목적",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        340.068359375,
        107.34153747558594,
        355.5904541015625
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’의 민감도 및 특이도, 일치도",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        366.0799255371094,
        538.1477661132812,
        381.6020202636719
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평가를 통한 임상적 유효성 평가",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        391.97161865234375,
        252.10308837890625,
        407.49371337890625
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 혈소판 기능검사",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        417.9831848144531,
        178.58233642578125,
        433.5052795410156
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "본 임상시험은 혈소판 기능부전이 의심되는 환자 및 정상대조군에서 시험기기의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        443.9947814941406,
        538.147216796875,
        459.5168762207031
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "광투과 혈소판응집능검사(light transmission aggregometry, LTA)를 기준검사법",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        469.886474609375,
        538.147216796875,
        485.4085693359375
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "으로 한 민감도 및 특이도를 기허가제품의 민감도 및 특이도와 비교하여 임상적",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        495.8980407714844,
        538.1477661132812,
        511.4201354980469
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유효성을 검증하는 것이 목적이다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        521.9096069335938,
        267.549072265625,
        537.4317016601562
      ],
      "page_num": 41,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 혈소판 약물반응검사",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        547.8013305664062,
        203.76809692382812,
        563.3234252929688
      ],
      "page_num": 41,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 임상시험은 aspirin 또는 P2Y12 수용체 저해제 복용예정 환자에서 시험기기의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        573.8129272460938,
        538.1502075195312,
        589.3350219726562
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "약물 복용 전후에 대한 민감도와 특이도를 기허가제품의 민감도 및 특이도와",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        599.824462890625,
        538.1490478515625,
        615.3465576171875
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비교하여 임상적 유효성을 검증하는 것이 목적이다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        625.7161865234375,
        371.17291259765625,
        641.23828125
      ],
      "page_num": 41,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 35 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 42,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6.2. 배경",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        68.92467498779297,
        107.34153747558594,
        84.4467544555664
      ],
      "page_num": 42,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈소판은 1차 지혈에서 중요한 역할을 하는 인자로, 혈관손상이 일어났을 때 부착,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.84593963623047,
        94.93624877929688,
        538.1224365234375,
        110.45832824707031
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "응집, 활성화 및 분비, 응고촉진 작용을 통해 지혈마개를 형성하며, 혈소판 기능에",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        120.82794952392578,
        538.1492919921875,
        136.3500213623047
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관한 검사는 주로 선천성 혈소판 기능 이상이나 수술전 선별검사로 많이 사용되고",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        146.83953857421875,
        538.1497802734375,
        162.36160278320312
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다. 특히 혈소판의 수적 이상이 없는 출혈질환에서 선천성 혹은 후천성 혈소판",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        172.85110473632812,
        538.1492919921875,
        188.3731689453125
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기능 이상을 감별하는데 중요한 검사이다. 최근에는 심혈관 질환의 치료 및 예방에",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        198.74281311035156,
        538.1482543945312,
        214.26487731933594
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용되는 아스피린, P2Y12 수용체 저해제 등의 항혈소판약제로 인한 출혈성",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        224.75437927246094,
        538.1494140625,
        240.2764434814453
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경향의 증가나 약제 내성에 대한 검사를 위해서도 많이 이용되고 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.84593963623047,
        250.7659454345703,
        492.3072509765625,
        266.28802490234375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈소판 기능검사 방법으로는 피부에 상처를 낸 후 출혈이 멈출 때까지의 시간을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        276.65765380859375,
        538.1477661132812,
        292.17974853515625
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "측정하는 고식적 방법인 출혈시간과 혈소판의 응집능만을 검사할 수 있는 혈소판",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        302.6692199707031,
        538.1477661132812,
        318.1913146972656
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "응집검사, 혈소판과 함께 본빌레브란드인자의 기능을 함께 측정할 수 있는 PFA-100,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.84593963623047,
        328.6807861328125,
        538.12255859375,
        344.202880859375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전반적인 응고과정을 측정하는 thromboelastography 등이 있다. 이 외에 혈소판의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        354.572509765625,
        538.1473388671875,
        370.0946044921875
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "활성화 여부를 유세포분석기를 이용하여 검사하거나, 특정 항혈소판 약제에 대한",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        380.5840759277344,
        538.1483154296875,
        396.1061706542969
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "반응을 검사하는 VerifyNow와 같은 기기들도 사용되고 있다. 하지만 기기에 따라",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        406.59564208984375,
        538.1483154296875,
        422.11773681640625
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검사방법이나 해석의 표준화가 미흡하거나 해석이 어려워 실제 임상에서 널리",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        432.4873352050781,
        538.1483764648438,
        448.0094299316406
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이용되는 검사 기기의 종류는 많지 않다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.84593963623047,
        458.4989318847656,
        301.2508239746094,
        474.0210266113281
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "광투과 혈소판응집검사(Light transmission aggregometry, LTA)는 현재까지 일차",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        484.510498046875,
        538.1480712890625,
        500.0325927734375
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지혈이상 진단의 가장 중요한 검사방법으로 자리잡고 있으며, 혈소판기능검사의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        510.4022216796875,
        538.1463012695312,
        525.92431640625
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표준으로 사용되고 있다. 검사원리는 전혈에서 혈소판풍부 혈장을 분리한 후 혈소판",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        536.4137573242188,
        538.147216796875,
        551.9358520507812
      ],
      "page_num": 42,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "응집에 관여하는 ADP, collagen, epinephrine 등의 작용제(agonist)를 넣고 작용제에",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        562.4253540039062,
        538.1473388671875,
        577.9474487304688
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "따른 혈소판의 응집정도를 관찰하는 것으로, 각 작용제의 기전에 따라 혈소판의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        588.3170776367188,
        538.1497802734375,
        603.8391723632812
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "응집정도를 보고 기능이상 여부를 측정할 수 있다. PFA-100은 체외에서 유속을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        614.32861328125,
        538.1477661132812,
        629.8507080078125
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이용해 혈소판의 부착 및 응집기능을 측정할 수 있는 검사장비로 체외에서 출혈",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        640.3402099609375,
        538.1480712890625,
        655.8623046875
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시간 측정 때와 유사한 조건을 만들어 주기 때문에 일차지혈 과정 평가에 유용한",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        666.2318725585938,
        538.1477661132812,
        681.7539672851562
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사로 검사자의 숙련도에 영향을 받지 않는 장점이 있으며, 선천성, 후천성 혈소판",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        692.2434692382812,
        538.14794921875,
        707.7655639648438
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기능이상을 비롯한 일차지혈 관련 선별검사에 이용된다. 특히 혈소판기능 뿐 아니라",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        718.2550659179688,
        538.1483764648438,
        733.7771606445312
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본빌레브란트병에 민감한 검사이며, 아스피린 복용자의 약제 저항성검사로도 사용되고 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.84593963623047,
        744.146728515625,
        538.2423706054688,
        759.6688232421875
      ],
      "page_num": 42,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 36 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 43,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "심혈관질환이 증가하고 치료 및 예방 목적으로 아스피린, 클로피도그렐 등의 항혈소판",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        68.92467498779297,
        538.14794921875,
        84.4467544555664
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "약제를 많이 사용함에 따라 약제의 혈소판 응집능 억제 기능을 측정하기 위한 검사",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        94.93624877929688,
        538.1487426757812,
        110.45832824707031
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방법들이 많이 사용되고 있으며, 광투과혈소판응집검사나 PFA-100, VerifyNow 등의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        120.82794952392578,
        538.1477661132812,
        136.3500213623047
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사법이 사용되고 있다. 특히 VerifyNow는 검사자의 숙련도에 영향을 받지 않고",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        146.83953857421875,
        538.1477661132812,
        162.36160278320312
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "손쉽게 검사를 할 수 있기 때문에 널리 사용되고 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.84593963623047,
        172.85110473632812,
        370.8131103515625,
        188.3731689453125
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "본 임상시험용 의료기기인 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        198.74281311035156,
        538.1483764648438,
        214.26487731933594
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈소판 기능부전 검출 및 aspirin, P2Y12 수용체 저해제를 복용하는 환자에서",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        224.75437927246094,
        538.1472778320312,
        240.2764434814453
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "약물로 인한 혈소판 기능 억제 기능을 측정하는 장비로, 혈소판 기능 부전이 의심",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        250.7659454345703,
        538.1488037109375,
        266.28802490234375
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "되는 환자 및 항혈소판제제에 대한 약물 저항을 보이는 환자를 확인할 수 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.84593963623047,
        276.65765380859375,
        521.33154296875,
        292.17974853515625
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "본 연구를 통해 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’의 민감도 및",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.96587371826172,
        302.6692199707031,
        538.1483764648438,
        318.1913146972656
      ],
      "page_num": 43,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특이도, 일치도를 평가하여 임상적 유효성을 검증하고자 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.84593963623047,
        328.6807861328125,
        429.4613342285156,
        344.202880859375
      ],
      "page_num": 43,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 37 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 44,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7. 임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다.)",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        74.19891357421875,
        529.5245971679688,
        93.31405639648438
      ],
      "page_num": 44,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        56.609317779541016,
        115.1973876953125,
        541.8339233398438,
        126.225341796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        73.99989318847656,
        132.81813049316406,
        301.63604736328125,
        143.8460693359375
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7.1. 임상시험용 의료기기 사용 목적",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        147.1991424560547,
        264.6962585449219,
        162.72120666503906
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 해당 임상시험용 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        180.16311645507812,
        533.35009765625,
        195.6851806640625
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대상 질환 또는 적응증을 포함하도록 함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        76.39859771728516,
        206.1746826171875,
        312.5246887207031,
        221.69674682617188
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        239.25852966308594,
        86.09606170654297,
        254.7805938720703
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 본체: 혈소판의 형상변화, 응집 과정을 측정하는 기기",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.96587371826172,
        265.15020751953125,
        388.8287353515625,
        280.67230224609375
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- SIPA test: 사람의 구연산 처리된 전혈에서 폐색 전 혈액이동거리 측정법으로",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.96587371826172,
        291.16180419921875,
        538.1467895507812,
        306.68389892578125
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정성하여 혈소판 기능장애 확인에 도움을 주는 체외진단용 의료기기",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.35969543457031,
        317.1733703613281,
        479.7389221191406,
        332.6954650878906
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- ADP test: 사람의 구연산 처리된 전혈에서 아데노신이인산(ADP)와 P2Y12의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.96587371826172,
        343.0650634765625,
        538.1483764648438,
        358.587158203125
      ],
      "page_num": 44,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결합",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        369.07666015625,
        538.146240234375,
        384.5987548828125
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정도를",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        369.07666015625,
        538.146240234375,
        384.5987548828125
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "폐색",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        75.43911743164062,
        369.07666015625,
        538.146240234375,
        384.5987548828125
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        369.07666015625,
        538.146240234375,
        384.5987548828125
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈액이동거리",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        369.07666015625,
        538.146240234375,
        384.5987548828125
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "측정법으로",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        369.07666015625,
        538.146240234375,
        384.5987548828125
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정성하여",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        369.07666015625,
        538.146240234375,
        384.5987548828125
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아데노신이인산",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        369.07666015625,
        538.146240234375,
        384.5987548828125
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(ADP)에 의한 혈소판 기능장애 확인에 도움을 주는 체외진단용 의료기기",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        395.0882263183594,
        510.4422912597656,
        410.6103210449219
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- EPI test: 사람의 구연산 처리된 전혈에서 에피네프린과 a2A-AR의 결합 정도를",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.96587371826172,
        420.97991943359375,
        538.1488037109375,
        436.50201416015625
      ],
      "page_num": 44,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "폐색 전 혈액이동거리 측정법으로 정성하여 에피네프린에 의한 혈소판 기능",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.59957122802734,
        446.9914855957031,
        538.1483764648438,
        462.5135803222656
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "장애 확인에 도움을 주는 체외진단용 의료기기",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.59957122802734,
        473.0030822753906,
        353.80877685546875,
        488.5251770019531
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- Aspirin test: 사람의 구연산 처리된 전혈에서 아스피린에 의한 TXA2 합성 억제",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.96587371826172,
        498.894775390625,
        538.1483764648438,
        514.4168701171875
      ],
      "page_num": 44,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정도를 폐색 전 혈액이동거리 측정법으로 정성하여 아스피린에 의한 혈소판",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.11982727050781,
        524.9063720703125,
        538.1488037109375,
        540.428466796875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기능장애 확인에 도움을 주는 체외진단용 의료기기",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.11982727050781,
        550.9179077148438,
        373.11846923828125,
        566.4400024414062
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- P2Y12 test: 사람의 구연산 처리된 전혈에서 P2Y12 수용체(ADP receptor) 억제",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.96587371826172,
        576.8096313476562,
        538.1483764648438,
        592.3317260742188
      ],
      "page_num": 44,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정도를 폐색 전 혈액이동거리 측정법으로 정성하여 P2Y12 억제제에 의한 혈소판",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.7195053100586,
        602.8211669921875,
        538.1482543945312,
        618.34326171875
      ],
      "page_num": 44,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기능장애 확인에 도움을 주는 체외진단용 의료기기",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.7195053100586,
        628.832763671875,
        365.56170654296875,
        644.3548583984375
      ],
      "page_num": 44,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 38 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 45,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7.2. 임상시험용 의료기기 정보",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        68.92467498779297,
        233.15335083007812,
        84.4467544555664
      ],
      "page_num": 45,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 해당 임상시험용 의료기기 및 대조시험용 의료기기의 코드명/품목명, 제조회사,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        99.13166046142578,
        527.5681762695312,
        114.65373992919922
      ],
      "page_num": 45,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원자재, 형상, 구조, 치수/중량, 성능, 보관조건 등을 구체적으로 기재하도록 함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.79891967773438,
        125.14324188232422,
        522.0511474609375,
        140.66531372070312
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        181.24192810058594,
        86.09606170654297,
        196.7639923095703
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7.2.1. 임상시험용 의료기기",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        223.1960906982422,
        217.4412841796875,
        238.71815490722656
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 품목명(품목분류번호)/모델명: (구체적이지 않을 시 중분류명 기재)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        275.2192077636719,
        472.40667724609375,
        290.7413024902344
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 본체",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        301.1109313964844,
        111.41932678222656,
        316.6330261230469
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "모델명: ○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        81.67573547363281,
        327.12249755859375,
        167.0694580078125,
        342.65753173828125
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "품목명 : 자동혈소판응집측정장치[1]",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        353.1340637207031,
        288.5461120605469,
        368.6561584472656
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "품목분류번호 : A22290.01",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        379.0257873535156,
        230.00936889648438,
        394.5478820800781
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 시약 :",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        405.037353515625,
        120.62870788574219,
        420.5594482421875
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "모델명 : 1) ○○ SIPA test",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        431.0489196777344,
        237.5896759033203,
        446.5839538574219
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) ○○ ADP test",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        131.92849731445312,
        456.94061279296875,
        233.15208435058594,
        472.47564697265625
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) ○○ EPI test",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        131.92849731445312,
        482.95220947265625,
        225.59747314453125,
        498.48724365234375
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) ○○ Aspirin test",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        131.92849731445312,
        508.9637451171875,
        248.3838348388672,
        524.498779296875
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5) ○○ P2Y12 tests",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        131.92849731445312,
        534.85546875,
        246.30908203125,
        550.3905029296875
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "품목명 : 혈액응고검사시약 [3]",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        560.8670654296875,
        257.0039978027344,
        576.38916015625
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "품목분류번호 : (D01050.01)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        586.8786010742188,
        238.29278564453125,
        602.4006958007812
      ],
      "page_num": 45,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 제조회사: ○○○",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        69.2024917602539,
        638.7819213867188,
        183.8603515625,
        654.3169555664062
      ],
      "page_num": 45,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 39 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 46,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일련번호",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        66.20411682128906,
        120.94781494140625,
        499.529296875,
        132.87681579589844
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "명칭",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        66.20411682128906,
        120.94781494140625,
        499.529296875,
        132.87681579589844
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "배합목적",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        66.20411682128906,
        120.94781494140625,
        499.529296875,
        132.87681579589844
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "원재료명 또는 성분명",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        66.20411682128906,
        120.94781494140625,
        499.529296875,
        132.87681579589844
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분량",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        66.20411682128906,
        120.94781494140625,
        499.529296875,
        132.87681579589844
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비고",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        66.20411682128906,
        120.94781494140625,
        499.529296875,
        132.87681579589844
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        84.19436645507812,
        139.40765380859375,
        418.45318603515625,
        151.3466033935547
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈액챔버",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        84.19436645507812,
        139.40765380859375,
        418.45318603515625,
        151.3466033935547
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지지체",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        84.19436645507812,
        139.40765380859375,
        418.45318603515625,
        151.3466033935547
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 9.951866149902344,
      "font_name": "T16",
      "bbox": [
        84.19436645507812,
        139.40765380859375,
        418.45318603515625,
        151.3466033935547
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1개",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        84.19436645507812,
        139.40765380859375,
        418.45318603515625,
        151.3466033935547
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1 strip x 50개",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        457.7919006347656,
        204.0170440673828,
        521.4773559570312,
        215.946044921875
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        84.19436645507812,
        157.8674774169922,
        418.45318603515625,
        169.80642700195312
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈액주입구",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        84.19436645507812,
        157.8674774169922,
        418.45318603515625,
        169.80642700195312
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지지체",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        84.19436645507812,
        157.8674774169922,
        418.45318603515625,
        169.80642700195312
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 9.951866149902344,
      "font_name": "T16",
      "bbox": [
        84.19436645507812,
        157.8674774169922,
        418.45318603515625,
        169.80642700195312
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1개",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        84.19436645507812,
        157.8674774169922,
        418.45318603515625,
        169.80642700195312
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        84.19436645507812,
        176.32730102539062,
        418.45318603515625,
        188.26625061035156
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "막힘부",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        84.19436645507812,
        176.32730102539062,
        418.45318603515625,
        188.26625061035156
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지지체",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        84.19436645507812,
        176.32730102539062,
        418.45318603515625,
        188.26625061035156
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 9.951866149902344,
      "font_name": "T16",
      "bbox": [
        84.19436645507812,
        176.32730102539062,
        418.45318603515625,
        188.26625061035156
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1개",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        84.19436645507812,
        176.32730102539062,
        418.45318603515625,
        188.26625061035156
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        84.19436645507812,
        194.78712463378906,
        418.45318603515625,
        206.72607421875
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈액이동부",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        84.19436645507812,
        194.78712463378906,
        418.45318603515625,
        206.72607421875
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지지체",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        84.19436645507812,
        194.78712463378906,
        418.45318603515625,
        206.72607421875
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 9.951866149902344,
      "font_name": "T16",
      "bbox": [
        84.19436645507812,
        194.78712463378906,
        418.45318603515625,
        206.72607421875
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1개",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        84.19436645507812,
        194.78712463378906,
        418.45318603515625,
        206.72607421875
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        84.19436645507812,
        213.2469482421875,
        418.45318603515625,
        225.18589782714844
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상판",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        84.19436645507812,
        213.2469482421875,
        418.45318603515625,
        225.18589782714844
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지지체",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        84.19436645507812,
        213.2469482421875,
        418.45318603515625,
        225.18589782714844
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 9.951866149902344,
      "font_name": "T16",
      "bbox": [
        84.19436645507812,
        213.2469482421875,
        418.45318603515625,
        225.18589782714844
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1개",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        84.19436645507812,
        213.2469482421875,
        418.45318603515625,
        225.18589782714844
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        84.19436645507812,
        231.70677185058594,
        418.45318603515625,
        243.64572143554688
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하판",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        84.19436645507812,
        231.70677185058594,
        418.45318603515625,
        243.64572143554688
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지지체",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        84.19436645507812,
        231.70677185058594,
        418.45318603515625,
        243.64572143554688
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 9.951866149902344,
      "font_name": "T16",
      "bbox": [
        84.19436645507812,
        231.70677185058594,
        418.45318603515625,
        243.64572143554688
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1개",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        84.19436645507812,
        231.70677185058594,
        418.45318603515625,
        243.64572143554688
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        84.19436645507812,
        250.16659545898438,
        89.15176391601562,
        262.0956115722656
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "막힘부",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        120.77454376220703,
        259.3965148925781,
        192.8558807373047,
        271.3255310058594
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "반응부",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        120.77454376220703,
        259.3965148925781,
        192.8558807373047,
        271.3255310058594
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "주성분",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        212.28494262695312,
        250.16659545898438,
        444.35919189453125,
        262.1055603027344
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 9.951866149902344,
      "font_name": "T16",
      "bbox": [
        212.28494262695312,
        250.16659545898438,
        444.35919189453125,
        262.1055603027344
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "OO±OO ㎍/㎖",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        212.28494262695312,
        250.16659545898438,
        444.35919189453125,
        262.1055603027344
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        84.19436645507812,
        268.6264343261719,
        420.85235595703125,
        280.5653991699219
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "보조성분",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        84.19436645507812,
        268.6264343261719,
        420.85235595703125,
        280.5653991699219
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "○○○",
      "font_size": 9.951866149902344,
      "font_name": "T16",
      "bbox": [
        84.19436645507812,
        268.6264343261719,
        420.85235595703125,
        280.5653991699219
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적량",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        84.19436645507812,
        268.6264343261719,
        420.85235595703125,
        280.5653991699219
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 원자재:",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        68.92467498779297,
        126.86532592773438,
        84.4467544555664
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모델명 : ○○ SIPA test",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        94.93624877929688,
        214.56216430664062,
        110.47127532958984
      ],
      "page_num": 46,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "* 각 모델명별로 구분하여 기재한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        285.2882080078125,
        266.10986328125,
        300.810302734375
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 형상:",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        337.1914978027344,
        114.27214813232422,
        352.7135925292969
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 본체",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        363.20306396484375,
        121.9736099243164,
        378.72515869140625
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) SIPA/ADP/EPI/Aspirin/P2Y12 tests",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        549.0,
        310.233154296875,
        564.5220947265625
      ],
      "page_num": 46,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 40 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5) 구조:",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        68.92467498779297,
        114.27214813232422,
        84.4467544555664
      ],
      "page_num": 47,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 본체",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        94.93624877929688,
        121.9736099243164,
        110.45832824707031
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① Tray(검사칩 삽입부): 검사칩을 올려놓고 여닫을 수 있는 Tray",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        282.5312194824219,
        460.0497131347656,
        298.0662536621094
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 디스플레이(사용자 화면): 별도로 제공되는 태블릿을 이용하여 검사 설정",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.67573547363281,
        308.4229431152344,
        538.1483764648438,
        323.9579772949219
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 검사결과를 확인할 수 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        102.66436004638672,
        334.43450927734375,
        282.06121826171875,
        349.95660400390625
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) SIPA/ADP/EPI/Aspirin/P2Y12 tests",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        360.4460754394531,
        310.233154296875,
        375.9681701660156
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 혈액주입구: 검사칩(test kit)에 혈액(전혈)을 로딩하는 주입구. 검체량은 400㎕이다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        518.6731567382812,
        537.40283203125,
        534.2081909179688
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 혈액챔버: 혈액주입구를 통해 로딩된 혈액이 채워지는 챔버. 샘플챔버와",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.67573547363281,
        544.5648803710938,
        538.1483764648438,
        560.0999145507812
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "컨트롤 챔버의 2개의 챔버로 구성되어 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        100.8653335571289,
        570.576416015625,
        358.3398742675781,
        586.0985107421875
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③ 막힘부: 내부에 Collagen이 채워져 있어 활성화된 혈소판의 부착을 유도하여",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.67573547363281,
        596.5880126953125,
        538.148193359375,
        612.123046875
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈액 폐색을 유발한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        101.3450698852539,
        622.479736328125,
        227.9705352783203,
        638.0018310546875
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "④ 혈액이동부: 막힘부에 폐색이 일어날 때까지 혈액은 혈액이동부를 통해 이동",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.67573547363281,
        648.4912719726562,
        538.1483154296875,
        664.0263061523438
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하게 되며, 이동거리를 측정하여 결과를 얻을 수 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        101.22513580322266,
        674.5028686523438,
        410.0318603515625,
        690.0249633789062
      ],
      "page_num": 47,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "⑤ 폐챔버: 혈액챔버에서 이동된 혈액이 모이는 끝단. 음압펌프가 연결된다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        700.3945922851562,
        519.2926635742188,
        715.9296264648438
      ],
      "page_num": 47,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 41 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6) 치수/중량:",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        68.92467498779297,
        147.13433837890625,
        84.4467544555664
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 본체 : 가로 x 세로 x 높이, 0㎏",
      "font_size": 12.94941520690918,
      "font_name": "T11",
      "bbox": [
        75.43911743164062,
        94.93624877929688,
        279.68841552734375,
        110.47127532958984
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2) SIPA/ADP/EPI/Aspirin/P2Y12 tests : 가로 x 세로 x 높이, ㎏",
      "font_size": 12.94941520690918,
      "font_name": "T11",
      "bbox": [
        75.43911743164062,
        120.82794952392578,
        461.9895935058594,
        136.36297607421875
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "7) 성능",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        146.83953857421875,
        111.41932678222656,
        162.36160278320312
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 카트리지(시약)의 분석적 성능을 기재한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        172.85110473632812,
        338.79046630859375,
        188.38612365722656
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8) 보관조건:",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        198.74281311035156,
        139.45849609375,
        214.26487731933594
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 본체 : 해당사항 없음",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        224.75437927246094,
        219.48074340820312,
        240.2764434814453
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) SIPA/ADP/EPI/Aspirin/P2Y12 tests",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        250.7659454345703,
        310.233154296875,
        266.28802490234375
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 미개봉: 2~8℃, 제조일로부터 12개월",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        81.67573547363281,
        276.65765380859375,
        301.5165710449219,
        292.19268798828125
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 개봉",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.67573547363281,
        302.6692199707031,
        117.77588653564453,
        318.1913146972656
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2~8℃(파우치 내 보관), 개봉일로부터 6일",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        88.03228759765625,
        328.6807861328125,
        327.7823486328125,
        344.2158203125
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "15~25℃(파우치 외 보관), 개봉일로부터 4시간",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        88.03228759765625,
        354.572509765625,
        352.9684143066406,
        370.1075439453125
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7.3. 임상시험용 의료기기 사용방법",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        406.59564208984375,
        258.339111328125,
        422.11773681640625
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 검체준비 및 저장방법",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        432.4873352050781,
        205.92752075195312,
        448.0094299316406
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 올바른 채혈법을 숙지한 후 채혈을 실시한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        458.4989318847656,
        351.3836364746094,
        474.0210266113281
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 바늘 굵기가 21G인 주사기를 사용한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        484.510498046875,
        316.9623107910156,
        500.0325927734375
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 항응고제 함유 채혈관(3.2% Na citrate tube)를 준비한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        510.4022216796875,
        418.18743896484375,
        525.92431640625
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4) 검체는 실온(15~25℃)에 보관한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        536.4137573242188,
        285.5393371582031,
        551.9487915039062
      ],
      "page_num": 48,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(5) 검사는 채혈 후 30분~4시간 내에 수행하도록 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        562.4253540039062,
        384.1258850097656,
        577.9474487304688
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 검사 전 준비사항",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        588.3170776367188,
        180.74114990234375,
        603.8391723632812
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 검사칩이 들어있는 파우치를 개봉하기 전, 실온에 약 10분간 방치한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        614.32861328125,
        499.26348876953125,
        629.8507080078125
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2) 사용 전, 임상시험용 장비와 검사칩의 손상여부 및 이상유무를 확인한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        640.3402099609375,
        511.8566589355469,
        655.8623046875
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 검사과정",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        666.2318725585938,
        130.3684844970703,
        681.7539672851562
      ],
      "page_num": 48,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 장비 작동",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        692.2434692382812,
        147.15994262695312,
        707.7655639648438
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 장비 후면 우측 하단의 전원 스위치를 “ON”상태로 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        718.2550659179688,
        426.22308349609375,
        733.7901000976562
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "② 태블릿에 로그인 화면이 나타나면 아이디와 비밀번호를 입력한 후, “Log",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        744.146728515625,
        538.1280517578125,
        759.6817626953125
      ],
      "page_num": 48,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 42 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 49,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "In”버튼을 눌러 로그인한다. 초기 설정값은 아이디: pi, 비밀번호: top이다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        96.78754425048828,
        68.92467498779297,
        525.2893676757812,
        84.4467544555664
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "③ 윈도우가 로딩되면 아이콘을 더블클릭하여 혈소판 기능검사 프로그램을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        94.93624877929688,
        538.1483764648438,
        110.47127532958984
      ],
      "page_num": 49,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실행한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        95.46826171875,
        120.82794952392578,
        150.13272094726562,
        136.3500213623047
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "④ 메인화면에서 “Start”버튼을 클릭하면 “Chip Selection”화면이 나타난다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        146.83953857421875,
        509.3380432128906,
        162.3745574951172
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "⑤ “Chip Selection”화면에서 검사 종류에 따라 해당하는 아이콘을 클릭한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        172.85110473632812,
        521.0916748046875,
        188.38612365722656
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "⑥ Tray가 나와 움직이지 않을 때까지 기다린다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        198.74281311035156,
        356.30096435546875,
        214.27783203125
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 검사칩 장착",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        224.75437927246094,
        159.75311279296875,
        240.2764434814453
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 검사칩을 임상시험용 장비의 Tray에 놓고, 끝까지 밀어 넣는다. Tray 에 심한",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        250.7659454345703,
        538.1483154296875,
        266.30096435546875
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "압력을 가해서는 안된다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        94.62871551513672,
        276.65765380859375,
        233.72740173339844,
        292.17974853515625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 피펫으로 400㎕의 혈액을 검사칩의 혈액 주입구 한쪽 내부 표면을 따라",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        302.6692199707031,
        538.1483764648438,
        318.2042541503906
      ],
      "page_num": 49,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "천천히 주입하는 방식으로 분주한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        95.10845184326172,
        328.6807861328125,
        312.6446228027344,
        344.202880859375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③ “Kit Information”에 ID(환자정보)를 입력하고 “Save”버튼을 눌러 저장한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        354.572509765625,
        531.8858032226562,
        370.1075439453125
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "④ 메인화면의 “Camera”탭에서 검사칩의 현재 모습, “Log”탭에서 현재 검사",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        406.59564208984375,
        538.1480712890625,
        422.13067626953125
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "단계, “Pressure”탭에서 현재 장비가 제공하는 압력을 확인할 수 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        96.42774200439453,
        432.4873352050781,
        503.1014099121094,
        448.0094299316406
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 검사가 종료될 때까지 기다린다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        458.4989318847656,
        275.8245849609375,
        474.0210266113281
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4) 검사가 종료되면 Tray가 밖으로 나온다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        484.510498046875,
        320.6802673339844,
        500.0325927734375
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(5) Tray에서 검사칩을 조심스럽게 빼내어 제거한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        510.4022216796875,
        371.052978515625,
        525.92431640625
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(6) 메인화면의 “Result”탭을 확인하여 검사에 대한 정보를 검토한다. 검사에 대한",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        536.4137573242188,
        538.1483154296875,
        551.9358520507812
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자세한 정보는 “pi/PFA/vision 경로”에서 “날짜_시간_ID.log” 파일을 통해",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        90.7907943725586,
        562.4253540039062,
        538.1488037109375,
        577.9474487304688
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "확인할 수 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        90.7907943725586,
        588.3170776367188,
        181.31581115722656,
        603.8391723632812
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(7) 다음 검사를 진행하려면, 새로운 검사칩을 준비하여 위의 과정을 반복한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        614.32861328125,
        524.4498291015625,
        629.8507080078125
      ],
      "page_num": 49,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(8) 검사를 종료하려면 “Kit Information”화면의 “Cancel”버튼을 클릭하여 종료한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        640.3402099609375,
        536.0835571289062,
        655.8623046875
      ],
      "page_num": 49,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(9) 사용한 검사칩 폐기: 환자나 사용자를 위한 감염방지 및 교차감염방지를 위해",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        666.2318725585938,
        538.1488037109375,
        681.7539672851562
      ],
      "page_num": 49,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "감염 방지 정책 및 병원의 규정에 의거하여 폐기한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        90.31105041503906,
        692.2434692382812,
        399.1177673339844,
        707.7655639648438
      ],
      "page_num": 49,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 결과판정 및 정도관리",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        718.2550659179688,
        205.92752075195312,
        733.7771606445312
      ],
      "page_num": 49,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 결과판정 : 검사결과는 혈액이동거리(MD), 혈액이동거리의 비율(MR)로 표시된다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        744.146728515625,
        537.2828979492188,
        759.6688232421875
      ],
      "page_num": 49,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 43 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 50,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2) 정도관리",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        68.92467498779297,
        140.80282592773438,
        84.4467544555664
      ],
      "page_num": 50,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 본체",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        94.93624877929688,
        119.81478118896484,
        110.47127532958984
      ],
      "page_num": 50,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "교대근무를 시작할때마다 “유지보수메뉴(Maintenance Menu)”에서 “Self Test”를",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.67573547363281,
        120.82794952392578,
        538.1483764648438,
        136.3500213623047
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수행한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        146.83953857421875,
        133.7016143798828,
        162.36160278320312
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 검사칩",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        75.43911743164062,
        172.85110473632812,
        132.40823364257812,
        188.38612365722656
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "QC 검사를 위해 대조 검체 공여자 그룹을 설정할 것을 권장한다. 적합한 QC",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        198.74281311035156,
        538.1907348632812,
        214.26487731933594
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공여자의 MD 또는 MR은 검사실의 참조 범위의 중간에 가까운 값과 허용",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.67573547363281,
        224.75437927246094,
        538.1478271484375,
        240.2764434814453
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가능한 반복정밀도를 보여주어야 한다. 정도관리의 일환으로 신규 로트의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.67573547363281,
        250.7659454345703,
        538.1488647460938,
        266.28802490234375
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사칩을 장착할 때마다 또는 시스템 성능의 검증이 필요할 때마다 대조 검체",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.67573547363281,
        276.65765380859375,
        538.1480712890625,
        292.17974853515625
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "공여자를 중복해서 검사할 것을 권장한다. 평균 MD 또는 MR이 개별 검사실",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.67573547363281,
        302.6692199707031,
        538.1477661132812,
        318.1913146972656
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "에서 설정된 진단경계치 범위 내에 속하는 경우, 검사칩이 완전하게 기능하는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.67573547363281,
        328.6807861328125,
        538.1474609375,
        344.202880859375
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "것으로 간주된다. 평균 MD 또는 MR이 진단경계치 범위를 벗어나는 경우",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        81.67573547363281,
        354.572509765625,
        538.1483764648438,
        370.0946044921875
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사실의 설정된 대조 검체 공여자 그룹에서 두 번째 공여자를 선택하여 이",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.67573547363281,
        380.5840759277344,
        538.1483764648438,
        396.1061706542969
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "절차를 반복한다. 두 검체의 평균 MD 또는 MR이 진단경계치 범위 내에",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.67573547363281,
        406.59564208984375,
        538.1481323242188,
        422.11773681640625
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "속하는 경우, 첫 번째 공여자의 혈소판 기능 상태 및 약물 복용 기록을 의심",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.67573547363281,
        432.4873352050781,
        538.1478271484375,
        448.0094299316406
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해야 한다. 첫 번째 공여자는 본 검사의 대조 검체 공여자 그룹에서 배제",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.67573547363281,
        458.4989318847656,
        538.148681640625,
        474.0210266113281
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        484.510498046875,
        157.92848205566406,
        500.0325927734375
      ],
      "page_num": 50,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7.4. 임상시험용 의료기기의 공급 및 관리",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        548.76025390625,
        296.11920166015625,
        564.2823486328125
      ],
      "page_num": 50,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        574.7718505859375,
        85.61631774902344,
        590.2939453125
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈액응고 시간측정기, 채혈을 위한 란셋, 사용설명서가 파우치에 포장되어 있는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.72600555419922,
        600.783447265625,
        538.1480712890625,
        616.3055419921875
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상태로 공급 소모품인 검사지는 별도 구매. 낱개포장 된 검사지가 1박스 당 48개가",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.72600555419922,
        626.6751098632812,
        538.1483154296875,
        642.1972045898438
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동봉. 임상시험 종료후 남은 제품은 폐기한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.72600555419922,
        652.6867065429688,
        322.23944091796875,
        668.2088012695312
      ],
      "page_num": 50,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 44 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 51,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "* 피험자의 선정기준/제외기준 · 인원 및 근거",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        153.91180419921875,
        334.0186767578125,
        169.4468231201172
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 피험자(Subject)란 임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        179.8035125732422,
        530.5923461914062,
        195.32557678222656
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "어 임상시험에 참여하는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        75.55905151367188,
        205.81507873535156,
        530.5924682617188,
        221.33714294433594
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "격한 피험자의 선정기준과 제외기준을 제시하여야 함. 이때 임상시험 참여와",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.55905151367188,
        231.82666015625,
        530.5933837890625,
        247.34872436523438
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연관된 이익을 기대하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.55905151367188,
        257.7183532714844,
        530.4725341796875,
        273.2404479980469
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "불이익을 우려하여 자발적인 참여 결정에 영향을 받을 소지가 있는 등, 취약",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.55905151367188,
        283.72991943359375,
        530.5924682617188,
        299.25201416015625
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한 환경에 있는 피험자(Vulnerable Subjects)는 선정대상에서 제외함. 또한,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.55905151367188,
        309.7414855957031,
        530.5665283203125,
        325.2635803222656
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험군과 대조군을 포함한 피험자 수는 해당 의료기기의 특성, 임상시험디자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.55905151367188,
        335.6331787109375,
        530.5924682617188,
        351.1552734375
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인, 근거를 통한 시험에서 기대하는 연구결과의 사전 예측, 통계적 유의성,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.55905151367188,
        361.644775390625,
        530.5665283203125,
        377.1668701171875
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검정 방법, 탈락률 등을 반영하여 통계학적으로 타당하게 제시되어야 하며, 임",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.55905151367188,
        387.6563415527344,
        530.5924682617188,
        403.1784362792969
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "상시험의 효능 및 안전성 입증에 필요한 충분한 수가 확보되어야 함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.55905151367188,
        413.54803466796875,
        475.2764892578125,
        429.07012939453125
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 피험자 수: 시험대상수 산출시 일반적인 고려사항",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        439.55963134765625,
        362.4432678222656,
        455.08172607421875
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임상연구에서 연구피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        465.5711975097656,
        530.5921630859375,
        481.0932922363281
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수가 보장되어야 하며, 일반적으로 1차 주효과 변수를 기준으로 정해지고, 연구",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.79891967773438,
        491.462890625,
        530.5924072265625,
        506.9849853515625
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "계획서상에 정확한 연구피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.79891967773438,
        517.4744873046875,
        530.5665283203125,
        532.99658203125
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "그러나 최근의 임상연구에서는 임상연구가 점차 복잡해지고 다양한 연구 목적을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.79891967773438,
        543.4860229492188,
        530.59130859375,
        559.0081176757812
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평가하기 위하여 1차 주효과 변수뿐만 아니라 안전성평가변수 및 2차 주효과",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.79891967773438,
        569.3777465820312,
        530.5918579101562,
        584.8998413085938
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "변수, 1차 주효과 변수의 조합 등을 고려하여 수행되고 있음.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.79891967773438,
        595.3893432617188,
        428.38189697265625,
        610.9114379882812
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8. 피험자의 선정기준·제외기준·인원 및 그 근거",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        74.19891357421875,
        439.20196533203125,
        93.31405639648438
      ],
      "page_num": 51,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        56.609317779541016,
        109.20393371582031,
        541.8339233398438,
        120.23188781738281
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        73.99989318847656,
        126.82469177246094,
        301.63604736328125,
        137.85263061523438
      ],
      "page_num": 51,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 성별, 나이, 교육정도(동의능력). 흡연여부, 알코올 혹은 약 남용자, 사회 경제적",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        634.4666137695312,
        538.1477661132812,
        649.9887084960938
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상태, 임신과 수유, 유전학적 병력, 정서적인 제한 등을 고려하여 제외한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        68.9626235961914,
        660.3583374023438,
        503.3412780761719,
        675.8804321289062
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        686.369873046875,
        86.09606170654297,
        701.8919677734375
      ],
      "page_num": 51,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "8.1. 피험자 선정기준",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        712.3814697265625,
        176.54342651367188,
        727.903564453125
      ],
      "page_num": 51,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 혈소판 기능검사",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        738.273193359375,
        179.6617431640625,
        753.7952880859375
      ],
      "page_num": 51,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 45 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 52,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand disease),",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        68.92467498779297,
        538.122802734375,
        84.4467544555664
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "글란즈만혈소판무력증(Glanzmann's thrombasthenia), 약물유발 혈소판기능부전",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        86.47313690185547,
        94.93624877929688,
        538.1480102539062,
        110.45832824707031
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(drug-induced platelet dysfunction) 등의 선천적/후천적 혈소판기능장애 환자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        86.47313690185547,
        120.82794952392578,
        531.0721435546875,
        136.3500213623047
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        69.2024917602539,
        146.83953857421875,
        465.22784423828125,
        162.36160278320312
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 혈소판 약물반응검사",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        172.85110473632812,
        204.84750366210938,
        188.3731689453125
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) Aspirin test: 혈관질환의 위험군, 혈관질환 병력 등으로 aspirin 복용 예정인",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        198.74281311035156,
        538.1477661132812,
        214.26487731933594
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "환자에서 aspirin 복용 전 1번과 최소 3일 이상의 Aspirin 복용 후 1번 측정",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        87.07280731201172,
        224.75437927246094,
        538.0281372070312,
        240.2764434814453
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        87.07280731201172,
        250.7659454345703,
        115.47149658203125,
        266.28802490234375
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2）P2Y12 test: 혈관질환의 위험군, 혈관질환 병력 등으로 clopidogrel 복용예정인",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        276.65765380859375,
        538.1502075195312,
        292.19268798828125
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환자에서 clopidogrel 복용 전 1번과 최소 5일이상 clopidogrel 복용 후 1번",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        88.03228759765625,
        302.6692199707031,
        538.1483764648438,
        318.1913146972656
      ],
      "page_num": 52,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "측정한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.03228759765625,
        328.6807861328125,
        141.13758850097656,
        344.202880859375
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8.2. 피험자 제외기준",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        380.5840759277344,
        176.54342651367188,
        396.1061706542969
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 공통 제외기준",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        406.59564208984375,
        167.06857299804688,
        422.11773681640625
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 피험자의 임상정보를 알 수 없는 경우",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        69.2024917602539,
        432.4873352050781,
        300.3172302246094,
        448.0094299316406
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 직전 1개월 내 시행한 검사 결과상 혈소판수가 100x10^9/uL이하인 경우",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        69.2024917602539,
        458.4989318847656,
        500.8485412597656,
        474.0210266113281
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 직전 1개월 내 시행한 검사 결과상 Hct 35% 이하, 50%이상인 경우",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        69.2024917602539,
        484.510498046875,
        470.5050048828125,
        500.0325927734375
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 직전 1개월 내 시행한 검사 결과상 PT, aPTT가 참고치를 벗어난 경우",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        69.2024917602539,
        510.4022216796875,
        486.45635986328125,
        525.92431640625
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 항응고제 치료중인 환자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        536.4137573242188,
        218.52127075195312,
        551.9358520507812
      ],
      "page_num": 52,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 임신중인 여성",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        562.4253540039062,
        161.79202270507812,
        577.9474487304688
      ],
      "page_num": 52,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 혈소판 약물반응검사 제외기준",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        588.3170776367188,
        261.5773620605469,
        603.8391723632812
      ],
      "page_num": 52,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 출혈성 질환, 응고장애의 병력이 있는 경우",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        69.2024917602539,
        614.32861328125,
        328.62188720703125,
        629.8507080078125
      ],
      "page_num": 52,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 46 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 53,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사항목",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        178.5832061767578,
        474.8011169433594,
        517.3995971679688,
        488.02362060546875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "양성(비정상 결과) 환자 수",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        178.5832061767578,
        474.8011169433594,
        517.3995971679688,
        488.02362060546875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "음성(정상 결과) 환자 수",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        178.5832061767578,
        474.8011169433594,
        517.3995971679688,
        488.02362060546875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈소판 기능검사",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        72.44074249267578,
        513.758544921875,
        151.2396240234375,
        526.9810791015625
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "EPI test",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        180.8619842529297,
        494.3397521972656,
        485.2575378417969,
        507.562255859375
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "105명 이상",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        180.8619842529297,
        494.3397521972656,
        485.2575378417969,
        507.562255859375
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "105명 이상",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        180.8619842529297,
        494.3397521972656,
        485.2575378417969,
        507.562255859375
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ADP test",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        177.6237335205078,
        513.758544921875,
        485.2575378417969,
        526.9810791015625
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "105명 이상",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        177.6237335205078,
        513.758544921875,
        485.2575378417969,
        526.9810791015625
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "132명 이상",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        177.6237335205078,
        513.758544921875,
        485.2575378417969,
        526.9810791015625
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "SIPA test",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        177.26393127441406,
        533.1773071289062,
        485.2575378417969,
        546.3998413085938
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "105명 이상",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        177.26393127441406,
        533.1773071289062,
        485.2575378417969,
        546.3998413085938
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "132명 이상",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        177.26393127441406,
        533.1773071289062,
        485.2575378417969,
        546.3998413085938
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검사항목",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        187.93814086914062,
        684.9314575195312,
        520.5178833007812,
        698.1539916992188
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "양성(약물반응) 환자군 수",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        187.93814086914062,
        684.9314575195312,
        520.5178833007812,
        698.1539916992188
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "음성(약물비반응) 환자군 수",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        187.93814086914062,
        684.9314575195312,
        520.5178833007812,
        698.1539916992188
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈소판 약물반응검사",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        67.1635971069336,
        718.3749389648438,
        166.9521484375,
        731.5974731445312
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Aspirin test",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        180.74205017089844,
        707.2271118164062,
        477.9414978027344,
        720.4496459960938
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "75명 이상",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        180.74205017089844,
        707.2271118164062,
        477.9414978027344,
        720.4496459960938
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "40명 이상",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        180.74205017089844,
        707.2271118164062,
        477.9414978027344,
        720.4496459960938
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "P2Y12 test",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        183.8603515625,
        729.522705078125,
        480.46014404296875,
        742.7452392578125
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "132명 이상",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        183.8603515625,
        729.522705078125,
        480.46014404296875,
        742.7452392578125
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "155명 이상",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        183.8603515625,
        729.522705078125,
        480.46014404296875,
        742.7452392578125
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8.3. 목표대상자 수 및 그 근거",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        68.92467498779297,
        233.15335083007812,
        84.4467544555664
      ],
      "page_num": 53,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "* 연구피험자 수를 결정하기 위해서는 사전 정보가 필요하며, 아래의 항목과 같을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        102.00851440429688,
        529.3931274414062,
        117.53059387207031
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        76.27865600585938,
        127.90021514892578,
        122.18785858154297,
        143.4222869873047
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 연구가설",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        70.76165008544922,
        153.91180419921875,
        142.4827880859375,
        169.43386840820312
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 유의수준",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        70.76165008544922,
        179.92337036132812,
        142.48190307617188,
        195.4454345703125
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 통계적 검정 방법",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        70.76165008544922,
        205.81507873535156,
        192.85519409179688,
        221.33714294433594
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4) 사용될 통계적 분석방법(즉, 연구디자인과도 관련)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        70.76165008544922,
        231.82666015625,
        380.4165344238281,
        247.34872436523438
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이 (및 표준편차): 피험자 수는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        70.76165008544922,
        257.8382263183594,
        529.3930053710938,
        273.3603210449219
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험 방법에 따라 “의료기기 임상시험 관련 통계기법 가이드라인”을 적용한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        92.11007690429688,
        283.72991943359375,
        525.0494995117188,
        299.25201416015625
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8.3.1 피험자 수",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        316.8137512207031,
        151.35797119140625,
        332.3358459472656
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 혈소판 기능검사",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        342.8253479003906,
        186.018310546875,
        358.3474426269531
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "EPI test 양성(비정상 결과) 환자 105명 이상, EPI test 음성(정상 결과) 대조군",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        77.95774841308594,
        368.717041015625,
        538.1483764648438,
        384.2391357421875
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "105명 이상, ADP test 양성(비정상 결과) 환자 105명 이상, ADP test 음성(정상",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        77.95774841308594,
        394.7286071777344,
        538.1480712890625,
        410.2507019042969
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과) 대조군 132명 이상, SIPA test 양성(비정상 결과) 환자 105명 이상, SIPA",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        77.95774841308594,
        420.74017333984375,
        538.1392211914062,
        436.26226806640625
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "test 음성(정상 결과) 대조군 132명 이상을 대상으로 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        77.95774841308594,
        446.63189697265625,
        411.231201171875,
        462.15399169921875
      ],
      "page_num": 53,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 혈소판 약물반응검사",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        577.0493774414062,
        211.20407104492188,
        592.5714721679688
      ],
      "page_num": 53,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Aspirin test 양성(약물 반응) 환자 75명 이상, Aspirin test 음성(약물 비반응)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        79.39697265625,
        603.0609130859375,
        538.131103515625,
        618.5830078125
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환자 40명 이상, P2Y12 test 양성(약물 반응) 환자 132명 이상, P2Y12 test 음성",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        628.95263671875,
        538.1480712890625,
        644.4747314453125
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(약물 비반응) 환자 155명 이상을 대상으로 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        654.9642333984375,
        357.6202697753906,
        670.486328125
      ],
      "page_num": 53,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 47 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 54,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "8.3.2 피험자 수 산출 방법",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        68.92467498779297,
        214.20361328125,
        84.4467544555664
      ],
      "page_num": 54,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험 시약의 예상 민감도와 특이도, 일치도를 이용한 통계학적 방법을 적용하여",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        94.93624877929688,
        538.1474609375,
        110.45832824707031
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체 수를 산출하였다. 계산식에 적용한 민감도와 특이도는 아래 ‘8.3.3 피험자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        120.82794952392578,
        538.1477661132812,
        136.3500213623047
      ],
      "page_num": 54,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 산출 근거’ 항에 기재하였으며, 유의수준 5%, 검정력 80%, 예상되는 차이",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        146.83953857421875,
        538.1480712890625,
        162.36160278320312
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10%로 가정하였다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        172.85110473632812,
        177.3579559326172,
        188.3731689453125
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가 혈소판 기능검사",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        224.75437927246094,
        182.78005981445312,
        240.2764434814453
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① EPI test 양성 검체 검사 시 (민감도 85%),",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        250.7659454345703,
        337.9507751464844,
        266.30096435546875
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 대립가설: 개발제품의 민감도가 85% 이상이다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        276.65765380859375,
        360.8585205078125,
        292.17974853515625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 귀무가설: 개발제품의 민감도가 85% 미만이다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        302.6692199707031,
        360.8585205078125,
        318.1913146972656
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 적용 계산식 : ",
      "font_size": 43.406349182128906,
      "font_name": "HyhwpEQ",
      "bbox": [
        81.67573547363281,
        336.4722900390625,
        291.0208435058594,
        361.94866943359375
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "   ",
      "font_size": 6.715545177459717,
      "font_name": "HyhwpEQ",
      "bbox": [
        81.67573547363281,
        336.4722900390625,
        291.0208435058594,
        361.94866943359375
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "       ",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        197.77281188964844,
        328.3853454589844,
        290.75360107421875,
        345.286865234375
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[n = sample size (검체 수), p (민감도) = 0.85,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.03228759765625,
        372.0733642578125,
        360.8592224121094,
        387.595458984375
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10]",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.03228759765625,
        397.965087890625,
        416.1578674316406,
        413.4871826171875
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "n = 99.96",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.03228759765625,
        423.9766540527344,
        143.89552307128906,
        439.4987487792969
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.67573547363281,
        449.98822021484375,
        409.4577941894531,
        465.51031494140625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② EPI test 음성 검체 검사 시 (특이도 85%),",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        475.8799133300781,
        337.9507751464844,
        491.4149475097656
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 대립가설: 개발제품의 특이도가 85% 이상이다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        501.8914794921875,
        360.8585205078125,
        517.41357421875
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 귀무가설: 개발제품의 특이도가 85% 미만이다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        527.903076171875,
        360.8585205078125,
        543.4251708984375
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 적용 계산식 : ",
      "font_size": 43.406349182128906,
      "font_name": "HyhwpEQ",
      "bbox": [
        81.67573547363281,
        561.5862426757812,
        291.0208435058594,
        587.1824951171875
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "   ",
      "font_size": 6.715545177459717,
      "font_name": "HyhwpEQ",
      "bbox": [
        81.67573547363281,
        561.5862426757812,
        291.0208435058594,
        587.1824951171875
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "       ",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        197.77281188964844,
        553.4993286132812,
        290.75360107421875,
        570.520751953125
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[n = sample size (검체 수), p (특이도) = 0.85,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.03228759765625,
        597.1873779296875,
        360.8592224121094,
        612.70947265625
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10]",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.03228759765625,
        623.1989135742188,
        416.1578674316406,
        638.7210083007812
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "n = 99.96",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.03228759765625,
        649.0906372070312,
        143.89552307128906,
        664.6127319335938
      ],
      "page_num": 54,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.67573547363281,
        675.1022338867188,
        409.4577941894531,
        690.6243286132812
      ],
      "page_num": 54,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "③ ADP test 양성 검체 검사 시 (민감도 85%),",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        701.11376953125,
        345.6278991699219,
        716.6488037109375
      ],
      "page_num": 54,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 대립가설: 개발제품의 민감도가 85% 이상이다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        727.0054931640625,
        360.8585205078125,
        742.527587890625
      ],
      "page_num": 54,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 귀무가설: 개발제품의 민감도가 85% 미만이다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        753.0170288085938,
        360.8585205078125,
        768.5391235351562
      ],
      "page_num": 54,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 48 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 55,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 적용 계산식 : ",
      "font_size": 43.406349182128906,
      "font_name": "HyhwpEQ",
      "bbox": [
        81.67573547363281,
        76.71615600585938,
        291.0208435058594,
        102.19254302978516
      ],
      "page_num": 55,
      "block_type": "heading",
      "level": 1,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "   ",
      "font_size": 6.715545177459717,
      "font_name": "HyhwpEQ",
      "bbox": [
        81.67573547363281,
        76.71615600585938,
        291.0208435058594,
        102.19254302978516
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "       ",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        197.77281188964844,
        68.62921905517578,
        290.75360107421875,
        85.65061950683594
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[n = sample size (검체 수), p (민감도) = 0.85,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.03228759765625,
        112.31725311279297,
        360.8592224121094,
        127.8393325805664
      ],
      "page_num": 55,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10]",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.03228759765625,
        138.32882690429688,
        416.1578674316406,
        153.85089111328125
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "n = 99.96",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.03228759765625,
        164.2205352783203,
        143.89552307128906,
        179.7425994873047
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.67573547363281,
        190.23211669921875,
        409.4577941894531,
        205.75418090820312
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "④ ADP test 음성 검체 검사 시 (특이도 80%),",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        216.24368286132812,
        345.6278991699219,
        231.77870178222656
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 대립가설: 개발제품의 특이도가 80% 이상이다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        242.13539123535156,
        360.8585205078125,
        257.657470703125
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 귀무가설: 개발제품의 특이도가 80% 미만이다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        268.1469421386719,
        360.8585205078125,
        283.6690368652344
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 적용 계산식 : ",
      "font_size": 43.406349182128906,
      "font_name": "HyhwpEQ",
      "bbox": [
        81.67573547363281,
        301.95001220703125,
        291.0208435058594,
        327.4263916015625
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "   ",
      "font_size": 6.715545177459717,
      "font_name": "HyhwpEQ",
      "bbox": [
        81.67573547363281,
        301.95001220703125,
        291.0208435058594,
        327.4263916015625
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "       ",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        197.77281188964844,
        293.8630676269531,
        290.75360107421875,
        310.7646179199219
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[n = sample size (검체 수), p (특이도) = 0.80,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.03228759765625,
        337.4312438964844,
        360.8592224121094,
        352.9533386230469
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10]",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.03228759765625,
        363.44281005859375,
        416.1578674316406,
        378.96490478515625
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "n = 125.44",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.03228759765625,
        389.4543762207031,
        150.25155639648438,
        404.9764709472656
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- Sample Size (5% 탈락률 적용) = 131.71, 약 132개 검체",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.67573547363281,
        415.3460693359375,
        415.69439697265625,
        430.8681640625
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "⑤ SIPA test 양성 검체 검사 시 (민감도 85%),",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        441.357666015625,
        346.7060241699219,
        456.8927001953125
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 대립가설: 개발제품의 민감도가 85% 이상이다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        467.3692321777344,
        360.8585205078125,
        482.8913269042969
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 귀무가설: 개발제품의 민감도가 85% 미만이다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        493.26092529296875,
        360.8585205078125,
        508.78302001953125
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 적용 계산식 : ",
      "font_size": 43.406349182128906,
      "font_name": "HyhwpEQ",
      "bbox": [
        81.67573547363281,
        527.06396484375,
        291.0208435058594,
        552.5404052734375
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "   ",
      "font_size": 6.715545177459717,
      "font_name": "HyhwpEQ",
      "bbox": [
        81.67573547363281,
        527.06396484375,
        291.0208435058594,
        552.5404052734375
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "       ",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        197.77281188964844,
        518.97705078125,
        290.75360107421875,
        535.9984741210938
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[n = sample size (검체 수), p (민감도) = 0.85,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.03228759765625,
        562.6651000976562,
        360.8592224121094,
        578.1871948242188
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10]",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.03228759765625,
        588.6766357421875,
        416.1578674316406,
        604.19873046875
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "n = 99.96",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.03228759765625,
        614.568359375,
        143.89552307128906,
        630.0904541015625
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.67573547363281,
        640.5799560546875,
        409.4577941894531,
        656.10205078125
      ],
      "page_num": 55,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "⑥ SIPA test 음성 검체 검사 시 (특이도 80%),",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        666.5914916992188,
        346.7060241699219,
        682.1265258789062
      ],
      "page_num": 55,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 대립가설: 개발제품의 특이도가 80% 이상이다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        692.4832153320312,
        360.8585205078125,
        708.0053100585938
      ],
      "page_num": 55,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 귀무가설: 개발제품의 특이도가 80% 미만이다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        718.4948120117188,
        360.8585205078125,
        734.0169067382812
      ],
      "page_num": 55,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 49 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 56,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 적용 계산식 : ",
      "font_size": 43.406349182128906,
      "font_name": "HyhwpEQ",
      "bbox": [
        81.67573547363281,
        76.71615600585938,
        291.0208435058594,
        102.19254302978516
      ],
      "page_num": 56,
      "block_type": "heading",
      "level": 1,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "   ",
      "font_size": 6.715545177459717,
      "font_name": "HyhwpEQ",
      "bbox": [
        81.67573547363281,
        76.71615600585938,
        291.0208435058594,
        102.19254302978516
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "       ",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        197.77281188964844,
        68.62921905517578,
        290.75360107421875,
        85.65061950683594
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "[n = sample size (검체 수), p (특이도) = 0.80,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.03228759765625,
        112.31725311279297,
        360.8592224121094,
        127.8393325805664
      ],
      "page_num": 56,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10]",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.03228759765625,
        138.32882690429688,
        416.1578674316406,
        153.85089111328125
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "n = 125.44",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.03228759765625,
        164.2205352783203,
        150.25155639648438,
        179.7425994873047
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- Sample Size (5% 탈락률 적용) = 131.71, 약 132개 검체",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.67573547363281,
        190.23211669921875,
        415.69439697265625,
        205.75418090820312
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 혈소판 약물반응검사",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        242.13539123535156,
        211.20407104492188,
        257.657470703125
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① Aspirin test 양성 검체 검사 시 (민감도 90%),",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        268.1469421386719,
        360.8596496582031,
        283.6819763183594
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 대립가설: 개발제품의 민감도가 90% 이상이다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        294.15850830078125,
        360.8585205078125,
        309.68060302734375
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 귀무가설: 개발제품의 민감도가 90% 미만이다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        320.05023193359375,
        360.8585205078125,
        335.57232666015625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 적용 계산식 : ",
      "font_size": 43.406349182128906,
      "font_name": "HyhwpEQ",
      "bbox": [
        81.67573547363281,
        353.853271484375,
        291.0208435058594,
        379.3296813964844
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "   ",
      "font_size": 6.715545177459717,
      "font_name": "HyhwpEQ",
      "bbox": [
        81.67573547363281,
        353.853271484375,
        291.0208435058594,
        379.3296813964844
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "       ",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        197.77281188964844,
        345.766357421875,
        290.75360107421875,
        362.7877502441406
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[n = sample size (검체 수), p (민감도) = 0.90,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.03228759765625,
        389.4543762207031,
        360.8592224121094,
        404.9764709472656
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10]",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.03228759765625,
        415.3460693359375,
        416.1578674316406,
        430.8681640625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "n = 70.56",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.03228759765625,
        441.357666015625,
        143.89552307128906,
        456.8797607421875
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- Sample Size (5% 탈락률 적용) = 74.09, 약 75개 검체",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.67573547363281,
        467.3692321777344,
        403.2211608886719,
        482.8913269042969
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② Aspirin test 음성 검체 검사 시 (특이도 95%),",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        493.26092529296875,
        360.8596496582031,
        508.79595947265625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 대립가설: 개발제품의 특이도가 95% 이상이다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        519.2725219726562,
        360.8585205078125,
        534.7946166992188
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 귀무가설: 개발제품의 특이도가 95% 미만이다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        545.2840576171875,
        360.8585205078125,
        560.80615234375
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 적용 계산식 : ",
      "font_size": 43.406349182128906,
      "font_name": "HyhwpEQ",
      "bbox": [
        81.67573547363281,
        579.087158203125,
        291.0208435058594,
        604.5635375976562
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "   ",
      "font_size": 6.715545177459717,
      "font_name": "HyhwpEQ",
      "bbox": [
        81.67573547363281,
        579.087158203125,
        291.0208435058594,
        604.5635375976562
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "       ",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        197.77281188964844,
        571.0001831054688,
        290.75360107421875,
        587.9017333984375
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[n = sample size (검체 수), p (특이도) = 0.95,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.03228759765625,
        614.568359375,
        360.8592224121094,
        630.0904541015625
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10]",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.03228759765625,
        640.5799560546875,
        416.1578674316406,
        656.10205078125
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "n = 37.24",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.03228759765625,
        666.5914916992188,
        143.89552307128906,
        682.1135864257812
      ],
      "page_num": 56,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- Sample Size (5% 탈락률 적용) = 39.10, 약 40개 검체",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.67573547363281,
        692.4832153320312,
        403.2211608886719,
        708.0053100585938
      ],
      "page_num": 56,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 50 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 57,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "③ P2Y12 test 양성 검체 검사 시 (민감도 80%),",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        68.92467498779297,
        353.3024597167969,
        84.45970153808594
      ],
      "page_num": 57,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 대립가설: 개발제품의 민감도가 80% 이상이다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        94.93624877929688,
        360.8585205078125,
        110.45832824707031
      ],
      "page_num": 57,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 귀무가설: 개발제품의 민감도가 80% 미만이다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        120.82794952392578,
        360.8585205078125,
        136.3500213623047
      ],
      "page_num": 57,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 적용 계산식 : ",
      "font_size": 43.406349182128906,
      "font_name": "HyhwpEQ",
      "bbox": [
        81.67573547363281,
        154.63101196289062,
        291.0208435058594,
        180.10739135742188
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "   ",
      "font_size": 6.715545177459717,
      "font_name": "HyhwpEQ",
      "bbox": [
        81.67573547363281,
        154.63101196289062,
        291.0208435058594,
        180.10739135742188
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "       ",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        197.77281188964844,
        146.5440673828125,
        290.75360107421875,
        163.5654754638672
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[n = sample size (검체 수), p (민감도) = 0.80,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.03228759765625,
        190.23211669921875,
        360.8592224121094,
        205.75418090820312
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10]",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.03228759765625,
        216.24368286132812,
        416.1578674316406,
        231.7657470703125
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "n = 125.44",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.03228759765625,
        242.13539123535156,
        150.25155639648438,
        257.657470703125
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- Sample Size (5% 탈락률 적용) = 131.71, 약 132개 검체",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.67573547363281,
        268.1469421386719,
        415.69439697265625,
        283.6690368652344
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "④ P2Y12 test 음성 검체 검사 시 (특이도 75%),",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        294.15850830078125,
        353.3024597167969,
        309.69354248046875
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 대립가설: 개발제품의 특이도가 75% 이상이다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        320.05023193359375,
        360.8585205078125,
        335.57232666015625
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 귀무가설: 개발제품의 특이도가 75% 미만이다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        346.0617980957031,
        360.8585205078125,
        361.5838928222656
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 적용 계산식 : ",
      "font_size": 43.406349182128906,
      "font_name": "HyhwpEQ",
      "bbox": [
        81.67573547363281,
        379.8648681640625,
        291.0208435058594,
        405.34124755859375
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "   ",
      "font_size": 6.715545177459717,
      "font_name": "HyhwpEQ",
      "bbox": [
        81.67573547363281,
        379.8648681640625,
        291.0208435058594,
        405.34124755859375
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "       ",
      "font_size": 9.951866149902344,
      "font_name": "HyhwpEQ",
      "bbox": [
        197.77281188964844,
        371.7779235839844,
        290.75360107421875,
        388.679443359375
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "[n = sample size (검체 수), p (특이도) = 0.75,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.03228759765625,
        415.3460693359375,
        360.8592224121094,
        430.8681640625
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10]",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.03228759765625,
        441.357666015625,
        416.1578674316406,
        456.8797607421875
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "n = 147.0",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.03228759765625,
        467.3692321777344,
        143.89552307128906,
        482.8913269042969
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- Sample Size (5% 탈락률 적용) = 154.35, 약 155개 검체",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.67573547363281,
        493.26092529296875,
        415.69439697265625,
        508.78302001953125
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8.3.3 피험자 수 산출 근거",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        545.2840576171875,
        214.20361328125,
        560.80615234375
      ],
      "page_num": 57,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 혈소판 기능검사",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        571.17578125,
        186.018310546875,
        586.6978759765625
      ],
      "page_num": 57,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 기허가 제품 (PFA-100Ⓡ)의 성능평가 임상논문을 조사한 결과, EPI test 평균",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        77.2381362915039,
        597.1873779296875,
        538.1480712890625,
        612.722412109375
      ],
      "page_num": 57,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "민감도 84.5% 및 평균 특이도 85.6%이었고, 표준편차는 민감도 16.1%, 특이도",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        88.27215576171875,
        623.1989135742188,
        538.1492919921875,
        638.7210083007812
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "8.0%이었다. ADP test는 평균 민감도 84.0%, 평균 특이도 81.0%이었고, 표준",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        88.27215576171875,
        649.0906372070312,
        538.1488037109375,
        664.6127319335938
      ],
      "page_num": 57,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "편차는 민감도 4.2%, 특이도 1.4%이었다. SIPA test는 검사원리가 비슷한 기존",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        88.27215576171875,
        675.1022338867188,
        538.1483154296875,
        690.6243286132812
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사법은 없으나, 혈소판 기능의 정상/비정상 유무를 판정하기 위한 목적은",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        88.27215576171875,
        701.11376953125,
        538.1482543945312,
        716.6358642578125
      ],
      "page_num": 57,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ADP test와 동일하므로, ADP test의 평가기준에 준하여 평가하였다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.27215576171875,
        727.0054931640625,
        476.11602783203125,
        742.527587890625
      ],
      "page_num": 57,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 51 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 58,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표 1.",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        63.08580780029297,
        73.35983276367188,
        87.17110443115234,
        86.58234405517578
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "PFA-100Ⓡ 성능평가 문헌",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        63.08580780029297,
        90.02162170410156,
        189.01766967773438,
        103.25515747070312
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평균 민감도",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        120.2947998046875,
        106.68341064453125,
        303.3158874511719,
        119.90592193603516
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평균 특이도",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        120.2947998046875,
        106.68341064453125,
        303.3158874511719,
        119.90592193603516
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참고문헌",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        120.2947998046875,
        106.68341064453125,
        303.3158874511719,
        119.90592193603516
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "EPI test",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        63.08580780029297,
        174.7689971923828,
        218.0645751953125,
        187.99151611328125
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "84.5%",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        63.08580780029297,
        174.7689971923828,
        218.0645751953125,
        187.99151611328125
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "85.6%",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        63.08580780029297,
        174.7689971923828,
        218.0645751953125,
        187.99151611328125
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. Rational use of the PFA-100 device for screening",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        126.70153045654297,
        529.7482299804688,
        139.92404174804688
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "of platelet function disorders and von Willebrand",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        148.63755798339844,
        529.8759155273438,
        161.86007690429688
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "disease",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        170.69345092773438,
        529.8511962890625,
        183.9159698486328
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Blood",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        170.69345092773438,
        529.8511962890625,
        183.9159698486328
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Coagul",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        170.69345092773438,
        529.8511962890625,
        183.9159698486328
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Fibrinolysis.",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        170.69345092773438,
        529.8511962890625,
        183.9159698486328
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2002",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        170.69345092773438,
        529.8511962890625,
        183.9159698486328
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Jun;13(4):349-53.)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        192.62948608398438,
        341.16015625,
        205.8520050048828
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. The PFA-100 : a potential rapid screening tool for",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        214.5655059814453,
        529.7822875976562,
        227.78802490234375
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "the",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        236.62139892578125,
        529.8469848632812,
        249.8439178466797
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "assessment",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        236.62139892578125,
        529.8469848632812,
        249.8439178466797
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "of",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        236.62139892578125,
        529.8469848632812,
        249.8439178466797
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "platelet",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        236.62139892578125,
        529.8469848632812,
        249.8439178466797
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "dysfunction",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        236.62139892578125,
        529.8469848632812,
        249.8439178466797
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Clin",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        236.62139892578125,
        529.8469848632812,
        249.8439178466797
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Lab",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        236.62139892578125,
        529.8469848632812,
        249.8439178466797
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Haematol. 2002 Aug;24(4):225-32.)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        258.55743408203125,
        426.5530700683594,
        271.7799377441406
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3.",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        280.49346923828125,
        529.86962890625,
        293.7159729003906
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Comparison",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        280.49346923828125,
        529.86962890625,
        293.7159729003906
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "of",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        280.49346923828125,
        529.86962890625,
        293.7159729003906
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PFA-100",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        280.49346923828125,
        529.86962890625,
        293.7159729003906
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "and",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        280.49346923828125,
        529.86962890625,
        293.7159729003906
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Bleeding",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        280.49346923828125,
        529.86962890625,
        293.7159729003906
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Time",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        280.49346923828125,
        529.86962890625,
        293.7159729003906
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Testing",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        302.5493469238281,
        529.876220703125,
        315.7718505859375
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "in",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        302.5493469238281,
        529.876220703125,
        315.7718505859375
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Pediatric",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        302.5493469238281,
        529.876220703125,
        315.7718505859375
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Patients",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        302.5493469238281,
        529.876220703125,
        315.7718505859375
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "With",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        302.5493469238281,
        529.876220703125,
        315.7718505859375
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Suspected",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        302.5493469238281,
        529.876220703125,
        315.7718505859375
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Hemorrhagic",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        324.4853820800781,
        529.8505249023438,
        337.7078857421875
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Problems",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        324.4853820800781,
        529.8505249023438,
        337.7078857421875
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(J",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        324.4853820800781,
        529.8505249023438,
        337.7078857421875
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Pediatr",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        324.4853820800781,
        529.8505249023438,
        337.7078857421875
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Hematol",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        324.4853820800781,
        529.8505249023438,
        337.7078857421875
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Oncol.",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        324.4853820800781,
        529.8505249023438,
        337.7078857421875
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2003 Jun;25(6):474-9.)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        346.4214172363281,
        362.3901062011719,
        359.6439208984375
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4. Comparison of Different Methods to Evaluate the",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        368.477294921875,
        529.749267578125,
        381.6997985839844
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Effect of Aspirin on Platelet Function in High-Risk",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        390.413330078125,
        529.747314453125,
        403.6358337402344
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Patients With Ischemic Heart Disease Receiving Dual",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        412.349365234375,
        529.8463134765625,
        425.5718688964844
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Antiplatelet",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        434.4052429199219,
        529.8511962890625,
        447.62774658203125
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Treatment",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        434.4052429199219,
        529.8511962890625,
        447.62774658203125
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Am",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        434.4052429199219,
        529.8511962890625,
        447.62774658203125
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "J",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        434.4052429199219,
        529.8511962890625,
        447.62774658203125
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Clin",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        434.4052429199219,
        529.8511962890625,
        447.62774658203125
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Pathol.",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        434.4052429199219,
        529.8511962890625,
        447.62774658203125
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2007",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        434.4052429199219,
        529.8511962890625,
        447.62774658203125
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Jul;128(1):143-9.)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        260.2589416503906,
        456.3412780761719,
        338.0430603027344,
        469.56378173828125
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ADP test",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        63.08580780029297,
        351.3360290527344,
        218.0645751953125,
        364.55853271484375
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "84.0%",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        63.08580780029297,
        351.3360290527344,
        218.0645751953125,
        364.55853271484375
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "81.0%",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        63.08580780029297,
        351.3360290527344,
        218.0645751953125,
        364.55853271484375
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "민감도",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        350.57000732421875,
        480.6746826171875,
        496.29119873046875,
        493.8971862792969
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "특이도",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        350.57000732421875,
        480.6746826171875,
        496.29119873046875,
        493.8971862792969
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "EPI test",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        102.54442596435547,
        519.5122680664062,
        141.0196075439453,
        532.7348022460938
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중위값",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        231.594482421875,
        500.0934753417969,
        489.432373046875,
        513.3159790039062
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "88.0",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        231.594482421875,
        500.0934753417969,
        489.432373046875,
        513.3159790039062
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "82.7",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        231.594482421875,
        500.0934753417969,
        489.432373046875,
        513.3159790039062
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표준편차",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        226.3173370361328,
        519.5122680664062,
        486.79412841796875,
        532.7348022460938
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "16.1",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        226.3173370361328,
        519.5122680664062,
        486.79412841796875,
        532.7348022460938
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8.0",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        226.3173370361328,
        519.5122680664062,
        486.79412841796875,
        532.7348022460938
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표준오차",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        226.3173370361328,
        539.0509033203125,
        486.79412841796875,
        552.2734375
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8.0",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        226.3173370361328,
        539.0509033203125,
        486.79412841796875,
        552.2734375
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4.0",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        226.3173370361328,
        539.0509033203125,
        486.79412841796875,
        552.2734375
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ADP test",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        99.3061752319336,
        577.888427734375,
        144.2578582763672,
        591.1109619140625
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중위값",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        231.594482421875,
        558.4696655273438,
        489.432373046875,
        571.6921997070312
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "84.0",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        231.594482421875,
        558.4696655273438,
        489.432373046875,
        571.6921997070312
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "81.0",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        231.594482421875,
        558.4696655273438,
        489.432373046875,
        571.6921997070312
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표준편차",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        226.3173370361328,
        577.888427734375,
        486.79412841796875,
        591.1109619140625
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4.2",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        226.3173370361328,
        577.888427734375,
        486.79412841796875,
        591.1109619140625
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1.4",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        226.3173370361328,
        577.888427734375,
        486.79412841796875,
        591.1109619140625
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표준오차",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        226.3173370361328,
        597.4271240234375,
        486.79412841796875,
        610.649658203125
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3.0",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        226.3173370361328,
        597.4271240234375,
        486.79412841796875,
        610.649658203125
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1.0",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        226.3173370361328,
        597.4271240234375,
        486.79412841796875,
        610.649658203125
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 따라서, 본 임상시험에서는 기허가 제품 성능 결과를 토대로 EPI test의 민감도",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        639.7408447265625,
        538.1483154296875,
        655.262939453125
      ],
      "page_num": 58,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 특이도 목표는 각각 85%, 85%로 설정하였으며 오차범위는 ±5% 설정하였다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        86.59307098388672,
        665.75244140625,
        538.1224365234375,
        681.2874755859375
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ADP 및 SIPA test의 민감도 및 특이도 목표는 각각 85%, 80%로 설정하였으며",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        86.59307098388672,
        691.7639770507812,
        538.1477661132812,
        707.2860717773438
      ],
      "page_num": 58,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "오차범위는 ±5% 설정하였다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        86.59307098388672,
        717.6557006835938,
        247.75979614257812,
        733.1907348632812
      ],
      "page_num": 58,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 52 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 59,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "표 3.",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        284.4858093261719,
        201.73951721191406,
        308.451171875,
        214.9620361328125
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "VerifyNowⓇ 성능평가 문헌",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        227.03695678710938,
        220.79869079589844,
        365.9217834472656,
        234.03224182128906
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평균 민감도",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        133.1278533935547,
        241.17642211914062,
        422.6512145996094,
        254.39894104003906
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "평균 특이도",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        133.1278533935547,
        241.17642211914062,
        422.6512145996094,
        254.39894104003906
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "참고문헌",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        133.1278533935547,
        241.17642211914062,
        422.6512145996094,
        254.39894104003906
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Aspirin test",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        63.92535400390625,
        296.076416015625,
        246.24929809570312,
        309.2989196777344
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "73.5%",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        63.92535400390625,
        296.076416015625,
        246.24929809570312,
        309.2989196777344
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "93.2%",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        63.92535400390625,
        296.076416015625,
        246.24929809570312,
        309.2989196777344
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. Comparison of Different Methods to Evaluate",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        260.7150573730469,
        529.870849609375,
        273.93756103515625
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "the",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        280.49346923828125,
        529.8180541992188,
        293.7159729003906
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Effect",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        280.49346923828125,
        529.8180541992188,
        293.7159729003906
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "of",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        280.49346923828125,
        529.8180541992188,
        293.7159729003906
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Aspirin",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        280.49346923828125,
        529.8180541992188,
        293.7159729003906
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "on",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        280.49346923828125,
        529.8180541992188,
        293.7159729003906
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Platelet",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        280.49346923828125,
        529.8180541992188,
        293.7159729003906
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Function",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        280.49346923828125,
        529.8180541992188,
        293.7159729003906
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "in",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        280.49346923828125,
        529.8180541992188,
        293.7159729003906
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "High-Risk Patients With Ischemic Heart Disease",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        300.2718505859375,
        529.7491455078125,
        313.4943542480469
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Receiving Dual Antiplatelet Treatment (Am J Clin",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        320.05023193359375,
        529.818115234375,
        333.2727355957031
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Pathol. 2007 Jul;128(1):143-9.)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        339.82861328125,
        414.9214172363281,
        353.0511169433594
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. VerifyNow AA FDA summary 510(k) summary",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        362.6037292480469,
        529.7489013671875,
        375.82623291015625
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "K042423",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        382.3821105957031,
        312.1697692871094,
        395.6046142578125
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. Incidence of Aspirin Resistance in the Patient",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        405.1572265625,
        529.848876953125,
        418.3797302246094
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Group of a University Hospital in Korea (Korean",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        424.93560791015625,
        529.8174438476562,
        438.1581115722656
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "J Lab Med. 2008 Aug;28(4):251-7.)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        444.7139892578125,
        440.4684143066406,
        457.9364929199219
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4.",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        467.4891052246094,
        529.8489990234375,
        480.71160888671875
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Correlation",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        467.4891052246094,
        529.8489990234375,
        480.71160888671875
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "of",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        467.4891052246094,
        529.8489990234375,
        480.71160888671875
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "high",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        467.4891052246094,
        529.8489990234375,
        480.71160888671875
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "post-treatment",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        467.4891052246094,
        529.8489990234375,
        480.71160888671875
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "platelet",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        467.4891052246094,
        529.8489990234375,
        480.71160888671875
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "reactivity",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        487.2674865722656,
        529.868408203125,
        500.489990234375
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "assessed",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        487.2674865722656,
        529.868408203125,
        500.489990234375
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "by",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        487.2674865722656,
        529.868408203125,
        500.489990234375
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "light",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        487.2674865722656,
        529.868408203125,
        500.489990234375
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "transmittance",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        487.2674865722656,
        529.868408203125,
        500.489990234375
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "aggregometry",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        507.0458984375,
        529.7489624023438,
        520.2684326171875
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "and",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        507.0458984375,
        529.7489624023438,
        520.2684326171875
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "the",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        507.0458984375,
        529.7489624023438,
        520.2684326171875
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "VerifyNow",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        507.0458984375,
        529.7489624023438,
        520.2684326171875
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "P2Y12",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        507.0458984375,
        529.7489624023438,
        520.2684326171875
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "assay",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        507.0458984375,
        529.7489624023438,
        520.2684326171875
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Thromb Thrombolysis. 2010 Nov;30(4):486-95.)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        526.8242797851562,
        504.1510009765625,
        540.0468139648438
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5.",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        549.599365234375,
        529.748779296875,
        562.8218994140625
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Comparison",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        549.599365234375,
        529.748779296875,
        562.8218994140625
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "of",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        549.599365234375,
        529.748779296875,
        562.8218994140625
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "methods",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        549.599365234375,
        529.748779296875,
        562.8218994140625
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "to",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        549.599365234375,
        529.748779296875,
        562.8218994140625
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "evaluate",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        549.599365234375,
        529.748779296875,
        562.8218994140625
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "clopidogrel-mediated",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        569.3777465820312,
        529.9027709960938,
        582.6002807617188
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "platelet",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        569.3777465820312,
        529.9027709960938,
        582.6002807617188
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "inhibition",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        569.3777465820312,
        529.9027709960938,
        582.6002807617188
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "after",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        569.3777465820312,
        529.9027709960938,
        582.6002807617188
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "percutaneous intervention with stent implantation",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        589.1561279296875,
        529.8167724609375,
        602.378662109375
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Thromb Haemost. 2009 Feb;101(2):333-9.)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        272.37237548828125,
        608.9345092773438,
        477.7666931152344,
        622.1570434570312
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "P2Y12 test",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        67.1635971069336,
        478.5170593261719,
        246.24929809570312,
        491.73956298828125
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "72.9%",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        67.1635971069336,
        478.5170593261719,
        246.24929809570312,
        491.73956298828125
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "74.1%",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        67.1635971069336,
        478.5170593261719,
        246.24929809570312,
        491.73956298828125
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "민감도",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        354.7677307128906,
        640.3402099609375,
        497.7304382324219,
        653.562744140625
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "특이도",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        354.7677307128906,
        640.3402099609375,
        497.7304382324219,
        653.562744140625
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Aspirin test",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        97.02741241455078,
        673.5438842773438,
        154.93206787109375,
        686.7664184570312
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중위값",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        238.670654296875,
        656.8821411132812,
        490.87158203125,
        670.1046752929688
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "89.3",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        238.670654296875,
        656.8821411132812,
        490.87158203125,
        670.1046752929688
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "96.4",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        238.670654296875,
        656.8821411132812,
        490.87158203125,
        670.1046752929688
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표준편차",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        233.3935089111328,
        673.5438842773438,
        488.23260498046875,
        686.7664184570312
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "29.6",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        233.3935089111328,
        673.5438842773438,
        488.23260498046875,
        686.7664184570312
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8.9",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        233.3935089111328,
        673.5438842773438,
        488.23260498046875,
        686.7664184570312
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표준오차",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        233.3935089111328,
        690.2056884765625,
        488.23260498046875,
        703.42822265625
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "17.1",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        233.3935089111328,
        690.2056884765625,
        488.23260498046875,
        703.42822265625
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5.1",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        233.3935089111328,
        690.2056884765625,
        488.23260498046875,
        703.42822265625
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "P2Y12 test",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        100.26565551757812,
        723.409423828125,
        151.6949462890625,
        736.6319580078125
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중위값",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        238.670654296875,
        706.8674926757812,
        490.87158203125,
        720.0900268554688
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "80.4",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        238.670654296875,
        706.8674926757812,
        490.87158203125,
        720.0900268554688
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "71.4",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        238.670654296875,
        706.8674926757812,
        490.87158203125,
        720.0900268554688
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표준편차",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        233.3935089111328,
        723.409423828125,
        488.23260498046875,
        736.6319580078125
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "15.5",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        233.3935089111328,
        723.409423828125,
        488.23260498046875,
        736.6319580078125
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9.8",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        233.3935089111328,
        723.409423828125,
        488.23260498046875,
        736.6319580078125
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표준오차",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        233.3935089111328,
        740.0712280273438,
        488.23260498046875,
        753.2937622070312
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9.0",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        233.3935089111328,
        740.0712280273438,
        488.23260498046875,
        753.2937622070312
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5.7",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        233.3935089111328,
        740.0712280273438,
        488.23260498046875,
        753.2937622070312
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 혈소판 약물반응검사",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        68.92467498779297,
        211.20407104492188,
        84.4467544555664
      ],
      "page_num": 59,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 기허가 제품 (VerifyNowⓇ)의 성능평가 임상논문을 조사한 결과, Aspirin test",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.79891967773438,
        94.93624877929688,
        538.1468505859375,
        110.47127532958984
      ],
      "page_num": 59,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "평균 민감도 73.5% 및 평균 특이도 93.2%이었고, 표준편차는 민감도 29.6%,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.99339294433594,
        120.82794952392578,
        538.2420654296875,
        136.3500213623047
      ],
      "page_num": 59,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특이도 8.9%이었다. P2Y12 test는 평균 민감도 72.9%, 평균 특이도 74.1%이었고,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.99339294433594,
        146.83953857421875,
        538.1224365234375,
        162.36160278320312
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "표준편차는 민감도 15.5%, 특이도 9.8%이었다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.99339294433594,
        172.85110473632812,
        344.3074645996094,
        188.3731689453125
      ],
      "page_num": 59,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 53 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 60,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 따라서, 본 임상시험에서는 기허가 제품 성능 결과를 토대로 Aspirin test의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        68.92467498779297,
        538.1483764648438,
        84.4467544555664
      ],
      "page_num": 60,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "민감도 및 특이도 목표는 각각 90%, 95%로 설정하였으며 오차범위는 ±5%",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.99339294433594,
        94.93624877929688,
        538.101806640625,
        110.47127532958984
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "설정하였다. P2Y12 test의 민감도 및 특이도 목표는 각각 80%, 75%로 설정",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        85.99339294433594,
        120.82794952392578,
        538.1483764648438,
        136.3500213623047
      ],
      "page_num": 60,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하였으며 오차범위는 ±5% 설정하였다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.99339294433594,
        146.83953857421875,
        313.843994140625,
        162.3745574951172
      ],
      "page_num": 60,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 54 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 61,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자의 모집기간, 임상관찰 및 시험수행 기간, 통계처리 기간, 결과보고서 작성",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        153.91180419921875,
        536.2291259765625,
        169.43386840820312
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기간, 임상시험심사위원회 심사기간 등 충분한 기간을 고려하여 “식품의약품안전",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        179.8035125732422,
        536.2276611328125,
        195.32557678222656
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "처의 임상계획 승인일로부터 OO개월”로 표시하고 근거자료 제출함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        205.81507873535156,
        458.84539794921875,
        221.33714294433594
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9. 임상시험기간",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        74.19891357421875,
        183.38002014160156,
        93.31405639648438
      ],
      "page_num": 61,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        56.609317779541016,
        109.20393371582031,
        541.8339233398438,
        120.23188781738281
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        73.99989318847656,
        126.82469177246094,
        301.63604736328125,
        137.85263061523438
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식품의약품안전처 및 임상시험기관 임상시험심사위원회의 임상시험계획서 승인일로",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        241.89564514160156,
        538.1492919921875,
        257.417724609375
      ],
      "page_num": 61,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부터 6개월",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        267.787353515625,
        119.45526123046875,
        283.3094482421875
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 대상자 모집기간 및 임상시험 수행 기간 : 약 4 개월",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        293.7989196777344,
        372.6380310058594,
        309.3210144042969
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 통계처리 기간 : 약 1 개월",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        319.81048583984375,
        221.639892578125,
        335.33258056640625
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 결과보고서 작성기간 : 약 1 개월",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        345.7021789550781,
        259.4194030761719,
        361.2242736816406
      ],
      "page_num": 61,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 55 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 62,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "PFA-100Ⓡ",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        247.18603515625,
        456.7008972167969,
        481.7789001464844,
        469.9344482421875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "VerifyNowⓇ",
      "font_size": 11.030982971191406,
      "font_name": "T16",
      "bbox": [
        247.18603515625,
        456.7008972167969,
        481.7789001464844,
        469.9344482421875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제조사",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        102.78429412841797,
        475.16070556640625,
        498.07867431640625,
        488.3832092285156
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Siemens",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        102.78429412841797,
        475.16070556640625,
        498.07867431640625,
        488.3832092285156
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Accriva Diagnostics",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        102.78429412841797,
        475.16070556640625,
        498.07867431640625,
        488.3832092285156
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "장비",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        66.32405090332031,
        514.3578491210938,
        88.03238677978516,
        527.5803833007812
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "품목명",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        123.41311645507812,
        490.7436828613281,
        508.645263671875,
        503.9661865234375
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자동혈소판응집측정장치",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        123.41311645507812,
        490.7436828613281,
        508.645263671875,
        503.9661865234375
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자동혈소판응집측정장치",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        123.41311645507812,
        490.7436828613281,
        508.645263671875,
        503.9661865234375
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "모델명",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        123.41311645507812,
        506.32666015625,
        496.06781005859375,
        519.5491943359375
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PFA-100 System",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        123.41311645507812,
        506.32666015625,
        496.06781005859375,
        519.5491943359375
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "VerifyNow System",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        123.41311645507812,
        506.32666015625,
        496.06781005859375,
        519.5491943359375
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "품목허가번호",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        107.46176147460938,
        530.0607299804688,
        502.28778076171875,
        543.2832641601562
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제 서울수신 06-710호",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        107.46176147460938,
        530.0607299804688,
        502.28778076171875,
        543.2832641601562
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제 경인수신 05-110호",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        107.46176147460938,
        530.0607299804688,
        502.28778076171875,
        543.2832641601562
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시약",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        66.32405090332031,
        606.2974243164062,
        88.03238677978516,
        619.5199584960938
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "품목명",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        123.41311645507812,
        561.5862426757812,
        524.5968627929688,
        574.8087768554688
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자동혈소판응집측정장치용시약",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        123.41311645507812,
        561.5862426757812,
        524.5968627929688,
        574.8087768554688
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자동혈소판응집측정장치용시약",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        123.41311645507812,
        561.5862426757812,
        524.5968627929688,
        574.8087768554688
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "모델명",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        123.41311645507812,
        606.2974243164062,
        155.79556274414062,
        619.5199584960938
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Dade PFA",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        200.6512451171875,
        584.3613891601562,
        252.0418701171875,
        597.5839233398438
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Collagen/EPI",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        193.6950225830078,
        606.2974243164062,
        258.9171142578125,
        619.5199584960938
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Test Cartridge",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        191.1763916015625,
        628.2334594726562,
        261.5730895996094,
        641.4559936523438
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Dade PFA",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        291.9217834472656,
        584.3613891601562,
        343.43231201171875,
        597.5839233398438
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Collagen/ADP",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        281.7273254394531,
        606.2974243164062,
        353.6249694824219,
        619.5199584960938
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Test Cartridge",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        282.4469299316406,
        628.2334594726562,
        352.8458557128906,
        641.4559936523438
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "VerifyNow",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        380.9135437011719,
        595.2694702148438,
        434.2288513183594,
        608.4920043945312
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "P2Y12 Test",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        380.3138732910156,
        617.3253784179688,
        434.8602600097656,
        630.5479125976562
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "VerifyNow",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        466.5471496582031,
        595.2694702148438,
        519.9838256835938,
        608.4920043945312
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Aspirin Test",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        462.709228515625,
        617.3253784179688,
        523.7332153320312,
        630.5479125976562
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "품목허가번호",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        107.46176147460938,
        651.008544921875,
        524.3341064453125,
        664.2310791015625
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수허 12-1710",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        107.46176147460938,
        651.008544921875,
        524.3341064453125,
        664.2310791015625
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수허 12-1743",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        107.46176147460938,
        651.008544921875,
        524.3341064453125,
        664.2310791015625
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수허 12-1648",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        107.46176147460938,
        651.008544921875,
        524.3341064453125,
        664.2310791015625
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수허 12-1652",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        107.46176147460938,
        651.008544921875,
        524.3341064453125,
        664.2310791015625
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10. 임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        76.45640563964844,
        532.5227661132812,
        92.39897918701172
      ],
      "page_num": 62,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        56.609317779541016,
        109.20393371582031,
        529.839599609375,
        120.23188781738281
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        73.16034698486328,
        126.82469177246094,
        300.7965087890625,
        137.85263061523438
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10.1. 시험방법",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        141.2056884765625,
        138.76393127441406,
        156.72775268554688
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험 방법은 해당 의료기기의 각 구성품에 대한 형상, 구조 및 사용 전 준비",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        61.64658737182617,
        171.4126739501953,
        533.3506469726562,
        186.9347381591797
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사항/피험자에 대한 준비 등 임상시험을 위한 준비절차와 사용 단계 절차의 각",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        61.64658737182617,
        197.30438232421875,
        533.3509521484375,
        212.82644653320312
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "단계별 조작 순서, 병용 요법 등을 기술함. 임상 시험을 위한 피험자 동의 및 준비,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        61.64658737182617,
        223.31594848632812,
        533.3250122070312,
        238.8380126953125
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "치료 및 수술 절차, 관찰 및 평가 절차 등을 상세히 시험방법을 기술함",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        61.64658737182617,
        249.32752990722656,
        474.2223815917969,
        264.849609375
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        295.4770812988281,
        86.09606170654297,
        310.9991760253906
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10.1.1. 시험기기 대조기기 정보",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        321.4886474609375,
        236.27166748046875,
        337.0107421875
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험기기: 출혈 시간 및 항혈소판제제 저항성 복합검사기기",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        347.3803405761719,
        406.33831787109375,
        362.9024353027344
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대조기기",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        373.3919372558594,
        113.57759094238281,
        388.9140319824219
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 혈소판 기능검사: light transmission aggregometry (LTA) 검사, PFA-100Ⓡ",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        69.2024917602539,
        399.40350341796875,
        518.958740234375,
        414.93853759765625
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 혈소판 약물반응검사: VerifyNowⓇ",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        69.2024917602539,
        425.2951965332031,
        290.7224426269531,
        440.8302307128906
      ],
      "page_num": 62,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10.1.2. 시험방법",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        697.9971923828125,
        148.23876953125,
        713.519287109375
      ],
      "page_num": 62,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 피험자 동의 및 준비",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        724.0087280273438,
        203.76925659179688,
        739.5308227539062
      ],
      "page_num": 62,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한 내용을 피험자 본인",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        750.0203247070312,
        538.1480712890625,
        765.5424194335938
      ],
      "page_num": 62,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 56 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 63,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 대리인에게 설명하고, 피험자 및 대리인이 내용을 잘 이해한 것을 확인한 다음,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        68.92467498779297,
        538.1224365234375,
        84.4467544555664
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "자유의사에 따른 임상시험 참가의 동의를 문서로 받는다. 또한 동의를 서명한",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        94.93624877929688,
        538.1477661132812,
        110.45832824707031
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연월일을 기록한다. 또한 동의서 사본을 환자에게 제공하여 환자가 지속적으로",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        120.82794952392578,
        538.147216796875,
        136.3500213623047
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험에 대한 사항을 확인할 수 있도록 해야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        146.83953857421875,
        380.7677307128906,
        162.36160278320312
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 인구학적 조사, 병력조사 요법",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        172.85110473632812,
        257.2602844238281,
        188.3731689453125
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력 등에 대하여 면담,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        198.74281311035156,
        538.1224365234375,
        214.26487731933594
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "차트확인 및 질문 등을 통하여 점검하고 증례기록서에 기록한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        224.75437927246094,
        443.73358154296875,
        240.2764434814453
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 인구학적 정보: 성명, 나이, 성별, 임신 유무",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        69.2024917602539,
        250.7659454345703,
        340.1356506347656,
        266.30096435546875
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 병력조사 :출혈성 질환, 응고장애, 암, 기타 만성질환 등",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        276.65765380859375,
        409.45806884765625,
        292.19268798828125
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③ 병용약물 : 아스피린, P2Y12 수용체 억제제 등의 항혈소판제제, 항응고제 치료 유무",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        69.2024917602539,
        302.6692199707031,
        534.1904907226562,
        318.2042541503906
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "④ CBC 결과 (혈색소, 헤마토크릿, 혈소판수 등)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        328.6807861328125,
        348.6337585449219,
        344.2158203125
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "⑤ PT, aPTT 결과",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        354.572509765625,
        173.90545654296875,
        370.1075439453125
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 피험자 식별코드 부여",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        380.5840759277344,
        210.12582397460938,
        396.1061706542969
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 임상시험 참여에 동의하고 인구학적 조사, 병력 문진 등을 통하여 피험자 선정",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        406.59564208984375,
        538.1483154296875,
        422.13067626953125
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및 제외 기준에 적합한 피험자에 한하여 피험자 식별코드를 부여한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.1522216796875,
        432.4873352050781,
        494.2262268066406,
        448.0094299316406
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 피험자 적합성 평가 : 피험자 선정 및 제외기준에 적합한지 평가한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        458.4989318847656,
        490.8680419921875,
        474.0339660644531
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③ 피험자 식별코드는 아래의 방법에 따라 기입한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        484.510498046875,
        374.5310974121094,
        500.0455322265625
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        75.43911743164062,
        510.4022216796875,
        479.739990234375,
        525.92431640625
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예) KFDA-12-34-56",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        536.4137573242188,
        190.9113311767578,
        551.9358520507812
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4) 검체 채취 및 보관 방법",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        562.4253540039062,
        222.59906005859375,
        577.9474487304688
      ],
      "page_num": 63,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 3.2% Na Citrate tube에 약 20mL의 정맥혈을 채혈한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        588.3170776367188,
        410.87139892578125,
        603.8521118164062
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 시험기기는 3.2% Na Citrate tube 검체를 실온(18∼25℃)에서 채혈 시 최소",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        614.32861328125,
        538.1480712890625,
        629.8636474609375
      ],
      "page_num": 63,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "30분, 최대 4시간 이내 검사를 시행한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        89.47151184082031,
        640.3402099609375,
        322.359375,
        655.8623046875
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③ LTA 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        666.2318725585938,
        538.1486206054688,
        681.7669067382812
      ],
      "page_num": 63,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분리하여 혈소판풍부혈장을 취하여 3시간 이내에 검사를 시행한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.1522216796875,
        692.2434692382812,
        479.1144104003906,
        707.7655639648438
      ],
      "page_num": 63,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "④ VerifyNow 대조기기는 3.2% Na Citrate tube 검체를 실온(18∼25℃)에서 2시간",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        718.2550659179688,
        538.1477661132812,
        733.7901000976562
      ],
      "page_num": 63,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이내 검사를 시행한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.27215576171875,
        744.146728515625,
        213.3384552001953,
        759.6688232421875
      ],
      "page_num": 63,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 57 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 64,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험의 설계방법(무작위배정, 단일 또는 이중눈가림, 교차설계 또는 병행설계",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        70.64171600341797,
        593.711181640625,
        532.151611328125,
        609.2332763671875
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "등)의 특성이 있는 경우 과학적 타당성과 근거자료를 바탕으로 구체적이고 명확히",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        619.7227172851562,
        532.1511840820312,
        635.2448120117188
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기술한다. 상기의 기술한 내용의 근거로서 관련 참고문헌(논문 등)을 하단부에 기재",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        645.7343139648438,
        532.271728515625,
        661.2564086914062
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하고, 첨부자료로서 이를 제출한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        671.6259765625,
        257.8343505859375,
        687.1480712890625
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "⑤ 검체는 6일간 냉장(2∼6℃) 보관 후 폐기한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        68.92467498779297,
        351.3836364746094,
        84.45970153808594
      ],
      "page_num": 64,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(5) 시험검사 방법",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        94.93624877929688,
        165.98974609375,
        110.45832824707031
      ],
      "page_num": 64,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) EPI test: 정상인 및 혈소판기능저하가 있는 환자의 검체에 대해 시험기기 및",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        120.82794952392578,
        538.1483764648438,
        136.3500213623047
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대조기기인 'epinephrine을 agonist로 사용한 LTA 검사'와 'PFA-100 EPI test'로",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        86.59307098388672,
        146.83953857421875,
        538.1483764648438,
        162.36160278320312
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사를 시행한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        86.59307098388672,
        172.85110473632812,
        181.1958770751953,
        188.3731689453125
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) ADP test:　정상인 및 혈소판기능저하가 있는 환자의 검체에 대해 시험기기",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        198.74281311035156,
        538.1474609375,
        214.27783203125
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및 대조기기인 'ADP를 agonist로 사용한 LTA 검사'와 'PFA-100 ADP test'로",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        87.07280731201172,
        224.75437927246094,
        538.1483764648438,
        240.2764434814453
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사를 시행한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        87.07280731201172,
        250.7659454345703,
        184.79393005371094,
        266.28802490234375
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) SIPA test:　정상인 및 혈소판기능저하가 있는 환자의 검체에 대해 시험기기",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        276.65765380859375,
        538.1472778320312,
        292.19268798828125
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및 대조기기인 'ADP를 agonist로 사용한 LTA 검사'와 'PFA-100 ADP test'로",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        86.95287322998047,
        302.6692199707031,
        538.1483764648438,
        318.1913146972656
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사를 시행한다. (SIPA test는 검사원리가 비슷한 기존검사법은 없으나,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        86.95287322998047,
        328.6807861328125,
        538.1224365234375,
        344.202880859375
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈소판 기능의 정상/비정상 유무를 판정하기 위한 목적은 ADP test와 동",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        86.95287322998047,
        354.572509765625,
        538.1483764648438,
        370.0946044921875
      ],
      "page_num": 64,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일하므로, ADP test의 평가기준에 준하여 평가한다.)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        86.95287322998047,
        380.5840759277344,
        402.2452392578125,
        396.1061706542969
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 혈소판 약물반응검사",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        406.59564208984375,
        211.08413696289062,
        422.11773681640625
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) Aspirin test: Aspirin 약물 복용 전/후의 검체에 대해 시험기기 및 대조기기인",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.67573547363281,
        432.4873352050781,
        538.1480102539062,
        448.0094299316406
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "'VerifyNow Aspirin test'로 검사를 시행한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        99.3061752319336,
        458.4989318847656,
        349.5846252441406,
        474.0210266113281
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2）P2Y12 test: Clopidogrel 약물 복용 전/후의 검체에 대해 시험기기 및 대조",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.67573547363281,
        484.510498046875,
        538.1480712890625,
        500.0455322265625
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기기인 'VerifyNow P2Y12 test'로 검사를 시행한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        100.6254653930664,
        510.4022216796875,
        397.9184265136719,
        525.92431640625
      ],
      "page_num": 64,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10.1.3. 임상시험 설계",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        562.4253540039062,
        179.66262817382812,
        577.9474487304688
      ],
      "page_num": 64,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 피험자군 또는 대조군 설정",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        704.8297119140625,
        242.62850952148438,
        720.351806640625
      ],
      "page_num": 64,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 혈소판 기능검사",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        730.84130859375,
        179.6617431640625,
        746.3634033203125
      ],
      "page_num": 64,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 58 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) EPI test",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        68.92467498779297,
        137.6851348876953,
        84.4467544555664
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 정상 대조군: 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        81.67573547363281,
        94.93624877929688,
        535.989501953125,
        110.47127532958984
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "② 피험자군: 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        120.82794952392578,
        538.2388916015625,
        136.36297607421875
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "disease),",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        100.98526763916016,
        146.83953857421875,
        538.1490478515625,
        162.36160278320312
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "글란즈만혈소판무력증(Glanzmann's",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        100.98526763916016,
        146.83953857421875,
        538.1490478515625,
        162.36160278320312
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "thrombasthenia),",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        100.98526763916016,
        146.83953857421875,
        538.1490478515625,
        162.36160278320312
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "약물유발",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        100.98526763916016,
        146.83953857421875,
        538.1490478515625,
        162.36160278320312
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈소판기능부전 (drug-induced platelet dysfunction) 등의 선천적/후천적",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        100.98526763916016,
        172.85110473632812,
        538.1488037109375,
        188.3731689453125
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈소판기능장애 환자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        100.98526763916016,
        198.74281311035156,
        221.99990844726562,
        214.26487731933594
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) ADP test",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        224.75437927246094,
        145.24102783203125,
        240.2764434814453
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 정상 대조군: 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        81.67573547363281,
        250.7659454345703,
        535.989501953125,
        266.30096435546875
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 피험자군: 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        276.65765380859375,
        538.2388916015625,
        292.19268798828125
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "disease),",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        100.98526763916016,
        302.6692199707031,
        538.1490478515625,
        318.1913146972656
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "글란즈만혈소판무력증(Glanzmann's",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        100.98526763916016,
        302.6692199707031,
        538.1490478515625,
        318.1913146972656
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "thrombasthenia),",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        100.98526763916016,
        302.6692199707031,
        538.1490478515625,
        318.1913146972656
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "약물유발",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        100.98526763916016,
        302.6692199707031,
        538.1490478515625,
        318.1913146972656
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈소판기능부전 (drug-induced platelet dysfunction) 등의 선천적/후천적",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        100.98526763916016,
        328.6807861328125,
        538.1488037109375,
        344.202880859375
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈소판기능장애 환자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        100.98526763916016,
        354.572509765625,
        221.99990844726562,
        370.0946044921875
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) SIPA test",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        380.5840759277344,
        146.44036865234375,
        396.1061706542969
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 정상 대조군: 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        81.67573547363281,
        406.59564208984375,
        535.989501953125,
        422.13067626953125
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 피험자군: 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        432.4873352050781,
        538.2388916015625,
        448.0223693847656
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "disease),",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        100.98526763916016,
        458.4989318847656,
        538.1490478515625,
        474.0210266113281
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "글란즈만혈소판무력증(Glanzmann's",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        100.98526763916016,
        458.4989318847656,
        538.1490478515625,
        474.0210266113281
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "thrombasthenia),",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        100.98526763916016,
        458.4989318847656,
        538.1490478515625,
        474.0210266113281
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "약물유발",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        100.98526763916016,
        458.4989318847656,
        538.1490478515625,
        474.0210266113281
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈소판기능부전 (drug-induced platelet dysfunction) 등의 선천적/후천적",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        100.98526763916016,
        484.510498046875,
        538.1488037109375,
        500.0325927734375
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈소판기능장애 환자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        100.98526763916016,
        510.4022216796875,
        221.99990844726562,
        525.92431640625
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 혈소판 약물반응검사",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        562.4253540039062,
        198.61090087890625,
        577.9474487304688
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) Aspirin test",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        588.3170776367188,
        160.47276306152344,
        603.8391723632812
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 대조군: 혈관질환의 위험군, 혈관질환 병력 등으로 aspirin 복용 예정인",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.67573547363281,
        614.32861328125,
        538.1478271484375,
        629.8636474609375
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환자의 aspirin 복용 전 검체",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        101.46501159667969,
        640.3402099609375,
        269.7332763671875,
        655.8623046875
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 피험자군: 혈관질환의 위험군, 혈관질환 병력 등으로 aspirin 복용 예정이었던",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.67573547363281,
        666.2318725585938,
        538.1467895507812,
        681.7669067382812
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환자의 3일 이상 aspirin 복용 후의 검체",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        100.74539947509766,
        692.2434692382812,
        328.0216369628906,
        707.7655639648438
      ],
      "page_num": 65,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2）P2Y12 test",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        718.2550659179688,
        155.07569885253906,
        733.7901000976562
      ],
      "page_num": 65,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "① 대조군: 혈관질환의 위험군, 혈관질환 병력 등으로 clopidogrel 복용 예정인",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.67573547363281,
        744.146728515625,
        538.1477661132812,
        759.6817626953125
      ],
      "page_num": 65,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 59 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환자의 clopidogrel",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        100.8653335571289,
        68.92467498779297,
        296.9587707519531,
        84.4467544555664
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "복용 전 검체",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        100.8653335571289,
        68.92467498779297,
        296.9587707519531,
        84.4467544555664
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "② 피험자군: 혈관질환의 위험군, 혈관질환 병력 등으로 clopidogrel",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        81.67573547363281,
        94.93624877929688,
        538.1483154296875,
        110.47127532958984
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "복용 예정",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.67573547363281,
        94.93624877929688,
        538.1483154296875,
        110.47127532958984
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이었던 환자의 5일 이상clopidogrel",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        101.46501159667969,
        120.82794952392578,
        398.90374755859375,
        136.3500213623047
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "복용 후의 검체",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        101.46501159667969,
        120.82794952392578,
        398.90374755859375,
        136.3500213623047
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. 처리 할당 방법: 단일눈가림",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        172.85110473632812,
        245.74652099609375,
        188.3731689453125
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 시험 책임자 및 임상시험 관련자가 개인 식별 표기를 가린 후 검사자에게 검체를",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        198.74281311035156,
        538.14794921875,
        214.26487731933594
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전달한다)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        80.59632110595703,
        224.75437927246094,
        133.7102508544922,
        240.2764434814453
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 배정방법: 비무작위 배정",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        276.65765380859375,
        226.91671752929688,
        292.17974853515625
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "라. 비열등성 검정",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        328.6807861328125,
        167.06915283203125,
        344.202880859375
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 혈소판 기능검사",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        354.572509765625,
        179.6617431640625,
        370.0946044921875
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) EPI test: 시험기기에서",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        76.39859771728516,
        380.5840759277344,
        538.1487426757812,
        396.1061706542969
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "LTA를 기준검사법으로 한 민감도와 특이도가",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        76.39859771728516,
        380.5840759277344,
        538.1487426757812,
        396.1061706542969
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인한다",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        92.8296890258789,
        406.59564208984375,
        538.1488647460938,
        422.11773681640625
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(비열등성한계 10%).",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        92.8296890258789,
        432.4873352050781,
        212.9783172607422,
        448.0094299316406
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) ADP test: 시험기기에서",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        458.4989318847656,
        538.1488647460938,
        474.0210266113281
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "LTA를 기준검사법으로 한 민감도와 특이도가",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        458.4989318847656,
        538.1488647460938,
        474.0210266113281
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인한다",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        93.42936706542969,
        484.510498046875,
        538.1488647460938,
        500.0325927734375
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(비열등성한계 10%)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        93.42936706542969,
        510.4022216796875,
        210.34881591796875,
        525.92431640625
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) SIPA test:　시험기기에서",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        562.4253540039062,
        538.1472778320312,
        577.9603881835938
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "LTA를 기준검사법으로 한 민감도와 특이도가",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        562.4253540039062,
        538.1472778320312,
        577.9603881835938
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인한다 (비",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        92.5898208618164,
        588.3170776367188,
        538.1483764648438,
        603.8391723632812
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "열등성한계 10%). SIPA　 test는 검사원리가 비슷한 기존검사법은 없으나,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        92.5898208618164,
        614.32861328125,
        538.2423706054688,
        629.8636474609375
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈소판 기능의 정상/비정상 유무를 판정하기 위한 목적은 ADP test와 동일",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        92.5898208618164,
        640.3402099609375,
        538.1486206054688,
        655.8623046875
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하므로, 이를 확인하는 LTA 검사결과를 참고치로 하여 결과를 비교한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        92.5898208618164,
        666.2318725585938,
        518.5730590820312,
        681.7539672851562
      ],
      "page_num": 66,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 혈소판 약물반응검사",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        718.2550659179688,
        204.84750366210938,
        733.7771606445312
      ],
      "page_num": 66,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) Aspirin test：Aspirin 복용예정 환자에서 약물 복용 전후에 대한 민감도와",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        744.146728515625,
        538.1477661132812,
        759.6817626953125
      ],
      "page_num": 66,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 60 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 67,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특이도가 기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        93.78916931152344,
        68.92467498779297,
        538.1480712890625,
        84.4467544555664
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다 (비열등성한계 10%).",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        93.78916931152344,
        94.93624877929688,
        241.76292419433594,
        110.45832824707031
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2）P2Y12 test：Clopidogrel 복용예정 환자에서 약물 복용 전후에 대한 민감도와",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        120.82794952392578,
        538.1482543945312,
        136.36297607421875
      ],
      "page_num": 67,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "특이도가 기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        94.26890563964844,
        146.83953857421875,
        538.1483154296875,
        162.36160278320312
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "한다 (비열등성한계 10%).",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        94.26890563964844,
        172.85110473632812,
        239.60458374023438,
        188.3731689453125
      ],
      "page_num": 67,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 61 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 68,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당 임상시험용 의료기기(체외진단용 시약)의 성능 및 유효성 평가를 위하여",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        183.03997802734375,
        523.7555541992188,
        198.56204223632812
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "측정하는 변수를 구체적으로 명확히 기술하며, 관찰항목 및 임상검사항목, 관",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        208.93167114257812,
        523.7561645507812,
        224.4537353515625
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "찰검사방법(선정검체 피험자 식별코드부여, 임상평가, 이상반응조사, 관찰항목",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        234.94325256347656,
        523.7552490234375,
        250.46531677246094
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "별 평가도구, 평가방법 등) 및 결과판정 방법을 해당 임상시험방법의 진행순서",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        260.9548034667969,
        523.7561645507812,
        276.4768981933594
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대로 기재하되, 대조군 및 확인군이 있는 경우 해당 임상시험용 의료기기(시험",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        286.84649658203125,
        523.756591796875,
        302.36859130859375
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "군)의 기술 형태와 마찬가지로 대조군 및 확인군 해당 항목별로 순서에 따라",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        312.85809326171875,
        523.755615234375,
        328.38018798828125
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개별 기술한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        338.8696594238281,
        151.33206176757812,
        354.3917541503906
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "11. 관찰항목, 임상검사항목 및 관찰검사방법",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        76.45640563964844,
        397.703857421875,
        92.39897918701172
      ],
      "page_num": 68,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        56.609317779541016,
        115.1973876953125,
        529.839599609375,
        126.225341796875
      ],
      "page_num": 68,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        73.04041290283203,
        132.81813049316406,
        300.67657470703125,
        143.8460693359375
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "11.1. 관찰항목(임상시험 일정표)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        147.1991424560547,
        241.2919464111328,
        162.72120666503906
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.64496612548828,
        372.0733642578125,
        94.13170623779297,
        387.595458984375
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 환자 및 대조군 내원시에 아래 11.2. 임상시험 절차에 따라 임상시험을 시행한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.84593963623047,
        392.8106994628906,
        534.7642822265625,
        408.3327941894531
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "스크리닝 및 검사일",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        218.0418243408203,
        424.69586181640625,
        445.43878173828125,
        437.9183654785156
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검사일",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        218.0418243408203,
        424.69586181640625,
        445.43878173828125,
        437.9183654785156
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방문일",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        122.09382629394531,
        446.87164306640625,
        532.5113525390625,
        460.0941467285156
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방문1",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        122.09382629394531,
        446.87164306640625,
        532.5113525390625,
        460.0941467285156
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방문2: 혈소판 약물반응검사의 경우만 해당",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        122.09382629394531,
        446.87164306640625,
        532.5113525390625,
        460.0941467285156
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "경과일수",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        116.81668853759766,
        480.1952209472656,
        278.70751953125,
        493.417724609375
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Day0",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        116.81668853759766,
        480.1952209472656,
        278.70751953125,
        493.417724609375
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Aspirin test: Aspirin 복용 3일 이후",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        339.4160461425781,
        469.1672668457031,
        519.1982421875,
        482.3897705078125
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "P2Y12 test: Clopidogrel 복용 5일 이후",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        331.9800720214844,
        491.2231750488281,
        526.5150146484375,
        504.4456787109375
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Visit window",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        104.82318878173828,
        513.518798828125,
        268.0000305175781,
        526.7413330078125
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        104.82318878173828,
        513.518798828125,
        268.0000305175781,
        526.7413330078125
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관찰형태",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        116.81668853759766,
        535.814453125,
        440.1615295410156,
        549.0369873046875
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "내원",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        116.81668853759766,
        535.814453125,
        440.1615295410156,
        549.0369873046875
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "내원",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        116.81668853759766,
        535.814453125,
        440.1615295410156,
        549.0369873046875
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "동의서 취득",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        108.78104400634766,
        557.9901733398438,
        270.4798278808594,
        571.2127075195312
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        108.78104400634766,
        557.9901733398438,
        270.4798278808594,
        571.2127075195312
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "선정/제외기준 확인",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        89.59144592285156,
        580.2858276367188,
        270.4798278808594,
        593.5083618164062
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        89.59144592285156,
        580.2858276367188,
        270.4798278808594,
        593.5083618164062
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인구학적 정보",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        103.50390625,
        602.5814819335938,
        270.4798278808594,
        615.8040161132812
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        103.50390625,
        602.5814819335938,
        270.4798278808594,
        615.8040161132812
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "과거병력 및 병용약물 조사",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        71.48126220703125,
        624.8770751953125,
        433.5914001464844,
        638.099609375
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        71.48126220703125,
        624.8770751953125,
        433.5914001464844,
        638.099609375
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        71.48126220703125,
        624.8770751953125,
        433.5914001464844,
        638.099609375
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검체 채취",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        114.17811584472656,
        647.1727294921875,
        433.5914001464844,
        660.395263671875
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        114.17811584472656,
        647.1727294921875,
        433.5914001464844,
        660.395263671875
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        114.17811584472656,
        647.1727294921875,
        433.5914001464844,
        660.395263671875
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검체 검사 및 분석",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        92.8296890258789,
        669.4683837890625,
        433.5914001464844,
        682.69091796875
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        92.8296890258789,
        669.4683837890625,
        433.5914001464844,
        682.69091796875
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "O",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        92.8296890258789,
        669.4683837890625,
        433.5914001464844,
        682.69091796875
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기타",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        127.49090576171875,
        691.7639770507812,
        149.19924926757812,
        704.9865112304688
      ],
      "page_num": 68,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 62 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 69,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "11.2. 관찰검사방법",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        68.92467498779297,
        163.94970703125,
        84.4467544555664
      ],
      "page_num": 69,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. 방문1 (스크리닝 및 검사일)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.84593963623047,
        94.93624877929688,
        244.41024780273438,
        110.45832824707031
      ],
      "page_num": 69,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 임상시험 설명 및 동의 및 스크리닝",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        69.2024917602539,
        120.82794952392578,
        293.9606628417969,
        136.3500213623047
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈소판 기능부전이 의심되는 환자 및 aspirin, clopidogrel 복용 예정 환자에서",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        146.83953857421875,
        538.1474609375,
        162.36160278320312
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "‘출혈 시간 및 항혈소판제제 저항성 복합검사기기(Anysis-200)’의 임상시험에 들어",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        172.85110473632812,
        538.1485595703125,
        188.3731689453125
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가기 전, 본 임상시험의 목적과 내용에 대하여 대상자 또는 법정대리인에게",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        75.43911743164062,
        198.74281311035156,
        538.1483764648438,
        214.26487731933594
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "상세히 설명한다. 서명일 및 서명일자를 정확히 기재하여야 하며 작성된 서명",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        224.75437927246094,
        538.1478271484375,
        240.2764434814453
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "동의서의 원본은 시험자가 보관하고 사본은 시험대상자 또는 법정대리인에게",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        75.43911743164062,
        250.7659454345703,
        538.1483764648438,
        266.28802490234375
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "교부한다. 대상자에게 서면 동의를 받은 후 동의취득",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        75.43911743164062,
        276.65765380859375,
        538.1483764648438,
        292.17974853515625
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "순서에 따라 스크리닝",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        75.43911743164062,
        276.65765380859375,
        538.1483764648438,
        292.17974853515625
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "번호를 부여한다. 스크리닝 번호는 다음과 같이 구성된다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        302.6692199707031,
        416.2684631347656,
        318.1913146972656
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 스크리닝",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        75.43911743164062,
        328.6807861328125,
        413.1751708984375,
        344.2158203125
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "번호: SXX(XX:일련번호), 예)S01,02,03…………",
      "font_size": 12.94941520690918,
      "font_name": "T11",
      "bbox": [
        75.43911743164062,
        328.6807861328125,
        413.1751708984375,
        344.2158203125
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 선정/제외기준",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        354.572509765625,
        169.46728515625,
        370.0946044921875
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그 위임자가 모든 선정",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        380.5840759277344,
        538.1485595703125,
        396.1061706542969
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 제외기준을 검토하여 피험자 식별코드를 부여한다. 피험자 식별코드는 아래의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        406.59564208984375,
        538.14794921875,
        422.11773681640625
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방법에 따라 기입한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        432.4873352050781,
        200.5054168701172,
        448.0094299316406
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순, 예) KFDA-12-34-56",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        73.28028106689453,
        458.4989318847656,
        536.801513671875,
        474.0210266113281
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 인구학적 정보 : 인구학적 정보로 대상자 이니셜, 나이, 성별 등을 조사한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        484.510498046875,
        526.6087036132812,
        500.0325927734375
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 과거병력 및 병용약물 조사",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        510.4022216796875,
        243.58767700195312,
        525.92431640625
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "출혈성 질환, 응고장애, 암, 기타 만성질환 등의 병력 및",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        76.03878784179688,
        536.4137573242188,
        538.1227416992188,
        551.9358520507812
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아스피린, P2Y12",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        76.03878784179688,
        536.4137573242188,
        538.1227416992188,
        551.9358520507812
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수용체 저해제 등의 항혈소판제제, 항응고제 복용 유무, CBC(혈색소, 헤마토크릿,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        562.4253540039062,
        538.2423706054688,
        577.9474487304688
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈소판수 포함), PT, aPTT 결과 등을 문진과 진료 기록을 통하여 조사한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        588.3170776367188,
        502.9814758300781,
        603.8391723632812
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5) 검체 채취 및 임상시험 시행",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        614.32861328125,
        249.94424438476562,
        629.8507080078125
      ],
      "page_num": 69,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검체를 채취하고 시험기기 및 대조기기에서 검사를 시행하고 결과를 기록한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        640.3402099609375,
        531.8858032226562,
        655.8623046875
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 3.2% Na Citrate tube에 약 20mL의 정맥혈을 채혈한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        666.2318725585938,
        414.9491882324219,
        681.7539672851562
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 시험기기는 3.2% Na Citrate tube 검체를 실온(18∼25℃)에서 채혈 후 최소",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        692.2434692382812,
        538.1480712890625,
        707.7785034179688
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "30분, 최대 4시간 이내 검사를 시행하고 그 결과를 데이터 수집용지에 기록",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        93.3094253540039,
        718.2550659179688,
        538.1480712890625,
        733.7771606445312
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        93.3094253540039,
        744.146728515625,
        121.70812225341797,
        759.6688232421875
      ],
      "page_num": 69,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 63 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) LTA 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        68.92467498779297,
        538.1480712890625,
        84.4467544555664
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분리하여 혈소판풍부혈장을 취하여 3시간 이내에 검사를 시행하고 그 결과를",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        93.0695571899414,
        94.93624877929688,
        538.1492919921875,
        110.45832824707031
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "데이터 수집용지에 기록한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        93.0695571899414,
        120.82794952392578,
        258.43402099609375,
        136.3500213623047
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "4) PFA-100 및 VerifyNow 대조기기는 3.2% Na Citrate tube 검체를 실온(18∼",
      "font_size": 12.94941520690918,
      "font_name": "T16",
      "bbox": [
        75.43911743164062,
        146.83953857421875,
        538.1483764648438,
        162.3745574951172
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "25℃)에서 2시간 이내 검사를 시행하고 그 결과를 데이터 수집용지에 기록한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        92.70975494384766,
        172.85110473632812,
        534.5244140625,
        188.38612365722656
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 방문2 (검사일)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.84593963623047,
        198.74281311035156,
        168.97113037109375,
        214.26487731933594
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 혈소판 약물반응검사의 경우에만 방문2에 검사를 시행한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        224.75437927246094,
        428.9815979003906,
        240.2764434814453
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) Aspirin 복용 후 3일, 또는 clopidogrel 복용 후 5일 이후 검체를 채취하여 시험",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        250.7659454345703,
        538.1485595703125,
        266.28802490234375
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기기 및 대조기기에서 검사를 시행하고 결과를 기록한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        86.11332702636719,
        276.65765380859375,
        406.3138732910156,
        292.17974853515625
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. 관찰항목 검사(평가) 방법",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        328.6807861328125,
        232.19387817382812,
        344.202880859375
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 혈소판 기능검사: 시험기기와 대조기기(LTA, PFA-100)에서 검사를 시행한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        354.572509765625,
        528.887451171875,
        370.0946044921875
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① LTA 대조기기 결과를 기준하여 시험기기의 민감도와 특이도를 확인한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        380.5840759277344,
        519.2926635742188,
        396.1191101074219
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② LTA 대조기기와 시험기기의 일치도를 확인한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        406.59564208984375,
        374.5310974121094,
        422.13067626953125
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "③ PFA-100 대조기기와 시험기기의 일치도를 확인한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        432.4873352050781,
        396.7190856933594,
        448.0223693847656
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "④ SIPA　test는 검사원리가 비슷한 기존검사법은 없으나, 혈소판 기능의 정상/",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        458.4989318847656,
        538.1890869140625,
        474.0339660644531
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비정상 유무를 판정하기 위한 목적은 ADP test와 동일하므로, 이를 확인하는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        94.38884735107422,
        484.510498046875,
        538.1497802734375,
        500.0325927734375
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "LTA 검사결과를 기준으로 하여 결과를 평가한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        94.38884735107422,
        510.4022216796875,
        378.24908447265625,
        525.92431640625
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 혈소판 약물반응 검사: 시험기기와 대조기기(VerifyNow)에서 검사를 시행하여",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        69.2024917602539,
        536.4137573242188,
        538.1497802734375,
        551.9358520507812
      ],
      "page_num": 70,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "약물 투여 전 반응여부와 약물 투여후 반응여부를 확인한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        87.6724853515625,
        562.4253540039062,
        433.89892578125,
        577.9474487304688
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "① 약물사용 전 환자를 약물반응 음성군, 약물사용 후 환자를 약물반응 양성군",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        75.43911743164062,
        588.3170776367188,
        538.1483764648438,
        603.8521118164062
      ],
      "page_num": 70,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "으로 간주하여 시험기기의 검사 결과에 대해 민감도와 특이도를 확인한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        94.86858367919922,
        614.32861328125,
        526.12890625,
        629.8507080078125
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "② 대조기기(VerifyNow) 결과와 시험기기의 일치도를 확인한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        640.3402099609375,
        445.7724914550781,
        655.875244140625
      ],
      "page_num": 70,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 64 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 등을 제시함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        155.23036193847656,
        528.7675170898438,
        170.75242614746094
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "12. 예측되는 부작용 및 사용 시 주의사항",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        59.60769271850586,
        76.45640563964844,
        369.8792419433594,
        92.39897918701172
      ],
      "page_num": 71,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        56.609317779541016,
        109.20393371582031,
        529.839599609375,
        120.23188781738281
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        73.04041290283203,
        126.82469177246094,
        300.67657470703125,
        137.85263061523438
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        197.5441131591797,
        86.09606170654297,
        213.06617736816406
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "12.1 예측되는 부작용",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        218.28146362304688,
        179.66204833984375,
        233.80352783203125
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 혈액검체 채취를 위한 채혈 과정에서 통증, 신경손상, 어지럼증, 메스꺼움, 구토,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.6060676574707,
        244.2930450439453,
        538.1224365234375,
        259.81512451171875
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈종, 출혈점(피부표면",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        80.23651123046875,
        270.1847229003906,
        538.1483764648438,
        285.7068176269531
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아래에 적은 량의 출혈을 의미하는 작고 붉은 반점)과 같은",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        80.23651123046875,
        270.1847229003906,
        538.1483764648438,
        285.7068176269531
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부작용 증세가 발생할 수 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        80.23651123046875,
        296.1962890625,
        248.9591522216797,
        311.7183837890625
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 혈관미주신경 반응",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        68.7227554321289,
        322.2078552246094,
        192.2559814453125,
        337.7299499511719
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 드물지만 채혈할 때 일시적으로 의식이 소실되어 하는 경우가 있다. 침에 찔리자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.7195053100586,
        348.0995788574219,
        538.1485595703125,
        363.6216735839844
      ],
      "page_num": 71,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마자 실신할 수도 있고 단순히 피 또는 주사침을 보는 것만으로도 쓰러질 수 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.0339126586914,
        374.11114501953125,
        538.1224365234375,
        389.63323974609375
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "처음으로 유발될 수도 있지만 과거력이 있는 경우도 있다. 어지럽고 메스껍고,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.0339126586914,
        400.1227111816406,
        538.1224365234375,
        415.6448059082031
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "얼굴이 창백해지고 이 나며, 맥박수가 줄어들고, 혈압이 심하게 떨어지며, 심하면",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        85.0339126586914,
        426.0144348144531,
        538.148193359375,
        441.5365295410156
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의식을 잃어 쓰러지게 된다. 이것은 혈관미주신경 반응에 의해 일어나며 피 또는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        85.0339126586914,
        452.0260009765625,
        538.1485595703125,
        467.548095703125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주사침에 대한 공포심과 관련이 있다. 채혈에 대한 두려움 등 과민한 정신적인",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        85.0339126586914,
        478.0375671386719,
        538.1483764648438,
        493.5596618652344
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반응으로 교감신경이 흥분한 상태에서 주사침에 찔리게 되면 갑자기 부교감신경인",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        85.0339126586914,
        503.92926025390625,
        538.1499633789062,
        519.4513549804688
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "미주신경이 반사적으로 작용하여 뇌혈류를 감소시키고 심장 박동을 감소시켜",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        85.0339126586914,
        529.9408569335938,
        538.148193359375,
        545.4629516601562
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일시적으로 의식 소실이 유발되는 것이다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.0339126586914,
        555.952392578125,
        322.839111328125,
        571.4744873046875
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "-",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        74.7195053100586,
        581.8441162109375,
        115.8573989868164,
        597.3662109375
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "치료",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.7195053100586,
        581.8441162109375,
        115.8573989868164,
        597.3662109375
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 증상이 나타나면 즉시 주저앉거나 머리를 다리보다 낮춘 자세로 10분 이상",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        80.71625518798828,
        607.855712890625,
        538.1488037109375,
        623.3907470703125
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "휴식을 취하면 대부분 회복된다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        92.46988677978516,
        633.8672485351562,
        276.544189453125,
        649.3893432617188
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 채혈에 대한 두려움을 없게 하기 위해 반드시 채혈 전에 채혈자를 안심시키는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        80.71625518798828,
        659.7589721679688,
        538.1480102539062,
        675.2940063476562
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것이 중요하다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        92.46988677978516,
        685.7705688476562,
        174.11972045898438,
        701.2926635742188
      ],
      "page_num": 71,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 넥타이와 허리띠를 느슨히 풀어주며 천천히 깊은 숨을 쉬도록 격려해 준다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        80.71625518798828,
        711.7821044921875,
        511.1370544433594,
        727.317138671875
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "· 혈관미주신경 반응에 의한 실신은 후유증 없이 완전히 회복되지만 다른 원인에",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        80.71625518798828,
        737.673828125,
        538.148193359375,
        753.2088623046875
      ],
      "page_num": 71,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 65 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 72,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의해서도 실신이 일어날 수 있으므로 회복이 안 되거나 경련이 동반되거나 하면",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        91.99014282226562,
        68.92467498779297,
        538.1480102539062,
        84.4467544555664
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "의료진에게 알리고 적절히 조치할 수 있도록 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        91.99014282226562,
        94.93624877929688,
        369.97357177734375,
        110.45832824707031
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2) 피하 출혈 및 혈종",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        68.7227554321289,
        120.82794952392578,
        192.2559814453125,
        136.3500213623047
      ],
      "page_num": 72,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 주사침이 정맥에 걸쳐 있거나 관통하는 경우 혈액이 새어 나와 피부 아래에",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.7195053100586,
        146.83953857421875,
        538.1492919921875,
        162.36160278320312
      ],
      "page_num": 72,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "고여서 생긴 것이다. 주사침을 찌른 부위의 피부가 부어오르면 혈종이 생긴",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        85.75352478027344,
        172.85110473632812,
        538.1488037109375,
        188.3731689453125
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것이다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        85.75352478027344,
        198.74281311035156,
        126.38558197021484,
        214.26487731933594
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 치료",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.7195053100586,
        224.75437927246094,
        109.74018859863281,
        240.2764434814453
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 주사침을 찌르다가 만약 피부가 부어오르면 재빨리 압박대를 풀고 주사침을 뺀",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        80.71625518798828,
        250.7659454345703,
        538.1483764648438,
        266.30096435546875
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "후 압박지혈을 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        91.99014282226562,
        276.65765380859375,
        203.86358642578125,
        292.17974853515625
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 혈종은 채혈 시 외에도 환자가 채혈 후 지혈을 충분히 하지 않은 경우에도",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        81.55580139160156,
        302.6692199707031,
        538.1488037109375,
        318.2042541503906
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "발생할 수 있으므로 충분한 지혈을 하도록 환자에게 교육한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        92.34994506835938,
        328.6807861328125,
        440.0155944824219,
        344.202880859375
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 채혈 이후에는 채혈된 전혈 검체만을 사용하는 체외진단 검사이므로 예측되는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.6060676574707,
        354.572509765625,
        538.148193359375,
        370.0946044921875
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "피험자의 부작용에 대한 내용은 해당사항 없다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        79.27703094482422,
        380.5840759277344,
        348.02545166015625,
        396.1061706542969
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "12.2 사용상의 주의사항",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        432.4873352050781,
        187.21856689453125,
        448.0094299316406
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 반드시 체외진단용으로 사용해야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.6060676574707,
        458.4989318847656,
        293.2151794433594,
        474.0210266113281
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 일반적인 실험실 안전 및 생물학적 위험물질 취급 시 안전 등의 주의사항",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.6060676574707,
        484.510498046875,
        490.0544738769531,
        500.0325927734375
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 검사를 진행하는 곳에서 음식물을 먹거나, 마시거나 담배를 피우지 않도록 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        68.7227554321289,
        510.4022216796875,
        535.6038208007812,
        525.92431640625
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 검체와 시약을 다룰 때에는 일회용 장갑과 검사용 가운을 착용하도록 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        68.7227554321289,
        536.4137573242188,
        508.4985046386719,
        551.9358520507812
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 검체와 시약을 다룬 이후에는 반드시 손을 깨끗이 씻도록 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        68.7227554321289,
        562.4253540039062,
        442.05450439453125,
        577.9474487304688
      ],
      "page_num": 72,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(4) 모든 혈액 검체와 혈액 성분은 전염성 감염원일 가능성이 있는 것으로 취급해야",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        68.7227554321289,
        588.3170776367188,
        538.1487426757812,
        603.8391723632812
      ],
      "page_num": 72,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하며, 모든 검체는 적절한 주의사항을 준수하는 우수실험실운영기준(GLP:",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.75189971923828,
        614.32861328125,
        538.241943359375,
        629.8507080078125
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Good",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.75189971923828,
        614.32861328125,
        538.241943359375,
        629.8507080078125
      ],
      "page_num": 72,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Laboratory",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.75189971923828,
        640.3402099609375,
        339.6300048828125,
        655.8623046875
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Practice)에",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        88.75189971923828,
        640.3402099609375,
        339.6300048828125,
        655.8623046875
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "따라 취급해야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        88.75189971923828,
        640.3402099609375,
        339.6300048828125,
        655.8623046875
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(5) 혈액 검체 채취는 오염이 발생하지 않도록 주의 깊게 수행하도록 하고, 응집이",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        68.7227554321289,
        666.2318725585938,
        538.148193359375,
        681.7539672851562
      ],
      "page_num": 72,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있는 검체는 사용하지 않는다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        89.71138000488281,
        692.2434692382812,
        255.91539001464844,
        707.7655639648438
      ],
      "page_num": 72,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 66 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 경고사항",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.6060676574707,
        68.92467498779297,
        127.85075378417969,
        84.4467544555664
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 본 제품의 안전하고 적절한 사용을 위해, 제품을 사용하기 전 사용방법에 대한",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        68.7227554321289,
        94.93624877929688,
        538.1485595703125,
        110.45832824707031
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "교육을 받아야 한다. 사용자 설명서 및 제품과 관련된 모든 문서를 숙지한 후,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        89.71138000488281,
        120.82794952392578,
        538.2423706054688,
        136.3500213623047
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "추가적인 정보가 필요한 경우 제조원에 요청한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        89.71138000488281,
        146.83953857421875,
        364.57647705078125,
        162.36160278320312
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 제품의 변경 및 변형은 허용되지 않는다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        68.7227554321289,
        172.85110473632812,
        315.283203125,
        188.3731689453125
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 제품 취급 및 보관상의 주의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.6060676574707,
        198.74281311035156,
        236.511474609375,
        214.26487731933594
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 유효기한이 지난 제품은 사용하지 않는다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        68.7227554321289,
        224.75437927246094,
        321.39990234375,
        240.2764434814453
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 제품의 보관방법 및 유효기간",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.7195053100586,
        250.7659454345703,
        248.62530517578125,
        266.28802490234375
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 미개봉시 2-8°C 보관, 제조일로부터 12개월· 개봉시 실온보관, 개봉시부터 4시간",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        80.71625518798828,
        276.65765380859375,
        536.9486694335938,
        292.19268798828125
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 이 검사는 개인 환자 또는 헌혈자로부터 얻은 검체를 사용하도록 설계되었다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        68.7227554321289,
        302.6692199707031,
        538.1224365234375,
        318.1913146972656
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "여러 검체가 혼합된 검체를 사용해서는 안된다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        90.5509262084961,
        328.6807861328125,
        353.3026123046875,
        344.202880859375
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 본 제품의 서비스와 수리는 제조원 담당자에 의해 행해져야",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        68.7227554321289,
        354.572509765625,
        538.1483764648438,
        370.0946044921875
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다. 서비스나",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        68.7227554321289,
        354.572509765625,
        538.1483764648438,
        370.0946044921875
      ],
      "page_num": 73,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수리 후 공인된 기사나 병원의 안전관리자에 의해 제품의 안전을 확인한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        89.11170196533203,
        380.5840759277344,
        538.1224365234375,
        396.1061706542969
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "승인된 자 이외에는 본 제품을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        89.11170196533203,
        406.59564208984375,
        454.0480041503906,
        422.11773681640625
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "분해하거나 수리해서는 안된다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        89.11170196533203,
        406.59564208984375,
        454.0480041503906,
        422.11773681640625
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4) 본 제품의 안전한 사용을 위해 제품 손상을 의미하는 어떤 증상을 발견했을 경우",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        68.7227554321289,
        432.4873352050781,
        538.1483764648438,
        448.0094299316406
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 사용을 금지하며 제조원 담당자에게 연락한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        89.35157012939453,
        458.4989318847656,
        385.32525634765625,
        474.0210266113281
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(5) 제품 손상을 방지하기 위해 제품을 단단한 표면에 떨어뜨리거나 부딪히지 않게 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        68.7227554321289,
        484.510498046875,
        537.882568359375,
        500.0325927734375
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(6) 열, 먼지, 일광(직사광선), 응축(제품 표면에 맺힌 물방울)을 피해 사용하여야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        68.7227554321289,
        510.4022216796875,
        536.2034912109375,
        525.92431640625
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5) 적용상의 주의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.6060676574707,
        536.4137573242188,
        158.07452392578125,
        551.9358520507812
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 본 제품은 일회용으로 재사용을 금한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        68.7227554321289,
        562.4253540039062,
        309.2864685058594,
        577.9474487304688
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2) 부적절한 혈액 채취 기법 및 지연된 검사는 결과의 오류를 야기할 수 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        68.7227554321289,
        588.3170776367188,
        508.4985046386719,
        603.8391723632812
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 데이터 전송 시, 데이터 전송이 완료된 후 장비를 사용한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        68.7227554321289,
        614.32861328125,
        420.9459533691406,
        629.8507080078125
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4) 가급적 장비의 케이스를 닫고 검사를 진행하도록 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        68.7227554321289,
        640.3402099609375,
        393.84063720703125,
        655.8623046875
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(5) 검사가 종료된 후, 데이터 처리에 시간이 오래 소요될 수 있으므로 검사가 완전히",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        68.7227554321289,
        666.2318725585938,
        538.1482543945312,
        681.7539672851562
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "끝날때까지 기다리도록 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        89.11170196533203,
        692.2434692382812,
        246.08071899414062,
        707.7655639648438
      ],
      "page_num": 73,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(6) 검사칩 외 이물질을 장비에 삽입해서는 안된다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        68.7227554321289,
        718.2550659179688,
        351.5035705566406,
        733.7771606445312
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(7) 장비의 이상동작 시 스스로 수리하려고 하지 않는다. 제조원에 문의한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        68.7227554321289,
        744.146728515625,
        493.3866882324219,
        759.6688232421875
      ],
      "page_num": 73,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 67 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 74,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "6) 결과 판정상 주의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.6060676574707,
        68.92467498779297,
        176.1846923828125,
        84.4467544555664
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 본 제품의 결과는 항상 환자의 약물 복용 여부를 포함한 의료 기록, 임상 증상",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        68.7227554321289,
        94.93624877929688,
        538.1480102539062,
        110.45832824707031
      ],
      "page_num": 74,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "및 시험연구를 포함한 기타 소견과 함께 해석되어야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        89.59144592285156,
        120.82794952392578,
        412.7903747558594,
        136.3500213623047
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2) 예상치 못한 결과 값이 도출된 경우, 부적절한 혈액 채취 여부 또는 부주의,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        68.7227554321289,
        146.83953857421875,
        538.1224365234375,
        162.36160278320312
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "잘못된 처리 여부를 조사하여야 한다. 새로운 혈액 검체와 새 검사칩으로 재",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        90.19111633300781,
        172.85110473632812,
        538.1483764648438,
        188.3731689453125
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사를 하도록 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        90.19111633300781,
        198.74281311035156,
        204.5832061767578,
        214.26487731933594
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7) 제품 폐기 시 주의사항",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.6060676574707,
        224.75437927246094,
        206.40817260742188,
        240.2764434814453
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 오염된 제품이나 사용한 제품은 병원의 규정에 의거하여 폐기한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        68.7227554321289,
        250.7659454345703,
        460.1646728515625,
        266.28802490234375
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 본 제품의 사용자는 환자나 사용자를 위한",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        68.7227554321289,
        276.65765380859375,
        538.1485595703125,
        292.17974853515625
      ],
      "page_num": 74,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "감염방지 및 교차감염방지를 위해",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        68.7227554321289,
        276.65765380859375,
        538.1485595703125,
        292.17974853515625
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "감염 방지 정책을 따라야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        90.07118225097656,
        302.6692199707031,
        262.2719421386719,
        318.1913146972656
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8) 검사칩은 항상 본체에 장착하여 사용하여야 한다. 임상시험용 장비 이외의 장비에서",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.6060676574707,
        328.6807861328125,
        538.1490478515625,
        344.202880859375
      ],
      "page_num": 74,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사칩을 사용하지 않도록 주의한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        79.03716278076172,
        354.572509765625,
        277.3837585449219,
        370.0946044921875
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 대조기기",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        68.7227554321289,
        380.5840759277344,
        137.92529296875,
        396.1061706542969
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 반드시 체외진단용으로 사용해야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        74.7195053100586,
        406.59564208984375,
        305.32861328125,
        422.11773681640625
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 검체는 감염성 질환에 대한 감염을 배제할 수 없으므로 취급에 주의한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        74.7195053100586,
        432.4873352050781,
        498.4239501953125,
        448.0094299316406
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 사용기한이 지난 제품은 사용하지 않는다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        74.7195053100586,
        458.4989318847656,
        323.43878173828125,
        474.0210266113281
      ],
      "page_num": 74,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 68 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 75,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이상사례 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상시험의 진행이",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        166.378173828125,
        530.5918579101562,
        181.90023803710938
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "피험자의 안전보호를 위협하여 그 진행을 멈추는 것을 “중지”라 하며, 임상시험",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        192.26988220214844,
        530.591552734375,
        207.7919464111328
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개시에서 완료까지 중지 될 수 있는 세부사항을 “중지 기준”에 제시함. “중지",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        218.28146362304688,
        530.5921630859375,
        233.80352783203125
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "처리”에는 각 중지 기준에 대한 유효성 평가 통계처리 시 그 산입 여부와",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        244.2930450439453,
        530.5914916992188,
        259.81512451171875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "피험자별 중지사유를 포함한 관련 임상시험자료의 처리방법을 제시함. 또 “탈락”",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        270.1847229003906,
        530.5665283203125,
        285.7068176269531
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상시험이",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        296.1962890625,
        530.5922241210938,
        311.7183837890625
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "완료되지 못한 경우를 말하며, 그 분류기준을 “탈락 기준”에 탈락의 사유와 관",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        322.2078552246094,
        530.5924682617188,
        337.7299499511719
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "련 임상자료의 처리방법을 “탈락 처리”에 구체적으로 제시함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        348.0995788574219,
        420.226318359375,
        363.6216735839844
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "13. 중지·탈락 기준",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        76.45640563964844,
        218.04153442382812,
        92.39897918701172
      ],
      "page_num": 75,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        56.609317779541016,
        115.1973876953125,
        529.839599609375,
        126.225341796875
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        73.04041290283203,
        137.1334228515625,
        300.67657470703125,
        148.16136169433594
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        394.1292724609375,
        86.09606170654297,
        409.6513671875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "본 임상시험인 혈소판 기능검사 및 혈소판 약물반응 검사는 혈소판 기능 부전이 의심되는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.24626541137695,
        420.1408386230469,
        538.1487426757812,
        435.6629333496094
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환자 및 정상 대조군, aspirin 또는 P2Y12 수용체 저해제인 clopidogrel을 복용 전후의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.3661994934082,
        446.15240478515625,
        538.1486206054688,
        461.67449951171875
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "환자를 대상으로 구연산 처리된 전혈을 채혈하여 체외에서 검사가 이뤄지므로 환자 또는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.3661994934082,
        472.04412841796875,
        538.1484985351562,
        487.56622314453125
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자에게 직접적인 위해를 발생시키지 않는다. 그러므로 아래 중지기준에 따라",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.3661994934082,
        498.0556945800781,
        538.1482543945312,
        513.5777587890625
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "본 임상시험의 일시중지 후 재개 가능하다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.3661994934082,
        524.0672607421875,
        296.0935974121094,
        539.58935546875
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "13.1.1. 중지 기준",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        575.9705200195312,
        147.4002685546875,
        591.4926147460938
      ],
      "page_num": 75,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지 시킬 수",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.3661994934082,
        601.9821166992188,
        538.1483764648438,
        617.5042114257812
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        79.6368408203125,
        627.8738403320312,
        106.23650360107422,
        643.3959350585938
      ],
      "page_num": 75,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는 것에 무리가 있다고",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.3661994934082,
        653.8853759765625,
        538.1475830078125,
        669.407470703125
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "판단되는 경우에는 임상시험 책임자는 임상시험을 중지할 수 있다 (표 1. 참조).",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        77.95774841308594,
        679.89697265625,
        506.21978759765625,
        695.4190673828125
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 대상자가 시험자의 지시에 불응하거나 또는 동의서에 제시된 사항을 준수하지 않아",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.3661994934082,
        705.7886962890625,
        538.1484985351562,
        721.310791015625
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "그 유효율의 평가에 영향을 미치는 경우 임상시험을 중지할 수 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        79.15709686279297,
        731.8002319335938,
        446.1322937011719,
        747.3223266601562
      ],
      "page_num": 75,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 69 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 76,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중지기준",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        92.8296890258789,
        96.85415649414062,
        370.59954833984375,
        108.78315734863281
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중지처리",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        92.8296890258789,
        96.85415649414062,
        370.59954833984375,
        108.78315734863281
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자 제공",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        85.51365661621094,
        150.31573486328125,
        139.00509643554688,
        162.24473571777344
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검체의",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        97.62709045410156,
        170.33384704589844,
        127.01109313964844,
        182.26284790039062
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "외부 오염 또는",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        190.3519744873047,
        146.32066345214844,
        202.28097534179688
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "부적절한 검체",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        80.71625518798828,
        210.25022888183594,
        143.92196655273438,
        222.17922973632812
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 피험자 제공 검체의 보관, 관리 또는 예기치 못한 문제로 인해 외부",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        195.73391723632812,
        120.34848022460938,
        506.36602783203125,
        132.27748107910156
      ],
      "page_num": 76,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "오염물질이 오염/혼합 또는 오염/혼합이 예상되는 경우 임상시험기관의",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        190.3368377685547,
        140.36660766601562,
        511.88330078125,
        152.2956085205078
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상검체 폐기절차에 따라 즉각 폐기한다.",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        257.9801940917969,
        160.3847198486328,
        444.1893615722656,
        172.313720703125
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 검체의 양이 적거나 응고 등 검체 상태가 좋지 않아 검사를 진행할 수 없는",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        177.6237335205078,
        180.28297424316406,
        524.5955810546875,
        192.21197509765625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "경우 임상시험기관의 임상검체 폐기절차에 따라 즉각 폐기한다.",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        209.5264434814453,
        200.3011016845703,
        492.6430969238281,
        212.2301025390625
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 피험자 제공 검체가 폐기된 경우, 임상시험담당자는 즉각 임상시험책임자, 및",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        175.22503662109375,
        220.31922912597656,
        526.994384765625,
        232.24822998046875
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험의뢰자에게 보고한다.",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        284.6057434082031,
        240.2174835205078,
        417.6837158203125,
        252.146484375
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자발적 의사에 의해",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        68.60282135009766,
        265.74957275390625,
        156.035400390625,
        277.6785888671875
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험에 대한",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        75.91885375976562,
        285.7677001953125,
        148.71937561035156,
        297.69671630859375
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "참여를 거부한 경우",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        68.60282135009766,
        305.66595458984375,
        156.03543090820312,
        317.594970703125
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 피험자의 자발적 의사에 의한 임상시험 중지 또는 거부 요청이 발생한 경우,",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        176.5443115234375,
        265.74957275390625,
        525.6251831054688,
        277.6785888671875
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험담당자는 즉각 임상시험책임자, 임상시험의뢰자에게 보고하고,",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        193.81495666503906,
        285.7677001953125,
        508.3545837402344,
        297.69671630859375
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험기관의 임상시료 폐기절차에 따라 즉각 폐기한다.",
      "font_size": 9.951866149902344,
      "font_name": "T2",
      "bbox": [
        221.63987731933594,
        305.66595458984375,
        480.5296630859375,
        317.594970703125
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "<표 1. 중지 기준 및 처리>",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        223.43890380859375,
        68.92467498779297,
        371.3595275878906,
        84.4467544555664
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "13.1.2. 중지 처리",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        347.9797058105469,
        147.4002685546875,
        363.5018005371094
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지 시킬 수 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.3661994934082,
        372.6727294921875,
        531.1661987304688,
        388.19482421875
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 중지 시점까지의 검사결과 관련 자료는 성능과 안전성 평가를 위한 통계 처리 시",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.3661994934082,
        397.36572265625,
        538.1483764648438,
        412.8878173828125
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "삽입할 수 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        79.03716278076172,
        422.0587463378906,
        165.00465393066406,
        437.5808410644531
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 임상시험을 통해 얻어진 자료는 성능 및 안전성 분석을 위한 데이터가 정해져야 하며,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.3661994934082,
        446.75177001953125,
        538.1224365234375,
        462.27386474609375
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "만약 자료에 결함이 생기면, 적절한 보정 방법을 임상시험계획서에 제시하고, 보정 후",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        77.83781433105469,
        471.44476318359375,
        538.1483764648438,
        486.96685791015625
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "분석을 시행하도록 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        77.83781433105469,
        496.1377868652344,
        208.0613250732422,
        511.6598815917969
      ],
      "page_num": 76,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "13.2.1. 탈락 기준",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        545.5238037109375,
        147.4002685546875,
        561.0458984375
      ],
      "page_num": 76,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험기기 또는 대조기기 검사상 에러가 발생하여 재검을 수행하였음에도 불구하고 지속",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.3661994934082,
        570.2168579101562,
        538.1484985351562,
        585.7389526367188
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적인 에러가 발생하여 결과확인이 어려운 경우 임상시험에서 탈락시킨다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        594.9098510742188,
        446.7319641113281,
        610.4319458007812
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "13.2.2. 탈락 처리",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        644.2958984375,
        147.4002685546875,
        659.8179931640625
      ],
      "page_num": 76,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 탈락률이 예상보다 높아 피험자 수가 부족할 경우, 부족한 수만큼 피함자를 추가로",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.3661994934082,
        668.9888916015625,
        538.1475830078125,
        684.510986328125
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "모집하여 임상시험을 시행한다. 임상시험 완료 후 통계 처리 시 탈락시킨 검체는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        77.71788024902344,
        693.681884765625,
        538.1484375,
        709.2039794921875
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제외하고 통계 처리 한다. 단, 임상 시험 검체 list에서는 제외하지 않는다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        77.71788024902344,
        718.3749389648438,
        485.1111755371094,
        733.8970336914062
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 증례기록서에 탈락의 사유를 기재한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        63.08580780029297,
        743.0679321289062,
        310.8456115722656,
        758.5900268554688
      ],
      "page_num": 76,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 70 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 77,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 성능 평가 기준: 해당 의료기기의 임상시험에 따른 성능(유효성)평가는 사용된",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        151.03494262695312,
        533.3504028320312,
        166.5570068359375
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "모든 의료기기를 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능평가",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.67898559570312,
        177.04652404785156,
        533.3499755859375,
        192.56858825683594
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기준을 제시함. 그밖에 임상시험결과의 사용 범위에 따른 성능평가를 위하여",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.67898559570312,
        202.93821716308594,
        533.3504028320312,
        218.4602813720703
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이차 유효성 평가변수를 제시하여 각 임상검사항목 및 검사방법에 대한 기준을 제시함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.67898559570312,
        228.94979858398438,
        531.2861328125,
        244.47186279296875
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 성능평가방법: 임상시험 기간 동안 일차/이차/ 유효성 평가변수에 대한",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        254.9613800048828,
        533.3504638671875,
        270.48345947265625
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험군과 대조군간의 비교분석방법을 통계적으로 타당하게 제시함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        76.27865600585938,
        280.8530578613281,
        463.5228576660156,
        296.3751525878906
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 통계분석에 의한 평가방법: 통계분석방법에 따른 통계적 유의성에 대해 평가",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        306.8646240234375,
        533.3511962890625,
        322.38671875
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "방법과 기준을 제시함. 의료기기기술문서 등 심사에 관한 규정에 따라 임상시험을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.1992416381836,
        332.876220703125,
        533.3511352539062,
        348.3983154296875
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "실시하는 병원은 2군데 이상이어야 한다. 기관에 따라 임상시험결과에 차이가",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.1992416381836,
        358.7679138183594,
        533.3504028320312,
        374.2900085449219
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 차이를 보정할 수",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.1992416381836,
        384.77947998046875,
        533.3509521484375,
        400.30157470703125
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있는 경우는 이를 반영하여 분석결과를 제시해야함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.1992416381836,
        410.7910461425781,
        374.2912292480469,
        426.3131408691406
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "14. 유효성의 평가기준, 평가방법 및 해석방법(통계 분석방법에 의함)",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        76.45640563964844,
        532.5227661132812,
        92.39897918701172
      ],
      "page_num": 77,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        56.609317779541016,
        109.20393371582031,
        541.8339233398438,
        120.23188781738281
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        73.99989318847656,
        126.82469177246094,
        301.63604736328125,
        137.85263061523438
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        459.9373474121094,
        86.09606170654297,
        475.4594421386719
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "14.1. 유효성(성능)의 평가기준",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        485.94891357421875,
        228.95504760742188,
        501.47100830078125
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "14.1.1. 혈소판 기능 검사",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        511.84063720703125,
        204.84869384765625,
        527.3627319335938
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. EPI test",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        537.8521728515625,
        136.60443115234375,
        553.374267578125
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대조기기(LTA 검사) 결과를 기준으로 하여 시험시약의 민감도 및 특이도를",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        563.86376953125,
        538.1472778320312,
        579.3858642578125
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "산출한다. 신뢰도 95% 구간에서 민감도 85%, 특이도 85%, 로 설정한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        589.7554931640625,
        499.74322509765625,
        605.277587890625
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. ADP test",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        615.7670288085938,
        144.2815399169922,
        631.2891235351562
      ],
      "page_num": 77,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대조기기(LTA 검사) 결과를 기준으로 하여 시험시약의 민감도 및 특이도를",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        641.7786254882812,
        538.1472778320312,
        657.3007202148438
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "산출한다. 신뢰도 95% 구간에서 민감도 85%, 특이도 80%, 로 설정한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        667.6703491210938,
        499.74322509765625,
        683.1924438476562
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "다. SIPA test",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        693.681884765625,
        145.3596649169922,
        709.2039794921875
      ],
      "page_num": 77,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대조기기(LTA 검사) 결과를 기준으로 하여 시험시약의 민감도 및 특이도를",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        719.6934814453125,
        538.1472778320312,
        735.215576171875
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "산출한다. 신뢰도 95% 구간에서 민감도 85%, 특이도 80%, 로 설정한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        745.585205078125,
        499.74322509765625,
        761.1072998046875
      ],
      "page_num": 77,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 71 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 78,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "14.1.2. 혈소판 기능 검사",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        94.93624877929688,
        204.84869384765625,
        110.45832824707031
      ],
      "page_num": 78,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "가. Aspirin test",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        120.82794952392578,
        159.51329040527344,
        136.3500213623047
      ],
      "page_num": 78,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Aspirin 복용 전후에 대한 시험시약의 민감도 및 특이도를 산출한다. 신뢰도",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        146.83953857421875,
        538.1477661132812,
        162.36160278320312
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "95% 구간에서 민감도 80%, 특이도 95%, 로 설정한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        172.85110473632812,
        387.24420166015625,
        188.3731689453125
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. P2Y12 test",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        198.74281311035156,
        151.95738220214844,
        214.26487731933594
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Clopidorel 복용 전후에 대한 시험시약의 민감도 및 특이도를 산출한다. 신뢰도",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        224.75437927246094,
        538.1477661132812,
        240.2764434814453
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "95% 구간에서 민감도 80%, 특이도 75%, 로 설정한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        250.7659454345703,
        387.24420166015625,
        266.28802490234375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "14.2. 유효성(성능) 평가방법",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        302.6692199707031,
        216.36184692382812,
        318.1913146972656
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "14.2.1. 혈소판 기능 검사",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        328.6807861328125,
        204.84869384765625,
        344.202880859375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. EPI test",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        354.572509765625,
        136.60443115234375,
        370.0946044921875
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 민감도: 대조기기 비정상 결과 검체 중 시험기기에서 비정상 결과를 보인",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        380.5840759277344,
        538.1486206054688,
        396.1061706542969
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        93.90910339355469,
        406.59564208984375,
        492.42718505859375,
        422.11773681640625
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 특이도: 대조기기 정상 결과 검체 중 시험기기에서 정상 결과를 보인 검체의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        432.4873352050781,
        538.1477661132812,
        448.0094299316406
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        92.34994506835938,
        458.4989318847656,
        443.01397705078125,
        474.0210266113281
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        484.510498046875,
        536.2034912109375,
        500.0325927734375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대조기기",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        310.7515869140625,
        520.591064453125,
        353.8085021972656,
        533.8135986328125
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "합계",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        479.739990234375,
        534.495849609375,
        501.4483337402344,
        547.7183837890625
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비정상",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        257.140625,
        548.5205688476562,
        402.022216796875,
        561.7431030273438
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정상",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        257.140625,
        548.5205688476562,
        402.022216796875,
        561.7431030273438
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험기기",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        78.43749237060547,
        612.4107055664062,
        121.49443817138672,
        625.6332397460938
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비정상",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        162.0321807861328,
        587.4779663085938,
        194.41482543945312,
        600.7005004882812
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        270.5733642578125,
        576.4500122070312,
        276.06829833984375,
        589.6725463867188
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(True Positive)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        237.23143005371094,
        598.3860473632812,
        309.4967956542969,
        611.6085815429688
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "b",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        388.1096496582031,
        576.4500122070312,
        394.200439453125,
        589.6725463867188
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(False Positive)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        354.1680603027344,
        598.3860473632812,
        428.2335205078125,
        611.6085815429688
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a+b",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        481.6589660644531,
        587.4779663085938,
        499.5043029785156,
        600.7005004882812
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정상",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        167.309326171875,
        637.3434448242188,
        189.01766967773438,
        650.5659790039062
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "c",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        270.93316650390625,
        626.3155517578125,
        275.82122802734375,
        639.5380859375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(False Negative)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        233.75331115722656,
        648.3713989257812,
        313.0955810546875,
        661.5939331054688
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "d",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        387.8697814941406,
        626.3155517578125,
        394.5895080566406,
        639.5380859375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(True Negative)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        352.3690185546875,
        648.3713989257812,
        430.0318908691406,
        661.5939331054688
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "c+b",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        482.0187683105469,
        637.3434448242188,
        499.263916015625,
        650.5659790039062
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "합계",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        125.45201110839844,
        676.3009033203125,
        511.6469421386719,
        689.5234375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a+c",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        125.45201110839844,
        676.3009033203125,
        511.6469421386719,
        689.5234375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "b+d",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        125.45201110839844,
        676.3009033203125,
        511.6469421386719,
        689.5234375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a+b+c+d",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        125.45201110839844,
        676.3009033203125,
        511.6469421386719,
        689.5234375
      ],
      "page_num": 78,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        709.8641967773438,
        317.331298828125,
        725.3862915039062
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)}",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        735.8757934570312,
        346.11688232421875,
        751.3978881835938
      ],
      "page_num": 78,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 72 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 79,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "나. ADP test",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        68.92467498779297,
        144.2815399169922,
        84.4467544555664
      ],
      "page_num": 79,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 민감도: 대조기기 비정상 결과 검체 중 시험기기에서 비정상 결과를 보인",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        94.93624877929688,
        538.1486206054688,
        110.45832824707031
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        92.34994506835938,
        120.82794952392578,
        490.98797607421875,
        136.3500213623047
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "2) 특이도: 대조기기 정상 결과 검체 중 시험기기에서 정상 결과를 보인 검체의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        146.83953857421875,
        538.1477661132812,
        162.36160278320312
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        92.34994506835938,
        172.85110473632812,
        443.01397705078125,
        188.3731689453125
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        198.74281311035156,
        536.2034912109375,
        214.26487731933594
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대조기기",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        310.7515869140625,
        239.8578643798828,
        353.8085021972656,
        253.08038330078125
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "합계",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        479.739990234375,
        253.88253784179688,
        501.4483337402344,
        267.10504150390625
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비정상",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        257.140625,
        267.787353515625,
        402.022216796875,
        281.0098571777344
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정상",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        257.140625,
        267.787353515625,
        402.022216796875,
        281.0098571777344
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험기기",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        78.43749237060547,
        331.6775207519531,
        121.49443817138672,
        344.9000244140625
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비정상",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        162.0321807861328,
        306.7447814941406,
        194.41482543945312,
        319.96728515625
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        270.5733642578125,
        295.7168273925781,
        276.06829833984375,
        308.9393310546875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(True Positive)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        237.23143005371094,
        317.772705078125,
        309.4967956542969,
        330.9952087402344
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "b",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        388.1096496582031,
        295.7168273925781,
        394.200439453125,
        308.9393310546875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(False Positive)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        354.1680603027344,
        317.772705078125,
        428.2335205078125,
        330.9952087402344
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a+b",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        481.6589660644531,
        306.7447814941406,
        499.5043029785156,
        319.96728515625
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정상",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        167.309326171875,
        356.6102600097656,
        189.01766967773438,
        369.832763671875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "c",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        270.93316650390625,
        345.7021789550781,
        275.82122802734375,
        358.9246826171875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(False Negative)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        233.75331115722656,
        367.6382141113281,
        313.0955810546875,
        380.8607177734375
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "d",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        387.8697814941406,
        345.7021789550781,
        394.5895080566406,
        358.9246826171875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(True Negative)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        352.3690185546875,
        367.6382141113281,
        430.0318908691406,
        380.8607177734375
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "c+b",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        482.0187683105469,
        356.6102600097656,
        499.263916015625,
        369.832763671875
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "합계",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        125.45201110839844,
        395.56768798828125,
        511.6469421386719,
        408.7901916503906
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a+c",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        125.45201110839844,
        395.56768798828125,
        511.6469421386719,
        408.7901916503906
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "b+d",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        125.45201110839844,
        395.56768798828125,
        511.6469421386719,
        408.7901916503906
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a+b+c+d",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        125.45201110839844,
        395.56768798828125,
        511.6469421386719,
        408.7901916503906
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        429.2508850097656,
        317.331298828125,
        444.7729797363281
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)}",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        455.142578125,
        346.11688232421875,
        470.6646728515625
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다. SIPA　test : 검사원리가 비슷한 기존검사법은 없으나, 혈소판 기능의 정상/",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        507.16571044921875,
        538.1890869140625,
        522.7007446289062
      ],
      "page_num": 79,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비정상 유무를 판정하기 위한 목적은 ADP test와 동일하므로, ADP test의 평가기",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        533.0574340820312,
        538.1477661132812,
        548.5795288085938
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "준에 준하여 평가한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        559.0690307617188,
        185.75340270996094,
        574.5911254882812
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 민감도: 대조기기 비정상 결과 검체 중 시험기기에서 비정상 결과를 보인",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        585.08056640625,
        538.1486206054688,
        600.6026611328125
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        92.34994506835938,
        610.9722900390625,
        490.98797607421875,
        626.494384765625
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 특이도: 대조기기 정상 결과 검체 중 시험기기에서 정상 결과를 보인 검체의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        636.98388671875,
        538.1477661132812,
        652.5059814453125
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        92.34994506835938,
        662.9954223632812,
        443.01397705078125,
        678.5175170898438
      ],
      "page_num": 79,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        688.8871459960938,
        536.2034912109375,
        704.4092407226562
      ],
      "page_num": 79,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 73 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 80,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대조기기",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        310.7515869140625,
        77.67511749267578,
        353.8085021972656,
        90.89762878417969
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "합계",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        479.739990234375,
        90.14148712158203,
        501.4483337402344,
        103.36399841308594
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "비정상",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        257.140625,
        102.72773742675781,
        402.022216796875,
        115.95024871826172
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정상",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        257.140625,
        102.72773742675781,
        402.022216796875,
        115.95024871826172
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험기기",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        78.43749237060547,
        162.4224853515625,
        121.49443817138672,
        175.64500427246094
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "비정상",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        162.0321807861328,
        138.8083038330078,
        194.41482543945312,
        152.03082275390625
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        270.5733642578125,
        127.90023040771484,
        276.06829833984375,
        141.12274169921875
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(True Positive)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        237.23143005371094,
        149.83624267578125,
        309.4967956542969,
        163.0587615966797
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "b",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        388.1096496582031,
        127.90023040771484,
        394.200439453125,
        141.12274169921875
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(False Positive)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        354.1680603027344,
        149.83624267578125,
        428.2335205078125,
        163.0587615966797
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a+b",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        481.6589660644531,
        138.8083038330078,
        499.5043029785156,
        152.03082275390625
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정상",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        167.309326171875,
        185.91680908203125,
        189.01766967773438,
        199.1393280029297
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "c",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        270.93316650390625,
        174.8888702392578,
        275.82122802734375,
        188.11138916015625
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(False Negative)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        233.75331115722656,
        196.94476318359375,
        313.0955810546875,
        210.1672821044922
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "d",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        387.8697814941406,
        174.8888702392578,
        394.5895080566406,
        188.11138916015625
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(True Negative)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        352.3690185546875,
        196.94476318359375,
        430.0318908691406,
        210.1672821044922
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "c+b",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        482.0187683105469,
        185.91680908203125,
        499.263916015625,
        199.1393280029297
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "합계",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        125.45201110839844,
        221.9973907470703,
        511.6469421386719,
        235.21990966796875
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a+c",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        125.45201110839844,
        221.9973907470703,
        511.6469421386719,
        235.21990966796875
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "b+d",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        125.45201110839844,
        221.9973907470703,
        511.6469421386719,
        235.21990966796875
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a+b+c+d",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        125.45201110839844,
        221.9973907470703,
        511.6469421386719,
        235.21990966796875
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        256.6395263671875,
        317.331298828125,
        272.16162109375
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)}",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        280.01397705078125,
        346.11688232421875,
        295.53607177734375
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "14.2.2. 혈소판 약물반응 검사",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        326.76287841796875,
        230.0350341796875,
        342.28497314453125
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. Aspirin test",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        350.1373291015625,
        159.51329040527344,
        365.659423828125
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 민감도: 아스피린 투약 후 검체 중 최종 약물반응 양성 결과를 보인 검체의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        376.14892578125,
        538.1477661132812,
        391.6710205078125
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        92.8296890258789,
        402.0406188964844,
        443.49371337890625,
        417.5627136230469
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 특이도: 아스피린 투약 전 검체 중 최종 약물반응 음성 결과를 보인 검체의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        428.05218505859375,
        538.1477661132812,
        443.57427978515625
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        92.8296890258789,
        454.06378173828125,
        443.49371337890625,
        469.58587646484375
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "아스피린 투약 유무",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        289.7629699707031,
        488.7059020996094,
        386.1907043457031,
        501.92840576171875
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "합계",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        481.17919921875,
        501.29217529296875,
        502.8875732421875,
        514.5147094726562
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "투약 후",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        261.5782165527344,
        513.758544921875,
        414.2554931640625,
        526.9810791015625
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "투약 전",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        261.5782165527344,
        513.758544921875,
        414.2554931640625,
        526.9810791015625
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        76.39859771728516,
        573.4533081054688,
        98.10692596435547,
        586.6758422851562
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "약물반응 양성",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        134.80694580078125,
        549.958984375,
        204.60922241210938,
        563.1815185546875
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        277.6495361328125,
        538.9310302734375,
        283.14447021484375,
        552.153564453125
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(True Positive)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        244.30758666992188,
        560.8670654296875,
        316.57293701171875,
        574.089599609375
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "b",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        392.42730712890625,
        538.9310302734375,
        398.5180969238281,
        552.153564453125
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(False Positive)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        358.36578369140625,
        560.8670654296875,
        432.4301452636719,
        574.089599609375
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a+b",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        483.0981750488281,
        549.958984375,
        500.94354248046875,
        563.1815185546875
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "약물반응 음성",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        134.80694580078125,
        596.9476318359375,
        204.60922241210938,
        610.170166015625
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "c",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        278.00933837890625,
        586.03955078125,
        282.89739990234375,
        599.2620849609375
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(False Negative)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        240.82948303222656,
        607.9755859375,
        320.1717529296875,
        621.1981201171875
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "d",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        392.0675048828125,
        586.03955078125,
        398.7872314453125,
        599.2620849609375
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(True Negative)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        356.5667419433594,
        607.9755859375,
        434.22955322265625,
        621.1981201171875
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "c+b",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        483.3380432128906,
        596.9476318359375,
        500.70343017578125,
        610.170166015625
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "합계",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        129.6497344970703,
        633.1480712890625,
        513.0872802734375,
        646.37060546875
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a+c",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        129.6497344970703,
        633.1480712890625,
        513.0872802734375,
        646.37060546875
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "b+d",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        129.6497344970703,
        633.1480712890625,
        513.0872802734375,
        646.37060546875
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a+b+c+d",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        129.6497344970703,
        633.1480712890625,
        513.0872802734375,
        646.37060546875
      ],
      "page_num": 80,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        665.27294921875,
        317.331298828125,
        680.7950439453125
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        711.3026733398438,
        536.2034912109375,
        726.8247680664062
      ],
      "page_num": 80,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 74 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 81,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대조기기",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        330.5408630371094,
        82.5897445678711,
        373.5977783203125,
        95.812255859375
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "합계",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        491.1338195800781,
        95.17598724365234,
        512.8421630859375,
        108.39849853515625
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "약물반응 양성",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        261.0984802246094,
        107.7622299194336,
        443.03997802734375,
        120.9847412109375
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "약물반응 음성",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        261.0984802246094,
        107.7622299194336,
        443.03997802734375,
        120.9847412109375
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험기기",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        75.55905151367188,
        167.3371124267578,
        118.61599731445312,
        180.55963134765625
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "약물반응 양성",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        153.2769317626953,
        143.84278869628906,
        222.95925903320312,
        157.0653076171875
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        293.2410583496094,
        132.81484985351562,
        298.7359924316406,
        146.03736877441406
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(True Positive)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        259.7792053222656,
        154.87074279785156,
        332.16448974609375,
        168.09326171875
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "b",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        405.1404113769531,
        132.81484985351562,
        411.231201171875,
        146.03736877441406
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(False Positive)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        371.1988220214844,
        154.87074279785156,
        445.1432800292969,
        168.09326171875
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a+b",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        492.9328308105469,
        143.84278869628906,
        510.8973693847656,
        157.0653076171875
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "약물반응 음성",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        153.2769317626953,
        190.95130920410156,
        222.95925903320312,
        204.173828125
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "c",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        293.60089111328125,
        179.92337036132812,
        298.48895263671875,
        193.14588928222656
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(False Negative)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        256.30108642578125,
        201.85939025878906,
        335.64300537109375,
        215.0819091796875
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "d",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        404.7806091308594,
        179.92337036132812,
        411.5003356933594,
        193.14588928222656
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(True Negative)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        369.27984619140625,
        201.85939025878906,
        446.94268798828125,
        215.0819091796875
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "c+b",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        493.29266357421875,
        190.95130920410156,
        510.5377502441406,
        204.173828125
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "합계",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        138.1651153564453,
        227.03187561035156,
        522.9216918945312,
        240.25439453125
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a+c",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        138.1651153564453,
        227.03187561035156,
        522.9216918945312,
        240.25439453125
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "b+d",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        138.1651153564453,
        227.03187561035156,
        522.9216918945312,
        240.25439453125
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a+b+c+d",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        138.1651153564453,
        227.03187561035156,
        522.9216918945312,
        240.25439453125
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)}",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        259.2766418457031,
        346.11688232421875,
        274.7987365722656
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. P2Y12 test",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        69.2024917602539,
        311.179931640625,
        151.95738220214844,
        326.7020263671875
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 민감도: 클로피도그렐 투약 후 검체 중 최종 약물반응 양성 결과를 보인",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        337.1914978027344,
        538.1478271484375,
        352.7135925292969
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        92.8296890258789,
        363.08319091796875,
        495.9053039550781,
        378.60528564453125
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 특이도: 클로피도그렐 투약 전 검체 중 최종 약물반응 음성 결과를 보인",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        75.43911743164062,
        389.0947570800781,
        538.1478271484375,
        404.6168518066406
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        92.8296890258789,
        415.1063537597656,
        495.9053039550781,
        430.6284484863281
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "클로피도그렐 투약 유무",
      "font_size": 11.030982971191406,
      "font_name": "T17",
      "bbox": [
        279.0887451171875,
        448.31005859375,
        396.86492919921875,
        461.5325622558594
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "합계",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        481.17919921875,
        459.4578857421875,
        502.8875732421875,
        472.6803894042969
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "투약 후",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        261.5782165527344,
        470.6056823730469,
        414.2554931640625,
        483.82818603515625
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "투약 전",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        261.5782165527344,
        470.6056823730469,
        414.2554931640625,
        483.82818603515625
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제품",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        76.39859771728516,
        525.9851684570312,
        98.10692596435547,
        539.2077026367188
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "약물반응 양성",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        134.80694580078125,
        503.92926025390625,
        204.60922241210938,
        517.1517944335938
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        277.6495361328125,
        492.9013366699219,
        283.14447021484375,
        506.12384033203125
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(True Positive)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        244.30758666992188,
        514.8373413085938,
        316.57293701171875,
        528.0598754882812
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "b",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        392.42730712890625,
        492.9013366699219,
        398.5180969238281,
        506.12384033203125
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(False Positive)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        358.36578369140625,
        514.8373413085938,
        432.4301452636719,
        528.0598754882812
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a+b",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        483.0981750488281,
        503.92926025390625,
        500.94354248046875,
        517.1517944335938
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "약물반응 음성",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        134.80694580078125,
        548.1609497070312,
        204.60922241210938,
        561.3834838867188
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "c",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        278.00933837890625,
        537.1329956054688,
        282.89739990234375,
        550.3555297851562
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(False Negative)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        240.82948303222656,
        559.1889038085938,
        320.1717529296875,
        572.4114379882812
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "d",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        392.0675048828125,
        537.1329956054688,
        398.7872314453125,
        550.3555297851562
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(True Negative)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        356.5667419433594,
        559.1889038085938,
        434.22955322265625,
        572.4114379882812
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "c+b",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        483.3380432128906,
        548.1609497070312,
        500.70343017578125,
        561.3834838867188
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "합계",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        129.6497344970703,
        581.3646240234375,
        513.0872802734375,
        594.587158203125
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a+c",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        129.6497344970703,
        581.3646240234375,
        513.0872802734375,
        594.587158203125
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "b+d",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        129.6497344970703,
        581.3646240234375,
        513.0872802734375,
        594.587158203125
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a+b+c+d",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        129.6497344970703,
        581.3646240234375,
        513.0872802734375,
        594.587158203125
      ],
      "page_num": 81,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.84593963623047,
        612.2908325195312,
        323.566650390625,
        627.8129272460938
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        75.43911743164062,
        664.1941528320312,
        536.2034912109375,
        679.7162475585938
      ],
      "page_num": 81,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 75 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 82,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "대조기기",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        330.5408630371094,
        77.67511749267578,
        373.5977783203125,
        90.89762878417969
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "합계",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        491.1338195800781,
        90.14148712158203,
        512.8421630859375,
        103.36399841308594
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "약물반응 양성",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        261.0984802246094,
        102.72773742675781,
        443.03997802734375,
        115.95024871826172
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "약물반응 음성",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        261.0984802246094,
        102.72773742675781,
        443.03997802734375,
        115.95024871826172
      ],
      "page_num": 82,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험기기",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        75.55905151367188,
        162.4224853515625,
        118.61599731445312,
        175.64500427246094
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "약물반응 양성",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        153.2769317626953,
        138.8083038330078,
        222.95925903320312,
        152.03082275390625
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        293.2410583496094,
        127.90023040771484,
        298.7359924316406,
        141.12274169921875
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(True Positive)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        259.7792053222656,
        149.83624267578125,
        332.16448974609375,
        163.0587615966797
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "b",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        405.1404113769531,
        127.90023040771484,
        411.231201171875,
        141.12274169921875
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(False Positive)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        371.1988220214844,
        149.83624267578125,
        445.1432800292969,
        163.0587615966797
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a+b",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        492.9328308105469,
        138.8083038330078,
        510.8973693847656,
        152.03082275390625
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "약물반응 음성",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        153.2769317626953,
        185.91680908203125,
        222.95925903320312,
        199.1393280029297
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "c",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        293.60089111328125,
        174.8888702392578,
        298.48895263671875,
        188.11138916015625
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(False Negative)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        256.30108642578125,
        196.94476318359375,
        335.64300537109375,
        210.1672821044922
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "d",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        404.7806091308594,
        174.8888702392578,
        411.5003356933594,
        188.11138916015625
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(True Negative)",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        369.27984619140625,
        196.94476318359375,
        446.94268798828125,
        210.1672821044922
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "c+b",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        493.29266357421875,
        185.91680908203125,
        510.5377502441406,
        199.1393280029297
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "합계",
      "font_size": 11.030982971191406,
      "font_name": "T15",
      "bbox": [
        138.1651153564453,
        221.9973907470703,
        522.9216918945312,
        235.21990966796875
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a+c",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        138.1651153564453,
        221.9973907470703,
        522.9216918945312,
        235.21990966796875
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "b+d",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        138.1651153564453,
        221.9973907470703,
        522.9216918945312,
        235.21990966796875
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "a+b+c+d",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        138.1651153564453,
        221.9973907470703,
        522.9216918945312,
        235.21990966796875
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)}",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        254.24217224121094,
        346.11688232421875,
        269.7642517089844
      ],
      "page_num": 82,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 76 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 83,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 이상사례에 대한 인과관계 평가기준",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        151.03494262695312,
        289.6435546875,
        166.5570068359375
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 이상사례(의료기기이상반응, 중대한 이상사례/의료기기이상반응 포함)의 발생",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        177.04652404785156,
        530.5927124023438,
        192.56858825683594
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시 의료기기 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에 의거, 정한",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        76.03878784179688,
        202.93821716308594,
        530.5927124023438,
        218.4602813720703
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기간 내에 가능한 신속한 보고가 되어야하며, 이상사례 등에 대한 의학적",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        76.03878784179688,
        228.94979858398438,
        530.5929565429688,
        244.47186279296875
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "소견·정도와 임상시험용 의료기기와의 인과관계를 평가하여 증례기록서에",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        76.03878784179688,
        254.9613800048828,
        530.593505859375,
        270.49639892578125
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기록하여야 함. 따라서 이상사례에 대한 임상시험용 의료기기와의 인과관계에",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        76.03878784179688,
        280.8530578613281,
        530.59130859375,
        296.3751525878906
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한 평가기준을 제시하여야 함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        76.03878784179688,
        306.8646240234375,
        261.7922058105469,
        322.38671875
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "15. 부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        76.45640563964844,
        520.87744140625,
        92.39897918701172
      ],
      "page_num": 83,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        56.609317779541016,
        109.20393371582031,
        529.839599609375,
        120.23188781738281
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        73.04041290283203,
        126.82469177246094,
        300.67657470703125,
        137.85263061523438
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        340.068359375,
        86.09606170654297,
        355.5904541015625
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 피험자 안전성(해당사항 없음)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        366.0799255371094,
        244.53018188476562,
        381.6020202636719
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당 임상시험은 전혈 검체에 대한 체외진단용 의료기기의 임상적 평가에 대한",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        391.97161865234375,
        538.1480712890625,
        407.49371337890625
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험으로 피험자가 직접적으로 받는 인체의 위해도가 없어 예측되는 부작용에",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        417.9831848144531,
        538.1474609375,
        433.5052795410156
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "따른 안전성 평가 및 방법은 따로 기재하지 않는다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        443.9947814941406,
        355.58135986328125,
        459.5168762207031
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 시험자안전성",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        495.8980407714844,
        148.23822021484375,
        511.4201354980469
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험용 의료기기인 체외진단용 의료기기는 인체 유래물질을 포함하고 있지",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.84593963623047,
        521.9096069335938,
        538.1480712890625,
        537.4317016601562
      ],
      "page_num": 83,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "않기 때문에 해당 의료기기에 의한 감염위험성은 없다. 다만, 검체가 감염성 물질을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        547.8013305664062,
        538.1492919921875,
        563.3234252929688
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "포함하고 있을 가능성이있는 인체 유래물이기 때문에 검사실 생물학적 안전수칙 및",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        573.8129272460938,
        538.1483764648438,
        589.3350219726562
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "사용시 주의사항을 참고하여 취급해야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        599.824462890625,
        309.2864685058594,
        615.3465576171875
      ],
      "page_num": 83,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 77 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 84,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동의서 버전 또는 버전 날짜:",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        68.12307739257812,
        402.87969970703125,
        512.90087890625,
        414.8087158203125
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Version  _________________  date ______________",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        68.12307739257812,
        402.87969970703125,
        512.90087890625,
        414.8087158203125
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연구 제목:",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        68.12307739257812,
        431.37890625,
        530.3525390625,
        454.72509765625
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "출혈 시간 및 항혈소판제제 저항성 복합검사기기(제품명: 000)의 정확도 검증을 위한",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        68.12307739257812,
        431.37890625,
        530.3525390625,
        454.72509765625
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        141.52330017089844,
        462.814208984375,
        181.46116638183594,
        474.74322509765625
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연구책임자:",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        68.12307739257812,
        477.04901123046875,
        469.125732421875,
        500.27532958984375
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(성명)",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        68.12307739257812,
        477.04901123046875,
        469.125732421875,
        500.27532958984375
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(소속)",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        68.12307739257812,
        477.04901123046875,
        469.125732421875,
        500.27532958984375
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(연락처)",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        68.12307739257812,
        477.04901123046875,
        469.125732421875,
        500.27532958984375
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연구담당자:",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        68.12307739257812,
        526.1051025390625,
        469.125732421875,
        538.0340576171875
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(성명)",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        68.12307739257812,
        526.1051025390625,
        469.125732421875,
        538.0340576171875
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(소속)",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        68.12307739257812,
        526.1051025390625,
        469.125732421875,
        538.0340576171875
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(연락처)",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        68.12307739257812,
        526.1051025390625,
        469.125732421875,
        538.0340576171875
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인체유래물 기증자의 권리에 대한 문의처",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        68.12307739257812,
        560.957275390625,
        413.89569091796875,
        584.303466796875
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자보호",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        68.12307739257812,
        560.957275390625,
        413.89569091796875,
        584.303466796875
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "연구",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        68.12307739257812,
        560.957275390625,
        413.89569091796875,
        584.303466796875
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "윤리담당자",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        330.5408630371094,
        592.272705078125,
        380.55377197265625,
        604.2017211914062
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(연락처)",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        429.1274108886719,
        572.37451171875,
        469.125732421875,
        584.303466796875
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험 책임자는 의료기기법 시행규칙 제24조제1항제4호의 규정에 따라 임상시험",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        153.91180419921875,
        530.591552734375,
        169.43386840820312
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화 할 때, 헬싱키선언에",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        179.8035125732422,
        530.5924682617188,
        195.32557678222656
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        205.81507873535156,
        530.5918579101562,
        221.33714294433594
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "서식, 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        231.82666015625,
        530.5665283203125,
        247.34872436523438
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        257.7183532714844,
        530.5921630859375,
        273.2404479980469
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "규칙 [별표 3])에서 정하고 있음. 이에 따른 피험자 동의서 서식을 제시하여야",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        283.72991943359375,
        530.59130859375,
        299.25201416015625
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하며, 피험자 설명서에는 동 기준의 제7호아목의10)을 포함하여야 함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        309.7414855957031,
        465.3218994140625,
        325.2635803222656
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "16. 피험자 동의서 서식",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        76.45640563964844,
        242.02853393554688,
        92.39897918701172
      ],
      "page_num": 84,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        56.609317779541016,
        109.20393371582031,
        529.839599609375,
        120.23188781738281
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        73.04041290283203,
        126.82469177246094,
        300.67657470703125,
        137.85263061523438
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        347.3803405761719,
        86.09606170654297,
        362.9024353027344
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연구과제 피험자 설명문 및 동의서",
      "font_size": 14.987749099731445,
      "font_name": "T15",
      "bbox": [
        180.02243041992188,
        375.3098449707031,
        419.7724914550781,
        393.27520751953125
      ],
      "page_num": 84,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 만일 본 연구에 문의사항이 있으시거나, 위험이나 불편 또는 손상이 발생할 경우, 상기 연구책임자",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        61.64658737182617,
        605.0987548828125,
        527.1143188476562,
        617.0277099609375
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 연구담당자에게 연락하여 주시기 바랍니다.",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        61.64658737182617,
        621.041259765625,
        284.3843688964844,
        632.9702758789062
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 참여 권유",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        652.5668334960938,
        128.21051025390625,
        668.0889282226562
      ],
      "page_num": 84,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 본 연구책임자는 귀하로부터 연구 참여에 대한 동의를 받고 이를 문서화 할 때",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        62.72600555419922,
        678.5784301757812,
        538.1483764648438,
        694.1005249023438
      ],
      "page_num": 84,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "관련 규정을 준수하며 헬싱키선언에 근거한 윤리적 원칙을 바탕으로 합법적인 절",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        74.23976135253906,
        703.2714233398438,
        538.1483764648438,
        718.7935180664062
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "차를 따를 것입니다. 귀하는 본 연구에 참여할 것인지 여부를 결정하기 전에, 이",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.23976135253906,
        727.9644165039062,
        538.1483764648438,
        743.4865112304688
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동의서를 신중하게 읽어보셔야 합니다. 이 연구는 왜 수행되며, 무엇을 조사하고",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.23976135253906,
        752.657470703125,
        538.148193359375,
        768.1795654296875
      ],
      "page_num": 84,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 78 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 85,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "귀하의 정보와 검체는 어떻게 사용될지, 본 연구에 따른 위험이나 불편은 무엇인지",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.23976135253906,
        68.92467498779297,
        538.1485595703125,
        84.4467544555664
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "귀하가 이해하는 것이 중요합니다. 충분한 시간을 가지고 결정해 주시기 바라며",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.23976135253906,
        93.61769104003906,
        538.14794921875,
        109.1397705078125
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "궁금한 점이 있으면 언제든지 질문하여 주십시오. 귀하께서 궁금해 하는 모든",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        74.23976135253906,
        118.31070709228516,
        538.1488037109375,
        133.83277893066406
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질문에 대해 답을 얻으셨고, 이 연구 참여를 결정하였다면 본 동의서에 서명과",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.23976135253906,
        143.00372314453125,
        538.1492919921875,
        158.52578735351562
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "서명일자를 직접 적어야 합니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        74.23976135253906,
        167.6967315673828,
        258.3140869140625,
        183.2187957763672
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 인체 유래물이란?",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        217.082763671875,
        170.40892028808594,
        232.60482788085938
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- “인체 유래물”이란 인체로부터 수집하거나 채취한 조직, 세포, 혈액, 체액 등이나",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.72600555419922,
        241.77578735351562,
        538.1482543945312,
        257.2978515625
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "또는 이들로부터 분리된 혈장, 혈청, 핵산, 단백질 등을 말합니다. 본 동의서에서는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.52015686035156,
        266.4687805175781,
        538.1470336914062,
        281.9908752441406
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "“검체”라는 용어로 부릅니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        73.52015686035156,
        291.16180419921875,
        235.1666259765625,
        306.68389892578125
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. 연구의 목적",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        340.5478210449219,
        140.56378173828125,
        356.0699157714844
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 혈소판 기능에 관한 검사는 주로 선천성 혈소판 기능 이상이나 수술전 선별검사로",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.72600555419922,
        365.2408447265625,
        538.1467895507812,
        380.762939453125
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "많이 사용되고 있습니다. 특히 혈소판의 수적 이상이 없는 출혈질환에서 선천성",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.76002502441406,
        389.933837890625,
        538.14794921875,
        405.4559326171875
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혹은 후천성 혈소판 기능 이상을 감별하는데 중요한 검사입니다. 최근에는 심혈관",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.76002502441406,
        414.6268615722656,
        538.147216796875,
        430.1489562988281
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "질환의 치료 및 예방에 사용되는 아스피린, 클로피도그렐 등의 항혈소판약제로 인한",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.76002502441406,
        439.31988525390625,
        538.1480102539062,
        454.84197998046875
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "출혈성 경향의 증가나 약제 내성에 대한 검사를 위해서도 많이 이용되고 있습니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        464.0129089355469,
        530.9263305664062,
        479.5350036621094
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 본 임상시험용 의료기기인 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.72600555419922,
        488.7059020996094,
        538.1483764648438,
        504.2279968261719
      ],
      "page_num": 85,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "혈소판 기능부전 검출 및 아스피린, 클로피도그렐와 같은 항혈소판제제에 대한",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.4796371459961,
        513.39892578125,
        538.1483154296875,
        528.9210205078125
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "약물 저항성을 확인하는 기기로, 본 연구를 통해 ‘출혈 시간 및 항혈소판제제",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        74.4796371459961,
        538.0919189453125,
        538.1469116210938,
        553.614013671875
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "저항성 복합검사기기’의 임상적 유효성을 비교 분석하는 것이 목적입니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        74.4796371459961,
        562.7849731445312,
        502.9814758300781,
        578.3070678710938
      ],
      "page_num": 85,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4. 연구 방법 및 절차",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        612.1709594726562,
        177.5037841796875,
        627.6930541992188
      ],
      "page_num": 85,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 본 연구에 참여하게 되면, 문진 및 혈액채취를 하게 됩니다. 문진에는 혈성 질환,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.72600555419922,
        636.864013671875,
        538.1224365234375,
        652.3861083984375
      ],
      "page_num": 85,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "응고장애, 암, 기타 만성질환 등의 병력 및 아스피린, P2Y12 수용체 저해제 등의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.52015686035156,
        661.5570068359375,
        538.1483154296875,
        677.0791015625
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "항혈소판제제, 항응고제 복용 유무에 대한 질문이 포함됩니다. 이 후 약 20 mL의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.52015686035156,
        686.25,
        538.1483764648438,
        701.7720947265625
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정맥혈을 채취하여 검사를 시행합니다. 본 연구를 위한 검사비용(혈소판 기능검사",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.52015686035156,
        710.9430541992188,
        538.148193359375,
        726.4651489257812
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또는 혈소판 약물반응 검사)은 연구비에서 지불되며, 단 귀하가 본 연구목적으로",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.52015686035156,
        735.6360473632812,
        538.1480712890625,
        751.1581420898438
      ],
      "page_num": 85,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 79 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 86,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "귀하의 검체를 사용하는 것을 허락하여야만 검체 채취가 가능합니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        73.52015686035156,
        68.92467498779297,
        465.68170166015625,
        84.4467544555664
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "5. 예상되는 위험 및 불편",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        119.62926483154297,
        202.21041870117188,
        135.15133666992188
      ],
      "page_num": 86,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 본 연구에 참여함으로 인하여 혈액을 채취하게 되므로 그 과정에서 약간의 통증",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.72600555419922,
        145.52096557617188,
        538.1483154296875,
        161.04302978515625
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및 어지러움이 발생할 수도 있으며 혈액을 채취한 자리가 부어 오르는 등의 약간의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.76002502441406,
        171.5325469970703,
        538.1484375,
        187.0546112060547
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "부작용이 나타날 수 있습니다. 그러나 이는 보통 일시적인 증상으로 금방 해소될",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.76002502441406,
        197.5441131591797,
        538.1487426757812,
        213.06617736816406
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "것이지만 증상이 지속될 경우 관련 진료 후 필요한 치료를 받으실 수 있습니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        223.43582153320312,
        517.613525390625,
        238.9578857421875
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6. 연구에 참여함으로써 기대되는 이익",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        275.4589538574219,
        276.3302307128906,
        290.9810485839844
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 이 연구의 참여로 귀하에게 직접적으로 기대되는 이익은 없으나, 이 연구를 통해",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.72600555419922,
        301.35064697265625,
        538.1483154296875,
        316.87274169921875
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "귀하의 혈소판 기능 또는 혈소판 약물 저항성을 확인할 수 있을 것으로 기대합니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        73.40022277832031,
        327.36224365234375,
        538.2423706054688,
        342.88433837890625
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "또한 궁극적으로는 혈소판 기능 또는 혈소판 약물 저항성을 확인하는 장비의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.40022277832031,
        353.3738098144531,
        538.1477661132812,
        368.8959045410156
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "개발에 기여함으로써 혈소판 기능 부전 및 혈소판 약물 저항성을 보이는 환자의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.40022277832031,
        379.2655029296875,
        538.1492919921875,
        394.78759765625
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "진단에 많은 도움을 줄 수 있습니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        73.40022277832031,
        405.2770690917969,
        282.4210205078125,
        420.7991638183594
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7. 검체의 처리 및 제공",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        457.18035888671875,
        189.8570556640625,
        472.70245361328125
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 귀하의 검체는 관련 법규 및 병원규정에 따라 적절히 처리됩니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.72600555419922,
        483.1919250488281,
        446.7319641113281,
        498.7140197753906
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 귀하는 귀하의 검체에 대해, 언제까지 보존하도록 허용할 것인지, 다른 사람 또는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.72600555419922,
        509.2034912109375,
        538.1483154296875,
        524.7255859375
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "다른 연구 목적에 대해 제공을 허용할 것인지, 만약 제공을 허용한다면 개인정보도",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.16034698486328,
        535.09521484375,
        538.1486206054688,
        550.6173095703125
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "함께 제공하도록 허용할 것인지 여부 등에 대해 인체유래물연구동의서에서 선택",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.16034698486328,
        561.1068115234375,
        538.1485595703125,
        576.62890625
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결정할 수 있습니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        73.16034698486328,
        587.1183471679688,
        185.03379821777344,
        602.6404418945312
      ],
      "page_num": 86,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 연구가 종료된 후 남은 검체는 귀하가 지정한 보존기간에 따라 폐기될 것입니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.72600555419922,
        613.0100708007812,
        538.2423706054688,
        628.5321655273438
      ],
      "page_num": 86,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "만약 검체를 제공한 후 마음이 변해서 동의를 철회할 경우, 검체가 익명화(귀하와",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.52015686035156,
        639.0216064453125,
        538.1483154296875,
        654.543701171875
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "귀하의 검체 간의 연결이 존재하지 않음)되지 않았다면 귀하의 검체는 귀하의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.52015686035156,
        665.033203125,
        538.1488037109375,
        680.5552978515625
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "요청에 따라 즉시 폐기될 것이며 더 이상 정보수집이 되지 않을 것입니다. 만약",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.52015686035156,
        690.9249267578125,
        538.1488037109375,
        706.447021484375
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "익명화된 경우라도 귀하가 지정한 보존기간에 따라 폐기될 것입니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        73.52015686035156,
        716.9364624023438,
        469.6395568847656,
        732.4585571289062
      ],
      "page_num": 86,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 80 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 87,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "8. 자유의사에 의한 연구 참여 동의 및 철회",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        94.93624877929688,
        307.1535339355469,
        110.45832824707031
      ],
      "page_num": 87,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 본 연구에 참여할지 여부는 전적으로 귀하의 선택에 의한 것이며 참여하지 않을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.72600555419922,
        120.82794952392578,
        538.1483154296875,
        136.3500213623047
      ],
      "page_num": 87,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "경우에도 전혀 불이익은 없습니다. 또한 참여에 동의한 이후에도 언제라도 아무런",
      "font_size": 12.94941520690918,
      "font_name": "T21",
      "bbox": [
        73.76002502441406,
        146.83953857421875,
        538.1483764648438,
        162.36160278320312
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "불이익 없이 연구 참여를 중단할 수 있습니다. 동의 철회를 원할 경우 귀하의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.76002502441406,
        172.85110473632812,
        538.1488037109375,
        188.3731689453125
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보존된 검체 및 조사된 자료는 폐기하도록 요청하실 수 있으며 이 경우 이미",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.76002502441406,
        198.74281311035156,
        538.1480712890625,
        214.26487731933594
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연구에 사용된 정보와 자원을 제외하고 모든 잔여 검체 및 자료는 적법한 절차에",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.76002502441406,
        224.75437927246094,
        538.1483154296875,
        240.2764434814453
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "따라 폐기됩니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        73.76002502441406,
        250.7659454345703,
        169.5621795654297,
        266.28802490234375
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "9. 개인정보 보호",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        302.6692199707031,
        152.91708374023438,
        318.1913146972656
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 만약 귀하가 본 연구에 참여하신다면 본 연구에서는 귀하의 개인정보(성명과 같은",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.72600555419922,
        328.6807861328125,
        538.1483764648438,
        344.202880859375
      ],
      "page_num": 87,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "개인 식별정보 및 건강에 관한 정보 등)를 수집하게 됩니다. 이렇게 수집된 개인",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.99989318847656,
        354.572509765625,
        538.1477661132812,
        370.0946044921875
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정보는 관련 법규에 따라 엄격하게 관리되며 연구에 관련된 담당자만이 수집된",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.99989318847656,
        380.5840759277344,
        538.1482543945312,
        396.1061706542969
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자료에 접근할 수 있습니다. 수집된 개인정보 중 개인식별정보는 연구에 직접",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.99989318847656,
        406.59564208984375,
        538.1488037109375,
        422.11773681640625
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "이용되거나 필요한 정보가 아니며 연구로 인해 획득되는 검체 및 임상 자료와",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.99989318847656,
        432.4873352050781,
        538.1492919921875,
        448.0094299316406
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "귀하를 연결하기 위한 목적으로만 사용됩니다. 귀하의 개인정보는 연구 목적을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.99989318847656,
        458.4989318847656,
        538.1492919921875,
        474.0210266113281
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "달성할 때까지 사용하게 되며 수집된 정보는 개인정보보호법에 따라 적절히 관리",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        73.99989318847656,
        484.510498046875,
        538.1483154296875,
        500.0325927734375
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "됩니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        73.99989318847656,
        510.4022216796875,
        114.27214813232422,
        525.92431640625
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10. 연구대상자 동의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        562.4253540039062,
        171.38705444335938,
        577.9474487304688
      ],
      "page_num": 87,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ü 본인은 본 동의서의 내용에 대해 충분히 설명을 들었고 그 내용을 잘 이해",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.72600555419922,
        588.3170776367188,
        538.1488647460938,
        603.9937133789062
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하였으며 자발적으로 이 연구에 참여하는 것에 동의합니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        79.27703094482422,
        614.32861328125,
        433.1793212890625,
        629.8507080078125
      ],
      "page_num": 87,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ü 본인은 본인의 정보와 검체가 질병 연구목적을 위하여 이용되는 것에 동의합니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.72600555419922,
        640.3402099609375,
        534.5244140625,
        656.016845703125
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ü 본인은 언제든지 자유롭게 본 연구참여를 거절할 수 있으며 또한 이로 인하여",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.72600555419922,
        666.2318725585938,
        538.1482543945312,
        681.9085083007812
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "본인의 진료나 법적인 권리에 어떤 불이익도 없다는 것을 설명 받았으며 또한",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        79.876708984375,
        692.2434692382812,
        538.1483154296875,
        707.7655639648438
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참여에 동의한 이후에도, 언제라도 이 동의를 철회할 수 있음을 이해합니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        79.876708984375,
        718.2550659179688,
        512.2164306640625,
        733.7771606445312
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "ü 본인은 본 연구를 위한 본인의 개인정보 수집 및 이용에 동의합니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.72600555419922,
        744.146728515625,
        470.7189636230469,
        759.8233642578125
      ],
      "page_num": 87,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 81 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 88,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자 :",
      "font_size": 9.951866149902344,
      "font_name": "T10",
      "bbox": [
        69.56230163574219,
        261.0746765136719,
        108.77001190185547,
        273.0136413574219
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(성명)",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        69.56230163574219,
        300.9910583496094,
        472.4239501953125,
        312.9300231933594
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(서명)",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        69.56230163574219,
        300.9910583496094,
        472.4239501953125,
        312.9300231933594
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(날짜)",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        69.56230163574219,
        300.9910583496094,
        472.4239501953125,
        312.9300231933594
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "년",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        69.56230163574219,
        300.9910583496094,
        472.4239501953125,
        312.9300231933594
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "월",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        69.56230163574219,
        300.9910583496094,
        472.4239501953125,
        312.9300231933594
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        69.56230163574219,
        300.9910583496094,
        472.4239501953125,
        312.9300231933594
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "법정 대리인(필요 시):",
      "font_size": 9.951866149902344,
      "font_name": "T10",
      "bbox": [
        69.56230163574219,
        340.9074401855469,
        175.0937042236328,
        352.8464050292969
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(성명)",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        69.56230163574219,
        380.9436950683594,
        472.4239501953125,
        392.8826599121094
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(서명)",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        69.56230163574219,
        380.9436950683594,
        472.4239501953125,
        392.8826599121094
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(날짜)",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        69.56230163574219,
        380.9436950683594,
        472.4239501953125,
        392.8826599121094
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "년",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        69.56230163574219,
        380.9436950683594,
        472.4239501953125,
        392.8826599121094
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "월",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        69.56230163574219,
        380.9436950683594,
        472.4239501953125,
        392.8826599121094
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        69.56230163574219,
        380.9436950683594,
        472.4239501953125,
        392.8826599121094
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(피험자와의 관계)",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        219.48104858398438,
        420.8600769042969,
        302.1213073730469,
        432.7990417480469
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "연구자:",
      "font_size": 9.951866149902344,
      "font_name": "T10",
      "bbox": [
        69.56230163574219,
        440.878173828125,
        103.85267639160156,
        452.817138671875
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(성명)",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        69.56230163574219,
        480.7945556640625,
        472.4239501953125,
        492.7335205078125
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(서명)",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        69.56230163574219,
        480.7945556640625,
        472.4239501953125,
        492.7335205078125
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(날짜)",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        69.56230163574219,
        480.7945556640625,
        472.4239501953125,
        492.7335205078125
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "년",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        69.56230163574219,
        480.7945556640625,
        472.4239501953125,
        492.7335205078125
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "월",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        69.56230163574219,
        480.7945556640625,
        472.4239501953125,
        492.7335205078125
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        69.56230163574219,
        480.7945556640625,
        472.4239501953125,
        492.7335205078125
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "ü 본인은 “연구과제 피험자 동의서”에 서명 후, 본 설명문 및 연구과제 피험자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.72600555419922,
        68.92467498779297,
        538.1477661132812,
        84.6012954711914
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "동의서의 사본을 제공받을 것임을 알고 있습니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        79.03716278076172,
        94.93624877929688,
        365.5359802246094,
        110.45832824707031
      ],
      "page_num": 88,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "아래 귀하의 서명은 이 연구에 참여함을 허락하며 귀하의 혈액이 이 연구목적을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        62.72600555419922,
        146.83953857421875,
        538.1481323242188,
        162.36160278320312
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위해 사용될 것임을 의미합니다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        172.85110473632812,
        238.88461303710938,
        188.3731689453125
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "* 만 18세 미만의 피험자의 경우 법정대리인도 동의서에 서명해야 합니다.",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        61.64658737182617,
        215.28472900390625,
        405.99847412109375,
        227.21372985839844
      ],
      "page_num": 88,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 82 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 89,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "17. 피해자 보상에 대한 규약",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        76.45640563964844,
        281.9671936035156,
        92.39897918701172
      ],
      "page_num": 89,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        56.609317779541016,
        109.20393371582031,
        529.839599609375,
        120.23188781738281
      ],
      "page_num": 89,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        73.04041290283203,
        131.1399688720703,
        300.67657470703125,
        142.16790771484375
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료방법 등을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        180.64259338378906,
        530.5921630859375,
        196.16465759277344
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제공하여 원칙과 절차를 수립하여 제시함. 피해자 보상에 대한 규약에는 보상",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        206.65415954589844,
        530.5927124023438,
        222.1762237548828
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "원칙과 보상이 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        232.66574096679688,
        530.5665283203125,
        248.18780517578125
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이 규약에는 피험자 보상사유, 보상요건, 보상 제외사유, 보상기준, 보상절차,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        258.55743408203125,
        530.5665283203125,
        274.07952880859375
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적용범위 등을 작성함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        284.5690002441406,
        194.86846923828125,
        300.0910949707031
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        326.64300537109375,
        86.09606170654297,
        342.16510009765625
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당 임상시험은 전혈 검체를 이용한 체외진단용 의료기기의 임상적 유효성 평가를",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        352.53472900390625,
        538.1482543945312,
        368.05682373046875
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "목적으로 하는 임상시험으로 피험자에게 발생할 피해가 없으므로 피험자 보상 규정은",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        378.5462951660156,
        538.148193359375,
        394.0683898925781
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "없음.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        404.557861328125,
        83.92859649658203,
        420.0799560546875
      ],
      "page_num": 89,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 83 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 90,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상사례 등에 대하여 임상",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        156.42904663085938,
        533.3506469726562,
        171.95111083984375
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을 제공",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        182.4406280517578,
        533.3504028320312,
        197.9626922607422
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "하여 원칙과 절차를 수립하여 제시함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        208.4521942138672,
        274.98504638671875,
        223.97425842285156
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "18. 임상시험 후 피험자의 진료에 관한 사항",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        76.45640563964844,
        393.8665466308594,
        92.39897918701172
      ],
      "page_num": 90,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        56.609317779541016,
        109.20393371582031,
        529.839599609375,
        120.23188781738281
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "제품의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        73.04041290283203,
        123.46835327148438,
        300.67657470703125,
        134.4962921142578
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        251.6050262451172,
        85.85619354248047,
        267.1271057128906
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 병원에서 진행하던 치료",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        277.6166076660156,
        538.1480712890625,
        293.1387023925781
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "절차가 임상시험 참여 전과 다름없이 진행되며, 이후의 치료비는 피험자가 지불하여야",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        303.50830078125,
        538.1487426757812,
        319.0303955078125
      ],
      "page_num": 90,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        329.5198669433594,
        83.92859649658203,
        345.0419616699219
      ],
      "page_num": 90,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 84 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 91,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "19. 피험자의 안전보호에 관한 대책",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        64.64496612548828,
        70.70269775390625,
        326.94281005859375,
        86.64527130126953
      ],
      "page_num": 91,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        123.7048110961914,
        533.3508911132812,
        139.2268829345703
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "및 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시함.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        149.7163848876953,
        445.4126892089844,
        165.2384490966797
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예시)",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        201.73953247070312,
        85.85619354248047,
        217.2615966796875
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "19.1. 임상시험 실시기관",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        227.75111389160156,
        195.37322998046875,
        243.27317810058594
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 임상시험실시기관의 장은 해당 임상시험의 실시에 필요한 임상시험실, 설비와",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        253.64280700683594,
        538.1480712890625,
        269.1648864746094
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를 취할 수 있도록 하는 등",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.79729461669922,
        279.65435791015625,
        538.1483764648438,
        295.17645263671875
      ],
      "page_num": 91,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "해당 임상시험을 적절하게 실시할 수 있도록 하여야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.79729461669922,
        305.66595458984375,
        415.6687927246094,
        321.18804931640625
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "19.2. 임상시험심사위원회",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        357.5692138671875,
        201.73068237304688,
        373.09130859375
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 임상시험심사위원회(Institutional Review Board)는 국내 법규/관례에 따라",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        383.5807800292969,
        538.1483764648438,
        399.1028747558594
      ],
      "page_num": 91,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "구성되어 있어야 한다. 임상시험심사위원회는 피험자의 권리, 안전, 복지를",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.79729461669922,
        409.4725036621094,
        538.1483764648438,
        424.9945983886719
      ],
      "page_num": 91,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보호해야 하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.79729461669922,
        435.48406982421875,
        538.1483764648438,
        451.00616455078125
      ],
      "page_num": 91,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "는 그 이유의 타당성을 면밀히 검토하여야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.79729461669922,
        461.4956359863281,
        376.5699768066406,
        477.0177307128906
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가 동의가 적절하게",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        487.3873596191406,
        538.1483764648438,
        502.9094543457031
      ],
      "page_num": 91,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "얻어지지 않았거나 임상시험이 임상시험계획서에 따라 진행되지 않은 경우 또는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.79729461669922,
        513.39892578125,
        538.1485595703125,
        528.9210205078125
      ],
      "page_num": 91,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "중대한 이상사례/의료기기이상반응이 나타난 경우에는 임상시험의 일부 또는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.79729461669922,
        539.4105224609375,
        538.1488037109375,
        554.9326171875
      ],
      "page_num": 91,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "전부에 대하여 중지 명령 등 필요한 조치를 시험책임자에게 할 수 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.79729461669922,
        565.3021850585938,
        493.6265563964844,
        580.8242797851562
      ],
      "page_num": 91,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "19.3. 시험자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        617.3253173828125,
        126.17105102539062,
        632.847412109375
      ],
      "page_num": 91,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 시험자(Investigator)라 함은 시험책임자, 시험담당자, 임상시험조정자를 말한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        643.217041015625,
        538.2423706054688,
        658.7391357421875
      ],
      "page_num": 91,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식품의약품안전처장의 승",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        78.79729461669922,
        669.2286376953125,
        538.1483764648438,
        684.750732421875
      ],
      "page_num": 91,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "인을 득한 임상시험 계획서를 준수하여 임상시험을 실시하여야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.79729461669922,
        695.2401733398438,
        478.6346740722656,
        710.7622680664062
      ],
      "page_num": 91,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미 있는 실험실적",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        721.1318969726562,
        538.1497802734375,
        736.6539916992188
      ],
      "page_num": 91,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검사치의 이상을 포함하여 임상시험에서 발생한 모든 이상사례에 대해 피험자가",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.55742645263672,
        747.1434936523438,
        538.148193359375,
        762.6655883789062
      ],
      "page_num": 91,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 85 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 92,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "적절한 의학적 처치를 받을 수 있도록 조치하여야하고, 시험자가 알게된",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.55742645263672,
        68.92467498779297,
        538.1483764648438,
        84.4467544555664
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자의 병발질환에 대해 의학적 처치가 필요한 경우 이를 피험자에게 알려",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        78.55742645263672,
        94.93624877929688,
        538.1478271484375,
        110.45832824707031
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주어야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.55742645263672,
        120.82794952392578,
        152.5314178466797,
        136.3500213623047
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의 문제점을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        146.83953857421875,
        538.1474609375,
        162.36160278320312
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "적극적으로 대응한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.79729461669922,
        172.85110473632812,
        201.7047576904297,
        188.3731689453125
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "19.4. 의뢰자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        224.75437927246094,
        126.17105102539062,
        240.2764434814453
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로 통상의료기기",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        250.7659454345703,
        538.1469116210938,
        266.28802490234375
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험의 경우 의료기기 제조업자(수입자를 포함한다)를 말한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.79729461669922,
        276.65765380859375,
        461.8437805175781,
        292.17974853515625
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상시험 계획서의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        302.6692199707031,
        538.1490478515625,
        318.1913146972656
      ],
      "page_num": 92,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "절차에 따라 이루어지도록 하여야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        77.59794616699219,
        328.6807861328125,
        309.6462707519531,
        344.202880859375
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수, 임상시험의 종류와",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        354.572509765625,
        538.1482543945312,
        370.0946044921875
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "복잡성, 피험자에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상시험",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        380.5840759277344,
        538.1483764648438,
        396.1061706542969
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "실시상의 문제점 등에 따라 결정되어야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.31755065917969,
        406.59564208984375,
        328.955810546875,
        422.11773681640625
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "19.5. 모니터링",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        458.4989318847656,
        138.76393127441406,
        474.0210266113281
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 모니터링(Monitoring)이라 함은 임상시험 진행 과정을 감독하고, 해당 임상시험이",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        484.510498046875,
        538.1475830078125,
        500.0325927734375
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험 계획서, 표준작업지침서, 임상시험 실시기준 및 관련 규정에 따라 실시,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        77.71788024902344,
        510.4022216796875,
        538.1224365234375,
        525.92431640625
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기록 되는지 여부를 검토, 확인하는 활동을 말한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        77.71788024902344,
        536.4137573242188,
        364.2166748046875,
        551.9358520507812
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 임상시험에 대한 모니터링은 임상시험 모니터요원의 정기적인 임상시험 실시기관",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        562.4253540039062,
        538.1473388671875,
        577.9474487304688
      ],
      "page_num": 92,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "방문과 전화 등을 통해서 이루어 질 것이다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        77.59794616699219,
        588.3170776367188,
        327.7564392089844,
        603.8391723632812
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 또한, 임상시험 모니터요원은 임상시험 진행과정을 잘 살피고, 문제가 있을 경우",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        56.609317779541016,
        614.32861328125,
        538.1483764648438,
        629.8507080078125
      ],
      "page_num": 92,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "시험자와 상의한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.79729461669922,
        640.3402099609375,
        187.07269287109375,
        655.8623046875
      ],
      "page_num": 92,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "19.6. 임상시험계획서의 변경",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        692.2434692382812,
        220.5601806640625,
        707.7655639648438
      ],
      "page_num": 92,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장으로부터 승인",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        718.2550659179688,
        538.1483764648438,
        733.7771606445312
      ],
      "page_num": 92,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "받은 후, 시험절차가 광범위해지거나 위험도가 높아지거나 피험자 선정기준에",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.79729461669922,
        744.146728515625,
        538.1492919921875,
        759.6688232421875
      ],
      "page_num": 92,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 86 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 93,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "변화가 있거나 추가적인 안전성 정보로 인해 임상시험계획서를 변경하는 경우",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        78.79729461669922,
        68.92467498779297,
        538.1483764648438,
        84.4467544555664
      ],
      "page_num": 93,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "에는 임상시험심사위원회 및 식품의약품안전처장의 승인을 받아야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.79729461669922,
        94.93624877929688,
        501.5422668457031,
        110.45832824707031
      ],
      "page_num": 93,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정 내용 등을 기록하여",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        120.82794952392578,
        538.1473388671875,
        136.3500213623047
      ],
      "page_num": 93,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "보관하여야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.79729461669922,
        146.83953857421875,
        173.52003479003906,
        162.36160278320312
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한 경우를 제외",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        172.85110473632812,
        538.1486206054688,
        188.3731689453125
      ],
      "page_num": 93,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하고는, 임상시험심사위원회 및 식품의약품안전처장의 변경승인 이전에는 계",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.79729461669922,
        198.74281311035156,
        538.1483764648438,
        214.26487731933594
      ],
      "page_num": 93,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "획서와 다르게 임상시험을 실시하여서는 안된다. 만일 피험자에게 발생한 즉",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        78.79729461669922,
        224.75437927246094,
        538.1483764648438,
        240.2764434814453
      ],
      "page_num": 93,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "각적 위험요소를 제거하기 위해 임상시험심사위원회의 승인을 얻기 전에 이러",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.79729461669922,
        250.7659454345703,
        538.1488037109375,
        266.28802490234375
      ],
      "page_num": 93,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "한 임상시험 계획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에 대하",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.79729461669922,
        276.65765380859375,
        538.1483154296875,
        292.17974853515625
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "여 임상시험심사위원회(사후검토 승인을 위하여), 의뢰자, 식품의약품안전처장에",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.79729461669922,
        302.6692199707031,
        538.1485595703125,
        318.1913146972656
      ],
      "page_num": 93,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "게 제출하여야 한다. 그리고 임상시험심사위원회 위원장이나 간사가 승인한 문서",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.79729461669922,
        328.6807861328125,
        538.1485595703125,
        344.202880859375
      ],
      "page_num": 93,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "를 의뢰자에게 보내야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.79729461669922,
        354.572509765625,
        233.00779724121094,
        370.0946044921875
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이 반드시 필요한",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        380.5840759277344,
        538.1480712890625,
        396.1061706542969
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "것은 아니며 행정상 변경이 필요하다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.79729461669922,
        406.59564208984375,
        296.0935974121094,
        422.11773681640625
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "19.7. 피험자 동의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        458.4989318847656,
        157.59429931640625,
        474.0210266113281
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 피험자 동의(Informed Consent)라 함은 피험자가 임상시험 참여 유무를 결정하기",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        484.510498046875,
        538.1473388671875,
        500.0325927734375
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전에 피험자를 위한 설명서를 통해 해당 임상시험과 관련된 모든 정보를 제공",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.79729461669922,
        510.4022216796875,
        538.1488037109375,
        525.92431640625
      ],
      "page_num": 93,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "받고, 서명과 서명 날짜가 포함된 문서를 통해 본인이 자발적으로 임상시험에",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.79729461669922,
        536.4137573242188,
        538.1502075195312,
        551.9358520507812
      ],
      "page_num": 93,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "참여함을 확인하는 절차를 말한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.79729461669922,
        562.4253540039062,
        275.3448486328125,
        577.9474487304688
      ],
      "page_num": 93,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 피험자 본인 또는 대리인이 동의서 서식, 피험자설명서 및 기타 문서화된 정보를",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        588.3170776367188,
        538.1482543945312,
        603.8391723632812
      ],
      "page_num": 93,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "읽을 수 없는 경우에는 공정한 입회자가 동의를 얻는 전 과정에 참석하여야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.79729461669922,
        614.32861328125,
        534.7642822265625,
        629.8507080078125
      ],
      "page_num": 93,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의 세부 사항에 대해",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        640.3402099609375,
        538.1483154296875,
        655.8623046875
      ],
      "page_num": 93,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "질문하고 해당 임상시험의 참여 여부를 결정할 수 있도록 충분한 시간과 기회를",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.79729461669922,
        666.2318725585938,
        538.1483764648438,
        681.7539672851562
      ],
      "page_num": 93,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "주어야 하며, 모든 임상시험 관련 질문에 대해 피험자 또는 대리인이 만족할 수",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.79729461669922,
        692.2434692382812,
        538.1483764648438,
        707.7655639648438
      ],
      "page_num": 93,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "있도록 대답해 주어야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.79729461669922,
        718.2550659179688,
        236.36598205566406,
        733.7771606445312
      ],
      "page_num": 93,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 87 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 94,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "19.8. 피험자 기록의 비밀보장",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        68.92467498779297,
        226.9161376953125,
        84.4467544555664
      ],
      "page_num": 94,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며, 임상 시험의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        94.93624877929688,
        538.1477661132812,
        110.45832824707031
      ],
      "page_num": 94,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "결과가 출관될 경우에도 피험자의 신원을 비밀상태로 유지한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.79729461669922,
        120.82794952392578,
        447.0917663574219,
        136.3500213623047
      ],
      "page_num": 94,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의 모니터링과",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        146.83953857421875,
        538.1483764648438,
        162.36160278320312
      ],
      "page_num": 94,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "점검 및 진행사항 관리를 위한 목적으로 피험자의 기록을 열람할 수 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.79729461669922,
        172.85110473632812,
        538.1224365234375,
        188.3731689453125
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험자는 본 임상시험 계획서에 서명함으로써, 국내의 법규와 윤리적 측면에서",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.79729461669922,
        198.74281311035156,
        538.1474609375,
        214.26487731933594
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험 의뢰자 또는 모니터 및 점검자가 피험자의 차트와 증례기록서 기록을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.79729461669922,
        224.75437927246094,
        538.1492919921875,
        240.2764434814453
      ],
      "page_num": 94,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "검증하기 위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다. 이러한",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.79729461669922,
        250.7659454345703,
        538.1492919921875,
        266.28802490234375
      ],
      "page_num": 94,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "정보들은 기밀로 보관되어야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.79729461669922,
        276.65765380859375,
        275.3448486328125,
        292.17974853515625
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 증례기록서 등 임상 시험에 관련된 모든 서류에는 피험자 이름이 아닌 피험자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        302.6692199707031,
        538.1477661132812,
        318.1913146972656
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식별코드(일반적으로 피험자 이니셜)로 기록하고 구분한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.79729461669922,
        328.6807861328125,
        417.82763671875,
        344.202880859375
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "19.9. 기록의 보존",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        380.5840759277344,
        157.59429931640625,
        396.1061706542969
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록 하여야 하며 보안을",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        406.59564208984375,
        538.147216796875,
        422.11773681640625
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "유지하도록 한다. 제조허가·수입허가 또는 그 변경허가를 위한 임상시험 관련",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        77.59794616699219,
        432.4873352050781,
        538.1480712890625,
        448.0223693847656
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "자료는 허가일로부터 3년간 보존하도록 하고, 그 밖의 임상시험 관련 자료는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        77.59794616699219,
        458.4989318847656,
        538.1477661132812,
        474.0210266113281
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험이 끝난 날부터 3년간 보존하도록 한다. 다만, 식품의약품안전처장이",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        77.59794616699219,
        484.510498046875,
        538.145751953125,
        500.0325927734375
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지시하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을 연장할 수 있다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        77.59794616699219,
        510.4022216796875,
        534.8842163085938,
        525.92431640625
      ],
      "page_num": 94,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 88 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 95,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "20. 그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        74.19891357421875,
        519.0782470703125,
        93.31405639648438
      ],
      "page_num": 95,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        129.45852661132812,
        530.5921630859375,
        144.9805908203125
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기록서(Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        155.35023498535156,
        530.5919189453125,
        170.87229919433594
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "책임자의 이력사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        64.52503204345703,
        181.36180114746094,
        530.5914306640625,
        196.8838653564453
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기의 공급과 취급에 관한 사항을 추가로 확보할 수 있음.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        64.52503204345703,
        207.37338256835938,
        432.81951904296875,
        222.89544677734375
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가. 임상시험용 의료기기의 사용 및 관리",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        253.40306091308594,
        293.00091552734375,
        268.9251403808594
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가 관리한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        62.84593963623047,
        276.77752685546875,
        538.2423706054688,
        292.29962158203125
      ],
      "page_num": 95,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급, 저장하며 “임상",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        84.31430053710938,
        300.1519775390625,
        538.1480712890625,
        315.674072265625
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "시험용”이라는 문구가 있어야한다. 임상시험용 의료기기 관리자는 임상시험에",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        84.31430053710938,
        323.52642822265625,
        538.147216796875,
        339.04852294921875
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사용되는 의료기기에 대해 인수, 재고관리, 반납 등의 업무를 수행하고 관련",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        84.31430053710938,
        346.90087890625,
        538.1480712890625,
        362.4229736328125
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기록을 유지하여야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        84.31430053710938,
        370.27532958984375,
        226.05157470703125,
        385.79742431640625
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나. 임상시험용 의료기기의 공급과 취급",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        417.02423095703125,
        286.76458740234375,
        432.54632568359375
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(1) 의뢰자는 임상시험계획서에 대한 임상시험심사위원회와 식품의약품안전처장의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        440.3987121582031,
        538.145751953125,
        455.9208068847656
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "승인을 얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는 아니",
      "font_size": 12.94941520690918,
      "font_name": "T17",
      "bbox": [
        79.27703094482422,
        463.7731628417969,
        538.1483764648438,
        479.2952575683594
      ],
      "page_num": 95,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "된다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        79.27703094482422,
        487.1476135253906,
        107.67572784423828,
        502.6697082519531
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(2) 의뢰자는 임상시험용 의료기기의 인수·취급·보관 및 미사용 의료기기를 피험자",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        510.5220947265625,
        538.1477661132812,
        526.05712890625
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "로부터 반납받거나 의뢰자에게 반납하는 방법에 관한 지침을 마련하여 시험",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.55742645263672,
        533.8965454101562,
        538.1483764648438,
        549.4186401367188
      ],
      "page_num": 95,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "책임자 및 관리자 등에게 주어야 하며, 임상시험용 의료기기의 공급, 인수,",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.55742645263672,
        557.27099609375,
        538.2423706054688,
        572.7930908203125
      ],
      "page_num": 95,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "반납 및 폐기에 관한 기록을 작성·보관하여야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.55742645263672,
        580.6454467773438,
        385.56512451171875,
        596.1804809570312
      ],
      "page_num": 95,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(3) 의뢰자는 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관으로의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        604.0198974609375,
        538.14599609375,
        619.5419921875
      ],
      "page_num": 95,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납 및 폐기에 관한",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.67736053466797,
        627.3943481445312,
        538.1483764648438,
        642.9164428710938
      ],
      "page_num": 95,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "기록을 작성·보관하여야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.67736053466797,
        650.768798828125,
        255.79544067382812,
        666.3038330078125
      ],
      "page_num": 95,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나 임상시험의 완료",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        56.609317779541016,
        674.1432495117188,
        538.1483764648438,
        689.6653442382812
      ],
      "page_num": 95,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(조기종료를 포함한다) 및 임상시험용 의료기기의 사용기한의 또는 유효기한의",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        697.5177001953125,
        538.147216796875,
        713.039794921875
      ],
      "page_num": 95,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "만료 등의 사유로 임상시험용 의료기기를 회수해야 하는 경우에 대한 절차를",
      "font_size": 12.94941520690918,
      "font_name": "T15",
      "bbox": [
        78.31755065917969,
        720.8921508789062,
        538.1480712890625,
        736.4142456054688
      ],
      "page_num": 95,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "마련하고 임상시험용 의료기기의 회수내용을 기록하여야 한다.",
      "font_size": 12.94941520690918,
      "font_name": "T2",
      "bbox": [
        78.31755065917969,
        744.2666015625,
        440.3753967285156,
        759.7886962890625
      ],
      "page_num": 95,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 89 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 96,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "21. 참고문헌",
      "font_size": 15.946965217590332,
      "font_name": "H2hdrM",
      "bbox": [
        67.64334106445312,
        74.19891357421875,
        160.7126007080078,
        93.31405639648438
      ],
      "page_num": 96,
      "block_type": "heading",
      "level": 8,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1. 대한진단검사의학회 편. 진단검사의학 제5판. 범문에듀케이션 p.295-299",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        128.6194305419922,
        418.5511779785156,
        141.84194946289062
      ],
      "page_num": 96,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. Paniccia R, Antonucci E, Gori AM, et al. Comparison of different methods to evaluate the",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        150.5554656982422,
        538.144775390625,
        163.77798461914062
      ],
      "page_num": 96,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "effect of aspirin on platelet function in high-risk patients with ischemic heart disease",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        70.16197204589844,
        172.49148559570312,
        538.1453857421875,
        185.71400451660156
      ],
      "page_num": 96,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "receiving dual antiplatelet treatment. Am J Clin Pathol 2007;128:143-149.",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        70.16197204589844,
        194.54737854003906,
        431.26593017578125,
        207.7698974609375
      ],
      "page_num": 96,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. Lee YK, Kim HS, Park JY, Kang HJ. Incidence of aspirin resistance in the patient group of",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        216.48341369628906,
        538.2130737304688,
        229.7059326171875
      ],
      "page_num": 96,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "a university hospital in Korea. Korean J Lab Med 2008;28:251-7.",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        70.16197204589844,
        238.41943359375,
        391.4470520019531,
        251.64195251464844
      ],
      "page_num": 96,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4. Kim H, Lee HK, Han K, Jeon HK. Prevalence and risk factors for aspirin and clopidogrel",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        260.475341796875,
        538.2405395507812,
        273.6978454589844
      ],
      "page_num": 96,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "resistance in patients with coronary artery disease or ischemic cerebrovascular disease. Ann",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        70.16197204589844,
        282.4113464355469,
        538.2134399414062,
        295.63385009765625
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Clin Lab Sci 2009;39:289-94.",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        70.16197204589844,
        304.3473815917969,
        207.22645568847656,
        317.56988525390625
      ],
      "page_num": 96,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5.",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        326.4032897949219,
        538.2464599609375,
        339.62579345703125
      ],
      "page_num": 96,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "FDA K970505: 510(k) summary of safety and effectiveness information Dade PFA-100",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        326.4032897949219,
        538.2464599609375,
        339.62579345703125
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Platelet",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        70.16197204589844,
        348.3393249511719,
        538.206787109375,
        361.56182861328125
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "function",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        70.16197204589844,
        348.3393249511719,
        538.206787109375,
        361.56182861328125
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "analyzer,",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        70.16197204589844,
        348.3393249511719,
        538.206787109375,
        361.56182861328125
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Dade",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        70.16197204589844,
        348.3393249511719,
        538.206787109375,
        361.56182861328125
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "PFA",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        70.16197204589844,
        348.3393249511719,
        538.206787109375,
        361.56182861328125
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Collagen/Epinephrine",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        70.16197204589844,
        348.3393249511719,
        538.206787109375,
        361.56182861328125
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Test",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        70.16197204589844,
        348.3393249511719,
        538.206787109375,
        361.56182861328125
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "cartridge,",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        70.16197204589844,
        348.3393249511719,
        538.206787109375,
        361.56182861328125
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Dade",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        70.16197204589844,
        348.3393249511719,
        538.206787109375,
        361.56182861328125
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "PFA",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        70.16197204589844,
        348.3393249511719,
        538.206787109375,
        361.56182861328125
      ],
      "page_num": 96,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Collagen/ADP Test cartridge Dade PFA Trigger solution February 7, 1997",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        70.16197204589844,
        370.27532958984375,
        443.4980163574219,
        383.4978332519531
      ],
      "page_num": 96,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6. FDA K042423: 510(k) summary. Accumetrics VerifyNow-Aspirin Assay",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        392.33123779296875,
        423.3661804199219,
        405.5537414550781
      ],
      "page_num": 96,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "7. FDA K051231: 510(k) substantial equivalence determination decision summary. VerifyNow",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        414.26727294921875,
        538.211669921875,
        427.4897766113281
      ],
      "page_num": 96,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "P2Y12 Assay",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        70.16197204589844,
        436.2032775878906,
        133.72427368164062,
        449.42578125
      ],
      "page_num": 96,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "8. FDA K013596-S2: 510(k) summary. Accumetrics Ultegra System Rapid Platelet Function",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        56.609317779541016,
        458.2591857910156,
        538.212890625,
        471.481689453125
      ],
      "page_num": 96,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Assay-TRAP",
      "font_size": 11.030982971191406,
      "font_name": "T2",
      "bbox": [
        70.16197204589844,
        480.1952209472656,
        130.90646362304688,
        493.417724609375
      ],
      "page_num": 96,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 90 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 97,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "임상시험 실시기관 및 책임 연구자 (소속과/직위/성명)",
      "font_size": 12.94941520690918,
      "font_name": "T11",
      "bbox": [
        106.3823471069336,
        280.37359619140625,
        431.6930847167969,
        295.90863037109375
      ],
      "page_num": 97,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "0000 병원 000 과/교수/000",
      "font_size": 12.94941520690918,
      "font_name": "T11",
      "bbox": [
        189.25743103027344,
        310.3408203125,
        348.8916015625,
        325.8758544921875
      ],
      "page_num": 97,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Ver. 1.0",
      "font_size": 12.94941520690918,
      "font_name": "T11",
      "bbox": [
        245.26707458496094,
        340.3080749511719,
        292.76080322265625,
        355.8431091308594
      ],
      "page_num": 97,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "피험자 이니셜(영문)",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        150.3984832763672,
        429.1153259277344,
        250.54795837402344,
        443.7833557128906
      ],
      "page_num": 97,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "피험자 식별번호",
      "font_size": 11.030982971191406,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        159.15374755859375,
        467.3535461425781,
        241.66867065429688,
        482.0215759277344
      ],
      "page_num": 97,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        56.609317779541016,
        70.72598266601562,
        541.8339233398438,
        81.75393676757812
      ],
      "page_num": 97,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "품목의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        73.99989318847656,
        92.66201782226562,
        301.63604736328125,
        103.6899642944336
      ],
      "page_num": 97,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "증례기록서(예시)",
      "font_size": 20.02363395690918,
      "font_name": "T10",
      "bbox": [
        215.2833251953125,
        140.00698852539062,
        378.5697937011719,
        164.02874755859375
      ],
      "page_num": 97,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 91 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.24920654296875,
        788.5885009765625,
        316.52520751953125,
        798.5376586914062
      ],
      "page_num": 98,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "Case Report Form 작성 지침",
      "font_size": 18.944515228271484,
      "font_name": "T10",
      "bbox": [
        159.75341796875,
        76.47642517089844,
        433.9242248535156,
        99.20358276367188
      ],
      "page_num": 98,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "일반적인 지침 사항",
      "font_size": 11.030982971191406,
      "font_name": "T10",
      "bbox": [
        245.6268768310547,
        107.8821029663086,
        348.5313415527344,
        121.11563873291016
      ],
      "page_num": 98,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "1) 검정색 볼펜을 사용하여 기록하여 주십시오.",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        65.12470245361328,
        147.79847717285156,
        305.5281677246094,
        161.0320281982422
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 가능하면 약어의 사용을 피하고 Full term으로 기록하여 주십시오.",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        65.12470245361328,
        169.7344970703125,
        420.9056396484375,
        182.96804809570312
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 정해진 칸 이외의 여백에 기록하지 마십시오.",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        65.12470245361328,
        191.79039001464844,
        308.1667175292969,
        205.02394104003906
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4) 증례 기록서 내에 기록하며, 모든 칸은 빈칸으로 두지 마십시오.",
      "font_size": 11.030982971191406,
      "font_name": "T10",
      "bbox": [
        65.12470245361328,
        213.72642517089844,
        412.0304260253906,
        226.95997619628906
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5) 자료를 기록할 수 없는 경우 “실시하지 않음(ND: not done)”또는 “알 수 없음(UK:",
      "font_size": 11.030982971191406,
      "font_name": "T10",
      "bbox": [
        65.12470245361328,
        235.66244506835938,
        528.961181640625,
        248.89599609375
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Unknown)”과 같이 분명한 이유를 기록하여 주십시오.",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        78.43749237060547,
        257.7183532714844,
        357.5799560546875,
        270.951904296875
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6) 서명은 반드시 시험책임자 혹은 시험 담당자가 서명하여 주십시오.",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        65.12470245361328,
        279.6543884277344,
        426.4226379394531,
        292.887939453125
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "증례 기록서 수정 방법",
      "font_size": 11.030982971191406,
      "font_name": "T10",
      "bbox": [
        237.1114959716797,
        323.88604736328125,
        357.0467224121094,
        337.1195983886719
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 잘못 기입된 부분은 한 줄로 긋고, 수정날짜(YY/MM/DD)와 수정자 서명, 필요시 수정",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        65.12470245361328,
        363.8023986816406,
        529.6329345703125,
        377.03594970703125
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "사유에 대하여 기록하여 주십시오.",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        78.67736053466797,
        385.7384338378906,
        251.6773681640625,
        398.97198486328125
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "11.6",
      "font_size": 11.030982971191406,
      "font_name": "T10",
      "bbox": [
        195.97378540039062,
        407.7943420410156,
        346.42120361328125,
        421.02789306640625
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "10/03/30 홍길동(오기)",
      "font_size": 11.030982971191406,
      "font_name": "T10",
      "bbox": [
        195.97378540039062,
        407.7943420410156,
        346.42120361328125,
        421.02789306640625
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "예) Hb 8.6 → Hb 8.6",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        105.06305694580078,
        429.7303771972656,
        215.523193359375,
        442.96392822265625
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 잘못 기입된 글자를 overwrite 해서 고치거나 수정액을 사용하여서는 안 됩니다.",
      "font_size": 11.030982971191406,
      "font_name": "T10",
      "bbox": [
        65.12470245361328,
        473.7222900390625,
        503.900634765625,
        486.9558410644531
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "증례기록서 작성에 대한 세부사항",
      "font_size": 11.030982971191406,
      "font_name": "T10",
      "bbox": [
        208.32708740234375,
        517.9539184570312,
        385.9507751464844,
        531.1874389648438
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 피험자 이니셜과 피험자 번호를 모든 페이지에서 적절하게 기록하여 주십시오.",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        65.12470245361328,
        557.8703002929688,
        478.47442626953125,
        571.1038208007812
      ],
      "page_num": 98,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "- 탈락 또는 임상시험이 중지된 피험자의 경우 실시된 visit까지 기록함.",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        76.03878784179688,
        579.8063354492188,
        441.8942565917969,
        593.0398559570312
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 방문이 누락된 경우에는 해당 visit의 방문일란에 “ND\"로 기록하여 주십시오.",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        65.12470245361328,
        601.7423706054688,
        471.5181884765625,
        614.9758911132812
      ],
      "page_num": 98,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "3) 임상시험이 종료(완료, 탈락 또는 중지)된 피험자의 경우, 증례결론란에 세부내용을 기록",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        65.12470245361328,
        623.7982788085938,
        529.6329345703125,
        637.0317993164062
      ],
      "page_num": 98,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "하여 주십시오.",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        79.75677490234375,
        645.7343139648438,
        153.81040954589844,
        658.9678344726562
      ],
      "page_num": 98,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 92 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.369140625,
        788.5885009765625,
        316.6451416015625,
        798.5376586914062
      ],
      "page_num": 99,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자 이니셜(영문)",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        92.94962310791016,
        143.00372314453125,
        484.4765930175781,
        154.93272399902344
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "피험자식별코드",
      "font_size": 9.951866149902344,
      "font_name": "T14",
      "bbox": [
        92.94962310791016,
        143.00372314453125,
        484.4765930175781,
        154.93272399902344
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "피험자 방문일 (YY/MM/DD)",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        92.94962310791016,
        143.00372314453125,
        484.4765930175781,
        154.93272399902344
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "◈ 피험자에게 서면 동의를 받았습니까?",
      "font_size": 9.951866149902344,
      "font_name": "T10",
      "bbox": [
        92.94962310791016,
        181.72140502929688,
        444.4786376953125,
        193.6603546142578
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 예",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        92.94962310791016,
        181.72140502929688,
        444.4786376953125,
        193.6603546142578
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 아니오",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        92.94962310791016,
        181.72140502929688,
        444.4786376953125,
        193.6603546142578
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "서면 동의 일자(YY/MM/DD)",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        123.65298461914062,
        212.64761352539062,
        256.0003967285156,
        224.5766143798828
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "◈ 인구학적 정보",
      "font_size": 9.951866149902344,
      "font_name": "T10",
      "bbox": [
        90.07118225097656,
        265.50982666015625,
        173.18572998046875,
        277.44879150390625
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "생년월일(YY/MM/DD)",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        93.3094253540039,
        298.11419677734375,
        195.67312622070312,
        310.043212890625
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "성별",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        214.2039031982422,
        298.11419677734375,
        486.816162109375,
        313.4278259277344
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 남",
      "font_size": 9.951866149902344,
      "font_name": "T17",
      "bbox": [
        214.2039031982422,
        298.11419677734375,
        486.816162109375,
        313.4278259277344
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 여",
      "font_size": 9.951866149902344,
      "font_name": "T15",
      "bbox": [
        214.2039031982422,
        298.11419677734375,
        486.816162109375,
        313.4278259277344
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "◈ 측정된 기록의 정보",
      "font_size": 9.951866149902344,
      "font_name": "T10",
      "bbox": [
        90.07118225097656,
        352.65460205078125,
        199.2116241455078,
        364.59356689453125
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "나이",
      "font_size": 9.951866149902344,
      "font_name": "T10",
      "bbox": [
        90.07118225097656,
        375.4297180175781,
        110.57965850830078,
        387.3686828613281
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "검체 채취일",
      "font_size": 9.951866149902344,
      "font_name": "T10",
      "bbox": [
        90.07118225097656,
        399.52337646484375,
        147.159423828125,
        411.46234130859375
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "◈ 혈관판 기능 장애",
      "font_size": 9.951866149902344,
      "font_name": "T10",
      "bbox": [
        90.07118225097656,
        444.2345275878906,
        188.6573486328125,
        456.1734924316406
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ YES",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        90.07118225097656,
        509.6830139160156,
        126.02546691894531,
        521.6219482421875
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 본 빌레브란트병(von Willebrand disease)",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        209.0467071533203,
        471.1754150390625,
        423.43121337890625,
        481.1245422363281
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 글란즈만혈소판무력증(Glanzmann's thrombasthenia)",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        209.0467071533203,
        487.1180114746094,
        470.9264221191406,
        497.067138671875
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 베르나르-술리에증후군(Bernard-Soulier syndrome)",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        209.0467071533203,
        503.0605773925781,
        474.1643371582031,
        513.0097045898438
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 약물유발 혈소판기능부전(drug-induced platelet",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        209.0467071533203,
        519.1229858398438,
        455.4711608886719,
        529.0721435546875
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "dysfunction)",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        209.0467071533203,
        535.0655517578125,
        292.3426208496094,
        545.0147094726562
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 기타:",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        209.0467071533203,
        551.0081787109375,
        305.67022705078125,
        560.9573364257812
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ NO",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        90.07118225097656,
        576.5699462890625,
        120.30455017089844,
        588.5088500976562
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "◈ 기타 출혈성 질환, 응고장애 유무",
      "font_size": 9.951866149902344,
      "font_name": "T10",
      "bbox": [
        90.07118225097656,
        621.281005859375,
        264.5762023925781,
        633.219970703125
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ YES",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        90.07118225097656,
        646.2137451171875,
        305.67022705078125,
        658.1527099609375
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 기타:",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        90.07118225097656,
        646.2137451171875,
        305.67022705078125,
        658.1527099609375
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ NO",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        90.07118225097656,
        672.704833984375,
        120.30455017089844,
        684.643798828125
      ],
      "page_num": 99,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 93 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.369140625,
        788.5885009765625,
        316.6451416015625,
        798.5376586914062
      ],
      "page_num": 100,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "◈ 혈관 질환 유무",
      "font_size": 9.951866149902344,
      "font_name": "T10",
      "bbox": [
        90.07118225097656,
        117.47161865234375,
        178.10354614257812,
        129.4105682373047
      ],
      "page_num": 100,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□ YES",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        90.07118225097656,
        142.5242462158203,
        126.02546691894531,
        154.46319580078125
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 허혈성 심질환    □ 심부정맥 혈전증   □ 부정맥",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        209.0467071533203,
        135.90184020996094,
        472.26031494140625,
        145.85096740722656
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 뇌졸중 □ 기타:",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        209.0467071533203,
        151.8444061279297,
        365.6374206542969,
        161.7935333251953
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ NO",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        90.07118225097656,
        168.89541625976562,
        120.30455017089844,
        180.83436584472656
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "◈ 기타",
      "font_size": 9.951866149902344,
      "font_name": "T10",
      "bbox": [
        90.07118225097656,
        213.6065673828125,
        157.11444091796875,
        225.54551696777344
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "질환",
      "font_size": 9.951866149902344,
      "font_name": "T10",
      "bbox": [
        90.07118225097656,
        213.6065673828125,
        157.11444091796875,
        225.54551696777344
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ YES",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        90.07118225097656,
        236.2617950439453,
        305.67022705078125,
        248.20074462890625
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 기타:",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        90.07118225097656,
        236.2617950439453,
        305.67022705078125,
        248.20074462890625
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ NO",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        90.07118225097656,
        260.475341796875,
        120.30455017089844,
        272.414306640625
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "◈ 항혈소판제제 사용력",
      "font_size": 9.951866149902344,
      "font_name": "T10",
      "bbox": [
        90.07118225097656,
        305.0666198730469,
        204.7282257080078,
        317.0055847167969
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ YES",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        90.07118225097656,
        338.15045166015625,
        126.02546691894531,
        350.08941650390625
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 아스피린    □ 클로피도그렐",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        209.0467071533203,
        323.496826171875,
        377.2716064453125,
        333.4459533691406
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 기타 P2Y12 수용체 저해제",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        209.0467071533203,
        339.55926513671875,
        359.4447021484375,
        349.5083923339844
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 기타(예, NOACs 등)",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        209.0467071533203,
        355.5018310546875,
        389.0250244140625,
        365.4509582519531
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ NO",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        90.07118225097656,
        371.11444091796875,
        120.30455017089844,
        383.05340576171875
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "◈ 기타 병용약물",
      "font_size": 9.951866149902344,
      "font_name": "T10",
      "bbox": [
        90.07118225097656,
        414.38714599609375,
        173.18539428710938,
        426.32611083984375
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ YES",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        90.07118225097656,
        435.72381591796875,
        389.84869384765625,
        447.66278076171875
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 항응고제 (예, 와파린, 헤파린 등)",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        90.07118225097656,
        435.72381591796875,
        389.84869384765625,
        447.66278076171875
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ NO",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        90.07118225097656,
        456.9406433105469,
        120.30455017089844,
        468.8796081542969
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "◈ 검사 결과",
      "font_size": 9.951866149902344,
      "font_name": "T10",
      "bbox": [
        90.07118225097656,
        500.2133483886719,
        152.07765197753906,
        512.1522827148438
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Hb (mg/dL)",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        90.07118225097656,
        522.9588012695312,
        146.62158203125,
        532.907958984375
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Platelet (/uL)",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        90.07118225097656,
        544.1755981445312,
        155.37579345703125,
        554.124755859375
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "Hematocrit (%)",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        90.07118225097656,
        565.5123291015625,
        165.45046997070312,
        575.4614868164062
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "aPTT (sec):",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        90.07118225097656,
        586.7291259765625,
        150.115234375,
        596.6782836914062
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "PT (INR):",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        90.07118225097656,
        608.0657958984375,
        143.3987274169922,
        618.0149536132812
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈소판 기능 검사",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        90.07118225097656,
        629.2825927734375,
        170.06735229492188,
        639.2317504882812
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "혈소판 약물반응검사",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        90.07118225097656,
        650.6193237304688,
        185.05873107910156,
        660.5684814453125
      ],
      "page_num": 100,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 94 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.369140625,
        788.5885009765625,
        316.6451416015625,
        798.5376586914062
      ],
      "page_num": 101,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        85.0339126586914,
        113.15962219238281,
        513.6490478515625,
        124.18756866455078
      ],
      "page_num": 101,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "수 있으며, 품목의 특성에 따라 자율적으로 설정이 가능함",
      "font_size": 11.030982971191406,
      "font_name": "Dotum",
      "bbox": [
        102.42449188232422,
        127.42402648925781,
        387.38958740234375,
        138.45196533203125
      ],
      "page_num": 101,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이상사례 서식지(예시)",
      "font_size": 20.98284912109375,
      "font_name": "T10",
      "bbox": [
        183.98028564453125,
        202.69847106933594,
        409.9917907714844,
        227.8709716796875
      ],
      "page_num": 101,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(Special form)",
      "font_size": 20.98284912109375,
      "font_name": "Haansoft Batang",
      "bbox": [
        224.518310546875,
        272.7955017089844,
        370.5367736816406,
        293.7725830078125
      ],
      "page_num": 101,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 95 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.369140625,
        788.5885009765625,
        316.6451416015625,
        798.5376586914062
      ],
      "page_num": 102,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "SPECIAL FORM 이상사례서식지",
      "font_size": 18.944515228271484,
      "font_name": "T10",
      "bbox": [
        141.8831024169922,
        118.91004943847656,
        452.1539611816406,
        141.63720703125
      ],
      "page_num": 102,
      "block_type": "heading",
      "level": 6,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "□ ‘이상 의료기기’의 반응",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        92.94962310791016,
        166.61790466308594,
        212.5243377685547,
        178.55685424804688
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험에 사용되는 임상시험용 의료기기에서 발생한, 모든 유해하고 의도되지 않은 반응으로서,",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        104.94312286376953,
        182.68035888671875,
        502.0029296875,
        193.46856689453125
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상시험에 사용되는 임상 시험용 의료기기와의 인과관계를 배제할 수 없는 경우를 말한다. 이용",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        104.94312286376953,
        197.06463623046875,
        502.047607421875,
        207.85284423828125
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가능한 임상시험용 의료기기 정보를 참고하여 인과관계를 평가한다.",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        104.94312286376953,
        211.44891357421875,
        379.8701477050781,
        222.23712158203125
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ ‘중증도’ 판정 참고기준",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        92.94962310791016,
        240.0976104736328,
        212.5243377685547,
        252.03656005859375
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 경증 (mild)",
      "font_size": 8.992650032043457,
      "font_name": "T10",
      "bbox": [
        104.94312286376953,
        256.1600646972656,
        168.27481079101562,
        266.9482727050781
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 피험자의 정상적인 일상생활(또는 기능)을 저해하지 않고, 최소한의 불편을 야기하며,",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        109.98039245605469,
        270.5443420410156,
        502.0029296875,
        281.3325500488281
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "피험자가 쉽게 견딜 수 있는 경우",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        118.97551727294922,
        284.9286193847656,
        266.3753356933594,
        295.7168273925781
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 중증도 (moderate)",
      "font_size": 8.992650032043457,
      "font_name": "T10",
      "bbox": [
        104.94312286376953,
        299.3128967285156,
        199.21743774414062,
        310.1011047363281
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 피험자의 정상적인 일상생활(또는 기능)을 유의하게 저해하는 불편을 야기하는 경우",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        109.98039245605469,
        313.6971740722656,
        466.4272155761719,
        324.4853820800781
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 중증 (severe)",
      "font_size": 8.992650032043457,
      "font_name": "T10",
      "bbox": [
        104.94312286376953,
        328.0814514160156,
        177.8681182861328,
        338.8696594238281
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 피험자의 정상적인 일상생활(또는 기능)을 불가능하게 하는 경우",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        109.98039245605469,
        342.4657287597656,
        385.59100341796875,
        353.2539367675781
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ ‘의료기기와의 관련성’ 판정 참고기준",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        92.94962310791016,
        371.11444091796875,
        277.4091796875,
        383.05340576171875
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1) 평가 불가능 (Unknown)",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        104.94312286376953,
        387.2967529296875,
        217.56777954101562,
        398.0849609375
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 정보가 불충분하거나 상충되어 판단할 수 없고 이를 보완하거나 확인할 수 없는 경우",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        109.98039245605469,
        401.6810302734375,
        473.02362060546875,
        412.46923828125
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2) 관련성이 없음 (Not related)",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        104.94312286376953,
        416.0653076171875,
        233.87985229492188,
        426.853515625
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 이상사례가 명백하게 피험자의 임상적 상태 또는 시험절차/조건에 기인한 경우",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        109.98039245605469,
        430.4495849609375,
        445.0787658691406,
        441.23779296875
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3) 관련성이 적음 (Unlikely)",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        104.94312286376953,
        444.8338623046875,
        221.1658477783203,
        455.6220703125
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 이상사례와 임상시험용 의료기기 간의 시간적 연관성으로 볼 때 어떠한 합리적인 관련도 있을 것",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        109.98039245605469,
        459.2181396484375,
        501.9279479980469,
        470.00634765625
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "같지 않은 경우",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        118.25590515136719,
        473.6024169921875,
        180.02273559570312,
        484.390625
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4)관련성이 의심됨 (Possible)",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        104.94312286376953,
        487.9866943359375,
        225.00462341308594,
        498.77490234375
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        109.98039245605469,
        502.3709716796875,
        502.047607421875,
        513.1591796875
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있으나, 해당 의료기기에서 알려진 이상사례와 직접적인 관련성이 없고, 피험자의 임상적 상",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        119.21538543701172,
        516.7552490234375,
        502.0478820800781,
        527.54345703125
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "태 또는 시험 절차/조건에 의해 발생하였을 가능성이 있는 경우",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        119.21538543701172,
        531.1395263671875,
        383.43218994140625,
        541.927734375
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5)관련성이 많음 (Probable)",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        104.94312286376953,
        545.5238037109375,
        218.0487060546875,
        556.31201171875
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 이상사례가 임상시험용 의료기기 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으며,",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        109.98039245605469,
        559.9080810546875,
        502.0029296875,
        570.6962890625
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "해당 의료기기의 알려진 특징으로 합리적인 설명을 할 수 있는 경우",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        118.13597106933594,
        574.2923583984375,
        393.0267028808594,
        585.08056640625
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6) 관련성이 명백함(Definite)",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        104.94312286376953,
        588.6766967773438,
        223.4451904296875,
        599.4649047851562
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        109.98039245605469,
        603.0609741210938,
        502.047607421875,
        613.8491821289062
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "있으며, 해당 의료기기의 알려진 이상사례와 직접적인 연관성을 배제할 수 없으며, 피험자의",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        119.21538543701172,
        617.4452514648438,
        502.0478820800781,
        628.2334594726562
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "임상적 상태에 대하여 알려진 특징으로는 합리적인 설명을 할 수 없는 경우.",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        119.21538543701172,
        631.8295288085938,
        438.8781433105469,
        642.6177368164062
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "□ 중대한 이상사례/ 이상 의료기기의 반응",
      "font_size": 9.951866149902344,
      "font_name": "T11",
      "bbox": [
        92.94962310791016,
        660.4781494140625,
        291.68194580078125,
        672.4171142578125
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 사망을 초래하거나 생명을 위협하는 경우",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        104.94312286376953,
        676.5406494140625,
        283.7662048339844,
        687.328857421875
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "· 입원 또는 입원 기간의 연장이 필요한 경우",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        104.94312286376953,
        690.9249267578125,
        292.6413879394531,
        701.713134765625
      ],
      "page_num": 102,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 96 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.369140625,
        788.5885009765625,
        316.6451416015625,
        798.5376586914062
      ],
      "page_num": 103,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "피험자 이니셜(영문)",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        92.94962310791016,
        144.41253662109375,
        482.9174499511719,
        154.36166381835938
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "피험자식별코드",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        92.94962310791016,
        144.41253662109375,
        482.9174499511719,
        154.36166381835938
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "피험자 방문일 (YY/MM/DD)",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        92.94962310791016,
        144.41253662109375,
        482.9174499511719,
        154.36166381835938
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "참 고 코 드",
      "font_size": 11.030982971191406,
      "font_name": "T11",
      "bbox": [
        267.3351135253906,
        184.2386474609375,
        327.7823486328125,
        197.47219848632812
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "증상의",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        94.38884735107422,
        206.89389038085938,
        121.37422180175781,
        217.68209838867188
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "범위",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        98.94637298583984,
        221.27818298339844,
        116.9366226196289,
        232.06639099121094
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "증상의",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        134.5670623779297,
        206.89389038085938,
        161.55242919921875,
        217.68209838867188
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정도",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        139.00466918945312,
        221.27818298339844,
        156.99490356445312,
        232.06639099121094
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기와의",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        186.6188507080078,
        206.89389038085938,
        240.589599609375,
        217.68209838867188
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관련성",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        200.05157470703125,
        221.27818298339844,
        227.03695678710938,
        232.06639099121094
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기에",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        265.05633544921875,
        206.89389038085938,
        310.0319519042969,
        217.68209838867188
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한 조치",
      "font_size": 8.992650032043457,
      "font_name": "T23",
      "bbox": [
        267.3351135253906,
        214.08604431152344,
        490.6540832519531,
        232.06639099121094
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "치료",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        267.3351135253906,
        214.08604431152344,
        490.6540832519531,
        232.06639099121094
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        267.3351135253906,
        214.08604431152344,
        490.6540832519531,
        232.06639099121094
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중대성",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        267.3351135253906,
        214.08604431152344,
        490.6540832519531,
        232.06639099121094
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 국소",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        92.94962310791016,
        270.4244689941406,
        122.09382629394531,
        281.2126770019531
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 전신",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        92.94962310791016,
        284.8087463378906,
        122.09382629394531,
        295.5969543457031
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 경증",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        133.00791931152344,
        263.2323303222656,
        162.27206420898438,
        274.0205383300781
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 중등",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        133.00791931152344,
        277.6166076660156,
        162.27206420898438,
        288.4048156738281
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. 중증",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        133.00791931152344,
        292.0008850097656,
        162.27206420898438,
        302.7890930175781
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 평가 불가능",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        173.18614196777344,
        241.65591430664062,
        233.75332641601562,
        252.44412231445312
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 관련성이 없음",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        173.18614196777344,
        256.0401916503906,
        242.74844360351562,
        266.8283996582031
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. 관련성이 적음",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        173.18614196777344,
        270.4244689941406,
        242.74844360351562,
        281.2126770019531
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4. 관련성이 의심됨",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        173.18614196777344,
        284.8087463378906,
        251.74356079101562,
        295.5969543457031
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "5. 관련성이 많음",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        173.18614196777344,
        299.1930236816406,
        242.74844360351562,
        309.9812316894531
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "6. 관련성이 명백함",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        173.18614196777344,
        313.5773010253906,
        251.74356079101562,
        324.3655090332031
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 이식체",
      "font_size": 8.992650032043457,
      "font_name": "T23",
      "bbox": [
        264.216796875,
        256.0401916503906,
        302.3561096191406,
        266.8283996582031
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "삽입유지",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        273.09197998046875,
        270.4244689941406,
        309.0724792480469,
        281.2126770019531
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 이식체",
      "font_size": 8.992650032043457,
      "font_name": "T23",
      "bbox": [
        264.216796875,
        284.8087463378906,
        302.3561096191406,
        295.5969543457031
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "제거",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        273.09197998046875,
        299.1930236816406,
        291.0822448730469,
        309.9812316894531
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 치료하지 않음",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        321.1859130859375,
        256.0401916503906,
        390.8681640625,
        266.8283996582031
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 약물치료",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        321.1859130859375,
        270.4244689941406,
        368.4403076171875,
        281.2126770019531
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. 비약물치료",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        321.1859130859375,
        284.8087463378906,
        377.4354248046875,
        295.5969543457031
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4. 수술적치료",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        321.1859130859375,
        299.1930236816406,
        377.4354248046875,
        309.9812316894531
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 회복",
      "font_size": 8.992650032043457,
      "font_name": "T23",
      "bbox": [
        403.8211364746094,
        256.0401916503906,
        432.96533203125,
        266.8283996582031
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 진행중",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        403.8211364746094,
        270.4244689941406,
        441.96044921875,
        281.2126770019531
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "3. 후유증",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        403.8211364746094,
        284.8087463378906,
        441.96044921875,
        295.5969543457031
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "4. 사망",
      "font_size": 8.992650032043457,
      "font_name": "T23",
      "bbox": [
        403.8211364746094,
        299.1930236816406,
        432.96533203125,
        309.9812316894531
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "1. 중대하지",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        452.3948059082031,
        263.2323303222656,
        499.5292663574219,
        274.0205383300781
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "않음",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        461.2699890136719,
        277.6166076660156,
        479.26025390625,
        288.4048156738281
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "2. 중대함",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        452.3948059082031,
        292.0008850097656,
        490.5341491699219,
        302.7890930175781
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "이상",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        107.1019515991211,
        370.99456787109375,
        125.09220123291016,
        381.78277587890625
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "반응명",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        102.54442596435547,
        385.37884521484375,
        129.52980041503906,
        396.16705322265625
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발생일.",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        159.39361572265625,
        363.80242919921875,
        188.57379150390625,
        374.59063720703125
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "종료일",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        160.4730224609375,
        378.18670654296875,
        187.45840454101562,
        388.97491455078125
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(yy/mm/dd)",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        149.1991424560547,
        392.57098388671875,
        198.73916625976562,
        403.35919189453125
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "지속시간",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        210.96566772460938,
        363.80242919921875,
        246.9461669921875,
        374.59063720703125
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "(hours/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        214.08396911621094,
        378.18670654296875,
        243.8575439453125,
        388.97491455078125
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "minutes)",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        211.20553588867188,
        392.57098388671875,
        246.71258544921875,
        403.35919189453125
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "증상의",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        259.0596008300781,
        370.99456787109375,
        286.0449523925781,
        381.78277587890625
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "범위",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        263.61712646484375,
        385.37884521484375,
        281.60736083984375,
        396.16705322265625
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "증상의",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        294.2005615234375,
        370.99456787109375,
        321.1859130859375,
        381.78277587890625
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "정도",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        298.7580871582031,
        385.37884521484375,
        316.7483215332031,
        396.16705322265625
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기기와의",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        327.66241455078125,
        370.99456787109375,
        363.6429138183594,
        381.78277587890625
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "관련성",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        332.1000061035156,
        385.37884521484375,
        359.08538818359375,
        396.16705322265625
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "기기에",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        378.6347961425781,
        370.99456787109375,
        405.6201477050781,
        381.78277587890625
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "대한 조치",
      "font_size": 8.992650032043457,
      "font_name": "T23",
      "bbox": [
        371.9184265136719,
        378.18670654296875,
        506.6054382324219,
        396.16705322265625
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "치료",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        371.9184265136719,
        378.18670654296875,
        506.6054382324219,
        396.16705322265625
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "결과",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        371.9184265136719,
        378.18670654296875,
        506.6054382324219,
        396.16705322265625
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "중대성",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        371.9184265136719,
        378.18670654296875,
        506.6054382324219,
        396.16705322265625
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        160.59295654296875,
        427.6925964355469,
        181.01190185546875,
        438.4808044433594
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        160.59295654296875,
        427.6925964355469,
        181.01190185546875,
        438.4808044433594
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        160.59295654296875,
        442.0768737792969,
        181.01190185546875,
        452.8650817871094
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        160.59295654296875,
        442.0768737792969,
        181.01190185546875,
        452.8650817871094
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        160.59295654296875,
        475.28057861328125,
        181.01190185546875,
        486.06878662109375
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        160.59295654296875,
        475.28057861328125,
        181.01190185546875,
        486.06878662109375
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        160.59295654296875,
        489.6648864746094,
        181.01190185546875,
        500.4530944824219
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        160.59295654296875,
        489.6648864746094,
        181.01190185546875,
        500.4530944824219
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        160.59295654296875,
        522.9884643554688,
        181.01190185546875,
        533.7766723632812
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        160.59295654296875,
        522.9884643554688,
        181.01190185546875,
        533.7766723632812
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        160.59295654296875,
        537.3727416992188,
        181.01190185546875,
        548.1609497070312
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        160.59295654296875,
        537.3727416992188,
        181.01190185546875,
        548.1609497070312
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        160.59295654296875,
        570.6962890625,
        181.01190185546875,
        581.4844970703125
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        160.59295654296875,
        570.6962890625,
        181.01190185546875,
        581.4844970703125
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        160.59295654296875,
        585.08056640625,
        181.01190185546875,
        595.8687744140625
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        160.59295654296875,
        585.08056640625,
        181.01190185546875,
        595.8687744140625
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        160.59295654296875,
        618.4041748046875,
        181.01190185546875,
        629.1923828125
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        160.59295654296875,
        618.4041748046875,
        181.01190185546875,
        629.1923828125
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        160.59295654296875,
        632.7884521484375,
        181.01190185546875,
        643.57666015625
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "/",
      "font_size": 8.992650032043457,
      "font_name": "T11",
      "bbox": [
        160.59295654296875,
        632.7884521484375,
        181.01190185546875,
        643.57666015625
      ],
      "page_num": 103,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 97 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.369140625,
        788.5885009765625,
        316.6451416015625,
        798.5376586914062
      ],
      "page_num": 104,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "출혈시간 및 항혈소판제제 저항성 복합검사기기 평가",
      "font_size": 15.946965217590332,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        122.57357025146484,
        414.65631103515625,
        519.88916015625,
        435.8611755371094
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "가이드라인(민원인 안내서)",
      "font_size": 15.946965217590332,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        221.63987731933594,
        440.18841552734375,
        415.2777404785156,
        461.3932800292969
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        91.51040649414062,
        472.4833679199219,
        375.3951416015625,
        485.71649169921875
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        91.51040649414062,
        472.4833679199219,
        375.3951416015625,
        485.71649169921875
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "처 식품의약품안전처 식품의약품안전평가원",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        91.51040649414062,
        472.4833679199219,
        375.3951416015625,
        485.71649169921875
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        91.51040649414062,
        498.1353454589844,
        248.62525939941406,
        511.36846923828125
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        91.51040649414062,
        498.1353454589844,
        248.62525939941406,
        511.36846923828125
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "일 2016년 12월",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        91.51040649414062,
        498.1353454589844,
        248.62525939941406,
        511.36846923828125
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "발",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        91.51040649414062,
        523.7872924804688,
        220.5599822998047,
        537.0204467773438
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "행",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        91.51040649414062,
        523.7872924804688,
        220.5599822998047,
        537.0204467773438
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "인",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        91.51040649414062,
        523.7872924804688,
        220.5599822998047,
        537.0204467773438
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "손여원",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        91.51040649414062,
        523.7872924804688,
        220.5599822998047,
        537.0204467773438
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "편 집 위 원 장 정희교",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        91.51040649414062,
        549.4392700195312,
        220.5599822998047,
        562.6724243164062
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "편",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        91.51040649414062,
        576.6495361328125,
        180.38223266601562,
        589.8826904296875
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "집",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        91.51040649414062,
        576.6495361328125,
        180.38223266601562,
        589.8826904296875
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "위",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        91.51040649414062,
        576.6495361328125,
        180.38223266601562,
        589.8826904296875
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "원",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        91.51040649414062,
        576.6495361328125,
        180.38223266601562,
        589.8826904296875
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "오현주, 조양하, 이원규, 정진백, 안영욱, 우승민, 김수영, 서두원, 양원선, 최윤정,",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        190.5767059326172,
        568.6183471679688,
        548.7245483398438,
        581.8515014648438
      ],
      "page_num": 104,
      "block_type": "paragraph",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "김윤영, 김서윤, 김민정",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        190.5767059326172,
        584.5609130859375,
        294.7022399902344,
        597.7940673828125
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "문",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        91.51040649414062,
        657.5610961914062,
        180.38223266601562,
        670.7942504882812
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        91.51040649414062,
        657.5610961914062,
        180.38223266601562,
        670.7942504882812
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "처",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicBold",
      "bbox": [
        91.51040649414062,
        657.5610961914062,
        180.38223266601562,
        670.7942504882812
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "28159 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        190.5767059326172,
        608.5347290039062,
        458.6524658203125,
        621.7678833007812
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "오송보건의료행정타운",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        190.5767059326172,
        625.9157104492188,
        290.48114013671875,
        639.1488647460938
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식품의약품안전평가원",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        190.5767059326172,
        656.1226806640625,
        293.9808044433594,
        669.3558349609375
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "의료기기심사부 체외진단기기과",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        190.5767059326172,
        673.3838500976562,
        335.457275390625,
        686.6170043945312
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "전화: 043-719-4652~63",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        190.5767059326172,
        690.7648315429688,
        299.2005920410156,
        703.9979858398438
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "팩스: 043-719-4650",
      "font_size": 9.951866149902344,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        190.5767059326172,
        708.0259399414062,
        281.0911560058594,
        721.2590942382812
      ],
      "page_num": 104,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "- 98 -",
      "font_size": 9.951866149902344,
      "font_name": "Haansoft Batang",
      "bbox": [
        278.369140625,
        788.5885009765625,
        316.6451416015625,
        798.5376586914062
      ],
      "page_num": 105,
      "block_type": "list_item",
      "level": 0,
      "table_info": null,
      "is_in_table": false
    },
    {
      "text": "(우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명2로 187",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        115.25753021240234,
        432.06243896484375,
        479.7991943359375,
        449.28143310546875
      ],
      "page_num": 105,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "오송보건의료행정타운",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        232.553955078125,
        452.7997741699219,
        362.44512939453125,
        470.0187683105469
      ],
      "page_num": 105,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "식품의약품안전평가원 의료기기심사부 체외진단기기과",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        135.166748046875,
        473.656982421875,
        459.8318176269531,
        490.8759765625
      ],
      "page_num": 105,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "TEL : 043-719-4652~63  FAX : 043-719-4650",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        159.9932861328125,
        494.3943176269531,
        435.06610107421875,
        511.6133117675781
      ],
      "page_num": 105,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    },
    {
      "text": "http://www.mfds.go.kr/medicaldevice",
      "font_size": 12.94941520690918,
      "font_name": "MalgunGothicRegular",
      "bbox": [
        188.29794311523438,
        515.1316528320312,
        406.794677734375,
        532.3506469726562
      ],
      "page_num": 105,
      "block_type": "table_cell",
      "level": 0,
      "table_info": null,
      "is_in_table": true
    }
  ],
  "markdown_content": "발간등록번호\n\n안내서-0662-01\n\n<!-- PAGE_1 -->\n### 출혈시간 및 항혈소판제제\n\n<!-- PAGE_1 -->\n### 저항성 복합검사기기 안전성·성능 및\n\n<!-- PAGE_1 -->\n### 임상시험계획서 평가 가이드라인\n\n<!-- PAGE_1 -->\n### (민원인 안내서)\n\n- 2016. 12.\n의료기기심사부 체외진단기기과\n\n<!-- PAGE_2 -->\n###### 제․개정 이력\n\n<!-- PAGE_2 -->\n###### 출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성·성능 및\n\n<!-- PAGE_2 -->\n###### 임상시험계획서 평가 가이드라인(민원인 안내서)\n\n<!-- PAGE_2 -->\n###### 제․개정번호\n\n<!-- PAGE_2 -->\n###### 승인일자\n\n<!-- PAGE_2 -->\n###### 주요 내용\n\n<!-- PAGE_2 -->\n###### B1-2016-5-054\n\n<!-- PAGE_2 -->\n###### 2016.12.30\n\n<!-- PAGE_2 -->\n###### 출혈시간 및 항혈소판제제 저항성 복합검사\n\n<!-- PAGE_2 -->\n###### 기기 안전성·성능 및 임상시험계획서 평가\n\n<!-- PAGE_2 -->\n###### 가이드라인\n\n<!-- PAGE_2 -->\n###### 안내서-0662-01\n\n<!-- PAGE_2 -->\n###### 「출혈시간 및 항혈소판제제 저항성 복합검사기기\n\n<!-- PAGE_2 -->\n###### 안전성·성능 및 임상시험계획서 평가 가이드라인\n\n<!-- PAGE_2 -->\n###### (민원인 안내서)」 명칭 변경 및 제·개정 점검표\n\n<!-- PAGE_2 -->\n###### 등 추가\n\n<!-- PAGE_2 -->\n###### [근거: 「식품의약품안전처 지침서등의 관리에\n\n<!-- PAGE_2 -->\n###### 관한 규정」 개정, ‘17.5.1.]\n\n<!-- PAGE_3 -->\n###### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성·성능 및\n\n임상시험계획서 평가 가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n등록대상\n\n**[표 시작]**\n\n| □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- |\n| □ NO | 검체의 | disease | (Blood | Coagul | Fibrinolysis. | 2002 |\n| 3 | 막힘부 | 지지체 | ○○○ | 1개 | 표준편차는 민감도 15.5%, 특이도 9.8%이었다. | 검사를 시행한다. | 내성으로부터 안전성을 보증함에 있다. | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. | 한다 (비열등성한계 10%). | c | c | d | d |\n| ◈ 피험자에게 서면 동의를 받았습니까? | □ 예 | □ 아니오 | - 검체의 양이 적거나 응고 등 검체 상태가 좋지 않아 검사를 진행할 수 없는 | c | d |\n| 임상시험에 사용되는 임상시험용 의료기기에서 발생한, 모든 유해하고 의도되지 않은 반응으로서, | 지침서ㆍ안내서가 있습니까? | 약물반응 음성 | 정상 | 참 고 코 드 | c+b | c+b |\n| [n = sample size (검체 수), p (민감도) = 0.80, | 라인이 없는 상태이다. | 약물반응 음성 | 신고 | 심사 등에 관한 규정」(식약처 고시) | c+b |\n| 4 | 혈액이동부 | 지지체 | ○○○ | 1개 | 임상시험에 사용되는 임상 시험용 의료기기와의 인과관계를 배제할 수 없는 경우를 말한다. 이용 | (False Negative) | (False Negative) | Jun;13(4):349-53.) | (True Negative) | (True Negative) |\n| 것이다. | 검사를 하도록 한다. | 기능 선별검사로 현재도 사용 중이다. | 혈소판기능장애 환자 | 경우 임상시험기관의 임상검체 폐기절차에 따라 즉각 폐기한다. | (False Negative) | 표 3. | (True Negative) |\n| 증상의 | 증상의 | 이상사례 서식지(예시) | 의료기기와의 | 의료기기에 | Function Analyzer | 1 strip x 50개 |\n| 가능한 임상시험용 의료기기 정보를 참고하여 인과관계를 평가한다. | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 |\n| 5 | 상판 | 지지체 | ○○○ | 1개 | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | ◈ 기타 | 질환 | 안전처고시) | 서면 동의 일자(YY/MM/DD) | [그림 4] 출혈시간 및 항혈소판제제 저항성 복합검사기기 | 2. The PFA-100 : a potential rapid screening tool for | 대한 조치 | 치료 | 결과 | 중대성 |\n| [표 3] 출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성 관련 시험 규격 | 정해진 확률 범위 내에서 분포할 것으로 예상되는 계산된 구간 | 하여 시험한다. (컷오프 근처의 검체 포함) | 준비하여 시험한다. (컷오프 근처의 검체 포함) | 저항성 복합검사기기에 적용한다. | 범위 | 인한 위해요인 방지시험에 관한 요구사항이 적용된다. | 합계 | a+c | b+d | a+b+c+d | 합계 | a+c | b+d | a+b+c+d | 정도 | - 피험자 제공 검체가 폐기된 경우, 임상시험담당자는 즉각 임상시험책임자, 및 | 관련성 | VerifyNowⓇ 성능평가 문헌 |\n| 합계 | a+c | b+d | a+b+c+d |\n| 6 | 하판 | 지지체 | ○○○ | 1개 |\n| □ YES | □ 기타: | 기계적 안전에 관한 공통기준규격」(식약처 고시) | the | assessment | of | platelet | dysfunction | (Clin | Lab |\n| n = 125.44 | □ ‘중증도’ 판정 참고기준 | 평균 민감도 | 평균 특이도 | 참고문헌 | 1. 평가 불가능 | 임상시험의뢰자에게 보고한다. | 대조기기 |\n| 7 | 혈소판 기능 이상 검체 각각의 이동거리 값을 구한다. | - 시험장비 | - 시험장비 | 한다. | 검사를 시행한다. | 마개가 형성되는 과정이 1차 혈소판 지혈과정이다. | 검사법이 검체에서 직접 측정할 수 있는 분석물질 값의 범위 | 전혈 검체에 분석대상 물질을 일정량 첨가한 시험물질 사용 | 측정한다. | 주성분 | ○○○ | OO±OO ㎍/㎖ |\n| stability of in vitro diagnostic reagents | 1) 경증 (mild) | 2. 관련성이 없음 | 1. 이식체 | 1. 치료하지 않음 | 1. 회복 | 합계 |\n| □ NO | 막힘부 | 반응부 | (사유 :                                                                 ) | Haematol. 2002 Aug;24(4):225-32.) | 1. Comparison of Different Methods to Evaluate |\n| ◈ 인구학적 정보 | 사항이 적용된다. | 1. 경증 | - 피험자의 자발적 의사에 의한 임상시험 중지 또는 거부 요청이 발생한 경우, | -「의료기기의 전기·기계적 안전에 관한 공통기준규격」 | 1. 중대하지 |\n| 8 | 보조성분 | ○○○ | 적량 | requirements for in vitro diagnostic (IVD) medical equipment | 1. 국소 | · 피험자의 정상적인 일상생활(또는 기능)을 저해하지 않고, 최소한의 불편을 야기하며, | 3. 관련성이 적음 | 비정상 | 정상 | 삽입유지 | 2. 약물치료 | 2. 진행중 |\n| 기기 및 대조기기에서 검사를 시행하고 결과를 기록한다. | 후 압박지혈을 한다. | 압력을 가해서는 안된다. | (Special form) | 외 규격 | 10 |\n| 사용 환경에 노출시켜 그 안정성을 평가하는 실험 | 가스, 폭발, 파열에 대한 보호시험에 관한 요구사항이 적용된다. | for Clinical Laboratory Measurement Procedures | 임상시험 실시기관 및 책임 연구자 (소속과/직위/성명) | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | 2. 중등 | - IEC 61010-1 Safety requirements for electrical equipment for | [그림 1] 1차 혈소판 지혈과정 | 3. | Comparison | of | PFA-100 | and | Bleeding | Time | the | Effect | of | Aspirin | on | Platelet | Function | in | 않음 |\n| 임상시험 방법에 따라 “의료기기 임상시험 관련 통계기법 가이드라인”을 적용한다. | 2. 전신 | 피험자가 쉽게 견딜 수 있는 경우 | [표 2] 국내업체 혈소판 기능검사 시약 허가사항 | 4. 관련성이 의심됨 | 임상시험담당자는 즉각 임상시험책임자, 임상시험의뢰자에게 보고하고, | 2. 이식체 | 3. 비약물치료 | 3. 후유증 |\n| 사용하기에는 부적합하다. | 3. 중증 | 2. 중대함 | □ 예 | ■ 아니오 |\n| 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까? |         | measurement, control, and laboratory use – Part 1: General | a | b |\n| 생년월일(YY/MM/DD) | 2) 중증도 (moderate) | 5. 관련성이 많음 | 성별 | □ 남 | □ 여 | High-Risk Patients With Ischemic Heart Disease | 제거 | 4. 수술적치료 | 4. 사망 |\n| 감염 방지 정책을 따라야 한다. | ◈ 항혈소판제제 사용력 | requirements | 전기·기계적 | 비정상 | 임상시험기관의 임상시료 폐기절차에 따라 즉각 폐기한다. | Testing | in | Pediatric | Patients | With | Suspected | a+b |\n| ☞ 사용 환경은 온도, 이동 조건, 진동, 빛, 습도를 포함한다. | 2개 로트로 대체 가능) | 2개 로트로 대체 가능) | 사용되고 있다. | 하여 최소이동거리를 제시한다. | 0000 병원 000 과/교수/000 | requirements |\n| · 피험자의 정상적인 일상생활(또는 기능)을 유의하게 저해하는 불편을 야기하는 경우 | 6. 관련성이 명백함 |\n| 기관명 | 소재지 | 전화 | 팩스 | 안전에 관한 시험 | (True Positive) | Receiving Dual Antiplatelet Treatment (Am J Clin | (False Positive) |\n| 여부 | 기술된 정전기 방전시험에 관한 요구사항이 적용된다. | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? | □ 예 | ■ 아니오 | - IEC 61010-2-101 Safety requirements for electrical equipment for | □ 아스피린    □ 클로피도그렐 | 증례 기록서 수정 방법 | Hemorrhagic | Problems | (J | Pediatr | Hematol | Oncol. |\n| 2~8℃(파우치 내 보관), 개봉일로부터 6일 | 측정한다. | 여러 검체가 혼합된 검체를 사용해서는 안된다. | 발생할 수 있으므로 충분한 지혈을 하도록 환자에게 교육한다. | 천천히 주입하는 방식으로 분주한다. | 3) 중증 (severe) |         |\n| [n = sample size (검체 수), p (특이도) = 0.80, | 및 검사결과를 확인할 수 있다. | 기재 등에 관한 규정」(식약처 고시) |\n| - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | □ YES | 2개 로트로 대체 가능) | 사항이 적용된다. | 증명하기 위한 평가방법 및 기준을 제시할 수 있다. | · 피험자의 정상적인 일상생활(또는 기능)을 불가능하게 하는 경우 | □ 기타 P2Y12 수용체 저해제 | Ver. 1.0 | Pathol. 2007 Jul;128(1):143-9.) |\n|         | measurement, control and laboratory use – Part 2-101: Particular | 2003 Jun;25(6):474-9.) | c | d |\n| 15~25℃(파우치 외 보관), 개봉일로부터 4시간 | ◈ 측정된 기록의 정보 | 혈소판기능장애 환자 | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | 정상 | □ 기타(예, NOACs 등) | □ 예 | ■ 아니오 | c+b |\n| ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것 | (식품의약품안전처 지침서등의 관리에 관한 규정 제2조) | requirements for in vitro diagnostic (IVD) medical equipment |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. | 발생일. | 지속시간 | 2. VerifyNow AA FDA summary 510(k) summary |\n| 기록을 유지하여야 한다. | 측정거리 대해 일치되는 기준거리를 구한다. | 전혈 검체에 분석대상 물질을 일정량 첨가한 시험물질 사용한다. | 측정하여 혈액 내부의 혈소판 인자의 기능을 확인하는 요소 | [n = sample size (검체 수), p (민감도) = 0.85, | □ NO | □ ‘의료기기와의 관련성’ 판정 참고기준 | 이상 | 내용입니까? |         | (False Negative) | 증상의 | 4. Comparison of Different Methods to Evaluate the | 증상의 | 기기와의 | (True Negative) | 기기에 |\n| 이내로 유지되는지 평가하기 위함 | 나이 | 연구과제 피험자 설명문 및 동의서 | -「의료기기의 전자파안전에 관한 공통기준규격」 |\n| 일하므로, ADP test의 평가기준에 준하여 평가한다.) | (‘16.10.31 기준) | 혈소판 부착 | →        응집 유도인자 분비 | →     혈소판 응집 | 종료일 | (hours/ | K042423 | 대한 조치 | 치료 | 결과 | 중대성 |\n| 전자기장 시험에 관한 요구사항이 적용된다. | 반응명 | 1) 평가 불가능 (Unknown) | □ 외국 규정을 번역하거나 설명하는 내용입니까? | □ 예 | ■ 아니오 | 범위 | 정도 | 관련성 |\n| n = 125.44 | [n = sample size (검체 수), p (민감도) = 0.90, | - IEC 61326-1 Electrical equipment for measurement, control and | Effect of Aspirin on Platelet Function in High-Risk |\n| 합계 | a+c | b+d | a+b+c+d | (yy/mm/dd) | minutes) |\n| ※ 구해진 기준값에 대하여 임상적으로 확증할 수 있다. | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 검체 채취일 | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. | 의한 보호에 관한 요구사항이 적용된다. | 저항성 복합검사기기에 적용한다. | Qualitative Test Performance; Approved Guideline | · 정보가 불충분하거나 상충되어 판단할 수 없고 이를 보완하거나 확인할 수 없는 경우 |\n| inhibitor (clopidogrel) 복용 예정인 환자 | 승인된 자 이외에는 본 제품을 | 분해하거나 수리해서는 안된다. | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. | 전자파 | laboratory use – EMC requirements – Part 1: General requirements | 3. Incidence of Aspirin Resistance in the Patient | Dade PFA Collagen/ADP Test |\n| 11.6 | 10/03/30 홍길동(오기) | Patients With Ischemic Heart Disease Receiving Dual |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | [n = sample size (검체 수), p (특이도) = 0.75, | ◈ 기타 병용약물 | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. | 2) 관련성이 없음 (Not related) | 출혈시간 및 항혈소판제제 저항성 복합검사기기 평가 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | □ 예 | ■ 아니오 |\n| 안전에 관한 시험 | - IEC 61326-2-6 Electrical equipment for measurement, control and | (피험자와의 관계) |\n| n = 99.96 | medical equipment | 스크리닝 및 검사일 | 검사일 | Group of a University Hospital in Korea (Korean | Cartridge |\n| ※ 제품의 특성에 따라 판정기준치 제시는 선택이 가능하다. | 및 제외 기준에 적합한 피험자에 한하여 피험자 식별코드를 부여한다. | 결과값 사이의 일치도의 근접성 | (비열등성한계 10%). | 단계, “Pressure”탭에서 현재 장비가 제공하는 압력을 확인할 수 있다. | 예) Hb 8.6 → Hb 8.6 | · 이상사례가 명백하게 피험자의 임상적 상태 또는 시험절차/조건에 기인한 경우 | (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명2로 187 | 정리한 자료입니까? | 피험자 이니셜(영문) | / | / |\n| □ YES | □ 항응고제 (예, 와파린, 헤파린 등) | laboratory use – EMC requirements – Part 2-6: Particular | Antiplatelet | Treatment | (Am | J | Clin | Pathol. | 2007 |\n| n = 70.56 | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | / | / | 가이드라인(민원인 안내서) |\n| ◈ 혈관판 기능 장애 | 3) 관련성이 적음 (Unlikely) | 방문일 | 방문1 | 방문2: 혈소판 약물반응검사의 경우만 해당 | J Lab Med. 2008 Aug;28(4):251-7.) |\n| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다. | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다. | 클로피도그렐 투약 유무 |\n| □ NO | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. | 2) ○○ ADP test | requirements – In vitro diagnostic (IVD) medical equipment | 오송보건의료행정타운 | PFA-100Ⓡ | VerifyNowⓇ | Jul;128(1):143-9.) |\n| 로트로 대체 가능) | 물질의 정량값 | 제품의 사용을 금지하며 제조원 담당자에게 연락한다. | 하게 적용되고 있다. | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. | stability of in vitro diagnostic reagents | 'VerifyNow Aspirin test'로 검사를 시행한다. | 측정기기에 관한 요구사항이 적용된다. | 저항성 복합검사기기에 적용한다. | 혈소판 기능이상 측정이 가능한 최소/최대 이동거리를 평가 | · 이상사례와 임상시험용 의료기기 간의 시간적 연관성으로 볼 때 어떠한 합리적인 관련도 있을 것 | Dade PFA Collagen/EPI Test | 합계 |\n| 체외진단기기과에 문의하시기 바랍니다. | n = 147.0 | 대한 검사를 위해서도 많이 이용되고 있다. | 임상시험 | 피험자 식별번호 | 4. | Correlation | of | high | post-treatment | platelet |\n| 발 | 행 | 처 식품의약품안전처 식품의약품안전평가원 | □ 본 빌레브란트병(von Willebrand disease) | 투약 후 | 투약 전 | Aspirin test: Aspirin 복용 3일 이후 |\n| [표 4] 출혈시간 및 항혈소판제제 저항성 복합검사기기 성능 관련 시험 규격 | 제조사 | Siemens | Accriva Diagnostics | 같지 않은 경우 | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | / | / | 검사항목 | 양성(비정상 결과) 환자 수 | 음성(정상 결과) 환자 수 | Cartridge |\n| 경과일수 | Day0 | 민감도 | 특이도 |\n| 전화번호: 043-719-4652~63 | 사용되는 체외진단용 분석기기에 적용한다. | 3) ○○ EPI test | □ 글란즈만혈소판무력증(Glanzmann's thrombasthenia) | reactivity | assessed | by | light | transmittance |\n| 있는 가장 높은 측정치 | 대한 이동거리를 구한다. | 결과들 가운데 일치도의 근접성 | 4)관련성이 의심됨 (Possible) | 품목명 | 자동혈소판응집측정장치 | 자동혈소판응집측정장치 | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | / | / | 아스피린 투약 유무 | P2Y12 test: Clopidogrel 복용 5일 이후 | □ 예(☞지침서) | ■ 아니오 |\n| TEL : 043-719-4652~63  FAX : 043-719-4650 | EPI test | 105명 이상 | 105명 이상 | a | b |\n| ◈ 검사 결과 | 발 | 행 | 일 2016년 12월 | · 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 | 중위값 | 88.0 | 82.7 | 합계 |\n| 팩스번호: 043-719-4650 | 모델명 | PFA-100 System | VerifyNow System | 약물반응 양성 | 사무의 세부기준이나 절차를 제시하는 것입니까? (공무원용) | □ 베르나르-술리에증후군(Bernard-Soulier syndrome) | aggregometry | and | the | VerifyNow | P2Y12 | assay | a+b |\n| 하는 데 중요한 검사이다. | □ YES | (비열등성한계 10%) | LTA 검사결과를 기준으로 하여 결과를 평가한다. | 기기인 'VerifyNow P2Y12 test'로 검사를 시행한다. | 혈소판기능장애 환자 | 4) ○○ Aspirin test |\n| 있으며 2020년 343억 달러까지 성장할 것으로 예상된다. | Visit window | - | 있으나, 해당 의료기기에서 알려진 이상사례와 직접적인 관련성이 없고, 피험자의 임상적 상 | [그림 5] 혈소판 기능검사 및 항혈소판제제 저항성 검사기기 | ADP test | 105명 이상 | 132명 이상 | http://www.mfds.go.kr/medicaldevice | (True Positive) | 투약 후 | 투약 전 | (False Positive) | 정밀도 평가방법에 |\n| - 시험물질 | EPI test | 하기 위한 평가 |         | 증례기록서 작성에 대한 세부사항 | □ 약물유발 혈소판기능부전(drug-induced platelet | 표준편차 | 16.1 | 8.0 | 대조기기 |\n| Hb (mg/dL) | 발 | 행 | 인 | 손여원 | □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 | / | / | (Thromb Thrombolysis. 2010 Nov;30(4):486-95.) |\n| 구분 | 품목허가번호 | 제 서울수신 06-710호 | 제 경인수신 05-110호 | 태 또는 시험 절차/조건에 의해 발생하였을 가능성이 있는 경우 | 대한 기준 가이드라인 |\n| 관찰형태 | 내원 | 내원 | 5) ○○ P2Y12 tests | / | / | SIPA test | 105명 이상 | 132명 이상 | dysfunction) | c | d | 합계 |\n| 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까? (민원인용) | 표준오차 | 8.0 | 4.0 | a | b |\n| 대하여 전기 | Platelet (/uL) | 5)관련성이 많음 (Probable) | Evaluation of the Linearity of Quantitative | Measurement Procedures; A Statistical Approach; | Approved Guideline | [그림 2] 혈소판 기능검사의 원리 |\n| 편 집 위 원 장 정희교 | Approved Guideline | 약물반응 양성 | 약물반응 음성 | □ 기타: | 비정상 | 정상 | 5. | Comparison | of | methods | to | evaluate | 직선성 평가방법에 | a+b | c+b |\n| 일시적으로 의식 소실이 유발되는 것이다. |         |\n| 약물 투여 전 반응여부와 약물 투여후 반응여부를 확인한다. | 동의서 취득 | O | · 이상사례가 임상시험용 의료기기 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으며, | 품목명 | 자동혈소판응집측정장치용시약 | 자동혈소판응집측정장치용시약 | 중위값 | 84.0 | 81.0 | (False Negative) | (True Positive) | (True Negative) | (False Positive) |\n| Procedures; A Statistical Approach; Approved Guideline | [n = sample size (검체 수), p (민감도) = 0.85, | Hematocrit (%) | 대한 기준 가이드라인 |\n| 컨트롤 챔버의 2개의 챔버로 구성되어 있다. | / | / |         | clopidogrel-mediated | platelet | inhibition | after | (연락처) |\n| □ NO | 편 | 집 | 위 | 원 | 수입 의료기기에 의존하여 검사를 진행하고 있다. | 해당 의료기기의 알려진 특징으로 합리적인 설명을 할 수 있는 경우 | a | b |\n| - 시험물질 | 제조자가 설정한 한계 이내로 유지되는지 평가하기 위함 | 선정/제외기준 확인 | O | 검체에 분석대상 물질을 일정량 첨가한 시험물질 사용한다. | ADP test | 으로 표현 | 합계 | a+c | b+d | a+b+c+d | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | 표준편차 | 4.2 | 1.4 | Roche Prostagladin E1 | □ 예 | ■ 아니오 |\n| aPTT (sec): | / | / | 비정상 | 김윤영, 김서윤, 김민정 | Dade PFA | c | Dade PFA | d | 간섭물질 반응에 대한 | a+b |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 확인할 수 있다. | 6) 관련성이 명백함(Definite) | percutaneous intervention with stent implantation | 윤리담당자 |\n| [n = sample size (검체 수), p (특이도) = 0.85, | 약물반응 음성 | 민원인을 구속하는 내용이 있습니까? | 표준오차 | 3.0 | 1.0 | VerifyNow | Reagent | VerifyNow | c+b |\n| (True Positive) | (False Positive) | 기준 가이드라인 |\n| 인구학적 정보 | O | · 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 | 모델명 | Collagen/EPI | Collagen/ADP |\n| - 시험장비 | 대한 간섭 평가 시험을 고려한다. | PT (INR): | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. | 증명하기 위한 평가방법 및 기준을 제시할 수 있다. | 변동계수값을 구한다. | 사항이 적용된다. | 28159 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187 | (False Negative) | (Thromb Haemost. 2009 Feb;101(2):333-9.) | (True Negative) | 검출한계 평가방법에 | 대한 기준 가이드라인 |\n| n = 99.96 | [n = sample size (검체 수), p (특이도) = 0.95, | 으로 간주하여 시험기기의 검사 결과에 대해 민감도와 특이도를 확인한다. | 있으며, 해당 의료기기의 알려진 이상사례와 직접적인 연관성을 배제할 수 없으며, 피험자의 | P2Y12 Test | Aspirin Test |\n| 사항 | ◈ 기타 출혈성 질환, 응고장애 유무 | 혈액 폐색을 유발한다. | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | / | / |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | Laboratory Measurement Procedures | 오송보건의료행정타운 | c | d |\n| 혈소판 기능 검사 | 보호시험에 관한 요구사항이 적용된다. | 임상적 상태에 대하여 알려진 특징으로는 합리적인 설명을 할 수 없는 경우. | Test Cartridge | Test Cartridge |\n| 휴식을 취하면 대부분 회복된다. | 합계 | a+c | b+d | a+b+c+d | / | / | 정상 | 판정기준치 평가방법에 | c+b |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | Laboratory | Practice)에 | 따라 취급해야 한다. | 30분, 최대 4시간 이내 검사를 시행한다. | 및 혈소판 기능 이상 검체를 각각 최소 50개 이상 사용한다. | 환자의 aspirin 복용 전 검체 | Measurement Methods; Approved Guideline | Measurement Methods; Approved Guideline | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다. | [표 6] 간섭물질 예 | 민감도 | 특이도 |\n| 받은 제품은 아래와 같다. | □ YES | □ 기타: | 검체 채취 | O | O |\n| n = 99.96 | 혈소판 약물반응검사 | 품목허가번호 | 수허 12-1710 | 수허 12-1743 | 수허 12-1648 | 수허 12-1652 | Performance; Approved Guideline | (False Negative) | (True Negative) | 대한 가이드라인 |\n| 식품의약품안전평가원 | 중위값 | 89.3 | 96.4 |\n| 문 | 의 | 처 | □ 중대한 이상사례/ 이상 의료기기의 반응 | 상기 사항에 대하여 확인하였음. |\n| n = 37.24 | 약물유발 혈소판기능부전(drug-induced platelet dysfunction) 등 | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. | 하므로, 이를 확인하는 LTA 검사결과를 참고치로 하여 결과를 비교한다. | 이용한 혈소판 기능검사가 요구되고 있다. | 간섭물질 | 예시 |\n| - 시험장비 | 2개 로트로 대체 가능) | 검체 검사 및 분석 | O | O | 저항성 복합검사기기에 적용한다. |\n| [표 5] 출혈시간 및 항혈소판제제 저항성 복합검사기기 안정성 관련 시험 규격 | □ NO | Aspirin test | 하게 되며, 이동거리를 측정하여 결과를 얻을 수 있다. | · 사망을 초래하거나 생명을 위협하는 경우 | 합계 | a+c | b+d | a+b+c+d | 의료기기심사부 체외진단기기과 | 표준편차 | 29.6 | 8.9 |\n| 외인성 물질 | 일반의약품, 고혈압, 협심증, 심부전 등 심장질환 치료제 등 |\n| 것이 중요하다. | 검사항목 | 양성(약물반응) 환자군 수 | 음성(약물비반응) 환자군 수 |\n| 분리하여 혈소판풍부혈장을 취하여 3시간 이내에 검사를 시행한다. | 끝날때까지 기다리도록 한다. | 있는 검체는 사용하지 않는다. | 감염 방지 정책 및 병원의 규정에 의거하여 폐기한다. | 환자의 3일 이상 aspirin 복용 후의 검체 | 위해요인 보호시험에 관한 요구사항이 적용된다. | · 입원 또는 입원 기간의 연장이 필요한 경우 | 기타 | 전화: 043-719-4652~63 | 표준오차 | 17.1 | 5.1 |\n| 2017 년    5 월   31  일 | 용혈, 혈색소, 지방산과 지질(콜레스테롤, 트리글리세리드), 빌리루빈, |\n| - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | 하여 R2값을 제시한다. | 저항성 복합검사기기에 적용한다. | 저항성 복합검사기기에 적용한다. | (Closeness of agreement) |\n| Aspirin test | 75명 이상 | 40명 이상 | 중위값 | 80.4 | 71.4 |\n**팩스: 043-719-4650**\n| 검체에 포함된 물질 | -「의료기기의 안정성시험 기준」 | 이상 단백질 및 펨타이드 등 |\n**오차범위는 ±5% 설정하였다.**\n| ADP test와 동일하므로, ADP test의 평가기준에 준하여 평가하였다. | P2Y12 test | 표준편차 | 15.5 | 9.8 | 담당자 | 확  인(부서장) | 서 두 원 |\n| 2개 로트로 대체 가능) | 에서 제외될 수 있다. | P2Y12 test | 132명 이상 | 155명 이상 | - ISO 23640 In vitro diagnostic medical devices – Evaluation of |\n**방식이다.**\n| 안정성 평가 | 표준오차 | 9.0 | 5.7 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다. 그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n지침서ㆍ안내서\n\n■ 예(☞안내서)\n\n□ 아니오\n\n기타 확인\n\n오 현 주\n\n<!-- PAGE_4 -->\n###### 이 안내서는 출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성·성능\n\n<!-- PAGE_4 -->\n###### 및 임상시험계획서 평가 시 요구되는 신청서 작성 방법 및 제출자료 요건에\n\n<!-- PAGE_4 -->\n###### 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n<!-- PAGE_4 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n<!-- PAGE_4 -->\n###### (‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는\n\n<!-- PAGE_4 -->\n###### 사항이 아님을 알려드립니다. 또한, 본 안내서는 2016년 12월 30일 현재의 과학적\n\n<!-- PAGE_4 -->\n###### ㆍ기술적 사실 및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규\n\n<!-- PAGE_4 -->\n###### 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 식품의약품안전평가원\n\n- 1. 관련 법규 등\n- (1) 「의료기기법」\n- (2) 「의료기기법 시행령」\n- (3) 「의료기기법 시행규칙」\n**[표 시작]**\n\n| (4) 「의료기기 허가 | 3) 정해진 칸 이외의 여백에 기록하지 마십시오. | 외부 오염 또는 | - Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체 | - Sample Size (5% 탈락률 적용) = 131.71, 약 132개 검체 |\n| --- | --- | --- | --- | --- |\n| receiving dual antiplatelet treatment. Am J Clin Pathol 2007;128:143-149. | ① 「의료기기의 안정성시험 기준」(식약처 고시) |\n| 4) 제품 취급 및 보관상의 주의 | 나. 방문2 (검사일) | 8) 보관조건: | 나. P2Y12 test | ⑥ Tray가 나와 움직이지 않을 때까지 기다린다. | control, and laboratory use – Part 1: General requirementsK. |\n| (4) 시험 항목 | 처의 임상계획 승인일로부터 OO개월”로 표시하고 근거자료 제출함. | 의료기기의 공급과 취급에 관한 사항을 추가로 확보할 수 있음. | (3) 통계적 검정 방법 | 대상 질환 또는 적응증을 포함하도록 함. |\n| 하여 원칙과 절차를 수립하여 제시함. | 실시기관으로 지정받은 곳이어야 함 | 부적절한 검체 |\n| (5) 「의료기기 품목 및 품목별 등급에 관한 규정」(식약처 고시) | * 만 18세 미만의 피험자의 경우 법정대리인도 동의서에 서명해야 합니다. | 4) 증례 기록서 내에 기록하며, 모든 칸은 빈칸으로 두지 마십시오. | 경험이 있는 자가 선정되어야 함. | ④ ADP test 음성 검체 검사 시 (특이도 80%), |\n| 바. 기준물질/보정물질 | 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에서 정하고 있음. | 1. 검출한계(Limit of detection) | 이상이 되도록 준비한 후 시험 시료에 첨가한다. | 시험 |\n| 7) 제품 폐기 시 주의사항 | 7.2.1. 임상시험용 의료기기 | (1) 유효기한이 지난 제품은 사용하지 않는다. | (2) 검사칩 장착 | 가 혈소판 기능검사 | 차트확인 및 질문 등을 통하여 점검하고 증례기록서에 기록한다. | 1) 혈소판 약물반응검사의 경우에만 방문2에 검사를 시행한다. | - 치료 | (1) 본체 : 해당사항 없음 | 2) ADP test | 증명하고자 하는 임상시험의 목적을 구체적으로 알 수 있도록 기입함. | 전달한다) |\n**(4) 사용될 통계적 분석방법(즉, 연구디자인과도 관련)**\n**(6) 「의료기기의 전기**\n| 나. 혈소판 약물반응검사 | a university hospital in Korea. Korean J Lab Med 2008;28:251-7. | 직명 등 인적사항을 기재함. | - 대립가설: 개발제품의 특이도가 80% 이상이다. |\n| 번호 | 안전성 평가 항목 | 관련 표준 또는 적용 규격 |\n| (1) 오염된 제품이나 사용한 제품은 병원의 규정에 의거하여 폐기한다. | ① 인구학적 정보: 성명, 나이, 성별, 임신 유무 | 검체를 준비한다. | 따라 폐기됩니다. | - 제품의 보관방법 및 유효기간 | (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests | ① EPI test 양성 검체 검사 시 (민감도 85%), | 95% 구간에서 민감도 80%, 특이도 75%, 로 설정한다. |\n| (7) 「의료기기의 전자파 안전에 관한 공통기준규격」(식약처 고시) | 피험자 : | Unknown)”과 같이 분명한 이유를 기록하여 주십시오. |\n| - 본체: 혈소판의 형상변화, 응집 과정을 측정하는 기기 | 자발적 의사에 의해 |\n| ① Aspirin test 양성 검체 검사 시 (민감도 90%), | - 귀무가설: 개발제품의 특이도가 80% 미만이다. | - Sample Size (5% 탈락률 적용) = 131.71, 약 132개 검체 |\n| 다. 배정방법: 비무작위 배정 | ② 병력조사 :출혈성 질환, 응고장애, 암, 기타 만성질환 등 | 임상시험의 경우 의료기기 제조업자(수입자를 포함한다)를 말한다. | 정보들은 기밀로 보관되어야 한다. | 4. 출혈시간 및 항혈소판제제 저항성 복합검사기기 관련국내 | - 미개봉: 2~8℃, 제조일로부터 12개월 | - 대립가설: 개발제품의 민감도가 85% 이상이다. |\n| 6) 서명은 반드시 시험책임자 혹은 시험 담당자가 서명하여 주십시오. | (4) 시험 조건 | 관리를 위한 기준물질 및 보정물질의 개발이 필요하다. | 함께 기재함. | 시험군과 대조군간의 비교분석방법을 통계적으로 타당하게 제시함. | (6) 결과 제시 | - 시험장비 | 이동거리 값을 구한다. |\n| (8) 「의료기기의 안정성시험 기준」(식약처 고시) | (2) 적용 범위 : 혈소판 기능이상 검사 키트에 적용한다. | 적용범위 등을 작성함. | 임상시험에 대한 | ① Tray(검사칩 삽입부): 검사칩을 올려놓고 여닫을 수 있는 Tray |\n**“검체”라는 용어로 부릅니다.**\n| Aspirin test | 73.5% | 93.2% | ④ P2Y12 test 음성 검체 검사 시 (특이도 75%), | 부작용 증세가 발생할 수 있다. | - 대립가설: 개발제품의 민감도가 90% 이상이다. |\n| - 본체 | - 적용 계산식 :  |     |\n| 참여를 거부한 경우 | Clin Lab Sci 2009;39:289-94. | 번호를 부여한다. 스크리닝 번호는 다음과 같이 구성된다. | 대한 평가기준을 제시하여야 함. | 해당 임상시험을 적절하게 실시할 수 있도록 하여야 한다. | - 개봉 | - 귀무가설: 개발제품의 민감도가 85% 미만이다. |\n| (9) 「의료기기 제조 및 품질관리 기준」(식약처 고시) | 나. P2Y12 test | 측정된 이동거리의 평균을 구하여 비교대상으로 설정한다. | 1 | - 시험물질 | 나는 인위적인 증가나 감소 |\n| 8.3.1 피험자 수 | 회사명 | 대표이사 | 소재지 | 전화 | use – EMC requirements – Part 1: General requirements |\n| (1) 혈관미주신경 반응 | - 귀무가설: 개발제품의 민감도가 90% 미만이다. | - 대립가설: 개발제품의 특이도가 75% 이상이다. |\n| 14.2.2. 혈소판 약물반응 검사 | 모델명: ○○○ |\n| 눈가림, 단일설계, 전향적 비교확증임상시험 | 특이도, 일치도를 평가하여 임상적 유효성을 검증하고자 한다. | 라. 비열등성 검정 | 다. 관찰항목 검사(평가) 방법 | 14.2.1. 혈소판 기능 검사 | ④ CBC 결과 (혈색소, 헤마토크릿, 혈소판수 등) | - 스크리닝 | 번호: SXX(XX:일련번호), 예)S01,02,03………… | 절차에 따라 이루어지도록 하여야 한다. | 시험기기 | 식별코드(일반적으로 피험자 이니셜)로 기록하고 구분한다. |\n**(10)「의료기기 표시**\n\n**[표 끝]**\n\n<!-- PAGE_6 -->\n## 목\n\n<!-- PAGE_6 -->\n## 차\n\n<!-- PAGE_6 -->\n##### Ⅰ. 안전성·성능 평가\n\n<!-- PAGE_6 -->\n###### 1\n\n<!-- PAGE_6 -->\n###### 1. 적용 범위\n\n<!-- PAGE_6 -->\n###### 1\n\n<!-- PAGE_6 -->\n###### 2. 약어 및 용어 정리\n\n<!-- PAGE_6 -->\n###### 2\n\n<!-- PAGE_6 -->\n###### 3. 출혈시간 및 항혈소판제제 저항성 복합검사기기정의 및 분류\n\n<!-- PAGE_6 -->\n###### 5\n\n<!-- PAGE_6 -->\n###### 5. 안전성 평가 항목\n\n<!-- PAGE_6 -->\n###### 11\n\n<!-- PAGE_6 -->\n###### 6. 분석적 성능 평가 항목\n\n<!-- PAGE_6 -->\n###### 14\n\n<!-- PAGE_6 -->\n###### 7. 안정성 평가 항목\n\n<!-- PAGE_6 -->\n###### 23\n\n<!-- PAGE_6 -->\n###### 8. 참고 문헌\n\n<!-- PAGE_6 -->\n###### 26\n\n<!-- PAGE_6 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_6 -->\n###### 27\n\n<!-- PAGE_6 -->\n##### Ⅱ. 임상시험계획서 작성 및 평가\n\n<!-- PAGE_6 -->\n###### 28\n\n<!-- PAGE_7 -->\n##### 개\n\n<!-- PAGE_7 -->\n##### 요\n\n<!-- PAGE_7 -->\n###### 식품의약품안전처는 정부지원과제 중 제품화가 임박한 제품에 대한\n\n<!-- PAGE_7 -->\n###### 시험방법 개발, 안전성·성능 평가, 임상시험계획서의 선제적 제공을 통한\n\n<!-- PAGE_7 -->\n###### 제품화 지원체계 구축을 위하여 「융복합 신개발의료기기 제품화 지원을\n\n<!-- PAGE_7 -->\n###### 위한 사업」을 진행하고 있다.\n\n<!-- PAGE_7 -->\n###### 본 가이드라인은 ‘16년 「융복합 신개발의료기기 제품화 지원을 위한\n\n<!-- PAGE_7 -->\n###### 사업」의 결과물이며, 주요 내용으로 “출혈시간 및 항혈소판제제 저항성\n\n<!-- PAGE_7 -->\n###### 복합검사기기”의 안전성 및 성능평가방법, 임상시험계획서 작성 및\n\n<!-- PAGE_7 -->\n###### 평가방법과 관련된 사항을 구체적으로 제시하여 신속제품화를 위한\n\n<!-- PAGE_7 -->\n###### 맞춤형 기술지원을 목적으로 하는 가이드라인이다.\n\n- - 1 -\n<!-- PAGE_8 -->\n##### Ⅰ\n\n<!-- PAGE_8 -->\n##### 안전성·성능 평가\n\n<!-- PAGE_8 -->\n###### 1. 적용범위\n\n<!-- PAGE_8 -->\n###### 본 가이드라인은 출혈시간 및 항혈소판제제 저항성 복합검사기기의\n\n<!-- PAGE_8 -->\n###### 분석적 성능 평가와 안정성에 대한 평가방법을 구축하여 신개발 융복합\n\n<!-- PAGE_8 -->\n###### 의료기기의 평가방법을 제시하고자 한다.\n\n출혈시간 및 항혈소판제제 저항성 복합검사기기는 『의료기기 품목 및\n\n<!-- PAGE_8 -->\n###### 품목별 등급에 관한 규정』의 분류에 따라 “혈액응고검사시약 D01050.01\n\n<!-- PAGE_8 -->\n###### (3등급)”과 “자동혈소판응집측정장치 A22290.01(1등급)”로 분류되고 있다.\n\n- - 2 -\n<!-- PAGE_9 -->\n###### 2. 약어 및 용어정리\n\n<!-- PAGE_9 -->\n###### (1) 가속노화시험 (Accelerated aging testing) : 제품의 실제 보관기간과\n\n<!-- PAGE_9 -->\n###### 상응되도록 짧은 기간 동안 시험하기 위하여 가혹한 온도조건 등에서\n\n<!-- PAGE_9 -->\n###### 의료기기의 화학적 또는 물리적 퇴보속도를 높이도록 계획한 안정성\n\n<!-- PAGE_9 -->\n###### (2) 간섭 (Interference) : 분석물질의 농도나 강도가 명백함에도 검출시약\n\n<!-- PAGE_9 -->\n###### 이나 신호 자체에 비특이적으로 반응하는 물질의 존재로 인해 일어\n\n<!-- PAGE_9 -->\n###### (3) 간섭물질 (Interfering substances) : 임상검체에 존재하는 내부물질\n\n<!-- PAGE_9 -->\n###### (예: 혈액 구성요소, acidic polysaccharides) 또는 외부물질(예: 항응고제 등)로\n\n<!-- PAGE_9 -->\n###### 위양성 또는 위음성 결과를 야기할 수 있는 물질\n\n<!-- PAGE_9 -->\n###### (4) 검출한계 (Limit of detection, LOD) : 검출될 수 있는 분석 물질의 최소량\n\n<!-- PAGE_9 -->\n###### (5) 공란한계 (Limit of blank, LOB) : blank 검체에서 관찰 가능할 수\n\n<!-- PAGE_9 -->\n###### (6) 교차반응 (Cross-reactivity) : 항원 이외에 공유 되었거나, 유사한 또는\n\n<!-- PAGE_9 -->\n###### 동일한 항원 결정기를 가진 항원과 항체가 반응하는 현상\n\n<!-- PAGE_9 -->\n###### (7) 대조물질 (Control / Control material) : 정도 관리를 위해 이용되는\n\n<!-- PAGE_9 -->\n###### 기기, 액체 또는 동결건조 물질\n\n<!-- PAGE_9 -->\n###### (8) 변동계수 (Coefficient of Variation, CV) : 표준편차의 크기를 평균치에\n\n<!-- PAGE_9 -->\n###### 대한 백분율로 나타낸 것\n\n<!-- PAGE_9 -->\n###### (9) 배치(Batch), 로트(Lot) : 특성이 균일하고 단일 또는 일련의 제조공정으로\n\n<!-- PAGE_9 -->\n###### 생산된 물질의 정의된 양\n\n- - 3 -\n<!-- PAGE_10 -->\n###### (10) 사용 시 안정성(In-use stability) : 제조사에서 제공한 용기를 개봉한\n\n<!-- PAGE_10 -->\n###### 이후에 사용자의 작동 조건에서 시약의 유효기간내의 검사수행능\n\n<!-- PAGE_10 -->\n###### (11) 사용기간(유효기간) (Shelf life) : 제조자가 특정한 저장조건 하에서\n\n<!-- PAGE_10 -->\n###### 최종 포장상태의 IVD 제품이 안정성을 유지하는 기간\n\n<!-- PAGE_10 -->\n###### (12) 신뢰구간 (Confidence interval) : 평균, 분율, 비율 등의 변수의 참값이\n\n<!-- PAGE_10 -->\n###### (13) 실시간 안정성(Real time stability) : IVD 제품을 제조자가 특정한\n\n<!-- PAGE_10 -->\n###### (14) 이동거리 (Migration Distance) : 검체가 카트리지에서 이동한 거리를\n\n<!-- PAGE_10 -->\n###### (15) 재현성 (Reproducibility) : 다른 측정조건에서 수행된 동일한 측정물의\n\n<!-- PAGE_10 -->\n###### (16) 정밀도 (Precision) : 규정된 조건 하에서 얻어진 독립적인 검사\n\n<!-- PAGE_10 -->\n###### ☞ 정밀도는 전형적으로 수치로 표현되지 않지만 비정밀도는 반복\n\n<!-- PAGE_10 -->\n###### 측정값 결과들의 ‘표준편차’ 또는 ‘변이계수’라는 용어로 정량적\n\n<!-- PAGE_10 -->\n###### (17) 정확도 (Accuracy) : 측정치와 참값 사이의 일치도\n\n<!-- PAGE_10 -->\n###### ☞ 평가대상 검사법에 의한 다수의 연속적인 결과값 들에서 얻은 평균값과\n\n<!-- PAGE_10 -->\n###### 공인된\n\n<!-- PAGE_10 -->\n###### 참고값(Accepted\n\n<!-- PAGE_10 -->\n###### reference\n\n<!-- PAGE_10 -->\n###### value)사이의\n\n<!-- PAGE_10 -->\n###### 일치\n\n<!-- PAGE_10 -->\n###### 근접도\n\n- - 4 -\n<!-- PAGE_11 -->\n###### (18) 직선성 (Linearity) : 실험 검체에 있는 분석물질의 농도[양]에 정비례\n\n<!-- PAGE_11 -->\n###### 하는 결과를 제공할 수 있는 능력\n\n<!-- PAGE_11 -->\n###### (19) 출혈시간(Bleeding time, BT) 검사 : 출혈시간 측정검사로 Duke법,\n\n<!-- PAGE_11 -->\n###### Ivy법, Template법 등을 이용하여 혈소판기능 선별검사로 사용\n\n<!-- PAGE_11 -->\n###### (20) 측정가능범위 (Analytical measurement range, AMR) : 일상적인\n\n<!-- PAGE_11 -->\n###### 측정 과정의 일부가 아닌 희석, 농축 또는 기타 전처리 없이 어떤\n\n<!-- PAGE_11 -->\n###### (21) 특이도 / 분석특이도 (Specificity / Analytical specificity) : 측정하고자\n\n<!-- PAGE_11 -->\n###### 하는 물질만 측정되고 검체 내 다른 물질은 측정 되지 않는 분석법의 능력\n\n<!-- PAGE_11 -->\n###### (22) 판정기준치 (Cut-off value) : 정성검사에서 경계치 이상을 양성으로,\n\n<!-- PAGE_11 -->\n###### 경계치 미만을 음성으로 보고할 수 있는 경계값을 말한다. 정량검사\n\n<!-- PAGE_11 -->\n###### 에서는 측정 결과가 임상적 또는 분석적 결정점(Decision point)의\n\n<!-- PAGE_11 -->\n###### 위 또는 아래에 있는지(양성 또는 음성) 결정하는데 사용되는 측정\n\n<!-- PAGE_11 -->\n###### (23) 편차 (Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n- - 5 -\n<!-- PAGE_12 -->\n###### 3. 출혈시간 및 항혈소판제제 저항성 복합검사기기의 정의 및 분류\n\n<!-- PAGE_12 -->\n###### 가. 개요\n\n<!-- PAGE_12 -->\n###### (1) 혈관벽 손상으로 출혈이 발생하면 혈소판은 손상 부위에 부착,\n\n<!-- PAGE_12 -->\n###### 다른 혈소판들과 응집, 추가 응집을 촉진시키기 위한 물질 분비 등\n\n<!-- PAGE_12 -->\n###### 3가지 과정을 통해 지혈을 유도한다. 이러한 반응으로 생긴 혈소판\n\n<!-- PAGE_12 -->\n###### (2) 혈소판 검사는 주로 선천성 혈소판기능이상이나 수술 전 선별검사로\n\n<!-- PAGE_12 -->\n###### 많이 사용된다. 특히 혈소판의 수적 이상이 없는 출혈성 질환에서\n\n<!-- PAGE_12 -->\n###### 선천성 혹은 후천성 혈소판 기능이상에 의한 출혈성 질환을 감별\n\n- - 6 -\n[그림 3] 혈소판 약물반응검사의 원리\n\n<!-- PAGE_13 -->\n###### (3) 최근에는 심혈관 및 뇌혈관 질환의 치료 및 예방에 사용되는 항혈소판\n\n<!-- PAGE_13 -->\n###### 약제의 선택과정에 있어서 환자에 적합한 올바른 약재 선택을 돕기 위한\n\n<!-- PAGE_13 -->\n###### 검사 및 약제의 장기간 복용으로 인한 출혈현상의 증가나 약제의 내성에\n\n<!-- PAGE_13 -->\n###### (4) 혈소판 기능검사 및 항혈소판제제 저항성을 측정하기 위한 측정방법은\n\n<!-- PAGE_13 -->\n###### 다양하며 현재 개발된 제품들의 측정방법은 Closure time(CT), 광투과량\n\n<!-- PAGE_13 -->\n###### 측정, 전기 임피던스 측정, 입사광산란 측정 등이다. CT측정은 혈액이\n\n<!-- PAGE_13 -->\n###### 혈소판 작용으로 인해 미세구멍이 폐색되기까지의 시간을 측정하는 것이고,\n\n<!-- PAGE_13 -->\n###### 광투과량 측정은 혈소판 응집에 대한 빛의 투과도를 관찰한다. 전기\n\n<!-- PAGE_13 -->\n###### 임피던스 방식은 혈소판 응집으로 인한 전기장애를 측정하는 방식이고\n\n<!-- PAGE_13 -->\n###### 입사광산란 측정방식은 콜라겐 코팅에 대한 빛의 산란정도를 측정하는\n\n- - 7 -\n<!-- PAGE_14 -->\n###### (5) 본 가이드라인에서 적용하고 있는 출혈시간 및 항혈소판제제 저항성\n\n<!-- PAGE_14 -->\n###### 복합검사기기는 혈액 이동거리를 기반으로 혈소판의 전단 활성화 기능을\n\n<!-- PAGE_14 -->\n###### 측정하는 방식으로 혈소판기능 스크리닝과 항혈소판제제에 대한 저항성\n\n<!-- PAGE_14 -->\n###### 측정을 하나의 기기로 동시에 관찰이 가능하다.\n\n<!-- PAGE_14 -->\n###### 나. 제품 허가 현황\n\n<!-- PAGE_14 -->\n###### (1) 출혈시간 및 항혈소판제제 저항성 복합검사기기는 주로 수입 의료\n\n<!-- PAGE_14 -->\n###### 기기에 의존하고 있고 국내 개발 제품은 없는 상태이다. (‘16.10.31 기준)\n\n<!-- PAGE_14 -->\n###### (2) 출혈시간 및 항혈소판제제 저항성 복합검사기기로 국내에서 수입허가를\n\n- - 8 -\n번호\n\n업체명\n\n품목허가번호\n\n허가/신고일\n\n모델명\n\n1\n\n티메드(주)\n\n서울 수신\n\n14-1203호\n\n2014년 4월 14일\n\nA-100\n\n2\n\n지멘스헬스케어(주)\n\n서울 수신\n\n11-522호\n\n2011년 4월 8일\n\nINNOVANCE PFA-200 System\n\n3\n\n한국로슈진단(주)\n\n서울 수신\n\n11-392호\n\n2011년 3월 21일\n\nMultiplate 5.0 - Platelet\n\n4\n\n백두대\n\n경인 수신\n\n05-110호\n\n2005년 9월 2일\n\nVerifyNow System\n\n5\n\n성원메디칼상사\n\n서울 수신\n\n05-1722호\n\n2005년 11월 14일\n\nHemoRam/AggRAM Analyzer\n\n[표 1] 국내업체 혈소판 기능검사 장비 허가사항\n\n(‘16.10.31 기준)\n\n번호\n\n업체명\n\n품목허가번호\n\n허가/신고일\n\n모델명\n\n1\n\n티메드(주)\n\n수허 16-200 호\n\n2016년 4월 1일\n\nAggreGuide A-100 ADP Assay\n\n2\n\n티메드(주)\n\n수허 15-467 호\n\n2015년 2월 12일\n\nAA assay cartridge\n\n3\n\n지멘스헬스케어(주)\n\n수허 12-1743 호\n\n2012년 12월 5일\n\n4\n\n지멘스헬스케어(주)\n\n수허 12-1735 호\n\n2012년 12월 5일\n\nINNOVANCE PFA P2Y\n\n5\n\n지멘스헬스케어(주)\n\n수허 12-1710 호\n\n2012년 12월 4일\n\n6\n\n성원메디칼상사\n\n수허 13-1207 호\n\n2013년 7월 10일\n\nEpinephrine Reagent\n\n7\n\n성원메디칼상사\n\n수허 13-1206 호\n\n2013년 7월 10일\n\nArachidonic Acid Reagent\n\n8\n\n성원메디칼상사\n\n수허 13-1205 호\n\n2013년 7월 10일\n\nADP Reagent\n\n9\n\n성원메디칼상사\n\n수허 13-1208 호\n\n2013년 7월 10일\n\nCollagen Reagent\n\n10\n\n한국로슈진단(주)\n\n수허 12-2234 호\n\n2012년 12월 27일\n\n11\n\n한국로슈진단(주)\n\n수허 12-2232 호\n\n2012년 12월 27일\n\nRoche TRAPtest\n\n12\n\n한국로슈진단(주)\n\n수허 12-2213 호\n\n2012년 12월 27일\n\nRoche COLtest\n\n13\n\n한국로슈진단(주)\n\n수허 12-2058 호\n\n2012년 12월 21일\n\nRoche ASPItest\n\n14\n\n한국로슈진단(주)\n\n수허 12-1932 호\n\n2012년 12월 13일\n\nRoche ADPtest\n\n15\n\n백두대\n\n수허 12-1648 호\n\n2012년 11월 26일\n\nVerifyNow P2Y12 Test\n\n16\n\n백두대\n\n수허 12-1652 호\n\n2012년 11월 27일\n\nVerifyNow Aspirin Test\n\n(‘16.10.31 기준)\n\n- - 9 -\n<!-- PAGE_16 -->\n###### 다. 국외 허가동향\n\n<!-- PAGE_16 -->\n###### (1) 혈소판 기능검사는 전혈이 주로 검체로 사용되기 때문에 표준물질\n\n<!-- PAGE_16 -->\n###### 개발이 어려워 제품 개발 및 시험 자체가 어려운 특성이 있다.\n\n<!-- PAGE_16 -->\n###### (2) 혈소판 기능검사를 평가를 위한 기준을 제시하는 국제규격 및 가이드\n\n<!-- PAGE_16 -->\n###### (3)\n\n<!-- PAGE_16 -->\n###### 침습적\n\n<!-- PAGE_16 -->\n###### 방식의\n\n<!-- PAGE_16 -->\n###### 출혈시간(Bleeding\n\n<!-- PAGE_16 -->\n###### time,\n\n<!-- PAGE_16 -->\n###### BT)검사\n\n<!-- PAGE_16 -->\n###### 이후\n\n<!-- PAGE_16 -->\n###### 독일\n\n<!-- PAGE_16 -->\n###### Siemens사의 PFA-100과 ITC사의 VerifyNow를 통해 혈소판 기능을\n\n<!-- PAGE_16 -->\n###### 자동 검사법과 항혈소판제제 저항성 검사법이 시장을 확대하며\n\n<!-- PAGE_16 -->\n###### (4) 혈소판 기능검사를 위한 검사법은 지속적으로 개발 및 발전하고\n\n<!-- PAGE_16 -->\n###### 있으며 검사를 위한 작용원리 또한 Closure time(혈소판 작용으로\n\n<!-- PAGE_16 -->\n###### 혈액이 미세구멍을 막는 시간 측정), 광투과량 측정방식, 전기 임피던스\n\n<!-- PAGE_16 -->\n###### 측정방식, 입사광산란 파악방식 등으로 업체의 개발 기술에 따라 다양\n\n- - 10 -\n<!-- PAGE_17 -->\n###### 4. 출혈시간 및 항혈소판제제 저항성 복합검사기기 관련 국내외 규격\n\n<!-- PAGE_17 -->\n###### 출혈시간 및 항혈소판제제 저항성 복합검사기기에 대한 국제규격이 부재\n\n<!-- PAGE_17 -->\n###### 하여 체외진단 장비에 대한 안전성과 해당 시약에 대한 성능 및 안정성에\n\n<!-- PAGE_17 -->\n###### 대해 적용이 가능한 규격을 아래와 같이 제시하였다.\n\n**[표 시작]**\n\n**정성하여 혈소판 기능장애 확인에 도움을 주는 체외진단용 의료기기**\n**위하여 임상시험기관 및 시험자의 의견을 조정하기 위하여 조정위원회를 설치**\n| 시험군과 대조군을 포함한 피험자 수는 해당 의료기기의 특성, 임상시험디자 | - 적용 계산식 :  |     |\n**비교한다.**\n| 하고 시험조정자를 선정할 수 있음. | - 귀무가설: 개발제품의 특이도가 75% 미만이다. |\n| 를 의뢰자에게 보내야 한다. | 검사칩을 사용하지 않도록 주의한다. | 품목명 : 자동혈소판응집측정장치[1] | - 적용 계산식 :  |     |\n| (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests | 인, 근거를 통한 시험에서 기대하는 연구결과의 사전 예측, 통계적 유의성, |\n**(1) 본체**\n| - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | (5) 시험 방법 | (5) 시험 방법 |\n| 3) SIPA test | ① LTA 대조기기 결과를 기준하여 시험기기의 민감도와 특이도를 확인한다. | 피험자의 부작용에 대한 내용은 해당사항 없다. | 품목분류번호 : A22290.01 | - 적용 계산식 :  |     |\n| 사유에 대하여 기록하여 주십시오. | diagnostic (IVD) medical equipment |\n**검정 방법, 탈락률 등을 반영하여 통계학적으로 타당하게 제시되어야 하며, 임**\n**(ADP)에 의한 혈소판 기능장애 확인에 도움을 주는 체외진단용 의료기기**\n| 작성할 수 있음 | - 시험장비 |\n| 1) 반드시 체외진단용으로 사용해야 한다. | - 시약 : | 2. 혈소판 약물반응검사 | ② LTA 대조기기와 시험기기의 일치도를 확인한다. | 실시상의 문제점 등에 따라 결정되어야 한다. | 것은 아니며 행정상 변경이 필요하다. |\n**있는 경우는 이를 반영하여 분석결과를 제시해야함.**\n| 2 | 상시험의 효능 및 안전성 입증에 필요한 충분한 수가 확보되어야 함. | ➂ 전기적 빠른 과도현상(Electrical Fast Transient, EFT)시험 | - Sample Size (5% 탈락률 적용) = 131.71, 약 132개 검체 |\n**삽입할 수 있다.**\n| 2) 검체는 감염성 질환에 대한 감염을 배제할 수 없으므로 취급에 주의한다. | 방법에 따라 기입한다. | ③ PFA-100 대조기기와 시험기기의 일치도를 확인한다. | in vitro diagnostic reagents | 모델명 : 1) ○○ SIPA test |\n**⑤ SIPA test 양성 검체 검사 시 (민감도 85%),**\n| test 음성(정상 결과) 대조군 132명 이상을 대상으로 한다. | ➃ 서지(Surge) 내성시험 |\n**- Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체**\n| 3) 사용기한이 지난 제품은 사용하지 않는다. | Antagonist)을 일정량 첨가하여 준비한다. | 는 그 이유의 타당성을 면밀히 검토하여야 한다. |\n| 출혈성 경향의 증가나 약제 내성에 대한 검사를 위해서도 많이 이용되고 있습니다. | - 대립가설: 개발제품의 민감도가 85% 이상이다. | - Sample Size (5% 탈락률 적용) = 74.09, 약 75개 검체 |\n| 장애 확인에 도움을 주는 체외진단용 의료기기 | ② EPI test 음성 검체 검사 시 (특이도 85%), | ➄ 전도성 RF 전자기장 내성시험 | Measurement Procedures |\n| 된다. | 검출하는 체외진단용 의료기기 | 하여야 한다. |\n| 수가 보장되어야 하며, 일반적으로 1차 주효과 변수를 기준으로 정해지고, 연구 | (4) 시험 조건 | - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | 시험결과의 차이를 구하여 제시한다. |\n| ② Aspirin test 음성 검체 검사 시 (특이도 95%), | 검체를 사용한다. | 분석을 시행하도록 한다. | - 귀무가설: 개발제품의 민감도가 85% 미만이다. | - Sample Size (5% 탈락률 적용) = 154.35, 약 155개 검체 |\n**- 대립가설: 개발제품의 특이도가 85% 이상이다.**\n**➅ 전원주파수 자기장 내성시험**\n| 됩니다. | - 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순 |\n| 1 | CLSI EP05 | Evaluation of Precision of Quantitative Measurement | Methods; Approved Guideline | 계획서상에 정확한 연구피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 함. |\n| - 간섭반응물질 | (6) 결과 제시 : 검사 결과에 대한 변동계수값(%)값을 구한다. | Approved Guideline | - 대립가설: 개발제품의 특이도가 95% 이상이다. |\n| 제품 | - 적용 계산식 :  |     |\n**- 귀무가설: 개발제품의 특이도가 85% 미만이다.**\n| 기록 되는지 여부를 검토, 확인하는 활동을 말한다. | ➆ 전압강하, 순간정전 및 전압변동 시험 | 예) KFDA-12-34-56 |\n| 그러나 최근의 임상연구에서는 임상연구가 점차 복잡해지고 다양한 연구 목적을 | - 귀무가설: 개발제품의 특이도가 95% 미만이다. |\n| 기능장애 확인에 도움을 주는 체외진단용 의료기기 | (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests | (4) 시험 조건 | 정한다. |\n| 2 | CLSI EP06 |\n| 참여함을 확인하는 절차를 말한다. | 품목명 : 혈액응고검사시약 [3] | - 적용 계산식 :  |     |\n| 저항성 복합검사기기’의 임상적 유효성을 비교 분석하는 것이 목적입니다. | 전부에 대하여 중지 명령 등 필요한 조치를 시험책임자에게 할 수 있다. |\n**평가하기 위하여 1차 주효과 변수뿐만 아니라 안전성평가변수 및 2차 주효과**\n**제품**\n| - | 치료 | - 탈락 또는 임상시험이 중지된 피험자의 경우 실시된 visit까지 기록함. | 내용을 기재함. | 반납 및 폐기에 관한 기록을 작성·보관하여야 한다. | - 적용 계산식 :  |     |\n| 3 | CLSI EP07 | Interference Testing in Clinical Chemistry; Approved | Guideline | 로트로 대체 가능) | 품목분류번호 : (D01050.01) |\n| 1) Aspirin test | 혈소판수 포함), PT, aPTT 결과 등을 문진과 진료 기록을 통하여 조사한다. | 산출한다. 신뢰도 95% 구간에서 민감도 85%, 특이도 85%, 로 설정한다. | 방문과 전화 등을 통해서 이루어 질 것이다. |\n**변수, 1차 주효과 변수의 조합 등을 고려하여 수행되고 있음.**\n| 4 | CLSI EP17 | Evaluation | of | Detection | Capability | for | Clinical | 시험기기 |\n**하였으며 자발적으로 이 연구에 참여하는 것에 동의합니다.**\n| 기능장애 확인에 도움을 주는 체외진단용 의료기기 | 있다. |\n| 5 | CLSI EP12 | User | Protocol | for | Evaluation | of | Qualitative | Test | Approved Guideline |\n| ② 대조기기(VerifyNow) 결과와 시험기기의 일치도를 확인한다. | 한다. | 시험자와 상의한다. | - Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체 |\n**하여 주십시오.**\n\n**[표 끝]**\n\n번호\n\n규격 번호\n\n제목\n\n내용\n\n번호\n\n안전성 평가 항목\n\n관련 표준 또는 적용 규격\n\n1\n\n개봉 전/후\n\nstability of in vitro diagnostic reagents\n\n- - 11 -\n<!-- PAGE_18 -->\n###### 5. 안전성 평가 항목\n\n**[표 시작]**\n\n| 가. 전기 | 피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자 | 1. 임상시험의 제목 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 개정되거나 사안에 따라 변경될 수 있으며, 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 원자재, 형상, 구조, 치수/중량, 성능, 보관조건 등을 구체적으로 기재하도록 함. | 수 있으며, 품목의 특성에 따라 자율적으로 설정이 가능함 | 기계적 안전성 시험 | 1. Rational use of the PFA-100 device for screening |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 1. 대한진단검사의학회 편. 진단검사의학 제5판. 범문에듀케이션 p.295-299 | 임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례 | 로트로 대체 가능) | (마) 기기 온도 한계치와 내열성 : IEC 61010-1의 10절에 기술된 온도 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 수 있다. | 시험할 간섭물질의 목록을 작성한다. | - 시험물질 | - 시험물질 | 혈소판 기능이상 측정이 가능한 최소/최대 이동거리를 평가 | a | a | b | b |\n| 가. 개봉 전 안정성평가 | 가. 의료기기 품목 및 품목별 등급에 관한 규정 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | □ 허혈성 심질환    □ 심부정맥 혈전증   □ 부정맥 | a | b |\n| 6.1 혈소판 기능검사키트에 대한 성능평가 | 10.1. 시험방법 | - 시험자는 시험책임자, 시험담당자, 임상시험조정자를 포함함. | - 임상시험기관에서 임상시험용 해당 의료기기를 보관·관리하는 임상의, 의료기사 | 임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 해당 의료기기의 | ① 출혈시간(Bleeding time, BT)검사는 약 100여년 전부터 개발되어 | 1 | 혈액챔버 | 지지체 | ○○○ | 1개 | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 약물반응 양성 | 비정상 | 오염물질이 오염/혼합 또는 오염/혼합이 예상되는 경우 임상시험기관의 | 증례기록서(예시) | a+b | a+b |\n| 7.1. 임상시험용 의료기기 사용 목적 | 11.1. 관찰항목(임상시험 일정표) | (3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의 문제점을 | - 본 연구에 참여함으로 인하여 혈액을 채취하게 되므로 그 과정에서 약간의 통증 | 아래 귀하의 서명은 이 연구에 참여함을 허락하며 귀하의 혈액이 이 연구목적을 | 검사법이 사용되고 있다. 특히 VerifyNow는 검사자의 숙련도에 영향을 받지 않고 | (2) 예상치 못한 결과 값이 도출된 경우, 부적절한 혈액 채취 여부 또는 부주의, | 7) 성능 | 2) 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군 | 수 산출 근거’ 항에 기재하였으며, 유의수준 5%, 검정력 80%, 예상되는 차이 | 임상시험에 대한 사항을 확인할 수 있도록 해야 한다. | ④ 메인화면에서 “Start”버튼을 클릭하면 “Chip Selection”화면이 나타난다. | 혈소판 기능부전이 의심되는 환자 및 aspirin, clopidogrel 복용 예정 환자에서 | Aspirin 복용 전후에 대한 시험시약의 민감도 및 특이도를 산출한다. 신뢰도 | 2) 특이도: 대조기기 정상 결과 검체 중 시험기기에서 정상 결과를 보인 검체의 | 보관하여야 한다. | 수행한다. | 특이도 8.9%이었다. P2Y12 test는 평균 민감도 72.9%, 평균 특이도 74.1%이었고, | 하였으며 오차범위는 ±5% 설정하였다. | 추가적인 정보가 필요한 경우 제조원에 요청한다. | □ YES | 피험자 이니셜(영문) | 피험자식별코드 | 피험자 방문일 (YY/MM/DD) | 피험자 이니셜(영문) | 피험자식별코드 | 피험자 방문일 (YY/MM/DD) | 특이도가 기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인 | 약물반응 양성 |         | a+b |\n| 2. Paniccia R, Antonucci E, Gori AM, et al. Comparison of different methods to evaluate the | - 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로 | - 성능 평가 기준: 해당 의료기기의 임상시험에 따른 성능(유효성)평가는 사용된 | - 이상사례에 대한 인과관계 평가기준 | 및 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시함. | 1) 검정색 볼펜을 사용하여 기록하여 주십시오. | 피험자 제공 | □ 뇌졸중 □ 기타: | (True Positive) | (True Positive) | of platelet function disorders and von Willebrand | (False Positive) | (False Positive) |\n| 나. 체외진단용 의료기기 1, 2 등급 허가·심사 및 신고서 작성 가이드라인 | (1) 관련 규격 | * 피험자의 선정기준/제외기준 · 인원 및 근거 | 피험자의 모집기간, 임상관찰 및 시험수행 기간, 통계처리 기간, 결과보고서 작성 | 임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 등을 제시함. | 시험 책임자는 의료기기법 시행규칙 제24조제1항제4호의 규정에 따라 임상시험 | 임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상사례 등에 대하여 임상 | 기록서(Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험 | (1) 연구가설 | - 적용 계산식 :  |     | (True Positive) | (False Positive) |\n| - 의료기기 임상시험기관은 「의료기기 임상시험기관 지정에 관한 규정」(식품 | 검체를 준비한다. | - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | (4) 시험 조건 | 항목을 제외한다. | 시험기기 | 준비된 동일 시료를 반으로 나누어 시험시료와 대조시료로 분리한다. | 시험기기 | 2 | 혈액주입구 | 지지체 | ○○○ | 1개 | 및 혈소판 기능 이상 검체를 각각 최소 50개 이상 준비한다. 각 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 | Approved Guideline | 한계치와 내열성 시험에 관한 요구사항이 적용된다. | 임상검체 폐기절차에 따라 즉각 폐기한다. |\n| (1) 관련 규격 | - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람으로서, | 제조업자 또는 수입업자가 해당됨. 의뢰자는 임상시험모니터 요원을 지정하여야 함. | 이상사례 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상시험의 진행이 | 시험기기 | 또는 간호사 등으로서 임상시험기관의 장이 지정한 자를 말함. | n = 99.96 | n = 125.44 | □ ‘이상 의료기기’의 반응 |\n| 임상시험 방법은 해당 의료기기의 각 구성품에 대한 형상, 구조 및 사용 전 준비 | 2) 가능하면 약어의 사용을 피하고 Full term으로 기록하여 주십시오. | effect of aspirin on platelet function in high-risk patients with ischemic heart disease | 서명일자를 직접 적어야 합니다. |\n| 나. 혈소판 약물반응검사 | 위해 사용될 것임을 의미합니다. | 손쉽게 검사를 할 수 있기 때문에 널리 사용되고 있다. | 나. 혈소판 약물반응검사 | (2) 인구학적 조사, 병력조사 요법 | 나. 처리 할당 방법: 단일눈가림 | EPI test | 84.5% | 85.6% | - 이상사례(의료기기이상반응, 중대한 이상사례/의료기기이상반응 포함)의 발생 | (2) 제품의 변경 및 변형은 허용되지 않는다. | 10%로 가정하였다. | 제품의 특성에 따라 자율적으로 설정이 가능함 | 기술 하는 것을 말함. | ※ 카트리지(시약)의 분석적 성능을 기재한다. | ⑤ “Chip Selection”화면에서 검사 종류에 따라 해당하는 아이콘을 클릭한다. | ② 검사칩 | 95% 구간에서 민감도 80%, 특이도 95%, 로 설정한다. | 모든 의료기기를 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능평가 | 적극적으로 대응한다. | 점검 및 진행사항 관리를 위한 목적으로 피험자의 기록을 열람할 수 있다. | 25℃)에서 2시간 이내 검사를 시행하고 그 결과를 데이터 수집용지에 기록한다. |\n| 예시) | - 해당 임상시험용 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며 | - 피험자(Subject)란 임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되 | 기간, 임상시험심사위원회 심사기간 등 충분한 기간을 고려하여 “식품의약품안전 | 을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화 할 때, 헬싱키선언에 | 임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료방법 등을 | 시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을 제공 | 책임자의 이력사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는 | (2) 유의수준 |\n| 해당 임상시험용 의료기기(체외진단용 시약)의 성능 및 유효성 평가를 위하여 | (가) 「의료기기의 전기 | 의약품안전처 고시)에 따라 식품의약품안전처장으로부터 의료기기 임상시험 | 기계적 안전에 관한 공통기준규격」(식품의약품 |\n| (5) 시험 방법 | 가. 분석적 민감도 | - 임상시험용 해당 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용할 경우 | 피험자의 안전보호를 위협하여 그 진행을 멈추는 것을 “중지”라 하며, 임상시험 | 각 로트 별로 검체에 대한 이동거리를 3회에 걸쳐 반복하여 측정한다. | (바) 유체로 인한 위해요인 방지 : IEC 61010-1의 11절에 기술된 유체로 | (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제 | 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시하기에 충분한 | - 시험물질 |\n| 사항/피험자에 대한 준비 등 임상시험을 위한 준비절차와 사용 단계 절차의 각 | 임상시험모니터 요원의 선정, 자격기준, 수행임무 등에 대한 사항을 의료기기 |\n| 예시) | 예시) | 기능 이상을 감별하는데 중요한 검사이다. 최근에는 심혈관 질환의 치료 및 예방에 | - 임상시험용 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’의 안전성과 유효성을 | 1) Aspirin test: 혈관질환의 위험군, 혈관질환 병력 등으로 aspirin 복용 예정인 | 임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력 등에 대하여 면담, | 2) ADP test:　정상인 및 혈소판기능저하가 있는 환자의 검체에 대해 시험기기 | - 시험 책임자 및 임상시험 관련자가 개인 식별 표기를 가린 후 검사자에게 검체를 | 보존된 검체 및 조사된 자료는 폐기하도록 요청하실 수 있으며 이 경우 이미 | 3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다. | 시험자는 본 임상시험 계획서에 서명함으로써, 국내의 법규와 윤리적 측면에서 |\n| - 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의 일반적인 사항, | 근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서 | 제공하여 원칙과 절차를 수립하여 제시함. 피해자 보상에 대한 규약에는 보상 | 어 임상시험에 참여하는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄 | 기준을 제시함. 그밖에 임상시험결과의 사용 범위에 따른 성능평가를 위하여 | 시 의료기기 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에 의거, 정한 |\n**측정하는 변수를 구체적으로 명확히 기술하며, 관찰항목 및 임상검사항목, 관**\n| 2. 인체 유래물이란? | 함께 관리함. 임상시험용 의료기기를 관리하는 관리자의 성명, 소속 기관명 및 |\n| 12.1 예측되는 부작용 | 개시에서 완료까지 중지 될 수 있는 세부사항을 “중지 기준”에 제시함. “중지 | 가속노화시험 개시 시점과 설정된 마지막 시점에 측정을 실시한다. | 검체 당 5∼10회 이상 반복 측정한다. 정상 검체의 이동거리와 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 | 정하고 낮은값 부터 3일 동안 검체 당 최소 60회 이상 반복 |\n| 19.4. 의뢰자 | 단계별 조작 순서, 병용 요법 등을 기술함. 임상 시험을 위한 피험자 동의 및 준비, | 혈소판 기능부전 검출 및 aspirin, P2Y12 수용체 저해제를 복용하는 환자에서 | ② ISO 23640 In vitro diagnostic medical devices – Evaluation of | 것이지만 증상이 지속될 경우 관련 진료 후 필요한 치료를 받으실 수 있습니다. | 연구에 사용된 정보와 자원을 제외하고 모든 잔여 검체 및 자료는 적법한 절차에 | 상세히 설명한다. 서명일 및 서명일자를 정확히 기재하여야 하며 작성된 서명 | Clopidorel 복용 전후에 대한 시험시약의 민감도 및 특이도를 산출한다. 신뢰도 | 공여자의 MD 또는 MR은 검사실의 참조 범위의 중간에 가까운 값과 허용 | 환자에서 aspirin 복용 전 1번과 최소 3일 이상의 Aspirin 복용 후 1번 측정 |\n| 19.1. 임상시험 실시기관 | 서식, 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 함. | ② 침습적 방식의 출혈시간(Bleeding time, BT)검사는 개인별 차이가 | 격한 피험자의 선정기준과 제외기준을 제시하여야 함. 이때 임상시험 참여와 | 이차 유효성 평가변수를 제시하여 각 임상검사항목 및 검사방법에 대한 기준을 제시함. | 기간 내에 가능한 신속한 보고가 되어야하며, 이상사례 등에 대한 의학적 | 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 또는 디자인 |\n| 찰검사방법(선정검체 피험자 식별코드부여, 임상평가, 이상반응조사, 관찰항목 | 원칙과 보상이 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함함. | 5) 자료를 기록할 수 없는 경우 “실시하지 않음(ND: not done)”또는 “알 수 없음(UK: | (가) 전자파내성 : IEC 61326에 기술된 전자파 내성시험에 관한 요구 |\n| 예시) | - “인체 유래물”이란 인체로부터 수집하거나 채취한 조직, 세포, 혈액, 체액 등이나 | - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를 |\n| 1) 혈액검체 채취를 위한 채혈 과정에서 통증, 신경손상, 어지럼증, 메스꺼움, 구토, | 처리”에는 각 중지 기준에 대한 유효성 평가 통계처리 시 그 산입 여부와 |\n| 예시) | (1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로 통상의료기기 | 치료 및 수술 절차, 관찰 및 평가 절차 등을 상세히 시험방법을 기술함 | 경향의 증가나 약제 내성에 대한 검사를 위해서도 많이 이용되고 있다. | 측정된 각 시점의 샘플의 이동거리값의 평균 및 표준편차를 계산 한다. | (3) 시험 목적 : 결과에 영향을 주는 간섭물질을 확인하기 위한 시험 | 출혈시간 및 항혈소판제제 저항성 복합검사기기에 대한 보정과 정도 | ① 검사칩을 임상시험용 장비의 Tray에 놓고, 끝까지 밀어 넣는다. Tray 에 심한 | 간섭물질이 포함된 검체와 포함되지 않은 검체를 3회 이상 반복 측정한 | ① 정상 대조군: 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군 |\n| 예시) | 예시) | 민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d) | Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | (1) 임상시험실시기관의 장은 해당 임상시험의 실시에 필요한 임상시험실, 설비와 | 가. 임상시험용 의료기기의 사용 및 관리 | - 성능평가방법: 임상시험 기간 동안 일차/이차/ 유효성 평가변수에 대한 | 소견·정도와 임상시험용 의료기기와의 인과관계를 평가하여 증례기록서에 | 특성, 원자재 및 화학적 구성요소, 성능, 새로운 제조방법 등에 대한 특이성을 |\n| Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | 별 평가도구, 평가방법 등) 및 결과판정 방법을 해당 임상시험방법의 진행순서 | 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행 | 이 규약에는 피험자 보상사유, 보상요건, 보상 제외사유, 보상기준, 보상절차, | (5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이 (및 표준편차): 피험자 수는 | 연관된 이익을 기대하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될 |\n**또는 이들로부터 분리된 혈장, 혈청, 핵산, 단백질 등을 말합니다. 본 동의서에서는**\n| 부터 6개월 | 피험자별 중지사유를 포함한 관련 임상시험자료의 처리방법을 제시함. 또 “탈락” | 담당하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상 |\n| 예시) | 6. 연구에 참여함으로써 기대되는 이익 | 혈소판 기능검사 방법으로는 피부에 상처를 낸 후 출혈이 멈출 때까지의 시간을 | 되는 환자 및 항혈소판제제에 대한 약물 저항을 보이는 환자를 확인할 수 있다. | 1) 품목명(품목분류번호)/모델명: (구체적이지 않을 시 중분류명 기재) | 3) SIPA test:　정상인 및 혈소판기능저하가 있는 환자의 검체에 대해 시험기기 | 한 임상시험 계획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에 대하 | · 미개봉시 2-8°C 보관, 제조일로부터 12개월· 개봉시 실온보관, 개봉시부터 4시간 | 검사칩을 장착할 때마다 또는 시스템 성능의 검증이 필요할 때마다 대조 검체 |\n| 가. 임상시험 실시기관 | 가. 의뢰자 | Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | 본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 병원에서 진행하던 치료 | (6) 결과 제시 : 가속노화 시작시점과 시험 마지막 시점 결과의 차이를 구한다. | 개봉 후 검체에 대한 이동거리를 3회에 걸쳐 반복하여 측정한다. | 기록하여야 함. 따라서 이상사례에 대한 임상시험용 의료기기와의 인과관계에 |\n| * 각 모델명별로 구분하여 기재한다. | 대로 기재하되, 대조군 및 확인군이 있는 경우 해당 임상시험용 의료기기(시험 | 규칙 [별표 3])에서 정하고 있음. 이에 따른 피험자 동의서 서식을 제시하여야 | 불이익을 우려하여 자발적인 참여 결정에 영향을 받을 소지가 있는 등, 취약 |\n| 마. IEC 61326-1 Electrical equipment for measurement, control and laboratory | - SIPA test: 사람의 구연산 처리된 전혈에서 폐색 전 혈액이동거리 측정법으로 |\n| - 대상자 모집기간 및 임상시험 수행 기간 : 약 4 개월 | 예시) | 이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상시험이 | 시험에 관여하는 사람을 말하며, 각 임상시험기관의 적절한 임상시험의 수행을 | ① 정전기방전(Electrostatic Discharge, ESD) 시험 : IEC 61000-4-2에 |\n| 가. 의료기기 관리자 | - 이 연구의 참여로 귀하에게 직접적으로 기대되는 이익은 없으나, 이 연구를 통해 | (성명) | (서명) | (날짜) | 년 | 월 | 일 | 임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급, 저장하며 “임상 |\n| 14.2. 유효성(성능) 평가방법 | 9. 개인정보 보호 | (3) 증례기록서 등 임상 시험에 관련된 모든 서류에는 피험자 이름이 아닌 피험자 | 측정하는 고식적 방법인 출혈시간과 혈소판의 응집능만을 검사할 수 있는 혈소판 | - 통계분석에 의한 평가방법: 통계분석방법에 따른 통계적 유의성에 대해 평가 | (2) 이 검사는 개인 환자 또는 헌혈자로부터 얻은 검체를 사용하도록 설계되었다. | ③ 병용약물 : 아스피린, P2Y12 수용체 억제제 등의 항혈소판제제, 항응고제 치료 유무 | 공여자를 중복해서 검사할 것을 권장한다. 평균 MD 또는 MR이 개별 검사실 |\n| 하며, 피험자 설명서에는 동 기준의 제7호아목의10)을 포함하여야 함. | (아) 구성요소 : IEC 61010-1의 14절에 기술된 구성요소에 관한 요구 | 한 환경에 있는 피험자(Vulnerable Subjects)는 선정대상에서 제외함. 또한, | 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과를 | 정상 검체의 이동거리 구간과 혈소판 기능 이상 검체 이동거리 구간을 |\n| 예시) | (3) 시험 목적 : 혈소판 기능이상 검사 키트가 특정 조건하에서 사용기간 | 군)의 기술 형태와 마찬가지로 대조군 및 확인군 해당 항목별로 순서에 따라 |\n| - 통계처리 기간 : 약 1 개월 | 10.1.1. 시험기기 대조기기 정보 | 완료되지 못한 경우를 말하며, 그 분류기준을 “탈락 기준”에 탈락의 사유와 관 |\n| 예시) | 시험용”이라는 문구가 있어야한다. 임상시험용 의료기기 관리자는 임상시험에 |\n| 한다. | 응집검사, 혈소판과 함께 본빌레브란드인자의 기능을 함께 측정할 수 있는 PFA-100, | (주) ○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○-○○○-○○○○ | 에서 설정된 진단경계치 범위 내에 속하는 경우, 검사칩이 완전하게 기능하는 | 검사를 시행한다. (SIPA test는 검사원리가 비슷한 기존검사법은 없으나, |\n| 4) 형상: | 방법과 기준을 제시함. 의료기기기술문서 등 심사에 관한 규정에 따라 임상시험을 | 1) 민감도: 클로피도그렐 투약 후 검체 중 최종 약물반응 양성 결과를 보인 |\n| 나. 개봉 후 안정성평가 | 6.1. 목적 | 예시) | 3. 연구의 목적 | 성명 | 소속 기관명 | 전공 | 직위 | 전화 | 개별 기술한다. | 법정 대리인(필요 시): | 설정된 3 포인트에서 차례로 이동거리를 3회에 걸쳐 측정한다. | 2. 판정 기준치(Cut-off value) | 제공할 수 있다. | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 |\n| - 결과보고서 작성기간 : 약 1 개월 | 예시) | 시험기기: 출혈 시간 및 항혈소판제제 저항성 복합검사기기 | 가. 혈소판 기능검사 | 사용되는 의료기기에 대해 인수, 재고관리, 반납 등의 업무를 수행하고 관련 |\n| 13.1.2. 중지 처리 | ADP test | 84.0% | 81.0% | 련 임상자료의 처리방법을 “탈락 처리”에 구체적으로 제시함. | 가. Aspirin test | 기기에 의존하고 있는 상황이고 국내 개발 제품은 없는 상태이다. |\n| 해당 임상시험은 전혈 검체를 이용한 체외진단용 의료기기의 임상적 유효성 평가를 | (3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수, 임상시험의 종류와 | 2) 채혈 이후에는 채혈된 전혈 검체만을 사용하는 체외진단 검사이므로 예측되는 | 전반적인 응고과정을 측정하는 thromboelastography 등이 있다. 이 외에 혈소판의 | ○○○ | ○○○병원 | ○○○○ | ○○○ | ○○-○○○-○○○○ | ⑤ PT, aPTT 결과 | 1. 혈소판 기능검사 | 2) 선정/제외기준 | 1) 혈소판 기능검사: 시험기기와 대조기기(LTA, PFA-100)에서 검사를 시행한다. | 가. EPI test | 또한 궁극적으로는 혈소판 기능 또는 혈소판 약물 저항성을 확인하는 장비의 | 개인 식별정보 및 건강에 관한 정보 등)를 수집하게 됩니다. 이렇게 수집된 개인 | ③ “Kit Information”에 ID(환자정보)를 입력하고 “Save”버튼을 눌러 저장한다. |\n| 19.2. 임상시험심사위원회 | 실시하는 병원은 2군데 이상이어야 한다. 기관에 따라 임상시험결과에 차이가 | use – EMC requirements – Part 2-6: Particular requirements – In vitro |\n| 나. 모니터요원 | 1. 피험자 안전성(해당사항 없음) | - 혈소판 기능에 관한 검사는 주로 선천성 혈소판 기능 이상이나 수술전 선별검사로 | ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’의 민감도 및 특이도, 일치도 | 1) 잘못 기입된 부분은 한 줄로 긋고, 수정날짜(YY/MM/DD)와 수정자 서명, 필요시 수정 | equipment for measurement, control and laboratory use–Part 2–101: |\n| (1) 관련 규격 | - 의학통계전문가, 의료기기전문가 등 공동연구자가 있을 경우 이를 포함하여 | 예시) | Collagen/ADP Test cartridge Dade PFA Trigger solution February 7, 1997 | (6) 결과 제시 | 결합 | 정도를 | 폐색 | 전 | 혈액이동거리 | 측정법으로 | 정성하여 | 아데노신이인산 | (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제 |\n| 예시) | 1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지 시킬 수 있다. | 대조기기 | 1) 민감도: 아스피린 투약 후 검체 중 최종 약물반응 양성 결과를 보인 검체의 | 마자 실신할 수도 있고 단순히 피 또는 주사침을 보는 것만으로도 쓰러질 수 있다. |\n| 8.2. 피험자 제외기준 | 목적으로 하는 임상시험으로 피험자에게 발생할 피해가 없으므로 피험자 보상 규정은 | (4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이 반드시 필요한 | 19.9. 기록의 보존 | 활성화 여부를 유세포분석기를 이용하여 검사하거나, 특정 항혈소판 약제에 대한 | (3) 피험자 식별코드 부여 | (2) 대조기기 | (성명) | (서명) | (날짜) | 년 | 월 | 일 | 정보는 관련 법규에 따라 엄격하게 관리되며 연구에 관련된 담당자만이 수집된 | 수리 후 공인된 기사나 병원의 안전관리자에 의해 제품의 안전을 확인한다. |\n**있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 차이를 보정할 수**\n| 6. FDA K042423: 510(k) summary. Accumetrics VerifyNow-Aspirin Assay | 평가를 통한 임상적 유효성 평가 | 해당 임상시험은 전혈 검체에 대한 체외진단용 의료기기의 임상적 평가에 대한 | 많이 사용되고 있습니다. 특히 혈소판의 수적 이상이 없는 출혈질환에서 선천성 | 2) 특이도: 클로피도그렐 투약 전 검체 중 최종 약물반응 음성 결과를 보인 |\n| 예시) | 가. 환자 및 대조군 내원시에 아래 11.2. 임상시험 절차에 따라 임상시험을 시행한다. | 회사명 | 성명 | 소재지 | 전화 | 105명 이상, ADP test 양성(비정상 결과) 환자 105명 이상, ADP test 음성(정상 |\n| 1) 혈소판 기능검사: light transmission aggregometry (LTA) 검사, PFA-100Ⓡ | ① 「의료기기의 안정성시험 기준」(식약처 고시) | 한다. | (5) 시험 방법 | (mimic)을 제조하여 제공 또는 각 검사실에서 설정하는 방법 등을 | 각각의 검체 및 시약 로트 조합을 측정장비로 반복 측정한 샘플의 | 처음으로 유발될 수도 있지만 과거력이 있는 경우도 있다. 어지럽고 메스껍고, | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈 |\n| 사. ISO 23640 In vitro diagnostic medical devices – Evaluation of stability of | 가. 혈소판 기능검사 | 7.3. 임상시험용 의료기기 사용방법 | 없음. | (1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록 하여야 하며 보안을 | 반응을 검사하는 VerifyNow와 같은 기기들도 사용되고 있다. 하지만 기기에 따라 | 가. 공통 제외기준 | (4) 시험 조건 | 동의서 버전 또는 버전 날짜: | Version  _________________  date ______________ | ① 임상시험 참여에 동의하고 인구학적 조사, 병력 문진 등을 통하여 피험자 선정 | 진단에 많은 도움을 줄 수 있습니다. | ④ 메인화면의 “Camera”탭에서 검사칩의 현재 모습, “Log”탭에서 현재 검사 | 및 제외기준을 검토하여 피험자 식별코드를 부여한다. 피험자 식별코드는 아래의 | 절차를 반복한다. 두 검체의 평균 MD 또는 MR이 진단경계치 범위 내에 | ① 정상 대조군: 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군 |\n| 나. 임상시험용 의료기기의 공급과 취급 | (주) ○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○-○○○-○○○○ | 혹은 후천성 혈소판 기능 이상을 감별하는데 중요한 검사입니다. 최근에는 심혈관 |\n| 임상시험으로 피험자가 직접적으로 받는 인체의 위해도가 없어 예측되는 부작용에 | (1) 혈소판 기능검사 | 결과) 대조군 132명 이상, SIPA test 양성(비정상 결과) 환자 105명 이상, SIPA |\n| (2) 국내외 개발동향 | 2) 혈소판 약물반응검사: VerifyNowⓇ | 얼굴이 창백해지고 이 나며, 맥박수가 줄어들고, 혈압이 심하게 떨어지며, 심하면 |\n| 예시) | 12.2 사용상의 주의사항 | 민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d) | 혈소판 기능 부전이 의심되는 환자의 구연산 처리된 전혈에서 혈소판 기능부전 | (2) 해당 의료기기의 사용목적：혈소판 약물반응 검사 | 1) 검체준비 및 저장방법 | (6) 결과 제시 : 개봉시점과 각 시점 간 시험결과의 차이를 구한다. | 연구 제목: | 출혈 시간 및 항혈소판제제 저항성 복합검사기기(제품명: 000)의 정확도 검증을 위한 | - 피험자의 임상정보를 알 수 없는 경우 | ② ISO 23640 In vitro diagnostic medical devices – Evaluation of | (차) 시험 기기와 측정기기 : IEC 61010-1의 16절에 기술된 시험 기기 | 제시할 수 있다. | 2) 특이도: 대조기기 정상 결과 검체 중 시험기기에서 정상 결과를 보인 검체의 | 2) 특이도: 아스피린 투약 전 검체 중 최종 약물반응 음성 결과를 보인 검체의 | 유지하도록 한다. 제조허가·수입허가 또는 그 변경허가를 위한 임상시험 관련 | (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제 | 3.2% | 구연산 | 처리된 | 전혈 | 검체에 | 분석대상물질(Agonist | 또는 | 이동거리값의 평균 및 표준편차를 계산하고 시험시료 측정결과의 | (3) 시험 목적 : 출혈시간 및 항혈소판제제 저항성 복합검사기기의 | 속하는 경우, 첫 번째 공여자의 혈소판 기능 상태 및 약물 복용 기록을 의심 | 1) Aspirin test: Aspirin 약물 복용 전/후의 검체에 대해 시험기기 및 대조기기인 | 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우 2개 | 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상 준비 | 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상 준비한다 |\n| P2Y12 Assay | - 시험물질 |\n| (1) 의뢰자는 임상시험계획서에 대한 임상시험심사위원회와 식품의약품안전처장의 | * 피험자 수: 시험대상수 산출시 일반적인 고려사항 | 연구자: | 질환의 치료 및 예방에 사용되는 아스피린, 클로피도그렐 등의 항혈소판약제로 인한 |\n| 다. 임상시험 수탁업체 | 따른 안전성 평가 및 방법은 따로 기재하지 않는다. | 3) 임상시험을 통해 얻어진 자료는 성능 및 안전성 분석을 위한 데이터가 정해져야 하며, | 본 임상시험은 혈소판 기능부전이 의심되는 환자 및 정상대조군에서 시험기기의 |\n**아. CLSI EP17-A2: Evaluation of Detection Capability for Clinical Laboratory**\n| 가. 시험책임자 | Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | 7. 검체의 처리 및 제공 | 검출을 위해 사용되는 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기-혈소판 | (가) 전 세계 혈소판 기능검사 시장 규모는 2015년 기준 약 100억 달러에 |\n| 예시) | 19.5. 모니터링 | 19.7. 피험자 동의 | 1) 반드시 체외진단용으로 사용해야 한다. | 이용되는 검사 기기의 종류는 많지 않다. | 3. 직선성/측정범위 | - 구연산 처리된 전혈에서 폐색 전 혈액이동거리를 측정하여 혈소판 약물반응을 | (1) 올바른 채혈법을 숙지한 후 채혈을 실시한다. | (3) 검사가 종료될 때까지 기다린다. | - 직전 1개월 내 시행한 검사 결과상 혈소판수가 100x10^9/uL이하인 경우 | ② 피험자 적합성 평가 : 피험자 선정 및 제외기준에 적합한지 평가한다. | - 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순, 예) KFDA-12-34-56 | 자료는 허가일로부터 3년간 보존하도록 하고, 그 밖의 임상시험 관련 자료는 | 한다. 각 검체에 대해 20일간 1일 2회의 반복시험을 실시하여 검체에 | 최소 3개의 로트의 시약을 이용하여 2곳 이상의 검사실 2명 이상의 |\n| - 임상연구에서 연구피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈 |\n**광투과 혈소판응집능검사(light transmission aggregometry, LTA)를 기준검사법**\n| 회사명 | 성명 | 소재지 | 전화 | 2) 잘못 기입된 글자를 overwrite 해서 고치거나 수정액을 사용하여서는 안 됩니다. | 연구책임자: | (성명) | (소속) | (연락처) |\n| 기능검사’의 | 임상적 | 성능을 | 광투과 | 혈소판응집능검사(light | transmission | P2Y12 test | 72.9% | 74.1% | (성명) | (서명) | (날짜) | 년 | 월 | 일 | Assay-TRAP |\n| 14.1. 유효성(성능)의 평가기준 | (1) 모니터링(Monitoring)이라 함은 임상시험 진행 과정을 감독하고, 해당 임상시험이 | (1) 피험자 동의(Informed Consent)라 함은 피험자가 임상시험 참여 유무를 결정하기 | 2) 일반적인 실험실 안전 및 생물학적 위험물질 취급 시 안전 등의 주의사항 | - 귀하의 검체는 관련 법규 및 병원규정에 따라 적절히 처리됩니다. | 광투과 혈소판응집검사(Light transmission aggregometry, LTA)는 현재까지 일차 | 성명 | 소속 기관명 | 전공 | 직위 | 전화 | (5) 제품 손상을 방지하기 위해 제품을 단단한 표면에 떨어뜨리거나 부딪히지 않게 한다. | (2) 바늘 굵기가 21G인 주사기를 사용한다. | (4) 검사가 종료되면 Tray가 밖으로 나온다. | - 직전 1개월 내 시행한 검사 결과상 Hct 35% 이하, 50%이상인 경우 | ③ 피험자 식별코드는 아래의 방법에 따라 기입한다. | 3) 인구학적 정보 : 인구학적 정보로 대상자 이니셜, 나이, 성별 등을 조사한다. | 달성할 때까지 사용하게 되며 수집된 정보는 개인정보보호법에 따라 적절히 관리 | 3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다. | 임상시험이 끝난 날부터 3년간 보존하도록 한다. 다만, 식품의약품안전처장이 | 2）P2Y12 test: Clopidogrel 약물 복용 전/후의 검체에 대해 시험기기 및 대조 | 달한다. 혈소판 기능검사 시장은 매년 10% 이상의 성장률을 보이고 |\n| (2) 적용 범위 : 혈소판 기능검사키트에 적용한다. | (1) | 관련 | 규격 | : | CLSI | EP06-A: | Evaluation | of | the | Linearity | of | (3) 시험 목적 : 혈소판 기능 이상의 양성, 음성의 판정 기준을 선정 | 검출한계로 추정되는 최소 검출 한계 이동거리 값을 기점을 최소 3개 | 검사자로 정상 검체 및 혈소판 기능 이상 검체를 1회 시험 할 때 |\n| 2. 시험자안전성 | (주) ○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○-○○○-○○○○ | 으로 한 민감도 및 특이도를 기허가제품의 민감도 및 특이도와 비교하여 임상적 |\n**피험자에게 직접적인 위해를 발생시키지 않는다. 그러므로 아래 중지기준에 따라**\n| 나. 전자파 안전성 시험 | aggregometry, LTA)를 기준 검사법으로 하여 기허가제품의 민감도 및 특이도와 | ○○○ | ○○○병원 | ○○○ | ○○○ | ○○-○○○-○○○○ |\n| (2) 의뢰자는 임상시험용 의료기기의 인수·취급·보관 및 미사용 의료기기를 피험자 | - 귀하는 귀하의 검체에 대해, 언제까지 보존하도록 허용할 것인지, 다른 사람 또는 | (3) 해당 의료기기 : 혈액응고검사시약과 자동혈소판응집측정장치 | 지혈이상 진단의 가장 중요한 검사방법으로 자리잡고 있으며, 혈소판기능검사의 | 14.1.1. 혈소판 기능 검사 | (1) 검사를 진행하는 곳에서 음식물을 먹거나, 마시거나 담배를 피우지 않도록 한다. | (6) 열, 먼지, 일광(직사광선), 응축(제품 표면에 맺힌 물방울)을 피해 사용하여야 한다. | (3) 항응고제 함유 채혈관(3.2% Na citrate tube)를 준비한다. | (5) Tray에서 검사칩을 조심스럽게 빼내어 제거한다. | - 직전 1개월 내 시행한 검사 결과상 PT, aPTT가 참고치를 벗어난 경우 | 4) 과거병력 및 병용약물 조사 | 지시하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을 연장할 수 있다. | 임상시험 계획서, 표준작업지침서, 임상시험 실시기준 및 관련 규정에 따라 실시, |\n| (3) 시험 목적 : 제조자가 채택한 구조의 설계와 방법이 조작자와 주위에 | 장비 | 혈소판 기능검사 | 혈소판 기능부전 검출 및 아스피린, 클로피도그렐와 같은 항혈소판제제에 대한 |\n| 임상시험용 의료기기인 체외진단용 의료기기는 인체 유래물질을 포함하고 있지 | (3) 시험 목적 : 혈소판 기능검사키트가 특정 조건하에서 사용 시 안정성을 | 유효성을 검증하는 것이 목적이다. | 이상 정하고 낮은 값부터 3∼5일 동안 검체 당 5∼10회 이상 반복 측 | ① 혈액주입구: 검사칩(test kit)에 혈액(전혈)을 로딩하는 주입구. 검체량은 400㎕이다. | Quantitative Measurement Procedures; A Statistical Approach; |\n| 본 임상시험의 일시중지 후 재개 가능하다. | 연구담당자: | (성명) | (소속) | (연락처) | - 시험장비 |\n**미주신경이 반사적으로 작용하여 뇌혈류를 감소시키고 심장 박동을 감소시켜**\n| 나. 시험담당자 | 비정상 유무를 판정하기 위한 목적은 ADP test와 동일하므로, ADP test의 평가기 | 5) 적용상의 주의 | 비교 평가하기 위한 다기관, 비무작위배정, 단일눈가림, 단일설계, 전향적 비교 | (4) 임상시험 평가내용 : 민감도 및 특이도, 일치도 | 표준으로 사용되고 있다. 검사원리는 전혈에서 혈소판풍부 혈장을 분리한 후 혈소판 | (1) 관련 규격 | (2) 검체와 시약을 다룰 때에는 일회용 장갑과 검사용 가운을 착용하도록 한다. | (4) 검체는 실온(15~25℃)에 보관한다. | (6) 메인화면의 “Result”탭을 확인하여 검사에 대한 정보를 검토한다. 검사에 대한 | - 항응고제 치료중인 환자 | 출혈성 질환, 응고장애, 암, 기타 만성질환 등의 병력 및 | 아스피린, P2Y12 |\n| 가. EPI test | 약물 저항성을 확인하는 기기로, 본 연구를 통해 ‘출혈 시간 및 항혈소판제제 |\n**기계적으로 적절하게 보호를 하고 있다는 것을 보증함에 있다.**\n\n**[표 끝]**\n\n<!-- PAGE_18 -->\n###### (나) IEC 61010-1: 2010 Safety requirements for electrical equipment\n\n<!-- PAGE_18 -->\n###### for measurement, control, and laboratory use–Part 1: General\n\n<!-- PAGE_18 -->\n###### (다)\n\n<!-- PAGE_18 -->\n###### IEC\n\n<!-- PAGE_18 -->\n###### 61010-2-101:\n\n<!-- PAGE_18 -->\n###### 2015\n\n<!-- PAGE_18 -->\n###### Safety\n\n<!-- PAGE_18 -->\n###### requirements\n\n<!-- PAGE_18 -->\n###### for\n\n<!-- PAGE_18 -->\n###### electrical\n\n<!-- PAGE_18 -->\n###### Particular\n\n<!-- PAGE_18 -->\n###### requirements\n\n<!-- PAGE_18 -->\n###### for\n\n<!-- PAGE_18 -->\n###### in\n\n<!-- PAGE_18 -->\n###### vitro\n\n<!-- PAGE_18 -->\n###### diagnostic\n\n<!-- PAGE_18 -->\n###### (IVD)\n\n<!-- PAGE_18 -->\n###### (2) 적용 범위 : 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데\n\n<!-- PAGE_18 -->\n###### (4) 시험 항목\n\n<!-- PAGE_18 -->\n###### (가) 전기충격에 대한 보호 : IEC 61010-1의 6절에 기술된 전기충격\n\n<!-- PAGE_18 -->\n###### (나) 기계적 위해요인에 대한 보호 : IEC 61010-1의 7절에 기술된 기계적\n\n<!-- PAGE_18 -->\n###### (다) 충격과 충돌에 대한 기계적 내성 : IEC 61010-1의 8절에 기술된\n\n<!-- PAGE_18 -->\n###### 충격과 충돌에 대한 기계적 내성에 관한 요구사항이 적용된다.\n\n- - 12 -\n<!-- PAGE_19 -->\n###### (라) 화재 확산 방지 : IEC 61010-1의 9절에 기술된 화재 확산 방지에\n\n<!-- PAGE_19 -->\n###### 관한 요구사항이 적용된다.\n\n<!-- PAGE_19 -->\n###### (사) 유리가스, 폭발, 파열에 대한 보호 : IEC 61010-1의 13절에 기술된\n\n<!-- PAGE_19 -->\n###### (자) 연동 장치에 의한 보호 : IEC 61010-1의 15절에 기술된 연동 장치에\n\n<!-- PAGE_19 -->\n###### (가) 「의료기기의 전자파 안전에 관한 공통기준규격」(식품의약품안전처고시)\n\n<!-- PAGE_19 -->\n###### (나) IEC 61326-1: 2012 Electrical equipment for measurement, control and\n\n<!-- PAGE_19 -->\n###### laboratory use -\n\n<!-- PAGE_19 -->\n###### EMC requirements – Part 1: General requirements\n\n<!-- PAGE_19 -->\n###### (다)\n\n<!-- PAGE_19 -->\n###### IEC\n\n<!-- PAGE_19 -->\n###### 61326-2-6:\n\n<!-- PAGE_19 -->\n###### 2012\n\n<!-- PAGE_19 -->\n###### Electrical\n\n<!-- PAGE_19 -->\n###### equipment\n\n<!-- PAGE_19 -->\n###### for\n\n<!-- PAGE_19 -->\n###### measurement,\n\n<!-- PAGE_19 -->\n###### control and laboratory use – EMC requirements – Part 2-6:\n\n<!-- PAGE_19 -->\n###### Particular requirements – In vitro diagnostic (IVD) medical\n\n<!-- PAGE_19 -->\n###### equipment\n\n- - 13 -\n<!-- PAGE_20 -->\n###### (2) 적용 범위 : 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데\n\n<!-- PAGE_20 -->\n###### 사용되는 체외진단용 분석기기에 적용한다.\n\n<!-- PAGE_20 -->\n###### (3) 시험 목적 :\n\n<!-- PAGE_20 -->\n###### 전자 의료기기에 전자파로 인한 전자파장해와 전자파\n\n<!-- PAGE_20 -->\n###### ② 방사성 RF 전자기장 시험 : IEC 61000-4-3에 기술된 방사성 RF\n\n<!-- PAGE_20 -->\n###### (나) 전자파방사 : IEC 61326에 기술된 전자파 방사시험에 관한 요구\n\n- - 14 -\n<!-- PAGE_21 -->\n###### 6. 분석적 성능 평가 항목\n\n※ 아래 제시하는 시험항목 등은 식약처장이 인정한 규격(KS, ISO 등)을 참고한 것으로, 관련 규격이\n\n<!-- PAGE_21 -->\n###### (1) 관련 규격 : CLSI EP17-A2: Evaluation of Detection Capability\n\n<!-- PAGE_21 -->\n###### ※ 관련 규격을 적용할 수 없는 경우, 제조원에서 설정한 측정범위를\n\n<!-- PAGE_21 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_21 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n- - 15 -\n<!-- PAGE_22 -->\n###### (5) 시험 방법 : 3.2% 구연산 처리된 전혈 검체에 분석 대상 물질\n\n<!-- PAGE_22 -->\n###### (Agonist or Antagonist)을 일정량 첨가하여 공란한계(LoD)와\n\n<!-- PAGE_22 -->\n###### 검출한계(LoD)에 해당하는 이동거리의 검체를 각각 4개 이상\n\n<!-- PAGE_22 -->\n###### 준비한다. 검출한계로 추정되는 이동거리 기점을 최소 3개 이상\n\n<!-- PAGE_22 -->\n###### (6) 결과제시 : 측정된 공란한계값과 검출한계값의 통계적 수치를 이용\n\n<!-- PAGE_22 -->\n###### (1) 관련 규격 : CLSI EP12-A2; User Protocol for Evaluation of\n\n<!-- PAGE_22 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 사람의 전혈 검체\n\n<!-- PAGE_22 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n- - 16 -\n<!-- PAGE_23 -->\n###### - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대\n\n<!-- PAGE_23 -->\n###### (5) 시험 방법\n\n<!-- PAGE_23 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 사람의 전혈 검체\n\n<!-- PAGE_23 -->\n###### 검체에 대한 검사를 실시하여 검체에 대한 이동거리를 구한다.\n\n<!-- PAGE_23 -->\n###### 확인 한 후 정상값과 비정상값의 통계치의 95% 신뢰구간을 구하여 두\n\n<!-- PAGE_23 -->\n###### ※ 관련 규격을 적용할 수 없는 경우, 제조원에서 설정한 측정범위를\n\n<!-- PAGE_23 -->\n###### (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제\n\n<!-- PAGE_23 -->\n###### ※ 해당 성능항목은 적용하지 않는 경우, 그 사유를 제시하여 적용\n\n- - 17 -\n<!-- PAGE_24 -->\n###### (3) 시험 목적 : 출혈시간 및 항혈소판제제 저항성 복합검사기기의\n\n<!-- PAGE_24 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n<!-- PAGE_24 -->\n###### 측정된\n\n<!-- PAGE_24 -->\n###### 최소\n\n<!-- PAGE_24 -->\n###### 이동거리값을\n\n<!-- PAGE_24 -->\n###### 기준으로\n\n<!-- PAGE_24 -->\n###### 분석대상물질(Agonist\n\n<!-- PAGE_24 -->\n###### 또는\n\n<!-- PAGE_24 -->\n###### Antagonist)을 일정한 비율로 첨가하여 직선성을 보이는 구간을 구\n\n<!-- PAGE_24 -->\n###### (6) 결과제시 : 각 측정값에 대한 직선성을 직선회귀분석을 통해 평가\n\n- - 18 -\n<!-- PAGE_25 -->\n###### 나. 분석적 특이도(간섭물질)\n\n<!-- PAGE_25 -->\n###### (1) 관련 규격 : CLSI EP07 Interference Testing in Clinical Chemistry\n\n<!-- PAGE_25 -->\n###### 간섭물질은 내부 또는 외부 요인일 수 있고 측정법에 따라 다양하므로,\n\n<!-- PAGE_25 -->\n###### 검사법에 따라 결과에 영향을 미칠 것으로 예측되는 다음과 같은 물질에\n\n드물지 않게 볼 수 있는 특이\n\n- - 19 -\n<!-- PAGE_26 -->\n###### (5) 시험 방법\n\n<!-- PAGE_26 -->\n###### 간섭물질의 농도는 임상검체에서 보일 수 있는 최대 농도의 3배\n\n<!-- PAGE_26 -->\n###### 평균과 대조시료 측정결과 평균의 편차를 계산한다. 대조시료 대비\n\n<!-- PAGE_26 -->\n###### 다. 정밀도\n\n<!-- PAGE_26 -->\n###### 1. 반복성\n\n<!-- PAGE_26 -->\n###### (1) 관련 규격 : CLSI EP05-A3: Evaluation of Precision of Quantitative\n\n<!-- PAGE_26 -->\n###### (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제\n\n<!-- PAGE_26 -->\n###### (3) 시험 목적 : 동일한 검체에 대한 시험에서 일정한 결과값이 나오는지\n\n- - 20 -\n<!-- PAGE_27 -->\n###### 확인하는 시험\n\n<!-- PAGE_27 -->\n###### (4) 시험 조건\n\n<!-- PAGE_27 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_27 -->\n###### 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상 준비\n\n<!-- PAGE_27 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n<!-- PAGE_27 -->\n###### 2. 재현성\n\n<!-- PAGE_27 -->\n###### (1) 관련 규격 : CLSI EP05-A3: Evaluation of Precision of Quantitative\n\n<!-- PAGE_27 -->\n###### (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제\n\n<!-- PAGE_27 -->\n###### (3) 시험 목적 : 동일 검체를 로트, 사용자, 시험 사이트 간 반복\n\n- - 21 -\n<!-- PAGE_28 -->\n###### 측정하여 재현성을 확인하는 시험\n\n<!-- PAGE_28 -->\n###### (4) 시험 조건\n\n<!-- PAGE_28 -->\n###### 전혈 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상\n\n<!-- PAGE_28 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n<!-- PAGE_28 -->\n###### 마다 2회 이상 반복 측정을 1일에 2회 이상, 5일 이상 동안 실시한다.\n\n<!-- PAGE_28 -->\n###### 각 로트 별 검체에 대한 MD값의 평균, 표준편차, 변동계수를 구한다.\n\n<!-- PAGE_28 -->\n###### (6) 결과 제시 : 로트간 정밀도, 시험기관간 정밀도, 시험자간 정밀도의\n\n<!-- PAGE_28 -->\n###### 라. 정확도\n\n<!-- PAGE_28 -->\n###### 표준물질이 부재 또는 기준장비가 명확하지 않은 경우 정확도에 대한\n\n<!-- PAGE_28 -->\n###### 성능평가항목을 제외한다.\n\n- - 22 -\n<!-- PAGE_29 -->\n###### 마. 교차반응\n\n<!-- PAGE_29 -->\n###### 검체에 대한 교차반응이 발생하지 않는 경우 교차반응에 대한 성능평가\n\n<!-- PAGE_29 -->\n###### 내부 대조물질은 해당 파장에 대한 기기적인 보정에 사용하기 위해\n\n<!-- PAGE_29 -->\n###### 정도관리물질은 파장의 유사 수치를 나타낼 수 있는 임의의 물질\n\n- - 23 -\n<!-- PAGE_30 -->\n###### 7. 안정성 평가 항목\n\n<!-- PAGE_30 -->\n###### (유효기간) 동안 의료기기의 특성이나 성능이 제조자가 설정한 한계\n\n<!-- PAGE_30 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우 2개\n\n<!-- PAGE_30 -->\n###### - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대\n\n<!-- PAGE_30 -->\n###### 가속노화시험의 기간에 따른 장기보존시험(실시간 안정성시험)을 병행한다.\n\n- - 24 -\n<!-- PAGE_31 -->\n###### (5) 시험 방법\n\n<!-- PAGE_31 -->\n###### 가속노화시험의 간격, 온도, 시험기간을 설정한다.\n\n<!-- PAGE_31 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_31 -->\n###### 보기 위해 사용기간(유효기간) 동안 의료기기의 특성이나 성능이\n\n<!-- PAGE_31 -->\n###### (4) 시험 조건\n\n<!-- PAGE_31 -->\n###### - 시험물질\n\n<!-- PAGE_31 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_31 -->\n###### 검체를 사용한다.\n\n- - 25 -\n<!-- PAGE_32 -->\n###### - 시험장비\n\n<!-- PAGE_32 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우 2개\n\n<!-- PAGE_32 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_32 -->\n###### 개봉시점 및 각 포인트 별 샘플의 이동거리값의 평균 및 표준편차를 계산\n\n- - 26 -\n<!-- PAGE_33 -->\n###### 8. 참고 문헌\n\n- 다. IEC 61010-1 Safety requirements for electrical equipment for measurement,\n- 라.\nIEC\n\n61010-2-101\n\nSafety\n\nrequirements\n\nfor\n\nelectrical\n\nequipment\n\nfor\n\nmeasurement,\n\ncontrol\n\nand\n\nlaboratory\n\nuse\n\n–\n\nPart\n\n2-101:\n\nParticular\n\n- 바. IEC 61326-2-6 Electrical equipment for measurement, control and laboratory\n- 자. CLSI EP12-A2; User Protocol for Evaluation of Qualitative Test Performance;\n- 차.\nCLSI\n\nEP06-A:\n\nEvaluation\n\nof\n\nthe\n\nLinearity\n\nof\n\nQuantitative\n\nMeasurement\n\n- 카. CLSI EP07: Interference Testing in Clinical Chemistry Approved Guideline\n- 타. CLSI EP05-A3: Evaluation of Precision of Quantitative Measurement Methods;\n- 파.\nPlatelet\n\nAggregation\n\nDevices\n\nMarket\n\nby\n\nProduct\n\n(Systems,\n\nReagents,\n\nConsumables,\n\nAccessories),\n\nApplication\n\n(Research,\n\nDiagnostic,\n\nCVD,\n\nOrthopedic,\n\nTrauma),\n\nEnd\n\nUser\n\n(Hospitals,\n\nDiagnostic\n\nLaboratories,\n\nAcademia,\n\nBlood\n\nBanks)\n\n- -\nGlobal\n\nForecasts\n\nto\n\n- 2020.\nmarketsandmarkets.com. August 2015\n\n- - 27 -\n<!-- PAGE_34 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_34 -->\n###### (1) 출혈시간 및 항혈소판제제 저항성 복합검사기기의 국내 개발 현황\n\n<!-- PAGE_34 -->\n###### 사용되어 온 Duke법, Ivy법, Template법 등을 이용하여 혈소판\n\n<!-- PAGE_34 -->\n###### 커서 표준화가 어렵고 임상적 유용성이 적어서 객관적인 데이터로\n\n<!-- PAGE_34 -->\n###### ③ 출혈시간 및 항혈소판제제 저항성 복합검사기기는 주로 수입 의료\n\n<!-- PAGE_34 -->\n###### (나) 국내의 혈소판 기능검사의 시장도 매년 성장하고 있으며 주로\n\n<!-- PAGE_34 -->\n###### (다) 혈소판 기능검사는 신의료기술로 인정되어 비급여항목으로 각 검사당\n\n<!-- PAGE_34 -->\n###### 약 4만원에서 8만원 정도의 검사비가 청구되고 있어 국내 기술을\n\n<!-- PAGE_34 -->\n###### (라) 2016년 9월 현재 급여항목으로 변경된 EPI(Epinephrine, 에피네프린)\n\n<!-- PAGE_34 -->\n###### 테스트 및\n\n<!-- PAGE_34 -->\n###### ADP(에이디피)의 경우\n\n<!-- PAGE_34 -->\n###### 본인부담금으로 9,000원이\n\n<!-- PAGE_34 -->\n###### 청구되고 있다.\n\n- - 28 -\n<!-- PAGE_35 -->\n##### Ⅱ\n\n<!-- PAGE_35 -->\n##### 임상시험계획서 작성 및 평가\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n확증임상시험\n\n- (1) 대상질환 : 선천적 · 후천적 혈소판기능장애 환자 :　본 빌레브란트병(von\nWillebrand disease), 글란즈만 혈소판무력증(Glanzmann's thrombasthenia),\n\n- (2) 해당 의료기기의 사용목적：혈소판 기능부전 검출\n- - 구연산 처리된 전혈에서 폐색 전 혈액이동거리를 측정하여 혈소판 기능부전을\n검출하는 체외진단용 의료기기\n\n- - 29 -\n- (3) 해당 의료기기 : 혈액응고검사시약과 자동혈소판응집측정장치\n- (4) 임상시험 평가내용 : 민감도 및 특이도, 일치도\n- (5) 임상시험 디자인 : 다기관, 비무작위배정, 단일눈가림, 단일설계, 전향적 임상시험\nAspirin 또는 P2Y12 수용제 저해제(clopidogrel) 복용중인 환자의 구연산 처리된\n\n전혈에서 혈소판 약물반응을 확인하기 위해 사용되는 ‘출혈 시간 및 항혈소판제제\n\n저항성 복합검사기기-혈소판 약물반응검사’의 임상적 성능평가를 위하여 aspirin\n\n또는 P2Y12 수용제 저해제(clopidogrel) 복용 전·후에 대한 민감도와 특이도를\n\n기허가제품의 민감도 및 특이도와 비교 평가하기 위한 다기관, 비무작위배정, 단일\n\n- (1) 대상질환 : 혈관질환의 병력, 혈관질환의 위험군 등으로 aspirin 또는 P2Y12\n- (5) 임상시험 디자인 : 다기관, 비무작위배정, 단일눈가림, 단일설계, 전향적 임상시험\n- - 30 -\n<!-- PAGE_37 -->\n###### 2. 임상시험기관의 명칭 및 소재지\n\n- - 31 -\n<!-- PAGE_38 -->\n###### 3. 임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n△△△\n\n△△△병원\n\n△△△△\n\n△△△\n\n△△-△△△-△△△△\n\n□□□\n\n□□□병원\n\n□□□□\n\n□□□\n\n□□-□□□-□□□□\n\n- 다. 공동연구자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n- - 32 -\n<!-- PAGE_39 -->\n###### 4. 임상시험용 의료기기관리자의 성명 및 직명\n\n- - 33 -\n<!-- PAGE_40 -->\n###### 5. 임상시험 의뢰자의 성명 및 주소\n\n※ 임상시험 수탁기관(CRO: Contact Reserach Organization)이 있는 경우 해당\n\n- - 34 -\n<!-- PAGE_41 -->\n###### 6. 임상시험의 목적 및 배경\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- (2) 혈소판 약물반응검사\n본 임상시험은 aspirin 또는 P2Y12 수용체 저해제 복용예정 환자에서 시험기기의\n\n약물 복용 전후에 대한 민감도와 특이도를 기허가제품의 민감도 및 특이도와\n\n비교하여 임상적 유효성을 검증하는 것이 목적이다.\n\n- - 35 -\n- 6.2. 배경\n혈소판은 1차 지혈에서 중요한 역할을 하는 인자로, 혈관손상이 일어났을 때 부착,\n\n응집, 활성화 및 분비, 응고촉진 작용을 통해 지혈마개를 형성하며, 혈소판 기능에\n\n관한 검사는 주로 선천성 혈소판 기능 이상이나 수술전 선별검사로 많이 사용되고\n\n있다. 특히 혈소판의 수적 이상이 없는 출혈질환에서 선천성 혹은 후천성 혈소판\n\n사용되는 아스피린, P2Y12 수용체 저해제 등의 항혈소판약제로 인한 출혈성\n\n검사방법이나 해석의 표준화가 미흡하거나 해석이 어려워 실제 임상에서 널리\n\n응집에 관여하는 ADP, collagen, epinephrine 등의 작용제(agonist)를 넣고 작용제에\n\n따른 혈소판의 응집정도를 관찰하는 것으로, 각 작용제의 기전에 따라 혈소판의\n\n응집정도를 보고 기능이상 여부를 측정할 수 있다. PFA-100은 체외에서 유속을\n\n이용해 혈소판의 부착 및 응집기능을 측정할 수 있는 검사장비로 체외에서 출혈\n\n시간 측정 때와 유사한 조건을 만들어 주기 때문에 일차지혈 과정 평가에 유용한\n\n검사로 검사자의 숙련도에 영향을 받지 않는 장점이 있으며, 선천성, 후천성 혈소판\n\n기능이상을 비롯한 일차지혈 관련 선별검사에 이용된다. 특히 혈소판기능 뿐 아니라\n\n본빌레브란트병에 민감한 검사이며, 아스피린 복용자의 약제 저항성검사로도 사용되고 있다.\n\n- - 36 -\n심혈관질환이 증가하고 치료 및 예방 목적으로 아스피린, 클로피도그렐 등의 항혈소판\n\n약제를 많이 사용함에 따라 약제의 혈소판 응집능 억제 기능을 측정하기 위한 검사\n\n방법들이 많이 사용되고 있으며, 광투과혈소판응집검사나 PFA-100, VerifyNow 등의\n\n본 임상시험용 의료기기인 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’는\n\n약물로 인한 혈소판 기능 억제 기능을 측정하는 장비로, 혈소판 기능 부전이 의심\n\n본 연구를 통해 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’의 민감도 및\n\n- - 37 -\n<!-- PAGE_44 -->\n###### 7. 임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다.)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- - ADP test: 사람의 구연산 처리된 전혈에서 아데노신이인산(ADP)와 P2Y12의\n- - EPI test: 사람의 구연산 처리된 전혈에서 에피네프린과 a2A-AR의 결합 정도를\n폐색 전 혈액이동거리 측정법으로 정성하여 에피네프린에 의한 혈소판 기능\n\n- - Aspirin test: 사람의 구연산 처리된 전혈에서 아스피린에 의한 TXA2 합성 억제\n정도를 폐색 전 혈액이동거리 측정법으로 정성하여 아스피린에 의한 혈소판\n\n- - P2Y12 test: 사람의 구연산 처리된 전혈에서 P2Y12 수용체(ADP receptor) 억제\n정도를 폐색 전 혈액이동거리 측정법으로 정성하여 P2Y12 억제제에 의한 혈소판\n\n- - 38 -\n- 7.2. 임상시험용 의료기기 정보\n- - 해당 임상시험용 의료기기 및 대조시험용 의료기기의 코드명/품목명, 제조회사,\n2) 제조회사: ○○○\n\n- - 39 -\n일련번호\n\n명칭\n\n배합목적\n\n원재료명 또는 성분명\n\n분량\n\n비고\n\n3) 원자재:\n\n모델명 : ○○ SIPA test\n\n- - 40 -\n5) 구조:\n\n- (1) 본체\n- ② 디스플레이(사용자 화면): 별도로 제공되는 태블릿을 이용하여 검사 설정\n- ② 혈액챔버: 혈액주입구를 통해 로딩된 혈액이 채워지는 챔버. 샘플챔버와\n- ③ 막힘부: 내부에 Collagen이 채워져 있어 활성화된 혈소판의 부착을 유도하여\n- ④ 혈액이동부: 막힘부에 폐색이 일어날 때까지 혈액은 혈액이동부를 통해 이동\n- ⑤ 폐챔버: 혈액챔버에서 이동된 혈액이 모이는 끝단. 음압펌프가 연결된다.\n- - 41 -\n6) 치수/중량:\n\n- (1) 본체 : 가로 x 세로 x 높이, 0㎏\n- (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests : 가로 x 세로 x 높이, ㎏\n- (5) 검사는 채혈 후 30분~4시간 내에 수행하도록 한다.\n2) 검사 전 준비사항\n\n- (1) 검사칩이 들어있는 파우치를 개봉하기 전, 실온에 약 10분간 방치한다.\n- (2) 사용 전, 임상시험용 장비와 검사칩의 손상여부 및 이상유무를 확인한다.\n3) 검사과정\n\n- (1) 장비 작동\n- ① 장비 후면 우측 하단의 전원 스위치를 “ON”상태로 한다.\n- ② 태블릿에 로그인 화면이 나타나면 아이디와 비밀번호를 입력한 후, “Log\n- - 42 -\nIn”버튼을 눌러 로그인한다. 초기 설정값은 아이디: pi, 비밀번호: top이다.\n\n- ③ 윈도우가 로딩되면 아이콘을 더블클릭하여 혈소판 기능검사 프로그램을\n실행한다.\n\n- ② 피펫으로 400㎕의 혈액을 검사칩의 혈액 주입구 한쪽 내부 표면을 따라\n자세한 정보는 “pi/PFA/vision 경로”에서 “날짜_시간_ID.log” 파일을 통해\n\n- (7) 다음 검사를 진행하려면, 새로운 검사칩을 준비하여 위의 과정을 반복한다.\n- (8) 검사를 종료하려면 “Kit Information”화면의 “Cancel”버튼을 클릭하여 종료한다.\n- (9) 사용한 검사칩 폐기: 환자나 사용자를 위한 감염방지 및 교차감염방지를 위해\n4) 결과판정 및 정도관리\n\n- (1) 결과판정 : 검사결과는 혈액이동거리(MD), 혈액이동거리의 비율(MR)로 표시된다.\n- - 43 -\n- (2) 정도관리\n- ① 본체\n교대근무를 시작할때마다 “유지보수메뉴(Maintenance Menu)”에서 “Self Test”를\n\nQC 검사를 위해 대조 검체 공여자 그룹을 설정할 것을 권장한다. 적합한 QC\n\n가능한 반복정밀도를 보여주어야 한다. 정도관리의 일환으로 신규 로트의\n\n것으로 간주된다. 평균 MD 또는 MR이 진단경계치 범위를 벗어나는 경우\n\n검사실의 설정된 대조 검체 공여자 그룹에서 두 번째 공여자를 선택하여 이\n\n해야 한다. 첫 번째 공여자는 본 검사의 대조 검체 공여자 그룹에서 배제\n\n- 7.4. 임상시험용 의료기기의 공급 및 관리\n예시)\n\n혈액응고 시간측정기, 채혈을 위한 란셋, 사용설명서가 파우치에 포장되어 있는\n\n상태로 공급 소모품인 검사지는 별도 구매. 낱개포장 된 검사지가 1박스 당 48개가\n\n동봉. 임상시험 종료후 남은 제품은 폐기한다.\n\n- - 44 -\n<!-- PAGE_51 -->\n###### 8. 피험자의 선정기준·제외기준·인원 및 그 근거\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n* 성별, 나이, 교육정도(동의능력). 흡연여부, 알코올 혹은 약 남용자, 사회 경제적\n\n상태, 임신과 수유, 유전학적 병력, 정서적인 제한 등을 고려하여 제외한다.\n\n예시)\n\n- 8.1. 피험자 선정기준\n- 가. 혈소판 기능검사\n- - 45 -\n1) 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand disease),\n\n글란즈만혈소판무력증(Glanzmann's thrombasthenia), 약물유발 혈소판기능부전\n\n(drug-induced platelet dysfunction) 등의 선천적/후천적 혈소판기능장애 환자\n\n2）P2Y12 test: 혈관질환의 위험군, 혈관질환 병력 등으로 clopidogrel 복용예정인\n\n환자에서 clopidogrel 복용 전 1번과 최소 5일이상 clopidogrel 복용 후 1번\n\n- - 임신중인 여성\n- 나. 혈소판 약물반응검사 제외기준\n- - 출혈성 질환, 응고장애의 병력이 있는 경우\n- - 46 -\n혈소판 약물반응검사\n\n- 8.3. 목표대상자 수 및 그 근거\n* 연구피험자 수를 결정하기 위해서는 사전 정보가 필요하며, 아래의 항목과 같을\n\nEPI test 양성(비정상 결과) 환자 105명 이상, EPI test 음성(정상 결과) 대조군\n\n- 나. 혈소판 약물반응검사\nAspirin test 양성(약물 반응) 환자 75명 이상, Aspirin test 음성(약물 비반응)\n\n환자 40명 이상, P2Y12 test 양성(약물 반응) 환자 132명 이상, P2Y12 test 음성\n\n(약물 비반응) 환자 155명 이상을 대상으로 한다.\n\n- - 47 -\n- 8.3.2 피험자 수 산출 방법\n시험 시약의 예상 민감도와 특이도, 일치도를 이용한 통계학적 방법을 적용하여\n\n검체 수를 산출하였다. 계산식에 적용한 민감도와 특이도는 아래 ‘8.3.3 피험자\n\n- - Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체\n- ③ ADP test 양성 검체 검사 시 (민감도 85%),\n- - 대립가설: 개발제품의 민감도가 85% 이상이다.\n- - 귀무가설: 개발제품의 민감도가 85% 미만이다.\n- - 48 -\n<!-- PAGE_55 -->\n# - 적용 계산식 : \n\n   \n\n       \n\n[n = sample size (검체 수), p (민감도) = 0.85,\n\n- ⑥ SIPA test 음성 검체 검사 시 (특이도 80%),\n- - 대립가설: 개발제품의 특이도가 80% 이상이다.\n- - 귀무가설: 개발제품의 특이도가 80% 미만이다.\n- - 49 -\n<!-- PAGE_56 -->\n# - 적용 계산식 : \n\n   \n\n       \n\n[n = sample size (검체 수), p (특이도) = 0.80,\n\n- - Sample Size (5% 탈락률 적용) = 39.10, 약 40개 검체\n- - 50 -\n- ③ P2Y12 test 양성 검체 검사 시 (민감도 80%),\n- - 대립가설: 개발제품의 민감도가 80% 이상이다.\n- - 귀무가설: 개발제품의 민감도가 80% 미만이다.\n- 8.3.3 피험자 수 산출 근거\n- 가. 혈소판 기능검사\n- - 기허가 제품 (PFA-100Ⓡ)의 성능평가 임상논문을 조사한 결과, EPI test 평균\n민감도 84.5% 및 평균 특이도 85.6%이었고, 표준편차는 민감도 16.1%, 특이도\n\n- 8.0%이었다. ADP test는 평균 민감도 84.0%, 평균 특이도 81.0%이었고, 표준\n편차는 민감도 4.2%, 특이도 1.4%이었다. SIPA test는 검사원리가 비슷한 기존\n\n검사법은 없으나, 혈소판 기능의 정상/비정상 유무를 판정하기 위한 목적은\n\n- - 51 -\n표 1.\n\nPFA-100Ⓡ 성능평가 문헌\n\n평균 민감도\n\n평균 특이도\n\n참고문헌\n\n- - 따라서, 본 임상시험에서는 기허가 제품 성능 결과를 토대로 EPI test의 민감도\n및 특이도 목표는 각각 85%, 85%로 설정하였으며 오차범위는 ±5% 설정하였다.\n\nADP 및 SIPA test의 민감도 및 특이도 목표는 각각 85%, 80%로 설정하였으며\n\n- - 52 -\n- 나. 혈소판 약물반응검사\n- - 기허가 제품 (VerifyNowⓇ)의 성능평가 임상논문을 조사한 결과, Aspirin test\n평균 민감도 73.5% 및 평균 특이도 93.2%이었고, 표준편차는 민감도 29.6%,\n\n- - 53 -\n- - 따라서, 본 임상시험에서는 기허가 제품 성능 결과를 토대로 Aspirin test의\n민감도 및 특이도 목표는 각각 90%, 95%로 설정하였으며 오차범위는 ±5%\n\n설정하였다. P2Y12 test의 민감도 및 특이도 목표는 각각 80%, 75%로 설정\n\n- - 54 -\n<!-- PAGE_61 -->\n###### 9. 임상시험기간\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n식품의약품안전처 및 임상시험기관 임상시험심사위원회의 임상시험계획서 승인일로\n\n- - 55 -\n**[표 시작]**\n\n**결정할 수 있습니다.**\n| (2) 부적절한 혈액 채취 기법 및 지연된 검사는 결과의 오류를 야기할 수 있다. | ① 3.2% Na Citrate tube에 약 20mL의 정맥혈을 채혈한다. |\n**시약**\n| (3) 데이터 전송 시, 데이터 전송이 완료된 후 장비를 사용한다. | 5) 검체 채취 및 임상시험 시행 | 나. ADP test |\n| 과거병력 및 병용약물 조사 | O | O |\n\n**[표 끝]**\n\n<!-- PAGE_62 -->\n###### 10. 임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 10.1.2. 시험방법\n- (1) 피험자 동의 및 준비\n본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한 내용을 피험자 본인\n\n- - 56 -\n및 대리인에게 설명하고, 피험자 및 대리인이 내용을 잘 이해한 것을 확인한 다음,\n\n자유의사에 따른 임상시험 참가의 동의를 문서로 받는다. 또한 동의를 서명한\n\n연월일을 기록한다. 또한 동의서 사본을 환자에게 제공하여 환자가 지속적으로\n\n- (4) 검체 채취 및 보관 방법\n- ② 시험기기는 3.2% Na Citrate tube 검체를 실온(18∼25℃)에서 채혈 시 최소\n- ③ LTA 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심\n- ④ VerifyNow 대조기기는 3.2% Na Citrate tube 검체를 실온(18∼25℃)에서 2시간\n이내 검사를 시행한다.\n\n- - 57 -\n임상시험의 설계방법(무작위배정, 단일 또는 이중눈가림, 교차설계 또는 병행설계\n\n등)의 특성이 있는 경우 과학적 타당성과 근거자료를 바탕으로 구체적이고 명확히\n\n기술한다. 상기의 기술한 내용의 근거로서 관련 참고문헌(논문 등)을 하단부에 기재\n\n하고, 첨부자료로서 이를 제출한다.\n\n- ⑤ 검체는 6일간 냉장(2∼6℃) 보관 후 폐기한다.\n- (5) 시험검사 방법\n1) EPI test: 정상인 및 혈소판기능저하가 있는 환자의 검체에 대해 시험기기 및\n\n대조기기인 'epinephrine을 agonist로 사용한 LTA 검사'와 'PFA-100 EPI test'로\n\n및 대조기기인 'ADP를 agonist로 사용한 LTA 검사'와 'PFA-100 ADP test'로\n\n및 대조기기인 'ADP를 agonist로 사용한 LTA 검사'와 'PFA-100 ADP test'로\n\n혈소판 기능의 정상/비정상 유무를 판정하기 위한 목적은 ADP test와 동\n\n- 10.1.3. 임상시험 설계\n- 가. 피험자군 또는 대조군 설정\n- 1. 혈소판 기능검사\n- - 58 -\n1) EPI test\n\n- ① 정상 대조군: 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군\n- ② 피험자군: 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand\ndisease),\n\n글란즈만혈소판무력증(Glanzmann's\n\nthrombasthenia),\n\n약물유발\n\n혈소판기능부전 (drug-induced platelet dysfunction) 등의 선천적/후천적\n\n- ② 피험자군: 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand\ndisease),\n\n글란즈만혈소판무력증(Glanzmann's\n\nthrombasthenia),\n\n약물유발\n\n혈소판기능부전 (drug-induced platelet dysfunction) 등의 선천적/후천적\n\n- ② 피험자군: 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand\ndisease),\n\n글란즈만혈소판무력증(Glanzmann's\n\nthrombasthenia),\n\n약물유발\n\n혈소판기능부전 (drug-induced platelet dysfunction) 등의 선천적/후천적\n\n- 2. 혈소판 약물반응검사\n- ① 대조군: 혈관질환의 위험군, 혈관질환 병력 등으로 aspirin 복용 예정인\n- ② 피험자군: 혈관질환의 위험군, 혈관질환 병력 등으로 aspirin 복용 예정이었던\n2）P2Y12 test\n\n- ① 대조군: 혈관질환의 위험군, 혈관질환 병력 등으로 clopidogrel 복용 예정인\n- - 59 -\n환자의 clopidogrel\n\n복용 전 검체\n\n- ② 피험자군: 혈관질환의 위험군, 혈관질환 병력 등으로 clopidogrel\n복용 예정\n\n이었던 환자의 5일 이상clopidogrel\n\n복용 후의 검체\n\n1) EPI test: 시험기기에서\n\nLTA를 기준검사법으로 한 민감도와 특이도가\n\n기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인한다\n\n2) ADP test: 시험기기에서\n\nLTA를 기준검사법으로 한 민감도와 특이도가\n\n기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인한다\n\n3) SIPA test:　시험기기에서\n\nLTA를 기준검사법으로 한 민감도와 특이도가\n\n기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인한다 (비\n\n열등성한계 10%). SIPA　 test는 검사원리가 비슷한 기존검사법은 없으나,\n\n혈소판 기능의 정상/비정상 유무를 판정하기 위한 목적은 ADP test와 동일\n\n- 2. 혈소판 약물반응검사\n1) Aspirin test：Aspirin 복용예정 환자에서 약물 복용 전후에 대한 민감도와\n\n- - 60 -\n특이도가 기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인\n\n한다 (비열등성한계 10%).\n\n2）P2Y12 test：Clopidogrel 복용예정 환자에서 약물 복용 전후에 대한 민감도와\n\n- - 61 -\n<!-- PAGE_68 -->\n###### 11. 관찰항목, 임상검사항목 및 관찰검사방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- - 62 -\n- 11.2. 관찰검사방법\n- 가. 방문1 (스크리닝 및 검사일)\n1) 임상시험 설명 및 동의 및 스크리닝\n\n‘출혈 시간 및 항혈소판제제 저항성 복합검사기기(Anysis-200)’의 임상시험에 들어\n\n가기 전, 본 임상시험의 목적과 내용에 대하여 대상자 또는 법정대리인에게\n\n동의서의 원본은 시험자가 보관하고 사본은 시험대상자 또는 법정대리인에게\n\n교부한다. 대상자에게 서면 동의를 받은 후 동의취득\n\n순서에 따라 스크리닝\n\n대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그 위임자가 모든 선정\n\n수용체 저해제 등의 항혈소판제제, 항응고제 복용 유무, CBC(혈색소, 헤마토크릿,\n\n검체를 채취하고 시험기기 및 대조기기에서 검사를 시행하고 결과를 기록한다.\n\n1) 3.2% Na Citrate tube에 약 20mL의 정맥혈을 채혈한다.\n\n2) 시험기기는 3.2% Na Citrate tube 검체를 실온(18∼25℃)에서 채혈 후 최소\n\n30분, 최대 4시간 이내 검사를 시행하고 그 결과를 데이터 수집용지에 기록\n\n한다.\n\n- - 63 -\n3) LTA 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심\n\n분리하여 혈소판풍부혈장을 취하여 3시간 이내에 검사를 시행하고 그 결과를\n\n데이터 수집용지에 기록한다.\n\n4) PFA-100 및 VerifyNow 대조기기는 3.2% Na Citrate tube 검체를 실온(18∼\n\n2) Aspirin 복용 후 3일, 또는 clopidogrel 복용 후 5일 이후 검체를 채취하여 시험\n\n- ④ SIPA　test는 검사원리가 비슷한 기존검사법은 없으나, 혈소판 기능의 정상/\n비정상 유무를 판정하기 위한 목적은 ADP test와 동일하므로, 이를 확인하는\n\n2) 혈소판 약물반응 검사: 시험기기와 대조기기(VerifyNow)에서 검사를 시행하여\n\n- ① 약물사용 전 환자를 약물반응 음성군, 약물사용 후 환자를 약물반응 양성군\n- - 64 -\n<!-- PAGE_71 -->\n###### 12. 예측되는 부작용 및 사용 시 주의사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n혈종, 출혈점(피부표면\n\n아래에 적은 량의 출혈을 의미하는 작고 붉은 반점)과 같은\n\n- - 드물지만 채혈할 때 일시적으로 의식이 소실되어 하는 경우가 있다. 침에 찔리자\n의식을 잃어 쓰러지게 된다. 이것은 혈관미주신경 반응에 의해 일어나며 피 또는\n\n주사침에 대한 공포심과 관련이 있다. 채혈에 대한 두려움 등 과민한 정신적인\n\n반응으로 교감신경이 흥분한 상태에서 주사침에 찔리게 되면 갑자기 부교감신경인\n\n· 증상이 나타나면 즉시 주저앉거나 머리를 다리보다 낮춘 자세로 10분 이상\n\n· 채혈에 대한 두려움을 없게 하기 위해 반드시 채혈 전에 채혈자를 안심시키는\n\n· 넥타이와 허리띠를 느슨히 풀어주며 천천히 깊은 숨을 쉬도록 격려해 준다.\n\n· 혈관미주신경 반응에 의한 실신은 후유증 없이 완전히 회복되지만 다른 원인에\n\n- - 65 -\n의해서도 실신이 일어날 수 있으므로 회복이 안 되거나 경련이 동반되거나 하면\n\n의료진에게 알리고 적절히 조치할 수 있도록 한다.\n\n- (2) 피하 출혈 및 혈종\n- - 주사침이 정맥에 걸쳐 있거나 관통하는 경우 혈액이 새어 나와 피부 아래에\n고여서 생긴 것이다. 주사침을 찌른 부위의 피부가 부어오르면 혈종이 생긴\n\n· 주사침을 찌르다가 만약 피부가 부어오르면 재빨리 압박대를 풀고 주사침을 뺀\n\n· 혈종은 채혈 시 외에도 환자가 채혈 후 지혈을 충분히 하지 않은 경우에도\n\n- (3) 검체와 시약을 다룬 이후에는 반드시 손을 깨끗이 씻도록 한다.\n- (4) 모든 혈액 검체와 혈액 성분은 전염성 감염원일 가능성이 있는 것으로 취급해야\n하며, 모든 검체는 적절한 주의사항을 준수하는 우수실험실운영기준(GLP:\n\nGood\n\n- (5) 혈액 검체 채취는 오염이 발생하지 않도록 주의 깊게 수행하도록 하고, 응집이\n- - 66 -\n3) 경고사항\n\n- (1) 본 제품의 안전하고 적절한 사용을 위해, 제품을 사용하기 전 사용방법에 대한\n교육을 받아야 한다. 사용자 설명서 및 제품과 관련된 모든 문서를 숙지한 후,\n\n- (3) 본 제품의 서비스와 수리는 제조원 담당자에 의해 행해져야\n한다. 서비스나\n\n- (4) 본 제품의 안전한 사용을 위해 제품 손상을 의미하는 어떤 증상을 발견했을 경우\n- (1) 본 제품은 일회용으로 재사용을 금한다.\n- (4) 가급적 장비의 케이스를 닫고 검사를 진행하도록 한다.\n- (5) 검사가 종료된 후, 데이터 처리에 시간이 오래 소요될 수 있으므로 검사가 완전히\n- (6) 검사칩 외 이물질을 장비에 삽입해서는 안된다.\n- (7) 장비의 이상동작 시 스스로 수리하려고 하지 않는다. 제조원에 문의한다.\n- - 67 -\n6) 결과 판정상 주의\n\n- (1) 본 제품의 결과는 항상 환자의 약물 복용 여부를 포함한 의료 기록, 임상 증상\n및 시험연구를 포함한 기타 소견과 함께 해석되어야 한다.\n\n잘못된 처리 여부를 조사하여야 한다. 새로운 혈액 검체와 새 검사칩으로 재\n\n- (2) 본 제품의 사용자는 환자나 사용자를 위한\n감염방지 및 교차감염방지를 위해\n\n8) 검사칩은 항상 본체에 장착하여 사용하여야 한다. 임상시험용 장비 이외의 장비에서\n\n- - 68 -\n<!-- PAGE_75 -->\n###### 13. 중지·탈락 기준\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n본 임상시험인 혈소판 기능검사 및 혈소판 약물반응 검사는 혈소판 기능 부전이 의심되는\n\n환자 및 정상 대조군, aspirin 또는 P2Y12 수용체 저해제인 clopidogrel을 복용 전후의\n\n환자를 대상으로 구연산 처리된 전혈을 채혈하여 체외에서 검사가 이뤄지므로 환자 또는\n\n- 13.1.1. 중지 기준\n1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지 시킬 수\n\n2) 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는 것에 무리가 있다고\n\n판단되는 경우에는 임상시험 책임자는 임상시험을 중지할 수 있다 (표 1. 참조).\n\n3) 대상자가 시험자의 지시에 불응하거나 또는 동의서에 제시된 사항을 준수하지 않아\n\n그 유효율의 평가에 영향을 미치는 경우 임상시험을 중지할 수 있다.\n\n- - 69 -\n중지기준\n\n중지처리\n\n- - 피험자 제공 검체의 보관, 관리 또는 예기치 못한 문제로 인해 외부\n<표 1. 중지 기준 및 처리>\n\n2) 중지 시점까지의 검사결과 관련 자료는 성능과 안전성 평가를 위한 통계 처리 시\n\n만약 자료에 결함이 생기면, 적절한 보정 방법을 임상시험계획서에 제시하고, 보정 후\n\n- 13.2.1. 탈락 기준\n시험기기 또는 대조기기 검사상 에러가 발생하여 재검을 수행하였음에도 불구하고 지속\n\n적인 에러가 발생하여 결과확인이 어려운 경우 임상시험에서 탈락시킨다.\n\n- 13.2.2. 탈락 처리\n1) 탈락률이 예상보다 높아 피험자 수가 부족할 경우, 부족한 수만큼 피함자를 추가로\n\n모집하여 임상시험을 시행한다. 임상시험 완료 후 통계 처리 시 탈락시킨 검체는\n\n제외하고 통계 처리 한다. 단, 임상 시험 검체 list에서는 제외하지 않는다.\n\n2) 증례기록서에 탈락의 사유를 기재한다.\n\n- - 70 -\n<!-- PAGE_77 -->\n###### 14. 유효성의 평가기준, 평가방법 및 해석방법(통계 분석방법에 의함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n대조기기(LTA 검사) 결과를 기준으로 하여 시험시약의 민감도 및 특이도를\n\n대조기기(LTA 검사) 결과를 기준으로 하여 시험시약의 민감도 및 특이도를\n\n산출한다. 신뢰도 95% 구간에서 민감도 85%, 특이도 80%, 로 설정한다.\n\n- 다. SIPA test\n대조기기(LTA 검사) 결과를 기준으로 하여 시험시약의 민감도 및 특이도를\n\n산출한다. 신뢰도 95% 구간에서 민감도 85%, 특이도 80%, 로 설정한다.\n\n- - 71 -\n- 14.1.2. 혈소판 기능 검사\n- 가. Aspirin test\n1) 민감도: 대조기기 비정상 결과 검체 중 시험기기에서 비정상 결과를 보인\n\n민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)\n\nKappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)}\n\n- - 72 -\n- 나. ADP test\n1) 민감도: 대조기기 비정상 결과 검체 중 시험기기에서 비정상 결과를 보인\n\n검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.\n\n- 다. SIPA　test : 검사원리가 비슷한 기존검사법은 없으나, 혈소판 기능의 정상/\n준에 준하여 평가한다.\n\n1) 민감도: 대조기기 비정상 결과 검체 중 시험기기에서 비정상 결과를 보인\n\n2) 특이도: 대조기기 정상 결과 검체 중 시험기기에서 정상 결과를 보인 검체의\n\n3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.\n\n- - 73 -\n대조기기\n\n합계\n\n비정상\n\n정상\n\n민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)\n\n3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.\n\n- - 74 -\n대조기기\n\n합계\n\n약물반응 양성\n\n약물반응 음성\n\n민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)\n\n3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.\n\n- - 75 -\n대조기기\n\n합계\n\n약물반응 양성\n\n약물반응 음성\n\n- - 76 -\n<!-- PAGE_83 -->\n###### 15. 부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n않기 때문에 해당 의료기기에 의한 감염위험성은 없다. 다만, 검체가 감염성 물질을\n\n포함하고 있을 가능성이있는 인체 유래물이기 때문에 검사실 생물학적 안전수칙 및\n\n사용시 주의사항을 참고하여 취급해야 한다.\n\n- - 77 -\n인체유래물 기증자의 권리에 대한 문의처\n\n피험자보호\n\n연구\n\n<!-- PAGE_84 -->\n###### 16. 피험자 동의서 서식\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n* 만일 본 연구에 문의사항이 있으시거나, 위험이나 불편 또는 손상이 발생할 경우, 상기 연구책임자\n\n또는 연구담당자에게 연락하여 주시기 바랍니다.\n\n- 1. 참여 권유\n- - 본 연구책임자는 귀하로부터 연구 참여에 대한 동의를 받고 이를 문서화 할 때\n관련 규정을 준수하며 헬싱키선언에 근거한 윤리적 원칙을 바탕으로 합법적인 절\n\n차를 따를 것입니다. 귀하는 본 연구에 참여할 것인지 여부를 결정하기 전에, 이\n\n동의서를 신중하게 읽어보셔야 합니다. 이 연구는 왜 수행되며, 무엇을 조사하고\n\n- - 78 -\n귀하의 정보와 검체는 어떻게 사용될지, 본 연구에 따른 위험이나 불편은 무엇인지\n\n귀하가 이해하는 것이 중요합니다. 충분한 시간을 가지고 결정해 주시기 바라며\n\n궁금한 점이 있으면 언제든지 질문하여 주십시오. 귀하께서 궁금해 하는 모든\n\n질문에 대해 답을 얻으셨고, 이 연구 참여를 결정하였다면 본 동의서에 서명과\n\n- - 본 임상시험용 의료기기인 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’는\n- 4. 연구 방법 및 절차\n- - 본 연구에 참여하게 되면, 문진 및 혈액채취를 하게 됩니다. 문진에는 혈성 질환,\n응고장애, 암, 기타 만성질환 등의 병력 및 아스피린, P2Y12 수용체 저해제 등의\n\n항혈소판제제, 항응고제 복용 유무에 대한 질문이 포함됩니다. 이 후 약 20 mL의\n\n정맥혈을 채취하여 검사를 시행합니다. 본 연구를 위한 검사비용(혈소판 기능검사\n\n또는 혈소판 약물반응 검사)은 연구비에서 지불되며, 단 귀하가 본 연구목적으로\n\n- - 79 -\n귀하의 검체를 사용하는 것을 허락하여야만 검체 채취가 가능합니다.\n\n- 5. 예상되는 위험 및 불편\n및 어지러움이 발생할 수도 있으며 혈액을 채취한 자리가 부어 오르는 등의 약간의\n\n부작용이 나타날 수 있습니다. 그러나 이는 보통 일시적인 증상으로 금방 해소될\n\n귀하의 혈소판 기능 또는 혈소판 약물 저항성을 확인할 수 있을 것으로 기대합니다.\n\n개발에 기여함으로써 혈소판 기능 부전 및 혈소판 약물 저항성을 보이는 환자의\n\n다른 연구 목적에 대해 제공을 허용할 것인지, 만약 제공을 허용한다면 개인정보도\n\n함께 제공하도록 허용할 것인지 여부 등에 대해 인체유래물연구동의서에서 선택\n\n- - 연구가 종료된 후 남은 검체는 귀하가 지정한 보존기간에 따라 폐기될 것입니다.\n만약 검체를 제공한 후 마음이 변해서 동의를 철회할 경우, 검체가 익명화(귀하와\n\n귀하의 검체 간의 연결이 존재하지 않음)되지 않았다면 귀하의 검체는 귀하의\n\n요청에 따라 즉시 폐기될 것이며 더 이상 정보수집이 되지 않을 것입니다. 만약\n\n익명화된 경우라도 귀하가 지정한 보존기간에 따라 폐기될 것입니다.\n\n- - 80 -\n- 8. 자유의사에 의한 연구 참여 동의 및 철회\n- - 본 연구에 참여할지 여부는 전적으로 귀하의 선택에 의한 것이며 참여하지 않을\n경우에도 전혀 불이익은 없습니다. 또한 참여에 동의한 이후에도 언제라도 아무런\n\n불이익 없이 연구 참여를 중단할 수 있습니다. 동의 철회를 원할 경우 귀하의\n\n- - 만약 귀하가 본 연구에 참여하신다면 본 연구에서는 귀하의 개인정보(성명과 같은\n자료에 접근할 수 있습니다. 수집된 개인정보 중 개인식별정보는 연구에 직접\n\n이용되거나 필요한 정보가 아니며 연구로 인해 획득되는 검체 및 임상 자료와\n\n귀하를 연결하기 위한 목적으로만 사용됩니다. 귀하의 개인정보는 연구 목적을\n\n- 10. 연구대상자 동의\nü 본인은 본 동의서의 내용에 대해 충분히 설명을 들었고 그 내용을 잘 이해\n\nü 본인은 본인의 정보와 검체가 질병 연구목적을 위하여 이용되는 것에 동의합니다.\n\nü 본인은 언제든지 자유롭게 본 연구참여를 거절할 수 있으며 또한 이로 인하여\n\n본인의 진료나 법적인 권리에 어떤 불이익도 없다는 것을 설명 받았으며 또한\n\n참여에 동의한 이후에도, 언제라도 이 동의를 철회할 수 있음을 이해합니다.\n\nü 본인은 본 연구를 위한 본인의 개인정보 수집 및 이용에 동의합니다.\n\n- - 81 -\nü 본인은 “연구과제 피험자 동의서”에 서명 후, 본 설명문 및 연구과제 피험자\n\n동의서의 사본을 제공받을 것임을 알고 있습니다.\n\n- - 82 -\n<!-- PAGE_89 -->\n###### 17. 피해자 보상에 대한 규약\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- - 83 -\n<!-- PAGE_90 -->\n###### 18. 임상시험 후 피험자의 진료에 관한 사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n절차가 임상시험 참여 전과 다름없이 진행되며, 이후의 치료비는 피험자가 지불하여야\n\n- - 84 -\n<!-- PAGE_91 -->\n###### 19. 피험자의 안전보호에 관한 대책\n\n전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를 취할 수 있도록 하는 등\n\n- (1) 임상시험심사위원회(Institutional Review Board)는 국내 법규/관례에 따라\n구성되어 있어야 한다. 임상시험심사위원회는 피험자의 권리, 안전, 복지를\n\n보호해야 하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에\n\n- (2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가 동의가 적절하게\n얻어지지 않았거나 임상시험이 임상시험계획서에 따라 진행되지 않은 경우 또는\n\n중대한 이상사례/의료기기이상반응이 나타난 경우에는 임상시험의 일부 또는\n\n- 19.3. 시험자\n- (1) 시험자(Investigator)라 함은 시험책임자, 시험담당자, 임상시험조정자를 말한다.\n시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식품의약품안전처장의 승\n\n인을 득한 임상시험 계획서를 준수하여 임상시험을 실시하여야 한다.\n\n- (2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미 있는 실험실적\n검사치의 이상을 포함하여 임상시험에서 발생한 모든 이상사례에 대해 피험자가\n\n- - 85 -\n적절한 의학적 처치를 받을 수 있도록 조치하여야하고, 시험자가 알게된\n\n피험자의 병발질환에 대해 의학적 처치가 필요한 경우 이를 피험자에게 알려\n\n주어야 한다.\n\n- (2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상시험 계획서의\n복잡성, 피험자에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상시험\n\n- (2) 임상시험에 대한 모니터링은 임상시험 모니터요원의 정기적인 임상시험 실시기관\n- (3) 또한, 임상시험 모니터요원은 임상시험 진행과정을 잘 살피고, 문제가 있을 경우\n- 19.6. 임상시험계획서의 변경\n- (1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장으로부터 승인\n받은 후, 시험절차가 광범위해지거나 위험도가 높아지거나 피험자 선정기준에\n\n- - 86 -\n변화가 있거나 추가적인 안전성 정보로 인해 임상시험계획서를 변경하는 경우\n\n에는 임상시험심사위원회 및 식품의약품안전처장의 승인을 받아야 한다.\n\n- (2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정 내용 등을 기록하여\n- (3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한 경우를 제외\n하고는, 임상시험심사위원회 및 식품의약품안전처장의 변경승인 이전에는 계\n\n획서와 다르게 임상시험을 실시하여서는 안된다. 만일 피험자에게 발생한 즉\n\n각적 위험요소를 제거하기 위해 임상시험심사위원회의 승인을 얻기 전에 이러\n\n여 임상시험심사위원회(사후검토 승인을 위하여), 의뢰자, 식품의약품안전처장에\n\n게 제출하여야 한다. 그리고 임상시험심사위원회 위원장이나 간사가 승인한 문서\n\n전에 피험자를 위한 설명서를 통해 해당 임상시험과 관련된 모든 정보를 제공\n\n받고, 서명과 서명 날짜가 포함된 문서를 통해 본인이 자발적으로 임상시험에\n\n- (2) 피험자 본인 또는 대리인이 동의서 서식, 피험자설명서 및 기타 문서화된 정보를\n읽을 수 없는 경우에는 공정한 입회자가 동의를 얻는 전 과정에 참석하여야 한다.\n\n- (3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의 세부 사항에 대해\n질문하고 해당 임상시험의 참여 여부를 결정할 수 있도록 충분한 시간과 기회를\n\n주어야 하며, 모든 임상시험 관련 질문에 대해 피험자 또는 대리인이 만족할 수\n\n있도록 대답해 주어야 한다.\n\n- - 87 -\n- 19.8. 피험자 기록의 비밀보장\n- (1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며, 임상 시험의\n결과가 출관될 경우에도 피험자의 신원을 비밀상태로 유지한다.\n\n- (2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의 모니터링과\n임상시험 의뢰자 또는 모니터 및 점검자가 피험자의 차트와 증례기록서 기록을\n\n검증하기 위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다. 이러한\n\n- - 88 -\n<!-- PAGE_95 -->\n###### 20. 그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n\n- (1) 임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가 관리한다.\n승인을 얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는 아니\n\n로부터 반납받거나 의뢰자에게 반납하는 방법에 관한 지침을 마련하여 시험\n\n책임자 및 관리자 등에게 주어야 하며, 임상시험용 의료기기의 공급, 인수,\n\n- (3) 의뢰자는 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관으로의\n공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납 및 폐기에 관한\n\n기록을 작성·보관하여야 한다.\n\n- (4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나 임상시험의 완료\n(조기종료를 포함한다) 및 임상시험용 의료기기의 사용기한의 또는 유효기한의\n\n만료 등의 사유로 임상시험용 의료기기를 회수해야 하는 경우에 대한 절차를\n\n마련하고 임상시험용 의료기기의 회수내용을 기록하여야 한다.\n\n- - 89 -\n<!-- PAGE_96 -->\n###### 21. 참고문헌\n\n- 3. Lee YK, Kim HS, Park JY, Kang HJ. Incidence of aspirin resistance in the patient group of\n- 4. Kim H, Lee HK, Han K, Jeon HK. Prevalence and risk factors for aspirin and clopidogrel\nresistance in patients with coronary artery disease or ischemic cerebrovascular disease. Ann\n\n- 5.\nFDA K970505: 510(k) summary of safety and effectiveness information Dade PFA-100\n\nPlatelet\n\nfunction\n\nanalyzer,\n\nDade\n\nPFA\n\nCollagen/Epinephrine\n\nTest\n\ncartridge,\n\nDade\n\nPFA\n\n- 7. FDA K051231: 510(k) substantial equivalence determination decision summary. VerifyNow\n- 8. FDA K013596-S2: 510(k) summary. Accumetrics Ultegra System Rapid Platelet Function\n- - 90 -\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- - 91 -\n<!-- PAGE_98 -->\n###### Case Report Form 작성 지침\n\n일반적인 지침 사항\n\n1) 피험자 이니셜과 피험자 번호를 모든 페이지에서 적절하게 기록하여 주십시오.\n\n2) 방문이 누락된 경우에는 해당 visit의 방문일란에 “ND\"로 기록하여 주십시오.\n\n3) 임상시험이 종료(완료, 탈락 또는 중지)된 피험자의 경우, 증례결론란에 세부내용을 기록\n\n- - 92 -\n- - 93 -\n◈ 혈관 질환 유무\n\n- - 94 -\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될\n\n- - 95 -\n<!-- PAGE_102 -->\n###### SPECIAL FORM 이상사례서식지\n\n- - 96 -\n- - 97 -\n오현주, 조양하, 이원규, 정진백, 안영욱, 우승민, 김수영, 서두원, 양원선, 최윤정,\n\n- - 98 -",
  "chunks": [
    {
      "chunk_id": "chunk_001",
      "text": "발간등록번호\n\n안내서-0662-01\n\n<!-- PAGE_1 -->\n### 출혈시간 및 항혈소판제제\n\n<!-- PAGE_1 -->\n### 저항성 복합검사기기 안전성·성능 및\n\n<!-- PAGE_1 -->\n### 임상시험계획서 평가 가이드라인\n\n<!-- PAGE_1 -->\n### (민원인 안내서)\n\n- 2016. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 0,
        "window_size": 3,
        "char_count": 174,
        "word_count": 32,
        "page_number": 1,
        "window_text": "발간등록번호\n\n안내서-0662-01\n\n<!-- PAGE_1 -->\n### 출혈시간 및 항혈소판제제\n\n<!-- PAGE_1 -->\n### 저항성 복합검사기기 안전성·성능 및\n\n<!-- PAGE_1 -->\n### 임상시험계획서 평가 가이드라인\n\n<!-- PAGE_1 -->\n### (민원인 안내서)\n\n- 2016.  12.\n 의료기기심사부 체외진단기기과\n\n<!-- PAGE_2 -->\n###### 제․개정 이력\n\n<!-- PAGE_2 -->\n###### 출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성·성능 및\n\n<!-- PAGE_2 -->\n###### 임상시험계획서 평가 가이드라인(민원인 안내서)\n\n<!-- PAGE_2 -->\n###### 제․개정번호\n\n<!-- PAGE_2 -->\n###### 승인일자\n\n<!-- PAGE_2 -->\n###### 주요 내용\n\n<!-- PAGE_2 -->\n###### B1-2016-5-054\n\n<!-- PAGE_2 -->\n###### 2016.12.30\n\n<!-- PAGE_2 -->\n###### 출혈시간 및 항혈소판제제 저항성 복합검사\n\n<!-- PAGE_2 -->\n###### 기기 안전성·성능 및 임상시험계획서 평가\n\n<!-- PAGE_2 -->\n###### 가이드라인\n\n<!-- PAGE_2 -->\n###### 안내서-0662-01\n\n<!-- PAGE_2 -->\n###### 「출혈시간 및 항혈소판제제 저항성 복합검사기기\n\n<!-- PAGE_2 -->\n###### 안전성·성능 및 임상시험계획서 평가 가이드라인\n\n<!-- PAGE_2 -->\n###### (민원인 안내서)」 명칭 변경 및 제·개정 점검표\n\n<!-- PAGE_2 -->\n###### 등 추가\n\n<!-- PAGE_2 -->\n###### [근거: 「식품의약품안전처 지침서등의 관리에\n\n<!-- PAGE_2 -->\n###### 관한 규정」 개정, ‘17.5.1.]\n\n <!-- PAGE_3 -->\n###### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성·성능 및\n\n임상시험계획서 평가 가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n",
        "original_sentence": "발간등록번호\n\n안내서-0662-01\n\n<!-- PAGE_1 -->\n### 출혈시간 및 항혈소판제제\n\n<!-- PAGE_1 -->\n### 저항성 복합검사기기 안전성·성능 및\n\n<!-- PAGE_1 -->\n### 임상시험계획서 평가 가이드라인\n\n<!-- PAGE_1 -->\n### (민원인 안내서)\n\n- 2016. "
      }
    },
    {
      "chunk_id": "chunk_002",
      "text": "12.\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 1,
        "window_size": 3,
        "char_count": 4,
        "word_count": 1,
        "page_number": 1,
        "window_text": "발간등록번호\n\n안내서-0662-01\n\n<!-- PAGE_1 -->\n### 출혈시간 및 항혈소판제제\n\n<!-- PAGE_1 -->\n### 저항성 복합검사기기 안전성·성능 및\n\n<!-- PAGE_1 -->\n### 임상시험계획서 평가 가이드라인\n\n<!-- PAGE_1 -->\n### (민원인 안내서)\n\n- 2016.  12.\n 의료기기심사부 체외진단기기과\n\n<!-- PAGE_2 -->\n###### 제․개정 이력\n\n<!-- PAGE_2 -->\n###### 출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성·성능 및\n\n<!-- PAGE_2 -->\n###### 임상시험계획서 평가 가이드라인(민원인 안내서)\n\n<!-- PAGE_2 -->\n###### 제․개정번호\n\n<!-- PAGE_2 -->\n###### 승인일자\n\n<!-- PAGE_2 -->\n###### 주요 내용\n\n<!-- PAGE_2 -->\n###### B1-2016-5-054\n\n<!-- PAGE_2 -->\n###### 2016.12.30\n\n<!-- PAGE_2 -->\n###### 출혈시간 및 항혈소판제제 저항성 복합검사\n\n<!-- PAGE_2 -->\n###### 기기 안전성·성능 및 임상시험계획서 평가\n\n<!-- PAGE_2 -->\n###### 가이드라인\n\n<!-- PAGE_2 -->\n###### 안내서-0662-01\n\n<!-- PAGE_2 -->\n###### 「출혈시간 및 항혈소판제제 저항성 복합검사기기\n\n<!-- PAGE_2 -->\n###### 안전성·성능 및 임상시험계획서 평가 가이드라인\n\n<!-- PAGE_2 -->\n###### (민원인 안내서)」 명칭 변경 및 제·개정 점검표\n\n<!-- PAGE_2 -->\n###### 등 추가\n\n<!-- PAGE_2 -->\n###### [근거: 「식품의약품안전처 지침서등의 관리에\n\n<!-- PAGE_2 -->\n###### 관한 규정」 개정, ‘17.5.1.]\n\n <!-- PAGE_3 -->\n###### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성·성능 및\n\n임상시험계획서 평가 가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n 등록대상\n\n**[표 시작]**\n\n| □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- |\n| □ NO | 검체의 | disease | (Blood | Coagul | Fibrinolysis. ",
        "original_sentence": "12.\n"
      }
    },
    {
      "chunk_id": "chunk_003",
      "text": "의료기기심사부 체외진단기기과\n\n<!-- PAGE_2 -->\n###### 제․개정 이력\n\n<!-- PAGE_2 -->\n###### 출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성·성능 및\n\n<!-- PAGE_2 -->\n###### 임상시험계획서 평가 가이드라인(민원인 안내서)\n\n<!-- PAGE_2 -->\n###### 제․개정번호\n\n<!-- PAGE_2 -->\n###### 승인일자\n\n<!-- PAGE_2 -->\n###### 주요 내용\n\n<!-- PAGE_2 -->\n###### B1-2016-5-054\n\n<!-- PAGE_2 -->\n###### 2016.12.30\n\n<!-- PAGE_2 -->\n###### 출혈시간 및 항혈소판제제 저항성 복합검사\n\n<!-- PAGE_2 -->\n###### 기기 안전성·성능 및 임상시험계획서 평가\n\n<!-- PAGE_2 -->\n###### 가이드라인\n\n<!-- PAGE_2 -->\n###### 안내서-0662-01\n\n<!-- PAGE_2 -->\n###### 「출혈시간 및 항혈소판제제 저항성 복합검사기기\n\n<!-- PAGE_2 -->\n###### 안전성·성능 및 임상시험계획서 평가 가이드라인\n\n<!-- PAGE_2 -->\n###### (민원인 안내서)」 명칭 변경 및 제·개정 점검표\n\n<!-- PAGE_2 -->\n###### 등 추가\n\n<!-- PAGE_2 -->\n###### [근거: 「식품의약품안전처 지침서등의 관리에\n\n<!-- PAGE_2 -->\n###### 관한 규정」 개정, ‘17.5.1.]\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 2,
        "window_size": 3,
        "char_count": 755,
        "word_count": 132,
        "page_number": 2,
        "window_text": "발간등록번호\n\n안내서-0662-01\n\n<!-- PAGE_1 -->\n### 출혈시간 및 항혈소판제제\n\n<!-- PAGE_1 -->\n### 저항성 복합검사기기 안전성·성능 및\n\n<!-- PAGE_1 -->\n### 임상시험계획서 평가 가이드라인\n\n<!-- PAGE_1 -->\n### (민원인 안내서)\n\n- 2016.  12.\n 의료기기심사부 체외진단기기과\n\n<!-- PAGE_2 -->\n###### 제․개정 이력\n\n<!-- PAGE_2 -->\n###### 출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성·성능 및\n\n<!-- PAGE_2 -->\n###### 임상시험계획서 평가 가이드라인(민원인 안내서)\n\n<!-- PAGE_2 -->\n###### 제․개정번호\n\n<!-- PAGE_2 -->\n###### 승인일자\n\n<!-- PAGE_2 -->\n###### 주요 내용\n\n<!-- PAGE_2 -->\n###### B1-2016-5-054\n\n<!-- PAGE_2 -->\n###### 2016.12.30\n\n<!-- PAGE_2 -->\n###### 출혈시간 및 항혈소판제제 저항성 복합검사\n\n<!-- PAGE_2 -->\n###### 기기 안전성·성능 및 임상시험계획서 평가\n\n<!-- PAGE_2 -->\n###### 가이드라인\n\n<!-- PAGE_2 -->\n###### 안내서-0662-01\n\n<!-- PAGE_2 -->\n###### 「출혈시간 및 항혈소판제제 저항성 복합검사기기\n\n<!-- PAGE_2 -->\n###### 안전성·성능 및 임상시험계획서 평가 가이드라인\n\n<!-- PAGE_2 -->\n###### (민원인 안내서)」 명칭 변경 및 제·개정 점검표\n\n<!-- PAGE_2 -->\n###### 등 추가\n\n<!-- PAGE_2 -->\n###### [근거: 「식품의약품안전처 지침서등의 관리에\n\n<!-- PAGE_2 -->\n###### 관한 규정」 개정, ‘17.5.1.]\n\n <!-- PAGE_3 -->\n###### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성·성능 및\n\n임상시험계획서 평가 가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n 등록대상\n\n**[표 시작]**\n\n| □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- |\n| □ NO | 검체의 | disease | (Blood | Coagul | Fibrinolysis.  | 2002 |\n| 3 | 막힘부 | 지지체 | ○○○ | 1개 | 표준편차는 민감도 15.5%, 특이도 9.8%이었다. ",
        "original_sentence": "의료기기심사부 체외진단기기과\n\n<!-- PAGE_2 -->\n###### 제․개정 이력\n\n<!-- PAGE_2 -->\n###### 출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성·성능 및\n\n<!-- PAGE_2 -->\n###### 임상시험계획서 평가 가이드라인(민원인 안내서)\n\n<!-- PAGE_2 -->\n###### 제․개정번호\n\n<!-- PAGE_2 -->\n###### 승인일자\n\n<!-- PAGE_2 -->\n###### 주요 내용\n\n<!-- PAGE_2 -->\n###### B1-2016-5-054\n\n<!-- PAGE_2 -->\n###### 2016.12.30\n\n<!-- PAGE_2 -->\n###### 출혈시간 및 항혈소판제제 저항성 복합검사\n\n<!-- PAGE_2 -->\n###### 기기 안전성·성능 및 임상시험계획서 평가\n\n<!-- PAGE_2 -->\n###### 가이드라인\n\n<!-- PAGE_2 -->\n###### 안내서-0662-01\n\n<!-- PAGE_2 -->\n###### 「출혈시간 및 항혈소판제제 저항성 복합검사기기\n\n<!-- PAGE_2 -->\n###### 안전성·성능 및 임상시험계획서 평가 가이드라인\n\n<!-- PAGE_2 -->\n###### (민원인 안내서)」 명칭 변경 및 제·개정 점검표\n\n<!-- PAGE_2 -->\n###### 등 추가\n\n<!-- PAGE_2 -->\n###### [근거: 「식품의약품안전처 지침서등의 관리에\n\n<!-- PAGE_2 -->\n###### 관한 규정」 개정, ‘17.5.1.]\n\n"
      }
    },
    {
      "chunk_id": "chunk_004",
      "text": "<!-- PAGE_3 -->\n###### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성·성능 및\n\n임상시험계획서 평가 가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 3,
        "window_size": 3,
        "char_count": 136,
        "word_count": 25,
        "page_number": 3,
        "window_text": "발간등록번호\n\n안내서-0662-01\n\n<!-- PAGE_1 -->\n### 출혈시간 및 항혈소판제제\n\n<!-- PAGE_1 -->\n### 저항성 복합검사기기 안전성·성능 및\n\n<!-- PAGE_1 -->\n### 임상시험계획서 평가 가이드라인\n\n<!-- PAGE_1 -->\n### (민원인 안내서)\n\n- 2016.  12.\n 의료기기심사부 체외진단기기과\n\n<!-- PAGE_2 -->\n###### 제․개정 이력\n\n<!-- PAGE_2 -->\n###### 출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성·성능 및\n\n<!-- PAGE_2 -->\n###### 임상시험계획서 평가 가이드라인(민원인 안내서)\n\n<!-- PAGE_2 -->\n###### 제․개정번호\n\n<!-- PAGE_2 -->\n###### 승인일자\n\n<!-- PAGE_2 -->\n###### 주요 내용\n\n<!-- PAGE_2 -->\n###### B1-2016-5-054\n\n<!-- PAGE_2 -->\n###### 2016.12.30\n\n<!-- PAGE_2 -->\n###### 출혈시간 및 항혈소판제제 저항성 복합검사\n\n<!-- PAGE_2 -->\n###### 기기 안전성·성능 및 임상시험계획서 평가\n\n<!-- PAGE_2 -->\n###### 가이드라인\n\n<!-- PAGE_2 -->\n###### 안내서-0662-01\n\n<!-- PAGE_2 -->\n###### 「출혈시간 및 항혈소판제제 저항성 복합검사기기\n\n<!-- PAGE_2 -->\n###### 안전성·성능 및 임상시험계획서 평가 가이드라인\n\n<!-- PAGE_2 -->\n###### (민원인 안내서)」 명칭 변경 및 제·개정 점검표\n\n<!-- PAGE_2 -->\n###### 등 추가\n\n<!-- PAGE_2 -->\n###### [근거: 「식품의약품안전처 지침서등의 관리에\n\n<!-- PAGE_2 -->\n###### 관한 규정」 개정, ‘17.5.1.]\n\n <!-- PAGE_3 -->\n###### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성·성능 및\n\n임상시험계획서 평가 가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n 등록대상\n\n**[표 시작]**\n\n| □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- |\n| □ NO | 검체의 | disease | (Blood | Coagul | Fibrinolysis.  | 2002 |\n| 3 | 막힘부 | 지지체 | ○○○ | 1개 | 표준편차는 민감도 15.5%, 특이도 9.8%이었다.  | 검사를 시행한다. ",
        "original_sentence": "<!-- PAGE_3 -->\n###### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성·성능 및\n\n임상시험계획서 평가 가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_005",
      "text": "등록대상\n\n**[표 시작]**\n\n| □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- |\n| □ NO | 검체의 | disease | (Blood | Coagul | Fibrinolysis. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 4,
        "window_size": 3,
        "char_count": 143,
        "word_count": 38,
        "page_number": 3,
        "window_text": "12.\n 의료기기심사부 체외진단기기과\n\n<!-- PAGE_2 -->\n###### 제․개정 이력\n\n<!-- PAGE_2 -->\n###### 출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성·성능 및\n\n<!-- PAGE_2 -->\n###### 임상시험계획서 평가 가이드라인(민원인 안내서)\n\n<!-- PAGE_2 -->\n###### 제․개정번호\n\n<!-- PAGE_2 -->\n###### 승인일자\n\n<!-- PAGE_2 -->\n###### 주요 내용\n\n<!-- PAGE_2 -->\n###### B1-2016-5-054\n\n<!-- PAGE_2 -->\n###### 2016.12.30\n\n<!-- PAGE_2 -->\n###### 출혈시간 및 항혈소판제제 저항성 복합검사\n\n<!-- PAGE_2 -->\n###### 기기 안전성·성능 및 임상시험계획서 평가\n\n<!-- PAGE_2 -->\n###### 가이드라인\n\n<!-- PAGE_2 -->\n###### 안내서-0662-01\n\n<!-- PAGE_2 -->\n###### 「출혈시간 및 항혈소판제제 저항성 복합검사기기\n\n<!-- PAGE_2 -->\n###### 안전성·성능 및 임상시험계획서 평가 가이드라인\n\n<!-- PAGE_2 -->\n###### (민원인 안내서)」 명칭 변경 및 제·개정 점검표\n\n<!-- PAGE_2 -->\n###### 등 추가\n\n<!-- PAGE_2 -->\n###### [근거: 「식품의약품안전처 지침서등의 관리에\n\n<!-- PAGE_2 -->\n###### 관한 규정」 개정, ‘17.5.1.]\n\n <!-- PAGE_3 -->\n###### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성·성능 및\n\n임상시험계획서 평가 가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n 등록대상\n\n**[표 시작]**\n\n| □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- |\n| □ NO | 검체의 | disease | (Blood | Coagul | Fibrinolysis.  | 2002 |\n| 3 | 막힘부 | 지지체 | ○○○ | 1개 | 표준편차는 민감도 15.5%, 특이도 9.8%이었다.  | 검사를 시행한다.  | 내성으로부터 안전성을 보증함에 있다. ",
        "original_sentence": "등록대상\n\n**[표 시작]**\n\n| □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- |\n| □ NO | 검체의 | disease | (Blood | Coagul | Fibrinolysis. "
      }
    },
    {
      "chunk_id": "chunk_006",
      "text": "| 2002 |\n| 3 | 막힘부 | 지지체 | ○○○ | 1개 | 표준편차는 민감도 15.5%, 특이도 9.8%이었다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 5,
        "window_size": 3,
        "char_count": 68,
        "word_count": 19,
        "page_number": 6,
        "window_text": "의료기기심사부 체외진단기기과\n\n<!-- PAGE_2 -->\n###### 제․개정 이력\n\n<!-- PAGE_2 -->\n###### 출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성·성능 및\n\n<!-- PAGE_2 -->\n###### 임상시험계획서 평가 가이드라인(민원인 안내서)\n\n<!-- PAGE_2 -->\n###### 제․개정번호\n\n<!-- PAGE_2 -->\n###### 승인일자\n\n<!-- PAGE_2 -->\n###### 주요 내용\n\n<!-- PAGE_2 -->\n###### B1-2016-5-054\n\n<!-- PAGE_2 -->\n###### 2016.12.30\n\n<!-- PAGE_2 -->\n###### 출혈시간 및 항혈소판제제 저항성 복합검사\n\n<!-- PAGE_2 -->\n###### 기기 안전성·성능 및 임상시험계획서 평가\n\n<!-- PAGE_2 -->\n###### 가이드라인\n\n<!-- PAGE_2 -->\n###### 안내서-0662-01\n\n<!-- PAGE_2 -->\n###### 「출혈시간 및 항혈소판제제 저항성 복합검사기기\n\n<!-- PAGE_2 -->\n###### 안전성·성능 및 임상시험계획서 평가 가이드라인\n\n<!-- PAGE_2 -->\n###### (민원인 안내서)」 명칭 변경 및 제·개정 점검표\n\n<!-- PAGE_2 -->\n###### 등 추가\n\n<!-- PAGE_2 -->\n###### [근거: 「식품의약품안전처 지침서등의 관리에\n\n<!-- PAGE_2 -->\n###### 관한 규정」 개정, ‘17.5.1.]\n\n <!-- PAGE_3 -->\n###### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성·성능 및\n\n임상시험계획서 평가 가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n 등록대상\n\n**[표 시작]**\n\n| □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- |\n| □ NO | 검체의 | disease | (Blood | Coagul | Fibrinolysis.  | 2002 |\n| 3 | 막힘부 | 지지체 | ○○○ | 1개 | 표준편차는 민감도 15.5%, 특이도 9.8%이었다.  | 검사를 시행한다.  | 내성으로부터 안전성을 보증함에 있다.  | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. ",
        "original_sentence": "| 2002 |\n| 3 | 막힘부 | 지지체 | ○○○ | 1개 | 표준편차는 민감도 15.5%, 특이도 9.8%이었다. "
      }
    },
    {
      "chunk_id": "chunk_007",
      "text": "| 검사를 시행한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 6,
        "window_size": 3,
        "char_count": 12,
        "word_count": 3,
        "page_number": 24,
        "window_text": "<!-- PAGE_3 -->\n###### 지침서ᆞ안내서 제ᆞ개정 점검표\n\n명칭\n\n출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성·성능 및\n\n임상시험계획서 평가 가이드라인(민원인 안내서)\n\n아래에 해당하는 사항에 체크하여 주시기 바랍니다.\n\n 등록대상\n\n**[표 시작]**\n\n| □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- |\n| □ NO | 검체의 | disease | (Blood | Coagul | Fibrinolysis.  | 2002 |\n| 3 | 막힘부 | 지지체 | ○○○ | 1개 | 표준편차는 민감도 15.5%, 특이도 9.8%이었다.  | 검사를 시행한다.  | 내성으로부터 안전성을 보증함에 있다.  | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 한다 (비열등성한계 10%). ",
        "original_sentence": "| 검사를 시행한다. "
      }
    },
    {
      "chunk_id": "chunk_008",
      "text": "| 내성으로부터 안전성을 보증함에 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 7,
        "window_size": 3,
        "char_count": 23,
        "word_count": 5,
        "page_number": 20,
        "window_text": "등록대상\n\n**[표 시작]**\n\n| □ 이미 등록된 지침서ㆍ안내서 중 동일ㆍ유사한 내용의 | □ 예 | ■ 아니오 |\n| --- | --- | --- |\n| □ NO | 검체의 | disease | (Blood | Coagul | Fibrinolysis.  | 2002 |\n| 3 | 막힘부 | 지지체 | ○○○ | 1개 | 표준편차는 민감도 15.5%, 특이도 9.8%이었다.  | 검사를 시행한다.  | 내성으로부터 안전성을 보증함에 있다.  | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 한다 (비열등성한계 10%).  | c | c | d | d |\n| ◈ 피험자에게 서면 동의를 받았습니까? ",
        "original_sentence": "| 내성으로부터 안전성을 보증함에 있다. "
      }
    },
    {
      "chunk_id": "chunk_009",
      "text": "| 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 8,
        "window_size": 3,
        "char_count": 38,
        "word_count": 8,
        "page_number": 6,
        "window_text": "| 2002 |\n| 3 | 막힘부 | 지지체 | ○○○ | 1개 | 표준편차는 민감도 15.5%, 특이도 9.8%이었다.  | 검사를 시행한다.  | 내성으로부터 안전성을 보증함에 있다.  | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 한다 (비열등성한계 10%).  | c | c | d | d |\n| ◈ 피험자에게 서면 동의를 받았습니까?  | □ 예 | □ 아니오 | - 검체의 양이 적거나 응고 등 검체 상태가 좋지 않아 검사를 진행할 수 없는 | c | d |\n| 임상시험에 사용되는 임상시험용 의료기기에서 발생한, 모든 유해하고 의도되지 않은 반응으로서, | 지침서ㆍ안내서가 있습니까? ",
        "original_sentence": "| 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_010",
      "text": "| 한다 (비열등성한계 10%). ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 9,
        "window_size": 3,
        "char_count": 19,
        "word_count": 4,
        "page_number": 6,
        "window_text": "| 검사를 시행한다.  | 내성으로부터 안전성을 보증함에 있다.  | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 한다 (비열등성한계 10%).  | c | c | d | d |\n| ◈ 피험자에게 서면 동의를 받았습니까?  | □ 예 | □ 아니오 | - 검체의 양이 적거나 응고 등 검체 상태가 좋지 않아 검사를 진행할 수 없는 | c | d |\n| 임상시험에 사용되는 임상시험용 의료기기에서 발생한, 모든 유해하고 의도되지 않은 반응으로서, | 지침서ㆍ안내서가 있습니까?  | 약물반응 음성 | 정상 | 참 고 코 드 | c+b | c+b |\n| [n = sample size (검체 수), p (민감도) = 0.80, | 라인이 없는 상태이다. ",
        "original_sentence": "| 한다 (비열등성한계 10%). "
      }
    },
    {
      "chunk_id": "chunk_011",
      "text": "| c | c | d | d |\n| ◈ 피험자에게 서면 동의를 받았습니까? ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 10,
        "window_size": 3,
        "char_count": 42,
        "word_count": 15,
        "page_number": 78,
        "window_text": "| 내성으로부터 안전성을 보증함에 있다.  | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 한다 (비열등성한계 10%).  | c | c | d | d |\n| ◈ 피험자에게 서면 동의를 받았습니까?  | □ 예 | □ 아니오 | - 검체의 양이 적거나 응고 등 검체 상태가 좋지 않아 검사를 진행할 수 없는 | c | d |\n| 임상시험에 사용되는 임상시험용 의료기기에서 발생한, 모든 유해하고 의도되지 않은 반응으로서, | 지침서ㆍ안내서가 있습니까?  | 약물반응 음성 | 정상 | 참 고 코 드 | c+b | c+b |\n| [n = sample size (검체 수), p (민감도) = 0.80, | 라인이 없는 상태이다.  | 약물반응 음성 | 신고 | 심사 등에 관한 규정」(식약처 고시) | c+b |\n| 4 | 혈액이동부 | 지지체 | ○○○ | 1개 | 임상시험에 사용되는 임상 시험용 의료기기와의 인과관계를 배제할 수 없는 경우를 말한다. ",
        "original_sentence": "| c | c | d | d |\n| ◈ 피험자에게 서면 동의를 받았습니까? "
      }
    },
    {
      "chunk_id": "chunk_012",
      "text": "| □ 예 | □ 아니오 | - 검체의 양이 적거나 응고 등 검체 상태가 좋지 않아 검사를 진행할 수 없는 | c | d |\n| 임상시험에 사용되는 임상시험용 의료기기에서 발생한, 모든 유해하고 의도되지 않은 반응으로서, | 지침서ㆍ안내서가 있습니까? ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 11,
        "window_size": 3,
        "char_count": 141,
        "word_count": 40,
        "page_number": 3,
        "window_text": "| 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 한다 (비열등성한계 10%).  | c | c | d | d |\n| ◈ 피험자에게 서면 동의를 받았습니까?  | □ 예 | □ 아니오 | - 검체의 양이 적거나 응고 등 검체 상태가 좋지 않아 검사를 진행할 수 없는 | c | d |\n| 임상시험에 사용되는 임상시험용 의료기기에서 발생한, 모든 유해하고 의도되지 않은 반응으로서, | 지침서ㆍ안내서가 있습니까?  | 약물반응 음성 | 정상 | 참 고 코 드 | c+b | c+b |\n| [n = sample size (검체 수), p (민감도) = 0.80, | 라인이 없는 상태이다.  | 약물반응 음성 | 신고 | 심사 등에 관한 규정」(식약처 고시) | c+b |\n| 4 | 혈액이동부 | 지지체 | ○○○ | 1개 | 임상시험에 사용되는 임상 시험용 의료기기와의 인과관계를 배제할 수 없는 경우를 말한다.  이용 | (False Negative) | (False Negative) | Jun;13(4):349-53.) ",
        "original_sentence": "| □ 예 | □ 아니오 | - 검체의 양이 적거나 응고 등 검체 상태가 좋지 않아 검사를 진행할 수 없는 | c | d |\n| 임상시험에 사용되는 임상시험용 의료기기에서 발생한, 모든 유해하고 의도되지 않은 반응으로서, | 지침서ㆍ안내서가 있습니까? "
      }
    },
    {
      "chunk_id": "chunk_013",
      "text": "| 약물반응 음성 | 정상 | 참 고 코 드 | c+b | c+b |\n| [n = sample size (검체 수), p (민감도) = 0.80, | 라인이 없는 상태이다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 12,
        "window_size": 3,
        "char_count": 97,
        "word_count": 30,
        "page_number": 78,
        "window_text": "| 한다 (비열등성한계 10%).  | c | c | d | d |\n| ◈ 피험자에게 서면 동의를 받았습니까?  | □ 예 | □ 아니오 | - 검체의 양이 적거나 응고 등 검체 상태가 좋지 않아 검사를 진행할 수 없는 | c | d |\n| 임상시험에 사용되는 임상시험용 의료기기에서 발생한, 모든 유해하고 의도되지 않은 반응으로서, | 지침서ㆍ안내서가 있습니까?  | 약물반응 음성 | 정상 | 참 고 코 드 | c+b | c+b |\n| [n = sample size (검체 수), p (민감도) = 0.80, | 라인이 없는 상태이다.  | 약물반응 음성 | 신고 | 심사 등에 관한 규정」(식약처 고시) | c+b |\n| 4 | 혈액이동부 | 지지체 | ○○○ | 1개 | 임상시험에 사용되는 임상 시험용 의료기기와의 인과관계를 배제할 수 없는 경우를 말한다.  이용 | (False Negative) | (False Negative) | Jun;13(4):349-53.)  | (True Negative) | (True Negative) |\n| 것이다. ",
        "original_sentence": "| 약물반응 음성 | 정상 | 참 고 코 드 | c+b | c+b |\n| [n = sample size (검체 수), p (민감도) = 0.80, | 라인이 없는 상태이다. "
      }
    },
    {
      "chunk_id": "chunk_014",
      "text": "| 약물반응 음성 | 신고 | 심사 등에 관한 규정」(식약처 고시) | c+b |\n| 4 | 혈액이동부 | 지지체 | ○○○ | 1개 | 임상시험에 사용되는 임상 시험용 의료기기와의 인과관계를 배제할 수 없는 경우를 말한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 13,
        "window_size": 3,
        "char_count": 126,
        "word_count": 36,
        "page_number": 5,
        "window_text": "| c | c | d | d |\n| ◈ 피험자에게 서면 동의를 받았습니까?  | □ 예 | □ 아니오 | - 검체의 양이 적거나 응고 등 검체 상태가 좋지 않아 검사를 진행할 수 없는 | c | d |\n| 임상시험에 사용되는 임상시험용 의료기기에서 발생한, 모든 유해하고 의도되지 않은 반응으로서, | 지침서ㆍ안내서가 있습니까?  | 약물반응 음성 | 정상 | 참 고 코 드 | c+b | c+b |\n| [n = sample size (검체 수), p (민감도) = 0.80, | 라인이 없는 상태이다.  | 약물반응 음성 | 신고 | 심사 등에 관한 규정」(식약처 고시) | c+b |\n| 4 | 혈액이동부 | 지지체 | ○○○ | 1개 | 임상시험에 사용되는 임상 시험용 의료기기와의 인과관계를 배제할 수 없는 경우를 말한다.  이용 | (False Negative) | (False Negative) | Jun;13(4):349-53.)  | (True Negative) | (True Negative) |\n| 것이다.  | 검사를 하도록 한다. ",
        "original_sentence": "| 약물반응 음성 | 신고 | 심사 등에 관한 규정」(식약처 고시) | c+b |\n| 4 | 혈액이동부 | 지지체 | ○○○ | 1개 | 임상시험에 사용되는 임상 시험용 의료기기와의 인과관계를 배제할 수 없는 경우를 말한다. "
      }
    },
    {
      "chunk_id": "chunk_015",
      "text": "이용 | (False Negative) | (False Negative) | Jun;13(4):349-53.) ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 14,
        "window_size": 3,
        "char_count": 62,
        "word_count": 9,
        "page_number": 6,
        "window_text": "| □ 예 | □ 아니오 | - 검체의 양이 적거나 응고 등 검체 상태가 좋지 않아 검사를 진행할 수 없는 | c | d |\n| 임상시험에 사용되는 임상시험용 의료기기에서 발생한, 모든 유해하고 의도되지 않은 반응으로서, | 지침서ㆍ안내서가 있습니까?  | 약물반응 음성 | 정상 | 참 고 코 드 | c+b | c+b |\n| [n = sample size (검체 수), p (민감도) = 0.80, | 라인이 없는 상태이다.  | 약물반응 음성 | 신고 | 심사 등에 관한 규정」(식약처 고시) | c+b |\n| 4 | 혈액이동부 | 지지체 | ○○○ | 1개 | 임상시험에 사용되는 임상 시험용 의료기기와의 인과관계를 배제할 수 없는 경우를 말한다.  이용 | (False Negative) | (False Negative) | Jun;13(4):349-53.)  | (True Negative) | (True Negative) |\n| 것이다.  | 검사를 하도록 한다.  | 기능 선별검사로 현재도 사용 중이다. ",
        "original_sentence": "이용 | (False Negative) | (False Negative) | Jun;13(4):349-53.) "
      }
    },
    {
      "chunk_id": "chunk_016",
      "text": "| (True Negative) | (True Negative) |\n| 것이다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 15,
        "window_size": 3,
        "char_count": 45,
        "word_count": 9,
        "page_number": 72,
        "window_text": "| 약물반응 음성 | 정상 | 참 고 코 드 | c+b | c+b |\n| [n = sample size (검체 수), p (민감도) = 0.80, | 라인이 없는 상태이다.  | 약물반응 음성 | 신고 | 심사 등에 관한 규정」(식약처 고시) | c+b |\n| 4 | 혈액이동부 | 지지체 | ○○○ | 1개 | 임상시험에 사용되는 임상 시험용 의료기기와의 인과관계를 배제할 수 없는 경우를 말한다.  이용 | (False Negative) | (False Negative) | Jun;13(4):349-53.)  | (True Negative) | (True Negative) |\n| 것이다.  | 검사를 하도록 한다.  | 기능 선별검사로 현재도 사용 중이다.  | 혈소판기능장애 환자 | 경우 임상시험기관의 임상검체 폐기절차에 따라 즉각 폐기한다. ",
        "original_sentence": "| (True Negative) | (True Negative) |\n| 것이다. "
      }
    },
    {
      "chunk_id": "chunk_017",
      "text": "| 검사를 하도록 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 16,
        "window_size": 3,
        "char_count": 14,
        "word_count": 4,
        "page_number": 24,
        "window_text": "| 약물반응 음성 | 신고 | 심사 등에 관한 규정」(식약처 고시) | c+b |\n| 4 | 혈액이동부 | 지지체 | ○○○ | 1개 | 임상시험에 사용되는 임상 시험용 의료기기와의 인과관계를 배제할 수 없는 경우를 말한다.  이용 | (False Negative) | (False Negative) | Jun;13(4):349-53.)  | (True Negative) | (True Negative) |\n| 것이다.  | 검사를 하도록 한다.  | 기능 선별검사로 현재도 사용 중이다.  | 혈소판기능장애 환자 | 경우 임상시험기관의 임상검체 폐기절차에 따라 즉각 폐기한다.  | (False Negative) | 표 3. ",
        "original_sentence": "| 검사를 하도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_018",
      "text": "| 기능 선별검사로 현재도 사용 중이다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 17,
        "window_size": 3,
        "char_count": 23,
        "word_count": 6,
        "page_number": 34,
        "window_text": "이용 | (False Negative) | (False Negative) | Jun;13(4):349-53.)  | (True Negative) | (True Negative) |\n| 것이다.  | 검사를 하도록 한다.  | 기능 선별검사로 현재도 사용 중이다.  | 혈소판기능장애 환자 | 경우 임상시험기관의 임상검체 폐기절차에 따라 즉각 폐기한다.  | (False Negative) | 표 3.  | (True Negative) |\n| 증상의 | 증상의 | 이상사례 서식지(예시) | 의료기기와의 | 의료기기에 | Function Analyzer | 1 strip x 50개 |\n| 가능한 임상시험용 의료기기 정보를 참고하여 인과관계를 평가한다. ",
        "original_sentence": "| 기능 선별검사로 현재도 사용 중이다. "
      }
    },
    {
      "chunk_id": "chunk_019",
      "text": "| 혈소판기능장애 환자 | 경우 임상시험기관의 임상검체 폐기절차에 따라 즉각 폐기한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 18,
        "window_size": 3,
        "char_count": 49,
        "word_count": 11,
        "page_number": 6,
        "window_text": "| (True Negative) | (True Negative) |\n| 것이다.  | 검사를 하도록 한다.  | 기능 선별검사로 현재도 사용 중이다.  | 혈소판기능장애 환자 | 경우 임상시험기관의 임상검체 폐기절차에 따라 즉각 폐기한다.  | (False Negative) | 표 3.  | (True Negative) |\n| 증상의 | 증상의 | 이상사례 서식지(예시) | 의료기기와의 | 의료기기에 | Function Analyzer | 1 strip x 50개 |\n| 가능한 임상시험용 의료기기 정보를 참고하여 인과관계를 평가한다.  | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 |\n| 5 | 상판 | 지지체 | ○○○ | 1개 | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | ◈ 기타 | 질환 | 안전처고시) | 서면 동의 일자(YY/MM/DD) | [그림 4] 출혈시간 및 항혈소판제제 저항성 복합검사기기 | 2. ",
        "original_sentence": "| 혈소판기능장애 환자 | 경우 임상시험기관의 임상검체 폐기절차에 따라 즉각 폐기한다. "
      }
    },
    {
      "chunk_id": "chunk_020",
      "text": "| (False Negative) | 표 3. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 19,
        "window_size": 3,
        "char_count": 26,
        "word_count": 6,
        "page_number": 15,
        "window_text": "| 검사를 하도록 한다.  | 기능 선별검사로 현재도 사용 중이다.  | 혈소판기능장애 환자 | 경우 임상시험기관의 임상검체 폐기절차에 따라 즉각 폐기한다.  | (False Negative) | 표 3.  | (True Negative) |\n| 증상의 | 증상의 | 이상사례 서식지(예시) | 의료기기와의 | 의료기기에 | Function Analyzer | 1 strip x 50개 |\n| 가능한 임상시험용 의료기기 정보를 참고하여 인과관계를 평가한다.  | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 |\n| 5 | 상판 | 지지체 | ○○○ | 1개 | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | ◈ 기타 | 질환 | 안전처고시) | 서면 동의 일자(YY/MM/DD) | [그림 4] 출혈시간 및 항혈소판제제 저항성 복합검사기기 | 2.  The PFA-100 : a potential rapid screening tool for | 대한 조치 | 치료 | 결과 | 중대성 |\n| [표 3] 출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성 관련 시험 규격 | 정해진 확률 범위 내에서 분포할 것으로 예상되는 계산된 구간 | 하여 시험한다. ",
        "original_sentence": "| (False Negative) | 표 3. "
      }
    },
    {
      "chunk_id": "chunk_021",
      "text": "| (True Negative) |\n| 증상의 | 증상의 | 이상사례 서식지(예시) | 의료기기와의 | 의료기기에 | Function Analyzer | 1 strip x 50개 |\n| 가능한 임상시험용 의료기기 정보를 참고하여 인과관계를 평가한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 20,
        "window_size": 3,
        "char_count": 140,
        "word_count": 32,
        "page_number": 25,
        "window_text": "| 기능 선별검사로 현재도 사용 중이다.  | 혈소판기능장애 환자 | 경우 임상시험기관의 임상검체 폐기절차에 따라 즉각 폐기한다.  | (False Negative) | 표 3.  | (True Negative) |\n| 증상의 | 증상의 | 이상사례 서식지(예시) | 의료기기와의 | 의료기기에 | Function Analyzer | 1 strip x 50개 |\n| 가능한 임상시험용 의료기기 정보를 참고하여 인과관계를 평가한다.  | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 |\n| 5 | 상판 | 지지체 | ○○○ | 1개 | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | ◈ 기타 | 질환 | 안전처고시) | 서면 동의 일자(YY/MM/DD) | [그림 4] 출혈시간 및 항혈소판제제 저항성 복합검사기기 | 2.  The PFA-100 : a potential rapid screening tool for | 대한 조치 | 치료 | 결과 | 중대성 |\n| [표 3] 출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성 관련 시험 규격 | 정해진 확률 범위 내에서 분포할 것으로 예상되는 계산된 구간 | 하여 시험한다.  (컷오프 근처의 검체 포함) | 준비하여 시험한다. ",
        "original_sentence": "| (True Negative) |\n| 증상의 | 증상의 | 이상사례 서식지(예시) | 의료기기와의 | 의료기기에 | Function Analyzer | 1 strip x 50개 |\n| 가능한 임상시험용 의료기기 정보를 참고하여 인과관계를 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_022",
      "text": "| ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 |\n| 5 | 상판 | 지지체 | ○○○ | 1개 | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | ◈ 기타 | 질환 | 안전처고시) | 서면 동의 일자(YY/MM/DD) | [그림 4] 출혈시간 및 항혈소판제제 저항성 복합검사기기 | 2. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 21,
        "window_size": 3,
        "char_count": 205,
        "word_count": 55,
        "page_number": 3,
        "window_text": "| 혈소판기능장애 환자 | 경우 임상시험기관의 임상검체 폐기절차에 따라 즉각 폐기한다.  | (False Negative) | 표 3.  | (True Negative) |\n| 증상의 | 증상의 | 이상사례 서식지(예시) | 의료기기와의 | 의료기기에 | Function Analyzer | 1 strip x 50개 |\n| 가능한 임상시험용 의료기기 정보를 참고하여 인과관계를 평가한다.  | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 |\n| 5 | 상판 | 지지체 | ○○○ | 1개 | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | ◈ 기타 | 질환 | 안전처고시) | 서면 동의 일자(YY/MM/DD) | [그림 4] 출혈시간 및 항혈소판제제 저항성 복합검사기기 | 2.  The PFA-100 : a potential rapid screening tool for | 대한 조치 | 치료 | 결과 | 중대성 |\n| [표 3] 출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성 관련 시험 규격 | 정해진 확률 범위 내에서 분포할 것으로 예상되는 계산된 구간 | 하여 시험한다.  (컷오프 근처의 검체 포함) | 준비하여 시험한다.  (컷오프 근처의 검체 포함) | 저항성 복합검사기기에 적용한다. ",
        "original_sentence": "| ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 |\n| 5 | 상판 | 지지체 | ○○○ | 1개 | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | ◈ 기타 | 질환 | 안전처고시) | 서면 동의 일자(YY/MM/DD) | [그림 4] 출혈시간 및 항혈소판제제 저항성 복합검사기기 | 2. "
      }
    },
    {
      "chunk_id": "chunk_023",
      "text": "The PFA-100 : a potential rapid screening tool for | 대한 조치 | 치료 | 결과 | 중대성 |\n| [표 3] 출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성 관련 시험 규격 | 정해진 확률 범위 내에서 분포할 것으로 예상되는 계산된 구간 | 하여 시험한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 22,
        "window_size": 3,
        "char_count": 170,
        "word_count": 44,
        "page_number": 6,
        "window_text": "| (False Negative) | 표 3.  | (True Negative) |\n| 증상의 | 증상의 | 이상사례 서식지(예시) | 의료기기와의 | 의료기기에 | Function Analyzer | 1 strip x 50개 |\n| 가능한 임상시험용 의료기기 정보를 참고하여 인과관계를 평가한다.  | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 |\n| 5 | 상판 | 지지체 | ○○○ | 1개 | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | ◈ 기타 | 질환 | 안전처고시) | 서면 동의 일자(YY/MM/DD) | [그림 4] 출혈시간 및 항혈소판제제 저항성 복합검사기기 | 2.  The PFA-100 : a potential rapid screening tool for | 대한 조치 | 치료 | 결과 | 중대성 |\n| [표 3] 출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성 관련 시험 규격 | 정해진 확률 범위 내에서 분포할 것으로 예상되는 계산된 구간 | 하여 시험한다.  (컷오프 근처의 검체 포함) | 준비하여 시험한다.  (컷오프 근처의 검체 포함) | 저항성 복합검사기기에 적용한다.  | 범위 | 인한 위해요인 방지시험에 관한 요구사항이 적용된다. ",
        "original_sentence": "The PFA-100 : a potential rapid screening tool for | 대한 조치 | 치료 | 결과 | 중대성 |\n| [표 3] 출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성 관련 시험 규격 | 정해진 확률 범위 내에서 분포할 것으로 예상되는 계산된 구간 | 하여 시험한다. "
      }
    },
    {
      "chunk_id": "chunk_024",
      "text": "(컷오프 근처의 검체 포함) | 준비하여 시험한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 23,
        "window_size": 3,
        "char_count": 29,
        "word_count": 7,
        "page_number": 9,
        "window_text": "| (True Negative) |\n| 증상의 | 증상의 | 이상사례 서식지(예시) | 의료기기와의 | 의료기기에 | Function Analyzer | 1 strip x 50개 |\n| 가능한 임상시험용 의료기기 정보를 참고하여 인과관계를 평가한다.  | ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 |\n| 5 | 상판 | 지지체 | ○○○ | 1개 | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | ◈ 기타 | 질환 | 안전처고시) | 서면 동의 일자(YY/MM/DD) | [그림 4] 출혈시간 및 항혈소판제제 저항성 복합검사기기 | 2.  The PFA-100 : a potential rapid screening tool for | 대한 조치 | 치료 | 결과 | 중대성 |\n| [표 3] 출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성 관련 시험 규격 | 정해진 확률 범위 내에서 분포할 것으로 예상되는 계산된 구간 | 하여 시험한다.  (컷오프 근처의 검체 포함) | 준비하여 시험한다.  (컷오프 근처의 검체 포함) | 저항성 복합검사기기에 적용한다.  | 범위 | 인한 위해요인 방지시험에 관한 요구사항이 적용된다.  | 합계 | a+c | b+d | a+b+c+d | 합계 | a+c | b+d | a+b+c+d | 정도 | - 피험자 제공 검체가 폐기된 경우, 임상시험담당자는 즉각 임상시험책임자, 및 | 관련성 | VerifyNowⓇ 성능평가 문헌 |\n| 합계 | a+c | b+d | a+b+c+d |\n| 6 | 하판 | 지지체 | ○○○ | 1개 |\n| □ YES | □ 기타: | 기계적 안전에 관한 공통기준규격」(식약처 고시) | the | assessment | of | platelet | dysfunction | (Clin | Lab |\n| n = 125.44 | □ ‘중증도’ 판정 참고기준 | 평균 민감도 | 평균 특이도 | 참고문헌 | 1. ",
        "original_sentence": "(컷오프 근처의 검체 포함) | 준비하여 시험한다. "
      }
    },
    {
      "chunk_id": "chunk_025",
      "text": "(컷오프 근처의 검체 포함) | 저항성 복합검사기기에 적용한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 24,
        "window_size": 3,
        "char_count": 36,
        "word_count": 8,
        "page_number": 21,
        "window_text": "| ☞ 상기 질문에 ‘예’라고 답하신 경우 기존의 지침서ㆍ안내서의 개정을 우선적 |\n| 5 | 상판 | 지지체 | ○○○ | 1개 | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | ◈ 기타 | 질환 | 안전처고시) | 서면 동의 일자(YY/MM/DD) | [그림 4] 출혈시간 및 항혈소판제제 저항성 복합검사기기 | 2.  The PFA-100 : a potential rapid screening tool for | 대한 조치 | 치료 | 결과 | 중대성 |\n| [표 3] 출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성 관련 시험 규격 | 정해진 확률 범위 내에서 분포할 것으로 예상되는 계산된 구간 | 하여 시험한다.  (컷오프 근처의 검체 포함) | 준비하여 시험한다.  (컷오프 근처의 검체 포함) | 저항성 복합검사기기에 적용한다.  | 범위 | 인한 위해요인 방지시험에 관한 요구사항이 적용된다.  | 합계 | a+c | b+d | a+b+c+d | 합계 | a+c | b+d | a+b+c+d | 정도 | - 피험자 제공 검체가 폐기된 경우, 임상시험담당자는 즉각 임상시험책임자, 및 | 관련성 | VerifyNowⓇ 성능평가 문헌 |\n| 합계 | a+c | b+d | a+b+c+d |\n| 6 | 하판 | 지지체 | ○○○ | 1개 |\n| □ YES | □ 기타: | 기계적 안전에 관한 공통기준규격」(식약처 고시) | the | assessment | of | platelet | dysfunction | (Clin | Lab |\n| n = 125.44 | □ ‘중증도’ 판정 참고기준 | 평균 민감도 | 평균 특이도 | 참고문헌 | 1.  평가 불가능 | 임상시험의뢰자에게 보고한다. ",
        "original_sentence": "(컷오프 근처의 검체 포함) | 저항성 복합검사기기에 적용한다. "
      }
    },
    {
      "chunk_id": "chunk_026",
      "text": "| 범위 | 인한 위해요인 방지시험에 관한 요구사항이 적용된다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 25,
        "window_size": 3,
        "char_count": 36,
        "word_count": 9,
        "page_number": 3,
        "window_text": "The PFA-100 : a potential rapid screening tool for | 대한 조치 | 치료 | 결과 | 중대성 |\n| [표 3] 출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성 관련 시험 규격 | 정해진 확률 범위 내에서 분포할 것으로 예상되는 계산된 구간 | 하여 시험한다.  (컷오프 근처의 검체 포함) | 준비하여 시험한다.  (컷오프 근처의 검체 포함) | 저항성 복합검사기기에 적용한다.  | 범위 | 인한 위해요인 방지시험에 관한 요구사항이 적용된다.  | 합계 | a+c | b+d | a+b+c+d | 합계 | a+c | b+d | a+b+c+d | 정도 | - 피험자 제공 검체가 폐기된 경우, 임상시험담당자는 즉각 임상시험책임자, 및 | 관련성 | VerifyNowⓇ 성능평가 문헌 |\n| 합계 | a+c | b+d | a+b+c+d |\n| 6 | 하판 | 지지체 | ○○○ | 1개 |\n| □ YES | □ 기타: | 기계적 안전에 관한 공통기준규격」(식약처 고시) | the | assessment | of | platelet | dysfunction | (Clin | Lab |\n| n = 125.44 | □ ‘중증도’ 판정 참고기준 | 평균 민감도 | 평균 특이도 | 참고문헌 | 1.  평가 불가능 | 임상시험의뢰자에게 보고한다.  | 대조기기 |\n| 7 | 혈소판 기능 이상 검체 각각의 이동거리 값을 구한다. ",
        "original_sentence": "| 범위 | 인한 위해요인 방지시험에 관한 요구사항이 적용된다. "
      }
    },
    {
      "chunk_id": "chunk_027",
      "text": "| 합계 | a+c | b+d | a+b+c+d | 합계 | a+c | b+d | a+b+c+d | 정도 | - 피험자 제공 검체가 폐기된 경우, 임상시험담당자는 즉각 임상시험책임자, 및 | 관련성 | VerifyNowⓇ 성능평가 문헌 |\n| 합계 | a+c | b+d | a+b+c+d |\n| 6 | 하판 | 지지체 | ○○○ | 1개 |\n| □ YES | □ 기타: | 기계적 안전에 관한 공통기준규격」(식약처 고시) | the | assessment | of | platelet | dysfunction | (Clin | Lab |\n| n = 125.44 | □ ‘중증도’ 판정 참고기준 | 평균 민감도 | 평균 특이도 | 참고문헌 | 1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 26,
        "window_size": 3,
        "char_count": 362,
        "word_count": 102,
        "page_number": 78,
        "window_text": "(컷오프 근처의 검체 포함) | 준비하여 시험한다.  (컷오프 근처의 검체 포함) | 저항성 복합검사기기에 적용한다.  | 범위 | 인한 위해요인 방지시험에 관한 요구사항이 적용된다.  | 합계 | a+c | b+d | a+b+c+d | 합계 | a+c | b+d | a+b+c+d | 정도 | - 피험자 제공 검체가 폐기된 경우, 임상시험담당자는 즉각 임상시험책임자, 및 | 관련성 | VerifyNowⓇ 성능평가 문헌 |\n| 합계 | a+c | b+d | a+b+c+d |\n| 6 | 하판 | 지지체 | ○○○ | 1개 |\n| □ YES | □ 기타: | 기계적 안전에 관한 공통기준규격」(식약처 고시) | the | assessment | of | platelet | dysfunction | (Clin | Lab |\n| n = 125.44 | □ ‘중증도’ 판정 참고기준 | 평균 민감도 | 평균 특이도 | 참고문헌 | 1.  평가 불가능 | 임상시험의뢰자에게 보고한다.  | 대조기기 |\n| 7 | 혈소판 기능 이상 검체 각각의 이동거리 값을 구한다.  | - 시험장비 | - 시험장비 | 한다. ",
        "original_sentence": "| 합계 | a+c | b+d | a+b+c+d | 합계 | a+c | b+d | a+b+c+d | 정도 | - 피험자 제공 검체가 폐기된 경우, 임상시험담당자는 즉각 임상시험책임자, 및 | 관련성 | VerifyNowⓇ 성능평가 문헌 |\n| 합계 | a+c | b+d | a+b+c+d |\n| 6 | 하판 | 지지체 | ○○○ | 1개 |\n| □ YES | □ 기타: | 기계적 안전에 관한 공통기준규격」(식약처 고시) | the | assessment | of | platelet | dysfunction | (Clin | Lab |\n| n = 125.44 | □ ‘중증도’ 판정 참고기준 | 평균 민감도 | 평균 특이도 | 참고문헌 | 1. "
      }
    },
    {
      "chunk_id": "chunk_028",
      "text": "평가 불가능 | 임상시험의뢰자에게 보고한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 27,
        "window_size": 3,
        "char_count": 25,
        "word_count": 5,
        "page_number": 9,
        "window_text": "(컷오프 근처의 검체 포함) | 저항성 복합검사기기에 적용한다.  | 범위 | 인한 위해요인 방지시험에 관한 요구사항이 적용된다.  | 합계 | a+c | b+d | a+b+c+d | 합계 | a+c | b+d | a+b+c+d | 정도 | - 피험자 제공 검체가 폐기된 경우, 임상시험담당자는 즉각 임상시험책임자, 및 | 관련성 | VerifyNowⓇ 성능평가 문헌 |\n| 합계 | a+c | b+d | a+b+c+d |\n| 6 | 하판 | 지지체 | ○○○ | 1개 |\n| □ YES | □ 기타: | 기계적 안전에 관한 공통기준규격」(식약처 고시) | the | assessment | of | platelet | dysfunction | (Clin | Lab |\n| n = 125.44 | □ ‘중증도’ 판정 참고기준 | 평균 민감도 | 평균 특이도 | 참고문헌 | 1.  평가 불가능 | 임상시험의뢰자에게 보고한다.  | 대조기기 |\n| 7 | 혈소판 기능 이상 검체 각각의 이동거리 값을 구한다.  | - 시험장비 | - 시험장비 | 한다.  | 검사를 시행한다. ",
        "original_sentence": "평가 불가능 | 임상시험의뢰자에게 보고한다. "
      }
    },
    {
      "chunk_id": "chunk_029",
      "text": "| 대조기기 |\n| 7 | 혈소판 기능 이상 검체 각각의 이동거리 값을 구한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 28,
        "window_size": 3,
        "char_count": 45,
        "word_count": 14,
        "page_number": 15,
        "window_text": "| 범위 | 인한 위해요인 방지시험에 관한 요구사항이 적용된다.  | 합계 | a+c | b+d | a+b+c+d | 합계 | a+c | b+d | a+b+c+d | 정도 | - 피험자 제공 검체가 폐기된 경우, 임상시험담당자는 즉각 임상시험책임자, 및 | 관련성 | VerifyNowⓇ 성능평가 문헌 |\n| 합계 | a+c | b+d | a+b+c+d |\n| 6 | 하판 | 지지체 | ○○○ | 1개 |\n| □ YES | □ 기타: | 기계적 안전에 관한 공통기준규격」(식약처 고시) | the | assessment | of | platelet | dysfunction | (Clin | Lab |\n| n = 125.44 | □ ‘중증도’ 판정 참고기준 | 평균 민감도 | 평균 특이도 | 참고문헌 | 1.  평가 불가능 | 임상시험의뢰자에게 보고한다.  | 대조기기 |\n| 7 | 혈소판 기능 이상 검체 각각의 이동거리 값을 구한다.  | - 시험장비 | - 시험장비 | 한다.  | 검사를 시행한다.  | 마개가 형성되는 과정이 1차 혈소판 지혈과정이다. ",
        "original_sentence": "| 대조기기 |\n| 7 | 혈소판 기능 이상 검체 각각의 이동거리 값을 구한다. "
      }
    },
    {
      "chunk_id": "chunk_030",
      "text": "| - 시험장비 | - 시험장비 | 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 29,
        "window_size": 3,
        "char_count": 24,
        "word_count": 8,
        "page_number": 9,
        "window_text": "| 합계 | a+c | b+d | a+b+c+d | 합계 | a+c | b+d | a+b+c+d | 정도 | - 피험자 제공 검체가 폐기된 경우, 임상시험담당자는 즉각 임상시험책임자, 및 | 관련성 | VerifyNowⓇ 성능평가 문헌 |\n| 합계 | a+c | b+d | a+b+c+d |\n| 6 | 하판 | 지지체 | ○○○ | 1개 |\n| □ YES | □ 기타: | 기계적 안전에 관한 공통기준규격」(식약처 고시) | the | assessment | of | platelet | dysfunction | (Clin | Lab |\n| n = 125.44 | □ ‘중증도’ 판정 참고기준 | 평균 민감도 | 평균 특이도 | 참고문헌 | 1.  평가 불가능 | 임상시험의뢰자에게 보고한다.  | 대조기기 |\n| 7 | 혈소판 기능 이상 검체 각각의 이동거리 값을 구한다.  | - 시험장비 | - 시험장비 | 한다.  | 검사를 시행한다.  | 마개가 형성되는 과정이 1차 혈소판 지혈과정이다.  | 검사법이 검체에서 직접 측정할 수 있는 분석물질 값의 범위 | 전혈 검체에 분석대상 물질을 일정량 첨가한 시험물질 사용 | 측정한다. ",
        "original_sentence": "| - 시험장비 | - 시험장비 | 한다. "
      }
    },
    {
      "chunk_id": "chunk_031",
      "text": "| 검사를 시행한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 30,
        "window_size": 3,
        "char_count": 12,
        "word_count": 3,
        "page_number": 24,
        "window_text": "평가 불가능 | 임상시험의뢰자에게 보고한다.  | 대조기기 |\n| 7 | 혈소판 기능 이상 검체 각각의 이동거리 값을 구한다.  | - 시험장비 | - 시험장비 | 한다.  | 검사를 시행한다.  | 마개가 형성되는 과정이 1차 혈소판 지혈과정이다.  | 검사법이 검체에서 직접 측정할 수 있는 분석물질 값의 범위 | 전혈 검체에 분석대상 물질을 일정량 첨가한 시험물질 사용 | 측정한다.  | 주성분 | ○○○ | OO±OO ㎍/㎖ |\n| stability of in vitro diagnostic reagents | 1) 경증 (mild) | 2. ",
        "original_sentence": "| 검사를 시행한다. "
      }
    },
    {
      "chunk_id": "chunk_032",
      "text": "| 마개가 형성되는 과정이 1차 혈소판 지혈과정이다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 31,
        "window_size": 3,
        "char_count": 30,
        "word_count": 7,
        "page_number": 6,
        "window_text": "| 대조기기 |\n| 7 | 혈소판 기능 이상 검체 각각의 이동거리 값을 구한다.  | - 시험장비 | - 시험장비 | 한다.  | 검사를 시행한다.  | 마개가 형성되는 과정이 1차 혈소판 지혈과정이다.  | 검사법이 검체에서 직접 측정할 수 있는 분석물질 값의 범위 | 전혈 검체에 분석대상 물질을 일정량 첨가한 시험물질 사용 | 측정한다.  | 주성분 | ○○○ | OO±OO ㎍/㎖ |\n| stability of in vitro diagnostic reagents | 1) 경증 (mild) | 2.  관련성이 없음 | 1. ",
        "original_sentence": "| 마개가 형성되는 과정이 1차 혈소판 지혈과정이다. "
      }
    },
    {
      "chunk_id": "chunk_033",
      "text": "| 검사법이 검체에서 직접 측정할 수 있는 분석물질 값의 범위 | 전혈 검체에 분석대상 물질을 일정량 첨가한 시험물질 사용 | 측정한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 32,
        "window_size": 3,
        "char_count": 77,
        "word_count": 21,
        "page_number": 11,
        "window_text": "| - 시험장비 | - 시험장비 | 한다.  | 검사를 시행한다.  | 마개가 형성되는 과정이 1차 혈소판 지혈과정이다.  | 검사법이 검체에서 직접 측정할 수 있는 분석물질 값의 범위 | 전혈 검체에 분석대상 물질을 일정량 첨가한 시험물질 사용 | 측정한다.  | 주성분 | ○○○ | OO±OO ㎍/㎖ |\n| stability of in vitro diagnostic reagents | 1) 경증 (mild) | 2.  관련성이 없음 | 1.  이식체 | 1. ",
        "original_sentence": "| 검사법이 검체에서 직접 측정할 수 있는 분석물질 값의 범위 | 전혈 검체에 분석대상 물질을 일정량 첨가한 시험물질 사용 | 측정한다. "
      }
    },
    {
      "chunk_id": "chunk_034",
      "text": "| 주성분 | ○○○ | OO±OO ㎍/㎖ |\n| stability of in vitro diagnostic reagents | 1) 경증 (mild) | 2. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 33,
        "window_size": 3,
        "char_count": 90,
        "word_count": 21,
        "page_number": 17,
        "window_text": "| 검사를 시행한다.  | 마개가 형성되는 과정이 1차 혈소판 지혈과정이다.  | 검사법이 검체에서 직접 측정할 수 있는 분석물질 값의 범위 | 전혈 검체에 분석대상 물질을 일정량 첨가한 시험물질 사용 | 측정한다.  | 주성분 | ○○○ | OO±OO ㎍/㎖ |\n| stability of in vitro diagnostic reagents | 1) 경증 (mild) | 2.  관련성이 없음 | 1.  이식체 | 1.  치료하지 않음 | 1. ",
        "original_sentence": "| 주성분 | ○○○ | OO±OO ㎍/㎖ |\n| stability of in vitro diagnostic reagents | 1) 경증 (mild) | 2. "
      }
    },
    {
      "chunk_id": "chunk_035",
      "text": "관련성이 없음 | 1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 34,
        "window_size": 3,
        "char_count": 13,
        "word_count": 4,
        "page_number": 6,
        "window_text": "| 마개가 형성되는 과정이 1차 혈소판 지혈과정이다.  | 검사법이 검체에서 직접 측정할 수 있는 분석물질 값의 범위 | 전혈 검체에 분석대상 물질을 일정량 첨가한 시험물질 사용 | 측정한다.  | 주성분 | ○○○ | OO±OO ㎍/㎖ |\n| stability of in vitro diagnostic reagents | 1) 경증 (mild) | 2.  관련성이 없음 | 1.  이식체 | 1.  치료하지 않음 | 1.  회복 | 합계 |\n| □ NO | 막힘부 | 반응부 | (사유 :                                                                 ) | Haematol. ",
        "original_sentence": "관련성이 없음 | 1. "
      }
    },
    {
      "chunk_id": "chunk_036",
      "text": "이식체 | 1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 35,
        "window_size": 3,
        "char_count": 9,
        "word_count": 3,
        "page_number": 6,
        "window_text": "| 검사법이 검체에서 직접 측정할 수 있는 분석물질 값의 범위 | 전혈 검체에 분석대상 물질을 일정량 첨가한 시험물질 사용 | 측정한다.  | 주성분 | ○○○ | OO±OO ㎍/㎖ |\n| stability of in vitro diagnostic reagents | 1) 경증 (mild) | 2.  관련성이 없음 | 1.  이식체 | 1.  치료하지 않음 | 1.  회복 | 합계 |\n| □ NO | 막힘부 | 반응부 | (사유 :                                                                 ) | Haematol.  2002 Aug;24(4):225-32.) ",
        "original_sentence": "이식체 | 1. "
      }
    },
    {
      "chunk_id": "chunk_037",
      "text": "치료하지 않음 | 1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 36,
        "window_size": 3,
        "char_count": 13,
        "word_count": 4,
        "page_number": 6,
        "window_text": "| 주성분 | ○○○ | OO±OO ㎍/㎖ |\n| stability of in vitro diagnostic reagents | 1) 경증 (mild) | 2.  관련성이 없음 | 1.  이식체 | 1.  치료하지 않음 | 1.  회복 | 합계 |\n| □ NO | 막힘부 | 반응부 | (사유 :                                                                 ) | Haematol.  2002 Aug;24(4):225-32.)  | 1. ",
        "original_sentence": "치료하지 않음 | 1. "
      }
    },
    {
      "chunk_id": "chunk_038",
      "text": "회복 | 합계 |\n| □ NO | 막힘부 | 반응부 | (사유 :                                                                 ) | Haematol. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 37,
        "window_size": 3,
        "char_count": 115,
        "word_count": 17,
        "page_number": 23,
        "window_text": "관련성이 없음 | 1.  이식체 | 1.  치료하지 않음 | 1.  회복 | 합계 |\n| □ NO | 막힘부 | 반응부 | (사유 :                                                                 ) | Haematol.  2002 Aug;24(4):225-32.)  | 1.  Comparison of Different Methods to Evaluate |\n| ◈ 인구학적 정보 | 사항이 적용된다. ",
        "original_sentence": "회복 | 합계 |\n| □ NO | 막힘부 | 반응부 | (사유 :                                                                 ) | Haematol. "
      }
    },
    {
      "chunk_id": "chunk_039",
      "text": "2002 Aug;24(4):225-32.) ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 38,
        "window_size": 3,
        "char_count": 24,
        "word_count": 2,
        "page_number": 6,
        "window_text": "이식체 | 1.  치료하지 않음 | 1.  회복 | 합계 |\n| □ NO | 막힘부 | 반응부 | (사유 :                                                                 ) | Haematol.  2002 Aug;24(4):225-32.)  | 1.  Comparison of Different Methods to Evaluate |\n| ◈ 인구학적 정보 | 사항이 적용된다.  | 1. ",
        "original_sentence": "2002 Aug;24(4):225-32.) "
      }
    },
    {
      "chunk_id": "chunk_040",
      "text": "| 1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 39,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 6,
        "window_text": "치료하지 않음 | 1.  회복 | 합계 |\n| □ NO | 막힘부 | 반응부 | (사유 :                                                                 ) | Haematol.  2002 Aug;24(4):225-32.)  | 1.  Comparison of Different Methods to Evaluate |\n| ◈ 인구학적 정보 | 사항이 적용된다.  | 1.  경증 | - 피험자의 자발적 의사에 의한 임상시험 중지 또는 거부 요청이 발생한 경우, | -「의료기기의 전기·기계적 안전에 관한 공통기준규격」 | 1. ",
        "original_sentence": "| 1. "
      }
    },
    {
      "chunk_id": "chunk_041",
      "text": "Comparison of Different Methods to Evaluate |\n| ◈ 인구학적 정보 | 사항이 적용된다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 40,
        "window_size": 3,
        "char_count": 70,
        "word_count": 14,
        "page_number": 17,
        "window_text": "회복 | 합계 |\n| □ NO | 막힘부 | 반응부 | (사유 :                                                                 ) | Haematol.  2002 Aug;24(4):225-32.)  | 1.  Comparison of Different Methods to Evaluate |\n| ◈ 인구학적 정보 | 사항이 적용된다.  | 1.  경증 | - 피험자의 자발적 의사에 의한 임상시험 중지 또는 거부 요청이 발생한 경우, | -「의료기기의 전기·기계적 안전에 관한 공통기준규격」 | 1.  중대하지 |\n| 8 | 보조성분 | ○○○ | 적량 | requirements for in vitro diagnostic (IVD) medical equipment | 1. ",
        "original_sentence": "Comparison of Different Methods to Evaluate |\n| ◈ 인구학적 정보 | 사항이 적용된다. "
      }
    },
    {
      "chunk_id": "chunk_042",
      "text": "| 1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 41,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 6,
        "window_text": "2002 Aug;24(4):225-32.)  | 1.  Comparison of Different Methods to Evaluate |\n| ◈ 인구학적 정보 | 사항이 적용된다.  | 1.  경증 | - 피험자의 자발적 의사에 의한 임상시험 중지 또는 거부 요청이 발생한 경우, | -「의료기기의 전기·기계적 안전에 관한 공통기준규격」 | 1.  중대하지 |\n| 8 | 보조성분 | ○○○ | 적량 | requirements for in vitro diagnostic (IVD) medical equipment | 1.  국소 | · 피험자의 정상적인 일상생활(또는 기능)을 저해하지 않고, 최소한의 불편을 야기하며, | 3. ",
        "original_sentence": "| 1. "
      }
    },
    {
      "chunk_id": "chunk_043",
      "text": "경증 | - 피험자의 자발적 의사에 의한 임상시험 중지 또는 거부 요청이 발생한 경우, | -「의료기기의 전기·기계적 안전에 관한 공통기준규격」 | 1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 42,
        "window_size": 3,
        "char_count": 86,
        "word_count": 22,
        "page_number": 7,
        "window_text": "| 1.  Comparison of Different Methods to Evaluate |\n| ◈ 인구학적 정보 | 사항이 적용된다.  | 1.  경증 | - 피험자의 자발적 의사에 의한 임상시험 중지 또는 거부 요청이 발생한 경우, | -「의료기기의 전기·기계적 안전에 관한 공통기준규격」 | 1.  중대하지 |\n| 8 | 보조성분 | ○○○ | 적량 | requirements for in vitro diagnostic (IVD) medical equipment | 1.  국소 | · 피험자의 정상적인 일상생활(또는 기능)을 저해하지 않고, 최소한의 불편을 야기하며, | 3.  관련성이 적음 | 비정상 | 정상 | 삽입유지 | 2. ",
        "original_sentence": "경증 | - 피험자의 자발적 의사에 의한 임상시험 중지 또는 거부 요청이 발생한 경우, | -「의료기기의 전기·기계적 안전에 관한 공통기준규격」 | 1. "
      }
    },
    {
      "chunk_id": "chunk_044",
      "text": "중대하지 |\n| 8 | 보조성분 | ○○○ | 적량 | requirements for in vitro diagnostic (IVD) medical equipment | 1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 43,
        "window_size": 3,
        "char_count": 97,
        "word_count": 21,
        "page_number": 15,
        "window_text": "Comparison of Different Methods to Evaluate |\n| ◈ 인구학적 정보 | 사항이 적용된다.  | 1.  경증 | - 피험자의 자발적 의사에 의한 임상시험 중지 또는 거부 요청이 발생한 경우, | -「의료기기의 전기·기계적 안전에 관한 공통기준규격」 | 1.  중대하지 |\n| 8 | 보조성분 | ○○○ | 적량 | requirements for in vitro diagnostic (IVD) medical equipment | 1.  국소 | · 피험자의 정상적인 일상생활(또는 기능)을 저해하지 않고, 최소한의 불편을 야기하며, | 3.  관련성이 적음 | 비정상 | 정상 | 삽입유지 | 2.  약물치료 | 2. ",
        "original_sentence": "중대하지 |\n| 8 | 보조성분 | ○○○ | 적량 | requirements for in vitro diagnostic (IVD) medical equipment | 1. "
      }
    },
    {
      "chunk_id": "chunk_045",
      "text": "국소 | · 피험자의 정상적인 일상생활(또는 기능)을 저해하지 않고, 최소한의 불편을 야기하며, | 3. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 44,
        "window_size": 3,
        "char_count": 59,
        "word_count": 14,
        "page_number": 24,
        "window_text": "| 1.  경증 | - 피험자의 자발적 의사에 의한 임상시험 중지 또는 거부 요청이 발생한 경우, | -「의료기기의 전기·기계적 안전에 관한 공통기준규격」 | 1.  중대하지 |\n| 8 | 보조성분 | ○○○ | 적량 | requirements for in vitro diagnostic (IVD) medical equipment | 1.  국소 | · 피험자의 정상적인 일상생활(또는 기능)을 저해하지 않고, 최소한의 불편을 야기하며, | 3.  관련성이 적음 | 비정상 | 정상 | 삽입유지 | 2.  약물치료 | 2.  진행중 |\n| 기기 및 대조기기에서 검사를 시행하고 결과를 기록한다. ",
        "original_sentence": "국소 | · 피험자의 정상적인 일상생활(또는 기능)을 저해하지 않고, 최소한의 불편을 야기하며, | 3. "
      }
    },
    {
      "chunk_id": "chunk_046",
      "text": "관련성이 적음 | 비정상 | 정상 | 삽입유지 | 2. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 45,
        "window_size": 3,
        "char_count": 31,
        "word_count": 10,
        "page_number": 6,
        "window_text": "경증 | - 피험자의 자발적 의사에 의한 임상시험 중지 또는 거부 요청이 발생한 경우, | -「의료기기의 전기·기계적 안전에 관한 공통기준규격」 | 1.  중대하지 |\n| 8 | 보조성분 | ○○○ | 적량 | requirements for in vitro diagnostic (IVD) medical equipment | 1.  국소 | · 피험자의 정상적인 일상생활(또는 기능)을 저해하지 않고, 최소한의 불편을 야기하며, | 3.  관련성이 적음 | 비정상 | 정상 | 삽입유지 | 2.  약물치료 | 2.  진행중 |\n| 기기 및 대조기기에서 검사를 시행하고 결과를 기록한다.  | 후 압박지혈을 한다. ",
        "original_sentence": "관련성이 적음 | 비정상 | 정상 | 삽입유지 | 2. "
      }
    },
    {
      "chunk_id": "chunk_047",
      "text": "약물치료 | 2. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 46,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 6,
        "window_text": "중대하지 |\n| 8 | 보조성분 | ○○○ | 적량 | requirements for in vitro diagnostic (IVD) medical equipment | 1.  국소 | · 피험자의 정상적인 일상생활(또는 기능)을 저해하지 않고, 최소한의 불편을 야기하며, | 3.  관련성이 적음 | 비정상 | 정상 | 삽입유지 | 2.  약물치료 | 2.  진행중 |\n| 기기 및 대조기기에서 검사를 시행하고 결과를 기록한다.  | 후 압박지혈을 한다.  | 압력을 가해서는 안된다. ",
        "original_sentence": "약물치료 | 2. "
      }
    },
    {
      "chunk_id": "chunk_048",
      "text": "진행중 |\n| 기기 및 대조기기에서 검사를 시행하고 결과를 기록한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 47,
        "window_size": 3,
        "char_count": 39,
        "word_count": 10,
        "page_number": 24,
        "window_text": "국소 | · 피험자의 정상적인 일상생활(또는 기능)을 저해하지 않고, 최소한의 불편을 야기하며, | 3.  관련성이 적음 | 비정상 | 정상 | 삽입유지 | 2.  약물치료 | 2.  진행중 |\n| 기기 및 대조기기에서 검사를 시행하고 결과를 기록한다.  | 후 압박지혈을 한다.  | 압력을 가해서는 안된다.  | (Special form) | 외 규격 | 10 |\n| 사용 환경에 노출시켜 그 안정성을 평가하는 실험 | 가스, 폭발, 파열에 대한 보호시험에 관한 요구사항이 적용된다. ",
        "original_sentence": "진행중 |\n| 기기 및 대조기기에서 검사를 시행하고 결과를 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_049",
      "text": "| 후 압박지혈을 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 48,
        "window_size": 3,
        "char_count": 14,
        "word_count": 4,
        "page_number": 24,
        "window_text": "관련성이 적음 | 비정상 | 정상 | 삽입유지 | 2.  약물치료 | 2.  진행중 |\n| 기기 및 대조기기에서 검사를 시행하고 결과를 기록한다.  | 후 압박지혈을 한다.  | 압력을 가해서는 안된다.  | (Special form) | 외 규격 | 10 |\n| 사용 환경에 노출시켜 그 안정성을 평가하는 실험 | 가스, 폭발, 파열에 대한 보호시험에 관한 요구사항이 적용된다.  | for Clinical Laboratory Measurement Procedures | 임상시험 실시기관 및 책임 연구자 (소속과/직위/성명) | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | 2. ",
        "original_sentence": "| 후 압박지혈을 한다. "
      }
    },
    {
      "chunk_id": "chunk_050",
      "text": "| 압력을 가해서는 안된다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 49,
        "window_size": 3,
        "char_count": 16,
        "word_count": 4,
        "page_number": 49,
        "window_text": "약물치료 | 2.  진행중 |\n| 기기 및 대조기기에서 검사를 시행하고 결과를 기록한다.  | 후 압박지혈을 한다.  | 압력을 가해서는 안된다.  | (Special form) | 외 규격 | 10 |\n| 사용 환경에 노출시켜 그 안정성을 평가하는 실험 | 가스, 폭발, 파열에 대한 보호시험에 관한 요구사항이 적용된다.  | for Clinical Laboratory Measurement Procedures | 임상시험 실시기관 및 책임 연구자 (소속과/직위/성명) | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | 2.  중등 | - IEC 61010-1 Safety requirements for electrical equipment for | [그림 1] 1차 혈소판 지혈과정 | 3. ",
        "original_sentence": "| 압력을 가해서는 안된다. "
      }
    },
    {
      "chunk_id": "chunk_051",
      "text": "| (Special form) | 외 규격 | 10 |\n| 사용 환경에 노출시켜 그 안정성을 평가하는 실험 | 가스, 폭발, 파열에 대한 보호시험에 관한 요구사항이 적용된다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 50,
        "window_size": 3,
        "char_count": 98,
        "word_count": 26,
        "page_number": 6,
        "window_text": "진행중 |\n| 기기 및 대조기기에서 검사를 시행하고 결과를 기록한다.  | 후 압박지혈을 한다.  | 압력을 가해서는 안된다.  | (Special form) | 외 규격 | 10 |\n| 사용 환경에 노출시켜 그 안정성을 평가하는 실험 | 가스, 폭발, 파열에 대한 보호시험에 관한 요구사항이 적용된다.  | for Clinical Laboratory Measurement Procedures | 임상시험 실시기관 및 책임 연구자 (소속과/직위/성명) | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | 2.  중등 | - IEC 61010-1 Safety requirements for electrical equipment for | [그림 1] 1차 혈소판 지혈과정 | 3.  | Comparison | of | PFA-100 | and | Bleeding | Time | the | Effect | of | Aspirin | on | Platelet | Function | in | 않음 |\n| 임상시험 방법에 따라 “의료기기 임상시험 관련 통계기법 가이드라인”을 적용한다. ",
        "original_sentence": "| (Special form) | 외 규격 | 10 |\n| 사용 환경에 노출시켜 그 안정성을 평가하는 실험 | 가스, 폭발, 파열에 대한 보호시험에 관한 요구사항이 적용된다. "
      }
    },
    {
      "chunk_id": "chunk_052",
      "text": "| for Clinical Laboratory Measurement Procedures | 임상시험 실시기관 및 책임 연구자 (소속과/직위/성명) | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | 2. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 51,
        "window_size": 3,
        "char_count": 109,
        "word_count": 19,
        "page_number": 17,
        "window_text": "| 후 압박지혈을 한다.  | 압력을 가해서는 안된다.  | (Special form) | 외 규격 | 10 |\n| 사용 환경에 노출시켜 그 안정성을 평가하는 실험 | 가스, 폭발, 파열에 대한 보호시험에 관한 요구사항이 적용된다.  | for Clinical Laboratory Measurement Procedures | 임상시험 실시기관 및 책임 연구자 (소속과/직위/성명) | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | 2.  중등 | - IEC 61010-1 Safety requirements for electrical equipment for | [그림 1] 1차 혈소판 지혈과정 | 3.  | Comparison | of | PFA-100 | and | Bleeding | Time | the | Effect | of | Aspirin | on | Platelet | Function | in | 않음 |\n| 임상시험 방법에 따라 “의료기기 임상시험 관련 통계기법 가이드라인”을 적용한다.  | 2. ",
        "original_sentence": "| for Clinical Laboratory Measurement Procedures | 임상시험 실시기관 및 책임 연구자 (소속과/직위/성명) | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | 2. "
      }
    },
    {
      "chunk_id": "chunk_053",
      "text": "중등 | - IEC 61010-1 Safety requirements for electrical equipment for | [그림 1] 1차 혈소판 지혈과정 | 3. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 52,
        "window_size": 3,
        "char_count": 94,
        "word_count": 19,
        "page_number": 6,
        "window_text": "| 압력을 가해서는 안된다.  | (Special form) | 외 규격 | 10 |\n| 사용 환경에 노출시켜 그 안정성을 평가하는 실험 | 가스, 폭발, 파열에 대한 보호시험에 관한 요구사항이 적용된다.  | for Clinical Laboratory Measurement Procedures | 임상시험 실시기관 및 책임 연구자 (소속과/직위/성명) | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | 2.  중등 | - IEC 61010-1 Safety requirements for electrical equipment for | [그림 1] 1차 혈소판 지혈과정 | 3.  | Comparison | of | PFA-100 | and | Bleeding | Time | the | Effect | of | Aspirin | on | Platelet | Function | in | 않음 |\n| 임상시험 방법에 따라 “의료기기 임상시험 관련 통계기법 가이드라인”을 적용한다.  | 2.  전신 | 피험자가 쉽게 견딜 수 있는 경우 | [표 2] 국내업체 혈소판 기능검사 시약 허가사항 | 4. ",
        "original_sentence": "중등 | - IEC 61010-1 Safety requirements for electrical equipment for | [그림 1] 1차 혈소판 지혈과정 | 3. "
      }
    },
    {
      "chunk_id": "chunk_054",
      "text": "| Comparison | of | PFA-100 | and | Bleeding | Time | the | Effect | of | Aspirin | on | Platelet | Function | in | 않음 |\n| 임상시험 방법에 따라 “의료기기 임상시험 관련 통계기법 가이드라인”을 적용한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 53,
        "window_size": 3,
        "char_count": 168,
        "word_count": 41,
        "page_number": 6,
        "window_text": "| (Special form) | 외 규격 | 10 |\n| 사용 환경에 노출시켜 그 안정성을 평가하는 실험 | 가스, 폭발, 파열에 대한 보호시험에 관한 요구사항이 적용된다.  | for Clinical Laboratory Measurement Procedures | 임상시험 실시기관 및 책임 연구자 (소속과/직위/성명) | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | 2.  중등 | - IEC 61010-1 Safety requirements for electrical equipment for | [그림 1] 1차 혈소판 지혈과정 | 3.  | Comparison | of | PFA-100 | and | Bleeding | Time | the | Effect | of | Aspirin | on | Platelet | Function | in | 않음 |\n| 임상시험 방법에 따라 “의료기기 임상시험 관련 통계기법 가이드라인”을 적용한다.  | 2.  전신 | 피험자가 쉽게 견딜 수 있는 경우 | [표 2] 국내업체 혈소판 기능검사 시약 허가사항 | 4.  관련성이 의심됨 | 임상시험담당자는 즉각 임상시험책임자, 임상시험의뢰자에게 보고하고, | 2. ",
        "original_sentence": "| Comparison | of | PFA-100 | and | Bleeding | Time | the | Effect | of | Aspirin | on | Platelet | Function | in | 않음 |\n| 임상시험 방법에 따라 “의료기기 임상시험 관련 통계기법 가이드라인”을 적용한다. "
      }
    },
    {
      "chunk_id": "chunk_055",
      "text": "| 2. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 54,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 6,
        "window_text": "| for Clinical Laboratory Measurement Procedures | 임상시험 실시기관 및 책임 연구자 (소속과/직위/성명) | □ 법령(법ㆍ시행령ㆍ시행규칙) 또는 | 2.  중등 | - IEC 61010-1 Safety requirements for electrical equipment for | [그림 1] 1차 혈소판 지혈과정 | 3.  | Comparison | of | PFA-100 | and | Bleeding | Time | the | Effect | of | Aspirin | on | Platelet | Function | in | 않음 |\n| 임상시험 방법에 따라 “의료기기 임상시험 관련 통계기법 가이드라인”을 적용한다.  | 2.  전신 | 피험자가 쉽게 견딜 수 있는 경우 | [표 2] 국내업체 혈소판 기능검사 시약 허가사항 | 4.  관련성이 의심됨 | 임상시험담당자는 즉각 임상시험책임자, 임상시험의뢰자에게 보고하고, | 2.  이식체 | 3. ",
        "original_sentence": "| 2. "
      }
    },
    {
      "chunk_id": "chunk_056",
      "text": "전신 | 피험자가 쉽게 견딜 수 있는 경우 | [표 2] 국내업체 혈소판 기능검사 시약 허가사항 | 4. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 55,
        "window_size": 3,
        "char_count": 59,
        "word_count": 18,
        "page_number": 6,
        "window_text": "중등 | - IEC 61010-1 Safety requirements for electrical equipment for | [그림 1] 1차 혈소판 지혈과정 | 3.  | Comparison | of | PFA-100 | and | Bleeding | Time | the | Effect | of | Aspirin | on | Platelet | Function | in | 않음 |\n| 임상시험 방법에 따라 “의료기기 임상시험 관련 통계기법 가이드라인”을 적용한다.  | 2.  전신 | 피험자가 쉽게 견딜 수 있는 경우 | [표 2] 국내업체 혈소판 기능검사 시약 허가사항 | 4.  관련성이 의심됨 | 임상시험담당자는 즉각 임상시험책임자, 임상시험의뢰자에게 보고하고, | 2.  이식체 | 3.  비약물치료 | 3. ",
        "original_sentence": "전신 | 피험자가 쉽게 견딜 수 있는 경우 | [표 2] 국내업체 혈소판 기능검사 시약 허가사항 | 4. "
      }
    },
    {
      "chunk_id": "chunk_057",
      "text": "관련성이 의심됨 | 임상시험담당자는 즉각 임상시험책임자, 임상시험의뢰자에게 보고하고, | 2. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 56,
        "window_size": 3,
        "char_count": 53,
        "word_count": 10,
        "page_number": 3,
        "window_text": "| Comparison | of | PFA-100 | and | Bleeding | Time | the | Effect | of | Aspirin | on | Platelet | Function | in | 않음 |\n| 임상시험 방법에 따라 “의료기기 임상시험 관련 통계기법 가이드라인”을 적용한다.  | 2.  전신 | 피험자가 쉽게 견딜 수 있는 경우 | [표 2] 국내업체 혈소판 기능검사 시약 허가사항 | 4.  관련성이 의심됨 | 임상시험담당자는 즉각 임상시험책임자, 임상시험의뢰자에게 보고하고, | 2.  이식체 | 3.  비약물치료 | 3.  후유증 |\n| 사용하기에는 부적합하다. ",
        "original_sentence": "관련성이 의심됨 | 임상시험담당자는 즉각 임상시험책임자, 임상시험의뢰자에게 보고하고, | 2. "
      }
    },
    {
      "chunk_id": "chunk_058",
      "text": "이식체 | 3. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 57,
        "window_size": 3,
        "char_count": 9,
        "word_count": 3,
        "page_number": 15,
        "window_text": "| 2.  전신 | 피험자가 쉽게 견딜 수 있는 경우 | [표 2] 국내업체 혈소판 기능검사 시약 허가사항 | 4.  관련성이 의심됨 | 임상시험담당자는 즉각 임상시험책임자, 임상시험의뢰자에게 보고하고, | 2.  이식체 | 3.  비약물치료 | 3.  후유증 |\n| 사용하기에는 부적합하다.  | 3. ",
        "original_sentence": "이식체 | 3. "
      }
    },
    {
      "chunk_id": "chunk_059",
      "text": "비약물치료 | 3. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 58,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 15,
        "window_text": "전신 | 피험자가 쉽게 견딜 수 있는 경우 | [표 2] 국내업체 혈소판 기능검사 시약 허가사항 | 4.  관련성이 의심됨 | 임상시험담당자는 즉각 임상시험책임자, 임상시험의뢰자에게 보고하고, | 2.  이식체 | 3.  비약물치료 | 3.  후유증 |\n| 사용하기에는 부적합하다.  | 3.  중증 | 2. ",
        "original_sentence": "비약물치료 | 3. "
      }
    },
    {
      "chunk_id": "chunk_060",
      "text": "후유증 |\n| 사용하기에는 부적합하다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 59,
        "window_size": 3,
        "char_count": 22,
        "word_count": 5,
        "page_number": 34,
        "window_text": "관련성이 의심됨 | 임상시험담당자는 즉각 임상시험책임자, 임상시험의뢰자에게 보고하고, | 2.  이식체 | 3.  비약물치료 | 3.  후유증 |\n| 사용하기에는 부적합하다.  | 3.  중증 | 2.  중대함 | □ 예 | ■ 아니오 |\n| 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까? ",
        "original_sentence": "후유증 |\n| 사용하기에는 부적합하다. "
      }
    },
    {
      "chunk_id": "chunk_061",
      "text": "| 3. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 60,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 15,
        "window_text": "이식체 | 3.  비약물치료 | 3.  후유증 |\n| 사용하기에는 부적합하다.  | 3.  중증 | 2.  중대함 | □ 예 | ■ 아니오 |\n| 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  |         | measurement, control, and laboratory use – Part 1: General | a | b |\n| 생년월일(YY/MM/DD) | 2) 중증도 (moderate) | 5. ",
        "original_sentence": "| 3. "
      }
    },
    {
      "chunk_id": "chunk_062",
      "text": "중증 | 2. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 61,
        "window_size": 3,
        "char_count": 8,
        "word_count": 3,
        "page_number": 6,
        "window_text": "비약물치료 | 3.  후유증 |\n| 사용하기에는 부적합하다.  | 3.  중증 | 2.  중대함 | □ 예 | ■ 아니오 |\n| 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  |         | measurement, control, and laboratory use – Part 1: General | a | b |\n| 생년월일(YY/MM/DD) | 2) 중증도 (moderate) | 5.  관련성이 많음 | 성별 | □ 남 | □ 여 | High-Risk Patients With Ischemic Heart Disease | 제거 | 4. ",
        "original_sentence": "중증 | 2. "
      }
    },
    {
      "chunk_id": "chunk_063",
      "text": "중대함 | □ 예 | ■ 아니오 |\n| 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까? ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 62,
        "window_size": 3,
        "char_count": 63,
        "word_count": 17,
        "page_number": 3,
        "window_text": "후유증 |\n| 사용하기에는 부적합하다.  | 3.  중증 | 2.  중대함 | □ 예 | ■ 아니오 |\n| 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  |         | measurement, control, and laboratory use – Part 1: General | a | b |\n| 생년월일(YY/MM/DD) | 2) 중증도 (moderate) | 5.  관련성이 많음 | 성별 | □ 남 | □ 여 | High-Risk Patients With Ischemic Heart Disease | 제거 | 4.  수술적치료 | 4. ",
        "original_sentence": "중대함 | □ 예 | ■ 아니오 |\n| 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까? "
      }
    },
    {
      "chunk_id": "chunk_064",
      "text": "|         | measurement, control, and laboratory use – Part 1: General | a | b |\n| 생년월일(YY/MM/DD) | 2) 중증도 (moderate) | 5. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 63,
        "window_size": 3,
        "char_count": 139,
        "word_count": 32,
        "page_number": 19,
        "window_text": "| 3.  중증 | 2.  중대함 | □ 예 | ■ 아니오 |\n| 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  |         | measurement, control, and laboratory use – Part 1: General | a | b |\n| 생년월일(YY/MM/DD) | 2) 중증도 (moderate) | 5.  관련성이 많음 | 성별 | □ 남 | □ 여 | High-Risk Patients With Ischemic Heart Disease | 제거 | 4.  수술적치료 | 4.  사망 |\n| 감염 방지 정책을 따라야 한다. ",
        "original_sentence": "|         | measurement, control, and laboratory use – Part 1: General | a | b |\n| 생년월일(YY/MM/DD) | 2) 중증도 (moderate) | 5. "
      }
    },
    {
      "chunk_id": "chunk_065",
      "text": "관련성이 많음 | 성별 | □ 남 | □ 여 | High-Risk Patients With Ischemic Heart Disease | 제거 | 4. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 64,
        "window_size": 3,
        "char_count": 84,
        "word_count": 21,
        "page_number": 23,
        "window_text": "중증 | 2.  중대함 | □ 예 | ■ 아니오 |\n| 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  |         | measurement, control, and laboratory use – Part 1: General | a | b |\n| 생년월일(YY/MM/DD) | 2) 중증도 (moderate) | 5.  관련성이 많음 | 성별 | □ 남 | □ 여 | High-Risk Patients With Ischemic Heart Disease | 제거 | 4.  수술적치료 | 4.  사망 |\n| 감염 방지 정책을 따라야 한다.  | ◈ 항혈소판제제 사용력 | requirements | 전기·기계적 | 비정상 | 임상시험기관의 임상시료 폐기절차에 따라 즉각 폐기한다. ",
        "original_sentence": "관련성이 많음 | 성별 | □ 남 | □ 여 | High-Risk Patients With Ischemic Heart Disease | 제거 | 4. "
      }
    },
    {
      "chunk_id": "chunk_066",
      "text": "수술적치료 | 4. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 65,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 15,
        "window_text": "중대함 | □ 예 | ■ 아니오 |\n| 행정규칙(고시ㆍ훈령ㆍ예규)의 내용을 단순 편집 또는 | 나열한 것입니까?  |         | measurement, control, and laboratory use – Part 1: General | a | b |\n| 생년월일(YY/MM/DD) | 2) 중증도 (moderate) | 5.  관련성이 많음 | 성별 | □ 남 | □ 여 | High-Risk Patients With Ischemic Heart Disease | 제거 | 4.  수술적치료 | 4.  사망 |\n| 감염 방지 정책을 따라야 한다.  | ◈ 항혈소판제제 사용력 | requirements | 전기·기계적 | 비정상 | 임상시험기관의 임상시료 폐기절차에 따라 즉각 폐기한다.  | Testing | in | Pediatric | Patients | With | Suspected | a+b |\n| ☞ 사용 환경은 온도, 이동 조건, 진동, 빛, 습도를 포함한다. ",
        "original_sentence": "수술적치료 | 4. "
      }
    },
    {
      "chunk_id": "chunk_067",
      "text": "사망 |\n| 감염 방지 정책을 따라야 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 66,
        "window_size": 3,
        "char_count": 25,
        "word_count": 8,
        "page_number": 24,
        "window_text": "|         | measurement, control, and laboratory use – Part 1: General | a | b |\n| 생년월일(YY/MM/DD) | 2) 중증도 (moderate) | 5.  관련성이 많음 | 성별 | □ 남 | □ 여 | High-Risk Patients With Ischemic Heart Disease | 제거 | 4.  수술적치료 | 4.  사망 |\n| 감염 방지 정책을 따라야 한다.  | ◈ 항혈소판제제 사용력 | requirements | 전기·기계적 | 비정상 | 임상시험기관의 임상시료 폐기절차에 따라 즉각 폐기한다.  | Testing | in | Pediatric | Patients | With | Suspected | a+b |\n| ☞ 사용 환경은 온도, 이동 조건, 진동, 빛, 습도를 포함한다.  | 2개 로트로 대체 가능) | 2개 로트로 대체 가능) | 사용되고 있다. ",
        "original_sentence": "사망 |\n| 감염 방지 정책을 따라야 한다. "
      }
    },
    {
      "chunk_id": "chunk_068",
      "text": "| ◈ 항혈소판제제 사용력 | requirements | 전기·기계적 | 비정상 | 임상시험기관의 임상시료 폐기절차에 따라 즉각 폐기한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 67,
        "window_size": 3,
        "char_count": 78,
        "word_count": 17,
        "page_number": 17,
        "window_text": "관련성이 많음 | 성별 | □ 남 | □ 여 | High-Risk Patients With Ischemic Heart Disease | 제거 | 4.  수술적치료 | 4.  사망 |\n| 감염 방지 정책을 따라야 한다.  | ◈ 항혈소판제제 사용력 | requirements | 전기·기계적 | 비정상 | 임상시험기관의 임상시료 폐기절차에 따라 즉각 폐기한다.  | Testing | in | Pediatric | Patients | With | Suspected | a+b |\n| ☞ 사용 환경은 온도, 이동 조건, 진동, 빛, 습도를 포함한다.  | 2개 로트로 대체 가능) | 2개 로트로 대체 가능) | 사용되고 있다.  | 하여 최소이동거리를 제시한다. ",
        "original_sentence": "| ◈ 항혈소판제제 사용력 | requirements | 전기·기계적 | 비정상 | 임상시험기관의 임상시료 폐기절차에 따라 즉각 폐기한다. "
      }
    },
    {
      "chunk_id": "chunk_069",
      "text": "| Testing | in | Pediatric | Patients | With | Suspected | a+b |\n| ☞ 사용 환경은 온도, 이동 조건, 진동, 빛, 습도를 포함한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 68,
        "window_size": 3,
        "char_count": 104,
        "word_count": 26,
        "page_number": 17,
        "window_text": "수술적치료 | 4.  사망 |\n| 감염 방지 정책을 따라야 한다.  | ◈ 항혈소판제제 사용력 | requirements | 전기·기계적 | 비정상 | 임상시험기관의 임상시료 폐기절차에 따라 즉각 폐기한다.  | Testing | in | Pediatric | Patients | With | Suspected | a+b |\n| ☞ 사용 환경은 온도, 이동 조건, 진동, 빛, 습도를 포함한다.  | 2개 로트로 대체 가능) | 2개 로트로 대체 가능) | 사용되고 있다.  | 하여 최소이동거리를 제시한다.  | 0000 병원 000 과/교수/000 | requirements |\n| · 피험자의 정상적인 일상생활(또는 기능)을 유의하게 저해하는 불편을 야기하는 경우 | 6. ",
        "original_sentence": "| Testing | in | Pediatric | Patients | With | Suspected | a+b |\n| ☞ 사용 환경은 온도, 이동 조건, 진동, 빛, 습도를 포함한다. "
      }
    },
    {
      "chunk_id": "chunk_070",
      "text": "| 2개 로트로 대체 가능) | 2개 로트로 대체 가능) | 사용되고 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 69,
        "window_size": 3,
        "char_count": 43,
        "word_count": 13,
        "page_number": 6,
        "window_text": "사망 |\n| 감염 방지 정책을 따라야 한다.  | ◈ 항혈소판제제 사용력 | requirements | 전기·기계적 | 비정상 | 임상시험기관의 임상시료 폐기절차에 따라 즉각 폐기한다.  | Testing | in | Pediatric | Patients | With | Suspected | a+b |\n| ☞ 사용 환경은 온도, 이동 조건, 진동, 빛, 습도를 포함한다.  | 2개 로트로 대체 가능) | 2개 로트로 대체 가능) | 사용되고 있다.  | 하여 최소이동거리를 제시한다.  | 0000 병원 000 과/교수/000 | requirements |\n| · 피험자의 정상적인 일상생활(또는 기능)을 유의하게 저해하는 불편을 야기하는 경우 | 6.  관련성이 명백함 |\n| 기관명 | 소재지 | 전화 | 팩스 | 안전에 관한 시험 | (True Positive) | Receiving Dual Antiplatelet Treatment (Am J Clin | (False Positive) |\n| 여부 | 기술된 정전기 방전시험에 관한 요구사항이 적용된다. ",
        "original_sentence": "| 2개 로트로 대체 가능) | 2개 로트로 대체 가능) | 사용되고 있다. "
      }
    },
    {
      "chunk_id": "chunk_071",
      "text": "| 하여 최소이동거리를 제시한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 70,
        "window_size": 3,
        "char_count": 19,
        "word_count": 4,
        "page_number": 22,
        "window_text": "| ◈ 항혈소판제제 사용력 | requirements | 전기·기계적 | 비정상 | 임상시험기관의 임상시료 폐기절차에 따라 즉각 폐기한다.  | Testing | in | Pediatric | Patients | With | Suspected | a+b |\n| ☞ 사용 환경은 온도, 이동 조건, 진동, 빛, 습도를 포함한다.  | 2개 로트로 대체 가능) | 2개 로트로 대체 가능) | 사용되고 있다.  | 하여 최소이동거리를 제시한다.  | 0000 병원 000 과/교수/000 | requirements |\n| · 피험자의 정상적인 일상생활(또는 기능)을 유의하게 저해하는 불편을 야기하는 경우 | 6.  관련성이 명백함 |\n| 기관명 | 소재지 | 전화 | 팩스 | 안전에 관한 시험 | (True Positive) | Receiving Dual Antiplatelet Treatment (Am J Clin | (False Positive) |\n| 여부 | 기술된 정전기 방전시험에 관한 요구사항이 적용된다.  | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? ",
        "original_sentence": "| 하여 최소이동거리를 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_072",
      "text": "| 0000 병원 000 과/교수/000 | requirements |\n| · 피험자의 정상적인 일상생활(또는 기능)을 유의하게 저해하는 불편을 야기하는 경우 | 6. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 71,
        "window_size": 3,
        "char_count": 94,
        "word_count": 21,
        "page_number": 17,
        "window_text": "| Testing | in | Pediatric | Patients | With | Suspected | a+b |\n| ☞ 사용 환경은 온도, 이동 조건, 진동, 빛, 습도를 포함한다.  | 2개 로트로 대체 가능) | 2개 로트로 대체 가능) | 사용되고 있다.  | 하여 최소이동거리를 제시한다.  | 0000 병원 000 과/교수/000 | requirements |\n| · 피험자의 정상적인 일상생활(또는 기능)을 유의하게 저해하는 불편을 야기하는 경우 | 6.  관련성이 명백함 |\n| 기관명 | 소재지 | 전화 | 팩스 | 안전에 관한 시험 | (True Positive) | Receiving Dual Antiplatelet Treatment (Am J Clin | (False Positive) |\n| 여부 | 기술된 정전기 방전시험에 관한 요구사항이 적용된다.  | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | - IEC 61010-2-101 Safety requirements for electrical equipment for | □ 아스피린    □ 클로피도그렐 | 증례 기록서 수정 방법 | Hemorrhagic | Problems | (J | Pediatr | Hematol | Oncol. ",
        "original_sentence": "| 0000 병원 000 과/교수/000 | requirements |\n| · 피험자의 정상적인 일상생활(또는 기능)을 유의하게 저해하는 불편을 야기하는 경우 | 6. "
      }
    },
    {
      "chunk_id": "chunk_073",
      "text": "관련성이 명백함 |\n| 기관명 | 소재지 | 전화 | 팩스 | 안전에 관한 시험 | (True Positive) | Receiving Dual Antiplatelet Treatment (Am J Clin | (False Positive) |\n| 여부 | 기술된 정전기 방전시험에 관한 요구사항이 적용된다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 72,
        "window_size": 3,
        "char_count": 171,
        "word_count": 39,
        "page_number": 9,
        "window_text": "| 2개 로트로 대체 가능) | 2개 로트로 대체 가능) | 사용되고 있다.  | 하여 최소이동거리를 제시한다.  | 0000 병원 000 과/교수/000 | requirements |\n| · 피험자의 정상적인 일상생활(또는 기능)을 유의하게 저해하는 불편을 야기하는 경우 | 6.  관련성이 명백함 |\n| 기관명 | 소재지 | 전화 | 팩스 | 안전에 관한 시험 | (True Positive) | Receiving Dual Antiplatelet Treatment (Am J Clin | (False Positive) |\n| 여부 | 기술된 정전기 방전시험에 관한 요구사항이 적용된다.  | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | - IEC 61010-2-101 Safety requirements for electrical equipment for | □ 아스피린    □ 클로피도그렐 | 증례 기록서 수정 방법 | Hemorrhagic | Problems | (J | Pediatr | Hematol | Oncol.  |\n| 2~8℃(파우치 내 보관), 개봉일로부터 6일 | 측정한다. ",
        "original_sentence": "관련성이 명백함 |\n| 기관명 | 소재지 | 전화 | 팩스 | 안전에 관한 시험 | (True Positive) | Receiving Dual Antiplatelet Treatment (Am J Clin | (False Positive) |\n| 여부 | 기술된 정전기 방전시험에 관한 요구사항이 적용된다. "
      }
    },
    {
      "chunk_id": "chunk_074",
      "text": "| □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 73,
        "window_size": 3,
        "char_count": 33,
        "word_count": 8,
        "page_number": 3,
        "window_text": "| 하여 최소이동거리를 제시한다.  | 0000 병원 000 과/교수/000 | requirements |\n| · 피험자의 정상적인 일상생활(또는 기능)을 유의하게 저해하는 불편을 야기하는 경우 | 6.  관련성이 명백함 |\n| 기관명 | 소재지 | 전화 | 팩스 | 안전에 관한 시험 | (True Positive) | Receiving Dual Antiplatelet Treatment (Am J Clin | (False Positive) |\n| 여부 | 기술된 정전기 방전시험에 관한 요구사항이 적용된다.  | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | - IEC 61010-2-101 Safety requirements for electrical equipment for | □ 아스피린    □ 클로피도그렐 | 증례 기록서 수정 방법 | Hemorrhagic | Problems | (J | Pediatr | Hematol | Oncol.  |\n| 2~8℃(파우치 내 보관), 개봉일로부터 6일 | 측정한다.  | 여러 검체가 혼합된 검체를 사용해서는 안된다. ",
        "original_sentence": "| □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까? "
      }
    },
    {
      "chunk_id": "chunk_075",
      "text": "| □ 예 | ■ 아니오 | - IEC 61010-2-101 Safety requirements for electrical equipment for | □ 아스피린    □ 클로피도그렐 | 증례 기록서 수정 방법 | Hemorrhagic | Problems | (J | Pediatr | Hematol | Oncol. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 74,
        "window_size": 3,
        "char_count": 178,
        "word_count": 38,
        "page_number": 3,
        "window_text": "| 0000 병원 000 과/교수/000 | requirements |\n| · 피험자의 정상적인 일상생활(또는 기능)을 유의하게 저해하는 불편을 야기하는 경우 | 6.  관련성이 명백함 |\n| 기관명 | 소재지 | 전화 | 팩스 | 안전에 관한 시험 | (True Positive) | Receiving Dual Antiplatelet Treatment (Am J Clin | (False Positive) |\n| 여부 | 기술된 정전기 방전시험에 관한 요구사항이 적용된다.  | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | - IEC 61010-2-101 Safety requirements for electrical equipment for | □ 아스피린    □ 클로피도그렐 | 증례 기록서 수정 방법 | Hemorrhagic | Problems | (J | Pediatr | Hematol | Oncol.  |\n| 2~8℃(파우치 내 보관), 개봉일로부터 6일 | 측정한다.  | 여러 검체가 혼합된 검체를 사용해서는 안된다.  | 발생할 수 있으므로 충분한 지혈을 하도록 환자에게 교육한다. ",
        "original_sentence": "| □ 예 | ■ 아니오 | - IEC 61010-2-101 Safety requirements for electrical equipment for | □ 아스피린    □ 클로피도그렐 | 증례 기록서 수정 방법 | Hemorrhagic | Problems | (J | Pediatr | Hematol | Oncol. "
      }
    },
    {
      "chunk_id": "chunk_076",
      "text": "|\n| 2~8℃(파우치 내 보관), 개봉일로부터 6일 | 측정한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 75,
        "window_size": 3,
        "char_count": 38,
        "word_count": 9,
        "page_number": 6,
        "window_text": "관련성이 명백함 |\n| 기관명 | 소재지 | 전화 | 팩스 | 안전에 관한 시험 | (True Positive) | Receiving Dual Antiplatelet Treatment (Am J Clin | (False Positive) |\n| 여부 | 기술된 정전기 방전시험에 관한 요구사항이 적용된다.  | □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | - IEC 61010-2-101 Safety requirements for electrical equipment for | □ 아스피린    □ 클로피도그렐 | 증례 기록서 수정 방법 | Hemorrhagic | Problems | (J | Pediatr | Hematol | Oncol.  |\n| 2~8℃(파우치 내 보관), 개봉일로부터 6일 | 측정한다.  | 여러 검체가 혼합된 검체를 사용해서는 안된다.  | 발생할 수 있으므로 충분한 지혈을 하도록 환자에게 교육한다.  | 천천히 주입하는 방식으로 분주한다. ",
        "original_sentence": "|\n| 2~8℃(파우치 내 보관), 개봉일로부터 6일 | 측정한다. "
      }
    },
    {
      "chunk_id": "chunk_077",
      "text": "| 여러 검체가 혼합된 검체를 사용해서는 안된다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 76,
        "window_size": 3,
        "char_count": 28,
        "word_count": 7,
        "page_number": 73,
        "window_text": "| □ 단순한 사실을 대외적으로 알리는 공고의 내용입니까?  | □ 예 | ■ 아니오 | - IEC 61010-2-101 Safety requirements for electrical equipment for | □ 아스피린    □ 클로피도그렐 | 증례 기록서 수정 방법 | Hemorrhagic | Problems | (J | Pediatr | Hematol | Oncol.  |\n| 2~8℃(파우치 내 보관), 개봉일로부터 6일 | 측정한다.  | 여러 검체가 혼합된 검체를 사용해서는 안된다.  | 발생할 수 있으므로 충분한 지혈을 하도록 환자에게 교육한다.  | 천천히 주입하는 방식으로 분주한다.  | 3) 중증 (severe) |         |\n| [n = sample size (검체 수), p (특이도) = 0.80, | 및 검사결과를 확인할 수 있다. ",
        "original_sentence": "| 여러 검체가 혼합된 검체를 사용해서는 안된다. "
      }
    },
    {
      "chunk_id": "chunk_078",
      "text": "| 발생할 수 있으므로 충분한 지혈을 하도록 환자에게 교육한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 77,
        "window_size": 3,
        "char_count": 36,
        "word_count": 9,
        "page_number": 24,
        "window_text": "| □ 예 | ■ 아니오 | - IEC 61010-2-101 Safety requirements for electrical equipment for | □ 아스피린    □ 클로피도그렐 | 증례 기록서 수정 방법 | Hemorrhagic | Problems | (J | Pediatr | Hematol | Oncol.  |\n| 2~8℃(파우치 내 보관), 개봉일로부터 6일 | 측정한다.  | 여러 검체가 혼합된 검체를 사용해서는 안된다.  | 발생할 수 있으므로 충분한 지혈을 하도록 환자에게 교육한다.  | 천천히 주입하는 방식으로 분주한다.  | 3) 중증 (severe) |         |\n| [n = sample size (검체 수), p (특이도) = 0.80, | 및 검사결과를 확인할 수 있다.  | 기재 등에 관한 규정」(식약처 고시) |\n| - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | □ YES | 2개 로트로 대체 가능) | 사항이 적용된다. ",
        "original_sentence": "| 발생할 수 있으므로 충분한 지혈을 하도록 환자에게 교육한다. "
      }
    },
    {
      "chunk_id": "chunk_079",
      "text": "| 천천히 주입하는 방식으로 분주한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 78,
        "window_size": 3,
        "char_count": 22,
        "word_count": 5,
        "page_number": 24,
        "window_text": "|\n| 2~8℃(파우치 내 보관), 개봉일로부터 6일 | 측정한다.  | 여러 검체가 혼합된 검체를 사용해서는 안된다.  | 발생할 수 있으므로 충분한 지혈을 하도록 환자에게 교육한다.  | 천천히 주입하는 방식으로 분주한다.  | 3) 중증 (severe) |         |\n| [n = sample size (검체 수), p (특이도) = 0.80, | 및 검사결과를 확인할 수 있다.  | 기재 등에 관한 규정」(식약처 고시) |\n| - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | □ YES | 2개 로트로 대체 가능) | 사항이 적용된다.  | 증명하기 위한 평가방법 및 기준을 제시할 수 있다. ",
        "original_sentence": "| 천천히 주입하는 방식으로 분주한다. "
      }
    },
    {
      "chunk_id": "chunk_080",
      "text": "| 3) 중증 (severe) |         |\n| [n = sample size (검체 수), p (특이도) = 0.80, | 및 검사결과를 확인할 수 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 79,
        "window_size": 3,
        "char_count": 108,
        "word_count": 31,
        "page_number": 15,
        "window_text": "| 여러 검체가 혼합된 검체를 사용해서는 안된다.  | 발생할 수 있으므로 충분한 지혈을 하도록 환자에게 교육한다.  | 천천히 주입하는 방식으로 분주한다.  | 3) 중증 (severe) |         |\n| [n = sample size (검체 수), p (특이도) = 0.80, | 및 검사결과를 확인할 수 있다.  | 기재 등에 관한 규정」(식약처 고시) |\n| - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | □ YES | 2개 로트로 대체 가능) | 사항이 적용된다.  | 증명하기 위한 평가방법 및 기준을 제시할 수 있다.  | · 피험자의 정상적인 일상생활(또는 기능)을 불가능하게 하는 경우 | □ 기타 P2Y12 수용체 저해제 | Ver. ",
        "original_sentence": "| 3) 중증 (severe) |         |\n| [n = sample size (검체 수), p (특이도) = 0.80, | 및 검사결과를 확인할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_081",
      "text": "| 기재 등에 관한 규정」(식약처 고시) |\n| - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | □ YES | 2개 로트로 대체 가능) | 사항이 적용된다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 80,
        "window_size": 3,
        "char_count": 163,
        "word_count": 43,
        "page_number": 1,
        "window_text": "| 발생할 수 있으므로 충분한 지혈을 하도록 환자에게 교육한다.  | 천천히 주입하는 방식으로 분주한다.  | 3) 중증 (severe) |         |\n| [n = sample size (검체 수), p (특이도) = 0.80, | 및 검사결과를 확인할 수 있다.  | 기재 등에 관한 규정」(식약처 고시) |\n| - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | □ YES | 2개 로트로 대체 가능) | 사항이 적용된다.  | 증명하기 위한 평가방법 및 기준을 제시할 수 있다.  | · 피험자의 정상적인 일상생활(또는 기능)을 불가능하게 하는 경우 | □ 기타 P2Y12 수용체 저해제 | Ver.  1.0 | Pathol. ",
        "original_sentence": "| 기재 등에 관한 규정」(식약처 고시) |\n| - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | □ YES | 2개 로트로 대체 가능) | 사항이 적용된다. "
      }
    },
    {
      "chunk_id": "chunk_082",
      "text": "| 증명하기 위한 평가방법 및 기준을 제시할 수 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 81,
        "window_size": 3,
        "char_count": 31,
        "word_count": 9,
        "page_number": 21,
        "window_text": "| 천천히 주입하는 방식으로 분주한다.  | 3) 중증 (severe) |         |\n| [n = sample size (검체 수), p (특이도) = 0.80, | 및 검사결과를 확인할 수 있다.  | 기재 등에 관한 규정」(식약처 고시) |\n| - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | □ YES | 2개 로트로 대체 가능) | 사항이 적용된다.  | 증명하기 위한 평가방법 및 기준을 제시할 수 있다.  | · 피험자의 정상적인 일상생활(또는 기능)을 불가능하게 하는 경우 | □ 기타 P2Y12 수용체 저해제 | Ver.  1.0 | Pathol.  2007 Jul;128(1):143-9.) ",
        "original_sentence": "| 증명하기 위한 평가방법 및 기준을 제시할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_083",
      "text": "| · 피험자의 정상적인 일상생활(또는 기능)을 불가능하게 하는 경우 | □ 기타 P2Y12 수용체 저해제 | Ver. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 82,
        "window_size": 3,
        "char_count": 67,
        "word_count": 17,
        "page_number": 6,
        "window_text": "| 3) 중증 (severe) |         |\n| [n = sample size (검체 수), p (특이도) = 0.80, | 및 검사결과를 확인할 수 있다.  | 기재 등에 관한 규정」(식약처 고시) |\n| - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | □ YES | 2개 로트로 대체 가능) | 사항이 적용된다.  | 증명하기 위한 평가방법 및 기준을 제시할 수 있다.  | · 피험자의 정상적인 일상생활(또는 기능)을 불가능하게 하는 경우 | □ 기타 P2Y12 수용체 저해제 | Ver.  1.0 | Pathol.  2007 Jul;128(1):143-9.)  |\n|         | measurement, control and laboratory use – Part 2-101: Particular | 2003 Jun;25(6):474-9.) ",
        "original_sentence": "| · 피험자의 정상적인 일상생활(또는 기능)을 불가능하게 하는 경우 | □ 기타 P2Y12 수용체 저해제 | Ver. "
      }
    },
    {
      "chunk_id": "chunk_084",
      "text": "1.0 | Pathol. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 83,
        "window_size": 3,
        "char_count": 14,
        "word_count": 3,
        "page_number": 6,
        "window_text": "| 기재 등에 관한 규정」(식약처 고시) |\n| - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | □ YES | 2개 로트로 대체 가능) | 사항이 적용된다.  | 증명하기 위한 평가방법 및 기준을 제시할 수 있다.  | · 피험자의 정상적인 일상생활(또는 기능)을 불가능하게 하는 경우 | □ 기타 P2Y12 수용체 저해제 | Ver.  1.0 | Pathol.  2007 Jul;128(1):143-9.)  |\n|         | measurement, control and laboratory use – Part 2-101: Particular | 2003 Jun;25(6):474-9.)  | c | d |\n| 15~25℃(파우치 외 보관), 개봉일로부터 4시간 | ◈ 측정된 기록의 정보 | 혈소판기능장애 환자 | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | 정상 | □ 기타(예, NOACs 등) | □ 예 | ■ 아니오 | c+b |\n| ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것 | (식품의약품안전처 지침서등의 관리에 관한 규정 제2조) | requirements for in vitro diagnostic (IVD) medical equipment |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. ",
        "original_sentence": "1.0 | Pathol. "
      }
    },
    {
      "chunk_id": "chunk_085",
      "text": "2007 Jul;128(1):143-9.) ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 84,
        "window_size": 3,
        "char_count": 24,
        "word_count": 2,
        "page_number": 6,
        "window_text": "| 증명하기 위한 평가방법 및 기준을 제시할 수 있다.  | · 피험자의 정상적인 일상생활(또는 기능)을 불가능하게 하는 경우 | □ 기타 P2Y12 수용체 저해제 | Ver.  1.0 | Pathol.  2007 Jul;128(1):143-9.)  |\n|         | measurement, control and laboratory use – Part 2-101: Particular | 2003 Jun;25(6):474-9.)  | c | d |\n| 15~25℃(파우치 외 보관), 개봉일로부터 4시간 | ◈ 측정된 기록의 정보 | 혈소판기능장애 환자 | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | 정상 | □ 기타(예, NOACs 등) | □ 예 | ■ 아니오 | c+b |\n| ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것 | (식품의약품안전처 지침서등의 관리에 관한 규정 제2조) | requirements for in vitro diagnostic (IVD) medical equipment |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 발생일. ",
        "original_sentence": "2007 Jul;128(1):143-9.) "
      }
    },
    {
      "chunk_id": "chunk_086",
      "text": "|\n|         | measurement, control and laboratory use – Part 2-101: Particular | 2003 Jun;25(6):474-9.) ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 85,
        "window_size": 3,
        "char_count": 120,
        "word_count": 23,
        "page_number": 19,
        "window_text": "| · 피험자의 정상적인 일상생활(또는 기능)을 불가능하게 하는 경우 | □ 기타 P2Y12 수용체 저해제 | Ver.  1.0 | Pathol.  2007 Jul;128(1):143-9.)  |\n|         | measurement, control and laboratory use – Part 2-101: Particular | 2003 Jun;25(6):474-9.)  | c | d |\n| 15~25℃(파우치 외 보관), 개봉일로부터 4시간 | ◈ 측정된 기록의 정보 | 혈소판기능장애 환자 | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | 정상 | □ 기타(예, NOACs 등) | □ 예 | ■ 아니오 | c+b |\n| ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것 | (식품의약품안전처 지침서등의 관리에 관한 규정 제2조) | requirements for in vitro diagnostic (IVD) medical equipment |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 발생일.  | 지속시간 | 2. ",
        "original_sentence": "|\n|         | measurement, control and laboratory use – Part 2-101: Particular | 2003 Jun;25(6):474-9.) "
      }
    },
    {
      "chunk_id": "chunk_087",
      "text": "| c | d |\n| 15~25℃(파우치 외 보관), 개봉일로부터 4시간 | ◈ 측정된 기록의 정보 | 혈소판기능장애 환자 | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | 정상 | □ 기타(예, NOACs 등) | □ 예 | ■ 아니오 | c+b |\n| ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것 | (식품의약품안전처 지침서등의 관리에 관한 규정 제2조) | requirements for in vitro diagnostic (IVD) medical equipment |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 86,
        "window_size": 3,
        "char_count": 427,
        "word_count": 102,
        "page_number": 6,
        "window_text": "1.0 | Pathol.  2007 Jul;128(1):143-9.)  |\n|         | measurement, control and laboratory use – Part 2-101: Particular | 2003 Jun;25(6):474-9.)  | c | d |\n| 15~25℃(파우치 외 보관), 개봉일로부터 4시간 | ◈ 측정된 기록의 정보 | 혈소판기능장애 환자 | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | 정상 | □ 기타(예, NOACs 등) | □ 예 | ■ 아니오 | c+b |\n| ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것 | (식품의약품안전처 지침서등의 관리에 관한 규정 제2조) | requirements for in vitro diagnostic (IVD) medical equipment |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 발생일.  | 지속시간 | 2.  VerifyNow AA FDA summary 510(k) summary |\n| 기록을 유지하여야 한다. ",
        "original_sentence": "| c | d |\n| 15~25℃(파우치 외 보관), 개봉일로부터 4시간 | ◈ 측정된 기록의 정보 | 혈소판기능장애 환자 | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | 정상 | □ 기타(예, NOACs 등) | □ 예 | ■ 아니오 | c+b |\n| ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것 | (식품의약품안전처 지침서등의 관리에 관한 규정 제2조) | requirements for in vitro diagnostic (IVD) medical equipment |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_088",
      "text": "| 발생일. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 87,
        "window_size": 3,
        "char_count": 7,
        "word_count": 2,
        "page_number": 88,
        "window_text": "2007 Jul;128(1):143-9.)  |\n|         | measurement, control and laboratory use – Part 2-101: Particular | 2003 Jun;25(6):474-9.)  | c | d |\n| 15~25℃(파우치 외 보관), 개봉일로부터 4시간 | ◈ 측정된 기록의 정보 | 혈소판기능장애 환자 | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | 정상 | □ 기타(예, NOACs 등) | □ 예 | ■ 아니오 | c+b |\n| ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것 | (식품의약품안전처 지침서등의 관리에 관한 규정 제2조) | requirements for in vitro diagnostic (IVD) medical equipment |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 발생일.  | 지속시간 | 2.  VerifyNow AA FDA summary 510(k) summary |\n| 기록을 유지하여야 한다.  | 측정거리 대해 일치되는 기준거리를 구한다. ",
        "original_sentence": "| 발생일. "
      }
    },
    {
      "chunk_id": "chunk_089",
      "text": "| 지속시간 | 2. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 88,
        "window_size": 3,
        "char_count": 12,
        "word_count": 4,
        "page_number": 6,
        "window_text": "|\n|         | measurement, control and laboratory use – Part 2-101: Particular | 2003 Jun;25(6):474-9.)  | c | d |\n| 15~25℃(파우치 외 보관), 개봉일로부터 4시간 | ◈ 측정된 기록의 정보 | 혈소판기능장애 환자 | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | 정상 | □ 기타(예, NOACs 등) | □ 예 | ■ 아니오 | c+b |\n| ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것 | (식품의약품안전처 지침서등의 관리에 관한 규정 제2조) | requirements for in vitro diagnostic (IVD) medical equipment |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 발생일.  | 지속시간 | 2.  VerifyNow AA FDA summary 510(k) summary |\n| 기록을 유지하여야 한다.  | 측정거리 대해 일치되는 기준거리를 구한다.  | 전혈 검체에 분석대상 물질을 일정량 첨가한 시험물질 사용한다. ",
        "original_sentence": "| 지속시간 | 2. "
      }
    },
    {
      "chunk_id": "chunk_090",
      "text": "VerifyNow AA FDA summary 510(k) summary |\n| 기록을 유지하여야 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 89,
        "window_size": 3,
        "char_count": 58,
        "word_count": 11,
        "page_number": 6,
        "window_text": "| c | d |\n| 15~25℃(파우치 외 보관), 개봉일로부터 4시간 | ◈ 측정된 기록의 정보 | 혈소판기능장애 환자 | □ 1년 이내 한시적 적용 또는 일회성 지시ㆍ명령에 해당하는 | 정상 | □ 기타(예, NOACs 등) | □ 예 | ■ 아니오 | c+b |\n| ○○○병원 | ○○시 ○○구 | ○○○-○○○○ | ○○○-○○○○ | 풀어서 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술하는 것 | (식품의약품안전처 지침서등의 관리에 관한 규정 제2조) | requirements for in vitro diagnostic (IVD) medical equipment |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 발생일.  | 지속시간 | 2.  VerifyNow AA FDA summary 510(k) summary |\n| 기록을 유지하여야 한다.  | 측정거리 대해 일치되는 기준거리를 구한다.  | 전혈 검체에 분석대상 물질을 일정량 첨가한 시험물질 사용한다.  | 측정하여 혈액 내부의 혈소판 인자의 기능을 확인하는 요소 | [n = sample size (검체 수), p (민감도) = 0.85, | □ NO | □ ‘의료기기와의 관련성’ 판정 참고기준 | 이상 | 내용입니까? ",
        "original_sentence": "VerifyNow AA FDA summary 510(k) summary |\n| 기록을 유지하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_091",
      "text": "| 측정거리 대해 일치되는 기준거리를 구한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 90,
        "window_size": 3,
        "char_count": 26,
        "word_count": 6,
        "page_number": 10,
        "window_text": "| 발생일.  | 지속시간 | 2.  VerifyNow AA FDA summary 510(k) summary |\n| 기록을 유지하여야 한다.  | 측정거리 대해 일치되는 기준거리를 구한다.  | 전혈 검체에 분석대상 물질을 일정량 첨가한 시험물질 사용한다.  | 측정하여 혈액 내부의 혈소판 인자의 기능을 확인하는 요소 | [n = sample size (검체 수), p (민감도) = 0.85, | □ NO | □ ‘의료기기와의 관련성’ 판정 참고기준 | 이상 | 내용입니까?  |         | (False Negative) | 증상의 | 4. ",
        "original_sentence": "| 측정거리 대해 일치되는 기준거리를 구한다. "
      }
    },
    {
      "chunk_id": "chunk_092",
      "text": "| 전혈 검체에 분석대상 물질을 일정량 첨가한 시험물질 사용한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 91,
        "window_size": 3,
        "char_count": 37,
        "word_count": 9,
        "page_number": 9,
        "window_text": "| 지속시간 | 2.  VerifyNow AA FDA summary 510(k) summary |\n| 기록을 유지하여야 한다.  | 측정거리 대해 일치되는 기준거리를 구한다.  | 전혈 검체에 분석대상 물질을 일정량 첨가한 시험물질 사용한다.  | 측정하여 혈액 내부의 혈소판 인자의 기능을 확인하는 요소 | [n = sample size (검체 수), p (민감도) = 0.85, | □ NO | □ ‘의료기기와의 관련성’ 판정 참고기준 | 이상 | 내용입니까?  |         | (False Negative) | 증상의 | 4.  Comparison of Different Methods to Evaluate the | 증상의 | 기기와의 | (True Negative) | 기기에 |\n| 이내로 유지되는지 평가하기 위함 | 나이 | 연구과제 피험자 설명문 및 동의서 | -「의료기기의 전자파안전에 관한 공통기준규격」 |\n| 일하므로, ADP test의 평가기준에 준하여 평가한다.) ",
        "original_sentence": "| 전혈 검체에 분석대상 물질을 일정량 첨가한 시험물질 사용한다. "
      }
    },
    {
      "chunk_id": "chunk_093",
      "text": "| 측정하여 혈액 내부의 혈소판 인자의 기능을 확인하는 요소 | [n = sample size (검체 수), p (민감도) = 0.85, | □ NO | □ ‘의료기기와의 관련성’ 판정 참고기준 | 이상 | 내용입니까? ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 92,
        "window_size": 3,
        "char_count": 123,
        "word_count": 33,
        "page_number": 7,
        "window_text": "VerifyNow AA FDA summary 510(k) summary |\n| 기록을 유지하여야 한다.  | 측정거리 대해 일치되는 기준거리를 구한다.  | 전혈 검체에 분석대상 물질을 일정량 첨가한 시험물질 사용한다.  | 측정하여 혈액 내부의 혈소판 인자의 기능을 확인하는 요소 | [n = sample size (검체 수), p (민감도) = 0.85, | □ NO | □ ‘의료기기와의 관련성’ 판정 참고기준 | 이상 | 내용입니까?  |         | (False Negative) | 증상의 | 4.  Comparison of Different Methods to Evaluate the | 증상의 | 기기와의 | (True Negative) | 기기에 |\n| 이내로 유지되는지 평가하기 위함 | 나이 | 연구과제 피험자 설명문 및 동의서 | -「의료기기의 전자파안전에 관한 공통기준규격」 |\n| 일하므로, ADP test의 평가기준에 준하여 평가한다.)  | (‘16.10.31 기준) | 혈소판 부착 | →        응집 유도인자 분비 | →     혈소판 응집 | 종료일 | (hours/ | K042423 | 대한 조치 | 치료 | 결과 | 중대성 |\n| 전자기장 시험에 관한 요구사항이 적용된다. ",
        "original_sentence": "| 측정하여 혈액 내부의 혈소판 인자의 기능을 확인하는 요소 | [n = sample size (검체 수), p (민감도) = 0.85, | □ NO | □ ‘의료기기와의 관련성’ 판정 참고기준 | 이상 | 내용입니까? "
      }
    },
    {
      "chunk_id": "chunk_094",
      "text": "|         | (False Negative) | 증상의 | 4. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 93,
        "window_size": 3,
        "char_count": 56,
        "word_count": 16,
        "page_number": 54,
        "window_text": "| 측정거리 대해 일치되는 기준거리를 구한다.  | 전혈 검체에 분석대상 물질을 일정량 첨가한 시험물질 사용한다.  | 측정하여 혈액 내부의 혈소판 인자의 기능을 확인하는 요소 | [n = sample size (검체 수), p (민감도) = 0.85, | □ NO | □ ‘의료기기와의 관련성’ 판정 참고기준 | 이상 | 내용입니까?  |         | (False Negative) | 증상의 | 4.  Comparison of Different Methods to Evaluate the | 증상의 | 기기와의 | (True Negative) | 기기에 |\n| 이내로 유지되는지 평가하기 위함 | 나이 | 연구과제 피험자 설명문 및 동의서 | -「의료기기의 전자파안전에 관한 공통기준규격」 |\n| 일하므로, ADP test의 평가기준에 준하여 평가한다.)  | (‘16.10.31 기준) | 혈소판 부착 | →        응집 유도인자 분비 | →     혈소판 응집 | 종료일 | (hours/ | K042423 | 대한 조치 | 치료 | 결과 | 중대성 |\n| 전자기장 시험에 관한 요구사항이 적용된다.  | 반응명 | 1) 평가 불가능 (Unknown) | □ 외국 규정을 번역하거나 설명하는 내용입니까? ",
        "original_sentence": "|         | (False Negative) | 증상의 | 4. "
      }
    },
    {
      "chunk_id": "chunk_095",
      "text": "Comparison of Different Methods to Evaluate the | 증상의 | 기기와의 | (True Negative) | 기기에 |\n| 이내로 유지되는지 평가하기 위함 | 나이 | 연구과제 피험자 설명문 및 동의서 | -「의료기기의 전자파안전에 관한 공통기준규격」 |\n| 일하므로, ADP test의 평가기준에 준하여 평가한다.) ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 94,
        "window_size": 3,
        "char_count": 198,
        "word_count": 43,
        "page_number": 17,
        "window_text": "| 전혈 검체에 분석대상 물질을 일정량 첨가한 시험물질 사용한다.  | 측정하여 혈액 내부의 혈소판 인자의 기능을 확인하는 요소 | [n = sample size (검체 수), p (민감도) = 0.85, | □ NO | □ ‘의료기기와의 관련성’ 판정 참고기준 | 이상 | 내용입니까?  |         | (False Negative) | 증상의 | 4.  Comparison of Different Methods to Evaluate the | 증상의 | 기기와의 | (True Negative) | 기기에 |\n| 이내로 유지되는지 평가하기 위함 | 나이 | 연구과제 피험자 설명문 및 동의서 | -「의료기기의 전자파안전에 관한 공통기준규격」 |\n| 일하므로, ADP test의 평가기준에 준하여 평가한다.)  | (‘16.10.31 기준) | 혈소판 부착 | →        응집 유도인자 분비 | →     혈소판 응집 | 종료일 | (hours/ | K042423 | 대한 조치 | 치료 | 결과 | 중대성 |\n| 전자기장 시험에 관한 요구사항이 적용된다.  | 반응명 | 1) 평가 불가능 (Unknown) | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | 범위 | 정도 | 관련성 |\n| n = 125.44 | [n = sample size (검체 수), p (민감도) = 0.90, | - IEC 61326-1 Electrical equipment for measurement, control and | Effect of Aspirin on Platelet Function in High-Risk |\n| 합계 | a+c | b+d | a+b+c+d | (yy/mm/dd) | minutes) |\n| ※ 구해진 기준값에 대하여 임상적으로 확증할 수 있다. ",
        "original_sentence": "Comparison of Different Methods to Evaluate the | 증상의 | 기기와의 | (True Negative) | 기기에 |\n| 이내로 유지되는지 평가하기 위함 | 나이 | 연구과제 피험자 설명문 및 동의서 | -「의료기기의 전자파안전에 관한 공통기준규격」 |\n| 일하므로, ADP test의 평가기준에 준하여 평가한다.) "
      }
    },
    {
      "chunk_id": "chunk_096",
      "text": "| (‘16.10.31 기준) | 혈소판 부착 | →        응집 유도인자 분비 | →     혈소판 응집 | 종료일 | (hours/ | K042423 | 대한 조치 | 치료 | 결과 | 중대성 |\n| 전자기장 시험에 관한 요구사항이 적용된다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 95,
        "window_size": 3,
        "char_count": 141,
        "word_count": 37,
        "page_number": 6,
        "window_text": "| 측정하여 혈액 내부의 혈소판 인자의 기능을 확인하는 요소 | [n = sample size (검체 수), p (민감도) = 0.85, | □ NO | □ ‘의료기기와의 관련성’ 판정 참고기준 | 이상 | 내용입니까?  |         | (False Negative) | 증상의 | 4.  Comparison of Different Methods to Evaluate the | 증상의 | 기기와의 | (True Negative) | 기기에 |\n| 이내로 유지되는지 평가하기 위함 | 나이 | 연구과제 피험자 설명문 및 동의서 | -「의료기기의 전자파안전에 관한 공통기준규격」 |\n| 일하므로, ADP test의 평가기준에 준하여 평가한다.)  | (‘16.10.31 기준) | 혈소판 부착 | →        응집 유도인자 분비 | →     혈소판 응집 | 종료일 | (hours/ | K042423 | 대한 조치 | 치료 | 결과 | 중대성 |\n| 전자기장 시험에 관한 요구사항이 적용된다.  | 반응명 | 1) 평가 불가능 (Unknown) | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | 범위 | 정도 | 관련성 |\n| n = 125.44 | [n = sample size (검체 수), p (민감도) = 0.90, | - IEC 61326-1 Electrical equipment for measurement, control and | Effect of Aspirin on Platelet Function in High-Risk |\n| 합계 | a+c | b+d | a+b+c+d | (yy/mm/dd) | minutes) |\n| ※ 구해진 기준값에 대하여 임상적으로 확증할 수 있다.  | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 검체 채취일 | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. ",
        "original_sentence": "| (‘16.10.31 기준) | 혈소판 부착 | →        응집 유도인자 분비 | →     혈소판 응집 | 종료일 | (hours/ | K042423 | 대한 조치 | 치료 | 결과 | 중대성 |\n| 전자기장 시험에 관한 요구사항이 적용된다. "
      }
    },
    {
      "chunk_id": "chunk_097",
      "text": "| 반응명 | 1) 평가 불가능 (Unknown) | □ 외국 규정을 번역하거나 설명하는 내용입니까? ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 96,
        "window_size": 3,
        "char_count": 57,
        "word_count": 14,
        "page_number": 6,
        "window_text": "|         | (False Negative) | 증상의 | 4.  Comparison of Different Methods to Evaluate the | 증상의 | 기기와의 | (True Negative) | 기기에 |\n| 이내로 유지되는지 평가하기 위함 | 나이 | 연구과제 피험자 설명문 및 동의서 | -「의료기기의 전자파안전에 관한 공통기준규격」 |\n| 일하므로, ADP test의 평가기준에 준하여 평가한다.)  | (‘16.10.31 기준) | 혈소판 부착 | →        응집 유도인자 분비 | →     혈소판 응집 | 종료일 | (hours/ | K042423 | 대한 조치 | 치료 | 결과 | 중대성 |\n| 전자기장 시험에 관한 요구사항이 적용된다.  | 반응명 | 1) 평가 불가능 (Unknown) | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | 범위 | 정도 | 관련성 |\n| n = 125.44 | [n = sample size (검체 수), p (민감도) = 0.90, | - IEC 61326-1 Electrical equipment for measurement, control and | Effect of Aspirin on Platelet Function in High-Risk |\n| 합계 | a+c | b+d | a+b+c+d | (yy/mm/dd) | minutes) |\n| ※ 구해진 기준값에 대하여 임상적으로 확증할 수 있다.  | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 검체 채취일 | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 의한 보호에 관한 요구사항이 적용된다. ",
        "original_sentence": "| 반응명 | 1) 평가 불가능 (Unknown) | □ 외국 규정을 번역하거나 설명하는 내용입니까? "
      }
    },
    {
      "chunk_id": "chunk_098",
      "text": "| □ 예 | ■ 아니오 | 범위 | 정도 | 관련성 |\n| n = 125.44 | [n = sample size (검체 수), p (민감도) = 0.90, | - IEC 61326-1 Electrical equipment for measurement, control and | Effect of Aspirin on Platelet Function in High-Risk |\n| 합계 | a+c | b+d | a+b+c+d | (yy/mm/dd) | minutes) |\n| ※ 구해진 기준값에 대하여 임상적으로 확증할 수 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 97,
        "window_size": 3,
        "char_count": 296,
        "word_count": 70,
        "page_number": 3,
        "window_text": "Comparison of Different Methods to Evaluate the | 증상의 | 기기와의 | (True Negative) | 기기에 |\n| 이내로 유지되는지 평가하기 위함 | 나이 | 연구과제 피험자 설명문 및 동의서 | -「의료기기의 전자파안전에 관한 공통기준규격」 |\n| 일하므로, ADP test의 평가기준에 준하여 평가한다.)  | (‘16.10.31 기준) | 혈소판 부착 | →        응집 유도인자 분비 | →     혈소판 응집 | 종료일 | (hours/ | K042423 | 대한 조치 | 치료 | 결과 | 중대성 |\n| 전자기장 시험에 관한 요구사항이 적용된다.  | 반응명 | 1) 평가 불가능 (Unknown) | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | 범위 | 정도 | 관련성 |\n| n = 125.44 | [n = sample size (검체 수), p (민감도) = 0.90, | - IEC 61326-1 Electrical equipment for measurement, control and | Effect of Aspirin on Platelet Function in High-Risk |\n| 합계 | a+c | b+d | a+b+c+d | (yy/mm/dd) | minutes) |\n| ※ 구해진 기준값에 대하여 임상적으로 확증할 수 있다.  | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 검체 채취일 | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 의한 보호에 관한 요구사항이 적용된다.  | 저항성 복합검사기기에 적용한다. ",
        "original_sentence": "| □ 예 | ■ 아니오 | 범위 | 정도 | 관련성 |\n| n = 125.44 | [n = sample size (검체 수), p (민감도) = 0.90, | - IEC 61326-1 Electrical equipment for measurement, control and | Effect of Aspirin on Platelet Function in High-Risk |\n| 합계 | a+c | b+d | a+b+c+d | (yy/mm/dd) | minutes) |\n| ※ 구해진 기준값에 대하여 임상적으로 확증할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_099",
      "text": "| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 검체 채취일 | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 98,
        "window_size": 3,
        "char_count": 98,
        "word_count": 23,
        "page_number": 6,
        "window_text": "| (‘16.10.31 기준) | 혈소판 부착 | →        응집 유도인자 분비 | →     혈소판 응집 | 종료일 | (hours/ | K042423 | 대한 조치 | 치료 | 결과 | 중대성 |\n| 전자기장 시험에 관한 요구사항이 적용된다.  | 반응명 | 1) 평가 불가능 (Unknown) | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | 범위 | 정도 | 관련성 |\n| n = 125.44 | [n = sample size (검체 수), p (민감도) = 0.90, | - IEC 61326-1 Electrical equipment for measurement, control and | Effect of Aspirin on Platelet Function in High-Risk |\n| 합계 | a+c | b+d | a+b+c+d | (yy/mm/dd) | minutes) |\n| ※ 구해진 기준값에 대하여 임상적으로 확증할 수 있다.  | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 검체 채취일 | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 의한 보호에 관한 요구사항이 적용된다.  | 저항성 복합검사기기에 적용한다.  | Qualitative Test Performance; Approved Guideline | · 정보가 불충분하거나 상충되어 판단할 수 없고 이를 보완하거나 확인할 수 없는 경우 |\n| inhibitor (clopidogrel) 복용 예정인 환자 | 승인된 자 이외에는 본 제품을 | 분해하거나 수리해서는 안된다. ",
        "original_sentence": "| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 검체 채취일 | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_100",
      "text": "| 의한 보호에 관한 요구사항이 적용된다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 99,
        "window_size": 3,
        "char_count": 24,
        "word_count": 6,
        "page_number": 3,
        "window_text": "| 반응명 | 1) 평가 불가능 (Unknown) | □ 외국 규정을 번역하거나 설명하는 내용입니까?  | □ 예 | ■ 아니오 | 범위 | 정도 | 관련성 |\n| n = 125.44 | [n = sample size (검체 수), p (민감도) = 0.90, | - IEC 61326-1 Electrical equipment for measurement, control and | Effect of Aspirin on Platelet Function in High-Risk |\n| 합계 | a+c | b+d | a+b+c+d | (yy/mm/dd) | minutes) |\n| ※ 구해진 기준값에 대하여 임상적으로 확증할 수 있다.  | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 검체 채취일 | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 의한 보호에 관한 요구사항이 적용된다.  | 저항성 복합검사기기에 적용한다.  | Qualitative Test Performance; Approved Guideline | · 정보가 불충분하거나 상충되어 판단할 수 없고 이를 보완하거나 확인할 수 없는 경우 |\n| inhibitor (clopidogrel) 복용 예정인 환자 | 승인된 자 이외에는 본 제품을 | 분해하거나 수리해서는 안된다.  | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. ",
        "original_sentence": "| 의한 보호에 관한 요구사항이 적용된다. "
      }
    },
    {
      "chunk_id": "chunk_101",
      "text": "| 저항성 복합검사기기에 적용한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 100,
        "window_size": 3,
        "char_count": 20,
        "word_count": 4,
        "page_number": 21,
        "window_text": "| □ 예 | ■ 아니오 | 범위 | 정도 | 관련성 |\n| n = 125.44 | [n = sample size (검체 수), p (민감도) = 0.90, | - IEC 61326-1 Electrical equipment for measurement, control and | Effect of Aspirin on Platelet Function in High-Risk |\n| 합계 | a+c | b+d | a+b+c+d | (yy/mm/dd) | minutes) |\n| ※ 구해진 기준값에 대하여 임상적으로 확증할 수 있다.  | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 검체 채취일 | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 의한 보호에 관한 요구사항이 적용된다.  | 저항성 복합검사기기에 적용한다.  | Qualitative Test Performance; Approved Guideline | · 정보가 불충분하거나 상충되어 판단할 수 없고 이를 보완하거나 확인할 수 없는 경우 |\n| inhibitor (clopidogrel) 복용 예정인 환자 | 승인된 자 이외에는 본 제품을 | 분해하거나 수리해서는 안된다.  | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 전자파 | laboratory use – EMC requirements – Part 1: General requirements | 3. ",
        "original_sentence": "| 저항성 복합검사기기에 적용한다. "
      }
    },
    {
      "chunk_id": "chunk_102",
      "text": "| Qualitative Test Performance; Approved Guideline | · 정보가 불충분하거나 상충되어 판단할 수 없고 이를 보완하거나 확인할 수 없는 경우 |\n| inhibitor (clopidogrel) 복용 예정인 환자 | 승인된 자 이외에는 본 제품을 | 분해하거나 수리해서는 안된다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 101,
        "window_size": 3,
        "char_count": 177,
        "word_count": 37,
        "page_number": 17,
        "window_text": "| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 검체 채취일 | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 의한 보호에 관한 요구사항이 적용된다.  | 저항성 복합검사기기에 적용한다.  | Qualitative Test Performance; Approved Guideline | · 정보가 불충분하거나 상충되어 판단할 수 없고 이를 보완하거나 확인할 수 없는 경우 |\n| inhibitor (clopidogrel) 복용 예정인 환자 | 승인된 자 이외에는 본 제품을 | 분해하거나 수리해서는 안된다.  | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 전자파 | laboratory use – EMC requirements – Part 1: General requirements | 3.  Incidence of Aspirin Resistance in the Patient | Dade PFA Collagen/ADP Test |\n| 11.6 | 10/03/30 홍길동(오기) | Patients With Ischemic Heart Disease Receiving Dual |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | [n = sample size (검체 수), p (특이도) = 0.75, | ◈ 기타 병용약물 | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. ",
        "original_sentence": "| Qualitative Test Performance; Approved Guideline | · 정보가 불충분하거나 상충되어 판단할 수 없고 이를 보완하거나 확인할 수 없는 경우 |\n| inhibitor (clopidogrel) 복용 예정인 환자 | 승인된 자 이외에는 본 제품을 | 분해하거나 수리해서는 안된다. "
      }
    },
    {
      "chunk_id": "chunk_103",
      "text": "| 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 102,
        "window_size": 3,
        "char_count": 42,
        "word_count": 9,
        "page_number": 6,
        "window_text": "| 의한 보호에 관한 요구사항이 적용된다.  | 저항성 복합검사기기에 적용한다.  | Qualitative Test Performance; Approved Guideline | · 정보가 불충분하거나 상충되어 판단할 수 없고 이를 보완하거나 확인할 수 없는 경우 |\n| inhibitor (clopidogrel) 복용 예정인 환자 | 승인된 자 이외에는 본 제품을 | 분해하거나 수리해서는 안된다.  | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 전자파 | laboratory use – EMC requirements – Part 1: General requirements | 3.  Incidence of Aspirin Resistance in the Patient | Dade PFA Collagen/ADP Test |\n| 11.6 | 10/03/30 홍길동(오기) | Patients With Ischemic Heart Disease Receiving Dual |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | [n = sample size (검체 수), p (특이도) = 0.75, | ◈ 기타 병용약물 | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 2) 관련성이 없음 (Not related) | 출혈시간 및 항혈소판제제 저항성 복합검사기기 평가 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | □ 예 | ■ 아니오 |\n| 안전에 관한 시험 | - IEC 61326-2-6 Electrical equipment for measurement, control and | (피험자와의 관계) |\n| n = 99.96 | medical equipment | 스크리닝 및 검사일 | 검사일 | Group of a University Hospital in Korea (Korean | Cartridge |\n| ※ 제품의 특성에 따라 판정기준치 제시는 선택이 가능하다. ",
        "original_sentence": "| 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_104",
      "text": "| 전자파 | laboratory use – EMC requirements – Part 1: General requirements | 3. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 103,
        "window_size": 3,
        "char_count": 78,
        "word_count": 15,
        "page_number": 6,
        "window_text": "| 저항성 복합검사기기에 적용한다.  | Qualitative Test Performance; Approved Guideline | · 정보가 불충분하거나 상충되어 판단할 수 없고 이를 보완하거나 확인할 수 없는 경우 |\n| inhibitor (clopidogrel) 복용 예정인 환자 | 승인된 자 이외에는 본 제품을 | 분해하거나 수리해서는 안된다.  | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 전자파 | laboratory use – EMC requirements – Part 1: General requirements | 3.  Incidence of Aspirin Resistance in the Patient | Dade PFA Collagen/ADP Test |\n| 11.6 | 10/03/30 홍길동(오기) | Patients With Ischemic Heart Disease Receiving Dual |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | [n = sample size (검체 수), p (특이도) = 0.75, | ◈ 기타 병용약물 | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 2) 관련성이 없음 (Not related) | 출혈시간 및 항혈소판제제 저항성 복합검사기기 평가 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | □ 예 | ■ 아니오 |\n| 안전에 관한 시험 | - IEC 61326-2-6 Electrical equipment for measurement, control and | (피험자와의 관계) |\n| n = 99.96 | medical equipment | 스크리닝 및 검사일 | 검사일 | Group of a University Hospital in Korea (Korean | Cartridge |\n| ※ 제품의 특성에 따라 판정기준치 제시는 선택이 가능하다.  | 및 제외 기준에 적합한 피험자에 한하여 피험자 식별코드를 부여한다. ",
        "original_sentence": "| 전자파 | laboratory use – EMC requirements – Part 1: General requirements | 3. "
      }
    },
    {
      "chunk_id": "chunk_105",
      "text": "Incidence of Aspirin Resistance in the Patient | Dade PFA Collagen/ADP Test |\n| 11.6 | 10/03/30 홍길동(오기) | Patients With Ischemic Heart Disease Receiving Dual |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | [n = sample size (검체 수), p (특이도) = 0.75, | ◈ 기타 병용약물 | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 104,
        "window_size": 3,
        "char_count": 308,
        "word_count": 63,
        "page_number": 17,
        "window_text": "| Qualitative Test Performance; Approved Guideline | · 정보가 불충분하거나 상충되어 판단할 수 없고 이를 보완하거나 확인할 수 없는 경우 |\n| inhibitor (clopidogrel) 복용 예정인 환자 | 승인된 자 이외에는 본 제품을 | 분해하거나 수리해서는 안된다.  | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 전자파 | laboratory use – EMC requirements – Part 1: General requirements | 3.  Incidence of Aspirin Resistance in the Patient | Dade PFA Collagen/ADP Test |\n| 11.6 | 10/03/30 홍길동(오기) | Patients With Ischemic Heart Disease Receiving Dual |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | [n = sample size (검체 수), p (특이도) = 0.75, | ◈ 기타 병용약물 | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 2) 관련성이 없음 (Not related) | 출혈시간 및 항혈소판제제 저항성 복합검사기기 평가 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | □ 예 | ■ 아니오 |\n| 안전에 관한 시험 | - IEC 61326-2-6 Electrical equipment for measurement, control and | (피험자와의 관계) |\n| n = 99.96 | medical equipment | 스크리닝 및 검사일 | 검사일 | Group of a University Hospital in Korea (Korean | Cartridge |\n| ※ 제품의 특성에 따라 판정기준치 제시는 선택이 가능하다.  | 및 제외 기준에 적합한 피험자에 한하여 피험자 식별코드를 부여한다.  | 결과값 사이의 일치도의 근접성 | (비열등성한계 10%). ",
        "original_sentence": "Incidence of Aspirin Resistance in the Patient | Dade PFA Collagen/ADP Test |\n| 11.6 | 10/03/30 홍길동(오기) | Patients With Ischemic Heart Disease Receiving Dual |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | [n = sample size (검체 수), p (특이도) = 0.75, | ◈ 기타 병용약물 | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_106",
      "text": "| 2) 관련성이 없음 (Not related) | 출혈시간 및 항혈소판제제 저항성 복합검사기기 평가 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | □ 예 | ■ 아니오 |\n| 안전에 관한 시험 | - IEC 61326-2-6 Electrical equipment for measurement, control and | (피험자와의 관계) |\n| n = 99.96 | medical equipment | 스크리닝 및 검사일 | 검사일 | Group of a University Hospital in Korea (Korean | Cartridge |\n| ※ 제품의 특성에 따라 판정기준치 제시는 선택이 가능하다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 105,
        "window_size": 3,
        "char_count": 353,
        "word_count": 83,
        "page_number": 1,
        "window_text": "| 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 전자파 | laboratory use – EMC requirements – Part 1: General requirements | 3.  Incidence of Aspirin Resistance in the Patient | Dade PFA Collagen/ADP Test |\n| 11.6 | 10/03/30 홍길동(오기) | Patients With Ischemic Heart Disease Receiving Dual |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | [n = sample size (검체 수), p (특이도) = 0.75, | ◈ 기타 병용약물 | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 2) 관련성이 없음 (Not related) | 출혈시간 및 항혈소판제제 저항성 복합검사기기 평가 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | □ 예 | ■ 아니오 |\n| 안전에 관한 시험 | - IEC 61326-2-6 Electrical equipment for measurement, control and | (피험자와의 관계) |\n| n = 99.96 | medical equipment | 스크리닝 및 검사일 | 검사일 | Group of a University Hospital in Korea (Korean | Cartridge |\n| ※ 제품의 특성에 따라 판정기준치 제시는 선택이 가능하다.  | 및 제외 기준에 적합한 피험자에 한하여 피험자 식별코드를 부여한다.  | 결과값 사이의 일치도의 근접성 | (비열등성한계 10%).  | 단계, “Pressure”탭에서 현재 장비가 제공하는 압력을 확인할 수 있다. ",
        "original_sentence": "| 2) 관련성이 없음 (Not related) | 출혈시간 및 항혈소판제제 저항성 복합검사기기 평가 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | □ 예 | ■ 아니오 |\n| 안전에 관한 시험 | - IEC 61326-2-6 Electrical equipment for measurement, control and | (피험자와의 관계) |\n| n = 99.96 | medical equipment | 스크리닝 및 검사일 | 검사일 | Group of a University Hospital in Korea (Korean | Cartridge |\n| ※ 제품의 특성에 따라 판정기준치 제시는 선택이 가능하다. "
      }
    },
    {
      "chunk_id": "chunk_107",
      "text": "| 및 제외 기준에 적합한 피험자에 한하여 피험자 식별코드를 부여한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 106,
        "window_size": 3,
        "char_count": 40,
        "word_count": 10,
        "page_number": 24,
        "window_text": "| 전자파 | laboratory use – EMC requirements – Part 1: General requirements | 3.  Incidence of Aspirin Resistance in the Patient | Dade PFA Collagen/ADP Test |\n| 11.6 | 10/03/30 홍길동(오기) | Patients With Ischemic Heart Disease Receiving Dual |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | [n = sample size (검체 수), p (특이도) = 0.75, | ◈ 기타 병용약물 | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 2) 관련성이 없음 (Not related) | 출혈시간 및 항혈소판제제 저항성 복합검사기기 평가 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | □ 예 | ■ 아니오 |\n| 안전에 관한 시험 | - IEC 61326-2-6 Electrical equipment for measurement, control and | (피험자와의 관계) |\n| n = 99.96 | medical equipment | 스크리닝 및 검사일 | 검사일 | Group of a University Hospital in Korea (Korean | Cartridge |\n| ※ 제품의 특성에 따라 판정기준치 제시는 선택이 가능하다.  | 및 제외 기준에 적합한 피험자에 한하여 피험자 식별코드를 부여한다.  | 결과값 사이의 일치도의 근접성 | (비열등성한계 10%).  | 단계, “Pressure”탭에서 현재 장비가 제공하는 압력을 확인할 수 있다.  | 예) Hb 8.6 → Hb 8.6 | · 이상사례가 명백하게 피험자의 임상적 상태 또는 시험절차/조건에 기인한 경우 | (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명2로 187 | 정리한 자료입니까? ",
        "original_sentence": "| 및 제외 기준에 적합한 피험자에 한하여 피험자 식별코드를 부여한다. "
      }
    },
    {
      "chunk_id": "chunk_108",
      "text": "| 결과값 사이의 일치도의 근접성 | (비열등성한계 10%). ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 107,
        "window_size": 3,
        "char_count": 35,
        "word_count": 8,
        "page_number": 6,
        "window_text": "Incidence of Aspirin Resistance in the Patient | Dade PFA Collagen/ADP Test |\n| 11.6 | 10/03/30 홍길동(오기) | Patients With Ischemic Heart Disease Receiving Dual |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | [n = sample size (검체 수), p (특이도) = 0.75, | ◈ 기타 병용약물 | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 2) 관련성이 없음 (Not related) | 출혈시간 및 항혈소판제제 저항성 복합검사기기 평가 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | □ 예 | ■ 아니오 |\n| 안전에 관한 시험 | - IEC 61326-2-6 Electrical equipment for measurement, control and | (피험자와의 관계) |\n| n = 99.96 | medical equipment | 스크리닝 및 검사일 | 검사일 | Group of a University Hospital in Korea (Korean | Cartridge |\n| ※ 제품의 특성에 따라 판정기준치 제시는 선택이 가능하다.  | 및 제외 기준에 적합한 피험자에 한하여 피험자 식별코드를 부여한다.  | 결과값 사이의 일치도의 근접성 | (비열등성한계 10%).  | 단계, “Pressure”탭에서 현재 장비가 제공하는 압력을 확인할 수 있다.  | 예) Hb 8.6 → Hb 8.6 | · 이상사례가 명백하게 피험자의 임상적 상태 또는 시험절차/조건에 기인한 경우 | (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명2로 187 | 정리한 자료입니까?  | 피험자 이니셜(영문) | / | / |\n| □ YES | □ 항응고제 (예, 와파린, 헤파린 등) | laboratory use – EMC requirements – Part 2-6: Particular | Antiplatelet | Treatment | (Am | J | Clin | Pathol. ",
        "original_sentence": "| 결과값 사이의 일치도의 근접성 | (비열등성한계 10%). "
      }
    },
    {
      "chunk_id": "chunk_109",
      "text": "| 단계, “Pressure”탭에서 현재 장비가 제공하는 압력을 확인할 수 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 108,
        "window_size": 3,
        "char_count": 46,
        "word_count": 10,
        "page_number": 49,
        "window_text": "| 2) 관련성이 없음 (Not related) | 출혈시간 및 항혈소판제제 저항성 복합검사기기 평가 | □ 신규 직원 교육을 위해 법령 또는 행정규칙을 알기 쉽게 | □ 예 | ■ 아니오 |\n| 안전에 관한 시험 | - IEC 61326-2-6 Electrical equipment for measurement, control and | (피험자와의 관계) |\n| n = 99.96 | medical equipment | 스크리닝 및 검사일 | 검사일 | Group of a University Hospital in Korea (Korean | Cartridge |\n| ※ 제품의 특성에 따라 판정기준치 제시는 선택이 가능하다.  | 및 제외 기준에 적합한 피험자에 한하여 피험자 식별코드를 부여한다.  | 결과값 사이의 일치도의 근접성 | (비열등성한계 10%).  | 단계, “Pressure”탭에서 현재 장비가 제공하는 압력을 확인할 수 있다.  | 예) Hb 8.6 → Hb 8.6 | · 이상사례가 명백하게 피험자의 임상적 상태 또는 시험절차/조건에 기인한 경우 | (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명2로 187 | 정리한 자료입니까?  | 피험자 이니셜(영문) | / | / |\n| □ YES | □ 항응고제 (예, 와파린, 헤파린 등) | laboratory use – EMC requirements – Part 2-6: Particular | Antiplatelet | Treatment | (Am | J | Clin | Pathol.  | 2007 |\n| n = 70.56 | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | / | / | 가이드라인(민원인 안내서) |\n| ◈ 혈관판 기능 장애 | 3) 관련성이 적음 (Unlikely) | 방문일 | 방문1 | 방문2: 혈소판 약물반응검사의 경우만 해당 | J Lab Med. ",
        "original_sentence": "| 단계, “Pressure”탭에서 현재 장비가 제공하는 압력을 확인할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_110",
      "text": "| 예) Hb 8.6 → Hb 8.6 | · 이상사례가 명백하게 피험자의 임상적 상태 또는 시험절차/조건에 기인한 경우 | (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명2로 187 | 정리한 자료입니까? ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 109,
        "window_size": 3,
        "char_count": 120,
        "word_count": 30,
        "page_number": 15,
        "window_text": "| 및 제외 기준에 적합한 피험자에 한하여 피험자 식별코드를 부여한다.  | 결과값 사이의 일치도의 근접성 | (비열등성한계 10%).  | 단계, “Pressure”탭에서 현재 장비가 제공하는 압력을 확인할 수 있다.  | 예) Hb 8.6 → Hb 8.6 | · 이상사례가 명백하게 피험자의 임상적 상태 또는 시험절차/조건에 기인한 경우 | (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명2로 187 | 정리한 자료입니까?  | 피험자 이니셜(영문) | / | / |\n| □ YES | □ 항응고제 (예, 와파린, 헤파린 등) | laboratory use – EMC requirements – Part 2-6: Particular | Antiplatelet | Treatment | (Am | J | Clin | Pathol.  | 2007 |\n| n = 70.56 | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | / | / | 가이드라인(민원인 안내서) |\n| ◈ 혈관판 기능 장애 | 3) 관련성이 적음 (Unlikely) | 방문일 | 방문1 | 방문2: 혈소판 약물반응검사의 경우만 해당 | J Lab Med.  2008 Aug;28(4):251-7.) ",
        "original_sentence": "| 예) Hb 8.6 → Hb 8.6 | · 이상사례가 명백하게 피험자의 임상적 상태 또는 시험절차/조건에 기인한 경우 | (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명2로 187 | 정리한 자료입니까? "
      }
    },
    {
      "chunk_id": "chunk_111",
      "text": "| 피험자 이니셜(영문) | / | / |\n| □ YES | □ 항응고제 (예, 와파린, 헤파린 등) | laboratory use – EMC requirements – Part 2-6: Particular | Antiplatelet | Treatment | (Am | J | Clin | Pathol. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 110,
        "window_size": 3,
        "char_count": 170,
        "word_count": 40,
        "page_number": 97,
        "window_text": "| 결과값 사이의 일치도의 근접성 | (비열등성한계 10%).  | 단계, “Pressure”탭에서 현재 장비가 제공하는 압력을 확인할 수 있다.  | 예) Hb 8.6 → Hb 8.6 | · 이상사례가 명백하게 피험자의 임상적 상태 또는 시험절차/조건에 기인한 경우 | (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명2로 187 | 정리한 자료입니까?  | 피험자 이니셜(영문) | / | / |\n| □ YES | □ 항응고제 (예, 와파린, 헤파린 등) | laboratory use – EMC requirements – Part 2-6: Particular | Antiplatelet | Treatment | (Am | J | Clin | Pathol.  | 2007 |\n| n = 70.56 | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | / | / | 가이드라인(민원인 안내서) |\n| ◈ 혈관판 기능 장애 | 3) 관련성이 적음 (Unlikely) | 방문일 | 방문1 | 방문2: 혈소판 약물반응검사의 경우만 해당 | J Lab Med.  2008 Aug;28(4):251-7.)  |\n| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다. ",
        "original_sentence": "| 피험자 이니셜(영문) | / | / |\n| □ YES | □ 항응고제 (예, 와파린, 헤파린 등) | laboratory use – EMC requirements – Part 2-6: Particular | Antiplatelet | Treatment | (Am | J | Clin | Pathol. "
      }
    },
    {
      "chunk_id": "chunk_112",
      "text": "| 2007 |\n| n = 70.56 | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | / | / | 가이드라인(민원인 안내서) |\n| ◈ 혈관판 기능 장애 | 3) 관련성이 적음 (Unlikely) | 방문일 | 방문1 | 방문2: 혈소판 약물반응검사의 경우만 해당 | J Lab Med. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 111,
        "window_size": 3,
        "char_count": 188,
        "word_count": 51,
        "page_number": 6,
        "window_text": "| 단계, “Pressure”탭에서 현재 장비가 제공하는 압력을 확인할 수 있다.  | 예) Hb 8.6 → Hb 8.6 | · 이상사례가 명백하게 피험자의 임상적 상태 또는 시험절차/조건에 기인한 경우 | (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명2로 187 | 정리한 자료입니까?  | 피험자 이니셜(영문) | / | / |\n| □ YES | □ 항응고제 (예, 와파린, 헤파린 등) | laboratory use – EMC requirements – Part 2-6: Particular | Antiplatelet | Treatment | (Am | J | Clin | Pathol.  | 2007 |\n| n = 70.56 | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | / | / | 가이드라인(민원인 안내서) |\n| ◈ 혈관판 기능 장애 | 3) 관련성이 적음 (Unlikely) | 방문일 | 방문1 | 방문2: 혈소판 약물반응검사의 경우만 해당 | J Lab Med.  2008 Aug;28(4):251-7.)  |\n| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다. ",
        "original_sentence": "| 2007 |\n| n = 70.56 | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | / | / | 가이드라인(민원인 안내서) |\n| ◈ 혈관판 기능 장애 | 3) 관련성이 적음 (Unlikely) | 방문일 | 방문1 | 방문2: 혈소판 약물반응검사의 경우만 해당 | J Lab Med. "
      }
    },
    {
      "chunk_id": "chunk_113",
      "text": "2008 Aug;28(4):251-7.) ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 112,
        "window_size": 3,
        "char_count": 23,
        "word_count": 2,
        "page_number": 6,
        "window_text": "| 예) Hb 8.6 → Hb 8.6 | · 이상사례가 명백하게 피험자의 임상적 상태 또는 시험절차/조건에 기인한 경우 | (우 28159) 충청북도 청주시 흥덕구 오송읍 오송생명2로 187 | 정리한 자료입니까?  | 피험자 이니셜(영문) | / | / |\n| □ YES | □ 항응고제 (예, 와파린, 헤파린 등) | laboratory use – EMC requirements – Part 2-6: Particular | Antiplatelet | Treatment | (Am | J | Clin | Pathol.  | 2007 |\n| n = 70.56 | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | / | / | 가이드라인(민원인 안내서) |\n| ◈ 혈관판 기능 장애 | 3) 관련성이 적음 (Unlikely) | 방문일 | 방문1 | 방문2: 혈소판 약물반응검사의 경우만 해당 | J Lab Med.  2008 Aug;28(4):251-7.)  |\n| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 클로피도그렐 투약 유무 |\n| □ NO | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. ",
        "original_sentence": "2008 Aug;28(4):251-7.) "
      }
    },
    {
      "chunk_id": "chunk_114",
      "text": "|\n| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 113,
        "window_size": 3,
        "char_count": 57,
        "word_count": 15,
        "page_number": 3,
        "window_text": "| 피험자 이니셜(영문) | / | / |\n| □ YES | □ 항응고제 (예, 와파린, 헤파린 등) | laboratory use – EMC requirements – Part 2-6: Particular | Antiplatelet | Treatment | (Am | J | Clin | Pathol.  | 2007 |\n| n = 70.56 | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | / | / | 가이드라인(민원인 안내서) |\n| ◈ 혈관판 기능 장애 | 3) 관련성이 적음 (Unlikely) | 방문일 | 방문1 | 방문2: 혈소판 약물반응검사의 경우만 해당 | J Lab Med.  2008 Aug;28(4):251-7.)  |\n| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 클로피도그렐 투약 유무 |\n| □ NO | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 2) ○○ ADP test | requirements – In vitro diagnostic (IVD) medical equipment | 오송보건의료행정타운 | PFA-100Ⓡ | VerifyNowⓇ | Jul;128(1):143-9.) ",
        "original_sentence": "|\n| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다. "
      }
    },
    {
      "chunk_id": "chunk_115",
      "text": "| 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 114,
        "window_size": 3,
        "char_count": 34,
        "word_count": 7,
        "page_number": 3,
        "window_text": "| 2007 |\n| n = 70.56 | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | / | / | 가이드라인(민원인 안내서) |\n| ◈ 혈관판 기능 장애 | 3) 관련성이 적음 (Unlikely) | 방문일 | 방문1 | 방문2: 혈소판 약물반응검사의 경우만 해당 | J Lab Med.  2008 Aug;28(4):251-7.)  |\n| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 클로피도그렐 투약 유무 |\n| □ NO | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 2) ○○ ADP test | requirements – In vitro diagnostic (IVD) medical equipment | 오송보건의료행정타운 | PFA-100Ⓡ | VerifyNowⓇ | Jul;128(1):143-9.)  |\n| 로트로 대체 가능) | 물질의 정량값 | 제품의 사용을 금지하며 제조원 담당자에게 연락한다. ",
        "original_sentence": "| 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다. "
      }
    },
    {
      "chunk_id": "chunk_116",
      "text": "| 클로피도그렐 투약 유무 |\n| □ NO | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 115,
        "window_size": 3,
        "char_count": 62,
        "word_count": 16,
        "page_number": 6,
        "window_text": "2008 Aug;28(4):251-7.)  |\n| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 클로피도그렐 투약 유무 |\n| □ NO | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 2) ○○ ADP test | requirements – In vitro diagnostic (IVD) medical equipment | 오송보건의료행정타운 | PFA-100Ⓡ | VerifyNowⓇ | Jul;128(1):143-9.)  |\n| 로트로 대체 가능) | 물질의 정량값 | 제품의 사용을 금지하며 제조원 담당자에게 연락한다.  | 하게 적용되고 있다. ",
        "original_sentence": "| 클로피도그렐 투약 유무 |\n| □ NO | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_117",
      "text": "| 2) ○○ ADP test | requirements – In vitro diagnostic (IVD) medical equipment | 오송보건의료행정타운 | PFA-100Ⓡ | VerifyNowⓇ | Jul;128(1):143-9.) ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 116,
        "window_size": 3,
        "char_count": 136,
        "word_count": 22,
        "page_number": 6,
        "window_text": "|\n| ☞ 상기 사항 중 어느 하나라도 ‘예’에 해당되는 경우에 지침서ㆍ안내서 등록 대상이 아닙니다.  | 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 클로피도그렐 투약 유무 |\n| □ NO | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 2) ○○ ADP test | requirements – In vitro diagnostic (IVD) medical equipment | 오송보건의료행정타운 | PFA-100Ⓡ | VerifyNowⓇ | Jul;128(1):143-9.)  |\n| 로트로 대체 가능) | 물질의 정량값 | 제품의 사용을 금지하며 제조원 담당자에게 연락한다.  | 하게 적용되고 있다.  | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. ",
        "original_sentence": "| 2) ○○ ADP test | requirements – In vitro diagnostic (IVD) medical equipment | 오송보건의료행정타운 | PFA-100Ⓡ | VerifyNowⓇ | Jul;128(1):143-9.) "
      }
    },
    {
      "chunk_id": "chunk_118",
      "text": "|\n| 로트로 대체 가능) | 물질의 정량값 | 제품의 사용을 금지하며 제조원 담당자에게 연락한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 117,
        "window_size": 3,
        "char_count": 56,
        "word_count": 15,
        "page_number": 3,
        "window_text": "| 지침서ㆍ안내서 제ㆍ개정 절차를 적용하실 필요는 없습니다.  | 클로피도그렐 투약 유무 |\n| □ NO | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 2) ○○ ADP test | requirements – In vitro diagnostic (IVD) medical equipment | 오송보건의료행정타운 | PFA-100Ⓡ | VerifyNowⓇ | Jul;128(1):143-9.)  |\n| 로트로 대체 가능) | 물질의 정량값 | 제품의 사용을 금지하며 제조원 담당자에게 연락한다.  | 하게 적용되고 있다.  | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | stability of in vitro diagnostic reagents | 'VerifyNow Aspirin test'로 검사를 시행한다. ",
        "original_sentence": "|\n| 로트로 대체 가능) | 물질의 정량값 | 제품의 사용을 금지하며 제조원 담당자에게 연락한다. "
      }
    },
    {
      "chunk_id": "chunk_119",
      "text": "| 하게 적용되고 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 118,
        "window_size": 3,
        "char_count": 14,
        "word_count": 4,
        "page_number": 16,
        "window_text": "| 클로피도그렐 투약 유무 |\n| □ NO | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 2) ○○ ADP test | requirements – In vitro diagnostic (IVD) medical equipment | 오송보건의료행정타운 | PFA-100Ⓡ | VerifyNowⓇ | Jul;128(1):143-9.)  |\n| 로트로 대체 가능) | 물질의 정량값 | 제품의 사용을 금지하며 제조원 담당자에게 연락한다.  | 하게 적용되고 있다.  | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | stability of in vitro diagnostic reagents | 'VerifyNow Aspirin test'로 검사를 시행한다.  | 측정기기에 관한 요구사항이 적용된다. ",
        "original_sentence": "| 하게 적용되고 있다. "
      }
    },
    {
      "chunk_id": "chunk_120",
      "text": "| 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 119,
        "window_size": 3,
        "char_count": 38,
        "word_count": 8,
        "page_number": 6,
        "window_text": "| 2) ○○ ADP test | requirements – In vitro diagnostic (IVD) medical equipment | 오송보건의료행정타운 | PFA-100Ⓡ | VerifyNowⓇ | Jul;128(1):143-9.)  |\n| 로트로 대체 가능) | 물질의 정량값 | 제품의 사용을 금지하며 제조원 담당자에게 연락한다.  | 하게 적용되고 있다.  | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | stability of in vitro diagnostic reagents | 'VerifyNow Aspirin test'로 검사를 시행한다.  | 측정기기에 관한 요구사항이 적용된다.  | 저항성 복합검사기기에 적용한다. ",
        "original_sentence": "| 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_121",
      "text": "| stability of in vitro diagnostic reagents | 'VerifyNow Aspirin test'로 검사를 시행한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 120,
        "window_size": 3,
        "char_count": 82,
        "word_count": 13,
        "page_number": 17,
        "window_text": "|\n| 로트로 대체 가능) | 물질의 정량값 | 제품의 사용을 금지하며 제조원 담당자에게 연락한다.  | 하게 적용되고 있다.  | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | stability of in vitro diagnostic reagents | 'VerifyNow Aspirin test'로 검사를 시행한다.  | 측정기기에 관한 요구사항이 적용된다.  | 저항성 복합검사기기에 적용한다.  | 혈소판 기능이상 측정이 가능한 최소/최대 이동거리를 평가 | · 이상사례와 임상시험용 의료기기 간의 시간적 연관성으로 볼 때 어떠한 합리적인 관련도 있을 것 | Dade PFA Collagen/EPI Test | 합계 |\n| 체외진단기기과에 문의하시기 바랍니다. ",
        "original_sentence": "| stability of in vitro diagnostic reagents | 'VerifyNow Aspirin test'로 검사를 시행한다. "
      }
    },
    {
      "chunk_id": "chunk_122",
      "text": "| 측정기기에 관한 요구사항이 적용된다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 121,
        "window_size": 3,
        "char_count": 23,
        "word_count": 5,
        "page_number": 3,
        "window_text": "| 하게 적용되고 있다.  | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | stability of in vitro diagnostic reagents | 'VerifyNow Aspirin test'로 검사를 시행한다.  | 측정기기에 관한 요구사항이 적용된다.  | 저항성 복합검사기기에 적용한다.  | 혈소판 기능이상 측정이 가능한 최소/최대 이동거리를 평가 | · 이상사례와 임상시험용 의료기기 간의 시간적 연관성으로 볼 때 어떠한 합리적인 관련도 있을 것 | Dade PFA Collagen/EPI Test | 합계 |\n| 체외진단기기과에 문의하시기 바랍니다.  | n = 147.0 | 대한 검사를 위해서도 많이 이용되고 있다. ",
        "original_sentence": "| 측정기기에 관한 요구사항이 적용된다. "
      }
    },
    {
      "chunk_id": "chunk_123",
      "text": "| 저항성 복합검사기기에 적용한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 122,
        "window_size": 3,
        "char_count": 20,
        "word_count": 4,
        "page_number": 21,
        "window_text": "| 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | stability of in vitro diagnostic reagents | 'VerifyNow Aspirin test'로 검사를 시행한다.  | 측정기기에 관한 요구사항이 적용된다.  | 저항성 복합검사기기에 적용한다.  | 혈소판 기능이상 측정이 가능한 최소/최대 이동거리를 평가 | · 이상사례와 임상시험용 의료기기 간의 시간적 연관성으로 볼 때 어떠한 합리적인 관련도 있을 것 | Dade PFA Collagen/EPI Test | 합계 |\n| 체외진단기기과에 문의하시기 바랍니다.  | n = 147.0 | 대한 검사를 위해서도 많이 이용되고 있다.  | 임상시험 | 피험자 식별번호 | 4. ",
        "original_sentence": "| 저항성 복합검사기기에 적용한다. "
      }
    },
    {
      "chunk_id": "chunk_124",
      "text": "| 혈소판 기능이상 측정이 가능한 최소/최대 이동거리를 평가 | · 이상사례와 임상시험용 의료기기 간의 시간적 연관성으로 볼 때 어떠한 합리적인 관련도 있을 것 | Dade PFA Collagen/EPI Test | 합계 |\n| 체외진단기기과에 문의하시기 바랍니다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 123,
        "window_size": 3,
        "char_count": 149,
        "word_count": 35,
        "page_number": 9,
        "window_text": "| stability of in vitro diagnostic reagents | 'VerifyNow Aspirin test'로 검사를 시행한다.  | 측정기기에 관한 요구사항이 적용된다.  | 저항성 복합검사기기에 적용한다.  | 혈소판 기능이상 측정이 가능한 최소/최대 이동거리를 평가 | · 이상사례와 임상시험용 의료기기 간의 시간적 연관성으로 볼 때 어떠한 합리적인 관련도 있을 것 | Dade PFA Collagen/EPI Test | 합계 |\n| 체외진단기기과에 문의하시기 바랍니다.  | n = 147.0 | 대한 검사를 위해서도 많이 이용되고 있다.  | 임상시험 | 피험자 식별번호 | 4.  | Correlation | of | high | post-treatment | platelet |\n| 발 | 행 | 처 식품의약품안전처 식품의약품안전평가원 | □ 본 빌레브란트병(von Willebrand disease) | 투약 후 | 투약 전 | Aspirin test: Aspirin 복용 3일 이후 |\n| [표 4] 출혈시간 및 항혈소판제제 저항성 복합검사기기 성능 관련 시험 규격 | 제조사 | Siemens | Accriva Diagnostics | 같지 않은 경우 | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | / | / | 검사항목 | 양성(비정상 결과) 환자 수 | 음성(정상 결과) 환자 수 | Cartridge |\n| 경과일수 | Day0 | 민감도 | 특이도 |\n| 전화번호: 043-719-4652~63 | 사용되는 체외진단용 분석기기에 적용한다. ",
        "original_sentence": "| 혈소판 기능이상 측정이 가능한 최소/최대 이동거리를 평가 | · 이상사례와 임상시험용 의료기기 간의 시간적 연관성으로 볼 때 어떠한 합리적인 관련도 있을 것 | Dade PFA Collagen/EPI Test | 합계 |\n| 체외진단기기과에 문의하시기 바랍니다. "
      }
    },
    {
      "chunk_id": "chunk_125",
      "text": "| n = 147.0 | 대한 검사를 위해서도 많이 이용되고 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 124,
        "window_size": 3,
        "char_count": 38,
        "word_count": 11,
        "page_number": 6,
        "window_text": "| 측정기기에 관한 요구사항이 적용된다.  | 저항성 복합검사기기에 적용한다.  | 혈소판 기능이상 측정이 가능한 최소/최대 이동거리를 평가 | · 이상사례와 임상시험용 의료기기 간의 시간적 연관성으로 볼 때 어떠한 합리적인 관련도 있을 것 | Dade PFA Collagen/EPI Test | 합계 |\n| 체외진단기기과에 문의하시기 바랍니다.  | n = 147.0 | 대한 검사를 위해서도 많이 이용되고 있다.  | 임상시험 | 피험자 식별번호 | 4.  | Correlation | of | high | post-treatment | platelet |\n| 발 | 행 | 처 식품의약품안전처 식품의약품안전평가원 | □ 본 빌레브란트병(von Willebrand disease) | 투약 후 | 투약 전 | Aspirin test: Aspirin 복용 3일 이후 |\n| [표 4] 출혈시간 및 항혈소판제제 저항성 복합검사기기 성능 관련 시험 규격 | 제조사 | Siemens | Accriva Diagnostics | 같지 않은 경우 | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | / | / | 검사항목 | 양성(비정상 결과) 환자 수 | 음성(정상 결과) 환자 수 | Cartridge |\n| 경과일수 | Day0 | 민감도 | 특이도 |\n| 전화번호: 043-719-4652~63 | 사용되는 체외진단용 분석기기에 적용한다.  | 3) ○○ EPI test | □ 글란즈만혈소판무력증(Glanzmann's thrombasthenia) | reactivity | assessed | by | light | transmittance |\n| 있는 가장 높은 측정치 | 대한 이동거리를 구한다. ",
        "original_sentence": "| n = 147.0 | 대한 검사를 위해서도 많이 이용되고 있다. "
      }
    },
    {
      "chunk_id": "chunk_126",
      "text": "| 임상시험 | 피험자 식별번호 | 4. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 125,
        "window_size": 3,
        "char_count": 23,
        "word_count": 7,
        "page_number": 9,
        "window_text": "| 저항성 복합검사기기에 적용한다.  | 혈소판 기능이상 측정이 가능한 최소/최대 이동거리를 평가 | · 이상사례와 임상시험용 의료기기 간의 시간적 연관성으로 볼 때 어떠한 합리적인 관련도 있을 것 | Dade PFA Collagen/EPI Test | 합계 |\n| 체외진단기기과에 문의하시기 바랍니다.  | n = 147.0 | 대한 검사를 위해서도 많이 이용되고 있다.  | 임상시험 | 피험자 식별번호 | 4.  | Correlation | of | high | post-treatment | platelet |\n| 발 | 행 | 처 식품의약품안전처 식품의약품안전평가원 | □ 본 빌레브란트병(von Willebrand disease) | 투약 후 | 투약 전 | Aspirin test: Aspirin 복용 3일 이후 |\n| [표 4] 출혈시간 및 항혈소판제제 저항성 복합검사기기 성능 관련 시험 규격 | 제조사 | Siemens | Accriva Diagnostics | 같지 않은 경우 | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | / | / | 검사항목 | 양성(비정상 결과) 환자 수 | 음성(정상 결과) 환자 수 | Cartridge |\n| 경과일수 | Day0 | 민감도 | 특이도 |\n| 전화번호: 043-719-4652~63 | 사용되는 체외진단용 분석기기에 적용한다.  | 3) ○○ EPI test | □ 글란즈만혈소판무력증(Glanzmann's thrombasthenia) | reactivity | assessed | by | light | transmittance |\n| 있는 가장 높은 측정치 | 대한 이동거리를 구한다.  | 결과들 가운데 일치도의 근접성 | 4)관련성이 의심됨 (Possible) | 품목명 | 자동혈소판응집측정장치 | 자동혈소판응집측정장치 | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | / | / | 아스피린 투약 유무 | P2Y12 test: Clopidogrel 복용 5일 이후 | □ 예(☞지침서) | ■ 아니오 |\n| TEL : 043-719-4652~63  FAX : 043-719-4650 | EPI test | 105명 이상 | 105명 이상 | a | b |\n| ◈ 검사 결과 | 발 | 행 | 일 2016년 12월 | · 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 | 중위값 | 88.0 | 82.7 | 합계 |\n| 팩스번호: 043-719-4650 | 모델명 | PFA-100 System | VerifyNow System | 약물반응 양성 | 사무의 세부기준이나 절차를 제시하는 것입니까? ",
        "original_sentence": "| 임상시험 | 피험자 식별번호 | 4. "
      }
    },
    {
      "chunk_id": "chunk_127",
      "text": "| Correlation | of | high | post-treatment | platelet |\n| 발 | 행 | 처 식품의약품안전처 식품의약품안전평가원 | □ 본 빌레브란트병(von Willebrand disease) | 투약 후 | 투약 전 | Aspirin test: Aspirin 복용 3일 이후 |\n| [표 4] 출혈시간 및 항혈소판제제 저항성 복합검사기기 성능 관련 시험 규격 | 제조사 | Siemens | Accriva Diagnostics | 같지 않은 경우 | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | / | / | 검사항목 | 양성(비정상 결과) 환자 수 | 음성(정상 결과) 환자 수 | Cartridge |\n| 경과일수 | Day0 | 민감도 | 특이도 |\n| 전화번호: 043-719-4652~63 | 사용되는 체외진단용 분석기기에 적용한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 126,
        "window_size": 3,
        "char_count": 438,
        "word_count": 102,
        "page_number": 17,
        "window_text": "| 혈소판 기능이상 측정이 가능한 최소/최대 이동거리를 평가 | · 이상사례와 임상시험용 의료기기 간의 시간적 연관성으로 볼 때 어떠한 합리적인 관련도 있을 것 | Dade PFA Collagen/EPI Test | 합계 |\n| 체외진단기기과에 문의하시기 바랍니다.  | n = 147.0 | 대한 검사를 위해서도 많이 이용되고 있다.  | 임상시험 | 피험자 식별번호 | 4.  | Correlation | of | high | post-treatment | platelet |\n| 발 | 행 | 처 식품의약품안전처 식품의약품안전평가원 | □ 본 빌레브란트병(von Willebrand disease) | 투약 후 | 투약 전 | Aspirin test: Aspirin 복용 3일 이후 |\n| [표 4] 출혈시간 및 항혈소판제제 저항성 복합검사기기 성능 관련 시험 규격 | 제조사 | Siemens | Accriva Diagnostics | 같지 않은 경우 | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | / | / | 검사항목 | 양성(비정상 결과) 환자 수 | 음성(정상 결과) 환자 수 | Cartridge |\n| 경과일수 | Day0 | 민감도 | 특이도 |\n| 전화번호: 043-719-4652~63 | 사용되는 체외진단용 분석기기에 적용한다.  | 3) ○○ EPI test | □ 글란즈만혈소판무력증(Glanzmann's thrombasthenia) | reactivity | assessed | by | light | transmittance |\n| 있는 가장 높은 측정치 | 대한 이동거리를 구한다.  | 결과들 가운데 일치도의 근접성 | 4)관련성이 의심됨 (Possible) | 품목명 | 자동혈소판응집측정장치 | 자동혈소판응집측정장치 | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | / | / | 아스피린 투약 유무 | P2Y12 test: Clopidogrel 복용 5일 이후 | □ 예(☞지침서) | ■ 아니오 |\n| TEL : 043-719-4652~63  FAX : 043-719-4650 | EPI test | 105명 이상 | 105명 이상 | a | b |\n| ◈ 검사 결과 | 발 | 행 | 일 2016년 12월 | · 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 | 중위값 | 88.0 | 82.7 | 합계 |\n| 팩스번호: 043-719-4650 | 모델명 | PFA-100 System | VerifyNow System | 약물반응 양성 | 사무의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) | □ 베르나르-술리에증후군(Bernard-Soulier syndrome) | aggregometry | and | the | VerifyNow | P2Y12 | assay | a+b |\n| 하는 데 중요한 검사이다. ",
        "original_sentence": "| Correlation | of | high | post-treatment | platelet |\n| 발 | 행 | 처 식품의약품안전처 식품의약품안전평가원 | □ 본 빌레브란트병(von Willebrand disease) | 투약 후 | 투약 전 | Aspirin test: Aspirin 복용 3일 이후 |\n| [표 4] 출혈시간 및 항혈소판제제 저항성 복합검사기기 성능 관련 시험 규격 | 제조사 | Siemens | Accriva Diagnostics | 같지 않은 경우 | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | / | / | 검사항목 | 양성(비정상 결과) 환자 수 | 음성(정상 결과) 환자 수 | Cartridge |\n| 경과일수 | Day0 | 민감도 | 특이도 |\n| 전화번호: 043-719-4652~63 | 사용되는 체외진단용 분석기기에 적용한다. "
      }
    },
    {
      "chunk_id": "chunk_128",
      "text": "| 3) ○○ EPI test | □ 글란즈만혈소판무력증(Glanzmann's thrombasthenia) | reactivity | assessed | by | light | transmittance |\n| 있는 가장 높은 측정치 | 대한 이동거리를 구한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 127,
        "window_size": 3,
        "char_count": 146,
        "word_count": 29,
        "page_number": 15,
        "window_text": "| n = 147.0 | 대한 검사를 위해서도 많이 이용되고 있다.  | 임상시험 | 피험자 식별번호 | 4.  | Correlation | of | high | post-treatment | platelet |\n| 발 | 행 | 처 식품의약품안전처 식품의약품안전평가원 | □ 본 빌레브란트병(von Willebrand disease) | 투약 후 | 투약 전 | Aspirin test: Aspirin 복용 3일 이후 |\n| [표 4] 출혈시간 및 항혈소판제제 저항성 복합검사기기 성능 관련 시험 규격 | 제조사 | Siemens | Accriva Diagnostics | 같지 않은 경우 | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | / | / | 검사항목 | 양성(비정상 결과) 환자 수 | 음성(정상 결과) 환자 수 | Cartridge |\n| 경과일수 | Day0 | 민감도 | 특이도 |\n| 전화번호: 043-719-4652~63 | 사용되는 체외진단용 분석기기에 적용한다.  | 3) ○○ EPI test | □ 글란즈만혈소판무력증(Glanzmann's thrombasthenia) | reactivity | assessed | by | light | transmittance |\n| 있는 가장 높은 측정치 | 대한 이동거리를 구한다.  | 결과들 가운데 일치도의 근접성 | 4)관련성이 의심됨 (Possible) | 품목명 | 자동혈소판응집측정장치 | 자동혈소판응집측정장치 | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | / | / | 아스피린 투약 유무 | P2Y12 test: Clopidogrel 복용 5일 이후 | □ 예(☞지침서) | ■ 아니오 |\n| TEL : 043-719-4652~63  FAX : 043-719-4650 | EPI test | 105명 이상 | 105명 이상 | a | b |\n| ◈ 검사 결과 | 발 | 행 | 일 2016년 12월 | · 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 | 중위값 | 88.0 | 82.7 | 합계 |\n| 팩스번호: 043-719-4650 | 모델명 | PFA-100 System | VerifyNow System | 약물반응 양성 | 사무의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) | □ 베르나르-술리에증후군(Bernard-Soulier syndrome) | aggregometry | and | the | VerifyNow | P2Y12 | assay | a+b |\n| 하는 데 중요한 검사이다.  | □ YES | (비열등성한계 10%) | LTA 검사결과를 기준으로 하여 결과를 평가한다. ",
        "original_sentence": "| 3) ○○ EPI test | □ 글란즈만혈소판무력증(Glanzmann's thrombasthenia) | reactivity | assessed | by | light | transmittance |\n| 있는 가장 높은 측정치 | 대한 이동거리를 구한다. "
      }
    },
    {
      "chunk_id": "chunk_129",
      "text": "| 결과들 가운데 일치도의 근접성 | 4)관련성이 의심됨 (Possible) | 품목명 | 자동혈소판응집측정장치 | 자동혈소판응집측정장치 | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | / | / | 아스피린 투약 유무 | P2Y12 test: Clopidogrel 복용 5일 이후 | □ 예(☞지침서) | ■ 아니오 |\n| TEL : 043-719-4652~63  FAX : 043-719-4650 | EPI test | 105명 이상 | 105명 이상 | a | b |\n| ◈ 검사 결과 | 발 | 행 | 일 2016년 12월 | · 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 | 중위값 | 88.0 | 82.7 | 합계 |\n| 팩스번호: 043-719-4650 | 모델명 | PFA-100 System | VerifyNow System | 약물반응 양성 | 사무의 세부기준이나 절차를 제시하는 것입니까? ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 128,
        "window_size": 3,
        "char_count": 487,
        "word_count": 119,
        "page_number": 6,
        "window_text": "| 임상시험 | 피험자 식별번호 | 4.  | Correlation | of | high | post-treatment | platelet |\n| 발 | 행 | 처 식품의약품안전처 식품의약품안전평가원 | □ 본 빌레브란트병(von Willebrand disease) | 투약 후 | 투약 전 | Aspirin test: Aspirin 복용 3일 이후 |\n| [표 4] 출혈시간 및 항혈소판제제 저항성 복합검사기기 성능 관련 시험 규격 | 제조사 | Siemens | Accriva Diagnostics | 같지 않은 경우 | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | / | / | 검사항목 | 양성(비정상 결과) 환자 수 | 음성(정상 결과) 환자 수 | Cartridge |\n| 경과일수 | Day0 | 민감도 | 특이도 |\n| 전화번호: 043-719-4652~63 | 사용되는 체외진단용 분석기기에 적용한다.  | 3) ○○ EPI test | □ 글란즈만혈소판무력증(Glanzmann's thrombasthenia) | reactivity | assessed | by | light | transmittance |\n| 있는 가장 높은 측정치 | 대한 이동거리를 구한다.  | 결과들 가운데 일치도의 근접성 | 4)관련성이 의심됨 (Possible) | 품목명 | 자동혈소판응집측정장치 | 자동혈소판응집측정장치 | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | / | / | 아스피린 투약 유무 | P2Y12 test: Clopidogrel 복용 5일 이후 | □ 예(☞지침서) | ■ 아니오 |\n| TEL : 043-719-4652~63  FAX : 043-719-4650 | EPI test | 105명 이상 | 105명 이상 | a | b |\n| ◈ 검사 결과 | 발 | 행 | 일 2016년 12월 | · 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 | 중위값 | 88.0 | 82.7 | 합계 |\n| 팩스번호: 043-719-4650 | 모델명 | PFA-100 System | VerifyNow System | 약물반응 양성 | 사무의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) | □ 베르나르-술리에증후군(Bernard-Soulier syndrome) | aggregometry | and | the | VerifyNow | P2Y12 | assay | a+b |\n| 하는 데 중요한 검사이다.  | □ YES | (비열등성한계 10%) | LTA 검사결과를 기준으로 하여 결과를 평가한다.  | 기기인 'VerifyNow P2Y12 test'로 검사를 시행한다. ",
        "original_sentence": "| 결과들 가운데 일치도의 근접성 | 4)관련성이 의심됨 (Possible) | 품목명 | 자동혈소판응집측정장치 | 자동혈소판응집측정장치 | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | / | / | 아스피린 투약 유무 | P2Y12 test: Clopidogrel 복용 5일 이후 | □ 예(☞지침서) | ■ 아니오 |\n| TEL : 043-719-4652~63  FAX : 043-719-4650 | EPI test | 105명 이상 | 105명 이상 | a | b |\n| ◈ 검사 결과 | 발 | 행 | 일 2016년 12월 | · 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 | 중위값 | 88.0 | 82.7 | 합계 |\n| 팩스번호: 043-719-4650 | 모델명 | PFA-100 System | VerifyNow System | 약물반응 양성 | 사무의 세부기준이나 절차를 제시하는 것입니까? "
      }
    },
    {
      "chunk_id": "chunk_130",
      "text": "(공무원용) | □ 베르나르-술리에증후군(Bernard-Soulier syndrome) | aggregometry | and | the | VerifyNow | P2Y12 | assay | a+b |\n| 하는 데 중요한 검사이다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 129,
        "window_size": 3,
        "char_count": 129,
        "word_count": 25,
        "page_number": 33,
        "window_text": "| Correlation | of | high | post-treatment | platelet |\n| 발 | 행 | 처 식품의약품안전처 식품의약품안전평가원 | □ 본 빌레브란트병(von Willebrand disease) | 투약 후 | 투약 전 | Aspirin test: Aspirin 복용 3일 이후 |\n| [표 4] 출혈시간 및 항혈소판제제 저항성 복합검사기기 성능 관련 시험 규격 | 제조사 | Siemens | Accriva Diagnostics | 같지 않은 경우 | 식품의약품안전평가원 의료기기심사부 체외진단기기과 | / | / | 검사항목 | 양성(비정상 결과) 환자 수 | 음성(정상 결과) 환자 수 | Cartridge |\n| 경과일수 | Day0 | 민감도 | 특이도 |\n| 전화번호: 043-719-4652~63 | 사용되는 체외진단용 분석기기에 적용한다.  | 3) ○○ EPI test | □ 글란즈만혈소판무력증(Glanzmann's thrombasthenia) | reactivity | assessed | by | light | transmittance |\n| 있는 가장 높은 측정치 | 대한 이동거리를 구한다.  | 결과들 가운데 일치도의 근접성 | 4)관련성이 의심됨 (Possible) | 품목명 | 자동혈소판응집측정장치 | 자동혈소판응집측정장치 | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | / | / | 아스피린 투약 유무 | P2Y12 test: Clopidogrel 복용 5일 이후 | □ 예(☞지침서) | ■ 아니오 |\n| TEL : 043-719-4652~63  FAX : 043-719-4650 | EPI test | 105명 이상 | 105명 이상 | a | b |\n| ◈ 검사 결과 | 발 | 행 | 일 2016년 12월 | · 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 | 중위값 | 88.0 | 82.7 | 합계 |\n| 팩스번호: 043-719-4650 | 모델명 | PFA-100 System | VerifyNow System | 약물반응 양성 | 사무의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) | □ 베르나르-술리에증후군(Bernard-Soulier syndrome) | aggregometry | and | the | VerifyNow | P2Y12 | assay | a+b |\n| 하는 데 중요한 검사이다.  | □ YES | (비열등성한계 10%) | LTA 검사결과를 기준으로 하여 결과를 평가한다.  | 기기인 'VerifyNow P2Y12 test'로 검사를 시행한다.  | 혈소판기능장애 환자 | 4) ○○ Aspirin test |\n| 있으며 2020년 343억 달러까지 성장할 것으로 예상된다. ",
        "original_sentence": "(공무원용) | □ 베르나르-술리에증후군(Bernard-Soulier syndrome) | aggregometry | and | the | VerifyNow | P2Y12 | assay | a+b |\n| 하는 데 중요한 검사이다. "
      }
    },
    {
      "chunk_id": "chunk_131",
      "text": "| □ YES | (비열등성한계 10%) | LTA 검사결과를 기준으로 하여 결과를 평가한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 130,
        "window_size": 3,
        "char_count": 53,
        "word_count": 13,
        "page_number": 6,
        "window_text": "| 3) ○○ EPI test | □ 글란즈만혈소판무력증(Glanzmann's thrombasthenia) | reactivity | assessed | by | light | transmittance |\n| 있는 가장 높은 측정치 | 대한 이동거리를 구한다.  | 결과들 가운데 일치도의 근접성 | 4)관련성이 의심됨 (Possible) | 품목명 | 자동혈소판응집측정장치 | 자동혈소판응집측정장치 | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | / | / | 아스피린 투약 유무 | P2Y12 test: Clopidogrel 복용 5일 이후 | □ 예(☞지침서) | ■ 아니오 |\n| TEL : 043-719-4652~63  FAX : 043-719-4650 | EPI test | 105명 이상 | 105명 이상 | a | b |\n| ◈ 검사 결과 | 발 | 행 | 일 2016년 12월 | · 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 | 중위값 | 88.0 | 82.7 | 합계 |\n| 팩스번호: 043-719-4650 | 모델명 | PFA-100 System | VerifyNow System | 약물반응 양성 | 사무의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) | □ 베르나르-술리에증후군(Bernard-Soulier syndrome) | aggregometry | and | the | VerifyNow | P2Y12 | assay | a+b |\n| 하는 데 중요한 검사이다.  | □ YES | (비열등성한계 10%) | LTA 검사결과를 기준으로 하여 결과를 평가한다.  | 기기인 'VerifyNow P2Y12 test'로 검사를 시행한다.  | 혈소판기능장애 환자 | 4) ○○ Aspirin test |\n| 있으며 2020년 343억 달러까지 성장할 것으로 예상된다.  | Visit window | - | 있으나, 해당 의료기기에서 알려진 이상사례와 직접적인 관련성이 없고, 피험자의 임상적 상 | [그림 5] 혈소판 기능검사 및 항혈소판제제 저항성 검사기기 | ADP test | 105명 이상 | 132명 이상 | http://www.mfds.go.kr/medicaldevice | (True Positive) | 투약 후 | 투약 전 | (False Positive) | 정밀도 평가방법에 |\n| - 시험물질 | EPI test | 하기 위한 평가 |         | 증례기록서 작성에 대한 세부사항 | □ 약물유발 혈소판기능부전(drug-induced platelet | 표준편차 | 16.1 | 8.0 | 대조기기 |\n| Hb (mg/dL) | 발 | 행 | 인 | 손여원 | □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 | / | / | (Thromb Thrombolysis. ",
        "original_sentence": "| □ YES | (비열등성한계 10%) | LTA 검사결과를 기준으로 하여 결과를 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_132",
      "text": "| 기기인 'VerifyNow P2Y12 test'로 검사를 시행한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 131,
        "window_size": 3,
        "char_count": 40,
        "word_count": 7,
        "page_number": 6,
        "window_text": "| 결과들 가운데 일치도의 근접성 | 4)관련성이 의심됨 (Possible) | 품목명 | 자동혈소판응집측정장치 | 자동혈소판응집측정장치 | □ 내부적으로 행정사무의 통일을 기하기 위하여 반복적으로 행정 | / | / | 아스피린 투약 유무 | P2Y12 test: Clopidogrel 복용 5일 이후 | □ 예(☞지침서) | ■ 아니오 |\n| TEL : 043-719-4652~63  FAX : 043-719-4650 | EPI test | 105명 이상 | 105명 이상 | a | b |\n| ◈ 검사 결과 | 발 | 행 | 일 2016년 12월 | · 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 | 중위값 | 88.0 | 82.7 | 합계 |\n| 팩스번호: 043-719-4650 | 모델명 | PFA-100 System | VerifyNow System | 약물반응 양성 | 사무의 세부기준이나 절차를 제시하는 것입니까?  (공무원용) | □ 베르나르-술리에증후군(Bernard-Soulier syndrome) | aggregometry | and | the | VerifyNow | P2Y12 | assay | a+b |\n| 하는 데 중요한 검사이다.  | □ YES | (비열등성한계 10%) | LTA 검사결과를 기준으로 하여 결과를 평가한다.  | 기기인 'VerifyNow P2Y12 test'로 검사를 시행한다.  | 혈소판기능장애 환자 | 4) ○○ Aspirin test |\n| 있으며 2020년 343억 달러까지 성장할 것으로 예상된다.  | Visit window | - | 있으나, 해당 의료기기에서 알려진 이상사례와 직접적인 관련성이 없고, 피험자의 임상적 상 | [그림 5] 혈소판 기능검사 및 항혈소판제제 저항성 검사기기 | ADP test | 105명 이상 | 132명 이상 | http://www.mfds.go.kr/medicaldevice | (True Positive) | 투약 후 | 투약 전 | (False Positive) | 정밀도 평가방법에 |\n| - 시험물질 | EPI test | 하기 위한 평가 |         | 증례기록서 작성에 대한 세부사항 | □ 약물유발 혈소판기능부전(drug-induced platelet | 표준편차 | 16.1 | 8.0 | 대조기기 |\n| Hb (mg/dL) | 발 | 행 | 인 | 손여원 | □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 | / | / | (Thromb Thrombolysis.  2010 Nov;30(4):486-95.) ",
        "original_sentence": "| 기기인 'VerifyNow P2Y12 test'로 검사를 시행한다. "
      }
    },
    {
      "chunk_id": "chunk_133",
      "text": "| 혈소판기능장애 환자 | 4) ○○ Aspirin test |\n| 있으며 2020년 343억 달러까지 성장할 것으로 예상된다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 132,
        "window_size": 3,
        "char_count": 72,
        "word_count": 17,
        "page_number": 6,
        "window_text": "(공무원용) | □ 베르나르-술리에증후군(Bernard-Soulier syndrome) | aggregometry | and | the | VerifyNow | P2Y12 | assay | a+b |\n| 하는 데 중요한 검사이다.  | □ YES | (비열등성한계 10%) | LTA 검사결과를 기준으로 하여 결과를 평가한다.  | 기기인 'VerifyNow P2Y12 test'로 검사를 시행한다.  | 혈소판기능장애 환자 | 4) ○○ Aspirin test |\n| 있으며 2020년 343억 달러까지 성장할 것으로 예상된다.  | Visit window | - | 있으나, 해당 의료기기에서 알려진 이상사례와 직접적인 관련성이 없고, 피험자의 임상적 상 | [그림 5] 혈소판 기능검사 및 항혈소판제제 저항성 검사기기 | ADP test | 105명 이상 | 132명 이상 | http://www.mfds.go.kr/medicaldevice | (True Positive) | 투약 후 | 투약 전 | (False Positive) | 정밀도 평가방법에 |\n| - 시험물질 | EPI test | 하기 위한 평가 |         | 증례기록서 작성에 대한 세부사항 | □ 약물유발 혈소판기능부전(drug-induced platelet | 표준편차 | 16.1 | 8.0 | 대조기기 |\n| Hb (mg/dL) | 발 | 행 | 인 | 손여원 | □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 | / | / | (Thromb Thrombolysis.  2010 Nov;30(4):486-95.)  |\n| 구분 | 품목허가번호 | 제 서울수신 06-710호 | 제 경인수신 05-110호 | 태 또는 시험 절차/조건에 의해 발생하였을 가능성이 있는 경우 | 대한 기준 가이드라인 |\n| 관찰형태 | 내원 | 내원 | 5) ○○ P2Y12 tests | / | / | SIPA test | 105명 이상 | 132명 이상 | dysfunction) | c | d | 합계 |\n| 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까? ",
        "original_sentence": "| 혈소판기능장애 환자 | 4) ○○ Aspirin test |\n| 있으며 2020년 343억 달러까지 성장할 것으로 예상된다. "
      }
    },
    {
      "chunk_id": "chunk_134",
      "text": "| Visit window | - | 있으나, 해당 의료기기에서 알려진 이상사례와 직접적인 관련성이 없고, 피험자의 임상적 상 | [그림 5] 혈소판 기능검사 및 항혈소판제제 저항성 검사기기 | ADP test | 105명 이상 | 132명 이상 | http://www.mfds.go.kr/medicaldevice | (True Positive) | 투약 후 | 투약 전 | (False Positive) | 정밀도 평가방법에 |\n| - 시험물질 | EPI test | 하기 위한 평가 |         | 증례기록서 작성에 대한 세부사항 | □ 약물유발 혈소판기능부전(drug-induced platelet | 표준편차 | 16.1 | 8.0 | 대조기기 |\n| Hb (mg/dL) | 발 | 행 | 인 | 손여원 | □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 | / | / | (Thromb Thrombolysis. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 133,
        "window_size": 3,
        "char_count": 488,
        "word_count": 119,
        "page_number": 18,
        "window_text": "| □ YES | (비열등성한계 10%) | LTA 검사결과를 기준으로 하여 결과를 평가한다.  | 기기인 'VerifyNow P2Y12 test'로 검사를 시행한다.  | 혈소판기능장애 환자 | 4) ○○ Aspirin test |\n| 있으며 2020년 343억 달러까지 성장할 것으로 예상된다.  | Visit window | - | 있으나, 해당 의료기기에서 알려진 이상사례와 직접적인 관련성이 없고, 피험자의 임상적 상 | [그림 5] 혈소판 기능검사 및 항혈소판제제 저항성 검사기기 | ADP test | 105명 이상 | 132명 이상 | http://www.mfds.go.kr/medicaldevice | (True Positive) | 투약 후 | 투약 전 | (False Positive) | 정밀도 평가방법에 |\n| - 시험물질 | EPI test | 하기 위한 평가 |         | 증례기록서 작성에 대한 세부사항 | □ 약물유발 혈소판기능부전(drug-induced platelet | 표준편차 | 16.1 | 8.0 | 대조기기 |\n| Hb (mg/dL) | 발 | 행 | 인 | 손여원 | □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 | / | / | (Thromb Thrombolysis.  2010 Nov;30(4):486-95.)  |\n| 구분 | 품목허가번호 | 제 서울수신 06-710호 | 제 경인수신 05-110호 | 태 또는 시험 절차/조건에 의해 발생하였을 가능성이 있는 경우 | 대한 기준 가이드라인 |\n| 관찰형태 | 내원 | 내원 | 5) ○○ P2Y12 tests | / | / | SIPA test | 105명 이상 | 132명 이상 | dysfunction) | c | d | 합계 |\n| 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까?  (민원인용) | 표준오차 | 8.0 | 4.0 | a | b |\n| 대하여 전기 | Platelet (/uL) | 5)관련성이 많음 (Probable) | Evaluation of the Linearity of Quantitative | Measurement Procedures; A Statistical Approach; | Approved Guideline | [그림 2] 혈소판 기능검사의 원리 |\n| 편 집 위 원 장 정희교 | Approved Guideline | 약물반응 양성 | 약물반응 음성 | □ 기타: | 비정상 | 정상 | 5. ",
        "original_sentence": "| Visit window | - | 있으나, 해당 의료기기에서 알려진 이상사례와 직접적인 관련성이 없고, 피험자의 임상적 상 | [그림 5] 혈소판 기능검사 및 항혈소판제제 저항성 검사기기 | ADP test | 105명 이상 | 132명 이상 | http://www.mfds.go.kr/medicaldevice | (True Positive) | 투약 후 | 투약 전 | (False Positive) | 정밀도 평가방법에 |\n| - 시험물질 | EPI test | 하기 위한 평가 |         | 증례기록서 작성에 대한 세부사항 | □ 약물유발 혈소판기능부전(drug-induced platelet | 표준편차 | 16.1 | 8.0 | 대조기기 |\n| Hb (mg/dL) | 발 | 행 | 인 | 손여원 | □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 | / | / | (Thromb Thrombolysis. "
      }
    },
    {
      "chunk_id": "chunk_135",
      "text": "2010 Nov;30(4):486-95.) ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 134,
        "window_size": 3,
        "char_count": 24,
        "word_count": 2,
        "page_number": 6,
        "window_text": "| 기기인 'VerifyNow P2Y12 test'로 검사를 시행한다.  | 혈소판기능장애 환자 | 4) ○○ Aspirin test |\n| 있으며 2020년 343억 달러까지 성장할 것으로 예상된다.  | Visit window | - | 있으나, 해당 의료기기에서 알려진 이상사례와 직접적인 관련성이 없고, 피험자의 임상적 상 | [그림 5] 혈소판 기능검사 및 항혈소판제제 저항성 검사기기 | ADP test | 105명 이상 | 132명 이상 | http://www.mfds.go.kr/medicaldevice | (True Positive) | 투약 후 | 투약 전 | (False Positive) | 정밀도 평가방법에 |\n| - 시험물질 | EPI test | 하기 위한 평가 |         | 증례기록서 작성에 대한 세부사항 | □ 약물유발 혈소판기능부전(drug-induced platelet | 표준편차 | 16.1 | 8.0 | 대조기기 |\n| Hb (mg/dL) | 발 | 행 | 인 | 손여원 | □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 | / | / | (Thromb Thrombolysis.  2010 Nov;30(4):486-95.)  |\n| 구분 | 품목허가번호 | 제 서울수신 06-710호 | 제 경인수신 05-110호 | 태 또는 시험 절차/조건에 의해 발생하였을 가능성이 있는 경우 | 대한 기준 가이드라인 |\n| 관찰형태 | 내원 | 내원 | 5) ○○ P2Y12 tests | / | / | SIPA test | 105명 이상 | 132명 이상 | dysfunction) | c | d | 합계 |\n| 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까?  (민원인용) | 표준오차 | 8.0 | 4.0 | a | b |\n| 대하여 전기 | Platelet (/uL) | 5)관련성이 많음 (Probable) | Evaluation of the Linearity of Quantitative | Measurement Procedures; A Statistical Approach; | Approved Guideline | [그림 2] 혈소판 기능검사의 원리 |\n| 편 집 위 원 장 정희교 | Approved Guideline | 약물반응 양성 | 약물반응 음성 | □ 기타: | 비정상 | 정상 | 5.  | Comparison | of | methods | to | evaluate | 직선성 평가방법에 | a+b | c+b |\n| 일시적으로 의식 소실이 유발되는 것이다. ",
        "original_sentence": "2010 Nov;30(4):486-95.) "
      }
    },
    {
      "chunk_id": "chunk_136",
      "text": "|\n| 구분 | 품목허가번호 | 제 서울수신 06-710호 | 제 경인수신 05-110호 | 태 또는 시험 절차/조건에 의해 발생하였을 가능성이 있는 경우 | 대한 기준 가이드라인 |\n| 관찰형태 | 내원 | 내원 | 5) ○○ P2Y12 tests | / | / | SIPA test | 105명 이상 | 132명 이상 | dysfunction) | c | d | 합계 |\n| 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까? ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 135,
        "window_size": 3,
        "char_count": 258,
        "word_count": 72,
        "page_number": 3,
        "window_text": "| 혈소판기능장애 환자 | 4) ○○ Aspirin test |\n| 있으며 2020년 343억 달러까지 성장할 것으로 예상된다.  | Visit window | - | 있으나, 해당 의료기기에서 알려진 이상사례와 직접적인 관련성이 없고, 피험자의 임상적 상 | [그림 5] 혈소판 기능검사 및 항혈소판제제 저항성 검사기기 | ADP test | 105명 이상 | 132명 이상 | http://www.mfds.go.kr/medicaldevice | (True Positive) | 투약 후 | 투약 전 | (False Positive) | 정밀도 평가방법에 |\n| - 시험물질 | EPI test | 하기 위한 평가 |         | 증례기록서 작성에 대한 세부사항 | □ 약물유발 혈소판기능부전(drug-induced platelet | 표준편차 | 16.1 | 8.0 | 대조기기 |\n| Hb (mg/dL) | 발 | 행 | 인 | 손여원 | □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 | / | / | (Thromb Thrombolysis.  2010 Nov;30(4):486-95.)  |\n| 구분 | 품목허가번호 | 제 서울수신 06-710호 | 제 경인수신 05-110호 | 태 또는 시험 절차/조건에 의해 발생하였을 가능성이 있는 경우 | 대한 기준 가이드라인 |\n| 관찰형태 | 내원 | 내원 | 5) ○○ P2Y12 tests | / | / | SIPA test | 105명 이상 | 132명 이상 | dysfunction) | c | d | 합계 |\n| 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까?  (민원인용) | 표준오차 | 8.0 | 4.0 | a | b |\n| 대하여 전기 | Platelet (/uL) | 5)관련성이 많음 (Probable) | Evaluation of the Linearity of Quantitative | Measurement Procedures; A Statistical Approach; | Approved Guideline | [그림 2] 혈소판 기능검사의 원리 |\n| 편 집 위 원 장 정희교 | Approved Guideline | 약물반응 양성 | 약물반응 음성 | □ 기타: | 비정상 | 정상 | 5.  | Comparison | of | methods | to | evaluate | 직선성 평가방법에 | a+b | c+b |\n| 일시적으로 의식 소실이 유발되는 것이다.  |         |\n| 약물 투여 전 반응여부와 약물 투여후 반응여부를 확인한다. ",
        "original_sentence": "|\n| 구분 | 품목허가번호 | 제 서울수신 06-710호 | 제 경인수신 05-110호 | 태 또는 시험 절차/조건에 의해 발생하였을 가능성이 있는 경우 | 대한 기준 가이드라인 |\n| 관찰형태 | 내원 | 내원 | 5) ○○ P2Y12 tests | / | / | SIPA test | 105명 이상 | 132명 이상 | dysfunction) | c | d | 합계 |\n| 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까? "
      }
    },
    {
      "chunk_id": "chunk_137",
      "text": "(민원인용) | 표준오차 | 8.0 | 4.0 | a | b |\n| 대하여 전기 | Platelet (/uL) | 5)관련성이 많음 (Probable) | Evaluation of the Linearity of Quantitative | Measurement Procedures; A Statistical Approach; | Approved Guideline | [그림 2] 혈소판 기능검사의 원리 |\n| 편 집 위 원 장 정희교 | Approved Guideline | 약물반응 양성 | 약물반응 음성 | □ 기타: | 비정상 | 정상 | 5. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 136,
        "window_size": 3,
        "char_count": 307,
        "word_count": 70,
        "page_number": 6,
        "window_text": "| Visit window | - | 있으나, 해당 의료기기에서 알려진 이상사례와 직접적인 관련성이 없고, 피험자의 임상적 상 | [그림 5] 혈소판 기능검사 및 항혈소판제제 저항성 검사기기 | ADP test | 105명 이상 | 132명 이상 | http://www.mfds.go.kr/medicaldevice | (True Positive) | 투약 후 | 투약 전 | (False Positive) | 정밀도 평가방법에 |\n| - 시험물질 | EPI test | 하기 위한 평가 |         | 증례기록서 작성에 대한 세부사항 | □ 약물유발 혈소판기능부전(drug-induced platelet | 표준편차 | 16.1 | 8.0 | 대조기기 |\n| Hb (mg/dL) | 발 | 행 | 인 | 손여원 | □ 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게 풀어서 | / | / | (Thromb Thrombolysis.  2010 Nov;30(4):486-95.)  |\n| 구분 | 품목허가번호 | 제 서울수신 06-710호 | 제 경인수신 05-110호 | 태 또는 시험 절차/조건에 의해 발생하였을 가능성이 있는 경우 | 대한 기준 가이드라인 |\n| 관찰형태 | 내원 | 내원 | 5) ○○ P2Y12 tests | / | / | SIPA test | 105명 이상 | 132명 이상 | dysfunction) | c | d | 합계 |\n| 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까?  (민원인용) | 표준오차 | 8.0 | 4.0 | a | b |\n| 대하여 전기 | Platelet (/uL) | 5)관련성이 많음 (Probable) | Evaluation of the Linearity of Quantitative | Measurement Procedures; A Statistical Approach; | Approved Guideline | [그림 2] 혈소판 기능검사의 원리 |\n| 편 집 위 원 장 정희교 | Approved Guideline | 약물반응 양성 | 약물반응 음성 | □ 기타: | 비정상 | 정상 | 5.  | Comparison | of | methods | to | evaluate | 직선성 평가방법에 | a+b | c+b |\n| 일시적으로 의식 소실이 유발되는 것이다.  |         |\n| 약물 투여 전 반응여부와 약물 투여후 반응여부를 확인한다.  | 동의서 취득 | O | · 이상사례가 임상시험용 의료기기 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으며, | 품목명 | 자동혈소판응집측정장치용시약 | 자동혈소판응집측정장치용시약 | 중위값 | 84.0 | 81.0 | (False Negative) | (True Positive) | (True Negative) | (False Positive) |\n| Procedures; A Statistical Approach; Approved Guideline | [n = sample size (검체 수), p (민감도) = 0.85, | Hematocrit (%) | 대한 기준 가이드라인 |\n| 컨트롤 챔버의 2개의 챔버로 구성되어 있다. ",
        "original_sentence": "(민원인용) | 표준오차 | 8.0 | 4.0 | a | b |\n| 대하여 전기 | Platelet (/uL) | 5)관련성이 많음 (Probable) | Evaluation of the Linearity of Quantitative | Measurement Procedures; A Statistical Approach; | Approved Guideline | [그림 2] 혈소판 기능검사의 원리 |\n| 편 집 위 원 장 정희교 | Approved Guideline | 약물반응 양성 | 약물반응 음성 | □ 기타: | 비정상 | 정상 | 5. "
      }
    },
    {
      "chunk_id": "chunk_138",
      "text": "| Comparison | of | methods | to | evaluate | 직선성 평가방법에 | a+b | c+b |\n| 일시적으로 의식 소실이 유발되는 것이다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 137,
        "window_size": 3,
        "char_count": 95,
        "word_count": 24,
        "page_number": 17,
        "window_text": "2010 Nov;30(4):486-95.)  |\n| 구분 | 품목허가번호 | 제 서울수신 06-710호 | 제 경인수신 05-110호 | 태 또는 시험 절차/조건에 의해 발생하였을 가능성이 있는 경우 | 대한 기준 가이드라인 |\n| 관찰형태 | 내원 | 내원 | 5) ○○ P2Y12 tests | / | / | SIPA test | 105명 이상 | 132명 이상 | dysfunction) | c | d | 합계 |\n| 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까?  (민원인용) | 표준오차 | 8.0 | 4.0 | a | b |\n| 대하여 전기 | Platelet (/uL) | 5)관련성이 많음 (Probable) | Evaluation of the Linearity of Quantitative | Measurement Procedures; A Statistical Approach; | Approved Guideline | [그림 2] 혈소판 기능검사의 원리 |\n| 편 집 위 원 장 정희교 | Approved Guideline | 약물반응 양성 | 약물반응 음성 | □ 기타: | 비정상 | 정상 | 5.  | Comparison | of | methods | to | evaluate | 직선성 평가방법에 | a+b | c+b |\n| 일시적으로 의식 소실이 유발되는 것이다.  |         |\n| 약물 투여 전 반응여부와 약물 투여후 반응여부를 확인한다.  | 동의서 취득 | O | · 이상사례가 임상시험용 의료기기 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으며, | 품목명 | 자동혈소판응집측정장치용시약 | 자동혈소판응집측정장치용시약 | 중위값 | 84.0 | 81.0 | (False Negative) | (True Positive) | (True Negative) | (False Positive) |\n| Procedures; A Statistical Approach; Approved Guideline | [n = sample size (검체 수), p (민감도) = 0.85, | Hematocrit (%) | 대한 기준 가이드라인 |\n| 컨트롤 챔버의 2개의 챔버로 구성되어 있다.  | / | / |         | clopidogrel-mediated | platelet | inhibition | after | (연락처) |\n| □ NO | 편 | 집 | 위 | 원 | 수입 의료기기에 의존하여 검사를 진행하고 있다. ",
        "original_sentence": "| Comparison | of | methods | to | evaluate | 직선성 평가방법에 | a+b | c+b |\n| 일시적으로 의식 소실이 유발되는 것이다. "
      }
    },
    {
      "chunk_id": "chunk_139",
      "text": "|         |\n| 약물 투여 전 반응여부와 약물 투여후 반응여부를 확인한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 138,
        "window_size": 3,
        "char_count": 63,
        "word_count": 19,
        "page_number": 3,
        "window_text": "|\n| 구분 | 품목허가번호 | 제 서울수신 06-710호 | 제 경인수신 05-110호 | 태 또는 시험 절차/조건에 의해 발생하였을 가능성이 있는 경우 | 대한 기준 가이드라인 |\n| 관찰형태 | 내원 | 내원 | 5) ○○ P2Y12 tests | / | / | SIPA test | 105명 이상 | 132명 이상 | dysfunction) | c | d | 합계 |\n| 설명하거나 특정한 사안에 대하여 식품의약품안전처의 입장을 기술 | 하는 것입니까?  (민원인용) | 표준오차 | 8.0 | 4.0 | a | b |\n| 대하여 전기 | Platelet (/uL) | 5)관련성이 많음 (Probable) | Evaluation of the Linearity of Quantitative | Measurement Procedures; A Statistical Approach; | Approved Guideline | [그림 2] 혈소판 기능검사의 원리 |\n| 편 집 위 원 장 정희교 | Approved Guideline | 약물반응 양성 | 약물반응 음성 | □ 기타: | 비정상 | 정상 | 5.  | Comparison | of | methods | to | evaluate | 직선성 평가방법에 | a+b | c+b |\n| 일시적으로 의식 소실이 유발되는 것이다.  |         |\n| 약물 투여 전 반응여부와 약물 투여후 반응여부를 확인한다.  | 동의서 취득 | O | · 이상사례가 임상시험용 의료기기 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으며, | 품목명 | 자동혈소판응집측정장치용시약 | 자동혈소판응집측정장치용시약 | 중위값 | 84.0 | 81.0 | (False Negative) | (True Positive) | (True Negative) | (False Positive) |\n| Procedures; A Statistical Approach; Approved Guideline | [n = sample size (검체 수), p (민감도) = 0.85, | Hematocrit (%) | 대한 기준 가이드라인 |\n| 컨트롤 챔버의 2개의 챔버로 구성되어 있다.  | / | / |         | clopidogrel-mediated | platelet | inhibition | after | (연락처) |\n| □ NO | 편 | 집 | 위 | 원 | 수입 의료기기에 의존하여 검사를 진행하고 있다.  | 해당 의료기기의 알려진 특징으로 합리적인 설명을 할 수 있는 경우 | a | b |\n| - 시험물질 | 제조자가 설정한 한계 이내로 유지되는지 평가하기 위함 | 선정/제외기준 확인 | O | 검체에 분석대상 물질을 일정량 첨가한 시험물질 사용한다. ",
        "original_sentence": "|         |\n| 약물 투여 전 반응여부와 약물 투여후 반응여부를 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_140",
      "text": "| 동의서 취득 | O | · 이상사례가 임상시험용 의료기기 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으며, | 품목명 | 자동혈소판응집측정장치용시약 | 자동혈소판응집측정장치용시약 | 중위값 | 84.0 | 81.0 | (False Negative) | (True Positive) | (True Negative) | (False Positive) |\n| Procedures; A Statistical Approach; Approved Guideline | [n = sample size (검체 수), p (민감도) = 0.85, | Hematocrit (%) | 대한 기준 가이드라인 |\n| 컨트롤 챔버의 2개의 챔버로 구성되어 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 139,
        "window_size": 3,
        "char_count": 363,
        "word_count": 75,
        "page_number": 9,
        "window_text": "(민원인용) | 표준오차 | 8.0 | 4.0 | a | b |\n| 대하여 전기 | Platelet (/uL) | 5)관련성이 많음 (Probable) | Evaluation of the Linearity of Quantitative | Measurement Procedures; A Statistical Approach; | Approved Guideline | [그림 2] 혈소판 기능검사의 원리 |\n| 편 집 위 원 장 정희교 | Approved Guideline | 약물반응 양성 | 약물반응 음성 | □ 기타: | 비정상 | 정상 | 5.  | Comparison | of | methods | to | evaluate | 직선성 평가방법에 | a+b | c+b |\n| 일시적으로 의식 소실이 유발되는 것이다.  |         |\n| 약물 투여 전 반응여부와 약물 투여후 반응여부를 확인한다.  | 동의서 취득 | O | · 이상사례가 임상시험용 의료기기 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으며, | 품목명 | 자동혈소판응집측정장치용시약 | 자동혈소판응집측정장치용시약 | 중위값 | 84.0 | 81.0 | (False Negative) | (True Positive) | (True Negative) | (False Positive) |\n| Procedures; A Statistical Approach; Approved Guideline | [n = sample size (검체 수), p (민감도) = 0.85, | Hematocrit (%) | 대한 기준 가이드라인 |\n| 컨트롤 챔버의 2개의 챔버로 구성되어 있다.  | / | / |         | clopidogrel-mediated | platelet | inhibition | after | (연락처) |\n| □ NO | 편 | 집 | 위 | 원 | 수입 의료기기에 의존하여 검사를 진행하고 있다.  | 해당 의료기기의 알려진 특징으로 합리적인 설명을 할 수 있는 경우 | a | b |\n| - 시험물질 | 제조자가 설정한 한계 이내로 유지되는지 평가하기 위함 | 선정/제외기준 확인 | O | 검체에 분석대상 물질을 일정량 첨가한 시험물질 사용한다.  | ADP test | 으로 표현 | 합계 | a+c | b+d | a+b+c+d | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | 표준편차 | 4.2 | 1.4 | Roche Prostagladin E1 | □ 예 | ■ 아니오 |\n| aPTT (sec): | / | / | 비정상 | 김윤영, 김서윤, 김민정 | Dade PFA | c | Dade PFA | d | 간섭물질 반응에 대한 | a+b |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 확인할 수 있다. ",
        "original_sentence": "| 동의서 취득 | O | · 이상사례가 임상시험용 의료기기 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으며, | 품목명 | 자동혈소판응집측정장치용시약 | 자동혈소판응집측정장치용시약 | 중위값 | 84.0 | 81.0 | (False Negative) | (True Positive) | (True Negative) | (False Positive) |\n| Procedures; A Statistical Approach; Approved Guideline | [n = sample size (검체 수), p (민감도) = 0.85, | Hematocrit (%) | 대한 기준 가이드라인 |\n| 컨트롤 챔버의 2개의 챔버로 구성되어 있다. "
      }
    },
    {
      "chunk_id": "chunk_141",
      "text": "| / | / |         | clopidogrel-mediated | platelet | inhibition | after | (연락처) |\n| □ NO | 편 | 집 | 위 | 원 | 수입 의료기기에 의존하여 검사를 진행하고 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 140,
        "window_size": 3,
        "char_count": 151,
        "word_count": 42,
        "page_number": 33,
        "window_text": "| Comparison | of | methods | to | evaluate | 직선성 평가방법에 | a+b | c+b |\n| 일시적으로 의식 소실이 유발되는 것이다.  |         |\n| 약물 투여 전 반응여부와 약물 투여후 반응여부를 확인한다.  | 동의서 취득 | O | · 이상사례가 임상시험용 의료기기 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으며, | 품목명 | 자동혈소판응집측정장치용시약 | 자동혈소판응집측정장치용시약 | 중위값 | 84.0 | 81.0 | (False Negative) | (True Positive) | (True Negative) | (False Positive) |\n| Procedures; A Statistical Approach; Approved Guideline | [n = sample size (검체 수), p (민감도) = 0.85, | Hematocrit (%) | 대한 기준 가이드라인 |\n| 컨트롤 챔버의 2개의 챔버로 구성되어 있다.  | / | / |         | clopidogrel-mediated | platelet | inhibition | after | (연락처) |\n| □ NO | 편 | 집 | 위 | 원 | 수입 의료기기에 의존하여 검사를 진행하고 있다.  | 해당 의료기기의 알려진 특징으로 합리적인 설명을 할 수 있는 경우 | a | b |\n| - 시험물질 | 제조자가 설정한 한계 이내로 유지되는지 평가하기 위함 | 선정/제외기준 확인 | O | 검체에 분석대상 물질을 일정량 첨가한 시험물질 사용한다.  | ADP test | 으로 표현 | 합계 | a+c | b+d | a+b+c+d | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | 표준편차 | 4.2 | 1.4 | Roche Prostagladin E1 | □ 예 | ■ 아니오 |\n| aPTT (sec): | / | / | 비정상 | 김윤영, 김서윤, 김민정 | Dade PFA | c | Dade PFA | d | 간섭물질 반응에 대한 | a+b |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 확인할 수 있다.  | 6) 관련성이 명백함(Definite) | percutaneous intervention with stent implantation | 윤리담당자 |\n| [n = sample size (검체 수), p (특이도) = 0.85, | 약물반응 음성 | 민원인을 구속하는 내용이 있습니까? ",
        "original_sentence": "| / | / |         | clopidogrel-mediated | platelet | inhibition | after | (연락처) |\n| □ NO | 편 | 집 | 위 | 원 | 수입 의료기기에 의존하여 검사를 진행하고 있다. "
      }
    },
    {
      "chunk_id": "chunk_142",
      "text": "| 해당 의료기기의 알려진 특징으로 합리적인 설명을 할 수 있는 경우 | a | b |\n| - 시험물질 | 제조자가 설정한 한계 이내로 유지되는지 평가하기 위함 | 선정/제외기준 확인 | O | 검체에 분석대상 물질을 일정량 첨가한 시험물질 사용한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 141,
        "window_size": 3,
        "char_count": 141,
        "word_count": 40,
        "page_number": 78,
        "window_text": "|         |\n| 약물 투여 전 반응여부와 약물 투여후 반응여부를 확인한다.  | 동의서 취득 | O | · 이상사례가 임상시험용 의료기기 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으며, | 품목명 | 자동혈소판응집측정장치용시약 | 자동혈소판응집측정장치용시약 | 중위값 | 84.0 | 81.0 | (False Negative) | (True Positive) | (True Negative) | (False Positive) |\n| Procedures; A Statistical Approach; Approved Guideline | [n = sample size (검체 수), p (민감도) = 0.85, | Hematocrit (%) | 대한 기준 가이드라인 |\n| 컨트롤 챔버의 2개의 챔버로 구성되어 있다.  | / | / |         | clopidogrel-mediated | platelet | inhibition | after | (연락처) |\n| □ NO | 편 | 집 | 위 | 원 | 수입 의료기기에 의존하여 검사를 진행하고 있다.  | 해당 의료기기의 알려진 특징으로 합리적인 설명을 할 수 있는 경우 | a | b |\n| - 시험물질 | 제조자가 설정한 한계 이내로 유지되는지 평가하기 위함 | 선정/제외기준 확인 | O | 검체에 분석대상 물질을 일정량 첨가한 시험물질 사용한다.  | ADP test | 으로 표현 | 합계 | a+c | b+d | a+b+c+d | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | 표준편차 | 4.2 | 1.4 | Roche Prostagladin E1 | □ 예 | ■ 아니오 |\n| aPTT (sec): | / | / | 비정상 | 김윤영, 김서윤, 김민정 | Dade PFA | c | Dade PFA | d | 간섭물질 반응에 대한 | a+b |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 확인할 수 있다.  | 6) 관련성이 명백함(Definite) | percutaneous intervention with stent implantation | 윤리담당자 |\n| [n = sample size (검체 수), p (특이도) = 0.85, | 약물반응 음성 | 민원인을 구속하는 내용이 있습니까?  | 표준오차 | 3.0 | 1.0 | VerifyNow | Reagent | VerifyNow | c+b |\n| (True Positive) | (False Positive) | 기준 가이드라인 |\n| 인구학적 정보 | O | · 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 | 모델명 | Collagen/EPI | Collagen/ADP |\n| - 시험장비 | 대한 간섭 평가 시험을 고려한다. ",
        "original_sentence": "| 해당 의료기기의 알려진 특징으로 합리적인 설명을 할 수 있는 경우 | a | b |\n| - 시험물질 | 제조자가 설정한 한계 이내로 유지되는지 평가하기 위함 | 선정/제외기준 확인 | O | 검체에 분석대상 물질을 일정량 첨가한 시험물질 사용한다. "
      }
    },
    {
      "chunk_id": "chunk_143",
      "text": "| ADP test | 으로 표현 | 합계 | a+c | b+d | a+b+c+d | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | 표준편차 | 4.2 | 1.4 | Roche Prostagladin E1 | □ 예 | ■ 아니오 |\n| aPTT (sec): | / | / | 비정상 | 김윤영, 김서윤, 김민정 | Dade PFA | c | Dade PFA | d | 간섭물질 반응에 대한 | a+b |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 확인할 수 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 142,
        "window_size": 3,
        "char_count": 297,
        "word_count": 85,
        "page_number": 10,
        "window_text": "| 동의서 취득 | O | · 이상사례가 임상시험용 의료기기 시술 시점으로부터 합리적인 시간적 연관성을 가지고 있으며, | 품목명 | 자동혈소판응집측정장치용시약 | 자동혈소판응집측정장치용시약 | 중위값 | 84.0 | 81.0 | (False Negative) | (True Positive) | (True Negative) | (False Positive) |\n| Procedures; A Statistical Approach; Approved Guideline | [n = sample size (검체 수), p (민감도) = 0.85, | Hematocrit (%) | 대한 기준 가이드라인 |\n| 컨트롤 챔버의 2개의 챔버로 구성되어 있다.  | / | / |         | clopidogrel-mediated | platelet | inhibition | after | (연락처) |\n| □ NO | 편 | 집 | 위 | 원 | 수입 의료기기에 의존하여 검사를 진행하고 있다.  | 해당 의료기기의 알려진 특징으로 합리적인 설명을 할 수 있는 경우 | a | b |\n| - 시험물질 | 제조자가 설정한 한계 이내로 유지되는지 평가하기 위함 | 선정/제외기준 확인 | O | 검체에 분석대상 물질을 일정량 첨가한 시험물질 사용한다.  | ADP test | 으로 표현 | 합계 | a+c | b+d | a+b+c+d | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | 표준편차 | 4.2 | 1.4 | Roche Prostagladin E1 | □ 예 | ■ 아니오 |\n| aPTT (sec): | / | / | 비정상 | 김윤영, 김서윤, 김민정 | Dade PFA | c | Dade PFA | d | 간섭물질 반응에 대한 | a+b |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 확인할 수 있다.  | 6) 관련성이 명백함(Definite) | percutaneous intervention with stent implantation | 윤리담당자 |\n| [n = sample size (검체 수), p (특이도) = 0.85, | 약물반응 음성 | 민원인을 구속하는 내용이 있습니까?  | 표준오차 | 3.0 | 1.0 | VerifyNow | Reagent | VerifyNow | c+b |\n| (True Positive) | (False Positive) | 기준 가이드라인 |\n| 인구학적 정보 | O | · 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 | 모델명 | Collagen/EPI | Collagen/ADP |\n| - 시험장비 | 대한 간섭 평가 시험을 고려한다.  | PT (INR): | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. ",
        "original_sentence": "| ADP test | 으로 표현 | 합계 | a+c | b+d | a+b+c+d | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | 표준편차 | 4.2 | 1.4 | Roche Prostagladin E1 | □ 예 | ■ 아니오 |\n| aPTT (sec): | / | / | 비정상 | 김윤영, 김서윤, 김민정 | Dade PFA | c | Dade PFA | d | 간섭물질 반응에 대한 | a+b |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 확인할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_144",
      "text": "| 6) 관련성이 명백함(Definite) | percutaneous intervention with stent implantation | 윤리담당자 |\n| [n = sample size (검체 수), p (특이도) = 0.85, | 약물반응 음성 | 민원인을 구속하는 내용이 있습니까? ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 143,
        "window_size": 3,
        "char_count": 161,
        "word_count": 32,
        "page_number": 15,
        "window_text": "| / | / |         | clopidogrel-mediated | platelet | inhibition | after | (연락처) |\n| □ NO | 편 | 집 | 위 | 원 | 수입 의료기기에 의존하여 검사를 진행하고 있다.  | 해당 의료기기의 알려진 특징으로 합리적인 설명을 할 수 있는 경우 | a | b |\n| - 시험물질 | 제조자가 설정한 한계 이내로 유지되는지 평가하기 위함 | 선정/제외기준 확인 | O | 검체에 분석대상 물질을 일정량 첨가한 시험물질 사용한다.  | ADP test | 으로 표현 | 합계 | a+c | b+d | a+b+c+d | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | 표준편차 | 4.2 | 1.4 | Roche Prostagladin E1 | □ 예 | ■ 아니오 |\n| aPTT (sec): | / | / | 비정상 | 김윤영, 김서윤, 김민정 | Dade PFA | c | Dade PFA | d | 간섭물질 반응에 대한 | a+b |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 확인할 수 있다.  | 6) 관련성이 명백함(Definite) | percutaneous intervention with stent implantation | 윤리담당자 |\n| [n = sample size (검체 수), p (특이도) = 0.85, | 약물반응 음성 | 민원인을 구속하는 내용이 있습니까?  | 표준오차 | 3.0 | 1.0 | VerifyNow | Reagent | VerifyNow | c+b |\n| (True Positive) | (False Positive) | 기준 가이드라인 |\n| 인구학적 정보 | O | · 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 | 모델명 | Collagen/EPI | Collagen/ADP |\n| - 시험장비 | 대한 간섭 평가 시험을 고려한다.  | PT (INR): | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 증명하기 위한 평가방법 및 기준을 제시할 수 있다. ",
        "original_sentence": "| 6) 관련성이 명백함(Definite) | percutaneous intervention with stent implantation | 윤리담당자 |\n| [n = sample size (검체 수), p (특이도) = 0.85, | 약물반응 음성 | 민원인을 구속하는 내용이 있습니까? "
      }
    },
    {
      "chunk_id": "chunk_145",
      "text": "| 표준오차 | 3.0 | 1.0 | VerifyNow | Reagent | VerifyNow | c+b |\n| (True Positive) | (False Positive) | 기준 가이드라인 |\n| 인구학적 정보 | O | · 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 | 모델명 | Collagen/EPI | Collagen/ADP |\n| - 시험장비 | 대한 간섭 평가 시험을 고려한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 144,
        "window_size": 3,
        "char_count": 243,
        "word_count": 57,
        "page_number": 6,
        "window_text": "| 해당 의료기기의 알려진 특징으로 합리적인 설명을 할 수 있는 경우 | a | b |\n| - 시험물질 | 제조자가 설정한 한계 이내로 유지되는지 평가하기 위함 | 선정/제외기준 확인 | O | 검체에 분석대상 물질을 일정량 첨가한 시험물질 사용한다.  | ADP test | 으로 표현 | 합계 | a+c | b+d | a+b+c+d | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | 표준편차 | 4.2 | 1.4 | Roche Prostagladin E1 | □ 예 | ■ 아니오 |\n| aPTT (sec): | / | / | 비정상 | 김윤영, 김서윤, 김민정 | Dade PFA | c | Dade PFA | d | 간섭물질 반응에 대한 | a+b |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 확인할 수 있다.  | 6) 관련성이 명백함(Definite) | percutaneous intervention with stent implantation | 윤리담당자 |\n| [n = sample size (검체 수), p (특이도) = 0.85, | 약물반응 음성 | 민원인을 구속하는 내용이 있습니까?  | 표준오차 | 3.0 | 1.0 | VerifyNow | Reagent | VerifyNow | c+b |\n| (True Positive) | (False Positive) | 기준 가이드라인 |\n| 인구학적 정보 | O | · 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 | 모델명 | Collagen/EPI | Collagen/ADP |\n| - 시험장비 | 대한 간섭 평가 시험을 고려한다.  | PT (INR): | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 증명하기 위한 평가방법 및 기준을 제시할 수 있다.  | 변동계수값을 구한다. ",
        "original_sentence": "| 표준오차 | 3.0 | 1.0 | VerifyNow | Reagent | VerifyNow | c+b |\n| (True Positive) | (False Positive) | 기준 가이드라인 |\n| 인구학적 정보 | O | · 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 | 모델명 | Collagen/EPI | Collagen/ADP |\n| - 시험장비 | 대한 간섭 평가 시험을 고려한다. "
      }
    },
    {
      "chunk_id": "chunk_146",
      "text": "| PT (INR): | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 145,
        "window_size": 3,
        "char_count": 54,
        "word_count": 12,
        "page_number": 6,
        "window_text": "| ADP test | 으로 표현 | 합계 | a+c | b+d | a+b+c+d | □ 상위 법령을 일탈하여 새로운 규제를 신설ㆍ강화하거나 | 표준편차 | 4.2 | 1.4 | Roche Prostagladin E1 | □ 예 | ■ 아니오 |\n| aPTT (sec): | / | / | 비정상 | 김윤영, 김서윤, 김민정 | Dade PFA | c | Dade PFA | d | 간섭물질 반응에 대한 | a+b |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 확인할 수 있다.  | 6) 관련성이 명백함(Definite) | percutaneous intervention with stent implantation | 윤리담당자 |\n| [n = sample size (검체 수), p (특이도) = 0.85, | 약물반응 음성 | 민원인을 구속하는 내용이 있습니까?  | 표준오차 | 3.0 | 1.0 | VerifyNow | Reagent | VerifyNow | c+b |\n| (True Positive) | (False Positive) | 기준 가이드라인 |\n| 인구학적 정보 | O | · 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 | 모델명 | Collagen/EPI | Collagen/ADP |\n| - 시험장비 | 대한 간섭 평가 시험을 고려한다.  | PT (INR): | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 증명하기 위한 평가방법 및 기준을 제시할 수 있다.  | 변동계수값을 구한다.  | 사항이 적용된다. ",
        "original_sentence": "| PT (INR): | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_147",
      "text": "| 증명하기 위한 평가방법 및 기준을 제시할 수 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 146,
        "window_size": 3,
        "char_count": 31,
        "word_count": 9,
        "page_number": 21,
        "window_text": "| 6) 관련성이 명백함(Definite) | percutaneous intervention with stent implantation | 윤리담당자 |\n| [n = sample size (검체 수), p (특이도) = 0.85, | 약물반응 음성 | 민원인을 구속하는 내용이 있습니까?  | 표준오차 | 3.0 | 1.0 | VerifyNow | Reagent | VerifyNow | c+b |\n| (True Positive) | (False Positive) | 기준 가이드라인 |\n| 인구학적 정보 | O | · 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 | 모델명 | Collagen/EPI | Collagen/ADP |\n| - 시험장비 | 대한 간섭 평가 시험을 고려한다.  | PT (INR): | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 증명하기 위한 평가방법 및 기준을 제시할 수 있다.  | 변동계수값을 구한다.  | 사항이 적용된다.  | 28159 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187 | (False Negative) | (Thromb Haemost. ",
        "original_sentence": "| 증명하기 위한 평가방법 및 기준을 제시할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_148",
      "text": "| 변동계수값을 구한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 147,
        "window_size": 3,
        "char_count": 14,
        "word_count": 3,
        "page_number": 24,
        "window_text": "| 표준오차 | 3.0 | 1.0 | VerifyNow | Reagent | VerifyNow | c+b |\n| (True Positive) | (False Positive) | 기준 가이드라인 |\n| 인구학적 정보 | O | · 이상사례가 임상시험용 의료기기의 시술 시점으로부터 합리적인 시간적 연관성을 가지고 | 모델명 | Collagen/EPI | Collagen/ADP |\n| - 시험장비 | 대한 간섭 평가 시험을 고려한다.  | PT (INR): | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 증명하기 위한 평가방법 및 기준을 제시할 수 있다.  | 변동계수값을 구한다.  | 사항이 적용된다.  | 28159 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187 | (False Negative) | (Thromb Haemost.  2009 Feb;101(2):333-9.) ",
        "original_sentence": "| 변동계수값을 구한다. "
      }
    },
    {
      "chunk_id": "chunk_149",
      "text": "| 사항이 적용된다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 148,
        "window_size": 3,
        "char_count": 12,
        "word_count": 3,
        "page_number": 3,
        "window_text": "| PT (INR): | 검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 증명하기 위한 평가방법 및 기준을 제시할 수 있다.  | 변동계수값을 구한다.  | 사항이 적용된다.  | 28159 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187 | (False Negative) | (Thromb Haemost.  2009 Feb;101(2):333-9.)  | (True Negative) | 검출한계 평가방법에 | 대한 기준 가이드라인 |\n| n = 99.96 | [n = sample size (검체 수), p (특이도) = 0.95, | 으로 간주하여 시험기기의 검사 결과에 대해 민감도와 특이도를 확인한다. ",
        "original_sentence": "| 사항이 적용된다. "
      }
    },
    {
      "chunk_id": "chunk_150",
      "text": "| 28159 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187 | (False Negative) | (Thromb Haemost. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 149,
        "window_size": 3,
        "char_count": 75,
        "word_count": 15,
        "page_number": 6,
        "window_text": "| 증명하기 위한 평가방법 및 기준을 제시할 수 있다.  | 변동계수값을 구한다.  | 사항이 적용된다.  | 28159 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187 | (False Negative) | (Thromb Haemost.  2009 Feb;101(2):333-9.)  | (True Negative) | 검출한계 평가방법에 | 대한 기준 가이드라인 |\n| n = 99.96 | [n = sample size (검체 수), p (특이도) = 0.95, | 으로 간주하여 시험기기의 검사 결과에 대해 민감도와 특이도를 확인한다.  | 있으며, 해당 의료기기의 알려진 이상사례와 직접적인 연관성을 배제할 수 없으며, 피험자의 | P2Y12 Test | Aspirin Test |\n| 사항 | ◈ 기타 출혈성 질환, 응고장애 유무 | 혈액 폐색을 유발한다. ",
        "original_sentence": "| 28159 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187 | (False Negative) | (Thromb Haemost. "
      }
    },
    {
      "chunk_id": "chunk_151",
      "text": "2009 Feb;101(2):333-9.) ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 150,
        "window_size": 3,
        "char_count": 24,
        "word_count": 2,
        "page_number": 6,
        "window_text": "| 변동계수값을 구한다.  | 사항이 적용된다.  | 28159 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187 | (False Negative) | (Thromb Haemost.  2009 Feb;101(2):333-9.)  | (True Negative) | 검출한계 평가방법에 | 대한 기준 가이드라인 |\n| n = 99.96 | [n = sample size (검체 수), p (특이도) = 0.95, | 으로 간주하여 시험기기의 검사 결과에 대해 민감도와 특이도를 확인한다.  | 있으며, 해당 의료기기의 알려진 이상사례와 직접적인 연관성을 배제할 수 없으며, 피험자의 | P2Y12 Test | Aspirin Test |\n| 사항 | ◈ 기타 출혈성 질환, 응고장애 유무 | 혈액 폐색을 유발한다.  | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | / | / |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | Laboratory Measurement Procedures | 오송보건의료행정타운 | c | d |\n| 혈소판 기능 검사 | 보호시험에 관한 요구사항이 적용된다. ",
        "original_sentence": "2009 Feb;101(2):333-9.) "
      }
    },
    {
      "chunk_id": "chunk_152",
      "text": "| (True Negative) | 검출한계 평가방법에 | 대한 기준 가이드라인 |\n| n = 99.96 | [n = sample size (검체 수), p (특이도) = 0.95, | 으로 간주하여 시험기기의 검사 결과에 대해 민감도와 특이도를 확인한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 151,
        "window_size": 3,
        "char_count": 144,
        "word_count": 36,
        "page_number": 2,
        "window_text": "| 사항이 적용된다.  | 28159 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187 | (False Negative) | (Thromb Haemost.  2009 Feb;101(2):333-9.)  | (True Negative) | 검출한계 평가방법에 | 대한 기준 가이드라인 |\n| n = 99.96 | [n = sample size (검체 수), p (특이도) = 0.95, | 으로 간주하여 시험기기의 검사 결과에 대해 민감도와 특이도를 확인한다.  | 있으며, 해당 의료기기의 알려진 이상사례와 직접적인 연관성을 배제할 수 없으며, 피험자의 | P2Y12 Test | Aspirin Test |\n| 사항 | ◈ 기타 출혈성 질환, 응고장애 유무 | 혈액 폐색을 유발한다.  | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | / | / |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | Laboratory Measurement Procedures | 오송보건의료행정타운 | c | d |\n| 혈소판 기능 검사 | 보호시험에 관한 요구사항이 적용된다.  | 임상적 상태에 대하여 알려진 특징으로는 합리적인 설명을 할 수 없는 경우. ",
        "original_sentence": "| (True Negative) | 검출한계 평가방법에 | 대한 기준 가이드라인 |\n| n = 99.96 | [n = sample size (검체 수), p (특이도) = 0.95, | 으로 간주하여 시험기기의 검사 결과에 대해 민감도와 특이도를 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_153",
      "text": "| 있으며, 해당 의료기기의 알려진 이상사례와 직접적인 연관성을 배제할 수 없으며, 피험자의 | P2Y12 Test | Aspirin Test |\n| 사항 | ◈ 기타 출혈성 질환, 응고장애 유무 | 혈액 폐색을 유발한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 152,
        "window_size": 3,
        "char_count": 125,
        "word_count": 32,
        "page_number": 103,
        "window_text": "| 28159 충청북도 청주시 흥덕구 오송읍 오송생명 2로 187 | (False Negative) | (Thromb Haemost.  2009 Feb;101(2):333-9.)  | (True Negative) | 검출한계 평가방법에 | 대한 기준 가이드라인 |\n| n = 99.96 | [n = sample size (검체 수), p (특이도) = 0.95, | 으로 간주하여 시험기기의 검사 결과에 대해 민감도와 특이도를 확인한다.  | 있으며, 해당 의료기기의 알려진 이상사례와 직접적인 연관성을 배제할 수 없으며, 피험자의 | P2Y12 Test | Aspirin Test |\n| 사항 | ◈ 기타 출혈성 질환, 응고장애 유무 | 혈액 폐색을 유발한다.  | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | / | / |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | Laboratory Measurement Procedures | 오송보건의료행정타운 | c | d |\n| 혈소판 기능 검사 | 보호시험에 관한 요구사항이 적용된다.  | 임상적 상태에 대하여 알려진 특징으로는 합리적인 설명을 할 수 없는 경우.  | Test Cartridge | Test Cartridge |\n| 휴식을 취하면 대부분 회복된다. ",
        "original_sentence": "| 있으며, 해당 의료기기의 알려진 이상사례와 직접적인 연관성을 배제할 수 없으며, 피험자의 | P2Y12 Test | Aspirin Test |\n| 사항 | ◈ 기타 출혈성 질환, 응고장애 유무 | 혈액 폐색을 유발한다. "
      }
    },
    {
      "chunk_id": "chunk_154",
      "text": "| ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | / | / |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | Laboratory Measurement Procedures | 오송보건의료행정타운 | c | d |\n| 혈소판 기능 검사 | 보호시험에 관한 요구사항이 적용된다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 153,
        "window_size": 3,
        "char_count": 202,
        "word_count": 49,
        "page_number": 3,
        "window_text": "2009 Feb;101(2):333-9.)  | (True Negative) | 검출한계 평가방법에 | 대한 기준 가이드라인 |\n| n = 99.96 | [n = sample size (검체 수), p (특이도) = 0.95, | 으로 간주하여 시험기기의 검사 결과에 대해 민감도와 특이도를 확인한다.  | 있으며, 해당 의료기기의 알려진 이상사례와 직접적인 연관성을 배제할 수 없으며, 피험자의 | P2Y12 Test | Aspirin Test |\n| 사항 | ◈ 기타 출혈성 질환, 응고장애 유무 | 혈액 폐색을 유발한다.  | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | / | / |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | Laboratory Measurement Procedures | 오송보건의료행정타운 | c | d |\n| 혈소판 기능 검사 | 보호시험에 관한 요구사항이 적용된다.  | 임상적 상태에 대하여 알려진 특징으로는 합리적인 설명을 할 수 없는 경우.  | Test Cartridge | Test Cartridge |\n| 휴식을 취하면 대부분 회복된다.  | 합계 | a+c | b+d | a+b+c+d | / | / | 정상 | 판정기준치 평가방법에 | c+b |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | Laboratory | Practice)에 | 따라 취급해야 한다. ",
        "original_sentence": "| ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | / | / |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | Laboratory Measurement Procedures | 오송보건의료행정타운 | c | d |\n| 혈소판 기능 검사 | 보호시험에 관한 요구사항이 적용된다. "
      }
    },
    {
      "chunk_id": "chunk_155",
      "text": "| 임상적 상태에 대하여 알려진 특징으로는 합리적인 설명을 할 수 없는 경우. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 154,
        "window_size": 3,
        "char_count": 44,
        "word_count": 12,
        "page_number": 35,
        "window_text": "| (True Negative) | 검출한계 평가방법에 | 대한 기준 가이드라인 |\n| n = 99.96 | [n = sample size (검체 수), p (특이도) = 0.95, | 으로 간주하여 시험기기의 검사 결과에 대해 민감도와 특이도를 확인한다.  | 있으며, 해당 의료기기의 알려진 이상사례와 직접적인 연관성을 배제할 수 없으며, 피험자의 | P2Y12 Test | Aspirin Test |\n| 사항 | ◈ 기타 출혈성 질환, 응고장애 유무 | 혈액 폐색을 유발한다.  | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | / | / |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | Laboratory Measurement Procedures | 오송보건의료행정타운 | c | d |\n| 혈소판 기능 검사 | 보호시험에 관한 요구사항이 적용된다.  | 임상적 상태에 대하여 알려진 특징으로는 합리적인 설명을 할 수 없는 경우.  | Test Cartridge | Test Cartridge |\n| 휴식을 취하면 대부분 회복된다.  | 합계 | a+c | b+d | a+b+c+d | / | / | 정상 | 판정기준치 평가방법에 | c+b |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | Laboratory | Practice)에 | 따라 취급해야 한다.  | 30분, 최대 4시간 이내 검사를 시행한다. ",
        "original_sentence": "| 임상적 상태에 대하여 알려진 특징으로는 합리적인 설명을 할 수 없는 경우. "
      }
    },
    {
      "chunk_id": "chunk_156",
      "text": "| Test Cartridge | Test Cartridge |\n| 휴식을 취하면 대부분 회복된다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 155,
        "window_size": 3,
        "char_count": 56,
        "word_count": 12,
        "page_number": 15,
        "window_text": "| 있으며, 해당 의료기기의 알려진 이상사례와 직접적인 연관성을 배제할 수 없으며, 피험자의 | P2Y12 Test | Aspirin Test |\n| 사항 | ◈ 기타 출혈성 질환, 응고장애 유무 | 혈액 폐색을 유발한다.  | ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | / | / |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | Laboratory Measurement Procedures | 오송보건의료행정타운 | c | d |\n| 혈소판 기능 검사 | 보호시험에 관한 요구사항이 적용된다.  | 임상적 상태에 대하여 알려진 특징으로는 합리적인 설명을 할 수 없는 경우.  | Test Cartridge | Test Cartridge |\n| 휴식을 취하면 대부분 회복된다.  | 합계 | a+c | b+d | a+b+c+d | / | / | 정상 | 판정기준치 평가방법에 | c+b |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | Laboratory | Practice)에 | 따라 취급해야 한다.  | 30분, 최대 4시간 이내 검사를 시행한다.  | 및 혈소판 기능 이상 검체를 각각 최소 50개 이상 사용한다. ",
        "original_sentence": "| Test Cartridge | Test Cartridge |\n| 휴식을 취하면 대부분 회복된다. "
      }
    },
    {
      "chunk_id": "chunk_157",
      "text": "| 합계 | a+c | b+d | a+b+c+d | / | / | 정상 | 판정기준치 평가방법에 | c+b |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | Laboratory | Practice)에 | 따라 취급해야 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 156,
        "window_size": 3,
        "char_count": 153,
        "word_count": 40,
        "page_number": 78,
        "window_text": "| ☞ 상기 질문에 ‘예’라고 답하신 경우 상위법령 일탈 내용을 삭제하시고 지침서ㆍ | / | / |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | Laboratory Measurement Procedures | 오송보건의료행정타운 | c | d |\n| 혈소판 기능 검사 | 보호시험에 관한 요구사항이 적용된다.  | 임상적 상태에 대하여 알려진 특징으로는 합리적인 설명을 할 수 없는 경우.  | Test Cartridge | Test Cartridge |\n| 휴식을 취하면 대부분 회복된다.  | 합계 | a+c | b+d | a+b+c+d | / | / | 정상 | 판정기준치 평가방법에 | c+b |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | Laboratory | Practice)에 | 따라 취급해야 한다.  | 30분, 최대 4시간 이내 검사를 시행한다.  | 및 혈소판 기능 이상 검체를 각각 최소 50개 이상 사용한다.  | 환자의 aspirin 복용 전 검체 | Measurement Methods; Approved Guideline | Measurement Methods; Approved Guideline | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다. ",
        "original_sentence": "| 합계 | a+c | b+d | a+b+c+d | / | / | 정상 | 판정기준치 평가방법에 | c+b |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | Laboratory | Practice)에 | 따라 취급해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_158",
      "text": "| 30분, 최대 4시간 이내 검사를 시행한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 157,
        "window_size": 3,
        "char_count": 27,
        "word_count": 7,
        "page_number": 15,
        "window_text": "| 임상적 상태에 대하여 알려진 특징으로는 합리적인 설명을 할 수 없는 경우.  | Test Cartridge | Test Cartridge |\n| 휴식을 취하면 대부분 회복된다.  | 합계 | a+c | b+d | a+b+c+d | / | / | 정상 | 판정기준치 평가방법에 | c+b |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | Laboratory | Practice)에 | 따라 취급해야 한다.  | 30분, 최대 4시간 이내 검사를 시행한다.  | 및 혈소판 기능 이상 검체를 각각 최소 50개 이상 사용한다.  | 환자의 aspirin 복용 전 검체 | Measurement Methods; Approved Guideline | Measurement Methods; Approved Guideline | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다.  | [표 6] 간섭물질 예 | 민감도 | 특이도 |\n| 받은 제품은 아래와 같다. ",
        "original_sentence": "| 30분, 최대 4시간 이내 검사를 시행한다. "
      }
    },
    {
      "chunk_id": "chunk_159",
      "text": "| 및 혈소판 기능 이상 검체를 각각 최소 50개 이상 사용한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 158,
        "window_size": 3,
        "char_count": 37,
        "word_count": 11,
        "page_number": 6,
        "window_text": "| Test Cartridge | Test Cartridge |\n| 휴식을 취하면 대부분 회복된다.  | 합계 | a+c | b+d | a+b+c+d | / | / | 정상 | 판정기준치 평가방법에 | c+b |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | Laboratory | Practice)에 | 따라 취급해야 한다.  | 30분, 최대 4시간 이내 검사를 시행한다.  | 및 혈소판 기능 이상 검체를 각각 최소 50개 이상 사용한다.  | 환자의 aspirin 복용 전 검체 | Measurement Methods; Approved Guideline | Measurement Methods; Approved Guideline | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다.  | [표 6] 간섭물질 예 | 민감도 | 특이도 |\n| 받은 제품은 아래와 같다.  | □ YES | □ 기타: | 검체 채취 | O | O |\n| n = 99.96 | 혈소판 약물반응검사 | 품목허가번호 | 수허 12-1710 | 수허 12-1743 | 수허 12-1648 | 수허 12-1652 | Performance; Approved Guideline | (False Negative) | (True Negative) | 대한 가이드라인 |\n| 식품의약품안전평가원 | 중위값 | 89.3 | 96.4 |\n| 문 | 의 | 처 | □ 중대한 이상사례/ 이상 의료기기의 반응 | 상기 사항에 대하여 확인하였음. ",
        "original_sentence": "| 및 혈소판 기능 이상 검체를 각각 최소 50개 이상 사용한다. "
      }
    },
    {
      "chunk_id": "chunk_160",
      "text": "| 환자의 aspirin 복용 전 검체 | Measurement Methods; Approved Guideline | Measurement Methods; Approved Guideline | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 159,
        "window_size": 3,
        "char_count": 133,
        "word_count": 22,
        "page_number": 18,
        "window_text": "| 합계 | a+c | b+d | a+b+c+d | / | / | 정상 | 판정기준치 평가방법에 | c+b |\n| Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | Laboratory | Practice)에 | 따라 취급해야 한다.  | 30분, 최대 4시간 이내 검사를 시행한다.  | 및 혈소판 기능 이상 검체를 각각 최소 50개 이상 사용한다.  | 환자의 aspirin 복용 전 검체 | Measurement Methods; Approved Guideline | Measurement Methods; Approved Guideline | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다.  | [표 6] 간섭물질 예 | 민감도 | 특이도 |\n| 받은 제품은 아래와 같다.  | □ YES | □ 기타: | 검체 채취 | O | O |\n| n = 99.96 | 혈소판 약물반응검사 | 품목허가번호 | 수허 12-1710 | 수허 12-1743 | 수허 12-1648 | 수허 12-1652 | Performance; Approved Guideline | (False Negative) | (True Negative) | 대한 가이드라인 |\n| 식품의약품안전평가원 | 중위값 | 89.3 | 96.4 |\n| 문 | 의 | 처 | □ 중대한 이상사례/ 이상 의료기기의 반응 | 상기 사항에 대하여 확인하였음.  |\n| n = 37.24 | 약물유발 혈소판기능부전(drug-induced platelet dysfunction) 등 | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. ",
        "original_sentence": "| 환자의 aspirin 복용 전 검체 | Measurement Methods; Approved Guideline | Measurement Methods; Approved Guideline | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다. "
      }
    },
    {
      "chunk_id": "chunk_161",
      "text": "| [표 6] 간섭물질 예 | 민감도 | 특이도 |\n| 받은 제품은 아래와 같다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 160,
        "window_size": 3,
        "char_count": 46,
        "word_count": 15,
        "page_number": 14,
        "window_text": "| 30분, 최대 4시간 이내 검사를 시행한다.  | 및 혈소판 기능 이상 검체를 각각 최소 50개 이상 사용한다.  | 환자의 aspirin 복용 전 검체 | Measurement Methods; Approved Guideline | Measurement Methods; Approved Guideline | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다.  | [표 6] 간섭물질 예 | 민감도 | 특이도 |\n| 받은 제품은 아래와 같다.  | □ YES | □ 기타: | 검체 채취 | O | O |\n| n = 99.96 | 혈소판 약물반응검사 | 품목허가번호 | 수허 12-1710 | 수허 12-1743 | 수허 12-1648 | 수허 12-1652 | Performance; Approved Guideline | (False Negative) | (True Negative) | 대한 가이드라인 |\n| 식품의약품안전평가원 | 중위값 | 89.3 | 96.4 |\n| 문 | 의 | 처 | □ 중대한 이상사례/ 이상 의료기기의 반응 | 상기 사항에 대하여 확인하였음.  |\n| n = 37.24 | 약물유발 혈소판기능부전(drug-induced platelet dysfunction) 등 | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 하므로, 이를 확인하는 LTA 검사결과를 참고치로 하여 결과를 비교한다. ",
        "original_sentence": "| [표 6] 간섭물질 예 | 민감도 | 특이도 |\n| 받은 제품은 아래와 같다. "
      }
    },
    {
      "chunk_id": "chunk_162",
      "text": "| □ YES | □ 기타: | 검체 채취 | O | O |\n| n = 99.96 | 혈소판 약물반응검사 | 품목허가번호 | 수허 12-1710 | 수허 12-1743 | 수허 12-1648 | 수허 12-1652 | Performance; Approved Guideline | (False Negative) | (True Negative) | 대한 가이드라인 |\n| 식품의약품안전평가원 | 중위값 | 89.3 | 96.4 |\n| 문 | 의 | 처 | □ 중대한 이상사례/ 이상 의료기기의 반응 | 상기 사항에 대하여 확인하였음. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 161,
        "window_size": 3,
        "char_count": 297,
        "word_count": 76,
        "page_number": 15,
        "window_text": "| 및 혈소판 기능 이상 검체를 각각 최소 50개 이상 사용한다.  | 환자의 aspirin 복용 전 검체 | Measurement Methods; Approved Guideline | Measurement Methods; Approved Guideline | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다.  | [표 6] 간섭물질 예 | 민감도 | 특이도 |\n| 받은 제품은 아래와 같다.  | □ YES | □ 기타: | 검체 채취 | O | O |\n| n = 99.96 | 혈소판 약물반응검사 | 품목허가번호 | 수허 12-1710 | 수허 12-1743 | 수허 12-1648 | 수허 12-1652 | Performance; Approved Guideline | (False Negative) | (True Negative) | 대한 가이드라인 |\n| 식품의약품안전평가원 | 중위값 | 89.3 | 96.4 |\n| 문 | 의 | 처 | □ 중대한 이상사례/ 이상 의료기기의 반응 | 상기 사항에 대하여 확인하였음.  |\n| n = 37.24 | 약물유발 혈소판기능부전(drug-induced platelet dysfunction) 등 | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 하므로, 이를 확인하는 LTA 검사결과를 참고치로 하여 결과를 비교한다.  | 이용한 혈소판 기능검사가 요구되고 있다. ",
        "original_sentence": "| □ YES | □ 기타: | 검체 채취 | O | O |\n| n = 99.96 | 혈소판 약물반응검사 | 품목허가번호 | 수허 12-1710 | 수허 12-1743 | 수허 12-1648 | 수허 12-1652 | Performance; Approved Guideline | (False Negative) | (True Negative) | 대한 가이드라인 |\n| 식품의약품안전평가원 | 중위값 | 89.3 | 96.4 |\n| 문 | 의 | 처 | □ 중대한 이상사례/ 이상 의료기기의 반응 | 상기 사항에 대하여 확인하였음. "
      }
    },
    {
      "chunk_id": "chunk_163",
      "text": "|\n| n = 37.24 | 약물유발 혈소판기능부전(drug-induced platelet dysfunction) 등 | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 162,
        "window_size": 3,
        "char_count": 104,
        "word_count": 19,
        "page_number": 6,
        "window_text": "| 환자의 aspirin 복용 전 검체 | Measurement Methods; Approved Guideline | Measurement Methods; Approved Guideline | 안내서 제ㆍ개정 절차를 진행하시기 바랍니다.  | [표 6] 간섭물질 예 | 민감도 | 특이도 |\n| 받은 제품은 아래와 같다.  | □ YES | □ 기타: | 검체 채취 | O | O |\n| n = 99.96 | 혈소판 약물반응검사 | 품목허가번호 | 수허 12-1710 | 수허 12-1743 | 수허 12-1648 | 수허 12-1652 | Performance; Approved Guideline | (False Negative) | (True Negative) | 대한 가이드라인 |\n| 식품의약품안전평가원 | 중위값 | 89.3 | 96.4 |\n| 문 | 의 | 처 | □ 중대한 이상사례/ 이상 의료기기의 반응 | 상기 사항에 대하여 확인하였음.  |\n| n = 37.24 | 약물유발 혈소판기능부전(drug-induced platelet dysfunction) 등 | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 하므로, 이를 확인하는 LTA 검사결과를 참고치로 하여 결과를 비교한다.  | 이용한 혈소판 기능검사가 요구되고 있다.  | 간섭물질 | 예시 |\n| - 시험장비 | 2개 로트로 대체 가능) | 검체 검사 및 분석 | O | O | 저항성 복합검사기기에 적용한다. ",
        "original_sentence": "|\n| n = 37.24 | 약물유발 혈소판기능부전(drug-induced platelet dysfunction) 등 | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_164",
      "text": "| 하므로, 이를 확인하는 LTA 검사결과를 참고치로 하여 결과를 비교한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 163,
        "window_size": 3,
        "char_count": 43,
        "word_count": 10,
        "page_number": 24,
        "window_text": "| [표 6] 간섭물질 예 | 민감도 | 특이도 |\n| 받은 제품은 아래와 같다.  | □ YES | □ 기타: | 검체 채취 | O | O |\n| n = 99.96 | 혈소판 약물반응검사 | 품목허가번호 | 수허 12-1710 | 수허 12-1743 | 수허 12-1648 | 수허 12-1652 | Performance; Approved Guideline | (False Negative) | (True Negative) | 대한 가이드라인 |\n| 식품의약품안전평가원 | 중위값 | 89.3 | 96.4 |\n| 문 | 의 | 처 | □ 중대한 이상사례/ 이상 의료기기의 반응 | 상기 사항에 대하여 확인하였음.  |\n| n = 37.24 | 약물유발 혈소판기능부전(drug-induced platelet dysfunction) 등 | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 하므로, 이를 확인하는 LTA 검사결과를 참고치로 하여 결과를 비교한다.  | 이용한 혈소판 기능검사가 요구되고 있다.  | 간섭물질 | 예시 |\n| - 시험장비 | 2개 로트로 대체 가능) | 검체 검사 및 분석 | O | O | 저항성 복합검사기기에 적용한다.  |\n| [표 5] 출혈시간 및 항혈소판제제 저항성 복합검사기기 안정성 관련 시험 규격 | □ NO | Aspirin test | 하게 되며, 이동거리를 측정하여 결과를 얻을 수 있다. ",
        "original_sentence": "| 하므로, 이를 확인하는 LTA 검사결과를 참고치로 하여 결과를 비교한다. "
      }
    },
    {
      "chunk_id": "chunk_165",
      "text": "| 이용한 혈소판 기능검사가 요구되고 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 164,
        "window_size": 3,
        "char_count": 25,
        "word_count": 6,
        "page_number": 7,
        "window_text": "| □ YES | □ 기타: | 검체 채취 | O | O |\n| n = 99.96 | 혈소판 약물반응검사 | 품목허가번호 | 수허 12-1710 | 수허 12-1743 | 수허 12-1648 | 수허 12-1652 | Performance; Approved Guideline | (False Negative) | (True Negative) | 대한 가이드라인 |\n| 식품의약품안전평가원 | 중위값 | 89.3 | 96.4 |\n| 문 | 의 | 처 | □ 중대한 이상사례/ 이상 의료기기의 반응 | 상기 사항에 대하여 확인하였음.  |\n| n = 37.24 | 약물유발 혈소판기능부전(drug-induced platelet dysfunction) 등 | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 하므로, 이를 확인하는 LTA 검사결과를 참고치로 하여 결과를 비교한다.  | 이용한 혈소판 기능검사가 요구되고 있다.  | 간섭물질 | 예시 |\n| - 시험장비 | 2개 로트로 대체 가능) | 검체 검사 및 분석 | O | O | 저항성 복합검사기기에 적용한다.  |\n| [표 5] 출혈시간 및 항혈소판제제 저항성 복합검사기기 안정성 관련 시험 규격 | □ NO | Aspirin test | 하게 되며, 이동거리를 측정하여 결과를 얻을 수 있다.  | · 사망을 초래하거나 생명을 위협하는 경우 | 합계 | a+c | b+d | a+b+c+d | 의료기기심사부 체외진단기기과 | 표준편차 | 29.6 | 8.9 |\n| 외인성 물질 | 일반의약품, 고혈압, 협심증, 심부전 등 심장질환 치료제 등 |\n| 것이 중요하다. ",
        "original_sentence": "| 이용한 혈소판 기능검사가 요구되고 있다. "
      }
    },
    {
      "chunk_id": "chunk_166",
      "text": "| 간섭물질 | 예시 |\n| - 시험장비 | 2개 로트로 대체 가능) | 검체 검사 및 분석 | O | O | 저항성 복합검사기기에 적용한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 165,
        "window_size": 3,
        "char_count": 80,
        "word_count": 26,
        "page_number": 6,
        "window_text": "|\n| n = 37.24 | 약물유발 혈소판기능부전(drug-induced platelet dysfunction) 등 | 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.  | 하므로, 이를 확인하는 LTA 검사결과를 참고치로 하여 결과를 비교한다.  | 이용한 혈소판 기능검사가 요구되고 있다.  | 간섭물질 | 예시 |\n| - 시험장비 | 2개 로트로 대체 가능) | 검체 검사 및 분석 | O | O | 저항성 복합검사기기에 적용한다.  |\n| [표 5] 출혈시간 및 항혈소판제제 저항성 복합검사기기 안정성 관련 시험 규격 | □ NO | Aspirin test | 하게 되며, 이동거리를 측정하여 결과를 얻을 수 있다.  | · 사망을 초래하거나 생명을 위협하는 경우 | 합계 | a+c | b+d | a+b+c+d | 의료기기심사부 체외진단기기과 | 표준편차 | 29.6 | 8.9 |\n| 외인성 물질 | 일반의약품, 고혈압, 협심증, 심부전 등 심장질환 치료제 등 |\n| 것이 중요하다.  | 검사항목 | 양성(약물반응) 환자군 수 | 음성(약물비반응) 환자군 수 |\n| 분리하여 혈소판풍부혈장을 취하여 3시간 이내에 검사를 시행한다. ",
        "original_sentence": "| 간섭물질 | 예시 |\n| - 시험장비 | 2개 로트로 대체 가능) | 검체 검사 및 분석 | O | O | 저항성 복합검사기기에 적용한다. "
      }
    },
    {
      "chunk_id": "chunk_167",
      "text": "|\n| [표 5] 출혈시간 및 항혈소판제제 저항성 복합검사기기 안정성 관련 시험 규격 | □ NO | Aspirin test | 하게 되며, 이동거리를 측정하여 결과를 얻을 수 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 166,
        "window_size": 3,
        "char_count": 103,
        "word_count": 28,
        "page_number": 1,
        "window_text": "| 하므로, 이를 확인하는 LTA 검사결과를 참고치로 하여 결과를 비교한다.  | 이용한 혈소판 기능검사가 요구되고 있다.  | 간섭물질 | 예시 |\n| - 시험장비 | 2개 로트로 대체 가능) | 검체 검사 및 분석 | O | O | 저항성 복합검사기기에 적용한다.  |\n| [표 5] 출혈시간 및 항혈소판제제 저항성 복합검사기기 안정성 관련 시험 규격 | □ NO | Aspirin test | 하게 되며, 이동거리를 측정하여 결과를 얻을 수 있다.  | · 사망을 초래하거나 생명을 위협하는 경우 | 합계 | a+c | b+d | a+b+c+d | 의료기기심사부 체외진단기기과 | 표준편차 | 29.6 | 8.9 |\n| 외인성 물질 | 일반의약품, 고혈압, 협심증, 심부전 등 심장질환 치료제 등 |\n| 것이 중요하다.  | 검사항목 | 양성(약물반응) 환자군 수 | 음성(약물비반응) 환자군 수 |\n| 분리하여 혈소판풍부혈장을 취하여 3시간 이내에 검사를 시행한다.  | 끝날때까지 기다리도록 한다. ",
        "original_sentence": "|\n| [표 5] 출혈시간 및 항혈소판제제 저항성 복합검사기기 안정성 관련 시험 규격 | □ NO | Aspirin test | 하게 되며, 이동거리를 측정하여 결과를 얻을 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_168",
      "text": "| · 사망을 초래하거나 생명을 위협하는 경우 | 합계 | a+c | b+d | a+b+c+d | 의료기기심사부 체외진단기기과 | 표준편차 | 29.6 | 8.9 |\n| 외인성 물질 | 일반의약품, 고혈압, 협심증, 심부전 등 심장질환 치료제 등 |\n| 것이 중요하다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 167,
        "window_size": 3,
        "char_count": 151,
        "word_count": 41,
        "page_number": 78,
        "window_text": "| 이용한 혈소판 기능검사가 요구되고 있다.  | 간섭물질 | 예시 |\n| - 시험장비 | 2개 로트로 대체 가능) | 검체 검사 및 분석 | O | O | 저항성 복합검사기기에 적용한다.  |\n| [표 5] 출혈시간 및 항혈소판제제 저항성 복합검사기기 안정성 관련 시험 규격 | □ NO | Aspirin test | 하게 되며, 이동거리를 측정하여 결과를 얻을 수 있다.  | · 사망을 초래하거나 생명을 위협하는 경우 | 합계 | a+c | b+d | a+b+c+d | 의료기기심사부 체외진단기기과 | 표준편차 | 29.6 | 8.9 |\n| 외인성 물질 | 일반의약품, 고혈압, 협심증, 심부전 등 심장질환 치료제 등 |\n| 것이 중요하다.  | 검사항목 | 양성(약물반응) 환자군 수 | 음성(약물비반응) 환자군 수 |\n| 분리하여 혈소판풍부혈장을 취하여 3시간 이내에 검사를 시행한다.  | 끝날때까지 기다리도록 한다.  | 있는 검체는 사용하지 않는다. ",
        "original_sentence": "| · 사망을 초래하거나 생명을 위협하는 경우 | 합계 | a+c | b+d | a+b+c+d | 의료기기심사부 체외진단기기과 | 표준편차 | 29.6 | 8.9 |\n| 외인성 물질 | 일반의약품, 고혈압, 협심증, 심부전 등 심장질환 치료제 등 |\n| 것이 중요하다. "
      }
    },
    {
      "chunk_id": "chunk_169",
      "text": "| 검사항목 | 양성(약물반응) 환자군 수 | 음성(약물비반응) 환자군 수 |\n| 분리하여 혈소판풍부혈장을 취하여 3시간 이내에 검사를 시행한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 168,
        "window_size": 3,
        "char_count": 82,
        "word_count": 19,
        "page_number": 3,
        "window_text": "| 간섭물질 | 예시 |\n| - 시험장비 | 2개 로트로 대체 가능) | 검체 검사 및 분석 | O | O | 저항성 복합검사기기에 적용한다.  |\n| [표 5] 출혈시간 및 항혈소판제제 저항성 복합검사기기 안정성 관련 시험 규격 | □ NO | Aspirin test | 하게 되며, 이동거리를 측정하여 결과를 얻을 수 있다.  | · 사망을 초래하거나 생명을 위협하는 경우 | 합계 | a+c | b+d | a+b+c+d | 의료기기심사부 체외진단기기과 | 표준편차 | 29.6 | 8.9 |\n| 외인성 물질 | 일반의약품, 고혈압, 협심증, 심부전 등 심장질환 치료제 등 |\n| 것이 중요하다.  | 검사항목 | 양성(약물반응) 환자군 수 | 음성(약물비반응) 환자군 수 |\n| 분리하여 혈소판풍부혈장을 취하여 3시간 이내에 검사를 시행한다.  | 끝날때까지 기다리도록 한다.  | 있는 검체는 사용하지 않는다.  | 감염 방지 정책 및 병원의 규정에 의거하여 폐기한다. ",
        "original_sentence": "| 검사항목 | 양성(약물반응) 환자군 수 | 음성(약물비반응) 환자군 수 |\n| 분리하여 혈소판풍부혈장을 취하여 3시간 이내에 검사를 시행한다. "
      }
    },
    {
      "chunk_id": "chunk_170",
      "text": "| 끝날때까지 기다리도록 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 169,
        "window_size": 3,
        "char_count": 18,
        "word_count": 4,
        "page_number": 24,
        "window_text": "|\n| [표 5] 출혈시간 및 항혈소판제제 저항성 복합검사기기 안정성 관련 시험 규격 | □ NO | Aspirin test | 하게 되며, 이동거리를 측정하여 결과를 얻을 수 있다.  | · 사망을 초래하거나 생명을 위협하는 경우 | 합계 | a+c | b+d | a+b+c+d | 의료기기심사부 체외진단기기과 | 표준편차 | 29.6 | 8.9 |\n| 외인성 물질 | 일반의약품, 고혈압, 협심증, 심부전 등 심장질환 치료제 등 |\n| 것이 중요하다.  | 검사항목 | 양성(약물반응) 환자군 수 | 음성(약물비반응) 환자군 수 |\n| 분리하여 혈소판풍부혈장을 취하여 3시간 이내에 검사를 시행한다.  | 끝날때까지 기다리도록 한다.  | 있는 검체는 사용하지 않는다.  | 감염 방지 정책 및 병원의 규정에 의거하여 폐기한다.  | 환자의 3일 이상 aspirin 복용 후의 검체 | 위해요인 보호시험에 관한 요구사항이 적용된다. ",
        "original_sentence": "| 끝날때까지 기다리도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_171",
      "text": "| 있는 검체는 사용하지 않는다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 170,
        "window_size": 3,
        "char_count": 19,
        "word_count": 5,
        "page_number": 72,
        "window_text": "| · 사망을 초래하거나 생명을 위협하는 경우 | 합계 | a+c | b+d | a+b+c+d | 의료기기심사부 체외진단기기과 | 표준편차 | 29.6 | 8.9 |\n| 외인성 물질 | 일반의약품, 고혈압, 협심증, 심부전 등 심장질환 치료제 등 |\n| 것이 중요하다.  | 검사항목 | 양성(약물반응) 환자군 수 | 음성(약물비반응) 환자군 수 |\n| 분리하여 혈소판풍부혈장을 취하여 3시간 이내에 검사를 시행한다.  | 끝날때까지 기다리도록 한다.  | 있는 검체는 사용하지 않는다.  | 감염 방지 정책 및 병원의 규정에 의거하여 폐기한다.  | 환자의 3일 이상 aspirin 복용 후의 검체 | 위해요인 보호시험에 관한 요구사항이 적용된다.  | · 입원 또는 입원 기간의 연장이 필요한 경우 | 기타 | 전화: 043-719-4652~63 | 표준오차 | 17.1 | 5.1 |\n| 2017 년    5 월   31  일 | 용혈, 혈색소, 지방산과 지질(콜레스테롤, 트리글리세리드), 빌리루빈, |\n| - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | 하여 R2값을 제시한다. ",
        "original_sentence": "| 있는 검체는 사용하지 않는다. "
      }
    },
    {
      "chunk_id": "chunk_172",
      "text": "| 감염 방지 정책 및 병원의 규정에 의거하여 폐기한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 171,
        "window_size": 3,
        "char_count": 32,
        "word_count": 9,
        "page_number": 24,
        "window_text": "| 검사항목 | 양성(약물반응) 환자군 수 | 음성(약물비반응) 환자군 수 |\n| 분리하여 혈소판풍부혈장을 취하여 3시간 이내에 검사를 시행한다.  | 끝날때까지 기다리도록 한다.  | 있는 검체는 사용하지 않는다.  | 감염 방지 정책 및 병원의 규정에 의거하여 폐기한다.  | 환자의 3일 이상 aspirin 복용 후의 검체 | 위해요인 보호시험에 관한 요구사항이 적용된다.  | · 입원 또는 입원 기간의 연장이 필요한 경우 | 기타 | 전화: 043-719-4652~63 | 표준오차 | 17.1 | 5.1 |\n| 2017 년    5 월   31  일 | 용혈, 혈색소, 지방산과 지질(콜레스테롤, 트리글리세리드), 빌리루빈, |\n| - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | 하여 R2값을 제시한다.  | 저항성 복합검사기기에 적용한다. ",
        "original_sentence": "| 감염 방지 정책 및 병원의 규정에 의거하여 폐기한다. "
      }
    },
    {
      "chunk_id": "chunk_173",
      "text": "| 환자의 3일 이상 aspirin 복용 후의 검체 | 위해요인 보호시험에 관한 요구사항이 적용된다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 172,
        "window_size": 3,
        "char_count": 57,
        "word_count": 14,
        "page_number": 3,
        "window_text": "| 끝날때까지 기다리도록 한다.  | 있는 검체는 사용하지 않는다.  | 감염 방지 정책 및 병원의 규정에 의거하여 폐기한다.  | 환자의 3일 이상 aspirin 복용 후의 검체 | 위해요인 보호시험에 관한 요구사항이 적용된다.  | · 입원 또는 입원 기간의 연장이 필요한 경우 | 기타 | 전화: 043-719-4652~63 | 표준오차 | 17.1 | 5.1 |\n| 2017 년    5 월   31  일 | 용혈, 혈색소, 지방산과 지질(콜레스테롤, 트리글리세리드), 빌리루빈, |\n| - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | 하여 R2값을 제시한다.  | 저항성 복합검사기기에 적용한다.  | 저항성 복합검사기기에 적용한다. ",
        "original_sentence": "| 환자의 3일 이상 aspirin 복용 후의 검체 | 위해요인 보호시험에 관한 요구사항이 적용된다. "
      }
    },
    {
      "chunk_id": "chunk_174",
      "text": "| · 입원 또는 입원 기간의 연장이 필요한 경우 | 기타 | 전화: 043-719-4652~63 | 표준오차 | 17.1 | 5.1 |\n| 2017 년    5 월   31  일 | 용혈, 혈색소, 지방산과 지질(콜레스테롤, 트리글리세리드), 빌리루빈, |\n| - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | 하여 R2값을 제시한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 173,
        "window_size": 3,
        "char_count": 192,
        "word_count": 48,
        "page_number": 6,
        "window_text": "| 있는 검체는 사용하지 않는다.  | 감염 방지 정책 및 병원의 규정에 의거하여 폐기한다.  | 환자의 3일 이상 aspirin 복용 후의 검체 | 위해요인 보호시험에 관한 요구사항이 적용된다.  | · 입원 또는 입원 기간의 연장이 필요한 경우 | 기타 | 전화: 043-719-4652~63 | 표준오차 | 17.1 | 5.1 |\n| 2017 년    5 월   31  일 | 용혈, 혈색소, 지방산과 지질(콜레스테롤, 트리글리세리드), 빌리루빈, |\n| - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | 하여 R2값을 제시한다.  | 저항성 복합검사기기에 적용한다.  | 저항성 복합검사기기에 적용한다.  | (Closeness of agreement) |\n| Aspirin test | 75명 이상 | 40명 이상 | 중위값 | 80.4 | 71.4 |\n**팩스: 043-719-4650**\n| 검체에 포함된 물질 | -「의료기기의 안정성시험 기준」 | 이상 단백질 및 펨타이드 등 |\n**오차범위는 ±5% 설정하였다.",
        "original_sentence": "| · 입원 또는 입원 기간의 연장이 필요한 경우 | 기타 | 전화: 043-719-4652~63 | 표준오차 | 17.1 | 5.1 |\n| 2017 년    5 월   31  일 | 용혈, 혈색소, 지방산과 지질(콜레스테롤, 트리글리세리드), 빌리루빈, |\n| - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | 하여 R2값을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_175",
      "text": "| 저항성 복합검사기기에 적용한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 174,
        "window_size": 3,
        "char_count": 20,
        "word_count": 4,
        "page_number": 21,
        "window_text": "| 감염 방지 정책 및 병원의 규정에 의거하여 폐기한다.  | 환자의 3일 이상 aspirin 복용 후의 검체 | 위해요인 보호시험에 관한 요구사항이 적용된다.  | · 입원 또는 입원 기간의 연장이 필요한 경우 | 기타 | 전화: 043-719-4652~63 | 표준오차 | 17.1 | 5.1 |\n| 2017 년    5 월   31  일 | 용혈, 혈색소, 지방산과 지질(콜레스테롤, 트리글리세리드), 빌리루빈, |\n| - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | 하여 R2값을 제시한다.  | 저항성 복합검사기기에 적용한다.  | 저항성 복합검사기기에 적용한다.  | (Closeness of agreement) |\n| Aspirin test | 75명 이상 | 40명 이상 | 중위값 | 80.4 | 71.4 |\n**팩스: 043-719-4650**\n| 검체에 포함된 물질 | -「의료기기의 안정성시험 기준」 | 이상 단백질 및 펨타이드 등 |\n**오차범위는 ±5% 설정하였다. **\n| ADP test와 동일하므로, ADP test의 평가기준에 준하여 평가하였다. ",
        "original_sentence": "| 저항성 복합검사기기에 적용한다. "
      }
    },
    {
      "chunk_id": "chunk_176",
      "text": "| 저항성 복합검사기기에 적용한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 175,
        "window_size": 3,
        "char_count": 20,
        "word_count": 4,
        "page_number": 21,
        "window_text": "| 환자의 3일 이상 aspirin 복용 후의 검체 | 위해요인 보호시험에 관한 요구사항이 적용된다.  | · 입원 또는 입원 기간의 연장이 필요한 경우 | 기타 | 전화: 043-719-4652~63 | 표준오차 | 17.1 | 5.1 |\n| 2017 년    5 월   31  일 | 용혈, 혈색소, 지방산과 지질(콜레스테롤, 트리글리세리드), 빌리루빈, |\n| - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | 하여 R2값을 제시한다.  | 저항성 복합검사기기에 적용한다.  | 저항성 복합검사기기에 적용한다.  | (Closeness of agreement) |\n| Aspirin test | 75명 이상 | 40명 이상 | 중위값 | 80.4 | 71.4 |\n**팩스: 043-719-4650**\n| 검체에 포함된 물질 | -「의료기기의 안정성시험 기준」 | 이상 단백질 및 펨타이드 등 |\n**오차범위는 ±5% 설정하였다. **\n| ADP test와 동일하므로, ADP test의 평가기준에 준하여 평가하였다.  | P2Y12 test | 표준편차 | 15.5 | 9.8 | 담당자 | 확  인(부서장) | 서 두 원 |\n| 2개 로트로 대체 가능) | 에서 제외될 수 있다. ",
        "original_sentence": "| 저항성 복합검사기기에 적용한다. "
      }
    },
    {
      "chunk_id": "chunk_177",
      "text": "| (Closeness of agreement) |\n| Aspirin test | 75명 이상 | 40명 이상 | 중위값 | 80.4 | 71.4 |\n**팩스: 043-719-4650**\n| 검체에 포함된 물질 | -「의료기기의 안정성시험 기준」 | 이상 단백질 및 펨타이드 등 |\n**오차범위는 ±5% 설정하였다.",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 176,
        "window_size": 3,
        "char_count": 176,
        "word_count": 41,
        "page_number": 6,
        "window_text": "| · 입원 또는 입원 기간의 연장이 필요한 경우 | 기타 | 전화: 043-719-4652~63 | 표준오차 | 17.1 | 5.1 |\n| 2017 년    5 월   31  일 | 용혈, 혈색소, 지방산과 지질(콜레스테롤, 트리글리세리드), 빌리루빈, |\n| - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | 하여 R2값을 제시한다.  | 저항성 복합검사기기에 적용한다.  | 저항성 복합검사기기에 적용한다.  | (Closeness of agreement) |\n| Aspirin test | 75명 이상 | 40명 이상 | 중위값 | 80.4 | 71.4 |\n**팩스: 043-719-4650**\n| 검체에 포함된 물질 | -「의료기기의 안정성시험 기준」 | 이상 단백질 및 펨타이드 등 |\n**오차범위는 ±5% 설정하였다. **\n| ADP test와 동일하므로, ADP test의 평가기준에 준하여 평가하였다.  | P2Y12 test | 표준편차 | 15.5 | 9.8 | 담당자 | 확  인(부서장) | 서 두 원 |\n| 2개 로트로 대체 가능) | 에서 제외될 수 있다.  | P2Y12 test | 132명 이상 | 155명 이상 | - ISO 23640 In vitro diagnostic medical devices – Evaluation of |\n**방식이다.",
        "original_sentence": "| (Closeness of agreement) |\n| Aspirin test | 75명 이상 | 40명 이상 | 중위값 | 80.4 | 71.4 |\n**팩스: 043-719-4650**\n| 검체에 포함된 물질 | -「의료기기의 안정성시험 기준」 | 이상 단백질 및 펨타이드 등 |\n**오차범위는 ±5% 설정하였다."
      }
    },
    {
      "chunk_id": "chunk_178",
      "text": "**\n| ADP test와 동일하므로, ADP test의 평가기준에 준하여 평가하였다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 177,
        "window_size": 3,
        "char_count": 49,
        "word_count": 10,
        "page_number": 53,
        "window_text": "| 저항성 복합검사기기에 적용한다.  | 저항성 복합검사기기에 적용한다.  | (Closeness of agreement) |\n| Aspirin test | 75명 이상 | 40명 이상 | 중위값 | 80.4 | 71.4 |\n**팩스: 043-719-4650**\n| 검체에 포함된 물질 | -「의료기기의 안정성시험 기준」 | 이상 단백질 및 펨타이드 등 |\n**오차범위는 ±5% 설정하였다. **\n| ADP test와 동일하므로, ADP test의 평가기준에 준하여 평가하였다.  | P2Y12 test | 표준편차 | 15.5 | 9.8 | 담당자 | 확  인(부서장) | 서 두 원 |\n| 2개 로트로 대체 가능) | 에서 제외될 수 있다.  | P2Y12 test | 132명 이상 | 155명 이상 | - ISO 23640 In vitro diagnostic medical devices – Evaluation of |\n**방식이다. **\n| 안정성 평가 | 표준오차 | 9.0 | 5.7 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다. ",
        "original_sentence": "**\n| ADP test와 동일하므로, ADP test의 평가기준에 준하여 평가하였다. "
      }
    },
    {
      "chunk_id": "chunk_179",
      "text": "| P2Y12 test | 표준편차 | 15.5 | 9.8 | 담당자 | 확  인(부서장) | 서 두 원 |\n| 2개 로트로 대체 가능) | 에서 제외될 수 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 178,
        "window_size": 3,
        "char_count": 92,
        "word_count": 29,
        "page_number": 3,
        "window_text": "| 저항성 복합검사기기에 적용한다.  | (Closeness of agreement) |\n| Aspirin test | 75명 이상 | 40명 이상 | 중위값 | 80.4 | 71.4 |\n**팩스: 043-719-4650**\n| 검체에 포함된 물질 | -「의료기기의 안정성시험 기준」 | 이상 단백질 및 펨타이드 등 |\n**오차범위는 ±5% 설정하였다. **\n| ADP test와 동일하므로, ADP test의 평가기준에 준하여 평가하였다.  | P2Y12 test | 표준편차 | 15.5 | 9.8 | 담당자 | 확  인(부서장) | 서 두 원 |\n| 2개 로트로 대체 가능) | 에서 제외될 수 있다.  | P2Y12 test | 132명 이상 | 155명 이상 | - ISO 23640 In vitro diagnostic medical devices – Evaluation of |\n**방식이다. **\n| 안정성 평가 | 표준오차 | 9.0 | 5.7 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n",
        "original_sentence": "| P2Y12 test | 표준편차 | 15.5 | 9.8 | 담당자 | 확  인(부서장) | 서 두 원 |\n| 2개 로트로 대체 가능) | 에서 제외될 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_180",
      "text": "| P2Y12 test | 132명 이상 | 155명 이상 | - ISO 23640 In vitro diagnostic medical devices – Evaluation of |\n**방식이다.",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 179,
        "window_size": 3,
        "char_count": 108,
        "word_count": 23,
        "page_number": 6,
        "window_text": "| (Closeness of agreement) |\n| Aspirin test | 75명 이상 | 40명 이상 | 중위값 | 80.4 | 71.4 |\n**팩스: 043-719-4650**\n| 검체에 포함된 물질 | -「의료기기의 안정성시험 기준」 | 이상 단백질 및 펨타이드 등 |\n**오차범위는 ±5% 설정하였다. **\n| ADP test와 동일하므로, ADP test의 평가기준에 준하여 평가하였다.  | P2Y12 test | 표준편차 | 15.5 | 9.8 | 담당자 | 확  인(부서장) | 서 두 원 |\n| 2개 로트로 대체 가능) | 에서 제외될 수 있다.  | P2Y12 test | 132명 이상 | 155명 이상 | - ISO 23640 In vitro diagnostic medical devices – Evaluation of |\n**방식이다. **\n| 안정성 평가 | 표준오차 | 9.0 | 5.7 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침서ㆍ안내서\n\n■ 예(☞안내서)\n\n□ 아니오\n\n기타 확인\n\n오 현 주\n\n<!-- PAGE_4 -->\n###### 이 안내서는 출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성·성능\n\n<!-- PAGE_4 -->\n###### 및 임상시험계획서 평가 시 요구되는 신청서 작성 방법 및 제출자료 요건에\n\n<!-- PAGE_4 -->\n###### 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n",
        "original_sentence": "| P2Y12 test | 132명 이상 | 155명 이상 | - ISO 23640 In vitro diagnostic medical devices – Evaluation of |\n**방식이다."
      }
    },
    {
      "chunk_id": "chunk_181",
      "text": "**\n| 안정성 평가 | 표준오차 | 9.0 | 5.7 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 180,
        "window_size": 3,
        "char_count": 60,
        "word_count": 16,
        "page_number": 6,
        "window_text": "**\n| ADP test와 동일하므로, ADP test의 평가기준에 준하여 평가하였다.  | P2Y12 test | 표준편차 | 15.5 | 9.8 | 담당자 | 확  인(부서장) | 서 두 원 |\n| 2개 로트로 대체 가능) | 에서 제외될 수 있다.  | P2Y12 test | 132명 이상 | 155명 이상 | - ISO 23640 In vitro diagnostic medical devices – Evaluation of |\n**방식이다. **\n| 안정성 평가 | 표준오차 | 9.0 | 5.7 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침서ㆍ안내서\n\n■ 예(☞안내서)\n\n□ 아니오\n\n기타 확인\n\n오 현 주\n\n<!-- PAGE_4 -->\n###### 이 안내서는 출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성·성능\n\n<!-- PAGE_4 -->\n###### 및 임상시험계획서 평가 시 요구되는 신청서 작성 방법 및 제출자료 요건에\n\n<!-- PAGE_4 -->\n###### 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n <!-- PAGE_4 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n<!-- PAGE_4 -->\n###### (‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는\n\n<!-- PAGE_4 -->\n###### 사항이 아님을 알려드립니다. ",
        "original_sentence": "**\n| 안정성 평가 | 표준오차 | 9.0 | 5.7 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다. "
      }
    },
    {
      "chunk_id": "chunk_182",
      "text": "그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 181,
        "window_size": 3,
        "char_count": 58,
        "word_count": 13,
        "page_number": 3,
        "window_text": "| P2Y12 test | 표준편차 | 15.5 | 9.8 | 담당자 | 확  인(부서장) | 서 두 원 |\n| 2개 로트로 대체 가능) | 에서 제외될 수 있다.  | P2Y12 test | 132명 이상 | 155명 이상 | - ISO 23640 In vitro diagnostic medical devices – Evaluation of |\n**방식이다. **\n| 안정성 평가 | 표준오차 | 9.0 | 5.7 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침서ㆍ안내서\n\n■ 예(☞안내서)\n\n□ 아니오\n\n기타 확인\n\n오 현 주\n\n<!-- PAGE_4 -->\n###### 이 안내서는 출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성·성능\n\n<!-- PAGE_4 -->\n###### 및 임상시험계획서 평가 시 요구되는 신청서 작성 방법 및 제출자료 요건에\n\n<!-- PAGE_4 -->\n###### 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n <!-- PAGE_4 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n<!-- PAGE_4 -->\n###### (‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는\n\n<!-- PAGE_4 -->\n###### 사항이 아님을 알려드립니다.  또한, 본 안내서는 2016년 12월 30일 현재의 과학적\n\n<!-- PAGE_4 -->\n###### ㆍ기술적 사실 및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규\n\n<!-- PAGE_4 -->\n###### 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n",
        "original_sentence": "그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_183",
      "text": "지침서ㆍ안내서\n\n■ 예(☞안내서)\n\n□ 아니오\n\n기타 확인\n\n오 현 주\n\n<!-- PAGE_4 -->\n###### 이 안내서는 출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성·성능\n\n<!-- PAGE_4 -->\n###### 및 임상시험계획서 평가 시 요구되는 신청서 작성 방법 및 제출자료 요건에\n\n<!-- PAGE_4 -->\n###### 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 182,
        "window_size": 3,
        "char_count": 233,
        "word_count": 49,
        "page_number": 4,
        "window_text": "| P2Y12 test | 132명 이상 | 155명 이상 | - ISO 23640 In vitro diagnostic medical devices – Evaluation of |\n**방식이다. **\n| 안정성 평가 | 표준오차 | 9.0 | 5.7 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침서ㆍ안내서\n\n■ 예(☞안내서)\n\n□ 아니오\n\n기타 확인\n\n오 현 주\n\n<!-- PAGE_4 -->\n###### 이 안내서는 출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성·성능\n\n<!-- PAGE_4 -->\n###### 및 임상시험계획서 평가 시 요구되는 신청서 작성 방법 및 제출자료 요건에\n\n<!-- PAGE_4 -->\n###### 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n <!-- PAGE_4 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n<!-- PAGE_4 -->\n###### (‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는\n\n<!-- PAGE_4 -->\n###### 사항이 아님을 알려드립니다.  또한, 본 안내서는 2016년 12월 30일 현재의 과학적\n\n<!-- PAGE_4 -->\n###### ㆍ기술적 사실 및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규\n\n<!-- PAGE_4 -->\n###### 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 식품의약품안전평가원\n\n- 1. ",
        "original_sentence": "지침서ㆍ안내서\n\n■ 예(☞안내서)\n\n□ 아니오\n\n기타 확인\n\n오 현 주\n\n<!-- PAGE_4 -->\n###### 이 안내서는 출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성·성능\n\n<!-- PAGE_4 -->\n###### 및 임상시험계획서 평가 시 요구되는 신청서 작성 방법 및 제출자료 요건에\n\n<!-- PAGE_4 -->\n###### 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_184",
      "text": "<!-- PAGE_4 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n<!-- PAGE_4 -->\n###### (‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는\n\n<!-- PAGE_4 -->\n###### 사항이 아님을 알려드립니다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 183,
        "window_size": 3,
        "char_count": 172,
        "word_count": 34,
        "page_number": 4,
        "window_text": "**\n| 안정성 평가 | 표준오차 | 9.0 | 5.7 |\n\n**[표 끝]**\n\n으로 고려하시기 바랍니다.  그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침서ㆍ안내서\n\n■ 예(☞안내서)\n\n□ 아니오\n\n기타 확인\n\n오 현 주\n\n<!-- PAGE_4 -->\n###### 이 안내서는 출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성·성능\n\n<!-- PAGE_4 -->\n###### 및 임상시험계획서 평가 시 요구되는 신청서 작성 방법 및 제출자료 요건에\n\n<!-- PAGE_4 -->\n###### 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n <!-- PAGE_4 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n<!-- PAGE_4 -->\n###### (‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는\n\n<!-- PAGE_4 -->\n###### 사항이 아님을 알려드립니다.  또한, 본 안내서는 2016년 12월 30일 현재의 과학적\n\n<!-- PAGE_4 -->\n###### ㆍ기술적 사실 및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규\n\n<!-- PAGE_4 -->\n###### 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 식품의약품안전평가원\n\n- 1.  관련 법규 등\n- (1) 「의료기기법」\n- (2) 「의료기기법 시행령」\n- (3) 「의료기기법 시행규칙」\n**[표 시작]**\n\n| (4) 「의료기기 허가 | 3) 정해진 칸 이외의 여백에 기록하지 마십시오. ",
        "original_sentence": "<!-- PAGE_4 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n<!-- PAGE_4 -->\n###### (‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는\n\n<!-- PAGE_4 -->\n###### 사항이 아님을 알려드립니다. "
      }
    },
    {
      "chunk_id": "chunk_185",
      "text": "또한, 본 안내서는 2016년 12월 30일 현재의 과학적\n\n<!-- PAGE_4 -->\n###### ㆍ기술적 사실 및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규\n\n<!-- PAGE_4 -->\n###### 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 184,
        "window_size": 3,
        "char_count": 166,
        "word_count": 38,
        "page_number": 4,
        "window_text": "그럼에도 불구하고 동 지침서ㆍ안내서의 제정이\n\n필요한 경우 그 사유를 아래에 기재해 주시기 바랍니다.\n\n 지침서ㆍ안내서\n\n■ 예(☞안내서)\n\n□ 아니오\n\n기타 확인\n\n오 현 주\n\n<!-- PAGE_4 -->\n###### 이 안내서는 출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성·성능\n\n<!-- PAGE_4 -->\n###### 및 임상시험계획서 평가 시 요구되는 신청서 작성 방법 및 제출자료 요건에\n\n<!-- PAGE_4 -->\n###### 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n <!-- PAGE_4 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n<!-- PAGE_4 -->\n###### (‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는\n\n<!-- PAGE_4 -->\n###### 사항이 아님을 알려드립니다.  또한, 본 안내서는 2016년 12월 30일 현재의 과학적\n\n<!-- PAGE_4 -->\n###### ㆍ기술적 사실 및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규\n\n<!-- PAGE_4 -->\n###### 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 식품의약품안전평가원\n\n- 1.  관련 법규 등\n- (1) 「의료기기법」\n- (2) 「의료기기법 시행령」\n- (3) 「의료기기법 시행규칙」\n**[표 시작]**\n\n| (4) 「의료기기 허가 | 3) 정해진 칸 이외의 여백에 기록하지 마십시오.  | 외부 오염 또는 | - Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체 | - Sample Size (5% 탈락률 적용) = 131.71, 약 132개 검체 |\n| --- | --- | --- | --- | --- |\n| receiving dual antiplatelet treatment. ",
        "original_sentence": "또한, 본 안내서는 2016년 12월 30일 현재의 과학적\n\n<!-- PAGE_4 -->\n###### ㆍ기술적 사실 및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규\n\n<!-- PAGE_4 -->\n###### 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_186",
      "text": "※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 식품의약품안전평가원\n\n- 1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 185,
        "window_size": 3,
        "char_count": 100,
        "word_count": 22,
        "page_number": 4,
        "window_text": "지침서ㆍ안내서\n\n■ 예(☞안내서)\n\n□ 아니오\n\n기타 확인\n\n오 현 주\n\n<!-- PAGE_4 -->\n###### 이 안내서는 출혈시간 및 항혈소판제제 저항성 복합검사기기 안전성·성능\n\n<!-- PAGE_4 -->\n###### 및 임상시험계획서 평가 시 요구되는 신청서 작성 방법 및 제출자료 요건에\n\n<!-- PAGE_4 -->\n###### 대하여 알기 쉽게 설명하거나 식품의약품안전처의 입장을 기술한 것입니다.\n\n <!-- PAGE_4 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n<!-- PAGE_4 -->\n###### (‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는\n\n<!-- PAGE_4 -->\n###### 사항이 아님을 알려드립니다.  또한, 본 안내서는 2016년 12월 30일 현재의 과학적\n\n<!-- PAGE_4 -->\n###### ㆍ기술적 사실 및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규\n\n<!-- PAGE_4 -->\n###### 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 식품의약품안전평가원\n\n- 1.  관련 법규 등\n- (1) 「의료기기법」\n- (2) 「의료기기법 시행령」\n- (3) 「의료기기법 시행규칙」\n**[표 시작]**\n\n| (4) 「의료기기 허가 | 3) 정해진 칸 이외의 여백에 기록하지 마십시오.  | 외부 오염 또는 | - Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체 | - Sample Size (5% 탈락률 적용) = 131.71, 약 132개 검체 |\n| --- | --- | --- | --- | --- |\n| receiving dual antiplatelet treatment.  Am J Clin Pathol 2007;128:143-149. ",
        "original_sentence": "※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 식품의약품안전평가원\n\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_187",
      "text": "관련 법규 등\n- (1) 「의료기기법」\n- (2) 「의료기기법 시행령」\n- (3) 「의료기기법 시행규칙」\n**[표 시작]**\n\n| (4) 「의료기기 허가 | 3) 정해진 칸 이외의 여백에 기록하지 마십시오. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 186,
        "window_size": 3,
        "char_count": 116,
        "word_count": 28,
        "page_number": 5,
        "window_text": "<!-- PAGE_4 -->\n###### 본 안내서는 대외적으로 법적 효력을 가지는 것이 아니므로 본문의 기술방식\n\n<!-- PAGE_4 -->\n###### (‘∼하여야 한다’ 등)에도 불구하고 민원인 여러분께서 반드시 준수하셔야 하는\n\n<!-- PAGE_4 -->\n###### 사항이 아님을 알려드립니다.  또한, 본 안내서는 2016년 12월 30일 현재의 과학적\n\n<!-- PAGE_4 -->\n###### ㆍ기술적 사실 및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규\n\n<!-- PAGE_4 -->\n###### 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 식품의약품안전평가원\n\n- 1.  관련 법규 등\n- (1) 「의료기기법」\n- (2) 「의료기기법 시행령」\n- (3) 「의료기기법 시행규칙」\n**[표 시작]**\n\n| (4) 「의료기기 허가 | 3) 정해진 칸 이외의 여백에 기록하지 마십시오.  | 외부 오염 또는 | - Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체 | - Sample Size (5% 탈락률 적용) = 131.71, 약 132개 검체 |\n| --- | --- | --- | --- | --- |\n| receiving dual antiplatelet treatment.  Am J Clin Pathol 2007;128:143-149.  | ① 「의료기기의 안정성시험 기준」(식약처 고시) |\n| 4) 제품 취급 및 보관상의 주의 | 나. ",
        "original_sentence": "관련 법규 등\n- (1) 「의료기기법」\n- (2) 「의료기기법 시행령」\n- (3) 「의료기기법 시행규칙」\n**[표 시작]**\n\n| (4) 「의료기기 허가 | 3) 정해진 칸 이외의 여백에 기록하지 마십시오. "
      }
    },
    {
      "chunk_id": "chunk_188",
      "text": "| 외부 오염 또는 | - Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체 | - Sample Size (5% 탈락률 적용) = 131.71, 약 132개 검체 |\n| --- | --- | --- | --- | --- |\n| receiving dual antiplatelet treatment. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 187,
        "window_size": 3,
        "char_count": 181,
        "word_count": 45,
        "page_number": 6,
        "window_text": "또한, 본 안내서는 2016년 12월 30일 현재의 과학적\n\n<!-- PAGE_4 -->\n###### ㆍ기술적 사실 및 유효한 법규를 토대로 작성되었으므로 이후 최신 개정 법규\n\n<!-- PAGE_4 -->\n###### 내용 및 구체적인 사실관계 등에 따라 달리 적용될 수 있음을 알려드립니다.\n\n ※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 식품의약품안전평가원\n\n- 1.  관련 법규 등\n- (1) 「의료기기법」\n- (2) 「의료기기법 시행령」\n- (3) 「의료기기법 시행규칙」\n**[표 시작]**\n\n| (4) 「의료기기 허가 | 3) 정해진 칸 이외의 여백에 기록하지 마십시오.  | 외부 오염 또는 | - Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체 | - Sample Size (5% 탈락률 적용) = 131.71, 약 132개 검체 |\n| --- | --- | --- | --- | --- |\n| receiving dual antiplatelet treatment.  Am J Clin Pathol 2007;128:143-149.  | ① 「의료기기의 안정성시험 기준」(식약처 고시) |\n| 4) 제품 취급 및 보관상의 주의 | 나.  방문2 (검사일) | 8) 보관조건: | 나. P2Y12 test | ⑥ Tray가 나와 움직이지 않을 때까지 기다린다. ",
        "original_sentence": "| 외부 오염 또는 | - Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체 | - Sample Size (5% 탈락률 적용) = 131.71, 약 132개 검체 |\n| --- | --- | --- | --- | --- |\n| receiving dual antiplatelet treatment. "
      }
    },
    {
      "chunk_id": "chunk_189",
      "text": "Am J Clin Pathol 2007;128:143-149. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 188,
        "window_size": 3,
        "char_count": 35,
        "word_count": 5,
        "page_number": 6,
        "window_text": "※ “민원인 안내서”란 대내외적으로 법령 또는 고시ㆍ훈령ㆍ예규 등을 알기 쉽게\n\n※ 본 안내서에 대한 의견이나 문의사항이 있을 경우 식품의약품안전처 식품의약품안전평가원\n\n- 1.  관련 법규 등\n- (1) 「의료기기법」\n- (2) 「의료기기법 시행령」\n- (3) 「의료기기법 시행규칙」\n**[표 시작]**\n\n| (4) 「의료기기 허가 | 3) 정해진 칸 이외의 여백에 기록하지 마십시오.  | 외부 오염 또는 | - Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체 | - Sample Size (5% 탈락률 적용) = 131.71, 약 132개 검체 |\n| --- | --- | --- | --- | --- |\n| receiving dual antiplatelet treatment.  Am J Clin Pathol 2007;128:143-149.  | ① 「의료기기의 안정성시험 기준」(식약처 고시) |\n| 4) 제품 취급 및 보관상의 주의 | 나.  방문2 (검사일) | 8) 보관조건: | 나. P2Y12 test | ⑥ Tray가 나와 움직이지 않을 때까지 기다린다.  | control, and laboratory use – Part 1: General requirementsK. ",
        "original_sentence": "Am J Clin Pathol 2007;128:143-149. "
      }
    },
    {
      "chunk_id": "chunk_190",
      "text": "| ① 「의료기기의 안정성시험 기준」(식약처 고시) |\n| 4) 제품 취급 및 보관상의 주의 | 나. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 189,
        "window_size": 3,
        "char_count": 57,
        "word_count": 16,
        "page_number": 9,
        "window_text": "관련 법규 등\n- (1) 「의료기기법」\n- (2) 「의료기기법 시행령」\n- (3) 「의료기기법 시행규칙」\n**[표 시작]**\n\n| (4) 「의료기기 허가 | 3) 정해진 칸 이외의 여백에 기록하지 마십시오.  | 외부 오염 또는 | - Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체 | - Sample Size (5% 탈락률 적용) = 131.71, 약 132개 검체 |\n| --- | --- | --- | --- | --- |\n| receiving dual antiplatelet treatment.  Am J Clin Pathol 2007;128:143-149.  | ① 「의료기기의 안정성시험 기준」(식약처 고시) |\n| 4) 제품 취급 및 보관상의 주의 | 나.  방문2 (검사일) | 8) 보관조건: | 나. P2Y12 test | ⑥ Tray가 나와 움직이지 않을 때까지 기다린다.  | control, and laboratory use – Part 1: General requirementsK.  |\n| (4) 시험 항목 | 처의 임상계획 승인일로부터 OO개월”로 표시하고 근거자료 제출함. ",
        "original_sentence": "| ① 「의료기기의 안정성시험 기준」(식약처 고시) |\n| 4) 제품 취급 및 보관상의 주의 | 나. "
      }
    },
    {
      "chunk_id": "chunk_191",
      "text": "방문2 (검사일) | 8) 보관조건: | 나. P2Y12 test | ⑥ Tray가 나와 움직이지 않을 때까지 기다린다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 190,
        "window_size": 3,
        "char_count": 68,
        "word_count": 17,
        "page_number": 6,
        "window_text": "| 외부 오염 또는 | - Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체 | - Sample Size (5% 탈락률 적용) = 131.71, 약 132개 검체 |\n| --- | --- | --- | --- | --- |\n| receiving dual antiplatelet treatment.  Am J Clin Pathol 2007;128:143-149.  | ① 「의료기기의 안정성시험 기준」(식약처 고시) |\n| 4) 제품 취급 및 보관상의 주의 | 나.  방문2 (검사일) | 8) 보관조건: | 나. P2Y12 test | ⑥ Tray가 나와 움직이지 않을 때까지 기다린다.  | control, and laboratory use – Part 1: General requirementsK.  |\n| (4) 시험 항목 | 처의 임상계획 승인일로부터 OO개월”로 표시하고 근거자료 제출함.  | 의료기기의 공급과 취급에 관한 사항을 추가로 확보할 수 있음. ",
        "original_sentence": "방문2 (검사일) | 8) 보관조건: | 나. P2Y12 test | ⑥ Tray가 나와 움직이지 않을 때까지 기다린다. "
      }
    },
    {
      "chunk_id": "chunk_192",
      "text": "| control, and laboratory use – Part 1: General requirementsK. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 191,
        "window_size": 3,
        "char_count": 63,
        "word_count": 10,
        "page_number": 6,
        "window_text": "Am J Clin Pathol 2007;128:143-149.  | ① 「의료기기의 안정성시험 기준」(식약처 고시) |\n| 4) 제품 취급 및 보관상의 주의 | 나.  방문2 (검사일) | 8) 보관조건: | 나. P2Y12 test | ⑥ Tray가 나와 움직이지 않을 때까지 기다린다.  | control, and laboratory use – Part 1: General requirementsK.  |\n| (4) 시험 항목 | 처의 임상계획 승인일로부터 OO개월”로 표시하고 근거자료 제출함.  | 의료기기의 공급과 취급에 관한 사항을 추가로 확보할 수 있음.  | (3) 통계적 검정 방법 | 대상 질환 또는 적응증을 포함하도록 함. ",
        "original_sentence": "| control, and laboratory use – Part 1: General requirementsK. "
      }
    },
    {
      "chunk_id": "chunk_193",
      "text": "|\n| (4) 시험 항목 | 처의 임상계획 승인일로부터 OO개월”로 표시하고 근거자료 제출함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 192,
        "window_size": 3,
        "char_count": 53,
        "word_count": 13,
        "page_number": 6,
        "window_text": "| ① 「의료기기의 안정성시험 기준」(식약처 고시) |\n| 4) 제품 취급 및 보관상의 주의 | 나.  방문2 (검사일) | 8) 보관조건: | 나. P2Y12 test | ⑥ Tray가 나와 움직이지 않을 때까지 기다린다.  | control, and laboratory use – Part 1: General requirementsK.  |\n| (4) 시험 항목 | 처의 임상계획 승인일로부터 OO개월”로 표시하고 근거자료 제출함.  | 의료기기의 공급과 취급에 관한 사항을 추가로 확보할 수 있음.  | (3) 통계적 검정 방법 | 대상 질환 또는 적응증을 포함하도록 함.  |\n| 하여 원칙과 절차를 수립하여 제시함. ",
        "original_sentence": "|\n| (4) 시험 항목 | 처의 임상계획 승인일로부터 OO개월”로 표시하고 근거자료 제출함. "
      }
    },
    {
      "chunk_id": "chunk_194",
      "text": "| 의료기기의 공급과 취급에 관한 사항을 추가로 확보할 수 있음. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 193,
        "window_size": 3,
        "char_count": 37,
        "word_count": 10,
        "page_number": 3,
        "window_text": "방문2 (검사일) | 8) 보관조건: | 나. P2Y12 test | ⑥ Tray가 나와 움직이지 않을 때까지 기다린다.  | control, and laboratory use – Part 1: General requirementsK.  |\n| (4) 시험 항목 | 처의 임상계획 승인일로부터 OO개월”로 표시하고 근거자료 제출함.  | 의료기기의 공급과 취급에 관한 사항을 추가로 확보할 수 있음.  | (3) 통계적 검정 방법 | 대상 질환 또는 적응증을 포함하도록 함.  |\n| 하여 원칙과 절차를 수립하여 제시함.  | 실시기관으로 지정받은 곳이어야 함 | 부적절한 검체 |\n| (5) 「의료기기 품목 및 품목별 등급에 관한 규정」(식약처 고시) | * 만 18세 미만의 피험자의 경우 법정대리인도 동의서에 서명해야 합니다. ",
        "original_sentence": "| 의료기기의 공급과 취급에 관한 사항을 추가로 확보할 수 있음. "
      }
    },
    {
      "chunk_id": "chunk_195",
      "text": "| (3) 통계적 검정 방법 | 대상 질환 또는 적응증을 포함하도록 함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 194,
        "window_size": 3,
        "char_count": 41,
        "word_count": 12,
        "page_number": 15,
        "window_text": "| control, and laboratory use – Part 1: General requirementsK.  |\n| (4) 시험 항목 | 처의 임상계획 승인일로부터 OO개월”로 표시하고 근거자료 제출함.  | 의료기기의 공급과 취급에 관한 사항을 추가로 확보할 수 있음.  | (3) 통계적 검정 방법 | 대상 질환 또는 적응증을 포함하도록 함.  |\n| 하여 원칙과 절차를 수립하여 제시함.  | 실시기관으로 지정받은 곳이어야 함 | 부적절한 검체 |\n| (5) 「의료기기 품목 및 품목별 등급에 관한 규정」(식약처 고시) | * 만 18세 미만의 피험자의 경우 법정대리인도 동의서에 서명해야 합니다.  | 4) 증례 기록서 내에 기록하며, 모든 칸은 빈칸으로 두지 마십시오. ",
        "original_sentence": "| (3) 통계적 검정 방법 | 대상 질환 또는 적응증을 포함하도록 함. "
      }
    },
    {
      "chunk_id": "chunk_196",
      "text": "|\n| 하여 원칙과 절차를 수립하여 제시함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 195,
        "window_size": 3,
        "char_count": 25,
        "word_count": 7,
        "page_number": 6,
        "window_text": "|\n| (4) 시험 항목 | 처의 임상계획 승인일로부터 OO개월”로 표시하고 근거자료 제출함.  | 의료기기의 공급과 취급에 관한 사항을 추가로 확보할 수 있음.  | (3) 통계적 검정 방법 | 대상 질환 또는 적응증을 포함하도록 함.  |\n| 하여 원칙과 절차를 수립하여 제시함.  | 실시기관으로 지정받은 곳이어야 함 | 부적절한 검체 |\n| (5) 「의료기기 품목 및 품목별 등급에 관한 규정」(식약처 고시) | * 만 18세 미만의 피험자의 경우 법정대리인도 동의서에 서명해야 합니다.  | 4) 증례 기록서 내에 기록하며, 모든 칸은 빈칸으로 두지 마십시오.  | 경험이 있는 자가 선정되어야 함. ",
        "original_sentence": "|\n| 하여 원칙과 절차를 수립하여 제시함. "
      }
    },
    {
      "chunk_id": "chunk_197",
      "text": "| 실시기관으로 지정받은 곳이어야 함 | 부적절한 검체 |\n| (5) 「의료기기 품목 및 품목별 등급에 관한 규정」(식약처 고시) | * 만 18세 미만의 피험자의 경우 법정대리인도 동의서에 서명해야 합니다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 196,
        "window_size": 3,
        "char_count": 117,
        "word_count": 30,
        "page_number": 6,
        "window_text": "| 의료기기의 공급과 취급에 관한 사항을 추가로 확보할 수 있음.  | (3) 통계적 검정 방법 | 대상 질환 또는 적응증을 포함하도록 함.  |\n| 하여 원칙과 절차를 수립하여 제시함.  | 실시기관으로 지정받은 곳이어야 함 | 부적절한 검체 |\n| (5) 「의료기기 품목 및 품목별 등급에 관한 규정」(식약처 고시) | * 만 18세 미만의 피험자의 경우 법정대리인도 동의서에 서명해야 합니다.  | 4) 증례 기록서 내에 기록하며, 모든 칸은 빈칸으로 두지 마십시오.  | 경험이 있는 자가 선정되어야 함.  | ④ ADP test 음성 검체 검사 시 (특이도 80%), |\n| 바. ",
        "original_sentence": "| 실시기관으로 지정받은 곳이어야 함 | 부적절한 검체 |\n| (5) 「의료기기 품목 및 품목별 등급에 관한 규정」(식약처 고시) | * 만 18세 미만의 피험자의 경우 법정대리인도 동의서에 서명해야 합니다. "
      }
    },
    {
      "chunk_id": "chunk_198",
      "text": "| 4) 증례 기록서 내에 기록하며, 모든 칸은 빈칸으로 두지 마십시오. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 197,
        "window_size": 3,
        "char_count": 41,
        "word_count": 11,
        "page_number": 15,
        "window_text": "| (3) 통계적 검정 방법 | 대상 질환 또는 적응증을 포함하도록 함.  |\n| 하여 원칙과 절차를 수립하여 제시함.  | 실시기관으로 지정받은 곳이어야 함 | 부적절한 검체 |\n| (5) 「의료기기 품목 및 품목별 등급에 관한 규정」(식약처 고시) | * 만 18세 미만의 피험자의 경우 법정대리인도 동의서에 서명해야 합니다.  | 4) 증례 기록서 내에 기록하며, 모든 칸은 빈칸으로 두지 마십시오.  | 경험이 있는 자가 선정되어야 함.  | ④ ADP test 음성 검체 검사 시 (특이도 80%), |\n| 바.  기준물질/보정물질 | 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에서 정하고 있음. ",
        "original_sentence": "| 4) 증례 기록서 내에 기록하며, 모든 칸은 빈칸으로 두지 마십시오. "
      }
    },
    {
      "chunk_id": "chunk_199",
      "text": "| 경험이 있는 자가 선정되어야 함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 198,
        "window_size": 3,
        "char_count": 21,
        "word_count": 6,
        "page_number": 38,
        "window_text": "|\n| 하여 원칙과 절차를 수립하여 제시함.  | 실시기관으로 지정받은 곳이어야 함 | 부적절한 검체 |\n| (5) 「의료기기 품목 및 품목별 등급에 관한 규정」(식약처 고시) | * 만 18세 미만의 피험자의 경우 법정대리인도 동의서에 서명해야 합니다.  | 4) 증례 기록서 내에 기록하며, 모든 칸은 빈칸으로 두지 마십시오.  | 경험이 있는 자가 선정되어야 함.  | ④ ADP test 음성 검체 검사 시 (특이도 80%), |\n| 바.  기준물질/보정물질 | 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에서 정하고 있음.  | 1. ",
        "original_sentence": "| 경험이 있는 자가 선정되어야 함. "
      }
    },
    {
      "chunk_id": "chunk_200",
      "text": "| ④ ADP test 음성 검체 검사 시 (특이도 80%), |\n| 바. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 199,
        "window_size": 3,
        "char_count": 42,
        "word_count": 13,
        "page_number": 15,
        "window_text": "| 실시기관으로 지정받은 곳이어야 함 | 부적절한 검체 |\n| (5) 「의료기기 품목 및 품목별 등급에 관한 규정」(식약처 고시) | * 만 18세 미만의 피험자의 경우 법정대리인도 동의서에 서명해야 합니다.  | 4) 증례 기록서 내에 기록하며, 모든 칸은 빈칸으로 두지 마십시오.  | 경험이 있는 자가 선정되어야 함.  | ④ ADP test 음성 검체 검사 시 (특이도 80%), |\n| 바.  기준물질/보정물질 | 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에서 정하고 있음.  | 1.  검출한계(Limit of detection) | 이상이 되도록 준비한 후 시험 시료에 첨가한다. ",
        "original_sentence": "| ④ ADP test 음성 검체 검사 시 (특이도 80%), |\n| 바. "
      }
    },
    {
      "chunk_id": "chunk_201",
      "text": "기준물질/보정물질 | 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에서 정하고 있음. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 200,
        "window_size": 3,
        "char_count": 51,
        "word_count": 9,
        "page_number": 9,
        "window_text": "| 4) 증례 기록서 내에 기록하며, 모든 칸은 빈칸으로 두지 마십시오.  | 경험이 있는 자가 선정되어야 함.  | ④ ADP test 음성 검체 검사 시 (특이도 80%), |\n| 바.  기준물질/보정물질 | 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에서 정하고 있음.  | 1.  검출한계(Limit of detection) | 이상이 되도록 준비한 후 시험 시료에 첨가한다.  | 시험 |\n| 7) 제품 폐기 시 주의사항 | 7.2.1. ",
        "original_sentence": "기준물질/보정물질 | 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에서 정하고 있음. "
      }
    },
    {
      "chunk_id": "chunk_202",
      "text": "| 1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 201,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 6,
        "window_text": "| 경험이 있는 자가 선정되어야 함.  | ④ ADP test 음성 검체 검사 시 (특이도 80%), |\n| 바.  기준물질/보정물질 | 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에서 정하고 있음.  | 1.  검출한계(Limit of detection) | 이상이 되도록 준비한 후 시험 시료에 첨가한다.  | 시험 |\n| 7) 제품 폐기 시 주의사항 | 7.2.1.  임상시험용 의료기기 | (1) 유효기한이 지난 제품은 사용하지 않는다. ",
        "original_sentence": "| 1. "
      }
    },
    {
      "chunk_id": "chunk_203",
      "text": "검출한계(Limit of detection) | 이상이 되도록 준비한 후 시험 시료에 첨가한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 202,
        "window_size": 3,
        "char_count": 54,
        "word_count": 11,
        "page_number": 9,
        "window_text": "| ④ ADP test 음성 검체 검사 시 (특이도 80%), |\n| 바.  기준물질/보정물질 | 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에서 정하고 있음.  | 1.  검출한계(Limit of detection) | 이상이 되도록 준비한 후 시험 시료에 첨가한다.  | 시험 |\n| 7) 제품 폐기 시 주의사항 | 7.2.1.  임상시험용 의료기기 | (1) 유효기한이 지난 제품은 사용하지 않는다.  | (2) 검사칩 장착 | 가 혈소판 기능검사 | 차트확인 및 질문 등을 통하여 점검하고 증례기록서에 기록한다. ",
        "original_sentence": "검출한계(Limit of detection) | 이상이 되도록 준비한 후 시험 시료에 첨가한다. "
      }
    },
    {
      "chunk_id": "chunk_204",
      "text": "| 시험 |\n| 7) 제품 폐기 시 주의사항 | 7.2.1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 203,
        "window_size": 3,
        "char_count": 34,
        "word_count": 11,
        "page_number": 3,
        "window_text": "기준물질/보정물질 | 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에서 정하고 있음.  | 1.  검출한계(Limit of detection) | 이상이 되도록 준비한 후 시험 시료에 첨가한다.  | 시험 |\n| 7) 제품 폐기 시 주의사항 | 7.2.1.  임상시험용 의료기기 | (1) 유효기한이 지난 제품은 사용하지 않는다.  | (2) 검사칩 장착 | 가 혈소판 기능검사 | 차트확인 및 질문 등을 통하여 점검하고 증례기록서에 기록한다.  | 1) 혈소판 약물반응검사의 경우에만 방문2에 검사를 시행한다. ",
        "original_sentence": "| 시험 |\n| 7) 제품 폐기 시 주의사항 | 7.2.1. "
      }
    },
    {
      "chunk_id": "chunk_205",
      "text": "임상시험용 의료기기 | (1) 유효기한이 지난 제품은 사용하지 않는다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 204,
        "window_size": 3,
        "char_count": 40,
        "word_count": 9,
        "page_number": 6,
        "window_text": "| 1.  검출한계(Limit of detection) | 이상이 되도록 준비한 후 시험 시료에 첨가한다.  | 시험 |\n| 7) 제품 폐기 시 주의사항 | 7.2.1.  임상시험용 의료기기 | (1) 유효기한이 지난 제품은 사용하지 않는다.  | (2) 검사칩 장착 | 가 혈소판 기능검사 | 차트확인 및 질문 등을 통하여 점검하고 증례기록서에 기록한다.  | 1) 혈소판 약물반응검사의 경우에만 방문2에 검사를 시행한다.  | - 치료 | (1) 본체 : 해당사항 없음 | 2) ADP test | 증명하고자 하는 임상시험의 목적을 구체적으로 알 수 있도록 기입함. ",
        "original_sentence": "임상시험용 의료기기 | (1) 유효기한이 지난 제품은 사용하지 않는다. "
      }
    },
    {
      "chunk_id": "chunk_206",
      "text": "| (2) 검사칩 장착 | 가 혈소판 기능검사 | 차트확인 및 질문 등을 통하여 점검하고 증례기록서에 기록한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 205,
        "window_size": 3,
        "char_count": 63,
        "word_count": 17,
        "page_number": 6,
        "window_text": "검출한계(Limit of detection) | 이상이 되도록 준비한 후 시험 시료에 첨가한다.  | 시험 |\n| 7) 제품 폐기 시 주의사항 | 7.2.1.  임상시험용 의료기기 | (1) 유효기한이 지난 제품은 사용하지 않는다.  | (2) 검사칩 장착 | 가 혈소판 기능검사 | 차트확인 및 질문 등을 통하여 점검하고 증례기록서에 기록한다.  | 1) 혈소판 약물반응검사의 경우에만 방문2에 검사를 시행한다.  | - 치료 | (1) 본체 : 해당사항 없음 | 2) ADP test | 증명하고자 하는 임상시험의 목적을 구체적으로 알 수 있도록 기입함.  | 전달한다) |\n**(4) 사용될 통계적 분석방법(즉, 연구디자인과도 관련)**\n**(6) 「의료기기의 전기**\n| 나. ",
        "original_sentence": "| (2) 검사칩 장착 | 가 혈소판 기능검사 | 차트확인 및 질문 등을 통하여 점검하고 증례기록서에 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_207",
      "text": "| 1) 혈소판 약물반응검사의 경우에만 방문2에 검사를 시행한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 206,
        "window_size": 3,
        "char_count": 37,
        "word_count": 8,
        "page_number": 6,
        "window_text": "| 시험 |\n| 7) 제품 폐기 시 주의사항 | 7.2.1.  임상시험용 의료기기 | (1) 유효기한이 지난 제품은 사용하지 않는다.  | (2) 검사칩 장착 | 가 혈소판 기능검사 | 차트확인 및 질문 등을 통하여 점검하고 증례기록서에 기록한다.  | 1) 혈소판 약물반응검사의 경우에만 방문2에 검사를 시행한다.  | - 치료 | (1) 본체 : 해당사항 없음 | 2) ADP test | 증명하고자 하는 임상시험의 목적을 구체적으로 알 수 있도록 기입함.  | 전달한다) |\n**(4) 사용될 통계적 분석방법(즉, 연구디자인과도 관련)**\n**(6) 「의료기기의 전기**\n| 나.  혈소판 약물반응검사 | a university hospital in Korea. ",
        "original_sentence": "| 1) 혈소판 약물반응검사의 경우에만 방문2에 검사를 시행한다. "
      }
    },
    {
      "chunk_id": "chunk_208",
      "text": "| - 치료 | (1) 본체 : 해당사항 없음 | 2) ADP test | 증명하고자 하는 임상시험의 목적을 구체적으로 알 수 있도록 기입함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 207,
        "window_size": 3,
        "char_count": 80,
        "word_count": 23,
        "page_number": 3,
        "window_text": "임상시험용 의료기기 | (1) 유효기한이 지난 제품은 사용하지 않는다.  | (2) 검사칩 장착 | 가 혈소판 기능검사 | 차트확인 및 질문 등을 통하여 점검하고 증례기록서에 기록한다.  | 1) 혈소판 약물반응검사의 경우에만 방문2에 검사를 시행한다.  | - 치료 | (1) 본체 : 해당사항 없음 | 2) ADP test | 증명하고자 하는 임상시험의 목적을 구체적으로 알 수 있도록 기입함.  | 전달한다) |\n**(4) 사용될 통계적 분석방법(즉, 연구디자인과도 관련)**\n**(6) 「의료기기의 전기**\n| 나.  혈소판 약물반응검사 | a university hospital in Korea.  Korean J Lab Med 2008;28:251-7. ",
        "original_sentence": "| - 치료 | (1) 본체 : 해당사항 없음 | 2) ADP test | 증명하고자 하는 임상시험의 목적을 구체적으로 알 수 있도록 기입함. "
      }
    },
    {
      "chunk_id": "chunk_209",
      "text": "| 전달한다) |\n**(4) 사용될 통계적 분석방법(즉, 연구디자인과도 관련)**\n**(6) 「의료기기의 전기**\n| 나. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 208,
        "window_size": 3,
        "char_count": 69,
        "word_count": 14,
        "page_number": 15,
        "window_text": "| (2) 검사칩 장착 | 가 혈소판 기능검사 | 차트확인 및 질문 등을 통하여 점검하고 증례기록서에 기록한다.  | 1) 혈소판 약물반응검사의 경우에만 방문2에 검사를 시행한다.  | - 치료 | (1) 본체 : 해당사항 없음 | 2) ADP test | 증명하고자 하는 임상시험의 목적을 구체적으로 알 수 있도록 기입함.  | 전달한다) |\n**(4) 사용될 통계적 분석방법(즉, 연구디자인과도 관련)**\n**(6) 「의료기기의 전기**\n| 나.  혈소판 약물반응검사 | a university hospital in Korea.  Korean J Lab Med 2008;28:251-7.  | 직명 등 인적사항을 기재함. ",
        "original_sentence": "| 전달한다) |\n**(4) 사용될 통계적 분석방법(즉, 연구디자인과도 관련)**\n**(6) 「의료기기의 전기**\n| 나. "
      }
    },
    {
      "chunk_id": "chunk_210",
      "text": "혈소판 약물반응검사 | a university hospital in Korea. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 209,
        "window_size": 3,
        "char_count": 45,
        "word_count": 8,
        "page_number": 18,
        "window_text": "| 1) 혈소판 약물반응검사의 경우에만 방문2에 검사를 시행한다.  | - 치료 | (1) 본체 : 해당사항 없음 | 2) ADP test | 증명하고자 하는 임상시험의 목적을 구체적으로 알 수 있도록 기입함.  | 전달한다) |\n**(4) 사용될 통계적 분석방법(즉, 연구디자인과도 관련)**\n**(6) 「의료기기의 전기**\n| 나.  혈소판 약물반응검사 | a university hospital in Korea.  Korean J Lab Med 2008;28:251-7.  | 직명 등 인적사항을 기재함.  | - 대립가설: 개발제품의 특이도가 80% 이상이다. ",
        "original_sentence": "혈소판 약물반응검사 | a university hospital in Korea. "
      }
    },
    {
      "chunk_id": "chunk_211",
      "text": "Korean J Lab Med 2008;28:251-7. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 210,
        "window_size": 3,
        "char_count": 32,
        "word_count": 5,
        "page_number": 6,
        "window_text": "| - 치료 | (1) 본체 : 해당사항 없음 | 2) ADP test | 증명하고자 하는 임상시험의 목적을 구체적으로 알 수 있도록 기입함.  | 전달한다) |\n**(4) 사용될 통계적 분석방법(즉, 연구디자인과도 관련)**\n**(6) 「의료기기의 전기**\n| 나.  혈소판 약물반응검사 | a university hospital in Korea.  Korean J Lab Med 2008;28:251-7.  | 직명 등 인적사항을 기재함.  | - 대립가설: 개발제품의 특이도가 80% 이상이다.  |\n| 번호 | 안전성 평가 항목 | 관련 표준 또는 적용 규격 |\n| (1) 오염된 제품이나 사용한 제품은 병원의 규정에 의거하여 폐기한다. ",
        "original_sentence": "Korean J Lab Med 2008;28:251-7. "
      }
    },
    {
      "chunk_id": "chunk_212",
      "text": "| 직명 등 인적사항을 기재함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 211,
        "window_size": 3,
        "char_count": 18,
        "word_count": 5,
        "page_number": 3,
        "window_text": "| 전달한다) |\n**(4) 사용될 통계적 분석방법(즉, 연구디자인과도 관련)**\n**(6) 「의료기기의 전기**\n| 나.  혈소판 약물반응검사 | a university hospital in Korea.  Korean J Lab Med 2008;28:251-7.  | 직명 등 인적사항을 기재함.  | - 대립가설: 개발제품의 특이도가 80% 이상이다.  |\n| 번호 | 안전성 평가 항목 | 관련 표준 또는 적용 규격 |\n| (1) 오염된 제품이나 사용한 제품은 병원의 규정에 의거하여 폐기한다.  | ① 인구학적 정보: 성명, 나이, 성별, 임신 유무 | 검체를 준비한다. ",
        "original_sentence": "| 직명 등 인적사항을 기재함. "
      }
    },
    {
      "chunk_id": "chunk_213",
      "text": "| - 대립가설: 개발제품의 특이도가 80% 이상이다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 212,
        "window_size": 3,
        "char_count": 31,
        "word_count": 7,
        "page_number": 7,
        "window_text": "혈소판 약물반응검사 | a university hospital in Korea.  Korean J Lab Med 2008;28:251-7.  | 직명 등 인적사항을 기재함.  | - 대립가설: 개발제품의 특이도가 80% 이상이다.  |\n| 번호 | 안전성 평가 항목 | 관련 표준 또는 적용 규격 |\n| (1) 오염된 제품이나 사용한 제품은 병원의 규정에 의거하여 폐기한다.  | ① 인구학적 정보: 성명, 나이, 성별, 임신 유무 | 검체를 준비한다.  | 따라 폐기됩니다. ",
        "original_sentence": "| - 대립가설: 개발제품의 특이도가 80% 이상이다. "
      }
    },
    {
      "chunk_id": "chunk_214",
      "text": "|\n| 번호 | 안전성 평가 항목 | 관련 표준 또는 적용 규격 |\n| (1) 오염된 제품이나 사용한 제품은 병원의 규정에 의거하여 폐기한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 213,
        "window_size": 3,
        "char_count": 80,
        "word_count": 24,
        "page_number": 6,
        "window_text": "Korean J Lab Med 2008;28:251-7.  | 직명 등 인적사항을 기재함.  | - 대립가설: 개발제품의 특이도가 80% 이상이다.  |\n| 번호 | 안전성 평가 항목 | 관련 표준 또는 적용 규격 |\n| (1) 오염된 제품이나 사용한 제품은 병원의 규정에 의거하여 폐기한다.  | ① 인구학적 정보: 성명, 나이, 성별, 임신 유무 | 검체를 준비한다.  | 따라 폐기됩니다.  | - 제품의 보관방법 및 유효기간 | (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests | ① EPI test 양성 검체 검사 시 (민감도 85%), | 95% 구간에서 민감도 80%, 특이도 75%, 로 설정한다. ",
        "original_sentence": "|\n| 번호 | 안전성 평가 항목 | 관련 표준 또는 적용 규격 |\n| (1) 오염된 제품이나 사용한 제품은 병원의 규정에 의거하여 폐기한다. "
      }
    },
    {
      "chunk_id": "chunk_215",
      "text": "| ① 인구학적 정보: 성명, 나이, 성별, 임신 유무 | 검체를 준비한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 214,
        "window_size": 3,
        "char_count": 43,
        "word_count": 12,
        "page_number": 23,
        "window_text": "| 직명 등 인적사항을 기재함.  | - 대립가설: 개발제품의 특이도가 80% 이상이다.  |\n| 번호 | 안전성 평가 항목 | 관련 표준 또는 적용 규격 |\n| (1) 오염된 제품이나 사용한 제품은 병원의 규정에 의거하여 폐기한다.  | ① 인구학적 정보: 성명, 나이, 성별, 임신 유무 | 검체를 준비한다.  | 따라 폐기됩니다.  | - 제품의 보관방법 및 유효기간 | (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests | ① EPI test 양성 검체 검사 시 (민감도 85%), | 95% 구간에서 민감도 80%, 특이도 75%, 로 설정한다.  |\n| (7) 「의료기기의 전자파 안전에 관한 공통기준규격」(식약처 고시) | 피험자 : | Unknown)”과 같이 분명한 이유를 기록하여 주십시오. ",
        "original_sentence": "| ① 인구학적 정보: 성명, 나이, 성별, 임신 유무 | 검체를 준비한다. "
      }
    },
    {
      "chunk_id": "chunk_216",
      "text": "| 따라 폐기됩니다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 215,
        "window_size": 3,
        "char_count": 12,
        "word_count": 3,
        "page_number": 87,
        "window_text": "| - 대립가설: 개발제품의 특이도가 80% 이상이다.  |\n| 번호 | 안전성 평가 항목 | 관련 표준 또는 적용 규격 |\n| (1) 오염된 제품이나 사용한 제품은 병원의 규정에 의거하여 폐기한다.  | ① 인구학적 정보: 성명, 나이, 성별, 임신 유무 | 검체를 준비한다.  | 따라 폐기됩니다.  | - 제품의 보관방법 및 유효기간 | (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests | ① EPI test 양성 검체 검사 시 (민감도 85%), | 95% 구간에서 민감도 80%, 특이도 75%, 로 설정한다.  |\n| (7) 「의료기기의 전자파 안전에 관한 공통기준규격」(식약처 고시) | 피험자 : | Unknown)”과 같이 분명한 이유를 기록하여 주십시오.  |\n| - 본체: 혈소판의 형상변화, 응집 과정을 측정하는 기기 | 자발적 의사에 의해 |\n| ① Aspirin test 양성 검체 검사 시 (민감도 90%), | - 귀무가설: 개발제품의 특이도가 80% 미만이다. ",
        "original_sentence": "| 따라 폐기됩니다. "
      }
    },
    {
      "chunk_id": "chunk_217",
      "text": "| - 제품의 보관방법 및 유효기간 | (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests | ① EPI test 양성 검체 검사 시 (민감도 85%), | 95% 구간에서 민감도 80%, 특이도 75%, 로 설정한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 216,
        "window_size": 3,
        "char_count": 131,
        "word_count": 29,
        "page_number": 6,
        "window_text": "|\n| 번호 | 안전성 평가 항목 | 관련 표준 또는 적용 규격 |\n| (1) 오염된 제품이나 사용한 제품은 병원의 규정에 의거하여 폐기한다.  | ① 인구학적 정보: 성명, 나이, 성별, 임신 유무 | 검체를 준비한다.  | 따라 폐기됩니다.  | - 제품의 보관방법 및 유효기간 | (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests | ① EPI test 양성 검체 검사 시 (민감도 85%), | 95% 구간에서 민감도 80%, 특이도 75%, 로 설정한다.  |\n| (7) 「의료기기의 전자파 안전에 관한 공통기준규격」(식약처 고시) | 피험자 : | Unknown)”과 같이 분명한 이유를 기록하여 주십시오.  |\n| - 본체: 혈소판의 형상변화, 응집 과정을 측정하는 기기 | 자발적 의사에 의해 |\n| ① Aspirin test 양성 검체 검사 시 (민감도 90%), | - 귀무가설: 개발제품의 특이도가 80% 미만이다.  | - Sample Size (5% 탈락률 적용) = 131.71, 약 132개 검체 |\n| 다. ",
        "original_sentence": "| - 제품의 보관방법 및 유효기간 | (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests | ① EPI test 양성 검체 검사 시 (민감도 85%), | 95% 구간에서 민감도 80%, 특이도 75%, 로 설정한다. "
      }
    },
    {
      "chunk_id": "chunk_218",
      "text": "|\n| (7) 「의료기기의 전자파 안전에 관한 공통기준규격」(식약처 고시) | 피험자 : | Unknown)”과 같이 분명한 이유를 기록하여 주십시오. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 217,
        "window_size": 3,
        "char_count": 85,
        "word_count": 19,
        "page_number": 5,
        "window_text": "| ① 인구학적 정보: 성명, 나이, 성별, 임신 유무 | 검체를 준비한다.  | 따라 폐기됩니다.  | - 제품의 보관방법 및 유효기간 | (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests | ① EPI test 양성 검체 검사 시 (민감도 85%), | 95% 구간에서 민감도 80%, 특이도 75%, 로 설정한다.  |\n| (7) 「의료기기의 전자파 안전에 관한 공통기준규격」(식약처 고시) | 피험자 : | Unknown)”과 같이 분명한 이유를 기록하여 주십시오.  |\n| - 본체: 혈소판의 형상변화, 응집 과정을 측정하는 기기 | 자발적 의사에 의해 |\n| ① Aspirin test 양성 검체 검사 시 (민감도 90%), | - 귀무가설: 개발제품의 특이도가 80% 미만이다.  | - Sample Size (5% 탈락률 적용) = 131.71, 약 132개 검체 |\n| 다.  배정방법: 비무작위 배정 | ② 병력조사 :출혈성 질환, 응고장애, 암, 기타 만성질환 등 | 임상시험의 경우 의료기기 제조업자(수입자를 포함한다)를 말한다. ",
        "original_sentence": "|\n| (7) 「의료기기의 전자파 안전에 관한 공통기준규격」(식약처 고시) | 피험자 : | Unknown)”과 같이 분명한 이유를 기록하여 주십시오. "
      }
    },
    {
      "chunk_id": "chunk_219",
      "text": "|\n| - 본체: 혈소판의 형상변화, 응집 과정을 측정하는 기기 | 자발적 의사에 의해 |\n| ① Aspirin test 양성 검체 검사 시 (민감도 90%), | - 귀무가설: 개발제품의 특이도가 80% 미만이다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 218,
        "window_size": 3,
        "char_count": 121,
        "word_count": 32,
        "page_number": 23,
        "window_text": "| 따라 폐기됩니다.  | - 제품의 보관방법 및 유효기간 | (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests | ① EPI test 양성 검체 검사 시 (민감도 85%), | 95% 구간에서 민감도 80%, 특이도 75%, 로 설정한다.  |\n| (7) 「의료기기의 전자파 안전에 관한 공통기준규격」(식약처 고시) | 피험자 : | Unknown)”과 같이 분명한 이유를 기록하여 주십시오.  |\n| - 본체: 혈소판의 형상변화, 응집 과정을 측정하는 기기 | 자발적 의사에 의해 |\n| ① Aspirin test 양성 검체 검사 시 (민감도 90%), | - 귀무가설: 개발제품의 특이도가 80% 미만이다.  | - Sample Size (5% 탈락률 적용) = 131.71, 약 132개 검체 |\n| 다.  배정방법: 비무작위 배정 | ② 병력조사 :출혈성 질환, 응고장애, 암, 기타 만성질환 등 | 임상시험의 경우 의료기기 제조업자(수입자를 포함한다)를 말한다.  | 정보들은 기밀로 보관되어야 한다. ",
        "original_sentence": "|\n| - 본체: 혈소판의 형상변화, 응집 과정을 측정하는 기기 | 자발적 의사에 의해 |\n| ① Aspirin test 양성 검체 검사 시 (민감도 90%), | - 귀무가설: 개발제품의 특이도가 80% 미만이다. "
      }
    },
    {
      "chunk_id": "chunk_220",
      "text": "| - Sample Size (5% 탈락률 적용) = 131.71, 약 132개 검체 |\n| 다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 219,
        "window_size": 3,
        "char_count": 55,
        "word_count": 15,
        "page_number": 6,
        "window_text": "| - 제품의 보관방법 및 유효기간 | (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests | ① EPI test 양성 검체 검사 시 (민감도 85%), | 95% 구간에서 민감도 80%, 특이도 75%, 로 설정한다.  |\n| (7) 「의료기기의 전자파 안전에 관한 공통기준규격」(식약처 고시) | 피험자 : | Unknown)”과 같이 분명한 이유를 기록하여 주십시오.  |\n| - 본체: 혈소판의 형상변화, 응집 과정을 측정하는 기기 | 자발적 의사에 의해 |\n| ① Aspirin test 양성 검체 검사 시 (민감도 90%), | - 귀무가설: 개발제품의 특이도가 80% 미만이다.  | - Sample Size (5% 탈락률 적용) = 131.71, 약 132개 검체 |\n| 다.  배정방법: 비무작위 배정 | ② 병력조사 :출혈성 질환, 응고장애, 암, 기타 만성질환 등 | 임상시험의 경우 의료기기 제조업자(수입자를 포함한다)를 말한다.  | 정보들은 기밀로 보관되어야 한다.  | 4. ",
        "original_sentence": "| - Sample Size (5% 탈락률 적용) = 131.71, 약 132개 검체 |\n| 다. "
      }
    },
    {
      "chunk_id": "chunk_221",
      "text": "배정방법: 비무작위 배정 | ② 병력조사 :출혈성 질환, 응고장애, 암, 기타 만성질환 등 | 임상시험의 경우 의료기기 제조업자(수입자를 포함한다)를 말한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 220,
        "window_size": 3,
        "char_count": 89,
        "word_count": 20,
        "page_number": 23,
        "window_text": "|\n| (7) 「의료기기의 전자파 안전에 관한 공통기준규격」(식약처 고시) | 피험자 : | Unknown)”과 같이 분명한 이유를 기록하여 주십시오.  |\n| - 본체: 혈소판의 형상변화, 응집 과정을 측정하는 기기 | 자발적 의사에 의해 |\n| ① Aspirin test 양성 검체 검사 시 (민감도 90%), | - 귀무가설: 개발제품의 특이도가 80% 미만이다.  | - Sample Size (5% 탈락률 적용) = 131.71, 약 132개 검체 |\n| 다.  배정방법: 비무작위 배정 | ② 병력조사 :출혈성 질환, 응고장애, 암, 기타 만성질환 등 | 임상시험의 경우 의료기기 제조업자(수입자를 포함한다)를 말한다.  | 정보들은 기밀로 보관되어야 한다.  | 4.  출혈시간 및 항혈소판제제 저항성 복합검사기기 관련국내 | - 미개봉: 2~8℃, 제조일로부터 12개월 | - 대립가설: 개발제품의 민감도가 85% 이상이다. ",
        "original_sentence": "배정방법: 비무작위 배정 | ② 병력조사 :출혈성 질환, 응고장애, 암, 기타 만성질환 등 | 임상시험의 경우 의료기기 제조업자(수입자를 포함한다)를 말한다. "
      }
    },
    {
      "chunk_id": "chunk_222",
      "text": "| 정보들은 기밀로 보관되어야 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 221,
        "window_size": 3,
        "char_count": 21,
        "word_count": 5,
        "page_number": 24,
        "window_text": "|\n| - 본체: 혈소판의 형상변화, 응집 과정을 측정하는 기기 | 자발적 의사에 의해 |\n| ① Aspirin test 양성 검체 검사 시 (민감도 90%), | - 귀무가설: 개발제품의 특이도가 80% 미만이다.  | - Sample Size (5% 탈락률 적용) = 131.71, 약 132개 검체 |\n| 다.  배정방법: 비무작위 배정 | ② 병력조사 :출혈성 질환, 응고장애, 암, 기타 만성질환 등 | 임상시험의 경우 의료기기 제조업자(수입자를 포함한다)를 말한다.  | 정보들은 기밀로 보관되어야 한다.  | 4.  출혈시간 및 항혈소판제제 저항성 복합검사기기 관련국내 | - 미개봉: 2~8℃, 제조일로부터 12개월 | - 대립가설: 개발제품의 민감도가 85% 이상이다.  |\n| 6) 서명은 반드시 시험책임자 혹은 시험 담당자가 서명하여 주십시오. ",
        "original_sentence": "| 정보들은 기밀로 보관되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_223",
      "text": "| 4. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 222,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 15,
        "window_text": "| - Sample Size (5% 탈락률 적용) = 131.71, 약 132개 검체 |\n| 다.  배정방법: 비무작위 배정 | ② 병력조사 :출혈성 질환, 응고장애, 암, 기타 만성질환 등 | 임상시험의 경우 의료기기 제조업자(수입자를 포함한다)를 말한다.  | 정보들은 기밀로 보관되어야 한다.  | 4.  출혈시간 및 항혈소판제제 저항성 복합검사기기 관련국내 | - 미개봉: 2~8℃, 제조일로부터 12개월 | - 대립가설: 개발제품의 민감도가 85% 이상이다.  |\n| 6) 서명은 반드시 시험책임자 혹은 시험 담당자가 서명하여 주십시오.  | (4) 시험 조건 | 관리를 위한 기준물질 및 보정물질의 개발이 필요하다. ",
        "original_sentence": "| 4. "
      }
    },
    {
      "chunk_id": "chunk_224",
      "text": "출혈시간 및 항혈소판제제 저항성 복합검사기기 관련국내 | - 미개봉: 2~8℃, 제조일로부터 12개월 | - 대립가설: 개발제품의 민감도가 85% 이상이다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 223,
        "window_size": 3,
        "char_count": 88,
        "word_count": 19,
        "page_number": 1,
        "window_text": "배정방법: 비무작위 배정 | ② 병력조사 :출혈성 질환, 응고장애, 암, 기타 만성질환 등 | 임상시험의 경우 의료기기 제조업자(수입자를 포함한다)를 말한다.  | 정보들은 기밀로 보관되어야 한다.  | 4.  출혈시간 및 항혈소판제제 저항성 복합검사기기 관련국내 | - 미개봉: 2~8℃, 제조일로부터 12개월 | - 대립가설: 개발제품의 민감도가 85% 이상이다.  |\n| 6) 서명은 반드시 시험책임자 혹은 시험 담당자가 서명하여 주십시오.  | (4) 시험 조건 | 관리를 위한 기준물질 및 보정물질의 개발이 필요하다.  | 함께 기재함. ",
        "original_sentence": "출혈시간 및 항혈소판제제 저항성 복합검사기기 관련국내 | - 미개봉: 2~8℃, 제조일로부터 12개월 | - 대립가설: 개발제품의 민감도가 85% 이상이다. "
      }
    },
    {
      "chunk_id": "chunk_225",
      "text": "|\n| 6) 서명은 반드시 시험책임자 혹은 시험 담당자가 서명하여 주십시오. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 224,
        "window_size": 3,
        "char_count": 43,
        "word_count": 11,
        "page_number": 3,
        "window_text": "| 정보들은 기밀로 보관되어야 한다.  | 4.  출혈시간 및 항혈소판제제 저항성 복합검사기기 관련국내 | - 미개봉: 2~8℃, 제조일로부터 12개월 | - 대립가설: 개발제품의 민감도가 85% 이상이다.  |\n| 6) 서명은 반드시 시험책임자 혹은 시험 담당자가 서명하여 주십시오.  | (4) 시험 조건 | 관리를 위한 기준물질 및 보정물질의 개발이 필요하다.  | 함께 기재함.  | 시험군과 대조군간의 비교분석방법을 통계적으로 타당하게 제시함. ",
        "original_sentence": "|\n| 6) 서명은 반드시 시험책임자 혹은 시험 담당자가 서명하여 주십시오. "
      }
    },
    {
      "chunk_id": "chunk_226",
      "text": "| (4) 시험 조건 | 관리를 위한 기준물질 및 보정물질의 개발이 필요하다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 225,
        "window_size": 3,
        "char_count": 44,
        "word_count": 12,
        "page_number": 7,
        "window_text": "| 4.  출혈시간 및 항혈소판제제 저항성 복합검사기기 관련국내 | - 미개봉: 2~8℃, 제조일로부터 12개월 | - 대립가설: 개발제품의 민감도가 85% 이상이다.  |\n| 6) 서명은 반드시 시험책임자 혹은 시험 담당자가 서명하여 주십시오.  | (4) 시험 조건 | 관리를 위한 기준물질 및 보정물질의 개발이 필요하다.  | 함께 기재함.  | 시험군과 대조군간의 비교분석방법을 통계적으로 타당하게 제시함.  | (6) 결과 제시 | - 시험장비 | 이동거리 값을 구한다. ",
        "original_sentence": "| (4) 시험 조건 | 관리를 위한 기준물질 및 보정물질의 개발이 필요하다. "
      }
    },
    {
      "chunk_id": "chunk_227",
      "text": "| 함께 기재함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 226,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 41,
        "window_text": "출혈시간 및 항혈소판제제 저항성 복합검사기기 관련국내 | - 미개봉: 2~8℃, 제조일로부터 12개월 | - 대립가설: 개발제품의 민감도가 85% 이상이다.  |\n| 6) 서명은 반드시 시험책임자 혹은 시험 담당자가 서명하여 주십시오.  | (4) 시험 조건 | 관리를 위한 기준물질 및 보정물질의 개발이 필요하다.  | 함께 기재함.  | 시험군과 대조군간의 비교분석방법을 통계적으로 타당하게 제시함.  | (6) 결과 제시 | - 시험장비 | 이동거리 값을 구한다.  |\n| (8) 「의료기기의 안정성시험 기준」(식약처 고시) | (2) 적용 범위 : 혈소판 기능이상 검사 키트에 적용한다. ",
        "original_sentence": "| 함께 기재함. "
      }
    },
    {
      "chunk_id": "chunk_228",
      "text": "| 시험군과 대조군간의 비교분석방법을 통계적으로 타당하게 제시함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 227,
        "window_size": 3,
        "char_count": 37,
        "word_count": 7,
        "page_number": 9,
        "window_text": "|\n| 6) 서명은 반드시 시험책임자 혹은 시험 담당자가 서명하여 주십시오.  | (4) 시험 조건 | 관리를 위한 기준물질 및 보정물질의 개발이 필요하다.  | 함께 기재함.  | 시험군과 대조군간의 비교분석방법을 통계적으로 타당하게 제시함.  | (6) 결과 제시 | - 시험장비 | 이동거리 값을 구한다.  |\n| (8) 「의료기기의 안정성시험 기준」(식약처 고시) | (2) 적용 범위 : 혈소판 기능이상 검사 키트에 적용한다.  | 적용범위 등을 작성함. ",
        "original_sentence": "| 시험군과 대조군간의 비교분석방법을 통계적으로 타당하게 제시함. "
      }
    },
    {
      "chunk_id": "chunk_229",
      "text": "| (6) 결과 제시 | - 시험장비 | 이동거리 값을 구한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 228,
        "window_size": 3,
        "char_count": 36,
        "word_count": 11,
        "page_number": 9,
        "window_text": "| (4) 시험 조건 | 관리를 위한 기준물질 및 보정물질의 개발이 필요하다.  | 함께 기재함.  | 시험군과 대조군간의 비교분석방법을 통계적으로 타당하게 제시함.  | (6) 결과 제시 | - 시험장비 | 이동거리 값을 구한다.  |\n| (8) 「의료기기의 안정성시험 기준」(식약처 고시) | (2) 적용 범위 : 혈소판 기능이상 검사 키트에 적용한다.  | 적용범위 등을 작성함.  | 임상시험에 대한 | ① Tray(검사칩 삽입부): 검사칩을 올려놓고 여닫을 수 있는 Tray |\n**“검체”라는 용어로 부릅니다.",
        "original_sentence": "| (6) 결과 제시 | - 시험장비 | 이동거리 값을 구한다. "
      }
    },
    {
      "chunk_id": "chunk_230",
      "text": "|\n| (8) 「의료기기의 안정성시험 기준」(식약처 고시) | (2) 적용 범위 : 혈소판 기능이상 검사 키트에 적용한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 229,
        "window_size": 3,
        "char_count": 69,
        "word_count": 17,
        "page_number": 5,
        "window_text": "| 함께 기재함.  | 시험군과 대조군간의 비교분석방법을 통계적으로 타당하게 제시함.  | (6) 결과 제시 | - 시험장비 | 이동거리 값을 구한다.  |\n| (8) 「의료기기의 안정성시험 기준」(식약처 고시) | (2) 적용 범위 : 혈소판 기능이상 검사 키트에 적용한다.  | 적용범위 등을 작성함.  | 임상시험에 대한 | ① Tray(검사칩 삽입부): 검사칩을 올려놓고 여닫을 수 있는 Tray |\n**“검체”라는 용어로 부릅니다. **\n| Aspirin test | 73.5% | 93.2% | ④ P2Y12 test 음성 검체 검사 시 (특이도 75%), | 부작용 증세가 발생할 수 있다. ",
        "original_sentence": "|\n| (8) 「의료기기의 안정성시험 기준」(식약처 고시) | (2) 적용 범위 : 혈소판 기능이상 검사 키트에 적용한다. "
      }
    },
    {
      "chunk_id": "chunk_231",
      "text": "| 적용범위 등을 작성함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 230,
        "window_size": 3,
        "char_count": 15,
        "word_count": 4,
        "page_number": 89,
        "window_text": "| 시험군과 대조군간의 비교분석방법을 통계적으로 타당하게 제시함.  | (6) 결과 제시 | - 시험장비 | 이동거리 값을 구한다.  |\n| (8) 「의료기기의 안정성시험 기준」(식약처 고시) | (2) 적용 범위 : 혈소판 기능이상 검사 키트에 적용한다.  | 적용범위 등을 작성함.  | 임상시험에 대한 | ① Tray(검사칩 삽입부): 검사칩을 올려놓고 여닫을 수 있는 Tray |\n**“검체”라는 용어로 부릅니다. **\n| Aspirin test | 73.5% | 93.2% | ④ P2Y12 test 음성 검체 검사 시 (특이도 75%), | 부작용 증세가 발생할 수 있다.  | - 대립가설: 개발제품의 민감도가 90% 이상이다. ",
        "original_sentence": "| 적용범위 등을 작성함. "
      }
    },
    {
      "chunk_id": "chunk_232",
      "text": "| 임상시험에 대한 | ① Tray(검사칩 삽입부): 검사칩을 올려놓고 여닫을 수 있는 Tray |\n**“검체”라는 용어로 부릅니다.",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 231,
        "window_size": 3,
        "char_count": 74,
        "word_count": 17,
        "page_number": 9,
        "window_text": "| (6) 결과 제시 | - 시험장비 | 이동거리 값을 구한다.  |\n| (8) 「의료기기의 안정성시험 기준」(식약처 고시) | (2) 적용 범위 : 혈소판 기능이상 검사 키트에 적용한다.  | 적용범위 등을 작성함.  | 임상시험에 대한 | ① Tray(검사칩 삽입부): 검사칩을 올려놓고 여닫을 수 있는 Tray |\n**“검체”라는 용어로 부릅니다. **\n| Aspirin test | 73.5% | 93.2% | ④ P2Y12 test 음성 검체 검사 시 (특이도 75%), | 부작용 증세가 발생할 수 있다.  | - 대립가설: 개발제품의 민감도가 90% 이상이다.  |\n| - 본체 | - 적용 계산식 :  |     |\n| 참여를 거부한 경우 | Clin Lab Sci 2009;39:289-94. ",
        "original_sentence": "| 임상시험에 대한 | ① Tray(검사칩 삽입부): 검사칩을 올려놓고 여닫을 수 있는 Tray |\n**“검체”라는 용어로 부릅니다."
      }
    },
    {
      "chunk_id": "chunk_233",
      "text": "**\n| Aspirin test | 73.5% | 93.2% | ④ P2Y12 test 음성 검체 검사 시 (특이도 75%), | 부작용 증세가 발생할 수 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 232,
        "window_size": 3,
        "char_count": 91,
        "word_count": 24,
        "page_number": 6,
        "window_text": "|\n| (8) 「의료기기의 안정성시험 기준」(식약처 고시) | (2) 적용 범위 : 혈소판 기능이상 검사 키트에 적용한다.  | 적용범위 등을 작성함.  | 임상시험에 대한 | ① Tray(검사칩 삽입부): 검사칩을 올려놓고 여닫을 수 있는 Tray |\n**“검체”라는 용어로 부릅니다. **\n| Aspirin test | 73.5% | 93.2% | ④ P2Y12 test 음성 검체 검사 시 (특이도 75%), | 부작용 증세가 발생할 수 있다.  | - 대립가설: 개발제품의 민감도가 90% 이상이다.  |\n| - 본체 | - 적용 계산식 :  |     |\n| 참여를 거부한 경우 | Clin Lab Sci 2009;39:289-94.  | 번호를 부여한다. ",
        "original_sentence": "**\n| Aspirin test | 73.5% | 93.2% | ④ P2Y12 test 음성 검체 검사 시 (특이도 75%), | 부작용 증세가 발생할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_234",
      "text": "| - 대립가설: 개발제품의 민감도가 90% 이상이다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 233,
        "window_size": 3,
        "char_count": 31,
        "word_count": 7,
        "page_number": 7,
        "window_text": "| 적용범위 등을 작성함.  | 임상시험에 대한 | ① Tray(검사칩 삽입부): 검사칩을 올려놓고 여닫을 수 있는 Tray |\n**“검체”라는 용어로 부릅니다. **\n| Aspirin test | 73.5% | 93.2% | ④ P2Y12 test 음성 검체 검사 시 (특이도 75%), | 부작용 증세가 발생할 수 있다.  | - 대립가설: 개발제품의 민감도가 90% 이상이다.  |\n| - 본체 | - 적용 계산식 :  |     |\n| 참여를 거부한 경우 | Clin Lab Sci 2009;39:289-94.  | 번호를 부여한다.  스크리닝 번호는 다음과 같이 구성된다. ",
        "original_sentence": "| - 대립가설: 개발제품의 민감도가 90% 이상이다. "
      }
    },
    {
      "chunk_id": "chunk_235",
      "text": "|\n| - 본체 | - 적용 계산식 :  |     |\n| 참여를 거부한 경우 | Clin Lab Sci 2009;39:289-94. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 234,
        "window_size": 3,
        "char_count": 85,
        "word_count": 25,
        "page_number": 23,
        "window_text": "| 임상시험에 대한 | ① Tray(검사칩 삽입부): 검사칩을 올려놓고 여닫을 수 있는 Tray |\n**“검체”라는 용어로 부릅니다. **\n| Aspirin test | 73.5% | 93.2% | ④ P2Y12 test 음성 검체 검사 시 (특이도 75%), | 부작용 증세가 발생할 수 있다.  | - 대립가설: 개발제품의 민감도가 90% 이상이다.  |\n| - 본체 | - 적용 계산식 :  |     |\n| 참여를 거부한 경우 | Clin Lab Sci 2009;39:289-94.  | 번호를 부여한다.  스크리닝 번호는 다음과 같이 구성된다.  | 대한 평가기준을 제시하여야 함. ",
        "original_sentence": "|\n| - 본체 | - 적용 계산식 :  |     |\n| 참여를 거부한 경우 | Clin Lab Sci 2009;39:289-94. "
      }
    },
    {
      "chunk_id": "chunk_236",
      "text": "| 번호를 부여한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 235,
        "window_size": 3,
        "char_count": 12,
        "word_count": 3,
        "page_number": 15,
        "window_text": "**\n| Aspirin test | 73.5% | 93.2% | ④ P2Y12 test 음성 검체 검사 시 (특이도 75%), | 부작용 증세가 발생할 수 있다.  | - 대립가설: 개발제품의 민감도가 90% 이상이다.  |\n| - 본체 | - 적용 계산식 :  |     |\n| 참여를 거부한 경우 | Clin Lab Sci 2009;39:289-94.  | 번호를 부여한다.  스크리닝 번호는 다음과 같이 구성된다.  | 대한 평가기준을 제시하여야 함.  | 해당 임상시험을 적절하게 실시할 수 있도록 하여야 한다. ",
        "original_sentence": "| 번호를 부여한다. "
      }
    },
    {
      "chunk_id": "chunk_237",
      "text": "스크리닝 번호는 다음과 같이 구성된다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 236,
        "window_size": 3,
        "char_count": 22,
        "word_count": 5,
        "page_number": 15,
        "window_text": "| - 대립가설: 개발제품의 민감도가 90% 이상이다.  |\n| - 본체 | - 적용 계산식 :  |     |\n| 참여를 거부한 경우 | Clin Lab Sci 2009;39:289-94.  | 번호를 부여한다.  스크리닝 번호는 다음과 같이 구성된다.  | 대한 평가기준을 제시하여야 함.  | 해당 임상시험을 적절하게 실시할 수 있도록 하여야 한다.  | - 개봉 | - 귀무가설: 개발제품의 민감도가 85% 미만이다. ",
        "original_sentence": "스크리닝 번호는 다음과 같이 구성된다. "
      }
    },
    {
      "chunk_id": "chunk_238",
      "text": "| 대한 평가기준을 제시하여야 함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 237,
        "window_size": 3,
        "char_count": 20,
        "word_count": 5,
        "page_number": 83,
        "window_text": "|\n| - 본체 | - 적용 계산식 :  |     |\n| 참여를 거부한 경우 | Clin Lab Sci 2009;39:289-94.  | 번호를 부여한다.  스크리닝 번호는 다음과 같이 구성된다.  | 대한 평가기준을 제시하여야 함.  | 해당 임상시험을 적절하게 실시할 수 있도록 하여야 한다.  | - 개봉 | - 귀무가설: 개발제품의 민감도가 85% 미만이다.  |\n| (9) 「의료기기 제조 및 품질관리 기준」(식약처 고시) | 나. P2Y12 test | 측정된 이동거리의 평균을 구하여 비교대상으로 설정한다. ",
        "original_sentence": "| 대한 평가기준을 제시하여야 함. "
      }
    },
    {
      "chunk_id": "chunk_239",
      "text": "| 해당 임상시험을 적절하게 실시할 수 있도록 하여야 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 238,
        "window_size": 3,
        "char_count": 34,
        "word_count": 9,
        "page_number": 9,
        "window_text": "| 번호를 부여한다.  스크리닝 번호는 다음과 같이 구성된다.  | 대한 평가기준을 제시하여야 함.  | 해당 임상시험을 적절하게 실시할 수 있도록 하여야 한다.  | - 개봉 | - 귀무가설: 개발제품의 민감도가 85% 미만이다.  |\n| (9) 「의료기기 제조 및 품질관리 기준」(식약처 고시) | 나. P2Y12 test | 측정된 이동거리의 평균을 구하여 비교대상으로 설정한다.  | 1 | - 시험물질 | 나는 인위적인 증가나 감소 |\n| 8.3.1 피험자 수 | 회사명 | 대표이사 | 소재지 | 전화 | use – EMC requirements – Part 1: General requirements |\n| (1) 혈관미주신경 반응 | - 귀무가설: 개발제품의 민감도가 90% 미만이다. ",
        "original_sentence": "| 해당 임상시험을 적절하게 실시할 수 있도록 하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_240",
      "text": "| - 개봉 | - 귀무가설: 개발제품의 민감도가 85% 미만이다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 239,
        "window_size": 3,
        "char_count": 38,
        "word_count": 10,
        "page_number": 6,
        "window_text": "스크리닝 번호는 다음과 같이 구성된다.  | 대한 평가기준을 제시하여야 함.  | 해당 임상시험을 적절하게 실시할 수 있도록 하여야 한다.  | - 개봉 | - 귀무가설: 개발제품의 민감도가 85% 미만이다.  |\n| (9) 「의료기기 제조 및 품질관리 기준」(식약처 고시) | 나. P2Y12 test | 측정된 이동거리의 평균을 구하여 비교대상으로 설정한다.  | 1 | - 시험물질 | 나는 인위적인 증가나 감소 |\n| 8.3.1 피험자 수 | 회사명 | 대표이사 | 소재지 | 전화 | use – EMC requirements – Part 1: General requirements |\n| (1) 혈관미주신경 반응 | - 귀무가설: 개발제품의 민감도가 90% 미만이다.  | - 대립가설: 개발제품의 특이도가 75% 이상이다. ",
        "original_sentence": "| - 개봉 | - 귀무가설: 개발제품의 민감도가 85% 미만이다. "
      }
    },
    {
      "chunk_id": "chunk_241",
      "text": "|\n| (9) 「의료기기 제조 및 품질관리 기준」(식약처 고시) | 나. P2Y12 test | 측정된 이동거리의 평균을 구하여 비교대상으로 설정한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 240,
        "window_size": 3,
        "char_count": 85,
        "word_count": 20,
        "page_number": 5,
        "window_text": "| 대한 평가기준을 제시하여야 함.  | 해당 임상시험을 적절하게 실시할 수 있도록 하여야 한다.  | - 개봉 | - 귀무가설: 개발제품의 민감도가 85% 미만이다.  |\n| (9) 「의료기기 제조 및 품질관리 기준」(식약처 고시) | 나. P2Y12 test | 측정된 이동거리의 평균을 구하여 비교대상으로 설정한다.  | 1 | - 시험물질 | 나는 인위적인 증가나 감소 |\n| 8.3.1 피험자 수 | 회사명 | 대표이사 | 소재지 | 전화 | use – EMC requirements – Part 1: General requirements |\n| (1) 혈관미주신경 반응 | - 귀무가설: 개발제품의 민감도가 90% 미만이다.  | - 대립가설: 개발제품의 특이도가 75% 이상이다.  |\n| 14.2.2. ",
        "original_sentence": "|\n| (9) 「의료기기 제조 및 품질관리 기준」(식약처 고시) | 나. P2Y12 test | 측정된 이동거리의 평균을 구하여 비교대상으로 설정한다. "
      }
    },
    {
      "chunk_id": "chunk_242",
      "text": "| 1 | - 시험물질 | 나는 인위적인 증가나 감소 |\n| 8.3.1 피험자 수 | 회사명 | 대표이사 | 소재지 | 전화 | use – EMC requirements – Part 1: General requirements |\n| (1) 혈관미주신경 반응 | - 귀무가설: 개발제품의 민감도가 90% 미만이다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 241,
        "window_size": 3,
        "char_count": 175,
        "word_count": 45,
        "page_number": 6,
        "window_text": "| 해당 임상시험을 적절하게 실시할 수 있도록 하여야 한다.  | - 개봉 | - 귀무가설: 개발제품의 민감도가 85% 미만이다.  |\n| (9) 「의료기기 제조 및 품질관리 기준」(식약처 고시) | 나. P2Y12 test | 측정된 이동거리의 평균을 구하여 비교대상으로 설정한다.  | 1 | - 시험물질 | 나는 인위적인 증가나 감소 |\n| 8.3.1 피험자 수 | 회사명 | 대표이사 | 소재지 | 전화 | use – EMC requirements – Part 1: General requirements |\n| (1) 혈관미주신경 반응 | - 귀무가설: 개발제품의 민감도가 90% 미만이다.  | - 대립가설: 개발제품의 특이도가 75% 이상이다.  |\n| 14.2.2.  혈소판 약물반응 검사 | 모델명: ○○○ |\n| 눈가림, 단일설계, 전향적 비교확증임상시험 | 특이도, 일치도를 평가하여 임상적 유효성을 검증하고자 한다. ",
        "original_sentence": "| 1 | - 시험물질 | 나는 인위적인 증가나 감소 |\n| 8.3.1 피험자 수 | 회사명 | 대표이사 | 소재지 | 전화 | use – EMC requirements – Part 1: General requirements |\n| (1) 혈관미주신경 반응 | - 귀무가설: 개발제품의 민감도가 90% 미만이다. "
      }
    },
    {
      "chunk_id": "chunk_243",
      "text": "| - 대립가설: 개발제품의 특이도가 75% 이상이다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 242,
        "window_size": 3,
        "char_count": 31,
        "word_count": 7,
        "page_number": 6,
        "window_text": "| - 개봉 | - 귀무가설: 개발제품의 민감도가 85% 미만이다.  |\n| (9) 「의료기기 제조 및 품질관리 기준」(식약처 고시) | 나. P2Y12 test | 측정된 이동거리의 평균을 구하여 비교대상으로 설정한다.  | 1 | - 시험물질 | 나는 인위적인 증가나 감소 |\n| 8.3.1 피험자 수 | 회사명 | 대표이사 | 소재지 | 전화 | use – EMC requirements – Part 1: General requirements |\n| (1) 혈관미주신경 반응 | - 귀무가설: 개발제품의 민감도가 90% 미만이다.  | - 대립가설: 개발제품의 특이도가 75% 이상이다.  |\n| 14.2.2.  혈소판 약물반응 검사 | 모델명: ○○○ |\n| 눈가림, 단일설계, 전향적 비교확증임상시험 | 특이도, 일치도를 평가하여 임상적 유효성을 검증하고자 한다.  | 라. ",
        "original_sentence": "| - 대립가설: 개발제품의 특이도가 75% 이상이다. "
      }
    },
    {
      "chunk_id": "chunk_244",
      "text": "|\n| 14.2.2. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 243,
        "window_size": 3,
        "char_count": 12,
        "word_count": 3,
        "page_number": 6,
        "window_text": "|\n| (9) 「의료기기 제조 및 품질관리 기준」(식약처 고시) | 나. P2Y12 test | 측정된 이동거리의 평균을 구하여 비교대상으로 설정한다.  | 1 | - 시험물질 | 나는 인위적인 증가나 감소 |\n| 8.3.1 피험자 수 | 회사명 | 대표이사 | 소재지 | 전화 | use – EMC requirements – Part 1: General requirements |\n| (1) 혈관미주신경 반응 | - 귀무가설: 개발제품의 민감도가 90% 미만이다.  | - 대립가설: 개발제품의 특이도가 75% 이상이다.  |\n| 14.2.2.  혈소판 약물반응 검사 | 모델명: ○○○ |\n| 눈가림, 단일설계, 전향적 비교확증임상시험 | 특이도, 일치도를 평가하여 임상적 유효성을 검증하고자 한다.  | 라.  비열등성 검정 | 다. ",
        "original_sentence": "|\n| 14.2.2. "
      }
    },
    {
      "chunk_id": "chunk_245",
      "text": "혈소판 약물반응 검사 | 모델명: ○○○ |\n| 눈가림, 단일설계, 전향적 비교확증임상시험 | 특이도, 일치도를 평가하여 임상적 유효성을 검증하고자 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 244,
        "window_size": 3,
        "char_count": 87,
        "word_count": 20,
        "page_number": 9,
        "window_text": "| 1 | - 시험물질 | 나는 인위적인 증가나 감소 |\n| 8.3.1 피험자 수 | 회사명 | 대표이사 | 소재지 | 전화 | use – EMC requirements – Part 1: General requirements |\n| (1) 혈관미주신경 반응 | - 귀무가설: 개발제품의 민감도가 90% 미만이다.  | - 대립가설: 개발제품의 특이도가 75% 이상이다.  |\n| 14.2.2.  혈소판 약물반응 검사 | 모델명: ○○○ |\n| 눈가림, 단일설계, 전향적 비교확증임상시험 | 특이도, 일치도를 평가하여 임상적 유효성을 검증하고자 한다.  | 라.  비열등성 검정 | 다.  관찰항목 검사(평가) 방법 | 14.2.1. ",
        "original_sentence": "혈소판 약물반응 검사 | 모델명: ○○○ |\n| 눈가림, 단일설계, 전향적 비교확증임상시험 | 특이도, 일치도를 평가하여 임상적 유효성을 검증하고자 한다. "
      }
    },
    {
      "chunk_id": "chunk_246",
      "text": "| 라. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 245,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 33,
        "window_text": "| - 대립가설: 개발제품의 특이도가 75% 이상이다.  |\n| 14.2.2.  혈소판 약물반응 검사 | 모델명: ○○○ |\n| 눈가림, 단일설계, 전향적 비교확증임상시험 | 특이도, 일치도를 평가하여 임상적 유효성을 검증하고자 한다.  | 라.  비열등성 검정 | 다.  관찰항목 검사(평가) 방법 | 14.2.1.  혈소판 기능 검사 | ④ CBC 결과 (혈색소, 헤마토크릿, 혈소판수 등) | - 스크리닝 | 번호: SXX(XX:일련번호), 예)S01,02,03………… | 절차에 따라 이루어지도록 하여야 한다. ",
        "original_sentence": "| 라. "
      }
    },
    {
      "chunk_id": "chunk_247",
      "text": "비열등성 검정 | 다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 246,
        "window_size": 3,
        "char_count": 13,
        "word_count": 4,
        "page_number": 1,
        "window_text": "|\n| 14.2.2.  혈소판 약물반응 검사 | 모델명: ○○○ |\n| 눈가림, 단일설계, 전향적 비교확증임상시험 | 특이도, 일치도를 평가하여 임상적 유효성을 검증하고자 한다.  | 라.  비열등성 검정 | 다.  관찰항목 검사(평가) 방법 | 14.2.1.  혈소판 기능 검사 | ④ CBC 결과 (혈색소, 헤마토크릿, 혈소판수 등) | - 스크리닝 | 번호: SXX(XX:일련번호), 예)S01,02,03………… | 절차에 따라 이루어지도록 하여야 한다.  | 시험기기 | 식별코드(일반적으로 피험자 이니셜)로 기록하고 구분한다. ",
        "original_sentence": "비열등성 검정 | 다. "
      }
    },
    {
      "chunk_id": "chunk_248",
      "text": "관찰항목 검사(평가) 방법 | 14.2.1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 247,
        "window_size": 3,
        "char_count": 25,
        "word_count": 5,
        "page_number": 6,
        "window_text": "혈소판 약물반응 검사 | 모델명: ○○○ |\n| 눈가림, 단일설계, 전향적 비교확증임상시험 | 특이도, 일치도를 평가하여 임상적 유효성을 검증하고자 한다.  | 라.  비열등성 검정 | 다.  관찰항목 검사(평가) 방법 | 14.2.1.  혈소판 기능 검사 | ④ CBC 결과 (혈색소, 헤마토크릿, 혈소판수 등) | - 스크리닝 | 번호: SXX(XX:일련번호), 예)S01,02,03………… | 절차에 따라 이루어지도록 하여야 한다.  | 시험기기 | 식별코드(일반적으로 피험자 이니셜)로 기록하고 구분한다.  |\n**(10)「의료기기 표시**\n\n**[표 끝]**\n\n<!-- PAGE_6 -->\n## 목\n\n<!-- PAGE_6 -->\n## 차\n\n<!-- PAGE_6 -->\n##### Ⅰ. ",
        "original_sentence": "관찰항목 검사(평가) 방법 | 14.2.1. "
      }
    },
    {
      "chunk_id": "chunk_249",
      "text": "혈소판 기능 검사 | ④ CBC 결과 (혈색소, 헤마토크릿, 혈소판수 등) | - 스크리닝 | 번호: SXX(XX:일련번호), 예)S01,02,03………… | 절차에 따라 이루어지도록 하여야 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 248,
        "window_size": 3,
        "char_count": 111,
        "word_count": 24,
        "page_number": 33,
        "window_text": "| 라.  비열등성 검정 | 다.  관찰항목 검사(평가) 방법 | 14.2.1.  혈소판 기능 검사 | ④ CBC 결과 (혈색소, 헤마토크릿, 혈소판수 등) | - 스크리닝 | 번호: SXX(XX:일련번호), 예)S01,02,03………… | 절차에 따라 이루어지도록 하여야 한다.  | 시험기기 | 식별코드(일반적으로 피험자 이니셜)로 기록하고 구분한다.  |\n**(10)「의료기기 표시**\n\n**[표 끝]**\n\n<!-- PAGE_6 -->\n## 목\n\n<!-- PAGE_6 -->\n## 차\n\n<!-- PAGE_6 -->\n##### Ⅰ.  안전성·성능 평가\n\n<!-- PAGE_6 -->\n###### 1\n\n<!-- PAGE_6 -->\n###### 1. ",
        "original_sentence": "혈소판 기능 검사 | ④ CBC 결과 (혈색소, 헤마토크릿, 혈소판수 등) | - 스크리닝 | 번호: SXX(XX:일련번호), 예)S01,02,03………… | 절차에 따라 이루어지도록 하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_250",
      "text": "| 시험기기 | 식별코드(일반적으로 피험자 이니셜)로 기록하고 구분한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 249,
        "window_size": 3,
        "char_count": 41,
        "word_count": 8,
        "page_number": 3,
        "window_text": "비열등성 검정 | 다.  관찰항목 검사(평가) 방법 | 14.2.1.  혈소판 기능 검사 | ④ CBC 결과 (혈색소, 헤마토크릿, 혈소판수 등) | - 스크리닝 | 번호: SXX(XX:일련번호), 예)S01,02,03………… | 절차에 따라 이루어지도록 하여야 한다.  | 시험기기 | 식별코드(일반적으로 피험자 이니셜)로 기록하고 구분한다.  |\n**(10)「의료기기 표시**\n\n**[표 끝]**\n\n<!-- PAGE_6 -->\n## 목\n\n<!-- PAGE_6 -->\n## 차\n\n<!-- PAGE_6 -->\n##### Ⅰ.  안전성·성능 평가\n\n<!-- PAGE_6 -->\n###### 1\n\n<!-- PAGE_6 -->\n###### 1.  적용 범위\n\n<!-- PAGE_6 -->\n###### 1\n\n<!-- PAGE_6 -->\n###### 2. ",
        "original_sentence": "| 시험기기 | 식별코드(일반적으로 피험자 이니셜)로 기록하고 구분한다. "
      }
    },
    {
      "chunk_id": "chunk_251",
      "text": "|\n**(10)「의료기기 표시**\n\n**[표 끝]**\n\n<!-- PAGE_6 -->\n## 목\n\n<!-- PAGE_6 -->\n## 차\n\n<!-- PAGE_6 -->\n##### Ⅰ. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 250,
        "window_size": 3,
        "char_count": 100,
        "word_count": 20,
        "page_number": 6,
        "window_text": "관찰항목 검사(평가) 방법 | 14.2.1.  혈소판 기능 검사 | ④ CBC 결과 (혈색소, 헤마토크릿, 혈소판수 등) | - 스크리닝 | 번호: SXX(XX:일련번호), 예)S01,02,03………… | 절차에 따라 이루어지도록 하여야 한다.  | 시험기기 | 식별코드(일반적으로 피험자 이니셜)로 기록하고 구분한다.  |\n**(10)「의료기기 표시**\n\n**[표 끝]**\n\n<!-- PAGE_6 -->\n## 목\n\n<!-- PAGE_6 -->\n## 차\n\n<!-- PAGE_6 -->\n##### Ⅰ.  안전성·성능 평가\n\n<!-- PAGE_6 -->\n###### 1\n\n<!-- PAGE_6 -->\n###### 1.  적용 범위\n\n<!-- PAGE_6 -->\n###### 1\n\n<!-- PAGE_6 -->\n###### 2.  약어 및 용어 정리\n\n<!-- PAGE_6 -->\n###### 2\n\n<!-- PAGE_6 -->\n###### 3. ",
        "original_sentence": "|\n**(10)「의료기기 표시**\n\n**[표 끝]**\n\n<!-- PAGE_6 -->\n## 목\n\n<!-- PAGE_6 -->\n## 차\n\n<!-- PAGE_6 -->\n##### Ⅰ. "
      }
    },
    {
      "chunk_id": "chunk_252",
      "text": "안전성·성능 평가\n\n<!-- PAGE_6 -->\n###### 1\n\n<!-- PAGE_6 -->\n###### 1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 251,
        "window_size": 3,
        "char_count": 63,
        "word_count": 12,
        "page_number": 6,
        "window_text": "혈소판 기능 검사 | ④ CBC 결과 (혈색소, 헤마토크릿, 혈소판수 등) | - 스크리닝 | 번호: SXX(XX:일련번호), 예)S01,02,03………… | 절차에 따라 이루어지도록 하여야 한다.  | 시험기기 | 식별코드(일반적으로 피험자 이니셜)로 기록하고 구분한다.  |\n**(10)「의료기기 표시**\n\n**[표 끝]**\n\n<!-- PAGE_6 -->\n## 목\n\n<!-- PAGE_6 -->\n## 차\n\n<!-- PAGE_6 -->\n##### Ⅰ.  안전성·성능 평가\n\n<!-- PAGE_6 -->\n###### 1\n\n<!-- PAGE_6 -->\n###### 1.  적용 범위\n\n<!-- PAGE_6 -->\n###### 1\n\n<!-- PAGE_6 -->\n###### 2.  약어 및 용어 정리\n\n<!-- PAGE_6 -->\n###### 2\n\n<!-- PAGE_6 -->\n###### 3.  출혈시간 및 항혈소판제제 저항성 복합검사기기정의 및 분류\n\n<!-- PAGE_6 -->\n###### 5\n\n<!-- PAGE_6 -->\n###### 5. ",
        "original_sentence": "안전성·성능 평가\n\n<!-- PAGE_6 -->\n###### 1\n\n<!-- PAGE_6 -->\n###### 1. "
      }
    },
    {
      "chunk_id": "chunk_253",
      "text": "적용 범위\n\n<!-- PAGE_6 -->\n###### 1\n\n<!-- PAGE_6 -->\n###### 2. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 252,
        "window_size": 3,
        "char_count": 59,
        "word_count": 12,
        "page_number": 6,
        "window_text": "| 시험기기 | 식별코드(일반적으로 피험자 이니셜)로 기록하고 구분한다.  |\n**(10)「의료기기 표시**\n\n**[표 끝]**\n\n<!-- PAGE_6 -->\n## 목\n\n<!-- PAGE_6 -->\n## 차\n\n<!-- PAGE_6 -->\n##### Ⅰ.  안전성·성능 평가\n\n<!-- PAGE_6 -->\n###### 1\n\n<!-- PAGE_6 -->\n###### 1.  적용 범위\n\n<!-- PAGE_6 -->\n###### 1\n\n<!-- PAGE_6 -->\n###### 2.  약어 및 용어 정리\n\n<!-- PAGE_6 -->\n###### 2\n\n<!-- PAGE_6 -->\n###### 3.  출혈시간 및 항혈소판제제 저항성 복합검사기기정의 및 분류\n\n<!-- PAGE_6 -->\n###### 5\n\n<!-- PAGE_6 -->\n###### 5.  안전성 평가 항목\n\n<!-- PAGE_6 -->\n###### 11\n\n<!-- PAGE_6 -->\n###### 6. ",
        "original_sentence": "적용 범위\n\n<!-- PAGE_6 -->\n###### 1\n\n<!-- PAGE_6 -->\n###### 2. "
      }
    },
    {
      "chunk_id": "chunk_254",
      "text": "약어 및 용어 정리\n\n<!-- PAGE_6 -->\n###### 2\n\n<!-- PAGE_6 -->\n###### 3. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 253,
        "window_size": 3,
        "char_count": 64,
        "word_count": 14,
        "page_number": 6,
        "window_text": "|\n**(10)「의료기기 표시**\n\n**[표 끝]**\n\n<!-- PAGE_6 -->\n## 목\n\n<!-- PAGE_6 -->\n## 차\n\n<!-- PAGE_6 -->\n##### Ⅰ.  안전성·성능 평가\n\n<!-- PAGE_6 -->\n###### 1\n\n<!-- PAGE_6 -->\n###### 1.  적용 범위\n\n<!-- PAGE_6 -->\n###### 1\n\n<!-- PAGE_6 -->\n###### 2.  약어 및 용어 정리\n\n<!-- PAGE_6 -->\n###### 2\n\n<!-- PAGE_6 -->\n###### 3.  출혈시간 및 항혈소판제제 저항성 복합검사기기정의 및 분류\n\n<!-- PAGE_6 -->\n###### 5\n\n<!-- PAGE_6 -->\n###### 5.  안전성 평가 항목\n\n<!-- PAGE_6 -->\n###### 11\n\n<!-- PAGE_6 -->\n###### 6.  분석적 성능 평가 항목\n\n<!-- PAGE_6 -->\n###### 14\n\n<!-- PAGE_6 -->\n###### 7. ",
        "original_sentence": "약어 및 용어 정리\n\n<!-- PAGE_6 -->\n###### 2\n\n<!-- PAGE_6 -->\n###### 3. "
      }
    },
    {
      "chunk_id": "chunk_255",
      "text": "출혈시간 및 항혈소판제제 저항성 복합검사기기정의 및 분류\n\n<!-- PAGE_6 -->\n###### 5\n\n<!-- PAGE_6 -->\n###### 5. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 254,
        "window_size": 3,
        "char_count": 85,
        "word_count": 17,
        "page_number": 6,
        "window_text": "안전성·성능 평가\n\n<!-- PAGE_6 -->\n###### 1\n\n<!-- PAGE_6 -->\n###### 1.  적용 범위\n\n<!-- PAGE_6 -->\n###### 1\n\n<!-- PAGE_6 -->\n###### 2.  약어 및 용어 정리\n\n<!-- PAGE_6 -->\n###### 2\n\n<!-- PAGE_6 -->\n###### 3.  출혈시간 및 항혈소판제제 저항성 복합검사기기정의 및 분류\n\n<!-- PAGE_6 -->\n###### 5\n\n<!-- PAGE_6 -->\n###### 5.  안전성 평가 항목\n\n<!-- PAGE_6 -->\n###### 11\n\n<!-- PAGE_6 -->\n###### 6.  분석적 성능 평가 항목\n\n<!-- PAGE_6 -->\n###### 14\n\n<!-- PAGE_6 -->\n###### 7.  안정성 평가 항목\n\n<!-- PAGE_6 -->\n###### 23\n\n<!-- PAGE_6 -->\n###### 8. ",
        "original_sentence": "출혈시간 및 항혈소판제제 저항성 복합검사기기정의 및 분류\n\n<!-- PAGE_6 -->\n###### 5\n\n<!-- PAGE_6 -->\n###### 5. "
      }
    },
    {
      "chunk_id": "chunk_256",
      "text": "안전성 평가 항목\n\n<!-- PAGE_6 -->\n###### 11\n\n<!-- PAGE_6 -->\n###### 6. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 255,
        "window_size": 3,
        "char_count": 64,
        "word_count": 13,
        "page_number": 6,
        "window_text": "적용 범위\n\n<!-- PAGE_6 -->\n###### 1\n\n<!-- PAGE_6 -->\n###### 2.  약어 및 용어 정리\n\n<!-- PAGE_6 -->\n###### 2\n\n<!-- PAGE_6 -->\n###### 3.  출혈시간 및 항혈소판제제 저항성 복합검사기기정의 및 분류\n\n<!-- PAGE_6 -->\n###### 5\n\n<!-- PAGE_6 -->\n###### 5.  안전성 평가 항목\n\n<!-- PAGE_6 -->\n###### 11\n\n<!-- PAGE_6 -->\n###### 6.  분석적 성능 평가 항목\n\n<!-- PAGE_6 -->\n###### 14\n\n<!-- PAGE_6 -->\n###### 7.  안정성 평가 항목\n\n<!-- PAGE_6 -->\n###### 23\n\n<!-- PAGE_6 -->\n###### 8.  참고 문헌\n\n<!-- PAGE_6 -->\n###### 26\n\n<!-- PAGE_6 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_6 -->\n###### 27\n\n<!-- PAGE_6 -->\n##### Ⅱ. ",
        "original_sentence": "안전성 평가 항목\n\n<!-- PAGE_6 -->\n###### 11\n\n<!-- PAGE_6 -->\n###### 6. "
      }
    },
    {
      "chunk_id": "chunk_257",
      "text": "분석적 성능 평가 항목\n\n<!-- PAGE_6 -->\n###### 14\n\n<!-- PAGE_6 -->\n###### 7. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 256,
        "window_size": 3,
        "char_count": 67,
        "word_count": 14,
        "page_number": 6,
        "window_text": "약어 및 용어 정리\n\n<!-- PAGE_6 -->\n###### 2\n\n<!-- PAGE_6 -->\n###### 3.  출혈시간 및 항혈소판제제 저항성 복합검사기기정의 및 분류\n\n<!-- PAGE_6 -->\n###### 5\n\n<!-- PAGE_6 -->\n###### 5.  안전성 평가 항목\n\n<!-- PAGE_6 -->\n###### 11\n\n<!-- PAGE_6 -->\n###### 6.  분석적 성능 평가 항목\n\n<!-- PAGE_6 -->\n###### 14\n\n<!-- PAGE_6 -->\n###### 7.  안정성 평가 항목\n\n<!-- PAGE_6 -->\n###### 23\n\n<!-- PAGE_6 -->\n###### 8.  참고 문헌\n\n<!-- PAGE_6 -->\n###### 26\n\n<!-- PAGE_6 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_6 -->\n###### 27\n\n<!-- PAGE_6 -->\n##### Ⅱ.  임상시험계획서 작성 및 평가\n\n<!-- PAGE_6 -->\n###### 28\n\n<!-- PAGE_7 -->\n##### 개\n\n<!-- PAGE_7 -->\n##### 요\n\n<!-- PAGE_7 -->\n###### 식품의약품안전처는 정부지원과제 중 제품화가 임박한 제품에 대한\n\n<!-- PAGE_7 -->\n###### 시험방법 개발, 안전성·성능 평가, 임상시험계획서의 선제적 제공을 통한\n\n<!-- PAGE_7 -->\n###### 제품화 지원체계 구축을 위하여 「융복합 신개발의료기기 제품화 지원을\n\n<!-- PAGE_7 -->\n###### 위한 사업」을 진행하고 있다.\n\n",
        "original_sentence": "분석적 성능 평가 항목\n\n<!-- PAGE_6 -->\n###### 14\n\n<!-- PAGE_6 -->\n###### 7. "
      }
    },
    {
      "chunk_id": "chunk_258",
      "text": "안정성 평가 항목\n\n<!-- PAGE_6 -->\n###### 23\n\n<!-- PAGE_6 -->\n###### 8. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 257,
        "window_size": 3,
        "char_count": 64,
        "word_count": 13,
        "page_number": 6,
        "window_text": "출혈시간 및 항혈소판제제 저항성 복합검사기기정의 및 분류\n\n<!-- PAGE_6 -->\n###### 5\n\n<!-- PAGE_6 -->\n###### 5.  안전성 평가 항목\n\n<!-- PAGE_6 -->\n###### 11\n\n<!-- PAGE_6 -->\n###### 6.  분석적 성능 평가 항목\n\n<!-- PAGE_6 -->\n###### 14\n\n<!-- PAGE_6 -->\n###### 7.  안정성 평가 항목\n\n<!-- PAGE_6 -->\n###### 23\n\n<!-- PAGE_6 -->\n###### 8.  참고 문헌\n\n<!-- PAGE_6 -->\n###### 26\n\n<!-- PAGE_6 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_6 -->\n###### 27\n\n<!-- PAGE_6 -->\n##### Ⅱ.  임상시험계획서 작성 및 평가\n\n<!-- PAGE_6 -->\n###### 28\n\n<!-- PAGE_7 -->\n##### 개\n\n<!-- PAGE_7 -->\n##### 요\n\n<!-- PAGE_7 -->\n###### 식품의약품안전처는 정부지원과제 중 제품화가 임박한 제품에 대한\n\n<!-- PAGE_7 -->\n###### 시험방법 개발, 안전성·성능 평가, 임상시험계획서의 선제적 제공을 통한\n\n<!-- PAGE_7 -->\n###### 제품화 지원체계 구축을 위하여 「융복합 신개발의료기기 제품화 지원을\n\n<!-- PAGE_7 -->\n###### 위한 사업」을 진행하고 있다.\n\n <!-- PAGE_7 -->\n###### 본 가이드라인은 ‘16년 「융복합 신개발의료기기 제품화 지원을 위한\n\n<!-- PAGE_7 -->\n###### 사업」의 결과물이며, 주요 내용으로 “출혈시간 및 항혈소판제제 저항성\n\n<!-- PAGE_7 -->\n###### 복합검사기기”의 안전성 및 성능평가방법, 임상시험계획서 작성 및\n\n<!-- PAGE_7 -->\n###### 평가방법과 관련된 사항을 구체적으로 제시하여 신속제품화를 위한\n\n<!-- PAGE_7 -->\n###### 맞춤형 기술지원을 목적으로 하는 가이드라인이다.\n\n",
        "original_sentence": "안정성 평가 항목\n\n<!-- PAGE_6 -->\n###### 23\n\n<!-- PAGE_6 -->\n###### 8. "
      }
    },
    {
      "chunk_id": "chunk_259",
      "text": "참고 문헌\n\n<!-- PAGE_6 -->\n###### 26\n\n<!-- PAGE_6 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_6 -->\n###### 27\n\n<!-- PAGE_6 -->\n##### Ⅱ. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 258,
        "window_size": 3,
        "char_count": 125,
        "word_count": 24,
        "page_number": 6,
        "window_text": "안전성 평가 항목\n\n<!-- PAGE_6 -->\n###### 11\n\n<!-- PAGE_6 -->\n###### 6.  분석적 성능 평가 항목\n\n<!-- PAGE_6 -->\n###### 14\n\n<!-- PAGE_6 -->\n###### 7.  안정성 평가 항목\n\n<!-- PAGE_6 -->\n###### 23\n\n<!-- PAGE_6 -->\n###### 8.  참고 문헌\n\n<!-- PAGE_6 -->\n###### 26\n\n<!-- PAGE_6 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_6 -->\n###### 27\n\n<!-- PAGE_6 -->\n##### Ⅱ.  임상시험계획서 작성 및 평가\n\n<!-- PAGE_6 -->\n###### 28\n\n<!-- PAGE_7 -->\n##### 개\n\n<!-- PAGE_7 -->\n##### 요\n\n<!-- PAGE_7 -->\n###### 식품의약품안전처는 정부지원과제 중 제품화가 임박한 제품에 대한\n\n<!-- PAGE_7 -->\n###### 시험방법 개발, 안전성·성능 평가, 임상시험계획서의 선제적 제공을 통한\n\n<!-- PAGE_7 -->\n###### 제품화 지원체계 구축을 위하여 「융복합 신개발의료기기 제품화 지원을\n\n<!-- PAGE_7 -->\n###### 위한 사업」을 진행하고 있다.\n\n <!-- PAGE_7 -->\n###### 본 가이드라인은 ‘16년 「융복합 신개발의료기기 제품화 지원을 위한\n\n<!-- PAGE_7 -->\n###### 사업」의 결과물이며, 주요 내용으로 “출혈시간 및 항혈소판제제 저항성\n\n<!-- PAGE_7 -->\n###### 복합검사기기”의 안전성 및 성능평가방법, 임상시험계획서 작성 및\n\n<!-- PAGE_7 -->\n###### 평가방법과 관련된 사항을 구체적으로 제시하여 신속제품화를 위한\n\n<!-- PAGE_7 -->\n###### 맞춤형 기술지원을 목적으로 하는 가이드라인이다.\n\n - - 1 -\n<!-- PAGE_8 -->\n##### Ⅰ\n\n<!-- PAGE_8 -->\n##### 안전성·성능 평가\n\n<!-- PAGE_8 -->\n###### 1. ",
        "original_sentence": "참고 문헌\n\n<!-- PAGE_6 -->\n###### 26\n\n<!-- PAGE_6 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_6 -->\n###### 27\n\n<!-- PAGE_6 -->\n##### Ⅱ. "
      }
    },
    {
      "chunk_id": "chunk_260",
      "text": "임상시험계획서 작성 및 평가\n\n<!-- PAGE_6 -->\n###### 28\n\n<!-- PAGE_7 -->\n##### 개\n\n<!-- PAGE_7 -->\n##### 요\n\n<!-- PAGE_7 -->\n###### 식품의약품안전처는 정부지원과제 중 제품화가 임박한 제품에 대한\n\n<!-- PAGE_7 -->\n###### 시험방법 개발, 안전성·성능 평가, 임상시험계획서의 선제적 제공을 통한\n\n<!-- PAGE_7 -->\n###### 제품화 지원체계 구축을 위하여 「융복합 신개발의료기기 제품화 지원을\n\n<!-- PAGE_7 -->\n###### 위한 사업」을 진행하고 있다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 259,
        "window_size": 3,
        "char_count": 320,
        "word_count": 62,
        "page_number": 6,
        "window_text": "분석적 성능 평가 항목\n\n<!-- PAGE_6 -->\n###### 14\n\n<!-- PAGE_6 -->\n###### 7.  안정성 평가 항목\n\n<!-- PAGE_6 -->\n###### 23\n\n<!-- PAGE_6 -->\n###### 8.  참고 문헌\n\n<!-- PAGE_6 -->\n###### 26\n\n<!-- PAGE_6 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_6 -->\n###### 27\n\n<!-- PAGE_6 -->\n##### Ⅱ.  임상시험계획서 작성 및 평가\n\n<!-- PAGE_6 -->\n###### 28\n\n<!-- PAGE_7 -->\n##### 개\n\n<!-- PAGE_7 -->\n##### 요\n\n<!-- PAGE_7 -->\n###### 식품의약품안전처는 정부지원과제 중 제품화가 임박한 제품에 대한\n\n<!-- PAGE_7 -->\n###### 시험방법 개발, 안전성·성능 평가, 임상시험계획서의 선제적 제공을 통한\n\n<!-- PAGE_7 -->\n###### 제품화 지원체계 구축을 위하여 「융복합 신개발의료기기 제품화 지원을\n\n<!-- PAGE_7 -->\n###### 위한 사업」을 진행하고 있다.\n\n <!-- PAGE_7 -->\n###### 본 가이드라인은 ‘16년 「융복합 신개발의료기기 제품화 지원을 위한\n\n<!-- PAGE_7 -->\n###### 사업」의 결과물이며, 주요 내용으로 “출혈시간 및 항혈소판제제 저항성\n\n<!-- PAGE_7 -->\n###### 복합검사기기”의 안전성 및 성능평가방법, 임상시험계획서 작성 및\n\n<!-- PAGE_7 -->\n###### 평가방법과 관련된 사항을 구체적으로 제시하여 신속제품화를 위한\n\n<!-- PAGE_7 -->\n###### 맞춤형 기술지원을 목적으로 하는 가이드라인이다.\n\n - - 1 -\n<!-- PAGE_8 -->\n##### Ⅰ\n\n<!-- PAGE_8 -->\n##### 안전성·성능 평가\n\n<!-- PAGE_8 -->\n###### 1.  적용범위\n\n<!-- PAGE_8 -->\n###### 본 가이드라인은 출혈시간 및 항혈소판제제 저항성 복합검사기기의\n\n<!-- PAGE_8 -->\n###### 분석적 성능 평가와 안정성에 대한 평가방법을 구축하여 신개발 융복합\n\n<!-- PAGE_8 -->\n###### 의료기기의 평가방법을 제시하고자 한다.\n\n",
        "original_sentence": "임상시험계획서 작성 및 평가\n\n<!-- PAGE_6 -->\n###### 28\n\n<!-- PAGE_7 -->\n##### 개\n\n<!-- PAGE_7 -->\n##### 요\n\n<!-- PAGE_7 -->\n###### 식품의약품안전처는 정부지원과제 중 제품화가 임박한 제품에 대한\n\n<!-- PAGE_7 -->\n###### 시험방법 개발, 안전성·성능 평가, 임상시험계획서의 선제적 제공을 통한\n\n<!-- PAGE_7 -->\n###### 제품화 지원체계 구축을 위하여 「융복합 신개발의료기기 제품화 지원을\n\n<!-- PAGE_7 -->\n###### 위한 사업」을 진행하고 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_261",
      "text": "<!-- PAGE_7 -->\n###### 본 가이드라인은 ‘16년 「융복합 신개발의료기기 제품화 지원을 위한\n\n<!-- PAGE_7 -->\n###### 사업」의 결과물이며, 주요 내용으로 “출혈시간 및 항혈소판제제 저항성\n\n<!-- PAGE_7 -->\n###### 복합검사기기”의 안전성 및 성능평가방법, 임상시험계획서 작성 및\n\n<!-- PAGE_7 -->\n###### 평가방법과 관련된 사항을 구체적으로 제시하여 신속제품화를 위한\n\n<!-- PAGE_7 -->\n###### 맞춤형 기술지원을 목적으로 하는 가이드라인이다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 260,
        "window_size": 3,
        "char_count": 295,
        "word_count": 55,
        "page_number": 7,
        "window_text": "안정성 평가 항목\n\n<!-- PAGE_6 -->\n###### 23\n\n<!-- PAGE_6 -->\n###### 8.  참고 문헌\n\n<!-- PAGE_6 -->\n###### 26\n\n<!-- PAGE_6 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_6 -->\n###### 27\n\n<!-- PAGE_6 -->\n##### Ⅱ.  임상시험계획서 작성 및 평가\n\n<!-- PAGE_6 -->\n###### 28\n\n<!-- PAGE_7 -->\n##### 개\n\n<!-- PAGE_7 -->\n##### 요\n\n<!-- PAGE_7 -->\n###### 식품의약품안전처는 정부지원과제 중 제품화가 임박한 제품에 대한\n\n<!-- PAGE_7 -->\n###### 시험방법 개발, 안전성·성능 평가, 임상시험계획서의 선제적 제공을 통한\n\n<!-- PAGE_7 -->\n###### 제품화 지원체계 구축을 위하여 「융복합 신개발의료기기 제품화 지원을\n\n<!-- PAGE_7 -->\n###### 위한 사업」을 진행하고 있다.\n\n <!-- PAGE_7 -->\n###### 본 가이드라인은 ‘16년 「융복합 신개발의료기기 제품화 지원을 위한\n\n<!-- PAGE_7 -->\n###### 사업」의 결과물이며, 주요 내용으로 “출혈시간 및 항혈소판제제 저항성\n\n<!-- PAGE_7 -->\n###### 복합검사기기”의 안전성 및 성능평가방법, 임상시험계획서 작성 및\n\n<!-- PAGE_7 -->\n###### 평가방법과 관련된 사항을 구체적으로 제시하여 신속제품화를 위한\n\n<!-- PAGE_7 -->\n###### 맞춤형 기술지원을 목적으로 하는 가이드라인이다.\n\n - - 1 -\n<!-- PAGE_8 -->\n##### Ⅰ\n\n<!-- PAGE_8 -->\n##### 안전성·성능 평가\n\n<!-- PAGE_8 -->\n###### 1.  적용범위\n\n<!-- PAGE_8 -->\n###### 본 가이드라인은 출혈시간 및 항혈소판제제 저항성 복합검사기기의\n\n<!-- PAGE_8 -->\n###### 분석적 성능 평가와 안정성에 대한 평가방법을 구축하여 신개발 융복합\n\n<!-- PAGE_8 -->\n###### 의료기기의 평가방법을 제시하고자 한다.\n\n 출혈시간 및 항혈소판제제 저항성 복합검사기기는 『의료기기 품목 및\n\n<!-- PAGE_8 -->\n###### 품목별 등급에 관한 규정』의 분류에 따라 “혈액응고검사시약 D01050.01\n\n<!-- PAGE_8 -->\n###### (3등급)”과 “자동혈소판응집측정장치 A22290.01(1등급)”로 분류되고 있다.\n\n",
        "original_sentence": "<!-- PAGE_7 -->\n###### 본 가이드라인은 ‘16년 「융복합 신개발의료기기 제품화 지원을 위한\n\n<!-- PAGE_7 -->\n###### 사업」의 결과물이며, 주요 내용으로 “출혈시간 및 항혈소판제제 저항성\n\n<!-- PAGE_7 -->\n###### 복합검사기기”의 안전성 및 성능평가방법, 임상시험계획서 작성 및\n\n<!-- PAGE_7 -->\n###### 평가방법과 관련된 사항을 구체적으로 제시하여 신속제품화를 위한\n\n<!-- PAGE_7 -->\n###### 맞춤형 기술지원을 목적으로 하는 가이드라인이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_262",
      "text": "- - 1 -\n<!-- PAGE_8 -->\n##### Ⅰ\n\n<!-- PAGE_8 -->\n##### 안전성·성능 평가\n\n<!-- PAGE_8 -->\n###### 1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 261,
        "window_size": 3,
        "char_count": 92,
        "word_count": 20,
        "page_number": 8,
        "window_text": "참고 문헌\n\n<!-- PAGE_6 -->\n###### 26\n\n<!-- PAGE_6 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_6 -->\n###### 27\n\n<!-- PAGE_6 -->\n##### Ⅱ.  임상시험계획서 작성 및 평가\n\n<!-- PAGE_6 -->\n###### 28\n\n<!-- PAGE_7 -->\n##### 개\n\n<!-- PAGE_7 -->\n##### 요\n\n<!-- PAGE_7 -->\n###### 식품의약품안전처는 정부지원과제 중 제품화가 임박한 제품에 대한\n\n<!-- PAGE_7 -->\n###### 시험방법 개발, 안전성·성능 평가, 임상시험계획서의 선제적 제공을 통한\n\n<!-- PAGE_7 -->\n###### 제품화 지원체계 구축을 위하여 「융복합 신개발의료기기 제품화 지원을\n\n<!-- PAGE_7 -->\n###### 위한 사업」을 진행하고 있다.\n\n <!-- PAGE_7 -->\n###### 본 가이드라인은 ‘16년 「융복합 신개발의료기기 제품화 지원을 위한\n\n<!-- PAGE_7 -->\n###### 사업」의 결과물이며, 주요 내용으로 “출혈시간 및 항혈소판제제 저항성\n\n<!-- PAGE_7 -->\n###### 복합검사기기”의 안전성 및 성능평가방법, 임상시험계획서 작성 및\n\n<!-- PAGE_7 -->\n###### 평가방법과 관련된 사항을 구체적으로 제시하여 신속제품화를 위한\n\n<!-- PAGE_7 -->\n###### 맞춤형 기술지원을 목적으로 하는 가이드라인이다.\n\n - - 1 -\n<!-- PAGE_8 -->\n##### Ⅰ\n\n<!-- PAGE_8 -->\n##### 안전성·성능 평가\n\n<!-- PAGE_8 -->\n###### 1.  적용범위\n\n<!-- PAGE_8 -->\n###### 본 가이드라인은 출혈시간 및 항혈소판제제 저항성 복합검사기기의\n\n<!-- PAGE_8 -->\n###### 분석적 성능 평가와 안정성에 대한 평가방법을 구축하여 신개발 융복합\n\n<!-- PAGE_8 -->\n###### 의료기기의 평가방법을 제시하고자 한다.\n\n 출혈시간 및 항혈소판제제 저항성 복합검사기기는 『의료기기 품목 및\n\n<!-- PAGE_8 -->\n###### 품목별 등급에 관한 규정』의 분류에 따라 “혈액응고검사시약 D01050.01\n\n<!-- PAGE_8 -->\n###### (3등급)”과 “자동혈소판응집측정장치 A22290.01(1등급)”로 분류되고 있다.\n\n - - 2 -\n<!-- PAGE_9 -->\n###### 2. ",
        "original_sentence": "- - 1 -\n<!-- PAGE_8 -->\n##### Ⅰ\n\n<!-- PAGE_8 -->\n##### 안전성·성능 평가\n\n<!-- PAGE_8 -->\n###### 1. "
      }
    },
    {
      "chunk_id": "chunk_263",
      "text": "적용범위\n\n<!-- PAGE_8 -->\n###### 본 가이드라인은 출혈시간 및 항혈소판제제 저항성 복합검사기기의\n\n<!-- PAGE_8 -->\n###### 분석적 성능 평가와 안정성에 대한 평가방법을 구축하여 신개발 융복합\n\n<!-- PAGE_8 -->\n###### 의료기기의 평가방법을 제시하고자 한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 262,
        "window_size": 3,
        "char_count": 173,
        "word_count": 33,
        "page_number": 8,
        "window_text": "임상시험계획서 작성 및 평가\n\n<!-- PAGE_6 -->\n###### 28\n\n<!-- PAGE_7 -->\n##### 개\n\n<!-- PAGE_7 -->\n##### 요\n\n<!-- PAGE_7 -->\n###### 식품의약품안전처는 정부지원과제 중 제품화가 임박한 제품에 대한\n\n<!-- PAGE_7 -->\n###### 시험방법 개발, 안전성·성능 평가, 임상시험계획서의 선제적 제공을 통한\n\n<!-- PAGE_7 -->\n###### 제품화 지원체계 구축을 위하여 「융복합 신개발의료기기 제품화 지원을\n\n<!-- PAGE_7 -->\n###### 위한 사업」을 진행하고 있다.\n\n <!-- PAGE_7 -->\n###### 본 가이드라인은 ‘16년 「융복합 신개발의료기기 제품화 지원을 위한\n\n<!-- PAGE_7 -->\n###### 사업」의 결과물이며, 주요 내용으로 “출혈시간 및 항혈소판제제 저항성\n\n<!-- PAGE_7 -->\n###### 복합검사기기”의 안전성 및 성능평가방법, 임상시험계획서 작성 및\n\n<!-- PAGE_7 -->\n###### 평가방법과 관련된 사항을 구체적으로 제시하여 신속제품화를 위한\n\n<!-- PAGE_7 -->\n###### 맞춤형 기술지원을 목적으로 하는 가이드라인이다.\n\n - - 1 -\n<!-- PAGE_8 -->\n##### Ⅰ\n\n<!-- PAGE_8 -->\n##### 안전성·성능 평가\n\n<!-- PAGE_8 -->\n###### 1.  적용범위\n\n<!-- PAGE_8 -->\n###### 본 가이드라인은 출혈시간 및 항혈소판제제 저항성 복합검사기기의\n\n<!-- PAGE_8 -->\n###### 분석적 성능 평가와 안정성에 대한 평가방법을 구축하여 신개발 융복합\n\n<!-- PAGE_8 -->\n###### 의료기기의 평가방법을 제시하고자 한다.\n\n 출혈시간 및 항혈소판제제 저항성 복합검사기기는 『의료기기 품목 및\n\n<!-- PAGE_8 -->\n###### 품목별 등급에 관한 규정』의 분류에 따라 “혈액응고검사시약 D01050.01\n\n<!-- PAGE_8 -->\n###### (3등급)”과 “자동혈소판응집측정장치 A22290.01(1등급)”로 분류되고 있다.\n\n - - 2 -\n<!-- PAGE_9 -->\n###### 2.  약어 및 용어정리\n\n<!-- PAGE_9 -->\n###### (1) 가속노화시험 (Accelerated aging testing) : 제품의 실제 보관기간과\n\n<!-- PAGE_9 -->\n###### 상응되도록 짧은 기간 동안 시험하기 위하여 가혹한 온도조건 등에서\n\n<!-- PAGE_9 -->\n###### 의료기기의 화학적 또는 물리적 퇴보속도를 높이도록 계획한 안정성\n\n<!-- PAGE_9 -->\n###### (2) 간섭 (Interference) : 분석물질의 농도나 강도가 명백함에도 검출시약\n\n<!-- PAGE_9 -->\n###### 이나 신호 자체에 비특이적으로 반응하는 물질의 존재로 인해 일어\n\n<!-- PAGE_9 -->\n###### (3) 간섭물질 (Interfering substances) : 임상검체에 존재하는 내부물질\n\n<!-- PAGE_9 -->\n###### (예: 혈액 구성요소, acidic polysaccharides) 또는 외부물질(예: 항응고제 등)로\n\n<!-- PAGE_9 -->\n###### 위양성 또는 위음성 결과를 야기할 수 있는 물질\n\n<!-- PAGE_9 -->\n###### (4) 검출한계 (Limit of detection, LOD) : 검출될 수 있는 분석 물질의 최소량\n\n<!-- PAGE_9 -->\n###### (5) 공란한계 (Limit of blank, LOB) : blank 검체에서 관찰 가능할 수\n\n<!-- PAGE_9 -->\n###### (6) 교차반응 (Cross-reactivity) : 항원 이외에 공유 되었거나, 유사한 또는\n\n<!-- PAGE_9 -->\n###### 동일한 항원 결정기를 가진 항원과 항체가 반응하는 현상\n\n<!-- PAGE_9 -->\n###### (7) 대조물질 (Control / Control material) : 정도 관리를 위해 이용되는\n\n<!-- PAGE_9 -->\n###### 기기, 액체 또는 동결건조 물질\n\n<!-- PAGE_9 -->\n###### (8) 변동계수 (Coefficient of Variation, CV) : 표준편차의 크기를 평균치에\n\n<!-- PAGE_9 -->\n###### 대한 백분율로 나타낸 것\n\n<!-- PAGE_9 -->\n###### (9) 배치(Batch), 로트(Lot) : 특성이 균일하고 단일 또는 일련의 제조공정으로\n\n<!-- PAGE_9 -->\n###### 생산된 물질의 정의된 양\n\n- - 3 -\n<!-- PAGE_10 -->\n###### (10) 사용 시 안정성(In-use stability) : 제조사에서 제공한 용기를 개봉한\n\n<!-- PAGE_10 -->\n###### 이후에 사용자의 작동 조건에서 시약의 유효기간내의 검사수행능\n\n<!-- PAGE_10 -->\n###### (11) 사용기간(유효기간) (Shelf life) : 제조자가 특정한 저장조건 하에서\n\n<!-- PAGE_10 -->\n###### 최종 포장상태의 IVD 제품이 안정성을 유지하는 기간\n\n<!-- PAGE_10 -->\n###### (12) 신뢰구간 (Confidence interval) : 평균, 분율, 비율 등의 변수의 참값이\n\n<!-- PAGE_10 -->\n###### (13) 실시간 안정성(Real time stability) : IVD 제품을 제조자가 특정한\n\n<!-- PAGE_10 -->\n###### (14) 이동거리 (Migration Distance) : 검체가 카트리지에서 이동한 거리를\n\n<!-- PAGE_10 -->\n###### (15) 재현성 (Reproducibility) : 다른 측정조건에서 수행된 동일한 측정물의\n\n<!-- PAGE_10 -->\n###### (16) 정밀도 (Precision) : 규정된 조건 하에서 얻어진 독립적인 검사\n\n<!-- PAGE_10 -->\n###### ☞ 정밀도는 전형적으로 수치로 표현되지 않지만 비정밀도는 반복\n\n<!-- PAGE_10 -->\n###### 측정값 결과들의 ‘표준편차’ 또는 ‘변이계수’라는 용어로 정량적\n\n<!-- PAGE_10 -->\n###### (17) 정확도 (Accuracy) : 측정치와 참값 사이의 일치도\n\n<!-- PAGE_10 -->\n###### ☞ 평가대상 검사법에 의한 다수의 연속적인 결과값 들에서 얻은 평균값과\n\n<!-- PAGE_10 -->\n###### 공인된\n\n<!-- PAGE_10 -->\n###### 참고값(Accepted\n\n<!-- PAGE_10 -->\n###### reference\n\n<!-- PAGE_10 -->\n###### value)사이의\n\n<!-- PAGE_10 -->\n###### 일치\n\n<!-- PAGE_10 -->\n###### 근접도\n\n- - 4 -\n<!-- PAGE_11 -->\n###### (18) 직선성 (Linearity) : 실험 검체에 있는 분석물질의 농도[양]에 정비례\n\n<!-- PAGE_11 -->\n###### 하는 결과를 제공할 수 있는 능력\n\n<!-- PAGE_11 -->\n###### (19) 출혈시간(Bleeding time, BT) 검사 : 출혈시간 측정검사로 Duke법,\n\n<!-- PAGE_11 -->\n###### Ivy법, Template법 등을 이용하여 혈소판기능 선별검사로 사용\n\n<!-- PAGE_11 -->\n###### (20) 측정가능범위 (Analytical measurement range, AMR) : 일상적인\n\n<!-- PAGE_11 -->\n###### 측정 과정의 일부가 아닌 희석, 농축 또는 기타 전처리 없이 어떤\n\n<!-- PAGE_11 -->\n###### (21) 특이도 / 분석특이도 (Specificity / Analytical specificity) : 측정하고자\n\n<!-- PAGE_11 -->\n###### 하는 물질만 측정되고 검체 내 다른 물질은 측정 되지 않는 분석법의 능력\n\n<!-- PAGE_11 -->\n###### (22) 판정기준치 (Cut-off value) : 정성검사에서 경계치 이상을 양성으로,\n\n<!-- PAGE_11 -->\n###### 경계치 미만을 음성으로 보고할 수 있는 경계값을 말한다. ",
        "original_sentence": "적용범위\n\n<!-- PAGE_8 -->\n###### 본 가이드라인은 출혈시간 및 항혈소판제제 저항성 복합검사기기의\n\n<!-- PAGE_8 -->\n###### 분석적 성능 평가와 안정성에 대한 평가방법을 구축하여 신개발 융복합\n\n<!-- PAGE_8 -->\n###### 의료기기의 평가방법을 제시하고자 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_264",
      "text": "출혈시간 및 항혈소판제제 저항성 복합검사기기는 『의료기기 품목 및\n\n<!-- PAGE_8 -->\n###### 품목별 등급에 관한 규정』의 분류에 따라 “혈액응고검사시약 D01050.01\n\n<!-- PAGE_8 -->\n###### (3등급)”과 “자동혈소판응집측정장치 A22290.01(1등급)”로 분류되고 있다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 263,
        "window_size": 3,
        "char_count": 176,
        "word_count": 29,
        "page_number": 8,
        "window_text": "<!-- PAGE_7 -->\n###### 본 가이드라인은 ‘16년 「융복합 신개발의료기기 제품화 지원을 위한\n\n<!-- PAGE_7 -->\n###### 사업」의 결과물이며, 주요 내용으로 “출혈시간 및 항혈소판제제 저항성\n\n<!-- PAGE_7 -->\n###### 복합검사기기”의 안전성 및 성능평가방법, 임상시험계획서 작성 및\n\n<!-- PAGE_7 -->\n###### 평가방법과 관련된 사항을 구체적으로 제시하여 신속제품화를 위한\n\n<!-- PAGE_7 -->\n###### 맞춤형 기술지원을 목적으로 하는 가이드라인이다.\n\n - - 1 -\n<!-- PAGE_8 -->\n##### Ⅰ\n\n<!-- PAGE_8 -->\n##### 안전성·성능 평가\n\n<!-- PAGE_8 -->\n###### 1.  적용범위\n\n<!-- PAGE_8 -->\n###### 본 가이드라인은 출혈시간 및 항혈소판제제 저항성 복합검사기기의\n\n<!-- PAGE_8 -->\n###### 분석적 성능 평가와 안정성에 대한 평가방법을 구축하여 신개발 융복합\n\n<!-- PAGE_8 -->\n###### 의료기기의 평가방법을 제시하고자 한다.\n\n 출혈시간 및 항혈소판제제 저항성 복합검사기기는 『의료기기 품목 및\n\n<!-- PAGE_8 -->\n###### 품목별 등급에 관한 규정』의 분류에 따라 “혈액응고검사시약 D01050.01\n\n<!-- PAGE_8 -->\n###### (3등급)”과 “자동혈소판응집측정장치 A22290.01(1등급)”로 분류되고 있다.\n\n - - 2 -\n<!-- PAGE_9 -->\n###### 2.  약어 및 용어정리\n\n<!-- PAGE_9 -->\n###### (1) 가속노화시험 (Accelerated aging testing) : 제품의 실제 보관기간과\n\n<!-- PAGE_9 -->\n###### 상응되도록 짧은 기간 동안 시험하기 위하여 가혹한 온도조건 등에서\n\n<!-- PAGE_9 -->\n###### 의료기기의 화학적 또는 물리적 퇴보속도를 높이도록 계획한 안정성\n\n<!-- PAGE_9 -->\n###### (2) 간섭 (Interference) : 분석물질의 농도나 강도가 명백함에도 검출시약\n\n<!-- PAGE_9 -->\n###### 이나 신호 자체에 비특이적으로 반응하는 물질의 존재로 인해 일어\n\n<!-- PAGE_9 -->\n###### (3) 간섭물질 (Interfering substances) : 임상검체에 존재하는 내부물질\n\n<!-- PAGE_9 -->\n###### (예: 혈액 구성요소, acidic polysaccharides) 또는 외부물질(예: 항응고제 등)로\n\n<!-- PAGE_9 -->\n###### 위양성 또는 위음성 결과를 야기할 수 있는 물질\n\n<!-- PAGE_9 -->\n###### (4) 검출한계 (Limit of detection, LOD) : 검출될 수 있는 분석 물질의 최소량\n\n<!-- PAGE_9 -->\n###### (5) 공란한계 (Limit of blank, LOB) : blank 검체에서 관찰 가능할 수\n\n<!-- PAGE_9 -->\n###### (6) 교차반응 (Cross-reactivity) : 항원 이외에 공유 되었거나, 유사한 또는\n\n<!-- PAGE_9 -->\n###### 동일한 항원 결정기를 가진 항원과 항체가 반응하는 현상\n\n<!-- PAGE_9 -->\n###### (7) 대조물질 (Control / Control material) : 정도 관리를 위해 이용되는\n\n<!-- PAGE_9 -->\n###### 기기, 액체 또는 동결건조 물질\n\n<!-- PAGE_9 -->\n###### (8) 변동계수 (Coefficient of Variation, CV) : 표준편차의 크기를 평균치에\n\n<!-- PAGE_9 -->\n###### 대한 백분율로 나타낸 것\n\n<!-- PAGE_9 -->\n###### (9) 배치(Batch), 로트(Lot) : 특성이 균일하고 단일 또는 일련의 제조공정으로\n\n<!-- PAGE_9 -->\n###### 생산된 물질의 정의된 양\n\n- - 3 -\n<!-- PAGE_10 -->\n###### (10) 사용 시 안정성(In-use stability) : 제조사에서 제공한 용기를 개봉한\n\n<!-- PAGE_10 -->\n###### 이후에 사용자의 작동 조건에서 시약의 유효기간내의 검사수행능\n\n<!-- PAGE_10 -->\n###### (11) 사용기간(유효기간) (Shelf life) : 제조자가 특정한 저장조건 하에서\n\n<!-- PAGE_10 -->\n###### 최종 포장상태의 IVD 제품이 안정성을 유지하는 기간\n\n<!-- PAGE_10 -->\n###### (12) 신뢰구간 (Confidence interval) : 평균, 분율, 비율 등의 변수의 참값이\n\n<!-- PAGE_10 -->\n###### (13) 실시간 안정성(Real time stability) : IVD 제품을 제조자가 특정한\n\n<!-- PAGE_10 -->\n###### (14) 이동거리 (Migration Distance) : 검체가 카트리지에서 이동한 거리를\n\n<!-- PAGE_10 -->\n###### (15) 재현성 (Reproducibility) : 다른 측정조건에서 수행된 동일한 측정물의\n\n<!-- PAGE_10 -->\n###### (16) 정밀도 (Precision) : 규정된 조건 하에서 얻어진 독립적인 검사\n\n<!-- PAGE_10 -->\n###### ☞ 정밀도는 전형적으로 수치로 표현되지 않지만 비정밀도는 반복\n\n<!-- PAGE_10 -->\n###### 측정값 결과들의 ‘표준편차’ 또는 ‘변이계수’라는 용어로 정량적\n\n<!-- PAGE_10 -->\n###### (17) 정확도 (Accuracy) : 측정치와 참값 사이의 일치도\n\n<!-- PAGE_10 -->\n###### ☞ 평가대상 검사법에 의한 다수의 연속적인 결과값 들에서 얻은 평균값과\n\n<!-- PAGE_10 -->\n###### 공인된\n\n<!-- PAGE_10 -->\n###### 참고값(Accepted\n\n<!-- PAGE_10 -->\n###### reference\n\n<!-- PAGE_10 -->\n###### value)사이의\n\n<!-- PAGE_10 -->\n###### 일치\n\n<!-- PAGE_10 -->\n###### 근접도\n\n- - 4 -\n<!-- PAGE_11 -->\n###### (18) 직선성 (Linearity) : 실험 검체에 있는 분석물질의 농도[양]에 정비례\n\n<!-- PAGE_11 -->\n###### 하는 결과를 제공할 수 있는 능력\n\n<!-- PAGE_11 -->\n###### (19) 출혈시간(Bleeding time, BT) 검사 : 출혈시간 측정검사로 Duke법,\n\n<!-- PAGE_11 -->\n###### Ivy법, Template법 등을 이용하여 혈소판기능 선별검사로 사용\n\n<!-- PAGE_11 -->\n###### (20) 측정가능범위 (Analytical measurement range, AMR) : 일상적인\n\n<!-- PAGE_11 -->\n###### 측정 과정의 일부가 아닌 희석, 농축 또는 기타 전처리 없이 어떤\n\n<!-- PAGE_11 -->\n###### (21) 특이도 / 분석특이도 (Specificity / Analytical specificity) : 측정하고자\n\n<!-- PAGE_11 -->\n###### 하는 물질만 측정되고 검체 내 다른 물질은 측정 되지 않는 분석법의 능력\n\n<!-- PAGE_11 -->\n###### (22) 판정기준치 (Cut-off value) : 정성검사에서 경계치 이상을 양성으로,\n\n<!-- PAGE_11 -->\n###### 경계치 미만을 음성으로 보고할 수 있는 경계값을 말한다.  정량검사\n\n<!-- PAGE_11 -->\n###### 에서는 측정 결과가 임상적 또는 분석적 결정점(Decision point)의\n\n<!-- PAGE_11 -->\n###### 위 또는 아래에 있는지(양성 또는 음성) 결정하는데 사용되는 측정\n\n<!-- PAGE_11 -->\n###### (23) 편차 (Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n- - 5 -\n<!-- PAGE_12 -->\n###### 3. ",
        "original_sentence": "출혈시간 및 항혈소판제제 저항성 복합검사기기는 『의료기기 품목 및\n\n<!-- PAGE_8 -->\n###### 품목별 등급에 관한 규정』의 분류에 따라 “혈액응고검사시약 D01050.01\n\n<!-- PAGE_8 -->\n###### (3등급)”과 “자동혈소판응집측정장치 A22290.01(1등급)”로 분류되고 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_265",
      "text": "- - 2 -\n<!-- PAGE_9 -->\n###### 2. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 264,
        "window_size": 3,
        "char_count": 34,
        "word_count": 9,
        "page_number": 9,
        "window_text": "- - 1 -\n<!-- PAGE_8 -->\n##### Ⅰ\n\n<!-- PAGE_8 -->\n##### 안전성·성능 평가\n\n<!-- PAGE_8 -->\n###### 1.  적용범위\n\n<!-- PAGE_8 -->\n###### 본 가이드라인은 출혈시간 및 항혈소판제제 저항성 복합검사기기의\n\n<!-- PAGE_8 -->\n###### 분석적 성능 평가와 안정성에 대한 평가방법을 구축하여 신개발 융복합\n\n<!-- PAGE_8 -->\n###### 의료기기의 평가방법을 제시하고자 한다.\n\n 출혈시간 및 항혈소판제제 저항성 복합검사기기는 『의료기기 품목 및\n\n<!-- PAGE_8 -->\n###### 품목별 등급에 관한 규정』의 분류에 따라 “혈액응고검사시약 D01050.01\n\n<!-- PAGE_8 -->\n###### (3등급)”과 “자동혈소판응집측정장치 A22290.01(1등급)”로 분류되고 있다.\n\n - - 2 -\n<!-- PAGE_9 -->\n###### 2.  약어 및 용어정리\n\n<!-- PAGE_9 -->\n###### (1) 가속노화시험 (Accelerated aging testing) : 제품의 실제 보관기간과\n\n<!-- PAGE_9 -->\n###### 상응되도록 짧은 기간 동안 시험하기 위하여 가혹한 온도조건 등에서\n\n<!-- PAGE_9 -->\n###### 의료기기의 화학적 또는 물리적 퇴보속도를 높이도록 계획한 안정성\n\n<!-- PAGE_9 -->\n###### (2) 간섭 (Interference) : 분석물질의 농도나 강도가 명백함에도 검출시약\n\n<!-- PAGE_9 -->\n###### 이나 신호 자체에 비특이적으로 반응하는 물질의 존재로 인해 일어\n\n<!-- PAGE_9 -->\n###### (3) 간섭물질 (Interfering substances) : 임상검체에 존재하는 내부물질\n\n<!-- PAGE_9 -->\n###### (예: 혈액 구성요소, acidic polysaccharides) 또는 외부물질(예: 항응고제 등)로\n\n<!-- PAGE_9 -->\n###### 위양성 또는 위음성 결과를 야기할 수 있는 물질\n\n<!-- PAGE_9 -->\n###### (4) 검출한계 (Limit of detection, LOD) : 검출될 수 있는 분석 물질의 최소량\n\n<!-- PAGE_9 -->\n###### (5) 공란한계 (Limit of blank, LOB) : blank 검체에서 관찰 가능할 수\n\n<!-- PAGE_9 -->\n###### (6) 교차반응 (Cross-reactivity) : 항원 이외에 공유 되었거나, 유사한 또는\n\n<!-- PAGE_9 -->\n###### 동일한 항원 결정기를 가진 항원과 항체가 반응하는 현상\n\n<!-- PAGE_9 -->\n###### (7) 대조물질 (Control / Control material) : 정도 관리를 위해 이용되는\n\n<!-- PAGE_9 -->\n###### 기기, 액체 또는 동결건조 물질\n\n<!-- PAGE_9 -->\n###### (8) 변동계수 (Coefficient of Variation, CV) : 표준편차의 크기를 평균치에\n\n<!-- PAGE_9 -->\n###### 대한 백분율로 나타낸 것\n\n<!-- PAGE_9 -->\n###### (9) 배치(Batch), 로트(Lot) : 특성이 균일하고 단일 또는 일련의 제조공정으로\n\n<!-- PAGE_9 -->\n###### 생산된 물질의 정의된 양\n\n- - 3 -\n<!-- PAGE_10 -->\n###### (10) 사용 시 안정성(In-use stability) : 제조사에서 제공한 용기를 개봉한\n\n<!-- PAGE_10 -->\n###### 이후에 사용자의 작동 조건에서 시약의 유효기간내의 검사수행능\n\n<!-- PAGE_10 -->\n###### (11) 사용기간(유효기간) (Shelf life) : 제조자가 특정한 저장조건 하에서\n\n<!-- PAGE_10 -->\n###### 최종 포장상태의 IVD 제품이 안정성을 유지하는 기간\n\n<!-- PAGE_10 -->\n###### (12) 신뢰구간 (Confidence interval) : 평균, 분율, 비율 등의 변수의 참값이\n\n<!-- PAGE_10 -->\n###### (13) 실시간 안정성(Real time stability) : IVD 제품을 제조자가 특정한\n\n<!-- PAGE_10 -->\n###### (14) 이동거리 (Migration Distance) : 검체가 카트리지에서 이동한 거리를\n\n<!-- PAGE_10 -->\n###### (15) 재현성 (Reproducibility) : 다른 측정조건에서 수행된 동일한 측정물의\n\n<!-- PAGE_10 -->\n###### (16) 정밀도 (Precision) : 규정된 조건 하에서 얻어진 독립적인 검사\n\n<!-- PAGE_10 -->\n###### ☞ 정밀도는 전형적으로 수치로 표현되지 않지만 비정밀도는 반복\n\n<!-- PAGE_10 -->\n###### 측정값 결과들의 ‘표준편차’ 또는 ‘변이계수’라는 용어로 정량적\n\n<!-- PAGE_10 -->\n###### (17) 정확도 (Accuracy) : 측정치와 참값 사이의 일치도\n\n<!-- PAGE_10 -->\n###### ☞ 평가대상 검사법에 의한 다수의 연속적인 결과값 들에서 얻은 평균값과\n\n<!-- PAGE_10 -->\n###### 공인된\n\n<!-- PAGE_10 -->\n###### 참고값(Accepted\n\n<!-- PAGE_10 -->\n###### reference\n\n<!-- PAGE_10 -->\n###### value)사이의\n\n<!-- PAGE_10 -->\n###### 일치\n\n<!-- PAGE_10 -->\n###### 근접도\n\n- - 4 -\n<!-- PAGE_11 -->\n###### (18) 직선성 (Linearity) : 실험 검체에 있는 분석물질의 농도[양]에 정비례\n\n<!-- PAGE_11 -->\n###### 하는 결과를 제공할 수 있는 능력\n\n<!-- PAGE_11 -->\n###### (19) 출혈시간(Bleeding time, BT) 검사 : 출혈시간 측정검사로 Duke법,\n\n<!-- PAGE_11 -->\n###### Ivy법, Template법 등을 이용하여 혈소판기능 선별검사로 사용\n\n<!-- PAGE_11 -->\n###### (20) 측정가능범위 (Analytical measurement range, AMR) : 일상적인\n\n<!-- PAGE_11 -->\n###### 측정 과정의 일부가 아닌 희석, 농축 또는 기타 전처리 없이 어떤\n\n<!-- PAGE_11 -->\n###### (21) 특이도 / 분석특이도 (Specificity / Analytical specificity) : 측정하고자\n\n<!-- PAGE_11 -->\n###### 하는 물질만 측정되고 검체 내 다른 물질은 측정 되지 않는 분석법의 능력\n\n<!-- PAGE_11 -->\n###### (22) 판정기준치 (Cut-off value) : 정성검사에서 경계치 이상을 양성으로,\n\n<!-- PAGE_11 -->\n###### 경계치 미만을 음성으로 보고할 수 있는 경계값을 말한다.  정량검사\n\n<!-- PAGE_11 -->\n###### 에서는 측정 결과가 임상적 또는 분석적 결정점(Decision point)의\n\n<!-- PAGE_11 -->\n###### 위 또는 아래에 있는지(양성 또는 음성) 결정하는데 사용되는 측정\n\n<!-- PAGE_11 -->\n###### (23) 편차 (Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n- - 5 -\n<!-- PAGE_12 -->\n###### 3.  출혈시간 및 항혈소판제제 저항성 복합검사기기의 정의 및 분류\n\n<!-- PAGE_12 -->\n###### 가. ",
        "original_sentence": "- - 2 -\n<!-- PAGE_9 -->\n###### 2. "
      }
    },
    {
      "chunk_id": "chunk_266",
      "text": "약어 및 용어정리\n\n<!-- PAGE_9 -->\n###### (1) 가속노화시험 (Accelerated aging testing) : 제품의 실제 보관기간과\n\n<!-- PAGE_9 -->\n###### 상응되도록 짧은 기간 동안 시험하기 위하여 가혹한 온도조건 등에서\n\n<!-- PAGE_9 -->\n###### 의료기기의 화학적 또는 물리적 퇴보속도를 높이도록 계획한 안정성\n\n<!-- PAGE_9 -->\n###### (2) 간섭 (Interference) : 분석물질의 농도나 강도가 명백함에도 검출시약\n\n<!-- PAGE_9 -->\n###### 이나 신호 자체에 비특이적으로 반응하는 물질의 존재로 인해 일어\n\n<!-- PAGE_9 -->\n###### (3) 간섭물질 (Interfering substances) : 임상검체에 존재하는 내부물질\n\n<!-- PAGE_9 -->\n###### (예: 혈액 구성요소, acidic polysaccharides) 또는 외부물질(예: 항응고제 등)로\n\n<!-- PAGE_9 -->\n###### 위양성 또는 위음성 결과를 야기할 수 있는 물질\n\n<!-- PAGE_9 -->\n###### (4) 검출한계 (Limit of detection, LOD) : 검출될 수 있는 분석 물질의 최소량\n\n<!-- PAGE_9 -->\n###### (5) 공란한계 (Limit of blank, LOB) : blank 검체에서 관찰 가능할 수\n\n<!-- PAGE_9 -->\n###### (6) 교차반응 (Cross-reactivity) : 항원 이외에 공유 되었거나, 유사한 또는\n\n<!-- PAGE_9 -->\n###### 동일한 항원 결정기를 가진 항원과 항체가 반응하는 현상\n\n<!-- PAGE_9 -->\n###### (7) 대조물질 (Control / Control material) : 정도 관리를 위해 이용되는\n\n<!-- PAGE_9 -->\n###### 기기, 액체 또는 동결건조 물질\n\n<!-- PAGE_9 -->\n###### (8) 변동계수 (Coefficient of Variation, CV) : 표준편차의 크기를 평균치에\n\n<!-- PAGE_9 -->\n###### 대한 백분율로 나타낸 것\n\n<!-- PAGE_9 -->\n###### (9) 배치(Batch), 로트(Lot) : 특성이 균일하고 단일 또는 일련의 제조공정으로\n\n<!-- PAGE_9 -->\n###### 생산된 물질의 정의된 양\n\n- - 3 -\n<!-- PAGE_10 -->\n###### (10) 사용 시 안정성(In-use stability) : 제조사에서 제공한 용기를 개봉한\n\n<!-- PAGE_10 -->\n###### 이후에 사용자의 작동 조건에서 시약의 유효기간내의 검사수행능\n\n<!-- PAGE_10 -->\n###### (11) 사용기간(유효기간) (Shelf life) : 제조자가 특정한 저장조건 하에서\n\n<!-- PAGE_10 -->\n###### 최종 포장상태의 IVD 제품이 안정성을 유지하는 기간\n\n<!-- PAGE_10 -->\n###### (12) 신뢰구간 (Confidence interval) : 평균, 분율, 비율 등의 변수의 참값이\n\n<!-- PAGE_10 -->\n###### (13) 실시간 안정성(Real time stability) : IVD 제품을 제조자가 특정한\n\n<!-- PAGE_10 -->\n###### (14) 이동거리 (Migration Distance) : 검체가 카트리지에서 이동한 거리를\n\n<!-- PAGE_10 -->\n###### (15) 재현성 (Reproducibility) : 다른 측정조건에서 수행된 동일한 측정물의\n\n<!-- PAGE_10 -->\n###### (16) 정밀도 (Precision) : 규정된 조건 하에서 얻어진 독립적인 검사\n\n<!-- PAGE_10 -->\n###### ☞ 정밀도는 전형적으로 수치로 표현되지 않지만 비정밀도는 반복\n\n<!-- PAGE_10 -->\n###### 측정값 결과들의 ‘표준편차’ 또는 ‘변이계수’라는 용어로 정량적\n\n<!-- PAGE_10 -->\n###### (17) 정확도 (Accuracy) : 측정치와 참값 사이의 일치도\n\n<!-- PAGE_10 -->\n###### ☞ 평가대상 검사법에 의한 다수의 연속적인 결과값 들에서 얻은 평균값과\n\n<!-- PAGE_10 -->\n###### 공인된\n\n<!-- PAGE_10 -->\n###### 참고값(Accepted\n\n<!-- PAGE_10 -->\n###### reference\n\n<!-- PAGE_10 -->\n###### value)사이의\n\n<!-- PAGE_10 -->\n###### 일치\n\n<!-- PAGE_10 -->\n###### 근접도\n\n- - 4 -\n<!-- PAGE_11 -->\n###### (18) 직선성 (Linearity) : 실험 검체에 있는 분석물질의 농도[양]에 정비례\n\n<!-- PAGE_11 -->\n###### 하는 결과를 제공할 수 있는 능력\n\n<!-- PAGE_11 -->\n###### (19) 출혈시간(Bleeding time, BT) 검사 : 출혈시간 측정검사로 Duke법,\n\n<!-- PAGE_11 -->\n###### Ivy법, Template법 등을 이용하여 혈소판기능 선별검사로 사용\n\n<!-- PAGE_11 -->\n###### (20) 측정가능범위 (Analytical measurement range, AMR) : 일상적인\n\n<!-- PAGE_11 -->\n###### 측정 과정의 일부가 아닌 희석, 농축 또는 기타 전처리 없이 어떤\n\n<!-- PAGE_11 -->\n###### (21) 특이도 / 분석특이도 (Specificity / Analytical specificity) : 측정하고자\n\n<!-- PAGE_11 -->\n###### 하는 물질만 측정되고 검체 내 다른 물질은 측정 되지 않는 분석법의 능력\n\n<!-- PAGE_11 -->\n###### (22) 판정기준치 (Cut-off value) : 정성검사에서 경계치 이상을 양성으로,\n\n<!-- PAGE_11 -->\n###### 경계치 미만을 음성으로 보고할 수 있는 경계값을 말한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 265,
        "window_size": 3,
        "char_count": 2990,
        "word_count": 566,
        "page_number": 9,
        "window_text": "적용범위\n\n<!-- PAGE_8 -->\n###### 본 가이드라인은 출혈시간 및 항혈소판제제 저항성 복합검사기기의\n\n<!-- PAGE_8 -->\n###### 분석적 성능 평가와 안정성에 대한 평가방법을 구축하여 신개발 융복합\n\n<!-- PAGE_8 -->\n###### 의료기기의 평가방법을 제시하고자 한다.\n\n 출혈시간 및 항혈소판제제 저항성 복합검사기기는 『의료기기 품목 및\n\n<!-- PAGE_8 -->\n###### 품목별 등급에 관한 규정』의 분류에 따라 “혈액응고검사시약 D01050.01\n\n<!-- PAGE_8 -->\n###### (3등급)”과 “자동혈소판응집측정장치 A22290.01(1등급)”로 분류되고 있다.\n\n - - 2 -\n<!-- PAGE_9 -->\n###### 2.  약어 및 용어정리\n\n<!-- PAGE_9 -->\n###### (1) 가속노화시험 (Accelerated aging testing) : 제품의 실제 보관기간과\n\n<!-- PAGE_9 -->\n###### 상응되도록 짧은 기간 동안 시험하기 위하여 가혹한 온도조건 등에서\n\n<!-- PAGE_9 -->\n###### 의료기기의 화학적 또는 물리적 퇴보속도를 높이도록 계획한 안정성\n\n<!-- PAGE_9 -->\n###### (2) 간섭 (Interference) : 분석물질의 농도나 강도가 명백함에도 검출시약\n\n<!-- PAGE_9 -->\n###### 이나 신호 자체에 비특이적으로 반응하는 물질의 존재로 인해 일어\n\n<!-- PAGE_9 -->\n###### (3) 간섭물질 (Interfering substances) : 임상검체에 존재하는 내부물질\n\n<!-- PAGE_9 -->\n###### (예: 혈액 구성요소, acidic polysaccharides) 또는 외부물질(예: 항응고제 등)로\n\n<!-- PAGE_9 -->\n###### 위양성 또는 위음성 결과를 야기할 수 있는 물질\n\n<!-- PAGE_9 -->\n###### (4) 검출한계 (Limit of detection, LOD) : 검출될 수 있는 분석 물질의 최소량\n\n<!-- PAGE_9 -->\n###### (5) 공란한계 (Limit of blank, LOB) : blank 검체에서 관찰 가능할 수\n\n<!-- PAGE_9 -->\n###### (6) 교차반응 (Cross-reactivity) : 항원 이외에 공유 되었거나, 유사한 또는\n\n<!-- PAGE_9 -->\n###### 동일한 항원 결정기를 가진 항원과 항체가 반응하는 현상\n\n<!-- PAGE_9 -->\n###### (7) 대조물질 (Control / Control material) : 정도 관리를 위해 이용되는\n\n<!-- PAGE_9 -->\n###### 기기, 액체 또는 동결건조 물질\n\n<!-- PAGE_9 -->\n###### (8) 변동계수 (Coefficient of Variation, CV) : 표준편차의 크기를 평균치에\n\n<!-- PAGE_9 -->\n###### 대한 백분율로 나타낸 것\n\n<!-- PAGE_9 -->\n###### (9) 배치(Batch), 로트(Lot) : 특성이 균일하고 단일 또는 일련의 제조공정으로\n\n<!-- PAGE_9 -->\n###### 생산된 물질의 정의된 양\n\n- - 3 -\n<!-- PAGE_10 -->\n###### (10) 사용 시 안정성(In-use stability) : 제조사에서 제공한 용기를 개봉한\n\n<!-- PAGE_10 -->\n###### 이후에 사용자의 작동 조건에서 시약의 유효기간내의 검사수행능\n\n<!-- PAGE_10 -->\n###### (11) 사용기간(유효기간) (Shelf life) : 제조자가 특정한 저장조건 하에서\n\n<!-- PAGE_10 -->\n###### 최종 포장상태의 IVD 제품이 안정성을 유지하는 기간\n\n<!-- PAGE_10 -->\n###### (12) 신뢰구간 (Confidence interval) : 평균, 분율, 비율 등의 변수의 참값이\n\n<!-- PAGE_10 -->\n###### (13) 실시간 안정성(Real time stability) : IVD 제품을 제조자가 특정한\n\n<!-- PAGE_10 -->\n###### (14) 이동거리 (Migration Distance) : 검체가 카트리지에서 이동한 거리를\n\n<!-- PAGE_10 -->\n###### (15) 재현성 (Reproducibility) : 다른 측정조건에서 수행된 동일한 측정물의\n\n<!-- PAGE_10 -->\n###### (16) 정밀도 (Precision) : 규정된 조건 하에서 얻어진 독립적인 검사\n\n<!-- PAGE_10 -->\n###### ☞ 정밀도는 전형적으로 수치로 표현되지 않지만 비정밀도는 반복\n\n<!-- PAGE_10 -->\n###### 측정값 결과들의 ‘표준편차’ 또는 ‘변이계수’라는 용어로 정량적\n\n<!-- PAGE_10 -->\n###### (17) 정확도 (Accuracy) : 측정치와 참값 사이의 일치도\n\n<!-- PAGE_10 -->\n###### ☞ 평가대상 검사법에 의한 다수의 연속적인 결과값 들에서 얻은 평균값과\n\n<!-- PAGE_10 -->\n###### 공인된\n\n<!-- PAGE_10 -->\n###### 참고값(Accepted\n\n<!-- PAGE_10 -->\n###### reference\n\n<!-- PAGE_10 -->\n###### value)사이의\n\n<!-- PAGE_10 -->\n###### 일치\n\n<!-- PAGE_10 -->\n###### 근접도\n\n- - 4 -\n<!-- PAGE_11 -->\n###### (18) 직선성 (Linearity) : 실험 검체에 있는 분석물질의 농도[양]에 정비례\n\n<!-- PAGE_11 -->\n###### 하는 결과를 제공할 수 있는 능력\n\n<!-- PAGE_11 -->\n###### (19) 출혈시간(Bleeding time, BT) 검사 : 출혈시간 측정검사로 Duke법,\n\n<!-- PAGE_11 -->\n###### Ivy법, Template법 등을 이용하여 혈소판기능 선별검사로 사용\n\n<!-- PAGE_11 -->\n###### (20) 측정가능범위 (Analytical measurement range, AMR) : 일상적인\n\n<!-- PAGE_11 -->\n###### 측정 과정의 일부가 아닌 희석, 농축 또는 기타 전처리 없이 어떤\n\n<!-- PAGE_11 -->\n###### (21) 특이도 / 분석특이도 (Specificity / Analytical specificity) : 측정하고자\n\n<!-- PAGE_11 -->\n###### 하는 물질만 측정되고 검체 내 다른 물질은 측정 되지 않는 분석법의 능력\n\n<!-- PAGE_11 -->\n###### (22) 판정기준치 (Cut-off value) : 정성검사에서 경계치 이상을 양성으로,\n\n<!-- PAGE_11 -->\n###### 경계치 미만을 음성으로 보고할 수 있는 경계값을 말한다.  정량검사\n\n<!-- PAGE_11 -->\n###### 에서는 측정 결과가 임상적 또는 분석적 결정점(Decision point)의\n\n<!-- PAGE_11 -->\n###### 위 또는 아래에 있는지(양성 또는 음성) 결정하는데 사용되는 측정\n\n<!-- PAGE_11 -->\n###### (23) 편차 (Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n- - 5 -\n<!-- PAGE_12 -->\n###### 3.  출혈시간 및 항혈소판제제 저항성 복합검사기기의 정의 및 분류\n\n<!-- PAGE_12 -->\n###### 가.  개요\n\n<!-- PAGE_12 -->\n###### (1) 혈관벽 손상으로 출혈이 발생하면 혈소판은 손상 부위에 부착,\n\n<!-- PAGE_12 -->\n###### 다른 혈소판들과 응집, 추가 응집을 촉진시키기 위한 물질 분비 등\n\n<!-- PAGE_12 -->\n###### 3가지 과정을 통해 지혈을 유도한다. ",
        "original_sentence": "약어 및 용어정리\n\n<!-- PAGE_9 -->\n###### (1) 가속노화시험 (Accelerated aging testing) : 제품의 실제 보관기간과\n\n<!-- PAGE_9 -->\n###### 상응되도록 짧은 기간 동안 시험하기 위하여 가혹한 온도조건 등에서\n\n<!-- PAGE_9 -->\n###### 의료기기의 화학적 또는 물리적 퇴보속도를 높이도록 계획한 안정성\n\n<!-- PAGE_9 -->\n###### (2) 간섭 (Interference) : 분석물질의 농도나 강도가 명백함에도 검출시약\n\n<!-- PAGE_9 -->\n###### 이나 신호 자체에 비특이적으로 반응하는 물질의 존재로 인해 일어\n\n<!-- PAGE_9 -->\n###### (3) 간섭물질 (Interfering substances) : 임상검체에 존재하는 내부물질\n\n<!-- PAGE_9 -->\n###### (예: 혈액 구성요소, acidic polysaccharides) 또는 외부물질(예: 항응고제 등)로\n\n<!-- PAGE_9 -->\n###### 위양성 또는 위음성 결과를 야기할 수 있는 물질\n\n<!-- PAGE_9 -->\n###### (4) 검출한계 (Limit of detection, LOD) : 검출될 수 있는 분석 물질의 최소량\n\n<!-- PAGE_9 -->\n###### (5) 공란한계 (Limit of blank, LOB) : blank 검체에서 관찰 가능할 수\n\n<!-- PAGE_9 -->\n###### (6) 교차반응 (Cross-reactivity) : 항원 이외에 공유 되었거나, 유사한 또는\n\n<!-- PAGE_9 -->\n###### 동일한 항원 결정기를 가진 항원과 항체가 반응하는 현상\n\n<!-- PAGE_9 -->\n###### (7) 대조물질 (Control / Control material) : 정도 관리를 위해 이용되는\n\n<!-- PAGE_9 -->\n###### 기기, 액체 또는 동결건조 물질\n\n<!-- PAGE_9 -->\n###### (8) 변동계수 (Coefficient of Variation, CV) : 표준편차의 크기를 평균치에\n\n<!-- PAGE_9 -->\n###### 대한 백분율로 나타낸 것\n\n<!-- PAGE_9 -->\n###### (9) 배치(Batch), 로트(Lot) : 특성이 균일하고 단일 또는 일련의 제조공정으로\n\n<!-- PAGE_9 -->\n###### 생산된 물질의 정의된 양\n\n- - 3 -\n<!-- PAGE_10 -->\n###### (10) 사용 시 안정성(In-use stability) : 제조사에서 제공한 용기를 개봉한\n\n<!-- PAGE_10 -->\n###### 이후에 사용자의 작동 조건에서 시약의 유효기간내의 검사수행능\n\n<!-- PAGE_10 -->\n###### (11) 사용기간(유효기간) (Shelf life) : 제조자가 특정한 저장조건 하에서\n\n<!-- PAGE_10 -->\n###### 최종 포장상태의 IVD 제품이 안정성을 유지하는 기간\n\n<!-- PAGE_10 -->\n###### (12) 신뢰구간 (Confidence interval) : 평균, 분율, 비율 등의 변수의 참값이\n\n<!-- PAGE_10 -->\n###### (13) 실시간 안정성(Real time stability) : IVD 제품을 제조자가 특정한\n\n<!-- PAGE_10 -->\n###### (14) 이동거리 (Migration Distance) : 검체가 카트리지에서 이동한 거리를\n\n<!-- PAGE_10 -->\n###### (15) 재현성 (Reproducibility) : 다른 측정조건에서 수행된 동일한 측정물의\n\n<!-- PAGE_10 -->\n###### (16) 정밀도 (Precision) : 규정된 조건 하에서 얻어진 독립적인 검사\n\n<!-- PAGE_10 -->\n###### ☞ 정밀도는 전형적으로 수치로 표현되지 않지만 비정밀도는 반복\n\n<!-- PAGE_10 -->\n###### 측정값 결과들의 ‘표준편차’ 또는 ‘변이계수’라는 용어로 정량적\n\n<!-- PAGE_10 -->\n###### (17) 정확도 (Accuracy) : 측정치와 참값 사이의 일치도\n\n<!-- PAGE_10 -->\n###### ☞ 평가대상 검사법에 의한 다수의 연속적인 결과값 들에서 얻은 평균값과\n\n<!-- PAGE_10 -->\n###### 공인된\n\n<!-- PAGE_10 -->\n###### 참고값(Accepted\n\n<!-- PAGE_10 -->\n###### reference\n\n<!-- PAGE_10 -->\n###### value)사이의\n\n<!-- PAGE_10 -->\n###### 일치\n\n<!-- PAGE_10 -->\n###### 근접도\n\n- - 4 -\n<!-- PAGE_11 -->\n###### (18) 직선성 (Linearity) : 실험 검체에 있는 분석물질의 농도[양]에 정비례\n\n<!-- PAGE_11 -->\n###### 하는 결과를 제공할 수 있는 능력\n\n<!-- PAGE_11 -->\n###### (19) 출혈시간(Bleeding time, BT) 검사 : 출혈시간 측정검사로 Duke법,\n\n<!-- PAGE_11 -->\n###### Ivy법, Template법 등을 이용하여 혈소판기능 선별검사로 사용\n\n<!-- PAGE_11 -->\n###### (20) 측정가능범위 (Analytical measurement range, AMR) : 일상적인\n\n<!-- PAGE_11 -->\n###### 측정 과정의 일부가 아닌 희석, 농축 또는 기타 전처리 없이 어떤\n\n<!-- PAGE_11 -->\n###### (21) 특이도 / 분석특이도 (Specificity / Analytical specificity) : 측정하고자\n\n<!-- PAGE_11 -->\n###### 하는 물질만 측정되고 검체 내 다른 물질은 측정 되지 않는 분석법의 능력\n\n<!-- PAGE_11 -->\n###### (22) 판정기준치 (Cut-off value) : 정성검사에서 경계치 이상을 양성으로,\n\n<!-- PAGE_11 -->\n###### 경계치 미만을 음성으로 보고할 수 있는 경계값을 말한다. "
      }
    },
    {
      "chunk_id": "chunk_267",
      "text": "정량검사\n\n<!-- PAGE_11 -->\n###### 에서는 측정 결과가 임상적 또는 분석적 결정점(Decision point)의\n\n<!-- PAGE_11 -->\n###### 위 또는 아래에 있는지(양성 또는 음성) 결정하는데 사용되는 측정\n\n<!-- PAGE_11 -->\n###### (23) 편차 (Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n- - 5 -\n<!-- PAGE_12 -->\n###### 3. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 266,
        "window_size": 3,
        "char_count": 240,
        "word_count": 50,
        "page_number": 11,
        "window_text": "출혈시간 및 항혈소판제제 저항성 복합검사기기는 『의료기기 품목 및\n\n<!-- PAGE_8 -->\n###### 품목별 등급에 관한 규정』의 분류에 따라 “혈액응고검사시약 D01050.01\n\n<!-- PAGE_8 -->\n###### (3등급)”과 “자동혈소판응집측정장치 A22290.01(1등급)”로 분류되고 있다.\n\n - - 2 -\n<!-- PAGE_9 -->\n###### 2.  약어 및 용어정리\n\n<!-- PAGE_9 -->\n###### (1) 가속노화시험 (Accelerated aging testing) : 제품의 실제 보관기간과\n\n<!-- PAGE_9 -->\n###### 상응되도록 짧은 기간 동안 시험하기 위하여 가혹한 온도조건 등에서\n\n<!-- PAGE_9 -->\n###### 의료기기의 화학적 또는 물리적 퇴보속도를 높이도록 계획한 안정성\n\n<!-- PAGE_9 -->\n###### (2) 간섭 (Interference) : 분석물질의 농도나 강도가 명백함에도 검출시약\n\n<!-- PAGE_9 -->\n###### 이나 신호 자체에 비특이적으로 반응하는 물질의 존재로 인해 일어\n\n<!-- PAGE_9 -->\n###### (3) 간섭물질 (Interfering substances) : 임상검체에 존재하는 내부물질\n\n<!-- PAGE_9 -->\n###### (예: 혈액 구성요소, acidic polysaccharides) 또는 외부물질(예: 항응고제 등)로\n\n<!-- PAGE_9 -->\n###### 위양성 또는 위음성 결과를 야기할 수 있는 물질\n\n<!-- PAGE_9 -->\n###### (4) 검출한계 (Limit of detection, LOD) : 검출될 수 있는 분석 물질의 최소량\n\n<!-- PAGE_9 -->\n###### (5) 공란한계 (Limit of blank, LOB) : blank 검체에서 관찰 가능할 수\n\n<!-- PAGE_9 -->\n###### (6) 교차반응 (Cross-reactivity) : 항원 이외에 공유 되었거나, 유사한 또는\n\n<!-- PAGE_9 -->\n###### 동일한 항원 결정기를 가진 항원과 항체가 반응하는 현상\n\n<!-- PAGE_9 -->\n###### (7) 대조물질 (Control / Control material) : 정도 관리를 위해 이용되는\n\n<!-- PAGE_9 -->\n###### 기기, 액체 또는 동결건조 물질\n\n<!-- PAGE_9 -->\n###### (8) 변동계수 (Coefficient of Variation, CV) : 표준편차의 크기를 평균치에\n\n<!-- PAGE_9 -->\n###### 대한 백분율로 나타낸 것\n\n<!-- PAGE_9 -->\n###### (9) 배치(Batch), 로트(Lot) : 특성이 균일하고 단일 또는 일련의 제조공정으로\n\n<!-- PAGE_9 -->\n###### 생산된 물질의 정의된 양\n\n- - 3 -\n<!-- PAGE_10 -->\n###### (10) 사용 시 안정성(In-use stability) : 제조사에서 제공한 용기를 개봉한\n\n<!-- PAGE_10 -->\n###### 이후에 사용자의 작동 조건에서 시약의 유효기간내의 검사수행능\n\n<!-- PAGE_10 -->\n###### (11) 사용기간(유효기간) (Shelf life) : 제조자가 특정한 저장조건 하에서\n\n<!-- PAGE_10 -->\n###### 최종 포장상태의 IVD 제품이 안정성을 유지하는 기간\n\n<!-- PAGE_10 -->\n###### (12) 신뢰구간 (Confidence interval) : 평균, 분율, 비율 등의 변수의 참값이\n\n<!-- PAGE_10 -->\n###### (13) 실시간 안정성(Real time stability) : IVD 제품을 제조자가 특정한\n\n<!-- PAGE_10 -->\n###### (14) 이동거리 (Migration Distance) : 검체가 카트리지에서 이동한 거리를\n\n<!-- PAGE_10 -->\n###### (15) 재현성 (Reproducibility) : 다른 측정조건에서 수행된 동일한 측정물의\n\n<!-- PAGE_10 -->\n###### (16) 정밀도 (Precision) : 규정된 조건 하에서 얻어진 독립적인 검사\n\n<!-- PAGE_10 -->\n###### ☞ 정밀도는 전형적으로 수치로 표현되지 않지만 비정밀도는 반복\n\n<!-- PAGE_10 -->\n###### 측정값 결과들의 ‘표준편차’ 또는 ‘변이계수’라는 용어로 정량적\n\n<!-- PAGE_10 -->\n###### (17) 정확도 (Accuracy) : 측정치와 참값 사이의 일치도\n\n<!-- PAGE_10 -->\n###### ☞ 평가대상 검사법에 의한 다수의 연속적인 결과값 들에서 얻은 평균값과\n\n<!-- PAGE_10 -->\n###### 공인된\n\n<!-- PAGE_10 -->\n###### 참고값(Accepted\n\n<!-- PAGE_10 -->\n###### reference\n\n<!-- PAGE_10 -->\n###### value)사이의\n\n<!-- PAGE_10 -->\n###### 일치\n\n<!-- PAGE_10 -->\n###### 근접도\n\n- - 4 -\n<!-- PAGE_11 -->\n###### (18) 직선성 (Linearity) : 실험 검체에 있는 분석물질의 농도[양]에 정비례\n\n<!-- PAGE_11 -->\n###### 하는 결과를 제공할 수 있는 능력\n\n<!-- PAGE_11 -->\n###### (19) 출혈시간(Bleeding time, BT) 검사 : 출혈시간 측정검사로 Duke법,\n\n<!-- PAGE_11 -->\n###### Ivy법, Template법 등을 이용하여 혈소판기능 선별검사로 사용\n\n<!-- PAGE_11 -->\n###### (20) 측정가능범위 (Analytical measurement range, AMR) : 일상적인\n\n<!-- PAGE_11 -->\n###### 측정 과정의 일부가 아닌 희석, 농축 또는 기타 전처리 없이 어떤\n\n<!-- PAGE_11 -->\n###### (21) 특이도 / 분석특이도 (Specificity / Analytical specificity) : 측정하고자\n\n<!-- PAGE_11 -->\n###### 하는 물질만 측정되고 검체 내 다른 물질은 측정 되지 않는 분석법의 능력\n\n<!-- PAGE_11 -->\n###### (22) 판정기준치 (Cut-off value) : 정성검사에서 경계치 이상을 양성으로,\n\n<!-- PAGE_11 -->\n###### 경계치 미만을 음성으로 보고할 수 있는 경계값을 말한다.  정량검사\n\n<!-- PAGE_11 -->\n###### 에서는 측정 결과가 임상적 또는 분석적 결정점(Decision point)의\n\n<!-- PAGE_11 -->\n###### 위 또는 아래에 있는지(양성 또는 음성) 결정하는데 사용되는 측정\n\n<!-- PAGE_11 -->\n###### (23) 편차 (Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n- - 5 -\n<!-- PAGE_12 -->\n###### 3.  출혈시간 및 항혈소판제제 저항성 복합검사기기의 정의 및 분류\n\n<!-- PAGE_12 -->\n###### 가.  개요\n\n<!-- PAGE_12 -->\n###### (1) 혈관벽 손상으로 출혈이 발생하면 혈소판은 손상 부위에 부착,\n\n<!-- PAGE_12 -->\n###### 다른 혈소판들과 응집, 추가 응집을 촉진시키기 위한 물질 분비 등\n\n<!-- PAGE_12 -->\n###### 3가지 과정을 통해 지혈을 유도한다.  이러한 반응으로 생긴 혈소판\n\n<!-- PAGE_12 -->\n###### (2) 혈소판 검사는 주로 선천성 혈소판기능이상이나 수술 전 선별검사로\n\n<!-- PAGE_12 -->\n###### 많이 사용된다. ",
        "original_sentence": "정량검사\n\n<!-- PAGE_11 -->\n###### 에서는 측정 결과가 임상적 또는 분석적 결정점(Decision point)의\n\n<!-- PAGE_11 -->\n###### 위 또는 아래에 있는지(양성 또는 음성) 결정하는데 사용되는 측정\n\n<!-- PAGE_11 -->\n###### (23) 편차 (Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n- - 5 -\n<!-- PAGE_12 -->\n###### 3. "
      }
    },
    {
      "chunk_id": "chunk_268",
      "text": "출혈시간 및 항혈소판제제 저항성 복합검사기기의 정의 및 분류\n\n<!-- PAGE_12 -->\n###### 가. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 267,
        "window_size": 3,
        "char_count": 62,
        "word_count": 13,
        "page_number": 12,
        "window_text": "- - 2 -\n<!-- PAGE_9 -->\n###### 2.  약어 및 용어정리\n\n<!-- PAGE_9 -->\n###### (1) 가속노화시험 (Accelerated aging testing) : 제품의 실제 보관기간과\n\n<!-- PAGE_9 -->\n###### 상응되도록 짧은 기간 동안 시험하기 위하여 가혹한 온도조건 등에서\n\n<!-- PAGE_9 -->\n###### 의료기기의 화학적 또는 물리적 퇴보속도를 높이도록 계획한 안정성\n\n<!-- PAGE_9 -->\n###### (2) 간섭 (Interference) : 분석물질의 농도나 강도가 명백함에도 검출시약\n\n<!-- PAGE_9 -->\n###### 이나 신호 자체에 비특이적으로 반응하는 물질의 존재로 인해 일어\n\n<!-- PAGE_9 -->\n###### (3) 간섭물질 (Interfering substances) : 임상검체에 존재하는 내부물질\n\n<!-- PAGE_9 -->\n###### (예: 혈액 구성요소, acidic polysaccharides) 또는 외부물질(예: 항응고제 등)로\n\n<!-- PAGE_9 -->\n###### 위양성 또는 위음성 결과를 야기할 수 있는 물질\n\n<!-- PAGE_9 -->\n###### (4) 검출한계 (Limit of detection, LOD) : 검출될 수 있는 분석 물질의 최소량\n\n<!-- PAGE_9 -->\n###### (5) 공란한계 (Limit of blank, LOB) : blank 검체에서 관찰 가능할 수\n\n<!-- PAGE_9 -->\n###### (6) 교차반응 (Cross-reactivity) : 항원 이외에 공유 되었거나, 유사한 또는\n\n<!-- PAGE_9 -->\n###### 동일한 항원 결정기를 가진 항원과 항체가 반응하는 현상\n\n<!-- PAGE_9 -->\n###### (7) 대조물질 (Control / Control material) : 정도 관리를 위해 이용되는\n\n<!-- PAGE_9 -->\n###### 기기, 액체 또는 동결건조 물질\n\n<!-- PAGE_9 -->\n###### (8) 변동계수 (Coefficient of Variation, CV) : 표준편차의 크기를 평균치에\n\n<!-- PAGE_9 -->\n###### 대한 백분율로 나타낸 것\n\n<!-- PAGE_9 -->\n###### (9) 배치(Batch), 로트(Lot) : 특성이 균일하고 단일 또는 일련의 제조공정으로\n\n<!-- PAGE_9 -->\n###### 생산된 물질의 정의된 양\n\n- - 3 -\n<!-- PAGE_10 -->\n###### (10) 사용 시 안정성(In-use stability) : 제조사에서 제공한 용기를 개봉한\n\n<!-- PAGE_10 -->\n###### 이후에 사용자의 작동 조건에서 시약의 유효기간내의 검사수행능\n\n<!-- PAGE_10 -->\n###### (11) 사용기간(유효기간) (Shelf life) : 제조자가 특정한 저장조건 하에서\n\n<!-- PAGE_10 -->\n###### 최종 포장상태의 IVD 제품이 안정성을 유지하는 기간\n\n<!-- PAGE_10 -->\n###### (12) 신뢰구간 (Confidence interval) : 평균, 분율, 비율 등의 변수의 참값이\n\n<!-- PAGE_10 -->\n###### (13) 실시간 안정성(Real time stability) : IVD 제품을 제조자가 특정한\n\n<!-- PAGE_10 -->\n###### (14) 이동거리 (Migration Distance) : 검체가 카트리지에서 이동한 거리를\n\n<!-- PAGE_10 -->\n###### (15) 재현성 (Reproducibility) : 다른 측정조건에서 수행된 동일한 측정물의\n\n<!-- PAGE_10 -->\n###### (16) 정밀도 (Precision) : 규정된 조건 하에서 얻어진 독립적인 검사\n\n<!-- PAGE_10 -->\n###### ☞ 정밀도는 전형적으로 수치로 표현되지 않지만 비정밀도는 반복\n\n<!-- PAGE_10 -->\n###### 측정값 결과들의 ‘표준편차’ 또는 ‘변이계수’라는 용어로 정량적\n\n<!-- PAGE_10 -->\n###### (17) 정확도 (Accuracy) : 측정치와 참값 사이의 일치도\n\n<!-- PAGE_10 -->\n###### ☞ 평가대상 검사법에 의한 다수의 연속적인 결과값 들에서 얻은 평균값과\n\n<!-- PAGE_10 -->\n###### 공인된\n\n<!-- PAGE_10 -->\n###### 참고값(Accepted\n\n<!-- PAGE_10 -->\n###### reference\n\n<!-- PAGE_10 -->\n###### value)사이의\n\n<!-- PAGE_10 -->\n###### 일치\n\n<!-- PAGE_10 -->\n###### 근접도\n\n- - 4 -\n<!-- PAGE_11 -->\n###### (18) 직선성 (Linearity) : 실험 검체에 있는 분석물질의 농도[양]에 정비례\n\n<!-- PAGE_11 -->\n###### 하는 결과를 제공할 수 있는 능력\n\n<!-- PAGE_11 -->\n###### (19) 출혈시간(Bleeding time, BT) 검사 : 출혈시간 측정검사로 Duke법,\n\n<!-- PAGE_11 -->\n###### Ivy법, Template법 등을 이용하여 혈소판기능 선별검사로 사용\n\n<!-- PAGE_11 -->\n###### (20) 측정가능범위 (Analytical measurement range, AMR) : 일상적인\n\n<!-- PAGE_11 -->\n###### 측정 과정의 일부가 아닌 희석, 농축 또는 기타 전처리 없이 어떤\n\n<!-- PAGE_11 -->\n###### (21) 특이도 / 분석특이도 (Specificity / Analytical specificity) : 측정하고자\n\n<!-- PAGE_11 -->\n###### 하는 물질만 측정되고 검체 내 다른 물질은 측정 되지 않는 분석법의 능력\n\n<!-- PAGE_11 -->\n###### (22) 판정기준치 (Cut-off value) : 정성검사에서 경계치 이상을 양성으로,\n\n<!-- PAGE_11 -->\n###### 경계치 미만을 음성으로 보고할 수 있는 경계값을 말한다.  정량검사\n\n<!-- PAGE_11 -->\n###### 에서는 측정 결과가 임상적 또는 분석적 결정점(Decision point)의\n\n<!-- PAGE_11 -->\n###### 위 또는 아래에 있는지(양성 또는 음성) 결정하는데 사용되는 측정\n\n<!-- PAGE_11 -->\n###### (23) 편차 (Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n- - 5 -\n<!-- PAGE_12 -->\n###### 3.  출혈시간 및 항혈소판제제 저항성 복합검사기기의 정의 및 분류\n\n<!-- PAGE_12 -->\n###### 가.  개요\n\n<!-- PAGE_12 -->\n###### (1) 혈관벽 손상으로 출혈이 발생하면 혈소판은 손상 부위에 부착,\n\n<!-- PAGE_12 -->\n###### 다른 혈소판들과 응집, 추가 응집을 촉진시키기 위한 물질 분비 등\n\n<!-- PAGE_12 -->\n###### 3가지 과정을 통해 지혈을 유도한다.  이러한 반응으로 생긴 혈소판\n\n<!-- PAGE_12 -->\n###### (2) 혈소판 검사는 주로 선천성 혈소판기능이상이나 수술 전 선별검사로\n\n<!-- PAGE_12 -->\n###### 많이 사용된다.  특히 혈소판의 수적 이상이 없는 출혈성 질환에서\n\n<!-- PAGE_12 -->\n###### 선천성 혹은 후천성 혈소판 기능이상에 의한 출혈성 질환을 감별\n\n- - 6 -\n[그림 3] 혈소판 약물반응검사의 원리\n\n<!-- PAGE_13 -->\n###### (3) 최근에는 심혈관 및 뇌혈관 질환의 치료 및 예방에 사용되는 항혈소판\n\n<!-- PAGE_13 -->\n###### 약제의 선택과정에 있어서 환자에 적합한 올바른 약재 선택을 돕기 위한\n\n<!-- PAGE_13 -->\n###### 검사 및 약제의 장기간 복용으로 인한 출혈현상의 증가나 약제의 내성에\n\n<!-- PAGE_13 -->\n###### (4) 혈소판 기능검사 및 항혈소판제제 저항성을 측정하기 위한 측정방법은\n\n<!-- PAGE_13 -->\n###### 다양하며 현재 개발된 제품들의 측정방법은 Closure time(CT), 광투과량\n\n<!-- PAGE_13 -->\n###### 측정, 전기 임피던스 측정, 입사광산란 측정 등이다. ",
        "original_sentence": "출혈시간 및 항혈소판제제 저항성 복합검사기기의 정의 및 분류\n\n<!-- PAGE_12 -->\n###### 가. "
      }
    },
    {
      "chunk_id": "chunk_269",
      "text": "개요\n\n<!-- PAGE_12 -->\n###### (1) 혈관벽 손상으로 출혈이 발생하면 혈소판은 손상 부위에 부착,\n\n<!-- PAGE_12 -->\n###### 다른 혈소판들과 응집, 추가 응집을 촉진시키기 위한 물질 분비 등\n\n<!-- PAGE_12 -->\n###### 3가지 과정을 통해 지혈을 유도한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 268,
        "window_size": 3,
        "char_count": 174,
        "word_count": 37,
        "page_number": 12,
        "window_text": "약어 및 용어정리\n\n<!-- PAGE_9 -->\n###### (1) 가속노화시험 (Accelerated aging testing) : 제품의 실제 보관기간과\n\n<!-- PAGE_9 -->\n###### 상응되도록 짧은 기간 동안 시험하기 위하여 가혹한 온도조건 등에서\n\n<!-- PAGE_9 -->\n###### 의료기기의 화학적 또는 물리적 퇴보속도를 높이도록 계획한 안정성\n\n<!-- PAGE_9 -->\n###### (2) 간섭 (Interference) : 분석물질의 농도나 강도가 명백함에도 검출시약\n\n<!-- PAGE_9 -->\n###### 이나 신호 자체에 비특이적으로 반응하는 물질의 존재로 인해 일어\n\n<!-- PAGE_9 -->\n###### (3) 간섭물질 (Interfering substances) : 임상검체에 존재하는 내부물질\n\n<!-- PAGE_9 -->\n###### (예: 혈액 구성요소, acidic polysaccharides) 또는 외부물질(예: 항응고제 등)로\n\n<!-- PAGE_9 -->\n###### 위양성 또는 위음성 결과를 야기할 수 있는 물질\n\n<!-- PAGE_9 -->\n###### (4) 검출한계 (Limit of detection, LOD) : 검출될 수 있는 분석 물질의 최소량\n\n<!-- PAGE_9 -->\n###### (5) 공란한계 (Limit of blank, LOB) : blank 검체에서 관찰 가능할 수\n\n<!-- PAGE_9 -->\n###### (6) 교차반응 (Cross-reactivity) : 항원 이외에 공유 되었거나, 유사한 또는\n\n<!-- PAGE_9 -->\n###### 동일한 항원 결정기를 가진 항원과 항체가 반응하는 현상\n\n<!-- PAGE_9 -->\n###### (7) 대조물질 (Control / Control material) : 정도 관리를 위해 이용되는\n\n<!-- PAGE_9 -->\n###### 기기, 액체 또는 동결건조 물질\n\n<!-- PAGE_9 -->\n###### (8) 변동계수 (Coefficient of Variation, CV) : 표준편차의 크기를 평균치에\n\n<!-- PAGE_9 -->\n###### 대한 백분율로 나타낸 것\n\n<!-- PAGE_9 -->\n###### (9) 배치(Batch), 로트(Lot) : 특성이 균일하고 단일 또는 일련의 제조공정으로\n\n<!-- PAGE_9 -->\n###### 생산된 물질의 정의된 양\n\n- - 3 -\n<!-- PAGE_10 -->\n###### (10) 사용 시 안정성(In-use stability) : 제조사에서 제공한 용기를 개봉한\n\n<!-- PAGE_10 -->\n###### 이후에 사용자의 작동 조건에서 시약의 유효기간내의 검사수행능\n\n<!-- PAGE_10 -->\n###### (11) 사용기간(유효기간) (Shelf life) : 제조자가 특정한 저장조건 하에서\n\n<!-- PAGE_10 -->\n###### 최종 포장상태의 IVD 제품이 안정성을 유지하는 기간\n\n<!-- PAGE_10 -->\n###### (12) 신뢰구간 (Confidence interval) : 평균, 분율, 비율 등의 변수의 참값이\n\n<!-- PAGE_10 -->\n###### (13) 실시간 안정성(Real time stability) : IVD 제품을 제조자가 특정한\n\n<!-- PAGE_10 -->\n###### (14) 이동거리 (Migration Distance) : 검체가 카트리지에서 이동한 거리를\n\n<!-- PAGE_10 -->\n###### (15) 재현성 (Reproducibility) : 다른 측정조건에서 수행된 동일한 측정물의\n\n<!-- PAGE_10 -->\n###### (16) 정밀도 (Precision) : 규정된 조건 하에서 얻어진 독립적인 검사\n\n<!-- PAGE_10 -->\n###### ☞ 정밀도는 전형적으로 수치로 표현되지 않지만 비정밀도는 반복\n\n<!-- PAGE_10 -->\n###### 측정값 결과들의 ‘표준편차’ 또는 ‘변이계수’라는 용어로 정량적\n\n<!-- PAGE_10 -->\n###### (17) 정확도 (Accuracy) : 측정치와 참값 사이의 일치도\n\n<!-- PAGE_10 -->\n###### ☞ 평가대상 검사법에 의한 다수의 연속적인 결과값 들에서 얻은 평균값과\n\n<!-- PAGE_10 -->\n###### 공인된\n\n<!-- PAGE_10 -->\n###### 참고값(Accepted\n\n<!-- PAGE_10 -->\n###### reference\n\n<!-- PAGE_10 -->\n###### value)사이의\n\n<!-- PAGE_10 -->\n###### 일치\n\n<!-- PAGE_10 -->\n###### 근접도\n\n- - 4 -\n<!-- PAGE_11 -->\n###### (18) 직선성 (Linearity) : 실험 검체에 있는 분석물질의 농도[양]에 정비례\n\n<!-- PAGE_11 -->\n###### 하는 결과를 제공할 수 있는 능력\n\n<!-- PAGE_11 -->\n###### (19) 출혈시간(Bleeding time, BT) 검사 : 출혈시간 측정검사로 Duke법,\n\n<!-- PAGE_11 -->\n###### Ivy법, Template법 등을 이용하여 혈소판기능 선별검사로 사용\n\n<!-- PAGE_11 -->\n###### (20) 측정가능범위 (Analytical measurement range, AMR) : 일상적인\n\n<!-- PAGE_11 -->\n###### 측정 과정의 일부가 아닌 희석, 농축 또는 기타 전처리 없이 어떤\n\n<!-- PAGE_11 -->\n###### (21) 특이도 / 분석특이도 (Specificity / Analytical specificity) : 측정하고자\n\n<!-- PAGE_11 -->\n###### 하는 물질만 측정되고 검체 내 다른 물질은 측정 되지 않는 분석법의 능력\n\n<!-- PAGE_11 -->\n###### (22) 판정기준치 (Cut-off value) : 정성검사에서 경계치 이상을 양성으로,\n\n<!-- PAGE_11 -->\n###### 경계치 미만을 음성으로 보고할 수 있는 경계값을 말한다.  정량검사\n\n<!-- PAGE_11 -->\n###### 에서는 측정 결과가 임상적 또는 분석적 결정점(Decision point)의\n\n<!-- PAGE_11 -->\n###### 위 또는 아래에 있는지(양성 또는 음성) 결정하는데 사용되는 측정\n\n<!-- PAGE_11 -->\n###### (23) 편차 (Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n- - 5 -\n<!-- PAGE_12 -->\n###### 3.  출혈시간 및 항혈소판제제 저항성 복합검사기기의 정의 및 분류\n\n<!-- PAGE_12 -->\n###### 가.  개요\n\n<!-- PAGE_12 -->\n###### (1) 혈관벽 손상으로 출혈이 발생하면 혈소판은 손상 부위에 부착,\n\n<!-- PAGE_12 -->\n###### 다른 혈소판들과 응집, 추가 응집을 촉진시키기 위한 물질 분비 등\n\n<!-- PAGE_12 -->\n###### 3가지 과정을 통해 지혈을 유도한다.  이러한 반응으로 생긴 혈소판\n\n<!-- PAGE_12 -->\n###### (2) 혈소판 검사는 주로 선천성 혈소판기능이상이나 수술 전 선별검사로\n\n<!-- PAGE_12 -->\n###### 많이 사용된다.  특히 혈소판의 수적 이상이 없는 출혈성 질환에서\n\n<!-- PAGE_12 -->\n###### 선천성 혹은 후천성 혈소판 기능이상에 의한 출혈성 질환을 감별\n\n- - 6 -\n[그림 3] 혈소판 약물반응검사의 원리\n\n<!-- PAGE_13 -->\n###### (3) 최근에는 심혈관 및 뇌혈관 질환의 치료 및 예방에 사용되는 항혈소판\n\n<!-- PAGE_13 -->\n###### 약제의 선택과정에 있어서 환자에 적합한 올바른 약재 선택을 돕기 위한\n\n<!-- PAGE_13 -->\n###### 검사 및 약제의 장기간 복용으로 인한 출혈현상의 증가나 약제의 내성에\n\n<!-- PAGE_13 -->\n###### (4) 혈소판 기능검사 및 항혈소판제제 저항성을 측정하기 위한 측정방법은\n\n<!-- PAGE_13 -->\n###### 다양하며 현재 개발된 제품들의 측정방법은 Closure time(CT), 광투과량\n\n<!-- PAGE_13 -->\n###### 측정, 전기 임피던스 측정, 입사광산란 측정 등이다.  CT측정은 혈액이\n\n<!-- PAGE_13 -->\n###### 혈소판 작용으로 인해 미세구멍이 폐색되기까지의 시간을 측정하는 것이고,\n\n<!-- PAGE_13 -->\n###### 광투과량 측정은 혈소판 응집에 대한 빛의 투과도를 관찰한다. ",
        "original_sentence": "개요\n\n<!-- PAGE_12 -->\n###### (1) 혈관벽 손상으로 출혈이 발생하면 혈소판은 손상 부위에 부착,\n\n<!-- PAGE_12 -->\n###### 다른 혈소판들과 응집, 추가 응집을 촉진시키기 위한 물질 분비 등\n\n<!-- PAGE_12 -->\n###### 3가지 과정을 통해 지혈을 유도한다. "
      }
    },
    {
      "chunk_id": "chunk_270",
      "text": "이러한 반응으로 생긴 혈소판\n\n<!-- PAGE_12 -->\n###### (2) 혈소판 검사는 주로 선천성 혈소판기능이상이나 수술 전 선별검사로\n\n<!-- PAGE_12 -->\n###### 많이 사용된다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 269,
        "window_size": 3,
        "char_count": 115,
        "word_count": 23,
        "page_number": 12,
        "window_text": "정량검사\n\n<!-- PAGE_11 -->\n###### 에서는 측정 결과가 임상적 또는 분석적 결정점(Decision point)의\n\n<!-- PAGE_11 -->\n###### 위 또는 아래에 있는지(양성 또는 음성) 결정하는데 사용되는 측정\n\n<!-- PAGE_11 -->\n###### (23) 편차 (Bias) : 검사 결과의 예상치와 허용된 기준치 사이의 차이\n\n- - 5 -\n<!-- PAGE_12 -->\n###### 3.  출혈시간 및 항혈소판제제 저항성 복합검사기기의 정의 및 분류\n\n<!-- PAGE_12 -->\n###### 가.  개요\n\n<!-- PAGE_12 -->\n###### (1) 혈관벽 손상으로 출혈이 발생하면 혈소판은 손상 부위에 부착,\n\n<!-- PAGE_12 -->\n###### 다른 혈소판들과 응집, 추가 응집을 촉진시키기 위한 물질 분비 등\n\n<!-- PAGE_12 -->\n###### 3가지 과정을 통해 지혈을 유도한다.  이러한 반응으로 생긴 혈소판\n\n<!-- PAGE_12 -->\n###### (2) 혈소판 검사는 주로 선천성 혈소판기능이상이나 수술 전 선별검사로\n\n<!-- PAGE_12 -->\n###### 많이 사용된다.  특히 혈소판의 수적 이상이 없는 출혈성 질환에서\n\n<!-- PAGE_12 -->\n###### 선천성 혹은 후천성 혈소판 기능이상에 의한 출혈성 질환을 감별\n\n- - 6 -\n[그림 3] 혈소판 약물반응검사의 원리\n\n<!-- PAGE_13 -->\n###### (3) 최근에는 심혈관 및 뇌혈관 질환의 치료 및 예방에 사용되는 항혈소판\n\n<!-- PAGE_13 -->\n###### 약제의 선택과정에 있어서 환자에 적합한 올바른 약재 선택을 돕기 위한\n\n<!-- PAGE_13 -->\n###### 검사 및 약제의 장기간 복용으로 인한 출혈현상의 증가나 약제의 내성에\n\n<!-- PAGE_13 -->\n###### (4) 혈소판 기능검사 및 항혈소판제제 저항성을 측정하기 위한 측정방법은\n\n<!-- PAGE_13 -->\n###### 다양하며 현재 개발된 제품들의 측정방법은 Closure time(CT), 광투과량\n\n<!-- PAGE_13 -->\n###### 측정, 전기 임피던스 측정, 입사광산란 측정 등이다.  CT측정은 혈액이\n\n<!-- PAGE_13 -->\n###### 혈소판 작용으로 인해 미세구멍이 폐색되기까지의 시간을 측정하는 것이고,\n\n<!-- PAGE_13 -->\n###### 광투과량 측정은 혈소판 응집에 대한 빛의 투과도를 관찰한다.  전기\n\n<!-- PAGE_13 -->\n###### 임피던스 방식은 혈소판 응집으로 인한 전기장애를 측정하는 방식이고\n\n<!-- PAGE_13 -->\n###### 입사광산란 측정방식은 콜라겐 코팅에 대한 빛의 산란정도를 측정하는\n\n- - 7 -\n<!-- PAGE_14 -->\n###### (5) 본 가이드라인에서 적용하고 있는 출혈시간 및 항혈소판제제 저항성\n\n<!-- PAGE_14 -->\n###### 복합검사기기는 혈액 이동거리를 기반으로 혈소판의 전단 활성화 기능을\n\n<!-- PAGE_14 -->\n###### 측정하는 방식으로 혈소판기능 스크리닝과 항혈소판제제에 대한 저항성\n\n<!-- PAGE_14 -->\n###### 측정을 하나의 기기로 동시에 관찰이 가능하다.\n\n",
        "original_sentence": "이러한 반응으로 생긴 혈소판\n\n<!-- PAGE_12 -->\n###### (2) 혈소판 검사는 주로 선천성 혈소판기능이상이나 수술 전 선별검사로\n\n<!-- PAGE_12 -->\n###### 많이 사용된다. "
      }
    },
    {
      "chunk_id": "chunk_271",
      "text": "특히 혈소판의 수적 이상이 없는 출혈성 질환에서\n\n<!-- PAGE_12 -->\n###### 선천성 혹은 후천성 혈소판 기능이상에 의한 출혈성 질환을 감별\n\n- - 6 -\n[그림 3] 혈소판 약물반응검사의 원리\n\n<!-- PAGE_13 -->\n###### (3) 최근에는 심혈관 및 뇌혈관 질환의 치료 및 예방에 사용되는 항혈소판\n\n<!-- PAGE_13 -->\n###### 약제의 선택과정에 있어서 환자에 적합한 올바른 약재 선택을 돕기 위한\n\n<!-- PAGE_13 -->\n###### 검사 및 약제의 장기간 복용으로 인한 출혈현상의 증가나 약제의 내성에\n\n<!-- PAGE_13 -->\n###### (4) 혈소판 기능검사 및 항혈소판제제 저항성을 측정하기 위한 측정방법은\n\n<!-- PAGE_13 -->\n###### 다양하며 현재 개발된 제품들의 측정방법은 Closure time(CT), 광투과량\n\n<!-- PAGE_13 -->\n###### 측정, 전기 임피던스 측정, 입사광산란 측정 등이다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 270,
        "window_size": 3,
        "char_count": 505,
        "word_count": 108,
        "page_number": 12,
        "window_text": "출혈시간 및 항혈소판제제 저항성 복합검사기기의 정의 및 분류\n\n<!-- PAGE_12 -->\n###### 가.  개요\n\n<!-- PAGE_12 -->\n###### (1) 혈관벽 손상으로 출혈이 발생하면 혈소판은 손상 부위에 부착,\n\n<!-- PAGE_12 -->\n###### 다른 혈소판들과 응집, 추가 응집을 촉진시키기 위한 물질 분비 등\n\n<!-- PAGE_12 -->\n###### 3가지 과정을 통해 지혈을 유도한다.  이러한 반응으로 생긴 혈소판\n\n<!-- PAGE_12 -->\n###### (2) 혈소판 검사는 주로 선천성 혈소판기능이상이나 수술 전 선별검사로\n\n<!-- PAGE_12 -->\n###### 많이 사용된다.  특히 혈소판의 수적 이상이 없는 출혈성 질환에서\n\n<!-- PAGE_12 -->\n###### 선천성 혹은 후천성 혈소판 기능이상에 의한 출혈성 질환을 감별\n\n- - 6 -\n[그림 3] 혈소판 약물반응검사의 원리\n\n<!-- PAGE_13 -->\n###### (3) 최근에는 심혈관 및 뇌혈관 질환의 치료 및 예방에 사용되는 항혈소판\n\n<!-- PAGE_13 -->\n###### 약제의 선택과정에 있어서 환자에 적합한 올바른 약재 선택을 돕기 위한\n\n<!-- PAGE_13 -->\n###### 검사 및 약제의 장기간 복용으로 인한 출혈현상의 증가나 약제의 내성에\n\n<!-- PAGE_13 -->\n###### (4) 혈소판 기능검사 및 항혈소판제제 저항성을 측정하기 위한 측정방법은\n\n<!-- PAGE_13 -->\n###### 다양하며 현재 개발된 제품들의 측정방법은 Closure time(CT), 광투과량\n\n<!-- PAGE_13 -->\n###### 측정, 전기 임피던스 측정, 입사광산란 측정 등이다.  CT측정은 혈액이\n\n<!-- PAGE_13 -->\n###### 혈소판 작용으로 인해 미세구멍이 폐색되기까지의 시간을 측정하는 것이고,\n\n<!-- PAGE_13 -->\n###### 광투과량 측정은 혈소판 응집에 대한 빛의 투과도를 관찰한다.  전기\n\n<!-- PAGE_13 -->\n###### 임피던스 방식은 혈소판 응집으로 인한 전기장애를 측정하는 방식이고\n\n<!-- PAGE_13 -->\n###### 입사광산란 측정방식은 콜라겐 코팅에 대한 빛의 산란정도를 측정하는\n\n- - 7 -\n<!-- PAGE_14 -->\n###### (5) 본 가이드라인에서 적용하고 있는 출혈시간 및 항혈소판제제 저항성\n\n<!-- PAGE_14 -->\n###### 복합검사기기는 혈액 이동거리를 기반으로 혈소판의 전단 활성화 기능을\n\n<!-- PAGE_14 -->\n###### 측정하는 방식으로 혈소판기능 스크리닝과 항혈소판제제에 대한 저항성\n\n<!-- PAGE_14 -->\n###### 측정을 하나의 기기로 동시에 관찰이 가능하다.\n\n <!-- PAGE_14 -->\n###### 나. ",
        "original_sentence": "특히 혈소판의 수적 이상이 없는 출혈성 질환에서\n\n<!-- PAGE_12 -->\n###### 선천성 혹은 후천성 혈소판 기능이상에 의한 출혈성 질환을 감별\n\n- - 6 -\n[그림 3] 혈소판 약물반응검사의 원리\n\n<!-- PAGE_13 -->\n###### (3) 최근에는 심혈관 및 뇌혈관 질환의 치료 및 예방에 사용되는 항혈소판\n\n<!-- PAGE_13 -->\n###### 약제의 선택과정에 있어서 환자에 적합한 올바른 약재 선택을 돕기 위한\n\n<!-- PAGE_13 -->\n###### 검사 및 약제의 장기간 복용으로 인한 출혈현상의 증가나 약제의 내성에\n\n<!-- PAGE_13 -->\n###### (4) 혈소판 기능검사 및 항혈소판제제 저항성을 측정하기 위한 측정방법은\n\n<!-- PAGE_13 -->\n###### 다양하며 현재 개발된 제품들의 측정방법은 Closure time(CT), 광투과량\n\n<!-- PAGE_13 -->\n###### 측정, 전기 임피던스 측정, 입사광산란 측정 등이다. "
      }
    },
    {
      "chunk_id": "chunk_272",
      "text": "CT측정은 혈액이\n\n<!-- PAGE_13 -->\n###### 혈소판 작용으로 인해 미세구멍이 폐색되기까지의 시간을 측정하는 것이고,\n\n<!-- PAGE_13 -->\n###### 광투과량 측정은 혈소판 응집에 대한 빛의 투과도를 관찰한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 271,
        "window_size": 3,
        "char_count": 134,
        "word_count": 26,
        "page_number": 13,
        "window_text": "개요\n\n<!-- PAGE_12 -->\n###### (1) 혈관벽 손상으로 출혈이 발생하면 혈소판은 손상 부위에 부착,\n\n<!-- PAGE_12 -->\n###### 다른 혈소판들과 응집, 추가 응집을 촉진시키기 위한 물질 분비 등\n\n<!-- PAGE_12 -->\n###### 3가지 과정을 통해 지혈을 유도한다.  이러한 반응으로 생긴 혈소판\n\n<!-- PAGE_12 -->\n###### (2) 혈소판 검사는 주로 선천성 혈소판기능이상이나 수술 전 선별검사로\n\n<!-- PAGE_12 -->\n###### 많이 사용된다.  특히 혈소판의 수적 이상이 없는 출혈성 질환에서\n\n<!-- PAGE_12 -->\n###### 선천성 혹은 후천성 혈소판 기능이상에 의한 출혈성 질환을 감별\n\n- - 6 -\n[그림 3] 혈소판 약물반응검사의 원리\n\n<!-- PAGE_13 -->\n###### (3) 최근에는 심혈관 및 뇌혈관 질환의 치료 및 예방에 사용되는 항혈소판\n\n<!-- PAGE_13 -->\n###### 약제의 선택과정에 있어서 환자에 적합한 올바른 약재 선택을 돕기 위한\n\n<!-- PAGE_13 -->\n###### 검사 및 약제의 장기간 복용으로 인한 출혈현상의 증가나 약제의 내성에\n\n<!-- PAGE_13 -->\n###### (4) 혈소판 기능검사 및 항혈소판제제 저항성을 측정하기 위한 측정방법은\n\n<!-- PAGE_13 -->\n###### 다양하며 현재 개발된 제품들의 측정방법은 Closure time(CT), 광투과량\n\n<!-- PAGE_13 -->\n###### 측정, 전기 임피던스 측정, 입사광산란 측정 등이다.  CT측정은 혈액이\n\n<!-- PAGE_13 -->\n###### 혈소판 작용으로 인해 미세구멍이 폐색되기까지의 시간을 측정하는 것이고,\n\n<!-- PAGE_13 -->\n###### 광투과량 측정은 혈소판 응집에 대한 빛의 투과도를 관찰한다.  전기\n\n<!-- PAGE_13 -->\n###### 임피던스 방식은 혈소판 응집으로 인한 전기장애를 측정하는 방식이고\n\n<!-- PAGE_13 -->\n###### 입사광산란 측정방식은 콜라겐 코팅에 대한 빛의 산란정도를 측정하는\n\n- - 7 -\n<!-- PAGE_14 -->\n###### (5) 본 가이드라인에서 적용하고 있는 출혈시간 및 항혈소판제제 저항성\n\n<!-- PAGE_14 -->\n###### 복합검사기기는 혈액 이동거리를 기반으로 혈소판의 전단 활성화 기능을\n\n<!-- PAGE_14 -->\n###### 측정하는 방식으로 혈소판기능 스크리닝과 항혈소판제제에 대한 저항성\n\n<!-- PAGE_14 -->\n###### 측정을 하나의 기기로 동시에 관찰이 가능하다.\n\n <!-- PAGE_14 -->\n###### 나.  제품 허가 현황\n\n<!-- PAGE_14 -->\n###### (1) 출혈시간 및 항혈소판제제 저항성 복합검사기기는 주로 수입 의료\n\n<!-- PAGE_14 -->\n###### 기기에 의존하고 있고 국내 개발 제품은 없는 상태이다. ",
        "original_sentence": "CT측정은 혈액이\n\n<!-- PAGE_13 -->\n###### 혈소판 작용으로 인해 미세구멍이 폐색되기까지의 시간을 측정하는 것이고,\n\n<!-- PAGE_13 -->\n###### 광투과량 측정은 혈소판 응집에 대한 빛의 투과도를 관찰한다. "
      }
    },
    {
      "chunk_id": "chunk_273",
      "text": "전기\n\n<!-- PAGE_13 -->\n###### 임피던스 방식은 혈소판 응집으로 인한 전기장애를 측정하는 방식이고\n\n<!-- PAGE_13 -->\n###### 입사광산란 측정방식은 콜라겐 코팅에 대한 빛의 산란정도를 측정하는\n\n- - 7 -\n<!-- PAGE_14 -->\n###### (5) 본 가이드라인에서 적용하고 있는 출혈시간 및 항혈소판제제 저항성\n\n<!-- PAGE_14 -->\n###### 복합검사기기는 혈액 이동거리를 기반으로 혈소판의 전단 활성화 기능을\n\n<!-- PAGE_14 -->\n###### 측정하는 방식으로 혈소판기능 스크리닝과 항혈소판제제에 대한 저항성\n\n<!-- PAGE_14 -->\n###### 측정을 하나의 기기로 동시에 관찰이 가능하다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 272,
        "window_size": 3,
        "char_count": 377,
        "word_count": 75,
        "page_number": 13,
        "window_text": "이러한 반응으로 생긴 혈소판\n\n<!-- PAGE_12 -->\n###### (2) 혈소판 검사는 주로 선천성 혈소판기능이상이나 수술 전 선별검사로\n\n<!-- PAGE_12 -->\n###### 많이 사용된다.  특히 혈소판의 수적 이상이 없는 출혈성 질환에서\n\n<!-- PAGE_12 -->\n###### 선천성 혹은 후천성 혈소판 기능이상에 의한 출혈성 질환을 감별\n\n- - 6 -\n[그림 3] 혈소판 약물반응검사의 원리\n\n<!-- PAGE_13 -->\n###### (3) 최근에는 심혈관 및 뇌혈관 질환의 치료 및 예방에 사용되는 항혈소판\n\n<!-- PAGE_13 -->\n###### 약제의 선택과정에 있어서 환자에 적합한 올바른 약재 선택을 돕기 위한\n\n<!-- PAGE_13 -->\n###### 검사 및 약제의 장기간 복용으로 인한 출혈현상의 증가나 약제의 내성에\n\n<!-- PAGE_13 -->\n###### (4) 혈소판 기능검사 및 항혈소판제제 저항성을 측정하기 위한 측정방법은\n\n<!-- PAGE_13 -->\n###### 다양하며 현재 개발된 제품들의 측정방법은 Closure time(CT), 광투과량\n\n<!-- PAGE_13 -->\n###### 측정, 전기 임피던스 측정, 입사광산란 측정 등이다.  CT측정은 혈액이\n\n<!-- PAGE_13 -->\n###### 혈소판 작용으로 인해 미세구멍이 폐색되기까지의 시간을 측정하는 것이고,\n\n<!-- PAGE_13 -->\n###### 광투과량 측정은 혈소판 응집에 대한 빛의 투과도를 관찰한다.  전기\n\n<!-- PAGE_13 -->\n###### 임피던스 방식은 혈소판 응집으로 인한 전기장애를 측정하는 방식이고\n\n<!-- PAGE_13 -->\n###### 입사광산란 측정방식은 콜라겐 코팅에 대한 빛의 산란정도를 측정하는\n\n- - 7 -\n<!-- PAGE_14 -->\n###### (5) 본 가이드라인에서 적용하고 있는 출혈시간 및 항혈소판제제 저항성\n\n<!-- PAGE_14 -->\n###### 복합검사기기는 혈액 이동거리를 기반으로 혈소판의 전단 활성화 기능을\n\n<!-- PAGE_14 -->\n###### 측정하는 방식으로 혈소판기능 스크리닝과 항혈소판제제에 대한 저항성\n\n<!-- PAGE_14 -->\n###### 측정을 하나의 기기로 동시에 관찰이 가능하다.\n\n <!-- PAGE_14 -->\n###### 나.  제품 허가 현황\n\n<!-- PAGE_14 -->\n###### (1) 출혈시간 및 항혈소판제제 저항성 복합검사기기는 주로 수입 의료\n\n<!-- PAGE_14 -->\n###### 기기에 의존하고 있고 국내 개발 제품은 없는 상태이다.  (‘16.10.31 기준)\n\n<!-- PAGE_14 -->\n###### (2) 출혈시간 및 항혈소판제제 저항성 복합검사기기로 국내에서 수입허가를\n\n- - 8 -\n번호\n\n업체명\n\n품목허가번호\n\n허가/신고일\n\n모델명\n\n1\n\n티메드(주)\n\n서울 수신\n\n14-1203호\n\n2014년 4월 14일\n\nA-100\n\n2\n\n지멘스헬스케어(주)\n\n서울 수신\n\n11-522호\n\n2011년 4월 8일\n\nINNOVANCE PFA-200 System\n\n3\n\n한국로슈진단(주)\n\n서울 수신\n\n11-392호\n\n2011년 3월 21일\n\nMultiplate 5.0 - Platelet\n\n4\n\n백두대\n\n경인 수신\n\n05-110호\n\n2005년 9월 2일\n\nVerifyNow System\n\n5\n\n성원메디칼상사\n\n서울 수신\n\n05-1722호\n\n2005년 11월 14일\n\nHemoRam/AggRAM Analyzer\n\n[표 1] 국내업체 혈소판 기능검사 장비 허가사항\n\n(‘16.10.31 기준)\n\n번호\n\n업체명\n\n품목허가번호\n\n허가/신고일\n\n모델명\n\n1\n\n티메드(주)\n\n수허 16-200 호\n\n2016년 4월 1일\n\nAggreGuide A-100 ADP Assay\n\n2\n\n티메드(주)\n\n수허 15-467 호\n\n2015년 2월 12일\n\nAA assay cartridge\n\n3\n\n지멘스헬스케어(주)\n\n수허 12-1743 호\n\n2012년 12월 5일\n\n4\n\n지멘스헬스케어(주)\n\n수허 12-1735 호\n\n2012년 12월 5일\n\nINNOVANCE PFA P2Y\n\n5\n\n지멘스헬스케어(주)\n\n수허 12-1710 호\n\n2012년 12월 4일\n\n6\n\n성원메디칼상사\n\n수허 13-1207 호\n\n2013년 7월 10일\n\nEpinephrine Reagent\n\n7\n\n성원메디칼상사\n\n수허 13-1206 호\n\n2013년 7월 10일\n\nArachidonic Acid Reagent\n\n8\n\n성원메디칼상사\n\n수허 13-1205 호\n\n2013년 7월 10일\n\nADP Reagent\n\n9\n\n성원메디칼상사\n\n수허 13-1208 호\n\n2013년 7월 10일\n\nCollagen Reagent\n\n10\n\n한국로슈진단(주)\n\n수허 12-2234 호\n\n2012년 12월 27일\n\n11\n\n한국로슈진단(주)\n\n수허 12-2232 호\n\n2012년 12월 27일\n\nRoche TRAPtest\n\n12\n\n한국로슈진단(주)\n\n수허 12-2213 호\n\n2012년 12월 27일\n\nRoche COLtest\n\n13\n\n한국로슈진단(주)\n\n수허 12-2058 호\n\n2012년 12월 21일\n\nRoche ASPItest\n\n14\n\n한국로슈진단(주)\n\n수허 12-1932 호\n\n2012년 12월 13일\n\nRoche ADPtest\n\n15\n\n백두대\n\n수허 12-1648 호\n\n2012년 11월 26일\n\nVerifyNow P2Y12 Test\n\n16\n\n백두대\n\n수허 12-1652 호\n\n2012년 11월 27일\n\nVerifyNow Aspirin Test\n\n(‘16.10.31 기준)\n\n- - 9 -\n<!-- PAGE_16 -->\n###### 다. ",
        "original_sentence": "전기\n\n<!-- PAGE_13 -->\n###### 임피던스 방식은 혈소판 응집으로 인한 전기장애를 측정하는 방식이고\n\n<!-- PAGE_13 -->\n###### 입사광산란 측정방식은 콜라겐 코팅에 대한 빛의 산란정도를 측정하는\n\n- - 7 -\n<!-- PAGE_14 -->\n###### (5) 본 가이드라인에서 적용하고 있는 출혈시간 및 항혈소판제제 저항성\n\n<!-- PAGE_14 -->\n###### 복합검사기기는 혈액 이동거리를 기반으로 혈소판의 전단 활성화 기능을\n\n<!-- PAGE_14 -->\n###### 측정하는 방식으로 혈소판기능 스크리닝과 항혈소판제제에 대한 저항성\n\n<!-- PAGE_14 -->\n###### 측정을 하나의 기기로 동시에 관찰이 가능하다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_274",
      "text": "<!-- PAGE_14 -->\n###### 나. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 273,
        "window_size": 3,
        "char_count": 27,
        "word_count": 5,
        "page_number": 14,
        "window_text": "특히 혈소판의 수적 이상이 없는 출혈성 질환에서\n\n<!-- PAGE_12 -->\n###### 선천성 혹은 후천성 혈소판 기능이상에 의한 출혈성 질환을 감별\n\n- - 6 -\n[그림 3] 혈소판 약물반응검사의 원리\n\n<!-- PAGE_13 -->\n###### (3) 최근에는 심혈관 및 뇌혈관 질환의 치료 및 예방에 사용되는 항혈소판\n\n<!-- PAGE_13 -->\n###### 약제의 선택과정에 있어서 환자에 적합한 올바른 약재 선택을 돕기 위한\n\n<!-- PAGE_13 -->\n###### 검사 및 약제의 장기간 복용으로 인한 출혈현상의 증가나 약제의 내성에\n\n<!-- PAGE_13 -->\n###### (4) 혈소판 기능검사 및 항혈소판제제 저항성을 측정하기 위한 측정방법은\n\n<!-- PAGE_13 -->\n###### 다양하며 현재 개발된 제품들의 측정방법은 Closure time(CT), 광투과량\n\n<!-- PAGE_13 -->\n###### 측정, 전기 임피던스 측정, 입사광산란 측정 등이다.  CT측정은 혈액이\n\n<!-- PAGE_13 -->\n###### 혈소판 작용으로 인해 미세구멍이 폐색되기까지의 시간을 측정하는 것이고,\n\n<!-- PAGE_13 -->\n###### 광투과량 측정은 혈소판 응집에 대한 빛의 투과도를 관찰한다.  전기\n\n<!-- PAGE_13 -->\n###### 임피던스 방식은 혈소판 응집으로 인한 전기장애를 측정하는 방식이고\n\n<!-- PAGE_13 -->\n###### 입사광산란 측정방식은 콜라겐 코팅에 대한 빛의 산란정도를 측정하는\n\n- - 7 -\n<!-- PAGE_14 -->\n###### (5) 본 가이드라인에서 적용하고 있는 출혈시간 및 항혈소판제제 저항성\n\n<!-- PAGE_14 -->\n###### 복합검사기기는 혈액 이동거리를 기반으로 혈소판의 전단 활성화 기능을\n\n<!-- PAGE_14 -->\n###### 측정하는 방식으로 혈소판기능 스크리닝과 항혈소판제제에 대한 저항성\n\n<!-- PAGE_14 -->\n###### 측정을 하나의 기기로 동시에 관찰이 가능하다.\n\n <!-- PAGE_14 -->\n###### 나.  제품 허가 현황\n\n<!-- PAGE_14 -->\n###### (1) 출혈시간 및 항혈소판제제 저항성 복합검사기기는 주로 수입 의료\n\n<!-- PAGE_14 -->\n###### 기기에 의존하고 있고 국내 개발 제품은 없는 상태이다.  (‘16.10.31 기준)\n\n<!-- PAGE_14 -->\n###### (2) 출혈시간 및 항혈소판제제 저항성 복합검사기기로 국내에서 수입허가를\n\n- - 8 -\n번호\n\n업체명\n\n품목허가번호\n\n허가/신고일\n\n모델명\n\n1\n\n티메드(주)\n\n서울 수신\n\n14-1203호\n\n2014년 4월 14일\n\nA-100\n\n2\n\n지멘스헬스케어(주)\n\n서울 수신\n\n11-522호\n\n2011년 4월 8일\n\nINNOVANCE PFA-200 System\n\n3\n\n한국로슈진단(주)\n\n서울 수신\n\n11-392호\n\n2011년 3월 21일\n\nMultiplate 5.0 - Platelet\n\n4\n\n백두대\n\n경인 수신\n\n05-110호\n\n2005년 9월 2일\n\nVerifyNow System\n\n5\n\n성원메디칼상사\n\n서울 수신\n\n05-1722호\n\n2005년 11월 14일\n\nHemoRam/AggRAM Analyzer\n\n[표 1] 국내업체 혈소판 기능검사 장비 허가사항\n\n(‘16.10.31 기준)\n\n번호\n\n업체명\n\n품목허가번호\n\n허가/신고일\n\n모델명\n\n1\n\n티메드(주)\n\n수허 16-200 호\n\n2016년 4월 1일\n\nAggreGuide A-100 ADP Assay\n\n2\n\n티메드(주)\n\n수허 15-467 호\n\n2015년 2월 12일\n\nAA assay cartridge\n\n3\n\n지멘스헬스케어(주)\n\n수허 12-1743 호\n\n2012년 12월 5일\n\n4\n\n지멘스헬스케어(주)\n\n수허 12-1735 호\n\n2012년 12월 5일\n\nINNOVANCE PFA P2Y\n\n5\n\n지멘스헬스케어(주)\n\n수허 12-1710 호\n\n2012년 12월 4일\n\n6\n\n성원메디칼상사\n\n수허 13-1207 호\n\n2013년 7월 10일\n\nEpinephrine Reagent\n\n7\n\n성원메디칼상사\n\n수허 13-1206 호\n\n2013년 7월 10일\n\nArachidonic Acid Reagent\n\n8\n\n성원메디칼상사\n\n수허 13-1205 호\n\n2013년 7월 10일\n\nADP Reagent\n\n9\n\n성원메디칼상사\n\n수허 13-1208 호\n\n2013년 7월 10일\n\nCollagen Reagent\n\n10\n\n한국로슈진단(주)\n\n수허 12-2234 호\n\n2012년 12월 27일\n\n11\n\n한국로슈진단(주)\n\n수허 12-2232 호\n\n2012년 12월 27일\n\nRoche TRAPtest\n\n12\n\n한국로슈진단(주)\n\n수허 12-2213 호\n\n2012년 12월 27일\n\nRoche COLtest\n\n13\n\n한국로슈진단(주)\n\n수허 12-2058 호\n\n2012년 12월 21일\n\nRoche ASPItest\n\n14\n\n한국로슈진단(주)\n\n수허 12-1932 호\n\n2012년 12월 13일\n\nRoche ADPtest\n\n15\n\n백두대\n\n수허 12-1648 호\n\n2012년 11월 26일\n\nVerifyNow P2Y12 Test\n\n16\n\n백두대\n\n수허 12-1652 호\n\n2012년 11월 27일\n\nVerifyNow Aspirin Test\n\n(‘16.10.31 기준)\n\n- - 9 -\n<!-- PAGE_16 -->\n###### 다.  국외 허가동향\n\n<!-- PAGE_16 -->\n###### (1) 혈소판 기능검사는 전혈이 주로 검체로 사용되기 때문에 표준물질\n\n<!-- PAGE_16 -->\n###### 개발이 어려워 제품 개발 및 시험 자체가 어려운 특성이 있다.\n\n",
        "original_sentence": "<!-- PAGE_14 -->\n###### 나. "
      }
    },
    {
      "chunk_id": "chunk_275",
      "text": "제품 허가 현황\n\n<!-- PAGE_14 -->\n###### (1) 출혈시간 및 항혈소판제제 저항성 복합검사기기는 주로 수입 의료\n\n<!-- PAGE_14 -->\n###### 기기에 의존하고 있고 국내 개발 제품은 없는 상태이다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 274,
        "window_size": 3,
        "char_count": 129,
        "word_count": 28,
        "page_number": 14,
        "window_text": "CT측정은 혈액이\n\n<!-- PAGE_13 -->\n###### 혈소판 작용으로 인해 미세구멍이 폐색되기까지의 시간을 측정하는 것이고,\n\n<!-- PAGE_13 -->\n###### 광투과량 측정은 혈소판 응집에 대한 빛의 투과도를 관찰한다.  전기\n\n<!-- PAGE_13 -->\n###### 임피던스 방식은 혈소판 응집으로 인한 전기장애를 측정하는 방식이고\n\n<!-- PAGE_13 -->\n###### 입사광산란 측정방식은 콜라겐 코팅에 대한 빛의 산란정도를 측정하는\n\n- - 7 -\n<!-- PAGE_14 -->\n###### (5) 본 가이드라인에서 적용하고 있는 출혈시간 및 항혈소판제제 저항성\n\n<!-- PAGE_14 -->\n###### 복합검사기기는 혈액 이동거리를 기반으로 혈소판의 전단 활성화 기능을\n\n<!-- PAGE_14 -->\n###### 측정하는 방식으로 혈소판기능 스크리닝과 항혈소판제제에 대한 저항성\n\n<!-- PAGE_14 -->\n###### 측정을 하나의 기기로 동시에 관찰이 가능하다.\n\n <!-- PAGE_14 -->\n###### 나.  제품 허가 현황\n\n<!-- PAGE_14 -->\n###### (1) 출혈시간 및 항혈소판제제 저항성 복합검사기기는 주로 수입 의료\n\n<!-- PAGE_14 -->\n###### 기기에 의존하고 있고 국내 개발 제품은 없는 상태이다.  (‘16.10.31 기준)\n\n<!-- PAGE_14 -->\n###### (2) 출혈시간 및 항혈소판제제 저항성 복합검사기기로 국내에서 수입허가를\n\n- - 8 -\n번호\n\n업체명\n\n품목허가번호\n\n허가/신고일\n\n모델명\n\n1\n\n티메드(주)\n\n서울 수신\n\n14-1203호\n\n2014년 4월 14일\n\nA-100\n\n2\n\n지멘스헬스케어(주)\n\n서울 수신\n\n11-522호\n\n2011년 4월 8일\n\nINNOVANCE PFA-200 System\n\n3\n\n한국로슈진단(주)\n\n서울 수신\n\n11-392호\n\n2011년 3월 21일\n\nMultiplate 5.0 - Platelet\n\n4\n\n백두대\n\n경인 수신\n\n05-110호\n\n2005년 9월 2일\n\nVerifyNow System\n\n5\n\n성원메디칼상사\n\n서울 수신\n\n05-1722호\n\n2005년 11월 14일\n\nHemoRam/AggRAM Analyzer\n\n[표 1] 국내업체 혈소판 기능검사 장비 허가사항\n\n(‘16.10.31 기준)\n\n번호\n\n업체명\n\n품목허가번호\n\n허가/신고일\n\n모델명\n\n1\n\n티메드(주)\n\n수허 16-200 호\n\n2016년 4월 1일\n\nAggreGuide A-100 ADP Assay\n\n2\n\n티메드(주)\n\n수허 15-467 호\n\n2015년 2월 12일\n\nAA assay cartridge\n\n3\n\n지멘스헬스케어(주)\n\n수허 12-1743 호\n\n2012년 12월 5일\n\n4\n\n지멘스헬스케어(주)\n\n수허 12-1735 호\n\n2012년 12월 5일\n\nINNOVANCE PFA P2Y\n\n5\n\n지멘스헬스케어(주)\n\n수허 12-1710 호\n\n2012년 12월 4일\n\n6\n\n성원메디칼상사\n\n수허 13-1207 호\n\n2013년 7월 10일\n\nEpinephrine Reagent\n\n7\n\n성원메디칼상사\n\n수허 13-1206 호\n\n2013년 7월 10일\n\nArachidonic Acid Reagent\n\n8\n\n성원메디칼상사\n\n수허 13-1205 호\n\n2013년 7월 10일\n\nADP Reagent\n\n9\n\n성원메디칼상사\n\n수허 13-1208 호\n\n2013년 7월 10일\n\nCollagen Reagent\n\n10\n\n한국로슈진단(주)\n\n수허 12-2234 호\n\n2012년 12월 27일\n\n11\n\n한국로슈진단(주)\n\n수허 12-2232 호\n\n2012년 12월 27일\n\nRoche TRAPtest\n\n12\n\n한국로슈진단(주)\n\n수허 12-2213 호\n\n2012년 12월 27일\n\nRoche COLtest\n\n13\n\n한국로슈진단(주)\n\n수허 12-2058 호\n\n2012년 12월 21일\n\nRoche ASPItest\n\n14\n\n한국로슈진단(주)\n\n수허 12-1932 호\n\n2012년 12월 13일\n\nRoche ADPtest\n\n15\n\n백두대\n\n수허 12-1648 호\n\n2012년 11월 26일\n\nVerifyNow P2Y12 Test\n\n16\n\n백두대\n\n수허 12-1652 호\n\n2012년 11월 27일\n\nVerifyNow Aspirin Test\n\n(‘16.10.31 기준)\n\n- - 9 -\n<!-- PAGE_16 -->\n###### 다.  국외 허가동향\n\n<!-- PAGE_16 -->\n###### (1) 혈소판 기능검사는 전혈이 주로 검체로 사용되기 때문에 표준물질\n\n<!-- PAGE_16 -->\n###### 개발이 어려워 제품 개발 및 시험 자체가 어려운 특성이 있다.\n\n <!-- PAGE_16 -->\n###### (2) 혈소판 기능검사를 평가를 위한 기준을 제시하는 국제규격 및 가이드\n\n<!-- PAGE_16 -->\n###### (3)\n\n<!-- PAGE_16 -->\n###### 침습적\n\n<!-- PAGE_16 -->\n###### 방식의\n\n<!-- PAGE_16 -->\n###### 출혈시간(Bleeding\n\n<!-- PAGE_16 -->\n###### time,\n\n<!-- PAGE_16 -->\n###### BT)검사\n\n<!-- PAGE_16 -->\n###### 이후\n\n<!-- PAGE_16 -->\n###### 독일\n\n<!-- PAGE_16 -->\n###### Siemens사의 PFA-100과 ITC사의 VerifyNow를 통해 혈소판 기능을\n\n<!-- PAGE_16 -->\n###### 자동 검사법과 항혈소판제제 저항성 검사법이 시장을 확대하며\n\n<!-- PAGE_16 -->\n###### (4) 혈소판 기능검사를 위한 검사법은 지속적으로 개발 및 발전하고\n\n<!-- PAGE_16 -->\n###### 있으며 검사를 위한 작용원리 또한 Closure time(혈소판 작용으로\n\n<!-- PAGE_16 -->\n###### 혈액이 미세구멍을 막는 시간 측정), 광투과량 측정방식, 전기 임피던스\n\n<!-- PAGE_16 -->\n###### 측정방식, 입사광산란 파악방식 등으로 업체의 개발 기술에 따라 다양\n\n- - 10 -\n<!-- PAGE_17 -->\n###### 4. ",
        "original_sentence": "제품 허가 현황\n\n<!-- PAGE_14 -->\n###### (1) 출혈시간 및 항혈소판제제 저항성 복합검사기기는 주로 수입 의료\n\n<!-- PAGE_14 -->\n###### 기기에 의존하고 있고 국내 개발 제품은 없는 상태이다. "
      }
    },
    {
      "chunk_id": "chunk_276",
      "text": "(‘16.10.31 기준)\n\n<!-- PAGE_14 -->\n###### (2) 출혈시간 및 항혈소판제제 저항성 복합검사기기로 국내에서 수입허가를\n\n- - 8 -\n번호\n\n업체명\n\n품목허가번호\n\n허가/신고일\n\n모델명\n\n1\n\n티메드(주)\n\n서울 수신\n\n14-1203호\n\n2014년 4월 14일\n\nA-100\n\n2\n\n지멘스헬스케어(주)\n\n서울 수신\n\n11-522호\n\n2011년 4월 8일\n\nINNOVANCE PFA-200 System\n\n3\n\n한국로슈진단(주)\n\n서울 수신\n\n11-392호\n\n2011년 3월 21일\n\nMultiplate 5.0 - Platelet\n\n4\n\n백두대\n\n경인 수신\n\n05-110호\n\n2005년 9월 2일\n\nVerifyNow System\n\n5\n\n성원메디칼상사\n\n서울 수신\n\n05-1722호\n\n2005년 11월 14일\n\nHemoRam/AggRAM Analyzer\n\n[표 1] 국내업체 혈소판 기능검사 장비 허가사항\n\n(‘16.10.31 기준)\n\n번호\n\n업체명\n\n품목허가번호\n\n허가/신고일\n\n모델명\n\n1\n\n티메드(주)\n\n수허 16-200 호\n\n2016년 4월 1일\n\nAggreGuide A-100 ADP Assay\n\n2\n\n티메드(주)\n\n수허 15-467 호\n\n2015년 2월 12일\n\nAA assay cartridge\n\n3\n\n지멘스헬스케어(주)\n\n수허 12-1743 호\n\n2012년 12월 5일\n\n4\n\n지멘스헬스케어(주)\n\n수허 12-1735 호\n\n2012년 12월 5일\n\nINNOVANCE PFA P2Y\n\n5\n\n지멘스헬스케어(주)\n\n수허 12-1710 호\n\n2012년 12월 4일\n\n6\n\n성원메디칼상사\n\n수허 13-1207 호\n\n2013년 7월 10일\n\nEpinephrine Reagent\n\n7\n\n성원메디칼상사\n\n수허 13-1206 호\n\n2013년 7월 10일\n\nArachidonic Acid Reagent\n\n8\n\n성원메디칼상사\n\n수허 13-1205 호\n\n2013년 7월 10일\n\nADP Reagent\n\n9\n\n성원메디칼상사\n\n수허 13-1208 호\n\n2013년 7월 10일\n\nCollagen Reagent\n\n10\n\n한국로슈진단(주)\n\n수허 12-2234 호\n\n2012년 12월 27일\n\n11\n\n한국로슈진단(주)\n\n수허 12-2232 호\n\n2012년 12월 27일\n\nRoche TRAPtest\n\n12\n\n한국로슈진단(주)\n\n수허 12-2213 호\n\n2012년 12월 27일\n\nRoche COLtest\n\n13\n\n한국로슈진단(주)\n\n수허 12-2058 호\n\n2012년 12월 21일\n\nRoche ASPItest\n\n14\n\n한국로슈진단(주)\n\n수허 12-1932 호\n\n2012년 12월 13일\n\nRoche ADPtest\n\n15\n\n백두대\n\n수허 12-1648 호\n\n2012년 11월 26일\n\nVerifyNow P2Y12 Test\n\n16\n\n백두대\n\n수허 12-1652 호\n\n2012년 11월 27일\n\nVerifyNow Aspirin Test\n\n(‘16.10.31 기준)\n\n- - 9 -\n<!-- PAGE_16 -->\n###### 다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 275,
        "window_size": 3,
        "char_count": 1473,
        "word_count": 261,
        "page_number": 14,
        "window_text": "전기\n\n<!-- PAGE_13 -->\n###### 임피던스 방식은 혈소판 응집으로 인한 전기장애를 측정하는 방식이고\n\n<!-- PAGE_13 -->\n###### 입사광산란 측정방식은 콜라겐 코팅에 대한 빛의 산란정도를 측정하는\n\n- - 7 -\n<!-- PAGE_14 -->\n###### (5) 본 가이드라인에서 적용하고 있는 출혈시간 및 항혈소판제제 저항성\n\n<!-- PAGE_14 -->\n###### 복합검사기기는 혈액 이동거리를 기반으로 혈소판의 전단 활성화 기능을\n\n<!-- PAGE_14 -->\n###### 측정하는 방식으로 혈소판기능 스크리닝과 항혈소판제제에 대한 저항성\n\n<!-- PAGE_14 -->\n###### 측정을 하나의 기기로 동시에 관찰이 가능하다.\n\n <!-- PAGE_14 -->\n###### 나.  제품 허가 현황\n\n<!-- PAGE_14 -->\n###### (1) 출혈시간 및 항혈소판제제 저항성 복합검사기기는 주로 수입 의료\n\n<!-- PAGE_14 -->\n###### 기기에 의존하고 있고 국내 개발 제품은 없는 상태이다.  (‘16.10.31 기준)\n\n<!-- PAGE_14 -->\n###### (2) 출혈시간 및 항혈소판제제 저항성 복합검사기기로 국내에서 수입허가를\n\n- - 8 -\n번호\n\n업체명\n\n품목허가번호\n\n허가/신고일\n\n모델명\n\n1\n\n티메드(주)\n\n서울 수신\n\n14-1203호\n\n2014년 4월 14일\n\nA-100\n\n2\n\n지멘스헬스케어(주)\n\n서울 수신\n\n11-522호\n\n2011년 4월 8일\n\nINNOVANCE PFA-200 System\n\n3\n\n한국로슈진단(주)\n\n서울 수신\n\n11-392호\n\n2011년 3월 21일\n\nMultiplate 5.0 - Platelet\n\n4\n\n백두대\n\n경인 수신\n\n05-110호\n\n2005년 9월 2일\n\nVerifyNow System\n\n5\n\n성원메디칼상사\n\n서울 수신\n\n05-1722호\n\n2005년 11월 14일\n\nHemoRam/AggRAM Analyzer\n\n[표 1] 국내업체 혈소판 기능검사 장비 허가사항\n\n(‘16.10.31 기준)\n\n번호\n\n업체명\n\n품목허가번호\n\n허가/신고일\n\n모델명\n\n1\n\n티메드(주)\n\n수허 16-200 호\n\n2016년 4월 1일\n\nAggreGuide A-100 ADP Assay\n\n2\n\n티메드(주)\n\n수허 15-467 호\n\n2015년 2월 12일\n\nAA assay cartridge\n\n3\n\n지멘스헬스케어(주)\n\n수허 12-1743 호\n\n2012년 12월 5일\n\n4\n\n지멘스헬스케어(주)\n\n수허 12-1735 호\n\n2012년 12월 5일\n\nINNOVANCE PFA P2Y\n\n5\n\n지멘스헬스케어(주)\n\n수허 12-1710 호\n\n2012년 12월 4일\n\n6\n\n성원메디칼상사\n\n수허 13-1207 호\n\n2013년 7월 10일\n\nEpinephrine Reagent\n\n7\n\n성원메디칼상사\n\n수허 13-1206 호\n\n2013년 7월 10일\n\nArachidonic Acid Reagent\n\n8\n\n성원메디칼상사\n\n수허 13-1205 호\n\n2013년 7월 10일\n\nADP Reagent\n\n9\n\n성원메디칼상사\n\n수허 13-1208 호\n\n2013년 7월 10일\n\nCollagen Reagent\n\n10\n\n한국로슈진단(주)\n\n수허 12-2234 호\n\n2012년 12월 27일\n\n11\n\n한국로슈진단(주)\n\n수허 12-2232 호\n\n2012년 12월 27일\n\nRoche TRAPtest\n\n12\n\n한국로슈진단(주)\n\n수허 12-2213 호\n\n2012년 12월 27일\n\nRoche COLtest\n\n13\n\n한국로슈진단(주)\n\n수허 12-2058 호\n\n2012년 12월 21일\n\nRoche ASPItest\n\n14\n\n한국로슈진단(주)\n\n수허 12-1932 호\n\n2012년 12월 13일\n\nRoche ADPtest\n\n15\n\n백두대\n\n수허 12-1648 호\n\n2012년 11월 26일\n\nVerifyNow P2Y12 Test\n\n16\n\n백두대\n\n수허 12-1652 호\n\n2012년 11월 27일\n\nVerifyNow Aspirin Test\n\n(‘16.10.31 기준)\n\n- - 9 -\n<!-- PAGE_16 -->\n###### 다.  국외 허가동향\n\n<!-- PAGE_16 -->\n###### (1) 혈소판 기능검사는 전혈이 주로 검체로 사용되기 때문에 표준물질\n\n<!-- PAGE_16 -->\n###### 개발이 어려워 제품 개발 및 시험 자체가 어려운 특성이 있다.\n\n <!-- PAGE_16 -->\n###### (2) 혈소판 기능검사를 평가를 위한 기준을 제시하는 국제규격 및 가이드\n\n<!-- PAGE_16 -->\n###### (3)\n\n<!-- PAGE_16 -->\n###### 침습적\n\n<!-- PAGE_16 -->\n###### 방식의\n\n<!-- PAGE_16 -->\n###### 출혈시간(Bleeding\n\n<!-- PAGE_16 -->\n###### time,\n\n<!-- PAGE_16 -->\n###### BT)검사\n\n<!-- PAGE_16 -->\n###### 이후\n\n<!-- PAGE_16 -->\n###### 독일\n\n<!-- PAGE_16 -->\n###### Siemens사의 PFA-100과 ITC사의 VerifyNow를 통해 혈소판 기능을\n\n<!-- PAGE_16 -->\n###### 자동 검사법과 항혈소판제제 저항성 검사법이 시장을 확대하며\n\n<!-- PAGE_16 -->\n###### (4) 혈소판 기능검사를 위한 검사법은 지속적으로 개발 및 발전하고\n\n<!-- PAGE_16 -->\n###### 있으며 검사를 위한 작용원리 또한 Closure time(혈소판 작용으로\n\n<!-- PAGE_16 -->\n###### 혈액이 미세구멍을 막는 시간 측정), 광투과량 측정방식, 전기 임피던스\n\n<!-- PAGE_16 -->\n###### 측정방식, 입사광산란 파악방식 등으로 업체의 개발 기술에 따라 다양\n\n- - 10 -\n<!-- PAGE_17 -->\n###### 4.  출혈시간 및 항혈소판제제 저항성 복합검사기기 관련 국내외 규격\n\n<!-- PAGE_17 -->\n###### 출혈시간 및 항혈소판제제 저항성 복합검사기기에 대한 국제규격이 부재\n\n<!-- PAGE_17 -->\n###### 하여 체외진단 장비에 대한 안전성과 해당 시약에 대한 성능 및 안정성에\n\n<!-- PAGE_17 -->\n###### 대해 적용이 가능한 규격을 아래와 같이 제시하였다.\n\n",
        "original_sentence": "(‘16.10.31 기준)\n\n<!-- PAGE_14 -->\n###### (2) 출혈시간 및 항혈소판제제 저항성 복합검사기기로 국내에서 수입허가를\n\n- - 8 -\n번호\n\n업체명\n\n품목허가번호\n\n허가/신고일\n\n모델명\n\n1\n\n티메드(주)\n\n서울 수신\n\n14-1203호\n\n2014년 4월 14일\n\nA-100\n\n2\n\n지멘스헬스케어(주)\n\n서울 수신\n\n11-522호\n\n2011년 4월 8일\n\nINNOVANCE PFA-200 System\n\n3\n\n한국로슈진단(주)\n\n서울 수신\n\n11-392호\n\n2011년 3월 21일\n\nMultiplate 5.0 - Platelet\n\n4\n\n백두대\n\n경인 수신\n\n05-110호\n\n2005년 9월 2일\n\nVerifyNow System\n\n5\n\n성원메디칼상사\n\n서울 수신\n\n05-1722호\n\n2005년 11월 14일\n\nHemoRam/AggRAM Analyzer\n\n[표 1] 국내업체 혈소판 기능검사 장비 허가사항\n\n(‘16.10.31 기준)\n\n번호\n\n업체명\n\n품목허가번호\n\n허가/신고일\n\n모델명\n\n1\n\n티메드(주)\n\n수허 16-200 호\n\n2016년 4월 1일\n\nAggreGuide A-100 ADP Assay\n\n2\n\n티메드(주)\n\n수허 15-467 호\n\n2015년 2월 12일\n\nAA assay cartridge\n\n3\n\n지멘스헬스케어(주)\n\n수허 12-1743 호\n\n2012년 12월 5일\n\n4\n\n지멘스헬스케어(주)\n\n수허 12-1735 호\n\n2012년 12월 5일\n\nINNOVANCE PFA P2Y\n\n5\n\n지멘스헬스케어(주)\n\n수허 12-1710 호\n\n2012년 12월 4일\n\n6\n\n성원메디칼상사\n\n수허 13-1207 호\n\n2013년 7월 10일\n\nEpinephrine Reagent\n\n7\n\n성원메디칼상사\n\n수허 13-1206 호\n\n2013년 7월 10일\n\nArachidonic Acid Reagent\n\n8\n\n성원메디칼상사\n\n수허 13-1205 호\n\n2013년 7월 10일\n\nADP Reagent\n\n9\n\n성원메디칼상사\n\n수허 13-1208 호\n\n2013년 7월 10일\n\nCollagen Reagent\n\n10\n\n한국로슈진단(주)\n\n수허 12-2234 호\n\n2012년 12월 27일\n\n11\n\n한국로슈진단(주)\n\n수허 12-2232 호\n\n2012년 12월 27일\n\nRoche TRAPtest\n\n12\n\n한국로슈진단(주)\n\n수허 12-2213 호\n\n2012년 12월 27일\n\nRoche COLtest\n\n13\n\n한국로슈진단(주)\n\n수허 12-2058 호\n\n2012년 12월 21일\n\nRoche ASPItest\n\n14\n\n한국로슈진단(주)\n\n수허 12-1932 호\n\n2012년 12월 13일\n\nRoche ADPtest\n\n15\n\n백두대\n\n수허 12-1648 호\n\n2012년 11월 26일\n\nVerifyNow P2Y12 Test\n\n16\n\n백두대\n\n수허 12-1652 호\n\n2012년 11월 27일\n\nVerifyNow Aspirin Test\n\n(‘16.10.31 기준)\n\n- - 9 -\n<!-- PAGE_16 -->\n###### 다. "
      }
    },
    {
      "chunk_id": "chunk_277",
      "text": "국외 허가동향\n\n<!-- PAGE_16 -->\n###### (1) 혈소판 기능검사는 전혈이 주로 검체로 사용되기 때문에 표준물질\n\n<!-- PAGE_16 -->\n###### 개발이 어려워 제품 개발 및 시험 자체가 어려운 특성이 있다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 276,
        "window_size": 3,
        "char_count": 133,
        "word_count": 29,
        "page_number": 16,
        "window_text": "<!-- PAGE_14 -->\n###### 나.  제품 허가 현황\n\n<!-- PAGE_14 -->\n###### (1) 출혈시간 및 항혈소판제제 저항성 복합검사기기는 주로 수입 의료\n\n<!-- PAGE_14 -->\n###### 기기에 의존하고 있고 국내 개발 제품은 없는 상태이다.  (‘16.10.31 기준)\n\n<!-- PAGE_14 -->\n###### (2) 출혈시간 및 항혈소판제제 저항성 복합검사기기로 국내에서 수입허가를\n\n- - 8 -\n번호\n\n업체명\n\n품목허가번호\n\n허가/신고일\n\n모델명\n\n1\n\n티메드(주)\n\n서울 수신\n\n14-1203호\n\n2014년 4월 14일\n\nA-100\n\n2\n\n지멘스헬스케어(주)\n\n서울 수신\n\n11-522호\n\n2011년 4월 8일\n\nINNOVANCE PFA-200 System\n\n3\n\n한국로슈진단(주)\n\n서울 수신\n\n11-392호\n\n2011년 3월 21일\n\nMultiplate 5.0 - Platelet\n\n4\n\n백두대\n\n경인 수신\n\n05-110호\n\n2005년 9월 2일\n\nVerifyNow System\n\n5\n\n성원메디칼상사\n\n서울 수신\n\n05-1722호\n\n2005년 11월 14일\n\nHemoRam/AggRAM Analyzer\n\n[표 1] 국내업체 혈소판 기능검사 장비 허가사항\n\n(‘16.10.31 기준)\n\n번호\n\n업체명\n\n품목허가번호\n\n허가/신고일\n\n모델명\n\n1\n\n티메드(주)\n\n수허 16-200 호\n\n2016년 4월 1일\n\nAggreGuide A-100 ADP Assay\n\n2\n\n티메드(주)\n\n수허 15-467 호\n\n2015년 2월 12일\n\nAA assay cartridge\n\n3\n\n지멘스헬스케어(주)\n\n수허 12-1743 호\n\n2012년 12월 5일\n\n4\n\n지멘스헬스케어(주)\n\n수허 12-1735 호\n\n2012년 12월 5일\n\nINNOVANCE PFA P2Y\n\n5\n\n지멘스헬스케어(주)\n\n수허 12-1710 호\n\n2012년 12월 4일\n\n6\n\n성원메디칼상사\n\n수허 13-1207 호\n\n2013년 7월 10일\n\nEpinephrine Reagent\n\n7\n\n성원메디칼상사\n\n수허 13-1206 호\n\n2013년 7월 10일\n\nArachidonic Acid Reagent\n\n8\n\n성원메디칼상사\n\n수허 13-1205 호\n\n2013년 7월 10일\n\nADP Reagent\n\n9\n\n성원메디칼상사\n\n수허 13-1208 호\n\n2013년 7월 10일\n\nCollagen Reagent\n\n10\n\n한국로슈진단(주)\n\n수허 12-2234 호\n\n2012년 12월 27일\n\n11\n\n한국로슈진단(주)\n\n수허 12-2232 호\n\n2012년 12월 27일\n\nRoche TRAPtest\n\n12\n\n한국로슈진단(주)\n\n수허 12-2213 호\n\n2012년 12월 27일\n\nRoche COLtest\n\n13\n\n한국로슈진단(주)\n\n수허 12-2058 호\n\n2012년 12월 21일\n\nRoche ASPItest\n\n14\n\n한국로슈진단(주)\n\n수허 12-1932 호\n\n2012년 12월 13일\n\nRoche ADPtest\n\n15\n\n백두대\n\n수허 12-1648 호\n\n2012년 11월 26일\n\nVerifyNow P2Y12 Test\n\n16\n\n백두대\n\n수허 12-1652 호\n\n2012년 11월 27일\n\nVerifyNow Aspirin Test\n\n(‘16.10.31 기준)\n\n- - 9 -\n<!-- PAGE_16 -->\n###### 다.  국외 허가동향\n\n<!-- PAGE_16 -->\n###### (1) 혈소판 기능검사는 전혈이 주로 검체로 사용되기 때문에 표준물질\n\n<!-- PAGE_16 -->\n###### 개발이 어려워 제품 개발 및 시험 자체가 어려운 특성이 있다.\n\n <!-- PAGE_16 -->\n###### (2) 혈소판 기능검사를 평가를 위한 기준을 제시하는 국제규격 및 가이드\n\n<!-- PAGE_16 -->\n###### (3)\n\n<!-- PAGE_16 -->\n###### 침습적\n\n<!-- PAGE_16 -->\n###### 방식의\n\n<!-- PAGE_16 -->\n###### 출혈시간(Bleeding\n\n<!-- PAGE_16 -->\n###### time,\n\n<!-- PAGE_16 -->\n###### BT)검사\n\n<!-- PAGE_16 -->\n###### 이후\n\n<!-- PAGE_16 -->\n###### 독일\n\n<!-- PAGE_16 -->\n###### Siemens사의 PFA-100과 ITC사의 VerifyNow를 통해 혈소판 기능을\n\n<!-- PAGE_16 -->\n###### 자동 검사법과 항혈소판제제 저항성 검사법이 시장을 확대하며\n\n<!-- PAGE_16 -->\n###### (4) 혈소판 기능검사를 위한 검사법은 지속적으로 개발 및 발전하고\n\n<!-- PAGE_16 -->\n###### 있으며 검사를 위한 작용원리 또한 Closure time(혈소판 작용으로\n\n<!-- PAGE_16 -->\n###### 혈액이 미세구멍을 막는 시간 측정), 광투과량 측정방식, 전기 임피던스\n\n<!-- PAGE_16 -->\n###### 측정방식, 입사광산란 파악방식 등으로 업체의 개발 기술에 따라 다양\n\n- - 10 -\n<!-- PAGE_17 -->\n###### 4.  출혈시간 및 항혈소판제제 저항성 복합검사기기 관련 국내외 규격\n\n<!-- PAGE_17 -->\n###### 출혈시간 및 항혈소판제제 저항성 복합검사기기에 대한 국제규격이 부재\n\n<!-- PAGE_17 -->\n###### 하여 체외진단 장비에 대한 안전성과 해당 시약에 대한 성능 및 안정성에\n\n<!-- PAGE_17 -->\n###### 대해 적용이 가능한 규격을 아래와 같이 제시하였다.\n\n **[표 시작]**\n\n**정성하여 혈소판 기능장애 확인에 도움을 주는 체외진단용 의료기기**\n**위하여 임상시험기관 및 시험자의 의견을 조정하기 위하여 조정위원회를 설치**\n| 시험군과 대조군을 포함한 피험자 수는 해당 의료기기의 특성, 임상시험디자 | - 적용 계산식 :  |     |\n**비교한다.",
        "original_sentence": "국외 허가동향\n\n<!-- PAGE_16 -->\n###### (1) 혈소판 기능검사는 전혈이 주로 검체로 사용되기 때문에 표준물질\n\n<!-- PAGE_16 -->\n###### 개발이 어려워 제품 개발 및 시험 자체가 어려운 특성이 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_278",
      "text": "<!-- PAGE_16 -->\n###### (2) 혈소판 기능검사를 평가를 위한 기준을 제시하는 국제규격 및 가이드\n\n<!-- PAGE_16 -->\n###### (3)\n\n<!-- PAGE_16 -->\n###### 침습적\n\n<!-- PAGE_16 -->\n###### 방식의\n\n<!-- PAGE_16 -->\n###### 출혈시간(Bleeding\n\n<!-- PAGE_16 -->\n###### time,\n\n<!-- PAGE_16 -->\n###### BT)검사\n\n<!-- PAGE_16 -->\n###### 이후\n\n<!-- PAGE_16 -->\n###### 독일\n\n<!-- PAGE_16 -->\n###### Siemens사의 PFA-100과 ITC사의 VerifyNow를 통해 혈소판 기능을\n\n<!-- PAGE_16 -->\n###### 자동 검사법과 항혈소판제제 저항성 검사법이 시장을 확대하며\n\n<!-- PAGE_16 -->\n###### (4) 혈소판 기능검사를 위한 검사법은 지속적으로 개발 및 발전하고\n\n<!-- PAGE_16 -->\n###### 있으며 검사를 위한 작용원리 또한 Closure time(혈소판 작용으로\n\n<!-- PAGE_16 -->\n###### 혈액이 미세구멍을 막는 시간 측정), 광투과량 측정방식, 전기 임피던스\n\n<!-- PAGE_16 -->\n###### 측정방식, 입사광산란 파악방식 등으로 업체의 개발 기술에 따라 다양\n\n- - 10 -\n<!-- PAGE_17 -->\n###### 4. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 277,
        "window_size": 3,
        "char_count": 733,
        "word_count": 136,
        "page_number": 16,
        "window_text": "제품 허가 현황\n\n<!-- PAGE_14 -->\n###### (1) 출혈시간 및 항혈소판제제 저항성 복합검사기기는 주로 수입 의료\n\n<!-- PAGE_14 -->\n###### 기기에 의존하고 있고 국내 개발 제품은 없는 상태이다.  (‘16.10.31 기준)\n\n<!-- PAGE_14 -->\n###### (2) 출혈시간 및 항혈소판제제 저항성 복합검사기기로 국내에서 수입허가를\n\n- - 8 -\n번호\n\n업체명\n\n품목허가번호\n\n허가/신고일\n\n모델명\n\n1\n\n티메드(주)\n\n서울 수신\n\n14-1203호\n\n2014년 4월 14일\n\nA-100\n\n2\n\n지멘스헬스케어(주)\n\n서울 수신\n\n11-522호\n\n2011년 4월 8일\n\nINNOVANCE PFA-200 System\n\n3\n\n한국로슈진단(주)\n\n서울 수신\n\n11-392호\n\n2011년 3월 21일\n\nMultiplate 5.0 - Platelet\n\n4\n\n백두대\n\n경인 수신\n\n05-110호\n\n2005년 9월 2일\n\nVerifyNow System\n\n5\n\n성원메디칼상사\n\n서울 수신\n\n05-1722호\n\n2005년 11월 14일\n\nHemoRam/AggRAM Analyzer\n\n[표 1] 국내업체 혈소판 기능검사 장비 허가사항\n\n(‘16.10.31 기준)\n\n번호\n\n업체명\n\n품목허가번호\n\n허가/신고일\n\n모델명\n\n1\n\n티메드(주)\n\n수허 16-200 호\n\n2016년 4월 1일\n\nAggreGuide A-100 ADP Assay\n\n2\n\n티메드(주)\n\n수허 15-467 호\n\n2015년 2월 12일\n\nAA assay cartridge\n\n3\n\n지멘스헬스케어(주)\n\n수허 12-1743 호\n\n2012년 12월 5일\n\n4\n\n지멘스헬스케어(주)\n\n수허 12-1735 호\n\n2012년 12월 5일\n\nINNOVANCE PFA P2Y\n\n5\n\n지멘스헬스케어(주)\n\n수허 12-1710 호\n\n2012년 12월 4일\n\n6\n\n성원메디칼상사\n\n수허 13-1207 호\n\n2013년 7월 10일\n\nEpinephrine Reagent\n\n7\n\n성원메디칼상사\n\n수허 13-1206 호\n\n2013년 7월 10일\n\nArachidonic Acid Reagent\n\n8\n\n성원메디칼상사\n\n수허 13-1205 호\n\n2013년 7월 10일\n\nADP Reagent\n\n9\n\n성원메디칼상사\n\n수허 13-1208 호\n\n2013년 7월 10일\n\nCollagen Reagent\n\n10\n\n한국로슈진단(주)\n\n수허 12-2234 호\n\n2012년 12월 27일\n\n11\n\n한국로슈진단(주)\n\n수허 12-2232 호\n\n2012년 12월 27일\n\nRoche TRAPtest\n\n12\n\n한국로슈진단(주)\n\n수허 12-2213 호\n\n2012년 12월 27일\n\nRoche COLtest\n\n13\n\n한국로슈진단(주)\n\n수허 12-2058 호\n\n2012년 12월 21일\n\nRoche ASPItest\n\n14\n\n한국로슈진단(주)\n\n수허 12-1932 호\n\n2012년 12월 13일\n\nRoche ADPtest\n\n15\n\n백두대\n\n수허 12-1648 호\n\n2012년 11월 26일\n\nVerifyNow P2Y12 Test\n\n16\n\n백두대\n\n수허 12-1652 호\n\n2012년 11월 27일\n\nVerifyNow Aspirin Test\n\n(‘16.10.31 기준)\n\n- - 9 -\n<!-- PAGE_16 -->\n###### 다.  국외 허가동향\n\n<!-- PAGE_16 -->\n###### (1) 혈소판 기능검사는 전혈이 주로 검체로 사용되기 때문에 표준물질\n\n<!-- PAGE_16 -->\n###### 개발이 어려워 제품 개발 및 시험 자체가 어려운 특성이 있다.\n\n <!-- PAGE_16 -->\n###### (2) 혈소판 기능검사를 평가를 위한 기준을 제시하는 국제규격 및 가이드\n\n<!-- PAGE_16 -->\n###### (3)\n\n<!-- PAGE_16 -->\n###### 침습적\n\n<!-- PAGE_16 -->\n###### 방식의\n\n<!-- PAGE_16 -->\n###### 출혈시간(Bleeding\n\n<!-- PAGE_16 -->\n###### time,\n\n<!-- PAGE_16 -->\n###### BT)검사\n\n<!-- PAGE_16 -->\n###### 이후\n\n<!-- PAGE_16 -->\n###### 독일\n\n<!-- PAGE_16 -->\n###### Siemens사의 PFA-100과 ITC사의 VerifyNow를 통해 혈소판 기능을\n\n<!-- PAGE_16 -->\n###### 자동 검사법과 항혈소판제제 저항성 검사법이 시장을 확대하며\n\n<!-- PAGE_16 -->\n###### (4) 혈소판 기능검사를 위한 검사법은 지속적으로 개발 및 발전하고\n\n<!-- PAGE_16 -->\n###### 있으며 검사를 위한 작용원리 또한 Closure time(혈소판 작용으로\n\n<!-- PAGE_16 -->\n###### 혈액이 미세구멍을 막는 시간 측정), 광투과량 측정방식, 전기 임피던스\n\n<!-- PAGE_16 -->\n###### 측정방식, 입사광산란 파악방식 등으로 업체의 개발 기술에 따라 다양\n\n- - 10 -\n<!-- PAGE_17 -->\n###### 4.  출혈시간 및 항혈소판제제 저항성 복합검사기기 관련 국내외 규격\n\n<!-- PAGE_17 -->\n###### 출혈시간 및 항혈소판제제 저항성 복합검사기기에 대한 국제규격이 부재\n\n<!-- PAGE_17 -->\n###### 하여 체외진단 장비에 대한 안전성과 해당 시약에 대한 성능 및 안정성에\n\n<!-- PAGE_17 -->\n###### 대해 적용이 가능한 규격을 아래와 같이 제시하였다.\n\n **[표 시작]**\n\n**정성하여 혈소판 기능장애 확인에 도움을 주는 체외진단용 의료기기**\n**위하여 임상시험기관 및 시험자의 의견을 조정하기 위하여 조정위원회를 설치**\n| 시험군과 대조군을 포함한 피험자 수는 해당 의료기기의 특성, 임상시험디자 | - 적용 계산식 :  |     |\n**비교한다. **\n| 하고 시험조정자를 선정할 수 있음. ",
        "original_sentence": "<!-- PAGE_16 -->\n###### (2) 혈소판 기능검사를 평가를 위한 기준을 제시하는 국제규격 및 가이드\n\n<!-- PAGE_16 -->\n###### (3)\n\n<!-- PAGE_16 -->\n###### 침습적\n\n<!-- PAGE_16 -->\n###### 방식의\n\n<!-- PAGE_16 -->\n###### 출혈시간(Bleeding\n\n<!-- PAGE_16 -->\n###### time,\n\n<!-- PAGE_16 -->\n###### BT)검사\n\n<!-- PAGE_16 -->\n###### 이후\n\n<!-- PAGE_16 -->\n###### 독일\n\n<!-- PAGE_16 -->\n###### Siemens사의 PFA-100과 ITC사의 VerifyNow를 통해 혈소판 기능을\n\n<!-- PAGE_16 -->\n###### 자동 검사법과 항혈소판제제 저항성 검사법이 시장을 확대하며\n\n<!-- PAGE_16 -->\n###### (4) 혈소판 기능검사를 위한 검사법은 지속적으로 개발 및 발전하고\n\n<!-- PAGE_16 -->\n###### 있으며 검사를 위한 작용원리 또한 Closure time(혈소판 작용으로\n\n<!-- PAGE_16 -->\n###### 혈액이 미세구멍을 막는 시간 측정), 광투과량 측정방식, 전기 임피던스\n\n<!-- PAGE_16 -->\n###### 측정방식, 입사광산란 파악방식 등으로 업체의 개발 기술에 따라 다양\n\n- - 10 -\n<!-- PAGE_17 -->\n###### 4. "
      }
    },
    {
      "chunk_id": "chunk_279",
      "text": "출혈시간 및 항혈소판제제 저항성 복합검사기기 관련 국내외 규격\n\n<!-- PAGE_17 -->\n###### 출혈시간 및 항혈소판제제 저항성 복합검사기기에 대한 국제규격이 부재\n\n<!-- PAGE_17 -->\n###### 하여 체외진단 장비에 대한 안전성과 해당 시약에 대한 성능 및 안정성에\n\n<!-- PAGE_17 -->\n###### 대해 적용이 가능한 규격을 아래와 같이 제시하였다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 278,
        "window_size": 3,
        "char_count": 218,
        "word_count": 46,
        "page_number": 17,
        "window_text": "(‘16.10.31 기준)\n\n<!-- PAGE_14 -->\n###### (2) 출혈시간 및 항혈소판제제 저항성 복합검사기기로 국내에서 수입허가를\n\n- - 8 -\n번호\n\n업체명\n\n품목허가번호\n\n허가/신고일\n\n모델명\n\n1\n\n티메드(주)\n\n서울 수신\n\n14-1203호\n\n2014년 4월 14일\n\nA-100\n\n2\n\n지멘스헬스케어(주)\n\n서울 수신\n\n11-522호\n\n2011년 4월 8일\n\nINNOVANCE PFA-200 System\n\n3\n\n한국로슈진단(주)\n\n서울 수신\n\n11-392호\n\n2011년 3월 21일\n\nMultiplate 5.0 - Platelet\n\n4\n\n백두대\n\n경인 수신\n\n05-110호\n\n2005년 9월 2일\n\nVerifyNow System\n\n5\n\n성원메디칼상사\n\n서울 수신\n\n05-1722호\n\n2005년 11월 14일\n\nHemoRam/AggRAM Analyzer\n\n[표 1] 국내업체 혈소판 기능검사 장비 허가사항\n\n(‘16.10.31 기준)\n\n번호\n\n업체명\n\n품목허가번호\n\n허가/신고일\n\n모델명\n\n1\n\n티메드(주)\n\n수허 16-200 호\n\n2016년 4월 1일\n\nAggreGuide A-100 ADP Assay\n\n2\n\n티메드(주)\n\n수허 15-467 호\n\n2015년 2월 12일\n\nAA assay cartridge\n\n3\n\n지멘스헬스케어(주)\n\n수허 12-1743 호\n\n2012년 12월 5일\n\n4\n\n지멘스헬스케어(주)\n\n수허 12-1735 호\n\n2012년 12월 5일\n\nINNOVANCE PFA P2Y\n\n5\n\n지멘스헬스케어(주)\n\n수허 12-1710 호\n\n2012년 12월 4일\n\n6\n\n성원메디칼상사\n\n수허 13-1207 호\n\n2013년 7월 10일\n\nEpinephrine Reagent\n\n7\n\n성원메디칼상사\n\n수허 13-1206 호\n\n2013년 7월 10일\n\nArachidonic Acid Reagent\n\n8\n\n성원메디칼상사\n\n수허 13-1205 호\n\n2013년 7월 10일\n\nADP Reagent\n\n9\n\n성원메디칼상사\n\n수허 13-1208 호\n\n2013년 7월 10일\n\nCollagen Reagent\n\n10\n\n한국로슈진단(주)\n\n수허 12-2234 호\n\n2012년 12월 27일\n\n11\n\n한국로슈진단(주)\n\n수허 12-2232 호\n\n2012년 12월 27일\n\nRoche TRAPtest\n\n12\n\n한국로슈진단(주)\n\n수허 12-2213 호\n\n2012년 12월 27일\n\nRoche COLtest\n\n13\n\n한국로슈진단(주)\n\n수허 12-2058 호\n\n2012년 12월 21일\n\nRoche ASPItest\n\n14\n\n한국로슈진단(주)\n\n수허 12-1932 호\n\n2012년 12월 13일\n\nRoche ADPtest\n\n15\n\n백두대\n\n수허 12-1648 호\n\n2012년 11월 26일\n\nVerifyNow P2Y12 Test\n\n16\n\n백두대\n\n수허 12-1652 호\n\n2012년 11월 27일\n\nVerifyNow Aspirin Test\n\n(‘16.10.31 기준)\n\n- - 9 -\n<!-- PAGE_16 -->\n###### 다.  국외 허가동향\n\n<!-- PAGE_16 -->\n###### (1) 혈소판 기능검사는 전혈이 주로 검체로 사용되기 때문에 표준물질\n\n<!-- PAGE_16 -->\n###### 개발이 어려워 제품 개발 및 시험 자체가 어려운 특성이 있다.\n\n <!-- PAGE_16 -->\n###### (2) 혈소판 기능검사를 평가를 위한 기준을 제시하는 국제규격 및 가이드\n\n<!-- PAGE_16 -->\n###### (3)\n\n<!-- PAGE_16 -->\n###### 침습적\n\n<!-- PAGE_16 -->\n###### 방식의\n\n<!-- PAGE_16 -->\n###### 출혈시간(Bleeding\n\n<!-- PAGE_16 -->\n###### time,\n\n<!-- PAGE_16 -->\n###### BT)검사\n\n<!-- PAGE_16 -->\n###### 이후\n\n<!-- PAGE_16 -->\n###### 독일\n\n<!-- PAGE_16 -->\n###### Siemens사의 PFA-100과 ITC사의 VerifyNow를 통해 혈소판 기능을\n\n<!-- PAGE_16 -->\n###### 자동 검사법과 항혈소판제제 저항성 검사법이 시장을 확대하며\n\n<!-- PAGE_16 -->\n###### (4) 혈소판 기능검사를 위한 검사법은 지속적으로 개발 및 발전하고\n\n<!-- PAGE_16 -->\n###### 있으며 검사를 위한 작용원리 또한 Closure time(혈소판 작용으로\n\n<!-- PAGE_16 -->\n###### 혈액이 미세구멍을 막는 시간 측정), 광투과량 측정방식, 전기 임피던스\n\n<!-- PAGE_16 -->\n###### 측정방식, 입사광산란 파악방식 등으로 업체의 개발 기술에 따라 다양\n\n- - 10 -\n<!-- PAGE_17 -->\n###### 4.  출혈시간 및 항혈소판제제 저항성 복합검사기기 관련 국내외 규격\n\n<!-- PAGE_17 -->\n###### 출혈시간 및 항혈소판제제 저항성 복합검사기기에 대한 국제규격이 부재\n\n<!-- PAGE_17 -->\n###### 하여 체외진단 장비에 대한 안전성과 해당 시약에 대한 성능 및 안정성에\n\n<!-- PAGE_17 -->\n###### 대해 적용이 가능한 규격을 아래와 같이 제시하였다.\n\n **[표 시작]**\n\n**정성하여 혈소판 기능장애 확인에 도움을 주는 체외진단용 의료기기**\n**위하여 임상시험기관 및 시험자의 의견을 조정하기 위하여 조정위원회를 설치**\n| 시험군과 대조군을 포함한 피험자 수는 해당 의료기기의 특성, 임상시험디자 | - 적용 계산식 :  |     |\n**비교한다. **\n| 하고 시험조정자를 선정할 수 있음.  | - 귀무가설: 개발제품의 특이도가 75% 미만이다. ",
        "original_sentence": "출혈시간 및 항혈소판제제 저항성 복합검사기기 관련 국내외 규격\n\n<!-- PAGE_17 -->\n###### 출혈시간 및 항혈소판제제 저항성 복합검사기기에 대한 국제규격이 부재\n\n<!-- PAGE_17 -->\n###### 하여 체외진단 장비에 대한 안전성과 해당 시약에 대한 성능 및 안정성에\n\n<!-- PAGE_17 -->\n###### 대해 적용이 가능한 규격을 아래와 같이 제시하였다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_280",
      "text": "**[표 시작]**\n\n**정성하여 혈소판 기능장애 확인에 도움을 주는 체외진단용 의료기기**\n**위하여 임상시험기관 및 시험자의 의견을 조정하기 위하여 조정위원회를 설치**\n| 시험군과 대조군을 포함한 피험자 수는 해당 의료기기의 특성, 임상시험디자 | - 적용 계산식 :  |     |\n**비교한다.",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 279,
        "window_size": 3,
        "char_count": 179,
        "word_count": 42,
        "page_number": 44,
        "window_text": "국외 허가동향\n\n<!-- PAGE_16 -->\n###### (1) 혈소판 기능검사는 전혈이 주로 검체로 사용되기 때문에 표준물질\n\n<!-- PAGE_16 -->\n###### 개발이 어려워 제품 개발 및 시험 자체가 어려운 특성이 있다.\n\n <!-- PAGE_16 -->\n###### (2) 혈소판 기능검사를 평가를 위한 기준을 제시하는 국제규격 및 가이드\n\n<!-- PAGE_16 -->\n###### (3)\n\n<!-- PAGE_16 -->\n###### 침습적\n\n<!-- PAGE_16 -->\n###### 방식의\n\n<!-- PAGE_16 -->\n###### 출혈시간(Bleeding\n\n<!-- PAGE_16 -->\n###### time,\n\n<!-- PAGE_16 -->\n###### BT)검사\n\n<!-- PAGE_16 -->\n###### 이후\n\n<!-- PAGE_16 -->\n###### 독일\n\n<!-- PAGE_16 -->\n###### Siemens사의 PFA-100과 ITC사의 VerifyNow를 통해 혈소판 기능을\n\n<!-- PAGE_16 -->\n###### 자동 검사법과 항혈소판제제 저항성 검사법이 시장을 확대하며\n\n<!-- PAGE_16 -->\n###### (4) 혈소판 기능검사를 위한 검사법은 지속적으로 개발 및 발전하고\n\n<!-- PAGE_16 -->\n###### 있으며 검사를 위한 작용원리 또한 Closure time(혈소판 작용으로\n\n<!-- PAGE_16 -->\n###### 혈액이 미세구멍을 막는 시간 측정), 광투과량 측정방식, 전기 임피던스\n\n<!-- PAGE_16 -->\n###### 측정방식, 입사광산란 파악방식 등으로 업체의 개발 기술에 따라 다양\n\n- - 10 -\n<!-- PAGE_17 -->\n###### 4.  출혈시간 및 항혈소판제제 저항성 복합검사기기 관련 국내외 규격\n\n<!-- PAGE_17 -->\n###### 출혈시간 및 항혈소판제제 저항성 복합검사기기에 대한 국제규격이 부재\n\n<!-- PAGE_17 -->\n###### 하여 체외진단 장비에 대한 안전성과 해당 시약에 대한 성능 및 안정성에\n\n<!-- PAGE_17 -->\n###### 대해 적용이 가능한 규격을 아래와 같이 제시하였다.\n\n **[표 시작]**\n\n**정성하여 혈소판 기능장애 확인에 도움을 주는 체외진단용 의료기기**\n**위하여 임상시험기관 및 시험자의 의견을 조정하기 위하여 조정위원회를 설치**\n| 시험군과 대조군을 포함한 피험자 수는 해당 의료기기의 특성, 임상시험디자 | - 적용 계산식 :  |     |\n**비교한다. **\n| 하고 시험조정자를 선정할 수 있음.  | - 귀무가설: 개발제품의 특이도가 75% 미만이다.  |\n| 를 의뢰자에게 보내야 한다. ",
        "original_sentence": "**[표 시작]**\n\n**정성하여 혈소판 기능장애 확인에 도움을 주는 체외진단용 의료기기**\n**위하여 임상시험기관 및 시험자의 의견을 조정하기 위하여 조정위원회를 설치**\n| 시험군과 대조군을 포함한 피험자 수는 해당 의료기기의 특성, 임상시험디자 | - 적용 계산식 :  |     |\n**비교한다."
      }
    },
    {
      "chunk_id": "chunk_281",
      "text": "**\n| 하고 시험조정자를 선정할 수 있음. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 280,
        "window_size": 3,
        "char_count": 25,
        "word_count": 7,
        "page_number": 9,
        "window_text": "<!-- PAGE_16 -->\n###### (2) 혈소판 기능검사를 평가를 위한 기준을 제시하는 국제규격 및 가이드\n\n<!-- PAGE_16 -->\n###### (3)\n\n<!-- PAGE_16 -->\n###### 침습적\n\n<!-- PAGE_16 -->\n###### 방식의\n\n<!-- PAGE_16 -->\n###### 출혈시간(Bleeding\n\n<!-- PAGE_16 -->\n###### time,\n\n<!-- PAGE_16 -->\n###### BT)검사\n\n<!-- PAGE_16 -->\n###### 이후\n\n<!-- PAGE_16 -->\n###### 독일\n\n<!-- PAGE_16 -->\n###### Siemens사의 PFA-100과 ITC사의 VerifyNow를 통해 혈소판 기능을\n\n<!-- PAGE_16 -->\n###### 자동 검사법과 항혈소판제제 저항성 검사법이 시장을 확대하며\n\n<!-- PAGE_16 -->\n###### (4) 혈소판 기능검사를 위한 검사법은 지속적으로 개발 및 발전하고\n\n<!-- PAGE_16 -->\n###### 있으며 검사를 위한 작용원리 또한 Closure time(혈소판 작용으로\n\n<!-- PAGE_16 -->\n###### 혈액이 미세구멍을 막는 시간 측정), 광투과량 측정방식, 전기 임피던스\n\n<!-- PAGE_16 -->\n###### 측정방식, 입사광산란 파악방식 등으로 업체의 개발 기술에 따라 다양\n\n- - 10 -\n<!-- PAGE_17 -->\n###### 4.  출혈시간 및 항혈소판제제 저항성 복합검사기기 관련 국내외 규격\n\n<!-- PAGE_17 -->\n###### 출혈시간 및 항혈소판제제 저항성 복합검사기기에 대한 국제규격이 부재\n\n<!-- PAGE_17 -->\n###### 하여 체외진단 장비에 대한 안전성과 해당 시약에 대한 성능 및 안정성에\n\n<!-- PAGE_17 -->\n###### 대해 적용이 가능한 규격을 아래와 같이 제시하였다.\n\n **[표 시작]**\n\n**정성하여 혈소판 기능장애 확인에 도움을 주는 체외진단용 의료기기**\n**위하여 임상시험기관 및 시험자의 의견을 조정하기 위하여 조정위원회를 설치**\n| 시험군과 대조군을 포함한 피험자 수는 해당 의료기기의 특성, 임상시험디자 | - 적용 계산식 :  |     |\n**비교한다. **\n| 하고 시험조정자를 선정할 수 있음.  | - 귀무가설: 개발제품의 특이도가 75% 미만이다.  |\n| 를 의뢰자에게 보내야 한다.  | 검사칩을 사용하지 않도록 주의한다. ",
        "original_sentence": "**\n| 하고 시험조정자를 선정할 수 있음. "
      }
    },
    {
      "chunk_id": "chunk_282",
      "text": "| - 귀무가설: 개발제품의 특이도가 75% 미만이다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 281,
        "window_size": 3,
        "char_count": 31,
        "word_count": 7,
        "page_number": 6,
        "window_text": "출혈시간 및 항혈소판제제 저항성 복합검사기기 관련 국내외 규격\n\n<!-- PAGE_17 -->\n###### 출혈시간 및 항혈소판제제 저항성 복합검사기기에 대한 국제규격이 부재\n\n<!-- PAGE_17 -->\n###### 하여 체외진단 장비에 대한 안전성과 해당 시약에 대한 성능 및 안정성에\n\n<!-- PAGE_17 -->\n###### 대해 적용이 가능한 규격을 아래와 같이 제시하였다.\n\n **[표 시작]**\n\n**정성하여 혈소판 기능장애 확인에 도움을 주는 체외진단용 의료기기**\n**위하여 임상시험기관 및 시험자의 의견을 조정하기 위하여 조정위원회를 설치**\n| 시험군과 대조군을 포함한 피험자 수는 해당 의료기기의 특성, 임상시험디자 | - 적용 계산식 :  |     |\n**비교한다. **\n| 하고 시험조정자를 선정할 수 있음.  | - 귀무가설: 개발제품의 특이도가 75% 미만이다.  |\n| 를 의뢰자에게 보내야 한다.  | 검사칩을 사용하지 않도록 주의한다.  | 품목명 : 자동혈소판응집측정장치[1] | - 적용 계산식 :  |     |\n| (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests | 인, 근거를 통한 시험에서 기대하는 연구결과의 사전 예측, 통계적 유의성, |\n**(1) 본체**\n| - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | (5) 시험 방법 | (5) 시험 방법 |\n| 3) SIPA test | ① LTA 대조기기 결과를 기준하여 시험기기의 민감도와 특이도를 확인한다. ",
        "original_sentence": "| - 귀무가설: 개발제품의 특이도가 75% 미만이다. "
      }
    },
    {
      "chunk_id": "chunk_283",
      "text": "|\n| 를 의뢰자에게 보내야 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 282,
        "window_size": 3,
        "char_count": 20,
        "word_count": 6,
        "page_number": 24,
        "window_text": "**[표 시작]**\n\n**정성하여 혈소판 기능장애 확인에 도움을 주는 체외진단용 의료기기**\n**위하여 임상시험기관 및 시험자의 의견을 조정하기 위하여 조정위원회를 설치**\n| 시험군과 대조군을 포함한 피험자 수는 해당 의료기기의 특성, 임상시험디자 | - 적용 계산식 :  |     |\n**비교한다. **\n| 하고 시험조정자를 선정할 수 있음.  | - 귀무가설: 개발제품의 특이도가 75% 미만이다.  |\n| 를 의뢰자에게 보내야 한다.  | 검사칩을 사용하지 않도록 주의한다.  | 품목명 : 자동혈소판응집측정장치[1] | - 적용 계산식 :  |     |\n| (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests | 인, 근거를 통한 시험에서 기대하는 연구결과의 사전 예측, 통계적 유의성, |\n**(1) 본체**\n| - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | (5) 시험 방법 | (5) 시험 방법 |\n| 3) SIPA test | ① LTA 대조기기 결과를 기준하여 시험기기의 민감도와 특이도를 확인한다.  | 피험자의 부작용에 대한 내용은 해당사항 없다. ",
        "original_sentence": "|\n| 를 의뢰자에게 보내야 한다. "
      }
    },
    {
      "chunk_id": "chunk_284",
      "text": "| 검사칩을 사용하지 않도록 주의한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 283,
        "window_size": 3,
        "char_count": 22,
        "word_count": 5,
        "page_number": 24,
        "window_text": "**\n| 하고 시험조정자를 선정할 수 있음.  | - 귀무가설: 개발제품의 특이도가 75% 미만이다.  |\n| 를 의뢰자에게 보내야 한다.  | 검사칩을 사용하지 않도록 주의한다.  | 품목명 : 자동혈소판응집측정장치[1] | - 적용 계산식 :  |     |\n| (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests | 인, 근거를 통한 시험에서 기대하는 연구결과의 사전 예측, 통계적 유의성, |\n**(1) 본체**\n| - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | (5) 시험 방법 | (5) 시험 방법 |\n| 3) SIPA test | ① LTA 대조기기 결과를 기준하여 시험기기의 민감도와 특이도를 확인한다.  | 피험자의 부작용에 대한 내용은 해당사항 없다.  | 품목분류번호 : A22290.01 | - 적용 계산식 :  |     |\n| 사유에 대하여 기록하여 주십시오. ",
        "original_sentence": "| 검사칩을 사용하지 않도록 주의한다. "
      }
    },
    {
      "chunk_id": "chunk_285",
      "text": "| 품목명 : 자동혈소판응집측정장치[1] | - 적용 계산식 :  |     |\n| (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests | 인, 근거를 통한 시험에서 기대하는 연구결과의 사전 예측, 통계적 유의성, |\n**(1) 본체**\n| - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | (5) 시험 방법 | (5) 시험 방법 |\n| 3) SIPA test | ① LTA 대조기기 결과를 기준하여 시험기기의 민감도와 특이도를 확인한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 284,
        "window_size": 3,
        "char_count": 267,
        "word_count": 65,
        "page_number": 6,
        "window_text": "| - 귀무가설: 개발제품의 특이도가 75% 미만이다.  |\n| 를 의뢰자에게 보내야 한다.  | 검사칩을 사용하지 않도록 주의한다.  | 품목명 : 자동혈소판응집측정장치[1] | - 적용 계산식 :  |     |\n| (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests | 인, 근거를 통한 시험에서 기대하는 연구결과의 사전 예측, 통계적 유의성, |\n**(1) 본체**\n| - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | (5) 시험 방법 | (5) 시험 방법 |\n| 3) SIPA test | ① LTA 대조기기 결과를 기준하여 시험기기의 민감도와 특이도를 확인한다.  | 피험자의 부작용에 대한 내용은 해당사항 없다.  | 품목분류번호 : A22290.01 | - 적용 계산식 :  |     |\n| 사유에 대하여 기록하여 주십시오.  | diagnostic (IVD) medical equipment |\n**검정 방법, 탈락률 등을 반영하여 통계학적으로 타당하게 제시되어야 하며, 임**\n**(ADP)에 의한 혈소판 기능장애 확인에 도움을 주는 체외진단용 의료기기**\n| 작성할 수 있음 | - 시험장비 |\n| 1) 반드시 체외진단용으로 사용해야 한다. ",
        "original_sentence": "| 품목명 : 자동혈소판응집측정장치[1] | - 적용 계산식 :  |     |\n| (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests | 인, 근거를 통한 시험에서 기대하는 연구결과의 사전 예측, 통계적 유의성, |\n**(1) 본체**\n| - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | (5) 시험 방법 | (5) 시험 방법 |\n| 3) SIPA test | ① LTA 대조기기 결과를 기준하여 시험기기의 민감도와 특이도를 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_286",
      "text": "| 피험자의 부작용에 대한 내용은 해당사항 없다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 285,
        "window_size": 3,
        "char_count": 28,
        "word_count": 7,
        "page_number": 3,
        "window_text": "|\n| 를 의뢰자에게 보내야 한다.  | 검사칩을 사용하지 않도록 주의한다.  | 품목명 : 자동혈소판응집측정장치[1] | - 적용 계산식 :  |     |\n| (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests | 인, 근거를 통한 시험에서 기대하는 연구결과의 사전 예측, 통계적 유의성, |\n**(1) 본체**\n| - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | (5) 시험 방법 | (5) 시험 방법 |\n| 3) SIPA test | ① LTA 대조기기 결과를 기준하여 시험기기의 민감도와 특이도를 확인한다.  | 피험자의 부작용에 대한 내용은 해당사항 없다.  | 품목분류번호 : A22290.01 | - 적용 계산식 :  |     |\n| 사유에 대하여 기록하여 주십시오.  | diagnostic (IVD) medical equipment |\n**검정 방법, 탈락률 등을 반영하여 통계학적으로 타당하게 제시되어야 하며, 임**\n**(ADP)에 의한 혈소판 기능장애 확인에 도움을 주는 체외진단용 의료기기**\n| 작성할 수 있음 | - 시험장비 |\n| 1) 반드시 체외진단용으로 사용해야 한다.  | - 시약 : | 2. ",
        "original_sentence": "| 피험자의 부작용에 대한 내용은 해당사항 없다. "
      }
    },
    {
      "chunk_id": "chunk_287",
      "text": "| 품목분류번호 : A22290.01 | - 적용 계산식 :  |     |\n| 사유에 대하여 기록하여 주십시오. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 286,
        "window_size": 3,
        "char_count": 74,
        "word_count": 21,
        "page_number": 6,
        "window_text": "| 검사칩을 사용하지 않도록 주의한다.  | 품목명 : 자동혈소판응집측정장치[1] | - 적용 계산식 :  |     |\n| (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests | 인, 근거를 통한 시험에서 기대하는 연구결과의 사전 예측, 통계적 유의성, |\n**(1) 본체**\n| - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | (5) 시험 방법 | (5) 시험 방법 |\n| 3) SIPA test | ① LTA 대조기기 결과를 기준하여 시험기기의 민감도와 특이도를 확인한다.  | 피험자의 부작용에 대한 내용은 해당사항 없다.  | 품목분류번호 : A22290.01 | - 적용 계산식 :  |     |\n| 사유에 대하여 기록하여 주십시오.  | diagnostic (IVD) medical equipment |\n**검정 방법, 탈락률 등을 반영하여 통계학적으로 타당하게 제시되어야 하며, 임**\n**(ADP)에 의한 혈소판 기능장애 확인에 도움을 주는 체외진단용 의료기기**\n| 작성할 수 있음 | - 시험장비 |\n| 1) 반드시 체외진단용으로 사용해야 한다.  | - 시약 : | 2.  혈소판 약물반응검사 | ② LTA 대조기기와 시험기기의 일치도를 확인한다. ",
        "original_sentence": "| 품목분류번호 : A22290.01 | - 적용 계산식 :  |     |\n| 사유에 대하여 기록하여 주십시오. "
      }
    },
    {
      "chunk_id": "chunk_288",
      "text": "| diagnostic (IVD) medical equipment |\n**검정 방법, 탈락률 등을 반영하여 통계학적으로 타당하게 제시되어야 하며, 임**\n**(ADP)에 의한 혈소판 기능장애 확인에 도움을 주는 체외진단용 의료기기**\n| 작성할 수 있음 | - 시험장비 |\n| 1) 반드시 체외진단용으로 사용해야 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 287,
        "window_size": 3,
        "char_count": 179,
        "word_count": 39,
        "page_number": 18,
        "window_text": "| 품목명 : 자동혈소판응집측정장치[1] | - 적용 계산식 :  |     |\n| (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests | 인, 근거를 통한 시험에서 기대하는 연구결과의 사전 예측, 통계적 유의성, |\n**(1) 본체**\n| - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | (5) 시험 방법 | (5) 시험 방법 |\n| 3) SIPA test | ① LTA 대조기기 결과를 기준하여 시험기기의 민감도와 특이도를 확인한다.  | 피험자의 부작용에 대한 내용은 해당사항 없다.  | 품목분류번호 : A22290.01 | - 적용 계산식 :  |     |\n| 사유에 대하여 기록하여 주십시오.  | diagnostic (IVD) medical equipment |\n**검정 방법, 탈락률 등을 반영하여 통계학적으로 타당하게 제시되어야 하며, 임**\n**(ADP)에 의한 혈소판 기능장애 확인에 도움을 주는 체외진단용 의료기기**\n| 작성할 수 있음 | - 시험장비 |\n| 1) 반드시 체외진단용으로 사용해야 한다.  | - 시약 : | 2.  혈소판 약물반응검사 | ② LTA 대조기기와 시험기기의 일치도를 확인한다.  | 실시상의 문제점 등에 따라 결정되어야 한다. ",
        "original_sentence": "| diagnostic (IVD) medical equipment |\n**검정 방법, 탈락률 등을 반영하여 통계학적으로 타당하게 제시되어야 하며, 임**\n**(ADP)에 의한 혈소판 기능장애 확인에 도움을 주는 체외진단용 의료기기**\n| 작성할 수 있음 | - 시험장비 |\n| 1) 반드시 체외진단용으로 사용해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_289",
      "text": "| - 시약 : | 2. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 288,
        "window_size": 3,
        "char_count": 14,
        "word_count": 6,
        "page_number": 6,
        "window_text": "| 피험자의 부작용에 대한 내용은 해당사항 없다.  | 품목분류번호 : A22290.01 | - 적용 계산식 :  |     |\n| 사유에 대하여 기록하여 주십시오.  | diagnostic (IVD) medical equipment |\n**검정 방법, 탈락률 등을 반영하여 통계학적으로 타당하게 제시되어야 하며, 임**\n**(ADP)에 의한 혈소판 기능장애 확인에 도움을 주는 체외진단용 의료기기**\n| 작성할 수 있음 | - 시험장비 |\n| 1) 반드시 체외진단용으로 사용해야 한다.  | - 시약 : | 2.  혈소판 약물반응검사 | ② LTA 대조기기와 시험기기의 일치도를 확인한다.  | 실시상의 문제점 등에 따라 결정되어야 한다.  | 것은 아니며 행정상 변경이 필요하다. ",
        "original_sentence": "| - 시약 : | 2. "
      }
    },
    {
      "chunk_id": "chunk_290",
      "text": "혈소판 약물반응검사 | ② LTA 대조기기와 시험기기의 일치도를 확인한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 289,
        "window_size": 3,
        "char_count": 42,
        "word_count": 9,
        "page_number": 9,
        "window_text": "| 품목분류번호 : A22290.01 | - 적용 계산식 :  |     |\n| 사유에 대하여 기록하여 주십시오.  | diagnostic (IVD) medical equipment |\n**검정 방법, 탈락률 등을 반영하여 통계학적으로 타당하게 제시되어야 하며, 임**\n**(ADP)에 의한 혈소판 기능장애 확인에 도움을 주는 체외진단용 의료기기**\n| 작성할 수 있음 | - 시험장비 |\n| 1) 반드시 체외진단용으로 사용해야 한다.  | - 시약 : | 2.  혈소판 약물반응검사 | ② LTA 대조기기와 시험기기의 일치도를 확인한다.  | 실시상의 문제점 등에 따라 결정되어야 한다.  | 것은 아니며 행정상 변경이 필요하다.  |\n**있는 경우는 이를 반영하여 분석결과를 제시해야함.",
        "original_sentence": "혈소판 약물반응검사 | ② LTA 대조기기와 시험기기의 일치도를 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_291",
      "text": "| 실시상의 문제점 등에 따라 결정되어야 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 290,
        "window_size": 3,
        "char_count": 27,
        "word_count": 7,
        "page_number": 24,
        "window_text": "| diagnostic (IVD) medical equipment |\n**검정 방법, 탈락률 등을 반영하여 통계학적으로 타당하게 제시되어야 하며, 임**\n**(ADP)에 의한 혈소판 기능장애 확인에 도움을 주는 체외진단용 의료기기**\n| 작성할 수 있음 | - 시험장비 |\n| 1) 반드시 체외진단용으로 사용해야 한다.  | - 시약 : | 2.  혈소판 약물반응검사 | ② LTA 대조기기와 시험기기의 일치도를 확인한다.  | 실시상의 문제점 등에 따라 결정되어야 한다.  | 것은 아니며 행정상 변경이 필요하다.  |\n**있는 경우는 이를 반영하여 분석결과를 제시해야함. **\n| 2 | 상시험의 효능 및 안전성 입증에 필요한 충분한 수가 확보되어야 함. ",
        "original_sentence": "| 실시상의 문제점 등에 따라 결정되어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_292",
      "text": "| 것은 아니며 행정상 변경이 필요하다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 291,
        "window_size": 3,
        "char_count": 23,
        "word_count": 6,
        "page_number": 7,
        "window_text": "| - 시약 : | 2.  혈소판 약물반응검사 | ② LTA 대조기기와 시험기기의 일치도를 확인한다.  | 실시상의 문제점 등에 따라 결정되어야 한다.  | 것은 아니며 행정상 변경이 필요하다.  |\n**있는 경우는 이를 반영하여 분석결과를 제시해야함. **\n| 2 | 상시험의 효능 및 안전성 입증에 필요한 충분한 수가 확보되어야 함.  | ➂ 전기적 빠른 과도현상(Electrical Fast Transient, EFT)시험 | - Sample Size (5% 탈락률 적용) = 131.71, 약 132개 검체 |\n**삽입할 수 있다.",
        "original_sentence": "| 것은 아니며 행정상 변경이 필요하다. "
      }
    },
    {
      "chunk_id": "chunk_293",
      "text": "|\n**있는 경우는 이를 반영하여 분석결과를 제시해야함.",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 292,
        "window_size": 3,
        "char_count": 31,
        "word_count": 7,
        "page_number": 77,
        "window_text": "혈소판 약물반응검사 | ② LTA 대조기기와 시험기기의 일치도를 확인한다.  | 실시상의 문제점 등에 따라 결정되어야 한다.  | 것은 아니며 행정상 변경이 필요하다.  |\n**있는 경우는 이를 반영하여 분석결과를 제시해야함. **\n| 2 | 상시험의 효능 및 안전성 입증에 필요한 충분한 수가 확보되어야 함.  | ➂ 전기적 빠른 과도현상(Electrical Fast Transient, EFT)시험 | - Sample Size (5% 탈락률 적용) = 131.71, 약 132개 검체 |\n**삽입할 수 있다. **\n| 2) 검체는 감염성 질환에 대한 감염을 배제할 수 없으므로 취급에 주의한다. ",
        "original_sentence": "|\n**있는 경우는 이를 반영하여 분석결과를 제시해야함."
      }
    },
    {
      "chunk_id": "chunk_294",
      "text": "**\n| 2 | 상시험의 효능 및 안전성 입증에 필요한 충분한 수가 확보되어야 함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 293,
        "window_size": 3,
        "char_count": 47,
        "word_count": 14,
        "page_number": 6,
        "window_text": "| 실시상의 문제점 등에 따라 결정되어야 한다.  | 것은 아니며 행정상 변경이 필요하다.  |\n**있는 경우는 이를 반영하여 분석결과를 제시해야함. **\n| 2 | 상시험의 효능 및 안전성 입증에 필요한 충분한 수가 확보되어야 함.  | ➂ 전기적 빠른 과도현상(Electrical Fast Transient, EFT)시험 | - Sample Size (5% 탈락률 적용) = 131.71, 약 132개 검체 |\n**삽입할 수 있다. **\n| 2) 검체는 감염성 질환에 대한 감염을 배제할 수 없으므로 취급에 주의한다.  | 방법에 따라 기입한다. ",
        "original_sentence": "**\n| 2 | 상시험의 효능 및 안전성 입증에 필요한 충분한 수가 확보되어야 함. "
      }
    },
    {
      "chunk_id": "chunk_295",
      "text": "| ➂ 전기적 빠른 과도현상(Electrical Fast Transient, EFT)시험 | - Sample Size (5% 탈락률 적용) = 131.71, 약 132개 검체 |\n**삽입할 수 있다.",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 294,
        "window_size": 3,
        "char_count": 111,
        "word_count": 24,
        "page_number": 9,
        "window_text": "| 것은 아니며 행정상 변경이 필요하다.  |\n**있는 경우는 이를 반영하여 분석결과를 제시해야함. **\n| 2 | 상시험의 효능 및 안전성 입증에 필요한 충분한 수가 확보되어야 함.  | ➂ 전기적 빠른 과도현상(Electrical Fast Transient, EFT)시험 | - Sample Size (5% 탈락률 적용) = 131.71, 약 132개 검체 |\n**삽입할 수 있다. **\n| 2) 검체는 감염성 질환에 대한 감염을 배제할 수 없으므로 취급에 주의한다.  | 방법에 따라 기입한다.  | ③ PFA-100 대조기기와 시험기기의 일치도를 확인한다. ",
        "original_sentence": "| ➂ 전기적 빠른 과도현상(Electrical Fast Transient, EFT)시험 | - Sample Size (5% 탈락률 적용) = 131.71, 약 132개 검체 |\n**삽입할 수 있다."
      }
    },
    {
      "chunk_id": "chunk_296",
      "text": "**\n| 2) 검체는 감염성 질환에 대한 감염을 배제할 수 없으므로 취급에 주의한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 295,
        "window_size": 3,
        "char_count": 48,
        "word_count": 13,
        "page_number": 6,
        "window_text": "|\n**있는 경우는 이를 반영하여 분석결과를 제시해야함. **\n| 2 | 상시험의 효능 및 안전성 입증에 필요한 충분한 수가 확보되어야 함.  | ➂ 전기적 빠른 과도현상(Electrical Fast Transient, EFT)시험 | - Sample Size (5% 탈락률 적용) = 131.71, 약 132개 검체 |\n**삽입할 수 있다. **\n| 2) 검체는 감염성 질환에 대한 감염을 배제할 수 없으므로 취급에 주의한다.  | 방법에 따라 기입한다.  | ③ PFA-100 대조기기와 시험기기의 일치도를 확인한다.  | in vitro diagnostic reagents | 모델명 : 1) ○○ SIPA test |\n**⑤ SIPA test 양성 검체 검사 시 (민감도 85%),**\n| test 음성(정상 결과) 대조군 132명 이상을 대상으로 한다. ",
        "original_sentence": "**\n| 2) 검체는 감염성 질환에 대한 감염을 배제할 수 없으므로 취급에 주의한다. "
      }
    },
    {
      "chunk_id": "chunk_297",
      "text": "| 방법에 따라 기입한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 296,
        "window_size": 3,
        "char_count": 15,
        "word_count": 4,
        "page_number": 24,
        "window_text": "**\n| 2 | 상시험의 효능 및 안전성 입증에 필요한 충분한 수가 확보되어야 함.  | ➂ 전기적 빠른 과도현상(Electrical Fast Transient, EFT)시험 | - Sample Size (5% 탈락률 적용) = 131.71, 약 132개 검체 |\n**삽입할 수 있다. **\n| 2) 검체는 감염성 질환에 대한 감염을 배제할 수 없으므로 취급에 주의한다.  | 방법에 따라 기입한다.  | ③ PFA-100 대조기기와 시험기기의 일치도를 확인한다.  | in vitro diagnostic reagents | 모델명 : 1) ○○ SIPA test |\n**⑤ SIPA test 양성 검체 검사 시 (민감도 85%),**\n| test 음성(정상 결과) 대조군 132명 이상을 대상으로 한다.  | ➃ 서지(Surge) 내성시험 |\n**- Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체**\n| 3) 사용기한이 지난 제품은 사용하지 않는다. ",
        "original_sentence": "| 방법에 따라 기입한다. "
      }
    },
    {
      "chunk_id": "chunk_298",
      "text": "| ③ PFA-100 대조기기와 시험기기의 일치도를 확인한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 297,
        "window_size": 3,
        "char_count": 35,
        "word_count": 7,
        "page_number": 6,
        "window_text": "| ➂ 전기적 빠른 과도현상(Electrical Fast Transient, EFT)시험 | - Sample Size (5% 탈락률 적용) = 131.71, 약 132개 검체 |\n**삽입할 수 있다. **\n| 2) 검체는 감염성 질환에 대한 감염을 배제할 수 없으므로 취급에 주의한다.  | 방법에 따라 기입한다.  | ③ PFA-100 대조기기와 시험기기의 일치도를 확인한다.  | in vitro diagnostic reagents | 모델명 : 1) ○○ SIPA test |\n**⑤ SIPA test 양성 검체 검사 시 (민감도 85%),**\n| test 음성(정상 결과) 대조군 132명 이상을 대상으로 한다.  | ➃ 서지(Surge) 내성시험 |\n**- Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체**\n| 3) 사용기한이 지난 제품은 사용하지 않는다.  | Antagonist)을 일정량 첨가하여 준비한다. ",
        "original_sentence": "| ③ PFA-100 대조기기와 시험기기의 일치도를 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_299",
      "text": "| in vitro diagnostic reagents | 모델명 : 1) ○○ SIPA test |\n**⑤ SIPA test 양성 검체 검사 시 (민감도 85%),**\n| test 음성(정상 결과) 대조군 132명 이상을 대상으로 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 298,
        "window_size": 3,
        "char_count": 134,
        "word_count": 31,
        "page_number": 6,
        "window_text": "**\n| 2) 검체는 감염성 질환에 대한 감염을 배제할 수 없으므로 취급에 주의한다.  | 방법에 따라 기입한다.  | ③ PFA-100 대조기기와 시험기기의 일치도를 확인한다.  | in vitro diagnostic reagents | 모델명 : 1) ○○ SIPA test |\n**⑤ SIPA test 양성 검체 검사 시 (민감도 85%),**\n| test 음성(정상 결과) 대조군 132명 이상을 대상으로 한다.  | ➃ 서지(Surge) 내성시험 |\n**- Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체**\n| 3) 사용기한이 지난 제품은 사용하지 않는다.  | Antagonist)을 일정량 첨가하여 준비한다.  | 는 그 이유의 타당성을 면밀히 검토하여야 한다. ",
        "original_sentence": "| in vitro diagnostic reagents | 모델명 : 1) ○○ SIPA test |\n**⑤ SIPA test 양성 검체 검사 시 (민감도 85%),**\n| test 음성(정상 결과) 대조군 132명 이상을 대상으로 한다. "
      }
    },
    {
      "chunk_id": "chunk_300",
      "text": "| ➃ 서지(Surge) 내성시험 |\n**- Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체**\n| 3) 사용기한이 지난 제품은 사용하지 않는다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 299,
        "window_size": 3,
        "char_count": 98,
        "word_count": 23,
        "page_number": 6,
        "window_text": "| 방법에 따라 기입한다.  | ③ PFA-100 대조기기와 시험기기의 일치도를 확인한다.  | in vitro diagnostic reagents | 모델명 : 1) ○○ SIPA test |\n**⑤ SIPA test 양성 검체 검사 시 (민감도 85%),**\n| test 음성(정상 결과) 대조군 132명 이상을 대상으로 한다.  | ➃ 서지(Surge) 내성시험 |\n**- Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체**\n| 3) 사용기한이 지난 제품은 사용하지 않는다.  | Antagonist)을 일정량 첨가하여 준비한다.  | 는 그 이유의 타당성을 면밀히 검토하여야 한다.  |\n| 출혈성 경향의 증가나 약제 내성에 대한 검사를 위해서도 많이 이용되고 있습니다. ",
        "original_sentence": "| ➃ 서지(Surge) 내성시험 |\n**- Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체**\n| 3) 사용기한이 지난 제품은 사용하지 않는다. "
      }
    },
    {
      "chunk_id": "chunk_301",
      "text": "| Antagonist)을 일정량 첨가하여 준비한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 300,
        "window_size": 3,
        "char_count": 30,
        "word_count": 5,
        "page_number": 24,
        "window_text": "| ③ PFA-100 대조기기와 시험기기의 일치도를 확인한다.  | in vitro diagnostic reagents | 모델명 : 1) ○○ SIPA test |\n**⑤ SIPA test 양성 검체 검사 시 (민감도 85%),**\n| test 음성(정상 결과) 대조군 132명 이상을 대상으로 한다.  | ➃ 서지(Surge) 내성시험 |\n**- Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체**\n| 3) 사용기한이 지난 제품은 사용하지 않는다.  | Antagonist)을 일정량 첨가하여 준비한다.  | 는 그 이유의 타당성을 면밀히 검토하여야 한다.  |\n| 출혈성 경향의 증가나 약제 내성에 대한 검사를 위해서도 많이 이용되고 있습니다.  | - 대립가설: 개발제품의 민감도가 85% 이상이다. ",
        "original_sentence": "| Antagonist)을 일정량 첨가하여 준비한다. "
      }
    },
    {
      "chunk_id": "chunk_302",
      "text": "| 는 그 이유의 타당성을 면밀히 검토하여야 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 301,
        "window_size": 3,
        "char_count": 29,
        "word_count": 8,
        "page_number": 24,
        "window_text": "| in vitro diagnostic reagents | 모델명 : 1) ○○ SIPA test |\n**⑤ SIPA test 양성 검체 검사 시 (민감도 85%),**\n| test 음성(정상 결과) 대조군 132명 이상을 대상으로 한다.  | ➃ 서지(Surge) 내성시험 |\n**- Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체**\n| 3) 사용기한이 지난 제품은 사용하지 않는다.  | Antagonist)을 일정량 첨가하여 준비한다.  | 는 그 이유의 타당성을 면밀히 검토하여야 한다.  |\n| 출혈성 경향의 증가나 약제 내성에 대한 검사를 위해서도 많이 이용되고 있습니다.  | - 대립가설: 개발제품의 민감도가 85% 이상이다.  | - Sample Size (5% 탈락률 적용) = 74.09, 약 75개 검체 |\n| 장애 확인에 도움을 주는 체외진단용 의료기기 | ② EPI test 음성 검체 검사 시 (특이도 85%), | ➄ 전도성 RF 전자기장 내성시험 | Measurement Procedures |\n| 된다. ",
        "original_sentence": "| 는 그 이유의 타당성을 면밀히 검토하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_303",
      "text": "|\n| 출혈성 경향의 증가나 약제 내성에 대한 검사를 위해서도 많이 이용되고 있습니다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 302,
        "window_size": 3,
        "char_count": 49,
        "word_count": 13,
        "page_number": 85,
        "window_text": "| ➃ 서지(Surge) 내성시험 |\n**- Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체**\n| 3) 사용기한이 지난 제품은 사용하지 않는다.  | Antagonist)을 일정량 첨가하여 준비한다.  | 는 그 이유의 타당성을 면밀히 검토하여야 한다.  |\n| 출혈성 경향의 증가나 약제 내성에 대한 검사를 위해서도 많이 이용되고 있습니다.  | - 대립가설: 개발제품의 민감도가 85% 이상이다.  | - Sample Size (5% 탈락률 적용) = 74.09, 약 75개 검체 |\n| 장애 확인에 도움을 주는 체외진단용 의료기기 | ② EPI test 음성 검체 검사 시 (특이도 85%), | ➄ 전도성 RF 전자기장 내성시험 | Measurement Procedures |\n| 된다.  | 검출하는 체외진단용 의료기기 | 하여야 한다. ",
        "original_sentence": "|\n| 출혈성 경향의 증가나 약제 내성에 대한 검사를 위해서도 많이 이용되고 있습니다. "
      }
    },
    {
      "chunk_id": "chunk_304",
      "text": "| - 대립가설: 개발제품의 민감도가 85% 이상이다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 303,
        "window_size": 3,
        "char_count": 31,
        "word_count": 7,
        "page_number": 6,
        "window_text": "| Antagonist)을 일정량 첨가하여 준비한다.  | 는 그 이유의 타당성을 면밀히 검토하여야 한다.  |\n| 출혈성 경향의 증가나 약제 내성에 대한 검사를 위해서도 많이 이용되고 있습니다.  | - 대립가설: 개발제품의 민감도가 85% 이상이다.  | - Sample Size (5% 탈락률 적용) = 74.09, 약 75개 검체 |\n| 장애 확인에 도움을 주는 체외진단용 의료기기 | ② EPI test 음성 검체 검사 시 (특이도 85%), | ➄ 전도성 RF 전자기장 내성시험 | Measurement Procedures |\n| 된다.  | 검출하는 체외진단용 의료기기 | 하여야 한다.  |\n| 수가 보장되어야 하며, 일반적으로 1차 주효과 변수를 기준으로 정해지고, 연구 | (4) 시험 조건 | - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | 시험결과의 차이를 구하여 제시한다. ",
        "original_sentence": "| - 대립가설: 개발제품의 민감도가 85% 이상이다. "
      }
    },
    {
      "chunk_id": "chunk_305",
      "text": "| - Sample Size (5% 탈락률 적용) = 74.09, 약 75개 검체 |\n| 장애 확인에 도움을 주는 체외진단용 의료기기 | ② EPI test 음성 검체 검사 시 (특이도 85%), | ➄ 전도성 RF 전자기장 내성시험 | Measurement Procedures |\n| 된다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 304,
        "window_size": 3,
        "char_count": 164,
        "word_count": 42,
        "page_number": 6,
        "window_text": "| 는 그 이유의 타당성을 면밀히 검토하여야 한다.  |\n| 출혈성 경향의 증가나 약제 내성에 대한 검사를 위해서도 많이 이용되고 있습니다.  | - 대립가설: 개발제품의 민감도가 85% 이상이다.  | - Sample Size (5% 탈락률 적용) = 74.09, 약 75개 검체 |\n| 장애 확인에 도움을 주는 체외진단용 의료기기 | ② EPI test 음성 검체 검사 시 (특이도 85%), | ➄ 전도성 RF 전자기장 내성시험 | Measurement Procedures |\n| 된다.  | 검출하는 체외진단용 의료기기 | 하여야 한다.  |\n| 수가 보장되어야 하며, 일반적으로 1차 주효과 변수를 기준으로 정해지고, 연구 | (4) 시험 조건 | - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | 시험결과의 차이를 구하여 제시한다.  |\n| ② Aspirin test 음성 검체 검사 시 (특이도 95%), | 검체를 사용한다. ",
        "original_sentence": "| - Sample Size (5% 탈락률 적용) = 74.09, 약 75개 검체 |\n| 장애 확인에 도움을 주는 체외진단용 의료기기 | ② EPI test 음성 검체 검사 시 (특이도 85%), | ➄ 전도성 RF 전자기장 내성시험 | Measurement Procedures |\n| 된다. "
      }
    },
    {
      "chunk_id": "chunk_306",
      "text": "| 검출하는 체외진단용 의료기기 | 하여야 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 305,
        "window_size": 3,
        "char_count": 28,
        "word_count": 7,
        "page_number": 24,
        "window_text": "|\n| 출혈성 경향의 증가나 약제 내성에 대한 검사를 위해서도 많이 이용되고 있습니다.  | - 대립가설: 개발제품의 민감도가 85% 이상이다.  | - Sample Size (5% 탈락률 적용) = 74.09, 약 75개 검체 |\n| 장애 확인에 도움을 주는 체외진단용 의료기기 | ② EPI test 음성 검체 검사 시 (특이도 85%), | ➄ 전도성 RF 전자기장 내성시험 | Measurement Procedures |\n| 된다.  | 검출하는 체외진단용 의료기기 | 하여야 한다.  |\n| 수가 보장되어야 하며, 일반적으로 1차 주효과 변수를 기준으로 정해지고, 연구 | (4) 시험 조건 | - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | 시험결과의 차이를 구하여 제시한다.  |\n| ② Aspirin test 음성 검체 검사 시 (특이도 95%), | 검체를 사용한다.  | 분석을 시행하도록 한다. ",
        "original_sentence": "| 검출하는 체외진단용 의료기기 | 하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_307",
      "text": "|\n| 수가 보장되어야 하며, 일반적으로 1차 주효과 변수를 기준으로 정해지고, 연구 | (4) 시험 조건 | - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | 시험결과의 차이를 구하여 제시한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 306,
        "window_size": 3,
        "char_count": 113,
        "word_count": 29,
        "page_number": 6,
        "window_text": "| - 대립가설: 개발제품의 민감도가 85% 이상이다.  | - Sample Size (5% 탈락률 적용) = 74.09, 약 75개 검체 |\n| 장애 확인에 도움을 주는 체외진단용 의료기기 | ② EPI test 음성 검체 검사 시 (특이도 85%), | ➄ 전도성 RF 전자기장 내성시험 | Measurement Procedures |\n| 된다.  | 검출하는 체외진단용 의료기기 | 하여야 한다.  |\n| 수가 보장되어야 하며, 일반적으로 1차 주효과 변수를 기준으로 정해지고, 연구 | (4) 시험 조건 | - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | 시험결과의 차이를 구하여 제시한다.  |\n| ② Aspirin test 음성 검체 검사 시 (특이도 95%), | 검체를 사용한다.  | 분석을 시행하도록 한다.  | - 귀무가설: 개발제품의 민감도가 85% 미만이다. ",
        "original_sentence": "|\n| 수가 보장되어야 하며, 일반적으로 1차 주효과 변수를 기준으로 정해지고, 연구 | (4) 시험 조건 | - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | 시험결과의 차이를 구하여 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_308",
      "text": "|\n| ② Aspirin test 음성 검체 검사 시 (특이도 95%), | 검체를 사용한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 307,
        "window_size": 3,
        "char_count": 53,
        "word_count": 14,
        "page_number": 6,
        "window_text": "| - Sample Size (5% 탈락률 적용) = 74.09, 약 75개 검체 |\n| 장애 확인에 도움을 주는 체외진단용 의료기기 | ② EPI test 음성 검체 검사 시 (특이도 85%), | ➄ 전도성 RF 전자기장 내성시험 | Measurement Procedures |\n| 된다.  | 검출하는 체외진단용 의료기기 | 하여야 한다.  |\n| 수가 보장되어야 하며, 일반적으로 1차 주효과 변수를 기준으로 정해지고, 연구 | (4) 시험 조건 | - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | 시험결과의 차이를 구하여 제시한다.  |\n| ② Aspirin test 음성 검체 검사 시 (특이도 95%), | 검체를 사용한다.  | 분석을 시행하도록 한다.  | - 귀무가설: 개발제품의 민감도가 85% 미만이다.  | - Sample Size (5% 탈락률 적용) = 154.35, 약 155개 검체 |\n**- 대립가설: 개발제품의 특이도가 85% 이상이다.",
        "original_sentence": "|\n| ② Aspirin test 음성 검체 검사 시 (특이도 95%), | 검체를 사용한다. "
      }
    },
    {
      "chunk_id": "chunk_309",
      "text": "| 분석을 시행하도록 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 308,
        "window_size": 3,
        "char_count": 16,
        "word_count": 4,
        "page_number": 24,
        "window_text": "| 검출하는 체외진단용 의료기기 | 하여야 한다.  |\n| 수가 보장되어야 하며, 일반적으로 1차 주효과 변수를 기준으로 정해지고, 연구 | (4) 시험 조건 | - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | 시험결과의 차이를 구하여 제시한다.  |\n| ② Aspirin test 음성 검체 검사 시 (특이도 95%), | 검체를 사용한다.  | 분석을 시행하도록 한다.  | - 귀무가설: 개발제품의 민감도가 85% 미만이다.  | - Sample Size (5% 탈락률 적용) = 154.35, 약 155개 검체 |\n**- 대립가설: 개발제품의 특이도가 85% 이상이다. **\n**➅ 전원주파수 자기장 내성시험**\n| 됩니다. ",
        "original_sentence": "| 분석을 시행하도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_310",
      "text": "| - 귀무가설: 개발제품의 민감도가 85% 미만이다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 309,
        "window_size": 3,
        "char_count": 31,
        "word_count": 7,
        "page_number": 6,
        "window_text": "|\n| 수가 보장되어야 하며, 일반적으로 1차 주효과 변수를 기준으로 정해지고, 연구 | (4) 시험 조건 | - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | 시험결과의 차이를 구하여 제시한다.  |\n| ② Aspirin test 음성 검체 검사 시 (특이도 95%), | 검체를 사용한다.  | 분석을 시행하도록 한다.  | - 귀무가설: 개발제품의 민감도가 85% 미만이다.  | - Sample Size (5% 탈락률 적용) = 154.35, 약 155개 검체 |\n**- 대립가설: 개발제품의 특이도가 85% 이상이다. **\n**➅ 전원주파수 자기장 내성시험**\n| 됩니다.  | - 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순 |\n| 1 | CLSI EP05 | Evaluation of Precision of Quantitative Measurement | Methods; Approved Guideline | 계획서상에 정확한 연구피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 함. ",
        "original_sentence": "| - 귀무가설: 개발제품의 민감도가 85% 미만이다. "
      }
    },
    {
      "chunk_id": "chunk_311",
      "text": "| - Sample Size (5% 탈락률 적용) = 154.35, 약 155개 검체 |\n**- 대립가설: 개발제품의 특이도가 85% 이상이다.",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 310,
        "window_size": 3,
        "char_count": 80,
        "word_count": 19,
        "page_number": 6,
        "window_text": "|\n| ② Aspirin test 음성 검체 검사 시 (특이도 95%), | 검체를 사용한다.  | 분석을 시행하도록 한다.  | - 귀무가설: 개발제품의 민감도가 85% 미만이다.  | - Sample Size (5% 탈락률 적용) = 154.35, 약 155개 검체 |\n**- 대립가설: 개발제품의 특이도가 85% 이상이다. **\n**➅ 전원주파수 자기장 내성시험**\n| 됩니다.  | - 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순 |\n| 1 | CLSI EP05 | Evaluation of Precision of Quantitative Measurement | Methods; Approved Guideline | 계획서상에 정확한 연구피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 함.  |\n| - 간섭반응물질 | (6) 결과 제시 : 검사 결과에 대한 변동계수값(%)값을 구한다. ",
        "original_sentence": "| - Sample Size (5% 탈락률 적용) = 154.35, 약 155개 검체 |\n**- 대립가설: 개발제품의 특이도가 85% 이상이다."
      }
    },
    {
      "chunk_id": "chunk_312",
      "text": "**\n**➅ 전원주파수 자기장 내성시험**\n| 됩니다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 311,
        "window_size": 3,
        "char_count": 31,
        "word_count": 7,
        "page_number": 9,
        "window_text": "| 분석을 시행하도록 한다.  | - 귀무가설: 개발제품의 민감도가 85% 미만이다.  | - Sample Size (5% 탈락률 적용) = 154.35, 약 155개 검체 |\n**- 대립가설: 개발제품의 특이도가 85% 이상이다. **\n**➅ 전원주파수 자기장 내성시험**\n| 됩니다.  | - 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순 |\n| 1 | CLSI EP05 | Evaluation of Precision of Quantitative Measurement | Methods; Approved Guideline | 계획서상에 정확한 연구피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 함.  |\n| - 간섭반응물질 | (6) 결과 제시 : 검사 결과에 대한 변동계수값(%)값을 구한다.  | Approved Guideline | - 대립가설: 개발제품의 특이도가 95% 이상이다. ",
        "original_sentence": "**\n**➅ 전원주파수 자기장 내성시험**\n| 됩니다. "
      }
    },
    {
      "chunk_id": "chunk_313",
      "text": "| - 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순 |\n| 1 | CLSI EP05 | Evaluation of Precision of Quantitative Measurement | Methods; Approved Guideline | 계획서상에 정확한 연구피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 312,
        "window_size": 3,
        "char_count": 191,
        "word_count": 37,
        "page_number": 6,
        "window_text": "| - 귀무가설: 개발제품의 민감도가 85% 미만이다.  | - Sample Size (5% 탈락률 적용) = 154.35, 약 155개 검체 |\n**- 대립가설: 개발제품의 특이도가 85% 이상이다. **\n**➅ 전원주파수 자기장 내성시험**\n| 됩니다.  | - 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순 |\n| 1 | CLSI EP05 | Evaluation of Precision of Quantitative Measurement | Methods; Approved Guideline | 계획서상에 정확한 연구피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 함.  |\n| - 간섭반응물질 | (6) 결과 제시 : 검사 결과에 대한 변동계수값(%)값을 구한다.  | Approved Guideline | - 대립가설: 개발제품의 특이도가 95% 이상이다.  |\n| 제품 | - 적용 계산식 :  |     |\n**- 귀무가설: 개발제품의 특이도가 85% 미만이다.",
        "original_sentence": "| - 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순 |\n| 1 | CLSI EP05 | Evaluation of Precision of Quantitative Measurement | Methods; Approved Guideline | 계획서상에 정확한 연구피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 함. "
      }
    },
    {
      "chunk_id": "chunk_314",
      "text": "|\n| - 간섭반응물질 | (6) 결과 제시 : 검사 결과에 대한 변동계수값(%)값을 구한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 313,
        "window_size": 3,
        "char_count": 53,
        "word_count": 14,
        "page_number": 15,
        "window_text": "| - Sample Size (5% 탈락률 적용) = 154.35, 약 155개 검체 |\n**- 대립가설: 개발제품의 특이도가 85% 이상이다. **\n**➅ 전원주파수 자기장 내성시험**\n| 됩니다.  | - 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순 |\n| 1 | CLSI EP05 | Evaluation of Precision of Quantitative Measurement | Methods; Approved Guideline | 계획서상에 정확한 연구피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 함.  |\n| - 간섭반응물질 | (6) 결과 제시 : 검사 결과에 대한 변동계수값(%)값을 구한다.  | Approved Guideline | - 대립가설: 개발제품의 특이도가 95% 이상이다.  |\n| 제품 | - 적용 계산식 :  |     |\n**- 귀무가설: 개발제품의 특이도가 85% 미만이다. **\n| 기록 되는지 여부를 검토, 확인하는 활동을 말한다. ",
        "original_sentence": "|\n| - 간섭반응물질 | (6) 결과 제시 : 검사 결과에 대한 변동계수값(%)값을 구한다. "
      }
    },
    {
      "chunk_id": "chunk_315",
      "text": "| Approved Guideline | - 대립가설: 개발제품의 특이도가 95% 이상이다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 314,
        "window_size": 3,
        "char_count": 52,
        "word_count": 10,
        "page_number": 6,
        "window_text": "**\n**➅ 전원주파수 자기장 내성시험**\n| 됩니다.  | - 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순 |\n| 1 | CLSI EP05 | Evaluation of Precision of Quantitative Measurement | Methods; Approved Guideline | 계획서상에 정확한 연구피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 함.  |\n| - 간섭반응물질 | (6) 결과 제시 : 검사 결과에 대한 변동계수값(%)값을 구한다.  | Approved Guideline | - 대립가설: 개발제품의 특이도가 95% 이상이다.  |\n| 제품 | - 적용 계산식 :  |     |\n**- 귀무가설: 개발제품의 특이도가 85% 미만이다. **\n| 기록 되는지 여부를 검토, 확인하는 활동을 말한다.  | ➆ 전압강하, 순간정전 및 전압변동 시험 | 예) KFDA-12-34-56 |\n| 그러나 최근의 임상연구에서는 임상연구가 점차 복잡해지고 다양한 연구 목적을 | - 귀무가설: 개발제품의 특이도가 95% 미만이다. ",
        "original_sentence": "| Approved Guideline | - 대립가설: 개발제품의 특이도가 95% 이상이다. "
      }
    },
    {
      "chunk_id": "chunk_316",
      "text": "|\n| 제품 | - 적용 계산식 :  |     |\n**- 귀무가설: 개발제품의 특이도가 85% 미만이다.",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 315,
        "window_size": 3,
        "char_count": 69,
        "word_count": 21,
        "page_number": 7,
        "window_text": "| - 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순 |\n| 1 | CLSI EP05 | Evaluation of Precision of Quantitative Measurement | Methods; Approved Guideline | 계획서상에 정확한 연구피험자 수의 결정방법, 근거에 대한 기술이 포함되어야 함.  |\n| - 간섭반응물질 | (6) 결과 제시 : 검사 결과에 대한 변동계수값(%)값을 구한다.  | Approved Guideline | - 대립가설: 개발제품의 특이도가 95% 이상이다.  |\n| 제품 | - 적용 계산식 :  |     |\n**- 귀무가설: 개발제품의 특이도가 85% 미만이다. **\n| 기록 되는지 여부를 검토, 확인하는 활동을 말한다.  | ➆ 전압강하, 순간정전 및 전압변동 시험 | 예) KFDA-12-34-56 |\n| 그러나 최근의 임상연구에서는 임상연구가 점차 복잡해지고 다양한 연구 목적을 | - 귀무가설: 개발제품의 특이도가 95% 미만이다.  |\n| 기능장애 확인에 도움을 주는 체외진단용 의료기기 | (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests | (4) 시험 조건 | 정한다. ",
        "original_sentence": "|\n| 제품 | - 적용 계산식 :  |     |\n**- 귀무가설: 개발제품의 특이도가 85% 미만이다."
      }
    },
    {
      "chunk_id": "chunk_317",
      "text": "**\n| 기록 되는지 여부를 검토, 확인하는 활동을 말한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 316,
        "window_size": 3,
        "char_count": 34,
        "word_count": 9,
        "page_number": 3,
        "window_text": "|\n| - 간섭반응물질 | (6) 결과 제시 : 검사 결과에 대한 변동계수값(%)값을 구한다.  | Approved Guideline | - 대립가설: 개발제품의 특이도가 95% 이상이다.  |\n| 제품 | - 적용 계산식 :  |     |\n**- 귀무가설: 개발제품의 특이도가 85% 미만이다. **\n| 기록 되는지 여부를 검토, 확인하는 활동을 말한다.  | ➆ 전압강하, 순간정전 및 전압변동 시험 | 예) KFDA-12-34-56 |\n| 그러나 최근의 임상연구에서는 임상연구가 점차 복잡해지고 다양한 연구 목적을 | - 귀무가설: 개발제품의 특이도가 95% 미만이다.  |\n| 기능장애 확인에 도움을 주는 체외진단용 의료기기 | (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests | (4) 시험 조건 | 정한다.  |\n| 2 | CLSI EP06 |\n| 참여함을 확인하는 절차를 말한다. ",
        "original_sentence": "**\n| 기록 되는지 여부를 검토, 확인하는 활동을 말한다. "
      }
    },
    {
      "chunk_id": "chunk_318",
      "text": "| ➆ 전압강하, 순간정전 및 전압변동 시험 | 예) KFDA-12-34-56 |\n| 그러나 최근의 임상연구에서는 임상연구가 점차 복잡해지고 다양한 연구 목적을 | - 귀무가설: 개발제품의 특이도가 95% 미만이다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 317,
        "window_size": 3,
        "char_count": 121,
        "word_count": 28,
        "page_number": 6,
        "window_text": "| Approved Guideline | - 대립가설: 개발제품의 특이도가 95% 이상이다.  |\n| 제품 | - 적용 계산식 :  |     |\n**- 귀무가설: 개발제품의 특이도가 85% 미만이다. **\n| 기록 되는지 여부를 검토, 확인하는 활동을 말한다.  | ➆ 전압강하, 순간정전 및 전압변동 시험 | 예) KFDA-12-34-56 |\n| 그러나 최근의 임상연구에서는 임상연구가 점차 복잡해지고 다양한 연구 목적을 | - 귀무가설: 개발제품의 특이도가 95% 미만이다.  |\n| 기능장애 확인에 도움을 주는 체외진단용 의료기기 | (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests | (4) 시험 조건 | 정한다.  |\n| 2 | CLSI EP06 |\n| 참여함을 확인하는 절차를 말한다.  | 품목명 : 혈액응고검사시약 [3] | - 적용 계산식 :  |     |\n| 저항성 복합검사기기’의 임상적 유효성을 비교 분석하는 것이 목적입니다. ",
        "original_sentence": "| ➆ 전압강하, 순간정전 및 전압변동 시험 | 예) KFDA-12-34-56 |\n| 그러나 최근의 임상연구에서는 임상연구가 점차 복잡해지고 다양한 연구 목적을 | - 귀무가설: 개발제품의 특이도가 95% 미만이다. "
      }
    },
    {
      "chunk_id": "chunk_319",
      "text": "|\n| 기능장애 확인에 도움을 주는 체외진단용 의료기기 | (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests | (4) 시험 조건 | 정한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 318,
        "window_size": 3,
        "char_count": 89,
        "word_count": 18,
        "page_number": 6,
        "window_text": "|\n| 제품 | - 적용 계산식 :  |     |\n**- 귀무가설: 개발제품의 특이도가 85% 미만이다. **\n| 기록 되는지 여부를 검토, 확인하는 활동을 말한다.  | ➆ 전압강하, 순간정전 및 전압변동 시험 | 예) KFDA-12-34-56 |\n| 그러나 최근의 임상연구에서는 임상연구가 점차 복잡해지고 다양한 연구 목적을 | - 귀무가설: 개발제품의 특이도가 95% 미만이다.  |\n| 기능장애 확인에 도움을 주는 체외진단용 의료기기 | (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests | (4) 시험 조건 | 정한다.  |\n| 2 | CLSI EP06 |\n| 참여함을 확인하는 절차를 말한다.  | 품목명 : 혈액응고검사시약 [3] | - 적용 계산식 :  |     |\n| 저항성 복합검사기기’의 임상적 유효성을 비교 분석하는 것이 목적입니다.  | 전부에 대하여 중지 명령 등 필요한 조치를 시험책임자에게 할 수 있다. ",
        "original_sentence": "|\n| 기능장애 확인에 도움을 주는 체외진단용 의료기기 | (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests | (4) 시험 조건 | 정한다. "
      }
    },
    {
      "chunk_id": "chunk_320",
      "text": "|\n| 2 | CLSI EP06 |\n| 참여함을 확인하는 절차를 말한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 319,
        "window_size": 3,
        "char_count": 41,
        "word_count": 12,
        "page_number": 6,
        "window_text": "**\n| 기록 되는지 여부를 검토, 확인하는 활동을 말한다.  | ➆ 전압강하, 순간정전 및 전압변동 시험 | 예) KFDA-12-34-56 |\n| 그러나 최근의 임상연구에서는 임상연구가 점차 복잡해지고 다양한 연구 목적을 | - 귀무가설: 개발제품의 특이도가 95% 미만이다.  |\n| 기능장애 확인에 도움을 주는 체외진단용 의료기기 | (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests | (4) 시험 조건 | 정한다.  |\n| 2 | CLSI EP06 |\n| 참여함을 확인하는 절차를 말한다.  | 품목명 : 혈액응고검사시약 [3] | - 적용 계산식 :  |     |\n| 저항성 복합검사기기’의 임상적 유효성을 비교 분석하는 것이 목적입니다.  | 전부에 대하여 중지 명령 등 필요한 조치를 시험책임자에게 할 수 있다.  |\n**평가하기 위하여 1차 주효과 변수뿐만 아니라 안전성평가변수 및 2차 주효과**\n**제품**\n| - | 치료 | - 탈락 또는 임상시험이 중지된 피험자의 경우 실시된 visit까지 기록함. ",
        "original_sentence": "|\n| 2 | CLSI EP06 |\n| 참여함을 확인하는 절차를 말한다. "
      }
    },
    {
      "chunk_id": "chunk_321",
      "text": "| 품목명 : 혈액응고검사시약 [3] | - 적용 계산식 :  |     |\n| 저항성 복합검사기기’의 임상적 유효성을 비교 분석하는 것이 목적입니다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 320,
        "window_size": 3,
        "char_count": 95,
        "word_count": 26,
        "page_number": 6,
        "window_text": "| ➆ 전압강하, 순간정전 및 전압변동 시험 | 예) KFDA-12-34-56 |\n| 그러나 최근의 임상연구에서는 임상연구가 점차 복잡해지고 다양한 연구 목적을 | - 귀무가설: 개발제품의 특이도가 95% 미만이다.  |\n| 기능장애 확인에 도움을 주는 체외진단용 의료기기 | (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests | (4) 시험 조건 | 정한다.  |\n| 2 | CLSI EP06 |\n| 참여함을 확인하는 절차를 말한다.  | 품목명 : 혈액응고검사시약 [3] | - 적용 계산식 :  |     |\n| 저항성 복합검사기기’의 임상적 유효성을 비교 분석하는 것이 목적입니다.  | 전부에 대하여 중지 명령 등 필요한 조치를 시험책임자에게 할 수 있다.  |\n**평가하기 위하여 1차 주효과 변수뿐만 아니라 안전성평가변수 및 2차 주효과**\n**제품**\n| - | 치료 | - 탈락 또는 임상시험이 중지된 피험자의 경우 실시된 visit까지 기록함.  | 내용을 기재함. ",
        "original_sentence": "| 품목명 : 혈액응고검사시약 [3] | - 적용 계산식 :  |     |\n| 저항성 복합검사기기’의 임상적 유효성을 비교 분석하는 것이 목적입니다. "
      }
    },
    {
      "chunk_id": "chunk_322",
      "text": "| 전부에 대하여 중지 명령 등 필요한 조치를 시험책임자에게 할 수 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 321,
        "window_size": 3,
        "char_count": 42,
        "word_count": 12,
        "page_number": 7,
        "window_text": "|\n| 기능장애 확인에 도움을 주는 체외진단용 의료기기 | (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests | (4) 시험 조건 | 정한다.  |\n| 2 | CLSI EP06 |\n| 참여함을 확인하는 절차를 말한다.  | 품목명 : 혈액응고검사시약 [3] | - 적용 계산식 :  |     |\n| 저항성 복합검사기기’의 임상적 유효성을 비교 분석하는 것이 목적입니다.  | 전부에 대하여 중지 명령 등 필요한 조치를 시험책임자에게 할 수 있다.  |\n**평가하기 위하여 1차 주효과 변수뿐만 아니라 안전성평가변수 및 2차 주효과**\n**제품**\n| - | 치료 | - 탈락 또는 임상시험이 중지된 피험자의 경우 실시된 visit까지 기록함.  | 내용을 기재함.  | 반납 및 폐기에 관한 기록을 작성·보관하여야 한다. ",
        "original_sentence": "| 전부에 대하여 중지 명령 등 필요한 조치를 시험책임자에게 할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_323",
      "text": "|\n**평가하기 위하여 1차 주효과 변수뿐만 아니라 안전성평가변수 및 2차 주효과**\n**제품**\n| - | 치료 | - 탈락 또는 임상시험이 중지된 피험자의 경우 실시된 visit까지 기록함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 322,
        "window_size": 3,
        "char_count": 109,
        "word_count": 27,
        "page_number": 6,
        "window_text": "|\n| 2 | CLSI EP06 |\n| 참여함을 확인하는 절차를 말한다.  | 품목명 : 혈액응고검사시약 [3] | - 적용 계산식 :  |     |\n| 저항성 복합검사기기’의 임상적 유효성을 비교 분석하는 것이 목적입니다.  | 전부에 대하여 중지 명령 등 필요한 조치를 시험책임자에게 할 수 있다.  |\n**평가하기 위하여 1차 주효과 변수뿐만 아니라 안전성평가변수 및 2차 주효과**\n**제품**\n| - | 치료 | - 탈락 또는 임상시험이 중지된 피험자의 경우 실시된 visit까지 기록함.  | 내용을 기재함.  | 반납 및 폐기에 관한 기록을 작성·보관하여야 한다.  | - 적용 계산식 :  |     |\n| 3 | CLSI EP07 | Interference Testing in Clinical Chemistry; Approved | Guideline | 로트로 대체 가능) | 품목분류번호 : (D01050.01) |\n| 1) Aspirin test | 혈소판수 포함), PT, aPTT 결과 등을 문진과 진료 기록을 통하여 조사한다. ",
        "original_sentence": "|\n**평가하기 위하여 1차 주효과 변수뿐만 아니라 안전성평가변수 및 2차 주효과**\n**제품**\n| - | 치료 | - 탈락 또는 임상시험이 중지된 피험자의 경우 실시된 visit까지 기록함. "
      }
    },
    {
      "chunk_id": "chunk_324",
      "text": "| 내용을 기재함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 323,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 17,
        "window_text": "| 품목명 : 혈액응고검사시약 [3] | - 적용 계산식 :  |     |\n| 저항성 복합검사기기’의 임상적 유효성을 비교 분석하는 것이 목적입니다.  | 전부에 대하여 중지 명령 등 필요한 조치를 시험책임자에게 할 수 있다.  |\n**평가하기 위하여 1차 주효과 변수뿐만 아니라 안전성평가변수 및 2차 주효과**\n**제품**\n| - | 치료 | - 탈락 또는 임상시험이 중지된 피험자의 경우 실시된 visit까지 기록함.  | 내용을 기재함.  | 반납 및 폐기에 관한 기록을 작성·보관하여야 한다.  | - 적용 계산식 :  |     |\n| 3 | CLSI EP07 | Interference Testing in Clinical Chemistry; Approved | Guideline | 로트로 대체 가능) | 품목분류번호 : (D01050.01) |\n| 1) Aspirin test | 혈소판수 포함), PT, aPTT 결과 등을 문진과 진료 기록을 통하여 조사한다.  | 산출한다. ",
        "original_sentence": "| 내용을 기재함. "
      }
    },
    {
      "chunk_id": "chunk_325",
      "text": "| 반납 및 폐기에 관한 기록을 작성·보관하여야 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 324,
        "window_size": 3,
        "char_count": 31,
        "word_count": 8,
        "page_number": 24,
        "window_text": "| 전부에 대하여 중지 명령 등 필요한 조치를 시험책임자에게 할 수 있다.  |\n**평가하기 위하여 1차 주효과 변수뿐만 아니라 안전성평가변수 및 2차 주효과**\n**제품**\n| - | 치료 | - 탈락 또는 임상시험이 중지된 피험자의 경우 실시된 visit까지 기록함.  | 내용을 기재함.  | 반납 및 폐기에 관한 기록을 작성·보관하여야 한다.  | - 적용 계산식 :  |     |\n| 3 | CLSI EP07 | Interference Testing in Clinical Chemistry; Approved | Guideline | 로트로 대체 가능) | 품목분류번호 : (D01050.01) |\n| 1) Aspirin test | 혈소판수 포함), PT, aPTT 결과 등을 문진과 진료 기록을 통하여 조사한다.  | 산출한다.  신뢰도 95% 구간에서 민감도 85%, 특이도 85%, 로 설정한다. ",
        "original_sentence": "| 반납 및 폐기에 관한 기록을 작성·보관하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_326",
      "text": "| - 적용 계산식 :  |     |\n| 3 | CLSI EP07 | Interference Testing in Clinical Chemistry; Approved | Guideline | 로트로 대체 가능) | 품목분류번호 : (D01050.01) |\n| 1) Aspirin test | 혈소판수 포함), PT, aPTT 결과 등을 문진과 진료 기록을 통하여 조사한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 325,
        "window_size": 3,
        "char_count": 219,
        "word_count": 51,
        "page_number": 15,
        "window_text": "|\n**평가하기 위하여 1차 주효과 변수뿐만 아니라 안전성평가변수 및 2차 주효과**\n**제품**\n| - | 치료 | - 탈락 또는 임상시험이 중지된 피험자의 경우 실시된 visit까지 기록함.  | 내용을 기재함.  | 반납 및 폐기에 관한 기록을 작성·보관하여야 한다.  | - 적용 계산식 :  |     |\n| 3 | CLSI EP07 | Interference Testing in Clinical Chemistry; Approved | Guideline | 로트로 대체 가능) | 품목분류번호 : (D01050.01) |\n| 1) Aspirin test | 혈소판수 포함), PT, aPTT 결과 등을 문진과 진료 기록을 통하여 조사한다.  | 산출한다.  신뢰도 95% 구간에서 민감도 85%, 특이도 85%, 로 설정한다.  | 방문과 전화 등을 통해서 이루어 질 것이다. ",
        "original_sentence": "| - 적용 계산식 :  |     |\n| 3 | CLSI EP07 | Interference Testing in Clinical Chemistry; Approved | Guideline | 로트로 대체 가능) | 품목분류번호 : (D01050.01) |\n| 1) Aspirin test | 혈소판수 포함), PT, aPTT 결과 등을 문진과 진료 기록을 통하여 조사한다. "
      }
    },
    {
      "chunk_id": "chunk_327",
      "text": "| 산출한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 326,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 24,
        "window_text": "| 내용을 기재함.  | 반납 및 폐기에 관한 기록을 작성·보관하여야 한다.  | - 적용 계산식 :  |     |\n| 3 | CLSI EP07 | Interference Testing in Clinical Chemistry; Approved | Guideline | 로트로 대체 가능) | 품목분류번호 : (D01050.01) |\n| 1) Aspirin test | 혈소판수 포함), PT, aPTT 결과 등을 문진과 진료 기록을 통하여 조사한다.  | 산출한다.  신뢰도 95% 구간에서 민감도 85%, 특이도 85%, 로 설정한다.  | 방문과 전화 등을 통해서 이루어 질 것이다.  |\n**변수, 1차 주효과 변수의 조합 등을 고려하여 수행되고 있음.",
        "original_sentence": "| 산출한다. "
      }
    },
    {
      "chunk_id": "chunk_328",
      "text": "신뢰도 95% 구간에서 민감도 85%, 특이도 85%, 로 설정한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 327,
        "window_size": 3,
        "char_count": 39,
        "word_count": 9,
        "page_number": 6,
        "window_text": "| 반납 및 폐기에 관한 기록을 작성·보관하여야 한다.  | - 적용 계산식 :  |     |\n| 3 | CLSI EP07 | Interference Testing in Clinical Chemistry; Approved | Guideline | 로트로 대체 가능) | 품목분류번호 : (D01050.01) |\n| 1) Aspirin test | 혈소판수 포함), PT, aPTT 결과 등을 문진과 진료 기록을 통하여 조사한다.  | 산출한다.  신뢰도 95% 구간에서 민감도 85%, 특이도 85%, 로 설정한다.  | 방문과 전화 등을 통해서 이루어 질 것이다.  |\n**변수, 1차 주효과 변수의 조합 등을 고려하여 수행되고 있음. **\n| 4 | CLSI EP17 | Evaluation | of | Detection | Capability | for | Clinical | 시험기기 |\n**하였으며 자발적으로 이 연구에 참여하는 것에 동의합니다.",
        "original_sentence": "신뢰도 95% 구간에서 민감도 85%, 특이도 85%, 로 설정한다. "
      }
    },
    {
      "chunk_id": "chunk_329",
      "text": "| 방문과 전화 등을 통해서 이루어 질 것이다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 328,
        "window_size": 3,
        "char_count": 27,
        "word_count": 8,
        "page_number": 37,
        "window_text": "| - 적용 계산식 :  |     |\n| 3 | CLSI EP07 | Interference Testing in Clinical Chemistry; Approved | Guideline | 로트로 대체 가능) | 품목분류번호 : (D01050.01) |\n| 1) Aspirin test | 혈소판수 포함), PT, aPTT 결과 등을 문진과 진료 기록을 통하여 조사한다.  | 산출한다.  신뢰도 95% 구간에서 민감도 85%, 특이도 85%, 로 설정한다.  | 방문과 전화 등을 통해서 이루어 질 것이다.  |\n**변수, 1차 주효과 변수의 조합 등을 고려하여 수행되고 있음. **\n| 4 | CLSI EP17 | Evaluation | of | Detection | Capability | for | Clinical | 시험기기 |\n**하였으며 자발적으로 이 연구에 참여하는 것에 동의합니다. **\n| 기능장애 확인에 도움을 주는 체외진단용 의료기기 | 있다. ",
        "original_sentence": "| 방문과 전화 등을 통해서 이루어 질 것이다. "
      }
    },
    {
      "chunk_id": "chunk_330",
      "text": "|\n**변수, 1차 주효과 변수의 조합 등을 고려하여 수행되고 있음.",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 329,
        "window_size": 3,
        "char_count": 38,
        "word_count": 10,
        "page_number": 6,
        "window_text": "| 산출한다.  신뢰도 95% 구간에서 민감도 85%, 특이도 85%, 로 설정한다.  | 방문과 전화 등을 통해서 이루어 질 것이다.  |\n**변수, 1차 주효과 변수의 조합 등을 고려하여 수행되고 있음. **\n| 4 | CLSI EP17 | Evaluation | of | Detection | Capability | for | Clinical | 시험기기 |\n**하였으며 자발적으로 이 연구에 참여하는 것에 동의합니다. **\n| 기능장애 확인에 도움을 주는 체외진단용 의료기기 | 있다.  |\n| 5 | CLSI EP12 | User | Protocol | for | Evaluation | of | Qualitative | Test | Approved Guideline |\n| ② 대조기기(VerifyNow) 결과와 시험기기의 일치도를 확인한다. ",
        "original_sentence": "|\n**변수, 1차 주효과 변수의 조합 등을 고려하여 수행되고 있음."
      }
    },
    {
      "chunk_id": "chunk_331",
      "text": "**\n| 4 | CLSI EP17 | Evaluation | of | Detection | Capability | for | Clinical | 시험기기 |\n**하였으며 자발적으로 이 연구에 참여하는 것에 동의합니다.",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 330,
        "window_size": 3,
        "char_count": 121,
        "word_count": 28,
        "page_number": 6,
        "window_text": "신뢰도 95% 구간에서 민감도 85%, 특이도 85%, 로 설정한다.  | 방문과 전화 등을 통해서 이루어 질 것이다.  |\n**변수, 1차 주효과 변수의 조합 등을 고려하여 수행되고 있음. **\n| 4 | CLSI EP17 | Evaluation | of | Detection | Capability | for | Clinical | 시험기기 |\n**하였으며 자발적으로 이 연구에 참여하는 것에 동의합니다. **\n| 기능장애 확인에 도움을 주는 체외진단용 의료기기 | 있다.  |\n| 5 | CLSI EP12 | User | Protocol | for | Evaluation | of | Qualitative | Test | Approved Guideline |\n| ② 대조기기(VerifyNow) 결과와 시험기기의 일치도를 확인한다.  | 한다. ",
        "original_sentence": "**\n| 4 | CLSI EP17 | Evaluation | of | Detection | Capability | for | Clinical | 시험기기 |\n**하였으며 자발적으로 이 연구에 참여하는 것에 동의합니다."
      }
    },
    {
      "chunk_id": "chunk_332",
      "text": "**\n| 기능장애 확인에 도움을 주는 체외진단용 의료기기 | 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 331,
        "window_size": 3,
        "char_count": 38,
        "word_count": 10,
        "page_number": 44,
        "window_text": "| 방문과 전화 등을 통해서 이루어 질 것이다.  |\n**변수, 1차 주효과 변수의 조합 등을 고려하여 수행되고 있음. **\n| 4 | CLSI EP17 | Evaluation | of | Detection | Capability | for | Clinical | 시험기기 |\n**하였으며 자발적으로 이 연구에 참여하는 것에 동의합니다. **\n| 기능장애 확인에 도움을 주는 체외진단용 의료기기 | 있다.  |\n| 5 | CLSI EP12 | User | Protocol | for | Evaluation | of | Qualitative | Test | Approved Guideline |\n| ② 대조기기(VerifyNow) 결과와 시험기기의 일치도를 확인한다.  | 한다.  | 시험자와 상의한다. ",
        "original_sentence": "**\n| 기능장애 확인에 도움을 주는 체외진단용 의료기기 | 있다. "
      }
    },
    {
      "chunk_id": "chunk_333",
      "text": "|\n| 5 | CLSI EP12 | User | Protocol | for | Evaluation | of | Qualitative | Test | Approved Guideline |\n| ② 대조기기(VerifyNow) 결과와 시험기기의 일치도를 확인한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 332,
        "window_size": 3,
        "char_count": 145,
        "word_count": 31,
        "page_number": 6,
        "window_text": "|\n**변수, 1차 주효과 변수의 조합 등을 고려하여 수행되고 있음. **\n| 4 | CLSI EP17 | Evaluation | of | Detection | Capability | for | Clinical | 시험기기 |\n**하였으며 자발적으로 이 연구에 참여하는 것에 동의합니다. **\n| 기능장애 확인에 도움을 주는 체외진단용 의료기기 | 있다.  |\n| 5 | CLSI EP12 | User | Protocol | for | Evaluation | of | Qualitative | Test | Approved Guideline |\n| ② 대조기기(VerifyNow) 결과와 시험기기의 일치도를 확인한다.  | 한다.  | 시험자와 상의한다.  | - Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체 |\n**하여 주십시오.",
        "original_sentence": "|\n| 5 | CLSI EP12 | User | Protocol | for | Evaluation | of | Qualitative | Test | Approved Guideline |\n| ② 대조기기(VerifyNow) 결과와 시험기기의 일치도를 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_334",
      "text": "| 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 333,
        "window_size": 3,
        "char_count": 6,
        "word_count": 2,
        "page_number": 24,
        "window_text": "**\n| 4 | CLSI EP17 | Evaluation | of | Detection | Capability | for | Clinical | 시험기기 |\n**하였으며 자발적으로 이 연구에 참여하는 것에 동의합니다. **\n| 기능장애 확인에 도움을 주는 체외진단용 의료기기 | 있다.  |\n| 5 | CLSI EP12 | User | Protocol | for | Evaluation | of | Qualitative | Test | Approved Guideline |\n| ② 대조기기(VerifyNow) 결과와 시험기기의 일치도를 확인한다.  | 한다.  | 시험자와 상의한다.  | - Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체 |\n**하여 주십시오. **\n\n**[표 끝]**\n\n번호\n\n규격 번호\n\n제목\n\n내용\n\n번호\n\n안전성 평가 항목\n\n관련 표준 또는 적용 규격\n\n1\n\n개봉 전/후\n\nstability of in vitro diagnostic reagents\n\n- - 11 -\n<!-- PAGE_18 -->\n###### 5. ",
        "original_sentence": "| 한다. "
      }
    },
    {
      "chunk_id": "chunk_335",
      "text": "| 시험자와 상의한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 334,
        "window_size": 3,
        "char_count": 13,
        "word_count": 3,
        "page_number": 9,
        "window_text": "**\n| 기능장애 확인에 도움을 주는 체외진단용 의료기기 | 있다.  |\n| 5 | CLSI EP12 | User | Protocol | for | Evaluation | of | Qualitative | Test | Approved Guideline |\n| ② 대조기기(VerifyNow) 결과와 시험기기의 일치도를 확인한다.  | 한다.  | 시험자와 상의한다.  | - Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체 |\n**하여 주십시오. **\n\n**[표 끝]**\n\n번호\n\n규격 번호\n\n제목\n\n내용\n\n번호\n\n안전성 평가 항목\n\n관련 표준 또는 적용 규격\n\n1\n\n개봉 전/후\n\nstability of in vitro diagnostic reagents\n\n- - 11 -\n<!-- PAGE_18 -->\n###### 5.  안전성 평가 항목\n\n**[표 시작]**\n\n| 가. ",
        "original_sentence": "| 시험자와 상의한다. "
      }
    },
    {
      "chunk_id": "chunk_336",
      "text": "| - Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체 |\n**하여 주십시오.",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 335,
        "window_size": 3,
        "char_count": 59,
        "word_count": 15,
        "page_number": 6,
        "window_text": "|\n| 5 | CLSI EP12 | User | Protocol | for | Evaluation | of | Qualitative | Test | Approved Guideline |\n| ② 대조기기(VerifyNow) 결과와 시험기기의 일치도를 확인한다.  | 한다.  | 시험자와 상의한다.  | - Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체 |\n**하여 주십시오. **\n\n**[표 끝]**\n\n번호\n\n규격 번호\n\n제목\n\n내용\n\n번호\n\n안전성 평가 항목\n\n관련 표준 또는 적용 규격\n\n1\n\n개봉 전/후\n\nstability of in vitro diagnostic reagents\n\n- - 11 -\n<!-- PAGE_18 -->\n###### 5.  안전성 평가 항목\n\n**[표 시작]**\n\n| 가.  전기 | 피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자 | 1. ",
        "original_sentence": "| - Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체 |\n**하여 주십시오."
      }
    },
    {
      "chunk_id": "chunk_337",
      "text": "**\n\n**[표 끝]**\n\n번호\n\n규격 번호\n\n제목\n\n내용\n\n번호\n\n안전성 평가 항목\n\n관련 표준 또는 적용 규격\n\n1\n\n개봉 전/후\n\nstability of in vitro diagnostic reagents\n\n- - 11 -\n<!-- PAGE_18 -->\n###### 5. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 336,
        "window_size": 3,
        "char_count": 155,
        "word_count": 35,
        "page_number": 18,
        "window_text": "| 한다.  | 시험자와 상의한다.  | - Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체 |\n**하여 주십시오. **\n\n**[표 끝]**\n\n번호\n\n규격 번호\n\n제목\n\n내용\n\n번호\n\n안전성 평가 항목\n\n관련 표준 또는 적용 규격\n\n1\n\n개봉 전/후\n\nstability of in vitro diagnostic reagents\n\n- - 11 -\n<!-- PAGE_18 -->\n###### 5.  안전성 평가 항목\n\n**[표 시작]**\n\n| 가.  전기 | 피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자 | 1.  임상시험의 제목 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 개정되거나 사안에 따라 변경될 수 있으며, 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 원자재, 형상, 구조, 치수/중량, 성능, 보관조건 등을 구체적으로 기재하도록 함. ",
        "original_sentence": "**\n\n**[표 끝]**\n\n번호\n\n규격 번호\n\n제목\n\n내용\n\n번호\n\n안전성 평가 항목\n\n관련 표준 또는 적용 규격\n\n1\n\n개봉 전/후\n\nstability of in vitro diagnostic reagents\n\n- - 11 -\n<!-- PAGE_18 -->\n###### 5. "
      }
    },
    {
      "chunk_id": "chunk_338",
      "text": "안전성 평가 항목\n\n**[표 시작]**\n\n| 가. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 337,
        "window_size": 3,
        "char_count": 28,
        "word_count": 7,
        "page_number": 6,
        "window_text": "| 시험자와 상의한다.  | - Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체 |\n**하여 주십시오. **\n\n**[표 끝]**\n\n번호\n\n규격 번호\n\n제목\n\n내용\n\n번호\n\n안전성 평가 항목\n\n관련 표준 또는 적용 규격\n\n1\n\n개봉 전/후\n\nstability of in vitro diagnostic reagents\n\n- - 11 -\n<!-- PAGE_18 -->\n###### 5.  안전성 평가 항목\n\n**[표 시작]**\n\n| 가.  전기 | 피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자 | 1.  임상시험의 제목 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 개정되거나 사안에 따라 변경될 수 있으며, 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 원자재, 형상, 구조, 치수/중량, 성능, 보관조건 등을 구체적으로 기재하도록 함.  | 수 있으며, 품목의 특성에 따라 자율적으로 설정이 가능함 | 기계적 안전성 시험 | 1. ",
        "original_sentence": "안전성 평가 항목\n\n**[표 시작]**\n\n| 가. "
      }
    },
    {
      "chunk_id": "chunk_339",
      "text": "전기 | 피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자 | 1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 338,
        "window_size": 3,
        "char_count": 53,
        "word_count": 12,
        "page_number": 9,
        "window_text": "| - Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체 |\n**하여 주십시오. **\n\n**[표 끝]**\n\n번호\n\n규격 번호\n\n제목\n\n내용\n\n번호\n\n안전성 평가 항목\n\n관련 표준 또는 적용 규격\n\n1\n\n개봉 전/후\n\nstability of in vitro diagnostic reagents\n\n- - 11 -\n<!-- PAGE_18 -->\n###### 5.  안전성 평가 항목\n\n**[표 시작]**\n\n| 가.  전기 | 피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자 | 1.  임상시험의 제목 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 개정되거나 사안에 따라 변경될 수 있으며, 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 원자재, 형상, 구조, 치수/중량, 성능, 보관조건 등을 구체적으로 기재하도록 함.  | 수 있으며, 품목의 특성에 따라 자율적으로 설정이 가능함 | 기계적 안전성 시험 | 1.  Rational use of the PFA-100 device for screening |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 1. ",
        "original_sentence": "전기 | 피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자 | 1. "
      }
    },
    {
      "chunk_id": "chunk_340",
      "text": "임상시험의 제목 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 개정되거나 사안에 따라 변경될 수 있으며, 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 원자재, 형상, 구조, 치수/중량, 성능, 보관조건 등을 구체적으로 기재하도록 함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 339,
        "window_size": 3,
        "char_count": 352,
        "word_count": 89,
        "page_number": 6,
        "window_text": "**\n\n**[표 끝]**\n\n번호\n\n규격 번호\n\n제목\n\n내용\n\n번호\n\n안전성 평가 항목\n\n관련 표준 또는 적용 규격\n\n1\n\n개봉 전/후\n\nstability of in vitro diagnostic reagents\n\n- - 11 -\n<!-- PAGE_18 -->\n###### 5.  안전성 평가 항목\n\n**[표 시작]**\n\n| 가.  전기 | 피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자 | 1.  임상시험의 제목 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 개정되거나 사안에 따라 변경될 수 있으며, 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 원자재, 형상, 구조, 치수/중량, 성능, 보관조건 등을 구체적으로 기재하도록 함.  | 수 있으며, 품목의 특성에 따라 자율적으로 설정이 가능함 | 기계적 안전성 시험 | 1.  Rational use of the PFA-100 device for screening |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 1.  대한진단검사의학회 편. ",
        "original_sentence": "임상시험의 제목 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 개정되거나 사안에 따라 변경될 수 있으며, 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 원자재, 형상, 구조, 치수/중량, 성능, 보관조건 등을 구체적으로 기재하도록 함. "
      }
    },
    {
      "chunk_id": "chunk_341",
      "text": "| 수 있으며, 품목의 특성에 따라 자율적으로 설정이 가능함 | 기계적 안전성 시험 | 1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 340,
        "window_size": 3,
        "char_count": 52,
        "word_count": 15,
        "page_number": 6,
        "window_text": "안전성 평가 항목\n\n**[표 시작]**\n\n| 가.  전기 | 피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자 | 1.  임상시험의 제목 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 개정되거나 사안에 따라 변경될 수 있으며, 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 원자재, 형상, 구조, 치수/중량, 성능, 보관조건 등을 구체적으로 기재하도록 함.  | 수 있으며, 품목의 특성에 따라 자율적으로 설정이 가능함 | 기계적 안전성 시험 | 1.  Rational use of the PFA-100 device for screening |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 1.  대한진단검사의학회 편.  진단검사의학 제5판. ",
        "original_sentence": "| 수 있으며, 품목의 특성에 따라 자율적으로 설정이 가능함 | 기계적 안전성 시험 | 1. "
      }
    },
    {
      "chunk_id": "chunk_342",
      "text": "Rational use of the PFA-100 device for screening |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 341,
        "window_size": 3,
        "char_count": 160,
        "word_count": 46,
        "page_number": 6,
        "window_text": "전기 | 피험자의 안전보호를 위한 임상시험 실시기관 및 임상시험심사위원회, 시험책임자 | 1.  임상시험의 제목 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 개정되거나 사안에 따라 변경될 수 있으며, 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 원자재, 형상, 구조, 치수/중량, 성능, 보관조건 등을 구체적으로 기재하도록 함.  | 수 있으며, 품목의 특성에 따라 자율적으로 설정이 가능함 | 기계적 안전성 시험 | 1.  Rational use of the PFA-100 device for screening |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 1.  대한진단검사의학회 편.  진단검사의학 제5판.  범문에듀케이션 p.295-299 | 임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례 | 로트로 대체 가능) | (마) 기기 온도 한계치와 내열성 : IEC 61010-1의 10절에 기술된 온도 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 수 있다. ",
        "original_sentence": "Rational use of the PFA-100 device for screening |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 1. "
      }
    },
    {
      "chunk_id": "chunk_343",
      "text": "대한진단검사의학회 편. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 342,
        "window_size": 3,
        "char_count": 13,
        "word_count": 2,
        "page_number": 96,
        "window_text": "임상시험의 제목 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 개정되거나 사안에 따라 변경될 수 있으며, 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 원자재, 형상, 구조, 치수/중량, 성능, 보관조건 등을 구체적으로 기재하도록 함.  | 수 있으며, 품목의 특성에 따라 자율적으로 설정이 가능함 | 기계적 안전성 시험 | 1.  Rational use of the PFA-100 device for screening |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 1.  대한진단검사의학회 편.  진단검사의학 제5판.  범문에듀케이션 p.295-299 | 임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례 | 로트로 대체 가능) | (마) 기기 온도 한계치와 내열성 : IEC 61010-1의 10절에 기술된 온도 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 수 있다.  | 시험할 간섭물질의 목록을 작성한다. ",
        "original_sentence": "대한진단검사의학회 편. "
      }
    },
    {
      "chunk_id": "chunk_344",
      "text": "진단검사의학 제5판. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 343,
        "window_size": 3,
        "char_count": 12,
        "word_count": 2,
        "page_number": 6,
        "window_text": "| 수 있으며, 품목의 특성에 따라 자율적으로 설정이 가능함 | 기계적 안전성 시험 | 1.  Rational use of the PFA-100 device for screening |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 1.  대한진단검사의학회 편.  진단검사의학 제5판.  범문에듀케이션 p.295-299 | 임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례 | 로트로 대체 가능) | (마) 기기 온도 한계치와 내열성 : IEC 61010-1의 10절에 기술된 온도 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 수 있다.  | 시험할 간섭물질의 목록을 작성한다.  | - 시험물질 | - 시험물질 | 혈소판 기능이상 측정이 가능한 최소/최대 이동거리를 평가 | a | a | b | b |\n| 가. ",
        "original_sentence": "진단검사의학 제5판. "
      }
    },
    {
      "chunk_id": "chunk_345",
      "text": "범문에듀케이션 p.295-299 | 임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례 | 로트로 대체 가능) | (마) 기기 온도 한계치와 내열성 : IEC 61010-1의 10절에 기술된 온도 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 수 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 344,
        "window_size": 3,
        "char_count": 158,
        "word_count": 39,
        "page_number": 6,
        "window_text": "Rational use of the PFA-100 device for screening |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n| 1.  대한진단검사의학회 편.  진단검사의학 제5판.  범문에듀케이션 p.295-299 | 임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례 | 로트로 대체 가능) | (마) 기기 온도 한계치와 내열성 : IEC 61010-1의 10절에 기술된 온도 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 수 있다.  | 시험할 간섭물질의 목록을 작성한다.  | - 시험물질 | - 시험물질 | 혈소판 기능이상 측정이 가능한 최소/최대 이동거리를 평가 | a | a | b | b |\n| 가.  개봉 전 안정성평가 | 가. ",
        "original_sentence": "범문에듀케이션 p.295-299 | 임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례 | 로트로 대체 가능) | (마) 기기 온도 한계치와 내열성 : IEC 61010-1의 10절에 기술된 온도 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_346",
      "text": "| 시험할 간섭물질의 목록을 작성한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 345,
        "window_size": 3,
        "char_count": 22,
        "word_count": 5,
        "page_number": 6,
        "window_text": "대한진단검사의학회 편.  진단검사의학 제5판.  범문에듀케이션 p.295-299 | 임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례 | 로트로 대체 가능) | (마) 기기 온도 한계치와 내열성 : IEC 61010-1의 10절에 기술된 온도 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 수 있다.  | 시험할 간섭물질의 목록을 작성한다.  | - 시험물질 | - 시험물질 | 혈소판 기능이상 측정이 가능한 최소/최대 이동거리를 평가 | a | a | b | b |\n| 가.  개봉 전 안정성평가 | 가.  의료기기 품목 및 품목별 등급에 관한 규정 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | □ 허혈성 심질환    □ 심부정맥 혈전증   □ 부정맥 | a | b |\n| 6.1 혈소판 기능검사키트에 대한 성능평가 | 10.1. ",
        "original_sentence": "| 시험할 간섭물질의 목록을 작성한다. "
      }
    },
    {
      "chunk_id": "chunk_347",
      "text": "| - 시험물질 | - 시험물질 | 혈소판 기능이상 측정이 가능한 최소/최대 이동거리를 평가 | a | a | b | b |\n| 가. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 346,
        "window_size": 3,
        "char_count": 75,
        "word_count": 25,
        "page_number": 9,
        "window_text": "진단검사의학 제5판.  범문에듀케이션 p.295-299 | 임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례 | 로트로 대체 가능) | (마) 기기 온도 한계치와 내열성 : IEC 61010-1의 10절에 기술된 온도 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 수 있다.  | 시험할 간섭물질의 목록을 작성한다.  | - 시험물질 | - 시험물질 | 혈소판 기능이상 측정이 가능한 최소/최대 이동거리를 평가 | a | a | b | b |\n| 가.  개봉 전 안정성평가 | 가.  의료기기 품목 및 품목별 등급에 관한 규정 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | □ 허혈성 심질환    □ 심부정맥 혈전증   □ 부정맥 | a | b |\n| 6.1 혈소판 기능검사키트에 대한 성능평가 | 10.1.  시험방법 | - 시험자는 시험책임자, 시험담당자, 임상시험조정자를 포함함. ",
        "original_sentence": "| - 시험물질 | - 시험물질 | 혈소판 기능이상 측정이 가능한 최소/최대 이동거리를 평가 | a | a | b | b |\n| 가. "
      }
    },
    {
      "chunk_id": "chunk_348",
      "text": "개봉 전 안정성평가 | 가. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 347,
        "window_size": 3,
        "char_count": 16,
        "word_count": 5,
        "page_number": 7,
        "window_text": "범문에듀케이션 p.295-299 | 임상시험을 안전하고 과학적으로 실시하기 위하여 그 밖에 필요한 서류로 증례 | 로트로 대체 가능) | (마) 기기 온도 한계치와 내열성 : IEC 61010-1의 10절에 기술된 온도 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 수 있다.  | 시험할 간섭물질의 목록을 작성한다.  | - 시험물질 | - 시험물질 | 혈소판 기능이상 측정이 가능한 최소/최대 이동거리를 평가 | a | a | b | b |\n| 가.  개봉 전 안정성평가 | 가.  의료기기 품목 및 품목별 등급에 관한 규정 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | □ 허혈성 심질환    □ 심부정맥 혈전증   □ 부정맥 | a | b |\n| 6.1 혈소판 기능검사키트에 대한 성능평가 | 10.1.  시험방법 | - 시험자는 시험책임자, 시험담당자, 임상시험조정자를 포함함.  | - 임상시험기관에서 임상시험용 해당 의료기기를 보관·관리하는 임상의, 의료기사 | 임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 해당 의료기기의 | ① 출혈시간(Bleeding time, BT)검사는 약 100여년 전부터 개발되어 | 1 | 혈액챔버 | 지지체 | ○○○ | 1개 | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 약물반응 양성 | 비정상 | 오염물질이 오염/혼합 또는 오염/혼합이 예상되는 경우 임상시험기관의 | 증례기록서(예시) | a+b | a+b |\n| 7.1. ",
        "original_sentence": "개봉 전 안정성평가 | 가. "
      }
    },
    {
      "chunk_id": "chunk_349",
      "text": "의료기기 품목 및 품목별 등급에 관한 규정 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | □ 허혈성 심질환    □ 심부정맥 혈전증   □ 부정맥 | a | b |\n| 6.1 혈소판 기능검사키트에 대한 성능평가 | 10.1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 348,
        "window_size": 3,
        "char_count": 183,
        "word_count": 50,
        "page_number": 6,
        "window_text": "| 시험할 간섭물질의 목록을 작성한다.  | - 시험물질 | - 시험물질 | 혈소판 기능이상 측정이 가능한 최소/최대 이동거리를 평가 | a | a | b | b |\n| 가.  개봉 전 안정성평가 | 가.  의료기기 품목 및 품목별 등급에 관한 규정 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | □ 허혈성 심질환    □ 심부정맥 혈전증   □ 부정맥 | a | b |\n| 6.1 혈소판 기능검사키트에 대한 성능평가 | 10.1.  시험방법 | - 시험자는 시험책임자, 시험담당자, 임상시험조정자를 포함함.  | - 임상시험기관에서 임상시험용 해당 의료기기를 보관·관리하는 임상의, 의료기사 | 임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 해당 의료기기의 | ① 출혈시간(Bleeding time, BT)검사는 약 100여년 전부터 개발되어 | 1 | 혈액챔버 | 지지체 | ○○○ | 1개 | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 약물반응 양성 | 비정상 | 오염물질이 오염/혼합 또는 오염/혼합이 예상되는 경우 임상시험기관의 | 증례기록서(예시) | a+b | a+b |\n| 7.1.  임상시험용 의료기기 사용 목적 | 11.1. ",
        "original_sentence": "의료기기 품목 및 품목별 등급에 관한 규정 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | □ 허혈성 심질환    □ 심부정맥 혈전증   □ 부정맥 | a | b |\n| 6.1 혈소판 기능검사키트에 대한 성능평가 | 10.1. "
      }
    },
    {
      "chunk_id": "chunk_350",
      "text": "시험방법 | - 시험자는 시험책임자, 시험담당자, 임상시험조정자를 포함함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 349,
        "window_size": 3,
        "char_count": 42,
        "word_count": 8,
        "page_number": 3,
        "window_text": "| - 시험물질 | - 시험물질 | 혈소판 기능이상 측정이 가능한 최소/최대 이동거리를 평가 | a | a | b | b |\n| 가.  개봉 전 안정성평가 | 가.  의료기기 품목 및 품목별 등급에 관한 규정 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | □ 허혈성 심질환    □ 심부정맥 혈전증   □ 부정맥 | a | b |\n| 6.1 혈소판 기능검사키트에 대한 성능평가 | 10.1.  시험방법 | - 시험자는 시험책임자, 시험담당자, 임상시험조정자를 포함함.  | - 임상시험기관에서 임상시험용 해당 의료기기를 보관·관리하는 임상의, 의료기사 | 임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 해당 의료기기의 | ① 출혈시간(Bleeding time, BT)검사는 약 100여년 전부터 개발되어 | 1 | 혈액챔버 | 지지체 | ○○○ | 1개 | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 약물반응 양성 | 비정상 | 오염물질이 오염/혼합 또는 오염/혼합이 예상되는 경우 임상시험기관의 | 증례기록서(예시) | a+b | a+b |\n| 7.1.  임상시험용 의료기기 사용 목적 | 11.1.  관찰항목(임상시험 일정표) | (3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의 문제점을 | - 본 연구에 참여함으로 인하여 혈액을 채취하게 되므로 그 과정에서 약간의 통증 | 아래 귀하의 서명은 이 연구에 참여함을 허락하며 귀하의 혈액이 이 연구목적을 | 검사법이 사용되고 있다. ",
        "original_sentence": "시험방법 | - 시험자는 시험책임자, 시험담당자, 임상시험조정자를 포함함. "
      }
    },
    {
      "chunk_id": "chunk_351",
      "text": "| - 임상시험기관에서 임상시험용 해당 의료기기를 보관·관리하는 임상의, 의료기사 | 임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 해당 의료기기의 | ① 출혈시간(Bleeding time, BT)검사는 약 100여년 전부터 개발되어 | 1 | 혈액챔버 | 지지체 | ○○○ | 1개 | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 약물반응 양성 | 비정상 | 오염물질이 오염/혼합 또는 오염/혼합이 예상되는 경우 임상시험기관의 | 증례기록서(예시) | a+b | a+b |\n| 7.1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 350,
        "window_size": 3,
        "char_count": 359,
        "word_count": 86,
        "page_number": 9,
        "window_text": "개봉 전 안정성평가 | 가.  의료기기 품목 및 품목별 등급에 관한 규정 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | □ 허혈성 심질환    □ 심부정맥 혈전증   □ 부정맥 | a | b |\n| 6.1 혈소판 기능검사키트에 대한 성능평가 | 10.1.  시험방법 | - 시험자는 시험책임자, 시험담당자, 임상시험조정자를 포함함.  | - 임상시험기관에서 임상시험용 해당 의료기기를 보관·관리하는 임상의, 의료기사 | 임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 해당 의료기기의 | ① 출혈시간(Bleeding time, BT)검사는 약 100여년 전부터 개발되어 | 1 | 혈액챔버 | 지지체 | ○○○ | 1개 | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 약물반응 양성 | 비정상 | 오염물질이 오염/혼합 또는 오염/혼합이 예상되는 경우 임상시험기관의 | 증례기록서(예시) | a+b | a+b |\n| 7.1.  임상시험용 의료기기 사용 목적 | 11.1.  관찰항목(임상시험 일정표) | (3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의 문제점을 | - 본 연구에 참여함으로 인하여 혈액을 채취하게 되므로 그 과정에서 약간의 통증 | 아래 귀하의 서명은 이 연구에 참여함을 허락하며 귀하의 혈액이 이 연구목적을 | 검사법이 사용되고 있다.  특히 VerifyNow는 검사자의 숙련도에 영향을 받지 않고 | (2) 예상치 못한 결과 값이 도출된 경우, 부적절한 혈액 채취 여부 또는 부주의, | 7) 성능 | 2) 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군 | 수 산출 근거’ 항에 기재하였으며, 유의수준 5%, 검정력 80%, 예상되는 차이 | 임상시험에 대한 사항을 확인할 수 있도록 해야 한다. ",
        "original_sentence": "| - 임상시험기관에서 임상시험용 해당 의료기기를 보관·관리하는 임상의, 의료기사 | 임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 해당 의료기기의 | ① 출혈시간(Bleeding time, BT)검사는 약 100여년 전부터 개발되어 | 1 | 혈액챔버 | 지지체 | ○○○ | 1개 | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 약물반응 양성 | 비정상 | 오염물질이 오염/혼합 또는 오염/혼합이 예상되는 경우 임상시험기관의 | 증례기록서(예시) | a+b | a+b |\n| 7.1. "
      }
    },
    {
      "chunk_id": "chunk_352",
      "text": "임상시험용 의료기기 사용 목적 | 11.1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 351,
        "window_size": 3,
        "char_count": 25,
        "word_count": 6,
        "page_number": 6,
        "window_text": "의료기기 품목 및 품목별 등급에 관한 규정 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | 제품의 특성에 따라 자율적으로 설정이 가능함 | □ 허혈성 심질환    □ 심부정맥 혈전증   □ 부정맥 | a | b |\n| 6.1 혈소판 기능검사키트에 대한 성능평가 | 10.1.  시험방법 | - 시험자는 시험책임자, 시험담당자, 임상시험조정자를 포함함.  | - 임상시험기관에서 임상시험용 해당 의료기기를 보관·관리하는 임상의, 의료기사 | 임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 해당 의료기기의 | ① 출혈시간(Bleeding time, BT)검사는 약 100여년 전부터 개발되어 | 1 | 혈액챔버 | 지지체 | ○○○ | 1개 | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 약물반응 양성 | 비정상 | 오염물질이 오염/혼합 또는 오염/혼합이 예상되는 경우 임상시험기관의 | 증례기록서(예시) | a+b | a+b |\n| 7.1.  임상시험용 의료기기 사용 목적 | 11.1.  관찰항목(임상시험 일정표) | (3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의 문제점을 | - 본 연구에 참여함으로 인하여 혈액을 채취하게 되므로 그 과정에서 약간의 통증 | 아래 귀하의 서명은 이 연구에 참여함을 허락하며 귀하의 혈액이 이 연구목적을 | 검사법이 사용되고 있다.  특히 VerifyNow는 검사자의 숙련도에 영향을 받지 않고 | (2) 예상치 못한 결과 값이 도출된 경우, 부적절한 혈액 채취 여부 또는 부주의, | 7) 성능 | 2) 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군 | 수 산출 근거’ 항에 기재하였으며, 유의수준 5%, 검정력 80%, 예상되는 차이 | 임상시험에 대한 사항을 확인할 수 있도록 해야 한다.  | ④ 메인화면에서 “Start”버튼을 클릭하면 “Chip Selection”화면이 나타난다. ",
        "original_sentence": "임상시험용 의료기기 사용 목적 | 11.1. "
      }
    },
    {
      "chunk_id": "chunk_353",
      "text": "관찰항목(임상시험 일정표) | (3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의 문제점을 | - 본 연구에 참여함으로 인하여 혈액을 채취하게 되므로 그 과정에서 약간의 통증 | 아래 귀하의 서명은 이 연구에 참여함을 허락하며 귀하의 혈액이 이 연구목적을 | 검사법이 사용되고 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 352,
        "window_size": 3,
        "char_count": 170,
        "word_count": 42,
        "page_number": 6,
        "window_text": "시험방법 | - 시험자는 시험책임자, 시험담당자, 임상시험조정자를 포함함.  | - 임상시험기관에서 임상시험용 해당 의료기기를 보관·관리하는 임상의, 의료기사 | 임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 해당 의료기기의 | ① 출혈시간(Bleeding time, BT)검사는 약 100여년 전부터 개발되어 | 1 | 혈액챔버 | 지지체 | ○○○ | 1개 | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 약물반응 양성 | 비정상 | 오염물질이 오염/혼합 또는 오염/혼합이 예상되는 경우 임상시험기관의 | 증례기록서(예시) | a+b | a+b |\n| 7.1.  임상시험용 의료기기 사용 목적 | 11.1.  관찰항목(임상시험 일정표) | (3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의 문제점을 | - 본 연구에 참여함으로 인하여 혈액을 채취하게 되므로 그 과정에서 약간의 통증 | 아래 귀하의 서명은 이 연구에 참여함을 허락하며 귀하의 혈액이 이 연구목적을 | 검사법이 사용되고 있다.  특히 VerifyNow는 검사자의 숙련도에 영향을 받지 않고 | (2) 예상치 못한 결과 값이 도출된 경우, 부적절한 혈액 채취 여부 또는 부주의, | 7) 성능 | 2) 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군 | 수 산출 근거’ 항에 기재하였으며, 유의수준 5%, 검정력 80%, 예상되는 차이 | 임상시험에 대한 사항을 확인할 수 있도록 해야 한다.  | ④ 메인화면에서 “Start”버튼을 클릭하면 “Chip Selection”화면이 나타난다.  | 혈소판 기능부전이 의심되는 환자 및 aspirin, clopidogrel 복용 예정 환자에서 | Aspirin 복용 전후에 대한 시험시약의 민감도 및 특이도를 산출한다. ",
        "original_sentence": "관찰항목(임상시험 일정표) | (3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의 문제점을 | - 본 연구에 참여함으로 인하여 혈액을 채취하게 되므로 그 과정에서 약간의 통증 | 아래 귀하의 서명은 이 연구에 참여함을 허락하며 귀하의 혈액이 이 연구목적을 | 검사법이 사용되고 있다. "
      }
    },
    {
      "chunk_id": "chunk_354",
      "text": "특히 VerifyNow는 검사자의 숙련도에 영향을 받지 않고 | (2) 예상치 못한 결과 값이 도출된 경우, 부적절한 혈액 채취 여부 또는 부주의, | 7) 성능 | 2) 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군 | 수 산출 근거’ 항에 기재하였으며, 유의수준 5%, 검정력 80%, 예상되는 차이 | 임상시험에 대한 사항을 확인할 수 있도록 해야 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 353,
        "window_size": 3,
        "char_count": 211,
        "word_count": 55,
        "page_number": 6,
        "window_text": "| - 임상시험기관에서 임상시험용 해당 의료기기를 보관·관리하는 임상의, 의료기사 | 임상시험의 계획, 관리, 재정 등에 관련된 책임이 있는 자로서 해당 의료기기의 | ① 출혈시간(Bleeding time, BT)검사는 약 100여년 전부터 개발되어 | 1 | 혈액챔버 | 지지체 | ○○○ | 1개 | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | Zα/2 (95% 신뢰구간 값) = 1.96, Zβ =0.84, p-p0 = 0.10] | 약물반응 양성 | 비정상 | 오염물질이 오염/혼합 또는 오염/혼합이 예상되는 경우 임상시험기관의 | 증례기록서(예시) | a+b | a+b |\n| 7.1.  임상시험용 의료기기 사용 목적 | 11.1.  관찰항목(임상시험 일정표) | (3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의 문제점을 | - 본 연구에 참여함으로 인하여 혈액을 채취하게 되므로 그 과정에서 약간의 통증 | 아래 귀하의 서명은 이 연구에 참여함을 허락하며 귀하의 혈액이 이 연구목적을 | 검사법이 사용되고 있다.  특히 VerifyNow는 검사자의 숙련도에 영향을 받지 않고 | (2) 예상치 못한 결과 값이 도출된 경우, 부적절한 혈액 채취 여부 또는 부주의, | 7) 성능 | 2) 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군 | 수 산출 근거’ 항에 기재하였으며, 유의수준 5%, 검정력 80%, 예상되는 차이 | 임상시험에 대한 사항을 확인할 수 있도록 해야 한다.  | ④ 메인화면에서 “Start”버튼을 클릭하면 “Chip Selection”화면이 나타난다.  | 혈소판 기능부전이 의심되는 환자 및 aspirin, clopidogrel 복용 예정 환자에서 | Aspirin 복용 전후에 대한 시험시약의 민감도 및 특이도를 산출한다.  신뢰도 | 2) 특이도: 대조기기 정상 결과 검체 중 시험기기에서 정상 결과를 보인 검체의 | 보관하여야 한다. ",
        "original_sentence": "특히 VerifyNow는 검사자의 숙련도에 영향을 받지 않고 | (2) 예상치 못한 결과 값이 도출된 경우, 부적절한 혈액 채취 여부 또는 부주의, | 7) 성능 | 2) 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군 | 수 산출 근거’ 항에 기재하였으며, 유의수준 5%, 검정력 80%, 예상되는 차이 | 임상시험에 대한 사항을 확인할 수 있도록 해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_355",
      "text": "| ④ 메인화면에서 “Start”버튼을 클릭하면 “Chip Selection”화면이 나타난다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 354,
        "window_size": 3,
        "char_count": 53,
        "word_count": 8,
        "page_number": 59,
        "window_text": "임상시험용 의료기기 사용 목적 | 11.1.  관찰항목(임상시험 일정표) | (3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의 문제점을 | - 본 연구에 참여함으로 인하여 혈액을 채취하게 되므로 그 과정에서 약간의 통증 | 아래 귀하의 서명은 이 연구에 참여함을 허락하며 귀하의 혈액이 이 연구목적을 | 검사법이 사용되고 있다.  특히 VerifyNow는 검사자의 숙련도에 영향을 받지 않고 | (2) 예상치 못한 결과 값이 도출된 경우, 부적절한 혈액 채취 여부 또는 부주의, | 7) 성능 | 2) 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군 | 수 산출 근거’ 항에 기재하였으며, 유의수준 5%, 검정력 80%, 예상되는 차이 | 임상시험에 대한 사항을 확인할 수 있도록 해야 한다.  | ④ 메인화면에서 “Start”버튼을 클릭하면 “Chip Selection”화면이 나타난다.  | 혈소판 기능부전이 의심되는 환자 및 aspirin, clopidogrel 복용 예정 환자에서 | Aspirin 복용 전후에 대한 시험시약의 민감도 및 특이도를 산출한다.  신뢰도 | 2) 특이도: 대조기기 정상 결과 검체 중 시험기기에서 정상 결과를 보인 검체의 | 보관하여야 한다.  | 수행한다. ",
        "original_sentence": "| ④ 메인화면에서 “Start”버튼을 클릭하면 “Chip Selection”화면이 나타난다. "
      }
    },
    {
      "chunk_id": "chunk_356",
      "text": "| 혈소판 기능부전이 의심되는 환자 및 aspirin, clopidogrel 복용 예정 환자에서 | Aspirin 복용 전후에 대한 시험시약의 민감도 및 특이도를 산출한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 355,
        "window_size": 3,
        "char_count": 97,
        "word_count": 21,
        "page_number": 18,
        "window_text": "관찰항목(임상시험 일정표) | (3) 시험자는 임상시험계획을 정확히 분석 및 숙지하고, 대상 피험자의 문제점을 | - 본 연구에 참여함으로 인하여 혈액을 채취하게 되므로 그 과정에서 약간의 통증 | 아래 귀하의 서명은 이 연구에 참여함을 허락하며 귀하의 혈액이 이 연구목적을 | 검사법이 사용되고 있다.  특히 VerifyNow는 검사자의 숙련도에 영향을 받지 않고 | (2) 예상치 못한 결과 값이 도출된 경우, 부적절한 혈액 채취 여부 또는 부주의, | 7) 성능 | 2) 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군 | 수 산출 근거’ 항에 기재하였으며, 유의수준 5%, 검정력 80%, 예상되는 차이 | 임상시험에 대한 사항을 확인할 수 있도록 해야 한다.  | ④ 메인화면에서 “Start”버튼을 클릭하면 “Chip Selection”화면이 나타난다.  | 혈소판 기능부전이 의심되는 환자 및 aspirin, clopidogrel 복용 예정 환자에서 | Aspirin 복용 전후에 대한 시험시약의 민감도 및 특이도를 산출한다.  신뢰도 | 2) 특이도: 대조기기 정상 결과 검체 중 시험기기에서 정상 결과를 보인 검체의 | 보관하여야 한다.  | 수행한다.  | 특이도 8.9%이었다. ",
        "original_sentence": "| 혈소판 기능부전이 의심되는 환자 및 aspirin, clopidogrel 복용 예정 환자에서 | Aspirin 복용 전후에 대한 시험시약의 민감도 및 특이도를 산출한다. "
      }
    },
    {
      "chunk_id": "chunk_357",
      "text": "신뢰도 | 2) 특이도: 대조기기 정상 결과 검체 중 시험기기에서 정상 결과를 보인 검체의 | 보관하여야 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 356,
        "window_size": 3,
        "char_count": 63,
        "word_count": 17,
        "page_number": 6,
        "window_text": "특히 VerifyNow는 검사자의 숙련도에 영향을 받지 않고 | (2) 예상치 못한 결과 값이 도출된 경우, 부적절한 혈액 채취 여부 또는 부주의, | 7) 성능 | 2) 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군 | 수 산출 근거’ 항에 기재하였으며, 유의수준 5%, 검정력 80%, 예상되는 차이 | 임상시험에 대한 사항을 확인할 수 있도록 해야 한다.  | ④ 메인화면에서 “Start”버튼을 클릭하면 “Chip Selection”화면이 나타난다.  | 혈소판 기능부전이 의심되는 환자 및 aspirin, clopidogrel 복용 예정 환자에서 | Aspirin 복용 전후에 대한 시험시약의 민감도 및 특이도를 산출한다.  신뢰도 | 2) 특이도: 대조기기 정상 결과 검체 중 시험기기에서 정상 결과를 보인 검체의 | 보관하여야 한다.  | 수행한다.  | 특이도 8.9%이었다.  P2Y12 test는 평균 민감도 72.9%, 평균 특이도 74.1%이었고, | 하였으며 오차범위는 ±5% 설정하였다. ",
        "original_sentence": "신뢰도 | 2) 특이도: 대조기기 정상 결과 검체 중 시험기기에서 정상 결과를 보인 검체의 | 보관하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_358",
      "text": "| 수행한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 357,
        "window_size": 3,
        "char_count": 8,
        "word_count": 2,
        "page_number": 24,
        "window_text": "| ④ 메인화면에서 “Start”버튼을 클릭하면 “Chip Selection”화면이 나타난다.  | 혈소판 기능부전이 의심되는 환자 및 aspirin, clopidogrel 복용 예정 환자에서 | Aspirin 복용 전후에 대한 시험시약의 민감도 및 특이도를 산출한다.  신뢰도 | 2) 특이도: 대조기기 정상 결과 검체 중 시험기기에서 정상 결과를 보인 검체의 | 보관하여야 한다.  | 수행한다.  | 특이도 8.9%이었다.  P2Y12 test는 평균 민감도 72.9%, 평균 특이도 74.1%이었고, | 하였으며 오차범위는 ±5% 설정하였다.  | 추가적인 정보가 필요한 경우 제조원에 요청한다. ",
        "original_sentence": "| 수행한다. "
      }
    },
    {
      "chunk_id": "chunk_359",
      "text": "| 특이도 8.9%이었다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 358,
        "window_size": 3,
        "char_count": 15,
        "word_count": 3,
        "page_number": 15,
        "window_text": "| 혈소판 기능부전이 의심되는 환자 및 aspirin, clopidogrel 복용 예정 환자에서 | Aspirin 복용 전후에 대한 시험시약의 민감도 및 특이도를 산출한다.  신뢰도 | 2) 특이도: 대조기기 정상 결과 검체 중 시험기기에서 정상 결과를 보인 검체의 | 보관하여야 한다.  | 수행한다.  | 특이도 8.9%이었다.  P2Y12 test는 평균 민감도 72.9%, 평균 특이도 74.1%이었고, | 하였으며 오차범위는 ±5% 설정하였다.  | 추가적인 정보가 필요한 경우 제조원에 요청한다.  | □ YES | 피험자 이니셜(영문) | 피험자식별코드 | 피험자 방문일 (YY/MM/DD) | 피험자 이니셜(영문) | 피험자식별코드 | 피험자 방문일 (YY/MM/DD) | 특이도가 기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인 | 약물반응 양성 |         | a+b |\n| 2. ",
        "original_sentence": "| 특이도 8.9%이었다. "
      }
    },
    {
      "chunk_id": "chunk_360",
      "text": "P2Y12 test는 평균 민감도 72.9%, 평균 특이도 74.1%이었고, | 하였으며 오차범위는 ±5% 설정하였다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 359,
        "window_size": 3,
        "char_count": 67,
        "word_count": 13,
        "page_number": 6,
        "window_text": "신뢰도 | 2) 특이도: 대조기기 정상 결과 검체 중 시험기기에서 정상 결과를 보인 검체의 | 보관하여야 한다.  | 수행한다.  | 특이도 8.9%이었다.  P2Y12 test는 평균 민감도 72.9%, 평균 특이도 74.1%이었고, | 하였으며 오차범위는 ±5% 설정하였다.  | 추가적인 정보가 필요한 경우 제조원에 요청한다.  | □ YES | 피험자 이니셜(영문) | 피험자식별코드 | 피험자 방문일 (YY/MM/DD) | 피험자 이니셜(영문) | 피험자식별코드 | 피험자 방문일 (YY/MM/DD) | 특이도가 기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인 | 약물반응 양성 |         | a+b |\n| 2.  Paniccia R, Antonucci E, Gori AM, et al. ",
        "original_sentence": "P2Y12 test는 평균 민감도 72.9%, 평균 특이도 74.1%이었고, | 하였으며 오차범위는 ±5% 설정하였다. "
      }
    },
    {
      "chunk_id": "chunk_361",
      "text": "| 추가적인 정보가 필요한 경우 제조원에 요청한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 360,
        "window_size": 3,
        "char_count": 29,
        "word_count": 7,
        "page_number": 7,
        "window_text": "| 수행한다.  | 특이도 8.9%이었다.  P2Y12 test는 평균 민감도 72.9%, 평균 특이도 74.1%이었고, | 하였으며 오차범위는 ±5% 설정하였다.  | 추가적인 정보가 필요한 경우 제조원에 요청한다.  | □ YES | 피험자 이니셜(영문) | 피험자식별코드 | 피험자 방문일 (YY/MM/DD) | 피험자 이니셜(영문) | 피험자식별코드 | 피험자 방문일 (YY/MM/DD) | 특이도가 기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인 | 약물반응 양성 |         | a+b |\n| 2.  Paniccia R, Antonucci E, Gori AM, et al.  Comparison of different methods to evaluate the | - 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로 | - 성능 평가 기준: 해당 의료기기의 임상시험에 따른 성능(유효성)평가는 사용된 | - 이상사례에 대한 인과관계 평가기준 | 및 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시함. ",
        "original_sentence": "| 추가적인 정보가 필요한 경우 제조원에 요청한다. "
      }
    },
    {
      "chunk_id": "chunk_362",
      "text": "| □ YES | 피험자 이니셜(영문) | 피험자식별코드 | 피험자 방문일 (YY/MM/DD) | 피험자 이니셜(영문) | 피험자식별코드 | 피험자 방문일 (YY/MM/DD) | 특이도가 기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인 | 약물반응 양성 |         | a+b |\n| 2. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 361,
        "window_size": 3,
        "char_count": 189,
        "word_count": 48,
        "page_number": 68,
        "window_text": "| 특이도 8.9%이었다.  P2Y12 test는 평균 민감도 72.9%, 평균 특이도 74.1%이었고, | 하였으며 오차범위는 ±5% 설정하였다.  | 추가적인 정보가 필요한 경우 제조원에 요청한다.  | □ YES | 피험자 이니셜(영문) | 피험자식별코드 | 피험자 방문일 (YY/MM/DD) | 피험자 이니셜(영문) | 피험자식별코드 | 피험자 방문일 (YY/MM/DD) | 특이도가 기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인 | 약물반응 양성 |         | a+b |\n| 2.  Paniccia R, Antonucci E, Gori AM, et al.  Comparison of different methods to evaluate the | - 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로 | - 성능 평가 기준: 해당 의료기기의 임상시험에 따른 성능(유효성)평가는 사용된 | - 이상사례에 대한 인과관계 평가기준 | 및 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시함.  | 1) 검정색 볼펜을 사용하여 기록하여 주십시오. ",
        "original_sentence": "| □ YES | 피험자 이니셜(영문) | 피험자식별코드 | 피험자 방문일 (YY/MM/DD) | 피험자 이니셜(영문) | 피험자식별코드 | 피험자 방문일 (YY/MM/DD) | 특이도가 기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인 | 약물반응 양성 |         | a+b |\n| 2. "
      }
    },
    {
      "chunk_id": "chunk_363",
      "text": "Paniccia R, Antonucci E, Gori AM, et al. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 362,
        "window_size": 3,
        "char_count": 41,
        "word_count": 8,
        "page_number": 33,
        "window_text": "P2Y12 test는 평균 민감도 72.9%, 평균 특이도 74.1%이었고, | 하였으며 오차범위는 ±5% 설정하였다.  | 추가적인 정보가 필요한 경우 제조원에 요청한다.  | □ YES | 피험자 이니셜(영문) | 피험자식별코드 | 피험자 방문일 (YY/MM/DD) | 피험자 이니셜(영문) | 피험자식별코드 | 피험자 방문일 (YY/MM/DD) | 특이도가 기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인 | 약물반응 양성 |         | a+b |\n| 2.  Paniccia R, Antonucci E, Gori AM, et al.  Comparison of different methods to evaluate the | - 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로 | - 성능 평가 기준: 해당 의료기기의 임상시험에 따른 성능(유효성)평가는 사용된 | - 이상사례에 대한 인과관계 평가기준 | 및 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시함.  | 1) 검정색 볼펜을 사용하여 기록하여 주십시오.  | 피험자 제공 | □ 뇌졸중 □ 기타: | (True Positive) | (True Positive) | of platelet function disorders and von Willebrand | (False Positive) | (False Positive) |\n| 나. ",
        "original_sentence": "Paniccia R, Antonucci E, Gori AM, et al. "
      }
    },
    {
      "chunk_id": "chunk_364",
      "text": "Comparison of different methods to evaluate the | - 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로 | - 성능 평가 기준: 해당 의료기기의 임상시험에 따른 성능(유효성)평가는 사용된 | - 이상사례에 대한 인과관계 평가기준 | 및 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 363,
        "window_size": 3,
        "char_count": 203,
        "word_count": 44,
        "page_number": 17,
        "window_text": "| 추가적인 정보가 필요한 경우 제조원에 요청한다.  | □ YES | 피험자 이니셜(영문) | 피험자식별코드 | 피험자 방문일 (YY/MM/DD) | 피험자 이니셜(영문) | 피험자식별코드 | 피험자 방문일 (YY/MM/DD) | 특이도가 기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인 | 약물반응 양성 |         | a+b |\n| 2.  Paniccia R, Antonucci E, Gori AM, et al.  Comparison of different methods to evaluate the | - 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로 | - 성능 평가 기준: 해당 의료기기의 임상시험에 따른 성능(유효성)평가는 사용된 | - 이상사례에 대한 인과관계 평가기준 | 및 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시함.  | 1) 검정색 볼펜을 사용하여 기록하여 주십시오.  | 피험자 제공 | □ 뇌졸중 □ 기타: | (True Positive) | (True Positive) | of platelet function disorders and von Willebrand | (False Positive) | (False Positive) |\n| 나.  체외진단용 의료기기 1, 2 등급 허가·심사 및 신고서 작성 가이드라인 | (1) 관련 규격 | * 피험자의 선정기준/제외기준 · 인원 및 근거 | 피험자의 모집기간, 임상관찰 및 시험수행 기간, 통계처리 기간, 결과보고서 작성 | 임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 등을 제시함. ",
        "original_sentence": "Comparison of different methods to evaluate the | - 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로 | - 성능 평가 기준: 해당 의료기기의 임상시험에 따른 성능(유효성)평가는 사용된 | - 이상사례에 대한 인과관계 평가기준 | 및 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시함. "
      }
    },
    {
      "chunk_id": "chunk_365",
      "text": "| 1) 검정색 볼펜을 사용하여 기록하여 주십시오. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 364,
        "window_size": 3,
        "char_count": 29,
        "word_count": 7,
        "page_number": 6,
        "window_text": "| □ YES | 피험자 이니셜(영문) | 피험자식별코드 | 피험자 방문일 (YY/MM/DD) | 피험자 이니셜(영문) | 피험자식별코드 | 피험자 방문일 (YY/MM/DD) | 특이도가 기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인 | 약물반응 양성 |         | a+b |\n| 2.  Paniccia R, Antonucci E, Gori AM, et al.  Comparison of different methods to evaluate the | - 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로 | - 성능 평가 기준: 해당 의료기기의 임상시험에 따른 성능(유효성)평가는 사용된 | - 이상사례에 대한 인과관계 평가기준 | 및 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시함.  | 1) 검정색 볼펜을 사용하여 기록하여 주십시오.  | 피험자 제공 | □ 뇌졸중 □ 기타: | (True Positive) | (True Positive) | of platelet function disorders and von Willebrand | (False Positive) | (False Positive) |\n| 나.  체외진단용 의료기기 1, 2 등급 허가·심사 및 신고서 작성 가이드라인 | (1) 관련 규격 | * 피험자의 선정기준/제외기준 · 인원 및 근거 | 피험자의 모집기간, 임상관찰 및 시험수행 기간, 통계처리 기간, 결과보고서 작성 | 임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 등을 제시함.  | 시험 책임자는 의료기기법 시행규칙 제24조제1항제4호의 규정에 따라 임상시험 | 임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상사례 등에 대하여 임상 | 기록서(Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험 | (1) 연구가설 | - 적용 계산식 :  |     | (True Positive) | (False Positive) |\n| - 의료기기 임상시험기관은 「의료기기 임상시험기관 지정에 관한 규정」(식품 | 검체를 준비한다. ",
        "original_sentence": "| 1) 검정색 볼펜을 사용하여 기록하여 주십시오. "
      }
    },
    {
      "chunk_id": "chunk_366",
      "text": "| 피험자 제공 | □ 뇌졸중 □ 기타: | (True Positive) | (True Positive) | of platelet function disorders and von Willebrand | (False Positive) | (False Positive) |\n| 나. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 365,
        "window_size": 3,
        "char_count": 156,
        "word_count": 31,
        "page_number": 23,
        "window_text": "Paniccia R, Antonucci E, Gori AM, et al.  Comparison of different methods to evaluate the | - 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로 | - 성능 평가 기준: 해당 의료기기의 임상시험에 따른 성능(유효성)평가는 사용된 | - 이상사례에 대한 인과관계 평가기준 | 및 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시함.  | 1) 검정색 볼펜을 사용하여 기록하여 주십시오.  | 피험자 제공 | □ 뇌졸중 □ 기타: | (True Positive) | (True Positive) | of platelet function disorders and von Willebrand | (False Positive) | (False Positive) |\n| 나.  체외진단용 의료기기 1, 2 등급 허가·심사 및 신고서 작성 가이드라인 | (1) 관련 규격 | * 피험자의 선정기준/제외기준 · 인원 및 근거 | 피험자의 모집기간, 임상관찰 및 시험수행 기간, 통계처리 기간, 결과보고서 작성 | 임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 등을 제시함.  | 시험 책임자는 의료기기법 시행규칙 제24조제1항제4호의 규정에 따라 임상시험 | 임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상사례 등에 대하여 임상 | 기록서(Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험 | (1) 연구가설 | - 적용 계산식 :  |     | (True Positive) | (False Positive) |\n| - 의료기기 임상시험기관은 「의료기기 임상시험기관 지정에 관한 규정」(식품 | 검체를 준비한다.  | - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | (4) 시험 조건 | 항목을 제외한다. ",
        "original_sentence": "| 피험자 제공 | □ 뇌졸중 □ 기타: | (True Positive) | (True Positive) | of platelet function disorders and von Willebrand | (False Positive) | (False Positive) |\n| 나. "
      }
    },
    {
      "chunk_id": "chunk_367",
      "text": "체외진단용 의료기기 1, 2 등급 허가·심사 및 신고서 작성 가이드라인 | (1) 관련 규격 | * 피험자의 선정기준/제외기준 · 인원 및 근거 | 피험자의 모집기간, 임상관찰 및 시험수행 기간, 통계처리 기간, 결과보고서 작성 | 임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 등을 제시함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 366,
        "window_size": 3,
        "char_count": 177,
        "word_count": 47,
        "page_number": 2,
        "window_text": "Comparison of different methods to evaluate the | - 임상시험의 목적은 해당 의료기기의 안전성과 유효성 평가에 대하여 구체적으로 | - 성능 평가 기준: 해당 의료기기의 임상시험에 따른 성능(유효성)평가는 사용된 | - 이상사례에 대한 인과관계 평가기준 | 및 시험자, 의뢰자, 모니터링요원 등의 의무사항을 정하여 제시함.  | 1) 검정색 볼펜을 사용하여 기록하여 주십시오.  | 피험자 제공 | □ 뇌졸중 □ 기타: | (True Positive) | (True Positive) | of platelet function disorders and von Willebrand | (False Positive) | (False Positive) |\n| 나.  체외진단용 의료기기 1, 2 등급 허가·심사 및 신고서 작성 가이드라인 | (1) 관련 규격 | * 피험자의 선정기준/제외기준 · 인원 및 근거 | 피험자의 모집기간, 임상관찰 및 시험수행 기간, 통계처리 기간, 결과보고서 작성 | 임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 등을 제시함.  | 시험 책임자는 의료기기법 시행규칙 제24조제1항제4호의 규정에 따라 임상시험 | 임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상사례 등에 대하여 임상 | 기록서(Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험 | (1) 연구가설 | - 적용 계산식 :  |     | (True Positive) | (False Positive) |\n| - 의료기기 임상시험기관은 「의료기기 임상시험기관 지정에 관한 규정」(식품 | 검체를 준비한다.  | - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | (4) 시험 조건 | 항목을 제외한다.  | 시험기기 | 준비된 동일 시료를 반으로 나누어 시험시료와 대조시료로 분리한다. ",
        "original_sentence": "체외진단용 의료기기 1, 2 등급 허가·심사 및 신고서 작성 가이드라인 | (1) 관련 규격 | * 피험자의 선정기준/제외기준 · 인원 및 근거 | 피험자의 모집기간, 임상관찰 및 시험수행 기간, 통계처리 기간, 결과보고서 작성 | 임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 등을 제시함. "
      }
    },
    {
      "chunk_id": "chunk_368",
      "text": "| 시험 책임자는 의료기기법 시행규칙 제24조제1항제4호의 규정에 따라 임상시험 | 임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상사례 등에 대하여 임상 | 기록서(Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험 | (1) 연구가설 | - 적용 계산식 :  |     | (True Positive) | (False Positive) |\n| - 의료기기 임상시험기관은 「의료기기 임상시험기관 지정에 관한 규정」(식품 | 검체를 준비한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 367,
        "window_size": 3,
        "char_count": 280,
        "word_count": 64,
        "page_number": 6,
        "window_text": "| 1) 검정색 볼펜을 사용하여 기록하여 주십시오.  | 피험자 제공 | □ 뇌졸중 □ 기타: | (True Positive) | (True Positive) | of platelet function disorders and von Willebrand | (False Positive) | (False Positive) |\n| 나.  체외진단용 의료기기 1, 2 등급 허가·심사 및 신고서 작성 가이드라인 | (1) 관련 규격 | * 피험자의 선정기준/제외기준 · 인원 및 근거 | 피험자의 모집기간, 임상관찰 및 시험수행 기간, 통계처리 기간, 결과보고서 작성 | 임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 등을 제시함.  | 시험 책임자는 의료기기법 시행규칙 제24조제1항제4호의 규정에 따라 임상시험 | 임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상사례 등에 대하여 임상 | 기록서(Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험 | (1) 연구가설 | - 적용 계산식 :  |     | (True Positive) | (False Positive) |\n| - 의료기기 임상시험기관은 「의료기기 임상시험기관 지정에 관한 규정」(식품 | 검체를 준비한다.  | - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | (4) 시험 조건 | 항목을 제외한다.  | 시험기기 | 준비된 동일 시료를 반으로 나누어 시험시료와 대조시료로 분리한다.  | 시험기기 | 2 | 혈액주입구 | 지지체 | ○○○ | 1개 | 및 혈소판 기능 이상 검체를 각각 최소 50개 이상 준비한다. ",
        "original_sentence": "| 시험 책임자는 의료기기법 시행규칙 제24조제1항제4호의 규정에 따라 임상시험 | 임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상사례 등에 대하여 임상 | 기록서(Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험 | (1) 연구가설 | - 적용 계산식 :  |     | (True Positive) | (False Positive) |\n| - 의료기기 임상시험기관은 「의료기기 임상시험기관 지정에 관한 규정」(식품 | 검체를 준비한다. "
      }
    },
    {
      "chunk_id": "chunk_369",
      "text": "| - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | (4) 시험 조건 | 항목을 제외한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 368,
        "window_size": 3,
        "char_count": 55,
        "word_count": 15,
        "page_number": 1,
        "window_text": "| 피험자 제공 | □ 뇌졸중 □ 기타: | (True Positive) | (True Positive) | of platelet function disorders and von Willebrand | (False Positive) | (False Positive) |\n| 나.  체외진단용 의료기기 1, 2 등급 허가·심사 및 신고서 작성 가이드라인 | (1) 관련 규격 | * 피험자의 선정기준/제외기준 · 인원 및 근거 | 피험자의 모집기간, 임상관찰 및 시험수행 기간, 통계처리 기간, 결과보고서 작성 | 임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 등을 제시함.  | 시험 책임자는 의료기기법 시행규칙 제24조제1항제4호의 규정에 따라 임상시험 | 임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상사례 등에 대하여 임상 | 기록서(Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험 | (1) 연구가설 | - 적용 계산식 :  |     | (True Positive) | (False Positive) |\n| - 의료기기 임상시험기관은 「의료기기 임상시험기관 지정에 관한 규정」(식품 | 검체를 준비한다.  | - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | (4) 시험 조건 | 항목을 제외한다.  | 시험기기 | 준비된 동일 시료를 반으로 나누어 시험시료와 대조시료로 분리한다.  | 시험기기 | 2 | 혈액주입구 | 지지체 | ○○○ | 1개 | 및 혈소판 기능 이상 검체를 각각 최소 50개 이상 준비한다.  각 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 | Approved Guideline | 한계치와 내열성 시험에 관한 요구사항이 적용된다. ",
        "original_sentence": "| - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | (4) 시험 조건 | 항목을 제외한다. "
      }
    },
    {
      "chunk_id": "chunk_370",
      "text": "| 시험기기 | 준비된 동일 시료를 반으로 나누어 시험시료와 대조시료로 분리한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 369,
        "window_size": 3,
        "char_count": 46,
        "word_count": 11,
        "page_number": 9,
        "window_text": "체외진단용 의료기기 1, 2 등급 허가·심사 및 신고서 작성 가이드라인 | (1) 관련 규격 | * 피험자의 선정기준/제외기준 · 인원 및 근거 | 피험자의 모집기간, 임상관찰 및 시험수행 기간, 통계처리 기간, 결과보고서 작성 | 임상시험을 실시하는 동안 발생할 수 있는 부작용 및 사용 시 주의사항 등을 제시함.  | 시험 책임자는 의료기기법 시행규칙 제24조제1항제4호의 규정에 따라 임상시험 | 임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상사례 등에 대하여 임상 | 기록서(Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험 | (1) 연구가설 | - 적용 계산식 :  |     | (True Positive) | (False Positive) |\n| - 의료기기 임상시험기관은 「의료기기 임상시험기관 지정에 관한 규정」(식품 | 검체를 준비한다.  | - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | (4) 시험 조건 | 항목을 제외한다.  | 시험기기 | 준비된 동일 시료를 반으로 나누어 시험시료와 대조시료로 분리한다.  | 시험기기 | 2 | 혈액주입구 | 지지체 | ○○○ | 1개 | 및 혈소판 기능 이상 검체를 각각 최소 50개 이상 준비한다.  각 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 | Approved Guideline | 한계치와 내열성 시험에 관한 요구사항이 적용된다.  | 임상검체 폐기절차에 따라 즉각 폐기한다. ",
        "original_sentence": "| 시험기기 | 준비된 동일 시료를 반으로 나누어 시험시료와 대조시료로 분리한다. "
      }
    },
    {
      "chunk_id": "chunk_371",
      "text": "| 시험기기 | 2 | 혈액주입구 | 지지체 | ○○○ | 1개 | 및 혈소판 기능 이상 검체를 각각 최소 50개 이상 준비한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 370,
        "window_size": 3,
        "char_count": 73,
        "word_count": 23,
        "page_number": 6,
        "window_text": "| 시험 책임자는 의료기기법 시행규칙 제24조제1항제4호의 규정에 따라 임상시험 | 임상시험이 종료된 후 피험자에게 발생한 부작용 및 이상사례 등에 대하여 임상 | 기록서(Case Report Form, CRF), 의뢰자와 임상시험기관 장과의 계약서, 시험 | (1) 연구가설 | - 적용 계산식 :  |     | (True Positive) | (False Positive) |\n| - 의료기기 임상시험기관은 「의료기기 임상시험기관 지정에 관한 규정」(식품 | 검체를 준비한다.  | - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | (4) 시험 조건 | 항목을 제외한다.  | 시험기기 | 준비된 동일 시료를 반으로 나누어 시험시료와 대조시료로 분리한다.  | 시험기기 | 2 | 혈액주입구 | 지지체 | ○○○ | 1개 | 및 혈소판 기능 이상 검체를 각각 최소 50개 이상 준비한다.  각 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 | Approved Guideline | 한계치와 내열성 시험에 관한 요구사항이 적용된다.  | 임상검체 폐기절차에 따라 즉각 폐기한다.  |\n| (1) 관련 규격 | - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람으로서, | 제조업자 또는 수입업자가 해당됨. ",
        "original_sentence": "| 시험기기 | 2 | 혈액주입구 | 지지체 | ○○○ | 1개 | 및 혈소판 기능 이상 검체를 각각 최소 50개 이상 준비한다. "
      }
    },
    {
      "chunk_id": "chunk_372",
      "text": "각 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 | Approved Guideline | 한계치와 내열성 시험에 관한 요구사항이 적용된다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 371,
        "window_size": 3,
        "char_count": 91,
        "word_count": 20,
        "page_number": 6,
        "window_text": "| - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대 | (4) 시험 조건 | 항목을 제외한다.  | 시험기기 | 준비된 동일 시료를 반으로 나누어 시험시료와 대조시료로 분리한다.  | 시험기기 | 2 | 혈액주입구 | 지지체 | ○○○ | 1개 | 및 혈소판 기능 이상 검체를 각각 최소 50개 이상 준비한다.  각 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 | Approved Guideline | 한계치와 내열성 시험에 관한 요구사항이 적용된다.  | 임상검체 폐기절차에 따라 즉각 폐기한다.  |\n| (1) 관련 규격 | - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람으로서, | 제조업자 또는 수입업자가 해당됨.  의뢰자는 임상시험모니터 요원을 지정하여야 함. ",
        "original_sentence": "각 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 | Approved Guideline | 한계치와 내열성 시험에 관한 요구사항이 적용된다. "
      }
    },
    {
      "chunk_id": "chunk_373",
      "text": "| 임상검체 폐기절차에 따라 즉각 폐기한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 372,
        "window_size": 3,
        "char_count": 25,
        "word_count": 6,
        "page_number": 6,
        "window_text": "| 시험기기 | 준비된 동일 시료를 반으로 나누어 시험시료와 대조시료로 분리한다.  | 시험기기 | 2 | 혈액주입구 | 지지체 | ○○○ | 1개 | 및 혈소판 기능 이상 검체를 각각 최소 50개 이상 준비한다.  각 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 | Approved Guideline | 한계치와 내열성 시험에 관한 요구사항이 적용된다.  | 임상검체 폐기절차에 따라 즉각 폐기한다.  |\n| (1) 관련 규격 | - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람으로서, | 제조업자 또는 수입업자가 해당됨.  의뢰자는 임상시험모니터 요원을 지정하여야 함.  | 이상사례 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상시험의 진행이 | 시험기기 | 또는 간호사 등으로서 임상시험기관의 장이 지정한 자를 말함. ",
        "original_sentence": "| 임상검체 폐기절차에 따라 즉각 폐기한다. "
      }
    },
    {
      "chunk_id": "chunk_374",
      "text": "|\n| (1) 관련 규격 | - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람으로서, | 제조업자 또는 수입업자가 해당됨. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 373,
        "window_size": 3,
        "char_count": 84,
        "word_count": 21,
        "page_number": 6,
        "window_text": "| 시험기기 | 2 | 혈액주입구 | 지지체 | ○○○ | 1개 | 및 혈소판 기능 이상 검체를 각각 최소 50개 이상 준비한다.  각 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 | Approved Guideline | 한계치와 내열성 시험에 관한 요구사항이 적용된다.  | 임상검체 폐기절차에 따라 즉각 폐기한다.  |\n| (1) 관련 규격 | - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람으로서, | 제조업자 또는 수입업자가 해당됨.  의뢰자는 임상시험모니터 요원을 지정하여야 함.  | 이상사례 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상시험의 진행이 | 시험기기 | 또는 간호사 등으로서 임상시험기관의 장이 지정한 자를 말함.  | n = 99.96 | n = 125.44 | □ ‘이상 의료기기’의 반응 |\n| 임상시험 방법은 해당 의료기기의 각 구성품에 대한 형상, 구조 및 사용 전 준비 | 2) 가능하면 약어의 사용을 피하고 Full term으로 기록하여 주십시오. ",
        "original_sentence": "|\n| (1) 관련 규격 | - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람으로서, | 제조업자 또는 수입업자가 해당됨. "
      }
    },
    {
      "chunk_id": "chunk_375",
      "text": "의뢰자는 임상시험모니터 요원을 지정하여야 함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 374,
        "window_size": 3,
        "char_count": 26,
        "word_count": 5,
        "page_number": 7,
        "window_text": "각 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 | Approved Guideline | 한계치와 내열성 시험에 관한 요구사항이 적용된다.  | 임상검체 폐기절차에 따라 즉각 폐기한다.  |\n| (1) 관련 규격 | - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람으로서, | 제조업자 또는 수입업자가 해당됨.  의뢰자는 임상시험모니터 요원을 지정하여야 함.  | 이상사례 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상시험의 진행이 | 시험기기 | 또는 간호사 등으로서 임상시험기관의 장이 지정한 자를 말함.  | n = 99.96 | n = 125.44 | □ ‘이상 의료기기’의 반응 |\n| 임상시험 방법은 해당 의료기기의 각 구성품에 대한 형상, 구조 및 사용 전 준비 | 2) 가능하면 약어의 사용을 피하고 Full term으로 기록하여 주십시오.  | effect of aspirin on platelet function in high-risk patients with ischemic heart disease | 서명일자를 직접 적어야 합니다. ",
        "original_sentence": "의뢰자는 임상시험모니터 요원을 지정하여야 함. "
      }
    },
    {
      "chunk_id": "chunk_376",
      "text": "| 이상사례 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상시험의 진행이 | 시험기기 | 또는 간호사 등으로서 임상시험기관의 장이 지정한 자를 말함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 375,
        "window_size": 3,
        "char_count": 87,
        "word_count": 22,
        "page_number": 9,
        "window_text": "| 임상검체 폐기절차에 따라 즉각 폐기한다.  |\n| (1) 관련 규격 | - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람으로서, | 제조업자 또는 수입업자가 해당됨.  의뢰자는 임상시험모니터 요원을 지정하여야 함.  | 이상사례 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상시험의 진행이 | 시험기기 | 또는 간호사 등으로서 임상시험기관의 장이 지정한 자를 말함.  | n = 99.96 | n = 125.44 | □ ‘이상 의료기기’의 반응 |\n| 임상시험 방법은 해당 의료기기의 각 구성품에 대한 형상, 구조 및 사용 전 준비 | 2) 가능하면 약어의 사용을 피하고 Full term으로 기록하여 주십시오.  | effect of aspirin on platelet function in high-risk patients with ischemic heart disease | 서명일자를 직접 적어야 합니다.  |\n| 나. ",
        "original_sentence": "| 이상사례 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상시험의 진행이 | 시험기기 | 또는 간호사 등으로서 임상시험기관의 장이 지정한 자를 말함. "
      }
    },
    {
      "chunk_id": "chunk_377",
      "text": "| n = 99.96 | n = 125.44 | □ ‘이상 의료기기’의 반응 |\n| 임상시험 방법은 해당 의료기기의 각 구성품에 대한 형상, 구조 및 사용 전 준비 | 2) 가능하면 약어의 사용을 피하고 Full term으로 기록하여 주십시오. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 376,
        "window_size": 3,
        "char_count": 137,
        "word_count": 38,
        "page_number": 6,
        "window_text": "|\n| (1) 관련 규격 | - 시험책임자는 임상시험기관에서 임상시험 수행에 대한 책임을 갖고 있는 사람으로서, | 제조업자 또는 수입업자가 해당됨.  의뢰자는 임상시험모니터 요원을 지정하여야 함.  | 이상사례 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상시험의 진행이 | 시험기기 | 또는 간호사 등으로서 임상시험기관의 장이 지정한 자를 말함.  | n = 99.96 | n = 125.44 | □ ‘이상 의료기기’의 반응 |\n| 임상시험 방법은 해당 의료기기의 각 구성품에 대한 형상, 구조 및 사용 전 준비 | 2) 가능하면 약어의 사용을 피하고 Full term으로 기록하여 주십시오.  | effect of aspirin on platelet function in high-risk patients with ischemic heart disease | 서명일자를 직접 적어야 합니다.  |\n| 나.  혈소판 약물반응검사 | 위해 사용될 것임을 의미합니다. ",
        "original_sentence": "| n = 99.96 | n = 125.44 | □ ‘이상 의료기기’의 반응 |\n| 임상시험 방법은 해당 의료기기의 각 구성품에 대한 형상, 구조 및 사용 전 준비 | 2) 가능하면 약어의 사용을 피하고 Full term으로 기록하여 주십시오. "
      }
    },
    {
      "chunk_id": "chunk_378",
      "text": "| effect of aspirin on platelet function in high-risk patients with ischemic heart disease | 서명일자를 직접 적어야 합니다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 377,
        "window_size": 3,
        "char_count": 111,
        "word_count": 19,
        "page_number": 17,
        "window_text": "의뢰자는 임상시험모니터 요원을 지정하여야 함.  | 이상사례 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상시험의 진행이 | 시험기기 | 또는 간호사 등으로서 임상시험기관의 장이 지정한 자를 말함.  | n = 99.96 | n = 125.44 | □ ‘이상 의료기기’의 반응 |\n| 임상시험 방법은 해당 의료기기의 각 구성품에 대한 형상, 구조 및 사용 전 준비 | 2) 가능하면 약어의 사용을 피하고 Full term으로 기록하여 주십시오.  | effect of aspirin on platelet function in high-risk patients with ischemic heart disease | 서명일자를 직접 적어야 합니다.  |\n| 나.  혈소판 약물반응검사 | 위해 사용될 것임을 의미합니다.  | 손쉽게 검사를 할 수 있기 때문에 널리 사용되고 있다. ",
        "original_sentence": "| effect of aspirin on platelet function in high-risk patients with ischemic heart disease | 서명일자를 직접 적어야 합니다. "
      }
    },
    {
      "chunk_id": "chunk_379",
      "text": "|\n| 나. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 378,
        "window_size": 3,
        "char_count": 7,
        "word_count": 3,
        "page_number": 1,
        "window_text": "| 이상사례 발생 등으로 인하여 임상시험을 진행할 수 없거나 임상시험의 진행이 | 시험기기 | 또는 간호사 등으로서 임상시험기관의 장이 지정한 자를 말함.  | n = 99.96 | n = 125.44 | □ ‘이상 의료기기’의 반응 |\n| 임상시험 방법은 해당 의료기기의 각 구성품에 대한 형상, 구조 및 사용 전 준비 | 2) 가능하면 약어의 사용을 피하고 Full term으로 기록하여 주십시오.  | effect of aspirin on platelet function in high-risk patients with ischemic heart disease | 서명일자를 직접 적어야 합니다.  |\n| 나.  혈소판 약물반응검사 | 위해 사용될 것임을 의미합니다.  | 손쉽게 검사를 할 수 있기 때문에 널리 사용되고 있다.  | 나. ",
        "original_sentence": "|\n| 나. "
      }
    },
    {
      "chunk_id": "chunk_380",
      "text": "혈소판 약물반응검사 | 위해 사용될 것임을 의미합니다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 379,
        "window_size": 3,
        "char_count": 31,
        "word_count": 7,
        "page_number": 53,
        "window_text": "| n = 99.96 | n = 125.44 | □ ‘이상 의료기기’의 반응 |\n| 임상시험 방법은 해당 의료기기의 각 구성품에 대한 형상, 구조 및 사용 전 준비 | 2) 가능하면 약어의 사용을 피하고 Full term으로 기록하여 주십시오.  | effect of aspirin on platelet function in high-risk patients with ischemic heart disease | 서명일자를 직접 적어야 합니다.  |\n| 나.  혈소판 약물반응검사 | 위해 사용될 것임을 의미합니다.  | 손쉽게 검사를 할 수 있기 때문에 널리 사용되고 있다.  | 나.  혈소판 약물반응검사 | (2) 인구학적 조사, 병력조사 요법 | 나. ",
        "original_sentence": "혈소판 약물반응검사 | 위해 사용될 것임을 의미합니다. "
      }
    },
    {
      "chunk_id": "chunk_381",
      "text": "| 손쉽게 검사를 할 수 있기 때문에 널리 사용되고 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 380,
        "window_size": 3,
        "char_count": 33,
        "word_count": 10,
        "page_number": 16,
        "window_text": "| effect of aspirin on platelet function in high-risk patients with ischemic heart disease | 서명일자를 직접 적어야 합니다.  |\n| 나.  혈소판 약물반응검사 | 위해 사용될 것임을 의미합니다.  | 손쉽게 검사를 할 수 있기 때문에 널리 사용되고 있다.  | 나.  혈소판 약물반응검사 | (2) 인구학적 조사, 병력조사 요법 | 나.  처리 할당 방법: 단일눈가림 | EPI test | 84.5% | 85.6% | - 이상사례(의료기기이상반응, 중대한 이상사례/의료기기이상반응 포함)의 발생 | (2) 제품의 변경 및 변형은 허용되지 않는다. ",
        "original_sentence": "| 손쉽게 검사를 할 수 있기 때문에 널리 사용되고 있다. "
      }
    },
    {
      "chunk_id": "chunk_382",
      "text": "| 나. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 381,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 1,
        "window_text": "|\n| 나.  혈소판 약물반응검사 | 위해 사용될 것임을 의미합니다.  | 손쉽게 검사를 할 수 있기 때문에 널리 사용되고 있다.  | 나.  혈소판 약물반응검사 | (2) 인구학적 조사, 병력조사 요법 | 나.  처리 할당 방법: 단일눈가림 | EPI test | 84.5% | 85.6% | - 이상사례(의료기기이상반응, 중대한 이상사례/의료기기이상반응 포함)의 발생 | (2) 제품의 변경 및 변형은 허용되지 않는다.  | 10%로 가정하였다. ",
        "original_sentence": "| 나. "
      }
    },
    {
      "chunk_id": "chunk_383",
      "text": "혈소판 약물반응검사 | (2) 인구학적 조사, 병력조사 요법 | 나. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 382,
        "window_size": 3,
        "char_count": 39,
        "word_count": 10,
        "page_number": 6,
        "window_text": "혈소판 약물반응검사 | 위해 사용될 것임을 의미합니다.  | 손쉽게 검사를 할 수 있기 때문에 널리 사용되고 있다.  | 나.  혈소판 약물반응검사 | (2) 인구학적 조사, 병력조사 요법 | 나.  처리 할당 방법: 단일눈가림 | EPI test | 84.5% | 85.6% | - 이상사례(의료기기이상반응, 중대한 이상사례/의료기기이상반응 포함)의 발생 | (2) 제품의 변경 및 변형은 허용되지 않는다.  | 10%로 가정하였다.  | 제품의 특성에 따라 자율적으로 설정이 가능함 | 기술 하는 것을 말함. ",
        "original_sentence": "혈소판 약물반응검사 | (2) 인구학적 조사, 병력조사 요법 | 나. "
      }
    },
    {
      "chunk_id": "chunk_384",
      "text": "처리 할당 방법: 단일눈가림 | EPI test | 84.5% | 85.6% | - 이상사례(의료기기이상반응, 중대한 이상사례/의료기기이상반응 포함)의 발생 | (2) 제품의 변경 및 변형은 허용되지 않는다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 383,
        "window_size": 3,
        "char_count": 117,
        "word_count": 26,
        "page_number": 6,
        "window_text": "| 손쉽게 검사를 할 수 있기 때문에 널리 사용되고 있다.  | 나.  혈소판 약물반응검사 | (2) 인구학적 조사, 병력조사 요법 | 나.  처리 할당 방법: 단일눈가림 | EPI test | 84.5% | 85.6% | - 이상사례(의료기기이상반응, 중대한 이상사례/의료기기이상반응 포함)의 발생 | (2) 제품의 변경 및 변형은 허용되지 않는다.  | 10%로 가정하였다.  | 제품의 특성에 따라 자율적으로 설정이 가능함 | 기술 하는 것을 말함.  | ※ 카트리지(시약)의 분석적 성능을 기재한다. ",
        "original_sentence": "처리 할당 방법: 단일눈가림 | EPI test | 84.5% | 85.6% | - 이상사례(의료기기이상반응, 중대한 이상사례/의료기기이상반응 포함)의 발생 | (2) 제품의 변경 및 변형은 허용되지 않는다. "
      }
    },
    {
      "chunk_id": "chunk_385",
      "text": "| 10%로 가정하였다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 384,
        "window_size": 3,
        "char_count": 14,
        "word_count": 3,
        "page_number": 6,
        "window_text": "| 나.  혈소판 약물반응검사 | (2) 인구학적 조사, 병력조사 요법 | 나.  처리 할당 방법: 단일눈가림 | EPI test | 84.5% | 85.6% | - 이상사례(의료기기이상반응, 중대한 이상사례/의료기기이상반응 포함)의 발생 | (2) 제품의 변경 및 변형은 허용되지 않는다.  | 10%로 가정하였다.  | 제품의 특성에 따라 자율적으로 설정이 가능함 | 기술 하는 것을 말함.  | ※ 카트리지(시약)의 분석적 성능을 기재한다.  | ⑤ “Chip Selection”화면에서 검사 종류에 따라 해당하는 아이콘을 클릭한다. ",
        "original_sentence": "| 10%로 가정하였다. "
      }
    },
    {
      "chunk_id": "chunk_386",
      "text": "| 제품의 특성에 따라 자율적으로 설정이 가능함 | 기술 하는 것을 말함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 385,
        "window_size": 3,
        "char_count": 42,
        "word_count": 12,
        "page_number": 35,
        "window_text": "혈소판 약물반응검사 | (2) 인구학적 조사, 병력조사 요법 | 나.  처리 할당 방법: 단일눈가림 | EPI test | 84.5% | 85.6% | - 이상사례(의료기기이상반응, 중대한 이상사례/의료기기이상반응 포함)의 발생 | (2) 제품의 변경 및 변형은 허용되지 않는다.  | 10%로 가정하였다.  | 제품의 특성에 따라 자율적으로 설정이 가능함 | 기술 하는 것을 말함.  | ※ 카트리지(시약)의 분석적 성능을 기재한다.  | ⑤ “Chip Selection”화면에서 검사 종류에 따라 해당하는 아이콘을 클릭한다.  | ② 검사칩 | 95% 구간에서 민감도 80%, 특이도 95%, 로 설정한다. ",
        "original_sentence": "| 제품의 특성에 따라 자율적으로 설정이 가능함 | 기술 하는 것을 말함. "
      }
    },
    {
      "chunk_id": "chunk_387",
      "text": "| ※ 카트리지(시약)의 분석적 성능을 기재한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 386,
        "window_size": 3,
        "char_count": 28,
        "word_count": 6,
        "page_number": 24,
        "window_text": "처리 할당 방법: 단일눈가림 | EPI test | 84.5% | 85.6% | - 이상사례(의료기기이상반응, 중대한 이상사례/의료기기이상반응 포함)의 발생 | (2) 제품의 변경 및 변형은 허용되지 않는다.  | 10%로 가정하였다.  | 제품의 특성에 따라 자율적으로 설정이 가능함 | 기술 하는 것을 말함.  | ※ 카트리지(시약)의 분석적 성능을 기재한다.  | ⑤ “Chip Selection”화면에서 검사 종류에 따라 해당하는 아이콘을 클릭한다.  | ② 검사칩 | 95% 구간에서 민감도 80%, 특이도 95%, 로 설정한다.  | 모든 의료기기를 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능평가 | 적극적으로 대응한다. ",
        "original_sentence": "| ※ 카트리지(시약)의 분석적 성능을 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_388",
      "text": "| ⑤ “Chip Selection”화면에서 검사 종류에 따라 해당하는 아이콘을 클릭한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 387,
        "window_size": 3,
        "char_count": 51,
        "word_count": 10,
        "page_number": 24,
        "window_text": "| 10%로 가정하였다.  | 제품의 특성에 따라 자율적으로 설정이 가능함 | 기술 하는 것을 말함.  | ※ 카트리지(시약)의 분석적 성능을 기재한다.  | ⑤ “Chip Selection”화면에서 검사 종류에 따라 해당하는 아이콘을 클릭한다.  | ② 검사칩 | 95% 구간에서 민감도 80%, 특이도 95%, 로 설정한다.  | 모든 의료기기를 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능평가 | 적극적으로 대응한다.  | 점검 및 진행사항 관리를 위한 목적으로 피험자의 기록을 열람할 수 있다. ",
        "original_sentence": "| ⑤ “Chip Selection”화면에서 검사 종류에 따라 해당하는 아이콘을 클릭한다. "
      }
    },
    {
      "chunk_id": "chunk_389",
      "text": "| ② 검사칩 | 95% 구간에서 민감도 80%, 특이도 95%, 로 설정한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 388,
        "window_size": 3,
        "char_count": 45,
        "word_count": 12,
        "page_number": 6,
        "window_text": "| 제품의 특성에 따라 자율적으로 설정이 가능함 | 기술 하는 것을 말함.  | ※ 카트리지(시약)의 분석적 성능을 기재한다.  | ⑤ “Chip Selection”화면에서 검사 종류에 따라 해당하는 아이콘을 클릭한다.  | ② 검사칩 | 95% 구간에서 민감도 80%, 특이도 95%, 로 설정한다.  | 모든 의료기기를 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능평가 | 적극적으로 대응한다.  | 점검 및 진행사항 관리를 위한 목적으로 피험자의 기록을 열람할 수 있다.  | 25℃)에서 2시간 이내 검사를 시행하고 그 결과를 데이터 수집용지에 기록한다. ",
        "original_sentence": "| ② 검사칩 | 95% 구간에서 민감도 80%, 특이도 95%, 로 설정한다. "
      }
    },
    {
      "chunk_id": "chunk_390",
      "text": "| 모든 의료기기를 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능평가 | 적극적으로 대응한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 389,
        "window_size": 3,
        "char_count": 59,
        "word_count": 13,
        "page_number": 6,
        "window_text": "| ※ 카트리지(시약)의 분석적 성능을 기재한다.  | ⑤ “Chip Selection”화면에서 검사 종류에 따라 해당하는 아이콘을 클릭한다.  | ② 검사칩 | 95% 구간에서 민감도 80%, 특이도 95%, 로 설정한다.  | 모든 의료기기를 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능평가 | 적극적으로 대응한다.  | 점검 및 진행사항 관리를 위한 목적으로 피험자의 기록을 열람할 수 있다.  | 25℃)에서 2시간 이내 검사를 시행하고 그 결과를 데이터 수집용지에 기록한다.  |\n| 예시) | - 해당 임상시험용 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며 | - 피험자(Subject)란 임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되 | 기간, 임상시험심사위원회 심사기간 등 충분한 기간을 고려하여 “식품의약품안전 | 을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화 할 때, 헬싱키선언에 | 임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료방법 등을 | 시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을 제공 | 책임자의 이력사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는 | (2) 유의수준 |\n| 해당 임상시험용 의료기기(체외진단용 시약)의 성능 및 유효성 평가를 위하여 | (가) 「의료기기의 전기 | 의약품안전처 고시)에 따라 식품의약품안전처장으로부터 의료기기 임상시험 | 기계적 안전에 관한 공통기준규격」(식품의약품 |\n| (5) 시험 방법 | 가. ",
        "original_sentence": "| 모든 의료기기를 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능평가 | 적극적으로 대응한다. "
      }
    },
    {
      "chunk_id": "chunk_391",
      "text": "| 점검 및 진행사항 관리를 위한 목적으로 피험자의 기록을 열람할 수 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 390,
        "window_size": 3,
        "char_count": 43,
        "word_count": 12,
        "page_number": 3,
        "window_text": "| ⑤ “Chip Selection”화면에서 검사 종류에 따라 해당하는 아이콘을 클릭한다.  | ② 검사칩 | 95% 구간에서 민감도 80%, 특이도 95%, 로 설정한다.  | 모든 의료기기를 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능평가 | 적극적으로 대응한다.  | 점검 및 진행사항 관리를 위한 목적으로 피험자의 기록을 열람할 수 있다.  | 25℃)에서 2시간 이내 검사를 시행하고 그 결과를 데이터 수집용지에 기록한다.  |\n| 예시) | - 해당 임상시험용 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며 | - 피험자(Subject)란 임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되 | 기간, 임상시험심사위원회 심사기간 등 충분한 기간을 고려하여 “식품의약품안전 | 을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화 할 때, 헬싱키선언에 | 임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료방법 등을 | 시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을 제공 | 책임자의 이력사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는 | (2) 유의수준 |\n| 해당 임상시험용 의료기기(체외진단용 시약)의 성능 및 유효성 평가를 위하여 | (가) 「의료기기의 전기 | 의약품안전처 고시)에 따라 식품의약품안전처장으로부터 의료기기 임상시험 | 기계적 안전에 관한 공통기준규격」(식품의약품 |\n| (5) 시험 방법 | 가.  분석적 민감도 | - 임상시험용 해당 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용할 경우 | 피험자의 안전보호를 위협하여 그 진행을 멈추는 것을 “중지”라 하며, 임상시험 | 각 로트 별로 검체에 대한 이동거리를 3회에 걸쳐 반복하여 측정한다. ",
        "original_sentence": "| 점검 및 진행사항 관리를 위한 목적으로 피험자의 기록을 열람할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_392",
      "text": "| 25℃)에서 2시간 이내 검사를 시행하고 그 결과를 데이터 수집용지에 기록한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 391,
        "window_size": 3,
        "char_count": 47,
        "word_count": 11,
        "page_number": 6,
        "window_text": "| ② 검사칩 | 95% 구간에서 민감도 80%, 특이도 95%, 로 설정한다.  | 모든 의료기기를 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능평가 | 적극적으로 대응한다.  | 점검 및 진행사항 관리를 위한 목적으로 피험자의 기록을 열람할 수 있다.  | 25℃)에서 2시간 이내 검사를 시행하고 그 결과를 데이터 수집용지에 기록한다.  |\n| 예시) | - 해당 임상시험용 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며 | - 피험자(Subject)란 임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되 | 기간, 임상시험심사위원회 심사기간 등 충분한 기간을 고려하여 “식품의약품안전 | 을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화 할 때, 헬싱키선언에 | 임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료방법 등을 | 시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을 제공 | 책임자의 이력사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는 | (2) 유의수준 |\n| 해당 임상시험용 의료기기(체외진단용 시약)의 성능 및 유효성 평가를 위하여 | (가) 「의료기기의 전기 | 의약품안전처 고시)에 따라 식품의약품안전처장으로부터 의료기기 임상시험 | 기계적 안전에 관한 공통기준규격」(식품의약품 |\n| (5) 시험 방법 | 가.  분석적 민감도 | - 임상시험용 해당 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용할 경우 | 피험자의 안전보호를 위협하여 그 진행을 멈추는 것을 “중지”라 하며, 임상시험 | 각 로트 별로 검체에 대한 이동거리를 3회에 걸쳐 반복하여 측정한다.  | (바) 유체로 인한 위해요인 방지 : IEC 61010-1의 11절에 기술된 유체로 | (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제 | 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시하기에 충분한 | - 시험물질 |\n| 사항/피험자에 대한 준비 등 임상시험을 위한 준비절차와 사용 단계 절차의 각 | 임상시험모니터 요원의 선정, 자격기준, 수행임무 등에 대한 사항을 의료기기 |\n| 예시) | 예시) | 기능 이상을 감별하는데 중요한 검사이다. ",
        "original_sentence": "| 25℃)에서 2시간 이내 검사를 시행하고 그 결과를 데이터 수집용지에 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_393",
      "text": "|\n| 예시) | - 해당 임상시험용 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며 | - 피험자(Subject)란 임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되 | 기간, 임상시험심사위원회 심사기간 등 충분한 기간을 고려하여 “식품의약품안전 | 을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화 할 때, 헬싱키선언에 | 임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료방법 등을 | 시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을 제공 | 책임자의 이력사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는 | (2) 유의수준 |\n| 해당 임상시험용 의료기기(체외진단용 시약)의 성능 및 유효성 평가를 위하여 | (가) 「의료기기의 전기 | 의약품안전처 고시)에 따라 식품의약품안전처장으로부터 의료기기 임상시험 | 기계적 안전에 관한 공통기준규격」(식품의약품 |\n| (5) 시험 방법 | 가. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 392,
        "window_size": 3,
        "char_count": 487,
        "word_count": 115,
        "page_number": 6,
        "window_text": "| 모든 의료기기를 대상으로 실시하며, 일차 유효성 평가변수의 근거되는 성능평가 | 적극적으로 대응한다.  | 점검 및 진행사항 관리를 위한 목적으로 피험자의 기록을 열람할 수 있다.  | 25℃)에서 2시간 이내 검사를 시행하고 그 결과를 데이터 수집용지에 기록한다.  |\n| 예시) | - 해당 임상시험용 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며 | - 피험자(Subject)란 임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되 | 기간, 임상시험심사위원회 심사기간 등 충분한 기간을 고려하여 “식품의약품안전 | 을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화 할 때, 헬싱키선언에 | 임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료방법 등을 | 시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을 제공 | 책임자의 이력사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는 | (2) 유의수준 |\n| 해당 임상시험용 의료기기(체외진단용 시약)의 성능 및 유효성 평가를 위하여 | (가) 「의료기기의 전기 | 의약품안전처 고시)에 따라 식품의약품안전처장으로부터 의료기기 임상시험 | 기계적 안전에 관한 공통기준규격」(식품의약품 |\n| (5) 시험 방법 | 가.  분석적 민감도 | - 임상시험용 해당 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용할 경우 | 피험자의 안전보호를 위협하여 그 진행을 멈추는 것을 “중지”라 하며, 임상시험 | 각 로트 별로 검체에 대한 이동거리를 3회에 걸쳐 반복하여 측정한다.  | (바) 유체로 인한 위해요인 방지 : IEC 61010-1의 11절에 기술된 유체로 | (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제 | 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시하기에 충분한 | - 시험물질 |\n| 사항/피험자에 대한 준비 등 임상시험을 위한 준비절차와 사용 단계 절차의 각 | 임상시험모니터 요원의 선정, 자격기준, 수행임무 등에 대한 사항을 의료기기 |\n| 예시) | 예시) | 기능 이상을 감별하는데 중요한 검사이다.  최근에는 심혈관 질환의 치료 및 예방에 | - 임상시험용 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’의 안전성과 유효성을 | 1) Aspirin test: 혈관질환의 위험군, 혈관질환 병력 등으로 aspirin 복용 예정인 | 임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력 등에 대하여 면담, | 2) ADP test:　정상인 및 혈소판기능저하가 있는 환자의 검체에 대해 시험기기 | - 시험 책임자 및 임상시험 관련자가 개인 식별 표기를 가린 후 검사자에게 검체를 | 보존된 검체 및 조사된 자료는 폐기하도록 요청하실 수 있으며 이 경우 이미 | 3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다. ",
        "original_sentence": "|\n| 예시) | - 해당 임상시험용 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며 | - 피험자(Subject)란 임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되 | 기간, 임상시험심사위원회 심사기간 등 충분한 기간을 고려하여 “식품의약품안전 | 을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화 할 때, 헬싱키선언에 | 임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료방법 등을 | 시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을 제공 | 책임자의 이력사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는 | (2) 유의수준 |\n| 해당 임상시험용 의료기기(체외진단용 시약)의 성능 및 유효성 평가를 위하여 | (가) 「의료기기의 전기 | 의약품안전처 고시)에 따라 식품의약품안전처장으로부터 의료기기 임상시험 | 기계적 안전에 관한 공통기준규격」(식품의약품 |\n| (5) 시험 방법 | 가. "
      }
    },
    {
      "chunk_id": "chunk_394",
      "text": "분석적 민감도 | - 임상시험용 해당 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용할 경우 | 피험자의 안전보호를 위협하여 그 진행을 멈추는 것을 “중지”라 하며, 임상시험 | 각 로트 별로 검체에 대한 이동거리를 3회에 걸쳐 반복하여 측정한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 393,
        "window_size": 3,
        "char_count": 142,
        "word_count": 35,
        "page_number": 9,
        "window_text": "| 점검 및 진행사항 관리를 위한 목적으로 피험자의 기록을 열람할 수 있다.  | 25℃)에서 2시간 이내 검사를 시행하고 그 결과를 데이터 수집용지에 기록한다.  |\n| 예시) | - 해당 임상시험용 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며 | - 피험자(Subject)란 임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되 | 기간, 임상시험심사위원회 심사기간 등 충분한 기간을 고려하여 “식품의약품안전 | 을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화 할 때, 헬싱키선언에 | 임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료방법 등을 | 시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을 제공 | 책임자의 이력사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는 | (2) 유의수준 |\n| 해당 임상시험용 의료기기(체외진단용 시약)의 성능 및 유효성 평가를 위하여 | (가) 「의료기기의 전기 | 의약품안전처 고시)에 따라 식품의약품안전처장으로부터 의료기기 임상시험 | 기계적 안전에 관한 공통기준규격」(식품의약품 |\n| (5) 시험 방법 | 가.  분석적 민감도 | - 임상시험용 해당 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용할 경우 | 피험자의 안전보호를 위협하여 그 진행을 멈추는 것을 “중지”라 하며, 임상시험 | 각 로트 별로 검체에 대한 이동거리를 3회에 걸쳐 반복하여 측정한다.  | (바) 유체로 인한 위해요인 방지 : IEC 61010-1의 11절에 기술된 유체로 | (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제 | 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시하기에 충분한 | - 시험물질 |\n| 사항/피험자에 대한 준비 등 임상시험을 위한 준비절차와 사용 단계 절차의 각 | 임상시험모니터 요원의 선정, 자격기준, 수행임무 등에 대한 사항을 의료기기 |\n| 예시) | 예시) | 기능 이상을 감별하는데 중요한 검사이다.  최근에는 심혈관 질환의 치료 및 예방에 | - 임상시험용 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’의 안전성과 유효성을 | 1) Aspirin test: 혈관질환의 위험군, 혈관질환 병력 등으로 aspirin 복용 예정인 | 임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력 등에 대하여 면담, | 2) ADP test:　정상인 및 혈소판기능저하가 있는 환자의 검체에 대해 시험기기 | - 시험 책임자 및 임상시험 관련자가 개인 식별 표기를 가린 후 검사자에게 검체를 | 보존된 검체 및 조사된 자료는 폐기하도록 요청하실 수 있으며 이 경우 이미 | 3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.  | 시험자는 본 임상시험 계획서에 서명함으로써, 국내의 법규와 윤리적 측면에서 |\n| - 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의 일반적인 사항, | 근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서 | 제공하여 원칙과 절차를 수립하여 제시함. ",
        "original_sentence": "분석적 민감도 | - 임상시험용 해당 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용할 경우 | 피험자의 안전보호를 위협하여 그 진행을 멈추는 것을 “중지”라 하며, 임상시험 | 각 로트 별로 검체에 대한 이동거리를 3회에 걸쳐 반복하여 측정한다. "
      }
    },
    {
      "chunk_id": "chunk_395",
      "text": "| (바) 유체로 인한 위해요인 방지 : IEC 61010-1의 11절에 기술된 유체로 | (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제 | 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시하기에 충분한 | - 시험물질 |\n| 사항/피험자에 대한 준비 등 임상시험을 위한 준비절차와 사용 단계 절차의 각 | 임상시험모니터 요원의 선정, 자격기준, 수행임무 등에 대한 사항을 의료기기 |\n| 예시) | 예시) | 기능 이상을 감별하는데 중요한 검사이다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 394,
        "window_size": 3,
        "char_count": 274,
        "word_count": 70,
        "page_number": 6,
        "window_text": "| 25℃)에서 2시간 이내 검사를 시행하고 그 결과를 데이터 수집용지에 기록한다.  |\n| 예시) | - 해당 임상시험용 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며 | - 피험자(Subject)란 임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되 | 기간, 임상시험심사위원회 심사기간 등 충분한 기간을 고려하여 “식품의약품안전 | 을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화 할 때, 헬싱키선언에 | 임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료방법 등을 | 시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을 제공 | 책임자의 이력사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는 | (2) 유의수준 |\n| 해당 임상시험용 의료기기(체외진단용 시약)의 성능 및 유효성 평가를 위하여 | (가) 「의료기기의 전기 | 의약품안전처 고시)에 따라 식품의약품안전처장으로부터 의료기기 임상시험 | 기계적 안전에 관한 공통기준규격」(식품의약품 |\n| (5) 시험 방법 | 가.  분석적 민감도 | - 임상시험용 해당 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용할 경우 | 피험자의 안전보호를 위협하여 그 진행을 멈추는 것을 “중지”라 하며, 임상시험 | 각 로트 별로 검체에 대한 이동거리를 3회에 걸쳐 반복하여 측정한다.  | (바) 유체로 인한 위해요인 방지 : IEC 61010-1의 11절에 기술된 유체로 | (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제 | 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시하기에 충분한 | - 시험물질 |\n| 사항/피험자에 대한 준비 등 임상시험을 위한 준비절차와 사용 단계 절차의 각 | 임상시험모니터 요원의 선정, 자격기준, 수행임무 등에 대한 사항을 의료기기 |\n| 예시) | 예시) | 기능 이상을 감별하는데 중요한 검사이다.  최근에는 심혈관 질환의 치료 및 예방에 | - 임상시험용 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’의 안전성과 유효성을 | 1) Aspirin test: 혈관질환의 위험군, 혈관질환 병력 등으로 aspirin 복용 예정인 | 임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력 등에 대하여 면담, | 2) ADP test:　정상인 및 혈소판기능저하가 있는 환자의 검체에 대해 시험기기 | - 시험 책임자 및 임상시험 관련자가 개인 식별 표기를 가린 후 검사자에게 검체를 | 보존된 검체 및 조사된 자료는 폐기하도록 요청하실 수 있으며 이 경우 이미 | 3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.  | 시험자는 본 임상시험 계획서에 서명함으로써, 국내의 법규와 윤리적 측면에서 |\n| - 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의 일반적인 사항, | 근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서 | 제공하여 원칙과 절차를 수립하여 제시함.  피해자 보상에 대한 규약에는 보상 | 어 임상시험에 참여하는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄 | 기준을 제시함. ",
        "original_sentence": "| (바) 유체로 인한 위해요인 방지 : IEC 61010-1의 11절에 기술된 유체로 | (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제 | 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시하기에 충분한 | - 시험물질 |\n| 사항/피험자에 대한 준비 등 임상시험을 위한 준비절차와 사용 단계 절차의 각 | 임상시험모니터 요원의 선정, 자격기준, 수행임무 등에 대한 사항을 의료기기 |\n| 예시) | 예시) | 기능 이상을 감별하는데 중요한 검사이다. "
      }
    },
    {
      "chunk_id": "chunk_396",
      "text": "최근에는 심혈관 질환의 치료 및 예방에 | - 임상시험용 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’의 안전성과 유효성을 | 1) Aspirin test: 혈관질환의 위험군, 혈관질환 병력 등으로 aspirin 복용 예정인 | 임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력 등에 대하여 면담, | 2) ADP test:　정상인 및 혈소판기능저하가 있는 환자의 검체에 대해 시험기기 | - 시험 책임자 및 임상시험 관련자가 개인 식별 표기를 가린 후 검사자에게 검체를 | 보존된 검체 및 조사된 자료는 폐기하도록 요청하실 수 있으며 이 경우 이미 | 3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 395,
        "window_size": 3,
        "char_count": 364,
        "word_count": 91,
        "page_number": 9,
        "window_text": "|\n| 예시) | - 해당 임상시험용 의료기기의 사용목적과 그 사용범위를 구체적으로 기재하며 | - 피험자(Subject)란 임상시험용 의료기기의 적용 대상이 되거나 대조군에 포함되 | 기간, 임상시험심사위원회 심사기간 등 충분한 기간을 고려하여 “식품의약품안전 | 을 시작하기 전에 피험자로부터 동의를 받고 이를 문서화 할 때, 헬싱키선언에 | 임상시험과 관련하여 발생한 손상에 대한 피험자의 치료비 및 치료방법 등을 | 시험용 의료기기와의 인과관계에 따른 피험자에 대한 보상 및 치료방법 등을 제공 | 책임자의 이력사항 및 임상시험용 의료기기의 사용 및 관리, 임상시험에 사용되는 | (2) 유의수준 |\n| 해당 임상시험용 의료기기(체외진단용 시약)의 성능 및 유효성 평가를 위하여 | (가) 「의료기기의 전기 | 의약품안전처 고시)에 따라 식품의약품안전처장으로부터 의료기기 임상시험 | 기계적 안전에 관한 공통기준규격」(식품의약품 |\n| (5) 시험 방법 | 가.  분석적 민감도 | - 임상시험용 해당 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용할 경우 | 피험자의 안전보호를 위협하여 그 진행을 멈추는 것을 “중지”라 하며, 임상시험 | 각 로트 별로 검체에 대한 이동거리를 3회에 걸쳐 반복하여 측정한다.  | (바) 유체로 인한 위해요인 방지 : IEC 61010-1의 11절에 기술된 유체로 | (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제 | 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시하기에 충분한 | - 시험물질 |\n| 사항/피험자에 대한 준비 등 임상시험을 위한 준비절차와 사용 단계 절차의 각 | 임상시험모니터 요원의 선정, 자격기준, 수행임무 등에 대한 사항을 의료기기 |\n| 예시) | 예시) | 기능 이상을 감별하는데 중요한 검사이다.  최근에는 심혈관 질환의 치료 및 예방에 | - 임상시험용 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’의 안전성과 유효성을 | 1) Aspirin test: 혈관질환의 위험군, 혈관질환 병력 등으로 aspirin 복용 예정인 | 임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력 등에 대하여 면담, | 2) ADP test:　정상인 및 혈소판기능저하가 있는 환자의 검체에 대해 시험기기 | - 시험 책임자 및 임상시험 관련자가 개인 식별 표기를 가린 후 검사자에게 검체를 | 보존된 검체 및 조사된 자료는 폐기하도록 요청하실 수 있으며 이 경우 이미 | 3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.  | 시험자는 본 임상시험 계획서에 서명함으로써, 국내의 법규와 윤리적 측면에서 |\n| - 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의 일반적인 사항, | 근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서 | 제공하여 원칙과 절차를 수립하여 제시함.  피해자 보상에 대한 규약에는 보상 | 어 임상시험에 참여하는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄 | 기준을 제시함.  그밖에 임상시험결과의 사용 범위에 따른 성능평가를 위하여 | 시 의료기기 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에 의거, 정한 |\n**측정하는 변수를 구체적으로 명확히 기술하며, 관찰항목 및 임상검사항목, 관**\n| 2. ",
        "original_sentence": "최근에는 심혈관 질환의 치료 및 예방에 | - 임상시험용 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’의 안전성과 유효성을 | 1) Aspirin test: 혈관질환의 위험군, 혈관질환 병력 등으로 aspirin 복용 예정인 | 임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력 등에 대하여 면담, | 2) ADP test:　정상인 및 혈소판기능저하가 있는 환자의 검체에 대해 시험기기 | - 시험 책임자 및 임상시험 관련자가 개인 식별 표기를 가린 후 검사자에게 검체를 | 보존된 검체 및 조사된 자료는 폐기하도록 요청하실 수 있으며 이 경우 이미 | 3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_397",
      "text": "| 시험자는 본 임상시험 계획서에 서명함으로써, 국내의 법규와 윤리적 측면에서 |\n| - 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의 일반적인 사항, | 근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서 | 제공하여 원칙과 절차를 수립하여 제시함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 396,
        "window_size": 3,
        "char_count": 160,
        "word_count": 39,
        "page_number": 9,
        "window_text": "분석적 민감도 | - 임상시험용 해당 의료기기와 비교하기 위하여 대조시험용 의료기기를 사용할 경우 | 피험자의 안전보호를 위협하여 그 진행을 멈추는 것을 “중지”라 하며, 임상시험 | 각 로트 별로 검체에 대한 이동거리를 3회에 걸쳐 반복하여 측정한다.  | (바) 유체로 인한 위해요인 방지 : IEC 61010-1의 11절에 기술된 유체로 | (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제 | 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시하기에 충분한 | - 시험물질 |\n| 사항/피험자에 대한 준비 등 임상시험을 위한 준비절차와 사용 단계 절차의 각 | 임상시험모니터 요원의 선정, 자격기준, 수행임무 등에 대한 사항을 의료기기 |\n| 예시) | 예시) | 기능 이상을 감별하는데 중요한 검사이다.  최근에는 심혈관 질환의 치료 및 예방에 | - 임상시험용 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’의 안전성과 유효성을 | 1) Aspirin test: 혈관질환의 위험군, 혈관질환 병력 등으로 aspirin 복용 예정인 | 임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력 등에 대하여 면담, | 2) ADP test:　정상인 및 혈소판기능저하가 있는 환자의 검체에 대해 시험기기 | - 시험 책임자 및 임상시험 관련자가 개인 식별 표기를 가린 후 검사자에게 검체를 | 보존된 검체 및 조사된 자료는 폐기하도록 요청하실 수 있으며 이 경우 이미 | 3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.  | 시험자는 본 임상시험 계획서에 서명함으로써, 국내의 법규와 윤리적 측면에서 |\n| - 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의 일반적인 사항, | 근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서 | 제공하여 원칙과 절차를 수립하여 제시함.  피해자 보상에 대한 규약에는 보상 | 어 임상시험에 참여하는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄 | 기준을 제시함.  그밖에 임상시험결과의 사용 범위에 따른 성능평가를 위하여 | 시 의료기기 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에 의거, 정한 |\n**측정하는 변수를 구체적으로 명확히 기술하며, 관찰항목 및 임상검사항목, 관**\n| 2.  인체 유래물이란? ",
        "original_sentence": "| 시험자는 본 임상시험 계획서에 서명함으로써, 국내의 법규와 윤리적 측면에서 |\n| - 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의 일반적인 사항, | 근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서 | 제공하여 원칙과 절차를 수립하여 제시함. "
      }
    },
    {
      "chunk_id": "chunk_398",
      "text": "피해자 보상에 대한 규약에는 보상 | 어 임상시험에 참여하는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄 | 기준을 제시함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 397,
        "window_size": 3,
        "char_count": 73,
        "word_count": 18,
        "page_number": 9,
        "window_text": "| (바) 유체로 인한 위해요인 방지 : IEC 61010-1의 11절에 기술된 유체로 | (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제 | 전문지식과 윤리적 소양을 갖추고 해당 의료기기의 임상시험을 실시하기에 충분한 | - 시험물질 |\n| 사항/피험자에 대한 준비 등 임상시험을 위한 준비절차와 사용 단계 절차의 각 | 임상시험모니터 요원의 선정, 자격기준, 수행임무 등에 대한 사항을 의료기기 |\n| 예시) | 예시) | 기능 이상을 감별하는데 중요한 검사이다.  최근에는 심혈관 질환의 치료 및 예방에 | - 임상시험용 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’의 안전성과 유효성을 | 1) Aspirin test: 혈관질환의 위험군, 혈관질환 병력 등으로 aspirin 복용 예정인 | 임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력 등에 대하여 면담, | 2) ADP test:　정상인 및 혈소판기능저하가 있는 환자의 검체에 대해 시험기기 | - 시험 책임자 및 임상시험 관련자가 개인 식별 표기를 가린 후 검사자에게 검체를 | 보존된 검체 및 조사된 자료는 폐기하도록 요청하실 수 있으며 이 경우 이미 | 3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.  | 시험자는 본 임상시험 계획서에 서명함으로써, 국내의 법규와 윤리적 측면에서 |\n| - 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의 일반적인 사항, | 근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서 | 제공하여 원칙과 절차를 수립하여 제시함.  피해자 보상에 대한 규약에는 보상 | 어 임상시험에 참여하는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄 | 기준을 제시함.  그밖에 임상시험결과의 사용 범위에 따른 성능평가를 위하여 | 시 의료기기 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에 의거, 정한 |\n**측정하는 변수를 구체적으로 명확히 기술하며, 관찰항목 및 임상검사항목, 관**\n| 2.  인체 유래물이란?  | 함께 관리함. ",
        "original_sentence": "피해자 보상에 대한 규약에는 보상 | 어 임상시험에 참여하는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄 | 기준을 제시함. "
      }
    },
    {
      "chunk_id": "chunk_399",
      "text": "그밖에 임상시험결과의 사용 범위에 따른 성능평가를 위하여 | 시 의료기기 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에 의거, 정한 |\n**측정하는 변수를 구체적으로 명확히 기술하며, 관찰항목 및 임상검사항목, 관**\n| 2. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 398,
        "window_size": 3,
        "char_count": 131,
        "word_count": 29,
        "page_number": 9,
        "window_text": "최근에는 심혈관 질환의 치료 및 예방에 | - 임상시험용 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’의 안전성과 유효성을 | 1) Aspirin test: 혈관질환의 위험군, 혈관질환 병력 등으로 aspirin 복용 예정인 | 임상시험에 들어가기 전에 피험자의 인구학적 조사 및 병력 등에 대하여 면담, | 2) ADP test:　정상인 및 혈소판기능저하가 있는 환자의 검체에 대해 시험기기 | - 시험 책임자 및 임상시험 관련자가 개인 식별 표기를 가린 후 검사자에게 검체를 | 보존된 검체 및 조사된 자료는 폐기하도록 요청하실 수 있으며 이 경우 이미 | 3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.  | 시험자는 본 임상시험 계획서에 서명함으로써, 국내의 법규와 윤리적 측면에서 |\n| - 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의 일반적인 사항, | 근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서 | 제공하여 원칙과 절차를 수립하여 제시함.  피해자 보상에 대한 규약에는 보상 | 어 임상시험에 참여하는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄 | 기준을 제시함.  그밖에 임상시험결과의 사용 범위에 따른 성능평가를 위하여 | 시 의료기기 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에 의거, 정한 |\n**측정하는 변수를 구체적으로 명확히 기술하며, 관찰항목 및 임상검사항목, 관**\n| 2.  인체 유래물이란?  | 함께 관리함.  임상시험용 의료기기를 관리하는 관리자의 성명, 소속 기관명 및 |\n| 12.1 예측되는 부작용 | 개시에서 완료까지 중지 될 수 있는 세부사항을 “중지 기준”에 제시함. ",
        "original_sentence": "그밖에 임상시험결과의 사용 범위에 따른 성능평가를 위하여 | 시 의료기기 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에 의거, 정한 |\n**측정하는 변수를 구체적으로 명확히 기술하며, 관찰항목 및 임상검사항목, 관**\n| 2. "
      }
    },
    {
      "chunk_id": "chunk_400",
      "text": "인체 유래물이란? ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 399,
        "window_size": 3,
        "char_count": 10,
        "word_count": 2,
        "page_number": 85,
        "window_text": "| 시험자는 본 임상시험 계획서에 서명함으로써, 국내의 법규와 윤리적 측면에서 |\n| - 임상시험의 배경은 임상시험을 실시하게 된 동기로서 제품의 일반적인 사항, | 근거한 윤리적 원칙과 이 기준을 준수하여야 하며 피험자에게 주어지는 동의서 | 제공하여 원칙과 절차를 수립하여 제시함.  피해자 보상에 대한 규약에는 보상 | 어 임상시험에 참여하는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄 | 기준을 제시함.  그밖에 임상시험결과의 사용 범위에 따른 성능평가를 위하여 | 시 의료기기 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에 의거, 정한 |\n**측정하는 변수를 구체적으로 명확히 기술하며, 관찰항목 및 임상검사항목, 관**\n| 2.  인체 유래물이란?  | 함께 관리함.  임상시험용 의료기기를 관리하는 관리자의 성명, 소속 기관명 및 |\n| 12.1 예측되는 부작용 | 개시에서 완료까지 중지 될 수 있는 세부사항을 “중지 기준”에 제시함.  “중지 | 가속노화시험 개시 시점과 설정된 마지막 시점에 측정을 실시한다. ",
        "original_sentence": "인체 유래물이란? "
      }
    },
    {
      "chunk_id": "chunk_401",
      "text": "| 함께 관리함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 400,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 1,
        "window_text": "피해자 보상에 대한 규약에는 보상 | 어 임상시험에 참여하는 사람을 말하며, 시험디자인에 적합한 구체적이고 엄 | 기준을 제시함.  그밖에 임상시험결과의 사용 범위에 따른 성능평가를 위하여 | 시 의료기기 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에 의거, 정한 |\n**측정하는 변수를 구체적으로 명확히 기술하며, 관찰항목 및 임상검사항목, 관**\n| 2.  인체 유래물이란?  | 함께 관리함.  임상시험용 의료기기를 관리하는 관리자의 성명, 소속 기관명 및 |\n| 12.1 예측되는 부작용 | 개시에서 완료까지 중지 될 수 있는 세부사항을 “중지 기준”에 제시함.  “중지 | 가속노화시험 개시 시점과 설정된 마지막 시점에 측정을 실시한다.  | 검체 당 5∼10회 이상 반복 측정한다. ",
        "original_sentence": "| 함께 관리함. "
      }
    },
    {
      "chunk_id": "chunk_402",
      "text": "임상시험용 의료기기를 관리하는 관리자의 성명, 소속 기관명 및 |\n| 12.1 예측되는 부작용 | 개시에서 완료까지 중지 될 수 있는 세부사항을 “중지 기준”에 제시함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 401,
        "window_size": 3,
        "char_count": 95,
        "word_count": 24,
        "page_number": 6,
        "window_text": "그밖에 임상시험결과의 사용 범위에 따른 성능평가를 위하여 | 시 의료기기 임상시험 관리기준(의료기기법 시행규칙 [별표 3])에 의거, 정한 |\n**측정하는 변수를 구체적으로 명확히 기술하며, 관찰항목 및 임상검사항목, 관**\n| 2.  인체 유래물이란?  | 함께 관리함.  임상시험용 의료기기를 관리하는 관리자의 성명, 소속 기관명 및 |\n| 12.1 예측되는 부작용 | 개시에서 완료까지 중지 될 수 있는 세부사항을 “중지 기준”에 제시함.  “중지 | 가속노화시험 개시 시점과 설정된 마지막 시점에 측정을 실시한다.  | 검체 당 5∼10회 이상 반복 측정한다.  정상 검체의 이동거리와 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 | 정하고 낮은값 부터 3일 동안 검체 당 최소 60회 이상 반복 |\n| 19.4. ",
        "original_sentence": "임상시험용 의료기기를 관리하는 관리자의 성명, 소속 기관명 및 |\n| 12.1 예측되는 부작용 | 개시에서 완료까지 중지 될 수 있는 세부사항을 “중지 기준”에 제시함. "
      }
    },
    {
      "chunk_id": "chunk_403",
      "text": "“중지 | 가속노화시험 개시 시점과 설정된 마지막 시점에 측정을 실시한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 402,
        "window_size": 3,
        "char_count": 42,
        "word_count": 10,
        "page_number": 7,
        "window_text": "인체 유래물이란?  | 함께 관리함.  임상시험용 의료기기를 관리하는 관리자의 성명, 소속 기관명 및 |\n| 12.1 예측되는 부작용 | 개시에서 완료까지 중지 될 수 있는 세부사항을 “중지 기준”에 제시함.  “중지 | 가속노화시험 개시 시점과 설정된 마지막 시점에 측정을 실시한다.  | 검체 당 5∼10회 이상 반복 측정한다.  정상 검체의 이동거리와 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 | 정하고 낮은값 부터 3일 동안 검체 당 최소 60회 이상 반복 |\n| 19.4.  의뢰자 | 단계별 조작 순서, 병용 요법 등을 기술함. ",
        "original_sentence": "“중지 | 가속노화시험 개시 시점과 설정된 마지막 시점에 측정을 실시한다. "
      }
    },
    {
      "chunk_id": "chunk_404",
      "text": "| 검체 당 5∼10회 이상 반복 측정한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 403,
        "window_size": 3,
        "char_count": 25,
        "word_count": 7,
        "page_number": 6,
        "window_text": "| 함께 관리함.  임상시험용 의료기기를 관리하는 관리자의 성명, 소속 기관명 및 |\n| 12.1 예측되는 부작용 | 개시에서 완료까지 중지 될 수 있는 세부사항을 “중지 기준”에 제시함.  “중지 | 가속노화시험 개시 시점과 설정된 마지막 시점에 측정을 실시한다.  | 검체 당 5∼10회 이상 반복 측정한다.  정상 검체의 이동거리와 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 | 정하고 낮은값 부터 3일 동안 검체 당 최소 60회 이상 반복 |\n| 19.4.  의뢰자 | 단계별 조작 순서, 병용 요법 등을 기술함.  임상 시험을 위한 피험자 동의 및 준비, | 혈소판 기능부전 검출 및 aspirin, P2Y12 수용체 저해제를 복용하는 환자에서 | ② ISO 23640 In vitro diagnostic medical devices – Evaluation of | 것이지만 증상이 지속될 경우 관련 진료 후 필요한 치료를 받으실 수 있습니다. ",
        "original_sentence": "| 검체 당 5∼10회 이상 반복 측정한다. "
      }
    },
    {
      "chunk_id": "chunk_405",
      "text": "정상 검체의 이동거리와 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 | 정하고 낮은값 부터 3일 동안 검체 당 최소 60회 이상 반복 |\n| 19.4. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 404,
        "window_size": 3,
        "char_count": 98,
        "word_count": 27,
        "page_number": 6,
        "window_text": "임상시험용 의료기기를 관리하는 관리자의 성명, 소속 기관명 및 |\n| 12.1 예측되는 부작용 | 개시에서 완료까지 중지 될 수 있는 세부사항을 “중지 기준”에 제시함.  “중지 | 가속노화시험 개시 시점과 설정된 마지막 시점에 측정을 실시한다.  | 검체 당 5∼10회 이상 반복 측정한다.  정상 검체의 이동거리와 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 | 정하고 낮은값 부터 3일 동안 검체 당 최소 60회 이상 반복 |\n| 19.4.  의뢰자 | 단계별 조작 순서, 병용 요법 등을 기술함.  임상 시험을 위한 피험자 동의 및 준비, | 혈소판 기능부전 검출 및 aspirin, P2Y12 수용체 저해제를 복용하는 환자에서 | ② ISO 23640 In vitro diagnostic medical devices – Evaluation of | 것이지만 증상이 지속될 경우 관련 진료 후 필요한 치료를 받으실 수 있습니다.  | 연구에 사용된 정보와 자원을 제외하고 모든 잔여 검체 및 자료는 적법한 절차에 | 상세히 설명한다. ",
        "original_sentence": "정상 검체의 이동거리와 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 | 정하고 낮은값 부터 3일 동안 검체 당 최소 60회 이상 반복 |\n| 19.4. "
      }
    },
    {
      "chunk_id": "chunk_406",
      "text": "의뢰자 | 단계별 조작 순서, 병용 요법 등을 기술함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 405,
        "window_size": 3,
        "char_count": 31,
        "word_count": 9,
        "page_number": 7,
        "window_text": "“중지 | 가속노화시험 개시 시점과 설정된 마지막 시점에 측정을 실시한다.  | 검체 당 5∼10회 이상 반복 측정한다.  정상 검체의 이동거리와 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 | 정하고 낮은값 부터 3일 동안 검체 당 최소 60회 이상 반복 |\n| 19.4.  의뢰자 | 단계별 조작 순서, 병용 요법 등을 기술함.  임상 시험을 위한 피험자 동의 및 준비, | 혈소판 기능부전 검출 및 aspirin, P2Y12 수용체 저해제를 복용하는 환자에서 | ② ISO 23640 In vitro diagnostic medical devices – Evaluation of | 것이지만 증상이 지속될 경우 관련 진료 후 필요한 치료를 받으실 수 있습니다.  | 연구에 사용된 정보와 자원을 제외하고 모든 잔여 검체 및 자료는 적법한 절차에 | 상세히 설명한다.  서명일 및 서명일자를 정확히 기재하여야 하며 작성된 서명 | Clopidorel 복용 전후에 대한 시험시약의 민감도 및 특이도를 산출한다. ",
        "original_sentence": "의뢰자 | 단계별 조작 순서, 병용 요법 등을 기술함. "
      }
    },
    {
      "chunk_id": "chunk_407",
      "text": "임상 시험을 위한 피험자 동의 및 준비, | 혈소판 기능부전 검출 및 aspirin, P2Y12 수용체 저해제를 복용하는 환자에서 | ② ISO 23640 In vitro diagnostic medical devices – Evaluation of | 것이지만 증상이 지속될 경우 관련 진료 후 필요한 치료를 받으실 수 있습니다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 406,
        "window_size": 3,
        "char_count": 185,
        "word_count": 43,
        "page_number": 6,
        "window_text": "| 검체 당 5∼10회 이상 반복 측정한다.  정상 검체의 이동거리와 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 | 정하고 낮은값 부터 3일 동안 검체 당 최소 60회 이상 반복 |\n| 19.4.  의뢰자 | 단계별 조작 순서, 병용 요법 등을 기술함.  임상 시험을 위한 피험자 동의 및 준비, | 혈소판 기능부전 검출 및 aspirin, P2Y12 수용체 저해제를 복용하는 환자에서 | ② ISO 23640 In vitro diagnostic medical devices – Evaluation of | 것이지만 증상이 지속될 경우 관련 진료 후 필요한 치료를 받으실 수 있습니다.  | 연구에 사용된 정보와 자원을 제외하고 모든 잔여 검체 및 자료는 적법한 절차에 | 상세히 설명한다.  서명일 및 서명일자를 정확히 기재하여야 하며 작성된 서명 | Clopidorel 복용 전후에 대한 시험시약의 민감도 및 특이도를 산출한다.  신뢰도 | 공여자의 MD 또는 MR은 검사실의 참조 범위의 중간에 가까운 값과 허용 | 환자에서 aspirin 복용 전 1번과 최소 3일 이상의 Aspirin 복용 후 1번 측정 |\n| 19.1. ",
        "original_sentence": "임상 시험을 위한 피험자 동의 및 준비, | 혈소판 기능부전 검출 및 aspirin, P2Y12 수용체 저해제를 복용하는 환자에서 | ② ISO 23640 In vitro diagnostic medical devices – Evaluation of | 것이지만 증상이 지속될 경우 관련 진료 후 필요한 치료를 받으실 수 있습니다. "
      }
    },
    {
      "chunk_id": "chunk_408",
      "text": "| 연구에 사용된 정보와 자원을 제외하고 모든 잔여 검체 및 자료는 적법한 절차에 | 상세히 설명한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 407,
        "window_size": 3,
        "char_count": 58,
        "word_count": 16,
        "page_number": 6,
        "window_text": "정상 검체의 이동거리와 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 | 정하고 낮은값 부터 3일 동안 검체 당 최소 60회 이상 반복 |\n| 19.4.  의뢰자 | 단계별 조작 순서, 병용 요법 등을 기술함.  임상 시험을 위한 피험자 동의 및 준비, | 혈소판 기능부전 검출 및 aspirin, P2Y12 수용체 저해제를 복용하는 환자에서 | ② ISO 23640 In vitro diagnostic medical devices – Evaluation of | 것이지만 증상이 지속될 경우 관련 진료 후 필요한 치료를 받으실 수 있습니다.  | 연구에 사용된 정보와 자원을 제외하고 모든 잔여 검체 및 자료는 적법한 절차에 | 상세히 설명한다.  서명일 및 서명일자를 정확히 기재하여야 하며 작성된 서명 | Clopidorel 복용 전후에 대한 시험시약의 민감도 및 특이도를 산출한다.  신뢰도 | 공여자의 MD 또는 MR은 검사실의 참조 범위의 중간에 가까운 값과 허용 | 환자에서 aspirin 복용 전 1번과 최소 3일 이상의 Aspirin 복용 후 1번 측정 |\n| 19.1.  임상시험 실시기관 | 서식, 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 함. ",
        "original_sentence": "| 연구에 사용된 정보와 자원을 제외하고 모든 잔여 검체 및 자료는 적법한 절차에 | 상세히 설명한다. "
      }
    },
    {
      "chunk_id": "chunk_409",
      "text": "서명일 및 서명일자를 정확히 기재하여야 하며 작성된 서명 | Clopidorel 복용 전후에 대한 시험시약의 민감도 및 특이도를 산출한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 408,
        "window_size": 3,
        "char_count": 78,
        "word_count": 18,
        "page_number": 44,
        "window_text": "의뢰자 | 단계별 조작 순서, 병용 요법 등을 기술함.  임상 시험을 위한 피험자 동의 및 준비, | 혈소판 기능부전 검출 및 aspirin, P2Y12 수용체 저해제를 복용하는 환자에서 | ② ISO 23640 In vitro diagnostic medical devices – Evaluation of | 것이지만 증상이 지속될 경우 관련 진료 후 필요한 치료를 받으실 수 있습니다.  | 연구에 사용된 정보와 자원을 제외하고 모든 잔여 검체 및 자료는 적법한 절차에 | 상세히 설명한다.  서명일 및 서명일자를 정확히 기재하여야 하며 작성된 서명 | Clopidorel 복용 전후에 대한 시험시약의 민감도 및 특이도를 산출한다.  신뢰도 | 공여자의 MD 또는 MR은 검사실의 참조 범위의 중간에 가까운 값과 허용 | 환자에서 aspirin 복용 전 1번과 최소 3일 이상의 Aspirin 복용 후 1번 측정 |\n| 19.1.  임상시험 실시기관 | 서식, 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 함.  | ② 침습적 방식의 출혈시간(Bleeding time, BT)검사는 개인별 차이가 | 격한 피험자의 선정기준과 제외기준을 제시하여야 함. ",
        "original_sentence": "서명일 및 서명일자를 정확히 기재하여야 하며 작성된 서명 | Clopidorel 복용 전후에 대한 시험시약의 민감도 및 특이도를 산출한다. "
      }
    },
    {
      "chunk_id": "chunk_410",
      "text": "신뢰도 | 공여자의 MD 또는 MR은 검사실의 참조 범위의 중간에 가까운 값과 허용 | 환자에서 aspirin 복용 전 1번과 최소 3일 이상의 Aspirin 복용 후 1번 측정 |\n| 19.1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 409,
        "window_size": 3,
        "char_count": 110,
        "word_count": 30,
        "page_number": 24,
        "window_text": "임상 시험을 위한 피험자 동의 및 준비, | 혈소판 기능부전 검출 및 aspirin, P2Y12 수용체 저해제를 복용하는 환자에서 | ② ISO 23640 In vitro diagnostic medical devices – Evaluation of | 것이지만 증상이 지속될 경우 관련 진료 후 필요한 치료를 받으실 수 있습니다.  | 연구에 사용된 정보와 자원을 제외하고 모든 잔여 검체 및 자료는 적법한 절차에 | 상세히 설명한다.  서명일 및 서명일자를 정확히 기재하여야 하며 작성된 서명 | Clopidorel 복용 전후에 대한 시험시약의 민감도 및 특이도를 산출한다.  신뢰도 | 공여자의 MD 또는 MR은 검사실의 참조 범위의 중간에 가까운 값과 허용 | 환자에서 aspirin 복용 전 1번과 최소 3일 이상의 Aspirin 복용 후 1번 측정 |\n| 19.1.  임상시험 실시기관 | 서식, 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 함.  | ② 침습적 방식의 출혈시간(Bleeding time, BT)검사는 개인별 차이가 | 격한 피험자의 선정기준과 제외기준을 제시하여야 함.  이때 임상시험 참여와 | 이차 유효성 평가변수를 제시하여 각 임상검사항목 및 검사방법에 대한 기준을 제시함. ",
        "original_sentence": "신뢰도 | 공여자의 MD 또는 MR은 검사실의 참조 범위의 중간에 가까운 값과 허용 | 환자에서 aspirin 복용 전 1번과 최소 3일 이상의 Aspirin 복용 후 1번 측정 |\n| 19.1. "
      }
    },
    {
      "chunk_id": "chunk_411",
      "text": "임상시험 실시기관 | 서식, 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 410,
        "window_size": 3,
        "char_count": 58,
        "word_count": 15,
        "page_number": 9,
        "window_text": "| 연구에 사용된 정보와 자원을 제외하고 모든 잔여 검체 및 자료는 적법한 절차에 | 상세히 설명한다.  서명일 및 서명일자를 정확히 기재하여야 하며 작성된 서명 | Clopidorel 복용 전후에 대한 시험시약의 민감도 및 특이도를 산출한다.  신뢰도 | 공여자의 MD 또는 MR은 검사실의 참조 범위의 중간에 가까운 값과 허용 | 환자에서 aspirin 복용 전 1번과 최소 3일 이상의 Aspirin 복용 후 1번 측정 |\n| 19.1.  임상시험 실시기관 | 서식, 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 함.  | ② 침습적 방식의 출혈시간(Bleeding time, BT)검사는 개인별 차이가 | 격한 피험자의 선정기준과 제외기준을 제시하여야 함.  이때 임상시험 참여와 | 이차 유효성 평가변수를 제시하여 각 임상검사항목 및 검사방법에 대한 기준을 제시함.  | 기간 내에 가능한 신속한 보고가 되어야하며, 이상사례 등에 대한 의학적 | 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 또는 디자인 |\n| 찰검사방법(선정검체 피험자 식별코드부여, 임상평가, 이상반응조사, 관찰항목 | 원칙과 보상이 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함함. ",
        "original_sentence": "임상시험 실시기관 | 서식, 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 함. "
      }
    },
    {
      "chunk_id": "chunk_412",
      "text": "| ② 침습적 방식의 출혈시간(Bleeding time, BT)검사는 개인별 차이가 | 격한 피험자의 선정기준과 제외기준을 제시하여야 함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 411,
        "window_size": 3,
        "char_count": 78,
        "word_count": 16,
        "page_number": 6,
        "window_text": "서명일 및 서명일자를 정확히 기재하여야 하며 작성된 서명 | Clopidorel 복용 전후에 대한 시험시약의 민감도 및 특이도를 산출한다.  신뢰도 | 공여자의 MD 또는 MR은 검사실의 참조 범위의 중간에 가까운 값과 허용 | 환자에서 aspirin 복용 전 1번과 최소 3일 이상의 Aspirin 복용 후 1번 측정 |\n| 19.1.  임상시험 실시기관 | 서식, 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 함.  | ② 침습적 방식의 출혈시간(Bleeding time, BT)검사는 개인별 차이가 | 격한 피험자의 선정기준과 제외기준을 제시하여야 함.  이때 임상시험 참여와 | 이차 유효성 평가변수를 제시하여 각 임상검사항목 및 검사방법에 대한 기준을 제시함.  | 기간 내에 가능한 신속한 보고가 되어야하며, 이상사례 등에 대한 의학적 | 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 또는 디자인 |\n| 찰검사방법(선정검체 피험자 식별코드부여, 임상평가, 이상반응조사, 관찰항목 | 원칙과 보상이 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함함.  | 5) 자료를 기록할 수 없는 경우 “실시하지 않음(ND: not done)”또는 “알 수 없음(UK: | (가) 전자파내성 : IEC 61326에 기술된 전자파 내성시험에 관한 요구 |\n| 예시) | - “인체 유래물”이란 인체로부터 수집하거나 채취한 조직, 세포, 혈액, 체액 등이나 | - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를 |\n| 1) 혈액검체 채취를 위한 채혈 과정에서 통증, 신경손상, 어지럼증, 메스꺼움, 구토, | 처리”에는 각 중지 기준에 대한 유효성 평가 통계처리 시 그 산입 여부와 |\n| 예시) | (1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로 통상의료기기 | 치료 및 수술 절차, 관찰 및 평가 절차 등을 상세히 시험방법을 기술함 | 경향의 증가나 약제 내성에 대한 검사를 위해서도 많이 이용되고 있다. ",
        "original_sentence": "| ② 침습적 방식의 출혈시간(Bleeding time, BT)검사는 개인별 차이가 | 격한 피험자의 선정기준과 제외기준을 제시하여야 함. "
      }
    },
    {
      "chunk_id": "chunk_413",
      "text": "이때 임상시험 참여와 | 이차 유효성 평가변수를 제시하여 각 임상검사항목 및 검사방법에 대한 기준을 제시함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 412,
        "window_size": 3,
        "char_count": 61,
        "word_count": 15,
        "page_number": 3,
        "window_text": "신뢰도 | 공여자의 MD 또는 MR은 검사실의 참조 범위의 중간에 가까운 값과 허용 | 환자에서 aspirin 복용 전 1번과 최소 3일 이상의 Aspirin 복용 후 1번 측정 |\n| 19.1.  임상시험 실시기관 | 서식, 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 함.  | ② 침습적 방식의 출혈시간(Bleeding time, BT)검사는 개인별 차이가 | 격한 피험자의 선정기준과 제외기준을 제시하여야 함.  이때 임상시험 참여와 | 이차 유효성 평가변수를 제시하여 각 임상검사항목 및 검사방법에 대한 기준을 제시함.  | 기간 내에 가능한 신속한 보고가 되어야하며, 이상사례 등에 대한 의학적 | 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 또는 디자인 |\n| 찰검사방법(선정검체 피험자 식별코드부여, 임상평가, 이상반응조사, 관찰항목 | 원칙과 보상이 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함함.  | 5) 자료를 기록할 수 없는 경우 “실시하지 않음(ND: not done)”또는 “알 수 없음(UK: | (가) 전자파내성 : IEC 61326에 기술된 전자파 내성시험에 관한 요구 |\n| 예시) | - “인체 유래물”이란 인체로부터 수집하거나 채취한 조직, 세포, 혈액, 체액 등이나 | - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를 |\n| 1) 혈액검체 채취를 위한 채혈 과정에서 통증, 신경손상, 어지럼증, 메스꺼움, 구토, | 처리”에는 각 중지 기준에 대한 유효성 평가 통계처리 시 그 산입 여부와 |\n| 예시) | (1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로 통상의료기기 | 치료 및 수술 절차, 관찰 및 평가 절차 등을 상세히 시험방법을 기술함 | 경향의 증가나 약제 내성에 대한 검사를 위해서도 많이 이용되고 있다.  | 측정된 각 시점의 샘플의 이동거리값의 평균 및 표준편차를 계산 한다. ",
        "original_sentence": "이때 임상시험 참여와 | 이차 유효성 평가변수를 제시하여 각 임상검사항목 및 검사방법에 대한 기준을 제시함. "
      }
    },
    {
      "chunk_id": "chunk_414",
      "text": "| 기간 내에 가능한 신속한 보고가 되어야하며, 이상사례 등에 대한 의학적 | 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 또는 디자인 |\n| 찰검사방법(선정검체 피험자 식별코드부여, 임상평가, 이상반응조사, 관찰항목 | 원칙과 보상이 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 413,
        "window_size": 3,
        "char_count": 177,
        "word_count": 42,
        "page_number": 80,
        "window_text": "임상시험 실시기관 | 서식, 피험자 설명서 및 그 밖의 문서화된 정보는 심사위원회의 승인을 받아야 함.  | ② 침습적 방식의 출혈시간(Bleeding time, BT)검사는 개인별 차이가 | 격한 피험자의 선정기준과 제외기준을 제시하여야 함.  이때 임상시험 참여와 | 이차 유효성 평가변수를 제시하여 각 임상검사항목 및 검사방법에 대한 기준을 제시함.  | 기간 내에 가능한 신속한 보고가 되어야하며, 이상사례 등에 대한 의학적 | 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 또는 디자인 |\n| 찰검사방법(선정검체 피험자 식별코드부여, 임상평가, 이상반응조사, 관찰항목 | 원칙과 보상이 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함함.  | 5) 자료를 기록할 수 없는 경우 “실시하지 않음(ND: not done)”또는 “알 수 없음(UK: | (가) 전자파내성 : IEC 61326에 기술된 전자파 내성시험에 관한 요구 |\n| 예시) | - “인체 유래물”이란 인체로부터 수집하거나 채취한 조직, 세포, 혈액, 체액 등이나 | - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를 |\n| 1) 혈액검체 채취를 위한 채혈 과정에서 통증, 신경손상, 어지럼증, 메스꺼움, 구토, | 처리”에는 각 중지 기준에 대한 유효성 평가 통계처리 시 그 산입 여부와 |\n| 예시) | (1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로 통상의료기기 | 치료 및 수술 절차, 관찰 및 평가 절차 등을 상세히 시험방법을 기술함 | 경향의 증가나 약제 내성에 대한 검사를 위해서도 많이 이용되고 있다.  | 측정된 각 시점의 샘플의 이동거리값의 평균 및 표준편차를 계산 한다.  | (3) 시험 목적 : 결과에 영향을 주는 간섭물질을 확인하기 위한 시험 | 출혈시간 및 항혈소판제제 저항성 복합검사기기에 대한 보정과 정도 | ① 검사칩을 임상시험용 장비의 Tray에 놓고, 끝까지 밀어 넣는다. ",
        "original_sentence": "| 기간 내에 가능한 신속한 보고가 되어야하며, 이상사례 등에 대한 의학적 | 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 또는 디자인 |\n| 찰검사방법(선정검체 피험자 식별코드부여, 임상평가, 이상반응조사, 관찰항목 | 원칙과 보상이 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함함. "
      }
    },
    {
      "chunk_id": "chunk_415",
      "text": "| 5) 자료를 기록할 수 없는 경우 “실시하지 않음(ND: not done)”또는 “알 수 없음(UK: | (가) 전자파내성 : IEC 61326에 기술된 전자파 내성시험에 관한 요구 |\n| 예시) | - “인체 유래물”이란 인체로부터 수집하거나 채취한 조직, 세포, 혈액, 체액 등이나 | - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를 |\n| 1) 혈액검체 채취를 위한 채혈 과정에서 통증, 신경손상, 어지럼증, 메스꺼움, 구토, | 처리”에는 각 중지 기준에 대한 유효성 평가 통계처리 시 그 산입 여부와 |\n| 예시) | (1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로 통상의료기기 | 치료 및 수술 절차, 관찰 및 평가 절차 등을 상세히 시험방법을 기술함 | 경향의 증가나 약제 내성에 대한 검사를 위해서도 많이 이용되고 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 414,
        "window_size": 3,
        "char_count": 442,
        "word_count": 117,
        "page_number": 6,
        "window_text": "| ② 침습적 방식의 출혈시간(Bleeding time, BT)검사는 개인별 차이가 | 격한 피험자의 선정기준과 제외기준을 제시하여야 함.  이때 임상시험 참여와 | 이차 유효성 평가변수를 제시하여 각 임상검사항목 및 검사방법에 대한 기준을 제시함.  | 기간 내에 가능한 신속한 보고가 되어야하며, 이상사례 등에 대한 의학적 | 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 또는 디자인 |\n| 찰검사방법(선정검체 피험자 식별코드부여, 임상평가, 이상반응조사, 관찰항목 | 원칙과 보상이 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함함.  | 5) 자료를 기록할 수 없는 경우 “실시하지 않음(ND: not done)”또는 “알 수 없음(UK: | (가) 전자파내성 : IEC 61326에 기술된 전자파 내성시험에 관한 요구 |\n| 예시) | - “인체 유래물”이란 인체로부터 수집하거나 채취한 조직, 세포, 혈액, 체액 등이나 | - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를 |\n| 1) 혈액검체 채취를 위한 채혈 과정에서 통증, 신경손상, 어지럼증, 메스꺼움, 구토, | 처리”에는 각 중지 기준에 대한 유효성 평가 통계처리 시 그 산입 여부와 |\n| 예시) | (1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로 통상의료기기 | 치료 및 수술 절차, 관찰 및 평가 절차 등을 상세히 시험방법을 기술함 | 경향의 증가나 약제 내성에 대한 검사를 위해서도 많이 이용되고 있다.  | 측정된 각 시점의 샘플의 이동거리값의 평균 및 표준편차를 계산 한다.  | (3) 시험 목적 : 결과에 영향을 주는 간섭물질을 확인하기 위한 시험 | 출혈시간 및 항혈소판제제 저항성 복합검사기기에 대한 보정과 정도 | ① 검사칩을 임상시험용 장비의 Tray에 놓고, 끝까지 밀어 넣는다.  Tray 에 심한 | 간섭물질이 포함된 검체와 포함되지 않은 검체를 3회 이상 반복 측정한 | ① 정상 대조군: 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군 |\n| 예시) | 예시) | 민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d) | Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | (1) 임상시험실시기관의 장은 해당 임상시험의 실시에 필요한 임상시험실, 설비와 | 가. ",
        "original_sentence": "| 5) 자료를 기록할 수 없는 경우 “실시하지 않음(ND: not done)”또는 “알 수 없음(UK: | (가) 전자파내성 : IEC 61326에 기술된 전자파 내성시험에 관한 요구 |\n| 예시) | - “인체 유래물”이란 인체로부터 수집하거나 채취한 조직, 세포, 혈액, 체액 등이나 | - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를 |\n| 1) 혈액검체 채취를 위한 채혈 과정에서 통증, 신경손상, 어지럼증, 메스꺼움, 구토, | 처리”에는 각 중지 기준에 대한 유효성 평가 통계처리 시 그 산입 여부와 |\n| 예시) | (1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로 통상의료기기 | 치료 및 수술 절차, 관찰 및 평가 절차 등을 상세히 시험방법을 기술함 | 경향의 증가나 약제 내성에 대한 검사를 위해서도 많이 이용되고 있다. "
      }
    },
    {
      "chunk_id": "chunk_416",
      "text": "| 측정된 각 시점의 샘플의 이동거리값의 평균 및 표준편차를 계산 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 415,
        "window_size": 3,
        "char_count": 41,
        "word_count": 11,
        "page_number": 6,
        "window_text": "이때 임상시험 참여와 | 이차 유효성 평가변수를 제시하여 각 임상검사항목 및 검사방법에 대한 기준을 제시함.  | 기간 내에 가능한 신속한 보고가 되어야하며, 이상사례 등에 대한 의학적 | 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 또는 디자인 |\n| 찰검사방법(선정검체 피험자 식별코드부여, 임상평가, 이상반응조사, 관찰항목 | 원칙과 보상이 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함함.  | 5) 자료를 기록할 수 없는 경우 “실시하지 않음(ND: not done)”또는 “알 수 없음(UK: | (가) 전자파내성 : IEC 61326에 기술된 전자파 내성시험에 관한 요구 |\n| 예시) | - “인체 유래물”이란 인체로부터 수집하거나 채취한 조직, 세포, 혈액, 체액 등이나 | - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를 |\n| 1) 혈액검체 채취를 위한 채혈 과정에서 통증, 신경손상, 어지럼증, 메스꺼움, 구토, | 처리”에는 각 중지 기준에 대한 유효성 평가 통계처리 시 그 산입 여부와 |\n| 예시) | (1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로 통상의료기기 | 치료 및 수술 절차, 관찰 및 평가 절차 등을 상세히 시험방법을 기술함 | 경향의 증가나 약제 내성에 대한 검사를 위해서도 많이 이용되고 있다.  | 측정된 각 시점의 샘플의 이동거리값의 평균 및 표준편차를 계산 한다.  | (3) 시험 목적 : 결과에 영향을 주는 간섭물질을 확인하기 위한 시험 | 출혈시간 및 항혈소판제제 저항성 복합검사기기에 대한 보정과 정도 | ① 검사칩을 임상시험용 장비의 Tray에 놓고, 끝까지 밀어 넣는다.  Tray 에 심한 | 간섭물질이 포함된 검체와 포함되지 않은 검체를 3회 이상 반복 측정한 | ① 정상 대조군: 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군 |\n| 예시) | 예시) | 민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d) | Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | (1) 임상시험실시기관의 장은 해당 임상시험의 실시에 필요한 임상시험실, 설비와 | 가.  임상시험용 의료기기의 사용 및 관리 | - 성능평가방법: 임상시험 기간 동안 일차/이차/ 유효성 평가변수에 대한 | 소견·정도와 임상시험용 의료기기와의 인과관계를 평가하여 증례기록서에 | 특성, 원자재 및 화학적 구성요소, 성능, 새로운 제조방법 등에 대한 특이성을 |\n| Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | 별 평가도구, 평가방법 등) 및 결과판정 방법을 해당 임상시험방법의 진행순서 | 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행 | 이 규약에는 피험자 보상사유, 보상요건, 보상 제외사유, 보상기준, 보상절차, | (5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이 (및 표준편차): 피험자 수는 | 연관된 이익을 기대하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될 |\n**또는 이들로부터 분리된 혈장, 혈청, 핵산, 단백질 등을 말합니다. ",
        "original_sentence": "| 측정된 각 시점의 샘플의 이동거리값의 평균 및 표준편차를 계산 한다. "
      }
    },
    {
      "chunk_id": "chunk_417",
      "text": "| (3) 시험 목적 : 결과에 영향을 주는 간섭물질을 확인하기 위한 시험 | 출혈시간 및 항혈소판제제 저항성 복합검사기기에 대한 보정과 정도 | ① 검사칩을 임상시험용 장비의 Tray에 놓고, 끝까지 밀어 넣는다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 416,
        "window_size": 3,
        "char_count": 121,
        "word_count": 31,
        "page_number": 6,
        "window_text": "| 기간 내에 가능한 신속한 보고가 되어야하며, 이상사례 등에 대한 의학적 | 해당 제품의 개발경위 및 임상시험용 의료기기의 작동원리, 설계 또는 디자인 |\n| 찰검사방법(선정검체 피험자 식별코드부여, 임상평가, 이상반응조사, 관찰항목 | 원칙과 보상이 되지 않는 경우에 대한 원칙, 보상수준에 대한 기준을 포함함.  | 5) 자료를 기록할 수 없는 경우 “실시하지 않음(ND: not done)”또는 “알 수 없음(UK: | (가) 전자파내성 : IEC 61326에 기술된 전자파 내성시험에 관한 요구 |\n| 예시) | - “인체 유래물”이란 인체로부터 수집하거나 채취한 조직, 세포, 혈액, 체액 등이나 | - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를 |\n| 1) 혈액검체 채취를 위한 채혈 과정에서 통증, 신경손상, 어지럼증, 메스꺼움, 구토, | 처리”에는 각 중지 기준에 대한 유효성 평가 통계처리 시 그 산입 여부와 |\n| 예시) | (1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로 통상의료기기 | 치료 및 수술 절차, 관찰 및 평가 절차 등을 상세히 시험방법을 기술함 | 경향의 증가나 약제 내성에 대한 검사를 위해서도 많이 이용되고 있다.  | 측정된 각 시점의 샘플의 이동거리값의 평균 및 표준편차를 계산 한다.  | (3) 시험 목적 : 결과에 영향을 주는 간섭물질을 확인하기 위한 시험 | 출혈시간 및 항혈소판제제 저항성 복합검사기기에 대한 보정과 정도 | ① 검사칩을 임상시험용 장비의 Tray에 놓고, 끝까지 밀어 넣는다.  Tray 에 심한 | 간섭물질이 포함된 검체와 포함되지 않은 검체를 3회 이상 반복 측정한 | ① 정상 대조군: 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군 |\n| 예시) | 예시) | 민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d) | Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | (1) 임상시험실시기관의 장은 해당 임상시험의 실시에 필요한 임상시험실, 설비와 | 가.  임상시험용 의료기기의 사용 및 관리 | - 성능평가방법: 임상시험 기간 동안 일차/이차/ 유효성 평가변수에 대한 | 소견·정도와 임상시험용 의료기기와의 인과관계를 평가하여 증례기록서에 | 특성, 원자재 및 화학적 구성요소, 성능, 새로운 제조방법 등에 대한 특이성을 |\n| Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | 별 평가도구, 평가방법 등) 및 결과판정 방법을 해당 임상시험방법의 진행순서 | 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행 | 이 규약에는 피험자 보상사유, 보상요건, 보상 제외사유, 보상기준, 보상절차, | (5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이 (및 표준편차): 피험자 수는 | 연관된 이익을 기대하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될 |\n**또는 이들로부터 분리된 혈장, 혈청, 핵산, 단백질 등을 말합니다.  본 동의서에서는**\n| 부터 6개월 | 피험자별 중지사유를 포함한 관련 임상시험자료의 처리방법을 제시함. ",
        "original_sentence": "| (3) 시험 목적 : 결과에 영향을 주는 간섭물질을 확인하기 위한 시험 | 출혈시간 및 항혈소판제제 저항성 복합검사기기에 대한 보정과 정도 | ① 검사칩을 임상시험용 장비의 Tray에 놓고, 끝까지 밀어 넣는다. "
      }
    },
    {
      "chunk_id": "chunk_418",
      "text": "Tray 에 심한 | 간섭물질이 포함된 검체와 포함되지 않은 검체를 3회 이상 반복 측정한 | ① 정상 대조군: 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군 |\n| 예시) | 예시) | 민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d) | Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | (1) 임상시험실시기관의 장은 해당 임상시험의 실시에 필요한 임상시험실, 설비와 | 가. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 417,
        "window_size": 3,
        "char_count": 250,
        "word_count": 55,
        "page_number": 15,
        "window_text": "| 5) 자료를 기록할 수 없는 경우 “실시하지 않음(ND: not done)”또는 “알 수 없음(UK: | (가) 전자파내성 : IEC 61326에 기술된 전자파 내성시험에 관한 요구 |\n| 예시) | - “인체 유래물”이란 인체로부터 수집하거나 채취한 조직, 세포, 혈액, 체액 등이나 | - 시험담당자는 시험책임자의 위임 및 감독 하에 임상시험과 관련된 업무를 |\n| 1) 혈액검체 채취를 위한 채혈 과정에서 통증, 신경손상, 어지럼증, 메스꺼움, 구토, | 처리”에는 각 중지 기준에 대한 유효성 평가 통계처리 시 그 산입 여부와 |\n| 예시) | (1) 임상연구의 계획, 관리, 재정 등에 관련된 책임을 갖고 있는 자로 통상의료기기 | 치료 및 수술 절차, 관찰 및 평가 절차 등을 상세히 시험방법을 기술함 | 경향의 증가나 약제 내성에 대한 검사를 위해서도 많이 이용되고 있다.  | 측정된 각 시점의 샘플의 이동거리값의 평균 및 표준편차를 계산 한다.  | (3) 시험 목적 : 결과에 영향을 주는 간섭물질을 확인하기 위한 시험 | 출혈시간 및 항혈소판제제 저항성 복합검사기기에 대한 보정과 정도 | ① 검사칩을 임상시험용 장비의 Tray에 놓고, 끝까지 밀어 넣는다.  Tray 에 심한 | 간섭물질이 포함된 검체와 포함되지 않은 검체를 3회 이상 반복 측정한 | ① 정상 대조군: 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군 |\n| 예시) | 예시) | 민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d) | Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | (1) 임상시험실시기관의 장은 해당 임상시험의 실시에 필요한 임상시험실, 설비와 | 가.  임상시험용 의료기기의 사용 및 관리 | - 성능평가방법: 임상시험 기간 동안 일차/이차/ 유효성 평가변수에 대한 | 소견·정도와 임상시험용 의료기기와의 인과관계를 평가하여 증례기록서에 | 특성, 원자재 및 화학적 구성요소, 성능, 새로운 제조방법 등에 대한 특이성을 |\n| Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | 별 평가도구, 평가방법 등) 및 결과판정 방법을 해당 임상시험방법의 진행순서 | 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행 | 이 규약에는 피험자 보상사유, 보상요건, 보상 제외사유, 보상기준, 보상절차, | (5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이 (및 표준편차): 피험자 수는 | 연관된 이익을 기대하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될 |\n**또는 이들로부터 분리된 혈장, 혈청, 핵산, 단백질 등을 말합니다.  본 동의서에서는**\n| 부터 6개월 | 피험자별 중지사유를 포함한 관련 임상시험자료의 처리방법을 제시함.  또 “탈락” | 담당하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상 |\n| 예시) | 6. ",
        "original_sentence": "Tray 에 심한 | 간섭물질이 포함된 검체와 포함되지 않은 검체를 3회 이상 반복 측정한 | ① 정상 대조군: 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군 |\n| 예시) | 예시) | 민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d) | Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | (1) 임상시험실시기관의 장은 해당 임상시험의 실시에 필요한 임상시험실, 설비와 | 가. "
      }
    },
    {
      "chunk_id": "chunk_419",
      "text": "임상시험용 의료기기의 사용 및 관리 | - 성능평가방법: 임상시험 기간 동안 일차/이차/ 유효성 평가변수에 대한 | 소견·정도와 임상시험용 의료기기와의 인과관계를 평가하여 증례기록서에 | 특성, 원자재 및 화학적 구성요소, 성능, 새로운 제조방법 등에 대한 특이성을 |\n| Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | 별 평가도구, 평가방법 등) 및 결과판정 방법을 해당 임상시험방법의 진행순서 | 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행 | 이 규약에는 피험자 보상사유, 보상요건, 보상 제외사유, 보상기준, 보상절차, | (5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이 (및 표준편차): 피험자 수는 | 연관된 이익을 기대하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될 |\n**또는 이들로부터 분리된 혈장, 혈청, 핵산, 단백질 등을 말합니다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 418,
        "window_size": 3,
        "char_count": 471,
        "word_count": 105,
        "page_number": 6,
        "window_text": "| 측정된 각 시점의 샘플의 이동거리값의 평균 및 표준편차를 계산 한다.  | (3) 시험 목적 : 결과에 영향을 주는 간섭물질을 확인하기 위한 시험 | 출혈시간 및 항혈소판제제 저항성 복합검사기기에 대한 보정과 정도 | ① 검사칩을 임상시험용 장비의 Tray에 놓고, 끝까지 밀어 넣는다.  Tray 에 심한 | 간섭물질이 포함된 검체와 포함되지 않은 검체를 3회 이상 반복 측정한 | ① 정상 대조군: 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군 |\n| 예시) | 예시) | 민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d) | Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | (1) 임상시험실시기관의 장은 해당 임상시험의 실시에 필요한 임상시험실, 설비와 | 가.  임상시험용 의료기기의 사용 및 관리 | - 성능평가방법: 임상시험 기간 동안 일차/이차/ 유효성 평가변수에 대한 | 소견·정도와 임상시험용 의료기기와의 인과관계를 평가하여 증례기록서에 | 특성, 원자재 및 화학적 구성요소, 성능, 새로운 제조방법 등에 대한 특이성을 |\n| Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | 별 평가도구, 평가방법 등) 및 결과판정 방법을 해당 임상시험방법의 진행순서 | 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행 | 이 규약에는 피험자 보상사유, 보상요건, 보상 제외사유, 보상기준, 보상절차, | (5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이 (및 표준편차): 피험자 수는 | 연관된 이익을 기대하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될 |\n**또는 이들로부터 분리된 혈장, 혈청, 핵산, 단백질 등을 말합니다.  본 동의서에서는**\n| 부터 6개월 | 피험자별 중지사유를 포함한 관련 임상시험자료의 처리방법을 제시함.  또 “탈락” | 담당하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상 |\n| 예시) | 6.  연구에 참여함으로써 기대되는 이익 | 혈소판 기능검사 방법으로는 피부에 상처를 낸 후 출혈이 멈출 때까지의 시간을 | 되는 환자 및 항혈소판제제에 대한 약물 저항을 보이는 환자를 확인할 수 있다. ",
        "original_sentence": "임상시험용 의료기기의 사용 및 관리 | - 성능평가방법: 임상시험 기간 동안 일차/이차/ 유효성 평가변수에 대한 | 소견·정도와 임상시험용 의료기기와의 인과관계를 평가하여 증례기록서에 | 특성, 원자재 및 화학적 구성요소, 성능, 새로운 제조방법 등에 대한 특이성을 |\n| Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | 별 평가도구, 평가방법 등) 및 결과판정 방법을 해당 임상시험방법의 진행순서 | 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행 | 이 규약에는 피험자 보상사유, 보상요건, 보상 제외사유, 보상기준, 보상절차, | (5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이 (및 표준편차): 피험자 수는 | 연관된 이익을 기대하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될 |\n**또는 이들로부터 분리된 혈장, 혈청, 핵산, 단백질 등을 말합니다. "
      }
    },
    {
      "chunk_id": "chunk_420",
      "text": "본 동의서에서는**\n| 부터 6개월 | 피험자별 중지사유를 포함한 관련 임상시험자료의 처리방법을 제시함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 419,
        "window_size": 3,
        "char_count": 59,
        "word_count": 13,
        "page_number": 7,
        "window_text": "| (3) 시험 목적 : 결과에 영향을 주는 간섭물질을 확인하기 위한 시험 | 출혈시간 및 항혈소판제제 저항성 복합검사기기에 대한 보정과 정도 | ① 검사칩을 임상시험용 장비의 Tray에 놓고, 끝까지 밀어 넣는다.  Tray 에 심한 | 간섭물질이 포함된 검체와 포함되지 않은 검체를 3회 이상 반복 측정한 | ① 정상 대조군: 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군 |\n| 예시) | 예시) | 민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d) | Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | (1) 임상시험실시기관의 장은 해당 임상시험의 실시에 필요한 임상시험실, 설비와 | 가.  임상시험용 의료기기의 사용 및 관리 | - 성능평가방법: 임상시험 기간 동안 일차/이차/ 유효성 평가변수에 대한 | 소견·정도와 임상시험용 의료기기와의 인과관계를 평가하여 증례기록서에 | 특성, 원자재 및 화학적 구성요소, 성능, 새로운 제조방법 등에 대한 특이성을 |\n| Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | 별 평가도구, 평가방법 등) 및 결과판정 방법을 해당 임상시험방법의 진행순서 | 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행 | 이 규약에는 피험자 보상사유, 보상요건, 보상 제외사유, 보상기준, 보상절차, | (5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이 (및 표준편차): 피험자 수는 | 연관된 이익을 기대하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될 |\n**또는 이들로부터 분리된 혈장, 혈청, 핵산, 단백질 등을 말합니다.  본 동의서에서는**\n| 부터 6개월 | 피험자별 중지사유를 포함한 관련 임상시험자료의 처리방법을 제시함.  또 “탈락” | 담당하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상 |\n| 예시) | 6.  연구에 참여함으로써 기대되는 이익 | 혈소판 기능검사 방법으로는 피부에 상처를 낸 후 출혈이 멈출 때까지의 시간을 | 되는 환자 및 항혈소판제제에 대한 약물 저항을 보이는 환자를 확인할 수 있다.  | 1) 품목명(품목분류번호)/모델명: (구체적이지 않을 시 중분류명 기재) | 3) SIPA test:　정상인 및 혈소판기능저하가 있는 환자의 검체에 대해 시험기기 | 한 임상시험 계획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에 대하 | · 미개봉시 2-8°C 보관, 제조일로부터 12개월· 개봉시 실온보관, 개봉시부터 4시간 | 검사칩을 장착할 때마다 또는 시스템 성능의 검증이 필요할 때마다 대조 검체 |\n| 가. ",
        "original_sentence": "본 동의서에서는**\n| 부터 6개월 | 피험자별 중지사유를 포함한 관련 임상시험자료의 처리방법을 제시함. "
      }
    },
    {
      "chunk_id": "chunk_421",
      "text": "또 “탈락” | 담당하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상 |\n| 예시) | 6. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 420,
        "window_size": 3,
        "char_count": 65,
        "word_count": 19,
        "page_number": 3,
        "window_text": "Tray 에 심한 | 간섭물질이 포함된 검체와 포함되지 않은 검체를 3회 이상 반복 측정한 | ① 정상 대조군: 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군 |\n| 예시) | 예시) | 민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d) | Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | (1) 임상시험실시기관의 장은 해당 임상시험의 실시에 필요한 임상시험실, 설비와 | 가.  임상시험용 의료기기의 사용 및 관리 | - 성능평가방법: 임상시험 기간 동안 일차/이차/ 유효성 평가변수에 대한 | 소견·정도와 임상시험용 의료기기와의 인과관계를 평가하여 증례기록서에 | 특성, 원자재 및 화학적 구성요소, 성능, 새로운 제조방법 등에 대한 특이성을 |\n| Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | 별 평가도구, 평가방법 등) 및 결과판정 방법을 해당 임상시험방법의 진행순서 | 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행 | 이 규약에는 피험자 보상사유, 보상요건, 보상 제외사유, 보상기준, 보상절차, | (5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이 (및 표준편차): 피험자 수는 | 연관된 이익을 기대하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될 |\n**또는 이들로부터 분리된 혈장, 혈청, 핵산, 단백질 등을 말합니다.  본 동의서에서는**\n| 부터 6개월 | 피험자별 중지사유를 포함한 관련 임상시험자료의 처리방법을 제시함.  또 “탈락” | 담당하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상 |\n| 예시) | 6.  연구에 참여함으로써 기대되는 이익 | 혈소판 기능검사 방법으로는 피부에 상처를 낸 후 출혈이 멈출 때까지의 시간을 | 되는 환자 및 항혈소판제제에 대한 약물 저항을 보이는 환자를 확인할 수 있다.  | 1) 품목명(품목분류번호)/모델명: (구체적이지 않을 시 중분류명 기재) | 3) SIPA test:　정상인 및 혈소판기능저하가 있는 환자의 검체에 대해 시험기기 | 한 임상시험 계획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에 대하 | · 미개봉시 2-8°C 보관, 제조일로부터 12개월· 개봉시 실온보관, 개봉시부터 4시간 | 검사칩을 장착할 때마다 또는 시스템 성능의 검증이 필요할 때마다 대조 검체 |\n| 가.  임상시험 실시기관 | 가. ",
        "original_sentence": "또 “탈락” | 담당하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상 |\n| 예시) | 6. "
      }
    },
    {
      "chunk_id": "chunk_422",
      "text": "연구에 참여함으로써 기대되는 이익 | 혈소판 기능검사 방법으로는 피부에 상처를 낸 후 출혈이 멈출 때까지의 시간을 | 되는 환자 및 항혈소판제제에 대한 약물 저항을 보이는 환자를 확인할 수 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 421,
        "window_size": 3,
        "char_count": 110,
        "word_count": 29,
        "page_number": 53,
        "window_text": "임상시험용 의료기기의 사용 및 관리 | - 성능평가방법: 임상시험 기간 동안 일차/이차/ 유효성 평가변수에 대한 | 소견·정도와 임상시험용 의료기기와의 인과관계를 평가하여 증례기록서에 | 특성, 원자재 및 화학적 구성요소, 성능, 새로운 제조방법 등에 대한 특이성을 |\n| Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | 별 평가도구, 평가방법 등) 및 결과판정 방법을 해당 임상시험방법의 진행순서 | 피험자 동의와 관련한 준수사항은 의료기기 임상시험 관리기준(의료기기법 시행 | 이 규약에는 피험자 보상사유, 보상요건, 보상 제외사유, 보상기준, 보상절차, | (5) 선행연구 또는 문헌 리뷰를 통한 예상되는 효과 차이 (및 표준편차): 피험자 수는 | 연관된 이익을 기대하거나, 참여를 거부할 경우 조직의 상급자에게서 받게 될 |\n**또는 이들로부터 분리된 혈장, 혈청, 핵산, 단백질 등을 말합니다.  본 동의서에서는**\n| 부터 6개월 | 피험자별 중지사유를 포함한 관련 임상시험자료의 처리방법을 제시함.  또 “탈락” | 담당하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상 |\n| 예시) | 6.  연구에 참여함으로써 기대되는 이익 | 혈소판 기능검사 방법으로는 피부에 상처를 낸 후 출혈이 멈출 때까지의 시간을 | 되는 환자 및 항혈소판제제에 대한 약물 저항을 보이는 환자를 확인할 수 있다.  | 1) 품목명(품목분류번호)/모델명: (구체적이지 않을 시 중분류명 기재) | 3) SIPA test:　정상인 및 혈소판기능저하가 있는 환자의 검체에 대해 시험기기 | 한 임상시험 계획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에 대하 | · 미개봉시 2-8°C 보관, 제조일로부터 12개월· 개봉시 실온보관, 개봉시부터 4시간 | 검사칩을 장착할 때마다 또는 시스템 성능의 검증이 필요할 때마다 대조 검체 |\n| 가.  임상시험 실시기관 | 가.  의뢰자 | Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | 본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 병원에서 진행하던 치료 | (6) 결과 제시 : 가속노화 시작시점과 시험 마지막 시점 결과의 차이를 구한다. ",
        "original_sentence": "연구에 참여함으로써 기대되는 이익 | 혈소판 기능검사 방법으로는 피부에 상처를 낸 후 출혈이 멈출 때까지의 시간을 | 되는 환자 및 항혈소판제제에 대한 약물 저항을 보이는 환자를 확인할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_423",
      "text": "| 1) 품목명(품목분류번호)/모델명: (구체적이지 않을 시 중분류명 기재) | 3) SIPA test:　정상인 및 혈소판기능저하가 있는 환자의 검체에 대해 시험기기 | 한 임상시험 계획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에 대하 | · 미개봉시 2-8°C 보관, 제조일로부터 12개월· 개봉시 실온보관, 개봉시부터 4시간 | 검사칩을 장착할 때마다 또는 시스템 성능의 검증이 필요할 때마다 대조 검체 |\n| 가. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 422,
        "window_size": 3,
        "char_count": 242,
        "word_count": 59,
        "page_number": 6,
        "window_text": "본 동의서에서는**\n| 부터 6개월 | 피험자별 중지사유를 포함한 관련 임상시험자료의 처리방법을 제시함.  또 “탈락” | 담당하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상 |\n| 예시) | 6.  연구에 참여함으로써 기대되는 이익 | 혈소판 기능검사 방법으로는 피부에 상처를 낸 후 출혈이 멈출 때까지의 시간을 | 되는 환자 및 항혈소판제제에 대한 약물 저항을 보이는 환자를 확인할 수 있다.  | 1) 품목명(품목분류번호)/모델명: (구체적이지 않을 시 중분류명 기재) | 3) SIPA test:　정상인 및 혈소판기능저하가 있는 환자의 검체에 대해 시험기기 | 한 임상시험 계획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에 대하 | · 미개봉시 2-8°C 보관, 제조일로부터 12개월· 개봉시 실온보관, 개봉시부터 4시간 | 검사칩을 장착할 때마다 또는 시스템 성능의 검증이 필요할 때마다 대조 검체 |\n| 가.  임상시험 실시기관 | 가.  의뢰자 | Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | 본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 병원에서 진행하던 치료 | (6) 결과 제시 : 가속노화 시작시점과 시험 마지막 시점 결과의 차이를 구한다.  | 개봉 후 검체에 대한 이동거리를 3회에 걸쳐 반복하여 측정한다. ",
        "original_sentence": "| 1) 품목명(품목분류번호)/모델명: (구체적이지 않을 시 중분류명 기재) | 3) SIPA test:　정상인 및 혈소판기능저하가 있는 환자의 검체에 대해 시험기기 | 한 임상시험 계획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에 대하 | · 미개봉시 2-8°C 보관, 제조일로부터 12개월· 개봉시 실온보관, 개봉시부터 4시간 | 검사칩을 장착할 때마다 또는 시스템 성능의 검증이 필요할 때마다 대조 검체 |\n| 가. "
      }
    },
    {
      "chunk_id": "chunk_424",
      "text": "임상시험 실시기관 | 가. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 423,
        "window_size": 3,
        "char_count": 15,
        "word_count": 4,
        "page_number": 9,
        "window_text": "또 “탈락” | 담당하거나 필요한 사항을 결정하는 의사, 치과의사, 한의사 및 그 밖의 임상 |\n| 예시) | 6.  연구에 참여함으로써 기대되는 이익 | 혈소판 기능검사 방법으로는 피부에 상처를 낸 후 출혈이 멈출 때까지의 시간을 | 되는 환자 및 항혈소판제제에 대한 약물 저항을 보이는 환자를 확인할 수 있다.  | 1) 품목명(품목분류번호)/모델명: (구체적이지 않을 시 중분류명 기재) | 3) SIPA test:　정상인 및 혈소판기능저하가 있는 환자의 검체에 대해 시험기기 | 한 임상시험 계획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에 대하 | · 미개봉시 2-8°C 보관, 제조일로부터 12개월· 개봉시 실온보관, 개봉시부터 4시간 | 검사칩을 장착할 때마다 또는 시스템 성능의 검증이 필요할 때마다 대조 검체 |\n| 가.  임상시험 실시기관 | 가.  의뢰자 | Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | 본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 병원에서 진행하던 치료 | (6) 결과 제시 : 가속노화 시작시점과 시험 마지막 시점 결과의 차이를 구한다.  | 개봉 후 검체에 대한 이동거리를 3회에 걸쳐 반복하여 측정한다.  | 기록하여야 함. ",
        "original_sentence": "임상시험 실시기관 | 가. "
      }
    },
    {
      "chunk_id": "chunk_425",
      "text": "의뢰자 | Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | 본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 병원에서 진행하던 치료 | (6) 결과 제시 : 가속노화 시작시점과 시험 마지막 시점 결과의 차이를 구한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 424,
        "window_size": 3,
        "char_count": 145,
        "word_count": 31,
        "page_number": 6,
        "window_text": "연구에 참여함으로써 기대되는 이익 | 혈소판 기능검사 방법으로는 피부에 상처를 낸 후 출혈이 멈출 때까지의 시간을 | 되는 환자 및 항혈소판제제에 대한 약물 저항을 보이는 환자를 확인할 수 있다.  | 1) 품목명(품목분류번호)/모델명: (구체적이지 않을 시 중분류명 기재) | 3) SIPA test:　정상인 및 혈소판기능저하가 있는 환자의 검체에 대해 시험기기 | 한 임상시험 계획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에 대하 | · 미개봉시 2-8°C 보관, 제조일로부터 12개월· 개봉시 실온보관, 개봉시부터 4시간 | 검사칩을 장착할 때마다 또는 시스템 성능의 검증이 필요할 때마다 대조 검체 |\n| 가.  임상시험 실시기관 | 가.  의뢰자 | Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | 본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 병원에서 진행하던 치료 | (6) 결과 제시 : 가속노화 시작시점과 시험 마지막 시점 결과의 차이를 구한다.  | 개봉 후 검체에 대한 이동거리를 3회에 걸쳐 반복하여 측정한다.  | 기록하여야 함.  따라서 이상사례에 대한 임상시험용 의료기기와의 인과관계에 |\n| * 각 모델명별로 구분하여 기재한다. ",
        "original_sentence": "의뢰자 | Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | 본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 병원에서 진행하던 치료 | (6) 결과 제시 : 가속노화 시작시점과 시험 마지막 시점 결과의 차이를 구한다. "
      }
    },
    {
      "chunk_id": "chunk_426",
      "text": "| 개봉 후 검체에 대한 이동거리를 3회에 걸쳐 반복하여 측정한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 425,
        "window_size": 3,
        "char_count": 38,
        "word_count": 10,
        "page_number": 7,
        "window_text": "| 1) 품목명(품목분류번호)/모델명: (구체적이지 않을 시 중분류명 기재) | 3) SIPA test:　정상인 및 혈소판기능저하가 있는 환자의 검체에 대해 시험기기 | 한 임상시험 계획서의 변경을 적용하게 되는 경우, 가능한 한 빨리 변경에 대하 | · 미개봉시 2-8°C 보관, 제조일로부터 12개월· 개봉시 실온보관, 개봉시부터 4시간 | 검사칩을 장착할 때마다 또는 시스템 성능의 검증이 필요할 때마다 대조 검체 |\n| 가.  임상시험 실시기관 | 가.  의뢰자 | Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | 본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 병원에서 진행하던 치료 | (6) 결과 제시 : 가속노화 시작시점과 시험 마지막 시점 결과의 차이를 구한다.  | 개봉 후 검체에 대한 이동거리를 3회에 걸쳐 반복하여 측정한다.  | 기록하여야 함.  따라서 이상사례에 대한 임상시험용 의료기기와의 인과관계에 |\n| * 각 모델명별로 구분하여 기재한다.  | 대로 기재하되, 대조군 및 확인군이 있는 경우 해당 임상시험용 의료기기(시험 | 규칙 [별표 3])에서 정하고 있음. ",
        "original_sentence": "| 개봉 후 검체에 대한 이동거리를 3회에 걸쳐 반복하여 측정한다. "
      }
    },
    {
      "chunk_id": "chunk_427",
      "text": "| 기록하여야 함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 426,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 1,
        "window_text": "임상시험 실시기관 | 가.  의뢰자 | Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | 본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 병원에서 진행하던 치료 | (6) 결과 제시 : 가속노화 시작시점과 시험 마지막 시점 결과의 차이를 구한다.  | 개봉 후 검체에 대한 이동거리를 3회에 걸쳐 반복하여 측정한다.  | 기록하여야 함.  따라서 이상사례에 대한 임상시험용 의료기기와의 인과관계에 |\n| * 각 모델명별로 구분하여 기재한다.  | 대로 기재하되, 대조군 및 확인군이 있는 경우 해당 임상시험용 의료기기(시험 | 규칙 [별표 3])에서 정하고 있음.  이에 따른 피험자 동의서 서식을 제시하여야 | 불이익을 우려하여 자발적인 참여 결정에 영향을 받을 소지가 있는 등, 취약 |\n| 마. IEC 61326-1 Electrical equipment for measurement, control and laboratory | - SIPA test: 사람의 구연산 처리된 전혈에서 폐색 전 혈액이동거리 측정법으로 |\n| - 대상자 모집기간 및 임상시험 수행 기간 : 약 4 개월 | 예시) | 이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상시험이 | 시험에 관여하는 사람을 말하며, 각 임상시험기관의 적절한 임상시험의 수행을 | ① 정전기방전(Electrostatic Discharge, ESD) 시험 : IEC 61000-4-2에 |\n| 가. ",
        "original_sentence": "| 기록하여야 함. "
      }
    },
    {
      "chunk_id": "chunk_428",
      "text": "따라서 이상사례에 대한 임상시험용 의료기기와의 인과관계에 |\n| * 각 모델명별로 구분하여 기재한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 427,
        "window_size": 3,
        "char_count": 57,
        "word_count": 13,
        "page_number": 3,
        "window_text": "의뢰자 | Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | 본 임상시험이 종료된 후 피험자는 이후의 진료에 대하여 병원에서 진행하던 치료 | (6) 결과 제시 : 가속노화 시작시점과 시험 마지막 시점 결과의 차이를 구한다.  | 개봉 후 검체에 대한 이동거리를 3회에 걸쳐 반복하여 측정한다.  | 기록하여야 함.  따라서 이상사례에 대한 임상시험용 의료기기와의 인과관계에 |\n| * 각 모델명별로 구분하여 기재한다.  | 대로 기재하되, 대조군 및 확인군이 있는 경우 해당 임상시험용 의료기기(시험 | 규칙 [별표 3])에서 정하고 있음.  이에 따른 피험자 동의서 서식을 제시하여야 | 불이익을 우려하여 자발적인 참여 결정에 영향을 받을 소지가 있는 등, 취약 |\n| 마. IEC 61326-1 Electrical equipment for measurement, control and laboratory | - SIPA test: 사람의 구연산 처리된 전혈에서 폐색 전 혈액이동거리 측정법으로 |\n| - 대상자 모집기간 및 임상시험 수행 기간 : 약 4 개월 | 예시) | 이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상시험이 | 시험에 관여하는 사람을 말하며, 각 임상시험기관의 적절한 임상시험의 수행을 | ① 정전기방전(Electrostatic Discharge, ESD) 시험 : IEC 61000-4-2에 |\n| 가.  의료기기 관리자 | - 이 연구의 참여로 귀하에게 직접적으로 기대되는 이익은 없으나, 이 연구를 통해 | (성명) | (서명) | (날짜) | 년 | 월 | 일 | 임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급, 저장하며 “임상 |\n| 14.2. ",
        "original_sentence": "따라서 이상사례에 대한 임상시험용 의료기기와의 인과관계에 |\n| * 각 모델명별로 구분하여 기재한다. "
      }
    },
    {
      "chunk_id": "chunk_429",
      "text": "| 대로 기재하되, 대조군 및 확인군이 있는 경우 해당 임상시험용 의료기기(시험 | 규칙 [별표 3])에서 정하고 있음. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 428,
        "window_size": 3,
        "char_count": 68,
        "word_count": 17,
        "page_number": 9,
        "window_text": "| 개봉 후 검체에 대한 이동거리를 3회에 걸쳐 반복하여 측정한다.  | 기록하여야 함.  따라서 이상사례에 대한 임상시험용 의료기기와의 인과관계에 |\n| * 각 모델명별로 구분하여 기재한다.  | 대로 기재하되, 대조군 및 확인군이 있는 경우 해당 임상시험용 의료기기(시험 | 규칙 [별표 3])에서 정하고 있음.  이에 따른 피험자 동의서 서식을 제시하여야 | 불이익을 우려하여 자발적인 참여 결정에 영향을 받을 소지가 있는 등, 취약 |\n| 마. IEC 61326-1 Electrical equipment for measurement, control and laboratory | - SIPA test: 사람의 구연산 처리된 전혈에서 폐색 전 혈액이동거리 측정법으로 |\n| - 대상자 모집기간 및 임상시험 수행 기간 : 약 4 개월 | 예시) | 이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상시험이 | 시험에 관여하는 사람을 말하며, 각 임상시험기관의 적절한 임상시험의 수행을 | ① 정전기방전(Electrostatic Discharge, ESD) 시험 : IEC 61000-4-2에 |\n| 가.  의료기기 관리자 | - 이 연구의 참여로 귀하에게 직접적으로 기대되는 이익은 없으나, 이 연구를 통해 | (성명) | (서명) | (날짜) | 년 | 월 | 일 | 임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급, 저장하며 “임상 |\n| 14.2.  유효성(성능) 평가방법 | 9. ",
        "original_sentence": "| 대로 기재하되, 대조군 및 확인군이 있는 경우 해당 임상시험용 의료기기(시험 | 규칙 [별표 3])에서 정하고 있음. "
      }
    },
    {
      "chunk_id": "chunk_430",
      "text": "이에 따른 피험자 동의서 서식을 제시하여야 | 불이익을 우려하여 자발적인 참여 결정에 영향을 받을 소지가 있는 등, 취약 |\n| 마. IEC 61326-1 Electrical equipment for measurement, control and laboratory | - SIPA test: 사람의 구연산 처리된 전혈에서 폐색 전 혈액이동거리 측정법으로 |\n| - 대상자 모집기간 및 임상시험 수행 기간 : 약 4 개월 | 예시) | 이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상시험이 | 시험에 관여하는 사람을 말하며, 각 임상시험기관의 적절한 임상시험의 수행을 | ① 정전기방전(Electrostatic Discharge, ESD) 시험 : IEC 61000-4-2에 |\n| 가. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 429,
        "window_size": 3,
        "char_count": 397,
        "word_count": 91,
        "page_number": 104,
        "window_text": "| 기록하여야 함.  따라서 이상사례에 대한 임상시험용 의료기기와의 인과관계에 |\n| * 각 모델명별로 구분하여 기재한다.  | 대로 기재하되, 대조군 및 확인군이 있는 경우 해당 임상시험용 의료기기(시험 | 규칙 [별표 3])에서 정하고 있음.  이에 따른 피험자 동의서 서식을 제시하여야 | 불이익을 우려하여 자발적인 참여 결정에 영향을 받을 소지가 있는 등, 취약 |\n| 마. IEC 61326-1 Electrical equipment for measurement, control and laboratory | - SIPA test: 사람의 구연산 처리된 전혈에서 폐색 전 혈액이동거리 측정법으로 |\n| - 대상자 모집기간 및 임상시험 수행 기간 : 약 4 개월 | 예시) | 이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상시험이 | 시험에 관여하는 사람을 말하며, 각 임상시험기관의 적절한 임상시험의 수행을 | ① 정전기방전(Electrostatic Discharge, ESD) 시험 : IEC 61000-4-2에 |\n| 가.  의료기기 관리자 | - 이 연구의 참여로 귀하에게 직접적으로 기대되는 이익은 없으나, 이 연구를 통해 | (성명) | (서명) | (날짜) | 년 | 월 | 일 | 임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급, 저장하며 “임상 |\n| 14.2.  유효성(성능) 평가방법 | 9.  개인정보 보호 | (3) 증례기록서 등 임상 시험에 관련된 모든 서류에는 피험자 이름이 아닌 피험자 | 측정하는 고식적 방법인 출혈시간과 혈소판의 응집능만을 검사할 수 있는 혈소판 | - 통계분석에 의한 평가방법: 통계분석방법에 따른 통계적 유의성에 대해 평가 | (2) 이 검사는 개인 환자 또는 헌혈자로부터 얻은 검체를 사용하도록 설계되었다. ",
        "original_sentence": "이에 따른 피험자 동의서 서식을 제시하여야 | 불이익을 우려하여 자발적인 참여 결정에 영향을 받을 소지가 있는 등, 취약 |\n| 마. IEC 61326-1 Electrical equipment for measurement, control and laboratory | - SIPA test: 사람의 구연산 처리된 전혈에서 폐색 전 혈액이동거리 측정법으로 |\n| - 대상자 모집기간 및 임상시험 수행 기간 : 약 4 개월 | 예시) | 이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상시험이 | 시험에 관여하는 사람을 말하며, 각 임상시험기관의 적절한 임상시험의 수행을 | ① 정전기방전(Electrostatic Discharge, ESD) 시험 : IEC 61000-4-2에 |\n| 가. "
      }
    },
    {
      "chunk_id": "chunk_431",
      "text": "의료기기 관리자 | - 이 연구의 참여로 귀하에게 직접적으로 기대되는 이익은 없으나, 이 연구를 통해 | (성명) | (서명) | (날짜) | 년 | 월 | 일 | 임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급, 저장하며 “임상 |\n| 14.2. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 430,
        "window_size": 3,
        "char_count": 144,
        "word_count": 40,
        "page_number": 33,
        "window_text": "따라서 이상사례에 대한 임상시험용 의료기기와의 인과관계에 |\n| * 각 모델명별로 구분하여 기재한다.  | 대로 기재하되, 대조군 및 확인군이 있는 경우 해당 임상시험용 의료기기(시험 | 규칙 [별표 3])에서 정하고 있음.  이에 따른 피험자 동의서 서식을 제시하여야 | 불이익을 우려하여 자발적인 참여 결정에 영향을 받을 소지가 있는 등, 취약 |\n| 마. IEC 61326-1 Electrical equipment for measurement, control and laboratory | - SIPA test: 사람의 구연산 처리된 전혈에서 폐색 전 혈액이동거리 측정법으로 |\n| - 대상자 모집기간 및 임상시험 수행 기간 : 약 4 개월 | 예시) | 이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상시험이 | 시험에 관여하는 사람을 말하며, 각 임상시험기관의 적절한 임상시험의 수행을 | ① 정전기방전(Electrostatic Discharge, ESD) 시험 : IEC 61000-4-2에 |\n| 가.  의료기기 관리자 | - 이 연구의 참여로 귀하에게 직접적으로 기대되는 이익은 없으나, 이 연구를 통해 | (성명) | (서명) | (날짜) | 년 | 월 | 일 | 임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급, 저장하며 “임상 |\n| 14.2.  유효성(성능) 평가방법 | 9.  개인정보 보호 | (3) 증례기록서 등 임상 시험에 관련된 모든 서류에는 피험자 이름이 아닌 피험자 | 측정하는 고식적 방법인 출혈시간과 혈소판의 응집능만을 검사할 수 있는 혈소판 | - 통계분석에 의한 평가방법: 통계분석방법에 따른 통계적 유의성에 대해 평가 | (2) 이 검사는 개인 환자 또는 헌혈자로부터 얻은 검체를 사용하도록 설계되었다.  | ③ 병용약물 : 아스피린, P2Y12 수용체 억제제 등의 항혈소판제제, 항응고제 치료 유무 | 공여자를 중복해서 검사할 것을 권장한다. ",
        "original_sentence": "의료기기 관리자 | - 이 연구의 참여로 귀하에게 직접적으로 기대되는 이익은 없으나, 이 연구를 통해 | (성명) | (서명) | (날짜) | 년 | 월 | 일 | 임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급, 저장하며 “임상 |\n| 14.2. "
      }
    },
    {
      "chunk_id": "chunk_432",
      "text": "유효성(성능) 평가방법 | 9. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 431,
        "window_size": 3,
        "char_count": 18,
        "word_count": 4,
        "page_number": 15,
        "window_text": "| 대로 기재하되, 대조군 및 확인군이 있는 경우 해당 임상시험용 의료기기(시험 | 규칙 [별표 3])에서 정하고 있음.  이에 따른 피험자 동의서 서식을 제시하여야 | 불이익을 우려하여 자발적인 참여 결정에 영향을 받을 소지가 있는 등, 취약 |\n| 마. IEC 61326-1 Electrical equipment for measurement, control and laboratory | - SIPA test: 사람의 구연산 처리된 전혈에서 폐색 전 혈액이동거리 측정법으로 |\n| - 대상자 모집기간 및 임상시험 수행 기간 : 약 4 개월 | 예시) | 이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상시험이 | 시험에 관여하는 사람을 말하며, 각 임상시험기관의 적절한 임상시험의 수행을 | ① 정전기방전(Electrostatic Discharge, ESD) 시험 : IEC 61000-4-2에 |\n| 가.  의료기기 관리자 | - 이 연구의 참여로 귀하에게 직접적으로 기대되는 이익은 없으나, 이 연구를 통해 | (성명) | (서명) | (날짜) | 년 | 월 | 일 | 임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급, 저장하며 “임상 |\n| 14.2.  유효성(성능) 평가방법 | 9.  개인정보 보호 | (3) 증례기록서 등 임상 시험에 관련된 모든 서류에는 피험자 이름이 아닌 피험자 | 측정하는 고식적 방법인 출혈시간과 혈소판의 응집능만을 검사할 수 있는 혈소판 | - 통계분석에 의한 평가방법: 통계분석방법에 따른 통계적 유의성에 대해 평가 | (2) 이 검사는 개인 환자 또는 헌혈자로부터 얻은 검체를 사용하도록 설계되었다.  | ③ 병용약물 : 아스피린, P2Y12 수용체 억제제 등의 항혈소판제제, 항응고제 치료 유무 | 공여자를 중복해서 검사할 것을 권장한다.  평균 MD 또는 MR이 개별 검사실 |\n| 하며, 피험자 설명서에는 동 기준의 제7호아목의10)을 포함하여야 함. ",
        "original_sentence": "유효성(성능) 평가방법 | 9. "
      }
    },
    {
      "chunk_id": "chunk_433",
      "text": "개인정보 보호 | (3) 증례기록서 등 임상 시험에 관련된 모든 서류에는 피험자 이름이 아닌 피험자 | 측정하는 고식적 방법인 출혈시간과 혈소판의 응집능만을 검사할 수 있는 혈소판 | - 통계분석에 의한 평가방법: 통계분석방법에 따른 통계적 유의성에 대해 평가 | (2) 이 검사는 개인 환자 또는 헌혈자로부터 얻은 검체를 사용하도록 설계되었다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 432,
        "window_size": 3,
        "char_count": 194,
        "word_count": 49,
        "page_number": 7,
        "window_text": "이에 따른 피험자 동의서 서식을 제시하여야 | 불이익을 우려하여 자발적인 참여 결정에 영향을 받을 소지가 있는 등, 취약 |\n| 마. IEC 61326-1 Electrical equipment for measurement, control and laboratory | - SIPA test: 사람의 구연산 처리된 전혈에서 폐색 전 혈액이동거리 측정법으로 |\n| - 대상자 모집기간 및 임상시험 수행 기간 : 약 4 개월 | 예시) | 이란 피험자의 요구 또는 중대한 임상시험 계획서 위반 등의 이유로 임상시험이 | 시험에 관여하는 사람을 말하며, 각 임상시험기관의 적절한 임상시험의 수행을 | ① 정전기방전(Electrostatic Discharge, ESD) 시험 : IEC 61000-4-2에 |\n| 가.  의료기기 관리자 | - 이 연구의 참여로 귀하에게 직접적으로 기대되는 이익은 없으나, 이 연구를 통해 | (성명) | (서명) | (날짜) | 년 | 월 | 일 | 임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급, 저장하며 “임상 |\n| 14.2.  유효성(성능) 평가방법 | 9.  개인정보 보호 | (3) 증례기록서 등 임상 시험에 관련된 모든 서류에는 피험자 이름이 아닌 피험자 | 측정하는 고식적 방법인 출혈시간과 혈소판의 응집능만을 검사할 수 있는 혈소판 | - 통계분석에 의한 평가방법: 통계분석방법에 따른 통계적 유의성에 대해 평가 | (2) 이 검사는 개인 환자 또는 헌혈자로부터 얻은 검체를 사용하도록 설계되었다.  | ③ 병용약물 : 아스피린, P2Y12 수용체 억제제 등의 항혈소판제제, 항응고제 치료 유무 | 공여자를 중복해서 검사할 것을 권장한다.  평균 MD 또는 MR이 개별 검사실 |\n| 하며, 피험자 설명서에는 동 기준의 제7호아목의10)을 포함하여야 함.  | (아) 구성요소 : IEC 61010-1의 14절에 기술된 구성요소에 관한 요구 | 한 환경에 있는 피험자(Vulnerable Subjects)는 선정대상에서 제외함. ",
        "original_sentence": "개인정보 보호 | (3) 증례기록서 등 임상 시험에 관련된 모든 서류에는 피험자 이름이 아닌 피험자 | 측정하는 고식적 방법인 출혈시간과 혈소판의 응집능만을 검사할 수 있는 혈소판 | - 통계분석에 의한 평가방법: 통계분석방법에 따른 통계적 유의성에 대해 평가 | (2) 이 검사는 개인 환자 또는 헌혈자로부터 얻은 검체를 사용하도록 설계되었다. "
      }
    },
    {
      "chunk_id": "chunk_434",
      "text": "| ③ 병용약물 : 아스피린, P2Y12 수용체 억제제 등의 항혈소판제제, 항응고제 치료 유무 | 공여자를 중복해서 검사할 것을 권장한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 433,
        "window_size": 3,
        "char_count": 78,
        "word_count": 19,
        "page_number": 6,
        "window_text": "의료기기 관리자 | - 이 연구의 참여로 귀하에게 직접적으로 기대되는 이익은 없으나, 이 연구를 통해 | (성명) | (서명) | (날짜) | 년 | 월 | 일 | 임상시험용 의료기기는 기재사항에 기술되어 있는 대로 취급, 저장하며 “임상 |\n| 14.2.  유효성(성능) 평가방법 | 9.  개인정보 보호 | (3) 증례기록서 등 임상 시험에 관련된 모든 서류에는 피험자 이름이 아닌 피험자 | 측정하는 고식적 방법인 출혈시간과 혈소판의 응집능만을 검사할 수 있는 혈소판 | - 통계분석에 의한 평가방법: 통계분석방법에 따른 통계적 유의성에 대해 평가 | (2) 이 검사는 개인 환자 또는 헌혈자로부터 얻은 검체를 사용하도록 설계되었다.  | ③ 병용약물 : 아스피린, P2Y12 수용체 억제제 등의 항혈소판제제, 항응고제 치료 유무 | 공여자를 중복해서 검사할 것을 권장한다.  평균 MD 또는 MR이 개별 검사실 |\n| 하며, 피험자 설명서에는 동 기준의 제7호아목의10)을 포함하여야 함.  | (아) 구성요소 : IEC 61010-1의 14절에 기술된 구성요소에 관한 요구 | 한 환경에 있는 피험자(Vulnerable Subjects)는 선정대상에서 제외함.  또한, | 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과를 | 정상 검체의 이동거리 구간과 혈소판 기능 이상 검체 이동거리 구간을 |\n| 예시) | (3) 시험 목적 : 혈소판 기능이상 검사 키트가 특정 조건하에서 사용기간 | 군)의 기술 형태와 마찬가지로 대조군 및 확인군 해당 항목별로 순서에 따라 |\n| - 통계처리 기간 : 약 1 개월 | 10.1.1. ",
        "original_sentence": "| ③ 병용약물 : 아스피린, P2Y12 수용체 억제제 등의 항혈소판제제, 항응고제 치료 유무 | 공여자를 중복해서 검사할 것을 권장한다. "
      }
    },
    {
      "chunk_id": "chunk_435",
      "text": "평균 MD 또는 MR이 개별 검사실 |\n| 하며, 피험자 설명서에는 동 기준의 제7호아목의10)을 포함하여야 함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 434,
        "window_size": 3,
        "char_count": 64,
        "word_count": 16,
        "page_number": 6,
        "window_text": "유효성(성능) 평가방법 | 9.  개인정보 보호 | (3) 증례기록서 등 임상 시험에 관련된 모든 서류에는 피험자 이름이 아닌 피험자 | 측정하는 고식적 방법인 출혈시간과 혈소판의 응집능만을 검사할 수 있는 혈소판 | - 통계분석에 의한 평가방법: 통계분석방법에 따른 통계적 유의성에 대해 평가 | (2) 이 검사는 개인 환자 또는 헌혈자로부터 얻은 검체를 사용하도록 설계되었다.  | ③ 병용약물 : 아스피린, P2Y12 수용체 억제제 등의 항혈소판제제, 항응고제 치료 유무 | 공여자를 중복해서 검사할 것을 권장한다.  평균 MD 또는 MR이 개별 검사실 |\n| 하며, 피험자 설명서에는 동 기준의 제7호아목의10)을 포함하여야 함.  | (아) 구성요소 : IEC 61010-1의 14절에 기술된 구성요소에 관한 요구 | 한 환경에 있는 피험자(Vulnerable Subjects)는 선정대상에서 제외함.  또한, | 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과를 | 정상 검체의 이동거리 구간과 혈소판 기능 이상 검체 이동거리 구간을 |\n| 예시) | (3) 시험 목적 : 혈소판 기능이상 검사 키트가 특정 조건하에서 사용기간 | 군)의 기술 형태와 마찬가지로 대조군 및 확인군 해당 항목별로 순서에 따라 |\n| - 통계처리 기간 : 약 1 개월 | 10.1.1.  시험기기 대조기기 정보 | 완료되지 못한 경우를 말하며, 그 분류기준을 “탈락 기준”에 탈락의 사유와 관 |\n| 예시) | 시험용”이라는 문구가 있어야한다. ",
        "original_sentence": "평균 MD 또는 MR이 개별 검사실 |\n| 하며, 피험자 설명서에는 동 기준의 제7호아목의10)을 포함하여야 함. "
      }
    },
    {
      "chunk_id": "chunk_436",
      "text": "| (아) 구성요소 : IEC 61010-1의 14절에 기술된 구성요소에 관한 요구 | 한 환경에 있는 피험자(Vulnerable Subjects)는 선정대상에서 제외함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 435,
        "window_size": 3,
        "char_count": 96,
        "word_count": 19,
        "page_number": 6,
        "window_text": "개인정보 보호 | (3) 증례기록서 등 임상 시험에 관련된 모든 서류에는 피험자 이름이 아닌 피험자 | 측정하는 고식적 방법인 출혈시간과 혈소판의 응집능만을 검사할 수 있는 혈소판 | - 통계분석에 의한 평가방법: 통계분석방법에 따른 통계적 유의성에 대해 평가 | (2) 이 검사는 개인 환자 또는 헌혈자로부터 얻은 검체를 사용하도록 설계되었다.  | ③ 병용약물 : 아스피린, P2Y12 수용체 억제제 등의 항혈소판제제, 항응고제 치료 유무 | 공여자를 중복해서 검사할 것을 권장한다.  평균 MD 또는 MR이 개별 검사실 |\n| 하며, 피험자 설명서에는 동 기준의 제7호아목의10)을 포함하여야 함.  | (아) 구성요소 : IEC 61010-1의 14절에 기술된 구성요소에 관한 요구 | 한 환경에 있는 피험자(Vulnerable Subjects)는 선정대상에서 제외함.  또한, | 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과를 | 정상 검체의 이동거리 구간과 혈소판 기능 이상 검체 이동거리 구간을 |\n| 예시) | (3) 시험 목적 : 혈소판 기능이상 검사 키트가 특정 조건하에서 사용기간 | 군)의 기술 형태와 마찬가지로 대조군 및 확인군 해당 항목별로 순서에 따라 |\n| - 통계처리 기간 : 약 1 개월 | 10.1.1.  시험기기 대조기기 정보 | 완료되지 못한 경우를 말하며, 그 분류기준을 “탈락 기준”에 탈락의 사유와 관 |\n| 예시) | 시험용”이라는 문구가 있어야한다.  임상시험용 의료기기 관리자는 임상시험에 |\n| 한다. ",
        "original_sentence": "| (아) 구성요소 : IEC 61010-1의 14절에 기술된 구성요소에 관한 요구 | 한 환경에 있는 피험자(Vulnerable Subjects)는 선정대상에서 제외함. "
      }
    },
    {
      "chunk_id": "chunk_437",
      "text": "또한, | 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과를 | 정상 검체의 이동거리 구간과 혈소판 기능 이상 검체 이동거리 구간을 |\n| 예시) | (3) 시험 목적 : 혈소판 기능이상 검사 키트가 특정 조건하에서 사용기간 | 군)의 기술 형태와 마찬가지로 대조군 및 확인군 해당 항목별로 순서에 따라 |\n| - 통계처리 기간 : 약 1 개월 | 10.1.1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 436,
        "window_size": 3,
        "char_count": 211,
        "word_count": 59,
        "page_number": 25,
        "window_text": "| ③ 병용약물 : 아스피린, P2Y12 수용체 억제제 등의 항혈소판제제, 항응고제 치료 유무 | 공여자를 중복해서 검사할 것을 권장한다.  평균 MD 또는 MR이 개별 검사실 |\n| 하며, 피험자 설명서에는 동 기준의 제7호아목의10)을 포함하여야 함.  | (아) 구성요소 : IEC 61010-1의 14절에 기술된 구성요소에 관한 요구 | 한 환경에 있는 피험자(Vulnerable Subjects)는 선정대상에서 제외함.  또한, | 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과를 | 정상 검체의 이동거리 구간과 혈소판 기능 이상 검체 이동거리 구간을 |\n| 예시) | (3) 시험 목적 : 혈소판 기능이상 검사 키트가 특정 조건하에서 사용기간 | 군)의 기술 형태와 마찬가지로 대조군 및 확인군 해당 항목별로 순서에 따라 |\n| - 통계처리 기간 : 약 1 개월 | 10.1.1.  시험기기 대조기기 정보 | 완료되지 못한 경우를 말하며, 그 분류기준을 “탈락 기준”에 탈락의 사유와 관 |\n| 예시) | 시험용”이라는 문구가 있어야한다.  임상시험용 의료기기 관리자는 임상시험에 |\n| 한다.  | 응집검사, 혈소판과 함께 본빌레브란드인자의 기능을 함께 측정할 수 있는 PFA-100, | (주) ○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○-○○○-○○○○ | 에서 설정된 진단경계치 범위 내에 속하는 경우, 검사칩이 완전하게 기능하는 | 검사를 시행한다. ",
        "original_sentence": "또한, | 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과를 | 정상 검체의 이동거리 구간과 혈소판 기능 이상 검체 이동거리 구간을 |\n| 예시) | (3) 시험 목적 : 혈소판 기능이상 검사 키트가 특정 조건하에서 사용기간 | 군)의 기술 형태와 마찬가지로 대조군 및 확인군 해당 항목별로 순서에 따라 |\n| - 통계처리 기간 : 약 1 개월 | 10.1.1. "
      }
    },
    {
      "chunk_id": "chunk_438",
      "text": "시험기기 대조기기 정보 | 완료되지 못한 경우를 말하며, 그 분류기준을 “탈락 기준”에 탈락의 사유와 관 |\n| 예시) | 시험용”이라는 문구가 있어야한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 437,
        "window_size": 3,
        "char_count": 88,
        "word_count": 22,
        "page_number": 9,
        "window_text": "평균 MD 또는 MR이 개별 검사실 |\n| 하며, 피험자 설명서에는 동 기준의 제7호아목의10)을 포함하여야 함.  | (아) 구성요소 : IEC 61010-1의 14절에 기술된 구성요소에 관한 요구 | 한 환경에 있는 피험자(Vulnerable Subjects)는 선정대상에서 제외함.  또한, | 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과를 | 정상 검체의 이동거리 구간과 혈소판 기능 이상 검체 이동거리 구간을 |\n| 예시) | (3) 시험 목적 : 혈소판 기능이상 검사 키트가 특정 조건하에서 사용기간 | 군)의 기술 형태와 마찬가지로 대조군 및 확인군 해당 항목별로 순서에 따라 |\n| - 통계처리 기간 : 약 1 개월 | 10.1.1.  시험기기 대조기기 정보 | 완료되지 못한 경우를 말하며, 그 분류기준을 “탈락 기준”에 탈락의 사유와 관 |\n| 예시) | 시험용”이라는 문구가 있어야한다.  임상시험용 의료기기 관리자는 임상시험에 |\n| 한다.  | 응집검사, 혈소판과 함께 본빌레브란드인자의 기능을 함께 측정할 수 있는 PFA-100, | (주) ○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○-○○○-○○○○ | 에서 설정된 진단경계치 범위 내에 속하는 경우, 검사칩이 완전하게 기능하는 | 검사를 시행한다.  (SIPA test는 검사원리가 비슷한 기존검사법은 없으나, |\n| 4) 형상: | 방법과 기준을 제시함. ",
        "original_sentence": "시험기기 대조기기 정보 | 완료되지 못한 경우를 말하며, 그 분류기준을 “탈락 기준”에 탈락의 사유와 관 |\n| 예시) | 시험용”이라는 문구가 있어야한다. "
      }
    },
    {
      "chunk_id": "chunk_439",
      "text": "임상시험용 의료기기 관리자는 임상시험에 |\n| 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 438,
        "window_size": 3,
        "char_count": 30,
        "word_count": 7,
        "page_number": 9,
        "window_text": "| (아) 구성요소 : IEC 61010-1의 14절에 기술된 구성요소에 관한 요구 | 한 환경에 있는 피험자(Vulnerable Subjects)는 선정대상에서 제외함.  또한, | 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과를 | 정상 검체의 이동거리 구간과 혈소판 기능 이상 검체 이동거리 구간을 |\n| 예시) | (3) 시험 목적 : 혈소판 기능이상 검사 키트가 특정 조건하에서 사용기간 | 군)의 기술 형태와 마찬가지로 대조군 및 확인군 해당 항목별로 순서에 따라 |\n| - 통계처리 기간 : 약 1 개월 | 10.1.1.  시험기기 대조기기 정보 | 완료되지 못한 경우를 말하며, 그 분류기준을 “탈락 기준”에 탈락의 사유와 관 |\n| 예시) | 시험용”이라는 문구가 있어야한다.  임상시험용 의료기기 관리자는 임상시험에 |\n| 한다.  | 응집검사, 혈소판과 함께 본빌레브란드인자의 기능을 함께 측정할 수 있는 PFA-100, | (주) ○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○-○○○-○○○○ | 에서 설정된 진단경계치 범위 내에 속하는 경우, 검사칩이 완전하게 기능하는 | 검사를 시행한다.  (SIPA test는 검사원리가 비슷한 기존검사법은 없으나, |\n| 4) 형상: | 방법과 기준을 제시함.  의료기기기술문서 등 심사에 관한 규정에 따라 임상시험을 | 1) 민감도: 클로피도그렐 투약 후 검체 중 최종 약물반응 양성 결과를 보인 |\n| 나. ",
        "original_sentence": "임상시험용 의료기기 관리자는 임상시험에 |\n| 한다. "
      }
    },
    {
      "chunk_id": "chunk_440",
      "text": "| 응집검사, 혈소판과 함께 본빌레브란드인자의 기능을 함께 측정할 수 있는 PFA-100, | (주) ○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○-○○○-○○○○ | 에서 설정된 진단경계치 범위 내에 속하는 경우, 검사칩이 완전하게 기능하는 | 검사를 시행한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 439,
        "window_size": 3,
        "char_count": 151,
        "word_count": 36,
        "page_number": 6,
        "window_text": "또한, | 간섭물질을 함유한 검체와 간섭물질을 함유하지 않은 검체의 결과를 | 정상 검체의 이동거리 구간과 혈소판 기능 이상 검체 이동거리 구간을 |\n| 예시) | (3) 시험 목적 : 혈소판 기능이상 검사 키트가 특정 조건하에서 사용기간 | 군)의 기술 형태와 마찬가지로 대조군 및 확인군 해당 항목별로 순서에 따라 |\n| - 통계처리 기간 : 약 1 개월 | 10.1.1.  시험기기 대조기기 정보 | 완료되지 못한 경우를 말하며, 그 분류기준을 “탈락 기준”에 탈락의 사유와 관 |\n| 예시) | 시험용”이라는 문구가 있어야한다.  임상시험용 의료기기 관리자는 임상시험에 |\n| 한다.  | 응집검사, 혈소판과 함께 본빌레브란드인자의 기능을 함께 측정할 수 있는 PFA-100, | (주) ○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○-○○○-○○○○ | 에서 설정된 진단경계치 범위 내에 속하는 경우, 검사칩이 완전하게 기능하는 | 검사를 시행한다.  (SIPA test는 검사원리가 비슷한 기존검사법은 없으나, |\n| 4) 형상: | 방법과 기준을 제시함.  의료기기기술문서 등 심사에 관한 규정에 따라 임상시험을 | 1) 민감도: 클로피도그렐 투약 후 검체 중 최종 약물반응 양성 결과를 보인 |\n| 나.  개봉 후 안정성평가 | 6.1. ",
        "original_sentence": "| 응집검사, 혈소판과 함께 본빌레브란드인자의 기능을 함께 측정할 수 있는 PFA-100, | (주) ○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○-○○○-○○○○ | 에서 설정된 진단경계치 범위 내에 속하는 경우, 검사칩이 완전하게 기능하는 | 검사를 시행한다. "
      }
    },
    {
      "chunk_id": "chunk_441",
      "text": "(SIPA test는 검사원리가 비슷한 기존검사법은 없으나, |\n| 4) 형상: | 방법과 기준을 제시함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 440,
        "window_size": 3,
        "char_count": 60,
        "word_count": 14,
        "page_number": 15,
        "window_text": "시험기기 대조기기 정보 | 완료되지 못한 경우를 말하며, 그 분류기준을 “탈락 기준”에 탈락의 사유와 관 |\n| 예시) | 시험용”이라는 문구가 있어야한다.  임상시험용 의료기기 관리자는 임상시험에 |\n| 한다.  | 응집검사, 혈소판과 함께 본빌레브란드인자의 기능을 함께 측정할 수 있는 PFA-100, | (주) ○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○-○○○-○○○○ | 에서 설정된 진단경계치 범위 내에 속하는 경우, 검사칩이 완전하게 기능하는 | 검사를 시행한다.  (SIPA test는 검사원리가 비슷한 기존검사법은 없으나, |\n| 4) 형상: | 방법과 기준을 제시함.  의료기기기술문서 등 심사에 관한 규정에 따라 임상시험을 | 1) 민감도: 클로피도그렐 투약 후 검체 중 최종 약물반응 양성 결과를 보인 |\n| 나.  개봉 후 안정성평가 | 6.1.  목적 | 예시) | 3. ",
        "original_sentence": "(SIPA test는 검사원리가 비슷한 기존검사법은 없으나, |\n| 4) 형상: | 방법과 기준을 제시함. "
      }
    },
    {
      "chunk_id": "chunk_442",
      "text": "의료기기기술문서 등 심사에 관한 규정에 따라 임상시험을 | 1) 민감도: 클로피도그렐 투약 후 검체 중 최종 약물반응 양성 결과를 보인 |\n| 나. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 441,
        "window_size": 3,
        "char_count": 83,
        "word_count": 23,
        "page_number": 6,
        "window_text": "임상시험용 의료기기 관리자는 임상시험에 |\n| 한다.  | 응집검사, 혈소판과 함께 본빌레브란드인자의 기능을 함께 측정할 수 있는 PFA-100, | (주) ○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○-○○○-○○○○ | 에서 설정된 진단경계치 범위 내에 속하는 경우, 검사칩이 완전하게 기능하는 | 검사를 시행한다.  (SIPA test는 검사원리가 비슷한 기존검사법은 없으나, |\n| 4) 형상: | 방법과 기준을 제시함.  의료기기기술문서 등 심사에 관한 규정에 따라 임상시험을 | 1) 민감도: 클로피도그렐 투약 후 검체 중 최종 약물반응 양성 결과를 보인 |\n| 나.  개봉 후 안정성평가 | 6.1.  목적 | 예시) | 3.  연구의 목적 | 성명 | 소속 기관명 | 전공 | 직위 | 전화 | 개별 기술한다. ",
        "original_sentence": "의료기기기술문서 등 심사에 관한 규정에 따라 임상시험을 | 1) 민감도: 클로피도그렐 투약 후 검체 중 최종 약물반응 양성 결과를 보인 |\n| 나. "
      }
    },
    {
      "chunk_id": "chunk_443",
      "text": "개봉 후 안정성평가 | 6.1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 442,
        "window_size": 3,
        "char_count": 18,
        "word_count": 5,
        "page_number": 6,
        "window_text": "| 응집검사, 혈소판과 함께 본빌레브란드인자의 기능을 함께 측정할 수 있는 PFA-100, | (주) ○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○-○○○-○○○○ | 에서 설정된 진단경계치 범위 내에 속하는 경우, 검사칩이 완전하게 기능하는 | 검사를 시행한다.  (SIPA test는 검사원리가 비슷한 기존검사법은 없으나, |\n| 4) 형상: | 방법과 기준을 제시함.  의료기기기술문서 등 심사에 관한 규정에 따라 임상시험을 | 1) 민감도: 클로피도그렐 투약 후 검체 중 최종 약물반응 양성 결과를 보인 |\n| 나.  개봉 후 안정성평가 | 6.1.  목적 | 예시) | 3.  연구의 목적 | 성명 | 소속 기관명 | 전공 | 직위 | 전화 | 개별 기술한다.  | 법정 대리인(필요 시): | 설정된 3 포인트에서 차례로 이동거리를 3회에 걸쳐 측정한다. ",
        "original_sentence": "개봉 후 안정성평가 | 6.1. "
      }
    },
    {
      "chunk_id": "chunk_444",
      "text": "목적 | 예시) | 3. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 443,
        "window_size": 3,
        "char_count": 14,
        "word_count": 5,
        "page_number": 6,
        "window_text": "(SIPA test는 검사원리가 비슷한 기존검사법은 없으나, |\n| 4) 형상: | 방법과 기준을 제시함.  의료기기기술문서 등 심사에 관한 규정에 따라 임상시험을 | 1) 민감도: 클로피도그렐 투약 후 검체 중 최종 약물반응 양성 결과를 보인 |\n| 나.  개봉 후 안정성평가 | 6.1.  목적 | 예시) | 3.  연구의 목적 | 성명 | 소속 기관명 | 전공 | 직위 | 전화 | 개별 기술한다.  | 법정 대리인(필요 시): | 설정된 3 포인트에서 차례로 이동거리를 3회에 걸쳐 측정한다.  | 2. ",
        "original_sentence": "목적 | 예시) | 3. "
      }
    },
    {
      "chunk_id": "chunk_445",
      "text": "연구의 목적 | 성명 | 소속 기관명 | 전공 | 직위 | 전화 | 개별 기술한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 444,
        "window_size": 3,
        "char_count": 47,
        "word_count": 16,
        "page_number": 6,
        "window_text": "의료기기기술문서 등 심사에 관한 규정에 따라 임상시험을 | 1) 민감도: 클로피도그렐 투약 후 검체 중 최종 약물반응 양성 결과를 보인 |\n| 나.  개봉 후 안정성평가 | 6.1.  목적 | 예시) | 3.  연구의 목적 | 성명 | 소속 기관명 | 전공 | 직위 | 전화 | 개별 기술한다.  | 법정 대리인(필요 시): | 설정된 3 포인트에서 차례로 이동거리를 3회에 걸쳐 측정한다.  | 2.  판정 기준치(Cut-off value) | 제공할 수 있다. ",
        "original_sentence": "연구의 목적 | 성명 | 소속 기관명 | 전공 | 직위 | 전화 | 개별 기술한다. "
      }
    },
    {
      "chunk_id": "chunk_446",
      "text": "| 법정 대리인(필요 시): | 설정된 3 포인트에서 차례로 이동거리를 3회에 걸쳐 측정한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 445,
        "window_size": 3,
        "char_count": 53,
        "word_count": 13,
        "page_number": 6,
        "window_text": "개봉 후 안정성평가 | 6.1.  목적 | 예시) | 3.  연구의 목적 | 성명 | 소속 기관명 | 전공 | 직위 | 전화 | 개별 기술한다.  | 법정 대리인(필요 시): | 설정된 3 포인트에서 차례로 이동거리를 3회에 걸쳐 측정한다.  | 2.  판정 기준치(Cut-off value) | 제공할 수 있다.  | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 |\n| - 결과보고서 작성기간 : 약 1 개월 | 예시) | 시험기기: 출혈 시간 및 항혈소판제제 저항성 복합검사기기 | 가. ",
        "original_sentence": "| 법정 대리인(필요 시): | 설정된 3 포인트에서 차례로 이동거리를 3회에 걸쳐 측정한다. "
      }
    },
    {
      "chunk_id": "chunk_447",
      "text": "| 2. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 446,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 6,
        "window_text": "목적 | 예시) | 3.  연구의 목적 | 성명 | 소속 기관명 | 전공 | 직위 | 전화 | 개별 기술한다.  | 법정 대리인(필요 시): | 설정된 3 포인트에서 차례로 이동거리를 3회에 걸쳐 측정한다.  | 2.  판정 기준치(Cut-off value) | 제공할 수 있다.  | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 |\n| - 결과보고서 작성기간 : 약 1 개월 | 예시) | 시험기기: 출혈 시간 및 항혈소판제제 저항성 복합검사기기 | 가.  혈소판 기능검사 | 사용되는 의료기기에 대해 인수, 재고관리, 반납 등의 업무를 수행하고 관련 |\n| 13.1.2. ",
        "original_sentence": "| 2. "
      }
    },
    {
      "chunk_id": "chunk_448",
      "text": "판정 기준치(Cut-off value) | 제공할 수 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 447,
        "window_size": 3,
        "char_count": 34,
        "word_count": 7,
        "page_number": 17,
        "window_text": "연구의 목적 | 성명 | 소속 기관명 | 전공 | 직위 | 전화 | 개별 기술한다.  | 법정 대리인(필요 시): | 설정된 3 포인트에서 차례로 이동거리를 3회에 걸쳐 측정한다.  | 2.  판정 기준치(Cut-off value) | 제공할 수 있다.  | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 |\n| - 결과보고서 작성기간 : 약 1 개월 | 예시) | 시험기기: 출혈 시간 및 항혈소판제제 저항성 복합검사기기 | 가.  혈소판 기능검사 | 사용되는 의료기기에 대해 인수, 재고관리, 반납 등의 업무를 수행하고 관련 |\n| 13.1.2.  중지 처리 | ADP test | 84.0% | 81.0% | 련 임상자료의 처리방법을 “탈락 처리”에 구체적으로 제시함. ",
        "original_sentence": "판정 기준치(Cut-off value) | 제공할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_449",
      "text": "| 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 |\n| - 결과보고서 작성기간 : 약 1 개월 | 예시) | 시험기기: 출혈 시간 및 항혈소판제제 저항성 복합검사기기 | 가. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 448,
        "window_size": 3,
        "char_count": 109,
        "word_count": 30,
        "page_number": 6,
        "window_text": "| 법정 대리인(필요 시): | 설정된 3 포인트에서 차례로 이동거리를 3회에 걸쳐 측정한다.  | 2.  판정 기준치(Cut-off value) | 제공할 수 있다.  | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 |\n| - 결과보고서 작성기간 : 약 1 개월 | 예시) | 시험기기: 출혈 시간 및 항혈소판제제 저항성 복합검사기기 | 가.  혈소판 기능검사 | 사용되는 의료기기에 대해 인수, 재고관리, 반납 등의 업무를 수행하고 관련 |\n| 13.1.2.  중지 처리 | ADP test | 84.0% | 81.0% | 련 임상자료의 처리방법을 “탈락 처리”에 구체적으로 제시함.  | 가. Aspirin test | 기기에 의존하고 있는 상황이고 국내 개발 제품은 없는 상태이다. ",
        "original_sentence": "| 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 |\n| - 결과보고서 작성기간 : 약 1 개월 | 예시) | 시험기기: 출혈 시간 및 항혈소판제제 저항성 복합검사기기 | 가. "
      }
    },
    {
      "chunk_id": "chunk_450",
      "text": "혈소판 기능검사 | 사용되는 의료기기에 대해 인수, 재고관리, 반납 등의 업무를 수행하고 관련 |\n| 13.1.2. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 449,
        "window_size": 3,
        "char_count": 65,
        "word_count": 16,
        "page_number": 53,
        "window_text": "| 2.  판정 기준치(Cut-off value) | 제공할 수 있다.  | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 |\n| - 결과보고서 작성기간 : 약 1 개월 | 예시) | 시험기기: 출혈 시간 및 항혈소판제제 저항성 복합검사기기 | 가.  혈소판 기능검사 | 사용되는 의료기기에 대해 인수, 재고관리, 반납 등의 업무를 수행하고 관련 |\n| 13.1.2.  중지 처리 | ADP test | 84.0% | 81.0% | 련 임상자료의 처리방법을 “탈락 처리”에 구체적으로 제시함.  | 가. Aspirin test | 기기에 의존하고 있는 상황이고 국내 개발 제품은 없는 상태이다.  |\n| 해당 임상시험은 전혈 검체를 이용한 체외진단용 의료기기의 임상적 유효성 평가를 | (3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수, 임상시험의 종류와 | 2) 채혈 이후에는 채혈된 전혈 검체만을 사용하는 체외진단 검사이므로 예측되는 | 전반적인 응고과정을 측정하는 thromboelastography 등이 있다. ",
        "original_sentence": "혈소판 기능검사 | 사용되는 의료기기에 대해 인수, 재고관리, 반납 등의 업무를 수행하고 관련 |\n| 13.1.2. "
      }
    },
    {
      "chunk_id": "chunk_451",
      "text": "중지 처리 | ADP test | 84.0% | 81.0% | 련 임상자료의 처리방법을 “탈락 처리”에 구체적으로 제시함. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 450,
        "window_size": 3,
        "char_count": 69,
        "word_count": 17,
        "page_number": 6,
        "window_text": "판정 기준치(Cut-off value) | 제공할 수 있다.  | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 |\n| - 결과보고서 작성기간 : 약 1 개월 | 예시) | 시험기기: 출혈 시간 및 항혈소판제제 저항성 복합검사기기 | 가.  혈소판 기능검사 | 사용되는 의료기기에 대해 인수, 재고관리, 반납 등의 업무를 수행하고 관련 |\n| 13.1.2.  중지 처리 | ADP test | 84.0% | 81.0% | 련 임상자료의 처리방법을 “탈락 처리”에 구체적으로 제시함.  | 가. Aspirin test | 기기에 의존하고 있는 상황이고 국내 개발 제품은 없는 상태이다.  |\n| 해당 임상시험은 전혈 검체를 이용한 체외진단용 의료기기의 임상적 유효성 평가를 | (3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수, 임상시험의 종류와 | 2) 채혈 이후에는 채혈된 전혈 검체만을 사용하는 체외진단 검사이므로 예측되는 | 전반적인 응고과정을 측정하는 thromboelastography 등이 있다.  이 외에 혈소판의 | ○○○ | ○○○병원 | ○○○○ | ○○○ | ○○-○○○-○○○○ | ⑤ PT, aPTT 결과 | 1. ",
        "original_sentence": "중지 처리 | ADP test | 84.0% | 81.0% | 련 임상자료의 처리방법을 “탈락 처리”에 구체적으로 제시함. "
      }
    },
    {
      "chunk_id": "chunk_452",
      "text": "| 가. Aspirin test | 기기에 의존하고 있는 상황이고 국내 개발 제품은 없는 상태이다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 451,
        "window_size": 3,
        "char_count": 56,
        "word_count": 14,
        "page_number": 7,
        "window_text": "| 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 |\n| - 결과보고서 작성기간 : 약 1 개월 | 예시) | 시험기기: 출혈 시간 및 항혈소판제제 저항성 복합검사기기 | 가.  혈소판 기능검사 | 사용되는 의료기기에 대해 인수, 재고관리, 반납 등의 업무를 수행하고 관련 |\n| 13.1.2.  중지 처리 | ADP test | 84.0% | 81.0% | 련 임상자료의 처리방법을 “탈락 처리”에 구체적으로 제시함.  | 가. Aspirin test | 기기에 의존하고 있는 상황이고 국내 개발 제품은 없는 상태이다.  |\n| 해당 임상시험은 전혈 검체를 이용한 체외진단용 의료기기의 임상적 유효성 평가를 | (3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수, 임상시험의 종류와 | 2) 채혈 이후에는 채혈된 전혈 검체만을 사용하는 체외진단 검사이므로 예측되는 | 전반적인 응고과정을 측정하는 thromboelastography 등이 있다.  이 외에 혈소판의 | ○○○ | ○○○병원 | ○○○○ | ○○○ | ○○-○○○-○○○○ | ⑤ PT, aPTT 결과 | 1.  혈소판 기능검사 | 2) 선정/제외기준 | 1) 혈소판 기능검사: 시험기기와 대조기기(LTA, PFA-100)에서 검사를 시행한다. ",
        "original_sentence": "| 가. Aspirin test | 기기에 의존하고 있는 상황이고 국내 개발 제품은 없는 상태이다. "
      }
    },
    {
      "chunk_id": "chunk_453",
      "text": "|\n| 해당 임상시험은 전혈 검체를 이용한 체외진단용 의료기기의 임상적 유효성 평가를 | (3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수, 임상시험의 종류와 | 2) 채혈 이후에는 채혈된 전혈 검체만을 사용하는 체외진단 검사이므로 예측되는 | 전반적인 응고과정을 측정하는 thromboelastography 등이 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 452,
        "window_size": 3,
        "char_count": 189,
        "word_count": 42,
        "page_number": 9,
        "window_text": "혈소판 기능검사 | 사용되는 의료기기에 대해 인수, 재고관리, 반납 등의 업무를 수행하고 관련 |\n| 13.1.2.  중지 처리 | ADP test | 84.0% | 81.0% | 련 임상자료의 처리방법을 “탈락 처리”에 구체적으로 제시함.  | 가. Aspirin test | 기기에 의존하고 있는 상황이고 국내 개발 제품은 없는 상태이다.  |\n| 해당 임상시험은 전혈 검체를 이용한 체외진단용 의료기기의 임상적 유효성 평가를 | (3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수, 임상시험의 종류와 | 2) 채혈 이후에는 채혈된 전혈 검체만을 사용하는 체외진단 검사이므로 예측되는 | 전반적인 응고과정을 측정하는 thromboelastography 등이 있다.  이 외에 혈소판의 | ○○○ | ○○○병원 | ○○○○ | ○○○ | ○○-○○○-○○○○ | ⑤ PT, aPTT 결과 | 1.  혈소판 기능검사 | 2) 선정/제외기준 | 1) 혈소판 기능검사: 시험기기와 대조기기(LTA, PFA-100)에서 검사를 시행한다.  | 가. EPI test | 또한 궁극적으로는 혈소판 기능 또는 혈소판 약물 저항성을 확인하는 장비의 | 개인 식별정보 및 건강에 관한 정보 등)를 수집하게 됩니다. ",
        "original_sentence": "|\n| 해당 임상시험은 전혈 검체를 이용한 체외진단용 의료기기의 임상적 유효성 평가를 | (3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수, 임상시험의 종류와 | 2) 채혈 이후에는 채혈된 전혈 검체만을 사용하는 체외진단 검사이므로 예측되는 | 전반적인 응고과정을 측정하는 thromboelastography 등이 있다. "
      }
    },
    {
      "chunk_id": "chunk_454",
      "text": "이 외에 혈소판의 | ○○○ | ○○○병원 | ○○○○ | ○○○ | ○○-○○○-○○○○ | ⑤ PT, aPTT 결과 | 1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 453,
        "window_size": 3,
        "char_count": 72,
        "word_count": 20,
        "page_number": 33,
        "window_text": "중지 처리 | ADP test | 84.0% | 81.0% | 련 임상자료의 처리방법을 “탈락 처리”에 구체적으로 제시함.  | 가. Aspirin test | 기기에 의존하고 있는 상황이고 국내 개발 제품은 없는 상태이다.  |\n| 해당 임상시험은 전혈 검체를 이용한 체외진단용 의료기기의 임상적 유효성 평가를 | (3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수, 임상시험의 종류와 | 2) 채혈 이후에는 채혈된 전혈 검체만을 사용하는 체외진단 검사이므로 예측되는 | 전반적인 응고과정을 측정하는 thromboelastography 등이 있다.  이 외에 혈소판의 | ○○○ | ○○○병원 | ○○○○ | ○○○ | ○○-○○○-○○○○ | ⑤ PT, aPTT 결과 | 1.  혈소판 기능검사 | 2) 선정/제외기준 | 1) 혈소판 기능검사: 시험기기와 대조기기(LTA, PFA-100)에서 검사를 시행한다.  | 가. EPI test | 또한 궁극적으로는 혈소판 기능 또는 혈소판 약물 저항성을 확인하는 장비의 | 개인 식별정보 및 건강에 관한 정보 등)를 수집하게 됩니다.  이렇게 수집된 개인 | ③ “Kit Information”에 ID(환자정보)를 입력하고 “Save”버튼을 눌러 저장한다. ",
        "original_sentence": "이 외에 혈소판의 | ○○○ | ○○○병원 | ○○○○ | ○○○ | ○○-○○○-○○○○ | ⑤ PT, aPTT 결과 | 1. "
      }
    },
    {
      "chunk_id": "chunk_455",
      "text": "혈소판 기능검사 | 2) 선정/제외기준 | 1) 혈소판 기능검사: 시험기기와 대조기기(LTA, PFA-100)에서 검사를 시행한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 454,
        "window_size": 3,
        "char_count": 74,
        "word_count": 14,
        "page_number": 6,
        "window_text": "| 가. Aspirin test | 기기에 의존하고 있는 상황이고 국내 개발 제품은 없는 상태이다.  |\n| 해당 임상시험은 전혈 검체를 이용한 체외진단용 의료기기의 임상적 유효성 평가를 | (3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수, 임상시험의 종류와 | 2) 채혈 이후에는 채혈된 전혈 검체만을 사용하는 체외진단 검사이므로 예측되는 | 전반적인 응고과정을 측정하는 thromboelastography 등이 있다.  이 외에 혈소판의 | ○○○ | ○○○병원 | ○○○○ | ○○○ | ○○-○○○-○○○○ | ⑤ PT, aPTT 결과 | 1.  혈소판 기능검사 | 2) 선정/제외기준 | 1) 혈소판 기능검사: 시험기기와 대조기기(LTA, PFA-100)에서 검사를 시행한다.  | 가. EPI test | 또한 궁극적으로는 혈소판 기능 또는 혈소판 약물 저항성을 확인하는 장비의 | 개인 식별정보 및 건강에 관한 정보 등)를 수집하게 됩니다.  이렇게 수집된 개인 | ③ “Kit Information”에 ID(환자정보)를 입력하고 “Save”버튼을 눌러 저장한다.  |\n| 19.2. ",
        "original_sentence": "혈소판 기능검사 | 2) 선정/제외기준 | 1) 혈소판 기능검사: 시험기기와 대조기기(LTA, PFA-100)에서 검사를 시행한다. "
      }
    },
    {
      "chunk_id": "chunk_456",
      "text": "| 가. EPI test | 또한 궁극적으로는 혈소판 기능 또는 혈소판 약물 저항성을 확인하는 장비의 | 개인 식별정보 및 건강에 관한 정보 등)를 수집하게 됩니다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 455,
        "window_size": 3,
        "char_count": 93,
        "word_count": 25,
        "page_number": 24,
        "window_text": "|\n| 해당 임상시험은 전혈 검체를 이용한 체외진단용 의료기기의 임상적 유효성 평가를 | (3) 의뢰자의 점검 계획과 절차는 임상시험의 중요도, 피험자 수, 임상시험의 종류와 | 2) 채혈 이후에는 채혈된 전혈 검체만을 사용하는 체외진단 검사이므로 예측되는 | 전반적인 응고과정을 측정하는 thromboelastography 등이 있다.  이 외에 혈소판의 | ○○○ | ○○○병원 | ○○○○ | ○○○ | ○○-○○○-○○○○ | ⑤ PT, aPTT 결과 | 1.  혈소판 기능검사 | 2) 선정/제외기준 | 1) 혈소판 기능검사: 시험기기와 대조기기(LTA, PFA-100)에서 검사를 시행한다.  | 가. EPI test | 또한 궁극적으로는 혈소판 기능 또는 혈소판 약물 저항성을 확인하는 장비의 | 개인 식별정보 및 건강에 관한 정보 등)를 수집하게 됩니다.  이렇게 수집된 개인 | ③ “Kit Information”에 ID(환자정보)를 입력하고 “Save”버튼을 눌러 저장한다.  |\n| 19.2.  임상시험심사위원회 | 실시하는 병원은 2군데 이상이어야 한다. ",
        "original_sentence": "| 가. EPI test | 또한 궁극적으로는 혈소판 기능 또는 혈소판 약물 저항성을 확인하는 장비의 | 개인 식별정보 및 건강에 관한 정보 등)를 수집하게 됩니다. "
      }
    },
    {
      "chunk_id": "chunk_457",
      "text": "이렇게 수집된 개인 | ③ “Kit Information”에 ID(환자정보)를 입력하고 “Save”버튼을 눌러 저장한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 456,
        "window_size": 3,
        "char_count": 68,
        "word_count": 12,
        "page_number": 7,
        "window_text": "이 외에 혈소판의 | ○○○ | ○○○병원 | ○○○○ | ○○○ | ○○-○○○-○○○○ | ⑤ PT, aPTT 결과 | 1.  혈소판 기능검사 | 2) 선정/제외기준 | 1) 혈소판 기능검사: 시험기기와 대조기기(LTA, PFA-100)에서 검사를 시행한다.  | 가. EPI test | 또한 궁극적으로는 혈소판 기능 또는 혈소판 약물 저항성을 확인하는 장비의 | 개인 식별정보 및 건강에 관한 정보 등)를 수집하게 됩니다.  이렇게 수집된 개인 | ③ “Kit Information”에 ID(환자정보)를 입력하고 “Save”버튼을 눌러 저장한다.  |\n| 19.2.  임상시험심사위원회 | 실시하는 병원은 2군데 이상이어야 한다.  기관에 따라 임상시험결과에 차이가 | use – EMC requirements – Part 2-6: Particular requirements – In vitro |\n| 나. ",
        "original_sentence": "이렇게 수집된 개인 | ③ “Kit Information”에 ID(환자정보)를 입력하고 “Save”버튼을 눌러 저장한다. "
      }
    },
    {
      "chunk_id": "chunk_458",
      "text": "|\n| 19.2. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 457,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 6,
        "window_text": "혈소판 기능검사 | 2) 선정/제외기준 | 1) 혈소판 기능검사: 시험기기와 대조기기(LTA, PFA-100)에서 검사를 시행한다.  | 가. EPI test | 또한 궁극적으로는 혈소판 기능 또는 혈소판 약물 저항성을 확인하는 장비의 | 개인 식별정보 및 건강에 관한 정보 등)를 수집하게 됩니다.  이렇게 수집된 개인 | ③ “Kit Information”에 ID(환자정보)를 입력하고 “Save”버튼을 눌러 저장한다.  |\n| 19.2.  임상시험심사위원회 | 실시하는 병원은 2군데 이상이어야 한다.  기관에 따라 임상시험결과에 차이가 | use – EMC requirements – Part 2-6: Particular requirements – In vitro |\n| 나.  모니터요원 | 1. ",
        "original_sentence": "|\n| 19.2. "
      }
    },
    {
      "chunk_id": "chunk_459",
      "text": "임상시험심사위원회 | 실시하는 병원은 2군데 이상이어야 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 458,
        "window_size": 3,
        "char_count": 35,
        "word_count": 7,
        "page_number": 6,
        "window_text": "| 가. EPI test | 또한 궁극적으로는 혈소판 기능 또는 혈소판 약물 저항성을 확인하는 장비의 | 개인 식별정보 및 건강에 관한 정보 등)를 수집하게 됩니다.  이렇게 수집된 개인 | ③ “Kit Information”에 ID(환자정보)를 입력하고 “Save”버튼을 눌러 저장한다.  |\n| 19.2.  임상시험심사위원회 | 실시하는 병원은 2군데 이상이어야 한다.  기관에 따라 임상시험결과에 차이가 | use – EMC requirements – Part 2-6: Particular requirements – In vitro |\n| 나.  모니터요원 | 1.  피험자 안전성(해당사항 없음) | - 혈소판 기능에 관한 검사는 주로 선천성 혈소판 기능 이상이나 수술전 선별검사로 | ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’의 민감도 및 특이도, 일치도 | 1) 잘못 기입된 부분은 한 줄로 긋고, 수정날짜(YY/MM/DD)와 수정자 서명, 필요시 수정 | equipment for measurement, control and laboratory use–Part 2–101: |\n| (1) 관련 규격 | - 의학통계전문가, 의료기기전문가 등 공동연구자가 있을 경우 이를 포함하여 | 예시) | Collagen/ADP Test cartridge Dade PFA Trigger solution February 7, 1997 | (6) 결과 제시 | 결합 | 정도를 | 폐색 | 전 | 혈액이동거리 | 측정법으로 | 정성하여 | 아데노신이인산 | (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제 |\n| 예시) | 1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지 시킬 수 있다. ",
        "original_sentence": "임상시험심사위원회 | 실시하는 병원은 2군데 이상이어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_460",
      "text": "기관에 따라 임상시험결과에 차이가 | use – EMC requirements – Part 2-6: Particular requirements – In vitro |\n| 나. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 459,
        "window_size": 3,
        "char_count": 98,
        "word_count": 20,
        "page_number": 6,
        "window_text": "이렇게 수집된 개인 | ③ “Kit Information”에 ID(환자정보)를 입력하고 “Save”버튼을 눌러 저장한다.  |\n| 19.2.  임상시험심사위원회 | 실시하는 병원은 2군데 이상이어야 한다.  기관에 따라 임상시험결과에 차이가 | use – EMC requirements – Part 2-6: Particular requirements – In vitro |\n| 나.  모니터요원 | 1.  피험자 안전성(해당사항 없음) | - 혈소판 기능에 관한 검사는 주로 선천성 혈소판 기능 이상이나 수술전 선별검사로 | ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’의 민감도 및 특이도, 일치도 | 1) 잘못 기입된 부분은 한 줄로 긋고, 수정날짜(YY/MM/DD)와 수정자 서명, 필요시 수정 | equipment for measurement, control and laboratory use–Part 2–101: |\n| (1) 관련 규격 | - 의학통계전문가, 의료기기전문가 등 공동연구자가 있을 경우 이를 포함하여 | 예시) | Collagen/ADP Test cartridge Dade PFA Trigger solution February 7, 1997 | (6) 결과 제시 | 결합 | 정도를 | 폐색 | 전 | 혈액이동거리 | 측정법으로 | 정성하여 | 아데노신이인산 | (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제 |\n| 예시) | 1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지 시킬 수 있다.  | 대조기기 | 1) 민감도: 아스피린 투약 후 검체 중 최종 약물반응 양성 결과를 보인 검체의 | 마자 실신할 수도 있고 단순히 피 또는 주사침을 보는 것만으로도 쓰러질 수 있다. ",
        "original_sentence": "기관에 따라 임상시험결과에 차이가 | use – EMC requirements – Part 2-6: Particular requirements – In vitro |\n| 나. "
      }
    },
    {
      "chunk_id": "chunk_461",
      "text": "모니터요원 | 1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 460,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 6,
        "window_text": "|\n| 19.2.  임상시험심사위원회 | 실시하는 병원은 2군데 이상이어야 한다.  기관에 따라 임상시험결과에 차이가 | use – EMC requirements – Part 2-6: Particular requirements – In vitro |\n| 나.  모니터요원 | 1.  피험자 안전성(해당사항 없음) | - 혈소판 기능에 관한 검사는 주로 선천성 혈소판 기능 이상이나 수술전 선별검사로 | ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’의 민감도 및 특이도, 일치도 | 1) 잘못 기입된 부분은 한 줄로 긋고, 수정날짜(YY/MM/DD)와 수정자 서명, 필요시 수정 | equipment for measurement, control and laboratory use–Part 2–101: |\n| (1) 관련 규격 | - 의학통계전문가, 의료기기전문가 등 공동연구자가 있을 경우 이를 포함하여 | 예시) | Collagen/ADP Test cartridge Dade PFA Trigger solution February 7, 1997 | (6) 결과 제시 | 결합 | 정도를 | 폐색 | 전 | 혈액이동거리 | 측정법으로 | 정성하여 | 아데노신이인산 | (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제 |\n| 예시) | 1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지 시킬 수 있다.  | 대조기기 | 1) 민감도: 아스피린 투약 후 검체 중 최종 약물반응 양성 결과를 보인 검체의 | 마자 실신할 수도 있고 단순히 피 또는 주사침을 보는 것만으로도 쓰러질 수 있다.  |\n| 8.2. ",
        "original_sentence": "모니터요원 | 1. "
      }
    },
    {
      "chunk_id": "chunk_462",
      "text": "피험자 안전성(해당사항 없음) | - 혈소판 기능에 관한 검사는 주로 선천성 혈소판 기능 이상이나 수술전 선별검사로 | ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’의 민감도 및 특이도, 일치도 | 1) 잘못 기입된 부분은 한 줄로 긋고, 수정날짜(YY/MM/DD)와 수정자 서명, 필요시 수정 | equipment for measurement, control and laboratory use–Part 2–101: |\n| (1) 관련 규격 | - 의학통계전문가, 의료기기전문가 등 공동연구자가 있을 경우 이를 포함하여 | 예시) | Collagen/ADP Test cartridge Dade PFA Trigger solution February 7, 1997 | (6) 결과 제시 | 결합 | 정도를 | 폐색 | 전 | 혈액이동거리 | 측정법으로 | 정성하여 | 아데노신이인산 | (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제 |\n| 예시) | 1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지 시킬 수 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 461,
        "window_size": 3,
        "char_count": 541,
        "word_count": 123,
        "page_number": 3,
        "window_text": "임상시험심사위원회 | 실시하는 병원은 2군데 이상이어야 한다.  기관에 따라 임상시험결과에 차이가 | use – EMC requirements – Part 2-6: Particular requirements – In vitro |\n| 나.  모니터요원 | 1.  피험자 안전성(해당사항 없음) | - 혈소판 기능에 관한 검사는 주로 선천성 혈소판 기능 이상이나 수술전 선별검사로 | ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’의 민감도 및 특이도, 일치도 | 1) 잘못 기입된 부분은 한 줄로 긋고, 수정날짜(YY/MM/DD)와 수정자 서명, 필요시 수정 | equipment for measurement, control and laboratory use–Part 2–101: |\n| (1) 관련 규격 | - 의학통계전문가, 의료기기전문가 등 공동연구자가 있을 경우 이를 포함하여 | 예시) | Collagen/ADP Test cartridge Dade PFA Trigger solution February 7, 1997 | (6) 결과 제시 | 결합 | 정도를 | 폐색 | 전 | 혈액이동거리 | 측정법으로 | 정성하여 | 아데노신이인산 | (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제 |\n| 예시) | 1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지 시킬 수 있다.  | 대조기기 | 1) 민감도: 아스피린 투약 후 검체 중 최종 약물반응 양성 결과를 보인 검체의 | 마자 실신할 수도 있고 단순히 피 또는 주사침을 보는 것만으로도 쓰러질 수 있다.  |\n| 8.2.  피험자 제외기준 | 목적으로 하는 임상시험으로 피험자에게 발생할 피해가 없으므로 피험자 보상 규정은 | (4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이 반드시 필요한 | 19.9. ",
        "original_sentence": "피험자 안전성(해당사항 없음) | - 혈소판 기능에 관한 검사는 주로 선천성 혈소판 기능 이상이나 수술전 선별검사로 | ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’의 민감도 및 특이도, 일치도 | 1) 잘못 기입된 부분은 한 줄로 긋고, 수정날짜(YY/MM/DD)와 수정자 서명, 필요시 수정 | equipment for measurement, control and laboratory use–Part 2–101: |\n| (1) 관련 규격 | - 의학통계전문가, 의료기기전문가 등 공동연구자가 있을 경우 이를 포함하여 | 예시) | Collagen/ADP Test cartridge Dade PFA Trigger solution February 7, 1997 | (6) 결과 제시 | 결합 | 정도를 | 폐색 | 전 | 혈액이동거리 | 측정법으로 | 정성하여 | 아데노신이인산 | (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제 |\n| 예시) | 1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지 시킬 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_463",
      "text": "| 대조기기 | 1) 민감도: 아스피린 투약 후 검체 중 최종 약물반응 양성 결과를 보인 검체의 | 마자 실신할 수도 있고 단순히 피 또는 주사침을 보는 것만으로도 쓰러질 수 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 462,
        "window_size": 3,
        "char_count": 102,
        "word_count": 30,
        "page_number": 6,
        "window_text": "기관에 따라 임상시험결과에 차이가 | use – EMC requirements – Part 2-6: Particular requirements – In vitro |\n| 나.  모니터요원 | 1.  피험자 안전성(해당사항 없음) | - 혈소판 기능에 관한 검사는 주로 선천성 혈소판 기능 이상이나 수술전 선별검사로 | ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’의 민감도 및 특이도, 일치도 | 1) 잘못 기입된 부분은 한 줄로 긋고, 수정날짜(YY/MM/DD)와 수정자 서명, 필요시 수정 | equipment for measurement, control and laboratory use–Part 2–101: |\n| (1) 관련 규격 | - 의학통계전문가, 의료기기전문가 등 공동연구자가 있을 경우 이를 포함하여 | 예시) | Collagen/ADP Test cartridge Dade PFA Trigger solution February 7, 1997 | (6) 결과 제시 | 결합 | 정도를 | 폐색 | 전 | 혈액이동거리 | 측정법으로 | 정성하여 | 아데노신이인산 | (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제 |\n| 예시) | 1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지 시킬 수 있다.  | 대조기기 | 1) 민감도: 아스피린 투약 후 검체 중 최종 약물반응 양성 결과를 보인 검체의 | 마자 실신할 수도 있고 단순히 피 또는 주사침을 보는 것만으로도 쓰러질 수 있다.  |\n| 8.2.  피험자 제외기준 | 목적으로 하는 임상시험으로 피험자에게 발생할 피해가 없으므로 피험자 보상 규정은 | (4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이 반드시 필요한 | 19.9.  기록의 보존 | 활성화 여부를 유세포분석기를 이용하여 검사하거나, 특정 항혈소판 약제에 대한 | (3) 피험자 식별코드 부여 | (2) 대조기기 | (성명) | (서명) | (날짜) | 년 | 월 | 일 | 정보는 관련 법규에 따라 엄격하게 관리되며 연구에 관련된 담당자만이 수집된 | 수리 후 공인된 기사나 병원의 안전관리자에 의해 제품의 안전을 확인한다. ",
        "original_sentence": "| 대조기기 | 1) 민감도: 아스피린 투약 후 검체 중 최종 약물반응 양성 결과를 보인 검체의 | 마자 실신할 수도 있고 단순히 피 또는 주사침을 보는 것만으로도 쓰러질 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_464",
      "text": "|\n| 8.2. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 463,
        "window_size": 3,
        "char_count": 9,
        "word_count": 3,
        "page_number": 6,
        "window_text": "모니터요원 | 1.  피험자 안전성(해당사항 없음) | - 혈소판 기능에 관한 검사는 주로 선천성 혈소판 기능 이상이나 수술전 선별검사로 | ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’의 민감도 및 특이도, 일치도 | 1) 잘못 기입된 부분은 한 줄로 긋고, 수정날짜(YY/MM/DD)와 수정자 서명, 필요시 수정 | equipment for measurement, control and laboratory use–Part 2–101: |\n| (1) 관련 규격 | - 의학통계전문가, 의료기기전문가 등 공동연구자가 있을 경우 이를 포함하여 | 예시) | Collagen/ADP Test cartridge Dade PFA Trigger solution February 7, 1997 | (6) 결과 제시 | 결합 | 정도를 | 폐색 | 전 | 혈액이동거리 | 측정법으로 | 정성하여 | 아데노신이인산 | (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제 |\n| 예시) | 1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지 시킬 수 있다.  | 대조기기 | 1) 민감도: 아스피린 투약 후 검체 중 최종 약물반응 양성 결과를 보인 검체의 | 마자 실신할 수도 있고 단순히 피 또는 주사침을 보는 것만으로도 쓰러질 수 있다.  |\n| 8.2.  피험자 제외기준 | 목적으로 하는 임상시험으로 피험자에게 발생할 피해가 없으므로 피험자 보상 규정은 | (4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이 반드시 필요한 | 19.9.  기록의 보존 | 활성화 여부를 유세포분석기를 이용하여 검사하거나, 특정 항혈소판 약제에 대한 | (3) 피험자 식별코드 부여 | (2) 대조기기 | (성명) | (서명) | (날짜) | 년 | 월 | 일 | 정보는 관련 법규에 따라 엄격하게 관리되며 연구에 관련된 담당자만이 수집된 | 수리 후 공인된 기사나 병원의 안전관리자에 의해 제품의 안전을 확인한다.  |\n**있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 차이를 보정할 수**\n| 6. ",
        "original_sentence": "|\n| 8.2. "
      }
    },
    {
      "chunk_id": "chunk_465",
      "text": "피험자 제외기준 | 목적으로 하는 임상시험으로 피험자에게 발생할 피해가 없으므로 피험자 보상 규정은 | (4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이 반드시 필요한 | 19.9. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 464,
        "window_size": 3,
        "char_count": 111,
        "word_count": 27,
        "page_number": 6,
        "window_text": "피험자 안전성(해당사항 없음) | - 혈소판 기능에 관한 검사는 주로 선천성 혈소판 기능 이상이나 수술전 선별검사로 | ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’의 민감도 및 특이도, 일치도 | 1) 잘못 기입된 부분은 한 줄로 긋고, 수정날짜(YY/MM/DD)와 수정자 서명, 필요시 수정 | equipment for measurement, control and laboratory use–Part 2–101: |\n| (1) 관련 규격 | - 의학통계전문가, 의료기기전문가 등 공동연구자가 있을 경우 이를 포함하여 | 예시) | Collagen/ADP Test cartridge Dade PFA Trigger solution February 7, 1997 | (6) 결과 제시 | 결합 | 정도를 | 폐색 | 전 | 혈액이동거리 | 측정법으로 | 정성하여 | 아데노신이인산 | (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제 |\n| 예시) | 1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지 시킬 수 있다.  | 대조기기 | 1) 민감도: 아스피린 투약 후 검체 중 최종 약물반응 양성 결과를 보인 검체의 | 마자 실신할 수도 있고 단순히 피 또는 주사침을 보는 것만으로도 쓰러질 수 있다.  |\n| 8.2.  피험자 제외기준 | 목적으로 하는 임상시험으로 피험자에게 발생할 피해가 없으므로 피험자 보상 규정은 | (4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이 반드시 필요한 | 19.9.  기록의 보존 | 활성화 여부를 유세포분석기를 이용하여 검사하거나, 특정 항혈소판 약제에 대한 | (3) 피험자 식별코드 부여 | (2) 대조기기 | (성명) | (서명) | (날짜) | 년 | 월 | 일 | 정보는 관련 법규에 따라 엄격하게 관리되며 연구에 관련된 담당자만이 수집된 | 수리 후 공인된 기사나 병원의 안전관리자에 의해 제품의 안전을 확인한다.  |\n**있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 차이를 보정할 수**\n| 6.  FDA K042423: 510(k) summary. ",
        "original_sentence": "피험자 제외기준 | 목적으로 하는 임상시험으로 피험자에게 발생할 피해가 없으므로 피험자 보상 규정은 | (4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이 반드시 필요한 | 19.9. "
      }
    },
    {
      "chunk_id": "chunk_466",
      "text": "기록의 보존 | 활성화 여부를 유세포분석기를 이용하여 검사하거나, 특정 항혈소판 약제에 대한 | (3) 피험자 식별코드 부여 | (2) 대조기기 | (성명) | (서명) | (날짜) | 년 | 월 | 일 | 정보는 관련 법규에 따라 엄격하게 관리되며 연구에 관련된 담당자만이 수집된 | 수리 후 공인된 기사나 병원의 안전관리자에 의해 제품의 안전을 확인한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 465,
        "window_size": 3,
        "char_count": 201,
        "word_count": 54,
        "page_number": 3,
        "window_text": "| 대조기기 | 1) 민감도: 아스피린 투약 후 검체 중 최종 약물반응 양성 결과를 보인 검체의 | 마자 실신할 수도 있고 단순히 피 또는 주사침을 보는 것만으로도 쓰러질 수 있다.  |\n| 8.2.  피험자 제외기준 | 목적으로 하는 임상시험으로 피험자에게 발생할 피해가 없으므로 피험자 보상 규정은 | (4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이 반드시 필요한 | 19.9.  기록의 보존 | 활성화 여부를 유세포분석기를 이용하여 검사하거나, 특정 항혈소판 약제에 대한 | (3) 피험자 식별코드 부여 | (2) 대조기기 | (성명) | (서명) | (날짜) | 년 | 월 | 일 | 정보는 관련 법규에 따라 엄격하게 관리되며 연구에 관련된 담당자만이 수집된 | 수리 후 공인된 기사나 병원의 안전관리자에 의해 제품의 안전을 확인한다.  |\n**있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 차이를 보정할 수**\n| 6.  FDA K042423: 510(k) summary.  Accumetrics VerifyNow-Aspirin Assay | 평가를 통한 임상적 유효성 평가 | 해당 임상시험은 전혈 검체에 대한 체외진단용 의료기기의 임상적 평가에 대한 | 많이 사용되고 있습니다. ",
        "original_sentence": "기록의 보존 | 활성화 여부를 유세포분석기를 이용하여 검사하거나, 특정 항혈소판 약제에 대한 | (3) 피험자 식별코드 부여 | (2) 대조기기 | (성명) | (서명) | (날짜) | 년 | 월 | 일 | 정보는 관련 법규에 따라 엄격하게 관리되며 연구에 관련된 담당자만이 수집된 | 수리 후 공인된 기사나 병원의 안전관리자에 의해 제품의 안전을 확인한다. "
      }
    },
    {
      "chunk_id": "chunk_467",
      "text": "|\n**있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 차이를 보정할 수**\n| 6. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 466,
        "window_size": 3,
        "char_count": 53,
        "word_count": 14,
        "page_number": 3,
        "window_text": "|\n| 8.2.  피험자 제외기준 | 목적으로 하는 임상시험으로 피험자에게 발생할 피해가 없으므로 피험자 보상 규정은 | (4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이 반드시 필요한 | 19.9.  기록의 보존 | 활성화 여부를 유세포분석기를 이용하여 검사하거나, 특정 항혈소판 약제에 대한 | (3) 피험자 식별코드 부여 | (2) 대조기기 | (성명) | (서명) | (날짜) | 년 | 월 | 일 | 정보는 관련 법규에 따라 엄격하게 관리되며 연구에 관련된 담당자만이 수집된 | 수리 후 공인된 기사나 병원의 안전관리자에 의해 제품의 안전을 확인한다.  |\n**있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 차이를 보정할 수**\n| 6.  FDA K042423: 510(k) summary.  Accumetrics VerifyNow-Aspirin Assay | 평가를 통한 임상적 유효성 평가 | 해당 임상시험은 전혈 검체에 대한 체외진단용 의료기기의 임상적 평가에 대한 | 많이 사용되고 있습니다.  특히 혈소판의 수적 이상이 없는 출혈질환에서 선천성 | 2) 특이도: 클로피도그렐 투약 전 검체 중 최종 약물반응 음성 결과를 보인 |\n| 예시) | 가. ",
        "original_sentence": "|\n**있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 차이를 보정할 수**\n| 6. "
      }
    },
    {
      "chunk_id": "chunk_468",
      "text": "FDA K042423: 510(k) summary. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 467,
        "window_size": 3,
        "char_count": 29,
        "word_count": 4,
        "page_number": 6,
        "window_text": "피험자 제외기준 | 목적으로 하는 임상시험으로 피험자에게 발생할 피해가 없으므로 피험자 보상 규정은 | (4) 임상시험에 영향을 주지 않는 사소한 수정이나 명시는 승인이 반드시 필요한 | 19.9.  기록의 보존 | 활성화 여부를 유세포분석기를 이용하여 검사하거나, 특정 항혈소판 약제에 대한 | (3) 피험자 식별코드 부여 | (2) 대조기기 | (성명) | (서명) | (날짜) | 년 | 월 | 일 | 정보는 관련 법규에 따라 엄격하게 관리되며 연구에 관련된 담당자만이 수집된 | 수리 후 공인된 기사나 병원의 안전관리자에 의해 제품의 안전을 확인한다.  |\n**있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 차이를 보정할 수**\n| 6.  FDA K042423: 510(k) summary.  Accumetrics VerifyNow-Aspirin Assay | 평가를 통한 임상적 유효성 평가 | 해당 임상시험은 전혈 검체에 대한 체외진단용 의료기기의 임상적 평가에 대한 | 많이 사용되고 있습니다.  특히 혈소판의 수적 이상이 없는 출혈질환에서 선천성 | 2) 특이도: 클로피도그렐 투약 전 검체 중 최종 약물반응 음성 결과를 보인 |\n| 예시) | 가.  환자 및 대조군 내원시에 아래 11.2. ",
        "original_sentence": "FDA K042423: 510(k) summary. "
      }
    },
    {
      "chunk_id": "chunk_469",
      "text": "Accumetrics VerifyNow-Aspirin Assay | 평가를 통한 임상적 유효성 평가 | 해당 임상시험은 전혈 검체에 대한 체외진단용 의료기기의 임상적 평가에 대한 | 많이 사용되고 있습니다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 468,
        "window_size": 3,
        "char_count": 116,
        "word_count": 24,
        "page_number": 18,
        "window_text": "기록의 보존 | 활성화 여부를 유세포분석기를 이용하여 검사하거나, 특정 항혈소판 약제에 대한 | (3) 피험자 식별코드 부여 | (2) 대조기기 | (성명) | (서명) | (날짜) | 년 | 월 | 일 | 정보는 관련 법규에 따라 엄격하게 관리되며 연구에 관련된 담당자만이 수집된 | 수리 후 공인된 기사나 병원의 안전관리자에 의해 제품의 안전을 확인한다.  |\n**있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 차이를 보정할 수**\n| 6.  FDA K042423: 510(k) summary.  Accumetrics VerifyNow-Aspirin Assay | 평가를 통한 임상적 유효성 평가 | 해당 임상시험은 전혈 검체에 대한 체외진단용 의료기기의 임상적 평가에 대한 | 많이 사용되고 있습니다.  특히 혈소판의 수적 이상이 없는 출혈질환에서 선천성 | 2) 특이도: 클로피도그렐 투약 전 검체 중 최종 약물반응 음성 결과를 보인 |\n| 예시) | 가.  환자 및 대조군 내원시에 아래 11.2.  임상시험 절차에 따라 임상시험을 시행한다. ",
        "original_sentence": "Accumetrics VerifyNow-Aspirin Assay | 평가를 통한 임상적 유효성 평가 | 해당 임상시험은 전혈 검체에 대한 체외진단용 의료기기의 임상적 평가에 대한 | 많이 사용되고 있습니다. "
      }
    },
    {
      "chunk_id": "chunk_470",
      "text": "특히 혈소판의 수적 이상이 없는 출혈질환에서 선천성 | 2) 특이도: 클로피도그렐 투약 전 검체 중 최종 약물반응 음성 결과를 보인 |\n| 예시) | 가. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 469,
        "window_size": 3,
        "char_count": 87,
        "word_count": 25,
        "page_number": 6,
        "window_text": "|\n**있는지에 대한 여부를 분석해야 하며, 기관에 따른 영향력 차이를 보정할 수**\n| 6.  FDA K042423: 510(k) summary.  Accumetrics VerifyNow-Aspirin Assay | 평가를 통한 임상적 유효성 평가 | 해당 임상시험은 전혈 검체에 대한 체외진단용 의료기기의 임상적 평가에 대한 | 많이 사용되고 있습니다.  특히 혈소판의 수적 이상이 없는 출혈질환에서 선천성 | 2) 특이도: 클로피도그렐 투약 전 검체 중 최종 약물반응 음성 결과를 보인 |\n| 예시) | 가.  환자 및 대조군 내원시에 아래 11.2.  임상시험 절차에 따라 임상시험을 시행한다.  | 회사명 | 성명 | 소재지 | 전화 | 105명 이상, ADP test 양성(비정상 결과) 환자 105명 이상, ADP test 음성(정상 |\n| 1) 혈소판 기능검사: light transmission aggregometry (LTA) 검사, PFA-100Ⓡ | ① 「의료기기의 안정성시험 기준」(식약처 고시) | 한다. ",
        "original_sentence": "특히 혈소판의 수적 이상이 없는 출혈질환에서 선천성 | 2) 특이도: 클로피도그렐 투약 전 검체 중 최종 약물반응 음성 결과를 보인 |\n| 예시) | 가. "
      }
    },
    {
      "chunk_id": "chunk_471",
      "text": "환자 및 대조군 내원시에 아래 11.2. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 470,
        "window_size": 3,
        "char_count": 23,
        "word_count": 6,
        "page_number": 6,
        "window_text": "FDA K042423: 510(k) summary.  Accumetrics VerifyNow-Aspirin Assay | 평가를 통한 임상적 유효성 평가 | 해당 임상시험은 전혈 검체에 대한 체외진단용 의료기기의 임상적 평가에 대한 | 많이 사용되고 있습니다.  특히 혈소판의 수적 이상이 없는 출혈질환에서 선천성 | 2) 특이도: 클로피도그렐 투약 전 검체 중 최종 약물반응 음성 결과를 보인 |\n| 예시) | 가.  환자 및 대조군 내원시에 아래 11.2.  임상시험 절차에 따라 임상시험을 시행한다.  | 회사명 | 성명 | 소재지 | 전화 | 105명 이상, ADP test 양성(비정상 결과) 환자 105명 이상, ADP test 음성(정상 |\n| 1) 혈소판 기능검사: light transmission aggregometry (LTA) 검사, PFA-100Ⓡ | ① 「의료기기의 안정성시험 기준」(식약처 고시) | 한다.  | (5) 시험 방법 | (mimic)을 제조하여 제공 또는 각 검사실에서 설정하는 방법 등을 | 각각의 검체 및 시약 로트 조합을 측정장비로 반복 측정한 샘플의 | 처음으로 유발될 수도 있지만 과거력이 있는 경우도 있다. ",
        "original_sentence": "환자 및 대조군 내원시에 아래 11.2. "
      }
    },
    {
      "chunk_id": "chunk_472",
      "text": "임상시험 절차에 따라 임상시험을 시행한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 471,
        "window_size": 3,
        "char_count": 24,
        "word_count": 5,
        "page_number": 6,
        "window_text": "Accumetrics VerifyNow-Aspirin Assay | 평가를 통한 임상적 유효성 평가 | 해당 임상시험은 전혈 검체에 대한 체외진단용 의료기기의 임상적 평가에 대한 | 많이 사용되고 있습니다.  특히 혈소판의 수적 이상이 없는 출혈질환에서 선천성 | 2) 특이도: 클로피도그렐 투약 전 검체 중 최종 약물반응 음성 결과를 보인 |\n| 예시) | 가.  환자 및 대조군 내원시에 아래 11.2.  임상시험 절차에 따라 임상시험을 시행한다.  | 회사명 | 성명 | 소재지 | 전화 | 105명 이상, ADP test 양성(비정상 결과) 환자 105명 이상, ADP test 음성(정상 |\n| 1) 혈소판 기능검사: light transmission aggregometry (LTA) 검사, PFA-100Ⓡ | ① 「의료기기의 안정성시험 기준」(식약처 고시) | 한다.  | (5) 시험 방법 | (mimic)을 제조하여 제공 또는 각 검사실에서 설정하는 방법 등을 | 각각의 검체 및 시약 로트 조합을 측정장비로 반복 측정한 샘플의 | 처음으로 유발될 수도 있지만 과거력이 있는 경우도 있다.  어지럽고 메스껍고, | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈 |\n| 사. ISO 23640 In vitro diagnostic medical devices – Evaluation of stability of | 가. ",
        "original_sentence": "임상시험 절차에 따라 임상시험을 시행한다. "
      }
    },
    {
      "chunk_id": "chunk_473",
      "text": "| 회사명 | 성명 | 소재지 | 전화 | 105명 이상, ADP test 양성(비정상 결과) 환자 105명 이상, ADP test 음성(정상 |\n| 1) 혈소판 기능검사: light transmission aggregometry (LTA) 검사, PFA-100Ⓡ | ① 「의료기기의 안정성시험 기준」(식약처 고시) | 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 472,
        "window_size": 3,
        "char_count": 183,
        "word_count": 40,
        "page_number": 6,
        "window_text": "특히 혈소판의 수적 이상이 없는 출혈질환에서 선천성 | 2) 특이도: 클로피도그렐 투약 전 검체 중 최종 약물반응 음성 결과를 보인 |\n| 예시) | 가.  환자 및 대조군 내원시에 아래 11.2.  임상시험 절차에 따라 임상시험을 시행한다.  | 회사명 | 성명 | 소재지 | 전화 | 105명 이상, ADP test 양성(비정상 결과) 환자 105명 이상, ADP test 음성(정상 |\n| 1) 혈소판 기능검사: light transmission aggregometry (LTA) 검사, PFA-100Ⓡ | ① 「의료기기의 안정성시험 기준」(식약처 고시) | 한다.  | (5) 시험 방법 | (mimic)을 제조하여 제공 또는 각 검사실에서 설정하는 방법 등을 | 각각의 검체 및 시약 로트 조합을 측정장비로 반복 측정한 샘플의 | 처음으로 유발될 수도 있지만 과거력이 있는 경우도 있다.  어지럽고 메스껍고, | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈 |\n| 사. ISO 23640 In vitro diagnostic medical devices – Evaluation of stability of | 가.  혈소판 기능검사 | 7.3. ",
        "original_sentence": "| 회사명 | 성명 | 소재지 | 전화 | 105명 이상, ADP test 양성(비정상 결과) 환자 105명 이상, ADP test 음성(정상 |\n| 1) 혈소판 기능검사: light transmission aggregometry (LTA) 검사, PFA-100Ⓡ | ① 「의료기기의 안정성시험 기준」(식약처 고시) | 한다. "
      }
    },
    {
      "chunk_id": "chunk_474",
      "text": "| (5) 시험 방법 | (mimic)을 제조하여 제공 또는 각 검사실에서 설정하는 방법 등을 | 각각의 검체 및 시약 로트 조합을 측정장비로 반복 측정한 샘플의 | 처음으로 유발될 수도 있지만 과거력이 있는 경우도 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 473,
        "window_size": 3,
        "char_count": 125,
        "word_count": 34,
        "page_number": 6,
        "window_text": "환자 및 대조군 내원시에 아래 11.2.  임상시험 절차에 따라 임상시험을 시행한다.  | 회사명 | 성명 | 소재지 | 전화 | 105명 이상, ADP test 양성(비정상 결과) 환자 105명 이상, ADP test 음성(정상 |\n| 1) 혈소판 기능검사: light transmission aggregometry (LTA) 검사, PFA-100Ⓡ | ① 「의료기기의 안정성시험 기준」(식약처 고시) | 한다.  | (5) 시험 방법 | (mimic)을 제조하여 제공 또는 각 검사실에서 설정하는 방법 등을 | 각각의 검체 및 시약 로트 조합을 측정장비로 반복 측정한 샘플의 | 처음으로 유발될 수도 있지만 과거력이 있는 경우도 있다.  어지럽고 메스껍고, | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈 |\n| 사. ISO 23640 In vitro diagnostic medical devices – Evaluation of stability of | 가.  혈소판 기능검사 | 7.3.  임상시험용 의료기기 사용방법 | 없음. ",
        "original_sentence": "| (5) 시험 방법 | (mimic)을 제조하여 제공 또는 각 검사실에서 설정하는 방법 등을 | 각각의 검체 및 시약 로트 조합을 측정장비로 반복 측정한 샘플의 | 처음으로 유발될 수도 있지만 과거력이 있는 경우도 있다. "
      }
    },
    {
      "chunk_id": "chunk_475",
      "text": "어지럽고 메스껍고, | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈 |\n| 사. ISO 23640 In vitro diagnostic medical devices – Evaluation of stability of | 가. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 474,
        "window_size": 3,
        "char_count": 180,
        "word_count": 39,
        "page_number": 6,
        "window_text": "임상시험 절차에 따라 임상시험을 시행한다.  | 회사명 | 성명 | 소재지 | 전화 | 105명 이상, ADP test 양성(비정상 결과) 환자 105명 이상, ADP test 음성(정상 |\n| 1) 혈소판 기능검사: light transmission aggregometry (LTA) 검사, PFA-100Ⓡ | ① 「의료기기의 안정성시험 기준」(식약처 고시) | 한다.  | (5) 시험 방법 | (mimic)을 제조하여 제공 또는 각 검사실에서 설정하는 방법 등을 | 각각의 검체 및 시약 로트 조합을 측정장비로 반복 측정한 샘플의 | 처음으로 유발될 수도 있지만 과거력이 있는 경우도 있다.  어지럽고 메스껍고, | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈 |\n| 사. ISO 23640 In vitro diagnostic medical devices – Evaluation of stability of | 가.  혈소판 기능검사 | 7.3.  임상시험용 의료기기 사용방법 | 없음.  | (1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록 하여야 하며 보안을 | 반응을 검사하는 VerifyNow와 같은 기기들도 사용되고 있다. ",
        "original_sentence": "어지럽고 메스껍고, | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈 |\n| 사. ISO 23640 In vitro diagnostic medical devices – Evaluation of stability of | 가. "
      }
    },
    {
      "chunk_id": "chunk_476",
      "text": "혈소판 기능검사 | 7.3. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 475,
        "window_size": 3,
        "char_count": 16,
        "word_count": 4,
        "page_number": 15,
        "window_text": "| 회사명 | 성명 | 소재지 | 전화 | 105명 이상, ADP test 양성(비정상 결과) 환자 105명 이상, ADP test 음성(정상 |\n| 1) 혈소판 기능검사: light transmission aggregometry (LTA) 검사, PFA-100Ⓡ | ① 「의료기기의 안정성시험 기준」(식약처 고시) | 한다.  | (5) 시험 방법 | (mimic)을 제조하여 제공 또는 각 검사실에서 설정하는 방법 등을 | 각각의 검체 및 시약 로트 조합을 측정장비로 반복 측정한 샘플의 | 처음으로 유발될 수도 있지만 과거력이 있는 경우도 있다.  어지럽고 메스껍고, | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈 |\n| 사. ISO 23640 In vitro diagnostic medical devices – Evaluation of stability of | 가.  혈소판 기능검사 | 7.3.  임상시험용 의료기기 사용방법 | 없음.  | (1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록 하여야 하며 보안을 | 반응을 검사하는 VerifyNow와 같은 기기들도 사용되고 있다.  하지만 기기에 따라 | 가. ",
        "original_sentence": "혈소판 기능검사 | 7.3. "
      }
    },
    {
      "chunk_id": "chunk_477",
      "text": "임상시험용 의료기기 사용방법 | 없음. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 476,
        "window_size": 3,
        "char_count": 22,
        "word_count": 5,
        "page_number": 9,
        "window_text": "| (5) 시험 방법 | (mimic)을 제조하여 제공 또는 각 검사실에서 설정하는 방법 등을 | 각각의 검체 및 시약 로트 조합을 측정장비로 반복 측정한 샘플의 | 처음으로 유발될 수도 있지만 과거력이 있는 경우도 있다.  어지럽고 메스껍고, | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈 |\n| 사. ISO 23640 In vitro diagnostic medical devices – Evaluation of stability of | 가.  혈소판 기능검사 | 7.3.  임상시험용 의료기기 사용방법 | 없음.  | (1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록 하여야 하며 보안을 | 반응을 검사하는 VerifyNow와 같은 기기들도 사용되고 있다.  하지만 기기에 따라 | 가.  공통 제외기준 | (4) 시험 조건 | 동의서 버전 또는 버전 날짜: | Version  _________________  date ______________ | ① 임상시험 참여에 동의하고 인구학적 조사, 병력 문진 등을 통하여 피험자 선정 | 진단에 많은 도움을 줄 수 있습니다. ",
        "original_sentence": "임상시험용 의료기기 사용방법 | 없음. "
      }
    },
    {
      "chunk_id": "chunk_478",
      "text": "| (1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록 하여야 하며 보안을 | 반응을 검사하는 VerifyNow와 같은 기기들도 사용되고 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 477,
        "window_size": 3,
        "char_count": 89,
        "word_count": 22,
        "page_number": 6,
        "window_text": "어지럽고 메스껍고, | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈 |\n| 사. ISO 23640 In vitro diagnostic medical devices – Evaluation of stability of | 가.  혈소판 기능검사 | 7.3.  임상시험용 의료기기 사용방법 | 없음.  | (1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록 하여야 하며 보안을 | 반응을 검사하는 VerifyNow와 같은 기기들도 사용되고 있다.  하지만 기기에 따라 | 가.  공통 제외기준 | (4) 시험 조건 | 동의서 버전 또는 버전 날짜: | Version  _________________  date ______________ | ① 임상시험 참여에 동의하고 인구학적 조사, 병력 문진 등을 통하여 피험자 선정 | 진단에 많은 도움을 줄 수 있습니다.  | ④ 메인화면의 “Camera”탭에서 검사칩의 현재 모습, “Log”탭에서 현재 검사 | 및 제외기준을 검토하여 피험자 식별코드를 부여한다. ",
        "original_sentence": "| (1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록 하여야 하며 보안을 | 반응을 검사하는 VerifyNow와 같은 기기들도 사용되고 있다. "
      }
    },
    {
      "chunk_id": "chunk_479",
      "text": "하지만 기기에 따라 | 가. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 478,
        "window_size": 3,
        "char_count": 16,
        "word_count": 5,
        "page_number": 103,
        "window_text": "혈소판 기능검사 | 7.3.  임상시험용 의료기기 사용방법 | 없음.  | (1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록 하여야 하며 보안을 | 반응을 검사하는 VerifyNow와 같은 기기들도 사용되고 있다.  하지만 기기에 따라 | 가.  공통 제외기준 | (4) 시험 조건 | 동의서 버전 또는 버전 날짜: | Version  _________________  date ______________ | ① 임상시험 참여에 동의하고 인구학적 조사, 병력 문진 등을 통하여 피험자 선정 | 진단에 많은 도움을 줄 수 있습니다.  | ④ 메인화면의 “Camera”탭에서 검사칩의 현재 모습, “Log”탭에서 현재 검사 | 및 제외기준을 검토하여 피험자 식별코드를 부여한다.  피험자 식별코드는 아래의 | 절차를 반복한다. ",
        "original_sentence": "하지만 기기에 따라 | 가. "
      }
    },
    {
      "chunk_id": "chunk_480",
      "text": "공통 제외기준 | (4) 시험 조건 | 동의서 버전 또는 버전 날짜: | Version  _________________  date ______________ | ① 임상시험 참여에 동의하고 인구학적 조사, 병력 문진 등을 통하여 피험자 선정 | 진단에 많은 도움을 줄 수 있습니다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 479,
        "window_size": 3,
        "char_count": 159,
        "word_count": 37,
        "page_number": 9,
        "window_text": "임상시험용 의료기기 사용방법 | 없음.  | (1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록 하여야 하며 보안을 | 반응을 검사하는 VerifyNow와 같은 기기들도 사용되고 있다.  하지만 기기에 따라 | 가.  공통 제외기준 | (4) 시험 조건 | 동의서 버전 또는 버전 날짜: | Version  _________________  date ______________ | ① 임상시험 참여에 동의하고 인구학적 조사, 병력 문진 등을 통하여 피험자 선정 | 진단에 많은 도움을 줄 수 있습니다.  | ④ 메인화면의 “Camera”탭에서 검사칩의 현재 모습, “Log”탭에서 현재 검사 | 및 제외기준을 검토하여 피험자 식별코드를 부여한다.  피험자 식별코드는 아래의 | 절차를 반복한다.  두 검체의 평균 MD 또는 MR이 진단경계치 범위 내에 | ① 정상 대조군: 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군 |\n| 나. ",
        "original_sentence": "공통 제외기준 | (4) 시험 조건 | 동의서 버전 또는 버전 날짜: | Version  _________________  date ______________ | ① 임상시험 참여에 동의하고 인구학적 조사, 병력 문진 등을 통하여 피험자 선정 | 진단에 많은 도움을 줄 수 있습니다. "
      }
    },
    {
      "chunk_id": "chunk_481",
      "text": "| ④ 메인화면의 “Camera”탭에서 검사칩의 현재 모습, “Log”탭에서 현재 검사 | 및 제외기준을 검토하여 피험자 식별코드를 부여한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 480,
        "window_size": 3,
        "char_count": 80,
        "word_count": 17,
        "page_number": 49,
        "window_text": "| (1) 임상시험 실시와 관련된 각종 자료 및 기록을 잘 보존하도록 하여야 하며 보안을 | 반응을 검사하는 VerifyNow와 같은 기기들도 사용되고 있다.  하지만 기기에 따라 | 가.  공통 제외기준 | (4) 시험 조건 | 동의서 버전 또는 버전 날짜: | Version  _________________  date ______________ | ① 임상시험 참여에 동의하고 인구학적 조사, 병력 문진 등을 통하여 피험자 선정 | 진단에 많은 도움을 줄 수 있습니다.  | ④ 메인화면의 “Camera”탭에서 검사칩의 현재 모습, “Log”탭에서 현재 검사 | 및 제외기준을 검토하여 피험자 식별코드를 부여한다.  피험자 식별코드는 아래의 | 절차를 반복한다.  두 검체의 평균 MD 또는 MR이 진단경계치 범위 내에 | ① 정상 대조군: 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군 |\n| 나.  임상시험용 의료기기의 공급과 취급 | (주) ○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○-○○○-○○○○ | 혹은 후천성 혈소판 기능 이상을 감별하는데 중요한 검사입니다. ",
        "original_sentence": "| ④ 메인화면의 “Camera”탭에서 검사칩의 현재 모습, “Log”탭에서 현재 검사 | 및 제외기준을 검토하여 피험자 식별코드를 부여한다. "
      }
    },
    {
      "chunk_id": "chunk_482",
      "text": "피험자 식별코드는 아래의 | 절차를 반복한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 481,
        "window_size": 3,
        "char_count": 26,
        "word_count": 6,
        "page_number": 6,
        "window_text": "하지만 기기에 따라 | 가.  공통 제외기준 | (4) 시험 조건 | 동의서 버전 또는 버전 날짜: | Version  _________________  date ______________ | ① 임상시험 참여에 동의하고 인구학적 조사, 병력 문진 등을 통하여 피험자 선정 | 진단에 많은 도움을 줄 수 있습니다.  | ④ 메인화면의 “Camera”탭에서 검사칩의 현재 모습, “Log”탭에서 현재 검사 | 및 제외기준을 검토하여 피험자 식별코드를 부여한다.  피험자 식별코드는 아래의 | 절차를 반복한다.  두 검체의 평균 MD 또는 MR이 진단경계치 범위 내에 | ① 정상 대조군: 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군 |\n| 나.  임상시험용 의료기기의 공급과 취급 | (주) ○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○-○○○-○○○○ | 혹은 후천성 혈소판 기능 이상을 감별하는데 중요한 검사입니다.  최근에는 심혈관 |\n| 임상시험으로 피험자가 직접적으로 받는 인체의 위해도가 없어 예측되는 부작용에 | (1) 혈소판 기능검사 | 결과) 대조군 132명 이상, SIPA test 양성(비정상 결과) 환자 105명 이상, SIPA |\n| (2) 국내외 개발동향 | 2) 혈소판 약물반응검사: VerifyNowⓇ | 얼굴이 창백해지고 이 나며, 맥박수가 줄어들고, 혈압이 심하게 떨어지며, 심하면 |\n| 예시) | 12.2 사용상의 주의사항 | 민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d) | 혈소판 기능 부전이 의심되는 환자의 구연산 처리된 전혈에서 혈소판 기능부전 | (2) 해당 의료기기의 사용목적：혈소판 약물반응 검사 | 1) 검체준비 및 저장방법 | (6) 결과 제시 : 개봉시점과 각 시점 간 시험결과의 차이를 구한다. ",
        "original_sentence": "피험자 식별코드는 아래의 | 절차를 반복한다. "
      }
    },
    {
      "chunk_id": "chunk_483",
      "text": "두 검체의 평균 MD 또는 MR이 진단경계치 범위 내에 | ① 정상 대조군: 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군 |\n| 나. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 482,
        "window_size": 3,
        "char_count": 85,
        "word_count": 24,
        "page_number": 23,
        "window_text": "공통 제외기준 | (4) 시험 조건 | 동의서 버전 또는 버전 날짜: | Version  _________________  date ______________ | ① 임상시험 참여에 동의하고 인구학적 조사, 병력 문진 등을 통하여 피험자 선정 | 진단에 많은 도움을 줄 수 있습니다.  | ④ 메인화면의 “Camera”탭에서 검사칩의 현재 모습, “Log”탭에서 현재 검사 | 및 제외기준을 검토하여 피험자 식별코드를 부여한다.  피험자 식별코드는 아래의 | 절차를 반복한다.  두 검체의 평균 MD 또는 MR이 진단경계치 범위 내에 | ① 정상 대조군: 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군 |\n| 나.  임상시험용 의료기기의 공급과 취급 | (주) ○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○-○○○-○○○○ | 혹은 후천성 혈소판 기능 이상을 감별하는데 중요한 검사입니다.  최근에는 심혈관 |\n| 임상시험으로 피험자가 직접적으로 받는 인체의 위해도가 없어 예측되는 부작용에 | (1) 혈소판 기능검사 | 결과) 대조군 132명 이상, SIPA test 양성(비정상 결과) 환자 105명 이상, SIPA |\n| (2) 국내외 개발동향 | 2) 혈소판 약물반응검사: VerifyNowⓇ | 얼굴이 창백해지고 이 나며, 맥박수가 줄어들고, 혈압이 심하게 떨어지며, 심하면 |\n| 예시) | 12.2 사용상의 주의사항 | 민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d) | 혈소판 기능 부전이 의심되는 환자의 구연산 처리된 전혈에서 혈소판 기능부전 | (2) 해당 의료기기의 사용목적：혈소판 약물반응 검사 | 1) 검체준비 및 저장방법 | (6) 결과 제시 : 개봉시점과 각 시점 간 시험결과의 차이를 구한다.  | 연구 제목: | 출혈 시간 및 항혈소판제제 저항성 복합검사기기(제품명: 000)의 정확도 검증을 위한 | - 피험자의 임상정보를 알 수 없는 경우 | ② ISO 23640 In vitro diagnostic medical devices – Evaluation of | (차) 시험 기기와 측정기기 : IEC 61010-1의 16절에 기술된 시험 기기 | 제시할 수 있다. ",
        "original_sentence": "두 검체의 평균 MD 또는 MR이 진단경계치 범위 내에 | ① 정상 대조군: 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군 |\n| 나. "
      }
    },
    {
      "chunk_id": "chunk_484",
      "text": "임상시험용 의료기기의 공급과 취급 | (주) ○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○-○○○-○○○○ | 혹은 후천성 혈소판 기능 이상을 감별하는데 중요한 검사입니다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 483,
        "window_size": 3,
        "char_count": 100,
        "word_count": 24,
        "page_number": 9,
        "window_text": "| ④ 메인화면의 “Camera”탭에서 검사칩의 현재 모습, “Log”탭에서 현재 검사 | 및 제외기준을 검토하여 피험자 식별코드를 부여한다.  피험자 식별코드는 아래의 | 절차를 반복한다.  두 검체의 평균 MD 또는 MR이 진단경계치 범위 내에 | ① 정상 대조군: 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군 |\n| 나.  임상시험용 의료기기의 공급과 취급 | (주) ○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○-○○○-○○○○ | 혹은 후천성 혈소판 기능 이상을 감별하는데 중요한 검사입니다.  최근에는 심혈관 |\n| 임상시험으로 피험자가 직접적으로 받는 인체의 위해도가 없어 예측되는 부작용에 | (1) 혈소판 기능검사 | 결과) 대조군 132명 이상, SIPA test 양성(비정상 결과) 환자 105명 이상, SIPA |\n| (2) 국내외 개발동향 | 2) 혈소판 약물반응검사: VerifyNowⓇ | 얼굴이 창백해지고 이 나며, 맥박수가 줄어들고, 혈압이 심하게 떨어지며, 심하면 |\n| 예시) | 12.2 사용상의 주의사항 | 민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d) | 혈소판 기능 부전이 의심되는 환자의 구연산 처리된 전혈에서 혈소판 기능부전 | (2) 해당 의료기기의 사용목적：혈소판 약물반응 검사 | 1) 검체준비 및 저장방법 | (6) 결과 제시 : 개봉시점과 각 시점 간 시험결과의 차이를 구한다.  | 연구 제목: | 출혈 시간 및 항혈소판제제 저항성 복합검사기기(제품명: 000)의 정확도 검증을 위한 | - 피험자의 임상정보를 알 수 없는 경우 | ② ISO 23640 In vitro diagnostic medical devices – Evaluation of | (차) 시험 기기와 측정기기 : IEC 61010-1의 16절에 기술된 시험 기기 | 제시할 수 있다.  | 2) 특이도: 대조기기 정상 결과 검체 중 시험기기에서 정상 결과를 보인 검체의 | 2) 특이도: 아스피린 투약 전 검체 중 최종 약물반응 음성 결과를 보인 검체의 | 유지하도록 한다. ",
        "original_sentence": "임상시험용 의료기기의 공급과 취급 | (주) ○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○-○○○-○○○○ | 혹은 후천성 혈소판 기능 이상을 감별하는데 중요한 검사입니다. "
      }
    },
    {
      "chunk_id": "chunk_485",
      "text": "최근에는 심혈관 |\n| 임상시험으로 피험자가 직접적으로 받는 인체의 위해도가 없어 예측되는 부작용에 | (1) 혈소판 기능검사 | 결과) 대조군 132명 이상, SIPA test 양성(비정상 결과) 환자 105명 이상, SIPA |\n| (2) 국내외 개발동향 | 2) 혈소판 약물반응검사: VerifyNowⓇ | 얼굴이 창백해지고 이 나며, 맥박수가 줄어들고, 혈압이 심하게 떨어지며, 심하면 |\n| 예시) | 12.2 사용상의 주의사항 | 민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d) | 혈소판 기능 부전이 의심되는 환자의 구연산 처리된 전혈에서 혈소판 기능부전 | (2) 해당 의료기기의 사용목적：혈소판 약물반응 검사 | 1) 검체준비 및 저장방법 | (6) 결과 제시 : 개봉시점과 각 시점 간 시험결과의 차이를 구한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 484,
        "window_size": 3,
        "char_count": 419,
        "word_count": 100,
        "page_number": 9,
        "window_text": "피험자 식별코드는 아래의 | 절차를 반복한다.  두 검체의 평균 MD 또는 MR이 진단경계치 범위 내에 | ① 정상 대조군: 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군 |\n| 나.  임상시험용 의료기기의 공급과 취급 | (주) ○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○-○○○-○○○○ | 혹은 후천성 혈소판 기능 이상을 감별하는데 중요한 검사입니다.  최근에는 심혈관 |\n| 임상시험으로 피험자가 직접적으로 받는 인체의 위해도가 없어 예측되는 부작용에 | (1) 혈소판 기능검사 | 결과) 대조군 132명 이상, SIPA test 양성(비정상 결과) 환자 105명 이상, SIPA |\n| (2) 국내외 개발동향 | 2) 혈소판 약물반응검사: VerifyNowⓇ | 얼굴이 창백해지고 이 나며, 맥박수가 줄어들고, 혈압이 심하게 떨어지며, 심하면 |\n| 예시) | 12.2 사용상의 주의사항 | 민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d) | 혈소판 기능 부전이 의심되는 환자의 구연산 처리된 전혈에서 혈소판 기능부전 | (2) 해당 의료기기의 사용목적：혈소판 약물반응 검사 | 1) 검체준비 및 저장방법 | (6) 결과 제시 : 개봉시점과 각 시점 간 시험결과의 차이를 구한다.  | 연구 제목: | 출혈 시간 및 항혈소판제제 저항성 복합검사기기(제품명: 000)의 정확도 검증을 위한 | - 피험자의 임상정보를 알 수 없는 경우 | ② ISO 23640 In vitro diagnostic medical devices – Evaluation of | (차) 시험 기기와 측정기기 : IEC 61010-1의 16절에 기술된 시험 기기 | 제시할 수 있다.  | 2) 특이도: 대조기기 정상 결과 검체 중 시험기기에서 정상 결과를 보인 검체의 | 2) 특이도: 아스피린 투약 전 검체 중 최종 약물반응 음성 결과를 보인 검체의 | 유지하도록 한다.  제조허가·수입허가 또는 그 변경허가를 위한 임상시험 관련 | (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제 | 3.2% | 구연산 | 처리된 | 전혈 | 검체에 | 분석대상물질(Agonist | 또는 | 이동거리값의 평균 및 표준편차를 계산하고 시험시료 측정결과의 | (3) 시험 목적 : 출혈시간 및 항혈소판제제 저항성 복합검사기기의 | 속하는 경우, 첫 번째 공여자의 혈소판 기능 상태 및 약물 복용 기록을 의심 | 1) Aspirin test: Aspirin 약물 복용 전/후의 검체에 대해 시험기기 및 대조기기인 | 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우 2개 | 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상 준비 | 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상 준비한다 |\n| P2Y12 Assay | - 시험물질 |\n| (1) 의뢰자는 임상시험계획서에 대한 임상시험심사위원회와 식품의약품안전처장의 | * 피험자 수: 시험대상수 산출시 일반적인 고려사항 | 연구자: | 질환의 치료 및 예방에 사용되는 아스피린, 클로피도그렐 등의 항혈소판약제로 인한 |\n| 다. ",
        "original_sentence": "최근에는 심혈관 |\n| 임상시험으로 피험자가 직접적으로 받는 인체의 위해도가 없어 예측되는 부작용에 | (1) 혈소판 기능검사 | 결과) 대조군 132명 이상, SIPA test 양성(비정상 결과) 환자 105명 이상, SIPA |\n| (2) 국내외 개발동향 | 2) 혈소판 약물반응검사: VerifyNowⓇ | 얼굴이 창백해지고 이 나며, 맥박수가 줄어들고, 혈압이 심하게 떨어지며, 심하면 |\n| 예시) | 12.2 사용상의 주의사항 | 민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d) | 혈소판 기능 부전이 의심되는 환자의 구연산 처리된 전혈에서 혈소판 기능부전 | (2) 해당 의료기기의 사용목적：혈소판 약물반응 검사 | 1) 검체준비 및 저장방법 | (6) 결과 제시 : 개봉시점과 각 시점 간 시험결과의 차이를 구한다. "
      }
    },
    {
      "chunk_id": "chunk_486",
      "text": "| 연구 제목: | 출혈 시간 및 항혈소판제제 저항성 복합검사기기(제품명: 000)의 정확도 검증을 위한 | - 피험자의 임상정보를 알 수 없는 경우 | ② ISO 23640 In vitro diagnostic medical devices – Evaluation of | (차) 시험 기기와 측정기기 : IEC 61010-1의 16절에 기술된 시험 기기 | 제시할 수 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 485,
        "window_size": 3,
        "char_count": 210,
        "word_count": 50,
        "page_number": 6,
        "window_text": "두 검체의 평균 MD 또는 MR이 진단경계치 범위 내에 | ① 정상 대조군: 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군 |\n| 나.  임상시험용 의료기기의 공급과 취급 | (주) ○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○-○○○-○○○○ | 혹은 후천성 혈소판 기능 이상을 감별하는데 중요한 검사입니다.  최근에는 심혈관 |\n| 임상시험으로 피험자가 직접적으로 받는 인체의 위해도가 없어 예측되는 부작용에 | (1) 혈소판 기능검사 | 결과) 대조군 132명 이상, SIPA test 양성(비정상 결과) 환자 105명 이상, SIPA |\n| (2) 국내외 개발동향 | 2) 혈소판 약물반응검사: VerifyNowⓇ | 얼굴이 창백해지고 이 나며, 맥박수가 줄어들고, 혈압이 심하게 떨어지며, 심하면 |\n| 예시) | 12.2 사용상의 주의사항 | 민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d) | 혈소판 기능 부전이 의심되는 환자의 구연산 처리된 전혈에서 혈소판 기능부전 | (2) 해당 의료기기의 사용목적：혈소판 약물반응 검사 | 1) 검체준비 및 저장방법 | (6) 결과 제시 : 개봉시점과 각 시점 간 시험결과의 차이를 구한다.  | 연구 제목: | 출혈 시간 및 항혈소판제제 저항성 복합검사기기(제품명: 000)의 정확도 검증을 위한 | - 피험자의 임상정보를 알 수 없는 경우 | ② ISO 23640 In vitro diagnostic medical devices – Evaluation of | (차) 시험 기기와 측정기기 : IEC 61010-1의 16절에 기술된 시험 기기 | 제시할 수 있다.  | 2) 특이도: 대조기기 정상 결과 검체 중 시험기기에서 정상 결과를 보인 검체의 | 2) 특이도: 아스피린 투약 전 검체 중 최종 약물반응 음성 결과를 보인 검체의 | 유지하도록 한다.  제조허가·수입허가 또는 그 변경허가를 위한 임상시험 관련 | (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제 | 3.2% | 구연산 | 처리된 | 전혈 | 검체에 | 분석대상물질(Agonist | 또는 | 이동거리값의 평균 및 표준편차를 계산하고 시험시료 측정결과의 | (3) 시험 목적 : 출혈시간 및 항혈소판제제 저항성 복합검사기기의 | 속하는 경우, 첫 번째 공여자의 혈소판 기능 상태 및 약물 복용 기록을 의심 | 1) Aspirin test: Aspirin 약물 복용 전/후의 검체에 대해 시험기기 및 대조기기인 | 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우 2개 | 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상 준비 | 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상 준비한다 |\n| P2Y12 Assay | - 시험물질 |\n| (1) 의뢰자는 임상시험계획서에 대한 임상시험심사위원회와 식품의약품안전처장의 | * 피험자 수: 시험대상수 산출시 일반적인 고려사항 | 연구자: | 질환의 치료 및 예방에 사용되는 아스피린, 클로피도그렐 등의 항혈소판약제로 인한 |\n| 다.  임상시험 수탁업체 | 따른 안전성 평가 및 방법은 따로 기재하지 않는다. ",
        "original_sentence": "| 연구 제목: | 출혈 시간 및 항혈소판제제 저항성 복합검사기기(제품명: 000)의 정확도 검증을 위한 | - 피험자의 임상정보를 알 수 없는 경우 | ② ISO 23640 In vitro diagnostic medical devices – Evaluation of | (차) 시험 기기와 측정기기 : IEC 61010-1의 16절에 기술된 시험 기기 | 제시할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_487",
      "text": "| 2) 특이도: 대조기기 정상 결과 검체 중 시험기기에서 정상 결과를 보인 검체의 | 2) 특이도: 아스피린 투약 전 검체 중 최종 약물반응 음성 결과를 보인 검체의 | 유지하도록 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 486,
        "window_size": 3,
        "char_count": 106,
        "word_count": 30,
        "page_number": 6,
        "window_text": "임상시험용 의료기기의 공급과 취급 | (주) ○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○-○○○-○○○○ | 혹은 후천성 혈소판 기능 이상을 감별하는데 중요한 검사입니다.  최근에는 심혈관 |\n| 임상시험으로 피험자가 직접적으로 받는 인체의 위해도가 없어 예측되는 부작용에 | (1) 혈소판 기능검사 | 결과) 대조군 132명 이상, SIPA test 양성(비정상 결과) 환자 105명 이상, SIPA |\n| (2) 국내외 개발동향 | 2) 혈소판 약물반응검사: VerifyNowⓇ | 얼굴이 창백해지고 이 나며, 맥박수가 줄어들고, 혈압이 심하게 떨어지며, 심하면 |\n| 예시) | 12.2 사용상의 주의사항 | 민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d) | 혈소판 기능 부전이 의심되는 환자의 구연산 처리된 전혈에서 혈소판 기능부전 | (2) 해당 의료기기의 사용목적：혈소판 약물반응 검사 | 1) 검체준비 및 저장방법 | (6) 결과 제시 : 개봉시점과 각 시점 간 시험결과의 차이를 구한다.  | 연구 제목: | 출혈 시간 및 항혈소판제제 저항성 복합검사기기(제품명: 000)의 정확도 검증을 위한 | - 피험자의 임상정보를 알 수 없는 경우 | ② ISO 23640 In vitro diagnostic medical devices – Evaluation of | (차) 시험 기기와 측정기기 : IEC 61010-1의 16절에 기술된 시험 기기 | 제시할 수 있다.  | 2) 특이도: 대조기기 정상 결과 검체 중 시험기기에서 정상 결과를 보인 검체의 | 2) 특이도: 아스피린 투약 전 검체 중 최종 약물반응 음성 결과를 보인 검체의 | 유지하도록 한다.  제조허가·수입허가 또는 그 변경허가를 위한 임상시험 관련 | (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제 | 3.2% | 구연산 | 처리된 | 전혈 | 검체에 | 분석대상물질(Agonist | 또는 | 이동거리값의 평균 및 표준편차를 계산하고 시험시료 측정결과의 | (3) 시험 목적 : 출혈시간 및 항혈소판제제 저항성 복합검사기기의 | 속하는 경우, 첫 번째 공여자의 혈소판 기능 상태 및 약물 복용 기록을 의심 | 1) Aspirin test: Aspirin 약물 복용 전/후의 검체에 대해 시험기기 및 대조기기인 | 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우 2개 | 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상 준비 | 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상 준비한다 |\n| P2Y12 Assay | - 시험물질 |\n| (1) 의뢰자는 임상시험계획서에 대한 임상시험심사위원회와 식품의약품안전처장의 | * 피험자 수: 시험대상수 산출시 일반적인 고려사항 | 연구자: | 질환의 치료 및 예방에 사용되는 아스피린, 클로피도그렐 등의 항혈소판약제로 인한 |\n| 다.  임상시험 수탁업체 | 따른 안전성 평가 및 방법은 따로 기재하지 않는다.  | 3) 임상시험을 통해 얻어진 자료는 성능 및 안전성 분석을 위한 데이터가 정해져야 하며, | 본 임상시험은 혈소판 기능부전이 의심되는 환자 및 정상대조군에서 시험기기의 |\n**아. CLSI EP17-A2: Evaluation of Detection Capability for Clinical Laboratory**\n| 가. ",
        "original_sentence": "| 2) 특이도: 대조기기 정상 결과 검체 중 시험기기에서 정상 결과를 보인 검체의 | 2) 특이도: 아스피린 투약 전 검체 중 최종 약물반응 음성 결과를 보인 검체의 | 유지하도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_488",
      "text": "제조허가·수입허가 또는 그 변경허가를 위한 임상시험 관련 | (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제 | 3.2% | 구연산 | 처리된 | 전혈 | 검체에 | 분석대상물질(Agonist | 또는 | 이동거리값의 평균 및 표준편차를 계산하고 시험시료 측정결과의 | (3) 시험 목적 : 출혈시간 및 항혈소판제제 저항성 복합검사기기의 | 속하는 경우, 첫 번째 공여자의 혈소판 기능 상태 및 약물 복용 기록을 의심 | 1) Aspirin test: Aspirin 약물 복용 전/후의 검체에 대해 시험기기 및 대조기기인 | 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우 2개 | 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상 준비 | 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상 준비한다 |\n| P2Y12 Assay | - 시험물질 |\n| (1) 의뢰자는 임상시험계획서에 대한 임상시험심사위원회와 식품의약품안전처장의 | * 피험자 수: 시험대상수 산출시 일반적인 고려사항 | 연구자: | 질환의 치료 및 예방에 사용되는 아스피린, 클로피도그렐 등의 항혈소판약제로 인한 |\n| 다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 487,
        "window_size": 3,
        "char_count": 597,
        "word_count": 151,
        "page_number": 6,
        "window_text": "최근에는 심혈관 |\n| 임상시험으로 피험자가 직접적으로 받는 인체의 위해도가 없어 예측되는 부작용에 | (1) 혈소판 기능검사 | 결과) 대조군 132명 이상, SIPA test 양성(비정상 결과) 환자 105명 이상, SIPA |\n| (2) 국내외 개발동향 | 2) 혈소판 약물반응검사: VerifyNowⓇ | 얼굴이 창백해지고 이 나며, 맥박수가 줄어들고, 혈압이 심하게 떨어지며, 심하면 |\n| 예시) | 12.2 사용상의 주의사항 | 민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d) | 혈소판 기능 부전이 의심되는 환자의 구연산 처리된 전혈에서 혈소판 기능부전 | (2) 해당 의료기기의 사용목적：혈소판 약물반응 검사 | 1) 검체준비 및 저장방법 | (6) 결과 제시 : 개봉시점과 각 시점 간 시험결과의 차이를 구한다.  | 연구 제목: | 출혈 시간 및 항혈소판제제 저항성 복합검사기기(제품명: 000)의 정확도 검증을 위한 | - 피험자의 임상정보를 알 수 없는 경우 | ② ISO 23640 In vitro diagnostic medical devices – Evaluation of | (차) 시험 기기와 측정기기 : IEC 61010-1의 16절에 기술된 시험 기기 | 제시할 수 있다.  | 2) 특이도: 대조기기 정상 결과 검체 중 시험기기에서 정상 결과를 보인 검체의 | 2) 특이도: 아스피린 투약 전 검체 중 최종 약물반응 음성 결과를 보인 검체의 | 유지하도록 한다.  제조허가·수입허가 또는 그 변경허가를 위한 임상시험 관련 | (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제 | 3.2% | 구연산 | 처리된 | 전혈 | 검체에 | 분석대상물질(Agonist | 또는 | 이동거리값의 평균 및 표준편차를 계산하고 시험시료 측정결과의 | (3) 시험 목적 : 출혈시간 및 항혈소판제제 저항성 복합검사기기의 | 속하는 경우, 첫 번째 공여자의 혈소판 기능 상태 및 약물 복용 기록을 의심 | 1) Aspirin test: Aspirin 약물 복용 전/후의 검체에 대해 시험기기 및 대조기기인 | 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우 2개 | 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상 준비 | 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상 준비한다 |\n| P2Y12 Assay | - 시험물질 |\n| (1) 의뢰자는 임상시험계획서에 대한 임상시험심사위원회와 식품의약품안전처장의 | * 피험자 수: 시험대상수 산출시 일반적인 고려사항 | 연구자: | 질환의 치료 및 예방에 사용되는 아스피린, 클로피도그렐 등의 항혈소판약제로 인한 |\n| 다.  임상시험 수탁업체 | 따른 안전성 평가 및 방법은 따로 기재하지 않는다.  | 3) 임상시험을 통해 얻어진 자료는 성능 및 안전성 분석을 위한 데이터가 정해져야 하며, | 본 임상시험은 혈소판 기능부전이 의심되는 환자 및 정상대조군에서 시험기기의 |\n**아. CLSI EP17-A2: Evaluation of Detection Capability for Clinical Laboratory**\n| 가.  시험책임자 | Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | 7. ",
        "original_sentence": "제조허가·수입허가 또는 그 변경허가를 위한 임상시험 관련 | (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제 | 3.2% | 구연산 | 처리된 | 전혈 | 검체에 | 분석대상물질(Agonist | 또는 | 이동거리값의 평균 및 표준편차를 계산하고 시험시료 측정결과의 | (3) 시험 목적 : 출혈시간 및 항혈소판제제 저항성 복합검사기기의 | 속하는 경우, 첫 번째 공여자의 혈소판 기능 상태 및 약물 복용 기록을 의심 | 1) Aspirin test: Aspirin 약물 복용 전/후의 검체에 대해 시험기기 및 대조기기인 | 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우 2개 | 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상 준비 | 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상 준비한다 |\n| P2Y12 Assay | - 시험물질 |\n| (1) 의뢰자는 임상시험계획서에 대한 임상시험심사위원회와 식품의약품안전처장의 | * 피험자 수: 시험대상수 산출시 일반적인 고려사항 | 연구자: | 질환의 치료 및 예방에 사용되는 아스피린, 클로피도그렐 등의 항혈소판약제로 인한 |\n| 다. "
      }
    },
    {
      "chunk_id": "chunk_489",
      "text": "임상시험 수탁업체 | 따른 안전성 평가 및 방법은 따로 기재하지 않는다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 488,
        "window_size": 3,
        "char_count": 41,
        "word_count": 11,
        "page_number": 9,
        "window_text": "| 연구 제목: | 출혈 시간 및 항혈소판제제 저항성 복합검사기기(제품명: 000)의 정확도 검증을 위한 | - 피험자의 임상정보를 알 수 없는 경우 | ② ISO 23640 In vitro diagnostic medical devices – Evaluation of | (차) 시험 기기와 측정기기 : IEC 61010-1의 16절에 기술된 시험 기기 | 제시할 수 있다.  | 2) 특이도: 대조기기 정상 결과 검체 중 시험기기에서 정상 결과를 보인 검체의 | 2) 특이도: 아스피린 투약 전 검체 중 최종 약물반응 음성 결과를 보인 검체의 | 유지하도록 한다.  제조허가·수입허가 또는 그 변경허가를 위한 임상시험 관련 | (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제 | 3.2% | 구연산 | 처리된 | 전혈 | 검체에 | 분석대상물질(Agonist | 또는 | 이동거리값의 평균 및 표준편차를 계산하고 시험시료 측정결과의 | (3) 시험 목적 : 출혈시간 및 항혈소판제제 저항성 복합검사기기의 | 속하는 경우, 첫 번째 공여자의 혈소판 기능 상태 및 약물 복용 기록을 의심 | 1) Aspirin test: Aspirin 약물 복용 전/후의 검체에 대해 시험기기 및 대조기기인 | 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우 2개 | 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상 준비 | 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상 준비한다 |\n| P2Y12 Assay | - 시험물질 |\n| (1) 의뢰자는 임상시험계획서에 대한 임상시험심사위원회와 식품의약품안전처장의 | * 피험자 수: 시험대상수 산출시 일반적인 고려사항 | 연구자: | 질환의 치료 및 예방에 사용되는 아스피린, 클로피도그렐 등의 항혈소판약제로 인한 |\n| 다.  임상시험 수탁업체 | 따른 안전성 평가 및 방법은 따로 기재하지 않는다.  | 3) 임상시험을 통해 얻어진 자료는 성능 및 안전성 분석을 위한 데이터가 정해져야 하며, | 본 임상시험은 혈소판 기능부전이 의심되는 환자 및 정상대조군에서 시험기기의 |\n**아. CLSI EP17-A2: Evaluation of Detection Capability for Clinical Laboratory**\n| 가.  시험책임자 | Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | 7.  검체의 처리 및 제공 | 검출을 위해 사용되는 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기-혈소판 | (가) 전 세계 혈소판 기능검사 시장 규모는 2015년 기준 약 100억 달러에 |\n| 예시) | 19.5. ",
        "original_sentence": "임상시험 수탁업체 | 따른 안전성 평가 및 방법은 따로 기재하지 않는다. "
      }
    },
    {
      "chunk_id": "chunk_490",
      "text": "| 3) 임상시험을 통해 얻어진 자료는 성능 및 안전성 분석을 위한 데이터가 정해져야 하며, | 본 임상시험은 혈소판 기능부전이 의심되는 환자 및 정상대조군에서 시험기기의 |\n**아. CLSI EP17-A2: Evaluation of Detection Capability for Clinical Laboratory**\n| 가. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 489,
        "window_size": 3,
        "char_count": 183,
        "word_count": 37,
        "page_number": 9,
        "window_text": "| 2) 특이도: 대조기기 정상 결과 검체 중 시험기기에서 정상 결과를 보인 검체의 | 2) 특이도: 아스피린 투약 전 검체 중 최종 약물반응 음성 결과를 보인 검체의 | 유지하도록 한다.  제조허가·수입허가 또는 그 변경허가를 위한 임상시험 관련 | (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제 | 3.2% | 구연산 | 처리된 | 전혈 | 검체에 | 분석대상물질(Agonist | 또는 | 이동거리값의 평균 및 표준편차를 계산하고 시험시료 측정결과의 | (3) 시험 목적 : 출혈시간 및 항혈소판제제 저항성 복합검사기기의 | 속하는 경우, 첫 번째 공여자의 혈소판 기능 상태 및 약물 복용 기록을 의심 | 1) Aspirin test: Aspirin 약물 복용 전/후의 검체에 대해 시험기기 및 대조기기인 | 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우 2개 | 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상 준비 | 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상 준비한다 |\n| P2Y12 Assay | - 시험물질 |\n| (1) 의뢰자는 임상시험계획서에 대한 임상시험심사위원회와 식품의약품안전처장의 | * 피험자 수: 시험대상수 산출시 일반적인 고려사항 | 연구자: | 질환의 치료 및 예방에 사용되는 아스피린, 클로피도그렐 등의 항혈소판약제로 인한 |\n| 다.  임상시험 수탁업체 | 따른 안전성 평가 및 방법은 따로 기재하지 않는다.  | 3) 임상시험을 통해 얻어진 자료는 성능 및 안전성 분석을 위한 데이터가 정해져야 하며, | 본 임상시험은 혈소판 기능부전이 의심되는 환자 및 정상대조군에서 시험기기의 |\n**아. CLSI EP17-A2: Evaluation of Detection Capability for Clinical Laboratory**\n| 가.  시험책임자 | Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | 7.  검체의 처리 및 제공 | 검출을 위해 사용되는 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기-혈소판 | (가) 전 세계 혈소판 기능검사 시장 규모는 2015년 기준 약 100억 달러에 |\n| 예시) | 19.5.  모니터링 | 19.7. ",
        "original_sentence": "| 3) 임상시험을 통해 얻어진 자료는 성능 및 안전성 분석을 위한 데이터가 정해져야 하며, | 본 임상시험은 혈소판 기능부전이 의심되는 환자 및 정상대조군에서 시험기기의 |\n**아. CLSI EP17-A2: Evaluation of Detection Capability for Clinical Laboratory**\n| 가. "
      }
    },
    {
      "chunk_id": "chunk_491",
      "text": "시험책임자 | Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | 7. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 490,
        "window_size": 3,
        "char_count": 58,
        "word_count": 8,
        "page_number": 6,
        "window_text": "제조허가·수입허가 또는 그 변경허가를 위한 임상시험 관련 | (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제 | 3.2% | 구연산 | 처리된 | 전혈 | 검체에 | 분석대상물질(Agonist | 또는 | 이동거리값의 평균 및 표준편차를 계산하고 시험시료 측정결과의 | (3) 시험 목적 : 출혈시간 및 항혈소판제제 저항성 복합검사기기의 | 속하는 경우, 첫 번째 공여자의 혈소판 기능 상태 및 약물 복용 기록을 의심 | 1) Aspirin test: Aspirin 약물 복용 전/후의 검체에 대해 시험기기 및 대조기기인 | 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우 2개 | 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상 준비 | 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상 준비한다 |\n| P2Y12 Assay | - 시험물질 |\n| (1) 의뢰자는 임상시험계획서에 대한 임상시험심사위원회와 식품의약품안전처장의 | * 피험자 수: 시험대상수 산출시 일반적인 고려사항 | 연구자: | 질환의 치료 및 예방에 사용되는 아스피린, 클로피도그렐 등의 항혈소판약제로 인한 |\n| 다.  임상시험 수탁업체 | 따른 안전성 평가 및 방법은 따로 기재하지 않는다.  | 3) 임상시험을 통해 얻어진 자료는 성능 및 안전성 분석을 위한 데이터가 정해져야 하며, | 본 임상시험은 혈소판 기능부전이 의심되는 환자 및 정상대조군에서 시험기기의 |\n**아. CLSI EP17-A2: Evaluation of Detection Capability for Clinical Laboratory**\n| 가.  시험책임자 | Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | 7.  검체의 처리 및 제공 | 검출을 위해 사용되는 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기-혈소판 | (가) 전 세계 혈소판 기능검사 시장 규모는 2015년 기준 약 100억 달러에 |\n| 예시) | 19.5.  모니터링 | 19.7.  피험자 동의 | 1) 반드시 체외진단용으로 사용해야 한다. ",
        "original_sentence": "시험책임자 | Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | 7. "
      }
    },
    {
      "chunk_id": "chunk_492",
      "text": "검체의 처리 및 제공 | 검출을 위해 사용되는 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기-혈소판 | (가) 전 세계 혈소판 기능검사 시장 규모는 2015년 기준 약 100억 달러에 |\n| 예시) | 19.5. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 491,
        "window_size": 3,
        "char_count": 120,
        "word_count": 32,
        "page_number": 76,
        "window_text": "임상시험 수탁업체 | 따른 안전성 평가 및 방법은 따로 기재하지 않는다.  | 3) 임상시험을 통해 얻어진 자료는 성능 및 안전성 분석을 위한 데이터가 정해져야 하며, | 본 임상시험은 혈소판 기능부전이 의심되는 환자 및 정상대조군에서 시험기기의 |\n**아. CLSI EP17-A2: Evaluation of Detection Capability for Clinical Laboratory**\n| 가.  시험책임자 | Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | 7.  검체의 처리 및 제공 | 검출을 위해 사용되는 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기-혈소판 | (가) 전 세계 혈소판 기능검사 시장 규모는 2015년 기준 약 100억 달러에 |\n| 예시) | 19.5.  모니터링 | 19.7.  피험자 동의 | 1) 반드시 체외진단용으로 사용해야 한다.  | 이용되는 검사 기기의 종류는 많지 않다. ",
        "original_sentence": "검체의 처리 및 제공 | 검출을 위해 사용되는 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기-혈소판 | (가) 전 세계 혈소판 기능검사 시장 규모는 2015년 기준 약 100억 달러에 |\n| 예시) | 19.5. "
      }
    },
    {
      "chunk_id": "chunk_493",
      "text": "모니터링 | 19.7. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 492,
        "window_size": 3,
        "char_count": 13,
        "word_count": 3,
        "page_number": 6,
        "window_text": "| 3) 임상시험을 통해 얻어진 자료는 성능 및 안전성 분석을 위한 데이터가 정해져야 하며, | 본 임상시험은 혈소판 기능부전이 의심되는 환자 및 정상대조군에서 시험기기의 |\n**아. CLSI EP17-A2: Evaluation of Detection Capability for Clinical Laboratory**\n| 가.  시험책임자 | Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | 7.  검체의 처리 및 제공 | 검출을 위해 사용되는 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기-혈소판 | (가) 전 세계 혈소판 기능검사 시장 규모는 2015년 기준 약 100억 달러에 |\n| 예시) | 19.5.  모니터링 | 19.7.  피험자 동의 | 1) 반드시 체외진단용으로 사용해야 한다.  | 이용되는 검사 기기의 종류는 많지 않다.  | 3. ",
        "original_sentence": "모니터링 | 19.7. "
      }
    },
    {
      "chunk_id": "chunk_494",
      "text": "피험자 동의 | 1) 반드시 체외진단용으로 사용해야 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 493,
        "window_size": 3,
        "char_count": 33,
        "word_count": 8,
        "page_number": 6,
        "window_text": "시험책임자 | Kappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)} | 7.  검체의 처리 및 제공 | 검출을 위해 사용되는 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기-혈소판 | (가) 전 세계 혈소판 기능검사 시장 규모는 2015년 기준 약 100억 달러에 |\n| 예시) | 19.5.  모니터링 | 19.7.  피험자 동의 | 1) 반드시 체외진단용으로 사용해야 한다.  | 이용되는 검사 기기의 종류는 많지 않다.  | 3.  직선성/측정범위 | - 구연산 처리된 전혈에서 폐색 전 혈액이동거리를 측정하여 혈소판 약물반응을 | (1) 올바른 채혈법을 숙지한 후 채혈을 실시한다. ",
        "original_sentence": "피험자 동의 | 1) 반드시 체외진단용으로 사용해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_495",
      "text": "| 이용되는 검사 기기의 종류는 많지 않다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 494,
        "window_size": 3,
        "char_count": 25,
        "word_count": 7,
        "page_number": 42,
        "window_text": "검체의 처리 및 제공 | 검출을 위해 사용되는 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기-혈소판 | (가) 전 세계 혈소판 기능검사 시장 규모는 2015년 기준 약 100억 달러에 |\n| 예시) | 19.5.  모니터링 | 19.7.  피험자 동의 | 1) 반드시 체외진단용으로 사용해야 한다.  | 이용되는 검사 기기의 종류는 많지 않다.  | 3.  직선성/측정범위 | - 구연산 처리된 전혈에서 폐색 전 혈액이동거리를 측정하여 혈소판 약물반응을 | (1) 올바른 채혈법을 숙지한 후 채혈을 실시한다.  | (3) 검사가 종료될 때까지 기다린다. ",
        "original_sentence": "| 이용되는 검사 기기의 종류는 많지 않다. "
      }
    },
    {
      "chunk_id": "chunk_496",
      "text": "| 3. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 495,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 15,
        "window_text": "모니터링 | 19.7.  피험자 동의 | 1) 반드시 체외진단용으로 사용해야 한다.  | 이용되는 검사 기기의 종류는 많지 않다.  | 3.  직선성/측정범위 | - 구연산 처리된 전혈에서 폐색 전 혈액이동거리를 측정하여 혈소판 약물반응을 | (1) 올바른 채혈법을 숙지한 후 채혈을 실시한다.  | (3) 검사가 종료될 때까지 기다린다.  | - 직전 1개월 내 시행한 검사 결과상 혈소판수가 100x10^9/uL이하인 경우 | ② 피험자 적합성 평가 : 피험자 선정 및 제외기준에 적합한지 평가한다. ",
        "original_sentence": "| 3. "
      }
    },
    {
      "chunk_id": "chunk_497",
      "text": "직선성/측정범위 | - 구연산 처리된 전혈에서 폐색 전 혈액이동거리를 측정하여 혈소판 약물반응을 | (1) 올바른 채혈법을 숙지한 후 채혈을 실시한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 496,
        "window_size": 3,
        "char_count": 85,
        "word_count": 20,
        "page_number": 24,
        "window_text": "피험자 동의 | 1) 반드시 체외진단용으로 사용해야 한다.  | 이용되는 검사 기기의 종류는 많지 않다.  | 3.  직선성/측정범위 | - 구연산 처리된 전혈에서 폐색 전 혈액이동거리를 측정하여 혈소판 약물반응을 | (1) 올바른 채혈법을 숙지한 후 채혈을 실시한다.  | (3) 검사가 종료될 때까지 기다린다.  | - 직전 1개월 내 시행한 검사 결과상 혈소판수가 100x10^9/uL이하인 경우 | ② 피험자 적합성 평가 : 피험자 선정 및 제외기준에 적합한지 평가한다.  | - 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순, 예) KFDA-12-34-56 | 자료는 허가일로부터 3년간 보존하도록 하고, 그 밖의 임상시험 관련 자료는 | 한다. ",
        "original_sentence": "직선성/측정범위 | - 구연산 처리된 전혈에서 폐색 전 혈액이동거리를 측정하여 혈소판 약물반응을 | (1) 올바른 채혈법을 숙지한 후 채혈을 실시한다. "
      }
    },
    {
      "chunk_id": "chunk_498",
      "text": "| (3) 검사가 종료될 때까지 기다린다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 497,
        "window_size": 3,
        "char_count": 24,
        "word_count": 6,
        "page_number": 15,
        "window_text": "| 이용되는 검사 기기의 종류는 많지 않다.  | 3.  직선성/측정범위 | - 구연산 처리된 전혈에서 폐색 전 혈액이동거리를 측정하여 혈소판 약물반응을 | (1) 올바른 채혈법을 숙지한 후 채혈을 실시한다.  | (3) 검사가 종료될 때까지 기다린다.  | - 직전 1개월 내 시행한 검사 결과상 혈소판수가 100x10^9/uL이하인 경우 | ② 피험자 적합성 평가 : 피험자 선정 및 제외기준에 적합한지 평가한다.  | - 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순, 예) KFDA-12-34-56 | 자료는 허가일로부터 3년간 보존하도록 하고, 그 밖의 임상시험 관련 자료는 | 한다.  각 검체에 대해 20일간 1일 2회의 반복시험을 실시하여 검체에 | 최소 3개의 로트의 시약을 이용하여 2곳 이상의 검사실 2명 이상의 |\n| - 임상연구에서 연구피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈 |\n**광투과 혈소판응집능검사(light transmission aggregometry, LTA)를 기준검사법**\n| 회사명 | 성명 | 소재지 | 전화 | 2) 잘못 기입된 글자를 overwrite 해서 고치거나 수정액을 사용하여서는 안 됩니다. ",
        "original_sentence": "| (3) 검사가 종료될 때까지 기다린다. "
      }
    },
    {
      "chunk_id": "chunk_499",
      "text": "| - 직전 1개월 내 시행한 검사 결과상 혈소판수가 100x10^9/uL이하인 경우 | ② 피험자 적합성 평가 : 피험자 선정 및 제외기준에 적합한지 평가한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 498,
        "window_size": 3,
        "char_count": 91,
        "word_count": 23,
        "page_number": 6,
        "window_text": "| 3.  직선성/측정범위 | - 구연산 처리된 전혈에서 폐색 전 혈액이동거리를 측정하여 혈소판 약물반응을 | (1) 올바른 채혈법을 숙지한 후 채혈을 실시한다.  | (3) 검사가 종료될 때까지 기다린다.  | - 직전 1개월 내 시행한 검사 결과상 혈소판수가 100x10^9/uL이하인 경우 | ② 피험자 적합성 평가 : 피험자 선정 및 제외기준에 적합한지 평가한다.  | - 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순, 예) KFDA-12-34-56 | 자료는 허가일로부터 3년간 보존하도록 하고, 그 밖의 임상시험 관련 자료는 | 한다.  각 검체에 대해 20일간 1일 2회의 반복시험을 실시하여 검체에 | 최소 3개의 로트의 시약을 이용하여 2곳 이상의 검사실 2명 이상의 |\n| - 임상연구에서 연구피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈 |\n**광투과 혈소판응집능검사(light transmission aggregometry, LTA)를 기준검사법**\n| 회사명 | 성명 | 소재지 | 전화 | 2) 잘못 기입된 글자를 overwrite 해서 고치거나 수정액을 사용하여서는 안 됩니다.  | 연구책임자: | (성명) | (소속) | (연락처) |\n| 기능검사’의 | 임상적 | 성능을 | 광투과 | 혈소판응집능검사(light | transmission | P2Y12 test | 72.9% | 74.1% | (성명) | (서명) | (날짜) | 년 | 월 | 일 | Assay-TRAP |\n| 14.1. ",
        "original_sentence": "| - 직전 1개월 내 시행한 검사 결과상 혈소판수가 100x10^9/uL이하인 경우 | ② 피험자 적합성 평가 : 피험자 선정 및 제외기준에 적합한지 평가한다. "
      }
    },
    {
      "chunk_id": "chunk_500",
      "text": "| - 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순, 예) KFDA-12-34-56 | 자료는 허가일로부터 3년간 보존하도록 하고, 그 밖의 임상시험 관련 자료는 | 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 499,
        "window_size": 3,
        "char_count": 110,
        "word_count": 24,
        "page_number": 9,
        "window_text": "직선성/측정범위 | - 구연산 처리된 전혈에서 폐색 전 혈액이동거리를 측정하여 혈소판 약물반응을 | (1) 올바른 채혈법을 숙지한 후 채혈을 실시한다.  | (3) 검사가 종료될 때까지 기다린다.  | - 직전 1개월 내 시행한 검사 결과상 혈소판수가 100x10^9/uL이하인 경우 | ② 피험자 적합성 평가 : 피험자 선정 및 제외기준에 적합한지 평가한다.  | - 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순, 예) KFDA-12-34-56 | 자료는 허가일로부터 3년간 보존하도록 하고, 그 밖의 임상시험 관련 자료는 | 한다.  각 검체에 대해 20일간 1일 2회의 반복시험을 실시하여 검체에 | 최소 3개의 로트의 시약을 이용하여 2곳 이상의 검사실 2명 이상의 |\n| - 임상연구에서 연구피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈 |\n**광투과 혈소판응집능검사(light transmission aggregometry, LTA)를 기준검사법**\n| 회사명 | 성명 | 소재지 | 전화 | 2) 잘못 기입된 글자를 overwrite 해서 고치거나 수정액을 사용하여서는 안 됩니다.  | 연구책임자: | (성명) | (소속) | (연락처) |\n| 기능검사’의 | 임상적 | 성능을 | 광투과 | 혈소판응집능검사(light | transmission | P2Y12 test | 72.9% | 74.1% | (성명) | (서명) | (날짜) | 년 | 월 | 일 | Assay-TRAP |\n| 14.1.  유효성(성능)의 평가기준 | (1) 모니터링(Monitoring)이라 함은 임상시험 진행 과정을 감독하고, 해당 임상시험이 | (1) 피험자 동의(Informed Consent)라 함은 피험자가 임상시험 참여 유무를 결정하기 | 2) 일반적인 실험실 안전 및 생물학적 위험물질 취급 시 안전 등의 주의사항 | - 귀하의 검체는 관련 법규 및 병원규정에 따라 적절히 처리됩니다. ",
        "original_sentence": "| - 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순, 예) KFDA-12-34-56 | 자료는 허가일로부터 3년간 보존하도록 하고, 그 밖의 임상시험 관련 자료는 | 한다. "
      }
    },
    {
      "chunk_id": "chunk_501",
      "text": "각 검체에 대해 20일간 1일 2회의 반복시험을 실시하여 검체에 | 최소 3개의 로트의 시약을 이용하여 2곳 이상의 검사실 2명 이상의 |\n| - 임상연구에서 연구피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈 |\n**광투과 혈소판응집능검사(light transmission aggregometry, LTA)를 기준검사법**\n| 회사명 | 성명 | 소재지 | 전화 | 2) 잘못 기입된 글자를 overwrite 해서 고치거나 수정액을 사용하여서는 안 됩니다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 500,
        "window_size": 3,
        "char_count": 303,
        "word_count": 70,
        "page_number": 6,
        "window_text": "| (3) 검사가 종료될 때까지 기다린다.  | - 직전 1개월 내 시행한 검사 결과상 혈소판수가 100x10^9/uL이하인 경우 | ② 피험자 적합성 평가 : 피험자 선정 및 제외기준에 적합한지 평가한다.  | - 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순, 예) KFDA-12-34-56 | 자료는 허가일로부터 3년간 보존하도록 하고, 그 밖의 임상시험 관련 자료는 | 한다.  각 검체에 대해 20일간 1일 2회의 반복시험을 실시하여 검체에 | 최소 3개의 로트의 시약을 이용하여 2곳 이상의 검사실 2명 이상의 |\n| - 임상연구에서 연구피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈 |\n**광투과 혈소판응집능검사(light transmission aggregometry, LTA)를 기준검사법**\n| 회사명 | 성명 | 소재지 | 전화 | 2) 잘못 기입된 글자를 overwrite 해서 고치거나 수정액을 사용하여서는 안 됩니다.  | 연구책임자: | (성명) | (소속) | (연락처) |\n| 기능검사’의 | 임상적 | 성능을 | 광투과 | 혈소판응집능검사(light | transmission | P2Y12 test | 72.9% | 74.1% | (성명) | (서명) | (날짜) | 년 | 월 | 일 | Assay-TRAP |\n| 14.1.  유효성(성능)의 평가기준 | (1) 모니터링(Monitoring)이라 함은 임상시험 진행 과정을 감독하고, 해당 임상시험이 | (1) 피험자 동의(Informed Consent)라 함은 피험자가 임상시험 참여 유무를 결정하기 | 2) 일반적인 실험실 안전 및 생물학적 위험물질 취급 시 안전 등의 주의사항 | - 귀하의 검체는 관련 법규 및 병원규정에 따라 적절히 처리됩니다.  | 광투과 혈소판응집검사(Light transmission aggregometry, LTA)는 현재까지 일차 | 성명 | 소속 기관명 | 전공 | 직위 | 전화 | (5) 제품 손상을 방지하기 위해 제품을 단단한 표면에 떨어뜨리거나 부딪히지 않게 한다. ",
        "original_sentence": "각 검체에 대해 20일간 1일 2회의 반복시험을 실시하여 검체에 | 최소 3개의 로트의 시약을 이용하여 2곳 이상의 검사실 2명 이상의 |\n| - 임상연구에서 연구피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈 |\n**광투과 혈소판응집능검사(light transmission aggregometry, LTA)를 기준검사법**\n| 회사명 | 성명 | 소재지 | 전화 | 2) 잘못 기입된 글자를 overwrite 해서 고치거나 수정액을 사용하여서는 안 됩니다. "
      }
    },
    {
      "chunk_id": "chunk_502",
      "text": "| 연구책임자: | (성명) | (소속) | (연락처) |\n| 기능검사’의 | 임상적 | 성능을 | 광투과 | 혈소판응집능검사(light | transmission | P2Y12 test | 72.9% | 74.1% | (성명) | (서명) | (날짜) | 년 | 월 | 일 | Assay-TRAP |\n| 14.1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 501,
        "window_size": 3,
        "char_count": 177,
        "word_count": 45,
        "page_number": 23,
        "window_text": "| - 직전 1개월 내 시행한 검사 결과상 혈소판수가 100x10^9/uL이하인 경우 | ② 피험자 적합성 평가 : 피험자 선정 및 제외기준에 적합한지 평가한다.  | - 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순, 예) KFDA-12-34-56 | 자료는 허가일로부터 3년간 보존하도록 하고, 그 밖의 임상시험 관련 자료는 | 한다.  각 검체에 대해 20일간 1일 2회의 반복시험을 실시하여 검체에 | 최소 3개의 로트의 시약을 이용하여 2곳 이상의 검사실 2명 이상의 |\n| - 임상연구에서 연구피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈 |\n**광투과 혈소판응집능검사(light transmission aggregometry, LTA)를 기준검사법**\n| 회사명 | 성명 | 소재지 | 전화 | 2) 잘못 기입된 글자를 overwrite 해서 고치거나 수정액을 사용하여서는 안 됩니다.  | 연구책임자: | (성명) | (소속) | (연락처) |\n| 기능검사’의 | 임상적 | 성능을 | 광투과 | 혈소판응집능검사(light | transmission | P2Y12 test | 72.9% | 74.1% | (성명) | (서명) | (날짜) | 년 | 월 | 일 | Assay-TRAP |\n| 14.1.  유효성(성능)의 평가기준 | (1) 모니터링(Monitoring)이라 함은 임상시험 진행 과정을 감독하고, 해당 임상시험이 | (1) 피험자 동의(Informed Consent)라 함은 피험자가 임상시험 참여 유무를 결정하기 | 2) 일반적인 실험실 안전 및 생물학적 위험물질 취급 시 안전 등의 주의사항 | - 귀하의 검체는 관련 법규 및 병원규정에 따라 적절히 처리됩니다.  | 광투과 혈소판응집검사(Light transmission aggregometry, LTA)는 현재까지 일차 | 성명 | 소속 기관명 | 전공 | 직위 | 전화 | (5) 제품 손상을 방지하기 위해 제품을 단단한 표면에 떨어뜨리거나 부딪히지 않게 한다.  | (2) 바늘 굵기가 21G인 주사기를 사용한다. ",
        "original_sentence": "| 연구책임자: | (성명) | (소속) | (연락처) |\n| 기능검사’의 | 임상적 | 성능을 | 광투과 | 혈소판응집능검사(light | transmission | P2Y12 test | 72.9% | 74.1% | (성명) | (서명) | (날짜) | 년 | 월 | 일 | Assay-TRAP |\n| 14.1. "
      }
    },
    {
      "chunk_id": "chunk_503",
      "text": "유효성(성능)의 평가기준 | (1) 모니터링(Monitoring)이라 함은 임상시험 진행 과정을 감독하고, 해당 임상시험이 | (1) 피험자 동의(Informed Consent)라 함은 피험자가 임상시험 참여 유무를 결정하기 | 2) 일반적인 실험실 안전 및 생물학적 위험물질 취급 시 안전 등의 주의사항 | - 귀하의 검체는 관련 법규 및 병원규정에 따라 적절히 처리됩니다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 502,
        "window_size": 3,
        "char_count": 211,
        "word_count": 47,
        "page_number": 6,
        "window_text": "| - 피험자 식별코드 : 실시기관 코드-실시년도-시험 일련번호-등록된 순, 예) KFDA-12-34-56 | 자료는 허가일로부터 3년간 보존하도록 하고, 그 밖의 임상시험 관련 자료는 | 한다.  각 검체에 대해 20일간 1일 2회의 반복시험을 실시하여 검체에 | 최소 3개의 로트의 시약을 이용하여 2곳 이상의 검사실 2명 이상의 |\n| - 임상연구에서 연구피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈 |\n**광투과 혈소판응집능검사(light transmission aggregometry, LTA)를 기준검사법**\n| 회사명 | 성명 | 소재지 | 전화 | 2) 잘못 기입된 글자를 overwrite 해서 고치거나 수정액을 사용하여서는 안 됩니다.  | 연구책임자: | (성명) | (소속) | (연락처) |\n| 기능검사’의 | 임상적 | 성능을 | 광투과 | 혈소판응집능검사(light | transmission | P2Y12 test | 72.9% | 74.1% | (성명) | (서명) | (날짜) | 년 | 월 | 일 | Assay-TRAP |\n| 14.1.  유효성(성능)의 평가기준 | (1) 모니터링(Monitoring)이라 함은 임상시험 진행 과정을 감독하고, 해당 임상시험이 | (1) 피험자 동의(Informed Consent)라 함은 피험자가 임상시험 참여 유무를 결정하기 | 2) 일반적인 실험실 안전 및 생물학적 위험물질 취급 시 안전 등의 주의사항 | - 귀하의 검체는 관련 법규 및 병원규정에 따라 적절히 처리됩니다.  | 광투과 혈소판응집검사(Light transmission aggregometry, LTA)는 현재까지 일차 | 성명 | 소속 기관명 | 전공 | 직위 | 전화 | (5) 제품 손상을 방지하기 위해 제품을 단단한 표면에 떨어뜨리거나 부딪히지 않게 한다.  | (2) 바늘 굵기가 21G인 주사기를 사용한다.  | (4) 검사가 종료되면 Tray가 밖으로 나온다. ",
        "original_sentence": "유효성(성능)의 평가기준 | (1) 모니터링(Monitoring)이라 함은 임상시험 진행 과정을 감독하고, 해당 임상시험이 | (1) 피험자 동의(Informed Consent)라 함은 피험자가 임상시험 참여 유무를 결정하기 | 2) 일반적인 실험실 안전 및 생물학적 위험물질 취급 시 안전 등의 주의사항 | - 귀하의 검체는 관련 법규 및 병원규정에 따라 적절히 처리됩니다. "
      }
    },
    {
      "chunk_id": "chunk_504",
      "text": "| 광투과 혈소판응집검사(Light transmission aggregometry, LTA)는 현재까지 일차 | 성명 | 소속 기관명 | 전공 | 직위 | 전화 | (5) 제품 손상을 방지하기 위해 제품을 단단한 표면에 떨어뜨리거나 부딪히지 않게 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 503,
        "window_size": 3,
        "char_count": 142,
        "word_count": 32,
        "page_number": 35,
        "window_text": "각 검체에 대해 20일간 1일 2회의 반복시험을 실시하여 검체에 | 최소 3개의 로트의 시약을 이용하여 2곳 이상의 검사실 2명 이상의 |\n| - 임상연구에서 연구피험자의 수는 연구 목적을 달성할 수 있을 정도의 충분한 | 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈 |\n**광투과 혈소판응집능검사(light transmission aggregometry, LTA)를 기준검사법**\n| 회사명 | 성명 | 소재지 | 전화 | 2) 잘못 기입된 글자를 overwrite 해서 고치거나 수정액을 사용하여서는 안 됩니다.  | 연구책임자: | (성명) | (소속) | (연락처) |\n| 기능검사’의 | 임상적 | 성능을 | 광투과 | 혈소판응집능검사(light | transmission | P2Y12 test | 72.9% | 74.1% | (성명) | (서명) | (날짜) | 년 | 월 | 일 | Assay-TRAP |\n| 14.1.  유효성(성능)의 평가기준 | (1) 모니터링(Monitoring)이라 함은 임상시험 진행 과정을 감독하고, 해당 임상시험이 | (1) 피험자 동의(Informed Consent)라 함은 피험자가 임상시험 참여 유무를 결정하기 | 2) 일반적인 실험실 안전 및 생물학적 위험물질 취급 시 안전 등의 주의사항 | - 귀하의 검체는 관련 법규 및 병원규정에 따라 적절히 처리됩니다.  | 광투과 혈소판응집검사(Light transmission aggregometry, LTA)는 현재까지 일차 | 성명 | 소속 기관명 | 전공 | 직위 | 전화 | (5) 제품 손상을 방지하기 위해 제품을 단단한 표면에 떨어뜨리거나 부딪히지 않게 한다.  | (2) 바늘 굵기가 21G인 주사기를 사용한다.  | (4) 검사가 종료되면 Tray가 밖으로 나온다.  | - 직전 1개월 내 시행한 검사 결과상 Hct 35% 이하, 50%이상인 경우 | ③ 피험자 식별코드는 아래의 방법에 따라 기입한다. ",
        "original_sentence": "| 광투과 혈소판응집검사(Light transmission aggregometry, LTA)는 현재까지 일차 | 성명 | 소속 기관명 | 전공 | 직위 | 전화 | (5) 제품 손상을 방지하기 위해 제품을 단단한 표면에 떨어뜨리거나 부딪히지 않게 한다. "
      }
    },
    {
      "chunk_id": "chunk_505",
      "text": "| (2) 바늘 굵기가 21G인 주사기를 사용한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 504,
        "window_size": 3,
        "char_count": 29,
        "word_count": 7,
        "page_number": 6,
        "window_text": "| 연구책임자: | (성명) | (소속) | (연락처) |\n| 기능검사’의 | 임상적 | 성능을 | 광투과 | 혈소판응집능검사(light | transmission | P2Y12 test | 72.9% | 74.1% | (성명) | (서명) | (날짜) | 년 | 월 | 일 | Assay-TRAP |\n| 14.1.  유효성(성능)의 평가기준 | (1) 모니터링(Monitoring)이라 함은 임상시험 진행 과정을 감독하고, 해당 임상시험이 | (1) 피험자 동의(Informed Consent)라 함은 피험자가 임상시험 참여 유무를 결정하기 | 2) 일반적인 실험실 안전 및 생물학적 위험물질 취급 시 안전 등의 주의사항 | - 귀하의 검체는 관련 법규 및 병원규정에 따라 적절히 처리됩니다.  | 광투과 혈소판응집검사(Light transmission aggregometry, LTA)는 현재까지 일차 | 성명 | 소속 기관명 | 전공 | 직위 | 전화 | (5) 제품 손상을 방지하기 위해 제품을 단단한 표면에 떨어뜨리거나 부딪히지 않게 한다.  | (2) 바늘 굵기가 21G인 주사기를 사용한다.  | (4) 검사가 종료되면 Tray가 밖으로 나온다.  | - 직전 1개월 내 시행한 검사 결과상 Hct 35% 이하, 50%이상인 경우 | ③ 피험자 식별코드는 아래의 방법에 따라 기입한다.  | 3) 인구학적 정보 : 인구학적 정보로 대상자 이니셜, 나이, 성별 등을 조사한다. ",
        "original_sentence": "| (2) 바늘 굵기가 21G인 주사기를 사용한다. "
      }
    },
    {
      "chunk_id": "chunk_506",
      "text": "| (4) 검사가 종료되면 Tray가 밖으로 나온다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 505,
        "window_size": 3,
        "char_count": 30,
        "word_count": 7,
        "page_number": 15,
        "window_text": "유효성(성능)의 평가기준 | (1) 모니터링(Monitoring)이라 함은 임상시험 진행 과정을 감독하고, 해당 임상시험이 | (1) 피험자 동의(Informed Consent)라 함은 피험자가 임상시험 참여 유무를 결정하기 | 2) 일반적인 실험실 안전 및 생물학적 위험물질 취급 시 안전 등의 주의사항 | - 귀하의 검체는 관련 법규 및 병원규정에 따라 적절히 처리됩니다.  | 광투과 혈소판응집검사(Light transmission aggregometry, LTA)는 현재까지 일차 | 성명 | 소속 기관명 | 전공 | 직위 | 전화 | (5) 제품 손상을 방지하기 위해 제품을 단단한 표면에 떨어뜨리거나 부딪히지 않게 한다.  | (2) 바늘 굵기가 21G인 주사기를 사용한다.  | (4) 검사가 종료되면 Tray가 밖으로 나온다.  | - 직전 1개월 내 시행한 검사 결과상 Hct 35% 이하, 50%이상인 경우 | ③ 피험자 식별코드는 아래의 방법에 따라 기입한다.  | 3) 인구학적 정보 : 인구학적 정보로 대상자 이니셜, 나이, 성별 등을 조사한다.  | 달성할 때까지 사용하게 되며 수집된 정보는 개인정보보호법에 따라 적절히 관리 | 3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다. ",
        "original_sentence": "| (4) 검사가 종료되면 Tray가 밖으로 나온다. "
      }
    },
    {
      "chunk_id": "chunk_507",
      "text": "| - 직전 1개월 내 시행한 검사 결과상 Hct 35% 이하, 50%이상인 경우 | ③ 피험자 식별코드는 아래의 방법에 따라 기입한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 506,
        "window_size": 3,
        "char_count": 77,
        "word_count": 21,
        "page_number": 6,
        "window_text": "| 광투과 혈소판응집검사(Light transmission aggregometry, LTA)는 현재까지 일차 | 성명 | 소속 기관명 | 전공 | 직위 | 전화 | (5) 제품 손상을 방지하기 위해 제품을 단단한 표면에 떨어뜨리거나 부딪히지 않게 한다.  | (2) 바늘 굵기가 21G인 주사기를 사용한다.  | (4) 검사가 종료되면 Tray가 밖으로 나온다.  | - 직전 1개월 내 시행한 검사 결과상 Hct 35% 이하, 50%이상인 경우 | ③ 피험자 식별코드는 아래의 방법에 따라 기입한다.  | 3) 인구학적 정보 : 인구학적 정보로 대상자 이니셜, 나이, 성별 등을 조사한다.  | 달성할 때까지 사용하게 되며 수집된 정보는 개인정보보호법에 따라 적절히 관리 | 3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.  | 임상시험이 끝난 날부터 3년간 보존하도록 한다. ",
        "original_sentence": "| - 직전 1개월 내 시행한 검사 결과상 Hct 35% 이하, 50%이상인 경우 | ③ 피험자 식별코드는 아래의 방법에 따라 기입한다. "
      }
    },
    {
      "chunk_id": "chunk_508",
      "text": "| 3) 인구학적 정보 : 인구학적 정보로 대상자 이니셜, 나이, 성별 등을 조사한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 507,
        "window_size": 3,
        "char_count": 49,
        "word_count": 13,
        "page_number": 15,
        "window_text": "| (2) 바늘 굵기가 21G인 주사기를 사용한다.  | (4) 검사가 종료되면 Tray가 밖으로 나온다.  | - 직전 1개월 내 시행한 검사 결과상 Hct 35% 이하, 50%이상인 경우 | ③ 피험자 식별코드는 아래의 방법에 따라 기입한다.  | 3) 인구학적 정보 : 인구학적 정보로 대상자 이니셜, 나이, 성별 등을 조사한다.  | 달성할 때까지 사용하게 되며 수집된 정보는 개인정보보호법에 따라 적절히 관리 | 3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.  | 임상시험이 끝난 날부터 3년간 보존하도록 한다.  다만, 식품의약품안전처장이 | 2）P2Y12 test: Clopidogrel 약물 복용 전/후의 검체에 대해 시험기기 및 대조 | 달한다. ",
        "original_sentence": "| 3) 인구학적 정보 : 인구학적 정보로 대상자 이니셜, 나이, 성별 등을 조사한다. "
      }
    },
    {
      "chunk_id": "chunk_509",
      "text": "| 달성할 때까지 사용하게 되며 수집된 정보는 개인정보보호법에 따라 적절히 관리 | 3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 508,
        "window_size": 3,
        "char_count": 95,
        "word_count": 22,
        "page_number": 7,
        "window_text": "| (4) 검사가 종료되면 Tray가 밖으로 나온다.  | - 직전 1개월 내 시행한 검사 결과상 Hct 35% 이하, 50%이상인 경우 | ③ 피험자 식별코드는 아래의 방법에 따라 기입한다.  | 3) 인구학적 정보 : 인구학적 정보로 대상자 이니셜, 나이, 성별 등을 조사한다.  | 달성할 때까지 사용하게 되며 수집된 정보는 개인정보보호법에 따라 적절히 관리 | 3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.  | 임상시험이 끝난 날부터 3년간 보존하도록 한다.  다만, 식품의약품안전처장이 | 2）P2Y12 test: Clopidogrel 약물 복용 전/후의 검체에 대해 시험기기 및 대조 | 달한다.  혈소판 기능검사 시장은 매년 10% 이상의 성장률을 보이고 |\n| (2) 적용 범위 : 혈소판 기능검사키트에 적용한다. ",
        "original_sentence": "| 달성할 때까지 사용하게 되며 수집된 정보는 개인정보보호법에 따라 적절히 관리 | 3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다. "
      }
    },
    {
      "chunk_id": "chunk_510",
      "text": "| 임상시험이 끝난 날부터 3년간 보존하도록 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 509,
        "window_size": 3,
        "char_count": 29,
        "word_count": 7,
        "page_number": 9,
        "window_text": "| - 직전 1개월 내 시행한 검사 결과상 Hct 35% 이하, 50%이상인 경우 | ③ 피험자 식별코드는 아래의 방법에 따라 기입한다.  | 3) 인구학적 정보 : 인구학적 정보로 대상자 이니셜, 나이, 성별 등을 조사한다.  | 달성할 때까지 사용하게 되며 수집된 정보는 개인정보보호법에 따라 적절히 관리 | 3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.  | 임상시험이 끝난 날부터 3년간 보존하도록 한다.  다만, 식품의약품안전처장이 | 2）P2Y12 test: Clopidogrel 약물 복용 전/후의 검체에 대해 시험기기 및 대조 | 달한다.  혈소판 기능검사 시장은 매년 10% 이상의 성장률을 보이고 |\n| (2) 적용 범위 : 혈소판 기능검사키트에 적용한다.  | (1) | 관련 | 규격 | : | CLSI | EP06-A: | Evaluation | of | the | Linearity | of | (3) 시험 목적 : 혈소판 기능 이상의 양성, 음성의 판정 기준을 선정 | 검출한계로 추정되는 최소 검출 한계 이동거리 값을 기점을 최소 3개 | 검사자로 정상 검체 및 혈소판 기능 이상 검체를 1회 시험 할 때 |\n| 2. ",
        "original_sentence": "| 임상시험이 끝난 날부터 3년간 보존하도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_511",
      "text": "다만, 식품의약품안전처장이 | 2）P2Y12 test: Clopidogrel 약물 복용 전/후의 검체에 대해 시험기기 및 대조 | 달한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 510,
        "window_size": 3,
        "char_count": 78,
        "word_count": 16,
        "page_number": 6,
        "window_text": "| 3) 인구학적 정보 : 인구학적 정보로 대상자 이니셜, 나이, 성별 등을 조사한다.  | 달성할 때까지 사용하게 되며 수집된 정보는 개인정보보호법에 따라 적절히 관리 | 3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.  | 임상시험이 끝난 날부터 3년간 보존하도록 한다.  다만, 식품의약품안전처장이 | 2）P2Y12 test: Clopidogrel 약물 복용 전/후의 검체에 대해 시험기기 및 대조 | 달한다.  혈소판 기능검사 시장은 매년 10% 이상의 성장률을 보이고 |\n| (2) 적용 범위 : 혈소판 기능검사키트에 적용한다.  | (1) | 관련 | 규격 | : | CLSI | EP06-A: | Evaluation | of | the | Linearity | of | (3) 시험 목적 : 혈소판 기능 이상의 양성, 음성의 판정 기준을 선정 | 검출한계로 추정되는 최소 검출 한계 이동거리 값을 기점을 최소 3개 | 검사자로 정상 검체 및 혈소판 기능 이상 검체를 1회 시험 할 때 |\n| 2.  시험자안전성 | (주) ○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○-○○○-○○○○ | 으로 한 민감도 및 특이도를 기허가제품의 민감도 및 특이도와 비교하여 임상적 |\n**피험자에게 직접적인 위해를 발생시키지 않는다. ",
        "original_sentence": "다만, 식품의약품안전처장이 | 2）P2Y12 test: Clopidogrel 약물 복용 전/후의 검체에 대해 시험기기 및 대조 | 달한다. "
      }
    },
    {
      "chunk_id": "chunk_512",
      "text": "혈소판 기능검사 시장은 매년 10% 이상의 성장률을 보이고 |\n| (2) 적용 범위 : 혈소판 기능검사키트에 적용한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 511,
        "window_size": 3,
        "char_count": 67,
        "word_count": 17,
        "page_number": 6,
        "window_text": "| 달성할 때까지 사용하게 되며 수집된 정보는 개인정보보호법에 따라 적절히 관리 | 3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.  | 임상시험이 끝난 날부터 3년간 보존하도록 한다.  다만, 식품의약품안전처장이 | 2）P2Y12 test: Clopidogrel 약물 복용 전/후의 검체에 대해 시험기기 및 대조 | 달한다.  혈소판 기능검사 시장은 매년 10% 이상의 성장률을 보이고 |\n| (2) 적용 범위 : 혈소판 기능검사키트에 적용한다.  | (1) | 관련 | 규격 | : | CLSI | EP06-A: | Evaluation | of | the | Linearity | of | (3) 시험 목적 : 혈소판 기능 이상의 양성, 음성의 판정 기준을 선정 | 검출한계로 추정되는 최소 검출 한계 이동거리 값을 기점을 최소 3개 | 검사자로 정상 검체 및 혈소판 기능 이상 검체를 1회 시험 할 때 |\n| 2.  시험자안전성 | (주) ○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○-○○○-○○○○ | 으로 한 민감도 및 특이도를 기허가제품의 민감도 및 특이도와 비교하여 임상적 |\n**피험자에게 직접적인 위해를 발생시키지 않는다.  그러므로 아래 중지기준에 따라**\n| 나. ",
        "original_sentence": "혈소판 기능검사 시장은 매년 10% 이상의 성장률을 보이고 |\n| (2) 적용 범위 : 혈소판 기능검사키트에 적용한다. "
      }
    },
    {
      "chunk_id": "chunk_513",
      "text": "| (1) | 관련 | 규격 | : | CLSI | EP06-A: | Evaluation | of | the | Linearity | of | (3) 시험 목적 : 혈소판 기능 이상의 양성, 음성의 판정 기준을 선정 | 검출한계로 추정되는 최소 검출 한계 이동거리 값을 기점을 최소 3개 | 검사자로 정상 검체 및 혈소판 기능 이상 검체를 1회 시험 할 때 |\n| 2. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 512,
        "window_size": 3,
        "char_count": 207,
        "word_count": 62,
        "page_number": 6,
        "window_text": "| 임상시험이 끝난 날부터 3년간 보존하도록 한다.  다만, 식품의약품안전처장이 | 2）P2Y12 test: Clopidogrel 약물 복용 전/후의 검체에 대해 시험기기 및 대조 | 달한다.  혈소판 기능검사 시장은 매년 10% 이상의 성장률을 보이고 |\n| (2) 적용 범위 : 혈소판 기능검사키트에 적용한다.  | (1) | 관련 | 규격 | : | CLSI | EP06-A: | Evaluation | of | the | Linearity | of | (3) 시험 목적 : 혈소판 기능 이상의 양성, 음성의 판정 기준을 선정 | 검출한계로 추정되는 최소 검출 한계 이동거리 값을 기점을 최소 3개 | 검사자로 정상 검체 및 혈소판 기능 이상 검체를 1회 시험 할 때 |\n| 2.  시험자안전성 | (주) ○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○-○○○-○○○○ | 으로 한 민감도 및 특이도를 기허가제품의 민감도 및 특이도와 비교하여 임상적 |\n**피험자에게 직접적인 위해를 발생시키지 않는다.  그러므로 아래 중지기준에 따라**\n| 나.  전자파 안전성 시험 | aggregometry, LTA)를 기준 검사법으로 하여 기허가제품의 민감도 및 특이도와 | ○○○ | ○○○병원 | ○○○ | ○○○ | ○○-○○○-○○○○ |\n| (2) 의뢰자는 임상시험용 의료기기의 인수·취급·보관 및 미사용 의료기기를 피험자 | - 귀하는 귀하의 검체에 대해, 언제까지 보존하도록 허용할 것인지, 다른 사람 또는 | (3) 해당 의료기기 : 혈액응고검사시약과 자동혈소판응집측정장치 | 지혈이상 진단의 가장 중요한 검사방법으로 자리잡고 있으며, 혈소판기능검사의 | 14.1.1. ",
        "original_sentence": "| (1) | 관련 | 규격 | : | CLSI | EP06-A: | Evaluation | of | the | Linearity | of | (3) 시험 목적 : 혈소판 기능 이상의 양성, 음성의 판정 기준을 선정 | 검출한계로 추정되는 최소 검출 한계 이동거리 값을 기점을 최소 3개 | 검사자로 정상 검체 및 혈소판 기능 이상 검체를 1회 시험 할 때 |\n| 2. "
      }
    },
    {
      "chunk_id": "chunk_514",
      "text": "시험자안전성 | (주) ○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○-○○○-○○○○ | 으로 한 민감도 및 특이도를 기허가제품의 민감도 및 특이도와 비교하여 임상적 |\n**피험자에게 직접적인 위해를 발생시키지 않는다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 513,
        "window_size": 3,
        "char_count": 126,
        "word_count": 30,
        "page_number": 9,
        "window_text": "다만, 식품의약품안전처장이 | 2）P2Y12 test: Clopidogrel 약물 복용 전/후의 검체에 대해 시험기기 및 대조 | 달한다.  혈소판 기능검사 시장은 매년 10% 이상의 성장률을 보이고 |\n| (2) 적용 범위 : 혈소판 기능검사키트에 적용한다.  | (1) | 관련 | 규격 | : | CLSI | EP06-A: | Evaluation | of | the | Linearity | of | (3) 시험 목적 : 혈소판 기능 이상의 양성, 음성의 판정 기준을 선정 | 검출한계로 추정되는 최소 검출 한계 이동거리 값을 기점을 최소 3개 | 검사자로 정상 검체 및 혈소판 기능 이상 검체를 1회 시험 할 때 |\n| 2.  시험자안전성 | (주) ○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○-○○○-○○○○ | 으로 한 민감도 및 특이도를 기허가제품의 민감도 및 특이도와 비교하여 임상적 |\n**피험자에게 직접적인 위해를 발생시키지 않는다.  그러므로 아래 중지기준에 따라**\n| 나.  전자파 안전성 시험 | aggregometry, LTA)를 기준 검사법으로 하여 기허가제품의 민감도 및 특이도와 | ○○○ | ○○○병원 | ○○○ | ○○○ | ○○-○○○-○○○○ |\n| (2) 의뢰자는 임상시험용 의료기기의 인수·취급·보관 및 미사용 의료기기를 피험자 | - 귀하는 귀하의 검체에 대해, 언제까지 보존하도록 허용할 것인지, 다른 사람 또는 | (3) 해당 의료기기 : 혈액응고검사시약과 자동혈소판응집측정장치 | 지혈이상 진단의 가장 중요한 검사방법으로 자리잡고 있으며, 혈소판기능검사의 | 14.1.1.  혈소판 기능 검사 | (1) 검사를 진행하는 곳에서 음식물을 먹거나, 마시거나 담배를 피우지 않도록 한다. ",
        "original_sentence": "시험자안전성 | (주) ○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○-○○○-○○○○ | 으로 한 민감도 및 특이도를 기허가제품의 민감도 및 특이도와 비교하여 임상적 |\n**피험자에게 직접적인 위해를 발생시키지 않는다. "
      }
    },
    {
      "chunk_id": "chunk_515",
      "text": "그러므로 아래 중지기준에 따라**\n| 나. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 514,
        "window_size": 3,
        "char_count": 24,
        "word_count": 6,
        "page_number": 76,
        "window_text": "혈소판 기능검사 시장은 매년 10% 이상의 성장률을 보이고 |\n| (2) 적용 범위 : 혈소판 기능검사키트에 적용한다.  | (1) | 관련 | 규격 | : | CLSI | EP06-A: | Evaluation | of | the | Linearity | of | (3) 시험 목적 : 혈소판 기능 이상의 양성, 음성의 판정 기준을 선정 | 검출한계로 추정되는 최소 검출 한계 이동거리 값을 기점을 최소 3개 | 검사자로 정상 검체 및 혈소판 기능 이상 검체를 1회 시험 할 때 |\n| 2.  시험자안전성 | (주) ○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○-○○○-○○○○ | 으로 한 민감도 및 특이도를 기허가제품의 민감도 및 특이도와 비교하여 임상적 |\n**피험자에게 직접적인 위해를 발생시키지 않는다.  그러므로 아래 중지기준에 따라**\n| 나.  전자파 안전성 시험 | aggregometry, LTA)를 기준 검사법으로 하여 기허가제품의 민감도 및 특이도와 | ○○○ | ○○○병원 | ○○○ | ○○○ | ○○-○○○-○○○○ |\n| (2) 의뢰자는 임상시험용 의료기기의 인수·취급·보관 및 미사용 의료기기를 피험자 | - 귀하는 귀하의 검체에 대해, 언제까지 보존하도록 허용할 것인지, 다른 사람 또는 | (3) 해당 의료기기 : 혈액응고검사시약과 자동혈소판응집측정장치 | 지혈이상 진단의 가장 중요한 검사방법으로 자리잡고 있으며, 혈소판기능검사의 | 14.1.1.  혈소판 기능 검사 | (1) 검사를 진행하는 곳에서 음식물을 먹거나, 마시거나 담배를 피우지 않도록 한다.  | (6) 열, 먼지, 일광(직사광선), 응축(제품 표면에 맺힌 물방울)을 피해 사용하여야 한다. ",
        "original_sentence": "그러므로 아래 중지기준에 따라**\n| 나. "
      }
    },
    {
      "chunk_id": "chunk_516",
      "text": "전자파 안전성 시험 | aggregometry, LTA)를 기준 검사법으로 하여 기허가제품의 민감도 및 특이도와 | ○○○ | ○○○병원 | ○○○ | ○○○ | ○○-○○○-○○○○ |\n| (2) 의뢰자는 임상시험용 의료기기의 인수·취급·보관 및 미사용 의료기기를 피험자 | - 귀하는 귀하의 검체에 대해, 언제까지 보존하도록 허용할 것인지, 다른 사람 또는 | (3) 해당 의료기기 : 혈액응고검사시약과 자동혈소판응집측정장치 | 지혈이상 진단의 가장 중요한 검사방법으로 자리잡고 있으며, 혈소판기능검사의 | 14.1.1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 515,
        "window_size": 3,
        "char_count": 294,
        "word_count": 65,
        "page_number": 9,
        "window_text": "| (1) | 관련 | 규격 | : | CLSI | EP06-A: | Evaluation | of | the | Linearity | of | (3) 시험 목적 : 혈소판 기능 이상의 양성, 음성의 판정 기준을 선정 | 검출한계로 추정되는 최소 검출 한계 이동거리 값을 기점을 최소 3개 | 검사자로 정상 검체 및 혈소판 기능 이상 검체를 1회 시험 할 때 |\n| 2.  시험자안전성 | (주) ○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○-○○○-○○○○ | 으로 한 민감도 및 특이도를 기허가제품의 민감도 및 특이도와 비교하여 임상적 |\n**피험자에게 직접적인 위해를 발생시키지 않는다.  그러므로 아래 중지기준에 따라**\n| 나.  전자파 안전성 시험 | aggregometry, LTA)를 기준 검사법으로 하여 기허가제품의 민감도 및 특이도와 | ○○○ | ○○○병원 | ○○○ | ○○○ | ○○-○○○-○○○○ |\n| (2) 의뢰자는 임상시험용 의료기기의 인수·취급·보관 및 미사용 의료기기를 피험자 | - 귀하는 귀하의 검체에 대해, 언제까지 보존하도록 허용할 것인지, 다른 사람 또는 | (3) 해당 의료기기 : 혈액응고검사시약과 자동혈소판응집측정장치 | 지혈이상 진단의 가장 중요한 검사방법으로 자리잡고 있으며, 혈소판기능검사의 | 14.1.1.  혈소판 기능 검사 | (1) 검사를 진행하는 곳에서 음식물을 먹거나, 마시거나 담배를 피우지 않도록 한다.  | (6) 열, 먼지, 일광(직사광선), 응축(제품 표면에 맺힌 물방울)을 피해 사용하여야 한다.  | (3) 항응고제 함유 채혈관(3.2% Na citrate tube)를 준비한다. ",
        "original_sentence": "전자파 안전성 시험 | aggregometry, LTA)를 기준 검사법으로 하여 기허가제품의 민감도 및 특이도와 | ○○○ | ○○○병원 | ○○○ | ○○○ | ○○-○○○-○○○○ |\n| (2) 의뢰자는 임상시험용 의료기기의 인수·취급·보관 및 미사용 의료기기를 피험자 | - 귀하는 귀하의 검체에 대해, 언제까지 보존하도록 허용할 것인지, 다른 사람 또는 | (3) 해당 의료기기 : 혈액응고검사시약과 자동혈소판응집측정장치 | 지혈이상 진단의 가장 중요한 검사방법으로 자리잡고 있으며, 혈소판기능검사의 | 14.1.1. "
      }
    },
    {
      "chunk_id": "chunk_517",
      "text": "혈소판 기능 검사 | (1) 검사를 진행하는 곳에서 음식물을 먹거나, 마시거나 담배를 피우지 않도록 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 516,
        "window_size": 3,
        "char_count": 60,
        "word_count": 15,
        "page_number": 6,
        "window_text": "시험자안전성 | (주) ○○○ | ○○○ | ○○○ ○○시 ○○구 | ○○-○○○-○○○○ | 으로 한 민감도 및 특이도를 기허가제품의 민감도 및 특이도와 비교하여 임상적 |\n**피험자에게 직접적인 위해를 발생시키지 않는다.  그러므로 아래 중지기준에 따라**\n| 나.  전자파 안전성 시험 | aggregometry, LTA)를 기준 검사법으로 하여 기허가제품의 민감도 및 특이도와 | ○○○ | ○○○병원 | ○○○ | ○○○ | ○○-○○○-○○○○ |\n| (2) 의뢰자는 임상시험용 의료기기의 인수·취급·보관 및 미사용 의료기기를 피험자 | - 귀하는 귀하의 검체에 대해, 언제까지 보존하도록 허용할 것인지, 다른 사람 또는 | (3) 해당 의료기기 : 혈액응고검사시약과 자동혈소판응집측정장치 | 지혈이상 진단의 가장 중요한 검사방법으로 자리잡고 있으며, 혈소판기능검사의 | 14.1.1.  혈소판 기능 검사 | (1) 검사를 진행하는 곳에서 음식물을 먹거나, 마시거나 담배를 피우지 않도록 한다.  | (6) 열, 먼지, 일광(직사광선), 응축(제품 표면에 맺힌 물방울)을 피해 사용하여야 한다.  | (3) 항응고제 함유 채혈관(3.2% Na citrate tube)를 준비한다.  | (5) Tray에서 검사칩을 조심스럽게 빼내어 제거한다. ",
        "original_sentence": "혈소판 기능 검사 | (1) 검사를 진행하는 곳에서 음식물을 먹거나, 마시거나 담배를 피우지 않도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_518",
      "text": "| (6) 열, 먼지, 일광(직사광선), 응축(제품 표면에 맺힌 물방울)을 피해 사용하여야 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 517,
        "window_size": 3,
        "char_count": 55,
        "word_count": 12,
        "page_number": 15,
        "window_text": "그러므로 아래 중지기준에 따라**\n| 나.  전자파 안전성 시험 | aggregometry, LTA)를 기준 검사법으로 하여 기허가제품의 민감도 및 특이도와 | ○○○ | ○○○병원 | ○○○ | ○○○ | ○○-○○○-○○○○ |\n| (2) 의뢰자는 임상시험용 의료기기의 인수·취급·보관 및 미사용 의료기기를 피험자 | - 귀하는 귀하의 검체에 대해, 언제까지 보존하도록 허용할 것인지, 다른 사람 또는 | (3) 해당 의료기기 : 혈액응고검사시약과 자동혈소판응집측정장치 | 지혈이상 진단의 가장 중요한 검사방법으로 자리잡고 있으며, 혈소판기능검사의 | 14.1.1.  혈소판 기능 검사 | (1) 검사를 진행하는 곳에서 음식물을 먹거나, 마시거나 담배를 피우지 않도록 한다.  | (6) 열, 먼지, 일광(직사광선), 응축(제품 표면에 맺힌 물방울)을 피해 사용하여야 한다.  | (3) 항응고제 함유 채혈관(3.2% Na citrate tube)를 준비한다.  | (5) Tray에서 검사칩을 조심스럽게 빼내어 제거한다.  | - 직전 1개월 내 시행한 검사 결과상 PT, aPTT가 참고치를 벗어난 경우 | 4) 과거병력 및 병용약물 조사 | 지시하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을 연장할 수 있다. ",
        "original_sentence": "| (6) 열, 먼지, 일광(직사광선), 응축(제품 표면에 맺힌 물방울)을 피해 사용하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_519",
      "text": "| (3) 항응고제 함유 채혈관(3.2% Na citrate tube)를 준비한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 518,
        "window_size": 3,
        "char_count": 47,
        "word_count": 9,
        "page_number": 6,
        "window_text": "전자파 안전성 시험 | aggregometry, LTA)를 기준 검사법으로 하여 기허가제품의 민감도 및 특이도와 | ○○○ | ○○○병원 | ○○○ | ○○○ | ○○-○○○-○○○○ |\n| (2) 의뢰자는 임상시험용 의료기기의 인수·취급·보관 및 미사용 의료기기를 피험자 | - 귀하는 귀하의 검체에 대해, 언제까지 보존하도록 허용할 것인지, 다른 사람 또는 | (3) 해당 의료기기 : 혈액응고검사시약과 자동혈소판응집측정장치 | 지혈이상 진단의 가장 중요한 검사방법으로 자리잡고 있으며, 혈소판기능검사의 | 14.1.1.  혈소판 기능 검사 | (1) 검사를 진행하는 곳에서 음식물을 먹거나, 마시거나 담배를 피우지 않도록 한다.  | (6) 열, 먼지, 일광(직사광선), 응축(제품 표면에 맺힌 물방울)을 피해 사용하여야 한다.  | (3) 항응고제 함유 채혈관(3.2% Na citrate tube)를 준비한다.  | (5) Tray에서 검사칩을 조심스럽게 빼내어 제거한다.  | - 직전 1개월 내 시행한 검사 결과상 PT, aPTT가 참고치를 벗어난 경우 | 4) 과거병력 및 병용약물 조사 | 지시하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을 연장할 수 있다.  | 임상시험 계획서, 표준작업지침서, 임상시험 실시기준 및 관련 규정에 따라 실시, |\n| (3) 시험 목적 : 제조자가 채택한 구조의 설계와 방법이 조작자와 주위에 | 장비 | 혈소판 기능검사 | 혈소판 기능부전 검출 및 아스피린, 클로피도그렐와 같은 항혈소판제제에 대한 |\n| 임상시험용 의료기기인 체외진단용 의료기기는 인체 유래물질을 포함하고 있지 | (3) 시험 목적 : 혈소판 기능검사키트가 특정 조건하에서 사용 시 안정성을 | 유효성을 검증하는 것이 목적이다. ",
        "original_sentence": "| (3) 항응고제 함유 채혈관(3.2% Na citrate tube)를 준비한다. "
      }
    },
    {
      "chunk_id": "chunk_520",
      "text": "| (5) Tray에서 검사칩을 조심스럽게 빼내어 제거한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 519,
        "window_size": 3,
        "char_count": 34,
        "word_count": 7,
        "page_number": 6,
        "window_text": "혈소판 기능 검사 | (1) 검사를 진행하는 곳에서 음식물을 먹거나, 마시거나 담배를 피우지 않도록 한다.  | (6) 열, 먼지, 일광(직사광선), 응축(제품 표면에 맺힌 물방울)을 피해 사용하여야 한다.  | (3) 항응고제 함유 채혈관(3.2% Na citrate tube)를 준비한다.  | (5) Tray에서 검사칩을 조심스럽게 빼내어 제거한다.  | - 직전 1개월 내 시행한 검사 결과상 PT, aPTT가 참고치를 벗어난 경우 | 4) 과거병력 및 병용약물 조사 | 지시하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을 연장할 수 있다.  | 임상시험 계획서, 표준작업지침서, 임상시험 실시기준 및 관련 규정에 따라 실시, |\n| (3) 시험 목적 : 제조자가 채택한 구조의 설계와 방법이 조작자와 주위에 | 장비 | 혈소판 기능검사 | 혈소판 기능부전 검출 및 아스피린, 클로피도그렐와 같은 항혈소판제제에 대한 |\n| 임상시험용 의료기기인 체외진단용 의료기기는 인체 유래물질을 포함하고 있지 | (3) 시험 목적 : 혈소판 기능검사키트가 특정 조건하에서 사용 시 안정성을 | 유효성을 검증하는 것이 목적이다.  | 이상 정하고 낮은 값부터 3∼5일 동안 검체 당 5∼10회 이상 반복 측 | ① 혈액주입구: 검사칩(test kit)에 혈액(전혈)을 로딩하는 주입구. ",
        "original_sentence": "| (5) Tray에서 검사칩을 조심스럽게 빼내어 제거한다. "
      }
    },
    {
      "chunk_id": "chunk_521",
      "text": "| - 직전 1개월 내 시행한 검사 결과상 PT, aPTT가 참고치를 벗어난 경우 | 4) 과거병력 및 병용약물 조사 | 지시하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을 연장할 수 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 520,
        "window_size": 3,
        "char_count": 112,
        "word_count": 29,
        "page_number": 6,
        "window_text": "| (6) 열, 먼지, 일광(직사광선), 응축(제품 표면에 맺힌 물방울)을 피해 사용하여야 한다.  | (3) 항응고제 함유 채혈관(3.2% Na citrate tube)를 준비한다.  | (5) Tray에서 검사칩을 조심스럽게 빼내어 제거한다.  | - 직전 1개월 내 시행한 검사 결과상 PT, aPTT가 참고치를 벗어난 경우 | 4) 과거병력 및 병용약물 조사 | 지시하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을 연장할 수 있다.  | 임상시험 계획서, 표준작업지침서, 임상시험 실시기준 및 관련 규정에 따라 실시, |\n| (3) 시험 목적 : 제조자가 채택한 구조의 설계와 방법이 조작자와 주위에 | 장비 | 혈소판 기능검사 | 혈소판 기능부전 검출 및 아스피린, 클로피도그렐와 같은 항혈소판제제에 대한 |\n| 임상시험용 의료기기인 체외진단용 의료기기는 인체 유래물질을 포함하고 있지 | (3) 시험 목적 : 혈소판 기능검사키트가 특정 조건하에서 사용 시 안정성을 | 유효성을 검증하는 것이 목적이다.  | 이상 정하고 낮은 값부터 3∼5일 동안 검체 당 5∼10회 이상 반복 측 | ① 혈액주입구: 검사칩(test kit)에 혈액(전혈)을 로딩하는 주입구.  검체량은 400㎕이다. ",
        "original_sentence": "| - 직전 1개월 내 시행한 검사 결과상 PT, aPTT가 참고치를 벗어난 경우 | 4) 과거병력 및 병용약물 조사 | 지시하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을 연장할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_522",
      "text": "| 임상시험 계획서, 표준작업지침서, 임상시험 실시기준 및 관련 규정에 따라 실시, |\n| (3) 시험 목적 : 제조자가 채택한 구조의 설계와 방법이 조작자와 주위에 | 장비 | 혈소판 기능검사 | 혈소판 기능부전 검출 및 아스피린, 클로피도그렐와 같은 항혈소판제제에 대한 |\n| 임상시험용 의료기기인 체외진단용 의료기기는 인체 유래물질을 포함하고 있지 | (3) 시험 목적 : 혈소판 기능검사키트가 특정 조건하에서 사용 시 안정성을 | 유효성을 검증하는 것이 목적이다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 521,
        "window_size": 3,
        "char_count": 264,
        "word_count": 66,
        "page_number": 9,
        "window_text": "| (3) 항응고제 함유 채혈관(3.2% Na citrate tube)를 준비한다.  | (5) Tray에서 검사칩을 조심스럽게 빼내어 제거한다.  | - 직전 1개월 내 시행한 검사 결과상 PT, aPTT가 참고치를 벗어난 경우 | 4) 과거병력 및 병용약물 조사 | 지시하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을 연장할 수 있다.  | 임상시험 계획서, 표준작업지침서, 임상시험 실시기준 및 관련 규정에 따라 실시, |\n| (3) 시험 목적 : 제조자가 채택한 구조의 설계와 방법이 조작자와 주위에 | 장비 | 혈소판 기능검사 | 혈소판 기능부전 검출 및 아스피린, 클로피도그렐와 같은 항혈소판제제에 대한 |\n| 임상시험용 의료기기인 체외진단용 의료기기는 인체 유래물질을 포함하고 있지 | (3) 시험 목적 : 혈소판 기능검사키트가 특정 조건하에서 사용 시 안정성을 | 유효성을 검증하는 것이 목적이다.  | 이상 정하고 낮은 값부터 3∼5일 동안 검체 당 5∼10회 이상 반복 측 | ① 혈액주입구: 검사칩(test kit)에 혈액(전혈)을 로딩하는 주입구.  검체량은 400㎕이다.  | Quantitative Measurement Procedures; A Statistical Approach; |\n| 본 임상시험의 일시중지 후 재개 가능하다. ",
        "original_sentence": "| 임상시험 계획서, 표준작업지침서, 임상시험 실시기준 및 관련 규정에 따라 실시, |\n| (3) 시험 목적 : 제조자가 채택한 구조의 설계와 방법이 조작자와 주위에 | 장비 | 혈소판 기능검사 | 혈소판 기능부전 검출 및 아스피린, 클로피도그렐와 같은 항혈소판제제에 대한 |\n| 임상시험용 의료기기인 체외진단용 의료기기는 인체 유래물질을 포함하고 있지 | (3) 시험 목적 : 혈소판 기능검사키트가 특정 조건하에서 사용 시 안정성을 | 유효성을 검증하는 것이 목적이다. "
      }
    },
    {
      "chunk_id": "chunk_523",
      "text": "| 이상 정하고 낮은 값부터 3∼5일 동안 검체 당 5∼10회 이상 반복 측 | ① 혈액주입구: 검사칩(test kit)에 혈액(전혈)을 로딩하는 주입구. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 522,
        "window_size": 3,
        "char_count": 87,
        "word_count": 21,
        "page_number": 6,
        "window_text": "| (5) Tray에서 검사칩을 조심스럽게 빼내어 제거한다.  | - 직전 1개월 내 시행한 검사 결과상 PT, aPTT가 참고치를 벗어난 경우 | 4) 과거병력 및 병용약물 조사 | 지시하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을 연장할 수 있다.  | 임상시험 계획서, 표준작업지침서, 임상시험 실시기준 및 관련 규정에 따라 실시, |\n| (3) 시험 목적 : 제조자가 채택한 구조의 설계와 방법이 조작자와 주위에 | 장비 | 혈소판 기능검사 | 혈소판 기능부전 검출 및 아스피린, 클로피도그렐와 같은 항혈소판제제에 대한 |\n| 임상시험용 의료기기인 체외진단용 의료기기는 인체 유래물질을 포함하고 있지 | (3) 시험 목적 : 혈소판 기능검사키트가 특정 조건하에서 사용 시 안정성을 | 유효성을 검증하는 것이 목적이다.  | 이상 정하고 낮은 값부터 3∼5일 동안 검체 당 5∼10회 이상 반복 측 | ① 혈액주입구: 검사칩(test kit)에 혈액(전혈)을 로딩하는 주입구.  검체량은 400㎕이다.  | Quantitative Measurement Procedures; A Statistical Approach; |\n| 본 임상시험의 일시중지 후 재개 가능하다.  | 연구담당자: | (성명) | (소속) | (연락처) | - 시험장비 |\n**미주신경이 반사적으로 작용하여 뇌혈류를 감소시키고 심장 박동을 감소시켜**\n| 나. ",
        "original_sentence": "| 이상 정하고 낮은 값부터 3∼5일 동안 검체 당 5∼10회 이상 반복 측 | ① 혈액주입구: 검사칩(test kit)에 혈액(전혈)을 로딩하는 주입구. "
      }
    },
    {
      "chunk_id": "chunk_524",
      "text": "검체량은 400㎕이다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 523,
        "window_size": 3,
        "char_count": 13,
        "word_count": 2,
        "page_number": 15,
        "window_text": "| - 직전 1개월 내 시행한 검사 결과상 PT, aPTT가 참고치를 벗어난 경우 | 4) 과거병력 및 병용약물 조사 | 지시하거나 시험책임자가 필요하다고 판단한 경우에는 보관기간을 연장할 수 있다.  | 임상시험 계획서, 표준작업지침서, 임상시험 실시기준 및 관련 규정에 따라 실시, |\n| (3) 시험 목적 : 제조자가 채택한 구조의 설계와 방법이 조작자와 주위에 | 장비 | 혈소판 기능검사 | 혈소판 기능부전 검출 및 아스피린, 클로피도그렐와 같은 항혈소판제제에 대한 |\n| 임상시험용 의료기기인 체외진단용 의료기기는 인체 유래물질을 포함하고 있지 | (3) 시험 목적 : 혈소판 기능검사키트가 특정 조건하에서 사용 시 안정성을 | 유효성을 검증하는 것이 목적이다.  | 이상 정하고 낮은 값부터 3∼5일 동안 검체 당 5∼10회 이상 반복 측 | ① 혈액주입구: 검사칩(test kit)에 혈액(전혈)을 로딩하는 주입구.  검체량은 400㎕이다.  | Quantitative Measurement Procedures; A Statistical Approach; |\n| 본 임상시험의 일시중지 후 재개 가능하다.  | 연구담당자: | (성명) | (소속) | (연락처) | - 시험장비 |\n**미주신경이 반사적으로 작용하여 뇌혈류를 감소시키고 심장 박동을 감소시켜**\n| 나.  시험담당자 | 비정상 유무를 판정하기 위한 목적은 ADP test와 동일하므로, ADP test의 평가기 | 5) 적용상의 주의 | 비교 평가하기 위한 다기관, 비무작위배정, 단일눈가림, 단일설계, 전향적 비교 | (4) 임상시험 평가내용 : 민감도 및 특이도, 일치도 | 표준으로 사용되고 있다. ",
        "original_sentence": "검체량은 400㎕이다. "
      }
    },
    {
      "chunk_id": "chunk_525",
      "text": "| Quantitative Measurement Procedures; A Statistical Approach; |\n| 본 임상시험의 일시중지 후 재개 가능하다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 524,
        "window_size": 3,
        "char_count": 91,
        "word_count": 15,
        "page_number": 33,
        "window_text": "| 임상시험 계획서, 표준작업지침서, 임상시험 실시기준 및 관련 규정에 따라 실시, |\n| (3) 시험 목적 : 제조자가 채택한 구조의 설계와 방법이 조작자와 주위에 | 장비 | 혈소판 기능검사 | 혈소판 기능부전 검출 및 아스피린, 클로피도그렐와 같은 항혈소판제제에 대한 |\n| 임상시험용 의료기기인 체외진단용 의료기기는 인체 유래물질을 포함하고 있지 | (3) 시험 목적 : 혈소판 기능검사키트가 특정 조건하에서 사용 시 안정성을 | 유효성을 검증하는 것이 목적이다.  | 이상 정하고 낮은 값부터 3∼5일 동안 검체 당 5∼10회 이상 반복 측 | ① 혈액주입구: 검사칩(test kit)에 혈액(전혈)을 로딩하는 주입구.  검체량은 400㎕이다.  | Quantitative Measurement Procedures; A Statistical Approach; |\n| 본 임상시험의 일시중지 후 재개 가능하다.  | 연구담당자: | (성명) | (소속) | (연락처) | - 시험장비 |\n**미주신경이 반사적으로 작용하여 뇌혈류를 감소시키고 심장 박동을 감소시켜**\n| 나.  시험담당자 | 비정상 유무를 판정하기 위한 목적은 ADP test와 동일하므로, ADP test의 평가기 | 5) 적용상의 주의 | 비교 평가하기 위한 다기관, 비무작위배정, 단일눈가림, 단일설계, 전향적 비교 | (4) 임상시험 평가내용 : 민감도 및 특이도, 일치도 | 표준으로 사용되고 있다.  검사원리는 전혈에서 혈소판풍부 혈장을 분리한 후 혈소판 | (1) 관련 규격 | (2) 검체와 시약을 다룰 때에는 일회용 장갑과 검사용 가운을 착용하도록 한다. ",
        "original_sentence": "| Quantitative Measurement Procedures; A Statistical Approach; |\n| 본 임상시험의 일시중지 후 재개 가능하다. "
      }
    },
    {
      "chunk_id": "chunk_526",
      "text": "| 연구담당자: | (성명) | (소속) | (연락처) | - 시험장비 |\n**미주신경이 반사적으로 작용하여 뇌혈류를 감소시키고 심장 박동을 감소시켜**\n| 나. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 525,
        "window_size": 3,
        "char_count": 91,
        "word_count": 22,
        "page_number": 3,
        "window_text": "| 이상 정하고 낮은 값부터 3∼5일 동안 검체 당 5∼10회 이상 반복 측 | ① 혈액주입구: 검사칩(test kit)에 혈액(전혈)을 로딩하는 주입구.  검체량은 400㎕이다.  | Quantitative Measurement Procedures; A Statistical Approach; |\n| 본 임상시험의 일시중지 후 재개 가능하다.  | 연구담당자: | (성명) | (소속) | (연락처) | - 시험장비 |\n**미주신경이 반사적으로 작용하여 뇌혈류를 감소시키고 심장 박동을 감소시켜**\n| 나.  시험담당자 | 비정상 유무를 판정하기 위한 목적은 ADP test와 동일하므로, ADP test의 평가기 | 5) 적용상의 주의 | 비교 평가하기 위한 다기관, 비무작위배정, 단일눈가림, 단일설계, 전향적 비교 | (4) 임상시험 평가내용 : 민감도 및 특이도, 일치도 | 표준으로 사용되고 있다.  검사원리는 전혈에서 혈소판풍부 혈장을 분리한 후 혈소판 | (1) 관련 규격 | (2) 검체와 시약을 다룰 때에는 일회용 장갑과 검사용 가운을 착용하도록 한다.  | (4) 검체는 실온(15~25℃)에 보관한다. ",
        "original_sentence": "| 연구담당자: | (성명) | (소속) | (연락처) | - 시험장비 |\n**미주신경이 반사적으로 작용하여 뇌혈류를 감소시키고 심장 박동을 감소시켜**\n| 나. "
      }
    },
    {
      "chunk_id": "chunk_527",
      "text": "시험담당자 | 비정상 유무를 판정하기 위한 목적은 ADP test와 동일하므로, ADP test의 평가기 | 5) 적용상의 주의 | 비교 평가하기 위한 다기관, 비무작위배정, 단일눈가림, 단일설계, 전향적 비교 | (4) 임상시험 평가내용 : 민감도 및 특이도, 일치도 | 표준으로 사용되고 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 526,
        "window_size": 3,
        "char_count": 167,
        "word_count": 40,
        "page_number": 3,
        "window_text": "검체량은 400㎕이다.  | Quantitative Measurement Procedures; A Statistical Approach; |\n| 본 임상시험의 일시중지 후 재개 가능하다.  | 연구담당자: | (성명) | (소속) | (연락처) | - 시험장비 |\n**미주신경이 반사적으로 작용하여 뇌혈류를 감소시키고 심장 박동을 감소시켜**\n| 나.  시험담당자 | 비정상 유무를 판정하기 위한 목적은 ADP test와 동일하므로, ADP test의 평가기 | 5) 적용상의 주의 | 비교 평가하기 위한 다기관, 비무작위배정, 단일눈가림, 단일설계, 전향적 비교 | (4) 임상시험 평가내용 : 민감도 및 특이도, 일치도 | 표준으로 사용되고 있다.  검사원리는 전혈에서 혈소판풍부 혈장을 분리한 후 혈소판 | (1) 관련 규격 | (2) 검체와 시약을 다룰 때에는 일회용 장갑과 검사용 가운을 착용하도록 한다.  | (4) 검체는 실온(15~25℃)에 보관한다.  | (6) 메인화면의 “Result”탭을 확인하여 검사에 대한 정보를 검토한다. ",
        "original_sentence": "시험담당자 | 비정상 유무를 판정하기 위한 목적은 ADP test와 동일하므로, ADP test의 평가기 | 5) 적용상의 주의 | 비교 평가하기 위한 다기관, 비무작위배정, 단일눈가림, 단일설계, 전향적 비교 | (4) 임상시험 평가내용 : 민감도 및 특이도, 일치도 | 표준으로 사용되고 있다. "
      }
    },
    {
      "chunk_id": "chunk_528",
      "text": "검사원리는 전혈에서 혈소판풍부 혈장을 분리한 후 혈소판 | (1) 관련 규격 | (2) 검체와 시약을 다룰 때에는 일회용 장갑과 검사용 가운을 착용하도록 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 527,
        "window_size": 3,
        "char_count": 90,
        "word_count": 23,
        "page_number": 6,
        "window_text": "| Quantitative Measurement Procedures; A Statistical Approach; |\n| 본 임상시험의 일시중지 후 재개 가능하다.  | 연구담당자: | (성명) | (소속) | (연락처) | - 시험장비 |\n**미주신경이 반사적으로 작용하여 뇌혈류를 감소시키고 심장 박동을 감소시켜**\n| 나.  시험담당자 | 비정상 유무를 판정하기 위한 목적은 ADP test와 동일하므로, ADP test의 평가기 | 5) 적용상의 주의 | 비교 평가하기 위한 다기관, 비무작위배정, 단일눈가림, 단일설계, 전향적 비교 | (4) 임상시험 평가내용 : 민감도 및 특이도, 일치도 | 표준으로 사용되고 있다.  검사원리는 전혈에서 혈소판풍부 혈장을 분리한 후 혈소판 | (1) 관련 규격 | (2) 검체와 시약을 다룰 때에는 일회용 장갑과 검사용 가운을 착용하도록 한다.  | (4) 검체는 실온(15~25℃)에 보관한다.  | (6) 메인화면의 “Result”탭을 확인하여 검사에 대한 정보를 검토한다.  검사에 대한 | - 항응고제 치료중인 환자 | 출혈성 질환, 응고장애, 암, 기타 만성질환 등의 병력 및 | 아스피린, P2Y12 |\n| 가. EPI test | 약물 저항성을 확인하는 기기로, 본 연구를 통해 ‘출혈 시간 및 항혈소판제제 |\n**기계적으로 적절하게 보호를 하고 있다는 것을 보증함에 있다.",
        "original_sentence": "검사원리는 전혈에서 혈소판풍부 혈장을 분리한 후 혈소판 | (1) 관련 규격 | (2) 검체와 시약을 다룰 때에는 일회용 장갑과 검사용 가운을 착용하도록 한다. "
      }
    },
    {
      "chunk_id": "chunk_529",
      "text": "| (4) 검체는 실온(15~25℃)에 보관한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 528,
        "window_size": 3,
        "char_count": 28,
        "word_count": 5,
        "page_number": 6,
        "window_text": "| 연구담당자: | (성명) | (소속) | (연락처) | - 시험장비 |\n**미주신경이 반사적으로 작용하여 뇌혈류를 감소시키고 심장 박동을 감소시켜**\n| 나.  시험담당자 | 비정상 유무를 판정하기 위한 목적은 ADP test와 동일하므로, ADP test의 평가기 | 5) 적용상의 주의 | 비교 평가하기 위한 다기관, 비무작위배정, 단일눈가림, 단일설계, 전향적 비교 | (4) 임상시험 평가내용 : 민감도 및 특이도, 일치도 | 표준으로 사용되고 있다.  검사원리는 전혈에서 혈소판풍부 혈장을 분리한 후 혈소판 | (1) 관련 규격 | (2) 검체와 시약을 다룰 때에는 일회용 장갑과 검사용 가운을 착용하도록 한다.  | (4) 검체는 실온(15~25℃)에 보관한다.  | (6) 메인화면의 “Result”탭을 확인하여 검사에 대한 정보를 검토한다.  검사에 대한 | - 항응고제 치료중인 환자 | 출혈성 질환, 응고장애, 암, 기타 만성질환 등의 병력 및 | 아스피린, P2Y12 |\n| 가. EPI test | 약물 저항성을 확인하는 기기로, 본 연구를 통해 ‘출혈 시간 및 항혈소판제제 |\n**기계적으로 적절하게 보호를 하고 있다는 것을 보증함에 있다. **\n\n**[표 끝]**\n\n<!-- PAGE_18 -->\n###### (나) IEC 61010-1: 2010 Safety requirements for electrical equipment\n\n<!-- PAGE_18 -->\n###### for measurement, control, and laboratory use–Part 1: General\n\n<!-- PAGE_18 -->\n###### (다)\n\n<!-- PAGE_18 -->\n###### IEC\n\n<!-- PAGE_18 -->\n###### 61010-2-101:\n\n<!-- PAGE_18 -->\n###### 2015\n\n<!-- PAGE_18 -->\n###### Safety\n\n<!-- PAGE_18 -->\n###### requirements\n\n<!-- PAGE_18 -->\n###### for\n\n<!-- PAGE_18 -->\n###### electrical\n\n<!-- PAGE_18 -->\n###### Particular\n\n<!-- PAGE_18 -->\n###### requirements\n\n<!-- PAGE_18 -->\n###### for\n\n<!-- PAGE_18 -->\n###### in\n\n<!-- PAGE_18 -->\n###### vitro\n\n<!-- PAGE_18 -->\n###### diagnostic\n\n<!-- PAGE_18 -->\n###### (IVD)\n\n<!-- PAGE_18 -->\n###### (2) 적용 범위 : 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데\n\n<!-- PAGE_18 -->\n###### (4) 시험 항목\n\n<!-- PAGE_18 -->\n###### (가) 전기충격에 대한 보호 : IEC 61010-1의 6절에 기술된 전기충격\n\n<!-- PAGE_18 -->\n###### (나) 기계적 위해요인에 대한 보호 : IEC 61010-1의 7절에 기술된 기계적\n\n<!-- PAGE_18 -->\n###### (다) 충격과 충돌에 대한 기계적 내성 : IEC 61010-1의 8절에 기술된\n\n<!-- PAGE_18 -->\n###### 충격과 충돌에 대한 기계적 내성에 관한 요구사항이 적용된다.\n\n",
        "original_sentence": "| (4) 검체는 실온(15~25℃)에 보관한다. "
      }
    },
    {
      "chunk_id": "chunk_530",
      "text": "| (6) 메인화면의 “Result”탭을 확인하여 검사에 대한 정보를 검토한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 529,
        "window_size": 3,
        "char_count": 45,
        "word_count": 9,
        "page_number": 15,
        "window_text": "시험담당자 | 비정상 유무를 판정하기 위한 목적은 ADP test와 동일하므로, ADP test의 평가기 | 5) 적용상의 주의 | 비교 평가하기 위한 다기관, 비무작위배정, 단일눈가림, 단일설계, 전향적 비교 | (4) 임상시험 평가내용 : 민감도 및 특이도, 일치도 | 표준으로 사용되고 있다.  검사원리는 전혈에서 혈소판풍부 혈장을 분리한 후 혈소판 | (1) 관련 규격 | (2) 검체와 시약을 다룰 때에는 일회용 장갑과 검사용 가운을 착용하도록 한다.  | (4) 검체는 실온(15~25℃)에 보관한다.  | (6) 메인화면의 “Result”탭을 확인하여 검사에 대한 정보를 검토한다.  검사에 대한 | - 항응고제 치료중인 환자 | 출혈성 질환, 응고장애, 암, 기타 만성질환 등의 병력 및 | 아스피린, P2Y12 |\n| 가. EPI test | 약물 저항성을 확인하는 기기로, 본 연구를 통해 ‘출혈 시간 및 항혈소판제제 |\n**기계적으로 적절하게 보호를 하고 있다는 것을 보증함에 있다. **\n\n**[표 끝]**\n\n<!-- PAGE_18 -->\n###### (나) IEC 61010-1: 2010 Safety requirements for electrical equipment\n\n<!-- PAGE_18 -->\n###### for measurement, control, and laboratory use–Part 1: General\n\n<!-- PAGE_18 -->\n###### (다)\n\n<!-- PAGE_18 -->\n###### IEC\n\n<!-- PAGE_18 -->\n###### 61010-2-101:\n\n<!-- PAGE_18 -->\n###### 2015\n\n<!-- PAGE_18 -->\n###### Safety\n\n<!-- PAGE_18 -->\n###### requirements\n\n<!-- PAGE_18 -->\n###### for\n\n<!-- PAGE_18 -->\n###### electrical\n\n<!-- PAGE_18 -->\n###### Particular\n\n<!-- PAGE_18 -->\n###### requirements\n\n<!-- PAGE_18 -->\n###### for\n\n<!-- PAGE_18 -->\n###### in\n\n<!-- PAGE_18 -->\n###### vitro\n\n<!-- PAGE_18 -->\n###### diagnostic\n\n<!-- PAGE_18 -->\n###### (IVD)\n\n<!-- PAGE_18 -->\n###### (2) 적용 범위 : 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데\n\n<!-- PAGE_18 -->\n###### (4) 시험 항목\n\n<!-- PAGE_18 -->\n###### (가) 전기충격에 대한 보호 : IEC 61010-1의 6절에 기술된 전기충격\n\n<!-- PAGE_18 -->\n###### (나) 기계적 위해요인에 대한 보호 : IEC 61010-1의 7절에 기술된 기계적\n\n<!-- PAGE_18 -->\n###### (다) 충격과 충돌에 대한 기계적 내성 : IEC 61010-1의 8절에 기술된\n\n<!-- PAGE_18 -->\n###### 충격과 충돌에 대한 기계적 내성에 관한 요구사항이 적용된다.\n\n - - 12 -\n<!-- PAGE_19 -->\n###### (라) 화재 확산 방지 : IEC 61010-1의 9절에 기술된 화재 확산 방지에\n\n<!-- PAGE_19 -->\n###### 관한 요구사항이 적용된다.\n\n",
        "original_sentence": "| (6) 메인화면의 “Result”탭을 확인하여 검사에 대한 정보를 검토한다. "
      }
    },
    {
      "chunk_id": "chunk_531",
      "text": "검사에 대한 | - 항응고제 치료중인 환자 | 출혈성 질환, 응고장애, 암, 기타 만성질환 등의 병력 및 | 아스피린, P2Y12 |\n| 가. EPI test | 약물 저항성을 확인하는 기기로, 본 연구를 통해 ‘출혈 시간 및 항혈소판제제 |\n**기계적으로 적절하게 보호를 하고 있다는 것을 보증함에 있다.",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 530,
        "window_size": 3,
        "char_count": 171,
        "word_count": 46,
        "page_number": 33,
        "window_text": "검사원리는 전혈에서 혈소판풍부 혈장을 분리한 후 혈소판 | (1) 관련 규격 | (2) 검체와 시약을 다룰 때에는 일회용 장갑과 검사용 가운을 착용하도록 한다.  | (4) 검체는 실온(15~25℃)에 보관한다.  | (6) 메인화면의 “Result”탭을 확인하여 검사에 대한 정보를 검토한다.  검사에 대한 | - 항응고제 치료중인 환자 | 출혈성 질환, 응고장애, 암, 기타 만성질환 등의 병력 및 | 아스피린, P2Y12 |\n| 가. EPI test | 약물 저항성을 확인하는 기기로, 본 연구를 통해 ‘출혈 시간 및 항혈소판제제 |\n**기계적으로 적절하게 보호를 하고 있다는 것을 보증함에 있다. **\n\n**[표 끝]**\n\n<!-- PAGE_18 -->\n###### (나) IEC 61010-1: 2010 Safety requirements for electrical equipment\n\n<!-- PAGE_18 -->\n###### for measurement, control, and laboratory use–Part 1: General\n\n<!-- PAGE_18 -->\n###### (다)\n\n<!-- PAGE_18 -->\n###### IEC\n\n<!-- PAGE_18 -->\n###### 61010-2-101:\n\n<!-- PAGE_18 -->\n###### 2015\n\n<!-- PAGE_18 -->\n###### Safety\n\n<!-- PAGE_18 -->\n###### requirements\n\n<!-- PAGE_18 -->\n###### for\n\n<!-- PAGE_18 -->\n###### electrical\n\n<!-- PAGE_18 -->\n###### Particular\n\n<!-- PAGE_18 -->\n###### requirements\n\n<!-- PAGE_18 -->\n###### for\n\n<!-- PAGE_18 -->\n###### in\n\n<!-- PAGE_18 -->\n###### vitro\n\n<!-- PAGE_18 -->\n###### diagnostic\n\n<!-- PAGE_18 -->\n###### (IVD)\n\n<!-- PAGE_18 -->\n###### (2) 적용 범위 : 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데\n\n<!-- PAGE_18 -->\n###### (4) 시험 항목\n\n<!-- PAGE_18 -->\n###### (가) 전기충격에 대한 보호 : IEC 61010-1의 6절에 기술된 전기충격\n\n<!-- PAGE_18 -->\n###### (나) 기계적 위해요인에 대한 보호 : IEC 61010-1의 7절에 기술된 기계적\n\n<!-- PAGE_18 -->\n###### (다) 충격과 충돌에 대한 기계적 내성 : IEC 61010-1의 8절에 기술된\n\n<!-- PAGE_18 -->\n###### 충격과 충돌에 대한 기계적 내성에 관한 요구사항이 적용된다.\n\n - - 12 -\n<!-- PAGE_19 -->\n###### (라) 화재 확산 방지 : IEC 61010-1의 9절에 기술된 화재 확산 방지에\n\n<!-- PAGE_19 -->\n###### 관한 요구사항이 적용된다.\n\n <!-- PAGE_19 -->\n###### (사) 유리가스, 폭발, 파열에 대한 보호 : IEC 61010-1의 13절에 기술된\n\n<!-- PAGE_19 -->\n###### (자) 연동 장치에 의한 보호 : IEC 61010-1의 15절에 기술된 연동 장치에\n\n<!-- PAGE_19 -->\n###### (가) 「의료기기의 전자파 안전에 관한 공통기준규격」(식품의약품안전처고시)\n\n<!-- PAGE_19 -->\n###### (나) IEC 61326-1: 2012 Electrical equipment for measurement, control and\n\n<!-- PAGE_19 -->\n###### laboratory use -\n\n<!-- PAGE_19 -->\n###### EMC requirements – Part 1: General requirements\n\n<!-- PAGE_19 -->\n###### (다)\n\n<!-- PAGE_19 -->\n###### IEC\n\n<!-- PAGE_19 -->\n###### 61326-2-6:\n\n<!-- PAGE_19 -->\n###### 2012\n\n<!-- PAGE_19 -->\n###### Electrical\n\n<!-- PAGE_19 -->\n###### equipment\n\n<!-- PAGE_19 -->\n###### for\n\n<!-- PAGE_19 -->\n###### measurement,\n\n<!-- PAGE_19 -->\n###### control and laboratory use – EMC requirements – Part 2-6:\n\n<!-- PAGE_19 -->\n###### Particular requirements – In vitro diagnostic (IVD) medical\n\n<!-- PAGE_19 -->\n###### equipment\n\n- - 13 -\n<!-- PAGE_20 -->\n###### (2) 적용 범위 : 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데\n\n<!-- PAGE_20 -->\n###### 사용되는 체외진단용 분석기기에 적용한다.\n\n",
        "original_sentence": "검사에 대한 | - 항응고제 치료중인 환자 | 출혈성 질환, 응고장애, 암, 기타 만성질환 등의 병력 및 | 아스피린, P2Y12 |\n| 가. EPI test | 약물 저항성을 확인하는 기기로, 본 연구를 통해 ‘출혈 시간 및 항혈소판제제 |\n**기계적으로 적절하게 보호를 하고 있다는 것을 보증함에 있다."
      }
    },
    {
      "chunk_id": "chunk_532",
      "text": "**\n\n**[표 끝]**\n\n<!-- PAGE_18 -->\n###### (나) IEC 61010-1: 2010 Safety requirements for electrical equipment\n\n<!-- PAGE_18 -->\n###### for measurement, control, and laboratory use–Part 1: General\n\n<!-- PAGE_18 -->\n###### (다)\n\n<!-- PAGE_18 -->\n###### IEC\n\n<!-- PAGE_18 -->\n###### 61010-2-101:\n\n<!-- PAGE_18 -->\n###### 2015\n\n<!-- PAGE_18 -->\n###### Safety\n\n<!-- PAGE_18 -->\n###### requirements\n\n<!-- PAGE_18 -->\n###### for\n\n<!-- PAGE_18 -->\n###### electrical\n\n<!-- PAGE_18 -->\n###### Particular\n\n<!-- PAGE_18 -->\n###### requirements\n\n<!-- PAGE_18 -->\n###### for\n\n<!-- PAGE_18 -->\n###### in\n\n<!-- PAGE_18 -->\n###### vitro\n\n<!-- PAGE_18 -->\n###### diagnostic\n\n<!-- PAGE_18 -->\n###### (IVD)\n\n<!-- PAGE_18 -->\n###### (2) 적용 범위 : 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데\n\n<!-- PAGE_18 -->\n###### (4) 시험 항목\n\n<!-- PAGE_18 -->\n###### (가) 전기충격에 대한 보호 : IEC 61010-1의 6절에 기술된 전기충격\n\n<!-- PAGE_18 -->\n###### (나) 기계적 위해요인에 대한 보호 : IEC 61010-1의 7절에 기술된 기계적\n\n<!-- PAGE_18 -->\n###### (다) 충격과 충돌에 대한 기계적 내성 : IEC 61010-1의 8절에 기술된\n\n<!-- PAGE_18 -->\n###### 충격과 충돌에 대한 기계적 내성에 관한 요구사항이 적용된다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 531,
        "window_size": 3,
        "char_count": 1056,
        "word_count": 181,
        "page_number": 18,
        "window_text": "| (4) 검체는 실온(15~25℃)에 보관한다.  | (6) 메인화면의 “Result”탭을 확인하여 검사에 대한 정보를 검토한다.  검사에 대한 | - 항응고제 치료중인 환자 | 출혈성 질환, 응고장애, 암, 기타 만성질환 등의 병력 및 | 아스피린, P2Y12 |\n| 가. EPI test | 약물 저항성을 확인하는 기기로, 본 연구를 통해 ‘출혈 시간 및 항혈소판제제 |\n**기계적으로 적절하게 보호를 하고 있다는 것을 보증함에 있다. **\n\n**[표 끝]**\n\n<!-- PAGE_18 -->\n###### (나) IEC 61010-1: 2010 Safety requirements for electrical equipment\n\n<!-- PAGE_18 -->\n###### for measurement, control, and laboratory use–Part 1: General\n\n<!-- PAGE_18 -->\n###### (다)\n\n<!-- PAGE_18 -->\n###### IEC\n\n<!-- PAGE_18 -->\n###### 61010-2-101:\n\n<!-- PAGE_18 -->\n###### 2015\n\n<!-- PAGE_18 -->\n###### Safety\n\n<!-- PAGE_18 -->\n###### requirements\n\n<!-- PAGE_18 -->\n###### for\n\n<!-- PAGE_18 -->\n###### electrical\n\n<!-- PAGE_18 -->\n###### Particular\n\n<!-- PAGE_18 -->\n###### requirements\n\n<!-- PAGE_18 -->\n###### for\n\n<!-- PAGE_18 -->\n###### in\n\n<!-- PAGE_18 -->\n###### vitro\n\n<!-- PAGE_18 -->\n###### diagnostic\n\n<!-- PAGE_18 -->\n###### (IVD)\n\n<!-- PAGE_18 -->\n###### (2) 적용 범위 : 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데\n\n<!-- PAGE_18 -->\n###### (4) 시험 항목\n\n<!-- PAGE_18 -->\n###### (가) 전기충격에 대한 보호 : IEC 61010-1의 6절에 기술된 전기충격\n\n<!-- PAGE_18 -->\n###### (나) 기계적 위해요인에 대한 보호 : IEC 61010-1의 7절에 기술된 기계적\n\n<!-- PAGE_18 -->\n###### (다) 충격과 충돌에 대한 기계적 내성 : IEC 61010-1의 8절에 기술된\n\n<!-- PAGE_18 -->\n###### 충격과 충돌에 대한 기계적 내성에 관한 요구사항이 적용된다.\n\n - - 12 -\n<!-- PAGE_19 -->\n###### (라) 화재 확산 방지 : IEC 61010-1의 9절에 기술된 화재 확산 방지에\n\n<!-- PAGE_19 -->\n###### 관한 요구사항이 적용된다.\n\n <!-- PAGE_19 -->\n###### (사) 유리가스, 폭발, 파열에 대한 보호 : IEC 61010-1의 13절에 기술된\n\n<!-- PAGE_19 -->\n###### (자) 연동 장치에 의한 보호 : IEC 61010-1의 15절에 기술된 연동 장치에\n\n<!-- PAGE_19 -->\n###### (가) 「의료기기의 전자파 안전에 관한 공통기준규격」(식품의약품안전처고시)\n\n<!-- PAGE_19 -->\n###### (나) IEC 61326-1: 2012 Electrical equipment for measurement, control and\n\n<!-- PAGE_19 -->\n###### laboratory use -\n\n<!-- PAGE_19 -->\n###### EMC requirements – Part 1: General requirements\n\n<!-- PAGE_19 -->\n###### (다)\n\n<!-- PAGE_19 -->\n###### IEC\n\n<!-- PAGE_19 -->\n###### 61326-2-6:\n\n<!-- PAGE_19 -->\n###### 2012\n\n<!-- PAGE_19 -->\n###### Electrical\n\n<!-- PAGE_19 -->\n###### equipment\n\n<!-- PAGE_19 -->\n###### for\n\n<!-- PAGE_19 -->\n###### measurement,\n\n<!-- PAGE_19 -->\n###### control and laboratory use – EMC requirements – Part 2-6:\n\n<!-- PAGE_19 -->\n###### Particular requirements – In vitro diagnostic (IVD) medical\n\n<!-- PAGE_19 -->\n###### equipment\n\n- - 13 -\n<!-- PAGE_20 -->\n###### (2) 적용 범위 : 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데\n\n<!-- PAGE_20 -->\n###### 사용되는 체외진단용 분석기기에 적용한다.\n\n <!-- PAGE_20 -->\n###### (3) 시험 목적 :\n\n<!-- PAGE_20 -->\n###### 전자 의료기기에 전자파로 인한 전자파장해와 전자파\n\n<!-- PAGE_20 -->\n###### ② 방사성 RF 전자기장 시험 : IEC 61000-4-3에 기술된 방사성 RF\n\n<!-- PAGE_20 -->\n###### (나) 전자파방사 : IEC 61326에 기술된 전자파 방사시험에 관한 요구\n\n- - 14 -\n<!-- PAGE_21 -->\n###### 6. ",
        "original_sentence": "**\n\n**[표 끝]**\n\n<!-- PAGE_18 -->\n###### (나) IEC 61010-1: 2010 Safety requirements for electrical equipment\n\n<!-- PAGE_18 -->\n###### for measurement, control, and laboratory use–Part 1: General\n\n<!-- PAGE_18 -->\n###### (다)\n\n<!-- PAGE_18 -->\n###### IEC\n\n<!-- PAGE_18 -->\n###### 61010-2-101:\n\n<!-- PAGE_18 -->\n###### 2015\n\n<!-- PAGE_18 -->\n###### Safety\n\n<!-- PAGE_18 -->\n###### requirements\n\n<!-- PAGE_18 -->\n###### for\n\n<!-- PAGE_18 -->\n###### electrical\n\n<!-- PAGE_18 -->\n###### Particular\n\n<!-- PAGE_18 -->\n###### requirements\n\n<!-- PAGE_18 -->\n###### for\n\n<!-- PAGE_18 -->\n###### in\n\n<!-- PAGE_18 -->\n###### vitro\n\n<!-- PAGE_18 -->\n###### diagnostic\n\n<!-- PAGE_18 -->\n###### (IVD)\n\n<!-- PAGE_18 -->\n###### (2) 적용 범위 : 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데\n\n<!-- PAGE_18 -->\n###### (4) 시험 항목\n\n<!-- PAGE_18 -->\n###### (가) 전기충격에 대한 보호 : IEC 61010-1의 6절에 기술된 전기충격\n\n<!-- PAGE_18 -->\n###### (나) 기계적 위해요인에 대한 보호 : IEC 61010-1의 7절에 기술된 기계적\n\n<!-- PAGE_18 -->\n###### (다) 충격과 충돌에 대한 기계적 내성 : IEC 61010-1의 8절에 기술된\n\n<!-- PAGE_18 -->\n###### 충격과 충돌에 대한 기계적 내성에 관한 요구사항이 적용된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_533",
      "text": "- - 12 -\n<!-- PAGE_19 -->\n###### (라) 화재 확산 방지 : IEC 61010-1의 9절에 기술된 화재 확산 방지에\n\n<!-- PAGE_19 -->\n###### 관한 요구사항이 적용된다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 532,
        "window_size": 3,
        "char_count": 120,
        "word_count": 27,
        "page_number": 19,
        "window_text": "| (6) 메인화면의 “Result”탭을 확인하여 검사에 대한 정보를 검토한다.  검사에 대한 | - 항응고제 치료중인 환자 | 출혈성 질환, 응고장애, 암, 기타 만성질환 등의 병력 및 | 아스피린, P2Y12 |\n| 가. EPI test | 약물 저항성을 확인하는 기기로, 본 연구를 통해 ‘출혈 시간 및 항혈소판제제 |\n**기계적으로 적절하게 보호를 하고 있다는 것을 보증함에 있다. **\n\n**[표 끝]**\n\n<!-- PAGE_18 -->\n###### (나) IEC 61010-1: 2010 Safety requirements for electrical equipment\n\n<!-- PAGE_18 -->\n###### for measurement, control, and laboratory use–Part 1: General\n\n<!-- PAGE_18 -->\n###### (다)\n\n<!-- PAGE_18 -->\n###### IEC\n\n<!-- PAGE_18 -->\n###### 61010-2-101:\n\n<!-- PAGE_18 -->\n###### 2015\n\n<!-- PAGE_18 -->\n###### Safety\n\n<!-- PAGE_18 -->\n###### requirements\n\n<!-- PAGE_18 -->\n###### for\n\n<!-- PAGE_18 -->\n###### electrical\n\n<!-- PAGE_18 -->\n###### Particular\n\n<!-- PAGE_18 -->\n###### requirements\n\n<!-- PAGE_18 -->\n###### for\n\n<!-- PAGE_18 -->\n###### in\n\n<!-- PAGE_18 -->\n###### vitro\n\n<!-- PAGE_18 -->\n###### diagnostic\n\n<!-- PAGE_18 -->\n###### (IVD)\n\n<!-- PAGE_18 -->\n###### (2) 적용 범위 : 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데\n\n<!-- PAGE_18 -->\n###### (4) 시험 항목\n\n<!-- PAGE_18 -->\n###### (가) 전기충격에 대한 보호 : IEC 61010-1의 6절에 기술된 전기충격\n\n<!-- PAGE_18 -->\n###### (나) 기계적 위해요인에 대한 보호 : IEC 61010-1의 7절에 기술된 기계적\n\n<!-- PAGE_18 -->\n###### (다) 충격과 충돌에 대한 기계적 내성 : IEC 61010-1의 8절에 기술된\n\n<!-- PAGE_18 -->\n###### 충격과 충돌에 대한 기계적 내성에 관한 요구사항이 적용된다.\n\n - - 12 -\n<!-- PAGE_19 -->\n###### (라) 화재 확산 방지 : IEC 61010-1의 9절에 기술된 화재 확산 방지에\n\n<!-- PAGE_19 -->\n###### 관한 요구사항이 적용된다.\n\n <!-- PAGE_19 -->\n###### (사) 유리가스, 폭발, 파열에 대한 보호 : IEC 61010-1의 13절에 기술된\n\n<!-- PAGE_19 -->\n###### (자) 연동 장치에 의한 보호 : IEC 61010-1의 15절에 기술된 연동 장치에\n\n<!-- PAGE_19 -->\n###### (가) 「의료기기의 전자파 안전에 관한 공통기준규격」(식품의약품안전처고시)\n\n<!-- PAGE_19 -->\n###### (나) IEC 61326-1: 2012 Electrical equipment for measurement, control and\n\n<!-- PAGE_19 -->\n###### laboratory use -\n\n<!-- PAGE_19 -->\n###### EMC requirements – Part 1: General requirements\n\n<!-- PAGE_19 -->\n###### (다)\n\n<!-- PAGE_19 -->\n###### IEC\n\n<!-- PAGE_19 -->\n###### 61326-2-6:\n\n<!-- PAGE_19 -->\n###### 2012\n\n<!-- PAGE_19 -->\n###### Electrical\n\n<!-- PAGE_19 -->\n###### equipment\n\n<!-- PAGE_19 -->\n###### for\n\n<!-- PAGE_19 -->\n###### measurement,\n\n<!-- PAGE_19 -->\n###### control and laboratory use – EMC requirements – Part 2-6:\n\n<!-- PAGE_19 -->\n###### Particular requirements – In vitro diagnostic (IVD) medical\n\n<!-- PAGE_19 -->\n###### equipment\n\n- - 13 -\n<!-- PAGE_20 -->\n###### (2) 적용 범위 : 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데\n\n<!-- PAGE_20 -->\n###### 사용되는 체외진단용 분석기기에 적용한다.\n\n <!-- PAGE_20 -->\n###### (3) 시험 목적 :\n\n<!-- PAGE_20 -->\n###### 전자 의료기기에 전자파로 인한 전자파장해와 전자파\n\n<!-- PAGE_20 -->\n###### ② 방사성 RF 전자기장 시험 : IEC 61000-4-3에 기술된 방사성 RF\n\n<!-- PAGE_20 -->\n###### (나) 전자파방사 : IEC 61326에 기술된 전자파 방사시험에 관한 요구\n\n- - 14 -\n<!-- PAGE_21 -->\n###### 6.  분석적 성능 평가 항목\n\n※ 아래 제시하는 시험항목 등은 식약처장이 인정한 규격(KS, ISO 등)을 참고한 것으로, 관련 규격이\n\n<!-- PAGE_21 -->\n###### (1) 관련 규격 : CLSI EP17-A2: Evaluation of Detection Capability\n\n<!-- PAGE_21 -->\n###### ※ 관련 규격을 적용할 수 없는 경우, 제조원에서 설정한 측정범위를\n\n<!-- PAGE_21 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_21 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n- - 15 -\n<!-- PAGE_22 -->\n###### (5) 시험 방법 : 3.2% 구연산 처리된 전혈 검체에 분석 대상 물질\n\n<!-- PAGE_22 -->\n###### (Agonist or Antagonist)을 일정량 첨가하여 공란한계(LoD)와\n\n<!-- PAGE_22 -->\n###### 검출한계(LoD)에 해당하는 이동거리의 검체를 각각 4개 이상\n\n<!-- PAGE_22 -->\n###### 준비한다. ",
        "original_sentence": "- - 12 -\n<!-- PAGE_19 -->\n###### (라) 화재 확산 방지 : IEC 61010-1의 9절에 기술된 화재 확산 방지에\n\n<!-- PAGE_19 -->\n###### 관한 요구사항이 적용된다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_534",
      "text": "<!-- PAGE_19 -->\n###### (사) 유리가스, 폭발, 파열에 대한 보호 : IEC 61010-1의 13절에 기술된\n\n<!-- PAGE_19 -->\n###### (자) 연동 장치에 의한 보호 : IEC 61010-1의 15절에 기술된 연동 장치에\n\n<!-- PAGE_19 -->\n###### (가) 「의료기기의 전자파 안전에 관한 공통기준규격」(식품의약품안전처고시)\n\n<!-- PAGE_19 -->\n###### (나) IEC 61326-1: 2012 Electrical equipment for measurement, control and\n\n<!-- PAGE_19 -->\n###### laboratory use -\n\n<!-- PAGE_19 -->\n###### EMC requirements – Part 1: General requirements\n\n<!-- PAGE_19 -->\n###### (다)\n\n<!-- PAGE_19 -->\n###### IEC\n\n<!-- PAGE_19 -->\n###### 61326-2-6:\n\n<!-- PAGE_19 -->\n###### 2012\n\n<!-- PAGE_19 -->\n###### Electrical\n\n<!-- PAGE_19 -->\n###### equipment\n\n<!-- PAGE_19 -->\n###### for\n\n<!-- PAGE_19 -->\n###### measurement,\n\n<!-- PAGE_19 -->\n###### control and laboratory use – EMC requirements – Part 2-6:\n\n<!-- PAGE_19 -->\n###### Particular requirements – In vitro diagnostic (IVD) medical\n\n<!-- PAGE_19 -->\n###### equipment\n\n- - 13 -\n<!-- PAGE_20 -->\n###### (2) 적용 범위 : 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데\n\n<!-- PAGE_20 -->\n###### 사용되는 체외진단용 분석기기에 적용한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 533,
        "window_size": 3,
        "char_count": 1015,
        "word_count": 171,
        "page_number": 19,
        "window_text": "검사에 대한 | - 항응고제 치료중인 환자 | 출혈성 질환, 응고장애, 암, 기타 만성질환 등의 병력 및 | 아스피린, P2Y12 |\n| 가. EPI test | 약물 저항성을 확인하는 기기로, 본 연구를 통해 ‘출혈 시간 및 항혈소판제제 |\n**기계적으로 적절하게 보호를 하고 있다는 것을 보증함에 있다. **\n\n**[표 끝]**\n\n<!-- PAGE_18 -->\n###### (나) IEC 61010-1: 2010 Safety requirements for electrical equipment\n\n<!-- PAGE_18 -->\n###### for measurement, control, and laboratory use–Part 1: General\n\n<!-- PAGE_18 -->\n###### (다)\n\n<!-- PAGE_18 -->\n###### IEC\n\n<!-- PAGE_18 -->\n###### 61010-2-101:\n\n<!-- PAGE_18 -->\n###### 2015\n\n<!-- PAGE_18 -->\n###### Safety\n\n<!-- PAGE_18 -->\n###### requirements\n\n<!-- PAGE_18 -->\n###### for\n\n<!-- PAGE_18 -->\n###### electrical\n\n<!-- PAGE_18 -->\n###### Particular\n\n<!-- PAGE_18 -->\n###### requirements\n\n<!-- PAGE_18 -->\n###### for\n\n<!-- PAGE_18 -->\n###### in\n\n<!-- PAGE_18 -->\n###### vitro\n\n<!-- PAGE_18 -->\n###### diagnostic\n\n<!-- PAGE_18 -->\n###### (IVD)\n\n<!-- PAGE_18 -->\n###### (2) 적용 범위 : 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데\n\n<!-- PAGE_18 -->\n###### (4) 시험 항목\n\n<!-- PAGE_18 -->\n###### (가) 전기충격에 대한 보호 : IEC 61010-1의 6절에 기술된 전기충격\n\n<!-- PAGE_18 -->\n###### (나) 기계적 위해요인에 대한 보호 : IEC 61010-1의 7절에 기술된 기계적\n\n<!-- PAGE_18 -->\n###### (다) 충격과 충돌에 대한 기계적 내성 : IEC 61010-1의 8절에 기술된\n\n<!-- PAGE_18 -->\n###### 충격과 충돌에 대한 기계적 내성에 관한 요구사항이 적용된다.\n\n - - 12 -\n<!-- PAGE_19 -->\n###### (라) 화재 확산 방지 : IEC 61010-1의 9절에 기술된 화재 확산 방지에\n\n<!-- PAGE_19 -->\n###### 관한 요구사항이 적용된다.\n\n <!-- PAGE_19 -->\n###### (사) 유리가스, 폭발, 파열에 대한 보호 : IEC 61010-1의 13절에 기술된\n\n<!-- PAGE_19 -->\n###### (자) 연동 장치에 의한 보호 : IEC 61010-1의 15절에 기술된 연동 장치에\n\n<!-- PAGE_19 -->\n###### (가) 「의료기기의 전자파 안전에 관한 공통기준규격」(식품의약품안전처고시)\n\n<!-- PAGE_19 -->\n###### (나) IEC 61326-1: 2012 Electrical equipment for measurement, control and\n\n<!-- PAGE_19 -->\n###### laboratory use -\n\n<!-- PAGE_19 -->\n###### EMC requirements – Part 1: General requirements\n\n<!-- PAGE_19 -->\n###### (다)\n\n<!-- PAGE_19 -->\n###### IEC\n\n<!-- PAGE_19 -->\n###### 61326-2-6:\n\n<!-- PAGE_19 -->\n###### 2012\n\n<!-- PAGE_19 -->\n###### Electrical\n\n<!-- PAGE_19 -->\n###### equipment\n\n<!-- PAGE_19 -->\n###### for\n\n<!-- PAGE_19 -->\n###### measurement,\n\n<!-- PAGE_19 -->\n###### control and laboratory use – EMC requirements – Part 2-6:\n\n<!-- PAGE_19 -->\n###### Particular requirements – In vitro diagnostic (IVD) medical\n\n<!-- PAGE_19 -->\n###### equipment\n\n- - 13 -\n<!-- PAGE_20 -->\n###### (2) 적용 범위 : 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데\n\n<!-- PAGE_20 -->\n###### 사용되는 체외진단용 분석기기에 적용한다.\n\n <!-- PAGE_20 -->\n###### (3) 시험 목적 :\n\n<!-- PAGE_20 -->\n###### 전자 의료기기에 전자파로 인한 전자파장해와 전자파\n\n<!-- PAGE_20 -->\n###### ② 방사성 RF 전자기장 시험 : IEC 61000-4-3에 기술된 방사성 RF\n\n<!-- PAGE_20 -->\n###### (나) 전자파방사 : IEC 61326에 기술된 전자파 방사시험에 관한 요구\n\n- - 14 -\n<!-- PAGE_21 -->\n###### 6.  분석적 성능 평가 항목\n\n※ 아래 제시하는 시험항목 등은 식약처장이 인정한 규격(KS, ISO 등)을 참고한 것으로, 관련 규격이\n\n<!-- PAGE_21 -->\n###### (1) 관련 규격 : CLSI EP17-A2: Evaluation of Detection Capability\n\n<!-- PAGE_21 -->\n###### ※ 관련 규격을 적용할 수 없는 경우, 제조원에서 설정한 측정범위를\n\n<!-- PAGE_21 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_21 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n- - 15 -\n<!-- PAGE_22 -->\n###### (5) 시험 방법 : 3.2% 구연산 처리된 전혈 검체에 분석 대상 물질\n\n<!-- PAGE_22 -->\n###### (Agonist or Antagonist)을 일정량 첨가하여 공란한계(LoD)와\n\n<!-- PAGE_22 -->\n###### 검출한계(LoD)에 해당하는 이동거리의 검체를 각각 4개 이상\n\n<!-- PAGE_22 -->\n###### 준비한다.  검출한계로 추정되는 이동거리 기점을 최소 3개 이상\n\n<!-- PAGE_22 -->\n###### (6) 결과제시 : 측정된 공란한계값과 검출한계값의 통계적 수치를 이용\n\n<!-- PAGE_22 -->\n###### (1) 관련 규격 : CLSI EP12-A2; User Protocol for Evaluation of\n\n<!-- PAGE_22 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 사람의 전혈 검체\n\n<!-- PAGE_22 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n- - 16 -\n<!-- PAGE_23 -->\n###### - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대\n\n<!-- PAGE_23 -->\n###### (5) 시험 방법\n\n<!-- PAGE_23 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 사람의 전혈 검체\n\n<!-- PAGE_23 -->\n###### 검체에 대한 검사를 실시하여 검체에 대한 이동거리를 구한다.\n\n",
        "original_sentence": "<!-- PAGE_19 -->\n###### (사) 유리가스, 폭발, 파열에 대한 보호 : IEC 61010-1의 13절에 기술된\n\n<!-- PAGE_19 -->\n###### (자) 연동 장치에 의한 보호 : IEC 61010-1의 15절에 기술된 연동 장치에\n\n<!-- PAGE_19 -->\n###### (가) 「의료기기의 전자파 안전에 관한 공통기준규격」(식품의약품안전처고시)\n\n<!-- PAGE_19 -->\n###### (나) IEC 61326-1: 2012 Electrical equipment for measurement, control and\n\n<!-- PAGE_19 -->\n###### laboratory use -\n\n<!-- PAGE_19 -->\n###### EMC requirements – Part 1: General requirements\n\n<!-- PAGE_19 -->\n###### (다)\n\n<!-- PAGE_19 -->\n###### IEC\n\n<!-- PAGE_19 -->\n###### 61326-2-6:\n\n<!-- PAGE_19 -->\n###### 2012\n\n<!-- PAGE_19 -->\n###### Electrical\n\n<!-- PAGE_19 -->\n###### equipment\n\n<!-- PAGE_19 -->\n###### for\n\n<!-- PAGE_19 -->\n###### measurement,\n\n<!-- PAGE_19 -->\n###### control and laboratory use – EMC requirements – Part 2-6:\n\n<!-- PAGE_19 -->\n###### Particular requirements – In vitro diagnostic (IVD) medical\n\n<!-- PAGE_19 -->\n###### equipment\n\n- - 13 -\n<!-- PAGE_20 -->\n###### (2) 적용 범위 : 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데\n\n<!-- PAGE_20 -->\n###### 사용되는 체외진단용 분석기기에 적용한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_535",
      "text": "<!-- PAGE_20 -->\n###### (3) 시험 목적 :\n\n<!-- PAGE_20 -->\n###### 전자 의료기기에 전자파로 인한 전자파장해와 전자파\n\n<!-- PAGE_20 -->\n###### ② 방사성 RF 전자기장 시험 : IEC 61000-4-3에 기술된 방사성 RF\n\n<!-- PAGE_20 -->\n###### (나) 전자파방사 : IEC 61326에 기술된 전자파 방사시험에 관한 요구\n\n- - 14 -\n<!-- PAGE_21 -->\n###### 6. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 534,
        "window_size": 3,
        "char_count": 264,
        "word_count": 56,
        "page_number": 20,
        "window_text": "**\n\n**[표 끝]**\n\n<!-- PAGE_18 -->\n###### (나) IEC 61010-1: 2010 Safety requirements for electrical equipment\n\n<!-- PAGE_18 -->\n###### for measurement, control, and laboratory use–Part 1: General\n\n<!-- PAGE_18 -->\n###### (다)\n\n<!-- PAGE_18 -->\n###### IEC\n\n<!-- PAGE_18 -->\n###### 61010-2-101:\n\n<!-- PAGE_18 -->\n###### 2015\n\n<!-- PAGE_18 -->\n###### Safety\n\n<!-- PAGE_18 -->\n###### requirements\n\n<!-- PAGE_18 -->\n###### for\n\n<!-- PAGE_18 -->\n###### electrical\n\n<!-- PAGE_18 -->\n###### Particular\n\n<!-- PAGE_18 -->\n###### requirements\n\n<!-- PAGE_18 -->\n###### for\n\n<!-- PAGE_18 -->\n###### in\n\n<!-- PAGE_18 -->\n###### vitro\n\n<!-- PAGE_18 -->\n###### diagnostic\n\n<!-- PAGE_18 -->\n###### (IVD)\n\n<!-- PAGE_18 -->\n###### (2) 적용 범위 : 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데\n\n<!-- PAGE_18 -->\n###### (4) 시험 항목\n\n<!-- PAGE_18 -->\n###### (가) 전기충격에 대한 보호 : IEC 61010-1의 6절에 기술된 전기충격\n\n<!-- PAGE_18 -->\n###### (나) 기계적 위해요인에 대한 보호 : IEC 61010-1의 7절에 기술된 기계적\n\n<!-- PAGE_18 -->\n###### (다) 충격과 충돌에 대한 기계적 내성 : IEC 61010-1의 8절에 기술된\n\n<!-- PAGE_18 -->\n###### 충격과 충돌에 대한 기계적 내성에 관한 요구사항이 적용된다.\n\n - - 12 -\n<!-- PAGE_19 -->\n###### (라) 화재 확산 방지 : IEC 61010-1의 9절에 기술된 화재 확산 방지에\n\n<!-- PAGE_19 -->\n###### 관한 요구사항이 적용된다.\n\n <!-- PAGE_19 -->\n###### (사) 유리가스, 폭발, 파열에 대한 보호 : IEC 61010-1의 13절에 기술된\n\n<!-- PAGE_19 -->\n###### (자) 연동 장치에 의한 보호 : IEC 61010-1의 15절에 기술된 연동 장치에\n\n<!-- PAGE_19 -->\n###### (가) 「의료기기의 전자파 안전에 관한 공통기준규격」(식품의약품안전처고시)\n\n<!-- PAGE_19 -->\n###### (나) IEC 61326-1: 2012 Electrical equipment for measurement, control and\n\n<!-- PAGE_19 -->\n###### laboratory use -\n\n<!-- PAGE_19 -->\n###### EMC requirements – Part 1: General requirements\n\n<!-- PAGE_19 -->\n###### (다)\n\n<!-- PAGE_19 -->\n###### IEC\n\n<!-- PAGE_19 -->\n###### 61326-2-6:\n\n<!-- PAGE_19 -->\n###### 2012\n\n<!-- PAGE_19 -->\n###### Electrical\n\n<!-- PAGE_19 -->\n###### equipment\n\n<!-- PAGE_19 -->\n###### for\n\n<!-- PAGE_19 -->\n###### measurement,\n\n<!-- PAGE_19 -->\n###### control and laboratory use – EMC requirements – Part 2-6:\n\n<!-- PAGE_19 -->\n###### Particular requirements – In vitro diagnostic (IVD) medical\n\n<!-- PAGE_19 -->\n###### equipment\n\n- - 13 -\n<!-- PAGE_20 -->\n###### (2) 적용 범위 : 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데\n\n<!-- PAGE_20 -->\n###### 사용되는 체외진단용 분석기기에 적용한다.\n\n <!-- PAGE_20 -->\n###### (3) 시험 목적 :\n\n<!-- PAGE_20 -->\n###### 전자 의료기기에 전자파로 인한 전자파장해와 전자파\n\n<!-- PAGE_20 -->\n###### ② 방사성 RF 전자기장 시험 : IEC 61000-4-3에 기술된 방사성 RF\n\n<!-- PAGE_20 -->\n###### (나) 전자파방사 : IEC 61326에 기술된 전자파 방사시험에 관한 요구\n\n- - 14 -\n<!-- PAGE_21 -->\n###### 6.  분석적 성능 평가 항목\n\n※ 아래 제시하는 시험항목 등은 식약처장이 인정한 규격(KS, ISO 등)을 참고한 것으로, 관련 규격이\n\n<!-- PAGE_21 -->\n###### (1) 관련 규격 : CLSI EP17-A2: Evaluation of Detection Capability\n\n<!-- PAGE_21 -->\n###### ※ 관련 규격을 적용할 수 없는 경우, 제조원에서 설정한 측정범위를\n\n<!-- PAGE_21 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_21 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n- - 15 -\n<!-- PAGE_22 -->\n###### (5) 시험 방법 : 3.2% 구연산 처리된 전혈 검체에 분석 대상 물질\n\n<!-- PAGE_22 -->\n###### (Agonist or Antagonist)을 일정량 첨가하여 공란한계(LoD)와\n\n<!-- PAGE_22 -->\n###### 검출한계(LoD)에 해당하는 이동거리의 검체를 각각 4개 이상\n\n<!-- PAGE_22 -->\n###### 준비한다.  검출한계로 추정되는 이동거리 기점을 최소 3개 이상\n\n<!-- PAGE_22 -->\n###### (6) 결과제시 : 측정된 공란한계값과 검출한계값의 통계적 수치를 이용\n\n<!-- PAGE_22 -->\n###### (1) 관련 규격 : CLSI EP12-A2; User Protocol for Evaluation of\n\n<!-- PAGE_22 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 사람의 전혈 검체\n\n<!-- PAGE_22 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n- - 16 -\n<!-- PAGE_23 -->\n###### - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대\n\n<!-- PAGE_23 -->\n###### (5) 시험 방법\n\n<!-- PAGE_23 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 사람의 전혈 검체\n\n<!-- PAGE_23 -->\n###### 검체에 대한 검사를 실시하여 검체에 대한 이동거리를 구한다.\n\n <!-- PAGE_23 -->\n###### 확인 한 후 정상값과 비정상값의 통계치의 95% 신뢰구간을 구하여 두\n\n<!-- PAGE_23 -->\n###### ※ 관련 규격을 적용할 수 없는 경우, 제조원에서 설정한 측정범위를\n\n<!-- PAGE_23 -->\n###### (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제\n\n<!-- PAGE_23 -->\n###### ※ 해당 성능항목은 적용하지 않는 경우, 그 사유를 제시하여 적용\n\n- - 17 -\n<!-- PAGE_24 -->\n###### (3) 시험 목적 : 출혈시간 및 항혈소판제제 저항성 복합검사기기의\n\n<!-- PAGE_24 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n<!-- PAGE_24 -->\n###### 측정된\n\n<!-- PAGE_24 -->\n###### 최소\n\n<!-- PAGE_24 -->\n###### 이동거리값을\n\n<!-- PAGE_24 -->\n###### 기준으로\n\n<!-- PAGE_24 -->\n###### 분석대상물질(Agonist\n\n<!-- PAGE_24 -->\n###### 또는\n\n<!-- PAGE_24 -->\n###### Antagonist)을 일정한 비율로 첨가하여 직선성을 보이는 구간을 구\n\n<!-- PAGE_24 -->\n###### (6) 결과제시 : 각 측정값에 대한 직선성을 직선회귀분석을 통해 평가\n\n- - 18 -\n<!-- PAGE_25 -->\n###### 나. ",
        "original_sentence": "<!-- PAGE_20 -->\n###### (3) 시험 목적 :\n\n<!-- PAGE_20 -->\n###### 전자 의료기기에 전자파로 인한 전자파장해와 전자파\n\n<!-- PAGE_20 -->\n###### ② 방사성 RF 전자기장 시험 : IEC 61000-4-3에 기술된 방사성 RF\n\n<!-- PAGE_20 -->\n###### (나) 전자파방사 : IEC 61326에 기술된 전자파 방사시험에 관한 요구\n\n- - 14 -\n<!-- PAGE_21 -->\n###### 6. "
      }
    },
    {
      "chunk_id": "chunk_536",
      "text": "분석적 성능 평가 항목\n\n※ 아래 제시하는 시험항목 등은 식약처장이 인정한 규격(KS, ISO 등)을 참고한 것으로, 관련 규격이\n\n<!-- PAGE_21 -->\n###### (1) 관련 규격 : CLSI EP17-A2: Evaluation of Detection Capability\n\n<!-- PAGE_21 -->\n###### ※ 관련 규격을 적용할 수 없는 경우, 제조원에서 설정한 측정범위를\n\n<!-- PAGE_21 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_21 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n- - 15 -\n<!-- PAGE_22 -->\n###### (5) 시험 방법 : 3.2% 구연산 처리된 전혈 검체에 분석 대상 물질\n\n<!-- PAGE_22 -->\n###### (Agonist or Antagonist)을 일정량 첨가하여 공란한계(LoD)와\n\n<!-- PAGE_22 -->\n###### 검출한계(LoD)에 해당하는 이동거리의 검체를 각각 4개 이상\n\n<!-- PAGE_22 -->\n###### 준비한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 535,
        "window_size": 3,
        "char_count": 585,
        "word_count": 118,
        "page_number": 21,
        "window_text": "- - 12 -\n<!-- PAGE_19 -->\n###### (라) 화재 확산 방지 : IEC 61010-1의 9절에 기술된 화재 확산 방지에\n\n<!-- PAGE_19 -->\n###### 관한 요구사항이 적용된다.\n\n <!-- PAGE_19 -->\n###### (사) 유리가스, 폭발, 파열에 대한 보호 : IEC 61010-1의 13절에 기술된\n\n<!-- PAGE_19 -->\n###### (자) 연동 장치에 의한 보호 : IEC 61010-1의 15절에 기술된 연동 장치에\n\n<!-- PAGE_19 -->\n###### (가) 「의료기기의 전자파 안전에 관한 공통기준규격」(식품의약품안전처고시)\n\n<!-- PAGE_19 -->\n###### (나) IEC 61326-1: 2012 Electrical equipment for measurement, control and\n\n<!-- PAGE_19 -->\n###### laboratory use -\n\n<!-- PAGE_19 -->\n###### EMC requirements – Part 1: General requirements\n\n<!-- PAGE_19 -->\n###### (다)\n\n<!-- PAGE_19 -->\n###### IEC\n\n<!-- PAGE_19 -->\n###### 61326-2-6:\n\n<!-- PAGE_19 -->\n###### 2012\n\n<!-- PAGE_19 -->\n###### Electrical\n\n<!-- PAGE_19 -->\n###### equipment\n\n<!-- PAGE_19 -->\n###### for\n\n<!-- PAGE_19 -->\n###### measurement,\n\n<!-- PAGE_19 -->\n###### control and laboratory use – EMC requirements – Part 2-6:\n\n<!-- PAGE_19 -->\n###### Particular requirements – In vitro diagnostic (IVD) medical\n\n<!-- PAGE_19 -->\n###### equipment\n\n- - 13 -\n<!-- PAGE_20 -->\n###### (2) 적용 범위 : 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데\n\n<!-- PAGE_20 -->\n###### 사용되는 체외진단용 분석기기에 적용한다.\n\n <!-- PAGE_20 -->\n###### (3) 시험 목적 :\n\n<!-- PAGE_20 -->\n###### 전자 의료기기에 전자파로 인한 전자파장해와 전자파\n\n<!-- PAGE_20 -->\n###### ② 방사성 RF 전자기장 시험 : IEC 61000-4-3에 기술된 방사성 RF\n\n<!-- PAGE_20 -->\n###### (나) 전자파방사 : IEC 61326에 기술된 전자파 방사시험에 관한 요구\n\n- - 14 -\n<!-- PAGE_21 -->\n###### 6.  분석적 성능 평가 항목\n\n※ 아래 제시하는 시험항목 등은 식약처장이 인정한 규격(KS, ISO 등)을 참고한 것으로, 관련 규격이\n\n<!-- PAGE_21 -->\n###### (1) 관련 규격 : CLSI EP17-A2: Evaluation of Detection Capability\n\n<!-- PAGE_21 -->\n###### ※ 관련 규격을 적용할 수 없는 경우, 제조원에서 설정한 측정범위를\n\n<!-- PAGE_21 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_21 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n- - 15 -\n<!-- PAGE_22 -->\n###### (5) 시험 방법 : 3.2% 구연산 처리된 전혈 검체에 분석 대상 물질\n\n<!-- PAGE_22 -->\n###### (Agonist or Antagonist)을 일정량 첨가하여 공란한계(LoD)와\n\n<!-- PAGE_22 -->\n###### 검출한계(LoD)에 해당하는 이동거리의 검체를 각각 4개 이상\n\n<!-- PAGE_22 -->\n###### 준비한다.  검출한계로 추정되는 이동거리 기점을 최소 3개 이상\n\n<!-- PAGE_22 -->\n###### (6) 결과제시 : 측정된 공란한계값과 검출한계값의 통계적 수치를 이용\n\n<!-- PAGE_22 -->\n###### (1) 관련 규격 : CLSI EP12-A2; User Protocol for Evaluation of\n\n<!-- PAGE_22 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 사람의 전혈 검체\n\n<!-- PAGE_22 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n- - 16 -\n<!-- PAGE_23 -->\n###### - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대\n\n<!-- PAGE_23 -->\n###### (5) 시험 방법\n\n<!-- PAGE_23 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 사람의 전혈 검체\n\n<!-- PAGE_23 -->\n###### 검체에 대한 검사를 실시하여 검체에 대한 이동거리를 구한다.\n\n <!-- PAGE_23 -->\n###### 확인 한 후 정상값과 비정상값의 통계치의 95% 신뢰구간을 구하여 두\n\n<!-- PAGE_23 -->\n###### ※ 관련 규격을 적용할 수 없는 경우, 제조원에서 설정한 측정범위를\n\n<!-- PAGE_23 -->\n###### (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제\n\n<!-- PAGE_23 -->\n###### ※ 해당 성능항목은 적용하지 않는 경우, 그 사유를 제시하여 적용\n\n- - 17 -\n<!-- PAGE_24 -->\n###### (3) 시험 목적 : 출혈시간 및 항혈소판제제 저항성 복합검사기기의\n\n<!-- PAGE_24 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n<!-- PAGE_24 -->\n###### 측정된\n\n<!-- PAGE_24 -->\n###### 최소\n\n<!-- PAGE_24 -->\n###### 이동거리값을\n\n<!-- PAGE_24 -->\n###### 기준으로\n\n<!-- PAGE_24 -->\n###### 분석대상물질(Agonist\n\n<!-- PAGE_24 -->\n###### 또는\n\n<!-- PAGE_24 -->\n###### Antagonist)을 일정한 비율로 첨가하여 직선성을 보이는 구간을 구\n\n<!-- PAGE_24 -->\n###### (6) 결과제시 : 각 측정값에 대한 직선성을 직선회귀분석을 통해 평가\n\n- - 18 -\n<!-- PAGE_25 -->\n###### 나.  분석적 특이도(간섭물질)\n\n<!-- PAGE_25 -->\n###### (1) 관련 규격 : CLSI EP07 Interference Testing in Clinical Chemistry\n\n<!-- PAGE_25 -->\n###### 간섭물질은 내부 또는 외부 요인일 수 있고 측정법에 따라 다양하므로,\n\n<!-- PAGE_25 -->\n###### 검사법에 따라 결과에 영향을 미칠 것으로 예측되는 다음과 같은 물질에\n\n드물지 않게 볼 수 있는 특이\n\n- - 19 -\n<!-- PAGE_26 -->\n###### (5) 시험 방법\n\n<!-- PAGE_26 -->\n###### 간섭물질의 농도는 임상검체에서 보일 수 있는 최대 농도의 3배\n\n<!-- PAGE_26 -->\n###### 평균과 대조시료 측정결과 평균의 편차를 계산한다. ",
        "original_sentence": "분석적 성능 평가 항목\n\n※ 아래 제시하는 시험항목 등은 식약처장이 인정한 규격(KS, ISO 등)을 참고한 것으로, 관련 규격이\n\n<!-- PAGE_21 -->\n###### (1) 관련 규격 : CLSI EP17-A2: Evaluation of Detection Capability\n\n<!-- PAGE_21 -->\n###### ※ 관련 규격을 적용할 수 없는 경우, 제조원에서 설정한 측정범위를\n\n<!-- PAGE_21 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_21 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n- - 15 -\n<!-- PAGE_22 -->\n###### (5) 시험 방법 : 3.2% 구연산 처리된 전혈 검체에 분석 대상 물질\n\n<!-- PAGE_22 -->\n###### (Agonist or Antagonist)을 일정량 첨가하여 공란한계(LoD)와\n\n<!-- PAGE_22 -->\n###### 검출한계(LoD)에 해당하는 이동거리의 검체를 각각 4개 이상\n\n<!-- PAGE_22 -->\n###### 준비한다. "
      }
    },
    {
      "chunk_id": "chunk_537",
      "text": "검출한계로 추정되는 이동거리 기점을 최소 3개 이상\n\n<!-- PAGE_22 -->\n###### (6) 결과제시 : 측정된 공란한계값과 검출한계값의 통계적 수치를 이용\n\n<!-- PAGE_22 -->\n###### (1) 관련 규격 : CLSI EP12-A2; User Protocol for Evaluation of\n\n<!-- PAGE_22 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 사람의 전혈 검체\n\n<!-- PAGE_22 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n- - 16 -\n<!-- PAGE_23 -->\n###### - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대\n\n<!-- PAGE_23 -->\n###### (5) 시험 방법\n\n<!-- PAGE_23 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 사람의 전혈 검체\n\n<!-- PAGE_23 -->\n###### 검체에 대한 검사를 실시하여 검체에 대한 이동거리를 구한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 536,
        "window_size": 3,
        "char_count": 524,
        "word_count": 108,
        "page_number": 22,
        "window_text": "<!-- PAGE_19 -->\n###### (사) 유리가스, 폭발, 파열에 대한 보호 : IEC 61010-1의 13절에 기술된\n\n<!-- PAGE_19 -->\n###### (자) 연동 장치에 의한 보호 : IEC 61010-1의 15절에 기술된 연동 장치에\n\n<!-- PAGE_19 -->\n###### (가) 「의료기기의 전자파 안전에 관한 공통기준규격」(식품의약품안전처고시)\n\n<!-- PAGE_19 -->\n###### (나) IEC 61326-1: 2012 Electrical equipment for measurement, control and\n\n<!-- PAGE_19 -->\n###### laboratory use -\n\n<!-- PAGE_19 -->\n###### EMC requirements – Part 1: General requirements\n\n<!-- PAGE_19 -->\n###### (다)\n\n<!-- PAGE_19 -->\n###### IEC\n\n<!-- PAGE_19 -->\n###### 61326-2-6:\n\n<!-- PAGE_19 -->\n###### 2012\n\n<!-- PAGE_19 -->\n###### Electrical\n\n<!-- PAGE_19 -->\n###### equipment\n\n<!-- PAGE_19 -->\n###### for\n\n<!-- PAGE_19 -->\n###### measurement,\n\n<!-- PAGE_19 -->\n###### control and laboratory use – EMC requirements – Part 2-6:\n\n<!-- PAGE_19 -->\n###### Particular requirements – In vitro diagnostic (IVD) medical\n\n<!-- PAGE_19 -->\n###### equipment\n\n- - 13 -\n<!-- PAGE_20 -->\n###### (2) 적용 범위 : 물질을 측정, 분석, 모니터링 하거나 시료를 준비하는데\n\n<!-- PAGE_20 -->\n###### 사용되는 체외진단용 분석기기에 적용한다.\n\n <!-- PAGE_20 -->\n###### (3) 시험 목적 :\n\n<!-- PAGE_20 -->\n###### 전자 의료기기에 전자파로 인한 전자파장해와 전자파\n\n<!-- PAGE_20 -->\n###### ② 방사성 RF 전자기장 시험 : IEC 61000-4-3에 기술된 방사성 RF\n\n<!-- PAGE_20 -->\n###### (나) 전자파방사 : IEC 61326에 기술된 전자파 방사시험에 관한 요구\n\n- - 14 -\n<!-- PAGE_21 -->\n###### 6.  분석적 성능 평가 항목\n\n※ 아래 제시하는 시험항목 등은 식약처장이 인정한 규격(KS, ISO 등)을 참고한 것으로, 관련 규격이\n\n<!-- PAGE_21 -->\n###### (1) 관련 규격 : CLSI EP17-A2: Evaluation of Detection Capability\n\n<!-- PAGE_21 -->\n###### ※ 관련 규격을 적용할 수 없는 경우, 제조원에서 설정한 측정범위를\n\n<!-- PAGE_21 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_21 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n- - 15 -\n<!-- PAGE_22 -->\n###### (5) 시험 방법 : 3.2% 구연산 처리된 전혈 검체에 분석 대상 물질\n\n<!-- PAGE_22 -->\n###### (Agonist or Antagonist)을 일정량 첨가하여 공란한계(LoD)와\n\n<!-- PAGE_22 -->\n###### 검출한계(LoD)에 해당하는 이동거리의 검체를 각각 4개 이상\n\n<!-- PAGE_22 -->\n###### 준비한다.  검출한계로 추정되는 이동거리 기점을 최소 3개 이상\n\n<!-- PAGE_22 -->\n###### (6) 결과제시 : 측정된 공란한계값과 검출한계값의 통계적 수치를 이용\n\n<!-- PAGE_22 -->\n###### (1) 관련 규격 : CLSI EP12-A2; User Protocol for Evaluation of\n\n<!-- PAGE_22 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 사람의 전혈 검체\n\n<!-- PAGE_22 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n- - 16 -\n<!-- PAGE_23 -->\n###### - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대\n\n<!-- PAGE_23 -->\n###### (5) 시험 방법\n\n<!-- PAGE_23 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 사람의 전혈 검체\n\n<!-- PAGE_23 -->\n###### 검체에 대한 검사를 실시하여 검체에 대한 이동거리를 구한다.\n\n <!-- PAGE_23 -->\n###### 확인 한 후 정상값과 비정상값의 통계치의 95% 신뢰구간을 구하여 두\n\n<!-- PAGE_23 -->\n###### ※ 관련 규격을 적용할 수 없는 경우, 제조원에서 설정한 측정범위를\n\n<!-- PAGE_23 -->\n###### (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제\n\n<!-- PAGE_23 -->\n###### ※ 해당 성능항목은 적용하지 않는 경우, 그 사유를 제시하여 적용\n\n- - 17 -\n<!-- PAGE_24 -->\n###### (3) 시험 목적 : 출혈시간 및 항혈소판제제 저항성 복합검사기기의\n\n<!-- PAGE_24 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n<!-- PAGE_24 -->\n###### 측정된\n\n<!-- PAGE_24 -->\n###### 최소\n\n<!-- PAGE_24 -->\n###### 이동거리값을\n\n<!-- PAGE_24 -->\n###### 기준으로\n\n<!-- PAGE_24 -->\n###### 분석대상물질(Agonist\n\n<!-- PAGE_24 -->\n###### 또는\n\n<!-- PAGE_24 -->\n###### Antagonist)을 일정한 비율로 첨가하여 직선성을 보이는 구간을 구\n\n<!-- PAGE_24 -->\n###### (6) 결과제시 : 각 측정값에 대한 직선성을 직선회귀분석을 통해 평가\n\n- - 18 -\n<!-- PAGE_25 -->\n###### 나.  분석적 특이도(간섭물질)\n\n<!-- PAGE_25 -->\n###### (1) 관련 규격 : CLSI EP07 Interference Testing in Clinical Chemistry\n\n<!-- PAGE_25 -->\n###### 간섭물질은 내부 또는 외부 요인일 수 있고 측정법에 따라 다양하므로,\n\n<!-- PAGE_25 -->\n###### 검사법에 따라 결과에 영향을 미칠 것으로 예측되는 다음과 같은 물질에\n\n드물지 않게 볼 수 있는 특이\n\n- - 19 -\n<!-- PAGE_26 -->\n###### (5) 시험 방법\n\n<!-- PAGE_26 -->\n###### 간섭물질의 농도는 임상검체에서 보일 수 있는 최대 농도의 3배\n\n<!-- PAGE_26 -->\n###### 평균과 대조시료 측정결과 평균의 편차를 계산한다.  대조시료 대비\n\n<!-- PAGE_26 -->\n###### 다. ",
        "original_sentence": "검출한계로 추정되는 이동거리 기점을 최소 3개 이상\n\n<!-- PAGE_22 -->\n###### (6) 결과제시 : 측정된 공란한계값과 검출한계값의 통계적 수치를 이용\n\n<!-- PAGE_22 -->\n###### (1) 관련 규격 : CLSI EP12-A2; User Protocol for Evaluation of\n\n<!-- PAGE_22 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 사람의 전혈 검체\n\n<!-- PAGE_22 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n- - 16 -\n<!-- PAGE_23 -->\n###### - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대\n\n<!-- PAGE_23 -->\n###### (5) 시험 방법\n\n<!-- PAGE_23 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 사람의 전혈 검체\n\n<!-- PAGE_23 -->\n###### 검체에 대한 검사를 실시하여 검체에 대한 이동거리를 구한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_538",
      "text": "<!-- PAGE_23 -->\n###### 확인 한 후 정상값과 비정상값의 통계치의 95% 신뢰구간을 구하여 두\n\n<!-- PAGE_23 -->\n###### ※ 관련 규격을 적용할 수 없는 경우, 제조원에서 설정한 측정범위를\n\n<!-- PAGE_23 -->\n###### (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제\n\n<!-- PAGE_23 -->\n###### ※ 해당 성능항목은 적용하지 않는 경우, 그 사유를 제시하여 적용\n\n- - 17 -\n<!-- PAGE_24 -->\n###### (3) 시험 목적 : 출혈시간 및 항혈소판제제 저항성 복합검사기기의\n\n<!-- PAGE_24 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n<!-- PAGE_24 -->\n###### 측정된\n\n<!-- PAGE_24 -->\n###### 최소\n\n<!-- PAGE_24 -->\n###### 이동거리값을\n\n<!-- PAGE_24 -->\n###### 기준으로\n\n<!-- PAGE_24 -->\n###### 분석대상물질(Agonist\n\n<!-- PAGE_24 -->\n###### 또는\n\n<!-- PAGE_24 -->\n###### Antagonist)을 일정한 비율로 첨가하여 직선성을 보이는 구간을 구\n\n<!-- PAGE_24 -->\n###### (6) 결과제시 : 각 측정값에 대한 직선성을 직선회귀분석을 통해 평가\n\n- - 18 -\n<!-- PAGE_25 -->\n###### 나. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 537,
        "window_size": 3,
        "char_count": 742,
        "word_count": 151,
        "page_number": 23,
        "window_text": "<!-- PAGE_20 -->\n###### (3) 시험 목적 :\n\n<!-- PAGE_20 -->\n###### 전자 의료기기에 전자파로 인한 전자파장해와 전자파\n\n<!-- PAGE_20 -->\n###### ② 방사성 RF 전자기장 시험 : IEC 61000-4-3에 기술된 방사성 RF\n\n<!-- PAGE_20 -->\n###### (나) 전자파방사 : IEC 61326에 기술된 전자파 방사시험에 관한 요구\n\n- - 14 -\n<!-- PAGE_21 -->\n###### 6.  분석적 성능 평가 항목\n\n※ 아래 제시하는 시험항목 등은 식약처장이 인정한 규격(KS, ISO 등)을 참고한 것으로, 관련 규격이\n\n<!-- PAGE_21 -->\n###### (1) 관련 규격 : CLSI EP17-A2: Evaluation of Detection Capability\n\n<!-- PAGE_21 -->\n###### ※ 관련 규격을 적용할 수 없는 경우, 제조원에서 설정한 측정범위를\n\n<!-- PAGE_21 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_21 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n- - 15 -\n<!-- PAGE_22 -->\n###### (5) 시험 방법 : 3.2% 구연산 처리된 전혈 검체에 분석 대상 물질\n\n<!-- PAGE_22 -->\n###### (Agonist or Antagonist)을 일정량 첨가하여 공란한계(LoD)와\n\n<!-- PAGE_22 -->\n###### 검출한계(LoD)에 해당하는 이동거리의 검체를 각각 4개 이상\n\n<!-- PAGE_22 -->\n###### 준비한다.  검출한계로 추정되는 이동거리 기점을 최소 3개 이상\n\n<!-- PAGE_22 -->\n###### (6) 결과제시 : 측정된 공란한계값과 검출한계값의 통계적 수치를 이용\n\n<!-- PAGE_22 -->\n###### (1) 관련 규격 : CLSI EP12-A2; User Protocol for Evaluation of\n\n<!-- PAGE_22 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 사람의 전혈 검체\n\n<!-- PAGE_22 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n- - 16 -\n<!-- PAGE_23 -->\n###### - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대\n\n<!-- PAGE_23 -->\n###### (5) 시험 방법\n\n<!-- PAGE_23 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 사람의 전혈 검체\n\n<!-- PAGE_23 -->\n###### 검체에 대한 검사를 실시하여 검체에 대한 이동거리를 구한다.\n\n <!-- PAGE_23 -->\n###### 확인 한 후 정상값과 비정상값의 통계치의 95% 신뢰구간을 구하여 두\n\n<!-- PAGE_23 -->\n###### ※ 관련 규격을 적용할 수 없는 경우, 제조원에서 설정한 측정범위를\n\n<!-- PAGE_23 -->\n###### (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제\n\n<!-- PAGE_23 -->\n###### ※ 해당 성능항목은 적용하지 않는 경우, 그 사유를 제시하여 적용\n\n- - 17 -\n<!-- PAGE_24 -->\n###### (3) 시험 목적 : 출혈시간 및 항혈소판제제 저항성 복합검사기기의\n\n<!-- PAGE_24 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n<!-- PAGE_24 -->\n###### 측정된\n\n<!-- PAGE_24 -->\n###### 최소\n\n<!-- PAGE_24 -->\n###### 이동거리값을\n\n<!-- PAGE_24 -->\n###### 기준으로\n\n<!-- PAGE_24 -->\n###### 분석대상물질(Agonist\n\n<!-- PAGE_24 -->\n###### 또는\n\n<!-- PAGE_24 -->\n###### Antagonist)을 일정한 비율로 첨가하여 직선성을 보이는 구간을 구\n\n<!-- PAGE_24 -->\n###### (6) 결과제시 : 각 측정값에 대한 직선성을 직선회귀분석을 통해 평가\n\n- - 18 -\n<!-- PAGE_25 -->\n###### 나.  분석적 특이도(간섭물질)\n\n<!-- PAGE_25 -->\n###### (1) 관련 규격 : CLSI EP07 Interference Testing in Clinical Chemistry\n\n<!-- PAGE_25 -->\n###### 간섭물질은 내부 또는 외부 요인일 수 있고 측정법에 따라 다양하므로,\n\n<!-- PAGE_25 -->\n###### 검사법에 따라 결과에 영향을 미칠 것으로 예측되는 다음과 같은 물질에\n\n드물지 않게 볼 수 있는 특이\n\n- - 19 -\n<!-- PAGE_26 -->\n###### (5) 시험 방법\n\n<!-- PAGE_26 -->\n###### 간섭물질의 농도는 임상검체에서 보일 수 있는 최대 농도의 3배\n\n<!-- PAGE_26 -->\n###### 평균과 대조시료 측정결과 평균의 편차를 계산한다.  대조시료 대비\n\n<!-- PAGE_26 -->\n###### 다.  정밀도\n\n<!-- PAGE_26 -->\n###### 1. ",
        "original_sentence": "<!-- PAGE_23 -->\n###### 확인 한 후 정상값과 비정상값의 통계치의 95% 신뢰구간을 구하여 두\n\n<!-- PAGE_23 -->\n###### ※ 관련 규격을 적용할 수 없는 경우, 제조원에서 설정한 측정범위를\n\n<!-- PAGE_23 -->\n###### (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제\n\n<!-- PAGE_23 -->\n###### ※ 해당 성능항목은 적용하지 않는 경우, 그 사유를 제시하여 적용\n\n- - 17 -\n<!-- PAGE_24 -->\n###### (3) 시험 목적 : 출혈시간 및 항혈소판제제 저항성 복합검사기기의\n\n<!-- PAGE_24 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n<!-- PAGE_24 -->\n###### 측정된\n\n<!-- PAGE_24 -->\n###### 최소\n\n<!-- PAGE_24 -->\n###### 이동거리값을\n\n<!-- PAGE_24 -->\n###### 기준으로\n\n<!-- PAGE_24 -->\n###### 분석대상물질(Agonist\n\n<!-- PAGE_24 -->\n###### 또는\n\n<!-- PAGE_24 -->\n###### Antagonist)을 일정한 비율로 첨가하여 직선성을 보이는 구간을 구\n\n<!-- PAGE_24 -->\n###### (6) 결과제시 : 각 측정값에 대한 직선성을 직선회귀분석을 통해 평가\n\n- - 18 -\n<!-- PAGE_25 -->\n###### 나. "
      }
    },
    {
      "chunk_id": "chunk_539",
      "text": "분석적 특이도(간섭물질)\n\n<!-- PAGE_25 -->\n###### (1) 관련 규격 : CLSI EP07 Interference Testing in Clinical Chemistry\n\n<!-- PAGE_25 -->\n###### 간섭물질은 내부 또는 외부 요인일 수 있고 측정법에 따라 다양하므로,\n\n<!-- PAGE_25 -->\n###### 검사법에 따라 결과에 영향을 미칠 것으로 예측되는 다음과 같은 물질에\n\n드물지 않게 볼 수 있는 특이\n\n- - 19 -\n<!-- PAGE_26 -->\n###### (5) 시험 방법\n\n<!-- PAGE_26 -->\n###### 간섭물질의 농도는 임상검체에서 보일 수 있는 최대 농도의 3배\n\n<!-- PAGE_26 -->\n###### 평균과 대조시료 측정결과 평균의 편차를 계산한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 538,
        "window_size": 3,
        "char_count": 407,
        "word_count": 85,
        "page_number": 25,
        "window_text": "분석적 성능 평가 항목\n\n※ 아래 제시하는 시험항목 등은 식약처장이 인정한 규격(KS, ISO 등)을 참고한 것으로, 관련 규격이\n\n<!-- PAGE_21 -->\n###### (1) 관련 규격 : CLSI EP17-A2: Evaluation of Detection Capability\n\n<!-- PAGE_21 -->\n###### ※ 관련 규격을 적용할 수 없는 경우, 제조원에서 설정한 측정범위를\n\n<!-- PAGE_21 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_21 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n- - 15 -\n<!-- PAGE_22 -->\n###### (5) 시험 방법 : 3.2% 구연산 처리된 전혈 검체에 분석 대상 물질\n\n<!-- PAGE_22 -->\n###### (Agonist or Antagonist)을 일정량 첨가하여 공란한계(LoD)와\n\n<!-- PAGE_22 -->\n###### 검출한계(LoD)에 해당하는 이동거리의 검체를 각각 4개 이상\n\n<!-- PAGE_22 -->\n###### 준비한다.  검출한계로 추정되는 이동거리 기점을 최소 3개 이상\n\n<!-- PAGE_22 -->\n###### (6) 결과제시 : 측정된 공란한계값과 검출한계값의 통계적 수치를 이용\n\n<!-- PAGE_22 -->\n###### (1) 관련 규격 : CLSI EP12-A2; User Protocol for Evaluation of\n\n<!-- PAGE_22 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 사람의 전혈 검체\n\n<!-- PAGE_22 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n- - 16 -\n<!-- PAGE_23 -->\n###### - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대\n\n<!-- PAGE_23 -->\n###### (5) 시험 방법\n\n<!-- PAGE_23 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 사람의 전혈 검체\n\n<!-- PAGE_23 -->\n###### 검체에 대한 검사를 실시하여 검체에 대한 이동거리를 구한다.\n\n <!-- PAGE_23 -->\n###### 확인 한 후 정상값과 비정상값의 통계치의 95% 신뢰구간을 구하여 두\n\n<!-- PAGE_23 -->\n###### ※ 관련 규격을 적용할 수 없는 경우, 제조원에서 설정한 측정범위를\n\n<!-- PAGE_23 -->\n###### (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제\n\n<!-- PAGE_23 -->\n###### ※ 해당 성능항목은 적용하지 않는 경우, 그 사유를 제시하여 적용\n\n- - 17 -\n<!-- PAGE_24 -->\n###### (3) 시험 목적 : 출혈시간 및 항혈소판제제 저항성 복합검사기기의\n\n<!-- PAGE_24 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n<!-- PAGE_24 -->\n###### 측정된\n\n<!-- PAGE_24 -->\n###### 최소\n\n<!-- PAGE_24 -->\n###### 이동거리값을\n\n<!-- PAGE_24 -->\n###### 기준으로\n\n<!-- PAGE_24 -->\n###### 분석대상물질(Agonist\n\n<!-- PAGE_24 -->\n###### 또는\n\n<!-- PAGE_24 -->\n###### Antagonist)을 일정한 비율로 첨가하여 직선성을 보이는 구간을 구\n\n<!-- PAGE_24 -->\n###### (6) 결과제시 : 각 측정값에 대한 직선성을 직선회귀분석을 통해 평가\n\n- - 18 -\n<!-- PAGE_25 -->\n###### 나.  분석적 특이도(간섭물질)\n\n<!-- PAGE_25 -->\n###### (1) 관련 규격 : CLSI EP07 Interference Testing in Clinical Chemistry\n\n<!-- PAGE_25 -->\n###### 간섭물질은 내부 또는 외부 요인일 수 있고 측정법에 따라 다양하므로,\n\n<!-- PAGE_25 -->\n###### 검사법에 따라 결과에 영향을 미칠 것으로 예측되는 다음과 같은 물질에\n\n드물지 않게 볼 수 있는 특이\n\n- - 19 -\n<!-- PAGE_26 -->\n###### (5) 시험 방법\n\n<!-- PAGE_26 -->\n###### 간섭물질의 농도는 임상검체에서 보일 수 있는 최대 농도의 3배\n\n<!-- PAGE_26 -->\n###### 평균과 대조시료 측정결과 평균의 편차를 계산한다.  대조시료 대비\n\n<!-- PAGE_26 -->\n###### 다.  정밀도\n\n<!-- PAGE_26 -->\n###### 1.  반복성\n\n<!-- PAGE_26 -->\n###### (1) 관련 규격 : CLSI EP05-A3: Evaluation of Precision of Quantitative\n\n<!-- PAGE_26 -->\n###### (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제\n\n<!-- PAGE_26 -->\n###### (3) 시험 목적 : 동일한 검체에 대한 시험에서 일정한 결과값이 나오는지\n\n- - 20 -\n<!-- PAGE_27 -->\n###### 확인하는 시험\n\n<!-- PAGE_27 -->\n###### (4) 시험 조건\n\n<!-- PAGE_27 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_27 -->\n###### 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상 준비\n\n<!-- PAGE_27 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n<!-- PAGE_27 -->\n###### 2. ",
        "original_sentence": "분석적 특이도(간섭물질)\n\n<!-- PAGE_25 -->\n###### (1) 관련 규격 : CLSI EP07 Interference Testing in Clinical Chemistry\n\n<!-- PAGE_25 -->\n###### 간섭물질은 내부 또는 외부 요인일 수 있고 측정법에 따라 다양하므로,\n\n<!-- PAGE_25 -->\n###### 검사법에 따라 결과에 영향을 미칠 것으로 예측되는 다음과 같은 물질에\n\n드물지 않게 볼 수 있는 특이\n\n- - 19 -\n<!-- PAGE_26 -->\n###### (5) 시험 방법\n\n<!-- PAGE_26 -->\n###### 간섭물질의 농도는 임상검체에서 보일 수 있는 최대 농도의 3배\n\n<!-- PAGE_26 -->\n###### 평균과 대조시료 측정결과 평균의 편차를 계산한다. "
      }
    },
    {
      "chunk_id": "chunk_540",
      "text": "대조시료 대비\n\n<!-- PAGE_26 -->\n###### 다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 539,
        "window_size": 3,
        "char_count": 36,
        "word_count": 7,
        "page_number": 26,
        "window_text": "검출한계로 추정되는 이동거리 기점을 최소 3개 이상\n\n<!-- PAGE_22 -->\n###### (6) 결과제시 : 측정된 공란한계값과 검출한계값의 통계적 수치를 이용\n\n<!-- PAGE_22 -->\n###### (1) 관련 규격 : CLSI EP12-A2; User Protocol for Evaluation of\n\n<!-- PAGE_22 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 사람의 전혈 검체\n\n<!-- PAGE_22 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n- - 16 -\n<!-- PAGE_23 -->\n###### - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대\n\n<!-- PAGE_23 -->\n###### (5) 시험 방법\n\n<!-- PAGE_23 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 사람의 전혈 검체\n\n<!-- PAGE_23 -->\n###### 검체에 대한 검사를 실시하여 검체에 대한 이동거리를 구한다.\n\n <!-- PAGE_23 -->\n###### 확인 한 후 정상값과 비정상값의 통계치의 95% 신뢰구간을 구하여 두\n\n<!-- PAGE_23 -->\n###### ※ 관련 규격을 적용할 수 없는 경우, 제조원에서 설정한 측정범위를\n\n<!-- PAGE_23 -->\n###### (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제\n\n<!-- PAGE_23 -->\n###### ※ 해당 성능항목은 적용하지 않는 경우, 그 사유를 제시하여 적용\n\n- - 17 -\n<!-- PAGE_24 -->\n###### (3) 시험 목적 : 출혈시간 및 항혈소판제제 저항성 복합검사기기의\n\n<!-- PAGE_24 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n<!-- PAGE_24 -->\n###### 측정된\n\n<!-- PAGE_24 -->\n###### 최소\n\n<!-- PAGE_24 -->\n###### 이동거리값을\n\n<!-- PAGE_24 -->\n###### 기준으로\n\n<!-- PAGE_24 -->\n###### 분석대상물질(Agonist\n\n<!-- PAGE_24 -->\n###### 또는\n\n<!-- PAGE_24 -->\n###### Antagonist)을 일정한 비율로 첨가하여 직선성을 보이는 구간을 구\n\n<!-- PAGE_24 -->\n###### (6) 결과제시 : 각 측정값에 대한 직선성을 직선회귀분석을 통해 평가\n\n- - 18 -\n<!-- PAGE_25 -->\n###### 나.  분석적 특이도(간섭물질)\n\n<!-- PAGE_25 -->\n###### (1) 관련 규격 : CLSI EP07 Interference Testing in Clinical Chemistry\n\n<!-- PAGE_25 -->\n###### 간섭물질은 내부 또는 외부 요인일 수 있고 측정법에 따라 다양하므로,\n\n<!-- PAGE_25 -->\n###### 검사법에 따라 결과에 영향을 미칠 것으로 예측되는 다음과 같은 물질에\n\n드물지 않게 볼 수 있는 특이\n\n- - 19 -\n<!-- PAGE_26 -->\n###### (5) 시험 방법\n\n<!-- PAGE_26 -->\n###### 간섭물질의 농도는 임상검체에서 보일 수 있는 최대 농도의 3배\n\n<!-- PAGE_26 -->\n###### 평균과 대조시료 측정결과 평균의 편차를 계산한다.  대조시료 대비\n\n<!-- PAGE_26 -->\n###### 다.  정밀도\n\n<!-- PAGE_26 -->\n###### 1.  반복성\n\n<!-- PAGE_26 -->\n###### (1) 관련 규격 : CLSI EP05-A3: Evaluation of Precision of Quantitative\n\n<!-- PAGE_26 -->\n###### (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제\n\n<!-- PAGE_26 -->\n###### (3) 시험 목적 : 동일한 검체에 대한 시험에서 일정한 결과값이 나오는지\n\n- - 20 -\n<!-- PAGE_27 -->\n###### 확인하는 시험\n\n<!-- PAGE_27 -->\n###### (4) 시험 조건\n\n<!-- PAGE_27 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_27 -->\n###### 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상 준비\n\n<!-- PAGE_27 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n<!-- PAGE_27 -->\n###### 2.  재현성\n\n<!-- PAGE_27 -->\n###### (1) 관련 규격 : CLSI EP05-A3: Evaluation of Precision of Quantitative\n\n<!-- PAGE_27 -->\n###### (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제\n\n<!-- PAGE_27 -->\n###### (3) 시험 목적 : 동일 검체를 로트, 사용자, 시험 사이트 간 반복\n\n- - 21 -\n<!-- PAGE_28 -->\n###### 측정하여 재현성을 확인하는 시험\n\n<!-- PAGE_28 -->\n###### (4) 시험 조건\n\n<!-- PAGE_28 -->\n###### 전혈 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상\n\n<!-- PAGE_28 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n<!-- PAGE_28 -->\n###### 마다 2회 이상 반복 측정을 1일에 2회 이상, 5일 이상 동안 실시한다.\n\n",
        "original_sentence": "대조시료 대비\n\n<!-- PAGE_26 -->\n###### 다. "
      }
    },
    {
      "chunk_id": "chunk_541",
      "text": "정밀도\n\n<!-- PAGE_26 -->\n###### 1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 540,
        "window_size": 3,
        "char_count": 32,
        "word_count": 6,
        "page_number": 26,
        "window_text": "<!-- PAGE_23 -->\n###### 확인 한 후 정상값과 비정상값의 통계치의 95% 신뢰구간을 구하여 두\n\n<!-- PAGE_23 -->\n###### ※ 관련 규격을 적용할 수 없는 경우, 제조원에서 설정한 측정범위를\n\n<!-- PAGE_23 -->\n###### (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제\n\n<!-- PAGE_23 -->\n###### ※ 해당 성능항목은 적용하지 않는 경우, 그 사유를 제시하여 적용\n\n- - 17 -\n<!-- PAGE_24 -->\n###### (3) 시험 목적 : 출혈시간 및 항혈소판제제 저항성 복합검사기기의\n\n<!-- PAGE_24 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n<!-- PAGE_24 -->\n###### 측정된\n\n<!-- PAGE_24 -->\n###### 최소\n\n<!-- PAGE_24 -->\n###### 이동거리값을\n\n<!-- PAGE_24 -->\n###### 기준으로\n\n<!-- PAGE_24 -->\n###### 분석대상물질(Agonist\n\n<!-- PAGE_24 -->\n###### 또는\n\n<!-- PAGE_24 -->\n###### Antagonist)을 일정한 비율로 첨가하여 직선성을 보이는 구간을 구\n\n<!-- PAGE_24 -->\n###### (6) 결과제시 : 각 측정값에 대한 직선성을 직선회귀분석을 통해 평가\n\n- - 18 -\n<!-- PAGE_25 -->\n###### 나.  분석적 특이도(간섭물질)\n\n<!-- PAGE_25 -->\n###### (1) 관련 규격 : CLSI EP07 Interference Testing in Clinical Chemistry\n\n<!-- PAGE_25 -->\n###### 간섭물질은 내부 또는 외부 요인일 수 있고 측정법에 따라 다양하므로,\n\n<!-- PAGE_25 -->\n###### 검사법에 따라 결과에 영향을 미칠 것으로 예측되는 다음과 같은 물질에\n\n드물지 않게 볼 수 있는 특이\n\n- - 19 -\n<!-- PAGE_26 -->\n###### (5) 시험 방법\n\n<!-- PAGE_26 -->\n###### 간섭물질의 농도는 임상검체에서 보일 수 있는 최대 농도의 3배\n\n<!-- PAGE_26 -->\n###### 평균과 대조시료 측정결과 평균의 편차를 계산한다.  대조시료 대비\n\n<!-- PAGE_26 -->\n###### 다.  정밀도\n\n<!-- PAGE_26 -->\n###### 1.  반복성\n\n<!-- PAGE_26 -->\n###### (1) 관련 규격 : CLSI EP05-A3: Evaluation of Precision of Quantitative\n\n<!-- PAGE_26 -->\n###### (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제\n\n<!-- PAGE_26 -->\n###### (3) 시험 목적 : 동일한 검체에 대한 시험에서 일정한 결과값이 나오는지\n\n- - 20 -\n<!-- PAGE_27 -->\n###### 확인하는 시험\n\n<!-- PAGE_27 -->\n###### (4) 시험 조건\n\n<!-- PAGE_27 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_27 -->\n###### 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상 준비\n\n<!-- PAGE_27 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n<!-- PAGE_27 -->\n###### 2.  재현성\n\n<!-- PAGE_27 -->\n###### (1) 관련 규격 : CLSI EP05-A3: Evaluation of Precision of Quantitative\n\n<!-- PAGE_27 -->\n###### (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제\n\n<!-- PAGE_27 -->\n###### (3) 시험 목적 : 동일 검체를 로트, 사용자, 시험 사이트 간 반복\n\n- - 21 -\n<!-- PAGE_28 -->\n###### 측정하여 재현성을 확인하는 시험\n\n<!-- PAGE_28 -->\n###### (4) 시험 조건\n\n<!-- PAGE_28 -->\n###### 전혈 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상\n\n<!-- PAGE_28 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n<!-- PAGE_28 -->\n###### 마다 2회 이상 반복 측정을 1일에 2회 이상, 5일 이상 동안 실시한다.\n\n <!-- PAGE_28 -->\n###### 각 로트 별 검체에 대한 MD값의 평균, 표준편차, 변동계수를 구한다.\n\n",
        "original_sentence": "정밀도\n\n<!-- PAGE_26 -->\n###### 1. "
      }
    },
    {
      "chunk_id": "chunk_542",
      "text": "반복성\n\n<!-- PAGE_26 -->\n###### (1) 관련 규격 : CLSI EP05-A3: Evaluation of Precision of Quantitative\n\n<!-- PAGE_26 -->\n###### (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제\n\n<!-- PAGE_26 -->\n###### (3) 시험 목적 : 동일한 검체에 대한 시험에서 일정한 결과값이 나오는지\n\n- - 20 -\n<!-- PAGE_27 -->\n###### 확인하는 시험\n\n<!-- PAGE_27 -->\n###### (4) 시험 조건\n\n<!-- PAGE_27 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_27 -->\n###### 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상 준비\n\n<!-- PAGE_27 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n<!-- PAGE_27 -->\n###### 2. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 541,
        "window_size": 3,
        "char_count": 523,
        "word_count": 108,
        "page_number": 26,
        "window_text": "분석적 특이도(간섭물질)\n\n<!-- PAGE_25 -->\n###### (1) 관련 규격 : CLSI EP07 Interference Testing in Clinical Chemistry\n\n<!-- PAGE_25 -->\n###### 간섭물질은 내부 또는 외부 요인일 수 있고 측정법에 따라 다양하므로,\n\n<!-- PAGE_25 -->\n###### 검사법에 따라 결과에 영향을 미칠 것으로 예측되는 다음과 같은 물질에\n\n드물지 않게 볼 수 있는 특이\n\n- - 19 -\n<!-- PAGE_26 -->\n###### (5) 시험 방법\n\n<!-- PAGE_26 -->\n###### 간섭물질의 농도는 임상검체에서 보일 수 있는 최대 농도의 3배\n\n<!-- PAGE_26 -->\n###### 평균과 대조시료 측정결과 평균의 편차를 계산한다.  대조시료 대비\n\n<!-- PAGE_26 -->\n###### 다.  정밀도\n\n<!-- PAGE_26 -->\n###### 1.  반복성\n\n<!-- PAGE_26 -->\n###### (1) 관련 규격 : CLSI EP05-A3: Evaluation of Precision of Quantitative\n\n<!-- PAGE_26 -->\n###### (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제\n\n<!-- PAGE_26 -->\n###### (3) 시험 목적 : 동일한 검체에 대한 시험에서 일정한 결과값이 나오는지\n\n- - 20 -\n<!-- PAGE_27 -->\n###### 확인하는 시험\n\n<!-- PAGE_27 -->\n###### (4) 시험 조건\n\n<!-- PAGE_27 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_27 -->\n###### 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상 준비\n\n<!-- PAGE_27 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n<!-- PAGE_27 -->\n###### 2.  재현성\n\n<!-- PAGE_27 -->\n###### (1) 관련 규격 : CLSI EP05-A3: Evaluation of Precision of Quantitative\n\n<!-- PAGE_27 -->\n###### (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제\n\n<!-- PAGE_27 -->\n###### (3) 시험 목적 : 동일 검체를 로트, 사용자, 시험 사이트 간 반복\n\n- - 21 -\n<!-- PAGE_28 -->\n###### 측정하여 재현성을 확인하는 시험\n\n<!-- PAGE_28 -->\n###### (4) 시험 조건\n\n<!-- PAGE_28 -->\n###### 전혈 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상\n\n<!-- PAGE_28 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n<!-- PAGE_28 -->\n###### 마다 2회 이상 반복 측정을 1일에 2회 이상, 5일 이상 동안 실시한다.\n\n <!-- PAGE_28 -->\n###### 각 로트 별 검체에 대한 MD값의 평균, 표준편차, 변동계수를 구한다.\n\n <!-- PAGE_28 -->\n###### (6) 결과 제시 : 로트간 정밀도, 시험기관간 정밀도, 시험자간 정밀도의\n\n<!-- PAGE_28 -->\n###### 라. ",
        "original_sentence": "반복성\n\n<!-- PAGE_26 -->\n###### (1) 관련 규격 : CLSI EP05-A3: Evaluation of Precision of Quantitative\n\n<!-- PAGE_26 -->\n###### (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제\n\n<!-- PAGE_26 -->\n###### (3) 시험 목적 : 동일한 검체에 대한 시험에서 일정한 결과값이 나오는지\n\n- - 20 -\n<!-- PAGE_27 -->\n###### 확인하는 시험\n\n<!-- PAGE_27 -->\n###### (4) 시험 조건\n\n<!-- PAGE_27 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_27 -->\n###### 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상 준비\n\n<!-- PAGE_27 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n<!-- PAGE_27 -->\n###### 2. "
      }
    },
    {
      "chunk_id": "chunk_543",
      "text": "재현성\n\n<!-- PAGE_27 -->\n###### (1) 관련 규격 : CLSI EP05-A3: Evaluation of Precision of Quantitative\n\n<!-- PAGE_27 -->\n###### (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제\n\n<!-- PAGE_27 -->\n###### (3) 시험 목적 : 동일 검체를 로트, 사용자, 시험 사이트 간 반복\n\n- - 21 -\n<!-- PAGE_28 -->\n###### 측정하여 재현성을 확인하는 시험\n\n<!-- PAGE_28 -->\n###### (4) 시험 조건\n\n<!-- PAGE_28 -->\n###### 전혈 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상\n\n<!-- PAGE_28 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n<!-- PAGE_28 -->\n###### 마다 2회 이상 반복 측정을 1일에 2회 이상, 5일 이상 동안 실시한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 542,
        "window_size": 3,
        "char_count": 507,
        "word_count": 109,
        "page_number": 27,
        "window_text": "대조시료 대비\n\n<!-- PAGE_26 -->\n###### 다.  정밀도\n\n<!-- PAGE_26 -->\n###### 1.  반복성\n\n<!-- PAGE_26 -->\n###### (1) 관련 규격 : CLSI EP05-A3: Evaluation of Precision of Quantitative\n\n<!-- PAGE_26 -->\n###### (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제\n\n<!-- PAGE_26 -->\n###### (3) 시험 목적 : 동일한 검체에 대한 시험에서 일정한 결과값이 나오는지\n\n- - 20 -\n<!-- PAGE_27 -->\n###### 확인하는 시험\n\n<!-- PAGE_27 -->\n###### (4) 시험 조건\n\n<!-- PAGE_27 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_27 -->\n###### 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상 준비\n\n<!-- PAGE_27 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n<!-- PAGE_27 -->\n###### 2.  재현성\n\n<!-- PAGE_27 -->\n###### (1) 관련 규격 : CLSI EP05-A3: Evaluation of Precision of Quantitative\n\n<!-- PAGE_27 -->\n###### (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제\n\n<!-- PAGE_27 -->\n###### (3) 시험 목적 : 동일 검체를 로트, 사용자, 시험 사이트 간 반복\n\n- - 21 -\n<!-- PAGE_28 -->\n###### 측정하여 재현성을 확인하는 시험\n\n<!-- PAGE_28 -->\n###### (4) 시험 조건\n\n<!-- PAGE_28 -->\n###### 전혈 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상\n\n<!-- PAGE_28 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n<!-- PAGE_28 -->\n###### 마다 2회 이상 반복 측정을 1일에 2회 이상, 5일 이상 동안 실시한다.\n\n <!-- PAGE_28 -->\n###### 각 로트 별 검체에 대한 MD값의 평균, 표준편차, 변동계수를 구한다.\n\n <!-- PAGE_28 -->\n###### (6) 결과 제시 : 로트간 정밀도, 시험기관간 정밀도, 시험자간 정밀도의\n\n<!-- PAGE_28 -->\n###### 라.  정확도\n\n<!-- PAGE_28 -->\n###### 표준물질이 부재 또는 기준장비가 명확하지 않은 경우 정확도에 대한\n\n<!-- PAGE_28 -->\n###### 성능평가항목을 제외한다.\n\n",
        "original_sentence": "재현성\n\n<!-- PAGE_27 -->\n###### (1) 관련 규격 : CLSI EP05-A3: Evaluation of Precision of Quantitative\n\n<!-- PAGE_27 -->\n###### (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제\n\n<!-- PAGE_27 -->\n###### (3) 시험 목적 : 동일 검체를 로트, 사용자, 시험 사이트 간 반복\n\n- - 21 -\n<!-- PAGE_28 -->\n###### 측정하여 재현성을 확인하는 시험\n\n<!-- PAGE_28 -->\n###### (4) 시험 조건\n\n<!-- PAGE_28 -->\n###### 전혈 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상\n\n<!-- PAGE_28 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n<!-- PAGE_28 -->\n###### 마다 2회 이상 반복 측정을 1일에 2회 이상, 5일 이상 동안 실시한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_544",
      "text": "<!-- PAGE_28 -->\n###### 각 로트 별 검체에 대한 MD값의 평균, 표준편차, 변동계수를 구한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 543,
        "window_size": 3,
        "char_count": 65,
        "word_count": 14,
        "page_number": 28,
        "window_text": "정밀도\n\n<!-- PAGE_26 -->\n###### 1.  반복성\n\n<!-- PAGE_26 -->\n###### (1) 관련 규격 : CLSI EP05-A3: Evaluation of Precision of Quantitative\n\n<!-- PAGE_26 -->\n###### (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제\n\n<!-- PAGE_26 -->\n###### (3) 시험 목적 : 동일한 검체에 대한 시험에서 일정한 결과값이 나오는지\n\n- - 20 -\n<!-- PAGE_27 -->\n###### 확인하는 시험\n\n<!-- PAGE_27 -->\n###### (4) 시험 조건\n\n<!-- PAGE_27 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_27 -->\n###### 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상 준비\n\n<!-- PAGE_27 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n<!-- PAGE_27 -->\n###### 2.  재현성\n\n<!-- PAGE_27 -->\n###### (1) 관련 규격 : CLSI EP05-A3: Evaluation of Precision of Quantitative\n\n<!-- PAGE_27 -->\n###### (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제\n\n<!-- PAGE_27 -->\n###### (3) 시험 목적 : 동일 검체를 로트, 사용자, 시험 사이트 간 반복\n\n- - 21 -\n<!-- PAGE_28 -->\n###### 측정하여 재현성을 확인하는 시험\n\n<!-- PAGE_28 -->\n###### (4) 시험 조건\n\n<!-- PAGE_28 -->\n###### 전혈 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상\n\n<!-- PAGE_28 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n<!-- PAGE_28 -->\n###### 마다 2회 이상 반복 측정을 1일에 2회 이상, 5일 이상 동안 실시한다.\n\n <!-- PAGE_28 -->\n###### 각 로트 별 검체에 대한 MD값의 평균, 표준편차, 변동계수를 구한다.\n\n <!-- PAGE_28 -->\n###### (6) 결과 제시 : 로트간 정밀도, 시험기관간 정밀도, 시험자간 정밀도의\n\n<!-- PAGE_28 -->\n###### 라.  정확도\n\n<!-- PAGE_28 -->\n###### 표준물질이 부재 또는 기준장비가 명확하지 않은 경우 정확도에 대한\n\n<!-- PAGE_28 -->\n###### 성능평가항목을 제외한다.\n\n - - 22 -\n<!-- PAGE_29 -->\n###### 마. ",
        "original_sentence": "<!-- PAGE_28 -->\n###### 각 로트 별 검체에 대한 MD값의 평균, 표준편차, 변동계수를 구한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_545",
      "text": "<!-- PAGE_28 -->\n###### (6) 결과 제시 : 로트간 정밀도, 시험기관간 정밀도, 시험자간 정밀도의\n\n<!-- PAGE_28 -->\n###### 라. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 544,
        "window_size": 3,
        "char_count": 94,
        "word_count": 19,
        "page_number": 28,
        "window_text": "반복성\n\n<!-- PAGE_26 -->\n###### (1) 관련 규격 : CLSI EP05-A3: Evaluation of Precision of Quantitative\n\n<!-- PAGE_26 -->\n###### (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제\n\n<!-- PAGE_26 -->\n###### (3) 시험 목적 : 동일한 검체에 대한 시험에서 일정한 결과값이 나오는지\n\n- - 20 -\n<!-- PAGE_27 -->\n###### 확인하는 시험\n\n<!-- PAGE_27 -->\n###### (4) 시험 조건\n\n<!-- PAGE_27 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_27 -->\n###### 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상 준비\n\n<!-- PAGE_27 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n<!-- PAGE_27 -->\n###### 2.  재현성\n\n<!-- PAGE_27 -->\n###### (1) 관련 규격 : CLSI EP05-A3: Evaluation of Precision of Quantitative\n\n<!-- PAGE_27 -->\n###### (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제\n\n<!-- PAGE_27 -->\n###### (3) 시험 목적 : 동일 검체를 로트, 사용자, 시험 사이트 간 반복\n\n- - 21 -\n<!-- PAGE_28 -->\n###### 측정하여 재현성을 확인하는 시험\n\n<!-- PAGE_28 -->\n###### (4) 시험 조건\n\n<!-- PAGE_28 -->\n###### 전혈 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상\n\n<!-- PAGE_28 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n<!-- PAGE_28 -->\n###### 마다 2회 이상 반복 측정을 1일에 2회 이상, 5일 이상 동안 실시한다.\n\n <!-- PAGE_28 -->\n###### 각 로트 별 검체에 대한 MD값의 평균, 표준편차, 변동계수를 구한다.\n\n <!-- PAGE_28 -->\n###### (6) 결과 제시 : 로트간 정밀도, 시험기관간 정밀도, 시험자간 정밀도의\n\n<!-- PAGE_28 -->\n###### 라.  정확도\n\n<!-- PAGE_28 -->\n###### 표준물질이 부재 또는 기준장비가 명확하지 않은 경우 정확도에 대한\n\n<!-- PAGE_28 -->\n###### 성능평가항목을 제외한다.\n\n - - 22 -\n<!-- PAGE_29 -->\n###### 마.  교차반응\n\n<!-- PAGE_29 -->\n###### 검체에 대한 교차반응이 발생하지 않는 경우 교차반응에 대한 성능평가\n\n<!-- PAGE_29 -->\n###### 내부 대조물질은 해당 파장에 대한 기기적인 보정에 사용하기 위해\n\n<!-- PAGE_29 -->\n###### 정도관리물질은 파장의 유사 수치를 나타낼 수 있는 임의의 물질\n\n- - 23 -\n<!-- PAGE_30 -->\n###### 7. ",
        "original_sentence": "<!-- PAGE_28 -->\n###### (6) 결과 제시 : 로트간 정밀도, 시험기관간 정밀도, 시험자간 정밀도의\n\n<!-- PAGE_28 -->\n###### 라. "
      }
    },
    {
      "chunk_id": "chunk_546",
      "text": "정확도\n\n<!-- PAGE_28 -->\n###### 표준물질이 부재 또는 기준장비가 명확하지 않은 경우 정확도에 대한\n\n<!-- PAGE_28 -->\n###### 성능평가항목을 제외한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 545,
        "window_size": 3,
        "char_count": 106,
        "word_count": 20,
        "page_number": 28,
        "window_text": "재현성\n\n<!-- PAGE_27 -->\n###### (1) 관련 규격 : CLSI EP05-A3: Evaluation of Precision of Quantitative\n\n<!-- PAGE_27 -->\n###### (2) 적용 범위 : 혈소판 기능검사키트 및 출혈시간 및 항혈소판제제\n\n<!-- PAGE_27 -->\n###### (3) 시험 목적 : 동일 검체를 로트, 사용자, 시험 사이트 간 반복\n\n- - 21 -\n<!-- PAGE_28 -->\n###### 측정하여 재현성을 확인하는 시험\n\n<!-- PAGE_28 -->\n###### (4) 시험 조건\n\n<!-- PAGE_28 -->\n###### 전혈 검체를 정상검체 10개 이상, 혈소판 기능 이상 검체 10개 이상\n\n<!-- PAGE_28 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우\n\n<!-- PAGE_28 -->\n###### 마다 2회 이상 반복 측정을 1일에 2회 이상, 5일 이상 동안 실시한다.\n\n <!-- PAGE_28 -->\n###### 각 로트 별 검체에 대한 MD값의 평균, 표준편차, 변동계수를 구한다.\n\n <!-- PAGE_28 -->\n###### (6) 결과 제시 : 로트간 정밀도, 시험기관간 정밀도, 시험자간 정밀도의\n\n<!-- PAGE_28 -->\n###### 라.  정확도\n\n<!-- PAGE_28 -->\n###### 표준물질이 부재 또는 기준장비가 명확하지 않은 경우 정확도에 대한\n\n<!-- PAGE_28 -->\n###### 성능평가항목을 제외한다.\n\n - - 22 -\n<!-- PAGE_29 -->\n###### 마.  교차반응\n\n<!-- PAGE_29 -->\n###### 검체에 대한 교차반응이 발생하지 않는 경우 교차반응에 대한 성능평가\n\n<!-- PAGE_29 -->\n###### 내부 대조물질은 해당 파장에 대한 기기적인 보정에 사용하기 위해\n\n<!-- PAGE_29 -->\n###### 정도관리물질은 파장의 유사 수치를 나타낼 수 있는 임의의 물질\n\n- - 23 -\n<!-- PAGE_30 -->\n###### 7.  안정성 평가 항목\n\n<!-- PAGE_30 -->\n###### (유효기간) 동안 의료기기의 특성이나 성능이 제조자가 설정한 한계\n\n<!-- PAGE_30 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우 2개\n\n<!-- PAGE_30 -->\n###### - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대\n\n<!-- PAGE_30 -->\n###### 가속노화시험의 기간에 따른 장기보존시험(실시간 안정성시험)을 병행한다.\n\n",
        "original_sentence": "정확도\n\n<!-- PAGE_28 -->\n###### 표준물질이 부재 또는 기준장비가 명확하지 않은 경우 정확도에 대한\n\n<!-- PAGE_28 -->\n###### 성능평가항목을 제외한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_547",
      "text": "- - 22 -\n<!-- PAGE_29 -->\n###### 마. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 546,
        "window_size": 3,
        "char_count": 36,
        "word_count": 9,
        "page_number": 29,
        "window_text": "<!-- PAGE_28 -->\n###### 각 로트 별 검체에 대한 MD값의 평균, 표준편차, 변동계수를 구한다.\n\n <!-- PAGE_28 -->\n###### (6) 결과 제시 : 로트간 정밀도, 시험기관간 정밀도, 시험자간 정밀도의\n\n<!-- PAGE_28 -->\n###### 라.  정확도\n\n<!-- PAGE_28 -->\n###### 표준물질이 부재 또는 기준장비가 명확하지 않은 경우 정확도에 대한\n\n<!-- PAGE_28 -->\n###### 성능평가항목을 제외한다.\n\n - - 22 -\n<!-- PAGE_29 -->\n###### 마.  교차반응\n\n<!-- PAGE_29 -->\n###### 검체에 대한 교차반응이 발생하지 않는 경우 교차반응에 대한 성능평가\n\n<!-- PAGE_29 -->\n###### 내부 대조물질은 해당 파장에 대한 기기적인 보정에 사용하기 위해\n\n<!-- PAGE_29 -->\n###### 정도관리물질은 파장의 유사 수치를 나타낼 수 있는 임의의 물질\n\n- - 23 -\n<!-- PAGE_30 -->\n###### 7.  안정성 평가 항목\n\n<!-- PAGE_30 -->\n###### (유효기간) 동안 의료기기의 특성이나 성능이 제조자가 설정한 한계\n\n<!-- PAGE_30 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우 2개\n\n<!-- PAGE_30 -->\n###### - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대\n\n<!-- PAGE_30 -->\n###### 가속노화시험의 기간에 따른 장기보존시험(실시간 안정성시험)을 병행한다.\n\n - - 24 -\n<!-- PAGE_31 -->\n###### (5) 시험 방법\n\n<!-- PAGE_31 -->\n###### 가속노화시험의 간격, 온도, 시험기간을 설정한다.\n\n",
        "original_sentence": "- - 22 -\n<!-- PAGE_29 -->\n###### 마. "
      }
    },
    {
      "chunk_id": "chunk_548",
      "text": "교차반응\n\n<!-- PAGE_29 -->\n###### 검체에 대한 교차반응이 발생하지 않는 경우 교차반응에 대한 성능평가\n\n<!-- PAGE_29 -->\n###### 내부 대조물질은 해당 파장에 대한 기기적인 보정에 사용하기 위해\n\n<!-- PAGE_29 -->\n###### 정도관리물질은 파장의 유사 수치를 나타낼 수 있는 임의의 물질\n\n- - 23 -\n<!-- PAGE_30 -->\n###### 7. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 547,
        "window_size": 3,
        "char_count": 226,
        "word_count": 49,
        "page_number": 29,
        "window_text": "<!-- PAGE_28 -->\n###### (6) 결과 제시 : 로트간 정밀도, 시험기관간 정밀도, 시험자간 정밀도의\n\n<!-- PAGE_28 -->\n###### 라.  정확도\n\n<!-- PAGE_28 -->\n###### 표준물질이 부재 또는 기준장비가 명확하지 않은 경우 정확도에 대한\n\n<!-- PAGE_28 -->\n###### 성능평가항목을 제외한다.\n\n - - 22 -\n<!-- PAGE_29 -->\n###### 마.  교차반응\n\n<!-- PAGE_29 -->\n###### 검체에 대한 교차반응이 발생하지 않는 경우 교차반응에 대한 성능평가\n\n<!-- PAGE_29 -->\n###### 내부 대조물질은 해당 파장에 대한 기기적인 보정에 사용하기 위해\n\n<!-- PAGE_29 -->\n###### 정도관리물질은 파장의 유사 수치를 나타낼 수 있는 임의의 물질\n\n- - 23 -\n<!-- PAGE_30 -->\n###### 7.  안정성 평가 항목\n\n<!-- PAGE_30 -->\n###### (유효기간) 동안 의료기기의 특성이나 성능이 제조자가 설정한 한계\n\n<!-- PAGE_30 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우 2개\n\n<!-- PAGE_30 -->\n###### - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대\n\n<!-- PAGE_30 -->\n###### 가속노화시험의 기간에 따른 장기보존시험(실시간 안정성시험)을 병행한다.\n\n - - 24 -\n<!-- PAGE_31 -->\n###### (5) 시험 방법\n\n<!-- PAGE_31 -->\n###### 가속노화시험의 간격, 온도, 시험기간을 설정한다.\n\n <!-- PAGE_31 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_31 -->\n###### 보기 위해 사용기간(유효기간) 동안 의료기기의 특성이나 성능이\n\n<!-- PAGE_31 -->\n###### (4) 시험 조건\n\n<!-- PAGE_31 -->\n###### - 시험물질\n\n<!-- PAGE_31 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_31 -->\n###### 검체를 사용한다.\n\n",
        "original_sentence": "교차반응\n\n<!-- PAGE_29 -->\n###### 검체에 대한 교차반응이 발생하지 않는 경우 교차반응에 대한 성능평가\n\n<!-- PAGE_29 -->\n###### 내부 대조물질은 해당 파장에 대한 기기적인 보정에 사용하기 위해\n\n<!-- PAGE_29 -->\n###### 정도관리물질은 파장의 유사 수치를 나타낼 수 있는 임의의 물질\n\n- - 23 -\n<!-- PAGE_30 -->\n###### 7. "
      }
    },
    {
      "chunk_id": "chunk_549",
      "text": "안정성 평가 항목\n\n<!-- PAGE_30 -->\n###### (유효기간) 동안 의료기기의 특성이나 성능이 제조자가 설정한 한계\n\n<!-- PAGE_30 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우 2개\n\n<!-- PAGE_30 -->\n###### - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대\n\n<!-- PAGE_30 -->\n###### 가속노화시험의 기간에 따른 장기보존시험(실시간 안정성시험)을 병행한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 548,
        "window_size": 3,
        "char_count": 258,
        "word_count": 50,
        "page_number": 30,
        "window_text": "정확도\n\n<!-- PAGE_28 -->\n###### 표준물질이 부재 또는 기준장비가 명확하지 않은 경우 정확도에 대한\n\n<!-- PAGE_28 -->\n###### 성능평가항목을 제외한다.\n\n - - 22 -\n<!-- PAGE_29 -->\n###### 마.  교차반응\n\n<!-- PAGE_29 -->\n###### 검체에 대한 교차반응이 발생하지 않는 경우 교차반응에 대한 성능평가\n\n<!-- PAGE_29 -->\n###### 내부 대조물질은 해당 파장에 대한 기기적인 보정에 사용하기 위해\n\n<!-- PAGE_29 -->\n###### 정도관리물질은 파장의 유사 수치를 나타낼 수 있는 임의의 물질\n\n- - 23 -\n<!-- PAGE_30 -->\n###### 7.  안정성 평가 항목\n\n<!-- PAGE_30 -->\n###### (유효기간) 동안 의료기기의 특성이나 성능이 제조자가 설정한 한계\n\n<!-- PAGE_30 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우 2개\n\n<!-- PAGE_30 -->\n###### - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대\n\n<!-- PAGE_30 -->\n###### 가속노화시험의 기간에 따른 장기보존시험(실시간 안정성시험)을 병행한다.\n\n - - 24 -\n<!-- PAGE_31 -->\n###### (5) 시험 방법\n\n<!-- PAGE_31 -->\n###### 가속노화시험의 간격, 온도, 시험기간을 설정한다.\n\n <!-- PAGE_31 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_31 -->\n###### 보기 위해 사용기간(유효기간) 동안 의료기기의 특성이나 성능이\n\n<!-- PAGE_31 -->\n###### (4) 시험 조건\n\n<!-- PAGE_31 -->\n###### - 시험물질\n\n<!-- PAGE_31 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_31 -->\n###### 검체를 사용한다.\n\n - - 25 -\n<!-- PAGE_32 -->\n###### - 시험장비\n\n<!-- PAGE_32 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우 2개\n\n<!-- PAGE_32 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_32 -->\n###### 개봉시점 및 각 포인트 별 샘플의 이동거리값의 평균 및 표준편차를 계산\n\n- - 26 -\n<!-- PAGE_33 -->\n###### 8. ",
        "original_sentence": "안정성 평가 항목\n\n<!-- PAGE_30 -->\n###### (유효기간) 동안 의료기기의 특성이나 성능이 제조자가 설정한 한계\n\n<!-- PAGE_30 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우 2개\n\n<!-- PAGE_30 -->\n###### - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대\n\n<!-- PAGE_30 -->\n###### 가속노화시험의 기간에 따른 장기보존시험(실시간 안정성시험)을 병행한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_550",
      "text": "- - 24 -\n<!-- PAGE_31 -->\n###### (5) 시험 방법\n\n<!-- PAGE_31 -->\n###### 가속노화시험의 간격, 온도, 시험기간을 설정한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 549,
        "window_size": 3,
        "char_count": 97,
        "word_count": 20,
        "page_number": 31,
        "window_text": "- - 22 -\n<!-- PAGE_29 -->\n###### 마.  교차반응\n\n<!-- PAGE_29 -->\n###### 검체에 대한 교차반응이 발생하지 않는 경우 교차반응에 대한 성능평가\n\n<!-- PAGE_29 -->\n###### 내부 대조물질은 해당 파장에 대한 기기적인 보정에 사용하기 위해\n\n<!-- PAGE_29 -->\n###### 정도관리물질은 파장의 유사 수치를 나타낼 수 있는 임의의 물질\n\n- - 23 -\n<!-- PAGE_30 -->\n###### 7.  안정성 평가 항목\n\n<!-- PAGE_30 -->\n###### (유효기간) 동안 의료기기의 특성이나 성능이 제조자가 설정한 한계\n\n<!-- PAGE_30 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우 2개\n\n<!-- PAGE_30 -->\n###### - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대\n\n<!-- PAGE_30 -->\n###### 가속노화시험의 기간에 따른 장기보존시험(실시간 안정성시험)을 병행한다.\n\n - - 24 -\n<!-- PAGE_31 -->\n###### (5) 시험 방법\n\n<!-- PAGE_31 -->\n###### 가속노화시험의 간격, 온도, 시험기간을 설정한다.\n\n <!-- PAGE_31 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_31 -->\n###### 보기 위해 사용기간(유효기간) 동안 의료기기의 특성이나 성능이\n\n<!-- PAGE_31 -->\n###### (4) 시험 조건\n\n<!-- PAGE_31 -->\n###### - 시험물질\n\n<!-- PAGE_31 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_31 -->\n###### 검체를 사용한다.\n\n - - 25 -\n<!-- PAGE_32 -->\n###### - 시험장비\n\n<!-- PAGE_32 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우 2개\n\n<!-- PAGE_32 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_32 -->\n###### 개봉시점 및 각 포인트 별 샘플의 이동거리값의 평균 및 표준편차를 계산\n\n- - 26 -\n<!-- PAGE_33 -->\n###### 8.  참고 문헌\n\n- 다. IEC 61010-1 Safety requirements for electrical equipment for measurement,\n- 라.\nIEC\n\n61010-2-101\n\nSafety\n\nrequirements\n\nfor\n\nelectrical\n\nequipment\n\nfor\n\nmeasurement,\n\ncontrol\n\nand\n\nlaboratory\n\nuse\n\n–\n\nPart\n\n2-101:\n\nParticular\n\n- 바. IEC 61326-2-6 Electrical equipment for measurement, control and laboratory\n- 자. CLSI EP12-A2; User Protocol for Evaluation of Qualitative Test Performance;\n- 차.\nCLSI\n\nEP06-A:\n\nEvaluation\n\nof\n\nthe\n\nLinearity\n\nof\n\nQuantitative\n\nMeasurement\n\n- 카. CLSI EP07: Interference Testing in Clinical Chemistry Approved Guideline\n- 타. CLSI EP05-A3: Evaluation of Precision of Quantitative Measurement Methods;\n- 파.\nPlatelet\n\nAggregation\n\nDevices\n\nMarket\n\nby\n\nProduct\n\n(Systems,\n\nReagents,\n\nConsumables,\n\nAccessories),\n\nApplication\n\n(Research,\n\nDiagnostic,\n\nCVD,\n\nOrthopedic,\n\nTrauma),\n\nEnd\n\nUser\n\n(Hospitals,\n\nDiagnostic\n\nLaboratories,\n\nAcademia,\n\nBlood\n\nBanks)\n\n- -\nGlobal\n\nForecasts\n\nto\n\n- 2020.\nmarketsandmarkets.com. ",
        "original_sentence": "- - 24 -\n<!-- PAGE_31 -->\n###### (5) 시험 방법\n\n<!-- PAGE_31 -->\n###### 가속노화시험의 간격, 온도, 시험기간을 설정한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_551",
      "text": "<!-- PAGE_31 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_31 -->\n###### 보기 위해 사용기간(유효기간) 동안 의료기기의 특성이나 성능이\n\n<!-- PAGE_31 -->\n###### (4) 시험 조건\n\n<!-- PAGE_31 -->\n###### - 시험물질\n\n<!-- PAGE_31 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_31 -->\n###### 검체를 사용한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 550,
        "window_size": 3,
        "char_count": 290,
        "word_count": 56,
        "page_number": 31,
        "window_text": "교차반응\n\n<!-- PAGE_29 -->\n###### 검체에 대한 교차반응이 발생하지 않는 경우 교차반응에 대한 성능평가\n\n<!-- PAGE_29 -->\n###### 내부 대조물질은 해당 파장에 대한 기기적인 보정에 사용하기 위해\n\n<!-- PAGE_29 -->\n###### 정도관리물질은 파장의 유사 수치를 나타낼 수 있는 임의의 물질\n\n- - 23 -\n<!-- PAGE_30 -->\n###### 7.  안정성 평가 항목\n\n<!-- PAGE_30 -->\n###### (유효기간) 동안 의료기기의 특성이나 성능이 제조자가 설정한 한계\n\n<!-- PAGE_30 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우 2개\n\n<!-- PAGE_30 -->\n###### - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대\n\n<!-- PAGE_30 -->\n###### 가속노화시험의 기간에 따른 장기보존시험(실시간 안정성시험)을 병행한다.\n\n - - 24 -\n<!-- PAGE_31 -->\n###### (5) 시험 방법\n\n<!-- PAGE_31 -->\n###### 가속노화시험의 간격, 온도, 시험기간을 설정한다.\n\n <!-- PAGE_31 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_31 -->\n###### 보기 위해 사용기간(유효기간) 동안 의료기기의 특성이나 성능이\n\n<!-- PAGE_31 -->\n###### (4) 시험 조건\n\n<!-- PAGE_31 -->\n###### - 시험물질\n\n<!-- PAGE_31 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_31 -->\n###### 검체를 사용한다.\n\n - - 25 -\n<!-- PAGE_32 -->\n###### - 시험장비\n\n<!-- PAGE_32 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우 2개\n\n<!-- PAGE_32 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_32 -->\n###### 개봉시점 및 각 포인트 별 샘플의 이동거리값의 평균 및 표준편차를 계산\n\n- - 26 -\n<!-- PAGE_33 -->\n###### 8.  참고 문헌\n\n- 다. IEC 61010-1 Safety requirements for electrical equipment for measurement,\n- 라.\nIEC\n\n61010-2-101\n\nSafety\n\nrequirements\n\nfor\n\nelectrical\n\nequipment\n\nfor\n\nmeasurement,\n\ncontrol\n\nand\n\nlaboratory\n\nuse\n\n–\n\nPart\n\n2-101:\n\nParticular\n\n- 바. IEC 61326-2-6 Electrical equipment for measurement, control and laboratory\n- 자. CLSI EP12-A2; User Protocol for Evaluation of Qualitative Test Performance;\n- 차.\nCLSI\n\nEP06-A:\n\nEvaluation\n\nof\n\nthe\n\nLinearity\n\nof\n\nQuantitative\n\nMeasurement\n\n- 카. CLSI EP07: Interference Testing in Clinical Chemistry Approved Guideline\n- 타. CLSI EP05-A3: Evaluation of Precision of Quantitative Measurement Methods;\n- 파.\nPlatelet\n\nAggregation\n\nDevices\n\nMarket\n\nby\n\nProduct\n\n(Systems,\n\nReagents,\n\nConsumables,\n\nAccessories),\n\nApplication\n\n(Research,\n\nDiagnostic,\n\nCVD,\n\nOrthopedic,\n\nTrauma),\n\nEnd\n\nUser\n\n(Hospitals,\n\nDiagnostic\n\nLaboratories,\n\nAcademia,\n\nBlood\n\nBanks)\n\n- -\nGlobal\n\nForecasts\n\nto\n\n- 2020.\nmarketsandmarkets.com.  August 2015\n\n- - 27 -\n<!-- PAGE_34 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_34 -->\n###### (1) 출혈시간 및 항혈소판제제 저항성 복합검사기기의 국내 개발 현황\n\n<!-- PAGE_34 -->\n###### 사용되어 온 Duke법, Ivy법, Template법 등을 이용하여 혈소판\n\n<!-- PAGE_34 -->\n###### 커서 표준화가 어렵고 임상적 유용성이 적어서 객관적인 데이터로\n\n<!-- PAGE_34 -->\n###### ③ 출혈시간 및 항혈소판제제 저항성 복합검사기기는 주로 수입 의료\n\n<!-- PAGE_34 -->\n###### (나) 국내의 혈소판 기능검사의 시장도 매년 성장하고 있으며 주로\n\n<!-- PAGE_34 -->\n###### (다) 혈소판 기능검사는 신의료기술로 인정되어 비급여항목으로 각 검사당\n\n<!-- PAGE_34 -->\n###### 약 4만원에서 8만원 정도의 검사비가 청구되고 있어 국내 기술을\n\n<!-- PAGE_34 -->\n###### (라) 2016년 9월 현재 급여항목으로 변경된 EPI(Epinephrine, 에피네프린)\n\n<!-- PAGE_34 -->\n###### 테스트 및\n\n<!-- PAGE_34 -->\n###### ADP(에이디피)의 경우\n\n<!-- PAGE_34 -->\n###### 본인부담금으로 9,000원이\n\n<!-- PAGE_34 -->\n###### 청구되고 있다.\n\n",
        "original_sentence": "<!-- PAGE_31 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_31 -->\n###### 보기 위해 사용기간(유효기간) 동안 의료기기의 특성이나 성능이\n\n<!-- PAGE_31 -->\n###### (4) 시험 조건\n\n<!-- PAGE_31 -->\n###### - 시험물질\n\n<!-- PAGE_31 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_31 -->\n###### 검체를 사용한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_552",
      "text": "- - 25 -\n<!-- PAGE_32 -->\n###### - 시험장비\n\n<!-- PAGE_32 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우 2개\n\n<!-- PAGE_32 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_32 -->\n###### 개봉시점 및 각 포인트 별 샘플의 이동거리값의 평균 및 표준편차를 계산\n\n- - 26 -\n<!-- PAGE_33 -->\n###### 8. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 551,
        "window_size": 3,
        "char_count": 272,
        "word_count": 61,
        "page_number": 32,
        "window_text": "안정성 평가 항목\n\n<!-- PAGE_30 -->\n###### (유효기간) 동안 의료기기의 특성이나 성능이 제조자가 설정한 한계\n\n<!-- PAGE_30 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우 2개\n\n<!-- PAGE_30 -->\n###### - 출혈시간 및 항혈소판제제 저항성 복합기기: 1대\n\n<!-- PAGE_30 -->\n###### 가속노화시험의 기간에 따른 장기보존시험(실시간 안정성시험)을 병행한다.\n\n - - 24 -\n<!-- PAGE_31 -->\n###### (5) 시험 방법\n\n<!-- PAGE_31 -->\n###### 가속노화시험의 간격, 온도, 시험기간을 설정한다.\n\n <!-- PAGE_31 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_31 -->\n###### 보기 위해 사용기간(유효기간) 동안 의료기기의 특성이나 성능이\n\n<!-- PAGE_31 -->\n###### (4) 시험 조건\n\n<!-- PAGE_31 -->\n###### - 시험물질\n\n<!-- PAGE_31 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_31 -->\n###### 검체를 사용한다.\n\n - - 25 -\n<!-- PAGE_32 -->\n###### - 시험장비\n\n<!-- PAGE_32 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우 2개\n\n<!-- PAGE_32 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_32 -->\n###### 개봉시점 및 각 포인트 별 샘플의 이동거리값의 평균 및 표준편차를 계산\n\n- - 26 -\n<!-- PAGE_33 -->\n###### 8.  참고 문헌\n\n- 다. IEC 61010-1 Safety requirements for electrical equipment for measurement,\n- 라.\nIEC\n\n61010-2-101\n\nSafety\n\nrequirements\n\nfor\n\nelectrical\n\nequipment\n\nfor\n\nmeasurement,\n\ncontrol\n\nand\n\nlaboratory\n\nuse\n\n–\n\nPart\n\n2-101:\n\nParticular\n\n- 바. IEC 61326-2-6 Electrical equipment for measurement, control and laboratory\n- 자. CLSI EP12-A2; User Protocol for Evaluation of Qualitative Test Performance;\n- 차.\nCLSI\n\nEP06-A:\n\nEvaluation\n\nof\n\nthe\n\nLinearity\n\nof\n\nQuantitative\n\nMeasurement\n\n- 카. CLSI EP07: Interference Testing in Clinical Chemistry Approved Guideline\n- 타. CLSI EP05-A3: Evaluation of Precision of Quantitative Measurement Methods;\n- 파.\nPlatelet\n\nAggregation\n\nDevices\n\nMarket\n\nby\n\nProduct\n\n(Systems,\n\nReagents,\n\nConsumables,\n\nAccessories),\n\nApplication\n\n(Research,\n\nDiagnostic,\n\nCVD,\n\nOrthopedic,\n\nTrauma),\n\nEnd\n\nUser\n\n(Hospitals,\n\nDiagnostic\n\nLaboratories,\n\nAcademia,\n\nBlood\n\nBanks)\n\n- -\nGlobal\n\nForecasts\n\nto\n\n- 2020.\nmarketsandmarkets.com.  August 2015\n\n- - 27 -\n<!-- PAGE_34 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_34 -->\n###### (1) 출혈시간 및 항혈소판제제 저항성 복합검사기기의 국내 개발 현황\n\n<!-- PAGE_34 -->\n###### 사용되어 온 Duke법, Ivy법, Template법 등을 이용하여 혈소판\n\n<!-- PAGE_34 -->\n###### 커서 표준화가 어렵고 임상적 유용성이 적어서 객관적인 데이터로\n\n<!-- PAGE_34 -->\n###### ③ 출혈시간 및 항혈소판제제 저항성 복합검사기기는 주로 수입 의료\n\n<!-- PAGE_34 -->\n###### (나) 국내의 혈소판 기능검사의 시장도 매년 성장하고 있으며 주로\n\n<!-- PAGE_34 -->\n###### (다) 혈소판 기능검사는 신의료기술로 인정되어 비급여항목으로 각 검사당\n\n<!-- PAGE_34 -->\n###### 약 4만원에서 8만원 정도의 검사비가 청구되고 있어 국내 기술을\n\n<!-- PAGE_34 -->\n###### (라) 2016년 9월 현재 급여항목으로 변경된 EPI(Epinephrine, 에피네프린)\n\n<!-- PAGE_34 -->\n###### 테스트 및\n\n<!-- PAGE_34 -->\n###### ADP(에이디피)의 경우\n\n<!-- PAGE_34 -->\n###### 본인부담금으로 9,000원이\n\n<!-- PAGE_34 -->\n###### 청구되고 있다.\n\n - - 28 -\n<!-- PAGE_35 -->\n##### Ⅱ\n\n<!-- PAGE_35 -->\n##### 임상시험계획서 작성 및 평가\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n확증임상시험\n\n- (1) 대상질환 : 선천적 · 후천적 혈소판기능장애 환자 :　본 빌레브란트병(von\nWillebrand disease), 글란즈만 혈소판무력증(Glanzmann's thrombasthenia),\n\n- (2) 해당 의료기기의 사용목적：혈소판 기능부전 검출\n- - 구연산 처리된 전혈에서 폐색 전 혈액이동거리를 측정하여 혈소판 기능부전을\n검출하는 체외진단용 의료기기\n\n- - 29 -\n- (3) 해당 의료기기 : 혈액응고검사시약과 자동혈소판응집측정장치\n- (4) 임상시험 평가내용 : 민감도 및 특이도, 일치도\n- (5) 임상시험 디자인 : 다기관, 비무작위배정, 단일눈가림, 단일설계, 전향적 임상시험\nAspirin 또는 P2Y12 수용제 저해제(clopidogrel) 복용중인 환자의 구연산 처리된\n\n전혈에서 혈소판 약물반응을 확인하기 위해 사용되는 ‘출혈 시간 및 항혈소판제제\n\n저항성 복합검사기기-혈소판 약물반응검사’의 임상적 성능평가를 위하여 aspirin\n\n또는 P2Y12 수용제 저해제(clopidogrel) 복용 전·후에 대한 민감도와 특이도를\n\n기허가제품의 민감도 및 특이도와 비교 평가하기 위한 다기관, 비무작위배정, 단일\n\n- (1) 대상질환 : 혈관질환의 병력, 혈관질환의 위험군 등으로 aspirin 또는 P2Y12\n- (5) 임상시험 디자인 : 다기관, 비무작위배정, 단일눈가림, 단일설계, 전향적 임상시험\n- - 30 -\n<!-- PAGE_37 -->\n###### 2. ",
        "original_sentence": "- - 25 -\n<!-- PAGE_32 -->\n###### - 시험장비\n\n<!-- PAGE_32 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우 2개\n\n<!-- PAGE_32 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_32 -->\n###### 개봉시점 및 각 포인트 별 샘플의 이동거리값의 평균 및 표준편차를 계산\n\n- - 26 -\n<!-- PAGE_33 -->\n###### 8. "
      }
    },
    {
      "chunk_id": "chunk_553",
      "text": "참고 문헌\n\n- 다. IEC 61010-1 Safety requirements for electrical equipment for measurement,\n- 라.\nIEC\n\n61010-2-101\n\nSafety\n\nrequirements\n\nfor\n\nelectrical\n\nequipment\n\nfor\n\nmeasurement,\n\ncontrol\n\nand\n\nlaboratory\n\nuse\n\n–\n\nPart\n\n2-101:\n\nParticular\n\n- 바. IEC 61326-2-6 Electrical equipment for measurement, control and laboratory\n- 자. CLSI EP12-A2; User Protocol for Evaluation of Qualitative Test Performance;\n- 차.\nCLSI\n\nEP06-A:\n\nEvaluation\n\nof\n\nthe\n\nLinearity\n\nof\n\nQuantitative\n\nMeasurement\n\n- 카. CLSI EP07: Interference Testing in Clinical Chemistry Approved Guideline\n- 타. CLSI EP05-A3: Evaluation of Precision of Quantitative Measurement Methods;\n- 파.\nPlatelet\n\nAggregation\n\nDevices\n\nMarket\n\nby\n\nProduct\n\n(Systems,\n\nReagents,\n\nConsumables,\n\nAccessories),\n\nApplication\n\n(Research,\n\nDiagnostic,\n\nCVD,\n\nOrthopedic,\n\nTrauma),\n\nEnd\n\nUser\n\n(Hospitals,\n\nDiagnostic\n\nLaboratories,\n\nAcademia,\n\nBlood\n\nBanks)\n\n- -\nGlobal\n\nForecasts\n\nto\n\n- 2020.\nmarketsandmarkets.com. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 552,
        "window_size": 3,
        "char_count": 951,
        "word_count": 122,
        "page_number": 6,
        "window_text": "- - 24 -\n<!-- PAGE_31 -->\n###### (5) 시험 방법\n\n<!-- PAGE_31 -->\n###### 가속노화시험의 간격, 온도, 시험기간을 설정한다.\n\n <!-- PAGE_31 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_31 -->\n###### 보기 위해 사용기간(유효기간) 동안 의료기기의 특성이나 성능이\n\n<!-- PAGE_31 -->\n###### (4) 시험 조건\n\n<!-- PAGE_31 -->\n###### - 시험물질\n\n<!-- PAGE_31 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_31 -->\n###### 검체를 사용한다.\n\n - - 25 -\n<!-- PAGE_32 -->\n###### - 시험장비\n\n<!-- PAGE_32 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우 2개\n\n<!-- PAGE_32 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_32 -->\n###### 개봉시점 및 각 포인트 별 샘플의 이동거리값의 평균 및 표준편차를 계산\n\n- - 26 -\n<!-- PAGE_33 -->\n###### 8.  참고 문헌\n\n- 다. IEC 61010-1 Safety requirements for electrical equipment for measurement,\n- 라.\nIEC\n\n61010-2-101\n\nSafety\n\nrequirements\n\nfor\n\nelectrical\n\nequipment\n\nfor\n\nmeasurement,\n\ncontrol\n\nand\n\nlaboratory\n\nuse\n\n–\n\nPart\n\n2-101:\n\nParticular\n\n- 바. IEC 61326-2-6 Electrical equipment for measurement, control and laboratory\n- 자. CLSI EP12-A2; User Protocol for Evaluation of Qualitative Test Performance;\n- 차.\nCLSI\n\nEP06-A:\n\nEvaluation\n\nof\n\nthe\n\nLinearity\n\nof\n\nQuantitative\n\nMeasurement\n\n- 카. CLSI EP07: Interference Testing in Clinical Chemistry Approved Guideline\n- 타. CLSI EP05-A3: Evaluation of Precision of Quantitative Measurement Methods;\n- 파.\nPlatelet\n\nAggregation\n\nDevices\n\nMarket\n\nby\n\nProduct\n\n(Systems,\n\nReagents,\n\nConsumables,\n\nAccessories),\n\nApplication\n\n(Research,\n\nDiagnostic,\n\nCVD,\n\nOrthopedic,\n\nTrauma),\n\nEnd\n\nUser\n\n(Hospitals,\n\nDiagnostic\n\nLaboratories,\n\nAcademia,\n\nBlood\n\nBanks)\n\n- -\nGlobal\n\nForecasts\n\nto\n\n- 2020.\nmarketsandmarkets.com.  August 2015\n\n- - 27 -\n<!-- PAGE_34 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_34 -->\n###### (1) 출혈시간 및 항혈소판제제 저항성 복합검사기기의 국내 개발 현황\n\n<!-- PAGE_34 -->\n###### 사용되어 온 Duke법, Ivy법, Template법 등을 이용하여 혈소판\n\n<!-- PAGE_34 -->\n###### 커서 표준화가 어렵고 임상적 유용성이 적어서 객관적인 데이터로\n\n<!-- PAGE_34 -->\n###### ③ 출혈시간 및 항혈소판제제 저항성 복합검사기기는 주로 수입 의료\n\n<!-- PAGE_34 -->\n###### (나) 국내의 혈소판 기능검사의 시장도 매년 성장하고 있으며 주로\n\n<!-- PAGE_34 -->\n###### (다) 혈소판 기능검사는 신의료기술로 인정되어 비급여항목으로 각 검사당\n\n<!-- PAGE_34 -->\n###### 약 4만원에서 8만원 정도의 검사비가 청구되고 있어 국내 기술을\n\n<!-- PAGE_34 -->\n###### (라) 2016년 9월 현재 급여항목으로 변경된 EPI(Epinephrine, 에피네프린)\n\n<!-- PAGE_34 -->\n###### 테스트 및\n\n<!-- PAGE_34 -->\n###### ADP(에이디피)의 경우\n\n<!-- PAGE_34 -->\n###### 본인부담금으로 9,000원이\n\n<!-- PAGE_34 -->\n###### 청구되고 있다.\n\n - - 28 -\n<!-- PAGE_35 -->\n##### Ⅱ\n\n<!-- PAGE_35 -->\n##### 임상시험계획서 작성 및 평가\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n확증임상시험\n\n- (1) 대상질환 : 선천적 · 후천적 혈소판기능장애 환자 :　본 빌레브란트병(von\nWillebrand disease), 글란즈만 혈소판무력증(Glanzmann's thrombasthenia),\n\n- (2) 해당 의료기기의 사용목적：혈소판 기능부전 검출\n- - 구연산 처리된 전혈에서 폐색 전 혈액이동거리를 측정하여 혈소판 기능부전을\n검출하는 체외진단용 의료기기\n\n- - 29 -\n- (3) 해당 의료기기 : 혈액응고검사시약과 자동혈소판응집측정장치\n- (4) 임상시험 평가내용 : 민감도 및 특이도, 일치도\n- (5) 임상시험 디자인 : 다기관, 비무작위배정, 단일눈가림, 단일설계, 전향적 임상시험\nAspirin 또는 P2Y12 수용제 저해제(clopidogrel) 복용중인 환자의 구연산 처리된\n\n전혈에서 혈소판 약물반응을 확인하기 위해 사용되는 ‘출혈 시간 및 항혈소판제제\n\n저항성 복합검사기기-혈소판 약물반응검사’의 임상적 성능평가를 위하여 aspirin\n\n또는 P2Y12 수용제 저해제(clopidogrel) 복용 전·후에 대한 민감도와 특이도를\n\n기허가제품의 민감도 및 특이도와 비교 평가하기 위한 다기관, 비무작위배정, 단일\n\n- (1) 대상질환 : 혈관질환의 병력, 혈관질환의 위험군 등으로 aspirin 또는 P2Y12\n- (5) 임상시험 디자인 : 다기관, 비무작위배정, 단일눈가림, 단일설계, 전향적 임상시험\n- - 30 -\n<!-- PAGE_37 -->\n###### 2.  임상시험기관의 명칭 및 소재지\n\n- - 31 -\n<!-- PAGE_38 -->\n###### 3. ",
        "original_sentence": "참고 문헌\n\n- 다. IEC 61010-1 Safety requirements for electrical equipment for measurement,\n- 라.\nIEC\n\n61010-2-101\n\nSafety\n\nrequirements\n\nfor\n\nelectrical\n\nequipment\n\nfor\n\nmeasurement,\n\ncontrol\n\nand\n\nlaboratory\n\nuse\n\n–\n\nPart\n\n2-101:\n\nParticular\n\n- 바. IEC 61326-2-6 Electrical equipment for measurement, control and laboratory\n- 자. CLSI EP12-A2; User Protocol for Evaluation of Qualitative Test Performance;\n- 차.\nCLSI\n\nEP06-A:\n\nEvaluation\n\nof\n\nthe\n\nLinearity\n\nof\n\nQuantitative\n\nMeasurement\n\n- 카. CLSI EP07: Interference Testing in Clinical Chemistry Approved Guideline\n- 타. CLSI EP05-A3: Evaluation of Precision of Quantitative Measurement Methods;\n- 파.\nPlatelet\n\nAggregation\n\nDevices\n\nMarket\n\nby\n\nProduct\n\n(Systems,\n\nReagents,\n\nConsumables,\n\nAccessories),\n\nApplication\n\n(Research,\n\nDiagnostic,\n\nCVD,\n\nOrthopedic,\n\nTrauma),\n\nEnd\n\nUser\n\n(Hospitals,\n\nDiagnostic\n\nLaboratories,\n\nAcademia,\n\nBlood\n\nBanks)\n\n- -\nGlobal\n\nForecasts\n\nto\n\n- 2020.\nmarketsandmarkets.com. "
      }
    },
    {
      "chunk_id": "chunk_554",
      "text": "August 2015\n\n- - 27 -\n<!-- PAGE_34 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_34 -->\n###### (1) 출혈시간 및 항혈소판제제 저항성 복합검사기기의 국내 개발 현황\n\n<!-- PAGE_34 -->\n###### 사용되어 온 Duke법, Ivy법, Template법 등을 이용하여 혈소판\n\n<!-- PAGE_34 -->\n###### 커서 표준화가 어렵고 임상적 유용성이 적어서 객관적인 데이터로\n\n<!-- PAGE_34 -->\n###### ③ 출혈시간 및 항혈소판제제 저항성 복합검사기기는 주로 수입 의료\n\n<!-- PAGE_34 -->\n###### (나) 국내의 혈소판 기능검사의 시장도 매년 성장하고 있으며 주로\n\n<!-- PAGE_34 -->\n###### (다) 혈소판 기능검사는 신의료기술로 인정되어 비급여항목으로 각 검사당\n\n<!-- PAGE_34 -->\n###### 약 4만원에서 8만원 정도의 검사비가 청구되고 있어 국내 기술을\n\n<!-- PAGE_34 -->\n###### (라) 2016년 9월 현재 급여항목으로 변경된 EPI(Epinephrine, 에피네프린)\n\n<!-- PAGE_34 -->\n###### 테스트 및\n\n<!-- PAGE_34 -->\n###### ADP(에이디피)의 경우\n\n<!-- PAGE_34 -->\n###### 본인부담금으로 9,000원이\n\n<!-- PAGE_34 -->\n###### 청구되고 있다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 553,
        "window_size": 3,
        "char_count": 724,
        "word_count": 137,
        "page_number": 34,
        "window_text": "<!-- PAGE_31 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_31 -->\n###### 보기 위해 사용기간(유효기간) 동안 의료기기의 특성이나 성능이\n\n<!-- PAGE_31 -->\n###### (4) 시험 조건\n\n<!-- PAGE_31 -->\n###### - 시험물질\n\n<!-- PAGE_31 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_31 -->\n###### 검체를 사용한다.\n\n - - 25 -\n<!-- PAGE_32 -->\n###### - 시험장비\n\n<!-- PAGE_32 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우 2개\n\n<!-- PAGE_32 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_32 -->\n###### 개봉시점 및 각 포인트 별 샘플의 이동거리값의 평균 및 표준편차를 계산\n\n- - 26 -\n<!-- PAGE_33 -->\n###### 8.  참고 문헌\n\n- 다. IEC 61010-1 Safety requirements for electrical equipment for measurement,\n- 라.\nIEC\n\n61010-2-101\n\nSafety\n\nrequirements\n\nfor\n\nelectrical\n\nequipment\n\nfor\n\nmeasurement,\n\ncontrol\n\nand\n\nlaboratory\n\nuse\n\n–\n\nPart\n\n2-101:\n\nParticular\n\n- 바. IEC 61326-2-6 Electrical equipment for measurement, control and laboratory\n- 자. CLSI EP12-A2; User Protocol for Evaluation of Qualitative Test Performance;\n- 차.\nCLSI\n\nEP06-A:\n\nEvaluation\n\nof\n\nthe\n\nLinearity\n\nof\n\nQuantitative\n\nMeasurement\n\n- 카. CLSI EP07: Interference Testing in Clinical Chemistry Approved Guideline\n- 타. CLSI EP05-A3: Evaluation of Precision of Quantitative Measurement Methods;\n- 파.\nPlatelet\n\nAggregation\n\nDevices\n\nMarket\n\nby\n\nProduct\n\n(Systems,\n\nReagents,\n\nConsumables,\n\nAccessories),\n\nApplication\n\n(Research,\n\nDiagnostic,\n\nCVD,\n\nOrthopedic,\n\nTrauma),\n\nEnd\n\nUser\n\n(Hospitals,\n\nDiagnostic\n\nLaboratories,\n\nAcademia,\n\nBlood\n\nBanks)\n\n- -\nGlobal\n\nForecasts\n\nto\n\n- 2020.\nmarketsandmarkets.com.  August 2015\n\n- - 27 -\n<!-- PAGE_34 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_34 -->\n###### (1) 출혈시간 및 항혈소판제제 저항성 복합검사기기의 국내 개발 현황\n\n<!-- PAGE_34 -->\n###### 사용되어 온 Duke법, Ivy법, Template법 등을 이용하여 혈소판\n\n<!-- PAGE_34 -->\n###### 커서 표준화가 어렵고 임상적 유용성이 적어서 객관적인 데이터로\n\n<!-- PAGE_34 -->\n###### ③ 출혈시간 및 항혈소판제제 저항성 복합검사기기는 주로 수입 의료\n\n<!-- PAGE_34 -->\n###### (나) 국내의 혈소판 기능검사의 시장도 매년 성장하고 있으며 주로\n\n<!-- PAGE_34 -->\n###### (다) 혈소판 기능검사는 신의료기술로 인정되어 비급여항목으로 각 검사당\n\n<!-- PAGE_34 -->\n###### 약 4만원에서 8만원 정도의 검사비가 청구되고 있어 국내 기술을\n\n<!-- PAGE_34 -->\n###### (라) 2016년 9월 현재 급여항목으로 변경된 EPI(Epinephrine, 에피네프린)\n\n<!-- PAGE_34 -->\n###### 테스트 및\n\n<!-- PAGE_34 -->\n###### ADP(에이디피)의 경우\n\n<!-- PAGE_34 -->\n###### 본인부담금으로 9,000원이\n\n<!-- PAGE_34 -->\n###### 청구되고 있다.\n\n - - 28 -\n<!-- PAGE_35 -->\n##### Ⅱ\n\n<!-- PAGE_35 -->\n##### 임상시험계획서 작성 및 평가\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n확증임상시험\n\n- (1) 대상질환 : 선천적 · 후천적 혈소판기능장애 환자 :　본 빌레브란트병(von\nWillebrand disease), 글란즈만 혈소판무력증(Glanzmann's thrombasthenia),\n\n- (2) 해당 의료기기의 사용목적：혈소판 기능부전 검출\n- - 구연산 처리된 전혈에서 폐색 전 혈액이동거리를 측정하여 혈소판 기능부전을\n검출하는 체외진단용 의료기기\n\n- - 29 -\n- (3) 해당 의료기기 : 혈액응고검사시약과 자동혈소판응집측정장치\n- (4) 임상시험 평가내용 : 민감도 및 특이도, 일치도\n- (5) 임상시험 디자인 : 다기관, 비무작위배정, 단일눈가림, 단일설계, 전향적 임상시험\nAspirin 또는 P2Y12 수용제 저해제(clopidogrel) 복용중인 환자의 구연산 처리된\n\n전혈에서 혈소판 약물반응을 확인하기 위해 사용되는 ‘출혈 시간 및 항혈소판제제\n\n저항성 복합검사기기-혈소판 약물반응검사’의 임상적 성능평가를 위하여 aspirin\n\n또는 P2Y12 수용제 저해제(clopidogrel) 복용 전·후에 대한 민감도와 특이도를\n\n기허가제품의 민감도 및 특이도와 비교 평가하기 위한 다기관, 비무작위배정, 단일\n\n- (1) 대상질환 : 혈관질환의 병력, 혈관질환의 위험군 등으로 aspirin 또는 P2Y12\n- (5) 임상시험 디자인 : 다기관, 비무작위배정, 단일눈가림, 단일설계, 전향적 임상시험\n- - 30 -\n<!-- PAGE_37 -->\n###### 2.  임상시험기관의 명칭 및 소재지\n\n- - 31 -\n<!-- PAGE_38 -->\n###### 3.  임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n△△△\n\n△△△병원\n\n△△△△\n\n△△△\n\n△△-△△△-△△△△\n\n□□□\n\n□□□병원\n\n□□□□\n\n□□□\n\n□□-□□□-□□□□\n\n- 다. ",
        "original_sentence": "August 2015\n\n- - 27 -\n<!-- PAGE_34 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_34 -->\n###### (1) 출혈시간 및 항혈소판제제 저항성 복합검사기기의 국내 개발 현황\n\n<!-- PAGE_34 -->\n###### 사용되어 온 Duke법, Ivy법, Template법 등을 이용하여 혈소판\n\n<!-- PAGE_34 -->\n###### 커서 표준화가 어렵고 임상적 유용성이 적어서 객관적인 데이터로\n\n<!-- PAGE_34 -->\n###### ③ 출혈시간 및 항혈소판제제 저항성 복합검사기기는 주로 수입 의료\n\n<!-- PAGE_34 -->\n###### (나) 국내의 혈소판 기능검사의 시장도 매년 성장하고 있으며 주로\n\n<!-- PAGE_34 -->\n###### (다) 혈소판 기능검사는 신의료기술로 인정되어 비급여항목으로 각 검사당\n\n<!-- PAGE_34 -->\n###### 약 4만원에서 8만원 정도의 검사비가 청구되고 있어 국내 기술을\n\n<!-- PAGE_34 -->\n###### (라) 2016년 9월 현재 급여항목으로 변경된 EPI(Epinephrine, 에피네프린)\n\n<!-- PAGE_34 -->\n###### 테스트 및\n\n<!-- PAGE_34 -->\n###### ADP(에이디피)의 경우\n\n<!-- PAGE_34 -->\n###### 본인부담금으로 9,000원이\n\n<!-- PAGE_34 -->\n###### 청구되고 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_555",
      "text": "- - 28 -\n<!-- PAGE_35 -->\n##### Ⅱ\n\n<!-- PAGE_35 -->\n##### 임상시험계획서 작성 및 평가\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n확증임상시험\n\n- (1) 대상질환 : 선천적 · 후천적 혈소판기능장애 환자 :　본 빌레브란트병(von\nWillebrand disease), 글란즈만 혈소판무력증(Glanzmann's thrombasthenia),\n\n- (2) 해당 의료기기의 사용목적：혈소판 기능부전 검출\n- - 구연산 처리된 전혈에서 폐색 전 혈액이동거리를 측정하여 혈소판 기능부전을\n검출하는 체외진단용 의료기기\n\n- - 29 -\n- (3) 해당 의료기기 : 혈액응고검사시약과 자동혈소판응집측정장치\n- (4) 임상시험 평가내용 : 민감도 및 특이도, 일치도\n- (5) 임상시험 디자인 : 다기관, 비무작위배정, 단일눈가림, 단일설계, 전향적 임상시험\nAspirin 또는 P2Y12 수용제 저해제(clopidogrel) 복용중인 환자의 구연산 처리된\n\n전혈에서 혈소판 약물반응을 확인하기 위해 사용되는 ‘출혈 시간 및 항혈소판제제\n\n저항성 복합검사기기-혈소판 약물반응검사’의 임상적 성능평가를 위하여 aspirin\n\n또는 P2Y12 수용제 저해제(clopidogrel) 복용 전·후에 대한 민감도와 특이도를\n\n기허가제품의 민감도 및 특이도와 비교 평가하기 위한 다기관, 비무작위배정, 단일\n\n- (1) 대상질환 : 혈관질환의 병력, 혈관질환의 위험군 등으로 aspirin 또는 P2Y12\n- (5) 임상시험 디자인 : 다기관, 비무작위배정, 단일눈가림, 단일설계, 전향적 임상시험\n- - 30 -\n<!-- PAGE_37 -->\n###### 2. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 554,
        "window_size": 3,
        "char_count": 861,
        "word_count": 178,
        "page_number": 35,
        "window_text": "- - 25 -\n<!-- PAGE_32 -->\n###### - 시험장비\n\n<!-- PAGE_32 -->\n###### 혈소판 기능검사키트: 3개 로트(2개 로트 이상 생산이 어려운 경우 2개\n\n<!-- PAGE_32 -->\n###### 3.2% 구연산나트륨 완충액을 함유한 진공 튜브에 채취한 사람의 전혈\n\n<!-- PAGE_32 -->\n###### 개봉시점 및 각 포인트 별 샘플의 이동거리값의 평균 및 표준편차를 계산\n\n- - 26 -\n<!-- PAGE_33 -->\n###### 8.  참고 문헌\n\n- 다. IEC 61010-1 Safety requirements for electrical equipment for measurement,\n- 라.\nIEC\n\n61010-2-101\n\nSafety\n\nrequirements\n\nfor\n\nelectrical\n\nequipment\n\nfor\n\nmeasurement,\n\ncontrol\n\nand\n\nlaboratory\n\nuse\n\n–\n\nPart\n\n2-101:\n\nParticular\n\n- 바. IEC 61326-2-6 Electrical equipment for measurement, control and laboratory\n- 자. CLSI EP12-A2; User Protocol for Evaluation of Qualitative Test Performance;\n- 차.\nCLSI\n\nEP06-A:\n\nEvaluation\n\nof\n\nthe\n\nLinearity\n\nof\n\nQuantitative\n\nMeasurement\n\n- 카. CLSI EP07: Interference Testing in Clinical Chemistry Approved Guideline\n- 타. CLSI EP05-A3: Evaluation of Precision of Quantitative Measurement Methods;\n- 파.\nPlatelet\n\nAggregation\n\nDevices\n\nMarket\n\nby\n\nProduct\n\n(Systems,\n\nReagents,\n\nConsumables,\n\nAccessories),\n\nApplication\n\n(Research,\n\nDiagnostic,\n\nCVD,\n\nOrthopedic,\n\nTrauma),\n\nEnd\n\nUser\n\n(Hospitals,\n\nDiagnostic\n\nLaboratories,\n\nAcademia,\n\nBlood\n\nBanks)\n\n- -\nGlobal\n\nForecasts\n\nto\n\n- 2020.\nmarketsandmarkets.com.  August 2015\n\n- - 27 -\n<!-- PAGE_34 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_34 -->\n###### (1) 출혈시간 및 항혈소판제제 저항성 복합검사기기의 국내 개발 현황\n\n<!-- PAGE_34 -->\n###### 사용되어 온 Duke법, Ivy법, Template법 등을 이용하여 혈소판\n\n<!-- PAGE_34 -->\n###### 커서 표준화가 어렵고 임상적 유용성이 적어서 객관적인 데이터로\n\n<!-- PAGE_34 -->\n###### ③ 출혈시간 및 항혈소판제제 저항성 복합검사기기는 주로 수입 의료\n\n<!-- PAGE_34 -->\n###### (나) 국내의 혈소판 기능검사의 시장도 매년 성장하고 있으며 주로\n\n<!-- PAGE_34 -->\n###### (다) 혈소판 기능검사는 신의료기술로 인정되어 비급여항목으로 각 검사당\n\n<!-- PAGE_34 -->\n###### 약 4만원에서 8만원 정도의 검사비가 청구되고 있어 국내 기술을\n\n<!-- PAGE_34 -->\n###### (라) 2016년 9월 현재 급여항목으로 변경된 EPI(Epinephrine, 에피네프린)\n\n<!-- PAGE_34 -->\n###### 테스트 및\n\n<!-- PAGE_34 -->\n###### ADP(에이디피)의 경우\n\n<!-- PAGE_34 -->\n###### 본인부담금으로 9,000원이\n\n<!-- PAGE_34 -->\n###### 청구되고 있다.\n\n - - 28 -\n<!-- PAGE_35 -->\n##### Ⅱ\n\n<!-- PAGE_35 -->\n##### 임상시험계획서 작성 및 평가\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n확증임상시험\n\n- (1) 대상질환 : 선천적 · 후천적 혈소판기능장애 환자 :　본 빌레브란트병(von\nWillebrand disease), 글란즈만 혈소판무력증(Glanzmann's thrombasthenia),\n\n- (2) 해당 의료기기의 사용목적：혈소판 기능부전 검출\n- - 구연산 처리된 전혈에서 폐색 전 혈액이동거리를 측정하여 혈소판 기능부전을\n검출하는 체외진단용 의료기기\n\n- - 29 -\n- (3) 해당 의료기기 : 혈액응고검사시약과 자동혈소판응집측정장치\n- (4) 임상시험 평가내용 : 민감도 및 특이도, 일치도\n- (5) 임상시험 디자인 : 다기관, 비무작위배정, 단일눈가림, 단일설계, 전향적 임상시험\nAspirin 또는 P2Y12 수용제 저해제(clopidogrel) 복용중인 환자의 구연산 처리된\n\n전혈에서 혈소판 약물반응을 확인하기 위해 사용되는 ‘출혈 시간 및 항혈소판제제\n\n저항성 복합검사기기-혈소판 약물반응검사’의 임상적 성능평가를 위하여 aspirin\n\n또는 P2Y12 수용제 저해제(clopidogrel) 복용 전·후에 대한 민감도와 특이도를\n\n기허가제품의 민감도 및 특이도와 비교 평가하기 위한 다기관, 비무작위배정, 단일\n\n- (1) 대상질환 : 혈관질환의 병력, 혈관질환의 위험군 등으로 aspirin 또는 P2Y12\n- (5) 임상시험 디자인 : 다기관, 비무작위배정, 단일눈가림, 단일설계, 전향적 임상시험\n- - 30 -\n<!-- PAGE_37 -->\n###### 2.  임상시험기관의 명칭 및 소재지\n\n- - 31 -\n<!-- PAGE_38 -->\n###### 3.  임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n△△△\n\n△△△병원\n\n△△△△\n\n△△△\n\n△△-△△△-△△△△\n\n□□□\n\n□□□병원\n\n□□□□\n\n□□□\n\n□□-□□□-□□□□\n\n- 다.  공동연구자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n- - 32 -\n<!-- PAGE_39 -->\n###### 4. ",
        "original_sentence": "- - 28 -\n<!-- PAGE_35 -->\n##### Ⅱ\n\n<!-- PAGE_35 -->\n##### 임상시험계획서 작성 및 평가\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n확증임상시험\n\n- (1) 대상질환 : 선천적 · 후천적 혈소판기능장애 환자 :　본 빌레브란트병(von\nWillebrand disease), 글란즈만 혈소판무력증(Glanzmann's thrombasthenia),\n\n- (2) 해당 의료기기의 사용목적：혈소판 기능부전 검출\n- - 구연산 처리된 전혈에서 폐색 전 혈액이동거리를 측정하여 혈소판 기능부전을\n검출하는 체외진단용 의료기기\n\n- - 29 -\n- (3) 해당 의료기기 : 혈액응고검사시약과 자동혈소판응집측정장치\n- (4) 임상시험 평가내용 : 민감도 및 특이도, 일치도\n- (5) 임상시험 디자인 : 다기관, 비무작위배정, 단일눈가림, 단일설계, 전향적 임상시험\nAspirin 또는 P2Y12 수용제 저해제(clopidogrel) 복용중인 환자의 구연산 처리된\n\n전혈에서 혈소판 약물반응을 확인하기 위해 사용되는 ‘출혈 시간 및 항혈소판제제\n\n저항성 복합검사기기-혈소판 약물반응검사’의 임상적 성능평가를 위하여 aspirin\n\n또는 P2Y12 수용제 저해제(clopidogrel) 복용 전·후에 대한 민감도와 특이도를\n\n기허가제품의 민감도 및 특이도와 비교 평가하기 위한 다기관, 비무작위배정, 단일\n\n- (1) 대상질환 : 혈관질환의 병력, 혈관질환의 위험군 등으로 aspirin 또는 P2Y12\n- (5) 임상시험 디자인 : 다기관, 비무작위배정, 단일눈가림, 단일설계, 전향적 임상시험\n- - 30 -\n<!-- PAGE_37 -->\n###### 2. "
      }
    },
    {
      "chunk_id": "chunk_556",
      "text": "임상시험기관의 명칭 및 소재지\n\n- - 31 -\n<!-- PAGE_38 -->\n###### 3. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 555,
        "window_size": 3,
        "char_count": 54,
        "word_count": 13,
        "page_number": 38,
        "window_text": "참고 문헌\n\n- 다. IEC 61010-1 Safety requirements for electrical equipment for measurement,\n- 라.\nIEC\n\n61010-2-101\n\nSafety\n\nrequirements\n\nfor\n\nelectrical\n\nequipment\n\nfor\n\nmeasurement,\n\ncontrol\n\nand\n\nlaboratory\n\nuse\n\n–\n\nPart\n\n2-101:\n\nParticular\n\n- 바. IEC 61326-2-6 Electrical equipment for measurement, control and laboratory\n- 자. CLSI EP12-A2; User Protocol for Evaluation of Qualitative Test Performance;\n- 차.\nCLSI\n\nEP06-A:\n\nEvaluation\n\nof\n\nthe\n\nLinearity\n\nof\n\nQuantitative\n\nMeasurement\n\n- 카. CLSI EP07: Interference Testing in Clinical Chemistry Approved Guideline\n- 타. CLSI EP05-A3: Evaluation of Precision of Quantitative Measurement Methods;\n- 파.\nPlatelet\n\nAggregation\n\nDevices\n\nMarket\n\nby\n\nProduct\n\n(Systems,\n\nReagents,\n\nConsumables,\n\nAccessories),\n\nApplication\n\n(Research,\n\nDiagnostic,\n\nCVD,\n\nOrthopedic,\n\nTrauma),\n\nEnd\n\nUser\n\n(Hospitals,\n\nDiagnostic\n\nLaboratories,\n\nAcademia,\n\nBlood\n\nBanks)\n\n- -\nGlobal\n\nForecasts\n\nto\n\n- 2020.\nmarketsandmarkets.com.  August 2015\n\n- - 27 -\n<!-- PAGE_34 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_34 -->\n###### (1) 출혈시간 및 항혈소판제제 저항성 복합검사기기의 국내 개발 현황\n\n<!-- PAGE_34 -->\n###### 사용되어 온 Duke법, Ivy법, Template법 등을 이용하여 혈소판\n\n<!-- PAGE_34 -->\n###### 커서 표준화가 어렵고 임상적 유용성이 적어서 객관적인 데이터로\n\n<!-- PAGE_34 -->\n###### ③ 출혈시간 및 항혈소판제제 저항성 복합검사기기는 주로 수입 의료\n\n<!-- PAGE_34 -->\n###### (나) 국내의 혈소판 기능검사의 시장도 매년 성장하고 있으며 주로\n\n<!-- PAGE_34 -->\n###### (다) 혈소판 기능검사는 신의료기술로 인정되어 비급여항목으로 각 검사당\n\n<!-- PAGE_34 -->\n###### 약 4만원에서 8만원 정도의 검사비가 청구되고 있어 국내 기술을\n\n<!-- PAGE_34 -->\n###### (라) 2016년 9월 현재 급여항목으로 변경된 EPI(Epinephrine, 에피네프린)\n\n<!-- PAGE_34 -->\n###### 테스트 및\n\n<!-- PAGE_34 -->\n###### ADP(에이디피)의 경우\n\n<!-- PAGE_34 -->\n###### 본인부담금으로 9,000원이\n\n<!-- PAGE_34 -->\n###### 청구되고 있다.\n\n - - 28 -\n<!-- PAGE_35 -->\n##### Ⅱ\n\n<!-- PAGE_35 -->\n##### 임상시험계획서 작성 및 평가\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n확증임상시험\n\n- (1) 대상질환 : 선천적 · 후천적 혈소판기능장애 환자 :　본 빌레브란트병(von\nWillebrand disease), 글란즈만 혈소판무력증(Glanzmann's thrombasthenia),\n\n- (2) 해당 의료기기의 사용목적：혈소판 기능부전 검출\n- - 구연산 처리된 전혈에서 폐색 전 혈액이동거리를 측정하여 혈소판 기능부전을\n검출하는 체외진단용 의료기기\n\n- - 29 -\n- (3) 해당 의료기기 : 혈액응고검사시약과 자동혈소판응집측정장치\n- (4) 임상시험 평가내용 : 민감도 및 특이도, 일치도\n- (5) 임상시험 디자인 : 다기관, 비무작위배정, 단일눈가림, 단일설계, 전향적 임상시험\nAspirin 또는 P2Y12 수용제 저해제(clopidogrel) 복용중인 환자의 구연산 처리된\n\n전혈에서 혈소판 약물반응을 확인하기 위해 사용되는 ‘출혈 시간 및 항혈소판제제\n\n저항성 복합검사기기-혈소판 약물반응검사’의 임상적 성능평가를 위하여 aspirin\n\n또는 P2Y12 수용제 저해제(clopidogrel) 복용 전·후에 대한 민감도와 특이도를\n\n기허가제품의 민감도 및 특이도와 비교 평가하기 위한 다기관, 비무작위배정, 단일\n\n- (1) 대상질환 : 혈관질환의 병력, 혈관질환의 위험군 등으로 aspirin 또는 P2Y12\n- (5) 임상시험 디자인 : 다기관, 비무작위배정, 단일눈가림, 단일설계, 전향적 임상시험\n- - 30 -\n<!-- PAGE_37 -->\n###### 2.  임상시험기관의 명칭 및 소재지\n\n- - 31 -\n<!-- PAGE_38 -->\n###### 3.  임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n△△△\n\n△△△병원\n\n△△△△\n\n△△△\n\n△△-△△△-△△△△\n\n□□□\n\n□□□병원\n\n□□□□\n\n□□□\n\n□□-□□□-□□□□\n\n- 다.  공동연구자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n- - 32 -\n<!-- PAGE_39 -->\n###### 4.  임상시험용 의료기기관리자의 성명 및 직명\n\n- - 33 -\n<!-- PAGE_40 -->\n###### 5. ",
        "original_sentence": "임상시험기관의 명칭 및 소재지\n\n- - 31 -\n<!-- PAGE_38 -->\n###### 3. "
      }
    },
    {
      "chunk_id": "chunk_557",
      "text": "임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n△△△\n\n△△△병원\n\n△△△△\n\n△△△\n\n△△-△△△-△△△△\n\n□□□\n\n□□□병원\n\n□□□□\n\n□□□\n\n□□-□□□-□□□□\n\n- 다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 556,
        "window_size": 3,
        "char_count": 173,
        "word_count": 35,
        "page_number": 3,
        "window_text": "August 2015\n\n- - 27 -\n<!-- PAGE_34 -->\n###### [별첨] 국내·외 연구동향\n\n<!-- PAGE_34 -->\n###### (1) 출혈시간 및 항혈소판제제 저항성 복합검사기기의 국내 개발 현황\n\n<!-- PAGE_34 -->\n###### 사용되어 온 Duke법, Ivy법, Template법 등을 이용하여 혈소판\n\n<!-- PAGE_34 -->\n###### 커서 표준화가 어렵고 임상적 유용성이 적어서 객관적인 데이터로\n\n<!-- PAGE_34 -->\n###### ③ 출혈시간 및 항혈소판제제 저항성 복합검사기기는 주로 수입 의료\n\n<!-- PAGE_34 -->\n###### (나) 국내의 혈소판 기능검사의 시장도 매년 성장하고 있으며 주로\n\n<!-- PAGE_34 -->\n###### (다) 혈소판 기능검사는 신의료기술로 인정되어 비급여항목으로 각 검사당\n\n<!-- PAGE_34 -->\n###### 약 4만원에서 8만원 정도의 검사비가 청구되고 있어 국내 기술을\n\n<!-- PAGE_34 -->\n###### (라) 2016년 9월 현재 급여항목으로 변경된 EPI(Epinephrine, 에피네프린)\n\n<!-- PAGE_34 -->\n###### 테스트 및\n\n<!-- PAGE_34 -->\n###### ADP(에이디피)의 경우\n\n<!-- PAGE_34 -->\n###### 본인부담금으로 9,000원이\n\n<!-- PAGE_34 -->\n###### 청구되고 있다.\n\n - - 28 -\n<!-- PAGE_35 -->\n##### Ⅱ\n\n<!-- PAGE_35 -->\n##### 임상시험계획서 작성 및 평가\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n확증임상시험\n\n- (1) 대상질환 : 선천적 · 후천적 혈소판기능장애 환자 :　본 빌레브란트병(von\nWillebrand disease), 글란즈만 혈소판무력증(Glanzmann's thrombasthenia),\n\n- (2) 해당 의료기기의 사용목적：혈소판 기능부전 검출\n- - 구연산 처리된 전혈에서 폐색 전 혈액이동거리를 측정하여 혈소판 기능부전을\n검출하는 체외진단용 의료기기\n\n- - 29 -\n- (3) 해당 의료기기 : 혈액응고검사시약과 자동혈소판응집측정장치\n- (4) 임상시험 평가내용 : 민감도 및 특이도, 일치도\n- (5) 임상시험 디자인 : 다기관, 비무작위배정, 단일눈가림, 단일설계, 전향적 임상시험\nAspirin 또는 P2Y12 수용제 저해제(clopidogrel) 복용중인 환자의 구연산 처리된\n\n전혈에서 혈소판 약물반응을 확인하기 위해 사용되는 ‘출혈 시간 및 항혈소판제제\n\n저항성 복합검사기기-혈소판 약물반응검사’의 임상적 성능평가를 위하여 aspirin\n\n또는 P2Y12 수용제 저해제(clopidogrel) 복용 전·후에 대한 민감도와 특이도를\n\n기허가제품의 민감도 및 특이도와 비교 평가하기 위한 다기관, 비무작위배정, 단일\n\n- (1) 대상질환 : 혈관질환의 병력, 혈관질환의 위험군 등으로 aspirin 또는 P2Y12\n- (5) 임상시험 디자인 : 다기관, 비무작위배정, 단일눈가림, 단일설계, 전향적 임상시험\n- - 30 -\n<!-- PAGE_37 -->\n###### 2.  임상시험기관의 명칭 및 소재지\n\n- - 31 -\n<!-- PAGE_38 -->\n###### 3.  임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n△△△\n\n△△△병원\n\n△△△△\n\n△△△\n\n△△-△△△-△△△△\n\n□□□\n\n□□□병원\n\n□□□□\n\n□□□\n\n□□-□□□-□□□□\n\n- 다.  공동연구자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n- - 32 -\n<!-- PAGE_39 -->\n###### 4.  임상시험용 의료기기관리자의 성명 및 직명\n\n- - 33 -\n<!-- PAGE_40 -->\n###### 5.  임상시험 의뢰자의 성명 및 주소\n\n※ 임상시험 수탁기관(CRO: Contact Reserach Organization)이 있는 경우 해당\n\n- - 34 -\n<!-- PAGE_41 -->\n###### 6. ",
        "original_sentence": "임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n△△△\n\n△△△병원\n\n△△△△\n\n△△△\n\n△△-△△△-△△△△\n\n□□□\n\n□□□병원\n\n□□□□\n\n□□□\n\n□□-□□□-□□□□\n\n- 다. "
      }
    },
    {
      "chunk_id": "chunk_558",
      "text": "공동연구자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n- - 32 -\n<!-- PAGE_39 -->\n###### 4. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 557,
        "window_size": 3,
        "char_count": 107,
        "word_count": 26,
        "page_number": 39,
        "window_text": "- - 28 -\n<!-- PAGE_35 -->\n##### Ⅱ\n\n<!-- PAGE_35 -->\n##### 임상시험계획서 작성 및 평가\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n확증임상시험\n\n- (1) 대상질환 : 선천적 · 후천적 혈소판기능장애 환자 :　본 빌레브란트병(von\nWillebrand disease), 글란즈만 혈소판무력증(Glanzmann's thrombasthenia),\n\n- (2) 해당 의료기기의 사용목적：혈소판 기능부전 검출\n- - 구연산 처리된 전혈에서 폐색 전 혈액이동거리를 측정하여 혈소판 기능부전을\n검출하는 체외진단용 의료기기\n\n- - 29 -\n- (3) 해당 의료기기 : 혈액응고검사시약과 자동혈소판응집측정장치\n- (4) 임상시험 평가내용 : 민감도 및 특이도, 일치도\n- (5) 임상시험 디자인 : 다기관, 비무작위배정, 단일눈가림, 단일설계, 전향적 임상시험\nAspirin 또는 P2Y12 수용제 저해제(clopidogrel) 복용중인 환자의 구연산 처리된\n\n전혈에서 혈소판 약물반응을 확인하기 위해 사용되는 ‘출혈 시간 및 항혈소판제제\n\n저항성 복합검사기기-혈소판 약물반응검사’의 임상적 성능평가를 위하여 aspirin\n\n또는 P2Y12 수용제 저해제(clopidogrel) 복용 전·후에 대한 민감도와 특이도를\n\n기허가제품의 민감도 및 특이도와 비교 평가하기 위한 다기관, 비무작위배정, 단일\n\n- (1) 대상질환 : 혈관질환의 병력, 혈관질환의 위험군 등으로 aspirin 또는 P2Y12\n- (5) 임상시험 디자인 : 다기관, 비무작위배정, 단일눈가림, 단일설계, 전향적 임상시험\n- - 30 -\n<!-- PAGE_37 -->\n###### 2.  임상시험기관의 명칭 및 소재지\n\n- - 31 -\n<!-- PAGE_38 -->\n###### 3.  임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n△△△\n\n△△△병원\n\n△△△△\n\n△△△\n\n△△-△△△-△△△△\n\n□□□\n\n□□□병원\n\n□□□□\n\n□□□\n\n□□-□□□-□□□□\n\n- 다.  공동연구자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n- - 32 -\n<!-- PAGE_39 -->\n###### 4.  임상시험용 의료기기관리자의 성명 및 직명\n\n- - 33 -\n<!-- PAGE_40 -->\n###### 5.  임상시험 의뢰자의 성명 및 주소\n\n※ 임상시험 수탁기관(CRO: Contact Reserach Organization)이 있는 경우 해당\n\n- - 34 -\n<!-- PAGE_41 -->\n###### 6.  임상시험의 목적 및 배경\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- (2) 혈소판 약물반응검사\n본 임상시험은 aspirin 또는 P2Y12 수용체 저해제 복용예정 환자에서 시험기기의\n\n약물 복용 전후에 대한 민감도와 특이도를 기허가제품의 민감도 및 특이도와\n\n비교하여 임상적 유효성을 검증하는 것이 목적이다.\n\n",
        "original_sentence": "공동연구자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n- - 32 -\n<!-- PAGE_39 -->\n###### 4. "
      }
    },
    {
      "chunk_id": "chunk_559",
      "text": "임상시험용 의료기기관리자의 성명 및 직명\n\n- - 33 -\n<!-- PAGE_40 -->\n###### 5. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 558,
        "window_size": 3,
        "char_count": 60,
        "word_count": 14,
        "page_number": 40,
        "window_text": "임상시험기관의 명칭 및 소재지\n\n- - 31 -\n<!-- PAGE_38 -->\n###### 3.  임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n△△△\n\n△△△병원\n\n△△△△\n\n△△△\n\n△△-△△△-△△△△\n\n□□□\n\n□□□병원\n\n□□□□\n\n□□□\n\n□□-□□□-□□□□\n\n- 다.  공동연구자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n- - 32 -\n<!-- PAGE_39 -->\n###### 4.  임상시험용 의료기기관리자의 성명 및 직명\n\n- - 33 -\n<!-- PAGE_40 -->\n###### 5.  임상시험 의뢰자의 성명 및 주소\n\n※ 임상시험 수탁기관(CRO: Contact Reserach Organization)이 있는 경우 해당\n\n- - 34 -\n<!-- PAGE_41 -->\n###### 6.  임상시험의 목적 및 배경\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- (2) 혈소판 약물반응검사\n본 임상시험은 aspirin 또는 P2Y12 수용체 저해제 복용예정 환자에서 시험기기의\n\n약물 복용 전후에 대한 민감도와 특이도를 기허가제품의 민감도 및 특이도와\n\n비교하여 임상적 유효성을 검증하는 것이 목적이다.\n\n - - 35 -\n- 6.2. ",
        "original_sentence": "임상시험용 의료기기관리자의 성명 및 직명\n\n- - 33 -\n<!-- PAGE_40 -->\n###### 5. "
      }
    },
    {
      "chunk_id": "chunk_560",
      "text": "임상시험 의뢰자의 성명 및 주소\n\n※ 임상시험 수탁기관(CRO: Contact Reserach Organization)이 있는 경우 해당\n\n- - 34 -\n<!-- PAGE_41 -->\n###### 6. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 559,
        "window_size": 3,
        "char_count": 114,
        "word_count": 23,
        "page_number": 41,
        "window_text": "임상시험 책임자·담당자 및 공동연구자의 성명 및 직명\n\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n△△△\n\n△△△병원\n\n△△△△\n\n△△△\n\n△△-△△△-△△△△\n\n□□□\n\n□□□병원\n\n□□□□\n\n□□□\n\n□□-□□□-□□□□\n\n- 다.  공동연구자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n- - 32 -\n<!-- PAGE_39 -->\n###### 4.  임상시험용 의료기기관리자의 성명 및 직명\n\n- - 33 -\n<!-- PAGE_40 -->\n###### 5.  임상시험 의뢰자의 성명 및 주소\n\n※ 임상시험 수탁기관(CRO: Contact Reserach Organization)이 있는 경우 해당\n\n- - 34 -\n<!-- PAGE_41 -->\n###### 6.  임상시험의 목적 및 배경\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- (2) 혈소판 약물반응검사\n본 임상시험은 aspirin 또는 P2Y12 수용체 저해제 복용예정 환자에서 시험기기의\n\n약물 복용 전후에 대한 민감도와 특이도를 기허가제품의 민감도 및 특이도와\n\n비교하여 임상적 유효성을 검증하는 것이 목적이다.\n\n - - 35 -\n- 6.2.  배경\n혈소판은 1차 지혈에서 중요한 역할을 하는 인자로, 혈관손상이 일어났을 때 부착,\n\n응집, 활성화 및 분비, 응고촉진 작용을 통해 지혈마개를 형성하며, 혈소판 기능에\n\n관한 검사는 주로 선천성 혈소판 기능 이상이나 수술전 선별검사로 많이 사용되고\n\n있다. ",
        "original_sentence": "임상시험 의뢰자의 성명 및 주소\n\n※ 임상시험 수탁기관(CRO: Contact Reserach Organization)이 있는 경우 해당\n\n- - 34 -\n<!-- PAGE_41 -->\n###### 6. "
      }
    },
    {
      "chunk_id": "chunk_561",
      "text": "임상시험의 목적 및 배경\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- (2) 혈소판 약물반응검사\n본 임상시험은 aspirin 또는 P2Y12 수용체 저해제 복용예정 환자에서 시험기기의\n\n약물 복용 전후에 대한 민감도와 특이도를 기허가제품의 민감도 및 특이도와\n\n비교하여 임상적 유효성을 검증하는 것이 목적이다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 560,
        "window_size": 3,
        "char_count": 205,
        "word_count": 48,
        "page_number": 6,
        "window_text": "공동연구자\n성명\n\n소속 기관명\n\n전공\n\n직위\n\n전화\n\n- ○○○\n- ○○○병원\n- ○○○○\n- ○○○\n- ○○-○○○-○○○○\n- - 32 -\n<!-- PAGE_39 -->\n###### 4.  임상시험용 의료기기관리자의 성명 및 직명\n\n- - 33 -\n<!-- PAGE_40 -->\n###### 5.  임상시험 의뢰자의 성명 및 주소\n\n※ 임상시험 수탁기관(CRO: Contact Reserach Organization)이 있는 경우 해당\n\n- - 34 -\n<!-- PAGE_41 -->\n###### 6.  임상시험의 목적 및 배경\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- (2) 혈소판 약물반응검사\n본 임상시험은 aspirin 또는 P2Y12 수용체 저해제 복용예정 환자에서 시험기기의\n\n약물 복용 전후에 대한 민감도와 특이도를 기허가제품의 민감도 및 특이도와\n\n비교하여 임상적 유효성을 검증하는 것이 목적이다.\n\n - - 35 -\n- 6.2.  배경\n혈소판은 1차 지혈에서 중요한 역할을 하는 인자로, 혈관손상이 일어났을 때 부착,\n\n응집, 활성화 및 분비, 응고촉진 작용을 통해 지혈마개를 형성하며, 혈소판 기능에\n\n관한 검사는 주로 선천성 혈소판 기능 이상이나 수술전 선별검사로 많이 사용되고\n\n있다.  특히 혈소판의 수적 이상이 없는 출혈질환에서 선천성 혹은 후천성 혈소판\n\n사용되는 아스피린, P2Y12 수용체 저해제 등의 항혈소판약제로 인한 출혈성\n\n검사방법이나 해석의 표준화가 미흡하거나 해석이 어려워 실제 임상에서 널리\n\n응집에 관여하는 ADP, collagen, epinephrine 등의 작용제(agonist)를 넣고 작용제에\n\n따른 혈소판의 응집정도를 관찰하는 것으로, 각 작용제의 기전에 따라 혈소판의\n\n응집정도를 보고 기능이상 여부를 측정할 수 있다. ",
        "original_sentence": "임상시험의 목적 및 배경\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- (2) 혈소판 약물반응검사\n본 임상시험은 aspirin 또는 P2Y12 수용체 저해제 복용예정 환자에서 시험기기의\n\n약물 복용 전후에 대한 민감도와 특이도를 기허가제품의 민감도 및 특이도와\n\n비교하여 임상적 유효성을 검증하는 것이 목적이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_562",
      "text": "- - 35 -\n- 6.2. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 561,
        "window_size": 3,
        "char_count": 16,
        "word_count": 6,
        "page_number": 6,
        "window_text": "임상시험용 의료기기관리자의 성명 및 직명\n\n- - 33 -\n<!-- PAGE_40 -->\n###### 5.  임상시험 의뢰자의 성명 및 주소\n\n※ 임상시험 수탁기관(CRO: Contact Reserach Organization)이 있는 경우 해당\n\n- - 34 -\n<!-- PAGE_41 -->\n###### 6.  임상시험의 목적 및 배경\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- (2) 혈소판 약물반응검사\n본 임상시험은 aspirin 또는 P2Y12 수용체 저해제 복용예정 환자에서 시험기기의\n\n약물 복용 전후에 대한 민감도와 특이도를 기허가제품의 민감도 및 특이도와\n\n비교하여 임상적 유효성을 검증하는 것이 목적이다.\n\n - - 35 -\n- 6.2.  배경\n혈소판은 1차 지혈에서 중요한 역할을 하는 인자로, 혈관손상이 일어났을 때 부착,\n\n응집, 활성화 및 분비, 응고촉진 작용을 통해 지혈마개를 형성하며, 혈소판 기능에\n\n관한 검사는 주로 선천성 혈소판 기능 이상이나 수술전 선별검사로 많이 사용되고\n\n있다.  특히 혈소판의 수적 이상이 없는 출혈질환에서 선천성 혹은 후천성 혈소판\n\n사용되는 아스피린, P2Y12 수용체 저해제 등의 항혈소판약제로 인한 출혈성\n\n검사방법이나 해석의 표준화가 미흡하거나 해석이 어려워 실제 임상에서 널리\n\n응집에 관여하는 ADP, collagen, epinephrine 등의 작용제(agonist)를 넣고 작용제에\n\n따른 혈소판의 응집정도를 관찰하는 것으로, 각 작용제의 기전에 따라 혈소판의\n\n응집정도를 보고 기능이상 여부를 측정할 수 있다.  PFA-100은 체외에서 유속을\n\n이용해 혈소판의 부착 및 응집기능을 측정할 수 있는 검사장비로 체외에서 출혈\n\n시간 측정 때와 유사한 조건을 만들어 주기 때문에 일차지혈 과정 평가에 유용한\n\n검사로 검사자의 숙련도에 영향을 받지 않는 장점이 있으며, 선천성, 후천성 혈소판\n\n기능이상을 비롯한 일차지혈 관련 선별검사에 이용된다. ",
        "original_sentence": "- - 35 -\n- 6.2. "
      }
    },
    {
      "chunk_id": "chunk_563",
      "text": "배경\n혈소판은 1차 지혈에서 중요한 역할을 하는 인자로, 혈관손상이 일어났을 때 부착,\n\n응집, 활성화 및 분비, 응고촉진 작용을 통해 지혈마개를 형성하며, 혈소판 기능에\n\n관한 검사는 주로 선천성 혈소판 기능 이상이나 수술전 선별검사로 많이 사용되고\n\n있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 562,
        "window_size": 3,
        "char_count": 146,
        "word_count": 35,
        "page_number": 6,
        "window_text": "임상시험 의뢰자의 성명 및 주소\n\n※ 임상시험 수탁기관(CRO: Contact Reserach Organization)이 있는 경우 해당\n\n- - 34 -\n<!-- PAGE_41 -->\n###### 6.  임상시험의 목적 및 배경\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- (2) 혈소판 약물반응검사\n본 임상시험은 aspirin 또는 P2Y12 수용체 저해제 복용예정 환자에서 시험기기의\n\n약물 복용 전후에 대한 민감도와 특이도를 기허가제품의 민감도 및 특이도와\n\n비교하여 임상적 유효성을 검증하는 것이 목적이다.\n\n - - 35 -\n- 6.2.  배경\n혈소판은 1차 지혈에서 중요한 역할을 하는 인자로, 혈관손상이 일어났을 때 부착,\n\n응집, 활성화 및 분비, 응고촉진 작용을 통해 지혈마개를 형성하며, 혈소판 기능에\n\n관한 검사는 주로 선천성 혈소판 기능 이상이나 수술전 선별검사로 많이 사용되고\n\n있다.  특히 혈소판의 수적 이상이 없는 출혈질환에서 선천성 혹은 후천성 혈소판\n\n사용되는 아스피린, P2Y12 수용체 저해제 등의 항혈소판약제로 인한 출혈성\n\n검사방법이나 해석의 표준화가 미흡하거나 해석이 어려워 실제 임상에서 널리\n\n응집에 관여하는 ADP, collagen, epinephrine 등의 작용제(agonist)를 넣고 작용제에\n\n따른 혈소판의 응집정도를 관찰하는 것으로, 각 작용제의 기전에 따라 혈소판의\n\n응집정도를 보고 기능이상 여부를 측정할 수 있다.  PFA-100은 체외에서 유속을\n\n이용해 혈소판의 부착 및 응집기능을 측정할 수 있는 검사장비로 체외에서 출혈\n\n시간 측정 때와 유사한 조건을 만들어 주기 때문에 일차지혈 과정 평가에 유용한\n\n검사로 검사자의 숙련도에 영향을 받지 않는 장점이 있으며, 선천성, 후천성 혈소판\n\n기능이상을 비롯한 일차지혈 관련 선별검사에 이용된다.  특히 혈소판기능 뿐 아니라\n\n본빌레브란트병에 민감한 검사이며, 아스피린 복용자의 약제 저항성검사로도 사용되고 있다.\n\n",
        "original_sentence": "배경\n혈소판은 1차 지혈에서 중요한 역할을 하는 인자로, 혈관손상이 일어났을 때 부착,\n\n응집, 활성화 및 분비, 응고촉진 작용을 통해 지혈마개를 형성하며, 혈소판 기능에\n\n관한 검사는 주로 선천성 혈소판 기능 이상이나 수술전 선별검사로 많이 사용되고\n\n있다. "
      }
    },
    {
      "chunk_id": "chunk_564",
      "text": "특히 혈소판의 수적 이상이 없는 출혈질환에서 선천성 혹은 후천성 혈소판\n\n사용되는 아스피린, P2Y12 수용체 저해제 등의 항혈소판약제로 인한 출혈성\n\n검사방법이나 해석의 표준화가 미흡하거나 해석이 어려워 실제 임상에서 널리\n\n응집에 관여하는 ADP, collagen, epinephrine 등의 작용제(agonist)를 넣고 작용제에\n\n따른 혈소판의 응집정도를 관찰하는 것으로, 각 작용제의 기전에 따라 혈소판의\n\n응집정도를 보고 기능이상 여부를 측정할 수 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 563,
        "window_size": 3,
        "char_count": 261,
        "word_count": 54,
        "page_number": 100,
        "window_text": "임상시험의 목적 및 배경\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- (2) 혈소판 약물반응검사\n본 임상시험은 aspirin 또는 P2Y12 수용체 저해제 복용예정 환자에서 시험기기의\n\n약물 복용 전후에 대한 민감도와 특이도를 기허가제품의 민감도 및 특이도와\n\n비교하여 임상적 유효성을 검증하는 것이 목적이다.\n\n - - 35 -\n- 6.2.  배경\n혈소판은 1차 지혈에서 중요한 역할을 하는 인자로, 혈관손상이 일어났을 때 부착,\n\n응집, 활성화 및 분비, 응고촉진 작용을 통해 지혈마개를 형성하며, 혈소판 기능에\n\n관한 검사는 주로 선천성 혈소판 기능 이상이나 수술전 선별검사로 많이 사용되고\n\n있다.  특히 혈소판의 수적 이상이 없는 출혈질환에서 선천성 혹은 후천성 혈소판\n\n사용되는 아스피린, P2Y12 수용체 저해제 등의 항혈소판약제로 인한 출혈성\n\n검사방법이나 해석의 표준화가 미흡하거나 해석이 어려워 실제 임상에서 널리\n\n응집에 관여하는 ADP, collagen, epinephrine 등의 작용제(agonist)를 넣고 작용제에\n\n따른 혈소판의 응집정도를 관찰하는 것으로, 각 작용제의 기전에 따라 혈소판의\n\n응집정도를 보고 기능이상 여부를 측정할 수 있다.  PFA-100은 체외에서 유속을\n\n이용해 혈소판의 부착 및 응집기능을 측정할 수 있는 검사장비로 체외에서 출혈\n\n시간 측정 때와 유사한 조건을 만들어 주기 때문에 일차지혈 과정 평가에 유용한\n\n검사로 검사자의 숙련도에 영향을 받지 않는 장점이 있으며, 선천성, 후천성 혈소판\n\n기능이상을 비롯한 일차지혈 관련 선별검사에 이용된다.  특히 혈소판기능 뿐 아니라\n\n본빌레브란트병에 민감한 검사이며, 아스피린 복용자의 약제 저항성검사로도 사용되고 있다.\n\n - - 36 -\n심혈관질환이 증가하고 치료 및 예방 목적으로 아스피린, 클로피도그렐 등의 항혈소판\n\n약제를 많이 사용함에 따라 약제의 혈소판 응집능 억제 기능을 측정하기 위한 검사\n\n방법들이 많이 사용되고 있으며, 광투과혈소판응집검사나 PFA-100, VerifyNow 등의\n\n본 임상시험용 의료기기인 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’는\n\n약물로 인한 혈소판 기능 억제 기능을 측정하는 장비로, 혈소판 기능 부전이 의심\n\n본 연구를 통해 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’의 민감도 및\n\n- - 37 -\n<!-- PAGE_44 -->\n###### 7. ",
        "original_sentence": "특히 혈소판의 수적 이상이 없는 출혈질환에서 선천성 혹은 후천성 혈소판\n\n사용되는 아스피린, P2Y12 수용체 저해제 등의 항혈소판약제로 인한 출혈성\n\n검사방법이나 해석의 표준화가 미흡하거나 해석이 어려워 실제 임상에서 널리\n\n응집에 관여하는 ADP, collagen, epinephrine 등의 작용제(agonist)를 넣고 작용제에\n\n따른 혈소판의 응집정도를 관찰하는 것으로, 각 작용제의 기전에 따라 혈소판의\n\n응집정도를 보고 기능이상 여부를 측정할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_565",
      "text": "PFA-100은 체외에서 유속을\n\n이용해 혈소판의 부착 및 응집기능을 측정할 수 있는 검사장비로 체외에서 출혈\n\n시간 측정 때와 유사한 조건을 만들어 주기 때문에 일차지혈 과정 평가에 유용한\n\n검사로 검사자의 숙련도에 영향을 받지 않는 장점이 있으며, 선천성, 후천성 혈소판\n\n기능이상을 비롯한 일차지혈 관련 선별검사에 이용된다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 564,
        "window_size": 3,
        "char_count": 185,
        "word_count": 43,
        "page_number": 6,
        "window_text": "- - 35 -\n- 6.2.  배경\n혈소판은 1차 지혈에서 중요한 역할을 하는 인자로, 혈관손상이 일어났을 때 부착,\n\n응집, 활성화 및 분비, 응고촉진 작용을 통해 지혈마개를 형성하며, 혈소판 기능에\n\n관한 검사는 주로 선천성 혈소판 기능 이상이나 수술전 선별검사로 많이 사용되고\n\n있다.  특히 혈소판의 수적 이상이 없는 출혈질환에서 선천성 혹은 후천성 혈소판\n\n사용되는 아스피린, P2Y12 수용체 저해제 등의 항혈소판약제로 인한 출혈성\n\n검사방법이나 해석의 표준화가 미흡하거나 해석이 어려워 실제 임상에서 널리\n\n응집에 관여하는 ADP, collagen, epinephrine 등의 작용제(agonist)를 넣고 작용제에\n\n따른 혈소판의 응집정도를 관찰하는 것으로, 각 작용제의 기전에 따라 혈소판의\n\n응집정도를 보고 기능이상 여부를 측정할 수 있다.  PFA-100은 체외에서 유속을\n\n이용해 혈소판의 부착 및 응집기능을 측정할 수 있는 검사장비로 체외에서 출혈\n\n시간 측정 때와 유사한 조건을 만들어 주기 때문에 일차지혈 과정 평가에 유용한\n\n검사로 검사자의 숙련도에 영향을 받지 않는 장점이 있으며, 선천성, 후천성 혈소판\n\n기능이상을 비롯한 일차지혈 관련 선별검사에 이용된다.  특히 혈소판기능 뿐 아니라\n\n본빌레브란트병에 민감한 검사이며, 아스피린 복용자의 약제 저항성검사로도 사용되고 있다.\n\n - - 36 -\n심혈관질환이 증가하고 치료 및 예방 목적으로 아스피린, 클로피도그렐 등의 항혈소판\n\n약제를 많이 사용함에 따라 약제의 혈소판 응집능 억제 기능을 측정하기 위한 검사\n\n방법들이 많이 사용되고 있으며, 광투과혈소판응집검사나 PFA-100, VerifyNow 등의\n\n본 임상시험용 의료기기인 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’는\n\n약물로 인한 혈소판 기능 억제 기능을 측정하는 장비로, 혈소판 기능 부전이 의심\n\n본 연구를 통해 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’의 민감도 및\n\n- - 37 -\n<!-- PAGE_44 -->\n###### 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다.)\n\n",
        "original_sentence": "PFA-100은 체외에서 유속을\n\n이용해 혈소판의 부착 및 응집기능을 측정할 수 있는 검사장비로 체외에서 출혈\n\n시간 측정 때와 유사한 조건을 만들어 주기 때문에 일차지혈 과정 평가에 유용한\n\n검사로 검사자의 숙련도에 영향을 받지 않는 장점이 있으며, 선천성, 후천성 혈소판\n\n기능이상을 비롯한 일차지혈 관련 선별검사에 이용된다. "
      }
    },
    {
      "chunk_id": "chunk_566",
      "text": "특히 혈소판기능 뿐 아니라\n\n본빌레브란트병에 민감한 검사이며, 아스피린 복용자의 약제 저항성검사로도 사용되고 있다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 565,
        "window_size": 3,
        "char_count": 66,
        "word_count": 13,
        "page_number": 104,
        "window_text": "배경\n혈소판은 1차 지혈에서 중요한 역할을 하는 인자로, 혈관손상이 일어났을 때 부착,\n\n응집, 활성화 및 분비, 응고촉진 작용을 통해 지혈마개를 형성하며, 혈소판 기능에\n\n관한 검사는 주로 선천성 혈소판 기능 이상이나 수술전 선별검사로 많이 사용되고\n\n있다.  특히 혈소판의 수적 이상이 없는 출혈질환에서 선천성 혹은 후천성 혈소판\n\n사용되는 아스피린, P2Y12 수용체 저해제 등의 항혈소판약제로 인한 출혈성\n\n검사방법이나 해석의 표준화가 미흡하거나 해석이 어려워 실제 임상에서 널리\n\n응집에 관여하는 ADP, collagen, epinephrine 등의 작용제(agonist)를 넣고 작용제에\n\n따른 혈소판의 응집정도를 관찰하는 것으로, 각 작용제의 기전에 따라 혈소판의\n\n응집정도를 보고 기능이상 여부를 측정할 수 있다.  PFA-100은 체외에서 유속을\n\n이용해 혈소판의 부착 및 응집기능을 측정할 수 있는 검사장비로 체외에서 출혈\n\n시간 측정 때와 유사한 조건을 만들어 주기 때문에 일차지혈 과정 평가에 유용한\n\n검사로 검사자의 숙련도에 영향을 받지 않는 장점이 있으며, 선천성, 후천성 혈소판\n\n기능이상을 비롯한 일차지혈 관련 선별검사에 이용된다.  특히 혈소판기능 뿐 아니라\n\n본빌레브란트병에 민감한 검사이며, 아스피린 복용자의 약제 저항성검사로도 사용되고 있다.\n\n - - 36 -\n심혈관질환이 증가하고 치료 및 예방 목적으로 아스피린, 클로피도그렐 등의 항혈소판\n\n약제를 많이 사용함에 따라 약제의 혈소판 응집능 억제 기능을 측정하기 위한 검사\n\n방법들이 많이 사용되고 있으며, 광투과혈소판응집검사나 PFA-100, VerifyNow 등의\n\n본 임상시험용 의료기기인 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’는\n\n약물로 인한 혈소판 기능 억제 기능을 측정하는 장비로, 혈소판 기능 부전이 의심\n\n본 연구를 통해 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’의 민감도 및\n\n- - 37 -\n<!-- PAGE_44 -->\n###### 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다.)\n\n ※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- - ADP test: 사람의 구연산 처리된 전혈에서 아데노신이인산(ADP)와 P2Y12의\n- - EPI test: 사람의 구연산 처리된 전혈에서 에피네프린과 a2A-AR의 결합 정도를\n폐색 전 혈액이동거리 측정법으로 정성하여 에피네프린에 의한 혈소판 기능\n\n- - Aspirin test: 사람의 구연산 처리된 전혈에서 아스피린에 의한 TXA2 합성 억제\n정도를 폐색 전 혈액이동거리 측정법으로 정성하여 아스피린에 의한 혈소판\n\n- - P2Y12 test: 사람의 구연산 처리된 전혈에서 P2Y12 수용체(ADP receptor) 억제\n정도를 폐색 전 혈액이동거리 측정법으로 정성하여 P2Y12 억제제에 의한 혈소판\n\n- - 38 -\n- 7.2. ",
        "original_sentence": "특히 혈소판기능 뿐 아니라\n\n본빌레브란트병에 민감한 검사이며, 아스피린 복용자의 약제 저항성검사로도 사용되고 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_567",
      "text": "- - 36 -\n심혈관질환이 증가하고 치료 및 예방 목적으로 아스피린, 클로피도그렐 등의 항혈소판\n\n약제를 많이 사용함에 따라 약제의 혈소판 응집능 억제 기능을 측정하기 위한 검사\n\n방법들이 많이 사용되고 있으며, 광투과혈소판응집검사나 PFA-100, VerifyNow 등의\n\n본 임상시험용 의료기기인 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’는\n\n약물로 인한 혈소판 기능 억제 기능을 측정하는 장비로, 혈소판 기능 부전이 의심\n\n본 연구를 통해 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’의 민감도 및\n\n- - 37 -\n<!-- PAGE_44 -->\n###### 7. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 566,
        "window_size": 3,
        "char_count": 326,
        "word_count": 75,
        "page_number": 44,
        "window_text": "특히 혈소판의 수적 이상이 없는 출혈질환에서 선천성 혹은 후천성 혈소판\n\n사용되는 아스피린, P2Y12 수용체 저해제 등의 항혈소판약제로 인한 출혈성\n\n검사방법이나 해석의 표준화가 미흡하거나 해석이 어려워 실제 임상에서 널리\n\n응집에 관여하는 ADP, collagen, epinephrine 등의 작용제(agonist)를 넣고 작용제에\n\n따른 혈소판의 응집정도를 관찰하는 것으로, 각 작용제의 기전에 따라 혈소판의\n\n응집정도를 보고 기능이상 여부를 측정할 수 있다.  PFA-100은 체외에서 유속을\n\n이용해 혈소판의 부착 및 응집기능을 측정할 수 있는 검사장비로 체외에서 출혈\n\n시간 측정 때와 유사한 조건을 만들어 주기 때문에 일차지혈 과정 평가에 유용한\n\n검사로 검사자의 숙련도에 영향을 받지 않는 장점이 있으며, 선천성, 후천성 혈소판\n\n기능이상을 비롯한 일차지혈 관련 선별검사에 이용된다.  특히 혈소판기능 뿐 아니라\n\n본빌레브란트병에 민감한 검사이며, 아스피린 복용자의 약제 저항성검사로도 사용되고 있다.\n\n - - 36 -\n심혈관질환이 증가하고 치료 및 예방 목적으로 아스피린, 클로피도그렐 등의 항혈소판\n\n약제를 많이 사용함에 따라 약제의 혈소판 응집능 억제 기능을 측정하기 위한 검사\n\n방법들이 많이 사용되고 있으며, 광투과혈소판응집검사나 PFA-100, VerifyNow 등의\n\n본 임상시험용 의료기기인 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’는\n\n약물로 인한 혈소판 기능 억제 기능을 측정하는 장비로, 혈소판 기능 부전이 의심\n\n본 연구를 통해 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’의 민감도 및\n\n- - 37 -\n<!-- PAGE_44 -->\n###### 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다.)\n\n ※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- - ADP test: 사람의 구연산 처리된 전혈에서 아데노신이인산(ADP)와 P2Y12의\n- - EPI test: 사람의 구연산 처리된 전혈에서 에피네프린과 a2A-AR의 결합 정도를\n폐색 전 혈액이동거리 측정법으로 정성하여 에피네프린에 의한 혈소판 기능\n\n- - Aspirin test: 사람의 구연산 처리된 전혈에서 아스피린에 의한 TXA2 합성 억제\n정도를 폐색 전 혈액이동거리 측정법으로 정성하여 아스피린에 의한 혈소판\n\n- - P2Y12 test: 사람의 구연산 처리된 전혈에서 P2Y12 수용체(ADP receptor) 억제\n정도를 폐색 전 혈액이동거리 측정법으로 정성하여 P2Y12 억제제에 의한 혈소판\n\n- - 38 -\n- 7.2.  임상시험용 의료기기 정보\n- - 해당 임상시험용 의료기기 및 대조시험용 의료기기의 코드명/품목명, 제조회사,\n2) 제조회사: ○○○\n\n- - 39 -\n일련번호\n\n명칭\n\n배합목적\n\n원재료명 또는 성분명\n\n분량\n\n비고\n\n3) 원자재:\n\n모델명 : ○○ SIPA test\n\n- - 40 -\n5) 구조:\n\n- (1) 본체\n- ② 디스플레이(사용자 화면): 별도로 제공되는 태블릿을 이용하여 검사 설정\n- ② 혈액챔버: 혈액주입구를 통해 로딩된 혈액이 채워지는 챔버. ",
        "original_sentence": "- - 36 -\n심혈관질환이 증가하고 치료 및 예방 목적으로 아스피린, 클로피도그렐 등의 항혈소판\n\n약제를 많이 사용함에 따라 약제의 혈소판 응집능 억제 기능을 측정하기 위한 검사\n\n방법들이 많이 사용되고 있으며, 광투과혈소판응집검사나 PFA-100, VerifyNow 등의\n\n본 임상시험용 의료기기인 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’는\n\n약물로 인한 혈소판 기능 억제 기능을 측정하는 장비로, 혈소판 기능 부전이 의심\n\n본 연구를 통해 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’의 민감도 및\n\n- - 37 -\n<!-- PAGE_44 -->\n###### 7. "
      }
    },
    {
      "chunk_id": "chunk_568",
      "text": "임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다.)\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 567,
        "window_size": 3,
        "char_count": 42,
        "word_count": 7,
        "page_number": 6,
        "window_text": "PFA-100은 체외에서 유속을\n\n이용해 혈소판의 부착 및 응집기능을 측정할 수 있는 검사장비로 체외에서 출혈\n\n시간 측정 때와 유사한 조건을 만들어 주기 때문에 일차지혈 과정 평가에 유용한\n\n검사로 검사자의 숙련도에 영향을 받지 않는 장점이 있으며, 선천성, 후천성 혈소판\n\n기능이상을 비롯한 일차지혈 관련 선별검사에 이용된다.  특히 혈소판기능 뿐 아니라\n\n본빌레브란트병에 민감한 검사이며, 아스피린 복용자의 약제 저항성검사로도 사용되고 있다.\n\n - - 36 -\n심혈관질환이 증가하고 치료 및 예방 목적으로 아스피린, 클로피도그렐 등의 항혈소판\n\n약제를 많이 사용함에 따라 약제의 혈소판 응집능 억제 기능을 측정하기 위한 검사\n\n방법들이 많이 사용되고 있으며, 광투과혈소판응집검사나 PFA-100, VerifyNow 등의\n\n본 임상시험용 의료기기인 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’는\n\n약물로 인한 혈소판 기능 억제 기능을 측정하는 장비로, 혈소판 기능 부전이 의심\n\n본 연구를 통해 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’의 민감도 및\n\n- - 37 -\n<!-- PAGE_44 -->\n###### 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다.)\n\n ※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- - ADP test: 사람의 구연산 처리된 전혈에서 아데노신이인산(ADP)와 P2Y12의\n- - EPI test: 사람의 구연산 처리된 전혈에서 에피네프린과 a2A-AR의 결합 정도를\n폐색 전 혈액이동거리 측정법으로 정성하여 에피네프린에 의한 혈소판 기능\n\n- - Aspirin test: 사람의 구연산 처리된 전혈에서 아스피린에 의한 TXA2 합성 억제\n정도를 폐색 전 혈액이동거리 측정법으로 정성하여 아스피린에 의한 혈소판\n\n- - P2Y12 test: 사람의 구연산 처리된 전혈에서 P2Y12 수용체(ADP receptor) 억제\n정도를 폐색 전 혈액이동거리 측정법으로 정성하여 P2Y12 억제제에 의한 혈소판\n\n- - 38 -\n- 7.2.  임상시험용 의료기기 정보\n- - 해당 임상시험용 의료기기 및 대조시험용 의료기기의 코드명/품목명, 제조회사,\n2) 제조회사: ○○○\n\n- - 39 -\n일련번호\n\n명칭\n\n배합목적\n\n원재료명 또는 성분명\n\n분량\n\n비고\n\n3) 원자재:\n\n모델명 : ○○ SIPA test\n\n- - 40 -\n5) 구조:\n\n- (1) 본체\n- ② 디스플레이(사용자 화면): 별도로 제공되는 태블릿을 이용하여 검사 설정\n- ② 혈액챔버: 혈액주입구를 통해 로딩된 혈액이 채워지는 챔버.  샘플챔버와\n- ③ 막힘부: 내부에 Collagen이 채워져 있어 활성화된 혈소판의 부착을 유도하여\n- ④ 혈액이동부: 막힘부에 폐색이 일어날 때까지 혈액은 혈액이동부를 통해 이동\n- ⑤ 폐챔버: 혈액챔버에서 이동된 혈액이 모이는 끝단. ",
        "original_sentence": "임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다.)\n\n"
      }
    },
    {
      "chunk_id": "chunk_569",
      "text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- - ADP test: 사람의 구연산 처리된 전혈에서 아데노신이인산(ADP)와 P2Y12의\n- - EPI test: 사람의 구연산 처리된 전혈에서 에피네프린과 a2A-AR의 결합 정도를\n폐색 전 혈액이동거리 측정법으로 정성하여 에피네프린에 의한 혈소판 기능\n\n- - Aspirin test: 사람의 구연산 처리된 전혈에서 아스피린에 의한 TXA2 합성 억제\n정도를 폐색 전 혈액이동거리 측정법으로 정성하여 아스피린에 의한 혈소판\n\n- - P2Y12 test: 사람의 구연산 처리된 전혈에서 P2Y12 수용체(ADP receptor) 억제\n정도를 폐색 전 혈액이동거리 측정법으로 정성하여 P2Y12 억제제에 의한 혈소판\n\n- - 38 -\n- 7.2. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 568,
        "window_size": 3,
        "char_count": 416,
        "word_count": 95,
        "page_number": 35,
        "window_text": "특히 혈소판기능 뿐 아니라\n\n본빌레브란트병에 민감한 검사이며, 아스피린 복용자의 약제 저항성검사로도 사용되고 있다.\n\n - - 36 -\n심혈관질환이 증가하고 치료 및 예방 목적으로 아스피린, 클로피도그렐 등의 항혈소판\n\n약제를 많이 사용함에 따라 약제의 혈소판 응집능 억제 기능을 측정하기 위한 검사\n\n방법들이 많이 사용되고 있으며, 광투과혈소판응집검사나 PFA-100, VerifyNow 등의\n\n본 임상시험용 의료기기인 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’는\n\n약물로 인한 혈소판 기능 억제 기능을 측정하는 장비로, 혈소판 기능 부전이 의심\n\n본 연구를 통해 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’의 민감도 및\n\n- - 37 -\n<!-- PAGE_44 -->\n###### 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다.)\n\n ※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- - ADP test: 사람의 구연산 처리된 전혈에서 아데노신이인산(ADP)와 P2Y12의\n- - EPI test: 사람의 구연산 처리된 전혈에서 에피네프린과 a2A-AR의 결합 정도를\n폐색 전 혈액이동거리 측정법으로 정성하여 에피네프린에 의한 혈소판 기능\n\n- - Aspirin test: 사람의 구연산 처리된 전혈에서 아스피린에 의한 TXA2 합성 억제\n정도를 폐색 전 혈액이동거리 측정법으로 정성하여 아스피린에 의한 혈소판\n\n- - P2Y12 test: 사람의 구연산 처리된 전혈에서 P2Y12 수용체(ADP receptor) 억제\n정도를 폐색 전 혈액이동거리 측정법으로 정성하여 P2Y12 억제제에 의한 혈소판\n\n- - 38 -\n- 7.2.  임상시험용 의료기기 정보\n- - 해당 임상시험용 의료기기 및 대조시험용 의료기기의 코드명/품목명, 제조회사,\n2) 제조회사: ○○○\n\n- - 39 -\n일련번호\n\n명칭\n\n배합목적\n\n원재료명 또는 성분명\n\n분량\n\n비고\n\n3) 원자재:\n\n모델명 : ○○ SIPA test\n\n- - 40 -\n5) 구조:\n\n- (1) 본체\n- ② 디스플레이(사용자 화면): 별도로 제공되는 태블릿을 이용하여 검사 설정\n- ② 혈액챔버: 혈액주입구를 통해 로딩된 혈액이 채워지는 챔버.  샘플챔버와\n- ③ 막힘부: 내부에 Collagen이 채워져 있어 활성화된 혈소판의 부착을 유도하여\n- ④ 혈액이동부: 막힘부에 폐색이 일어날 때까지 혈액은 혈액이동부를 통해 이동\n- ⑤ 폐챔버: 혈액챔버에서 이동된 혈액이 모이는 끝단.  음압펌프가 연결된다.\n",
        "original_sentence": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- - ADP test: 사람의 구연산 처리된 전혈에서 아데노신이인산(ADP)와 P2Y12의\n- - EPI test: 사람의 구연산 처리된 전혈에서 에피네프린과 a2A-AR의 결합 정도를\n폐색 전 혈액이동거리 측정법으로 정성하여 에피네프린에 의한 혈소판 기능\n\n- - Aspirin test: 사람의 구연산 처리된 전혈에서 아스피린에 의한 TXA2 합성 억제\n정도를 폐색 전 혈액이동거리 측정법으로 정성하여 아스피린에 의한 혈소판\n\n- - P2Y12 test: 사람의 구연산 처리된 전혈에서 P2Y12 수용체(ADP receptor) 억제\n정도를 폐색 전 혈액이동거리 측정법으로 정성하여 P2Y12 억제제에 의한 혈소판\n\n- - 38 -\n- 7.2. "
      }
    },
    {
      "chunk_id": "chunk_570",
      "text": "임상시험용 의료기기 정보\n- - 해당 임상시험용 의료기기 및 대조시험용 의료기기의 코드명/품목명, 제조회사,\n2) 제조회사: ○○○\n\n- - 39 -\n일련번호\n\n명칭\n\n배합목적\n\n원재료명 또는 성분명\n\n분량\n\n비고\n\n3) 원자재:\n\n모델명 : ○○ SIPA test\n\n- - 40 -\n5) 구조:\n\n- (1) 본체\n- ② 디스플레이(사용자 화면): 별도로 제공되는 태블릿을 이용하여 검사 설정\n- ② 혈액챔버: 혈액주입구를 통해 로딩된 혈액이 채워지는 챔버. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 569,
        "window_size": 3,
        "char_count": 257,
        "word_count": 63,
        "page_number": 9,
        "window_text": "- - 36 -\n심혈관질환이 증가하고 치료 및 예방 목적으로 아스피린, 클로피도그렐 등의 항혈소판\n\n약제를 많이 사용함에 따라 약제의 혈소판 응집능 억제 기능을 측정하기 위한 검사\n\n방법들이 많이 사용되고 있으며, 광투과혈소판응집검사나 PFA-100, VerifyNow 등의\n\n본 임상시험용 의료기기인 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’는\n\n약물로 인한 혈소판 기능 억제 기능을 측정하는 장비로, 혈소판 기능 부전이 의심\n\n본 연구를 통해 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’의 민감도 및\n\n- - 37 -\n<!-- PAGE_44 -->\n###### 7.  임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다.)\n\n ※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- - ADP test: 사람의 구연산 처리된 전혈에서 아데노신이인산(ADP)와 P2Y12의\n- - EPI test: 사람의 구연산 처리된 전혈에서 에피네프린과 a2A-AR의 결합 정도를\n폐색 전 혈액이동거리 측정법으로 정성하여 에피네프린에 의한 혈소판 기능\n\n- - Aspirin test: 사람의 구연산 처리된 전혈에서 아스피린에 의한 TXA2 합성 억제\n정도를 폐색 전 혈액이동거리 측정법으로 정성하여 아스피린에 의한 혈소판\n\n- - P2Y12 test: 사람의 구연산 처리된 전혈에서 P2Y12 수용체(ADP receptor) 억제\n정도를 폐색 전 혈액이동거리 측정법으로 정성하여 P2Y12 억제제에 의한 혈소판\n\n- - 38 -\n- 7.2.  임상시험용 의료기기 정보\n- - 해당 임상시험용 의료기기 및 대조시험용 의료기기의 코드명/품목명, 제조회사,\n2) 제조회사: ○○○\n\n- - 39 -\n일련번호\n\n명칭\n\n배합목적\n\n원재료명 또는 성분명\n\n분량\n\n비고\n\n3) 원자재:\n\n모델명 : ○○ SIPA test\n\n- - 40 -\n5) 구조:\n\n- (1) 본체\n- ② 디스플레이(사용자 화면): 별도로 제공되는 태블릿을 이용하여 검사 설정\n- ② 혈액챔버: 혈액주입구를 통해 로딩된 혈액이 채워지는 챔버.  샘플챔버와\n- ③ 막힘부: 내부에 Collagen이 채워져 있어 활성화된 혈소판의 부착을 유도하여\n- ④ 혈액이동부: 막힘부에 폐색이 일어날 때까지 혈액은 혈액이동부를 통해 이동\n- ⑤ 폐챔버: 혈액챔버에서 이동된 혈액이 모이는 끝단.  음압펌프가 연결된다.\n - - 41 -\n6) 치수/중량:\n\n- (1) 본체 : 가로 x 세로 x 높이, 0㎏\n- (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests : 가로 x 세로 x 높이, ㎏\n- (5) 검사는 채혈 후 30분~4시간 내에 수행하도록 한다.\n",
        "original_sentence": "임상시험용 의료기기 정보\n- - 해당 임상시험용 의료기기 및 대조시험용 의료기기의 코드명/품목명, 제조회사,\n2) 제조회사: ○○○\n\n- - 39 -\n일련번호\n\n명칭\n\n배합목적\n\n원재료명 또는 성분명\n\n분량\n\n비고\n\n3) 원자재:\n\n모델명 : ○○ SIPA test\n\n- - 40 -\n5) 구조:\n\n- (1) 본체\n- ② 디스플레이(사용자 화면): 별도로 제공되는 태블릿을 이용하여 검사 설정\n- ② 혈액챔버: 혈액주입구를 통해 로딩된 혈액이 채워지는 챔버. "
      }
    },
    {
      "chunk_id": "chunk_571",
      "text": "샘플챔버와\n- ③ 막힘부: 내부에 Collagen이 채워져 있어 활성화된 혈소판의 부착을 유도하여\n- ④ 혈액이동부: 막힘부에 폐색이 일어날 때까지 혈액은 혈액이동부를 통해 이동\n- ⑤ 폐챔버: 혈액챔버에서 이동된 혈액이 모이는 끝단. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 570,
        "window_size": 3,
        "char_count": 132,
        "word_count": 31,
        "page_number": 23,
        "window_text": "임상시험용 의료기기의 개요(사용목적, 대상질환 또는 적응증을 포함한다.)\n\n ※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- - ADP test: 사람의 구연산 처리된 전혈에서 아데노신이인산(ADP)와 P2Y12의\n- - EPI test: 사람의 구연산 처리된 전혈에서 에피네프린과 a2A-AR의 결합 정도를\n폐색 전 혈액이동거리 측정법으로 정성하여 에피네프린에 의한 혈소판 기능\n\n- - Aspirin test: 사람의 구연산 처리된 전혈에서 아스피린에 의한 TXA2 합성 억제\n정도를 폐색 전 혈액이동거리 측정법으로 정성하여 아스피린에 의한 혈소판\n\n- - P2Y12 test: 사람의 구연산 처리된 전혈에서 P2Y12 수용체(ADP receptor) 억제\n정도를 폐색 전 혈액이동거리 측정법으로 정성하여 P2Y12 억제제에 의한 혈소판\n\n- - 38 -\n- 7.2.  임상시험용 의료기기 정보\n- - 해당 임상시험용 의료기기 및 대조시험용 의료기기의 코드명/품목명, 제조회사,\n2) 제조회사: ○○○\n\n- - 39 -\n일련번호\n\n명칭\n\n배합목적\n\n원재료명 또는 성분명\n\n분량\n\n비고\n\n3) 원자재:\n\n모델명 : ○○ SIPA test\n\n- - 40 -\n5) 구조:\n\n- (1) 본체\n- ② 디스플레이(사용자 화면): 별도로 제공되는 태블릿을 이용하여 검사 설정\n- ② 혈액챔버: 혈액주입구를 통해 로딩된 혈액이 채워지는 챔버.  샘플챔버와\n- ③ 막힘부: 내부에 Collagen이 채워져 있어 활성화된 혈소판의 부착을 유도하여\n- ④ 혈액이동부: 막힘부에 폐색이 일어날 때까지 혈액은 혈액이동부를 통해 이동\n- ⑤ 폐챔버: 혈액챔버에서 이동된 혈액이 모이는 끝단.  음압펌프가 연결된다.\n - - 41 -\n6) 치수/중량:\n\n- (1) 본체 : 가로 x 세로 x 높이, 0㎏\n- (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests : 가로 x 세로 x 높이, ㎏\n- (5) 검사는 채혈 후 30분~4시간 내에 수행하도록 한다.\n 2) 검사 전 준비사항\n\n- (1) 검사칩이 들어있는 파우치를 개봉하기 전, 실온에 약 10분간 방치한다.\n",
        "original_sentence": "샘플챔버와\n- ③ 막힘부: 내부에 Collagen이 채워져 있어 활성화된 혈소판의 부착을 유도하여\n- ④ 혈액이동부: 막힘부에 폐색이 일어날 때까지 혈액은 혈액이동부를 통해 이동\n- ⑤ 폐챔버: 혈액챔버에서 이동된 혈액이 모이는 끝단. "
      }
    },
    {
      "chunk_id": "chunk_572",
      "text": "음압펌프가 연결된다.\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 571,
        "window_size": 3,
        "char_count": 12,
        "word_count": 2,
        "page_number": 47,
        "window_text": "※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- - ADP test: 사람의 구연산 처리된 전혈에서 아데노신이인산(ADP)와 P2Y12의\n- - EPI test: 사람의 구연산 처리된 전혈에서 에피네프린과 a2A-AR의 결합 정도를\n폐색 전 혈액이동거리 측정법으로 정성하여 에피네프린에 의한 혈소판 기능\n\n- - Aspirin test: 사람의 구연산 처리된 전혈에서 아스피린에 의한 TXA2 합성 억제\n정도를 폐색 전 혈액이동거리 측정법으로 정성하여 아스피린에 의한 혈소판\n\n- - P2Y12 test: 사람의 구연산 처리된 전혈에서 P2Y12 수용체(ADP receptor) 억제\n정도를 폐색 전 혈액이동거리 측정법으로 정성하여 P2Y12 억제제에 의한 혈소판\n\n- - 38 -\n- 7.2.  임상시험용 의료기기 정보\n- - 해당 임상시험용 의료기기 및 대조시험용 의료기기의 코드명/품목명, 제조회사,\n2) 제조회사: ○○○\n\n- - 39 -\n일련번호\n\n명칭\n\n배합목적\n\n원재료명 또는 성분명\n\n분량\n\n비고\n\n3) 원자재:\n\n모델명 : ○○ SIPA test\n\n- - 40 -\n5) 구조:\n\n- (1) 본체\n- ② 디스플레이(사용자 화면): 별도로 제공되는 태블릿을 이용하여 검사 설정\n- ② 혈액챔버: 혈액주입구를 통해 로딩된 혈액이 채워지는 챔버.  샘플챔버와\n- ③ 막힘부: 내부에 Collagen이 채워져 있어 활성화된 혈소판의 부착을 유도하여\n- ④ 혈액이동부: 막힘부에 폐색이 일어날 때까지 혈액은 혈액이동부를 통해 이동\n- ⑤ 폐챔버: 혈액챔버에서 이동된 혈액이 모이는 끝단.  음압펌프가 연결된다.\n - - 41 -\n6) 치수/중량:\n\n- (1) 본체 : 가로 x 세로 x 높이, 0㎏\n- (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests : 가로 x 세로 x 높이, ㎏\n- (5) 검사는 채혈 후 30분~4시간 내에 수행하도록 한다.\n 2) 검사 전 준비사항\n\n- (1) 검사칩이 들어있는 파우치를 개봉하기 전, 실온에 약 10분간 방치한다.\n - (2) 사용 전, 임상시험용 장비와 검사칩의 손상여부 및 이상유무를 확인한다.\n",
        "original_sentence": "음압펌프가 연결된다.\n"
      }
    },
    {
      "chunk_id": "chunk_573",
      "text": "- - 41 -\n6) 치수/중량:\n\n- (1) 본체 : 가로 x 세로 x 높이, 0㎏\n- (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests : 가로 x 세로 x 높이, ㎏\n- (5) 검사는 채혈 후 30분~4시간 내에 수행하도록 한다.\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 572,
        "window_size": 3,
        "char_count": 141,
        "word_count": 36,
        "page_number": 6,
        "window_text": "임상시험용 의료기기 정보\n- - 해당 임상시험용 의료기기 및 대조시험용 의료기기의 코드명/품목명, 제조회사,\n2) 제조회사: ○○○\n\n- - 39 -\n일련번호\n\n명칭\n\n배합목적\n\n원재료명 또는 성분명\n\n분량\n\n비고\n\n3) 원자재:\n\n모델명 : ○○ SIPA test\n\n- - 40 -\n5) 구조:\n\n- (1) 본체\n- ② 디스플레이(사용자 화면): 별도로 제공되는 태블릿을 이용하여 검사 설정\n- ② 혈액챔버: 혈액주입구를 통해 로딩된 혈액이 채워지는 챔버.  샘플챔버와\n- ③ 막힘부: 내부에 Collagen이 채워져 있어 활성화된 혈소판의 부착을 유도하여\n- ④ 혈액이동부: 막힘부에 폐색이 일어날 때까지 혈액은 혈액이동부를 통해 이동\n- ⑤ 폐챔버: 혈액챔버에서 이동된 혈액이 모이는 끝단.  음압펌프가 연결된다.\n - - 41 -\n6) 치수/중량:\n\n- (1) 본체 : 가로 x 세로 x 높이, 0㎏\n- (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests : 가로 x 세로 x 높이, ㎏\n- (5) 검사는 채혈 후 30분~4시간 내에 수행하도록 한다.\n 2) 검사 전 준비사항\n\n- (1) 검사칩이 들어있는 파우치를 개봉하기 전, 실온에 약 10분간 방치한다.\n - (2) 사용 전, 임상시험용 장비와 검사칩의 손상여부 및 이상유무를 확인한다.\n 3) 검사과정\n\n- (1) 장비 작동\n- ① 장비 후면 우측 하단의 전원 스위치를 “ON”상태로 한다.\n",
        "original_sentence": "- - 41 -\n6) 치수/중량:\n\n- (1) 본체 : 가로 x 세로 x 높이, 0㎏\n- (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests : 가로 x 세로 x 높이, ㎏\n- (5) 검사는 채혈 후 30분~4시간 내에 수행하도록 한다.\n"
      }
    },
    {
      "chunk_id": "chunk_574",
      "text": "2) 검사 전 준비사항\n\n- (1) 검사칩이 들어있는 파우치를 개봉하기 전, 실온에 약 10분간 방치한다.\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 573,
        "window_size": 3,
        "char_count": 60,
        "word_count": 15,
        "page_number": 3,
        "window_text": "샘플챔버와\n- ③ 막힘부: 내부에 Collagen이 채워져 있어 활성화된 혈소판의 부착을 유도하여\n- ④ 혈액이동부: 막힘부에 폐색이 일어날 때까지 혈액은 혈액이동부를 통해 이동\n- ⑤ 폐챔버: 혈액챔버에서 이동된 혈액이 모이는 끝단.  음압펌프가 연결된다.\n - - 41 -\n6) 치수/중량:\n\n- (1) 본체 : 가로 x 세로 x 높이, 0㎏\n- (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests : 가로 x 세로 x 높이, ㎏\n- (5) 검사는 채혈 후 30분~4시간 내에 수행하도록 한다.\n 2) 검사 전 준비사항\n\n- (1) 검사칩이 들어있는 파우치를 개봉하기 전, 실온에 약 10분간 방치한다.\n - (2) 사용 전, 임상시험용 장비와 검사칩의 손상여부 및 이상유무를 확인한다.\n 3) 검사과정\n\n- (1) 장비 작동\n- ① 장비 후면 우측 하단의 전원 스위치를 “ON”상태로 한다.\n - ② 태블릿에 로그인 화면이 나타나면 아이디와 비밀번호를 입력한 후, “Log\n- - 42 -\nIn”버튼을 눌러 로그인한다. ",
        "original_sentence": "2) 검사 전 준비사항\n\n- (1) 검사칩이 들어있는 파우치를 개봉하기 전, 실온에 약 10분간 방치한다.\n"
      }
    },
    {
      "chunk_id": "chunk_575",
      "text": "- (2) 사용 전, 임상시험용 장비와 검사칩의 손상여부 및 이상유무를 확인한다.\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 574,
        "window_size": 3,
        "char_count": 46,
        "word_count": 11,
        "page_number": 3,
        "window_text": "음압펌프가 연결된다.\n - - 41 -\n6) 치수/중량:\n\n- (1) 본체 : 가로 x 세로 x 높이, 0㎏\n- (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests : 가로 x 세로 x 높이, ㎏\n- (5) 검사는 채혈 후 30분~4시간 내에 수행하도록 한다.\n 2) 검사 전 준비사항\n\n- (1) 검사칩이 들어있는 파우치를 개봉하기 전, 실온에 약 10분간 방치한다.\n - (2) 사용 전, 임상시험용 장비와 검사칩의 손상여부 및 이상유무를 확인한다.\n 3) 검사과정\n\n- (1) 장비 작동\n- ① 장비 후면 우측 하단의 전원 스위치를 “ON”상태로 한다.\n - ② 태블릿에 로그인 화면이 나타나면 아이디와 비밀번호를 입력한 후, “Log\n- - 42 -\nIn”버튼을 눌러 로그인한다.  초기 설정값은 아이디: pi, 비밀번호: top이다.\n\n",
        "original_sentence": "- (2) 사용 전, 임상시험용 장비와 검사칩의 손상여부 및 이상유무를 확인한다.\n"
      }
    },
    {
      "chunk_id": "chunk_576",
      "text": "3) 검사과정\n\n- (1) 장비 작동\n- ① 장비 후면 우측 하단의 전원 스위치를 “ON”상태로 한다.\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 575,
        "window_size": 3,
        "char_count": 58,
        "word_count": 16,
        "page_number": 6,
        "window_text": "- - 41 -\n6) 치수/중량:\n\n- (1) 본체 : 가로 x 세로 x 높이, 0㎏\n- (2) SIPA/ADP/EPI/Aspirin/P2Y12 tests : 가로 x 세로 x 높이, ㎏\n- (5) 검사는 채혈 후 30분~4시간 내에 수행하도록 한다.\n 2) 검사 전 준비사항\n\n- (1) 검사칩이 들어있는 파우치를 개봉하기 전, 실온에 약 10분간 방치한다.\n - (2) 사용 전, 임상시험용 장비와 검사칩의 손상여부 및 이상유무를 확인한다.\n 3) 검사과정\n\n- (1) 장비 작동\n- ① 장비 후면 우측 하단의 전원 스위치를 “ON”상태로 한다.\n - ② 태블릿에 로그인 화면이 나타나면 아이디와 비밀번호를 입력한 후, “Log\n- - 42 -\nIn”버튼을 눌러 로그인한다.  초기 설정값은 아이디: pi, 비밀번호: top이다.\n\n - ③ 윈도우가 로딩되면 아이콘을 더블클릭하여 혈소판 기능검사 프로그램을\n실행한다.\n\n",
        "original_sentence": "3) 검사과정\n\n- (1) 장비 작동\n- ① 장비 후면 우측 하단의 전원 스위치를 “ON”상태로 한다.\n"
      }
    },
    {
      "chunk_id": "chunk_577",
      "text": "- ② 태블릿에 로그인 화면이 나타나면 아이디와 비밀번호를 입력한 후, “Log\n- - 42 -\nIn”버튼을 눌러 로그인한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 576,
        "window_size": 3,
        "char_count": 71,
        "word_count": 18,
        "page_number": 15,
        "window_text": "2) 검사 전 준비사항\n\n- (1) 검사칩이 들어있는 파우치를 개봉하기 전, 실온에 약 10분간 방치한다.\n - (2) 사용 전, 임상시험용 장비와 검사칩의 손상여부 및 이상유무를 확인한다.\n 3) 검사과정\n\n- (1) 장비 작동\n- ① 장비 후면 우측 하단의 전원 스위치를 “ON”상태로 한다.\n - ② 태블릿에 로그인 화면이 나타나면 아이디와 비밀번호를 입력한 후, “Log\n- - 42 -\nIn”버튼을 눌러 로그인한다.  초기 설정값은 아이디: pi, 비밀번호: top이다.\n\n - ③ 윈도우가 로딩되면 아이콘을 더블클릭하여 혈소판 기능검사 프로그램을\n실행한다.\n\n - ② 피펫으로 400㎕의 혈액을 검사칩의 혈액 주입구 한쪽 내부 표면을 따라\n자세한 정보는 “pi/PFA/vision 경로”에서 “날짜_시간_ID.log” 파일을 통해\n\n- (7) 다음 검사를 진행하려면, 새로운 검사칩을 준비하여 위의 과정을 반복한다.\n",
        "original_sentence": "- ② 태블릿에 로그인 화면이 나타나면 아이디와 비밀번호를 입력한 후, “Log\n- - 42 -\nIn”버튼을 눌러 로그인한다. "
      }
    },
    {
      "chunk_id": "chunk_578",
      "text": "초기 설정값은 아이디: pi, 비밀번호: top이다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 577,
        "window_size": 3,
        "char_count": 31,
        "word_count": 6,
        "page_number": 15,
        "window_text": "- (2) 사용 전, 임상시험용 장비와 검사칩의 손상여부 및 이상유무를 확인한다.\n 3) 검사과정\n\n- (1) 장비 작동\n- ① 장비 후면 우측 하단의 전원 스위치를 “ON”상태로 한다.\n - ② 태블릿에 로그인 화면이 나타나면 아이디와 비밀번호를 입력한 후, “Log\n- - 42 -\nIn”버튼을 눌러 로그인한다.  초기 설정값은 아이디: pi, 비밀번호: top이다.\n\n - ③ 윈도우가 로딩되면 아이콘을 더블클릭하여 혈소판 기능검사 프로그램을\n실행한다.\n\n - ② 피펫으로 400㎕의 혈액을 검사칩의 혈액 주입구 한쪽 내부 표면을 따라\n자세한 정보는 “pi/PFA/vision 경로”에서 “날짜_시간_ID.log” 파일을 통해\n\n- (7) 다음 검사를 진행하려면, 새로운 검사칩을 준비하여 위의 과정을 반복한다.\n - (8) 검사를 종료하려면 “Kit Information”화면의 “Cancel”버튼을 클릭하여 종료한다.\n",
        "original_sentence": "초기 설정값은 아이디: pi, 비밀번호: top이다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_579",
      "text": "- ③ 윈도우가 로딩되면 아이콘을 더블클릭하여 혈소판 기능검사 프로그램을\n실행한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 578,
        "window_size": 3,
        "char_count": 48,
        "word_count": 10,
        "page_number": 24,
        "window_text": "3) 검사과정\n\n- (1) 장비 작동\n- ① 장비 후면 우측 하단의 전원 스위치를 “ON”상태로 한다.\n - ② 태블릿에 로그인 화면이 나타나면 아이디와 비밀번호를 입력한 후, “Log\n- - 42 -\nIn”버튼을 눌러 로그인한다.  초기 설정값은 아이디: pi, 비밀번호: top이다.\n\n - ③ 윈도우가 로딩되면 아이콘을 더블클릭하여 혈소판 기능검사 프로그램을\n실행한다.\n\n - ② 피펫으로 400㎕의 혈액을 검사칩의 혈액 주입구 한쪽 내부 표면을 따라\n자세한 정보는 “pi/PFA/vision 경로”에서 “날짜_시간_ID.log” 파일을 통해\n\n- (7) 다음 검사를 진행하려면, 새로운 검사칩을 준비하여 위의 과정을 반복한다.\n - (8) 검사를 종료하려면 “Kit Information”화면의 “Cancel”버튼을 클릭하여 종료한다.\n - (9) 사용한 검사칩 폐기: 환자나 사용자를 위한 감염방지 및 교차감염방지를 위해\n4) 결과판정 및 정도관리\n\n- (1) 결과판정 : 검사결과는 혈액이동거리(MD), 혈액이동거리의 비율(MR)로 표시된다.\n",
        "original_sentence": "- ③ 윈도우가 로딩되면 아이콘을 더블클릭하여 혈소판 기능검사 프로그램을\n실행한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_580",
      "text": "- ② 피펫으로 400㎕의 혈액을 검사칩의 혈액 주입구 한쪽 내부 표면을 따라\n자세한 정보는 “pi/PFA/vision 경로”에서 “날짜_시간_ID.log” 파일을 통해\n\n- (7) 다음 검사를 진행하려면, 새로운 검사칩을 준비하여 위의 과정을 반복한다.\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 579,
        "window_size": 3,
        "char_count": 143,
        "word_count": 30,
        "page_number": 15,
        "window_text": "- ② 태블릿에 로그인 화면이 나타나면 아이디와 비밀번호를 입력한 후, “Log\n- - 42 -\nIn”버튼을 눌러 로그인한다.  초기 설정값은 아이디: pi, 비밀번호: top이다.\n\n - ③ 윈도우가 로딩되면 아이콘을 더블클릭하여 혈소판 기능검사 프로그램을\n실행한다.\n\n - ② 피펫으로 400㎕의 혈액을 검사칩의 혈액 주입구 한쪽 내부 표면을 따라\n자세한 정보는 “pi/PFA/vision 경로”에서 “날짜_시간_ID.log” 파일을 통해\n\n- (7) 다음 검사를 진행하려면, 새로운 검사칩을 준비하여 위의 과정을 반복한다.\n - (8) 검사를 종료하려면 “Kit Information”화면의 “Cancel”버튼을 클릭하여 종료한다.\n - (9) 사용한 검사칩 폐기: 환자나 사용자를 위한 감염방지 및 교차감염방지를 위해\n4) 결과판정 및 정도관리\n\n- (1) 결과판정 : 검사결과는 혈액이동거리(MD), 혈액이동거리의 비율(MR)로 표시된다.\n - - 43 -\n- (2) 정도관리\n- ① 본체\n교대근무를 시작할때마다 “유지보수메뉴(Maintenance Menu)”에서 “Self Test”를\n\nQC 검사를 위해 대조 검체 공여자 그룹을 설정할 것을 권장한다. ",
        "original_sentence": "- ② 피펫으로 400㎕의 혈액을 검사칩의 혈액 주입구 한쪽 내부 표면을 따라\n자세한 정보는 “pi/PFA/vision 경로”에서 “날짜_시간_ID.log” 파일을 통해\n\n- (7) 다음 검사를 진행하려면, 새로운 검사칩을 준비하여 위의 과정을 반복한다.\n"
      }
    },
    {
      "chunk_id": "chunk_581",
      "text": "- (8) 검사를 종료하려면 “Kit Information”화면의 “Cancel”버튼을 클릭하여 종료한다.\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 580,
        "window_size": 3,
        "char_count": 60,
        "word_count": 9,
        "page_number": 15,
        "window_text": "초기 설정값은 아이디: pi, 비밀번호: top이다.\n\n - ③ 윈도우가 로딩되면 아이콘을 더블클릭하여 혈소판 기능검사 프로그램을\n실행한다.\n\n - ② 피펫으로 400㎕의 혈액을 검사칩의 혈액 주입구 한쪽 내부 표면을 따라\n자세한 정보는 “pi/PFA/vision 경로”에서 “날짜_시간_ID.log” 파일을 통해\n\n- (7) 다음 검사를 진행하려면, 새로운 검사칩을 준비하여 위의 과정을 반복한다.\n - (8) 검사를 종료하려면 “Kit Information”화면의 “Cancel”버튼을 클릭하여 종료한다.\n - (9) 사용한 검사칩 폐기: 환자나 사용자를 위한 감염방지 및 교차감염방지를 위해\n4) 결과판정 및 정도관리\n\n- (1) 결과판정 : 검사결과는 혈액이동거리(MD), 혈액이동거리의 비율(MR)로 표시된다.\n - - 43 -\n- (2) 정도관리\n- ① 본체\n교대근무를 시작할때마다 “유지보수메뉴(Maintenance Menu)”에서 “Self Test”를\n\nQC 검사를 위해 대조 검체 공여자 그룹을 설정할 것을 권장한다.  적합한 QC\n\n가능한 반복정밀도를 보여주어야 한다. ",
        "original_sentence": "- (8) 검사를 종료하려면 “Kit Information”화면의 “Cancel”버튼을 클릭하여 종료한다.\n"
      }
    },
    {
      "chunk_id": "chunk_582",
      "text": "- (9) 사용한 검사칩 폐기: 환자나 사용자를 위한 감염방지 및 교차감염방지를 위해\n4) 결과판정 및 정도관리\n\n- (1) 결과판정 : 검사결과는 혈액이동거리(MD), 혈액이동거리의 비율(MR)로 표시된다.\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 581,
        "window_size": 3,
        "char_count": 117,
        "word_count": 25,
        "page_number": 6,
        "window_text": "- ③ 윈도우가 로딩되면 아이콘을 더블클릭하여 혈소판 기능검사 프로그램을\n실행한다.\n\n - ② 피펫으로 400㎕의 혈액을 검사칩의 혈액 주입구 한쪽 내부 표면을 따라\n자세한 정보는 “pi/PFA/vision 경로”에서 “날짜_시간_ID.log” 파일을 통해\n\n- (7) 다음 검사를 진행하려면, 새로운 검사칩을 준비하여 위의 과정을 반복한다.\n - (8) 검사를 종료하려면 “Kit Information”화면의 “Cancel”버튼을 클릭하여 종료한다.\n - (9) 사용한 검사칩 폐기: 환자나 사용자를 위한 감염방지 및 교차감염방지를 위해\n4) 결과판정 및 정도관리\n\n- (1) 결과판정 : 검사결과는 혈액이동거리(MD), 혈액이동거리의 비율(MR)로 표시된다.\n - - 43 -\n- (2) 정도관리\n- ① 본체\n교대근무를 시작할때마다 “유지보수메뉴(Maintenance Menu)”에서 “Self Test”를\n\nQC 검사를 위해 대조 검체 공여자 그룹을 설정할 것을 권장한다.  적합한 QC\n\n가능한 반복정밀도를 보여주어야 한다.  정도관리의 일환으로 신규 로트의\n\n것으로 간주된다. ",
        "original_sentence": "- (9) 사용한 검사칩 폐기: 환자나 사용자를 위한 감염방지 및 교차감염방지를 위해\n4) 결과판정 및 정도관리\n\n- (1) 결과판정 : 검사결과는 혈액이동거리(MD), 혈액이동거리의 비율(MR)로 표시된다.\n"
      }
    },
    {
      "chunk_id": "chunk_583",
      "text": "- - 43 -\n- (2) 정도관리\n- ① 본체\n교대근무를 시작할때마다 “유지보수메뉴(Maintenance Menu)”에서 “Self Test”를\n\nQC 검사를 위해 대조 검체 공여자 그룹을 설정할 것을 권장한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 582,
        "window_size": 3,
        "char_count": 120,
        "word_count": 26,
        "page_number": 6,
        "window_text": "- ② 피펫으로 400㎕의 혈액을 검사칩의 혈액 주입구 한쪽 내부 표면을 따라\n자세한 정보는 “pi/PFA/vision 경로”에서 “날짜_시간_ID.log” 파일을 통해\n\n- (7) 다음 검사를 진행하려면, 새로운 검사칩을 준비하여 위의 과정을 반복한다.\n - (8) 검사를 종료하려면 “Kit Information”화면의 “Cancel”버튼을 클릭하여 종료한다.\n - (9) 사용한 검사칩 폐기: 환자나 사용자를 위한 감염방지 및 교차감염방지를 위해\n4) 결과판정 및 정도관리\n\n- (1) 결과판정 : 검사결과는 혈액이동거리(MD), 혈액이동거리의 비율(MR)로 표시된다.\n - - 43 -\n- (2) 정도관리\n- ① 본체\n교대근무를 시작할때마다 “유지보수메뉴(Maintenance Menu)”에서 “Self Test”를\n\nQC 검사를 위해 대조 검체 공여자 그룹을 설정할 것을 권장한다.  적합한 QC\n\n가능한 반복정밀도를 보여주어야 한다.  정도관리의 일환으로 신규 로트의\n\n것으로 간주된다.  평균 MD 또는 MR이 진단경계치 범위를 벗어나는 경우\n\n검사실의 설정된 대조 검체 공여자 그룹에서 두 번째 공여자를 선택하여 이\n\n해야 한다. ",
        "original_sentence": "- - 43 -\n- (2) 정도관리\n- ① 본체\n교대근무를 시작할때마다 “유지보수메뉴(Maintenance Menu)”에서 “Self Test”를\n\nQC 검사를 위해 대조 검체 공여자 그룹을 설정할 것을 권장한다. "
      }
    },
    {
      "chunk_id": "chunk_584",
      "text": "적합한 QC\n\n가능한 반복정밀도를 보여주어야 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 583,
        "window_size": 3,
        "char_count": 29,
        "word_count": 6,
        "page_number": 24,
        "window_text": "- (8) 검사를 종료하려면 “Kit Information”화면의 “Cancel”버튼을 클릭하여 종료한다.\n - (9) 사용한 검사칩 폐기: 환자나 사용자를 위한 감염방지 및 교차감염방지를 위해\n4) 결과판정 및 정도관리\n\n- (1) 결과판정 : 검사결과는 혈액이동거리(MD), 혈액이동거리의 비율(MR)로 표시된다.\n - - 43 -\n- (2) 정도관리\n- ① 본체\n교대근무를 시작할때마다 “유지보수메뉴(Maintenance Menu)”에서 “Self Test”를\n\nQC 검사를 위해 대조 검체 공여자 그룹을 설정할 것을 권장한다.  적합한 QC\n\n가능한 반복정밀도를 보여주어야 한다.  정도관리의 일환으로 신규 로트의\n\n것으로 간주된다.  평균 MD 또는 MR이 진단경계치 범위를 벗어나는 경우\n\n검사실의 설정된 대조 검체 공여자 그룹에서 두 번째 공여자를 선택하여 이\n\n해야 한다.  첫 번째 공여자는 본 검사의 대조 검체 공여자 그룹에서 배제\n\n- 7.4. ",
        "original_sentence": "적합한 QC\n\n가능한 반복정밀도를 보여주어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_585",
      "text": "정도관리의 일환으로 신규 로트의\n\n것으로 간주된다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 584,
        "window_size": 3,
        "char_count": 29,
        "word_count": 6,
        "page_number": 88,
        "window_text": "- (9) 사용한 검사칩 폐기: 환자나 사용자를 위한 감염방지 및 교차감염방지를 위해\n4) 결과판정 및 정도관리\n\n- (1) 결과판정 : 검사결과는 혈액이동거리(MD), 혈액이동거리의 비율(MR)로 표시된다.\n - - 43 -\n- (2) 정도관리\n- ① 본체\n교대근무를 시작할때마다 “유지보수메뉴(Maintenance Menu)”에서 “Self Test”를\n\nQC 검사를 위해 대조 검체 공여자 그룹을 설정할 것을 권장한다.  적합한 QC\n\n가능한 반복정밀도를 보여주어야 한다.  정도관리의 일환으로 신규 로트의\n\n것으로 간주된다.  평균 MD 또는 MR이 진단경계치 범위를 벗어나는 경우\n\n검사실의 설정된 대조 검체 공여자 그룹에서 두 번째 공여자를 선택하여 이\n\n해야 한다.  첫 번째 공여자는 본 검사의 대조 검체 공여자 그룹에서 배제\n\n- 7.4.  임상시험용 의료기기의 공급 및 관리\n예시)\n\n혈액응고 시간측정기, 채혈을 위한 란셋, 사용설명서가 파우치에 포장되어 있는\n\n상태로 공급 소모품인 검사지는 별도 구매. ",
        "original_sentence": "정도관리의 일환으로 신규 로트의\n\n것으로 간주된다. "
      }
    },
    {
      "chunk_id": "chunk_586",
      "text": "평균 MD 또는 MR이 진단경계치 범위를 벗어나는 경우\n\n검사실의 설정된 대조 검체 공여자 그룹에서 두 번째 공여자를 선택하여 이\n\n해야 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 585,
        "window_size": 3,
        "char_count": 81,
        "word_count": 21,
        "page_number": 24,
        "window_text": "- - 43 -\n- (2) 정도관리\n- ① 본체\n교대근무를 시작할때마다 “유지보수메뉴(Maintenance Menu)”에서 “Self Test”를\n\nQC 검사를 위해 대조 검체 공여자 그룹을 설정할 것을 권장한다.  적합한 QC\n\n가능한 반복정밀도를 보여주어야 한다.  정도관리의 일환으로 신규 로트의\n\n것으로 간주된다.  평균 MD 또는 MR이 진단경계치 범위를 벗어나는 경우\n\n검사실의 설정된 대조 검체 공여자 그룹에서 두 번째 공여자를 선택하여 이\n\n해야 한다.  첫 번째 공여자는 본 검사의 대조 검체 공여자 그룹에서 배제\n\n- 7.4.  임상시험용 의료기기의 공급 및 관리\n예시)\n\n혈액응고 시간측정기, 채혈을 위한 란셋, 사용설명서가 파우치에 포장되어 있는\n\n상태로 공급 소모품인 검사지는 별도 구매.  낱개포장 된 검사지가 1박스 당 48개가\n\n동봉. ",
        "original_sentence": "평균 MD 또는 MR이 진단경계치 범위를 벗어나는 경우\n\n검사실의 설정된 대조 검체 공여자 그룹에서 두 번째 공여자를 선택하여 이\n\n해야 한다. "
      }
    },
    {
      "chunk_id": "chunk_587",
      "text": "첫 번째 공여자는 본 검사의 대조 검체 공여자 그룹에서 배제\n\n- 7.4. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 586,
        "window_size": 3,
        "char_count": 42,
        "word_count": 12,
        "page_number": 15,
        "window_text": "적합한 QC\n\n가능한 반복정밀도를 보여주어야 한다.  정도관리의 일환으로 신규 로트의\n\n것으로 간주된다.  평균 MD 또는 MR이 진단경계치 범위를 벗어나는 경우\n\n검사실의 설정된 대조 검체 공여자 그룹에서 두 번째 공여자를 선택하여 이\n\n해야 한다.  첫 번째 공여자는 본 검사의 대조 검체 공여자 그룹에서 배제\n\n- 7.4.  임상시험용 의료기기의 공급 및 관리\n예시)\n\n혈액응고 시간측정기, 채혈을 위한 란셋, 사용설명서가 파우치에 포장되어 있는\n\n상태로 공급 소모품인 검사지는 별도 구매.  낱개포장 된 검사지가 1박스 당 48개가\n\n동봉.  임상시험 종료후 남은 제품은 폐기한다.\n\n",
        "original_sentence": "첫 번째 공여자는 본 검사의 대조 검체 공여자 그룹에서 배제\n\n- 7.4. "
      }
    },
    {
      "chunk_id": "chunk_588",
      "text": "임상시험용 의료기기의 공급 및 관리\n예시)\n\n혈액응고 시간측정기, 채혈을 위한 란셋, 사용설명서가 파우치에 포장되어 있는\n\n상태로 공급 소모품인 검사지는 별도 구매. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 587,
        "window_size": 3,
        "char_count": 93,
        "word_count": 21,
        "page_number": 9,
        "window_text": "정도관리의 일환으로 신규 로트의\n\n것으로 간주된다.  평균 MD 또는 MR이 진단경계치 범위를 벗어나는 경우\n\n검사실의 설정된 대조 검체 공여자 그룹에서 두 번째 공여자를 선택하여 이\n\n해야 한다.  첫 번째 공여자는 본 검사의 대조 검체 공여자 그룹에서 배제\n\n- 7.4.  임상시험용 의료기기의 공급 및 관리\n예시)\n\n혈액응고 시간측정기, 채혈을 위한 란셋, 사용설명서가 파우치에 포장되어 있는\n\n상태로 공급 소모품인 검사지는 별도 구매.  낱개포장 된 검사지가 1박스 당 48개가\n\n동봉.  임상시험 종료후 남은 제품은 폐기한다.\n\n - - 44 -\n<!-- PAGE_51 -->\n###### 8. ",
        "original_sentence": "임상시험용 의료기기의 공급 및 관리\n예시)\n\n혈액응고 시간측정기, 채혈을 위한 란셋, 사용설명서가 파우치에 포장되어 있는\n\n상태로 공급 소모품인 검사지는 별도 구매. "
      }
    },
    {
      "chunk_id": "chunk_589",
      "text": "낱개포장 된 검사지가 1박스 당 48개가\n\n동봉. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 588,
        "window_size": 3,
        "char_count": 28,
        "word_count": 7,
        "page_number": 6,
        "window_text": "평균 MD 또는 MR이 진단경계치 범위를 벗어나는 경우\n\n검사실의 설정된 대조 검체 공여자 그룹에서 두 번째 공여자를 선택하여 이\n\n해야 한다.  첫 번째 공여자는 본 검사의 대조 검체 공여자 그룹에서 배제\n\n- 7.4.  임상시험용 의료기기의 공급 및 관리\n예시)\n\n혈액응고 시간측정기, 채혈을 위한 란셋, 사용설명서가 파우치에 포장되어 있는\n\n상태로 공급 소모품인 검사지는 별도 구매.  낱개포장 된 검사지가 1박스 당 48개가\n\n동봉.  임상시험 종료후 남은 제품은 폐기한다.\n\n - - 44 -\n<!-- PAGE_51 -->\n###### 8.  피험자의 선정기준·제외기준·인원 및 그 근거\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n* 성별, 나이, 교육정도(동의능력). ",
        "original_sentence": "낱개포장 된 검사지가 1박스 당 48개가\n\n동봉. "
      }
    },
    {
      "chunk_id": "chunk_590",
      "text": "임상시험 종료후 남은 제품은 폐기한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 589,
        "window_size": 3,
        "char_count": 23,
        "word_count": 5,
        "page_number": 9,
        "window_text": "첫 번째 공여자는 본 검사의 대조 검체 공여자 그룹에서 배제\n\n- 7.4.  임상시험용 의료기기의 공급 및 관리\n예시)\n\n혈액응고 시간측정기, 채혈을 위한 란셋, 사용설명서가 파우치에 포장되어 있는\n\n상태로 공급 소모품인 검사지는 별도 구매.  낱개포장 된 검사지가 1박스 당 48개가\n\n동봉.  임상시험 종료후 남은 제품은 폐기한다.\n\n - - 44 -\n<!-- PAGE_51 -->\n###### 8.  피험자의 선정기준·제외기준·인원 및 그 근거\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n* 성별, 나이, 교육정도(동의능력).  흡연여부, 알코올 혹은 약 남용자, 사회 경제적\n\n상태, 임신과 수유, 유전학적 병력, 정서적인 제한 등을 고려하여 제외한다.\n\n",
        "original_sentence": "임상시험 종료후 남은 제품은 폐기한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_591",
      "text": "- - 44 -\n<!-- PAGE_51 -->\n###### 8. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 590,
        "window_size": 3,
        "char_count": 36,
        "word_count": 9,
        "page_number": 51,
        "window_text": "임상시험용 의료기기의 공급 및 관리\n예시)\n\n혈액응고 시간측정기, 채혈을 위한 란셋, 사용설명서가 파우치에 포장되어 있는\n\n상태로 공급 소모품인 검사지는 별도 구매.  낱개포장 된 검사지가 1박스 당 48개가\n\n동봉.  임상시험 종료후 남은 제품은 폐기한다.\n\n - - 44 -\n<!-- PAGE_51 -->\n###### 8.  피험자의 선정기준·제외기준·인원 및 그 근거\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n* 성별, 나이, 교육정도(동의능력).  흡연여부, 알코올 혹은 약 남용자, 사회 경제적\n\n상태, 임신과 수유, 유전학적 병력, 정서적인 제한 등을 고려하여 제외한다.\n\n 예시)\n\n- 8.1. ",
        "original_sentence": "- - 44 -\n<!-- PAGE_51 -->\n###### 8. "
      }
    },
    {
      "chunk_id": "chunk_592",
      "text": "피험자의 선정기준·제외기준·인원 및 그 근거\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n* 성별, 나이, 교육정도(동의능력). ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 591,
        "window_size": 3,
        "char_count": 100,
        "word_count": 23,
        "page_number": 6,
        "window_text": "낱개포장 된 검사지가 1박스 당 48개가\n\n동봉.  임상시험 종료후 남은 제품은 폐기한다.\n\n - - 44 -\n<!-- PAGE_51 -->\n###### 8.  피험자의 선정기준·제외기준·인원 및 그 근거\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n* 성별, 나이, 교육정도(동의능력).  흡연여부, 알코올 혹은 약 남용자, 사회 경제적\n\n상태, 임신과 수유, 유전학적 병력, 정서적인 제한 등을 고려하여 제외한다.\n\n 예시)\n\n- 8.1.  피험자 선정기준\n- 가. ",
        "original_sentence": "피험자의 선정기준·제외기준·인원 및 그 근거\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n* 성별, 나이, 교육정도(동의능력). "
      }
    },
    {
      "chunk_id": "chunk_593",
      "text": "흡연여부, 알코올 혹은 약 남용자, 사회 경제적\n\n상태, 임신과 수유, 유전학적 병력, 정서적인 제한 등을 고려하여 제외한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 592,
        "window_size": 3,
        "char_count": 72,
        "word_count": 17,
        "page_number": 3,
        "window_text": "임상시험 종료후 남은 제품은 폐기한다.\n\n - - 44 -\n<!-- PAGE_51 -->\n###### 8.  피험자의 선정기준·제외기준·인원 및 그 근거\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n* 성별, 나이, 교육정도(동의능력).  흡연여부, 알코올 혹은 약 남용자, 사회 경제적\n\n상태, 임신과 수유, 유전학적 병력, 정서적인 제한 등을 고려하여 제외한다.\n\n 예시)\n\n- 8.1.  피험자 선정기준\n- 가.  혈소판 기능검사\n- - 45 -\n1) 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand disease),\n\n글란즈만혈소판무력증(Glanzmann's thrombasthenia), 약물유발 혈소판기능부전\n\n(drug-induced platelet dysfunction) 등의 선천적/후천적 혈소판기능장애 환자\n\n2）P2Y12 test: 혈관질환의 위험군, 혈관질환 병력 등으로 clopidogrel 복용예정인\n\n환자에서 clopidogrel 복용 전 1번과 최소 5일이상 clopidogrel 복용 후 1번\n\n- - 임신중인 여성\n- 나. ",
        "original_sentence": "흡연여부, 알코올 혹은 약 남용자, 사회 경제적\n\n상태, 임신과 수유, 유전학적 병력, 정서적인 제한 등을 고려하여 제외한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_594",
      "text": "예시)\n\n- 8.1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 593,
        "window_size": 3,
        "char_count": 12,
        "word_count": 3,
        "page_number": 6,
        "window_text": "- - 44 -\n<!-- PAGE_51 -->\n###### 8.  피험자의 선정기준·제외기준·인원 및 그 근거\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n* 성별, 나이, 교육정도(동의능력).  흡연여부, 알코올 혹은 약 남용자, 사회 경제적\n\n상태, 임신과 수유, 유전학적 병력, 정서적인 제한 등을 고려하여 제외한다.\n\n 예시)\n\n- 8.1.  피험자 선정기준\n- 가.  혈소판 기능검사\n- - 45 -\n1) 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand disease),\n\n글란즈만혈소판무력증(Glanzmann's thrombasthenia), 약물유발 혈소판기능부전\n\n(drug-induced platelet dysfunction) 등의 선천적/후천적 혈소판기능장애 환자\n\n2）P2Y12 test: 혈관질환의 위험군, 혈관질환 병력 등으로 clopidogrel 복용예정인\n\n환자에서 clopidogrel 복용 전 1번과 최소 5일이상 clopidogrel 복용 후 1번\n\n- - 임신중인 여성\n- 나.  혈소판 약물반응검사 제외기준\n- - 출혈성 질환, 응고장애의 병력이 있는 경우\n- - 46 -\n혈소판 약물반응검사\n\n- 8.3. ",
        "original_sentence": "예시)\n\n- 8.1. "
      }
    },
    {
      "chunk_id": "chunk_595",
      "text": "피험자 선정기준\n- 가. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 594,
        "window_size": 3,
        "char_count": 14,
        "word_count": 4,
        "page_number": 33,
        "window_text": "피험자의 선정기준·제외기준·인원 및 그 근거\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n* 성별, 나이, 교육정도(동의능력).  흡연여부, 알코올 혹은 약 남용자, 사회 경제적\n\n상태, 임신과 수유, 유전학적 병력, 정서적인 제한 등을 고려하여 제외한다.\n\n 예시)\n\n- 8.1.  피험자 선정기준\n- 가.  혈소판 기능검사\n- - 45 -\n1) 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand disease),\n\n글란즈만혈소판무력증(Glanzmann's thrombasthenia), 약물유발 혈소판기능부전\n\n(drug-induced platelet dysfunction) 등의 선천적/후천적 혈소판기능장애 환자\n\n2）P2Y12 test: 혈관질환의 위험군, 혈관질환 병력 등으로 clopidogrel 복용예정인\n\n환자에서 clopidogrel 복용 전 1번과 최소 5일이상 clopidogrel 복용 후 1번\n\n- - 임신중인 여성\n- 나.  혈소판 약물반응검사 제외기준\n- - 출혈성 질환, 응고장애의 병력이 있는 경우\n- - 46 -\n혈소판 약물반응검사\n\n- 8.3.  목표대상자 수 및 그 근거\n* 연구피험자 수를 결정하기 위해서는 사전 정보가 필요하며, 아래의 항목과 같을\n\nEPI test 양성(비정상 결과) 환자 105명 이상, EPI test 음성(정상 결과) 대조군\n\n- 나. ",
        "original_sentence": "피험자 선정기준\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_596",
      "text": "혈소판 기능검사\n- - 45 -\n1) 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand disease),\n\n글란즈만혈소판무력증(Glanzmann's thrombasthenia), 약물유발 혈소판기능부전\n\n(drug-induced platelet dysfunction) 등의 선천적/후천적 혈소판기능장애 환자\n\n2）P2Y12 test: 혈관질환의 위험군, 혈관질환 병력 등으로 clopidogrel 복용예정인\n\n환자에서 clopidogrel 복용 전 1번과 최소 5일이상 clopidogrel 복용 후 1번\n\n- - 임신중인 여성\n- 나. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 595,
        "window_size": 3,
        "char_count": 314,
        "word_count": 51,
        "page_number": 6,
        "window_text": "흡연여부, 알코올 혹은 약 남용자, 사회 경제적\n\n상태, 임신과 수유, 유전학적 병력, 정서적인 제한 등을 고려하여 제외한다.\n\n 예시)\n\n- 8.1.  피험자 선정기준\n- 가.  혈소판 기능검사\n- - 45 -\n1) 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand disease),\n\n글란즈만혈소판무력증(Glanzmann's thrombasthenia), 약물유발 혈소판기능부전\n\n(drug-induced platelet dysfunction) 등의 선천적/후천적 혈소판기능장애 환자\n\n2）P2Y12 test: 혈관질환의 위험군, 혈관질환 병력 등으로 clopidogrel 복용예정인\n\n환자에서 clopidogrel 복용 전 1번과 최소 5일이상 clopidogrel 복용 후 1번\n\n- - 임신중인 여성\n- 나.  혈소판 약물반응검사 제외기준\n- - 출혈성 질환, 응고장애의 병력이 있는 경우\n- - 46 -\n혈소판 약물반응검사\n\n- 8.3.  목표대상자 수 및 그 근거\n* 연구피험자 수를 결정하기 위해서는 사전 정보가 필요하며, 아래의 항목과 같을\n\nEPI test 양성(비정상 결과) 환자 105명 이상, EPI test 음성(정상 결과) 대조군\n\n- 나.  혈소판 약물반응검사\nAspirin test 양성(약물 반응) 환자 75명 이상, Aspirin test 음성(약물 비반응)\n\n환자 40명 이상, P2Y12 test 양성(약물 반응) 환자 132명 이상, P2Y12 test 음성\n\n(약물 비반응) 환자 155명 이상을 대상으로 한다.\n\n",
        "original_sentence": "혈소판 기능검사\n- - 45 -\n1) 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand disease),\n\n글란즈만혈소판무력증(Glanzmann's thrombasthenia), 약물유발 혈소판기능부전\n\n(drug-induced platelet dysfunction) 등의 선천적/후천적 혈소판기능장애 환자\n\n2）P2Y12 test: 혈관질환의 위험군, 혈관질환 병력 등으로 clopidogrel 복용예정인\n\n환자에서 clopidogrel 복용 전 1번과 최소 5일이상 clopidogrel 복용 후 1번\n\n- - 임신중인 여성\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_597",
      "text": "혈소판 약물반응검사 제외기준\n- - 출혈성 질환, 응고장애의 병력이 있는 경우\n- - 46 -\n혈소판 약물반응검사\n\n- 8.3. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 596,
        "window_size": 3,
        "char_count": 72,
        "word_count": 19,
        "page_number": 15,
        "window_text": "예시)\n\n- 8.1.  피험자 선정기준\n- 가.  혈소판 기능검사\n- - 45 -\n1) 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand disease),\n\n글란즈만혈소판무력증(Glanzmann's thrombasthenia), 약물유발 혈소판기능부전\n\n(drug-induced platelet dysfunction) 등의 선천적/후천적 혈소판기능장애 환자\n\n2）P2Y12 test: 혈관질환의 위험군, 혈관질환 병력 등으로 clopidogrel 복용예정인\n\n환자에서 clopidogrel 복용 전 1번과 최소 5일이상 clopidogrel 복용 후 1번\n\n- - 임신중인 여성\n- 나.  혈소판 약물반응검사 제외기준\n- - 출혈성 질환, 응고장애의 병력이 있는 경우\n- - 46 -\n혈소판 약물반응검사\n\n- 8.3.  목표대상자 수 및 그 근거\n* 연구피험자 수를 결정하기 위해서는 사전 정보가 필요하며, 아래의 항목과 같을\n\nEPI test 양성(비정상 결과) 환자 105명 이상, EPI test 음성(정상 결과) 대조군\n\n- 나.  혈소판 약물반응검사\nAspirin test 양성(약물 반응) 환자 75명 이상, Aspirin test 음성(약물 비반응)\n\n환자 40명 이상, P2Y12 test 양성(약물 반응) 환자 132명 이상, P2Y12 test 음성\n\n(약물 비반응) 환자 155명 이상을 대상으로 한다.\n\n - - 47 -\n- 8.3.2 피험자 수 산출 방법\n시험 시약의 예상 민감도와 특이도, 일치도를 이용한 통계학적 방법을 적용하여\n\n검체 수를 산출하였다. ",
        "original_sentence": "혈소판 약물반응검사 제외기준\n- - 출혈성 질환, 응고장애의 병력이 있는 경우\n- - 46 -\n혈소판 약물반응검사\n\n- 8.3. "
      }
    },
    {
      "chunk_id": "chunk_598",
      "text": "목표대상자 수 및 그 근거\n* 연구피험자 수를 결정하기 위해서는 사전 정보가 필요하며, 아래의 항목과 같을\n\nEPI test 양성(비정상 결과) 환자 105명 이상, EPI test 음성(정상 결과) 대조군\n\n- 나. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 597,
        "window_size": 3,
        "char_count": 122,
        "word_count": 30,
        "page_number": 6,
        "window_text": "피험자 선정기준\n- 가.  혈소판 기능검사\n- - 45 -\n1) 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand disease),\n\n글란즈만혈소판무력증(Glanzmann's thrombasthenia), 약물유발 혈소판기능부전\n\n(drug-induced platelet dysfunction) 등의 선천적/후천적 혈소판기능장애 환자\n\n2）P2Y12 test: 혈관질환의 위험군, 혈관질환 병력 등으로 clopidogrel 복용예정인\n\n환자에서 clopidogrel 복용 전 1번과 최소 5일이상 clopidogrel 복용 후 1번\n\n- - 임신중인 여성\n- 나.  혈소판 약물반응검사 제외기준\n- - 출혈성 질환, 응고장애의 병력이 있는 경우\n- - 46 -\n혈소판 약물반응검사\n\n- 8.3.  목표대상자 수 및 그 근거\n* 연구피험자 수를 결정하기 위해서는 사전 정보가 필요하며, 아래의 항목과 같을\n\nEPI test 양성(비정상 결과) 환자 105명 이상, EPI test 음성(정상 결과) 대조군\n\n- 나.  혈소판 약물반응검사\nAspirin test 양성(약물 반응) 환자 75명 이상, Aspirin test 음성(약물 비반응)\n\n환자 40명 이상, P2Y12 test 양성(약물 반응) 환자 132명 이상, P2Y12 test 음성\n\n(약물 비반응) 환자 155명 이상을 대상으로 한다.\n\n - - 47 -\n- 8.3.2 피험자 수 산출 방법\n시험 시약의 예상 민감도와 특이도, 일치도를 이용한 통계학적 방법을 적용하여\n\n검체 수를 산출하였다.  계산식에 적용한 민감도와 특이도는 아래 ‘8.3.3 피험자\n\n- - Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체\n- ③ ADP test 양성 검체 검사 시 (민감도 85%),\n- - 대립가설: 개발제품의 민감도가 85% 이상이다.\n",
        "original_sentence": "목표대상자 수 및 그 근거\n* 연구피험자 수를 결정하기 위해서는 사전 정보가 필요하며, 아래의 항목과 같을\n\nEPI test 양성(비정상 결과) 환자 105명 이상, EPI test 음성(정상 결과) 대조군\n\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_599",
      "text": "혈소판 약물반응검사\nAspirin test 양성(약물 반응) 환자 75명 이상, Aspirin test 음성(약물 비반응)\n\n환자 40명 이상, P2Y12 test 양성(약물 반응) 환자 132명 이상, P2Y12 test 음성\n\n(약물 비반응) 환자 155명 이상을 대상으로 한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 598,
        "window_size": 3,
        "char_count": 160,
        "word_count": 33,
        "page_number": 6,
        "window_text": "혈소판 기능검사\n- - 45 -\n1) 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand disease),\n\n글란즈만혈소판무력증(Glanzmann's thrombasthenia), 약물유발 혈소판기능부전\n\n(drug-induced platelet dysfunction) 등의 선천적/후천적 혈소판기능장애 환자\n\n2）P2Y12 test: 혈관질환의 위험군, 혈관질환 병력 등으로 clopidogrel 복용예정인\n\n환자에서 clopidogrel 복용 전 1번과 최소 5일이상 clopidogrel 복용 후 1번\n\n- - 임신중인 여성\n- 나.  혈소판 약물반응검사 제외기준\n- - 출혈성 질환, 응고장애의 병력이 있는 경우\n- - 46 -\n혈소판 약물반응검사\n\n- 8.3.  목표대상자 수 및 그 근거\n* 연구피험자 수를 결정하기 위해서는 사전 정보가 필요하며, 아래의 항목과 같을\n\nEPI test 양성(비정상 결과) 환자 105명 이상, EPI test 음성(정상 결과) 대조군\n\n- 나.  혈소판 약물반응검사\nAspirin test 양성(약물 반응) 환자 75명 이상, Aspirin test 음성(약물 비반응)\n\n환자 40명 이상, P2Y12 test 양성(약물 반응) 환자 132명 이상, P2Y12 test 음성\n\n(약물 비반응) 환자 155명 이상을 대상으로 한다.\n\n - - 47 -\n- 8.3.2 피험자 수 산출 방법\n시험 시약의 예상 민감도와 특이도, 일치도를 이용한 통계학적 방법을 적용하여\n\n검체 수를 산출하였다.  계산식에 적용한 민감도와 특이도는 아래 ‘8.3.3 피험자\n\n- - Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체\n- ③ ADP test 양성 검체 검사 시 (민감도 85%),\n- - 대립가설: 개발제품의 민감도가 85% 이상이다.\n - - 귀무가설: 개발제품의 민감도가 85% 미만이다.\n",
        "original_sentence": "혈소판 약물반응검사\nAspirin test 양성(약물 반응) 환자 75명 이상, Aspirin test 음성(약물 비반응)\n\n환자 40명 이상, P2Y12 test 양성(약물 반응) 환자 132명 이상, P2Y12 test 음성\n\n(약물 비반응) 환자 155명 이상을 대상으로 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_600",
      "text": "- - 47 -\n- 8.3.2 피험자 수 산출 방법\n시험 시약의 예상 민감도와 특이도, 일치도를 이용한 통계학적 방법을 적용하여\n\n검체 수를 산출하였다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 599,
        "window_size": 3,
        "char_count": 86,
        "word_count": 23,
        "page_number": 6,
        "window_text": "혈소판 약물반응검사 제외기준\n- - 출혈성 질환, 응고장애의 병력이 있는 경우\n- - 46 -\n혈소판 약물반응검사\n\n- 8.3.  목표대상자 수 및 그 근거\n* 연구피험자 수를 결정하기 위해서는 사전 정보가 필요하며, 아래의 항목과 같을\n\nEPI test 양성(비정상 결과) 환자 105명 이상, EPI test 음성(정상 결과) 대조군\n\n- 나.  혈소판 약물반응검사\nAspirin test 양성(약물 반응) 환자 75명 이상, Aspirin test 음성(약물 비반응)\n\n환자 40명 이상, P2Y12 test 양성(약물 반응) 환자 132명 이상, P2Y12 test 음성\n\n(약물 비반응) 환자 155명 이상을 대상으로 한다.\n\n - - 47 -\n- 8.3.2 피험자 수 산출 방법\n시험 시약의 예상 민감도와 특이도, 일치도를 이용한 통계학적 방법을 적용하여\n\n검체 수를 산출하였다.  계산식에 적용한 민감도와 특이도는 아래 ‘8.3.3 피험자\n\n- - Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체\n- ③ ADP test 양성 검체 검사 시 (민감도 85%),\n- - 대립가설: 개발제품의 민감도가 85% 이상이다.\n - - 귀무가설: 개발제품의 민감도가 85% 미만이다.\n - - 48 -\n<!-- PAGE_55 -->\n# - 적용 계산식 : \n\n   \n\n       \n\n[n = sample size (검체 수), p (민감도) = 0.85,\n\n- ⑥ SIPA test 음성 검체 검사 시 (특이도 80%),\n- - 대립가설: 개발제품의 특이도가 80% 이상이다.\n",
        "original_sentence": "- - 47 -\n- 8.3.2 피험자 수 산출 방법\n시험 시약의 예상 민감도와 특이도, 일치도를 이용한 통계학적 방법을 적용하여\n\n검체 수를 산출하였다. "
      }
    },
    {
      "chunk_id": "chunk_601",
      "text": "계산식에 적용한 민감도와 특이도는 아래 ‘8.3.3 피험자\n\n- - Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체\n- ③ ADP test 양성 검체 검사 시 (민감도 85%),\n- - 대립가설: 개발제품의 민감도가 85% 이상이다.\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 600,
        "window_size": 3,
        "char_count": 147,
        "word_count": 36,
        "page_number": 15,
        "window_text": "목표대상자 수 및 그 근거\n* 연구피험자 수를 결정하기 위해서는 사전 정보가 필요하며, 아래의 항목과 같을\n\nEPI test 양성(비정상 결과) 환자 105명 이상, EPI test 음성(정상 결과) 대조군\n\n- 나.  혈소판 약물반응검사\nAspirin test 양성(약물 반응) 환자 75명 이상, Aspirin test 음성(약물 비반응)\n\n환자 40명 이상, P2Y12 test 양성(약물 반응) 환자 132명 이상, P2Y12 test 음성\n\n(약물 비반응) 환자 155명 이상을 대상으로 한다.\n\n - - 47 -\n- 8.3.2 피험자 수 산출 방법\n시험 시약의 예상 민감도와 특이도, 일치도를 이용한 통계학적 방법을 적용하여\n\n검체 수를 산출하였다.  계산식에 적용한 민감도와 특이도는 아래 ‘8.3.3 피험자\n\n- - Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체\n- ③ ADP test 양성 검체 검사 시 (민감도 85%),\n- - 대립가설: 개발제품의 민감도가 85% 이상이다.\n - - 귀무가설: 개발제품의 민감도가 85% 미만이다.\n - - 48 -\n<!-- PAGE_55 -->\n# - 적용 계산식 : \n\n   \n\n       \n\n[n = sample size (검체 수), p (민감도) = 0.85,\n\n- ⑥ SIPA test 음성 검체 검사 시 (특이도 80%),\n- - 대립가설: 개발제품의 특이도가 80% 이상이다.\n - - 귀무가설: 개발제품의 특이도가 80% 미만이다.\n",
        "original_sentence": "계산식에 적용한 민감도와 특이도는 아래 ‘8.3.3 피험자\n\n- - Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체\n- ③ ADP test 양성 검체 검사 시 (민감도 85%),\n- - 대립가설: 개발제품의 민감도가 85% 이상이다.\n"
      }
    },
    {
      "chunk_id": "chunk_602",
      "text": "- - 귀무가설: 개발제품의 민감도가 85% 미만이다.\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 601,
        "window_size": 3,
        "char_count": 31,
        "word_count": 7,
        "page_number": 6,
        "window_text": "혈소판 약물반응검사\nAspirin test 양성(약물 반응) 환자 75명 이상, Aspirin test 음성(약물 비반응)\n\n환자 40명 이상, P2Y12 test 양성(약물 반응) 환자 132명 이상, P2Y12 test 음성\n\n(약물 비반응) 환자 155명 이상을 대상으로 한다.\n\n - - 47 -\n- 8.3.2 피험자 수 산출 방법\n시험 시약의 예상 민감도와 특이도, 일치도를 이용한 통계학적 방법을 적용하여\n\n검체 수를 산출하였다.  계산식에 적용한 민감도와 특이도는 아래 ‘8.3.3 피험자\n\n- - Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체\n- ③ ADP test 양성 검체 검사 시 (민감도 85%),\n- - 대립가설: 개발제품의 민감도가 85% 이상이다.\n - - 귀무가설: 개발제품의 민감도가 85% 미만이다.\n - - 48 -\n<!-- PAGE_55 -->\n# - 적용 계산식 : \n\n   \n\n       \n\n[n = sample size (검체 수), p (민감도) = 0.85,\n\n- ⑥ SIPA test 음성 검체 검사 시 (특이도 80%),\n- - 대립가설: 개발제품의 특이도가 80% 이상이다.\n - - 귀무가설: 개발제품의 특이도가 80% 미만이다.\n - - 49 -\n<!-- PAGE_56 -->\n# - 적용 계산식 : \n\n   \n\n       \n\n[n = sample size (검체 수), p (특이도) = 0.80,\n\n- - Sample Size (5% 탈락률 적용) = 39.10, 약 40개 검체\n- - 50 -\n- ③ P2Y12 test 양성 검체 검사 시 (민감도 80%),\n- - 대립가설: 개발제품의 민감도가 80% 이상이다.\n",
        "original_sentence": "- - 귀무가설: 개발제품의 민감도가 85% 미만이다.\n"
      }
    },
    {
      "chunk_id": "chunk_603",
      "text": "- - 48 -\n<!-- PAGE_55 -->\n# - 적용 계산식 : \n\n   \n\n       \n\n[n = sample size (검체 수), p (민감도) = 0.85,\n\n- ⑥ SIPA test 음성 검체 검사 시 (특이도 80%),\n- - 대립가설: 개발제품의 특이도가 80% 이상이다.\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 602,
        "window_size": 3,
        "char_count": 190,
        "word_count": 52,
        "page_number": 55,
        "window_text": "- - 47 -\n- 8.3.2 피험자 수 산출 방법\n시험 시약의 예상 민감도와 특이도, 일치도를 이용한 통계학적 방법을 적용하여\n\n검체 수를 산출하였다.  계산식에 적용한 민감도와 특이도는 아래 ‘8.3.3 피험자\n\n- - Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체\n- ③ ADP test 양성 검체 검사 시 (민감도 85%),\n- - 대립가설: 개발제품의 민감도가 85% 이상이다.\n - - 귀무가설: 개발제품의 민감도가 85% 미만이다.\n - - 48 -\n<!-- PAGE_55 -->\n# - 적용 계산식 : \n\n   \n\n       \n\n[n = sample size (검체 수), p (민감도) = 0.85,\n\n- ⑥ SIPA test 음성 검체 검사 시 (특이도 80%),\n- - 대립가설: 개발제품의 특이도가 80% 이상이다.\n - - 귀무가설: 개발제품의 특이도가 80% 미만이다.\n - - 49 -\n<!-- PAGE_56 -->\n# - 적용 계산식 : \n\n   \n\n       \n\n[n = sample size (검체 수), p (특이도) = 0.80,\n\n- - Sample Size (5% 탈락률 적용) = 39.10, 약 40개 검체\n- - 50 -\n- ③ P2Y12 test 양성 검체 검사 시 (민감도 80%),\n- - 대립가설: 개발제품의 민감도가 80% 이상이다.\n - - 귀무가설: 개발제품의 민감도가 80% 미만이다.\n",
        "original_sentence": "- - 48 -\n<!-- PAGE_55 -->\n# - 적용 계산식 : \n\n   \n\n       \n\n[n = sample size (검체 수), p (민감도) = 0.85,\n\n- ⑥ SIPA test 음성 검체 검사 시 (특이도 80%),\n- - 대립가설: 개발제품의 특이도가 80% 이상이다.\n"
      }
    },
    {
      "chunk_id": "chunk_604",
      "text": "- - 귀무가설: 개발제품의 특이도가 80% 미만이다.\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 603,
        "window_size": 3,
        "char_count": 31,
        "word_count": 7,
        "page_number": 7,
        "window_text": "계산식에 적용한 민감도와 특이도는 아래 ‘8.3.3 피험자\n\n- - Sample Size (5% 탈락률 적용) = 104.9, 약 105개 검체\n- ③ ADP test 양성 검체 검사 시 (민감도 85%),\n- - 대립가설: 개발제품의 민감도가 85% 이상이다.\n - - 귀무가설: 개발제품의 민감도가 85% 미만이다.\n - - 48 -\n<!-- PAGE_55 -->\n# - 적용 계산식 : \n\n   \n\n       \n\n[n = sample size (검체 수), p (민감도) = 0.85,\n\n- ⑥ SIPA test 음성 검체 검사 시 (특이도 80%),\n- - 대립가설: 개발제품의 특이도가 80% 이상이다.\n - - 귀무가설: 개발제품의 특이도가 80% 미만이다.\n - - 49 -\n<!-- PAGE_56 -->\n# - 적용 계산식 : \n\n   \n\n       \n\n[n = sample size (검체 수), p (특이도) = 0.80,\n\n- - Sample Size (5% 탈락률 적용) = 39.10, 약 40개 검체\n- - 50 -\n- ③ P2Y12 test 양성 검체 검사 시 (민감도 80%),\n- - 대립가설: 개발제품의 민감도가 80% 이상이다.\n - - 귀무가설: 개발제품의 민감도가 80% 미만이다.\n - 8.3.3 피험자 수 산출 근거\n- 가. ",
        "original_sentence": "- - 귀무가설: 개발제품의 특이도가 80% 미만이다.\n"
      }
    },
    {
      "chunk_id": "chunk_605",
      "text": "- - 49 -\n<!-- PAGE_56 -->\n# - 적용 계산식 : \n\n   \n\n       \n\n[n = sample size (검체 수), p (특이도) = 0.80,\n\n- - Sample Size (5% 탈락률 적용) = 39.10, 약 40개 검체\n- - 50 -\n- ③ P2Y12 test 양성 검체 검사 시 (민감도 80%),\n- - 대립가설: 개발제품의 민감도가 80% 이상이다.\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 604,
        "window_size": 3,
        "char_count": 246,
        "word_count": 68,
        "page_number": 56,
        "window_text": "- - 귀무가설: 개발제품의 민감도가 85% 미만이다.\n - - 48 -\n<!-- PAGE_55 -->\n# - 적용 계산식 : \n\n   \n\n       \n\n[n = sample size (검체 수), p (민감도) = 0.85,\n\n- ⑥ SIPA test 음성 검체 검사 시 (특이도 80%),\n- - 대립가설: 개발제품의 특이도가 80% 이상이다.\n - - 귀무가설: 개발제품의 특이도가 80% 미만이다.\n - - 49 -\n<!-- PAGE_56 -->\n# - 적용 계산식 : \n\n   \n\n       \n\n[n = sample size (검체 수), p (특이도) = 0.80,\n\n- - Sample Size (5% 탈락률 적용) = 39.10, 약 40개 검체\n- - 50 -\n- ③ P2Y12 test 양성 검체 검사 시 (민감도 80%),\n- - 대립가설: 개발제품의 민감도가 80% 이상이다.\n - - 귀무가설: 개발제품의 민감도가 80% 미만이다.\n - 8.3.3 피험자 수 산출 근거\n- 가.  혈소판 기능검사\n- - 기허가 제품 (PFA-100Ⓡ)의 성능평가 임상논문을 조사한 결과, EPI test 평균\n민감도 84.5% 및 평균 특이도 85.6%이었고, 표준편차는 민감도 16.1%, 특이도\n\n- 8.0%이었다. ",
        "original_sentence": "- - 49 -\n<!-- PAGE_56 -->\n# - 적용 계산식 : \n\n   \n\n       \n\n[n = sample size (검체 수), p (특이도) = 0.80,\n\n- - Sample Size (5% 탈락률 적용) = 39.10, 약 40개 검체\n- - 50 -\n- ③ P2Y12 test 양성 검체 검사 시 (민감도 80%),\n- - 대립가설: 개발제품의 민감도가 80% 이상이다.\n"
      }
    },
    {
      "chunk_id": "chunk_606",
      "text": "- - 귀무가설: 개발제품의 민감도가 80% 미만이다.\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 605,
        "window_size": 3,
        "char_count": 31,
        "word_count": 7,
        "page_number": 7,
        "window_text": "- - 48 -\n<!-- PAGE_55 -->\n# - 적용 계산식 : \n\n   \n\n       \n\n[n = sample size (검체 수), p (민감도) = 0.85,\n\n- ⑥ SIPA test 음성 검체 검사 시 (특이도 80%),\n- - 대립가설: 개발제품의 특이도가 80% 이상이다.\n - - 귀무가설: 개발제품의 특이도가 80% 미만이다.\n - - 49 -\n<!-- PAGE_56 -->\n# - 적용 계산식 : \n\n   \n\n       \n\n[n = sample size (검체 수), p (특이도) = 0.80,\n\n- - Sample Size (5% 탈락률 적용) = 39.10, 약 40개 검체\n- - 50 -\n- ③ P2Y12 test 양성 검체 검사 시 (민감도 80%),\n- - 대립가설: 개발제품의 민감도가 80% 이상이다.\n - - 귀무가설: 개발제품의 민감도가 80% 미만이다.\n - 8.3.3 피험자 수 산출 근거\n- 가.  혈소판 기능검사\n- - 기허가 제품 (PFA-100Ⓡ)의 성능평가 임상논문을 조사한 결과, EPI test 평균\n민감도 84.5% 및 평균 특이도 85.6%이었고, 표준편차는 민감도 16.1%, 특이도\n\n- 8.0%이었다.  ADP test는 평균 민감도 84.0%, 평균 특이도 81.0%이었고, 표준\n편차는 민감도 4.2%, 특이도 1.4%이었다. ",
        "original_sentence": "- - 귀무가설: 개발제품의 민감도가 80% 미만이다.\n"
      }
    },
    {
      "chunk_id": "chunk_607",
      "text": "- 8.3.3 피험자 수 산출 근거\n- 가. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 606,
        "window_size": 3,
        "char_count": 25,
        "word_count": 8,
        "page_number": 15,
        "window_text": "- - 귀무가설: 개발제품의 특이도가 80% 미만이다.\n - - 49 -\n<!-- PAGE_56 -->\n# - 적용 계산식 : \n\n   \n\n       \n\n[n = sample size (검체 수), p (특이도) = 0.80,\n\n- - Sample Size (5% 탈락률 적용) = 39.10, 약 40개 검체\n- - 50 -\n- ③ P2Y12 test 양성 검체 검사 시 (민감도 80%),\n- - 대립가설: 개발제품의 민감도가 80% 이상이다.\n - - 귀무가설: 개발제품의 민감도가 80% 미만이다.\n - 8.3.3 피험자 수 산출 근거\n- 가.  혈소판 기능검사\n- - 기허가 제품 (PFA-100Ⓡ)의 성능평가 임상논문을 조사한 결과, EPI test 평균\n민감도 84.5% 및 평균 특이도 85.6%이었고, 표준편차는 민감도 16.1%, 특이도\n\n- 8.0%이었다.  ADP test는 평균 민감도 84.0%, 평균 특이도 81.0%이었고, 표준\n편차는 민감도 4.2%, 특이도 1.4%이었다.  SIPA test는 검사원리가 비슷한 기존\n\n검사법은 없으나, 혈소판 기능의 정상/비정상 유무를 판정하기 위한 목적은\n\n- - 51 -\n표 1.\n\n",
        "original_sentence": "- 8.3.3 피험자 수 산출 근거\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_608",
      "text": "혈소판 기능검사\n- - 기허가 제품 (PFA-100Ⓡ)의 성능평가 임상논문을 조사한 결과, EPI test 평균\n민감도 84.5% 및 평균 특이도 85.6%이었고, 표준편차는 민감도 16.1%, 특이도\n\n- 8.0%이었다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 607,
        "window_size": 3,
        "char_count": 125,
        "word_count": 26,
        "page_number": 6,
        "window_text": "- - 49 -\n<!-- PAGE_56 -->\n# - 적용 계산식 : \n\n   \n\n       \n\n[n = sample size (검체 수), p (특이도) = 0.80,\n\n- - Sample Size (5% 탈락률 적용) = 39.10, 약 40개 검체\n- - 50 -\n- ③ P2Y12 test 양성 검체 검사 시 (민감도 80%),\n- - 대립가설: 개발제품의 민감도가 80% 이상이다.\n - - 귀무가설: 개발제품의 민감도가 80% 미만이다.\n - 8.3.3 피험자 수 산출 근거\n- 가.  혈소판 기능검사\n- - 기허가 제품 (PFA-100Ⓡ)의 성능평가 임상논문을 조사한 결과, EPI test 평균\n민감도 84.5% 및 평균 특이도 85.6%이었고, 표준편차는 민감도 16.1%, 특이도\n\n- 8.0%이었다.  ADP test는 평균 민감도 84.0%, 평균 특이도 81.0%이었고, 표준\n편차는 민감도 4.2%, 특이도 1.4%이었다.  SIPA test는 검사원리가 비슷한 기존\n\n검사법은 없으나, 혈소판 기능의 정상/비정상 유무를 판정하기 위한 목적은\n\n- - 51 -\n표 1.\n\n PFA-100Ⓡ 성능평가 문헌\n\n평균 민감도\n\n평균 특이도\n\n참고문헌\n\n- - 따라서, 본 임상시험에서는 기허가 제품 성능 결과를 토대로 EPI test의 민감도\n및 특이도 목표는 각각 85%, 85%로 설정하였으며 오차범위는 ±5% 설정하였다.\n\n",
        "original_sentence": "혈소판 기능검사\n- - 기허가 제품 (PFA-100Ⓡ)의 성능평가 임상논문을 조사한 결과, EPI test 평균\n민감도 84.5% 및 평균 특이도 85.6%이었고, 표준편차는 민감도 16.1%, 특이도\n\n- 8.0%이었다. "
      }
    },
    {
      "chunk_id": "chunk_609",
      "text": "ADP test는 평균 민감도 84.0%, 평균 특이도 81.0%이었고, 표준\n편차는 민감도 4.2%, 특이도 1.4%이었다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 608,
        "window_size": 3,
        "char_count": 71,
        "word_count": 14,
        "page_number": 6,
        "window_text": "- - 귀무가설: 개발제품의 민감도가 80% 미만이다.\n - 8.3.3 피험자 수 산출 근거\n- 가.  혈소판 기능검사\n- - 기허가 제품 (PFA-100Ⓡ)의 성능평가 임상논문을 조사한 결과, EPI test 평균\n민감도 84.5% 및 평균 특이도 85.6%이었고, 표준편차는 민감도 16.1%, 특이도\n\n- 8.0%이었다.  ADP test는 평균 민감도 84.0%, 평균 특이도 81.0%이었고, 표준\n편차는 민감도 4.2%, 특이도 1.4%이었다.  SIPA test는 검사원리가 비슷한 기존\n\n검사법은 없으나, 혈소판 기능의 정상/비정상 유무를 판정하기 위한 목적은\n\n- - 51 -\n표 1.\n\n PFA-100Ⓡ 성능평가 문헌\n\n평균 민감도\n\n평균 특이도\n\n참고문헌\n\n- - 따라서, 본 임상시험에서는 기허가 제품 성능 결과를 토대로 EPI test의 민감도\n및 특이도 목표는 각각 85%, 85%로 설정하였으며 오차범위는 ±5% 설정하였다.\n\n ADP 및 SIPA test의 민감도 및 특이도 목표는 각각 85%, 80%로 설정하였으며\n\n- - 52 -\n- 나. ",
        "original_sentence": "ADP test는 평균 민감도 84.0%, 평균 특이도 81.0%이었고, 표준\n편차는 민감도 4.2%, 특이도 1.4%이었다. "
      }
    },
    {
      "chunk_id": "chunk_610",
      "text": "SIPA test는 검사원리가 비슷한 기존\n\n검사법은 없으나, 혈소판 기능의 정상/비정상 유무를 판정하기 위한 목적은\n\n- - 51 -\n표 1.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 609,
        "window_size": 3,
        "char_count": 82,
        "word_count": 20,
        "page_number": 53,
        "window_text": "- 8.3.3 피험자 수 산출 근거\n- 가.  혈소판 기능검사\n- - 기허가 제품 (PFA-100Ⓡ)의 성능평가 임상논문을 조사한 결과, EPI test 평균\n민감도 84.5% 및 평균 특이도 85.6%이었고, 표준편차는 민감도 16.1%, 특이도\n\n- 8.0%이었다.  ADP test는 평균 민감도 84.0%, 평균 특이도 81.0%이었고, 표준\n편차는 민감도 4.2%, 특이도 1.4%이었다.  SIPA test는 검사원리가 비슷한 기존\n\n검사법은 없으나, 혈소판 기능의 정상/비정상 유무를 판정하기 위한 목적은\n\n- - 51 -\n표 1.\n\n PFA-100Ⓡ 성능평가 문헌\n\n평균 민감도\n\n평균 특이도\n\n참고문헌\n\n- - 따라서, 본 임상시험에서는 기허가 제품 성능 결과를 토대로 EPI test의 민감도\n및 특이도 목표는 각각 85%, 85%로 설정하였으며 오차범위는 ±5% 설정하였다.\n\n ADP 및 SIPA test의 민감도 및 특이도 목표는 각각 85%, 80%로 설정하였으며\n\n- - 52 -\n- 나.  혈소판 약물반응검사\n- - 기허가 제품 (VerifyNowⓇ)의 성능평가 임상논문을 조사한 결과, Aspirin test\n평균 민감도 73.5% 및 평균 특이도 93.2%이었고, 표준편차는 민감도 29.6%,\n\n- - 53 -\n- - 따라서, 본 임상시험에서는 기허가 제품 성능 결과를 토대로 Aspirin test의\n민감도 및 특이도 목표는 각각 90%, 95%로 설정하였으며 오차범위는 ±5%\n\n설정하였다. ",
        "original_sentence": "SIPA test는 검사원리가 비슷한 기존\n\n검사법은 없으나, 혈소판 기능의 정상/비정상 유무를 판정하기 위한 목적은\n\n- - 51 -\n표 1.\n\n"
      }
    },
    {
      "chunk_id": "chunk_611",
      "text": "PFA-100Ⓡ 성능평가 문헌\n\n평균 민감도\n\n평균 특이도\n\n참고문헌\n\n- - 따라서, 본 임상시험에서는 기허가 제품 성능 결과를 토대로 EPI test의 민감도\n및 특이도 목표는 각각 85%, 85%로 설정하였으며 오차범위는 ±5% 설정하였다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 610,
        "window_size": 3,
        "char_count": 139,
        "word_count": 31,
        "page_number": 6,
        "window_text": "혈소판 기능검사\n- - 기허가 제품 (PFA-100Ⓡ)의 성능평가 임상논문을 조사한 결과, EPI test 평균\n민감도 84.5% 및 평균 특이도 85.6%이었고, 표준편차는 민감도 16.1%, 특이도\n\n- 8.0%이었다.  ADP test는 평균 민감도 84.0%, 평균 특이도 81.0%이었고, 표준\n편차는 민감도 4.2%, 특이도 1.4%이었다.  SIPA test는 검사원리가 비슷한 기존\n\n검사법은 없으나, 혈소판 기능의 정상/비정상 유무를 판정하기 위한 목적은\n\n- - 51 -\n표 1.\n\n PFA-100Ⓡ 성능평가 문헌\n\n평균 민감도\n\n평균 특이도\n\n참고문헌\n\n- - 따라서, 본 임상시험에서는 기허가 제품 성능 결과를 토대로 EPI test의 민감도\n및 특이도 목표는 각각 85%, 85%로 설정하였으며 오차범위는 ±5% 설정하였다.\n\n ADP 및 SIPA test의 민감도 및 특이도 목표는 각각 85%, 80%로 설정하였으며\n\n- - 52 -\n- 나.  혈소판 약물반응검사\n- - 기허가 제품 (VerifyNowⓇ)의 성능평가 임상논문을 조사한 결과, Aspirin test\n평균 민감도 73.5% 및 평균 특이도 93.2%이었고, 표준편차는 민감도 29.6%,\n\n- - 53 -\n- - 따라서, 본 임상시험에서는 기허가 제품 성능 결과를 토대로 Aspirin test의\n민감도 및 특이도 목표는 각각 90%, 95%로 설정하였으며 오차범위는 ±5%\n\n설정하였다.  P2Y12 test의 민감도 및 특이도 목표는 각각 80%, 75%로 설정\n\n- - 54 -\n<!-- PAGE_61 -->\n###### 9. ",
        "original_sentence": "PFA-100Ⓡ 성능평가 문헌\n\n평균 민감도\n\n평균 특이도\n\n참고문헌\n\n- - 따라서, 본 임상시험에서는 기허가 제품 성능 결과를 토대로 EPI test의 민감도\n및 특이도 목표는 각각 85%, 85%로 설정하였으며 오차범위는 ±5% 설정하였다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_612",
      "text": "ADP 및 SIPA test의 민감도 및 특이도 목표는 각각 85%, 80%로 설정하였으며\n\n- - 52 -\n- 나. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 611,
        "window_size": 3,
        "char_count": 66,
        "word_count": 18,
        "page_number": 58,
        "window_text": "ADP test는 평균 민감도 84.0%, 평균 특이도 81.0%이었고, 표준\n편차는 민감도 4.2%, 특이도 1.4%이었다.  SIPA test는 검사원리가 비슷한 기존\n\n검사법은 없으나, 혈소판 기능의 정상/비정상 유무를 판정하기 위한 목적은\n\n- - 51 -\n표 1.\n\n PFA-100Ⓡ 성능평가 문헌\n\n평균 민감도\n\n평균 특이도\n\n참고문헌\n\n- - 따라서, 본 임상시험에서는 기허가 제품 성능 결과를 토대로 EPI test의 민감도\n및 특이도 목표는 각각 85%, 85%로 설정하였으며 오차범위는 ±5% 설정하였다.\n\n ADP 및 SIPA test의 민감도 및 특이도 목표는 각각 85%, 80%로 설정하였으며\n\n- - 52 -\n- 나.  혈소판 약물반응검사\n- - 기허가 제품 (VerifyNowⓇ)의 성능평가 임상논문을 조사한 결과, Aspirin test\n평균 민감도 73.5% 및 평균 특이도 93.2%이었고, 표준편차는 민감도 29.6%,\n\n- - 53 -\n- - 따라서, 본 임상시험에서는 기허가 제품 성능 결과를 토대로 Aspirin test의\n민감도 및 특이도 목표는 각각 90%, 95%로 설정하였으며 오차범위는 ±5%\n\n설정하였다.  P2Y12 test의 민감도 및 특이도 목표는 각각 80%, 75%로 설정\n\n- - 54 -\n<!-- PAGE_61 -->\n###### 9.  임상시험기간\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n식품의약품안전처 및 임상시험기관 임상시험심사위원회의 임상시험계획서 승인일로\n\n- - 55 -\n**[표 시작]**\n\n**결정할 수 있습니다.",
        "original_sentence": "ADP 및 SIPA test의 민감도 및 특이도 목표는 각각 85%, 80%로 설정하였으며\n\n- - 52 -\n- 나. "
      }
    },
    {
      "chunk_id": "chunk_613",
      "text": "혈소판 약물반응검사\n- - 기허가 제품 (VerifyNowⓇ)의 성능평가 임상논문을 조사한 결과, Aspirin test\n평균 민감도 73.5% 및 평균 특이도 93.2%이었고, 표준편차는 민감도 29.6%,\n\n- - 53 -\n- - 따라서, 본 임상시험에서는 기허가 제품 성능 결과를 토대로 Aspirin test의\n민감도 및 특이도 목표는 각각 90%, 95%로 설정하였으며 오차범위는 ±5%\n\n설정하였다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 612,
        "window_size": 3,
        "char_count": 230,
        "word_count": 50,
        "page_number": 33,
        "window_text": "SIPA test는 검사원리가 비슷한 기존\n\n검사법은 없으나, 혈소판 기능의 정상/비정상 유무를 판정하기 위한 목적은\n\n- - 51 -\n표 1.\n\n PFA-100Ⓡ 성능평가 문헌\n\n평균 민감도\n\n평균 특이도\n\n참고문헌\n\n- - 따라서, 본 임상시험에서는 기허가 제품 성능 결과를 토대로 EPI test의 민감도\n및 특이도 목표는 각각 85%, 85%로 설정하였으며 오차범위는 ±5% 설정하였다.\n\n ADP 및 SIPA test의 민감도 및 특이도 목표는 각각 85%, 80%로 설정하였으며\n\n- - 52 -\n- 나.  혈소판 약물반응검사\n- - 기허가 제품 (VerifyNowⓇ)의 성능평가 임상논문을 조사한 결과, Aspirin test\n평균 민감도 73.5% 및 평균 특이도 93.2%이었고, 표준편차는 민감도 29.6%,\n\n- - 53 -\n- - 따라서, 본 임상시험에서는 기허가 제품 성능 결과를 토대로 Aspirin test의\n민감도 및 특이도 목표는 각각 90%, 95%로 설정하였으며 오차범위는 ±5%\n\n설정하였다.  P2Y12 test의 민감도 및 특이도 목표는 각각 80%, 75%로 설정\n\n- - 54 -\n<!-- PAGE_61 -->\n###### 9.  임상시험기간\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n식품의약품안전처 및 임상시험기관 임상시험심사위원회의 임상시험계획서 승인일로\n\n- - 55 -\n**[표 시작]**\n\n**결정할 수 있습니다. **\n| (2) 부적절한 혈액 채취 기법 및 지연된 검사는 결과의 오류를 야기할 수 있다. ",
        "original_sentence": "혈소판 약물반응검사\n- - 기허가 제품 (VerifyNowⓇ)의 성능평가 임상논문을 조사한 결과, Aspirin test\n평균 민감도 73.5% 및 평균 특이도 93.2%이었고, 표준편차는 민감도 29.6%,\n\n- - 53 -\n- - 따라서, 본 임상시험에서는 기허가 제품 성능 결과를 토대로 Aspirin test의\n민감도 및 특이도 목표는 각각 90%, 95%로 설정하였으며 오차범위는 ±5%\n\n설정하였다. "
      }
    },
    {
      "chunk_id": "chunk_614",
      "text": "P2Y12 test의 민감도 및 특이도 목표는 각각 80%, 75%로 설정\n\n- - 54 -\n<!-- PAGE_61 -->\n###### 9. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 613,
        "window_size": 3,
        "char_count": 79,
        "word_count": 19,
        "page_number": 61,
        "window_text": "PFA-100Ⓡ 성능평가 문헌\n\n평균 민감도\n\n평균 특이도\n\n참고문헌\n\n- - 따라서, 본 임상시험에서는 기허가 제품 성능 결과를 토대로 EPI test의 민감도\n및 특이도 목표는 각각 85%, 85%로 설정하였으며 오차범위는 ±5% 설정하였다.\n\n ADP 및 SIPA test의 민감도 및 특이도 목표는 각각 85%, 80%로 설정하였으며\n\n- - 52 -\n- 나.  혈소판 약물반응검사\n- - 기허가 제품 (VerifyNowⓇ)의 성능평가 임상논문을 조사한 결과, Aspirin test\n평균 민감도 73.5% 및 평균 특이도 93.2%이었고, 표준편차는 민감도 29.6%,\n\n- - 53 -\n- - 따라서, 본 임상시험에서는 기허가 제품 성능 결과를 토대로 Aspirin test의\n민감도 및 특이도 목표는 각각 90%, 95%로 설정하였으며 오차범위는 ±5%\n\n설정하였다.  P2Y12 test의 민감도 및 특이도 목표는 각각 80%, 75%로 설정\n\n- - 54 -\n<!-- PAGE_61 -->\n###### 9.  임상시험기간\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n식품의약품안전처 및 임상시험기관 임상시험심사위원회의 임상시험계획서 승인일로\n\n- - 55 -\n**[표 시작]**\n\n**결정할 수 있습니다. **\n| (2) 부적절한 혈액 채취 기법 및 지연된 검사는 결과의 오류를 야기할 수 있다.  | ① 3.2% Na Citrate tube에 약 20mL의 정맥혈을 채혈한다. ",
        "original_sentence": "P2Y12 test의 민감도 및 특이도 목표는 각각 80%, 75%로 설정\n\n- - 54 -\n<!-- PAGE_61 -->\n###### 9. "
      }
    },
    {
      "chunk_id": "chunk_615",
      "text": "임상시험기간\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n식품의약품안전처 및 임상시험기관 임상시험심사위원회의 임상시험계획서 승인일로\n\n- - 55 -\n**[표 시작]**\n\n**결정할 수 있습니다.",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 614,
        "window_size": 3,
        "char_count": 137,
        "word_count": 30,
        "page_number": 6,
        "window_text": "ADP 및 SIPA test의 민감도 및 특이도 목표는 각각 85%, 80%로 설정하였으며\n\n- - 52 -\n- 나.  혈소판 약물반응검사\n- - 기허가 제품 (VerifyNowⓇ)의 성능평가 임상논문을 조사한 결과, Aspirin test\n평균 민감도 73.5% 및 평균 특이도 93.2%이었고, 표준편차는 민감도 29.6%,\n\n- - 53 -\n- - 따라서, 본 임상시험에서는 기허가 제품 성능 결과를 토대로 Aspirin test의\n민감도 및 특이도 목표는 각각 90%, 95%로 설정하였으며 오차범위는 ±5%\n\n설정하였다.  P2Y12 test의 민감도 및 특이도 목표는 각각 80%, 75%로 설정\n\n- - 54 -\n<!-- PAGE_61 -->\n###### 9.  임상시험기간\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n식품의약품안전처 및 임상시험기관 임상시험심사위원회의 임상시험계획서 승인일로\n\n- - 55 -\n**[표 시작]**\n\n**결정할 수 있습니다. **\n| (2) 부적절한 혈액 채취 기법 및 지연된 검사는 결과의 오류를 야기할 수 있다.  | ① 3.2% Na Citrate tube에 약 20mL의 정맥혈을 채혈한다.  |\n**시약**\n| (3) 데이터 전송 시, 데이터 전송이 완료된 후 장비를 사용한다. ",
        "original_sentence": "임상시험기간\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n식품의약품안전처 및 임상시험기관 임상시험심사위원회의 임상시험계획서 승인일로\n\n- - 55 -\n**[표 시작]**\n\n**결정할 수 있습니다."
      }
    },
    {
      "chunk_id": "chunk_616",
      "text": "**\n| (2) 부적절한 혈액 채취 기법 및 지연된 검사는 결과의 오류를 야기할 수 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 615,
        "window_size": 3,
        "char_count": 51,
        "word_count": 15,
        "page_number": 6,
        "window_text": "혈소판 약물반응검사\n- - 기허가 제품 (VerifyNowⓇ)의 성능평가 임상논문을 조사한 결과, Aspirin test\n평균 민감도 73.5% 및 평균 특이도 93.2%이었고, 표준편차는 민감도 29.6%,\n\n- - 53 -\n- - 따라서, 본 임상시험에서는 기허가 제품 성능 결과를 토대로 Aspirin test의\n민감도 및 특이도 목표는 각각 90%, 95%로 설정하였으며 오차범위는 ±5%\n\n설정하였다.  P2Y12 test의 민감도 및 특이도 목표는 각각 80%, 75%로 설정\n\n- - 54 -\n<!-- PAGE_61 -->\n###### 9.  임상시험기간\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n식품의약품안전처 및 임상시험기관 임상시험심사위원회의 임상시험계획서 승인일로\n\n- - 55 -\n**[표 시작]**\n\n**결정할 수 있습니다. **\n| (2) 부적절한 혈액 채취 기법 및 지연된 검사는 결과의 오류를 야기할 수 있다.  | ① 3.2% Na Citrate tube에 약 20mL의 정맥혈을 채혈한다.  |\n**시약**\n| (3) 데이터 전송 시, 데이터 전송이 완료된 후 장비를 사용한다.  | 5) 검체 채취 및 임상시험 시행 | 나. ADP test |\n| 과거병력 및 병용약물 조사 | O | O |\n\n**[표 끝]**\n\n<!-- PAGE_62 -->\n###### 10. ",
        "original_sentence": "**\n| (2) 부적절한 혈액 채취 기법 및 지연된 검사는 결과의 오류를 야기할 수 있다. "
      }
    },
    {
      "chunk_id": "chunk_617",
      "text": "| ① 3.2% Na Citrate tube에 약 20mL의 정맥혈을 채혈한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 616,
        "window_size": 3,
        "char_count": 45,
        "word_count": 10,
        "page_number": 6,
        "window_text": "P2Y12 test의 민감도 및 특이도 목표는 각각 80%, 75%로 설정\n\n- - 54 -\n<!-- PAGE_61 -->\n###### 9.  임상시험기간\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n식품의약품안전처 및 임상시험기관 임상시험심사위원회의 임상시험계획서 승인일로\n\n- - 55 -\n**[표 시작]**\n\n**결정할 수 있습니다. **\n| (2) 부적절한 혈액 채취 기법 및 지연된 검사는 결과의 오류를 야기할 수 있다.  | ① 3.2% Na Citrate tube에 약 20mL의 정맥혈을 채혈한다.  |\n**시약**\n| (3) 데이터 전송 시, 데이터 전송이 완료된 후 장비를 사용한다.  | 5) 검체 채취 및 임상시험 시행 | 나. ADP test |\n| 과거병력 및 병용약물 조사 | O | O |\n\n**[표 끝]**\n\n<!-- PAGE_62 -->\n###### 10.  임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 10.1.2. ",
        "original_sentence": "| ① 3.2% Na Citrate tube에 약 20mL의 정맥혈을 채혈한다. "
      }
    },
    {
      "chunk_id": "chunk_618",
      "text": "|\n**시약**\n| (3) 데이터 전송 시, 데이터 전송이 완료된 후 장비를 사용한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 617,
        "window_size": 3,
        "char_count": 49,
        "word_count": 13,
        "page_number": 15,
        "window_text": "임상시험기간\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n식품의약품안전처 및 임상시험기관 임상시험심사위원회의 임상시험계획서 승인일로\n\n- - 55 -\n**[표 시작]**\n\n**결정할 수 있습니다. **\n| (2) 부적절한 혈액 채취 기법 및 지연된 검사는 결과의 오류를 야기할 수 있다.  | ① 3.2% Na Citrate tube에 약 20mL의 정맥혈을 채혈한다.  |\n**시약**\n| (3) 데이터 전송 시, 데이터 전송이 완료된 후 장비를 사용한다.  | 5) 검체 채취 및 임상시험 시행 | 나. ADP test |\n| 과거병력 및 병용약물 조사 | O | O |\n\n**[표 끝]**\n\n<!-- PAGE_62 -->\n###### 10.  임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 10.1.2.  시험방법\n- (1) 피험자 동의 및 준비\n본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한 내용을 피험자 본인\n\n- - 56 -\n및 대리인에게 설명하고, 피험자 및 대리인이 내용을 잘 이해한 것을 확인한 다음,\n\n자유의사에 따른 임상시험 참가의 동의를 문서로 받는다. ",
        "original_sentence": "|\n**시약**\n| (3) 데이터 전송 시, 데이터 전송이 완료된 후 장비를 사용한다. "
      }
    },
    {
      "chunk_id": "chunk_619",
      "text": "| 5) 검체 채취 및 임상시험 시행 | 나. ADP test |\n| 과거병력 및 병용약물 조사 | O | O |\n\n**[표 끝]**\n\n<!-- PAGE_62 -->\n###### 10. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 618,
        "window_size": 3,
        "char_count": 104,
        "word_count": 29,
        "page_number": 62,
        "window_text": "**\n| (2) 부적절한 혈액 채취 기법 및 지연된 검사는 결과의 오류를 야기할 수 있다.  | ① 3.2% Na Citrate tube에 약 20mL의 정맥혈을 채혈한다.  |\n**시약**\n| (3) 데이터 전송 시, 데이터 전송이 완료된 후 장비를 사용한다.  | 5) 검체 채취 및 임상시험 시행 | 나. ADP test |\n| 과거병력 및 병용약물 조사 | O | O |\n\n**[표 끝]**\n\n<!-- PAGE_62 -->\n###### 10.  임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 10.1.2.  시험방법\n- (1) 피험자 동의 및 준비\n본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한 내용을 피험자 본인\n\n- - 56 -\n및 대리인에게 설명하고, 피험자 및 대리인이 내용을 잘 이해한 것을 확인한 다음,\n\n자유의사에 따른 임상시험 참가의 동의를 문서로 받는다.  또한 동의를 서명한\n\n연월일을 기록한다. ",
        "original_sentence": "| 5) 검체 채취 및 임상시험 시행 | 나. ADP test |\n| 과거병력 및 병용약물 조사 | O | O |\n\n**[표 끝]**\n\n<!-- PAGE_62 -->\n###### 10. "
      }
    },
    {
      "chunk_id": "chunk_620",
      "text": "임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 10.1.2. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 619,
        "window_size": 3,
        "char_count": 95,
        "word_count": 19,
        "page_number": 6,
        "window_text": "| ① 3.2% Na Citrate tube에 약 20mL의 정맥혈을 채혈한다.  |\n**시약**\n| (3) 데이터 전송 시, 데이터 전송이 완료된 후 장비를 사용한다.  | 5) 검체 채취 및 임상시험 시행 | 나. ADP test |\n| 과거병력 및 병용약물 조사 | O | O |\n\n**[표 끝]**\n\n<!-- PAGE_62 -->\n###### 10.  임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 10.1.2.  시험방법\n- (1) 피험자 동의 및 준비\n본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한 내용을 피험자 본인\n\n- - 56 -\n및 대리인에게 설명하고, 피험자 및 대리인이 내용을 잘 이해한 것을 확인한 다음,\n\n자유의사에 따른 임상시험 참가의 동의를 문서로 받는다.  또한 동의를 서명한\n\n연월일을 기록한다.  또한 동의서 사본을 환자에게 제공하여 환자가 지속적으로\n\n- (4) 검체 채취 및 보관 방법\n- ② 시험기기는 3.2% Na Citrate tube 검체를 실온(18∼25℃)에서 채혈 시 최소\n- ③ LTA 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심\n- ④ VerifyNow 대조기기는 3.2% Na Citrate tube 검체를 실온(18∼25℃)에서 2시간\n이내 검사를 시행한다.\n\n",
        "original_sentence": "임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 10.1.2. "
      }
    },
    {
      "chunk_id": "chunk_621",
      "text": "시험방법\n- (1) 피험자 동의 및 준비\n본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한 내용을 피험자 본인\n\n- - 56 -\n및 대리인에게 설명하고, 피험자 및 대리인이 내용을 잘 이해한 것을 확인한 다음,\n\n자유의사에 따른 임상시험 참가의 동의를 문서로 받는다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 620,
        "window_size": 3,
        "char_count": 154,
        "word_count": 40,
        "page_number": 6,
        "window_text": "|\n**시약**\n| (3) 데이터 전송 시, 데이터 전송이 완료된 후 장비를 사용한다.  | 5) 검체 채취 및 임상시험 시행 | 나. ADP test |\n| 과거병력 및 병용약물 조사 | O | O |\n\n**[표 끝]**\n\n<!-- PAGE_62 -->\n###### 10.  임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 10.1.2.  시험방법\n- (1) 피험자 동의 및 준비\n본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한 내용을 피험자 본인\n\n- - 56 -\n및 대리인에게 설명하고, 피험자 및 대리인이 내용을 잘 이해한 것을 확인한 다음,\n\n자유의사에 따른 임상시험 참가의 동의를 문서로 받는다.  또한 동의를 서명한\n\n연월일을 기록한다.  또한 동의서 사본을 환자에게 제공하여 환자가 지속적으로\n\n- (4) 검체 채취 및 보관 방법\n- ② 시험기기는 3.2% Na Citrate tube 검체를 실온(18∼25℃)에서 채혈 시 최소\n- ③ LTA 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심\n- ④ VerifyNow 대조기기는 3.2% Na Citrate tube 검체를 실온(18∼25℃)에서 2시간\n이내 검사를 시행한다.\n\n - - 57 -\n임상시험의 설계방법(무작위배정, 단일 또는 이중눈가림, 교차설계 또는 병행설계\n\n등)의 특성이 있는 경우 과학적 타당성과 근거자료를 바탕으로 구체적이고 명확히\n\n기술한다. ",
        "original_sentence": "시험방법\n- (1) 피험자 동의 및 준비\n본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한 내용을 피험자 본인\n\n- - 56 -\n및 대리인에게 설명하고, 피험자 및 대리인이 내용을 잘 이해한 것을 확인한 다음,\n\n자유의사에 따른 임상시험 참가의 동의를 문서로 받는다. "
      }
    },
    {
      "chunk_id": "chunk_622",
      "text": "또한 동의를 서명한\n\n연월일을 기록한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 621,
        "window_size": 3,
        "char_count": 23,
        "word_count": 5,
        "page_number": 24,
        "window_text": "| 5) 검체 채취 및 임상시험 시행 | 나. ADP test |\n| 과거병력 및 병용약물 조사 | O | O |\n\n**[표 끝]**\n\n<!-- PAGE_62 -->\n###### 10.  임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 10.1.2.  시험방법\n- (1) 피험자 동의 및 준비\n본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한 내용을 피험자 본인\n\n- - 56 -\n및 대리인에게 설명하고, 피험자 및 대리인이 내용을 잘 이해한 것을 확인한 다음,\n\n자유의사에 따른 임상시험 참가의 동의를 문서로 받는다.  또한 동의를 서명한\n\n연월일을 기록한다.  또한 동의서 사본을 환자에게 제공하여 환자가 지속적으로\n\n- (4) 검체 채취 및 보관 방법\n- ② 시험기기는 3.2% Na Citrate tube 검체를 실온(18∼25℃)에서 채혈 시 최소\n- ③ LTA 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심\n- ④ VerifyNow 대조기기는 3.2% Na Citrate tube 검체를 실온(18∼25℃)에서 2시간\n이내 검사를 시행한다.\n\n - - 57 -\n임상시험의 설계방법(무작위배정, 단일 또는 이중눈가림, 교차설계 또는 병행설계\n\n등)의 특성이 있는 경우 과학적 타당성과 근거자료를 바탕으로 구체적이고 명확히\n\n기술한다.  상기의 기술한 내용의 근거로서 관련 참고문헌(논문 등)을 하단부에 기재\n\n하고, 첨부자료로서 이를 제출한다.\n\n",
        "original_sentence": "또한 동의를 서명한\n\n연월일을 기록한다. "
      }
    },
    {
      "chunk_id": "chunk_623",
      "text": "또한 동의서 사본을 환자에게 제공하여 환자가 지속적으로\n\n- (4) 검체 채취 및 보관 방법\n- ② 시험기기는 3.2% Na Citrate tube 검체를 실온(18∼25℃)에서 채혈 시 최소\n- ③ LTA 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심\n- ④ VerifyNow 대조기기는 3.2% Na Citrate tube 검체를 실온(18∼25℃)에서 2시간\n이내 검사를 시행한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 622,
        "window_size": 3,
        "char_count": 239,
        "word_count": 53,
        "page_number": 15,
        "window_text": "임상시험방법(사용량·사용방법·사용기간·병용요법 등 포함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- 10.1.2.  시험방법\n- (1) 피험자 동의 및 준비\n본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한 내용을 피험자 본인\n\n- - 56 -\n및 대리인에게 설명하고, 피험자 및 대리인이 내용을 잘 이해한 것을 확인한 다음,\n\n자유의사에 따른 임상시험 참가의 동의를 문서로 받는다.  또한 동의를 서명한\n\n연월일을 기록한다.  또한 동의서 사본을 환자에게 제공하여 환자가 지속적으로\n\n- (4) 검체 채취 및 보관 방법\n- ② 시험기기는 3.2% Na Citrate tube 검체를 실온(18∼25℃)에서 채혈 시 최소\n- ③ LTA 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심\n- ④ VerifyNow 대조기기는 3.2% Na Citrate tube 검체를 실온(18∼25℃)에서 2시간\n이내 검사를 시행한다.\n\n - - 57 -\n임상시험의 설계방법(무작위배정, 단일 또는 이중눈가림, 교차설계 또는 병행설계\n\n등)의 특성이 있는 경우 과학적 타당성과 근거자료를 바탕으로 구체적이고 명확히\n\n기술한다.  상기의 기술한 내용의 근거로서 관련 참고문헌(논문 등)을 하단부에 기재\n\n하고, 첨부자료로서 이를 제출한다.\n\n - ⑤ 검체는 6일간 냉장(2∼6℃) 보관 후 폐기한다.\n",
        "original_sentence": "또한 동의서 사본을 환자에게 제공하여 환자가 지속적으로\n\n- (4) 검체 채취 및 보관 방법\n- ② 시험기기는 3.2% Na Citrate tube 검체를 실온(18∼25℃)에서 채혈 시 최소\n- ③ LTA 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심\n- ④ VerifyNow 대조기기는 3.2% Na Citrate tube 검체를 실온(18∼25℃)에서 2시간\n이내 검사를 시행한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_624",
      "text": "- - 57 -\n임상시험의 설계방법(무작위배정, 단일 또는 이중눈가림, 교차설계 또는 병행설계\n\n등)의 특성이 있는 경우 과학적 타당성과 근거자료를 바탕으로 구체적이고 명확히\n\n기술한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 623,
        "window_size": 3,
        "char_count": 105,
        "word_count": 23,
        "page_number": 6,
        "window_text": "시험방법\n- (1) 피험자 동의 및 준비\n본 임상시험을 실시하기에 앞서, 시험자는 임상시험에 관한 내용을 피험자 본인\n\n- - 56 -\n및 대리인에게 설명하고, 피험자 및 대리인이 내용을 잘 이해한 것을 확인한 다음,\n\n자유의사에 따른 임상시험 참가의 동의를 문서로 받는다.  또한 동의를 서명한\n\n연월일을 기록한다.  또한 동의서 사본을 환자에게 제공하여 환자가 지속적으로\n\n- (4) 검체 채취 및 보관 방법\n- ② 시험기기는 3.2% Na Citrate tube 검체를 실온(18∼25℃)에서 채혈 시 최소\n- ③ LTA 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심\n- ④ VerifyNow 대조기기는 3.2% Na Citrate tube 검체를 실온(18∼25℃)에서 2시간\n이내 검사를 시행한다.\n\n - - 57 -\n임상시험의 설계방법(무작위배정, 단일 또는 이중눈가림, 교차설계 또는 병행설계\n\n등)의 특성이 있는 경우 과학적 타당성과 근거자료를 바탕으로 구체적이고 명확히\n\n기술한다.  상기의 기술한 내용의 근거로서 관련 참고문헌(논문 등)을 하단부에 기재\n\n하고, 첨부자료로서 이를 제출한다.\n\n - ⑤ 검체는 6일간 냉장(2∼6℃) 보관 후 폐기한다.\n - (5) 시험검사 방법\n1) EPI test: 정상인 및 혈소판기능저하가 있는 환자의 검체에 대해 시험기기 및\n\n대조기기인 'epinephrine을 agonist로 사용한 LTA 검사'와 'PFA-100 EPI test'로\n\n및 대조기기인 'ADP를 agonist로 사용한 LTA 검사'와 'PFA-100 ADP test'로\n\n및 대조기기인 'ADP를 agonist로 사용한 LTA 검사'와 'PFA-100 ADP test'로\n\n혈소판 기능의 정상/비정상 유무를 판정하기 위한 목적은 ADP test와 동\n\n- 10.1.3. ",
        "original_sentence": "- - 57 -\n임상시험의 설계방법(무작위배정, 단일 또는 이중눈가림, 교차설계 또는 병행설계\n\n등)의 특성이 있는 경우 과학적 타당성과 근거자료를 바탕으로 구체적이고 명확히\n\n기술한다. "
      }
    },
    {
      "chunk_id": "chunk_625",
      "text": "상기의 기술한 내용의 근거로서 관련 참고문헌(논문 등)을 하단부에 기재\n\n하고, 첨부자료로서 이를 제출한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 624,
        "window_size": 3,
        "char_count": 62,
        "word_count": 13,
        "page_number": 17,
        "window_text": "또한 동의를 서명한\n\n연월일을 기록한다.  또한 동의서 사본을 환자에게 제공하여 환자가 지속적으로\n\n- (4) 검체 채취 및 보관 방법\n- ② 시험기기는 3.2% Na Citrate tube 검체를 실온(18∼25℃)에서 채혈 시 최소\n- ③ LTA 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심\n- ④ VerifyNow 대조기기는 3.2% Na Citrate tube 검체를 실온(18∼25℃)에서 2시간\n이내 검사를 시행한다.\n\n - - 57 -\n임상시험의 설계방법(무작위배정, 단일 또는 이중눈가림, 교차설계 또는 병행설계\n\n등)의 특성이 있는 경우 과학적 타당성과 근거자료를 바탕으로 구체적이고 명확히\n\n기술한다.  상기의 기술한 내용의 근거로서 관련 참고문헌(논문 등)을 하단부에 기재\n\n하고, 첨부자료로서 이를 제출한다.\n\n - ⑤ 검체는 6일간 냉장(2∼6℃) 보관 후 폐기한다.\n - (5) 시험검사 방법\n1) EPI test: 정상인 및 혈소판기능저하가 있는 환자의 검체에 대해 시험기기 및\n\n대조기기인 'epinephrine을 agonist로 사용한 LTA 검사'와 'PFA-100 EPI test'로\n\n및 대조기기인 'ADP를 agonist로 사용한 LTA 검사'와 'PFA-100 ADP test'로\n\n및 대조기기인 'ADP를 agonist로 사용한 LTA 검사'와 'PFA-100 ADP test'로\n\n혈소판 기능의 정상/비정상 유무를 판정하기 위한 목적은 ADP test와 동\n\n- 10.1.3.  임상시험 설계\n- 가. ",
        "original_sentence": "상기의 기술한 내용의 근거로서 관련 참고문헌(논문 등)을 하단부에 기재\n\n하고, 첨부자료로서 이를 제출한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_626",
      "text": "- ⑤ 검체는 6일간 냉장(2∼6℃) 보관 후 폐기한다.\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 625,
        "window_size": 3,
        "char_count": 32,
        "word_count": 8,
        "page_number": 6,
        "window_text": "또한 동의서 사본을 환자에게 제공하여 환자가 지속적으로\n\n- (4) 검체 채취 및 보관 방법\n- ② 시험기기는 3.2% Na Citrate tube 검체를 실온(18∼25℃)에서 채혈 시 최소\n- ③ LTA 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심\n- ④ VerifyNow 대조기기는 3.2% Na Citrate tube 검체를 실온(18∼25℃)에서 2시간\n이내 검사를 시행한다.\n\n - - 57 -\n임상시험의 설계방법(무작위배정, 단일 또는 이중눈가림, 교차설계 또는 병행설계\n\n등)의 특성이 있는 경우 과학적 타당성과 근거자료를 바탕으로 구체적이고 명확히\n\n기술한다.  상기의 기술한 내용의 근거로서 관련 참고문헌(논문 등)을 하단부에 기재\n\n하고, 첨부자료로서 이를 제출한다.\n\n - ⑤ 검체는 6일간 냉장(2∼6℃) 보관 후 폐기한다.\n - (5) 시험검사 방법\n1) EPI test: 정상인 및 혈소판기능저하가 있는 환자의 검체에 대해 시험기기 및\n\n대조기기인 'epinephrine을 agonist로 사용한 LTA 검사'와 'PFA-100 EPI test'로\n\n및 대조기기인 'ADP를 agonist로 사용한 LTA 검사'와 'PFA-100 ADP test'로\n\n및 대조기기인 'ADP를 agonist로 사용한 LTA 검사'와 'PFA-100 ADP test'로\n\n혈소판 기능의 정상/비정상 유무를 판정하기 위한 목적은 ADP test와 동\n\n- 10.1.3.  임상시험 설계\n- 가.  피험자군 또는 대조군 설정\n- 1. ",
        "original_sentence": "- ⑤ 검체는 6일간 냉장(2∼6℃) 보관 후 폐기한다.\n"
      }
    },
    {
      "chunk_id": "chunk_627",
      "text": "- (5) 시험검사 방법\n1) EPI test: 정상인 및 혈소판기능저하가 있는 환자의 검체에 대해 시험기기 및\n\n대조기기인 'epinephrine을 agonist로 사용한 LTA 검사'와 'PFA-100 EPI test'로\n\n및 대조기기인 'ADP를 agonist로 사용한 LTA 검사'와 'PFA-100 ADP test'로\n\n및 대조기기인 'ADP를 agonist로 사용한 LTA 검사'와 'PFA-100 ADP test'로\n\n혈소판 기능의 정상/비정상 유무를 판정하기 위한 목적은 ADP test와 동\n\n- 10.1.3. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 626,
        "window_size": 3,
        "char_count": 295,
        "word_count": 57,
        "page_number": 6,
        "window_text": "- - 57 -\n임상시험의 설계방법(무작위배정, 단일 또는 이중눈가림, 교차설계 또는 병행설계\n\n등)의 특성이 있는 경우 과학적 타당성과 근거자료를 바탕으로 구체적이고 명확히\n\n기술한다.  상기의 기술한 내용의 근거로서 관련 참고문헌(논문 등)을 하단부에 기재\n\n하고, 첨부자료로서 이를 제출한다.\n\n - ⑤ 검체는 6일간 냉장(2∼6℃) 보관 후 폐기한다.\n - (5) 시험검사 방법\n1) EPI test: 정상인 및 혈소판기능저하가 있는 환자의 검체에 대해 시험기기 및\n\n대조기기인 'epinephrine을 agonist로 사용한 LTA 검사'와 'PFA-100 EPI test'로\n\n및 대조기기인 'ADP를 agonist로 사용한 LTA 검사'와 'PFA-100 ADP test'로\n\n및 대조기기인 'ADP를 agonist로 사용한 LTA 검사'와 'PFA-100 ADP test'로\n\n혈소판 기능의 정상/비정상 유무를 판정하기 위한 목적은 ADP test와 동\n\n- 10.1.3.  임상시험 설계\n- 가.  피험자군 또는 대조군 설정\n- 1.  혈소판 기능검사\n- - 58 -\n1) EPI test\n\n- ① 정상 대조군: 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군\n- ② 피험자군: 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand\ndisease),\n\n글란즈만혈소판무력증(Glanzmann's\n\nthrombasthenia),\n\n약물유발\n\n혈소판기능부전 (drug-induced platelet dysfunction) 등의 선천적/후천적\n\n- ② 피험자군: 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand\ndisease),\n\n글란즈만혈소판무력증(Glanzmann's\n\nthrombasthenia),\n\n약물유발\n\n혈소판기능부전 (drug-induced platelet dysfunction) 등의 선천적/후천적\n\n- ② 피험자군: 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand\ndisease),\n\n글란즈만혈소판무력증(Glanzmann's\n\nthrombasthenia),\n\n약물유발\n\n혈소판기능부전 (drug-induced platelet dysfunction) 등의 선천적/후천적\n\n- 2. ",
        "original_sentence": "- (5) 시험검사 방법\n1) EPI test: 정상인 및 혈소판기능저하가 있는 환자의 검체에 대해 시험기기 및\n\n대조기기인 'epinephrine을 agonist로 사용한 LTA 검사'와 'PFA-100 EPI test'로\n\n및 대조기기인 'ADP를 agonist로 사용한 LTA 검사'와 'PFA-100 ADP test'로\n\n및 대조기기인 'ADP를 agonist로 사용한 LTA 검사'와 'PFA-100 ADP test'로\n\n혈소판 기능의 정상/비정상 유무를 판정하기 위한 목적은 ADP test와 동\n\n- 10.1.3. "
      }
    },
    {
      "chunk_id": "chunk_628",
      "text": "임상시험 설계\n- 가. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 627,
        "window_size": 3,
        "char_count": 13,
        "word_count": 4,
        "page_number": 9,
        "window_text": "상기의 기술한 내용의 근거로서 관련 참고문헌(논문 등)을 하단부에 기재\n\n하고, 첨부자료로서 이를 제출한다.\n\n - ⑤ 검체는 6일간 냉장(2∼6℃) 보관 후 폐기한다.\n - (5) 시험검사 방법\n1) EPI test: 정상인 및 혈소판기능저하가 있는 환자의 검체에 대해 시험기기 및\n\n대조기기인 'epinephrine을 agonist로 사용한 LTA 검사'와 'PFA-100 EPI test'로\n\n및 대조기기인 'ADP를 agonist로 사용한 LTA 검사'와 'PFA-100 ADP test'로\n\n및 대조기기인 'ADP를 agonist로 사용한 LTA 검사'와 'PFA-100 ADP test'로\n\n혈소판 기능의 정상/비정상 유무를 판정하기 위한 목적은 ADP test와 동\n\n- 10.1.3.  임상시험 설계\n- 가.  피험자군 또는 대조군 설정\n- 1.  혈소판 기능검사\n- - 58 -\n1) EPI test\n\n- ① 정상 대조군: 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군\n- ② 피험자군: 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand\ndisease),\n\n글란즈만혈소판무력증(Glanzmann's\n\nthrombasthenia),\n\n약물유발\n\n혈소판기능부전 (drug-induced platelet dysfunction) 등의 선천적/후천적\n\n- ② 피험자군: 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand\ndisease),\n\n글란즈만혈소판무력증(Glanzmann's\n\nthrombasthenia),\n\n약물유발\n\n혈소판기능부전 (drug-induced platelet dysfunction) 등의 선천적/후천적\n\n- ② 피험자군: 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand\ndisease),\n\n글란즈만혈소판무력증(Glanzmann's\n\nthrombasthenia),\n\n약물유발\n\n혈소판기능부전 (drug-induced platelet dysfunction) 등의 선천적/후천적\n\n- 2.  혈소판 약물반응검사\n- ① 대조군: 혈관질환의 위험군, 혈관질환 병력 등으로 aspirin 복용 예정인\n- ② 피험자군: 혈관질환의 위험군, 혈관질환 병력 등으로 aspirin 복용 예정이었던\n2）P2Y12 test\n\n- ① 대조군: 혈관질환의 위험군, 혈관질환 병력 등으로 clopidogrel 복용 예정인\n- - 59 -\n환자의 clopidogrel\n\n복용 전 검체\n\n- ② 피험자군: 혈관질환의 위험군, 혈관질환 병력 등으로 clopidogrel\n복용 예정\n\n이었던 환자의 5일 이상clopidogrel\n\n복용 후의 검체\n\n1) EPI test: 시험기기에서\n\nLTA를 기준검사법으로 한 민감도와 특이도가\n\n기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인한다\n\n2) ADP test: 시험기기에서\n\nLTA를 기준검사법으로 한 민감도와 특이도가\n\n기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인한다\n\n3) SIPA test:　시험기기에서\n\nLTA를 기준검사법으로 한 민감도와 특이도가\n\n기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인한다 (비\n\n열등성한계 10%). ",
        "original_sentence": "임상시험 설계\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_629",
      "text": "피험자군 또는 대조군 설정\n- 1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 628,
        "window_size": 3,
        "char_count": 20,
        "word_count": 6,
        "page_number": 6,
        "window_text": "- ⑤ 검체는 6일간 냉장(2∼6℃) 보관 후 폐기한다.\n - (5) 시험검사 방법\n1) EPI test: 정상인 및 혈소판기능저하가 있는 환자의 검체에 대해 시험기기 및\n\n대조기기인 'epinephrine을 agonist로 사용한 LTA 검사'와 'PFA-100 EPI test'로\n\n및 대조기기인 'ADP를 agonist로 사용한 LTA 검사'와 'PFA-100 ADP test'로\n\n및 대조기기인 'ADP를 agonist로 사용한 LTA 검사'와 'PFA-100 ADP test'로\n\n혈소판 기능의 정상/비정상 유무를 판정하기 위한 목적은 ADP test와 동\n\n- 10.1.3.  임상시험 설계\n- 가.  피험자군 또는 대조군 설정\n- 1.  혈소판 기능검사\n- - 58 -\n1) EPI test\n\n- ① 정상 대조군: 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군\n- ② 피험자군: 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand\ndisease),\n\n글란즈만혈소판무력증(Glanzmann's\n\nthrombasthenia),\n\n약물유발\n\n혈소판기능부전 (drug-induced platelet dysfunction) 등의 선천적/후천적\n\n- ② 피험자군: 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand\ndisease),\n\n글란즈만혈소판무력증(Glanzmann's\n\nthrombasthenia),\n\n약물유발\n\n혈소판기능부전 (drug-induced platelet dysfunction) 등의 선천적/후천적\n\n- ② 피험자군: 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand\ndisease),\n\n글란즈만혈소판무력증(Glanzmann's\n\nthrombasthenia),\n\n약물유발\n\n혈소판기능부전 (drug-induced platelet dysfunction) 등의 선천적/후천적\n\n- 2.  혈소판 약물반응검사\n- ① 대조군: 혈관질환의 위험군, 혈관질환 병력 등으로 aspirin 복용 예정인\n- ② 피험자군: 혈관질환의 위험군, 혈관질환 병력 등으로 aspirin 복용 예정이었던\n2）P2Y12 test\n\n- ① 대조군: 혈관질환의 위험군, 혈관질환 병력 등으로 clopidogrel 복용 예정인\n- - 59 -\n환자의 clopidogrel\n\n복용 전 검체\n\n- ② 피험자군: 혈관질환의 위험군, 혈관질환 병력 등으로 clopidogrel\n복용 예정\n\n이었던 환자의 5일 이상clopidogrel\n\n복용 후의 검체\n\n1) EPI test: 시험기기에서\n\nLTA를 기준검사법으로 한 민감도와 특이도가\n\n기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인한다\n\n2) ADP test: 시험기기에서\n\nLTA를 기준검사법으로 한 민감도와 특이도가\n\n기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인한다\n\n3) SIPA test:　시험기기에서\n\nLTA를 기준검사법으로 한 민감도와 특이도가\n\n기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인한다 (비\n\n열등성한계 10%).  SIPA　 test는 검사원리가 비슷한 기존검사법은 없으나,\n\n혈소판 기능의 정상/비정상 유무를 판정하기 위한 목적은 ADP test와 동일\n\n- 2. ",
        "original_sentence": "피험자군 또는 대조군 설정\n- 1. "
      }
    },
    {
      "chunk_id": "chunk_630",
      "text": "혈소판 기능검사\n- - 58 -\n1) EPI test\n\n- ① 정상 대조군: 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군\n- ② 피험자군: 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand\ndisease),\n\n글란즈만혈소판무력증(Glanzmann's\n\nthrombasthenia),\n\n약물유발\n\n혈소판기능부전 (drug-induced platelet dysfunction) 등의 선천적/후천적\n\n- ② 피험자군: 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand\ndisease),\n\n글란즈만혈소판무력증(Glanzmann's\n\nthrombasthenia),\n\n약물유발\n\n혈소판기능부전 (drug-induced platelet dysfunction) 등의 선천적/후천적\n\n- ② 피험자군: 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand\ndisease),\n\n글란즈만혈소판무력증(Glanzmann's\n\nthrombasthenia),\n\n약물유발\n\n혈소판기능부전 (drug-induced platelet dysfunction) 등의 선천적/후천적\n\n- 2. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 629,
        "window_size": 3,
        "char_count": 581,
        "word_count": 80,
        "page_number": 6,
        "window_text": "- (5) 시험검사 방법\n1) EPI test: 정상인 및 혈소판기능저하가 있는 환자의 검체에 대해 시험기기 및\n\n대조기기인 'epinephrine을 agonist로 사용한 LTA 검사'와 'PFA-100 EPI test'로\n\n및 대조기기인 'ADP를 agonist로 사용한 LTA 검사'와 'PFA-100 ADP test'로\n\n및 대조기기인 'ADP를 agonist로 사용한 LTA 검사'와 'PFA-100 ADP test'로\n\n혈소판 기능의 정상/비정상 유무를 판정하기 위한 목적은 ADP test와 동\n\n- 10.1.3.  임상시험 설계\n- 가.  피험자군 또는 대조군 설정\n- 1.  혈소판 기능검사\n- - 58 -\n1) EPI test\n\n- ① 정상 대조군: 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군\n- ② 피험자군: 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand\ndisease),\n\n글란즈만혈소판무력증(Glanzmann's\n\nthrombasthenia),\n\n약물유발\n\n혈소판기능부전 (drug-induced platelet dysfunction) 등의 선천적/후천적\n\n- ② 피험자군: 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand\ndisease),\n\n글란즈만혈소판무력증(Glanzmann's\n\nthrombasthenia),\n\n약물유발\n\n혈소판기능부전 (drug-induced platelet dysfunction) 등의 선천적/후천적\n\n- ② 피험자군: 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand\ndisease),\n\n글란즈만혈소판무력증(Glanzmann's\n\nthrombasthenia),\n\n약물유발\n\n혈소판기능부전 (drug-induced platelet dysfunction) 등의 선천적/후천적\n\n- 2.  혈소판 약물반응검사\n- ① 대조군: 혈관질환의 위험군, 혈관질환 병력 등으로 aspirin 복용 예정인\n- ② 피험자군: 혈관질환의 위험군, 혈관질환 병력 등으로 aspirin 복용 예정이었던\n2）P2Y12 test\n\n- ① 대조군: 혈관질환의 위험군, 혈관질환 병력 등으로 clopidogrel 복용 예정인\n- - 59 -\n환자의 clopidogrel\n\n복용 전 검체\n\n- ② 피험자군: 혈관질환의 위험군, 혈관질환 병력 등으로 clopidogrel\n복용 예정\n\n이었던 환자의 5일 이상clopidogrel\n\n복용 후의 검체\n\n1) EPI test: 시험기기에서\n\nLTA를 기준검사법으로 한 민감도와 특이도가\n\n기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인한다\n\n2) ADP test: 시험기기에서\n\nLTA를 기준검사법으로 한 민감도와 특이도가\n\n기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인한다\n\n3) SIPA test:　시험기기에서\n\nLTA를 기준검사법으로 한 민감도와 특이도가\n\n기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인한다 (비\n\n열등성한계 10%).  SIPA　 test는 검사원리가 비슷한 기존검사법은 없으나,\n\n혈소판 기능의 정상/비정상 유무를 판정하기 위한 목적은 ADP test와 동일\n\n- 2.  혈소판 약물반응검사\n1) Aspirin test：Aspirin 복용예정 환자에서 약물 복용 전후에 대한 민감도와\n\n- - 60 -\n특이도가 기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인\n\n한다 (비열등성한계 10%).\n\n",
        "original_sentence": "혈소판 기능검사\n- - 58 -\n1) EPI test\n\n- ① 정상 대조군: 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군\n- ② 피험자군: 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand\ndisease),\n\n글란즈만혈소판무력증(Glanzmann's\n\nthrombasthenia),\n\n약물유발\n\n혈소판기능부전 (drug-induced platelet dysfunction) 등의 선천적/후천적\n\n- ② 피험자군: 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand\ndisease),\n\n글란즈만혈소판무력증(Glanzmann's\n\nthrombasthenia),\n\n약물유발\n\n혈소판기능부전 (drug-induced platelet dysfunction) 등의 선천적/후천적\n\n- ② 피험자군: 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand\ndisease),\n\n글란즈만혈소판무력증(Glanzmann's\n\nthrombasthenia),\n\n약물유발\n\n혈소판기능부전 (drug-induced platelet dysfunction) 등의 선천적/후천적\n\n- 2. "
      }
    },
    {
      "chunk_id": "chunk_631",
      "text": "혈소판 약물반응검사\n- ① 대조군: 혈관질환의 위험군, 혈관질환 병력 등으로 aspirin 복용 예정인\n- ② 피험자군: 혈관질환의 위험군, 혈관질환 병력 등으로 aspirin 복용 예정이었던\n2）P2Y12 test\n\n- ① 대조군: 혈관질환의 위험군, 혈관질환 병력 등으로 clopidogrel 복용 예정인\n- - 59 -\n환자의 clopidogrel\n\n복용 전 검체\n\n- ② 피험자군: 혈관질환의 위험군, 혈관질환 병력 등으로 clopidogrel\n복용 예정\n\n이었던 환자의 5일 이상clopidogrel\n\n복용 후의 검체\n\n1) EPI test: 시험기기에서\n\nLTA를 기준검사법으로 한 민감도와 특이도가\n\n기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인한다\n\n2) ADP test: 시험기기에서\n\nLTA를 기준검사법으로 한 민감도와 특이도가\n\n기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인한다\n\n3) SIPA test:　시험기기에서\n\nLTA를 기준검사법으로 한 민감도와 특이도가\n\n기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인한다 (비\n\n열등성한계 10%). ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 630,
        "window_size": 3,
        "char_count": 567,
        "word_count": 118,
        "page_number": 18,
        "window_text": "임상시험 설계\n- 가.  피험자군 또는 대조군 설정\n- 1.  혈소판 기능검사\n- - 58 -\n1) EPI test\n\n- ① 정상 대조군: 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군\n- ② 피험자군: 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand\ndisease),\n\n글란즈만혈소판무력증(Glanzmann's\n\nthrombasthenia),\n\n약물유발\n\n혈소판기능부전 (drug-induced platelet dysfunction) 등의 선천적/후천적\n\n- ② 피험자군: 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand\ndisease),\n\n글란즈만혈소판무력증(Glanzmann's\n\nthrombasthenia),\n\n약물유발\n\n혈소판기능부전 (drug-induced platelet dysfunction) 등의 선천적/후천적\n\n- ② 피험자군: 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand\ndisease),\n\n글란즈만혈소판무력증(Glanzmann's\n\nthrombasthenia),\n\n약물유발\n\n혈소판기능부전 (drug-induced platelet dysfunction) 등의 선천적/후천적\n\n- 2.  혈소판 약물반응검사\n- ① 대조군: 혈관질환의 위험군, 혈관질환 병력 등으로 aspirin 복용 예정인\n- ② 피험자군: 혈관질환의 위험군, 혈관질환 병력 등으로 aspirin 복용 예정이었던\n2）P2Y12 test\n\n- ① 대조군: 혈관질환의 위험군, 혈관질환 병력 등으로 clopidogrel 복용 예정인\n- - 59 -\n환자의 clopidogrel\n\n복용 전 검체\n\n- ② 피험자군: 혈관질환의 위험군, 혈관질환 병력 등으로 clopidogrel\n복용 예정\n\n이었던 환자의 5일 이상clopidogrel\n\n복용 후의 검체\n\n1) EPI test: 시험기기에서\n\nLTA를 기준검사법으로 한 민감도와 특이도가\n\n기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인한다\n\n2) ADP test: 시험기기에서\n\nLTA를 기준검사법으로 한 민감도와 특이도가\n\n기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인한다\n\n3) SIPA test:　시험기기에서\n\nLTA를 기준검사법으로 한 민감도와 특이도가\n\n기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인한다 (비\n\n열등성한계 10%).  SIPA　 test는 검사원리가 비슷한 기존검사법은 없으나,\n\n혈소판 기능의 정상/비정상 유무를 판정하기 위한 목적은 ADP test와 동일\n\n- 2.  혈소판 약물반응검사\n1) Aspirin test：Aspirin 복용예정 환자에서 약물 복용 전후에 대한 민감도와\n\n- - 60 -\n특이도가 기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인\n\n한다 (비열등성한계 10%).\n\n 2）P2Y12 test：Clopidogrel 복용예정 환자에서 약물 복용 전후에 대한 민감도와\n\n- - 61 -\n<!-- PAGE_68 -->\n###### 11. ",
        "original_sentence": "혈소판 약물반응검사\n- ① 대조군: 혈관질환의 위험군, 혈관질환 병력 등으로 aspirin 복용 예정인\n- ② 피험자군: 혈관질환의 위험군, 혈관질환 병력 등으로 aspirin 복용 예정이었던\n2）P2Y12 test\n\n- ① 대조군: 혈관질환의 위험군, 혈관질환 병력 등으로 clopidogrel 복용 예정인\n- - 59 -\n환자의 clopidogrel\n\n복용 전 검체\n\n- ② 피험자군: 혈관질환의 위험군, 혈관질환 병력 등으로 clopidogrel\n복용 예정\n\n이었던 환자의 5일 이상clopidogrel\n\n복용 후의 검체\n\n1) EPI test: 시험기기에서\n\nLTA를 기준검사법으로 한 민감도와 특이도가\n\n기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인한다\n\n2) ADP test: 시험기기에서\n\nLTA를 기준검사법으로 한 민감도와 특이도가\n\n기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인한다\n\n3) SIPA test:　시험기기에서\n\nLTA를 기준검사법으로 한 민감도와 특이도가\n\n기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인한다 (비\n\n열등성한계 10%). "
      }
    },
    {
      "chunk_id": "chunk_632",
      "text": "SIPA　 test는 검사원리가 비슷한 기존검사법은 없으나,\n\n혈소판 기능의 정상/비정상 유무를 판정하기 위한 목적은 ADP test와 동일\n\n- 2. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 631,
        "window_size": 3,
        "char_count": 85,
        "word_count": 18,
        "page_number": 78,
        "window_text": "피험자군 또는 대조군 설정\n- 1.  혈소판 기능검사\n- - 58 -\n1) EPI test\n\n- ① 정상 대조군: 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군\n- ② 피험자군: 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand\ndisease),\n\n글란즈만혈소판무력증(Glanzmann's\n\nthrombasthenia),\n\n약물유발\n\n혈소판기능부전 (drug-induced platelet dysfunction) 등의 선천적/후천적\n\n- ② 피험자군: 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand\ndisease),\n\n글란즈만혈소판무력증(Glanzmann's\n\nthrombasthenia),\n\n약물유발\n\n혈소판기능부전 (drug-induced platelet dysfunction) 등의 선천적/후천적\n\n- ② 피험자군: 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand\ndisease),\n\n글란즈만혈소판무력증(Glanzmann's\n\nthrombasthenia),\n\n약물유발\n\n혈소판기능부전 (drug-induced platelet dysfunction) 등의 선천적/후천적\n\n- 2.  혈소판 약물반응검사\n- ① 대조군: 혈관질환의 위험군, 혈관질환 병력 등으로 aspirin 복용 예정인\n- ② 피험자군: 혈관질환의 위험군, 혈관질환 병력 등으로 aspirin 복용 예정이었던\n2）P2Y12 test\n\n- ① 대조군: 혈관질환의 위험군, 혈관질환 병력 등으로 clopidogrel 복용 예정인\n- - 59 -\n환자의 clopidogrel\n\n복용 전 검체\n\n- ② 피험자군: 혈관질환의 위험군, 혈관질환 병력 등으로 clopidogrel\n복용 예정\n\n이었던 환자의 5일 이상clopidogrel\n\n복용 후의 검체\n\n1) EPI test: 시험기기에서\n\nLTA를 기준검사법으로 한 민감도와 특이도가\n\n기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인한다\n\n2) ADP test: 시험기기에서\n\nLTA를 기준검사법으로 한 민감도와 특이도가\n\n기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인한다\n\n3) SIPA test:　시험기기에서\n\nLTA를 기준검사법으로 한 민감도와 특이도가\n\n기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인한다 (비\n\n열등성한계 10%).  SIPA　 test는 검사원리가 비슷한 기존검사법은 없으나,\n\n혈소판 기능의 정상/비정상 유무를 판정하기 위한 목적은 ADP test와 동일\n\n- 2.  혈소판 약물반응검사\n1) Aspirin test：Aspirin 복용예정 환자에서 약물 복용 전후에 대한 민감도와\n\n- - 60 -\n특이도가 기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인\n\n한다 (비열등성한계 10%).\n\n 2）P2Y12 test：Clopidogrel 복용예정 환자에서 약물 복용 전후에 대한 민감도와\n\n- - 61 -\n<!-- PAGE_68 -->\n###### 11.  관찰항목, 임상검사항목 및 관찰검사방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- - 62 -\n- 11.2. ",
        "original_sentence": "SIPA　 test는 검사원리가 비슷한 기존검사법은 없으나,\n\n혈소판 기능의 정상/비정상 유무를 판정하기 위한 목적은 ADP test와 동일\n\n- 2. "
      }
    },
    {
      "chunk_id": "chunk_633",
      "text": "혈소판 약물반응검사\n1) Aspirin test：Aspirin 복용예정 환자에서 약물 복용 전후에 대한 민감도와\n\n- - 60 -\n특이도가 기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인\n\n한다 (비열등성한계 10%).\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 632,
        "window_size": 3,
        "char_count": 132,
        "word_count": 28,
        "page_number": 6,
        "window_text": "혈소판 기능검사\n- - 58 -\n1) EPI test\n\n- ① 정상 대조군: 정상 혈소판기능을 갖는 특이 기왕력/약물력이 없는 정상 대조군\n- ② 피험자군: 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand\ndisease),\n\n글란즈만혈소판무력증(Glanzmann's\n\nthrombasthenia),\n\n약물유발\n\n혈소판기능부전 (drug-induced platelet dysfunction) 등의 선천적/후천적\n\n- ② 피험자군: 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand\ndisease),\n\n글란즈만혈소판무력증(Glanzmann's\n\nthrombasthenia),\n\n약물유발\n\n혈소판기능부전 (drug-induced platelet dysfunction) 등의 선천적/후천적\n\n- ② 피험자군: 혈소판기능장애가 있는 환자군: 본 빌레브란트병(von Willebrand\ndisease),\n\n글란즈만혈소판무력증(Glanzmann's\n\nthrombasthenia),\n\n약물유발\n\n혈소판기능부전 (drug-induced platelet dysfunction) 등의 선천적/후천적\n\n- 2.  혈소판 약물반응검사\n- ① 대조군: 혈관질환의 위험군, 혈관질환 병력 등으로 aspirin 복용 예정인\n- ② 피험자군: 혈관질환의 위험군, 혈관질환 병력 등으로 aspirin 복용 예정이었던\n2）P2Y12 test\n\n- ① 대조군: 혈관질환의 위험군, 혈관질환 병력 등으로 clopidogrel 복용 예정인\n- - 59 -\n환자의 clopidogrel\n\n복용 전 검체\n\n- ② 피험자군: 혈관질환의 위험군, 혈관질환 병력 등으로 clopidogrel\n복용 예정\n\n이었던 환자의 5일 이상clopidogrel\n\n복용 후의 검체\n\n1) EPI test: 시험기기에서\n\nLTA를 기준검사법으로 한 민감도와 특이도가\n\n기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인한다\n\n2) ADP test: 시험기기에서\n\nLTA를 기준검사법으로 한 민감도와 특이도가\n\n기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인한다\n\n3) SIPA test:　시험기기에서\n\nLTA를 기준검사법으로 한 민감도와 특이도가\n\n기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인한다 (비\n\n열등성한계 10%).  SIPA　 test는 검사원리가 비슷한 기존검사법은 없으나,\n\n혈소판 기능의 정상/비정상 유무를 판정하기 위한 목적은 ADP test와 동일\n\n- 2.  혈소판 약물반응검사\n1) Aspirin test：Aspirin 복용예정 환자에서 약물 복용 전후에 대한 민감도와\n\n- - 60 -\n특이도가 기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인\n\n한다 (비열등성한계 10%).\n\n 2）P2Y12 test：Clopidogrel 복용예정 환자에서 약물 복용 전후에 대한 민감도와\n\n- - 61 -\n<!-- PAGE_68 -->\n###### 11.  관찰항목, 임상검사항목 및 관찰검사방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- - 62 -\n- 11.2.  관찰검사방법\n- 가. ",
        "original_sentence": "혈소판 약물반응검사\n1) Aspirin test：Aspirin 복용예정 환자에서 약물 복용 전후에 대한 민감도와\n\n- - 60 -\n특이도가 기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인\n\n한다 (비열등성한계 10%).\n\n"
      }
    },
    {
      "chunk_id": "chunk_634",
      "text": "2）P2Y12 test：Clopidogrel 복용예정 환자에서 약물 복용 전후에 대한 민감도와\n\n- - 61 -\n<!-- PAGE_68 -->\n###### 11. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 633,
        "window_size": 3,
        "char_count": 91,
        "word_count": 18,
        "page_number": 68,
        "window_text": "혈소판 약물반응검사\n- ① 대조군: 혈관질환의 위험군, 혈관질환 병력 등으로 aspirin 복용 예정인\n- ② 피험자군: 혈관질환의 위험군, 혈관질환 병력 등으로 aspirin 복용 예정이었던\n2）P2Y12 test\n\n- ① 대조군: 혈관질환의 위험군, 혈관질환 병력 등으로 clopidogrel 복용 예정인\n- - 59 -\n환자의 clopidogrel\n\n복용 전 검체\n\n- ② 피험자군: 혈관질환의 위험군, 혈관질환 병력 등으로 clopidogrel\n복용 예정\n\n이었던 환자의 5일 이상clopidogrel\n\n복용 후의 검체\n\n1) EPI test: 시험기기에서\n\nLTA를 기준검사법으로 한 민감도와 특이도가\n\n기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인한다\n\n2) ADP test: 시험기기에서\n\nLTA를 기준검사법으로 한 민감도와 특이도가\n\n기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인한다\n\n3) SIPA test:　시험기기에서\n\nLTA를 기준검사법으로 한 민감도와 특이도가\n\n기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인한다 (비\n\n열등성한계 10%).  SIPA　 test는 검사원리가 비슷한 기존검사법은 없으나,\n\n혈소판 기능의 정상/비정상 유무를 판정하기 위한 목적은 ADP test와 동일\n\n- 2.  혈소판 약물반응검사\n1) Aspirin test：Aspirin 복용예정 환자에서 약물 복용 전후에 대한 민감도와\n\n- - 60 -\n특이도가 기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인\n\n한다 (비열등성한계 10%).\n\n 2）P2Y12 test：Clopidogrel 복용예정 환자에서 약물 복용 전후에 대한 민감도와\n\n- - 61 -\n<!-- PAGE_68 -->\n###### 11.  관찰항목, 임상검사항목 및 관찰검사방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- - 62 -\n- 11.2.  관찰검사방법\n- 가.  방문1 (스크리닝 및 검사일)\n1) 임상시험 설명 및 동의 및 스크리닝\n\n‘출혈 시간 및 항혈소판제제 저항성 복합검사기기(Anysis-200)’의 임상시험에 들어\n\n가기 전, 본 임상시험의 목적과 내용에 대하여 대상자 또는 법정대리인에게\n\n동의서의 원본은 시험자가 보관하고 사본은 시험대상자 또는 법정대리인에게\n\n교부한다. ",
        "original_sentence": "2）P2Y12 test：Clopidogrel 복용예정 환자에서 약물 복용 전후에 대한 민감도와\n\n- - 61 -\n<!-- PAGE_68 -->\n###### 11. "
      }
    },
    {
      "chunk_id": "chunk_635",
      "text": "관찰항목, 임상검사항목 및 관찰검사방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- - 62 -\n- 11.2. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 634,
        "window_size": 3,
        "char_count": 92,
        "word_count": 24,
        "page_number": 3,
        "window_text": "SIPA　 test는 검사원리가 비슷한 기존검사법은 없으나,\n\n혈소판 기능의 정상/비정상 유무를 판정하기 위한 목적은 ADP test와 동일\n\n- 2.  혈소판 약물반응검사\n1) Aspirin test：Aspirin 복용예정 환자에서 약물 복용 전후에 대한 민감도와\n\n- - 60 -\n특이도가 기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인\n\n한다 (비열등성한계 10%).\n\n 2）P2Y12 test：Clopidogrel 복용예정 환자에서 약물 복용 전후에 대한 민감도와\n\n- - 61 -\n<!-- PAGE_68 -->\n###### 11.  관찰항목, 임상검사항목 및 관찰검사방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- - 62 -\n- 11.2.  관찰검사방법\n- 가.  방문1 (스크리닝 및 검사일)\n1) 임상시험 설명 및 동의 및 스크리닝\n\n‘출혈 시간 및 항혈소판제제 저항성 복합검사기기(Anysis-200)’의 임상시험에 들어\n\n가기 전, 본 임상시험의 목적과 내용에 대하여 대상자 또는 법정대리인에게\n\n동의서의 원본은 시험자가 보관하고 사본은 시험대상자 또는 법정대리인에게\n\n교부한다.  대상자에게 서면 동의를 받은 후 동의취득\n\n순서에 따라 스크리닝\n\n대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그 위임자가 모든 선정\n\n수용체 저해제 등의 항혈소판제제, 항응고제 복용 유무, CBC(혈색소, 헤마토크릿,\n\n검체를 채취하고 시험기기 및 대조기기에서 검사를 시행하고 결과를 기록한다.\n\n",
        "original_sentence": "관찰항목, 임상검사항목 및 관찰검사방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- - 62 -\n- 11.2. "
      }
    },
    {
      "chunk_id": "chunk_636",
      "text": "관찰검사방법\n- 가. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 635,
        "window_size": 3,
        "char_count": 12,
        "word_count": 3,
        "page_number": 33,
        "window_text": "혈소판 약물반응검사\n1) Aspirin test：Aspirin 복용예정 환자에서 약물 복용 전후에 대한 민감도와\n\n- - 60 -\n특이도가 기허가제품인 대조기기의 민감도 및 특이도보다 낮지 않음을 확인\n\n한다 (비열등성한계 10%).\n\n 2）P2Y12 test：Clopidogrel 복용예정 환자에서 약물 복용 전후에 대한 민감도와\n\n- - 61 -\n<!-- PAGE_68 -->\n###### 11.  관찰항목, 임상검사항목 및 관찰검사방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- - 62 -\n- 11.2.  관찰검사방법\n- 가.  방문1 (스크리닝 및 검사일)\n1) 임상시험 설명 및 동의 및 스크리닝\n\n‘출혈 시간 및 항혈소판제제 저항성 복합검사기기(Anysis-200)’의 임상시험에 들어\n\n가기 전, 본 임상시험의 목적과 내용에 대하여 대상자 또는 법정대리인에게\n\n동의서의 원본은 시험자가 보관하고 사본은 시험대상자 또는 법정대리인에게\n\n교부한다.  대상자에게 서면 동의를 받은 후 동의취득\n\n순서에 따라 스크리닝\n\n대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그 위임자가 모든 선정\n\n수용체 저해제 등의 항혈소판제제, 항응고제 복용 유무, CBC(혈색소, 헤마토크릿,\n\n검체를 채취하고 시험기기 및 대조기기에서 검사를 시행하고 결과를 기록한다.\n\n 1) 3.2% Na Citrate tube에 약 20mL의 정맥혈을 채혈한다.\n\n",
        "original_sentence": "관찰검사방법\n- 가. "
      }
    },
    {
      "chunk_id": "chunk_637",
      "text": "방문1 (스크리닝 및 검사일)\n1) 임상시험 설명 및 동의 및 스크리닝\n\n‘출혈 시간 및 항혈소판제제 저항성 복합검사기기(Anysis-200)’의 임상시험에 들어\n\n가기 전, 본 임상시험의 목적과 내용에 대하여 대상자 또는 법정대리인에게\n\n동의서의 원본은 시험자가 보관하고 사본은 시험대상자 또는 법정대리인에게\n\n교부한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 636,
        "window_size": 3,
        "char_count": 181,
        "word_count": 38,
        "page_number": 6,
        "window_text": "2）P2Y12 test：Clopidogrel 복용예정 환자에서 약물 복용 전후에 대한 민감도와\n\n- - 61 -\n<!-- PAGE_68 -->\n###### 11.  관찰항목, 임상검사항목 및 관찰검사방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- - 62 -\n- 11.2.  관찰검사방법\n- 가.  방문1 (스크리닝 및 검사일)\n1) 임상시험 설명 및 동의 및 스크리닝\n\n‘출혈 시간 및 항혈소판제제 저항성 복합검사기기(Anysis-200)’의 임상시험에 들어\n\n가기 전, 본 임상시험의 목적과 내용에 대하여 대상자 또는 법정대리인에게\n\n동의서의 원본은 시험자가 보관하고 사본은 시험대상자 또는 법정대리인에게\n\n교부한다.  대상자에게 서면 동의를 받은 후 동의취득\n\n순서에 따라 스크리닝\n\n대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그 위임자가 모든 선정\n\n수용체 저해제 등의 항혈소판제제, 항응고제 복용 유무, CBC(혈색소, 헤마토크릿,\n\n검체를 채취하고 시험기기 및 대조기기에서 검사를 시행하고 결과를 기록한다.\n\n 1) 3.2% Na Citrate tube에 약 20mL의 정맥혈을 채혈한다.\n\n 2) 시험기기는 3.2% Na Citrate tube 검체를 실온(18∼25℃)에서 채혈 후 최소\n\n30분, 최대 4시간 이내 검사를 시행하고 그 결과를 데이터 수집용지에 기록\n\n한다.\n\n",
        "original_sentence": "방문1 (스크리닝 및 검사일)\n1) 임상시험 설명 및 동의 및 스크리닝\n\n‘출혈 시간 및 항혈소판제제 저항성 복합검사기기(Anysis-200)’의 임상시험에 들어\n\n가기 전, 본 임상시험의 목적과 내용에 대하여 대상자 또는 법정대리인에게\n\n동의서의 원본은 시험자가 보관하고 사본은 시험대상자 또는 법정대리인에게\n\n교부한다. "
      }
    },
    {
      "chunk_id": "chunk_638",
      "text": "대상자에게 서면 동의를 받은 후 동의취득\n\n순서에 따라 스크리닝\n\n대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그 위임자가 모든 선정\n\n수용체 저해제 등의 항혈소판제제, 항응고제 복용 유무, CBC(혈색소, 헤마토크릿,\n\n검체를 채취하고 시험기기 및 대조기기에서 검사를 시행하고 결과를 기록한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 637,
        "window_size": 3,
        "char_count": 173,
        "word_count": 39,
        "page_number": 9,
        "window_text": "관찰항목, 임상검사항목 및 관찰검사방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- - 62 -\n- 11.2.  관찰검사방법\n- 가.  방문1 (스크리닝 및 검사일)\n1) 임상시험 설명 및 동의 및 스크리닝\n\n‘출혈 시간 및 항혈소판제제 저항성 복합검사기기(Anysis-200)’의 임상시험에 들어\n\n가기 전, 본 임상시험의 목적과 내용에 대하여 대상자 또는 법정대리인에게\n\n동의서의 원본은 시험자가 보관하고 사본은 시험대상자 또는 법정대리인에게\n\n교부한다.  대상자에게 서면 동의를 받은 후 동의취득\n\n순서에 따라 스크리닝\n\n대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그 위임자가 모든 선정\n\n수용체 저해제 등의 항혈소판제제, 항응고제 복용 유무, CBC(혈색소, 헤마토크릿,\n\n검체를 채취하고 시험기기 및 대조기기에서 검사를 시행하고 결과를 기록한다.\n\n 1) 3.2% Na Citrate tube에 약 20mL의 정맥혈을 채혈한다.\n\n 2) 시험기기는 3.2% Na Citrate tube 검체를 실온(18∼25℃)에서 채혈 후 최소\n\n30분, 최대 4시간 이내 검사를 시행하고 그 결과를 데이터 수집용지에 기록\n\n한다.\n\n - - 63 -\n3) LTA 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심\n\n분리하여 혈소판풍부혈장을 취하여 3시간 이내에 검사를 시행하고 그 결과를\n\n데이터 수집용지에 기록한다.\n\n",
        "original_sentence": "대상자에게 서면 동의를 받은 후 동의취득\n\n순서에 따라 스크리닝\n\n대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그 위임자가 모든 선정\n\n수용체 저해제 등의 항혈소판제제, 항응고제 복용 유무, CBC(혈색소, 헤마토크릿,\n\n검체를 채취하고 시험기기 및 대조기기에서 검사를 시행하고 결과를 기록한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_639",
      "text": "1) 3.2% Na Citrate tube에 약 20mL의 정맥혈을 채혈한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 638,
        "window_size": 3,
        "char_count": 45,
        "word_count": 9,
        "page_number": 69,
        "window_text": "관찰검사방법\n- 가.  방문1 (스크리닝 및 검사일)\n1) 임상시험 설명 및 동의 및 스크리닝\n\n‘출혈 시간 및 항혈소판제제 저항성 복합검사기기(Anysis-200)’의 임상시험에 들어\n\n가기 전, 본 임상시험의 목적과 내용에 대하여 대상자 또는 법정대리인에게\n\n동의서의 원본은 시험자가 보관하고 사본은 시험대상자 또는 법정대리인에게\n\n교부한다.  대상자에게 서면 동의를 받은 후 동의취득\n\n순서에 따라 스크리닝\n\n대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그 위임자가 모든 선정\n\n수용체 저해제 등의 항혈소판제제, 항응고제 복용 유무, CBC(혈색소, 헤마토크릿,\n\n검체를 채취하고 시험기기 및 대조기기에서 검사를 시행하고 결과를 기록한다.\n\n 1) 3.2% Na Citrate tube에 약 20mL의 정맥혈을 채혈한다.\n\n 2) 시험기기는 3.2% Na Citrate tube 검체를 실온(18∼25℃)에서 채혈 후 최소\n\n30분, 최대 4시간 이내 검사를 시행하고 그 결과를 데이터 수집용지에 기록\n\n한다.\n\n - - 63 -\n3) LTA 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심\n\n분리하여 혈소판풍부혈장을 취하여 3시간 이내에 검사를 시행하고 그 결과를\n\n데이터 수집용지에 기록한다.\n\n 4) PFA-100 및 VerifyNow 대조기기는 3.2% Na Citrate tube 검체를 실온(18∼\n\n2) Aspirin 복용 후 3일, 또는 clopidogrel 복용 후 5일 이후 검체를 채취하여 시험\n\n- ④ SIPA　test는 검사원리가 비슷한 기존검사법은 없으나, 혈소판 기능의 정상/\n비정상 유무를 판정하기 위한 목적은 ADP test와 동일하므로, 이를 확인하는\n\n2) 혈소판 약물반응 검사: 시험기기와 대조기기(VerifyNow)에서 검사를 시행하여\n\n- ① 약물사용 전 환자를 약물반응 음성군, 약물사용 후 환자를 약물반응 양성군\n- - 64 -\n<!-- PAGE_71 -->\n###### 12. ",
        "original_sentence": "1) 3.2% Na Citrate tube에 약 20mL의 정맥혈을 채혈한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_640",
      "text": "2) 시험기기는 3.2% Na Citrate tube 검체를 실온(18∼25℃)에서 채혈 후 최소\n\n30분, 최대 4시간 이내 검사를 시행하고 그 결과를 데이터 수집용지에 기록\n\n한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 639,
        "window_size": 3,
        "char_count": 105,
        "word_count": 23,
        "page_number": 6,
        "window_text": "방문1 (스크리닝 및 검사일)\n1) 임상시험 설명 및 동의 및 스크리닝\n\n‘출혈 시간 및 항혈소판제제 저항성 복합검사기기(Anysis-200)’의 임상시험에 들어\n\n가기 전, 본 임상시험의 목적과 내용에 대하여 대상자 또는 법정대리인에게\n\n동의서의 원본은 시험자가 보관하고 사본은 시험대상자 또는 법정대리인에게\n\n교부한다.  대상자에게 서면 동의를 받은 후 동의취득\n\n순서에 따라 스크리닝\n\n대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그 위임자가 모든 선정\n\n수용체 저해제 등의 항혈소판제제, 항응고제 복용 유무, CBC(혈색소, 헤마토크릿,\n\n검체를 채취하고 시험기기 및 대조기기에서 검사를 시행하고 결과를 기록한다.\n\n 1) 3.2% Na Citrate tube에 약 20mL의 정맥혈을 채혈한다.\n\n 2) 시험기기는 3.2% Na Citrate tube 검체를 실온(18∼25℃)에서 채혈 후 최소\n\n30분, 최대 4시간 이내 검사를 시행하고 그 결과를 데이터 수집용지에 기록\n\n한다.\n\n - - 63 -\n3) LTA 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심\n\n분리하여 혈소판풍부혈장을 취하여 3시간 이내에 검사를 시행하고 그 결과를\n\n데이터 수집용지에 기록한다.\n\n 4) PFA-100 및 VerifyNow 대조기기는 3.2% Na Citrate tube 검체를 실온(18∼\n\n2) Aspirin 복용 후 3일, 또는 clopidogrel 복용 후 5일 이후 검체를 채취하여 시험\n\n- ④ SIPA　test는 검사원리가 비슷한 기존검사법은 없으나, 혈소판 기능의 정상/\n비정상 유무를 판정하기 위한 목적은 ADP test와 동일하므로, 이를 확인하는\n\n2) 혈소판 약물반응 검사: 시험기기와 대조기기(VerifyNow)에서 검사를 시행하여\n\n- ① 약물사용 전 환자를 약물반응 음성군, 약물사용 후 환자를 약물반응 양성군\n- - 64 -\n<!-- PAGE_71 -->\n###### 12.  예측되는 부작용 및 사용 시 주의사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n혈종, 출혈점(피부표면\n\n아래에 적은 량의 출혈을 의미하는 작고 붉은 반점)과 같은\n\n- - 드물지만 채혈할 때 일시적으로 의식이 소실되어 하는 경우가 있다. ",
        "original_sentence": "2) 시험기기는 3.2% Na Citrate tube 검체를 실온(18∼25℃)에서 채혈 후 최소\n\n30분, 최대 4시간 이내 검사를 시행하고 그 결과를 데이터 수집용지에 기록\n\n한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_641",
      "text": "- - 63 -\n3) LTA 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심\n\n분리하여 혈소판풍부혈장을 취하여 3시간 이내에 검사를 시행하고 그 결과를\n\n데이터 수집용지에 기록한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 640,
        "window_size": 3,
        "char_count": 123,
        "word_count": 28,
        "page_number": 6,
        "window_text": "대상자에게 서면 동의를 받은 후 동의취득\n\n순서에 따라 스크리닝\n\n대상자가 본 시험에 적합함을 보증하기 위해 시험자 또는 그 위임자가 모든 선정\n\n수용체 저해제 등의 항혈소판제제, 항응고제 복용 유무, CBC(혈색소, 헤마토크릿,\n\n검체를 채취하고 시험기기 및 대조기기에서 검사를 시행하고 결과를 기록한다.\n\n 1) 3.2% Na Citrate tube에 약 20mL의 정맥혈을 채혈한다.\n\n 2) 시험기기는 3.2% Na Citrate tube 검체를 실온(18∼25℃)에서 채혈 후 최소\n\n30분, 최대 4시간 이내 검사를 시행하고 그 결과를 데이터 수집용지에 기록\n\n한다.\n\n - - 63 -\n3) LTA 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심\n\n분리하여 혈소판풍부혈장을 취하여 3시간 이내에 검사를 시행하고 그 결과를\n\n데이터 수집용지에 기록한다.\n\n 4) PFA-100 및 VerifyNow 대조기기는 3.2% Na Citrate tube 검체를 실온(18∼\n\n2) Aspirin 복용 후 3일, 또는 clopidogrel 복용 후 5일 이후 검체를 채취하여 시험\n\n- ④ SIPA　test는 검사원리가 비슷한 기존검사법은 없으나, 혈소판 기능의 정상/\n비정상 유무를 판정하기 위한 목적은 ADP test와 동일하므로, 이를 확인하는\n\n2) 혈소판 약물반응 검사: 시험기기와 대조기기(VerifyNow)에서 검사를 시행하여\n\n- ① 약물사용 전 환자를 약물반응 음성군, 약물사용 후 환자를 약물반응 양성군\n- - 64 -\n<!-- PAGE_71 -->\n###### 12.  예측되는 부작용 및 사용 시 주의사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n혈종, 출혈점(피부표면\n\n아래에 적은 량의 출혈을 의미하는 작고 붉은 반점)과 같은\n\n- - 드물지만 채혈할 때 일시적으로 의식이 소실되어 하는 경우가 있다.  침에 찔리자\n의식을 잃어 쓰러지게 된다. ",
        "original_sentence": "- - 63 -\n3) LTA 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심\n\n분리하여 혈소판풍부혈장을 취하여 3시간 이내에 검사를 시행하고 그 결과를\n\n데이터 수집용지에 기록한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_642",
      "text": "4) PFA-100 및 VerifyNow 대조기기는 3.2% Na Citrate tube 검체를 실온(18∼\n\n2) Aspirin 복용 후 3일, 또는 clopidogrel 복용 후 5일 이후 검체를 채취하여 시험\n\n- ④ SIPA　test는 검사원리가 비슷한 기존검사법은 없으나, 혈소판 기능의 정상/\n비정상 유무를 판정하기 위한 목적은 ADP test와 동일하므로, 이를 확인하는\n\n2) 혈소판 약물반응 검사: 시험기기와 대조기기(VerifyNow)에서 검사를 시행하여\n\n- ① 약물사용 전 환자를 약물반응 음성군, 약물사용 후 환자를 약물반응 양성군\n- - 64 -\n<!-- PAGE_71 -->\n###### 12. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 641,
        "window_size": 3,
        "char_count": 348,
        "word_count": 75,
        "page_number": 71,
        "window_text": "1) 3.2% Na Citrate tube에 약 20mL의 정맥혈을 채혈한다.\n\n 2) 시험기기는 3.2% Na Citrate tube 검체를 실온(18∼25℃)에서 채혈 후 최소\n\n30분, 최대 4시간 이내 검사를 시행하고 그 결과를 데이터 수집용지에 기록\n\n한다.\n\n - - 63 -\n3) LTA 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심\n\n분리하여 혈소판풍부혈장을 취하여 3시간 이내에 검사를 시행하고 그 결과를\n\n데이터 수집용지에 기록한다.\n\n 4) PFA-100 및 VerifyNow 대조기기는 3.2% Na Citrate tube 검체를 실온(18∼\n\n2) Aspirin 복용 후 3일, 또는 clopidogrel 복용 후 5일 이후 검체를 채취하여 시험\n\n- ④ SIPA　test는 검사원리가 비슷한 기존검사법은 없으나, 혈소판 기능의 정상/\n비정상 유무를 판정하기 위한 목적은 ADP test와 동일하므로, 이를 확인하는\n\n2) 혈소판 약물반응 검사: 시험기기와 대조기기(VerifyNow)에서 검사를 시행하여\n\n- ① 약물사용 전 환자를 약물반응 음성군, 약물사용 후 환자를 약물반응 양성군\n- - 64 -\n<!-- PAGE_71 -->\n###### 12.  예측되는 부작용 및 사용 시 주의사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n혈종, 출혈점(피부표면\n\n아래에 적은 량의 출혈을 의미하는 작고 붉은 반점)과 같은\n\n- - 드물지만 채혈할 때 일시적으로 의식이 소실되어 하는 경우가 있다.  침에 찔리자\n의식을 잃어 쓰러지게 된다.  이것은 혈관미주신경 반응에 의해 일어나며 피 또는\n\n주사침에 대한 공포심과 관련이 있다. ",
        "original_sentence": "4) PFA-100 및 VerifyNow 대조기기는 3.2% Na Citrate tube 검체를 실온(18∼\n\n2) Aspirin 복용 후 3일, 또는 clopidogrel 복용 후 5일 이후 검체를 채취하여 시험\n\n- ④ SIPA　test는 검사원리가 비슷한 기존검사법은 없으나, 혈소판 기능의 정상/\n비정상 유무를 판정하기 위한 목적은 ADP test와 동일하므로, 이를 확인하는\n\n2) 혈소판 약물반응 검사: 시험기기와 대조기기(VerifyNow)에서 검사를 시행하여\n\n- ① 약물사용 전 환자를 약물반응 음성군, 약물사용 후 환자를 약물반응 양성군\n- - 64 -\n<!-- PAGE_71 -->\n###### 12. "
      }
    },
    {
      "chunk_id": "chunk_643",
      "text": "예측되는 부작용 및 사용 시 주의사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n혈종, 출혈점(피부표면\n\n아래에 적은 량의 출혈을 의미하는 작고 붉은 반점)과 같은\n\n- - 드물지만 채혈할 때 일시적으로 의식이 소실되어 하는 경우가 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 642,
        "window_size": 3,
        "char_count": 163,
        "word_count": 42,
        "page_number": 3,
        "window_text": "2) 시험기기는 3.2% Na Citrate tube 검체를 실온(18∼25℃)에서 채혈 후 최소\n\n30분, 최대 4시간 이내 검사를 시행하고 그 결과를 데이터 수집용지에 기록\n\n한다.\n\n - - 63 -\n3) LTA 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심\n\n분리하여 혈소판풍부혈장을 취하여 3시간 이내에 검사를 시행하고 그 결과를\n\n데이터 수집용지에 기록한다.\n\n 4) PFA-100 및 VerifyNow 대조기기는 3.2% Na Citrate tube 검체를 실온(18∼\n\n2) Aspirin 복용 후 3일, 또는 clopidogrel 복용 후 5일 이후 검체를 채취하여 시험\n\n- ④ SIPA　test는 검사원리가 비슷한 기존검사법은 없으나, 혈소판 기능의 정상/\n비정상 유무를 판정하기 위한 목적은 ADP test와 동일하므로, 이를 확인하는\n\n2) 혈소판 약물반응 검사: 시험기기와 대조기기(VerifyNow)에서 검사를 시행하여\n\n- ① 약물사용 전 환자를 약물반응 음성군, 약물사용 후 환자를 약물반응 양성군\n- - 64 -\n<!-- PAGE_71 -->\n###### 12.  예측되는 부작용 및 사용 시 주의사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n혈종, 출혈점(피부표면\n\n아래에 적은 량의 출혈을 의미하는 작고 붉은 반점)과 같은\n\n- - 드물지만 채혈할 때 일시적으로 의식이 소실되어 하는 경우가 있다.  침에 찔리자\n의식을 잃어 쓰러지게 된다.  이것은 혈관미주신경 반응에 의해 일어나며 피 또는\n\n주사침에 대한 공포심과 관련이 있다.  채혈에 대한 두려움 등 과민한 정신적인\n\n반응으로 교감신경이 흥분한 상태에서 주사침에 찔리게 되면 갑자기 부교감신경인\n\n· 증상이 나타나면 즉시 주저앉거나 머리를 다리보다 낮춘 자세로 10분 이상\n\n· 채혈에 대한 두려움을 없게 하기 위해 반드시 채혈 전에 채혈자를 안심시키는\n\n· 넥타이와 허리띠를 느슨히 풀어주며 천천히 깊은 숨을 쉬도록 격려해 준다.\n\n",
        "original_sentence": "예측되는 부작용 및 사용 시 주의사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n혈종, 출혈점(피부표면\n\n아래에 적은 량의 출혈을 의미하는 작고 붉은 반점)과 같은\n\n- - 드물지만 채혈할 때 일시적으로 의식이 소실되어 하는 경우가 있다. "
      }
    },
    {
      "chunk_id": "chunk_644",
      "text": "침에 찔리자\n의식을 잃어 쓰러지게 된다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 643,
        "window_size": 3,
        "char_count": 23,
        "word_count": 6,
        "page_number": 95,
        "window_text": "- - 63 -\n3) LTA 대조기기에 대해서는 3.2% Na citrate tube 검체를 1시간 이내에 원심\n\n분리하여 혈소판풍부혈장을 취하여 3시간 이내에 검사를 시행하고 그 결과를\n\n데이터 수집용지에 기록한다.\n\n 4) PFA-100 및 VerifyNow 대조기기는 3.2% Na Citrate tube 검체를 실온(18∼\n\n2) Aspirin 복용 후 3일, 또는 clopidogrel 복용 후 5일 이후 검체를 채취하여 시험\n\n- ④ SIPA　test는 검사원리가 비슷한 기존검사법은 없으나, 혈소판 기능의 정상/\n비정상 유무를 판정하기 위한 목적은 ADP test와 동일하므로, 이를 확인하는\n\n2) 혈소판 약물반응 검사: 시험기기와 대조기기(VerifyNow)에서 검사를 시행하여\n\n- ① 약물사용 전 환자를 약물반응 음성군, 약물사용 후 환자를 약물반응 양성군\n- - 64 -\n<!-- PAGE_71 -->\n###### 12.  예측되는 부작용 및 사용 시 주의사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n혈종, 출혈점(피부표면\n\n아래에 적은 량의 출혈을 의미하는 작고 붉은 반점)과 같은\n\n- - 드물지만 채혈할 때 일시적으로 의식이 소실되어 하는 경우가 있다.  침에 찔리자\n의식을 잃어 쓰러지게 된다.  이것은 혈관미주신경 반응에 의해 일어나며 피 또는\n\n주사침에 대한 공포심과 관련이 있다.  채혈에 대한 두려움 등 과민한 정신적인\n\n반응으로 교감신경이 흥분한 상태에서 주사침에 찔리게 되면 갑자기 부교감신경인\n\n· 증상이 나타나면 즉시 주저앉거나 머리를 다리보다 낮춘 자세로 10분 이상\n\n· 채혈에 대한 두려움을 없게 하기 위해 반드시 채혈 전에 채혈자를 안심시키는\n\n· 넥타이와 허리띠를 느슨히 풀어주며 천천히 깊은 숨을 쉬도록 격려해 준다.\n\n · 혈관미주신경 반응에 의한 실신은 후유증 없이 완전히 회복되지만 다른 원인에\n\n- - 65 -\n의해서도 실신이 일어날 수 있으므로 회복이 안 되거나 경련이 동반되거나 하면\n\n의료진에게 알리고 적절히 조치할 수 있도록 한다.\n\n",
        "original_sentence": "침에 찔리자\n의식을 잃어 쓰러지게 된다. "
      }
    },
    {
      "chunk_id": "chunk_645",
      "text": "이것은 혈관미주신경 반응에 의해 일어나며 피 또는\n\n주사침에 대한 공포심과 관련이 있다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 644,
        "window_size": 3,
        "char_count": 50,
        "word_count": 12,
        "page_number": 23,
        "window_text": "4) PFA-100 및 VerifyNow 대조기기는 3.2% Na Citrate tube 검체를 실온(18∼\n\n2) Aspirin 복용 후 3일, 또는 clopidogrel 복용 후 5일 이후 검체를 채취하여 시험\n\n- ④ SIPA　test는 검사원리가 비슷한 기존검사법은 없으나, 혈소판 기능의 정상/\n비정상 유무를 판정하기 위한 목적은 ADP test와 동일하므로, 이를 확인하는\n\n2) 혈소판 약물반응 검사: 시험기기와 대조기기(VerifyNow)에서 검사를 시행하여\n\n- ① 약물사용 전 환자를 약물반응 음성군, 약물사용 후 환자를 약물반응 양성군\n- - 64 -\n<!-- PAGE_71 -->\n###### 12.  예측되는 부작용 및 사용 시 주의사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n혈종, 출혈점(피부표면\n\n아래에 적은 량의 출혈을 의미하는 작고 붉은 반점)과 같은\n\n- - 드물지만 채혈할 때 일시적으로 의식이 소실되어 하는 경우가 있다.  침에 찔리자\n의식을 잃어 쓰러지게 된다.  이것은 혈관미주신경 반응에 의해 일어나며 피 또는\n\n주사침에 대한 공포심과 관련이 있다.  채혈에 대한 두려움 등 과민한 정신적인\n\n반응으로 교감신경이 흥분한 상태에서 주사침에 찔리게 되면 갑자기 부교감신경인\n\n· 증상이 나타나면 즉시 주저앉거나 머리를 다리보다 낮춘 자세로 10분 이상\n\n· 채혈에 대한 두려움을 없게 하기 위해 반드시 채혈 전에 채혈자를 안심시키는\n\n· 넥타이와 허리띠를 느슨히 풀어주며 천천히 깊은 숨을 쉬도록 격려해 준다.\n\n · 혈관미주신경 반응에 의한 실신은 후유증 없이 완전히 회복되지만 다른 원인에\n\n- - 65 -\n의해서도 실신이 일어날 수 있으므로 회복이 안 되거나 경련이 동반되거나 하면\n\n의료진에게 알리고 적절히 조치할 수 있도록 한다.\n\n - (2) 피하 출혈 및 혈종\n- - 주사침이 정맥에 걸쳐 있거나 관통하는 경우 혈액이 새어 나와 피부 아래에\n고여서 생긴 것이다. ",
        "original_sentence": "이것은 혈관미주신경 반응에 의해 일어나며 피 또는\n\n주사침에 대한 공포심과 관련이 있다. "
      }
    },
    {
      "chunk_id": "chunk_646",
      "text": "채혈에 대한 두려움 등 과민한 정신적인\n\n반응으로 교감신경이 흥분한 상태에서 주사침에 찔리게 되면 갑자기 부교감신경인\n\n· 증상이 나타나면 즉시 주저앉거나 머리를 다리보다 낮춘 자세로 10분 이상\n\n· 채혈에 대한 두려움을 없게 하기 위해 반드시 채혈 전에 채혈자를 안심시키는\n\n· 넥타이와 허리띠를 느슨히 풀어주며 천천히 깊은 숨을 쉬도록 격려해 준다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 645,
        "window_size": 3,
        "char_count": 200,
        "word_count": 49,
        "page_number": 104,
        "window_text": "예측되는 부작용 및 사용 시 주의사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n혈종, 출혈점(피부표면\n\n아래에 적은 량의 출혈을 의미하는 작고 붉은 반점)과 같은\n\n- - 드물지만 채혈할 때 일시적으로 의식이 소실되어 하는 경우가 있다.  침에 찔리자\n의식을 잃어 쓰러지게 된다.  이것은 혈관미주신경 반응에 의해 일어나며 피 또는\n\n주사침에 대한 공포심과 관련이 있다.  채혈에 대한 두려움 등 과민한 정신적인\n\n반응으로 교감신경이 흥분한 상태에서 주사침에 찔리게 되면 갑자기 부교감신경인\n\n· 증상이 나타나면 즉시 주저앉거나 머리를 다리보다 낮춘 자세로 10분 이상\n\n· 채혈에 대한 두려움을 없게 하기 위해 반드시 채혈 전에 채혈자를 안심시키는\n\n· 넥타이와 허리띠를 느슨히 풀어주며 천천히 깊은 숨을 쉬도록 격려해 준다.\n\n · 혈관미주신경 반응에 의한 실신은 후유증 없이 완전히 회복되지만 다른 원인에\n\n- - 65 -\n의해서도 실신이 일어날 수 있으므로 회복이 안 되거나 경련이 동반되거나 하면\n\n의료진에게 알리고 적절히 조치할 수 있도록 한다.\n\n - (2) 피하 출혈 및 혈종\n- - 주사침이 정맥에 걸쳐 있거나 관통하는 경우 혈액이 새어 나와 피부 아래에\n고여서 생긴 것이다.  주사침을 찌른 부위의 피부가 부어오르면 혈종이 생긴\n\n· 주사침을 찌르다가 만약 피부가 부어오르면 재빨리 압박대를 풀고 주사침을 뺀\n\n· 혈종은 채혈 시 외에도 환자가 채혈 후 지혈을 충분히 하지 않은 경우에도\n\n- (3) 검체와 시약을 다룬 이후에는 반드시 손을 깨끗이 씻도록 한다.\n",
        "original_sentence": "채혈에 대한 두려움 등 과민한 정신적인\n\n반응으로 교감신경이 흥분한 상태에서 주사침에 찔리게 되면 갑자기 부교감신경인\n\n· 증상이 나타나면 즉시 주저앉거나 머리를 다리보다 낮춘 자세로 10분 이상\n\n· 채혈에 대한 두려움을 없게 하기 위해 반드시 채혈 전에 채혈자를 안심시키는\n\n· 넥타이와 허리띠를 느슨히 풀어주며 천천히 깊은 숨을 쉬도록 격려해 준다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_647",
      "text": "· 혈관미주신경 반응에 의한 실신은 후유증 없이 완전히 회복되지만 다른 원인에\n\n- - 65 -\n의해서도 실신이 일어날 수 있으므로 회복이 안 되거나 경련이 동반되거나 하면\n\n의료진에게 알리고 적절히 조치할 수 있도록 한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 646,
        "window_size": 3,
        "char_count": 127,
        "word_count": 33,
        "page_number": 15,
        "window_text": "침에 찔리자\n의식을 잃어 쓰러지게 된다.  이것은 혈관미주신경 반응에 의해 일어나며 피 또는\n\n주사침에 대한 공포심과 관련이 있다.  채혈에 대한 두려움 등 과민한 정신적인\n\n반응으로 교감신경이 흥분한 상태에서 주사침에 찔리게 되면 갑자기 부교감신경인\n\n· 증상이 나타나면 즉시 주저앉거나 머리를 다리보다 낮춘 자세로 10분 이상\n\n· 채혈에 대한 두려움을 없게 하기 위해 반드시 채혈 전에 채혈자를 안심시키는\n\n· 넥타이와 허리띠를 느슨히 풀어주며 천천히 깊은 숨을 쉬도록 격려해 준다.\n\n · 혈관미주신경 반응에 의한 실신은 후유증 없이 완전히 회복되지만 다른 원인에\n\n- - 65 -\n의해서도 실신이 일어날 수 있으므로 회복이 안 되거나 경련이 동반되거나 하면\n\n의료진에게 알리고 적절히 조치할 수 있도록 한다.\n\n - (2) 피하 출혈 및 혈종\n- - 주사침이 정맥에 걸쳐 있거나 관통하는 경우 혈액이 새어 나와 피부 아래에\n고여서 생긴 것이다.  주사침을 찌른 부위의 피부가 부어오르면 혈종이 생긴\n\n· 주사침을 찌르다가 만약 피부가 부어오르면 재빨리 압박대를 풀고 주사침을 뺀\n\n· 혈종은 채혈 시 외에도 환자가 채혈 후 지혈을 충분히 하지 않은 경우에도\n\n- (3) 검체와 시약을 다룬 이후에는 반드시 손을 깨끗이 씻도록 한다.\n - (4) 모든 혈액 검체와 혈액 성분은 전염성 감염원일 가능성이 있는 것으로 취급해야\n하며, 모든 검체는 적절한 주의사항을 준수하는 우수실험실운영기준(GLP:\n\nGood\n\n- (5) 혈액 검체 채취는 오염이 발생하지 않도록 주의 깊게 수행하도록 하고, 응집이\n- - 66 -\n3) 경고사항\n\n- (1) 본 제품의 안전하고 적절한 사용을 위해, 제품을 사용하기 전 사용방법에 대한\n교육을 받아야 한다. ",
        "original_sentence": "· 혈관미주신경 반응에 의한 실신은 후유증 없이 완전히 회복되지만 다른 원인에\n\n- - 65 -\n의해서도 실신이 일어날 수 있으므로 회복이 안 되거나 경련이 동반되거나 하면\n\n의료진에게 알리고 적절히 조치할 수 있도록 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_648",
      "text": "- (2) 피하 출혈 및 혈종\n- - 주사침이 정맥에 걸쳐 있거나 관통하는 경우 혈액이 새어 나와 피부 아래에\n고여서 생긴 것이다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 647,
        "window_size": 3,
        "char_count": 74,
        "word_count": 22,
        "page_number": 6,
        "window_text": "이것은 혈관미주신경 반응에 의해 일어나며 피 또는\n\n주사침에 대한 공포심과 관련이 있다.  채혈에 대한 두려움 등 과민한 정신적인\n\n반응으로 교감신경이 흥분한 상태에서 주사침에 찔리게 되면 갑자기 부교감신경인\n\n· 증상이 나타나면 즉시 주저앉거나 머리를 다리보다 낮춘 자세로 10분 이상\n\n· 채혈에 대한 두려움을 없게 하기 위해 반드시 채혈 전에 채혈자를 안심시키는\n\n· 넥타이와 허리띠를 느슨히 풀어주며 천천히 깊은 숨을 쉬도록 격려해 준다.\n\n · 혈관미주신경 반응에 의한 실신은 후유증 없이 완전히 회복되지만 다른 원인에\n\n- - 65 -\n의해서도 실신이 일어날 수 있으므로 회복이 안 되거나 경련이 동반되거나 하면\n\n의료진에게 알리고 적절히 조치할 수 있도록 한다.\n\n - (2) 피하 출혈 및 혈종\n- - 주사침이 정맥에 걸쳐 있거나 관통하는 경우 혈액이 새어 나와 피부 아래에\n고여서 생긴 것이다.  주사침을 찌른 부위의 피부가 부어오르면 혈종이 생긴\n\n· 주사침을 찌르다가 만약 피부가 부어오르면 재빨리 압박대를 풀고 주사침을 뺀\n\n· 혈종은 채혈 시 외에도 환자가 채혈 후 지혈을 충분히 하지 않은 경우에도\n\n- (3) 검체와 시약을 다룬 이후에는 반드시 손을 깨끗이 씻도록 한다.\n - (4) 모든 혈액 검체와 혈액 성분은 전염성 감염원일 가능성이 있는 것으로 취급해야\n하며, 모든 검체는 적절한 주의사항을 준수하는 우수실험실운영기준(GLP:\n\nGood\n\n- (5) 혈액 검체 채취는 오염이 발생하지 않도록 주의 깊게 수행하도록 하고, 응집이\n- - 66 -\n3) 경고사항\n\n- (1) 본 제품의 안전하고 적절한 사용을 위해, 제품을 사용하기 전 사용방법에 대한\n교육을 받아야 한다.  사용자 설명서 및 제품과 관련된 모든 문서를 숙지한 후,\n\n- (3) 본 제품의 서비스와 수리는 제조원 담당자에 의해 행해져야\n한다. ",
        "original_sentence": "- (2) 피하 출혈 및 혈종\n- - 주사침이 정맥에 걸쳐 있거나 관통하는 경우 혈액이 새어 나와 피부 아래에\n고여서 생긴 것이다. "
      }
    },
    {
      "chunk_id": "chunk_649",
      "text": "주사침을 찌른 부위의 피부가 부어오르면 혈종이 생긴\n\n· 주사침을 찌르다가 만약 피부가 부어오르면 재빨리 압박대를 풀고 주사침을 뺀\n\n· 혈종은 채혈 시 외에도 환자가 채혈 후 지혈을 충분히 하지 않은 경우에도\n\n- (3) 검체와 시약을 다룬 이후에는 반드시 손을 깨끗이 씻도록 한다.\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 648,
        "window_size": 3,
        "char_count": 160,
        "word_count": 42,
        "page_number": 104,
        "window_text": "채혈에 대한 두려움 등 과민한 정신적인\n\n반응으로 교감신경이 흥분한 상태에서 주사침에 찔리게 되면 갑자기 부교감신경인\n\n· 증상이 나타나면 즉시 주저앉거나 머리를 다리보다 낮춘 자세로 10분 이상\n\n· 채혈에 대한 두려움을 없게 하기 위해 반드시 채혈 전에 채혈자를 안심시키는\n\n· 넥타이와 허리띠를 느슨히 풀어주며 천천히 깊은 숨을 쉬도록 격려해 준다.\n\n · 혈관미주신경 반응에 의한 실신은 후유증 없이 완전히 회복되지만 다른 원인에\n\n- - 65 -\n의해서도 실신이 일어날 수 있으므로 회복이 안 되거나 경련이 동반되거나 하면\n\n의료진에게 알리고 적절히 조치할 수 있도록 한다.\n\n - (2) 피하 출혈 및 혈종\n- - 주사침이 정맥에 걸쳐 있거나 관통하는 경우 혈액이 새어 나와 피부 아래에\n고여서 생긴 것이다.  주사침을 찌른 부위의 피부가 부어오르면 혈종이 생긴\n\n· 주사침을 찌르다가 만약 피부가 부어오르면 재빨리 압박대를 풀고 주사침을 뺀\n\n· 혈종은 채혈 시 외에도 환자가 채혈 후 지혈을 충분히 하지 않은 경우에도\n\n- (3) 검체와 시약을 다룬 이후에는 반드시 손을 깨끗이 씻도록 한다.\n - (4) 모든 혈액 검체와 혈액 성분은 전염성 감염원일 가능성이 있는 것으로 취급해야\n하며, 모든 검체는 적절한 주의사항을 준수하는 우수실험실운영기준(GLP:\n\nGood\n\n- (5) 혈액 검체 채취는 오염이 발생하지 않도록 주의 깊게 수행하도록 하고, 응집이\n- - 66 -\n3) 경고사항\n\n- (1) 본 제품의 안전하고 적절한 사용을 위해, 제품을 사용하기 전 사용방법에 대한\n교육을 받아야 한다.  사용자 설명서 및 제품과 관련된 모든 문서를 숙지한 후,\n\n- (3) 본 제품의 서비스와 수리는 제조원 담당자에 의해 행해져야\n한다.  서비스나\n\n- (4) 본 제품의 안전한 사용을 위해 제품 손상을 의미하는 어떤 증상을 발견했을 경우\n- (1) 본 제품은 일회용으로 재사용을 금한다.\n",
        "original_sentence": "주사침을 찌른 부위의 피부가 부어오르면 혈종이 생긴\n\n· 주사침을 찌르다가 만약 피부가 부어오르면 재빨리 압박대를 풀고 주사침을 뺀\n\n· 혈종은 채혈 시 외에도 환자가 채혈 후 지혈을 충분히 하지 않은 경우에도\n\n- (3) 검체와 시약을 다룬 이후에는 반드시 손을 깨끗이 씻도록 한다.\n"
      }
    },
    {
      "chunk_id": "chunk_650",
      "text": "- (4) 모든 혈액 검체와 혈액 성분은 전염성 감염원일 가능성이 있는 것으로 취급해야\n하며, 모든 검체는 적절한 주의사항을 준수하는 우수실험실운영기준(GLP:\n\nGood\n\n- (5) 혈액 검체 채취는 오염이 발생하지 않도록 주의 깊게 수행하도록 하고, 응집이\n- - 66 -\n3) 경고사항\n\n- (1) 본 제품의 안전하고 적절한 사용을 위해, 제품을 사용하기 전 사용방법에 대한\n교육을 받아야 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 649,
        "window_size": 3,
        "char_count": 225,
        "word_count": 56,
        "page_number": 15,
        "window_text": "· 혈관미주신경 반응에 의한 실신은 후유증 없이 완전히 회복되지만 다른 원인에\n\n- - 65 -\n의해서도 실신이 일어날 수 있으므로 회복이 안 되거나 경련이 동반되거나 하면\n\n의료진에게 알리고 적절히 조치할 수 있도록 한다.\n\n - (2) 피하 출혈 및 혈종\n- - 주사침이 정맥에 걸쳐 있거나 관통하는 경우 혈액이 새어 나와 피부 아래에\n고여서 생긴 것이다.  주사침을 찌른 부위의 피부가 부어오르면 혈종이 생긴\n\n· 주사침을 찌르다가 만약 피부가 부어오르면 재빨리 압박대를 풀고 주사침을 뺀\n\n· 혈종은 채혈 시 외에도 환자가 채혈 후 지혈을 충분히 하지 않은 경우에도\n\n- (3) 검체와 시약을 다룬 이후에는 반드시 손을 깨끗이 씻도록 한다.\n - (4) 모든 혈액 검체와 혈액 성분은 전염성 감염원일 가능성이 있는 것으로 취급해야\n하며, 모든 검체는 적절한 주의사항을 준수하는 우수실험실운영기준(GLP:\n\nGood\n\n- (5) 혈액 검체 채취는 오염이 발생하지 않도록 주의 깊게 수행하도록 하고, 응집이\n- - 66 -\n3) 경고사항\n\n- (1) 본 제품의 안전하고 적절한 사용을 위해, 제품을 사용하기 전 사용방법에 대한\n교육을 받아야 한다.  사용자 설명서 및 제품과 관련된 모든 문서를 숙지한 후,\n\n- (3) 본 제품의 서비스와 수리는 제조원 담당자에 의해 행해져야\n한다.  서비스나\n\n- (4) 본 제품의 안전한 사용을 위해 제품 손상을 의미하는 어떤 증상을 발견했을 경우\n- (1) 본 제품은 일회용으로 재사용을 금한다.\n - (4) 가급적 장비의 케이스를 닫고 검사를 진행하도록 한다.\n",
        "original_sentence": "- (4) 모든 혈액 검체와 혈액 성분은 전염성 감염원일 가능성이 있는 것으로 취급해야\n하며, 모든 검체는 적절한 주의사항을 준수하는 우수실험실운영기준(GLP:\n\nGood\n\n- (5) 혈액 검체 채취는 오염이 발생하지 않도록 주의 깊게 수행하도록 하고, 응집이\n- - 66 -\n3) 경고사항\n\n- (1) 본 제품의 안전하고 적절한 사용을 위해, 제품을 사용하기 전 사용방법에 대한\n교육을 받아야 한다. "
      }
    },
    {
      "chunk_id": "chunk_651",
      "text": "사용자 설명서 및 제품과 관련된 모든 문서를 숙지한 후,\n\n- (3) 본 제품의 서비스와 수리는 제조원 담당자에 의해 행해져야\n한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 650,
        "window_size": 3,
        "char_count": 75,
        "word_count": 20,
        "page_number": 15,
        "window_text": "- (2) 피하 출혈 및 혈종\n- - 주사침이 정맥에 걸쳐 있거나 관통하는 경우 혈액이 새어 나와 피부 아래에\n고여서 생긴 것이다.  주사침을 찌른 부위의 피부가 부어오르면 혈종이 생긴\n\n· 주사침을 찌르다가 만약 피부가 부어오르면 재빨리 압박대를 풀고 주사침을 뺀\n\n· 혈종은 채혈 시 외에도 환자가 채혈 후 지혈을 충분히 하지 않은 경우에도\n\n- (3) 검체와 시약을 다룬 이후에는 반드시 손을 깨끗이 씻도록 한다.\n - (4) 모든 혈액 검체와 혈액 성분은 전염성 감염원일 가능성이 있는 것으로 취급해야\n하며, 모든 검체는 적절한 주의사항을 준수하는 우수실험실운영기준(GLP:\n\nGood\n\n- (5) 혈액 검체 채취는 오염이 발생하지 않도록 주의 깊게 수행하도록 하고, 응집이\n- - 66 -\n3) 경고사항\n\n- (1) 본 제품의 안전하고 적절한 사용을 위해, 제품을 사용하기 전 사용방법에 대한\n교육을 받아야 한다.  사용자 설명서 및 제품과 관련된 모든 문서를 숙지한 후,\n\n- (3) 본 제품의 서비스와 수리는 제조원 담당자에 의해 행해져야\n한다.  서비스나\n\n- (4) 본 제품의 안전한 사용을 위해 제품 손상을 의미하는 어떤 증상을 발견했을 경우\n- (1) 본 제품은 일회용으로 재사용을 금한다.\n - (4) 가급적 장비의 케이스를 닫고 검사를 진행하도록 한다.\n - (5) 검사가 종료된 후, 데이터 처리에 시간이 오래 소요될 수 있으므로 검사가 완전히\n- (6) 검사칩 외 이물질을 장비에 삽입해서는 안된다.\n",
        "original_sentence": "사용자 설명서 및 제품과 관련된 모든 문서를 숙지한 후,\n\n- (3) 본 제품의 서비스와 수리는 제조원 담당자에 의해 행해져야\n한다. "
      }
    },
    {
      "chunk_id": "chunk_652",
      "text": "서비스나\n\n- (4) 본 제품의 안전한 사용을 위해 제품 손상을 의미하는 어떤 증상을 발견했을 경우\n- (1) 본 제품은 일회용으로 재사용을 금한다.\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 651,
        "window_size": 3,
        "char_count": 84,
        "word_count": 22,
        "page_number": 15,
        "window_text": "주사침을 찌른 부위의 피부가 부어오르면 혈종이 생긴\n\n· 주사침을 찌르다가 만약 피부가 부어오르면 재빨리 압박대를 풀고 주사침을 뺀\n\n· 혈종은 채혈 시 외에도 환자가 채혈 후 지혈을 충분히 하지 않은 경우에도\n\n- (3) 검체와 시약을 다룬 이후에는 반드시 손을 깨끗이 씻도록 한다.\n - (4) 모든 혈액 검체와 혈액 성분은 전염성 감염원일 가능성이 있는 것으로 취급해야\n하며, 모든 검체는 적절한 주의사항을 준수하는 우수실험실운영기준(GLP:\n\nGood\n\n- (5) 혈액 검체 채취는 오염이 발생하지 않도록 주의 깊게 수행하도록 하고, 응집이\n- - 66 -\n3) 경고사항\n\n- (1) 본 제품의 안전하고 적절한 사용을 위해, 제품을 사용하기 전 사용방법에 대한\n교육을 받아야 한다.  사용자 설명서 및 제품과 관련된 모든 문서를 숙지한 후,\n\n- (3) 본 제품의 서비스와 수리는 제조원 담당자에 의해 행해져야\n한다.  서비스나\n\n- (4) 본 제품의 안전한 사용을 위해 제품 손상을 의미하는 어떤 증상을 발견했을 경우\n- (1) 본 제품은 일회용으로 재사용을 금한다.\n - (4) 가급적 장비의 케이스를 닫고 검사를 진행하도록 한다.\n - (5) 검사가 종료된 후, 데이터 처리에 시간이 오래 소요될 수 있으므로 검사가 완전히\n- (6) 검사칩 외 이물질을 장비에 삽입해서는 안된다.\n - (7) 장비의 이상동작 시 스스로 수리하려고 하지 않는다. ",
        "original_sentence": "서비스나\n\n- (4) 본 제품의 안전한 사용을 위해 제품 손상을 의미하는 어떤 증상을 발견했을 경우\n- (1) 본 제품은 일회용으로 재사용을 금한다.\n"
      }
    },
    {
      "chunk_id": "chunk_653",
      "text": "- (4) 가급적 장비의 케이스를 닫고 검사를 진행하도록 한다.\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 652,
        "window_size": 3,
        "char_count": 36,
        "word_count": 9,
        "page_number": 15,
        "window_text": "- (4) 모든 혈액 검체와 혈액 성분은 전염성 감염원일 가능성이 있는 것으로 취급해야\n하며, 모든 검체는 적절한 주의사항을 준수하는 우수실험실운영기준(GLP:\n\nGood\n\n- (5) 혈액 검체 채취는 오염이 발생하지 않도록 주의 깊게 수행하도록 하고, 응집이\n- - 66 -\n3) 경고사항\n\n- (1) 본 제품의 안전하고 적절한 사용을 위해, 제품을 사용하기 전 사용방법에 대한\n교육을 받아야 한다.  사용자 설명서 및 제품과 관련된 모든 문서를 숙지한 후,\n\n- (3) 본 제품의 서비스와 수리는 제조원 담당자에 의해 행해져야\n한다.  서비스나\n\n- (4) 본 제품의 안전한 사용을 위해 제품 손상을 의미하는 어떤 증상을 발견했을 경우\n- (1) 본 제품은 일회용으로 재사용을 금한다.\n - (4) 가급적 장비의 케이스를 닫고 검사를 진행하도록 한다.\n - (5) 검사가 종료된 후, 데이터 처리에 시간이 오래 소요될 수 있으므로 검사가 완전히\n- (6) 검사칩 외 이물질을 장비에 삽입해서는 안된다.\n - (7) 장비의 이상동작 시 스스로 수리하려고 하지 않는다.  제조원에 문의한다.\n",
        "original_sentence": "- (4) 가급적 장비의 케이스를 닫고 검사를 진행하도록 한다.\n"
      }
    },
    {
      "chunk_id": "chunk_654",
      "text": "- (5) 검사가 종료된 후, 데이터 처리에 시간이 오래 소요될 수 있으므로 검사가 완전히\n- (6) 검사칩 외 이물질을 장비에 삽입해서는 안된다.\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 653,
        "window_size": 3,
        "char_count": 83,
        "word_count": 22,
        "page_number": 6,
        "window_text": "사용자 설명서 및 제품과 관련된 모든 문서를 숙지한 후,\n\n- (3) 본 제품의 서비스와 수리는 제조원 담당자에 의해 행해져야\n한다.  서비스나\n\n- (4) 본 제품의 안전한 사용을 위해 제품 손상을 의미하는 어떤 증상을 발견했을 경우\n- (1) 본 제품은 일회용으로 재사용을 금한다.\n - (4) 가급적 장비의 케이스를 닫고 검사를 진행하도록 한다.\n - (5) 검사가 종료된 후, 데이터 처리에 시간이 오래 소요될 수 있으므로 검사가 완전히\n- (6) 검사칩 외 이물질을 장비에 삽입해서는 안된다.\n - (7) 장비의 이상동작 시 스스로 수리하려고 하지 않는다.  제조원에 문의한다.\n - - 67 -\n6) 결과 판정상 주의\n\n- (1) 본 제품의 결과는 항상 환자의 약물 복용 여부를 포함한 의료 기록, 임상 증상\n및 시험연구를 포함한 기타 소견과 함께 해석되어야 한다.\n\n",
        "original_sentence": "- (5) 검사가 종료된 후, 데이터 처리에 시간이 오래 소요될 수 있으므로 검사가 완전히\n- (6) 검사칩 외 이물질을 장비에 삽입해서는 안된다.\n"
      }
    },
    {
      "chunk_id": "chunk_655",
      "text": "- (7) 장비의 이상동작 시 스스로 수리하려고 하지 않는다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 654,
        "window_size": 3,
        "char_count": 35,
        "word_count": 9,
        "page_number": 15,
        "window_text": "서비스나\n\n- (4) 본 제품의 안전한 사용을 위해 제품 손상을 의미하는 어떤 증상을 발견했을 경우\n- (1) 본 제품은 일회용으로 재사용을 금한다.\n - (4) 가급적 장비의 케이스를 닫고 검사를 진행하도록 한다.\n - (5) 검사가 종료된 후, 데이터 처리에 시간이 오래 소요될 수 있으므로 검사가 완전히\n- (6) 검사칩 외 이물질을 장비에 삽입해서는 안된다.\n - (7) 장비의 이상동작 시 스스로 수리하려고 하지 않는다.  제조원에 문의한다.\n - - 67 -\n6) 결과 판정상 주의\n\n- (1) 본 제품의 결과는 항상 환자의 약물 복용 여부를 포함한 의료 기록, 임상 증상\n및 시험연구를 포함한 기타 소견과 함께 해석되어야 한다.\n\n 잘못된 처리 여부를 조사하여야 한다. ",
        "original_sentence": "- (7) 장비의 이상동작 시 스스로 수리하려고 하지 않는다. "
      }
    },
    {
      "chunk_id": "chunk_656",
      "text": "제조원에 문의한다.\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 655,
        "window_size": 3,
        "char_count": 11,
        "word_count": 2,
        "page_number": 24,
        "window_text": "- (4) 가급적 장비의 케이스를 닫고 검사를 진행하도록 한다.\n - (5) 검사가 종료된 후, 데이터 처리에 시간이 오래 소요될 수 있으므로 검사가 완전히\n- (6) 검사칩 외 이물질을 장비에 삽입해서는 안된다.\n - (7) 장비의 이상동작 시 스스로 수리하려고 하지 않는다.  제조원에 문의한다.\n - - 67 -\n6) 결과 판정상 주의\n\n- (1) 본 제품의 결과는 항상 환자의 약물 복용 여부를 포함한 의료 기록, 임상 증상\n및 시험연구를 포함한 기타 소견과 함께 해석되어야 한다.\n\n 잘못된 처리 여부를 조사하여야 한다.  새로운 혈액 검체와 새 검사칩으로 재\n\n- (2) 본 제품의 사용자는 환자나 사용자를 위한\n감염방지 및 교차감염방지를 위해\n\n8) 검사칩은 항상 본체에 장착하여 사용하여야 한다. ",
        "original_sentence": "제조원에 문의한다.\n"
      }
    },
    {
      "chunk_id": "chunk_657",
      "text": "- - 67 -\n6) 결과 판정상 주의\n\n- (1) 본 제품의 결과는 항상 환자의 약물 복용 여부를 포함한 의료 기록, 임상 증상\n및 시험연구를 포함한 기타 소견과 함께 해석되어야 한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 656,
        "window_size": 3,
        "char_count": 106,
        "word_count": 31,
        "page_number": 6,
        "window_text": "- (5) 검사가 종료된 후, 데이터 처리에 시간이 오래 소요될 수 있으므로 검사가 완전히\n- (6) 검사칩 외 이물질을 장비에 삽입해서는 안된다.\n - (7) 장비의 이상동작 시 스스로 수리하려고 하지 않는다.  제조원에 문의한다.\n - - 67 -\n6) 결과 판정상 주의\n\n- (1) 본 제품의 결과는 항상 환자의 약물 복용 여부를 포함한 의료 기록, 임상 증상\n및 시험연구를 포함한 기타 소견과 함께 해석되어야 한다.\n\n 잘못된 처리 여부를 조사하여야 한다.  새로운 혈액 검체와 새 검사칩으로 재\n\n- (2) 본 제품의 사용자는 환자나 사용자를 위한\n감염방지 및 교차감염방지를 위해\n\n8) 검사칩은 항상 본체에 장착하여 사용하여야 한다.  임상시험용 장비 이외의 장비에서\n\n- - 68 -\n<!-- PAGE_75 -->\n###### 13. ",
        "original_sentence": "- - 67 -\n6) 결과 판정상 주의\n\n- (1) 본 제품의 결과는 항상 환자의 약물 복용 여부를 포함한 의료 기록, 임상 증상\n및 시험연구를 포함한 기타 소견과 함께 해석되어야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_658",
      "text": "잘못된 처리 여부를 조사하여야 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 657,
        "window_size": 3,
        "char_count": 21,
        "word_count": 5,
        "page_number": 3,
        "window_text": "- (7) 장비의 이상동작 시 스스로 수리하려고 하지 않는다.  제조원에 문의한다.\n - - 67 -\n6) 결과 판정상 주의\n\n- (1) 본 제품의 결과는 항상 환자의 약물 복용 여부를 포함한 의료 기록, 임상 증상\n및 시험연구를 포함한 기타 소견과 함께 해석되어야 한다.\n\n 잘못된 처리 여부를 조사하여야 한다.  새로운 혈액 검체와 새 검사칩으로 재\n\n- (2) 본 제품의 사용자는 환자나 사용자를 위한\n감염방지 및 교차감염방지를 위해\n\n8) 검사칩은 항상 본체에 장착하여 사용하여야 한다.  임상시험용 장비 이외의 장비에서\n\n- - 68 -\n<!-- PAGE_75 -->\n###### 13.  중지·탈락 기준\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n본 임상시험인 혈소판 기능검사 및 혈소판 약물반응 검사는 혈소판 기능 부전이 의심되는\n\n환자 및 정상 대조군, aspirin 또는 P2Y12 수용체 저해제인 clopidogrel을 복용 전후의\n\n환자를 대상으로 구연산 처리된 전혈을 채혈하여 체외에서 검사가 이뤄지므로 환자 또는\n\n- 13.1.1. ",
        "original_sentence": "잘못된 처리 여부를 조사하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_659",
      "text": "새로운 혈액 검체와 새 검사칩으로 재\n\n- (2) 본 제품의 사용자는 환자나 사용자를 위한\n감염방지 및 교차감염방지를 위해\n\n8) 검사칩은 항상 본체에 장착하여 사용하여야 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 658,
        "window_size": 3,
        "char_count": 100,
        "word_count": 25,
        "page_number": 6,
        "window_text": "제조원에 문의한다.\n - - 67 -\n6) 결과 판정상 주의\n\n- (1) 본 제품의 결과는 항상 환자의 약물 복용 여부를 포함한 의료 기록, 임상 증상\n및 시험연구를 포함한 기타 소견과 함께 해석되어야 한다.\n\n 잘못된 처리 여부를 조사하여야 한다.  새로운 혈액 검체와 새 검사칩으로 재\n\n- (2) 본 제품의 사용자는 환자나 사용자를 위한\n감염방지 및 교차감염방지를 위해\n\n8) 검사칩은 항상 본체에 장착하여 사용하여야 한다.  임상시험용 장비 이외의 장비에서\n\n- - 68 -\n<!-- PAGE_75 -->\n###### 13.  중지·탈락 기준\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n본 임상시험인 혈소판 기능검사 및 혈소판 약물반응 검사는 혈소판 기능 부전이 의심되는\n\n환자 및 정상 대조군, aspirin 또는 P2Y12 수용체 저해제인 clopidogrel을 복용 전후의\n\n환자를 대상으로 구연산 처리된 전혈을 채혈하여 체외에서 검사가 이뤄지므로 환자 또는\n\n- 13.1.1.  중지 기준\n1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지 시킬 수\n\n2) 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는 것에 무리가 있다고\n\n판단되는 경우에는 임상시험 책임자는 임상시험을 중지할 수 있다 (표 1. ",
        "original_sentence": "새로운 혈액 검체와 새 검사칩으로 재\n\n- (2) 본 제품의 사용자는 환자나 사용자를 위한\n감염방지 및 교차감염방지를 위해\n\n8) 검사칩은 항상 본체에 장착하여 사용하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_660",
      "text": "임상시험용 장비 이외의 장비에서\n\n- - 68 -\n<!-- PAGE_75 -->\n###### 13. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 659,
        "window_size": 3,
        "char_count": 56,
        "word_count": 13,
        "page_number": 75,
        "window_text": "- - 67 -\n6) 결과 판정상 주의\n\n- (1) 본 제품의 결과는 항상 환자의 약물 복용 여부를 포함한 의료 기록, 임상 증상\n및 시험연구를 포함한 기타 소견과 함께 해석되어야 한다.\n\n 잘못된 처리 여부를 조사하여야 한다.  새로운 혈액 검체와 새 검사칩으로 재\n\n- (2) 본 제품의 사용자는 환자나 사용자를 위한\n감염방지 및 교차감염방지를 위해\n\n8) 검사칩은 항상 본체에 장착하여 사용하여야 한다.  임상시험용 장비 이외의 장비에서\n\n- - 68 -\n<!-- PAGE_75 -->\n###### 13.  중지·탈락 기준\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n본 임상시험인 혈소판 기능검사 및 혈소판 약물반응 검사는 혈소판 기능 부전이 의심되는\n\n환자 및 정상 대조군, aspirin 또는 P2Y12 수용체 저해제인 clopidogrel을 복용 전후의\n\n환자를 대상으로 구연산 처리된 전혈을 채혈하여 체외에서 검사가 이뤄지므로 환자 또는\n\n- 13.1.1.  중지 기준\n1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지 시킬 수\n\n2) 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는 것에 무리가 있다고\n\n판단되는 경우에는 임상시험 책임자는 임상시험을 중지할 수 있다 (표 1.  참조).\n\n",
        "original_sentence": "임상시험용 장비 이외의 장비에서\n\n- - 68 -\n<!-- PAGE_75 -->\n###### 13. "
      }
    },
    {
      "chunk_id": "chunk_661",
      "text": "중지·탈락 기준\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n본 임상시험인 혈소판 기능검사 및 혈소판 약물반응 검사는 혈소판 기능 부전이 의심되는\n\n환자 및 정상 대조군, aspirin 또는 P2Y12 수용체 저해제인 clopidogrel을 복용 전후의\n\n환자를 대상으로 구연산 처리된 전혈을 채혈하여 체외에서 검사가 이뤄지므로 환자 또는\n\n- 13.1.1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 660,
        "window_size": 3,
        "char_count": 229,
        "word_count": 53,
        "page_number": 6,
        "window_text": "잘못된 처리 여부를 조사하여야 한다.  새로운 혈액 검체와 새 검사칩으로 재\n\n- (2) 본 제품의 사용자는 환자나 사용자를 위한\n감염방지 및 교차감염방지를 위해\n\n8) 검사칩은 항상 본체에 장착하여 사용하여야 한다.  임상시험용 장비 이외의 장비에서\n\n- - 68 -\n<!-- PAGE_75 -->\n###### 13.  중지·탈락 기준\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n본 임상시험인 혈소판 기능검사 및 혈소판 약물반응 검사는 혈소판 기능 부전이 의심되는\n\n환자 및 정상 대조군, aspirin 또는 P2Y12 수용체 저해제인 clopidogrel을 복용 전후의\n\n환자를 대상으로 구연산 처리된 전혈을 채혈하여 체외에서 검사가 이뤄지므로 환자 또는\n\n- 13.1.1.  중지 기준\n1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지 시킬 수\n\n2) 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는 것에 무리가 있다고\n\n판단되는 경우에는 임상시험 책임자는 임상시험을 중지할 수 있다 (표 1.  참조).\n\n 3) 대상자가 시험자의 지시에 불응하거나 또는 동의서에 제시된 사항을 준수하지 않아\n\n그 유효율의 평가에 영향을 미치는 경우 임상시험을 중지할 수 있다.\n\n",
        "original_sentence": "중지·탈락 기준\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n본 임상시험인 혈소판 기능검사 및 혈소판 약물반응 검사는 혈소판 기능 부전이 의심되는\n\n환자 및 정상 대조군, aspirin 또는 P2Y12 수용체 저해제인 clopidogrel을 복용 전후의\n\n환자를 대상으로 구연산 처리된 전혈을 채혈하여 체외에서 검사가 이뤄지므로 환자 또는\n\n- 13.1.1. "
      }
    },
    {
      "chunk_id": "chunk_662",
      "text": "중지 기준\n1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지 시킬 수\n\n2) 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는 것에 무리가 있다고\n\n판단되는 경우에는 임상시험 책임자는 임상시험을 중지할 수 있다 (표 1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 661,
        "window_size": 3,
        "char_count": 144,
        "word_count": 34,
        "page_number": 6,
        "window_text": "새로운 혈액 검체와 새 검사칩으로 재\n\n- (2) 본 제품의 사용자는 환자나 사용자를 위한\n감염방지 및 교차감염방지를 위해\n\n8) 검사칩은 항상 본체에 장착하여 사용하여야 한다.  임상시험용 장비 이외의 장비에서\n\n- - 68 -\n<!-- PAGE_75 -->\n###### 13.  중지·탈락 기준\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n본 임상시험인 혈소판 기능검사 및 혈소판 약물반응 검사는 혈소판 기능 부전이 의심되는\n\n환자 및 정상 대조군, aspirin 또는 P2Y12 수용체 저해제인 clopidogrel을 복용 전후의\n\n환자를 대상으로 구연산 처리된 전혈을 채혈하여 체외에서 검사가 이뤄지므로 환자 또는\n\n- 13.1.1.  중지 기준\n1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지 시킬 수\n\n2) 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는 것에 무리가 있다고\n\n판단되는 경우에는 임상시험 책임자는 임상시험을 중지할 수 있다 (표 1.  참조).\n\n 3) 대상자가 시험자의 지시에 불응하거나 또는 동의서에 제시된 사항을 준수하지 않아\n\n그 유효율의 평가에 영향을 미치는 경우 임상시험을 중지할 수 있다.\n\n - - 69 -\n중지기준\n\n중지처리\n\n- - 피험자 제공 검체의 보관, 관리 또는 예기치 못한 문제로 인해 외부\n<표 1. ",
        "original_sentence": "중지 기준\n1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지 시킬 수\n\n2) 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는 것에 무리가 있다고\n\n판단되는 경우에는 임상시험 책임자는 임상시험을 중지할 수 있다 (표 1. "
      }
    },
    {
      "chunk_id": "chunk_663",
      "text": "참조).\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 662,
        "window_size": 3,
        "char_count": 6,
        "word_count": 1,
        "page_number": 75,
        "window_text": "임상시험용 장비 이외의 장비에서\n\n- - 68 -\n<!-- PAGE_75 -->\n###### 13.  중지·탈락 기준\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n본 임상시험인 혈소판 기능검사 및 혈소판 약물반응 검사는 혈소판 기능 부전이 의심되는\n\n환자 및 정상 대조군, aspirin 또는 P2Y12 수용체 저해제인 clopidogrel을 복용 전후의\n\n환자를 대상으로 구연산 처리된 전혈을 채혈하여 체외에서 검사가 이뤄지므로 환자 또는\n\n- 13.1.1.  중지 기준\n1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지 시킬 수\n\n2) 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는 것에 무리가 있다고\n\n판단되는 경우에는 임상시험 책임자는 임상시험을 중지할 수 있다 (표 1.  참조).\n\n 3) 대상자가 시험자의 지시에 불응하거나 또는 동의서에 제시된 사항을 준수하지 않아\n\n그 유효율의 평가에 영향을 미치는 경우 임상시험을 중지할 수 있다.\n\n - - 69 -\n중지기준\n\n중지처리\n\n- - 피험자 제공 검체의 보관, 관리 또는 예기치 못한 문제로 인해 외부\n<표 1.  중지 기준 및 처리>\n\n2) 중지 시점까지의 검사결과 관련 자료는 성능과 안전성 평가를 위한 통계 처리 시\n\n만약 자료에 결함이 생기면, 적절한 보정 방법을 임상시험계획서에 제시하고, 보정 후\n\n- 13.2.1. ",
        "original_sentence": "참조).\n\n"
      }
    },
    {
      "chunk_id": "chunk_664",
      "text": "3) 대상자가 시험자의 지시에 불응하거나 또는 동의서에 제시된 사항을 준수하지 않아\n\n그 유효율의 평가에 영향을 미치는 경우 임상시험을 중지할 수 있다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 663,
        "window_size": 3,
        "char_count": 87,
        "word_count": 21,
        "page_number": 3,
        "window_text": "중지·탈락 기준\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n본 임상시험인 혈소판 기능검사 및 혈소판 약물반응 검사는 혈소판 기능 부전이 의심되는\n\n환자 및 정상 대조군, aspirin 또는 P2Y12 수용체 저해제인 clopidogrel을 복용 전후의\n\n환자를 대상으로 구연산 처리된 전혈을 채혈하여 체외에서 검사가 이뤄지므로 환자 또는\n\n- 13.1.1.  중지 기준\n1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지 시킬 수\n\n2) 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는 것에 무리가 있다고\n\n판단되는 경우에는 임상시험 책임자는 임상시험을 중지할 수 있다 (표 1.  참조).\n\n 3) 대상자가 시험자의 지시에 불응하거나 또는 동의서에 제시된 사항을 준수하지 않아\n\n그 유효율의 평가에 영향을 미치는 경우 임상시험을 중지할 수 있다.\n\n - - 69 -\n중지기준\n\n중지처리\n\n- - 피험자 제공 검체의 보관, 관리 또는 예기치 못한 문제로 인해 외부\n<표 1.  중지 기준 및 처리>\n\n2) 중지 시점까지의 검사결과 관련 자료는 성능과 안전성 평가를 위한 통계 처리 시\n\n만약 자료에 결함이 생기면, 적절한 보정 방법을 임상시험계획서에 제시하고, 보정 후\n\n- 13.2.1.  탈락 기준\n시험기기 또는 대조기기 검사상 에러가 발생하여 재검을 수행하였음에도 불구하고 지속\n\n적인 에러가 발생하여 결과확인이 어려운 경우 임상시험에서 탈락시킨다.\n\n",
        "original_sentence": "3) 대상자가 시험자의 지시에 불응하거나 또는 동의서에 제시된 사항을 준수하지 않아\n\n그 유효율의 평가에 영향을 미치는 경우 임상시험을 중지할 수 있다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_665",
      "text": "- - 69 -\n중지기준\n\n중지처리\n\n- - 피험자 제공 검체의 보관, 관리 또는 예기치 못한 문제로 인해 외부\n<표 1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 664,
        "window_size": 3,
        "char_count": 69,
        "word_count": 21,
        "page_number": 15,
        "window_text": "중지 기준\n1) 임상시험은 시험책임자, 임상시험심사위원회에 의해 조기종료 또는 일시중지 시킬 수\n\n2) 임상시험 진행 중 관찰되는 상황이 임상시험을 계속 진행하는 것에 무리가 있다고\n\n판단되는 경우에는 임상시험 책임자는 임상시험을 중지할 수 있다 (표 1.  참조).\n\n 3) 대상자가 시험자의 지시에 불응하거나 또는 동의서에 제시된 사항을 준수하지 않아\n\n그 유효율의 평가에 영향을 미치는 경우 임상시험을 중지할 수 있다.\n\n - - 69 -\n중지기준\n\n중지처리\n\n- - 피험자 제공 검체의 보관, 관리 또는 예기치 못한 문제로 인해 외부\n<표 1.  중지 기준 및 처리>\n\n2) 중지 시점까지의 검사결과 관련 자료는 성능과 안전성 평가를 위한 통계 처리 시\n\n만약 자료에 결함이 생기면, 적절한 보정 방법을 임상시험계획서에 제시하고, 보정 후\n\n- 13.2.1.  탈락 기준\n시험기기 또는 대조기기 검사상 에러가 발생하여 재검을 수행하였음에도 불구하고 지속\n\n적인 에러가 발생하여 결과확인이 어려운 경우 임상시험에서 탈락시킨다.\n\n - 13.2.2. ",
        "original_sentence": "- - 69 -\n중지기준\n\n중지처리\n\n- - 피험자 제공 검체의 보관, 관리 또는 예기치 못한 문제로 인해 외부\n<표 1. "
      }
    },
    {
      "chunk_id": "chunk_666",
      "text": "중지 기준 및 처리>\n\n2) 중지 시점까지의 검사결과 관련 자료는 성능과 안전성 평가를 위한 통계 처리 시\n\n만약 자료에 결함이 생기면, 적절한 보정 방법을 임상시험계획서에 제시하고, 보정 후\n\n- 13.2.1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 665,
        "window_size": 3,
        "char_count": 119,
        "word_count": 30,
        "page_number": 6,
        "window_text": "참조).\n\n 3) 대상자가 시험자의 지시에 불응하거나 또는 동의서에 제시된 사항을 준수하지 않아\n\n그 유효율의 평가에 영향을 미치는 경우 임상시험을 중지할 수 있다.\n\n - - 69 -\n중지기준\n\n중지처리\n\n- - 피험자 제공 검체의 보관, 관리 또는 예기치 못한 문제로 인해 외부\n<표 1.  중지 기준 및 처리>\n\n2) 중지 시점까지의 검사결과 관련 자료는 성능과 안전성 평가를 위한 통계 처리 시\n\n만약 자료에 결함이 생기면, 적절한 보정 방법을 임상시험계획서에 제시하고, 보정 후\n\n- 13.2.1.  탈락 기준\n시험기기 또는 대조기기 검사상 에러가 발생하여 재검을 수행하였음에도 불구하고 지속\n\n적인 에러가 발생하여 결과확인이 어려운 경우 임상시험에서 탈락시킨다.\n\n - 13.2.2.  탈락 처리\n1) 탈락률이 예상보다 높아 피험자 수가 부족할 경우, 부족한 수만큼 피함자를 추가로\n\n모집하여 임상시험을 시행한다. ",
        "original_sentence": "중지 기준 및 처리>\n\n2) 중지 시점까지의 검사결과 관련 자료는 성능과 안전성 평가를 위한 통계 처리 시\n\n만약 자료에 결함이 생기면, 적절한 보정 방법을 임상시험계획서에 제시하고, 보정 후\n\n- 13.2.1. "
      }
    },
    {
      "chunk_id": "chunk_667",
      "text": "탈락 기준\n시험기기 또는 대조기기 검사상 에러가 발생하여 재검을 수행하였음에도 불구하고 지속\n\n적인 에러가 발생하여 결과확인이 어려운 경우 임상시험에서 탈락시킨다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 666,
        "window_size": 3,
        "char_count": 93,
        "word_count": 20,
        "page_number": 9,
        "window_text": "3) 대상자가 시험자의 지시에 불응하거나 또는 동의서에 제시된 사항을 준수하지 않아\n\n그 유효율의 평가에 영향을 미치는 경우 임상시험을 중지할 수 있다.\n\n - - 69 -\n중지기준\n\n중지처리\n\n- - 피험자 제공 검체의 보관, 관리 또는 예기치 못한 문제로 인해 외부\n<표 1.  중지 기준 및 처리>\n\n2) 중지 시점까지의 검사결과 관련 자료는 성능과 안전성 평가를 위한 통계 처리 시\n\n만약 자료에 결함이 생기면, 적절한 보정 방법을 임상시험계획서에 제시하고, 보정 후\n\n- 13.2.1.  탈락 기준\n시험기기 또는 대조기기 검사상 에러가 발생하여 재검을 수행하였음에도 불구하고 지속\n\n적인 에러가 발생하여 결과확인이 어려운 경우 임상시험에서 탈락시킨다.\n\n - 13.2.2.  탈락 처리\n1) 탈락률이 예상보다 높아 피험자 수가 부족할 경우, 부족한 수만큼 피함자를 추가로\n\n모집하여 임상시험을 시행한다.  임상시험 완료 후 통계 처리 시 탈락시킨 검체는\n\n제외하고 통계 처리 한다. ",
        "original_sentence": "탈락 기준\n시험기기 또는 대조기기 검사상 에러가 발생하여 재검을 수행하였음에도 불구하고 지속\n\n적인 에러가 발생하여 결과확인이 어려운 경우 임상시험에서 탈락시킨다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_668",
      "text": "- 13.2.2. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 667,
        "window_size": 3,
        "char_count": 10,
        "word_count": 2,
        "page_number": 6,
        "window_text": "- - 69 -\n중지기준\n\n중지처리\n\n- - 피험자 제공 검체의 보관, 관리 또는 예기치 못한 문제로 인해 외부\n<표 1.  중지 기준 및 처리>\n\n2) 중지 시점까지의 검사결과 관련 자료는 성능과 안전성 평가를 위한 통계 처리 시\n\n만약 자료에 결함이 생기면, 적절한 보정 방법을 임상시험계획서에 제시하고, 보정 후\n\n- 13.2.1.  탈락 기준\n시험기기 또는 대조기기 검사상 에러가 발생하여 재검을 수행하였음에도 불구하고 지속\n\n적인 에러가 발생하여 결과확인이 어려운 경우 임상시험에서 탈락시킨다.\n\n - 13.2.2.  탈락 처리\n1) 탈락률이 예상보다 높아 피험자 수가 부족할 경우, 부족한 수만큼 피함자를 추가로\n\n모집하여 임상시험을 시행한다.  임상시험 완료 후 통계 처리 시 탈락시킨 검체는\n\n제외하고 통계 처리 한다.  단, 임상 시험 검체 list에서는 제외하지 않는다.\n\n",
        "original_sentence": "- 13.2.2. "
      }
    },
    {
      "chunk_id": "chunk_669",
      "text": "탈락 처리\n1) 탈락률이 예상보다 높아 피험자 수가 부족할 경우, 부족한 수만큼 피함자를 추가로\n\n모집하여 임상시험을 시행한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 668,
        "window_size": 3,
        "char_count": 72,
        "word_count": 17,
        "page_number": 6,
        "window_text": "중지 기준 및 처리>\n\n2) 중지 시점까지의 검사결과 관련 자료는 성능과 안전성 평가를 위한 통계 처리 시\n\n만약 자료에 결함이 생기면, 적절한 보정 방법을 임상시험계획서에 제시하고, 보정 후\n\n- 13.2.1.  탈락 기준\n시험기기 또는 대조기기 검사상 에러가 발생하여 재검을 수행하였음에도 불구하고 지속\n\n적인 에러가 발생하여 결과확인이 어려운 경우 임상시험에서 탈락시킨다.\n\n - 13.2.2.  탈락 처리\n1) 탈락률이 예상보다 높아 피험자 수가 부족할 경우, 부족한 수만큼 피함자를 추가로\n\n모집하여 임상시험을 시행한다.  임상시험 완료 후 통계 처리 시 탈락시킨 검체는\n\n제외하고 통계 처리 한다.  단, 임상 시험 검체 list에서는 제외하지 않는다.\n\n 2) 증례기록서에 탈락의 사유를 기재한다.\n\n",
        "original_sentence": "탈락 처리\n1) 탈락률이 예상보다 높아 피험자 수가 부족할 경우, 부족한 수만큼 피함자를 추가로\n\n모집하여 임상시험을 시행한다. "
      }
    },
    {
      "chunk_id": "chunk_670",
      "text": "임상시험 완료 후 통계 처리 시 탈락시킨 검체는\n\n제외하고 통계 처리 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 669,
        "window_size": 3,
        "char_count": 43,
        "word_count": 12,
        "page_number": 9,
        "window_text": "탈락 기준\n시험기기 또는 대조기기 검사상 에러가 발생하여 재검을 수행하였음에도 불구하고 지속\n\n적인 에러가 발생하여 결과확인이 어려운 경우 임상시험에서 탈락시킨다.\n\n - 13.2.2.  탈락 처리\n1) 탈락률이 예상보다 높아 피험자 수가 부족할 경우, 부족한 수만큼 피함자를 추가로\n\n모집하여 임상시험을 시행한다.  임상시험 완료 후 통계 처리 시 탈락시킨 검체는\n\n제외하고 통계 처리 한다.  단, 임상 시험 검체 list에서는 제외하지 않는다.\n\n 2) 증례기록서에 탈락의 사유를 기재한다.\n\n - - 70 -\n<!-- PAGE_77 -->\n###### 14. ",
        "original_sentence": "임상시험 완료 후 통계 처리 시 탈락시킨 검체는\n\n제외하고 통계 처리 한다. "
      }
    },
    {
      "chunk_id": "chunk_671",
      "text": "단, 임상 시험 검체 list에서는 제외하지 않는다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 670,
        "window_size": 3,
        "char_count": 31,
        "word_count": 7,
        "page_number": 9,
        "window_text": "- 13.2.2.  탈락 처리\n1) 탈락률이 예상보다 높아 피험자 수가 부족할 경우, 부족한 수만큼 피함자를 추가로\n\n모집하여 임상시험을 시행한다.  임상시험 완료 후 통계 처리 시 탈락시킨 검체는\n\n제외하고 통계 처리 한다.  단, 임상 시험 검체 list에서는 제외하지 않는다.\n\n 2) 증례기록서에 탈락의 사유를 기재한다.\n\n - - 70 -\n<!-- PAGE_77 -->\n###### 14.  유효성의 평가기준, 평가방법 및 해석방법(통계 분석방법에 의함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n대조기기(LTA 검사) 결과를 기준으로 하여 시험시약의 민감도 및 특이도를\n\n대조기기(LTA 검사) 결과를 기준으로 하여 시험시약의 민감도 및 특이도를\n\n산출한다. ",
        "original_sentence": "단, 임상 시험 검체 list에서는 제외하지 않는다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_672",
      "text": "2) 증례기록서에 탈락의 사유를 기재한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 671,
        "window_size": 3,
        "char_count": 25,
        "word_count": 5,
        "page_number": 76,
        "window_text": "탈락 처리\n1) 탈락률이 예상보다 높아 피험자 수가 부족할 경우, 부족한 수만큼 피함자를 추가로\n\n모집하여 임상시험을 시행한다.  임상시험 완료 후 통계 처리 시 탈락시킨 검체는\n\n제외하고 통계 처리 한다.  단, 임상 시험 검체 list에서는 제외하지 않는다.\n\n 2) 증례기록서에 탈락의 사유를 기재한다.\n\n - - 70 -\n<!-- PAGE_77 -->\n###### 14.  유효성의 평가기준, 평가방법 및 해석방법(통계 분석방법에 의함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n대조기기(LTA 검사) 결과를 기준으로 하여 시험시약의 민감도 및 특이도를\n\n대조기기(LTA 검사) 결과를 기준으로 하여 시험시약의 민감도 및 특이도를\n\n산출한다.  신뢰도 95% 구간에서 민감도 85%, 특이도 80%, 로 설정한다.\n\n",
        "original_sentence": "2) 증례기록서에 탈락의 사유를 기재한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_673",
      "text": "- - 70 -\n<!-- PAGE_77 -->\n###### 14. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 672,
        "window_size": 3,
        "char_count": 37,
        "word_count": 9,
        "page_number": 77,
        "window_text": "임상시험 완료 후 통계 처리 시 탈락시킨 검체는\n\n제외하고 통계 처리 한다.  단, 임상 시험 검체 list에서는 제외하지 않는다.\n\n 2) 증례기록서에 탈락의 사유를 기재한다.\n\n - - 70 -\n<!-- PAGE_77 -->\n###### 14.  유효성의 평가기준, 평가방법 및 해석방법(통계 분석방법에 의함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n대조기기(LTA 검사) 결과를 기준으로 하여 시험시약의 민감도 및 특이도를\n\n대조기기(LTA 검사) 결과를 기준으로 하여 시험시약의 민감도 및 특이도를\n\n산출한다.  신뢰도 95% 구간에서 민감도 85%, 특이도 80%, 로 설정한다.\n\n - 다. SIPA test\n대조기기(LTA 검사) 결과를 기준으로 하여 시험시약의 민감도 및 특이도를\n\n산출한다. ",
        "original_sentence": "- - 70 -\n<!-- PAGE_77 -->\n###### 14. "
      }
    },
    {
      "chunk_id": "chunk_674",
      "text": "유효성의 평가기준, 평가방법 및 해석방법(통계 분석방법에 의함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n대조기기(LTA 검사) 결과를 기준으로 하여 시험시약의 민감도 및 특이도를\n\n대조기기(LTA 검사) 결과를 기준으로 하여 시험시약의 민감도 및 특이도를\n\n산출한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 673,
        "window_size": 3,
        "char_count": 181,
        "word_count": 40,
        "page_number": 6,
        "window_text": "단, 임상 시험 검체 list에서는 제외하지 않는다.\n\n 2) 증례기록서에 탈락의 사유를 기재한다.\n\n - - 70 -\n<!-- PAGE_77 -->\n###### 14.  유효성의 평가기준, 평가방법 및 해석방법(통계 분석방법에 의함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n대조기기(LTA 검사) 결과를 기준으로 하여 시험시약의 민감도 및 특이도를\n\n대조기기(LTA 검사) 결과를 기준으로 하여 시험시약의 민감도 및 특이도를\n\n산출한다.  신뢰도 95% 구간에서 민감도 85%, 특이도 80%, 로 설정한다.\n\n - 다. SIPA test\n대조기기(LTA 검사) 결과를 기준으로 하여 시험시약의 민감도 및 특이도를\n\n산출한다.  신뢰도 95% 구간에서 민감도 85%, 특이도 80%, 로 설정한다.\n\n",
        "original_sentence": "유효성의 평가기준, 평가방법 및 해석방법(통계 분석방법에 의함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n대조기기(LTA 검사) 결과를 기준으로 하여 시험시약의 민감도 및 특이도를\n\n대조기기(LTA 검사) 결과를 기준으로 하여 시험시약의 민감도 및 특이도를\n\n산출한다. "
      }
    },
    {
      "chunk_id": "chunk_675",
      "text": "신뢰도 95% 구간에서 민감도 85%, 특이도 80%, 로 설정한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 674,
        "window_size": 3,
        "char_count": 40,
        "word_count": 9,
        "page_number": 6,
        "window_text": "2) 증례기록서에 탈락의 사유를 기재한다.\n\n - - 70 -\n<!-- PAGE_77 -->\n###### 14.  유효성의 평가기준, 평가방법 및 해석방법(통계 분석방법에 의함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n대조기기(LTA 검사) 결과를 기준으로 하여 시험시약의 민감도 및 특이도를\n\n대조기기(LTA 검사) 결과를 기준으로 하여 시험시약의 민감도 및 특이도를\n\n산출한다.  신뢰도 95% 구간에서 민감도 85%, 특이도 80%, 로 설정한다.\n\n - 다. SIPA test\n대조기기(LTA 검사) 결과를 기준으로 하여 시험시약의 민감도 및 특이도를\n\n산출한다.  신뢰도 95% 구간에서 민감도 85%, 특이도 80%, 로 설정한다.\n\n - - 71 -\n- 14.1.2. ",
        "original_sentence": "신뢰도 95% 구간에서 민감도 85%, 특이도 80%, 로 설정한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_676",
      "text": "- 다. SIPA test\n대조기기(LTA 검사) 결과를 기준으로 하여 시험시약의 민감도 및 특이도를\n\n산출한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 675,
        "window_size": 3,
        "char_count": 64,
        "word_count": 14,
        "page_number": 9,
        "window_text": "- - 70 -\n<!-- PAGE_77 -->\n###### 14.  유효성의 평가기준, 평가방법 및 해석방법(통계 분석방법에 의함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n대조기기(LTA 검사) 결과를 기준으로 하여 시험시약의 민감도 및 특이도를\n\n대조기기(LTA 검사) 결과를 기준으로 하여 시험시약의 민감도 및 특이도를\n\n산출한다.  신뢰도 95% 구간에서 민감도 85%, 특이도 80%, 로 설정한다.\n\n - 다. SIPA test\n대조기기(LTA 검사) 결과를 기준으로 하여 시험시약의 민감도 및 특이도를\n\n산출한다.  신뢰도 95% 구간에서 민감도 85%, 특이도 80%, 로 설정한다.\n\n - - 71 -\n- 14.1.2.  혈소판 기능 검사\n- 가. Aspirin test\n1) 민감도: 대조기기 비정상 결과 검체 중 시험기기에서 비정상 결과를 보인\n\n민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)\n\nKappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)}\n\n- - 72 -\n- 나. ADP test\n1) 민감도: 대조기기 비정상 결과 검체 중 시험기기에서 비정상 결과를 보인\n\n검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.\n\n",
        "original_sentence": "- 다. SIPA test\n대조기기(LTA 검사) 결과를 기준으로 하여 시험시약의 민감도 및 특이도를\n\n산출한다. "
      }
    },
    {
      "chunk_id": "chunk_677",
      "text": "신뢰도 95% 구간에서 민감도 85%, 특이도 80%, 로 설정한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 676,
        "window_size": 3,
        "char_count": 40,
        "word_count": 9,
        "page_number": 6,
        "window_text": "유효성의 평가기준, 평가방법 및 해석방법(통계 분석방법에 의함)\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n대조기기(LTA 검사) 결과를 기준으로 하여 시험시약의 민감도 및 특이도를\n\n대조기기(LTA 검사) 결과를 기준으로 하여 시험시약의 민감도 및 특이도를\n\n산출한다.  신뢰도 95% 구간에서 민감도 85%, 특이도 80%, 로 설정한다.\n\n - 다. SIPA test\n대조기기(LTA 검사) 결과를 기준으로 하여 시험시약의 민감도 및 특이도를\n\n산출한다.  신뢰도 95% 구간에서 민감도 85%, 특이도 80%, 로 설정한다.\n\n - - 71 -\n- 14.1.2.  혈소판 기능 검사\n- 가. Aspirin test\n1) 민감도: 대조기기 비정상 결과 검체 중 시험기기에서 비정상 결과를 보인\n\n민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)\n\nKappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)}\n\n- - 72 -\n- 나. ADP test\n1) 민감도: 대조기기 비정상 결과 검체 중 시험기기에서 비정상 결과를 보인\n\n검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.\n\n - 다. SIPA　test : 검사원리가 비슷한 기존검사법은 없으나, 혈소판 기능의 정상/\n준에 준하여 평가한다.\n\n",
        "original_sentence": "신뢰도 95% 구간에서 민감도 85%, 특이도 80%, 로 설정한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_678",
      "text": "- - 71 -\n- 14.1.2. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 677,
        "window_size": 3,
        "char_count": 19,
        "word_count": 6,
        "page_number": 6,
        "window_text": "신뢰도 95% 구간에서 민감도 85%, 특이도 80%, 로 설정한다.\n\n - 다. SIPA test\n대조기기(LTA 검사) 결과를 기준으로 하여 시험시약의 민감도 및 특이도를\n\n산출한다.  신뢰도 95% 구간에서 민감도 85%, 특이도 80%, 로 설정한다.\n\n - - 71 -\n- 14.1.2.  혈소판 기능 검사\n- 가. Aspirin test\n1) 민감도: 대조기기 비정상 결과 검체 중 시험기기에서 비정상 결과를 보인\n\n민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)\n\nKappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)}\n\n- - 72 -\n- 나. ADP test\n1) 민감도: 대조기기 비정상 결과 검체 중 시험기기에서 비정상 결과를 보인\n\n검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.\n\n - 다. SIPA　test : 검사원리가 비슷한 기존검사법은 없으나, 혈소판 기능의 정상/\n준에 준하여 평가한다.\n\n 1) 민감도: 대조기기 비정상 결과 검체 중 시험기기에서 비정상 결과를 보인\n\n2) 특이도: 대조기기 정상 결과 검체 중 시험기기에서 정상 결과를 보인 검체의\n\n3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.\n\n",
        "original_sentence": "- - 71 -\n- 14.1.2. "
      }
    },
    {
      "chunk_id": "chunk_679",
      "text": "혈소판 기능 검사\n- 가. Aspirin test\n1) 민감도: 대조기기 비정상 결과 검체 중 시험기기에서 비정상 결과를 보인\n\n민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)\n\nKappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)}\n\n- - 72 -\n- 나. ADP test\n1) 민감도: 대조기기 비정상 결과 검체 중 시험기기에서 비정상 결과를 보인\n\n검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 678,
        "window_size": 3,
        "char_count": 264,
        "word_count": 55,
        "page_number": 6,
        "window_text": "- 다. SIPA test\n대조기기(LTA 검사) 결과를 기준으로 하여 시험시약의 민감도 및 특이도를\n\n산출한다.  신뢰도 95% 구간에서 민감도 85%, 특이도 80%, 로 설정한다.\n\n - - 71 -\n- 14.1.2.  혈소판 기능 검사\n- 가. Aspirin test\n1) 민감도: 대조기기 비정상 결과 검체 중 시험기기에서 비정상 결과를 보인\n\n민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)\n\nKappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)}\n\n- - 72 -\n- 나. ADP test\n1) 민감도: 대조기기 비정상 결과 검체 중 시험기기에서 비정상 결과를 보인\n\n검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.\n\n - 다. SIPA　test : 검사원리가 비슷한 기존검사법은 없으나, 혈소판 기능의 정상/\n준에 준하여 평가한다.\n\n 1) 민감도: 대조기기 비정상 결과 검체 중 시험기기에서 비정상 결과를 보인\n\n2) 특이도: 대조기기 정상 결과 검체 중 시험기기에서 정상 결과를 보인 검체의\n\n3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.\n\n - - 73 -\n대조기기\n\n합계\n\n비정상\n\n정상\n\n민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)\n\n3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.\n\n",
        "original_sentence": "혈소판 기능 검사\n- 가. Aspirin test\n1) 민감도: 대조기기 비정상 결과 검체 중 시험기기에서 비정상 결과를 보인\n\n민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)\n\nKappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)}\n\n- - 72 -\n- 나. ADP test\n1) 민감도: 대조기기 비정상 결과 검체 중 시험기기에서 비정상 결과를 보인\n\n검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_680",
      "text": "- 다. SIPA　test : 검사원리가 비슷한 기존검사법은 없으나, 혈소판 기능의 정상/\n준에 준하여 평가한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 679,
        "window_size": 3,
        "char_count": 65,
        "word_count": 15,
        "page_number": 23,
        "window_text": "신뢰도 95% 구간에서 민감도 85%, 특이도 80%, 로 설정한다.\n\n - - 71 -\n- 14.1.2.  혈소판 기능 검사\n- 가. Aspirin test\n1) 민감도: 대조기기 비정상 결과 검체 중 시험기기에서 비정상 결과를 보인\n\n민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)\n\nKappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)}\n\n- - 72 -\n- 나. ADP test\n1) 민감도: 대조기기 비정상 결과 검체 중 시험기기에서 비정상 결과를 보인\n\n검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.\n\n - 다. SIPA　test : 검사원리가 비슷한 기존검사법은 없으나, 혈소판 기능의 정상/\n준에 준하여 평가한다.\n\n 1) 민감도: 대조기기 비정상 결과 검체 중 시험기기에서 비정상 결과를 보인\n\n2) 특이도: 대조기기 정상 결과 검체 중 시험기기에서 정상 결과를 보인 검체의\n\n3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.\n\n - - 73 -\n대조기기\n\n합계\n\n비정상\n\n정상\n\n민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)\n\n3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.\n\n - - 74 -\n대조기기\n\n합계\n\n약물반응 양성\n\n약물반응 음성\n\n민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)\n\n3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.\n\n",
        "original_sentence": "- 다. SIPA　test : 검사원리가 비슷한 기존검사법은 없으나, 혈소판 기능의 정상/\n준에 준하여 평가한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_681",
      "text": "1) 민감도: 대조기기 비정상 결과 검체 중 시험기기에서 비정상 결과를 보인\n\n2) 특이도: 대조기기 정상 결과 검체 중 시험기기에서 정상 결과를 보인 검체의\n\n3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 680,
        "window_size": 3,
        "char_count": 139,
        "word_count": 33,
        "page_number": 6,
        "window_text": "- - 71 -\n- 14.1.2.  혈소판 기능 검사\n- 가. Aspirin test\n1) 민감도: 대조기기 비정상 결과 검체 중 시험기기에서 비정상 결과를 보인\n\n민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)\n\nKappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)}\n\n- - 72 -\n- 나. ADP test\n1) 민감도: 대조기기 비정상 결과 검체 중 시험기기에서 비정상 결과를 보인\n\n검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.\n\n - 다. SIPA　test : 검사원리가 비슷한 기존검사법은 없으나, 혈소판 기능의 정상/\n준에 준하여 평가한다.\n\n 1) 민감도: 대조기기 비정상 결과 검체 중 시험기기에서 비정상 결과를 보인\n\n2) 특이도: 대조기기 정상 결과 검체 중 시험기기에서 정상 결과를 보인 검체의\n\n3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.\n\n - - 73 -\n대조기기\n\n합계\n\n비정상\n\n정상\n\n민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)\n\n3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.\n\n - - 74 -\n대조기기\n\n합계\n\n약물반응 양성\n\n약물반응 음성\n\n민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)\n\n3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.\n\n - - 75 -\n대조기기\n\n합계\n\n약물반응 양성\n\n약물반응 음성\n\n- - 76 -\n<!-- PAGE_83 -->\n###### 15. ",
        "original_sentence": "1) 민감도: 대조기기 비정상 결과 검체 중 시험기기에서 비정상 결과를 보인\n\n2) 특이도: 대조기기 정상 결과 검체 중 시험기기에서 정상 결과를 보인 검체의\n\n3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_682",
      "text": "- - 73 -\n대조기기\n\n합계\n\n비정상\n\n정상\n\n민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)\n\n3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 681,
        "window_size": 3,
        "char_count": 115,
        "word_count": 24,
        "page_number": 6,
        "window_text": "혈소판 기능 검사\n- 가. Aspirin test\n1) 민감도: 대조기기 비정상 결과 검체 중 시험기기에서 비정상 결과를 보인\n\n민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)\n\nKappa 통계량 = 2(ad-bd)/{(a+b)(b+d)+(a+c)(c+d)}\n\n- - 72 -\n- 나. ADP test\n1) 민감도: 대조기기 비정상 결과 검체 중 시험기기에서 비정상 결과를 보인\n\n검체의 수를 각각 백분율(%)로 나타내고, 95% 신뢰구간을 제시한다.\n\n - 다. SIPA　test : 검사원리가 비슷한 기존검사법은 없으나, 혈소판 기능의 정상/\n준에 준하여 평가한다.\n\n 1) 민감도: 대조기기 비정상 결과 검체 중 시험기기에서 비정상 결과를 보인\n\n2) 특이도: 대조기기 정상 결과 검체 중 시험기기에서 정상 결과를 보인 검체의\n\n3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.\n\n - - 73 -\n대조기기\n\n합계\n\n비정상\n\n정상\n\n민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)\n\n3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.\n\n - - 74 -\n대조기기\n\n합계\n\n약물반응 양성\n\n약물반응 음성\n\n민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)\n\n3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.\n\n - - 75 -\n대조기기\n\n합계\n\n약물반응 양성\n\n약물반응 음성\n\n- - 76 -\n<!-- PAGE_83 -->\n###### 15.  부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n않기 때문에 해당 의료기기에 의한 감염위험성은 없다. ",
        "original_sentence": "- - 73 -\n대조기기\n\n합계\n\n비정상\n\n정상\n\n민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)\n\n3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_683",
      "text": "- - 74 -\n대조기기\n\n합계\n\n약물반응 양성\n\n약물반응 음성\n\n민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)\n\n3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 682,
        "window_size": 3,
        "char_count": 124,
        "word_count": 26,
        "page_number": 6,
        "window_text": "- 다. SIPA　test : 검사원리가 비슷한 기존검사법은 없으나, 혈소판 기능의 정상/\n준에 준하여 평가한다.\n\n 1) 민감도: 대조기기 비정상 결과 검체 중 시험기기에서 비정상 결과를 보인\n\n2) 특이도: 대조기기 정상 결과 검체 중 시험기기에서 정상 결과를 보인 검체의\n\n3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.\n\n - - 73 -\n대조기기\n\n합계\n\n비정상\n\n정상\n\n민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)\n\n3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.\n\n - - 74 -\n대조기기\n\n합계\n\n약물반응 양성\n\n약물반응 음성\n\n민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)\n\n3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.\n\n - - 75 -\n대조기기\n\n합계\n\n약물반응 양성\n\n약물반응 음성\n\n- - 76 -\n<!-- PAGE_83 -->\n###### 15.  부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n않기 때문에 해당 의료기기에 의한 감염위험성은 없다.  다만, 검체가 감염성 물질을\n\n포함하고 있을 가능성이있는 인체 유래물이기 때문에 검사실 생물학적 안전수칙 및\n\n사용시 주의사항을 참고하여 취급해야 한다.\n\n",
        "original_sentence": "- - 74 -\n대조기기\n\n합계\n\n약물반응 양성\n\n약물반응 음성\n\n민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)\n\n3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_684",
      "text": "- - 75 -\n대조기기\n\n합계\n\n약물반응 양성\n\n약물반응 음성\n\n- - 76 -\n<!-- PAGE_83 -->\n###### 15. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 683,
        "window_size": 3,
        "char_count": 74,
        "word_count": 19,
        "page_number": 83,
        "window_text": "1) 민감도: 대조기기 비정상 결과 검체 중 시험기기에서 비정상 결과를 보인\n\n2) 특이도: 대조기기 정상 결과 검체 중 시험기기에서 정상 결과를 보인 검체의\n\n3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.\n\n - - 73 -\n대조기기\n\n합계\n\n비정상\n\n정상\n\n민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)\n\n3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.\n\n - - 74 -\n대조기기\n\n합계\n\n약물반응 양성\n\n약물반응 음성\n\n민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)\n\n3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.\n\n - - 75 -\n대조기기\n\n합계\n\n약물반응 양성\n\n약물반응 음성\n\n- - 76 -\n<!-- PAGE_83 -->\n###### 15.  부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n않기 때문에 해당 의료기기에 의한 감염위험성은 없다.  다만, 검체가 감염성 물질을\n\n포함하고 있을 가능성이있는 인체 유래물이기 때문에 검사실 생물학적 안전수칙 및\n\n사용시 주의사항을 참고하여 취급해야 한다.\n\n - - 77 -\n인체유래물 기증자의 권리에 대한 문의처\n\n피험자보호\n\n연구\n\n<!-- PAGE_84 -->\n###### 16. ",
        "original_sentence": "- - 75 -\n대조기기\n\n합계\n\n약물반응 양성\n\n약물반응 음성\n\n- - 76 -\n<!-- PAGE_83 -->\n###### 15. "
      }
    },
    {
      "chunk_id": "chunk_685",
      "text": "부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n않기 때문에 해당 의료기기에 의한 감염위험성은 없다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 684,
        "window_size": 3,
        "char_count": 114,
        "word_count": 27,
        "page_number": 6,
        "window_text": "- - 73 -\n대조기기\n\n합계\n\n비정상\n\n정상\n\n민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)\n\n3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.\n\n - - 74 -\n대조기기\n\n합계\n\n약물반응 양성\n\n약물반응 음성\n\n민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)\n\n3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.\n\n - - 75 -\n대조기기\n\n합계\n\n약물반응 양성\n\n약물반응 음성\n\n- - 76 -\n<!-- PAGE_83 -->\n###### 15.  부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n않기 때문에 해당 의료기기에 의한 감염위험성은 없다.  다만, 검체가 감염성 물질을\n\n포함하고 있을 가능성이있는 인체 유래물이기 때문에 검사실 생물학적 안전수칙 및\n\n사용시 주의사항을 참고하여 취급해야 한다.\n\n - - 77 -\n인체유래물 기증자의 권리에 대한 문의처\n\n피험자보호\n\n연구\n\n<!-- PAGE_84 -->\n###### 16.  피험자 동의서 서식\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n* 만일 본 연구에 문의사항이 있으시거나, 위험이나 불편 또는 손상이 발생할 경우, 상기 연구책임자\n\n또는 연구담당자에게 연락하여 주시기 바랍니다.\n\n",
        "original_sentence": "부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n않기 때문에 해당 의료기기에 의한 감염위험성은 없다. "
      }
    },
    {
      "chunk_id": "chunk_686",
      "text": "다만, 검체가 감염성 물질을\n\n포함하고 있을 가능성이있는 인체 유래물이기 때문에 검사실 생물학적 안전수칙 및\n\n사용시 주의사항을 참고하여 취급해야 한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 685,
        "window_size": 3,
        "char_count": 87,
        "word_count": 19,
        "page_number": 104,
        "window_text": "- - 74 -\n대조기기\n\n합계\n\n약물반응 양성\n\n약물반응 음성\n\n민감도 = 100*(a/a+c), 특이도 = 100*(d/b+d)\n\n3) 일치도: 시험기기 및 대조기기의 Kappa 통계량과 95% 신뢰구간을 제시한다.\n\n - - 75 -\n대조기기\n\n합계\n\n약물반응 양성\n\n약물반응 음성\n\n- - 76 -\n<!-- PAGE_83 -->\n###### 15.  부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n않기 때문에 해당 의료기기에 의한 감염위험성은 없다.  다만, 검체가 감염성 물질을\n\n포함하고 있을 가능성이있는 인체 유래물이기 때문에 검사실 생물학적 안전수칙 및\n\n사용시 주의사항을 참고하여 취급해야 한다.\n\n - - 77 -\n인체유래물 기증자의 권리에 대한 문의처\n\n피험자보호\n\n연구\n\n<!-- PAGE_84 -->\n###### 16.  피험자 동의서 서식\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n* 만일 본 연구에 문의사항이 있으시거나, 위험이나 불편 또는 손상이 발생할 경우, 상기 연구책임자\n\n또는 연구담당자에게 연락하여 주시기 바랍니다.\n\n - 1. ",
        "original_sentence": "다만, 검체가 감염성 물질을\n\n포함하고 있을 가능성이있는 인체 유래물이기 때문에 검사실 생물학적 안전수칙 및\n\n사용시 주의사항을 참고하여 취급해야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_687",
      "text": "- - 77 -\n인체유래물 기증자의 권리에 대한 문의처\n\n피험자보호\n\n연구\n\n<!-- PAGE_84 -->\n###### 16. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 686,
        "window_size": 3,
        "char_count": 71,
        "word_count": 16,
        "page_number": 84,
        "window_text": "- - 75 -\n대조기기\n\n합계\n\n약물반응 양성\n\n약물반응 음성\n\n- - 76 -\n<!-- PAGE_83 -->\n###### 15.  부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n않기 때문에 해당 의료기기에 의한 감염위험성은 없다.  다만, 검체가 감염성 물질을\n\n포함하고 있을 가능성이있는 인체 유래물이기 때문에 검사실 생물학적 안전수칙 및\n\n사용시 주의사항을 참고하여 취급해야 한다.\n\n - - 77 -\n인체유래물 기증자의 권리에 대한 문의처\n\n피험자보호\n\n연구\n\n<!-- PAGE_84 -->\n###### 16.  피험자 동의서 서식\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n* 만일 본 연구에 문의사항이 있으시거나, 위험이나 불편 또는 손상이 발생할 경우, 상기 연구책임자\n\n또는 연구담당자에게 연락하여 주시기 바랍니다.\n\n - 1.  참여 권유\n- - 본 연구책임자는 귀하로부터 연구 참여에 대한 동의를 받고 이를 문서화 할 때\n관련 규정을 준수하며 헬싱키선언에 근거한 윤리적 원칙을 바탕으로 합법적인 절\n\n차를 따를 것입니다. ",
        "original_sentence": "- - 77 -\n인체유래물 기증자의 권리에 대한 문의처\n\n피험자보호\n\n연구\n\n<!-- PAGE_84 -->\n###### 16. "
      }
    },
    {
      "chunk_id": "chunk_688",
      "text": "피험자 동의서 서식\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n* 만일 본 연구에 문의사항이 있으시거나, 위험이나 불편 또는 손상이 발생할 경우, 상기 연구책임자\n\n또는 연구담당자에게 연락하여 주시기 바랍니다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 687,
        "window_size": 3,
        "char_count": 148,
        "word_count": 36,
        "page_number": 6,
        "window_text": "부작용을 포함한 안전성의 평가기준·평가방법 및 보고방법\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n않기 때문에 해당 의료기기에 의한 감염위험성은 없다.  다만, 검체가 감염성 물질을\n\n포함하고 있을 가능성이있는 인체 유래물이기 때문에 검사실 생물학적 안전수칙 및\n\n사용시 주의사항을 참고하여 취급해야 한다.\n\n - - 77 -\n인체유래물 기증자의 권리에 대한 문의처\n\n피험자보호\n\n연구\n\n<!-- PAGE_84 -->\n###### 16.  피험자 동의서 서식\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n* 만일 본 연구에 문의사항이 있으시거나, 위험이나 불편 또는 손상이 발생할 경우, 상기 연구책임자\n\n또는 연구담당자에게 연락하여 주시기 바랍니다.\n\n - 1.  참여 권유\n- - 본 연구책임자는 귀하로부터 연구 참여에 대한 동의를 받고 이를 문서화 할 때\n관련 규정을 준수하며 헬싱키선언에 근거한 윤리적 원칙을 바탕으로 합법적인 절\n\n차를 따를 것입니다.  귀하는 본 연구에 참여할 것인지 여부를 결정하기 전에, 이\n\n동의서를 신중하게 읽어보셔야 합니다. ",
        "original_sentence": "피험자 동의서 서식\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n* 만일 본 연구에 문의사항이 있으시거나, 위험이나 불편 또는 손상이 발생할 경우, 상기 연구책임자\n\n또는 연구담당자에게 연락하여 주시기 바랍니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_689",
      "text": "- 1. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 688,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 6,
        "window_text": "다만, 검체가 감염성 물질을\n\n포함하고 있을 가능성이있는 인체 유래물이기 때문에 검사실 생물학적 안전수칙 및\n\n사용시 주의사항을 참고하여 취급해야 한다.\n\n - - 77 -\n인체유래물 기증자의 권리에 대한 문의처\n\n피험자보호\n\n연구\n\n<!-- PAGE_84 -->\n###### 16.  피험자 동의서 서식\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n* 만일 본 연구에 문의사항이 있으시거나, 위험이나 불편 또는 손상이 발생할 경우, 상기 연구책임자\n\n또는 연구담당자에게 연락하여 주시기 바랍니다.\n\n - 1.  참여 권유\n- - 본 연구책임자는 귀하로부터 연구 참여에 대한 동의를 받고 이를 문서화 할 때\n관련 규정을 준수하며 헬싱키선언에 근거한 윤리적 원칙을 바탕으로 합법적인 절\n\n차를 따를 것입니다.  귀하는 본 연구에 참여할 것인지 여부를 결정하기 전에, 이\n\n동의서를 신중하게 읽어보셔야 합니다.  이 연구는 왜 수행되며, 무엇을 조사하고\n\n- - 78 -\n귀하의 정보와 검체는 어떻게 사용될지, 본 연구에 따른 위험이나 불편은 무엇인지\n\n귀하가 이해하는 것이 중요합니다. ",
        "original_sentence": "- 1. "
      }
    },
    {
      "chunk_id": "chunk_690",
      "text": "참여 권유\n- - 본 연구책임자는 귀하로부터 연구 참여에 대한 동의를 받고 이를 문서화 할 때\n관련 규정을 준수하며 헬싱키선언에 근거한 윤리적 원칙을 바탕으로 합법적인 절\n\n차를 따를 것입니다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 689,
        "window_size": 3,
        "char_count": 109,
        "word_count": 29,
        "page_number": 33,
        "window_text": "- - 77 -\n인체유래물 기증자의 권리에 대한 문의처\n\n피험자보호\n\n연구\n\n<!-- PAGE_84 -->\n###### 16.  피험자 동의서 서식\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n* 만일 본 연구에 문의사항이 있으시거나, 위험이나 불편 또는 손상이 발생할 경우, 상기 연구책임자\n\n또는 연구담당자에게 연락하여 주시기 바랍니다.\n\n - 1.  참여 권유\n- - 본 연구책임자는 귀하로부터 연구 참여에 대한 동의를 받고 이를 문서화 할 때\n관련 규정을 준수하며 헬싱키선언에 근거한 윤리적 원칙을 바탕으로 합법적인 절\n\n차를 따를 것입니다.  귀하는 본 연구에 참여할 것인지 여부를 결정하기 전에, 이\n\n동의서를 신중하게 읽어보셔야 합니다.  이 연구는 왜 수행되며, 무엇을 조사하고\n\n- - 78 -\n귀하의 정보와 검체는 어떻게 사용될지, 본 연구에 따른 위험이나 불편은 무엇인지\n\n귀하가 이해하는 것이 중요합니다.  충분한 시간을 가지고 결정해 주시기 바라며\n\n궁금한 점이 있으면 언제든지 질문하여 주십시오. ",
        "original_sentence": "참여 권유\n- - 본 연구책임자는 귀하로부터 연구 참여에 대한 동의를 받고 이를 문서화 할 때\n관련 규정을 준수하며 헬싱키선언에 근거한 윤리적 원칙을 바탕으로 합법적인 절\n\n차를 따를 것입니다. "
      }
    },
    {
      "chunk_id": "chunk_691",
      "text": "귀하는 본 연구에 참여할 것인지 여부를 결정하기 전에, 이\n\n동의서를 신중하게 읽어보셔야 합니다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 690,
        "window_size": 3,
        "char_count": 55,
        "word_count": 13,
        "page_number": 3,
        "window_text": "피험자 동의서 서식\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n* 만일 본 연구에 문의사항이 있으시거나, 위험이나 불편 또는 손상이 발생할 경우, 상기 연구책임자\n\n또는 연구담당자에게 연락하여 주시기 바랍니다.\n\n - 1.  참여 권유\n- - 본 연구책임자는 귀하로부터 연구 참여에 대한 동의를 받고 이를 문서화 할 때\n관련 규정을 준수하며 헬싱키선언에 근거한 윤리적 원칙을 바탕으로 합법적인 절\n\n차를 따를 것입니다.  귀하는 본 연구에 참여할 것인지 여부를 결정하기 전에, 이\n\n동의서를 신중하게 읽어보셔야 합니다.  이 연구는 왜 수행되며, 무엇을 조사하고\n\n- - 78 -\n귀하의 정보와 검체는 어떻게 사용될지, 본 연구에 따른 위험이나 불편은 무엇인지\n\n귀하가 이해하는 것이 중요합니다.  충분한 시간을 가지고 결정해 주시기 바라며\n\n궁금한 점이 있으면 언제든지 질문하여 주십시오.  귀하께서 궁금해 하는 모든\n\n질문에 대해 답을 얻으셨고, 이 연구 참여를 결정하였다면 본 동의서에 서명과\n\n- - 본 임상시험용 의료기기인 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’는\n- 4. ",
        "original_sentence": "귀하는 본 연구에 참여할 것인지 여부를 결정하기 전에, 이\n\n동의서를 신중하게 읽어보셔야 합니다. "
      }
    },
    {
      "chunk_id": "chunk_692",
      "text": "이 연구는 왜 수행되며, 무엇을 조사하고\n\n- - 78 -\n귀하의 정보와 검체는 어떻게 사용될지, 본 연구에 따른 위험이나 불편은 무엇인지\n\n귀하가 이해하는 것이 중요합니다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 691,
        "window_size": 3,
        "char_count": 98,
        "word_count": 25,
        "page_number": 15,
        "window_text": "- 1.  참여 권유\n- - 본 연구책임자는 귀하로부터 연구 참여에 대한 동의를 받고 이를 문서화 할 때\n관련 규정을 준수하며 헬싱키선언에 근거한 윤리적 원칙을 바탕으로 합법적인 절\n\n차를 따를 것입니다.  귀하는 본 연구에 참여할 것인지 여부를 결정하기 전에, 이\n\n동의서를 신중하게 읽어보셔야 합니다.  이 연구는 왜 수행되며, 무엇을 조사하고\n\n- - 78 -\n귀하의 정보와 검체는 어떻게 사용될지, 본 연구에 따른 위험이나 불편은 무엇인지\n\n귀하가 이해하는 것이 중요합니다.  충분한 시간을 가지고 결정해 주시기 바라며\n\n궁금한 점이 있으면 언제든지 질문하여 주십시오.  귀하께서 궁금해 하는 모든\n\n질문에 대해 답을 얻으셨고, 이 연구 참여를 결정하였다면 본 동의서에 서명과\n\n- - 본 임상시험용 의료기기인 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’는\n- 4.  연구 방법 및 절차\n- - 본 연구에 참여하게 되면, 문진 및 혈액채취를 하게 됩니다. ",
        "original_sentence": "이 연구는 왜 수행되며, 무엇을 조사하고\n\n- - 78 -\n귀하의 정보와 검체는 어떻게 사용될지, 본 연구에 따른 위험이나 불편은 무엇인지\n\n귀하가 이해하는 것이 중요합니다. "
      }
    },
    {
      "chunk_id": "chunk_693",
      "text": "충분한 시간을 가지고 결정해 주시기 바라며\n\n궁금한 점이 있으면 언제든지 질문하여 주십시오. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 692,
        "window_size": 3,
        "char_count": 52,
        "word_count": 12,
        "page_number": 104,
        "window_text": "참여 권유\n- - 본 연구책임자는 귀하로부터 연구 참여에 대한 동의를 받고 이를 문서화 할 때\n관련 규정을 준수하며 헬싱키선언에 근거한 윤리적 원칙을 바탕으로 합법적인 절\n\n차를 따를 것입니다.  귀하는 본 연구에 참여할 것인지 여부를 결정하기 전에, 이\n\n동의서를 신중하게 읽어보셔야 합니다.  이 연구는 왜 수행되며, 무엇을 조사하고\n\n- - 78 -\n귀하의 정보와 검체는 어떻게 사용될지, 본 연구에 따른 위험이나 불편은 무엇인지\n\n귀하가 이해하는 것이 중요합니다.  충분한 시간을 가지고 결정해 주시기 바라며\n\n궁금한 점이 있으면 언제든지 질문하여 주십시오.  귀하께서 궁금해 하는 모든\n\n질문에 대해 답을 얻으셨고, 이 연구 참여를 결정하였다면 본 동의서에 서명과\n\n- - 본 임상시험용 의료기기인 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’는\n- 4.  연구 방법 및 절차\n- - 본 연구에 참여하게 되면, 문진 및 혈액채취를 하게 됩니다.  문진에는 혈성 질환,\n응고장애, 암, 기타 만성질환 등의 병력 및 아스피린, P2Y12 수용체 저해제 등의\n\n항혈소판제제, 항응고제 복용 유무에 대한 질문이 포함됩니다. ",
        "original_sentence": "충분한 시간을 가지고 결정해 주시기 바라며\n\n궁금한 점이 있으면 언제든지 질문하여 주십시오. "
      }
    },
    {
      "chunk_id": "chunk_694",
      "text": "귀하께서 궁금해 하는 모든\n\n질문에 대해 답을 얻으셨고, 이 연구 참여를 결정하였다면 본 동의서에 서명과\n\n- - 본 임상시험용 의료기기인 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’는\n- 4. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 693,
        "window_size": 3,
        "char_count": 112,
        "word_count": 28,
        "page_number": 84,
        "window_text": "귀하는 본 연구에 참여할 것인지 여부를 결정하기 전에, 이\n\n동의서를 신중하게 읽어보셔야 합니다.  이 연구는 왜 수행되며, 무엇을 조사하고\n\n- - 78 -\n귀하의 정보와 검체는 어떻게 사용될지, 본 연구에 따른 위험이나 불편은 무엇인지\n\n귀하가 이해하는 것이 중요합니다.  충분한 시간을 가지고 결정해 주시기 바라며\n\n궁금한 점이 있으면 언제든지 질문하여 주십시오.  귀하께서 궁금해 하는 모든\n\n질문에 대해 답을 얻으셨고, 이 연구 참여를 결정하였다면 본 동의서에 서명과\n\n- - 본 임상시험용 의료기기인 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’는\n- 4.  연구 방법 및 절차\n- - 본 연구에 참여하게 되면, 문진 및 혈액채취를 하게 됩니다.  문진에는 혈성 질환,\n응고장애, 암, 기타 만성질환 등의 병력 및 아스피린, P2Y12 수용체 저해제 등의\n\n항혈소판제제, 항응고제 복용 유무에 대한 질문이 포함됩니다.  이 후 약 20 mL의\n\n정맥혈을 채취하여 검사를 시행합니다. ",
        "original_sentence": "귀하께서 궁금해 하는 모든\n\n질문에 대해 답을 얻으셨고, 이 연구 참여를 결정하였다면 본 동의서에 서명과\n\n- - 본 임상시험용 의료기기인 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’는\n- 4. "
      }
    },
    {
      "chunk_id": "chunk_695",
      "text": "연구 방법 및 절차\n- - 본 연구에 참여하게 되면, 문진 및 혈액채취를 하게 됩니다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 694,
        "window_size": 3,
        "char_count": 49,
        "word_count": 15,
        "page_number": 6,
        "window_text": "이 연구는 왜 수행되며, 무엇을 조사하고\n\n- - 78 -\n귀하의 정보와 검체는 어떻게 사용될지, 본 연구에 따른 위험이나 불편은 무엇인지\n\n귀하가 이해하는 것이 중요합니다.  충분한 시간을 가지고 결정해 주시기 바라며\n\n궁금한 점이 있으면 언제든지 질문하여 주십시오.  귀하께서 궁금해 하는 모든\n\n질문에 대해 답을 얻으셨고, 이 연구 참여를 결정하였다면 본 동의서에 서명과\n\n- - 본 임상시험용 의료기기인 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’는\n- 4.  연구 방법 및 절차\n- - 본 연구에 참여하게 되면, 문진 및 혈액채취를 하게 됩니다.  문진에는 혈성 질환,\n응고장애, 암, 기타 만성질환 등의 병력 및 아스피린, P2Y12 수용체 저해제 등의\n\n항혈소판제제, 항응고제 복용 유무에 대한 질문이 포함됩니다.  이 후 약 20 mL의\n\n정맥혈을 채취하여 검사를 시행합니다.  본 연구를 위한 검사비용(혈소판 기능검사\n\n또는 혈소판 약물반응 검사)은 연구비에서 지불되며, 단 귀하가 본 연구목적으로\n\n- - 79 -\n귀하의 검체를 사용하는 것을 허락하여야만 검체 채취가 가능합니다.\n\n",
        "original_sentence": "연구 방법 및 절차\n- - 본 연구에 참여하게 되면, 문진 및 혈액채취를 하게 됩니다. "
      }
    },
    {
      "chunk_id": "chunk_696",
      "text": "문진에는 혈성 질환,\n응고장애, 암, 기타 만성질환 등의 병력 및 아스피린, P2Y12 수용체 저해제 등의\n\n항혈소판제제, 항응고제 복용 유무에 대한 질문이 포함됩니다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 695,
        "window_size": 3,
        "char_count": 95,
        "word_count": 22,
        "page_number": 6,
        "window_text": "충분한 시간을 가지고 결정해 주시기 바라며\n\n궁금한 점이 있으면 언제든지 질문하여 주십시오.  귀하께서 궁금해 하는 모든\n\n질문에 대해 답을 얻으셨고, 이 연구 참여를 결정하였다면 본 동의서에 서명과\n\n- - 본 임상시험용 의료기기인 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’는\n- 4.  연구 방법 및 절차\n- - 본 연구에 참여하게 되면, 문진 및 혈액채취를 하게 됩니다.  문진에는 혈성 질환,\n응고장애, 암, 기타 만성질환 등의 병력 및 아스피린, P2Y12 수용체 저해제 등의\n\n항혈소판제제, 항응고제 복용 유무에 대한 질문이 포함됩니다.  이 후 약 20 mL의\n\n정맥혈을 채취하여 검사를 시행합니다.  본 연구를 위한 검사비용(혈소판 기능검사\n\n또는 혈소판 약물반응 검사)은 연구비에서 지불되며, 단 귀하가 본 연구목적으로\n\n- - 79 -\n귀하의 검체를 사용하는 것을 허락하여야만 검체 채취가 가능합니다.\n\n - 5. ",
        "original_sentence": "문진에는 혈성 질환,\n응고장애, 암, 기타 만성질환 등의 병력 및 아스피린, P2Y12 수용체 저해제 등의\n\n항혈소판제제, 항응고제 복용 유무에 대한 질문이 포함됩니다. "
      }
    },
    {
      "chunk_id": "chunk_697",
      "text": "이 후 약 20 mL의\n\n정맥혈을 채취하여 검사를 시행합니다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 696,
        "window_size": 3,
        "char_count": 35,
        "word_count": 9,
        "page_number": 6,
        "window_text": "귀하께서 궁금해 하는 모든\n\n질문에 대해 답을 얻으셨고, 이 연구 참여를 결정하였다면 본 동의서에 서명과\n\n- - 본 임상시험용 의료기기인 ‘출혈 시간 및 항혈소판제제 저항성 복합검사기기’는\n- 4.  연구 방법 및 절차\n- - 본 연구에 참여하게 되면, 문진 및 혈액채취를 하게 됩니다.  문진에는 혈성 질환,\n응고장애, 암, 기타 만성질환 등의 병력 및 아스피린, P2Y12 수용체 저해제 등의\n\n항혈소판제제, 항응고제 복용 유무에 대한 질문이 포함됩니다.  이 후 약 20 mL의\n\n정맥혈을 채취하여 검사를 시행합니다.  본 연구를 위한 검사비용(혈소판 기능검사\n\n또는 혈소판 약물반응 검사)은 연구비에서 지불되며, 단 귀하가 본 연구목적으로\n\n- - 79 -\n귀하의 검체를 사용하는 것을 허락하여야만 검체 채취가 가능합니다.\n\n - 5.  예상되는 위험 및 불편\n및 어지러움이 발생할 수도 있으며 혈액을 채취한 자리가 부어 오르는 등의 약간의\n\n부작용이 나타날 수 있습니다. ",
        "original_sentence": "이 후 약 20 mL의\n\n정맥혈을 채취하여 검사를 시행합니다. "
      }
    },
    {
      "chunk_id": "chunk_698",
      "text": "본 연구를 위한 검사비용(혈소판 기능검사\n\n또는 혈소판 약물반응 검사)은 연구비에서 지불되며, 단 귀하가 본 연구목적으로\n\n- - 79 -\n귀하의 검체를 사용하는 것을 허락하여야만 검체 채취가 가능합니다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 697,
        "window_size": 3,
        "char_count": 116,
        "word_count": 27,
        "page_number": 24,
        "window_text": "연구 방법 및 절차\n- - 본 연구에 참여하게 되면, 문진 및 혈액채취를 하게 됩니다.  문진에는 혈성 질환,\n응고장애, 암, 기타 만성질환 등의 병력 및 아스피린, P2Y12 수용체 저해제 등의\n\n항혈소판제제, 항응고제 복용 유무에 대한 질문이 포함됩니다.  이 후 약 20 mL의\n\n정맥혈을 채취하여 검사를 시행합니다.  본 연구를 위한 검사비용(혈소판 기능검사\n\n또는 혈소판 약물반응 검사)은 연구비에서 지불되며, 단 귀하가 본 연구목적으로\n\n- - 79 -\n귀하의 검체를 사용하는 것을 허락하여야만 검체 채취가 가능합니다.\n\n - 5.  예상되는 위험 및 불편\n및 어지러움이 발생할 수도 있으며 혈액을 채취한 자리가 부어 오르는 등의 약간의\n\n부작용이 나타날 수 있습니다.  그러나 이는 보통 일시적인 증상으로 금방 해소될\n\n귀하의 혈소판 기능 또는 혈소판 약물 저항성을 확인할 수 있을 것으로 기대합니다.\n\n",
        "original_sentence": "본 연구를 위한 검사비용(혈소판 기능검사\n\n또는 혈소판 약물반응 검사)은 연구비에서 지불되며, 단 귀하가 본 연구목적으로\n\n- - 79 -\n귀하의 검체를 사용하는 것을 허락하여야만 검체 채취가 가능합니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_699",
      "text": "- 5. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 698,
        "window_size": 3,
        "char_count": 5,
        "word_count": 2,
        "page_number": 6,
        "window_text": "문진에는 혈성 질환,\n응고장애, 암, 기타 만성질환 등의 병력 및 아스피린, P2Y12 수용체 저해제 등의\n\n항혈소판제제, 항응고제 복용 유무에 대한 질문이 포함됩니다.  이 후 약 20 mL의\n\n정맥혈을 채취하여 검사를 시행합니다.  본 연구를 위한 검사비용(혈소판 기능검사\n\n또는 혈소판 약물반응 검사)은 연구비에서 지불되며, 단 귀하가 본 연구목적으로\n\n- - 79 -\n귀하의 검체를 사용하는 것을 허락하여야만 검체 채취가 가능합니다.\n\n - 5.  예상되는 위험 및 불편\n및 어지러움이 발생할 수도 있으며 혈액을 채취한 자리가 부어 오르는 등의 약간의\n\n부작용이 나타날 수 있습니다.  그러나 이는 보통 일시적인 증상으로 금방 해소될\n\n귀하의 혈소판 기능 또는 혈소판 약물 저항성을 확인할 수 있을 것으로 기대합니다.\n\n 개발에 기여함으로써 혈소판 기능 부전 및 혈소판 약물 저항성을 보이는 환자의\n\n다른 연구 목적에 대해 제공을 허용할 것인지, 만약 제공을 허용한다면 개인정보도\n\n함께 제공하도록 허용할 것인지 여부 등에 대해 인체유래물연구동의서에서 선택\n\n- - 연구가 종료된 후 남은 검체는 귀하가 지정한 보존기간에 따라 폐기될 것입니다.\n",
        "original_sentence": "- 5. "
      }
    },
    {
      "chunk_id": "chunk_700",
      "text": "예상되는 위험 및 불편\n및 어지러움이 발생할 수도 있으며 혈액을 채취한 자리가 부어 오르는 등의 약간의\n\n부작용이 나타날 수 있습니다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 699,
        "window_size": 3,
        "char_count": 76,
        "word_count": 20,
        "page_number": 104,
        "window_text": "이 후 약 20 mL의\n\n정맥혈을 채취하여 검사를 시행합니다.  본 연구를 위한 검사비용(혈소판 기능검사\n\n또는 혈소판 약물반응 검사)은 연구비에서 지불되며, 단 귀하가 본 연구목적으로\n\n- - 79 -\n귀하의 검체를 사용하는 것을 허락하여야만 검체 채취가 가능합니다.\n\n - 5.  예상되는 위험 및 불편\n및 어지러움이 발생할 수도 있으며 혈액을 채취한 자리가 부어 오르는 등의 약간의\n\n부작용이 나타날 수 있습니다.  그러나 이는 보통 일시적인 증상으로 금방 해소될\n\n귀하의 혈소판 기능 또는 혈소판 약물 저항성을 확인할 수 있을 것으로 기대합니다.\n\n 개발에 기여함으로써 혈소판 기능 부전 및 혈소판 약물 저항성을 보이는 환자의\n\n다른 연구 목적에 대해 제공을 허용할 것인지, 만약 제공을 허용한다면 개인정보도\n\n함께 제공하도록 허용할 것인지 여부 등에 대해 인체유래물연구동의서에서 선택\n\n- - 연구가 종료된 후 남은 검체는 귀하가 지정한 보존기간에 따라 폐기될 것입니다.\n 만약 검체를 제공한 후 마음이 변해서 동의를 철회할 경우, 검체가 익명화(귀하와\n\n귀하의 검체 간의 연결이 존재하지 않음)되지 않았다면 귀하의 검체는 귀하의\n\n요청에 따라 즉시 폐기될 것이며 더 이상 정보수집이 되지 않을 것입니다. ",
        "original_sentence": "예상되는 위험 및 불편\n및 어지러움이 발생할 수도 있으며 혈액을 채취한 자리가 부어 오르는 등의 약간의\n\n부작용이 나타날 수 있습니다. "
      }
    },
    {
      "chunk_id": "chunk_701",
      "text": "그러나 이는 보통 일시적인 증상으로 금방 해소될\n\n귀하의 혈소판 기능 또는 혈소판 약물 저항성을 확인할 수 있을 것으로 기대합니다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 700,
        "window_size": 3,
        "char_count": 75,
        "word_count": 19,
        "page_number": 24,
        "window_text": "본 연구를 위한 검사비용(혈소판 기능검사\n\n또는 혈소판 약물반응 검사)은 연구비에서 지불되며, 단 귀하가 본 연구목적으로\n\n- - 79 -\n귀하의 검체를 사용하는 것을 허락하여야만 검체 채취가 가능합니다.\n\n - 5.  예상되는 위험 및 불편\n및 어지러움이 발생할 수도 있으며 혈액을 채취한 자리가 부어 오르는 등의 약간의\n\n부작용이 나타날 수 있습니다.  그러나 이는 보통 일시적인 증상으로 금방 해소될\n\n귀하의 혈소판 기능 또는 혈소판 약물 저항성을 확인할 수 있을 것으로 기대합니다.\n\n 개발에 기여함으로써 혈소판 기능 부전 및 혈소판 약물 저항성을 보이는 환자의\n\n다른 연구 목적에 대해 제공을 허용할 것인지, 만약 제공을 허용한다면 개인정보도\n\n함께 제공하도록 허용할 것인지 여부 등에 대해 인체유래물연구동의서에서 선택\n\n- - 연구가 종료된 후 남은 검체는 귀하가 지정한 보존기간에 따라 폐기될 것입니다.\n 만약 검체를 제공한 후 마음이 변해서 동의를 철회할 경우, 검체가 익명화(귀하와\n\n귀하의 검체 간의 연결이 존재하지 않음)되지 않았다면 귀하의 검체는 귀하의\n\n요청에 따라 즉시 폐기될 것이며 더 이상 정보수집이 되지 않을 것입니다.  만약\n\n익명화된 경우라도 귀하가 지정한 보존기간에 따라 폐기될 것입니다.\n\n",
        "original_sentence": "그러나 이는 보통 일시적인 증상으로 금방 해소될\n\n귀하의 혈소판 기능 또는 혈소판 약물 저항성을 확인할 수 있을 것으로 기대합니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_702",
      "text": "개발에 기여함으로써 혈소판 기능 부전 및 혈소판 약물 저항성을 보이는 환자의\n\n다른 연구 목적에 대해 제공을 허용할 것인지, 만약 제공을 허용한다면 개인정보도\n\n함께 제공하도록 허용할 것인지 여부 등에 대해 인체유래물연구동의서에서 선택\n\n- - 연구가 종료된 후 남은 검체는 귀하가 지정한 보존기간에 따라 폐기될 것입니다.\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 701,
        "window_size": 3,
        "char_count": 181,
        "word_count": 44,
        "page_number": 7,
        "window_text": "- 5.  예상되는 위험 및 불편\n및 어지러움이 발생할 수도 있으며 혈액을 채취한 자리가 부어 오르는 등의 약간의\n\n부작용이 나타날 수 있습니다.  그러나 이는 보통 일시적인 증상으로 금방 해소될\n\n귀하의 혈소판 기능 또는 혈소판 약물 저항성을 확인할 수 있을 것으로 기대합니다.\n\n 개발에 기여함으로써 혈소판 기능 부전 및 혈소판 약물 저항성을 보이는 환자의\n\n다른 연구 목적에 대해 제공을 허용할 것인지, 만약 제공을 허용한다면 개인정보도\n\n함께 제공하도록 허용할 것인지 여부 등에 대해 인체유래물연구동의서에서 선택\n\n- - 연구가 종료된 후 남은 검체는 귀하가 지정한 보존기간에 따라 폐기될 것입니다.\n 만약 검체를 제공한 후 마음이 변해서 동의를 철회할 경우, 검체가 익명화(귀하와\n\n귀하의 검체 간의 연결이 존재하지 않음)되지 않았다면 귀하의 검체는 귀하의\n\n요청에 따라 즉시 폐기될 것이며 더 이상 정보수집이 되지 않을 것입니다.  만약\n\n익명화된 경우라도 귀하가 지정한 보존기간에 따라 폐기될 것입니다.\n\n - - 80 -\n- 8. ",
        "original_sentence": "개발에 기여함으로써 혈소판 기능 부전 및 혈소판 약물 저항성을 보이는 환자의\n\n다른 연구 목적에 대해 제공을 허용할 것인지, 만약 제공을 허용한다면 개인정보도\n\n함께 제공하도록 허용할 것인지 여부 등에 대해 인체유래물연구동의서에서 선택\n\n- - 연구가 종료된 후 남은 검체는 귀하가 지정한 보존기간에 따라 폐기될 것입니다.\n"
      }
    },
    {
      "chunk_id": "chunk_703",
      "text": "만약 검체를 제공한 후 마음이 변해서 동의를 철회할 경우, 검체가 익명화(귀하와\n\n귀하의 검체 간의 연결이 존재하지 않음)되지 않았다면 귀하의 검체는 귀하의\n\n요청에 따라 즉시 폐기될 것이며 더 이상 정보수집이 되지 않을 것입니다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 702,
        "window_size": 3,
        "char_count": 130,
        "word_count": 32,
        "page_number": 86,
        "window_text": "예상되는 위험 및 불편\n및 어지러움이 발생할 수도 있으며 혈액을 채취한 자리가 부어 오르는 등의 약간의\n\n부작용이 나타날 수 있습니다.  그러나 이는 보통 일시적인 증상으로 금방 해소될\n\n귀하의 혈소판 기능 또는 혈소판 약물 저항성을 확인할 수 있을 것으로 기대합니다.\n\n 개발에 기여함으로써 혈소판 기능 부전 및 혈소판 약물 저항성을 보이는 환자의\n\n다른 연구 목적에 대해 제공을 허용할 것인지, 만약 제공을 허용한다면 개인정보도\n\n함께 제공하도록 허용할 것인지 여부 등에 대해 인체유래물연구동의서에서 선택\n\n- - 연구가 종료된 후 남은 검체는 귀하가 지정한 보존기간에 따라 폐기될 것입니다.\n 만약 검체를 제공한 후 마음이 변해서 동의를 철회할 경우, 검체가 익명화(귀하와\n\n귀하의 검체 간의 연결이 존재하지 않음)되지 않았다면 귀하의 검체는 귀하의\n\n요청에 따라 즉시 폐기될 것이며 더 이상 정보수집이 되지 않을 것입니다.  만약\n\n익명화된 경우라도 귀하가 지정한 보존기간에 따라 폐기될 것입니다.\n\n - - 80 -\n- 8.  자유의사에 의한 연구 참여 동의 및 철회\n- - 본 연구에 참여할지 여부는 전적으로 귀하의 선택에 의한 것이며 참여하지 않을\n경우에도 전혀 불이익은 없습니다. ",
        "original_sentence": "만약 검체를 제공한 후 마음이 변해서 동의를 철회할 경우, 검체가 익명화(귀하와\n\n귀하의 검체 간의 연결이 존재하지 않음)되지 않았다면 귀하의 검체는 귀하의\n\n요청에 따라 즉시 폐기될 것이며 더 이상 정보수집이 되지 않을 것입니다. "
      }
    },
    {
      "chunk_id": "chunk_704",
      "text": "만약\n\n익명화된 경우라도 귀하가 지정한 보존기간에 따라 폐기될 것입니다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 703,
        "window_size": 3,
        "char_count": 42,
        "word_count": 9,
        "page_number": 86,
        "window_text": "그러나 이는 보통 일시적인 증상으로 금방 해소될\n\n귀하의 혈소판 기능 또는 혈소판 약물 저항성을 확인할 수 있을 것으로 기대합니다.\n\n 개발에 기여함으로써 혈소판 기능 부전 및 혈소판 약물 저항성을 보이는 환자의\n\n다른 연구 목적에 대해 제공을 허용할 것인지, 만약 제공을 허용한다면 개인정보도\n\n함께 제공하도록 허용할 것인지 여부 등에 대해 인체유래물연구동의서에서 선택\n\n- - 연구가 종료된 후 남은 검체는 귀하가 지정한 보존기간에 따라 폐기될 것입니다.\n 만약 검체를 제공한 후 마음이 변해서 동의를 철회할 경우, 검체가 익명화(귀하와\n\n귀하의 검체 간의 연결이 존재하지 않음)되지 않았다면 귀하의 검체는 귀하의\n\n요청에 따라 즉시 폐기될 것이며 더 이상 정보수집이 되지 않을 것입니다.  만약\n\n익명화된 경우라도 귀하가 지정한 보존기간에 따라 폐기될 것입니다.\n\n - - 80 -\n- 8.  자유의사에 의한 연구 참여 동의 및 철회\n- - 본 연구에 참여할지 여부는 전적으로 귀하의 선택에 의한 것이며 참여하지 않을\n경우에도 전혀 불이익은 없습니다.  또한 참여에 동의한 이후에도 언제라도 아무런\n\n불이익 없이 연구 참여를 중단할 수 있습니다. ",
        "original_sentence": "만약\n\n익명화된 경우라도 귀하가 지정한 보존기간에 따라 폐기될 것입니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_705",
      "text": "- - 80 -\n- 8. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 704,
        "window_size": 3,
        "char_count": 14,
        "word_count": 6,
        "page_number": 15,
        "window_text": "개발에 기여함으로써 혈소판 기능 부전 및 혈소판 약물 저항성을 보이는 환자의\n\n다른 연구 목적에 대해 제공을 허용할 것인지, 만약 제공을 허용한다면 개인정보도\n\n함께 제공하도록 허용할 것인지 여부 등에 대해 인체유래물연구동의서에서 선택\n\n- - 연구가 종료된 후 남은 검체는 귀하가 지정한 보존기간에 따라 폐기될 것입니다.\n 만약 검체를 제공한 후 마음이 변해서 동의를 철회할 경우, 검체가 익명화(귀하와\n\n귀하의 검체 간의 연결이 존재하지 않음)되지 않았다면 귀하의 검체는 귀하의\n\n요청에 따라 즉시 폐기될 것이며 더 이상 정보수집이 되지 않을 것입니다.  만약\n\n익명화된 경우라도 귀하가 지정한 보존기간에 따라 폐기될 것입니다.\n\n - - 80 -\n- 8.  자유의사에 의한 연구 참여 동의 및 철회\n- - 본 연구에 참여할지 여부는 전적으로 귀하의 선택에 의한 것이며 참여하지 않을\n경우에도 전혀 불이익은 없습니다.  또한 참여에 동의한 이후에도 언제라도 아무런\n\n불이익 없이 연구 참여를 중단할 수 있습니다.  동의 철회를 원할 경우 귀하의\n\n- - 만약 귀하가 본 연구에 참여하신다면 본 연구에서는 귀하의 개인정보(성명과 같은\n자료에 접근할 수 있습니다. ",
        "original_sentence": "- - 80 -\n- 8. "
      }
    },
    {
      "chunk_id": "chunk_706",
      "text": "자유의사에 의한 연구 참여 동의 및 철회\n- - 본 연구에 참여할지 여부는 전적으로 귀하의 선택에 의한 것이며 참여하지 않을\n경우에도 전혀 불이익은 없습니다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 705,
        "window_size": 3,
        "char_count": 89,
        "word_count": 24,
        "page_number": 3,
        "window_text": "만약 검체를 제공한 후 마음이 변해서 동의를 철회할 경우, 검체가 익명화(귀하와\n\n귀하의 검체 간의 연결이 존재하지 않음)되지 않았다면 귀하의 검체는 귀하의\n\n요청에 따라 즉시 폐기될 것이며 더 이상 정보수집이 되지 않을 것입니다.  만약\n\n익명화된 경우라도 귀하가 지정한 보존기간에 따라 폐기될 것입니다.\n\n - - 80 -\n- 8.  자유의사에 의한 연구 참여 동의 및 철회\n- - 본 연구에 참여할지 여부는 전적으로 귀하의 선택에 의한 것이며 참여하지 않을\n경우에도 전혀 불이익은 없습니다.  또한 참여에 동의한 이후에도 언제라도 아무런\n\n불이익 없이 연구 참여를 중단할 수 있습니다.  동의 철회를 원할 경우 귀하의\n\n- - 만약 귀하가 본 연구에 참여하신다면 본 연구에서는 귀하의 개인정보(성명과 같은\n자료에 접근할 수 있습니다.  수집된 개인정보 중 개인식별정보는 연구에 직접\n\n이용되거나 필요한 정보가 아니며 연구로 인해 획득되는 검체 및 임상 자료와\n\n귀하를 연결하기 위한 목적으로만 사용됩니다. ",
        "original_sentence": "자유의사에 의한 연구 참여 동의 및 철회\n- - 본 연구에 참여할지 여부는 전적으로 귀하의 선택에 의한 것이며 참여하지 않을\n경우에도 전혀 불이익은 없습니다. "
      }
    },
    {
      "chunk_id": "chunk_707",
      "text": "또한 참여에 동의한 이후에도 언제라도 아무런\n\n불이익 없이 연구 참여를 중단할 수 있습니다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 706,
        "window_size": 3,
        "char_count": 52,
        "word_count": 13,
        "page_number": 16,
        "window_text": "만약\n\n익명화된 경우라도 귀하가 지정한 보존기간에 따라 폐기될 것입니다.\n\n - - 80 -\n- 8.  자유의사에 의한 연구 참여 동의 및 철회\n- - 본 연구에 참여할지 여부는 전적으로 귀하의 선택에 의한 것이며 참여하지 않을\n경우에도 전혀 불이익은 없습니다.  또한 참여에 동의한 이후에도 언제라도 아무런\n\n불이익 없이 연구 참여를 중단할 수 있습니다.  동의 철회를 원할 경우 귀하의\n\n- - 만약 귀하가 본 연구에 참여하신다면 본 연구에서는 귀하의 개인정보(성명과 같은\n자료에 접근할 수 있습니다.  수집된 개인정보 중 개인식별정보는 연구에 직접\n\n이용되거나 필요한 정보가 아니며 연구로 인해 획득되는 검체 및 임상 자료와\n\n귀하를 연결하기 위한 목적으로만 사용됩니다.  귀하의 개인정보는 연구 목적을\n\n- 10. ",
        "original_sentence": "또한 참여에 동의한 이후에도 언제라도 아무런\n\n불이익 없이 연구 참여를 중단할 수 있습니다. "
      }
    },
    {
      "chunk_id": "chunk_708",
      "text": "동의 철회를 원할 경우 귀하의\n\n- - 만약 귀하가 본 연구에 참여하신다면 본 연구에서는 귀하의 개인정보(성명과 같은\n자료에 접근할 수 있습니다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 707,
        "window_size": 3,
        "char_count": 82,
        "word_count": 21,
        "page_number": 33,
        "window_text": "- - 80 -\n- 8.  자유의사에 의한 연구 참여 동의 및 철회\n- - 본 연구에 참여할지 여부는 전적으로 귀하의 선택에 의한 것이며 참여하지 않을\n경우에도 전혀 불이익은 없습니다.  또한 참여에 동의한 이후에도 언제라도 아무런\n\n불이익 없이 연구 참여를 중단할 수 있습니다.  동의 철회를 원할 경우 귀하의\n\n- - 만약 귀하가 본 연구에 참여하신다면 본 연구에서는 귀하의 개인정보(성명과 같은\n자료에 접근할 수 있습니다.  수집된 개인정보 중 개인식별정보는 연구에 직접\n\n이용되거나 필요한 정보가 아니며 연구로 인해 획득되는 검체 및 임상 자료와\n\n귀하를 연결하기 위한 목적으로만 사용됩니다.  귀하의 개인정보는 연구 목적을\n\n- 10.  연구대상자 동의\nü 본인은 본 동의서의 내용에 대해 충분히 설명을 들었고 그 내용을 잘 이해\n\nü 본인은 본인의 정보와 검체가 질병 연구목적을 위하여 이용되는 것에 동의합니다.\n\n",
        "original_sentence": "동의 철회를 원할 경우 귀하의\n\n- - 만약 귀하가 본 연구에 참여하신다면 본 연구에서는 귀하의 개인정보(성명과 같은\n자료에 접근할 수 있습니다. "
      }
    },
    {
      "chunk_id": "chunk_709",
      "text": "수집된 개인정보 중 개인식별정보는 연구에 직접\n\n이용되거나 필요한 정보가 아니며 연구로 인해 획득되는 검체 및 임상 자료와\n\n귀하를 연결하기 위한 목적으로만 사용됩니다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 708,
        "window_size": 3,
        "char_count": 95,
        "word_count": 22,
        "page_number": 7,
        "window_text": "자유의사에 의한 연구 참여 동의 및 철회\n- - 본 연구에 참여할지 여부는 전적으로 귀하의 선택에 의한 것이며 참여하지 않을\n경우에도 전혀 불이익은 없습니다.  또한 참여에 동의한 이후에도 언제라도 아무런\n\n불이익 없이 연구 참여를 중단할 수 있습니다.  동의 철회를 원할 경우 귀하의\n\n- - 만약 귀하가 본 연구에 참여하신다면 본 연구에서는 귀하의 개인정보(성명과 같은\n자료에 접근할 수 있습니다.  수집된 개인정보 중 개인식별정보는 연구에 직접\n\n이용되거나 필요한 정보가 아니며 연구로 인해 획득되는 검체 및 임상 자료와\n\n귀하를 연결하기 위한 목적으로만 사용됩니다.  귀하의 개인정보는 연구 목적을\n\n- 10.  연구대상자 동의\nü 본인은 본 동의서의 내용에 대해 충분히 설명을 들었고 그 내용을 잘 이해\n\nü 본인은 본인의 정보와 검체가 질병 연구목적을 위하여 이용되는 것에 동의합니다.\n\n ü 본인은 언제든지 자유롭게 본 연구참여를 거절할 수 있으며 또한 이로 인하여\n\n본인의 진료나 법적인 권리에 어떤 불이익도 없다는 것을 설명 받았으며 또한\n\n참여에 동의한 이후에도, 언제라도 이 동의를 철회할 수 있음을 이해합니다.\n\n",
        "original_sentence": "수집된 개인정보 중 개인식별정보는 연구에 직접\n\n이용되거나 필요한 정보가 아니며 연구로 인해 획득되는 검체 및 임상 자료와\n\n귀하를 연결하기 위한 목적으로만 사용됩니다. "
      }
    },
    {
      "chunk_id": "chunk_710",
      "text": "귀하의 개인정보는 연구 목적을\n\n- 10. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 709,
        "window_size": 3,
        "char_count": 24,
        "word_count": 6,
        "page_number": 6,
        "window_text": "또한 참여에 동의한 이후에도 언제라도 아무런\n\n불이익 없이 연구 참여를 중단할 수 있습니다.  동의 철회를 원할 경우 귀하의\n\n- - 만약 귀하가 본 연구에 참여하신다면 본 연구에서는 귀하의 개인정보(성명과 같은\n자료에 접근할 수 있습니다.  수집된 개인정보 중 개인식별정보는 연구에 직접\n\n이용되거나 필요한 정보가 아니며 연구로 인해 획득되는 검체 및 임상 자료와\n\n귀하를 연결하기 위한 목적으로만 사용됩니다.  귀하의 개인정보는 연구 목적을\n\n- 10.  연구대상자 동의\nü 본인은 본 동의서의 내용에 대해 충분히 설명을 들었고 그 내용을 잘 이해\n\nü 본인은 본인의 정보와 검체가 질병 연구목적을 위하여 이용되는 것에 동의합니다.\n\n ü 본인은 언제든지 자유롭게 본 연구참여를 거절할 수 있으며 또한 이로 인하여\n\n본인의 진료나 법적인 권리에 어떤 불이익도 없다는 것을 설명 받았으며 또한\n\n참여에 동의한 이후에도, 언제라도 이 동의를 철회할 수 있음을 이해합니다.\n\n ü 본인은 본 연구를 위한 본인의 개인정보 수집 및 이용에 동의합니다.\n\n",
        "original_sentence": "귀하의 개인정보는 연구 목적을\n\n- 10. "
      }
    },
    {
      "chunk_id": "chunk_711",
      "text": "연구대상자 동의\nü 본인은 본 동의서의 내용에 대해 충분히 설명을 들었고 그 내용을 잘 이해\n\nü 본인은 본인의 정보와 검체가 질병 연구목적을 위하여 이용되는 것에 동의합니다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 710,
        "window_size": 3,
        "char_count": 100,
        "word_count": 26,
        "page_number": 17,
        "window_text": "동의 철회를 원할 경우 귀하의\n\n- - 만약 귀하가 본 연구에 참여하신다면 본 연구에서는 귀하의 개인정보(성명과 같은\n자료에 접근할 수 있습니다.  수집된 개인정보 중 개인식별정보는 연구에 직접\n\n이용되거나 필요한 정보가 아니며 연구로 인해 획득되는 검체 및 임상 자료와\n\n귀하를 연결하기 위한 목적으로만 사용됩니다.  귀하의 개인정보는 연구 목적을\n\n- 10.  연구대상자 동의\nü 본인은 본 동의서의 내용에 대해 충분히 설명을 들었고 그 내용을 잘 이해\n\nü 본인은 본인의 정보와 검체가 질병 연구목적을 위하여 이용되는 것에 동의합니다.\n\n ü 본인은 언제든지 자유롭게 본 연구참여를 거절할 수 있으며 또한 이로 인하여\n\n본인의 진료나 법적인 권리에 어떤 불이익도 없다는 것을 설명 받았으며 또한\n\n참여에 동의한 이후에도, 언제라도 이 동의를 철회할 수 있음을 이해합니다.\n\n ü 본인은 본 연구를 위한 본인의 개인정보 수집 및 이용에 동의합니다.\n\n - - 81 -\nü 본인은 “연구과제 피험자 동의서”에 서명 후, 본 설명문 및 연구과제 피험자\n\n동의서의 사본을 제공받을 것임을 알고 있습니다.\n\n",
        "original_sentence": "연구대상자 동의\nü 본인은 본 동의서의 내용에 대해 충분히 설명을 들었고 그 내용을 잘 이해\n\nü 본인은 본인의 정보와 검체가 질병 연구목적을 위하여 이용되는 것에 동의합니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_712",
      "text": "ü 본인은 언제든지 자유롭게 본 연구참여를 거절할 수 있으며 또한 이로 인하여\n\n본인의 진료나 법적인 권리에 어떤 불이익도 없다는 것을 설명 받았으며 또한\n\n참여에 동의한 이후에도, 언제라도 이 동의를 철회할 수 있음을 이해합니다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 711,
        "window_size": 3,
        "char_count": 131,
        "word_count": 33,
        "page_number": 84,
        "window_text": "수집된 개인정보 중 개인식별정보는 연구에 직접\n\n이용되거나 필요한 정보가 아니며 연구로 인해 획득되는 검체 및 임상 자료와\n\n귀하를 연결하기 위한 목적으로만 사용됩니다.  귀하의 개인정보는 연구 목적을\n\n- 10.  연구대상자 동의\nü 본인은 본 동의서의 내용에 대해 충분히 설명을 들었고 그 내용을 잘 이해\n\nü 본인은 본인의 정보와 검체가 질병 연구목적을 위하여 이용되는 것에 동의합니다.\n\n ü 본인은 언제든지 자유롭게 본 연구참여를 거절할 수 있으며 또한 이로 인하여\n\n본인의 진료나 법적인 권리에 어떤 불이익도 없다는 것을 설명 받았으며 또한\n\n참여에 동의한 이후에도, 언제라도 이 동의를 철회할 수 있음을 이해합니다.\n\n ü 본인은 본 연구를 위한 본인의 개인정보 수집 및 이용에 동의합니다.\n\n - - 81 -\nü 본인은 “연구과제 피험자 동의서”에 서명 후, 본 설명문 및 연구과제 피험자\n\n동의서의 사본을 제공받을 것임을 알고 있습니다.\n\n - - 82 -\n<!-- PAGE_89 -->\n###### 17. ",
        "original_sentence": "ü 본인은 언제든지 자유롭게 본 연구참여를 거절할 수 있으며 또한 이로 인하여\n\n본인의 진료나 법적인 권리에 어떤 불이익도 없다는 것을 설명 받았으며 또한\n\n참여에 동의한 이후에도, 언제라도 이 동의를 철회할 수 있음을 이해합니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_713",
      "text": "ü 본인은 본 연구를 위한 본인의 개인정보 수집 및 이용에 동의합니다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 712,
        "window_size": 3,
        "char_count": 41,
        "word_count": 11,
        "page_number": 87,
        "window_text": "귀하의 개인정보는 연구 목적을\n\n- 10.  연구대상자 동의\nü 본인은 본 동의서의 내용에 대해 충분히 설명을 들었고 그 내용을 잘 이해\n\nü 본인은 본인의 정보와 검체가 질병 연구목적을 위하여 이용되는 것에 동의합니다.\n\n ü 본인은 언제든지 자유롭게 본 연구참여를 거절할 수 있으며 또한 이로 인하여\n\n본인의 진료나 법적인 권리에 어떤 불이익도 없다는 것을 설명 받았으며 또한\n\n참여에 동의한 이후에도, 언제라도 이 동의를 철회할 수 있음을 이해합니다.\n\n ü 본인은 본 연구를 위한 본인의 개인정보 수집 및 이용에 동의합니다.\n\n - - 81 -\nü 본인은 “연구과제 피험자 동의서”에 서명 후, 본 설명문 및 연구과제 피험자\n\n동의서의 사본을 제공받을 것임을 알고 있습니다.\n\n - - 82 -\n<!-- PAGE_89 -->\n###### 17.  피해자 보상에 대한 규약\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- - 83 -\n<!-- PAGE_90 -->\n###### 18. ",
        "original_sentence": "ü 본인은 본 연구를 위한 본인의 개인정보 수집 및 이용에 동의합니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_714",
      "text": "- - 81 -\nü 본인은 “연구과제 피험자 동의서”에 서명 후, 본 설명문 및 연구과제 피험자\n\n동의서의 사본을 제공받을 것임을 알고 있습니다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 713,
        "window_size": 3,
        "char_count": 83,
        "word_count": 22,
        "page_number": 6,
        "window_text": "연구대상자 동의\nü 본인은 본 동의서의 내용에 대해 충분히 설명을 들었고 그 내용을 잘 이해\n\nü 본인은 본인의 정보와 검체가 질병 연구목적을 위하여 이용되는 것에 동의합니다.\n\n ü 본인은 언제든지 자유롭게 본 연구참여를 거절할 수 있으며 또한 이로 인하여\n\n본인의 진료나 법적인 권리에 어떤 불이익도 없다는 것을 설명 받았으며 또한\n\n참여에 동의한 이후에도, 언제라도 이 동의를 철회할 수 있음을 이해합니다.\n\n ü 본인은 본 연구를 위한 본인의 개인정보 수집 및 이용에 동의합니다.\n\n - - 81 -\nü 본인은 “연구과제 피험자 동의서”에 서명 후, 본 설명문 및 연구과제 피험자\n\n동의서의 사본을 제공받을 것임을 알고 있습니다.\n\n - - 82 -\n<!-- PAGE_89 -->\n###### 17.  피해자 보상에 대한 규약\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- - 83 -\n<!-- PAGE_90 -->\n###### 18.  임상시험 후 피험자의 진료에 관한 사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n절차가 임상시험 참여 전과 다름없이 진행되며, 이후의 치료비는 피험자가 지불하여야\n\n- - 84 -\n<!-- PAGE_91 -->\n###### 19. ",
        "original_sentence": "- - 81 -\nü 본인은 “연구과제 피험자 동의서”에 서명 후, 본 설명문 및 연구과제 피험자\n\n동의서의 사본을 제공받을 것임을 알고 있습니다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_715",
      "text": "- - 82 -\n<!-- PAGE_89 -->\n###### 17. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 714,
        "window_size": 3,
        "char_count": 37,
        "word_count": 9,
        "page_number": 89,
        "window_text": "ü 본인은 언제든지 자유롭게 본 연구참여를 거절할 수 있으며 또한 이로 인하여\n\n본인의 진료나 법적인 권리에 어떤 불이익도 없다는 것을 설명 받았으며 또한\n\n참여에 동의한 이후에도, 언제라도 이 동의를 철회할 수 있음을 이해합니다.\n\n ü 본인은 본 연구를 위한 본인의 개인정보 수집 및 이용에 동의합니다.\n\n - - 81 -\nü 본인은 “연구과제 피험자 동의서”에 서명 후, 본 설명문 및 연구과제 피험자\n\n동의서의 사본을 제공받을 것임을 알고 있습니다.\n\n - - 82 -\n<!-- PAGE_89 -->\n###### 17.  피해자 보상에 대한 규약\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- - 83 -\n<!-- PAGE_90 -->\n###### 18.  임상시험 후 피험자의 진료에 관한 사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n절차가 임상시험 참여 전과 다름없이 진행되며, 이후의 치료비는 피험자가 지불하여야\n\n- - 84 -\n<!-- PAGE_91 -->\n###### 19.  피험자의 안전보호에 관한 대책\n\n전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를 취할 수 있도록 하는 등\n\n- (1) 임상시험심사위원회(Institutional Review Board)는 국내 법규/관례에 따라\n구성되어 있어야 한다. ",
        "original_sentence": "- - 82 -\n<!-- PAGE_89 -->\n###### 17. "
      }
    },
    {
      "chunk_id": "chunk_716",
      "text": "피해자 보상에 대한 규약\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- - 83 -\n<!-- PAGE_90 -->\n###### 18. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 715,
        "window_size": 3,
        "char_count": 104,
        "word_count": 27,
        "page_number": 90,
        "window_text": "ü 본인은 본 연구를 위한 본인의 개인정보 수집 및 이용에 동의합니다.\n\n - - 81 -\nü 본인은 “연구과제 피험자 동의서”에 서명 후, 본 설명문 및 연구과제 피험자\n\n동의서의 사본을 제공받을 것임을 알고 있습니다.\n\n - - 82 -\n<!-- PAGE_89 -->\n###### 17.  피해자 보상에 대한 규약\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- - 83 -\n<!-- PAGE_90 -->\n###### 18.  임상시험 후 피험자의 진료에 관한 사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n절차가 임상시험 참여 전과 다름없이 진행되며, 이후의 치료비는 피험자가 지불하여야\n\n- - 84 -\n<!-- PAGE_91 -->\n###### 19.  피험자의 안전보호에 관한 대책\n\n전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를 취할 수 있도록 하는 등\n\n- (1) 임상시험심사위원회(Institutional Review Board)는 국내 법규/관례에 따라\n구성되어 있어야 한다.  임상시험심사위원회는 피험자의 권리, 안전, 복지를\n\n보호해야 하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에\n\n- (2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가 동의가 적절하게\n얻어지지 않았거나 임상시험이 임상시험계획서에 따라 진행되지 않은 경우 또는\n\n중대한 이상사례/의료기기이상반응이 나타난 경우에는 임상시험의 일부 또는\n\n- 19.3. ",
        "original_sentence": "피해자 보상에 대한 규약\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- - 83 -\n<!-- PAGE_90 -->\n###### 18. "
      }
    },
    {
      "chunk_id": "chunk_717",
      "text": "임상시험 후 피험자의 진료에 관한 사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n절차가 임상시험 참여 전과 다름없이 진행되며, 이후의 치료비는 피험자가 지불하여야\n\n- - 84 -\n<!-- PAGE_91 -->\n###### 19. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 716,
        "window_size": 3,
        "char_count": 159,
        "word_count": 39,
        "page_number": 91,
        "window_text": "- - 81 -\nü 본인은 “연구과제 피험자 동의서”에 서명 후, 본 설명문 및 연구과제 피험자\n\n동의서의 사본을 제공받을 것임을 알고 있습니다.\n\n - - 82 -\n<!-- PAGE_89 -->\n###### 17.  피해자 보상에 대한 규약\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- - 83 -\n<!-- PAGE_90 -->\n###### 18.  임상시험 후 피험자의 진료에 관한 사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n절차가 임상시험 참여 전과 다름없이 진행되며, 이후의 치료비는 피험자가 지불하여야\n\n- - 84 -\n<!-- PAGE_91 -->\n###### 19.  피험자의 안전보호에 관한 대책\n\n전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를 취할 수 있도록 하는 등\n\n- (1) 임상시험심사위원회(Institutional Review Board)는 국내 법규/관례에 따라\n구성되어 있어야 한다.  임상시험심사위원회는 피험자의 권리, 안전, 복지를\n\n보호해야 하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에\n\n- (2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가 동의가 적절하게\n얻어지지 않았거나 임상시험이 임상시험계획서에 따라 진행되지 않은 경우 또는\n\n중대한 이상사례/의료기기이상반응이 나타난 경우에는 임상시험의 일부 또는\n\n- 19.3.  시험자\n- (1) 시험자(Investigator)라 함은 시험책임자, 시험담당자, 임상시험조정자를 말한다.\n",
        "original_sentence": "임상시험 후 피험자의 진료에 관한 사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n절차가 임상시험 참여 전과 다름없이 진행되며, 이후의 치료비는 피험자가 지불하여야\n\n- - 84 -\n<!-- PAGE_91 -->\n###### 19. "
      }
    },
    {
      "chunk_id": "chunk_718",
      "text": "피험자의 안전보호에 관한 대책\n\n전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를 취할 수 있도록 하는 등\n\n- (1) 임상시험심사위원회(Institutional Review Board)는 국내 법규/관례에 따라\n구성되어 있어야 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 717,
        "window_size": 3,
        "char_count": 133,
        "word_count": 28,
        "page_number": 7,
        "window_text": "- - 82 -\n<!-- PAGE_89 -->\n###### 17.  피해자 보상에 대한 규약\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- - 83 -\n<!-- PAGE_90 -->\n###### 18.  임상시험 후 피험자의 진료에 관한 사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n절차가 임상시험 참여 전과 다름없이 진행되며, 이후의 치료비는 피험자가 지불하여야\n\n- - 84 -\n<!-- PAGE_91 -->\n###### 19.  피험자의 안전보호에 관한 대책\n\n전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를 취할 수 있도록 하는 등\n\n- (1) 임상시험심사위원회(Institutional Review Board)는 국내 법규/관례에 따라\n구성되어 있어야 한다.  임상시험심사위원회는 피험자의 권리, 안전, 복지를\n\n보호해야 하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에\n\n- (2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가 동의가 적절하게\n얻어지지 않았거나 임상시험이 임상시험계획서에 따라 진행되지 않은 경우 또는\n\n중대한 이상사례/의료기기이상반응이 나타난 경우에는 임상시험의 일부 또는\n\n- 19.3.  시험자\n- (1) 시험자(Investigator)라 함은 시험책임자, 시험담당자, 임상시험조정자를 말한다.\n 시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식품의약품안전처장의 승\n\n인을 득한 임상시험 계획서를 준수하여 임상시험을 실시하여야 한다.\n\n",
        "original_sentence": "피험자의 안전보호에 관한 대책\n\n전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를 취할 수 있도록 하는 등\n\n- (1) 임상시험심사위원회(Institutional Review Board)는 국내 법규/관례에 따라\n구성되어 있어야 한다. "
      }
    },
    {
      "chunk_id": "chunk_719",
      "text": "임상시험심사위원회는 피험자의 권리, 안전, 복지를\n\n보호해야 하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에\n\n- (2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가 동의가 적절하게\n얻어지지 않았거나 임상시험이 임상시험계획서에 따라 진행되지 않은 경우 또는\n\n중대한 이상사례/의료기기이상반응이 나타난 경우에는 임상시험의 일부 또는\n\n- 19.3. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 718,
        "window_size": 3,
        "char_count": 210,
        "word_count": 42,
        "page_number": 9,
        "window_text": "피해자 보상에 대한 규약\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n- - 83 -\n<!-- PAGE_90 -->\n###### 18.  임상시험 후 피험자의 진료에 관한 사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n절차가 임상시험 참여 전과 다름없이 진행되며, 이후의 치료비는 피험자가 지불하여야\n\n- - 84 -\n<!-- PAGE_91 -->\n###### 19.  피험자의 안전보호에 관한 대책\n\n전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를 취할 수 있도록 하는 등\n\n- (1) 임상시험심사위원회(Institutional Review Board)는 국내 법규/관례에 따라\n구성되어 있어야 한다.  임상시험심사위원회는 피험자의 권리, 안전, 복지를\n\n보호해야 하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에\n\n- (2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가 동의가 적절하게\n얻어지지 않았거나 임상시험이 임상시험계획서에 따라 진행되지 않은 경우 또는\n\n중대한 이상사례/의료기기이상반응이 나타난 경우에는 임상시험의 일부 또는\n\n- 19.3.  시험자\n- (1) 시험자(Investigator)라 함은 시험책임자, 시험담당자, 임상시험조정자를 말한다.\n 시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식품의약품안전처장의 승\n\n인을 득한 임상시험 계획서를 준수하여 임상시험을 실시하여야 한다.\n\n - (2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미 있는 실험실적\n검사치의 이상을 포함하여 임상시험에서 발생한 모든 이상사례에 대해 피험자가\n\n- - 85 -\n적절한 의학적 처치를 받을 수 있도록 조치하여야하고, 시험자가 알게된\n\n피험자의 병발질환에 대해 의학적 처치가 필요한 경우 이를 피험자에게 알려\n\n주어야 한다.\n\n",
        "original_sentence": "임상시험심사위원회는 피험자의 권리, 안전, 복지를\n\n보호해야 하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에\n\n- (2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가 동의가 적절하게\n얻어지지 않았거나 임상시험이 임상시험계획서에 따라 진행되지 않은 경우 또는\n\n중대한 이상사례/의료기기이상반응이 나타난 경우에는 임상시험의 일부 또는\n\n- 19.3. "
      }
    },
    {
      "chunk_id": "chunk_720",
      "text": "시험자\n- (1) 시험자(Investigator)라 함은 시험책임자, 시험담당자, 임상시험조정자를 말한다.\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 719,
        "window_size": 3,
        "char_count": 60,
        "word_count": 9,
        "page_number": 3,
        "window_text": "임상시험 후 피험자의 진료에 관한 사항\n\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n절차가 임상시험 참여 전과 다름없이 진행되며, 이후의 치료비는 피험자가 지불하여야\n\n- - 84 -\n<!-- PAGE_91 -->\n###### 19.  피험자의 안전보호에 관한 대책\n\n전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를 취할 수 있도록 하는 등\n\n- (1) 임상시험심사위원회(Institutional Review Board)는 국내 법규/관례에 따라\n구성되어 있어야 한다.  임상시험심사위원회는 피험자의 권리, 안전, 복지를\n\n보호해야 하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에\n\n- (2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가 동의가 적절하게\n얻어지지 않았거나 임상시험이 임상시험계획서에 따라 진행되지 않은 경우 또는\n\n중대한 이상사례/의료기기이상반응이 나타난 경우에는 임상시험의 일부 또는\n\n- 19.3.  시험자\n- (1) 시험자(Investigator)라 함은 시험책임자, 시험담당자, 임상시험조정자를 말한다.\n 시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식품의약품안전처장의 승\n\n인을 득한 임상시험 계획서를 준수하여 임상시험을 실시하여야 한다.\n\n - (2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미 있는 실험실적\n검사치의 이상을 포함하여 임상시험에서 발생한 모든 이상사례에 대해 피험자가\n\n- - 85 -\n적절한 의학적 처치를 받을 수 있도록 조치하여야하고, 시험자가 알게된\n\n피험자의 병발질환에 대해 의학적 처치가 필요한 경우 이를 피험자에게 알려\n\n주어야 한다.\n\n - (2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상시험 계획서의\n복잡성, 피험자에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상시험\n\n- (2) 임상시험에 대한 모니터링은 임상시험 모니터요원의 정기적인 임상시험 실시기관\n- (3) 또한, 임상시험 모니터요원은 임상시험 진행과정을 잘 살피고, 문제가 있을 경우\n- 19.6. ",
        "original_sentence": "시험자\n- (1) 시험자(Investigator)라 함은 시험책임자, 시험담당자, 임상시험조정자를 말한다.\n"
      }
    },
    {
      "chunk_id": "chunk_721",
      "text": "시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식품의약품안전처장의 승\n\n인을 득한 임상시험 계획서를 준수하여 임상시험을 실시하여야 한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 720,
        "window_size": 3,
        "char_count": 79,
        "word_count": 15,
        "page_number": 9,
        "window_text": "피험자의 안전보호에 관한 대책\n\n전문 인력을 갖추어야 하고, 긴급 시 필요한 조치를 취할 수 있도록 하는 등\n\n- (1) 임상시험심사위원회(Institutional Review Board)는 국내 법규/관례에 따라\n구성되어 있어야 한다.  임상시험심사위원회는 피험자의 권리, 안전, 복지를\n\n보호해야 하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에\n\n- (2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가 동의가 적절하게\n얻어지지 않았거나 임상시험이 임상시험계획서에 따라 진행되지 않은 경우 또는\n\n중대한 이상사례/의료기기이상반응이 나타난 경우에는 임상시험의 일부 또는\n\n- 19.3.  시험자\n- (1) 시험자(Investigator)라 함은 시험책임자, 시험담당자, 임상시험조정자를 말한다.\n 시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식품의약품안전처장의 승\n\n인을 득한 임상시험 계획서를 준수하여 임상시험을 실시하여야 한다.\n\n - (2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미 있는 실험실적\n검사치의 이상을 포함하여 임상시험에서 발생한 모든 이상사례에 대해 피험자가\n\n- - 85 -\n적절한 의학적 처치를 받을 수 있도록 조치하여야하고, 시험자가 알게된\n\n피험자의 병발질환에 대해 의학적 처치가 필요한 경우 이를 피험자에게 알려\n\n주어야 한다.\n\n - (2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상시험 계획서의\n복잡성, 피험자에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상시험\n\n- (2) 임상시험에 대한 모니터링은 임상시험 모니터요원의 정기적인 임상시험 실시기관\n- (3) 또한, 임상시험 모니터요원은 임상시험 진행과정을 잘 살피고, 문제가 있을 경우\n- 19.6.  임상시험계획서의 변경\n- (1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장으로부터 승인\n받은 후, 시험절차가 광범위해지거나 위험도가 높아지거나 피험자 선정기준에\n\n- - 86 -\n변화가 있거나 추가적인 안전성 정보로 인해 임상시험계획서를 변경하는 경우\n\n에는 임상시험심사위원회 및 식품의약품안전처장의 승인을 받아야 한다.\n\n",
        "original_sentence": "시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식품의약품안전처장의 승\n\n인을 득한 임상시험 계획서를 준수하여 임상시험을 실시하여야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_722",
      "text": "- (2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미 있는 실험실적\n검사치의 이상을 포함하여 임상시험에서 발생한 모든 이상사례에 대해 피험자가\n\n- - 85 -\n적절한 의학적 처치를 받을 수 있도록 조치하여야하고, 시험자가 알게된\n\n피험자의 병발질환에 대해 의학적 처치가 필요한 경우 이를 피험자에게 알려\n\n주어야 한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 721,
        "window_size": 3,
        "char_count": 192,
        "word_count": 46,
        "page_number": 6,
        "window_text": "임상시험심사위원회는 피험자의 권리, 안전, 복지를\n\n보호해야 하며, 취약한 환경에 있는 피험자가 임상시험에 참여하는 경우에\n\n- (2) 임상시험심사위원회는 임무를 수행함에 있어 피험자의 시험참가 동의가 적절하게\n얻어지지 않았거나 임상시험이 임상시험계획서에 따라 진행되지 않은 경우 또는\n\n중대한 이상사례/의료기기이상반응이 나타난 경우에는 임상시험의 일부 또는\n\n- 19.3.  시험자\n- (1) 시험자(Investigator)라 함은 시험책임자, 시험담당자, 임상시험조정자를 말한다.\n 시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식품의약품안전처장의 승\n\n인을 득한 임상시험 계획서를 준수하여 임상시험을 실시하여야 한다.\n\n - (2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미 있는 실험실적\n검사치의 이상을 포함하여 임상시험에서 발생한 모든 이상사례에 대해 피험자가\n\n- - 85 -\n적절한 의학적 처치를 받을 수 있도록 조치하여야하고, 시험자가 알게된\n\n피험자의 병발질환에 대해 의학적 처치가 필요한 경우 이를 피험자에게 알려\n\n주어야 한다.\n\n - (2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상시험 계획서의\n복잡성, 피험자에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상시험\n\n- (2) 임상시험에 대한 모니터링은 임상시험 모니터요원의 정기적인 임상시험 실시기관\n- (3) 또한, 임상시험 모니터요원은 임상시험 진행과정을 잘 살피고, 문제가 있을 경우\n- 19.6.  임상시험계획서의 변경\n- (1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장으로부터 승인\n받은 후, 시험절차가 광범위해지거나 위험도가 높아지거나 피험자 선정기준에\n\n- - 86 -\n변화가 있거나 추가적인 안전성 정보로 인해 임상시험계획서를 변경하는 경우\n\n에는 임상시험심사위원회 및 식품의약품안전처장의 승인을 받아야 한다.\n\n - (2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정 내용 등을 기록하여\n- (3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한 경우를 제외\n하고는, 임상시험심사위원회 및 식품의약품안전처장의 변경승인 이전에는 계\n\n획서와 다르게 임상시험을 실시하여서는 안된다. ",
        "original_sentence": "- (2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미 있는 실험실적\n검사치의 이상을 포함하여 임상시험에서 발생한 모든 이상사례에 대해 피험자가\n\n- - 85 -\n적절한 의학적 처치를 받을 수 있도록 조치하여야하고, 시험자가 알게된\n\n피험자의 병발질환에 대해 의학적 처치가 필요한 경우 이를 피험자에게 알려\n\n주어야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_723",
      "text": "- (2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상시험 계획서의\n복잡성, 피험자에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상시험\n\n- (2) 임상시험에 대한 모니터링은 임상시험 모니터요원의 정기적인 임상시험 실시기관\n- (3) 또한, 임상시험 모니터요원은 임상시험 진행과정을 잘 살피고, 문제가 있을 경우\n- 19.6. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 722,
        "window_size": 3,
        "char_count": 199,
        "word_count": 46,
        "page_number": 6,
        "window_text": "시험자\n- (1) 시험자(Investigator)라 함은 시험책임자, 시험담당자, 임상시험조정자를 말한다.\n 시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식품의약품안전처장의 승\n\n인을 득한 임상시험 계획서를 준수하여 임상시험을 실시하여야 한다.\n\n - (2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미 있는 실험실적\n검사치의 이상을 포함하여 임상시험에서 발생한 모든 이상사례에 대해 피험자가\n\n- - 85 -\n적절한 의학적 처치를 받을 수 있도록 조치하여야하고, 시험자가 알게된\n\n피험자의 병발질환에 대해 의학적 처치가 필요한 경우 이를 피험자에게 알려\n\n주어야 한다.\n\n - (2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상시험 계획서의\n복잡성, 피험자에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상시험\n\n- (2) 임상시험에 대한 모니터링은 임상시험 모니터요원의 정기적인 임상시험 실시기관\n- (3) 또한, 임상시험 모니터요원은 임상시험 진행과정을 잘 살피고, 문제가 있을 경우\n- 19.6.  임상시험계획서의 변경\n- (1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장으로부터 승인\n받은 후, 시험절차가 광범위해지거나 위험도가 높아지거나 피험자 선정기준에\n\n- - 86 -\n변화가 있거나 추가적인 안전성 정보로 인해 임상시험계획서를 변경하는 경우\n\n에는 임상시험심사위원회 및 식품의약품안전처장의 승인을 받아야 한다.\n\n - (2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정 내용 등을 기록하여\n- (3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한 경우를 제외\n하고는, 임상시험심사위원회 및 식품의약품안전처장의 변경승인 이전에는 계\n\n획서와 다르게 임상시험을 실시하여서는 안된다.  만일 피험자에게 발생한 즉\n\n각적 위험요소를 제거하기 위해 임상시험심사위원회의 승인을 얻기 전에 이러\n\n여 임상시험심사위원회(사후검토 승인을 위하여), 의뢰자, 식품의약품안전처장에\n\n게 제출하여야 한다. ",
        "original_sentence": "- (2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상시험 계획서의\n복잡성, 피험자에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상시험\n\n- (2) 임상시험에 대한 모니터링은 임상시험 모니터요원의 정기적인 임상시험 실시기관\n- (3) 또한, 임상시험 모니터요원은 임상시험 진행과정을 잘 살피고, 문제가 있을 경우\n- 19.6. "
      }
    },
    {
      "chunk_id": "chunk_724",
      "text": "임상시험계획서의 변경\n- (1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장으로부터 승인\n받은 후, 시험절차가 광범위해지거나 위험도가 높아지거나 피험자 선정기준에\n\n- - 86 -\n변화가 있거나 추가적인 안전성 정보로 인해 임상시험계획서를 변경하는 경우\n\n에는 임상시험심사위원회 및 식품의약품안전처장의 승인을 받아야 한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 723,
        "window_size": 3,
        "char_count": 188,
        "word_count": 37,
        "page_number": 6,
        "window_text": "시험자는 의뢰자와 합의되고 임상시험심사위원회 및 식품의약품안전처장의 승\n\n인을 득한 임상시험 계획서를 준수하여 임상시험을 실시하여야 한다.\n\n - (2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미 있는 실험실적\n검사치의 이상을 포함하여 임상시험에서 발생한 모든 이상사례에 대해 피험자가\n\n- - 85 -\n적절한 의학적 처치를 받을 수 있도록 조치하여야하고, 시험자가 알게된\n\n피험자의 병발질환에 대해 의학적 처치가 필요한 경우 이를 피험자에게 알려\n\n주어야 한다.\n\n - (2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상시험 계획서의\n복잡성, 피험자에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상시험\n\n- (2) 임상시험에 대한 모니터링은 임상시험 모니터요원의 정기적인 임상시험 실시기관\n- (3) 또한, 임상시험 모니터요원은 임상시험 진행과정을 잘 살피고, 문제가 있을 경우\n- 19.6.  임상시험계획서의 변경\n- (1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장으로부터 승인\n받은 후, 시험절차가 광범위해지거나 위험도가 높아지거나 피험자 선정기준에\n\n- - 86 -\n변화가 있거나 추가적인 안전성 정보로 인해 임상시험계획서를 변경하는 경우\n\n에는 임상시험심사위원회 및 식품의약품안전처장의 승인을 받아야 한다.\n\n - (2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정 내용 등을 기록하여\n- (3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한 경우를 제외\n하고는, 임상시험심사위원회 및 식품의약품안전처장의 변경승인 이전에는 계\n\n획서와 다르게 임상시험을 실시하여서는 안된다.  만일 피험자에게 발생한 즉\n\n각적 위험요소를 제거하기 위해 임상시험심사위원회의 승인을 얻기 전에 이러\n\n여 임상시험심사위원회(사후검토 승인을 위하여), 의뢰자, 식품의약품안전처장에\n\n게 제출하여야 한다.  그리고 임상시험심사위원회 위원장이나 간사가 승인한 문서\n\n전에 피험자를 위한 설명서를 통해 해당 임상시험과 관련된 모든 정보를 제공\n\n받고, 서명과 서명 날짜가 포함된 문서를 통해 본인이 자발적으로 임상시험에\n\n- (2) 피험자 본인 또는 대리인이 동의서 서식, 피험자설명서 및 기타 문서화된 정보를\n읽을 수 없는 경우에는 공정한 입회자가 동의를 얻는 전 과정에 참석하여야 한다.\n\n",
        "original_sentence": "임상시험계획서의 변경\n- (1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장으로부터 승인\n받은 후, 시험절차가 광범위해지거나 위험도가 높아지거나 피험자 선정기준에\n\n- - 86 -\n변화가 있거나 추가적인 안전성 정보로 인해 임상시험계획서를 변경하는 경우\n\n에는 임상시험심사위원회 및 식품의약품안전처장의 승인을 받아야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_725",
      "text": "- (2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정 내용 등을 기록하여\n- (3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한 경우를 제외\n하고는, 임상시험심사위원회 및 식품의약품안전처장의 변경승인 이전에는 계\n\n획서와 다르게 임상시험을 실시하여서는 안된다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 724,
        "window_size": 3,
        "char_count": 165,
        "word_count": 37,
        "page_number": 6,
        "window_text": "- (2) 임상시험 중 또는 임상시험 이후에도, 시험자는 임상적으로 의미 있는 실험실적\n검사치의 이상을 포함하여 임상시험에서 발생한 모든 이상사례에 대해 피험자가\n\n- - 85 -\n적절한 의학적 처치를 받을 수 있도록 조치하여야하고, 시험자가 알게된\n\n피험자의 병발질환에 대해 의학적 처치가 필요한 경우 이를 피험자에게 알려\n\n주어야 한다.\n\n - (2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상시험 계획서의\n복잡성, 피험자에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상시험\n\n- (2) 임상시험에 대한 모니터링은 임상시험 모니터요원의 정기적인 임상시험 실시기관\n- (3) 또한, 임상시험 모니터요원은 임상시험 진행과정을 잘 살피고, 문제가 있을 경우\n- 19.6.  임상시험계획서의 변경\n- (1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장으로부터 승인\n받은 후, 시험절차가 광범위해지거나 위험도가 높아지거나 피험자 선정기준에\n\n- - 86 -\n변화가 있거나 추가적인 안전성 정보로 인해 임상시험계획서를 변경하는 경우\n\n에는 임상시험심사위원회 및 식품의약품안전처장의 승인을 받아야 한다.\n\n - (2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정 내용 등을 기록하여\n- (3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한 경우를 제외\n하고는, 임상시험심사위원회 및 식품의약품안전처장의 변경승인 이전에는 계\n\n획서와 다르게 임상시험을 실시하여서는 안된다.  만일 피험자에게 발생한 즉\n\n각적 위험요소를 제거하기 위해 임상시험심사위원회의 승인을 얻기 전에 이러\n\n여 임상시험심사위원회(사후검토 승인을 위하여), 의뢰자, 식품의약품안전처장에\n\n게 제출하여야 한다.  그리고 임상시험심사위원회 위원장이나 간사가 승인한 문서\n\n전에 피험자를 위한 설명서를 통해 해당 임상시험과 관련된 모든 정보를 제공\n\n받고, 서명과 서명 날짜가 포함된 문서를 통해 본인이 자발적으로 임상시험에\n\n- (2) 피험자 본인 또는 대리인이 동의서 서식, 피험자설명서 및 기타 문서화된 정보를\n읽을 수 없는 경우에는 공정한 입회자가 동의를 얻는 전 과정에 참석하여야 한다.\n\n - (3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의 세부 사항에 대해\n질문하고 해당 임상시험의 참여 여부를 결정할 수 있도록 충분한 시간과 기회를\n\n주어야 하며, 모든 임상시험 관련 질문에 대해 피험자 또는 대리인이 만족할 수\n\n있도록 대답해 주어야 한다.\n\n",
        "original_sentence": "- (2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정 내용 등을 기록하여\n- (3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한 경우를 제외\n하고는, 임상시험심사위원회 및 식품의약품안전처장의 변경승인 이전에는 계\n\n획서와 다르게 임상시험을 실시하여서는 안된다. "
      }
    },
    {
      "chunk_id": "chunk_726",
      "text": "만일 피험자에게 발생한 즉\n\n각적 위험요소를 제거하기 위해 임상시험심사위원회의 승인을 얻기 전에 이러\n\n여 임상시험심사위원회(사후검토 승인을 위하여), 의뢰자, 식품의약품안전처장에\n\n게 제출하여야 한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 725,
        "window_size": 3,
        "char_count": 114,
        "word_count": 22,
        "page_number": 7,
        "window_text": "- (2) 임상시험대상, 시험방법, 증례보고서의 서식과 내용 등이 임상시험 계획서의\n복잡성, 피험자에게 미칠 수 있는 잠재적인 위험의 정도 및 이미 확인된 임상시험\n\n- (2) 임상시험에 대한 모니터링은 임상시험 모니터요원의 정기적인 임상시험 실시기관\n- (3) 또한, 임상시험 모니터요원은 임상시험 진행과정을 잘 살피고, 문제가 있을 경우\n- 19.6.  임상시험계획서의 변경\n- (1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장으로부터 승인\n받은 후, 시험절차가 광범위해지거나 위험도가 높아지거나 피험자 선정기준에\n\n- - 86 -\n변화가 있거나 추가적인 안전성 정보로 인해 임상시험계획서를 변경하는 경우\n\n에는 임상시험심사위원회 및 식품의약품안전처장의 승인을 받아야 한다.\n\n - (2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정 내용 등을 기록하여\n- (3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한 경우를 제외\n하고는, 임상시험심사위원회 및 식품의약품안전처장의 변경승인 이전에는 계\n\n획서와 다르게 임상시험을 실시하여서는 안된다.  만일 피험자에게 발생한 즉\n\n각적 위험요소를 제거하기 위해 임상시험심사위원회의 승인을 얻기 전에 이러\n\n여 임상시험심사위원회(사후검토 승인을 위하여), 의뢰자, 식품의약품안전처장에\n\n게 제출하여야 한다.  그리고 임상시험심사위원회 위원장이나 간사가 승인한 문서\n\n전에 피험자를 위한 설명서를 통해 해당 임상시험과 관련된 모든 정보를 제공\n\n받고, 서명과 서명 날짜가 포함된 문서를 통해 본인이 자발적으로 임상시험에\n\n- (2) 피험자 본인 또는 대리인이 동의서 서식, 피험자설명서 및 기타 문서화된 정보를\n읽을 수 없는 경우에는 공정한 입회자가 동의를 얻는 전 과정에 참석하여야 한다.\n\n - (3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의 세부 사항에 대해\n질문하고 해당 임상시험의 참여 여부를 결정할 수 있도록 충분한 시간과 기회를\n\n주어야 하며, 모든 임상시험 관련 질문에 대해 피험자 또는 대리인이 만족할 수\n\n있도록 대답해 주어야 한다.\n\n - - 87 -\n- 19.8. ",
        "original_sentence": "만일 피험자에게 발생한 즉\n\n각적 위험요소를 제거하기 위해 임상시험심사위원회의 승인을 얻기 전에 이러\n\n여 임상시험심사위원회(사후검토 승인을 위하여), 의뢰자, 식품의약품안전처장에\n\n게 제출하여야 한다. "
      }
    },
    {
      "chunk_id": "chunk_727",
      "text": "그리고 임상시험심사위원회 위원장이나 간사가 승인한 문서\n\n전에 피험자를 위한 설명서를 통해 해당 임상시험과 관련된 모든 정보를 제공\n\n받고, 서명과 서명 날짜가 포함된 문서를 통해 본인이 자발적으로 임상시험에\n\n- (2) 피험자 본인 또는 대리인이 동의서 서식, 피험자설명서 및 기타 문서화된 정보를\n읽을 수 없는 경우에는 공정한 입회자가 동의를 얻는 전 과정에 참석하여야 한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 726,
        "window_size": 3,
        "char_count": 214,
        "word_count": 52,
        "page_number": 9,
        "window_text": "임상시험계획서의 변경\n- (1) 임상시험계획서를 임상시험심사위원회 및 식품의약품안전처장으로부터 승인\n받은 후, 시험절차가 광범위해지거나 위험도가 높아지거나 피험자 선정기준에\n\n- - 86 -\n변화가 있거나 추가적인 안전성 정보로 인해 임상시험계획서를 변경하는 경우\n\n에는 임상시험심사위원회 및 식품의약품안전처장의 승인을 받아야 한다.\n\n - (2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정 내용 등을 기록하여\n- (3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한 경우를 제외\n하고는, 임상시험심사위원회 및 식품의약품안전처장의 변경승인 이전에는 계\n\n획서와 다르게 임상시험을 실시하여서는 안된다.  만일 피험자에게 발생한 즉\n\n각적 위험요소를 제거하기 위해 임상시험심사위원회의 승인을 얻기 전에 이러\n\n여 임상시험심사위원회(사후검토 승인을 위하여), 의뢰자, 식품의약품안전처장에\n\n게 제출하여야 한다.  그리고 임상시험심사위원회 위원장이나 간사가 승인한 문서\n\n전에 피험자를 위한 설명서를 통해 해당 임상시험과 관련된 모든 정보를 제공\n\n받고, 서명과 서명 날짜가 포함된 문서를 통해 본인이 자발적으로 임상시험에\n\n- (2) 피험자 본인 또는 대리인이 동의서 서식, 피험자설명서 및 기타 문서화된 정보를\n읽을 수 없는 경우에는 공정한 입회자가 동의를 얻는 전 과정에 참석하여야 한다.\n\n - (3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의 세부 사항에 대해\n질문하고 해당 임상시험의 참여 여부를 결정할 수 있도록 충분한 시간과 기회를\n\n주어야 하며, 모든 임상시험 관련 질문에 대해 피험자 또는 대리인이 만족할 수\n\n있도록 대답해 주어야 한다.\n\n - - 87 -\n- 19.8.  피험자 기록의 비밀보장\n- (1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며, 임상 시험의\n결과가 출관될 경우에도 피험자의 신원을 비밀상태로 유지한다.\n\n",
        "original_sentence": "그리고 임상시험심사위원회 위원장이나 간사가 승인한 문서\n\n전에 피험자를 위한 설명서를 통해 해당 임상시험과 관련된 모든 정보를 제공\n\n받고, 서명과 서명 날짜가 포함된 문서를 통해 본인이 자발적으로 임상시험에\n\n- (2) 피험자 본인 또는 대리인이 동의서 서식, 피험자설명서 및 기타 문서화된 정보를\n읽을 수 없는 경우에는 공정한 입회자가 동의를 얻는 전 과정에 참석하여야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_728",
      "text": "- (3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의 세부 사항에 대해\n질문하고 해당 임상시험의 참여 여부를 결정할 수 있도록 충분한 시간과 기회를\n\n주어야 하며, 모든 임상시험 관련 질문에 대해 피험자 또는 대리인이 만족할 수\n\n있도록 대답해 주어야 한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 727,
        "window_size": 3,
        "char_count": 155,
        "word_count": 40,
        "page_number": 3,
        "window_text": "- (2) 임상시험계획서를 수정할 때에는 개정 일자, 개정 이유, 개정 내용 등을 기록하여\n- (3) 시험자는 피험자에게 발생한 즉각적 위험 요소의 제거가 필요한 경우를 제외\n하고는, 임상시험심사위원회 및 식품의약품안전처장의 변경승인 이전에는 계\n\n획서와 다르게 임상시험을 실시하여서는 안된다.  만일 피험자에게 발생한 즉\n\n각적 위험요소를 제거하기 위해 임상시험심사위원회의 승인을 얻기 전에 이러\n\n여 임상시험심사위원회(사후검토 승인을 위하여), 의뢰자, 식품의약품안전처장에\n\n게 제출하여야 한다.  그리고 임상시험심사위원회 위원장이나 간사가 승인한 문서\n\n전에 피험자를 위한 설명서를 통해 해당 임상시험과 관련된 모든 정보를 제공\n\n받고, 서명과 서명 날짜가 포함된 문서를 통해 본인이 자발적으로 임상시험에\n\n- (2) 피험자 본인 또는 대리인이 동의서 서식, 피험자설명서 및 기타 문서화된 정보를\n읽을 수 없는 경우에는 공정한 입회자가 동의를 얻는 전 과정에 참석하여야 한다.\n\n - (3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의 세부 사항에 대해\n질문하고 해당 임상시험의 참여 여부를 결정할 수 있도록 충분한 시간과 기회를\n\n주어야 하며, 모든 임상시험 관련 질문에 대해 피험자 또는 대리인이 만족할 수\n\n있도록 대답해 주어야 한다.\n\n - - 87 -\n- 19.8.  피험자 기록의 비밀보장\n- (1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며, 임상 시험의\n결과가 출관될 경우에도 피험자의 신원을 비밀상태로 유지한다.\n\n - (2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의 모니터링과\n임상시험 의뢰자 또는 모니터 및 점검자가 피험자의 차트와 증례기록서 기록을\n\n검증하기 위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다. ",
        "original_sentence": "- (3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의 세부 사항에 대해\n질문하고 해당 임상시험의 참여 여부를 결정할 수 있도록 충분한 시간과 기회를\n\n주어야 하며, 모든 임상시험 관련 질문에 대해 피험자 또는 대리인이 만족할 수\n\n있도록 대답해 주어야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_729",
      "text": "- - 87 -\n- 19.8. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 728,
        "window_size": 3,
        "char_count": 17,
        "word_count": 6,
        "page_number": 6,
        "window_text": "만일 피험자에게 발생한 즉\n\n각적 위험요소를 제거하기 위해 임상시험심사위원회의 승인을 얻기 전에 이러\n\n여 임상시험심사위원회(사후검토 승인을 위하여), 의뢰자, 식품의약품안전처장에\n\n게 제출하여야 한다.  그리고 임상시험심사위원회 위원장이나 간사가 승인한 문서\n\n전에 피험자를 위한 설명서를 통해 해당 임상시험과 관련된 모든 정보를 제공\n\n받고, 서명과 서명 날짜가 포함된 문서를 통해 본인이 자발적으로 임상시험에\n\n- (2) 피험자 본인 또는 대리인이 동의서 서식, 피험자설명서 및 기타 문서화된 정보를\n읽을 수 없는 경우에는 공정한 입회자가 동의를 얻는 전 과정에 참석하여야 한다.\n\n - (3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의 세부 사항에 대해\n질문하고 해당 임상시험의 참여 여부를 결정할 수 있도록 충분한 시간과 기회를\n\n주어야 하며, 모든 임상시험 관련 질문에 대해 피험자 또는 대리인이 만족할 수\n\n있도록 대답해 주어야 한다.\n\n - - 87 -\n- 19.8.  피험자 기록의 비밀보장\n- (1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며, 임상 시험의\n결과가 출관될 경우에도 피험자의 신원을 비밀상태로 유지한다.\n\n - (2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의 모니터링과\n임상시험 의뢰자 또는 모니터 및 점검자가 피험자의 차트와 증례기록서 기록을\n\n검증하기 위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.  이러한\n\n- - 88 -\n<!-- PAGE_95 -->\n###### 20. ",
        "original_sentence": "- - 87 -\n- 19.8. "
      }
    },
    {
      "chunk_id": "chunk_730",
      "text": "피험자 기록의 비밀보장\n- (1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며, 임상 시험의\n결과가 출관될 경우에도 피험자의 신원을 비밀상태로 유지한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 729,
        "window_size": 3,
        "char_count": 96,
        "word_count": 23,
        "page_number": 6,
        "window_text": "그리고 임상시험심사위원회 위원장이나 간사가 승인한 문서\n\n전에 피험자를 위한 설명서를 통해 해당 임상시험과 관련된 모든 정보를 제공\n\n받고, 서명과 서명 날짜가 포함된 문서를 통해 본인이 자발적으로 임상시험에\n\n- (2) 피험자 본인 또는 대리인이 동의서 서식, 피험자설명서 및 기타 문서화된 정보를\n읽을 수 없는 경우에는 공정한 입회자가 동의를 얻는 전 과정에 참석하여야 한다.\n\n - (3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의 세부 사항에 대해\n질문하고 해당 임상시험의 참여 여부를 결정할 수 있도록 충분한 시간과 기회를\n\n주어야 하며, 모든 임상시험 관련 질문에 대해 피험자 또는 대리인이 만족할 수\n\n있도록 대답해 주어야 한다.\n\n - - 87 -\n- 19.8.  피험자 기록의 비밀보장\n- (1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며, 임상 시험의\n결과가 출관될 경우에도 피험자의 신원을 비밀상태로 유지한다.\n\n - (2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의 모니터링과\n임상시험 의뢰자 또는 모니터 및 점검자가 피험자의 차트와 증례기록서 기록을\n\n검증하기 위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.  이러한\n\n- - 88 -\n<!-- PAGE_95 -->\n###### 20.  그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n\n- (1) 임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가 관리한다.\n",
        "original_sentence": "피험자 기록의 비밀보장\n- (1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며, 임상 시험의\n결과가 출관될 경우에도 피험자의 신원을 비밀상태로 유지한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_731",
      "text": "- (2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의 모니터링과\n임상시험 의뢰자 또는 모니터 및 점검자가 피험자의 차트와 증례기록서 기록을\n\n검증하기 위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 730,
        "window_size": 3,
        "char_count": 130,
        "word_count": 31,
        "page_number": 6,
        "window_text": "- (3) 동의를 얻기 전에 시험자는 피험자 또는 대리인이 임상시험의 세부 사항에 대해\n질문하고 해당 임상시험의 참여 여부를 결정할 수 있도록 충분한 시간과 기회를\n\n주어야 하며, 모든 임상시험 관련 질문에 대해 피험자 또는 대리인이 만족할 수\n\n있도록 대답해 주어야 한다.\n\n - - 87 -\n- 19.8.  피험자 기록의 비밀보장\n- (1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며, 임상 시험의\n결과가 출관될 경우에도 피험자의 신원을 비밀상태로 유지한다.\n\n - (2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의 모니터링과\n임상시험 의뢰자 또는 모니터 및 점검자가 피험자의 차트와 증례기록서 기록을\n\n검증하기 위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.  이러한\n\n- - 88 -\n<!-- PAGE_95 -->\n###### 20.  그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n\n- (1) 임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가 관리한다.\n 승인을 얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는 아니\n\n로부터 반납받거나 의뢰자에게 반납하는 방법에 관한 지침을 마련하여 시험\n\n책임자 및 관리자 등에게 주어야 하며, 임상시험용 의료기기의 공급, 인수,\n\n- (3) 의뢰자는 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관으로의\n공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납 및 폐기에 관한\n\n기록을 작성·보관하여야 한다.\n\n",
        "original_sentence": "- (2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의 모니터링과\n임상시험 의뢰자 또는 모니터 및 점검자가 피험자의 차트와 증례기록서 기록을\n\n검증하기 위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다. "
      }
    },
    {
      "chunk_id": "chunk_732",
      "text": "이러한\n\n- - 88 -\n<!-- PAGE_95 -->\n###### 20. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 731,
        "window_size": 3,
        "char_count": 42,
        "word_count": 10,
        "page_number": 95,
        "window_text": "- - 87 -\n- 19.8.  피험자 기록의 비밀보장\n- (1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며, 임상 시험의\n결과가 출관될 경우에도 피험자의 신원을 비밀상태로 유지한다.\n\n - (2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의 모니터링과\n임상시험 의뢰자 또는 모니터 및 점검자가 피험자의 차트와 증례기록서 기록을\n\n검증하기 위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.  이러한\n\n- - 88 -\n<!-- PAGE_95 -->\n###### 20.  그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n\n- (1) 임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가 관리한다.\n 승인을 얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는 아니\n\n로부터 반납받거나 의뢰자에게 반납하는 방법에 관한 지침을 마련하여 시험\n\n책임자 및 관리자 등에게 주어야 하며, 임상시험용 의료기기의 공급, 인수,\n\n- (3) 의뢰자는 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관으로의\n공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납 및 폐기에 관한\n\n기록을 작성·보관하여야 한다.\n\n - (4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나 임상시험의 완료\n(조기종료를 포함한다) 및 임상시험용 의료기기의 사용기한의 또는 유효기한의\n\n만료 등의 사유로 임상시험용 의료기기를 회수해야 하는 경우에 대한 절차를\n\n마련하고 임상시험용 의료기기의 회수내용을 기록하여야 한다.\n\n",
        "original_sentence": "이러한\n\n- - 88 -\n<!-- PAGE_95 -->\n###### 20. "
      }
    },
    {
      "chunk_id": "chunk_733",
      "text": "그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n\n- (1) 임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가 관리한다.\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 732,
        "window_size": 3,
        "char_count": 84,
        "word_count": 19,
        "page_number": 3,
        "window_text": "피험자 기록의 비밀보장\n- (1) 피험자의 신원을 파악할 수 있는 기록은 비밀로 보장될 것이며, 임상 시험의\n결과가 출관될 경우에도 피험자의 신원을 비밀상태로 유지한다.\n\n - (2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의 모니터링과\n임상시험 의뢰자 또는 모니터 및 점검자가 피험자의 차트와 증례기록서 기록을\n\n검증하기 위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.  이러한\n\n- - 88 -\n<!-- PAGE_95 -->\n###### 20.  그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n\n- (1) 임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가 관리한다.\n 승인을 얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는 아니\n\n로부터 반납받거나 의뢰자에게 반납하는 방법에 관한 지침을 마련하여 시험\n\n책임자 및 관리자 등에게 주어야 하며, 임상시험용 의료기기의 공급, 인수,\n\n- (3) 의뢰자는 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관으로의\n공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납 및 폐기에 관한\n\n기록을 작성·보관하여야 한다.\n\n - (4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나 임상시험의 완료\n(조기종료를 포함한다) 및 임상시험용 의료기기의 사용기한의 또는 유효기한의\n\n만료 등의 사유로 임상시험용 의료기기를 회수해야 하는 경우에 대한 절차를\n\n마련하고 임상시험용 의료기기의 회수내용을 기록하여야 한다.\n\n - - 89 -\n<!-- PAGE_96 -->\n###### 21. ",
        "original_sentence": "그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n\n- (1) 임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가 관리한다.\n"
      }
    },
    {
      "chunk_id": "chunk_734",
      "text": "승인을 얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는 아니\n\n로부터 반납받거나 의뢰자에게 반납하는 방법에 관한 지침을 마련하여 시험\n\n책임자 및 관리자 등에게 주어야 하며, 임상시험용 의료기기의 공급, 인수,\n\n- (3) 의뢰자는 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관으로의\n공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납 및 폐기에 관한\n\n기록을 작성·보관하여야 한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 733,
        "window_size": 3,
        "char_count": 232,
        "word_count": 48,
        "page_number": 9,
        "window_text": "- (2) 본 임상시험에 관련된 의뢰자, 모니터 및 점검자는 본 임상시험의 모니터링과\n임상시험 의뢰자 또는 모니터 및 점검자가 피험자의 차트와 증례기록서 기록을\n\n검증하기 위하여 해당 문서를 검토하거나 복사할 수도 있음을 인정한다.  이러한\n\n- - 88 -\n<!-- PAGE_95 -->\n###### 20.  그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n\n- (1) 임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가 관리한다.\n 승인을 얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는 아니\n\n로부터 반납받거나 의뢰자에게 반납하는 방법에 관한 지침을 마련하여 시험\n\n책임자 및 관리자 등에게 주어야 하며, 임상시험용 의료기기의 공급, 인수,\n\n- (3) 의뢰자는 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관으로의\n공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납 및 폐기에 관한\n\n기록을 작성·보관하여야 한다.\n\n - (4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나 임상시험의 완료\n(조기종료를 포함한다) 및 임상시험용 의료기기의 사용기한의 또는 유효기한의\n\n만료 등의 사유로 임상시험용 의료기기를 회수해야 하는 경우에 대한 절차를\n\n마련하고 임상시험용 의료기기의 회수내용을 기록하여야 한다.\n\n - - 89 -\n<!-- PAGE_96 -->\n###### 21.  참고문헌\n\n- 3. ",
        "original_sentence": "승인을 얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는 아니\n\n로부터 반납받거나 의뢰자에게 반납하는 방법에 관한 지침을 마련하여 시험\n\n책임자 및 관리자 등에게 주어야 하며, 임상시험용 의료기기의 공급, 인수,\n\n- (3) 의뢰자는 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관으로의\n공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납 및 폐기에 관한\n\n기록을 작성·보관하여야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_735",
      "text": "- (4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나 임상시험의 완료\n(조기종료를 포함한다) 및 임상시험용 의료기기의 사용기한의 또는 유효기한의\n\n만료 등의 사유로 임상시험용 의료기기를 회수해야 하는 경우에 대한 절차를\n\n마련하고 임상시험용 의료기기의 회수내용을 기록하여야 한다.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 734,
        "window_size": 3,
        "char_count": 166,
        "word_count": 35,
        "page_number": 9,
        "window_text": "이러한\n\n- - 88 -\n<!-- PAGE_95 -->\n###### 20.  그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n\n- (1) 임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가 관리한다.\n 승인을 얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는 아니\n\n로부터 반납받거나 의뢰자에게 반납하는 방법에 관한 지침을 마련하여 시험\n\n책임자 및 관리자 등에게 주어야 하며, 임상시험용 의료기기의 공급, 인수,\n\n- (3) 의뢰자는 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관으로의\n공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납 및 폐기에 관한\n\n기록을 작성·보관하여야 한다.\n\n - (4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나 임상시험의 완료\n(조기종료를 포함한다) 및 임상시험용 의료기기의 사용기한의 또는 유효기한의\n\n만료 등의 사유로 임상시험용 의료기기를 회수해야 하는 경우에 대한 절차를\n\n마련하고 임상시험용 의료기기의 회수내용을 기록하여야 한다.\n\n - - 89 -\n<!-- PAGE_96 -->\n###### 21.  참고문헌\n\n- 3.  Lee YK, Kim HS, Park JY, Kang HJ. ",
        "original_sentence": "- (4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나 임상시험의 완료\n(조기종료를 포함한다) 및 임상시험용 의료기기의 사용기한의 또는 유효기한의\n\n만료 등의 사유로 임상시험용 의료기기를 회수해야 하는 경우에 대한 절차를\n\n마련하고 임상시험용 의료기기의 회수내용을 기록하여야 한다.\n\n"
      }
    },
    {
      "chunk_id": "chunk_736",
      "text": "- - 89 -\n<!-- PAGE_96 -->\n###### 21. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 735,
        "window_size": 3,
        "char_count": 37,
        "word_count": 9,
        "page_number": 96,
        "window_text": "그 밖에 임상시험을 안전하고 과학적으로 하기 위하여 필요한 사항\n\n- (1) 임상시험용 의료기기는 해당 임상시험실시기관의 장이 지정한 자가 관리한다.\n 승인을 얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는 아니\n\n로부터 반납받거나 의뢰자에게 반납하는 방법에 관한 지침을 마련하여 시험\n\n책임자 및 관리자 등에게 주어야 하며, 임상시험용 의료기기의 공급, 인수,\n\n- (3) 의뢰자는 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관으로의\n공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납 및 폐기에 관한\n\n기록을 작성·보관하여야 한다.\n\n - (4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나 임상시험의 완료\n(조기종료를 포함한다) 및 임상시험용 의료기기의 사용기한의 또는 유효기한의\n\n만료 등의 사유로 임상시험용 의료기기를 회수해야 하는 경우에 대한 절차를\n\n마련하고 임상시험용 의료기기의 회수내용을 기록하여야 한다.\n\n - - 89 -\n<!-- PAGE_96 -->\n###### 21.  참고문헌\n\n- 3.  Lee YK, Kim HS, Park JY, Kang HJ.  Incidence of aspirin resistance in the patient group of\n- 4. ",
        "original_sentence": "- - 89 -\n<!-- PAGE_96 -->\n###### 21. "
      }
    },
    {
      "chunk_id": "chunk_737",
      "text": "참고문헌\n\n- 3. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 736,
        "window_size": 3,
        "char_count": 11,
        "word_count": 3,
        "page_number": 15,
        "window_text": "승인을 얻기 이전에는 임상시험용 의료기기를 관리자 등에게 공급해서는 아니\n\n로부터 반납받거나 의뢰자에게 반납하는 방법에 관한 지침을 마련하여 시험\n\n책임자 및 관리자 등에게 주어야 하며, 임상시험용 의료기기의 공급, 인수,\n\n- (3) 의뢰자는 임상시험용 의료기기를 적시에 공급하여야 하며, 임상시험기관으로의\n공급, 임상시험기관의 인수, 임상시험기관으로부터의 반납 및 폐기에 관한\n\n기록을 작성·보관하여야 한다.\n\n - (4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나 임상시험의 완료\n(조기종료를 포함한다) 및 임상시험용 의료기기의 사용기한의 또는 유효기한의\n\n만료 등의 사유로 임상시험용 의료기기를 회수해야 하는 경우에 대한 절차를\n\n마련하고 임상시험용 의료기기의 회수내용을 기록하여야 한다.\n\n - - 89 -\n<!-- PAGE_96 -->\n###### 21.  참고문헌\n\n- 3.  Lee YK, Kim HS, Park JY, Kang HJ.  Incidence of aspirin resistance in the patient group of\n- 4.  Kim H, Lee HK, Han K, Jeon HK. ",
        "original_sentence": "참고문헌\n\n- 3. "
      }
    },
    {
      "chunk_id": "chunk_738",
      "text": "Lee YK, Kim HS, Park JY, Kang HJ. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 737,
        "window_size": 3,
        "char_count": 34,
        "word_count": 8,
        "page_number": 58,
        "window_text": "- (4) 의뢰자는 임상시험용 의료기기에 고장 등 문제가 발생하거나 임상시험의 완료\n(조기종료를 포함한다) 및 임상시험용 의료기기의 사용기한의 또는 유효기한의\n\n만료 등의 사유로 임상시험용 의료기기를 회수해야 하는 경우에 대한 절차를\n\n마련하고 임상시험용 의료기기의 회수내용을 기록하여야 한다.\n\n - - 89 -\n<!-- PAGE_96 -->\n###### 21.  참고문헌\n\n- 3.  Lee YK, Kim HS, Park JY, Kang HJ.  Incidence of aspirin resistance in the patient group of\n- 4.  Kim H, Lee HK, Han K, Jeon HK.  Prevalence and risk factors for aspirin and clopidogrel\nresistance in patients with coronary artery disease or ischemic cerebrovascular disease. ",
        "original_sentence": "Lee YK, Kim HS, Park JY, Kang HJ. "
      }
    },
    {
      "chunk_id": "chunk_739",
      "text": "Incidence of aspirin resistance in the patient group of\n- 4. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 738,
        "window_size": 3,
        "char_count": 61,
        "word_count": 11,
        "page_number": 17,
        "window_text": "- - 89 -\n<!-- PAGE_96 -->\n###### 21.  참고문헌\n\n- 3.  Lee YK, Kim HS, Park JY, Kang HJ.  Incidence of aspirin resistance in the patient group of\n- 4.  Kim H, Lee HK, Han K, Jeon HK.  Prevalence and risk factors for aspirin and clopidogrel\nresistance in patients with coronary artery disease or ischemic cerebrovascular disease.  Ann\n\n- 5.\n",
        "original_sentence": "Incidence of aspirin resistance in the patient group of\n- 4. "
      }
    },
    {
      "chunk_id": "chunk_740",
      "text": "Kim H, Lee HK, Han K, Jeon HK. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 739,
        "window_size": 3,
        "char_count": 31,
        "word_count": 8,
        "page_number": 58,
        "window_text": "참고문헌\n\n- 3.  Lee YK, Kim HS, Park JY, Kang HJ.  Incidence of aspirin resistance in the patient group of\n- 4.  Kim H, Lee HK, Han K, Jeon HK.  Prevalence and risk factors for aspirin and clopidogrel\nresistance in patients with coronary artery disease or ischemic cerebrovascular disease.  Ann\n\n- 5.\n FDA K970505: 510(k) summary of safety and effectiveness information Dade PFA-100\n\nPlatelet\n\nfunction\n\nanalyzer,\n\nDade\n\nPFA\n\nCollagen/Epinephrine\n\nTest\n\ncartridge,\n\nDade\n\nPFA\n\n- 7. ",
        "original_sentence": "Kim H, Lee HK, Han K, Jeon HK. "
      }
    },
    {
      "chunk_id": "chunk_741",
      "text": "Prevalence and risk factors for aspirin and clopidogrel\nresistance in patients with coronary artery disease or ischemic cerebrovascular disease. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 740,
        "window_size": 3,
        "char_count": 145,
        "word_count": 19,
        "page_number": 17,
        "window_text": "Lee YK, Kim HS, Park JY, Kang HJ.  Incidence of aspirin resistance in the patient group of\n- 4.  Kim H, Lee HK, Han K, Jeon HK.  Prevalence and risk factors for aspirin and clopidogrel\nresistance in patients with coronary artery disease or ischemic cerebrovascular disease.  Ann\n\n- 5.\n FDA K970505: 510(k) summary of safety and effectiveness information Dade PFA-100\n\nPlatelet\n\nfunction\n\nanalyzer,\n\nDade\n\nPFA\n\nCollagen/Epinephrine\n\nTest\n\ncartridge,\n\nDade\n\nPFA\n\n- 7.  FDA K051231: 510(k) substantial equivalence determination decision summary. ",
        "original_sentence": "Prevalence and risk factors for aspirin and clopidogrel\nresistance in patients with coronary artery disease or ischemic cerebrovascular disease. "
      }
    },
    {
      "chunk_id": "chunk_742",
      "text": "Ann\n\n- 5.\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 741,
        "window_size": 3,
        "char_count": 10,
        "word_count": 3,
        "page_number": 6,
        "window_text": "Incidence of aspirin resistance in the patient group of\n- 4.  Kim H, Lee HK, Han K, Jeon HK.  Prevalence and risk factors for aspirin and clopidogrel\nresistance in patients with coronary artery disease or ischemic cerebrovascular disease.  Ann\n\n- 5.\n FDA K970505: 510(k) summary of safety and effectiveness information Dade PFA-100\n\nPlatelet\n\nfunction\n\nanalyzer,\n\nDade\n\nPFA\n\nCollagen/Epinephrine\n\nTest\n\ncartridge,\n\nDade\n\nPFA\n\n- 7.  FDA K051231: 510(k) substantial equivalence determination decision summary.  VerifyNow\n- 8. ",
        "original_sentence": "Ann\n\n- 5.\n"
      }
    },
    {
      "chunk_id": "chunk_743",
      "text": "FDA K970505: 510(k) summary of safety and effectiveness information Dade PFA-100\n\nPlatelet\n\nfunction\n\nanalyzer,\n\nDade\n\nPFA\n\nCollagen/Epinephrine\n\nTest\n\ncartridge,\n\nDade\n\nPFA\n\n- 7. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 742,
        "window_size": 3,
        "char_count": 180,
        "word_count": 23,
        "page_number": 6,
        "window_text": "Kim H, Lee HK, Han K, Jeon HK.  Prevalence and risk factors for aspirin and clopidogrel\nresistance in patients with coronary artery disease or ischemic cerebrovascular disease.  Ann\n\n- 5.\n FDA K970505: 510(k) summary of safety and effectiveness information Dade PFA-100\n\nPlatelet\n\nfunction\n\nanalyzer,\n\nDade\n\nPFA\n\nCollagen/Epinephrine\n\nTest\n\ncartridge,\n\nDade\n\nPFA\n\n- 7.  FDA K051231: 510(k) substantial equivalence determination decision summary.  VerifyNow\n- 8.  FDA K013596-S2: 510(k) summary. ",
        "original_sentence": "FDA K970505: 510(k) summary of safety and effectiveness information Dade PFA-100\n\nPlatelet\n\nfunction\n\nanalyzer,\n\nDade\n\nPFA\n\nCollagen/Epinephrine\n\nTest\n\ncartridge,\n\nDade\n\nPFA\n\n- 7. "
      }
    },
    {
      "chunk_id": "chunk_744",
      "text": "FDA K051231: 510(k) substantial equivalence determination decision summary. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 743,
        "window_size": 3,
        "char_count": 76,
        "word_count": 8,
        "page_number": 6,
        "window_text": "Prevalence and risk factors for aspirin and clopidogrel\nresistance in patients with coronary artery disease or ischemic cerebrovascular disease.  Ann\n\n- 5.\n FDA K970505: 510(k) summary of safety and effectiveness information Dade PFA-100\n\nPlatelet\n\nfunction\n\nanalyzer,\n\nDade\n\nPFA\n\nCollagen/Epinephrine\n\nTest\n\ncartridge,\n\nDade\n\nPFA\n\n- 7.  FDA K051231: 510(k) substantial equivalence determination decision summary.  VerifyNow\n- 8.  FDA K013596-S2: 510(k) summary.  Accumetrics Ultegra System Rapid Platelet Function\n- - 90 -\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- - 91 -\n<!-- PAGE_98 -->\n###### Case Report Form 작성 지침\n\n일반적인 지침 사항\n\n1) 피험자 이니셜과 피험자 번호를 모든 페이지에서 적절하게 기록하여 주십시오.\n\n",
        "original_sentence": "FDA K051231: 510(k) substantial equivalence determination decision summary. "
      }
    },
    {
      "chunk_id": "chunk_745",
      "text": "VerifyNow\n- 8. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 744,
        "window_size": 3,
        "char_count": 15,
        "word_count": 3,
        "page_number": 15,
        "window_text": "Ann\n\n- 5.\n FDA K970505: 510(k) summary of safety and effectiveness information Dade PFA-100\n\nPlatelet\n\nfunction\n\nanalyzer,\n\nDade\n\nPFA\n\nCollagen/Epinephrine\n\nTest\n\ncartridge,\n\nDade\n\nPFA\n\n- 7.  FDA K051231: 510(k) substantial equivalence determination decision summary.  VerifyNow\n- 8.  FDA K013596-S2: 510(k) summary.  Accumetrics Ultegra System Rapid Platelet Function\n- - 90 -\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- - 91 -\n<!-- PAGE_98 -->\n###### Case Report Form 작성 지침\n\n일반적인 지침 사항\n\n1) 피험자 이니셜과 피험자 번호를 모든 페이지에서 적절하게 기록하여 주십시오.\n\n 2) 방문이 누락된 경우에는 해당 visit의 방문일란에 “ND\"로 기록하여 주십시오.\n\n",
        "original_sentence": "VerifyNow\n- 8. "
      }
    },
    {
      "chunk_id": "chunk_746",
      "text": "FDA K013596-S2: 510(k) summary. ",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 745,
        "window_size": 3,
        "char_count": 32,
        "word_count": 4,
        "page_number": 6,
        "window_text": "FDA K970505: 510(k) summary of safety and effectiveness information Dade PFA-100\n\nPlatelet\n\nfunction\n\nanalyzer,\n\nDade\n\nPFA\n\nCollagen/Epinephrine\n\nTest\n\ncartridge,\n\nDade\n\nPFA\n\n- 7.  FDA K051231: 510(k) substantial equivalence determination decision summary.  VerifyNow\n- 8.  FDA K013596-S2: 510(k) summary.  Accumetrics Ultegra System Rapid Platelet Function\n- - 90 -\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- - 91 -\n<!-- PAGE_98 -->\n###### Case Report Form 작성 지침\n\n일반적인 지침 사항\n\n1) 피험자 이니셜과 피험자 번호를 모든 페이지에서 적절하게 기록하여 주십시오.\n\n 2) 방문이 누락된 경우에는 해당 visit의 방문일란에 “ND\"로 기록하여 주십시오.\n\n 3) 임상시험이 종료(완료, 탈락 또는 중지)된 피험자의 경우, 증례결론란에 세부내용을 기록\n\n- - 92 -\n- - 93 -\n◈ 혈관 질환 유무\n\n- - 94 -\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될\n\n- - 95 -\n<!-- PAGE_102 -->\n###### SPECIAL FORM 이상사례서식지\n\n- - 96 -\n- - 97 -\n오현주, 조양하, 이원규, 정진백, 안영욱, 우승민, 김수영, 서두원, 양원선, 최윤정,\n\n- - 98 -",
        "original_sentence": "FDA K013596-S2: 510(k) summary. "
      }
    },
    {
      "chunk_id": "chunk_747",
      "text": "Accumetrics Ultegra System Rapid Platelet Function\n- - 90 -\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- - 91 -\n<!-- PAGE_98 -->\n###### Case Report Form 작성 지침\n\n일반적인 지침 사항\n\n1) 피험자 이니셜과 피험자 번호를 모든 페이지에서 적절하게 기록하여 주십시오.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 746,
        "window_size": 3,
        "char_count": 253,
        "word_count": 56,
        "page_number": 98,
        "window_text": "FDA K051231: 510(k) substantial equivalence determination decision summary.  VerifyNow\n- 8.  FDA K013596-S2: 510(k) summary.  Accumetrics Ultegra System Rapid Platelet Function\n- - 90 -\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- - 91 -\n<!-- PAGE_98 -->\n###### Case Report Form 작성 지침\n\n일반적인 지침 사항\n\n1) 피험자 이니셜과 피험자 번호를 모든 페이지에서 적절하게 기록하여 주십시오.\n\n 2) 방문이 누락된 경우에는 해당 visit의 방문일란에 “ND\"로 기록하여 주십시오.\n\n 3) 임상시험이 종료(완료, 탈락 또는 중지)된 피험자의 경우, 증례결론란에 세부내용을 기록\n\n- - 92 -\n- - 93 -\n◈ 혈관 질환 유무\n\n- - 94 -\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될\n\n- - 95 -\n<!-- PAGE_102 -->\n###### SPECIAL FORM 이상사례서식지\n\n- - 96 -\n- - 97 -\n오현주, 조양하, 이원규, 정진백, 안영욱, 우승민, 김수영, 서두원, 양원선, 최윤정,\n\n- - 98 -",
        "original_sentence": "Accumetrics Ultegra System Rapid Platelet Function\n- - 90 -\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- - 91 -\n<!-- PAGE_98 -->\n###### Case Report Form 작성 지침\n\n일반적인 지침 사항\n\n1) 피험자 이니셜과 피험자 번호를 모든 페이지에서 적절하게 기록하여 주십시오.\n\n"
      }
    },
    {
      "chunk_id": "chunk_748",
      "text": "2) 방문이 누락된 경우에는 해당 visit의 방문일란에 “ND\"로 기록하여 주십시오.\n\n",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 747,
        "window_size": 3,
        "char_count": 50,
        "word_count": 10,
        "page_number": 98,
        "window_text": "VerifyNow\n- 8.  FDA K013596-S2: 510(k) summary.  Accumetrics Ultegra System Rapid Platelet Function\n- - 90 -\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- - 91 -\n<!-- PAGE_98 -->\n###### Case Report Form 작성 지침\n\n일반적인 지침 사항\n\n1) 피험자 이니셜과 피험자 번호를 모든 페이지에서 적절하게 기록하여 주십시오.\n\n 2) 방문이 누락된 경우에는 해당 visit의 방문일란에 “ND\"로 기록하여 주십시오.\n\n 3) 임상시험이 종료(완료, 탈락 또는 중지)된 피험자의 경우, 증례결론란에 세부내용을 기록\n\n- - 92 -\n- - 93 -\n◈ 혈관 질환 유무\n\n- - 94 -\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될\n\n- - 95 -\n<!-- PAGE_102 -->\n###### SPECIAL FORM 이상사례서식지\n\n- - 96 -\n- - 97 -\n오현주, 조양하, 이원규, 정진백, 안영욱, 우승민, 김수영, 서두원, 양원선, 최윤정,\n\n- - 98 -",
        "original_sentence": "2) 방문이 누락된 경우에는 해당 visit의 방문일란에 “ND\"로 기록하여 주십시오.\n\n"
      }
    },
    {
      "chunk_id": "chunk_749",
      "text": "3) 임상시험이 종료(완료, 탈락 또는 중지)된 피험자의 경우, 증례결론란에 세부내용을 기록\n\n- - 92 -\n- - 93 -\n◈ 혈관 질환 유무\n\n- - 94 -\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될\n\n- - 95 -\n<!-- PAGE_102 -->\n###### SPECIAL FORM 이상사례서식지\n\n- - 96 -\n- - 97 -\n오현주, 조양하, 이원규, 정진백, 안영욱, 우승민, 김수영, 서두원, 양원선, 최윤정,\n\n- - 98 -",
      "metadata": {
        "source": "815_출혈시간+및+항혈소판제제+저항성+복합검사기기+안전성·성능+및+임상시험계획서+평가+가이드라인(민원인+안내서).pdf",
        "chunk_index": 748,
        "window_size": 3,
        "char_count": 270,
        "word_count": 72,
        "page_number": 102,
        "window_text": "FDA K013596-S2: 510(k) summary.  Accumetrics Ultegra System Rapid Platelet Function\n- - 90 -\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될 수 있으며,\n\n품목의 특성에 따라 자율적으로 설정이 가능함\n\n- - 91 -\n<!-- PAGE_98 -->\n###### Case Report Form 작성 지침\n\n일반적인 지침 사항\n\n1) 피험자 이니셜과 피험자 번호를 모든 페이지에서 적절하게 기록하여 주십시오.\n\n 2) 방문이 누락된 경우에는 해당 visit의 방문일란에 “ND\"로 기록하여 주십시오.\n\n 3) 임상시험이 종료(완료, 탈락 또는 중지)된 피험자의 경우, 증례결론란에 세부내용을 기록\n\n- - 92 -\n- - 93 -\n◈ 혈관 질환 유무\n\n- - 94 -\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될\n\n- - 95 -\n<!-- PAGE_102 -->\n###### SPECIAL FORM 이상사례서식지\n\n- - 96 -\n- - 97 -\n오현주, 조양하, 이원규, 정진백, 안영욱, 우승민, 김수영, 서두원, 양원선, 최윤정,\n\n- - 98 -",
        "original_sentence": "3) 임상시험이 종료(완료, 탈락 또는 중지)된 피험자의 경우, 증례결론란에 세부내용을 기록\n\n- - 92 -\n- - 93 -\n◈ 혈관 질환 유무\n\n- - 94 -\n※ 아래 제시하는 항목 및 예시는 참고용으로 작성한 것으로 사안에 따라 변경될\n\n- - 95 -\n<!-- PAGE_102 -->\n###### SPECIAL FORM 이상사례서식지\n\n- - 96 -\n- - 97 -\n오현주, 조양하, 이원규, 정진백, 안영욱, 우승민, 김수영, 서두원, 양원선, 최윤정,\n\n- - 98 -"
      }
    }
  ],
  "chunking_analysis": {
    "total_chunks": 749,
    "avg_chunk_length": 112.50066755674233,
    "min_chunk_length": 4,
    "max_chunk_length": 2990,
    "total_characters": 84263,
    "total_words": 19049,
    "window_size": 3
  },
  "statistics": {
    "total_text_blocks": 3075,
    "heading_count": 343,
    "paragraph_count": 583,
    "list_item_count": 276,
    "table_cell_count": 1873,
    "tables_detected": 12,
    "chunks_generated": 749
  }
}